<DOC>
<DOCNO>WT08-B10-1</DOCNO>
<DOCOLDNO>IA018-000200-B033-22</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/rxlinks.htm 206.86.175.201 19970106223458 text/html 27691
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:28:38 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 27508
Last-modified: Mon, 06 Jan 1997 19:37:41 GMT
</DOCHDR>
<html>                                                                          
<head>
<title>
www.rxlist.com - Neil Sandow, Pharm.D.
</title>
</head>
<body bgcolor="#ffffff">
<a href="http://www.rxlist.com"><img
src="rx.gif" height=50 width=50 align=left><img
src="rx.gif" height=50 width=50 align=right></a><center> <h2>Known 
Links To RxList</h2><p> <hr>
<hr>
</center><b><font size=4>
<li><a href="http://www.achoo.com/achoo/human/diseases/">Achoo</a>
<li><a href="http://www.dmu.ac.uk/ln/CyberRx">CyberRx</a>
<li><a href="http://www.hon.ch">Health on the Net Foundation</a>
<li><a href="http://www.healthseek.com">HealthSeek</a>
<li><a href="http://www-sci.lib.uci.edu:80/~martindale/Pharmacy.html">Martindale's Health Science Guide</a>
<li><a href="http://www.slackinc.com/matrix/">Medical Matrix </a>
<li><a href="http://pharminfo.com">Pharmaceutical Information Network</a>
<li><a href="http://www.pharmweb.net/">PharmWeb - Department of Pharmacy - University of Manchester</a>
<li><a href="http://www.cpb.uokhsc.edu/pharmacy/pharmint.html">Virtual Library Pharmacy Page - Univ. of Oklahoma</a>
<li><a href="http://community.net/~neils/new.html">World Wide Drugs</a>
<hr>
<li><a href="http://wizard.pharm.wayne.edu/items.html">American Chemical Society - Wayne State Universiy</a>
<li><a href="http://nrc.med.auth.gr/drugs.html">Aristotle University of Thessaloniki - GREECE </a>
<li><a href="http://aspin.asu.edu/msnews/meds.htm">ASPIN - Arizona State Public Information Network</a>
<li><a href="http://diogenes.baylor.edu/Library/BeyondLib/nursing.html">Baylor University Libraries - Selected Nursing Resources</a>
<li><a href="http://med-amsa.bu.edu/Pharmacology/links.html">Boston University - School of Medicine - Biomolecular Pharmacology</a>
<li><a href="http://http2.brunel.ac.uk:8080/~hssrsdn/">Brunel University - UK - CSHSD</a>
<li><a href="http://www.cato.com/interweb/cato/biotech/bio-info.html">Cato Research - WWW Virtual Library</a>
<li><a href="http://www.cdc.gov/nchswww/sites/sites.htm">CDC - National Center for Health Statistics</a>
<li><a href="http://telemachus.creighton.edu">Creighton U. Pharmacocybernetics Center - School of Pharmacy</a>
<li><a href="http://www.hitchcock.org/">Dartmouth-Hitchcock Medical Center</a>
<li><a href="http://www.uni-kassel.de/fb16/ipm/mt/java/javae.html">Department of Engineering - Universitt Gesamthochschule Kassel</a>
<li><a href="http://wizard.pharm.wayne.edu/drh/drhhome1.htm">Detroit Receiving Hospital and University</a>
<li><a href="http://152.3.86.75/druginfo/adr.htm#Section8">Duke Univertisy - Pharmacy 74 Internet Module</a> 
<li><a href="http://www.humed.com">Hackensack University Medical Center</a>
<li><a href="http://www.hamline.edu/HyperNews/get.cgi/lupus/73/1.html">Hamiline University - Conferencing System</a>
<li><a href="http://www.med.harvard.edu/webref/hsciref.html">Harvard University - Countway Library of Medicine</a>
<li><a href="http://dem0nmac.mgh.harvard.edu/hospitalweb.html">Hospital Web - Massachusetts General Hospital </a>
<li><a href="http://www.drugs.indiana.edu/druginfo/other_drug.html">Indiana Prevention Resource Center - Indiana University</a>
<li><a href="http://www.med.jhu.edu/peds/neonatology/poi.html">John Hokins Hospital - Pediatric Points of Interest</a>
<li><a href="http://maple.lemoyne.edu/%7Ehevern/psychref3.html">Le Moyne College - Psych Refs</a>
<li><a href="http://www.lij.edu/links/medical_reference.html">Long Island Jewish Medical Center - Medical References</a>
<li><a href="http://nimrod.mit.edu/common/reference/tools.html">M.I.T. - Virtual Reference Collection</a>
<li><a href="http://www2.pitt.edu/~martint/">Medical, Clinical & Occupational Toxicology Resources</a>
<li><a href="http://www.intmed.mcw.edu/drug.html">Medical College of Wisconsin - Doyne & FMLH Drug Formulary </a>
<li><a href="http://rzstud1.rz.uni-karlsruhe.de/~ukpq/medical.html">Medical Informations -  University of Karlsruhe, Germany </a>
<li><a href="http://www.musc.edu/pharmacy/linx/linx.html">Medical University of South Carolina </a>
<li><a href="http://golgi.harvard.edu:80/biopages/medicine.html">Medicine (Biosciences) - Harvard University</a>
<li><a href="http://www.meds.com">Medicine On Line</a>
<li><a href="http://www.medfarm.unito.it/">MedPharm - University of Torino Medical School, Italy</a>
<li><a href="http://web.cc.emory.edu/WHSCL/medweb.pharmacy.html">MedWeb Pharmacy and Pharmacology - Emory University</a>
<li><a href="http://www.mercy.org/~bchrist/bill1.html">Mercy Medical Center, Redding, CA</a>
<li><a href="http://www.nihs.go.jp/">National Institute of Health Sciences - Japan</a>
<li><a href="http://www.pharm.nwu.edu">Northwestern University Medical School - Molecular Pharmacology</a>
<li><a href="http://www.ntu.ac.uk/lis/health.htm">Nottingham Trent University - Electronic Library Resources</a>
<li><a href="http://"http://www.med.nyu.edu/biomedinfo.html">NYU Medical Center - Biomedical Information Resources</a>
<li><a href="http://www.onu.edu/Pharmacy/links.html">Ohio Northern University - Rudolph H. Raabe College of Pharmacy</a>
<li><a href="http://solar.rtd.utk.edu/~esmith/rxtra.html">Rxtra Info - University of Tennessee Medical Center</a>
<li><a href="http://www.tcom.ohiou.edu/oucom/medsite.htm">Ohio University College of Osteopathic Medicine</a>
<li><a href="http://www.qut.edu.au/hlth/sph/phlinks_us.html">Queensland University of Technology - Brisbane, Australia</a>
<li><a href="http://wn.apc.org/health/health.html">SangoNet Health - South Africa</a>
<li><a href="http://www.sendit.nodak.edu/sendit/health.html">Sendit - North Dakota's Educational Network</a>  
<li><a href="http://www.estyle.com/thl/">Stanford University - The Health Library</a>
<li><a href="http://www.stlcop.edu/library/library.html">St.Louis College of Pharmacy</a>
<li><a href="http://tmc.edu.tw/">Taipei Medical College</a>
<li><a href="http://www.ashp.com/pub/ashp">The American Society of Health System Pharmacists</a>
<li><a href="http://biosci.cbs.umn.edu/biophys/biophys.html">The Biophysical Society</a>
<li><a href="http://falcon.cc.ukans.edu/~nsween/bscience.html">The Interactive Medical Student Lounge</a>
<li><a href="http://ipl.sils.umich.edu/ref/RR/HEA/medication-rr.html">The Internet Public Library</a>
<li><a href="http://www.rutgers.edu/NB-Pharmacy/resrce.html">The Rutgers College of Pharmacy Information Resource Area</a>
<li><a href="http://www.vicnet.net.au/~shpa/shpa1.htm">The Society of Hospital Pharmacy - Australia</a>
<li><a href="http://midget.towson.edu/~cooklib/bibliographies/drugs96.htm">Towson State University</a>
<li><a href="http://www.toyama-mpu.ac.jp/">Toyama Medical and Pharmaceutical University</a>
<li><a href="http://www.md.ucl.ac.be/">Universite Catholique de Louvain - Faculte de medecin</a>
<li><a href="http://www.physiol.ox.ac.uk/">University Laboratory of Physiology - Oxford University
<li><a href="http://www.ualberta.ca/PHARMACE/">University of Alberta - Continuing Pharmacy Education</a>
<li><a href="http://aloe.ahsl.arizona.edu/pharm.htm#Reference">University of Arizona - Health Services Library</a>
<li><a href="http://www.ub.es/farcli/wp0.htm">University of Barcelona - Department of Pharmacy</a>
<li><a href="http://www.bath.ac.uk/">University of Bath - School of Pharmacy</a>
<li><a href="http://unixg.ubc.ca:880/chweiz/links.html">University of British Columbia</a>
<li><a href="http://www-informatics.ucdmc.ucdavis.edu/weboff.htm">Univ. of  California - Davis - Medical Informatics</a>
<li><a href="http://health.ucsd.edu/">University of California - San Diego</a>
<li><a href="http://galen.library.ucsf.edu/kr/subs/pharm/rxlist.html">University of California - SF - Galen Digital Library</a>
<li><a href="http://www.phar.cam.ac.uk/">University of Cambridge - Department of Pharmacology</a>
<li><a href="http://www.phm.ed.ac.uk/links/links.htm">University of Edinburgh - Department of Pharmacology</a>
<li><a href="http://nervm.nerdc.ufl.edu/~cop28/index.html">University of Florida - College of Pharmacy</a>
<li><a href="http://calvin.mri.uky.edu/pcc">University of Kentucky - Primary Care Information Network</a>
<li><a href="http://www.med.miami.edu/catalog/subject/pharmacology_and_toxicology.html">University of Miami School of Medicine</a>
<li><a href="http://www3.umdnj.edu/~libcwis/univlibs.html">Univ. of Medicine and Dentistry of New Jersey</a>
<li><a href="http://molbio.cbs.umn.edu/biophys/RelatedSites.html">University of Minnesota - Biophysics Related Resources</a>
<li><a href="http://www.pitt.edu/~rxschool/">University of Pittsburgh - School of Pharmacy</a>
<li><a href="http://www.usc.edu/hsc/resources/pharmacy.html/">University of Southern California</a>
<li><a href="http://utmgopher.utmem.edu/psweb/cool.html">University of Tennessee-Memphis - Cool Pharmacy Links</a>
<li><a href="http://www.utmb.edu/">University of Texas Medical Branch at Galveston</a>
<li><a href="http://www.utoronto.ca/pharmacy/resource.htm">University of Toronto - Faculty of Pharmacy</a>
<li><a href="http://merian.pch.univie.ac.at/pch/others.html">University of Vienna, Austria - Institute of Pharmaceutical Chemistry</a>
<li><a href="http://www.hslib.washington.edu/your_health/">University of Washington - Healthlinks</a>
<li><a href="http://www.uww.edu/library/medicine.htm">University of Wisconsin - Whitewater</a>
<li><a href="http://maddog.fammed.wisc.edu/hmid/hmid10_2_95.html">University of Wisconsin - Schools of Medicine and Nursing</a>
<li><a href="http://www.au.af.mil/au.html">US Air Force - Air University</a>
<li><a href="http://www.vichosp.london.on.ca">Victoria Hospital, London, Ontario, Canada</a>
<li><a href="http://library.uwaterloo.ca/discipline/Disability_Issues/otherinfo.html">Waterloo University Library - Disability Issues</a>
<hr>
<li><a href="http://www.aos-jax.com/rxlist.htm">Advanced Otolaryngology Services, P.A.</a>
<li><a href="http://www.ailments.com">Ailments.com</a>
<li><a href="http://www.alpha1.org">Alpha 1 National Association - Antitrypsin Deficiency</a>
<li><a href="http://www.psych.org/index.html">American Psychiatric Association</a>
<li><a href="http://www.ritcom.com/amerisource/">Amerisource</a>
<li><a href="http://207.51.37.199:8888/DSM/cafe/links.html">Apollonia Cafe</a>
<li><a href="http://www.arraydev.com/commerce/news-1.html">Array Development</a>
<li><a href="http://www.ascrs.org/links.html">ASCRS-ASOA</a>
<li><a href="http://www.gis.net/~rogeryoung">Ask A Pharmacist - Roger Young</a>
<li><a href="http://www.gate.net/~library/med.htm">Barbara's Health and Medicine Page</a>
<li><a href="http://www.Tyler.Net/Bear/">Bears' Den</a>
<li><a href="http://www.ci.berkeley.ca.us/bpl/bkmk/health.html">Berkeley Public Library - Health Index</a>
<li><a href="http://www.bhglive.com/guidpags/hlthguid.html">Better Homes and Gardens</a>
<li><a href="http://werple.mira.net.au/~lions/medical.htm">Beyond the Black Stump - Medical & Health</a>
<li><a href="http://biotechlaw.ari.net/page6.html">Biotechnology Law Web Server</a>
<li><a href="http://www.bcbsmd.com">Blue Cross - Blue Shield of Maryland</a>
<li><a href="http://www.erols.com/owl/planet/homepage.html">Blue Planet</a>
<li><a href="http://www.afn.org/~afn05660/health.html">Brues' News:Health</a>
<li><a href="http://www.ceoexpress.com/">CEO Express</a>
<li><a href="http://WWW.BLUECRAB.ORG/">Chesapeake Free-Net</a>
<li><a href="http://www.motility.org/">Children's Motility Disorder Foundation</a>
<li><a href="http://www.Tracknet.com/radio.html">CKNW Radio 98 8/12/96 Internet Update with Margot Sinclair</a>
<li><a href="http://www.cmic.co.jp:443/">Clinical Medicine Information Center Co. - Tokyo, Japan</a>
<li><a href="http://cnn.com">CNN Interactive</a>
<li><a href="http://cnn.com/HEALTH/9612/09/preventing.strokes.ap/index.html">CNN Health Story Page</a>
<li><a href="http://www.zdnet.com/clifeuk/yahoo/oldyahoo/yh0996.html">Computer Life</a>
<li><a href="http://www.con2.com/CONNECT2/mednet/">Connect2 Internet Networks</a>
<li><a href="http://www.consumerworld.org/edgar/pages/resource.htm">Consumer World</a>
<li><a href="http://www.coolcentral.com">Cool Central - Cool Site of the Hour</a>
<li><a href="http://www.odyssee.net/~fnord/nurselink.html">Cool Nursing Site of the Week (8/1/96)</a>
<li><a href="http://www.netins.net/showcase/crn/crnlinks.htm">CRN - Court Reporter Net</a>
<li><a href="http://www.cwmars.org/">C/W Mars Web Page</a>
<li><a href="http://ch.nus.sg/">Cyberspace Hospital - Singapore</a>
<li><a href="http://www.telemedical.com">Cyberspace Telemedical Office</a>
<li><a href="http://gladstone.uoregon.edu/~dvb/">David Baldwin's Trauma Info Pages</a>
<li><a href="http://www.interface.co.nz:8001/">David Merritt HomePages</a>
<li><a href="http://dentalxchange.com/chkitout/test/faileduc.htm">Dental X Change</a>
<li><a href="http://DentalGlobe.com/edu.html">Dental Globe</a>
<li><a href="http://www.mediware.com/digi.html">Digimedics - My Hospital Pharmacy Information System Vendor</a>
<li><a href="http://www.divanet.com/search/">Divanet Search Page</a>
<li><a href="http://www.iosphere.net/~dixonr">Dixon's Doorway </a>
<li><a href="http://uhs.bsd.uchicago.edu/~bhsiung/mental.html">Doctor Bob's Mental Health Links</a>
<li><a href="http://www.doctorreferral.com">Doctorreferral.com - Internet Doctor Referral Service</a>
<li><a href="http://www.pslgroup.com/dg/6e06.htm">Doctor's Guide</a>
<li><a href="http://www.psycom.net/depression.central.html">Dr. Ivan's Depression Central</a>
<li><a href="http://www.valley-bbs.com.br/sergio/index.htm">Dr. Sergio dos Passos Ramos - Brazil</a>
<li><a href="http://www.dotpharmacy.co.uk/hotlink1.html">Dot Pharmacy - UK</a> 
<li><a href="http://community.net/~neils">Earl's Urls</a>
<li><a href="http://www.easysearcher.com/ez2.html">Easy Searcher II</a>
<li><a href="http://www.li.net/~edhayes/ed.html">Edmund Hayes - Links to the Medical Professions</a>
<li><a href="http://www.pjbpubs.co.uk/a/emedhome.html">e-med News</a>
<li><a href="http://www.clandjop.com/~aclark/">Emergency Minded</a>
<li><a href="http://www.goodnet.com/%7Eee72478/enable/care.htm">Enable</a>
<li><a href="http://www.ezconnect.com//home.htm">EZ Connect</a>
<li><a href="http://www.fastsearch.com/">Fast Search</a>
<li><a href="http://users.icanect.net/~visionx/">Florida School Psychologist Network</a>
<li><a href="http://www.bcl.net/~jtreese/medical.html">Gem's Medical Links</a>
<li><a href="http://www.gate.net/~gmatt/">Glen Matthews - North Broward Hospital District </a>
<li><a href="http://members.aol.com/poison5249/GrierPharm/ghpharm.html">Grier's Pharmacy Page</a>
<li><a href="http://www.gte.net/start/educ&ref/ed-sci.html">GTE Net - Educational Resources - Science</a>
<li><a href="http://www.healthbiz.com">Healthbiz Notes</a>
<li><a href="http://www.zamnet.zm/zamnet/health.html">Health in Zambia</a>
<li><a href="http://www.healthnetconnect.net/drug.html">Healthnet  Connection - Drug Formulary</a>
<li><a href="http://www.heartinfo.org/SD_STATM.htm#-1010341423">Heart Information Network</a>
<li><a href="http://www.hollyberry.com/hot.htm#health">Hollyberry - Hotsites</a>
<li><a href="http://www.eskimo.com/~pageless">Home Pages for the Page Homeless</a>
<li><a href="http://hcn.cleaf.com/">Hood County News</a>
<li><a href="http://www.doctorbbs.com/inter.htm">Hot Sites Internacionais</a>
<li><a href="http://www2.inetconcepts.net/hotsites/search.html">Hotsites.net</a>
<li><a href="http://www.bighug.com/">H.U.G. - Healthcare Users Group</a>
<li><a href="http://he.net/~sagent/resource.html">Internet Resource Center</a>
<li><a href="http://www.cam.org/~ismael/">Ismael's Home Page</a>
<li><a href="http://www.acsu.buffalo.edu/~ivanlau/links.html">Ivan Lau's Pharmacy Links</a>
<li><a href="http://ccnet4.ccnet.com/~jbond/toolkit.html">James Bond - Investigator's Internet Resources</a>
<li><a href="http://logic.csc.cuhk.hk/~s945755/">Jeffrey's Home Page</a>
<li><a href="http://www.jsusco.com">John Susco Healthcare Promotions</a>
<li><a href="http://ivory.lm.com/~kholt/WebSampler/medical.html">Ken's Web Sampler - Medical/Health</a>
<li><a href="http://www.achiever.com/freehmpg/kynurses/">Kentucky Coalition of Nurse Practitioners/Midwives</a>
<li><a href="http://www.eden.com/%7Ekevinaus/">Kevin and Franny Austin</a>
<li><a href="http://kfwb.com/">KFWB News 98 - Los Angeles</a>
<li><a href="http://www.tricky.com/lfm/awards.htm">Leading Learning Fountain - Award</a>
<li><a href="http://sashimi.wwa.com/~jayhawk/sitejour.html">Librarians' Site Du Jour</a>
<li><a href="http://www.lifestyle.co.uk/">Lifestyle.UK</a>
<li><a href="http://www.lisco.com/lisco/health.htm">Lisco</a>
<li><a href="http://www.looksmart.com/r?l3,f&e65241">LookSmart - Reader's Digest</a>
<li><a href="http://www.lpage.com">LPage - Developer of My Fuzzy Search Engine!</a>
<li><a href="http://www.texas.net/users/pusher/index5.htm">Lynn Ray's Medical Informatics Links</a>
<li><a href="http://www.mindspring.com/~mconti/medical.htm">Maggie's Medical Links</a>
<li><a href="http://www.access.digex.net/~jamba/index.html">Marcia's Bookmarks</a>
<li><a href="http://www.unm.edu/~vuksan/mario/clinic10.html">Mario's Cyberspace Station</a>
<li><a href="http://www.tv.cbc.ca/market/files/health/index.html">Market Place - Your Health and Safety</a>
<li><a href="http://www.marriagebuilders.com">Marriage Builders</a>
<li><a href="http://www.MSHP.org/MSHP/MSHPlink.htm">Maryland Society of Hospital Pharmacists</a>
<li><a href="http://www.mastercard.com/health/index.htm">MasterCard Healthcare</a> 
<li><a href="http://www.mckesson.com/Links.html">McKesson Pharmaceutical Management Solutions</a>
<li><a href="http://www.cris.com/~chenrybu/index.htm">MCP-Logics</a>
<li><a href="http://www.medexcard.com/save.htm">MedEx Prescription Drug Card</a>
<li><a href="http://www.cyber.nl/medibyte/">Medibyte</a>
<li><a href="http://www.pipeline.com/~emu/mt.htm">Medical Information Desk</a>
<li><a href="http://medsource.com/">Medical Source</a>
<li><a href="www.MedicapRx.com">Medicap Pharmacies, Inc.</a>
<li><a href="http://www.medicinenet.com">Medicine Net</a>
<li><a href="http://www.medimall.com/">MediMall</a>
<li><a href="http://www.medlinks.com/links.htm">Medlinks</a>
<li><a href="http://192.115.75.10/web/medline/GenMed/DrugIndex.htm">MedSite Israel</a>
<li><a href="http://www.medsupport.com/headache/t_meds.htm">MedSupport</a>
<li><a href="http://www.medsurf.com/Health_Tips/">MedSurf</a>
<li><a href="http://www.mhsource.com/">Mental Health Infosource</a>
<li><a href="http://www.cmhc.com/guide/pro12.htm">Mental Health Net</a>
<li><a href="http://www.msms.org/siteindx.html">Michigan State Medical Society Site of the Week</a>
<li><a href="http://www.alumni.caltech.edu/~mike/lymphoma.html">Mike's Lymphoma Resource Pages</a>
<li><a href="http://www.netcom.com/~mdponce/favsites.html">Mitzi Ponce's Favorite Sites</a>
<li><a href="http://lamp0.arl.army.mil:8080/~morris/scripts/morris_hotlist_chrono.shtml">Morris Berman's Hotlist</a>
<li><a href="http://www.angelfire.com/mt/links.html">MT Daily - Medical Links</a>
<li><a href="http://www.pipeline.com/~emu/msearch.htm">MT Medical Information</a>
<li><a href="http://www.nashville.com/~health/health_2.htm">Nashville Health Page</a>
<li><a href="http://www.psoriasis.org/">National Psoriasis Foundation</a>
<li><a href="http://www.tricky.com/liz/">NBNSOFT Content Awards - May'96</a>
<li><a href="http://www.nctc.net/">Nebraska Central Telephone Company</a>
<li><a href="http://www.teleport.com/~iexportc/ng-helth.htm">Netgiver Award - November '96</a>
<li><a href="http://www.netmedicine.com">NetMedicine</a>
<li><a href="http://www.wazoo.com/~netnerd/">NetNerd's Medical Home Page</a>
<li><a href="http://netvet.wustl.edu/dec95.htm">Net Vet & The Electric Zoo</a>
<li><a href="http://www.novagate.com/novasurf/healthandhappiness.html">Novagate - Health and Happiness</a>
<li><a href="http://www.nurseweek.com/alana.html">NurseWeek - Hotlinks</a>
<li><a href="http://www.healthweek.com/hotlink/allied.html">Nursing and Allied Healthweek</a>
<li><a href="http://www.obgyn.net/english/drugs/drugs.htm">OB-Gyn.net - Clinical Collection</a>
<li><a href="http://www.opma.org/">Ohio Podiatric Medical Association</a>
<li><a href="http://www.ihr.com/topics.html">Online Health Topics - Internet Health Resources Co.</a>
<li><a href="http://www.yellow.net.au/medical/">Oz Medicine Online - A Healthy Idea</a>
<li><a href="http://www.pachealth.com/">Pacific Health Links</a>
<li><a href="http://www.iaehv.nl/users/paul/potd-12.html">Page of the Day - December 13 1995</a>
<li><a href="http://www.pmrinc.com/">Patient Medical Records, Inc.</a>
<li><a href="http://www.pcpro.co.uk/hot24.htm">PC Pro On the Web</a>
<li><a href="http://prep.net/training-sites.html">Pennsylvania PrepNet</a>
<li><a href="http://acs.oakton.edu/~kkalata/index.htm">Pharmacology for Allied Health Professionals</a>
<li><a href="http://www.pharsight.com/links.htm">Pharsight Corporation</a>
<li><a href="http://emporium.turnpike.net/C/CAPNET/medicine.htm">Pharmacy and Pharmaceutical Companies Meta-List</a>
<li><a href="http://members.aol.com/bertrx/phamedmc.htm">Pharmacy, Medicine and Managed Care Springboard</a>
<li><a href="http://www.tassie.net.au/pharmacy/">Pharmacy Web Australia</a>
<li><a href="http://php2.silverplatter.com/physicians/library/pharmco.htm">Physician's Home Page</a>
<li><a href="http://www.newscientist.com">Planet Science - Site of the Day</a>
<li><a href="http://pw2.netcom.com/~kpearl/practical.html">Practical Uses For the Internet</a>
<li><a href="http://www.cybergate.net/~cjmele">Preferred Rx - Online Pharmacy</a>
<li><a href="www.priority.net"> Priority EMS - Mobile Health Services</a>
<li><a href="http://www.yle.fi/prisma/linkit.htm">Prisma</a>
<li><a href="http://www.awod.com/gallery/rwav/dorietz/cancer.html">Prostate Cancer Sucks</a>
<li><a href="http://www.puppynet.com/">Puppynet</a>
<li><a href="http://minf.vub.ac.be/~fquestie/">Questier Frederik - Pharmacy Related Servers</a>
<li><a href="https://wwws.quick-reilly.com/info/links.htm">Quick & Reilly's Internet Trading Site</a>
<li><a href="http://www.ratiopharm.de/">Ratiopharm Arzneimittel</a>
<li><a href="http://www.iinet.net.au/~raymondo/index.html">Ray's Retreat</a>
<li><a href="http://www.rexallshowcaseintl.com/health.htm">Rexall Showcase International</a>
<li><a href="http://www.rimentalhealth.com/">Rhode Island Mental Health Network</a>
<li><a href="http://www.digisys.net/users/ntstalkr/medical.htm">Sandy's EMS and Medical Room</a>
<li><a href="http://www.sciweb.com/">SciWeb - The LIfe Science Home Page</a>
<li><a href="http://www.infinet.com/~sstickle/">Scott Stickle's Home Page</a>
<li><a href="http://bbs.ci.seaside.ca.us/sealib/referenc.htm">Seaside Community Library</a>
<li><a href="http://208.128.16.30/">Search Engines</a>
<li><a href="http://www.scn.org/test/">Seattle Community Network</a>
<li><a href="http://www.swtexas.net/coolsite.htm">Southwest Texas Telnet Coolsites</a>
<li><a href="http://www.springnet.com/">SpringNet - Nursing '96</a>
<li><a href="http://www.thecodex.com/search.html">Spyking</a>
<li><a href="http://www.win.org/library/intres/irr/health.htm">St. Charles City-County Library District - (SCCCLD)
<li><a href="http://www.starkscripts.com/">Stark Scripts</a>
<li><a href="http://www.synthon.nl/">Synthon BV - Netherlands</a>
<li><a href="http://www.tampatrib.com/tribcar/medical.htm">Tampa Tribune</a>
<li><a href="http://www.ability.org.uk/">The Ability Web Site</a>
<li><a href="http://execpc.com/~edi/aaaai.html">The American Academy of Allergy Asthma & Immunology</a>
<li><a href="http://aimc.com/aimc/Health.html">The American Individual Magazine</a>
<li><a href="http://www.edenia.com/medical">The Complete Online Medical Directory of Costa Rica</a>
<li><a href="http://users.aol.com/cducrx/">The Crohn's and Colitis Website</a>
<li><a href="http://members.aol.com/DrsPage/medlinks.htm">The Doctors' Page - Medical Websites</a>
<li><a href="http://www.dogpatch.org/health.html">The Dogpatch</a>
<li><a href="http://www.itai.com">The Institute of Transcendent Analysis International</a>
<li><a href="http://www.loop.com/~bkrentzman/">The Science of Obesity and Weight Control - B. Krentzman, MD</a>
<li><a href="http://www.isleuth.com/heal.html">The Internet Sleuth</a>
<li><a href="http://member.gnn.com/PeterC/medeng.htm">The Med Engine </a>
<li><a href="http://www.tracknet.com/hotlists/aug12.html">Tracknet - August 12th Hotlist</a>
<li><a href="http://www.io.com/~tradew/vet/drug.html">TW Medical Veterinary Division</a>
<li><a href="http://http://www.usit.net/public/rscarp/medical.htm">U.S. Internet - Medical Links</a>
<li><a href="http://www.volition.com/health.html">Volition Health Links</a>
<li><a href="http://www.wanet.com/">Wanet Internet Services</a>
<li><a href="http://www.wplwloo.org/">Waterloo Public Library</a>
<li><a href="http://www.gretmar.com/WebDoctorHome.html">WebDoctor - Internet Resources for Primary Care Physicians</a>
<li><a href="http://www.stayhealthy.com/index.html">Wellness Interactive Network</a>
<li><a href="http://www.weslaco.lib.tx.us/ENGINES.HTM">Weslaco Public Library</a>
<li><a href="http://www.ivf.com/womhtml.html">Women's Health - Atlanta Reproductive Health Center WWW</a>
<li><a href="http://www.women.com/web/otw/health.html">Women On the Web</a>
<li><a href="http://women.com/web/otw/health.html">Women's Wire - On the Web</a>
<li><a href="http://www.woodtech.com/explore.html">Woodtech Information Systems</a>
<li><a href="http://www.dreamscape.com/frankvad/reference-health.html">WWW Virtual Reference Sites</a>
<li><a href="http://www.physiol.ox.ac.uk/~xl/">Xuguang Liu - Oxford University Lab of Physiology</a>
<li><a href="http://www.xplore.com/xplore500/medium/reference.html">Xplore Reference</a>
<li><a href="http://indigo.ie/~comdiet/eyeathot.htm">Yeats Country Dietitians Office - Ireland</a>
<li><a href="http://www.yona.com/fitness/phenfen.shtml">Yona Health and Fitness Page</a>
<li><a href="http://www.ypn.com:80/">Your Personal Net</a>
<li><a href="http://www.pi.net/~neutel/home.html">Zeestraat Apotheek Homepage</a> 
<li><a href="http://www.zia.com">ZIA</a>
<hr>
<li><a href="http://altavista.digital.com">Alta Vista Digital</a>
<li><a href="http://www.excite.com">Excite</a>
<li><a href="http://www.infoseek.com">Infoseek</a>
<li><a href="http://lycos.cs.cmu.edu/">Lycos</a>
<li><a href="http://www.opentext.com:8080/omw/f-omw.html">Open Text</a>
<li><a href="http://www.pointcom.com">Point - Top 5% of the Web!</a>
<li><a href="http://webcrawler.com">Webcrawler</a>
<li><a href="http://www.wellweb.com/THYROID/OVERVIEW.HTM">Wellness Web</a>
<li><a href="http://www.yahoo.com/Health/Pharmacology/Drugs/">Yahoo:Health:Pharmacology:Drugs</a>
 <p>
<FORM method=GET action="http://altavista.digital.com/cgi-bin/query">           
<INPUT TYPE=hidden NAME=pg VALUE=q>
<B>Search <SELECT NAME=what>
<OPTION VALUE=web SELECTED>the Web
<OPTION VALUE=news>Usenet
</SELECT>
and Display the Results <SELECT NAME=fmt>
<OPTION VALUE="" SELECTED>in Standard Form
<OPTION VALUE=c>in Compact Form
<OPTION VALUE=d>in Detailed Form
</SELECT></B><BR>
<INPUT NAME=q size=55 maxlength=200 VALUE="+link:http://www.rxlist.com/
 -url:http://www.rxlist.com/">
<INPUT TYPE=submit VALUE=Submit>
</FORM>
<hr><hr><center>
<a href="http://www.rxlist.com">RETURN TO RXLIST</A><hr><hr><p>

<img src="mbox.gif" height=45 width=45><a
href="mailto:missing-links@rxlist.com"><h4>E-mail 'Missing Links' to </a><br>
 missing-links@rxlist.com </h4>
<pre>




</pre>
<h5>
copyright 1996 - Neil Sandow, Pharm.D.
</h5></center>
</body>        
</DOC>
<DOC>
<DOCNO>WT08-B10-2</DOCNO>
<DOCOLDNO>IA018-000200-B033-180</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/fluoxetine.htm 206.86.175.201 19970106223750 text/html 47795
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:31:34 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 47612
Last-modified: Thu, 11 Jul 1996 06:07:34 GMT
</DOCHDR>
<html>
<head>
   <title>Fluoxetine - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Fluoxetine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information! &nbsp;&nbsp;</b></p>

<p>
<hr width="100%" >
<a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>
<P></P>
<p>Fluoxetine is an antidepressant for oral administration; it is chemically
unrelated to tricyclic, tetracyclic, or other available antidepressant
agents. It is designated (+/-)-N-methyl-3-phenyl-3- ((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
hydrochloride and has the empirical formula of C17H18F3NO.HCl. Its molecular
weight is 345.79. </p>
<P></P>
<p>Fluoxetine hydrochloride is a white to off-white crystalline solid with
a solubility of 14 mg/mL in water. </p><P></P>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY</b>
</p>
<P></P>
<p>Pharmacodynamics--The antidepressant action of fluoxetine is presumed
to be linked to its inhibition of CNS neuronal uptake of serotonin. Studies
at clinically relevant doses in man have demonstrated that fluoxetine blocks
the uptake of serotonin into human platelets. Studies in animals also suggest
that fluoxetine is a much more potent uptake inhibitor of serotonin than
of norepinephrine. </p><P></P>

<p>Antagonism of muscarinic, histaminergic, and alpha1-adrenergic receptors
has been hypothesized to be associated with various anticholinergic, sedative,
and cardiovascular effects of classical tricyclic antidepressant drugs.
Fluoxetine binds to these and other membrane receptors from brain tissue
much less potently in vitro than do the tricyclic drugs. </p><P></P>

<p>Absorption, Distribution, Metabolism, And Excretion: </p>
<P></P>
<p>SYSTEMIC BIOAVAILABILITY--In man, following a single oral 40 mg dose,
peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed
after 6 to 8 hours. </p><P></P>

<p>The Capsule and oral solution dosage forms of fluoxetine are bioequivalent.
Food does not appear to affect the systemic bioavailability of fluoxetine,
although it may delay its absorption inconsequentially. Thus, fluoxetine
may be administered with or without food. </p>
<P></P>
<p>PROTEIN BINDING--Over the concentration range from 200 to 1,000 ng/mL,
approximately 94.5% of fluoxetine is bound in vitro to human serum proteins,
including albumin and alpha1-glycoprotein. The interaction between fluoxetine
and other highly protein-bound drugs has not been fully evaluated, but
may be important (See Precautions). </p>
<P></P>
<p>ENANTIOMERS--Fluoxetine is a racemic mixture (50/50) of R-fluoxetine
and S- fluoxetine enantiomers. In animal models, both enantiomers are specific
and potent serotonin uptake inhibitors with essentially equivalent pharmacologic
activity. The S-fluoxetine enantiomer is eliminated more slowly and is
the predominant enantiomer present in plasma at steady state. </p>
<P></P>
<p>METABOLISM--Fluoxetine is extensively metabolized in the liver to norfluoxetine
and a number of other, unidentified metabolites. The only identified active
metabolite, norfluoxetine, is formed by demethylation of fluoxetine. In
animal models, S-norfluoxetine is a potent and selective inhibitor of serotonin
uptake and has activity essentially equivalent to R- or S-fluoxetine. R-norfluoxetine
is significantly less potent than the parent drug in the inhibition of
serotonin uptake. The primary route of elimination appears to be hepatic
metabolism to inactive metabolites excreted by the kidney. </p><P></P>

<p>Clinical Issues Related To Metabolism/Elimination--The complexity of
the metabolism of fluoxetine has several consequences that may potentially
affect fluoxetine's clinical use. </p>
<P></P>
<p>VARIABILITY IN METABOLISM--A subset (3% to 10%) of the population has
reduced activity of certain drug metabolizing enzymes, such as the cytochrome
P450 isoenzyme PA450IID6. Such individuals are referred to as &quot;poor
metabolizers&quot; of drugs such as debrisoquin, dextromethorphan, and
the tricyclic antidepressants. In a study involving labeled and unlabeled
enantiomers administered as a racemate, these individuals metabolized S-fluoxetine
at a slower rate and thus achieved higher concentrations of S-fluoxetine.
Consequently, concentrations of S-norfluoxetine at steady state were lower.
The metabolism of R-fluoxetine in these poor metabolizers appears normal.
When compared with normal metabolizers, the total sum at steady state of
the plasma concentrations of the 4 active enantiomers was not significantly
greater among poor metabolizers. Thus, the net pharmacodynamic activities
were essentially the same. Alternative, nonsaturable pathways (non-IID6)
also contribute to the metabolism of fluoxetine. This explains how fluoxetine
achieves a steady-state concentration rather than increasing without limit.
</p>
<P></P>
<p>Because fluoxetine's metabolism, like that of a number of other compounds
including tricyclic and other selective serotonin antidepressants, involves
the P450IID6 system, concomitant therapy with drugs also metabolized by
this enzyme system (such as the tricyclic antidepressants) may lead to
drug interactions (See Drug Interactions Under Precautions). </p>
<P></P>
<p>ACCUMULATION AND SLOW ELIMINATION--The relatively slow elimination of
fluoxetine (elimination half-life of 1 to 3 days after acute administration
and 4 to 6 days after chronic administration) and its active metabolite,
norfluoxetine (elimination half-life of 4 to 16 days after acute and chronic
administration), assures significant accumulation of these active species
in chronic use. After 30 days of dosing at 40 mg/day, plasma concentrations
of fluoxetine in the range of 91 to 302 ng/mL and norfluoxetine in the
range of 72 to 258 ng/mL have been observed. Plasma concentrations of fluoxetine
were higher than those predicted by single-dose studies, presumably because
fluoxetine's metabolism is not proportional to dose. Norfluoxetine, however,
appears to have linear pharmacokinetics. Its mean terminal half-life after
a single dose was 8.6 days and after multiple dosing was 9.3 days. </p>
<P></P>
<p>Thus, even if patients are given a fixed dose, steady state plasma concentrations
are only achieved after continuous dosing for weeks. Nevertheless, plasma
concentrations do NOT appear to increase without limit. Specifically, patients
receiving fluoxetine at doses of 40 to 80 mg/day over periods as long as
3 years exhibited, on average, plasma concentrations similar to those seen
among patients treated for 4 or 5 weeks. </p>
<P></P>
<p>The long elimination half-lives of fluoxetine and norfluoxetine assure
that, even when dosing is stopped, active drug substance will persist in
the body for weeks (primarily depending on individual patient characteristics,
previous dosing regimen, and length of previous therapy at discontinuation).
This is of potential consequence when drug discontinuation is required
or when drugs are prescribed that might interact with fluoxetine and norfluoxetine
following the discontinuation of Fluoxetine. </p><P></P>

<p>LIVER DISEASE--As might be predicted from its primary site of metabolism,
liver impairment can affect the elimination of fluoxetine. The elimination
half-life of fluoxetine was prolonged in a study of cirrhotic patients,
with a mean of 7.6 days compared to the range of 2 to 3 days seen in subjects
without liver disease; norfluoxetine elimination was also delayed, with
a mean duration of 12 days for cirrhotic patients compared to the range
of 7 to 9 days in normal subjects. This suggests that the use of fluoxetine
in patients with liver disease must be approached with caution. If fluoxetine
is administered to patients with liver disease, a lower or less frequent
dose should be used (See Precautions And Dosage and Administration). </p>
<P></P>
<p>RENAL DISEASE--In single dose studies, the pharmacokinetics of fluoxetine
and norfluoxetine were similar among subjects with all levels of impaired
renal function including anephric patients on chronic hemodialysis. However,
with chronic administration, additional accumulation of fluoxetine or its
metabolites (possibly including some not yet identified) may occur in patients
with severely impaired renal function and use of a lower or less frequent
dose is advised (See Precautions). </p><P></P>

<p>AGE--The effects of age upon the metabolism of fluoxetine have not been
fully explored. The disposition of single doses of fluoxetine in healthy
elderly subjects (greater than 65 years of age) did not differ significantly
from that in younger normal subjects. However, given the long half-life
and nonlinear disposition of the drug, a single-dose study is not adequate
to rule out the possibility of altered pharmacokinetics in the elderly,
particularly if they have systemic illness or are receiving multiple drugs
for concomitant diseases. </p>
<P></P>
<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>
<P></P>
<p>Fluoxetine is indicated for the treatment of depression. The efficacy
of Fluoxetine was established in 5- and 6-week trials with depressed outpatients
whose diagnoses corresponded most closely to the DSM-III category of major
depressive disorder. </p><P></P>

<p>A major depressive episode implies a prominent and relatively persistent
depressed or dysphoric mood that usually interferes with daily functioning
(nearly every day for at least 2 weeks); it should include at least 4 of
the following 8 symptoms: change in appetite, change in sleep, psychomotor
agitation or retardation, loss of interest in usual activities or decrease
in sexual drive, increased fatigue, feelings of guilt or worthlessness,
slowed thinking or impaired concentration, and a suicide attempt or suicidal
ideation. </p>
<P></P>
<p>The antidepressant action of Fluoxetine in hospitalized depressed patients
has not been adequately studied. </p><P></P>

<p>The effectiveness of Fluoxetine in long-term use, that is, for more
than 5 to 6 weeks, has not been systematically evaluated in controlled
trials. Therefore, the physician who elects to use Fluoxetine for extended
periods should periodically reevaluate the long-term usefulness of the
drug for the individual patient. </p>
<P></P>
<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>
<P></P>
<p>Fluoxetine is contraindicated in patients known to be hypersensitive
to it. </p><P></P>

<p>Monoamine Oxidase Inhibitors--There have been reports of serious, sometimes
fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic
instability with possible rapid fluctuations of vital signs, and mental
status changes that include extreme agitation progressing to delirium and
coma) in patients receiving fluoxetine in combination with a monoamine
oxidase inhibitor (MAOI), and in patients who have recently discontinued
fluoxetine and are then started on an MAOI. Some cases presented with features
resembling neuroleptic malignant syndrome. Therefore, Fluoxetine should
not be used in combination with an MAOI, or within 14 days of discontinuing
therapy with an MAOI. Since fluoxetine and its major metabolite have very
long elimination half-lives, at least 5 weeks (perhaps longer, especially
if fluoxetine has been prescribed chronically and/or at higher doses (See
Accumulation and Slow Elimination Under Clinical Pharmacology)) should
be allowed after stopping Fluoxetine before starting an MAOI. </p>
<P></P>
<p><a name="WARNINGS"></a><b>WARNINGS </b></p>
<P></P>
<p>Rash And Possibly Allergic Events--During premarketing testing of more
than 5 600 US patients given fluoxetine, approximately 4% developed a rash
and/or urticaria. Among these cases, almost a third were withdrawn from
treatment because of the rash and/or systemic signs or symptoms associated
with the rash. Clinical findings reported in association with rash include
fever, leukocytosis, arthralgias, edema, carpal tunnel syndrome, respiratory
distress, lymphadenopathy, proteinuria, and mild transaminase elevation.
Most patients improved promptly with discontinuation of fluoxetine and/or
adjunctive treatment with antihistamines or steroids, and all patients
experiencing these events were reported to recover completely. </p>
<P></P>
<p>In premarketing clinical trials, 2 patients are known to have developed
a serious cutaneous systemic illness. In neither patient was there an unequivocal
diagnosis, but 1 was considered to have a leukocytoclastic vasculitis,
and the other, a severe desquamating syndrome that was considered variously
to be a vasculitis or erythema multiforme. Other patients have had systemic
syndromes suggestive of serum sickness. </p><P></P>

<p>Since the introduction of Fluoxetine, systemic events, possibly related
to vasculitis, have developed in patients with rash. Although these events
are rare, they may be serious, involving the lung, kidney, or liver. Death
has been reported to occur in association with these systemic events. </p>
<P></P>
<p>Anaphylactoid events, including bronchospasm, angioedema, and urticaria
alone and in combination, have been reported. </p><P></P>

<p>Pulmonary events, including inflammatory processes of varying histopathology
and/or fibrosis, have been reported rarely. These events have occurred
with dyspnea as the only preceding symptom. </p><P></P>

<p>Whether these systemic events and rash have a common underlying cause
or are due to different etiologies or pathogenic processes is not known.
Furthermore, a specific underlying immunologic basis for these events has
not been identified. Upon the appearance of rash or of other possibly allergic
phenomena for which an alternative etiology cannot be identified, Fluoxetine
should be discontinued. </p>
<P></P>
<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS</b> </p>
<P></P>
<p>General--ANXIETY AND INSOMNIA--Anxiety, nervousness, and insomnia were
reported by 10% to 15% of patients treated with Fluoxetine. These symptoms
led to drug discontinuation in 5% of patients treated with Fluoxetine.
</p>
<P></P>
<p>ALTERED APPETITE AND WEIGHT--Significant weight loss, especially in
underweight depressed patients, may be an undesirable result of treatment
with Fluoxetine. </p><P></P>

<p>In controlled clinical trials, approximately 9% of patients treated
with Fluoxetine experienced anorexia. This incidence is approximately sixfold
that seen in placebo controls. A weight loss of greater than 5% of body
weight occurred in 13% of patients treated with Fluoxetine compared to
4% of placebo and 3% of patients treated with tricyclics. However, only
rarely have patients discontinued treatment with Fluoxetine because of
weight loss. </p><P></P>

<p>ACTIVATION OF MANIA/HYPOMANIA--During premarketing testing, hypomania
or mania occurred in approximately 1% of fluoxetine treated patients. Activation
of mania/hypomania has also been reported in a small proportion of patients
with Major Affective Disorder treated with other marketed antidepressants.
</p><P></P>

<p>SEIZURES--Twelve patients among more than 6,000 evaluated worldwide
in the course of premarketing development of fluoxetine experienced convulsions
(or events described as possibly having been seizures), a rate of 0.2%
that appears to be similar to that associated with other marketed antidepressants.
Fluoxetine should be introduced with care in patients with a history of
seizures. </p>
<P></P>
<p>SUICIDE--The possibility of a suicide attempt is inherent in depression
and may persist until significant remission occurs. Close supervision of
high risk patients should accompany initial drug therapy. Prescriptions
for Fluoxetine should be written for the smallest quantity of capsules
consistent with good patient management, in order to reduce the risk of
overdose. </p>
<P></P>
<p>THE LONG ELIMINATION HALF-LIVES OF FLUOXETINE AND ITS METABOLITES--Because
of the long elimination half-lives of the parent drug and its major active
metabolite, changes in dose will not be fully reflected in plasma for several
weeks, affecting both strategies for titration to final dose and withdrawal
from treatment (See Clinical Pharmacology And Dosage and Administration).
</p>
<P></P>
<p>USE IN PATIENTS WITH CONCOMITANT ILLNESS--Clinical experience with Fluoxetine
(Fluoxetine Hydrochloride) in patients with concomitant systemic illness
is limited. Caution is advisable in using Fluoxetine in patients with diseases
or conditions that could affect metabolism or hemodynamic responses. </p>
<P></P>
<p>Fluoxetine has NOT been evaluated or used to any appreciable extent
in patients with a recent history of myocardial infarction or unstable
heart disease. Patients with these diagnoses were systematically excluded
from clinical studies during the product's premarket testing. However,
the electrocardiograms of 312 patients who received Fluoxetine in double-blind
trials were retrospectively evaluated; no conduction abnormalities that
resulted in heart block were observed. The mean heart rate was reduced
by approximately 3 beats/min. </p><P></P>

<p>In subjects with cirrhosis of the liver, the clearances of fluoxetine
and its active metabolite, norfluoxetine, were decreased, thus increasing
the elimination half-lives of these substances. A lower or less frequent
dose should be used in patients with cirrhosis. </p>
<P></P>
<p>Since fluoxetine is extensively metabolized, excretion of unchanged
drug in urine is a minor route of elimination. However, until adequate
numbers of patients with severe renal impairment have been evaluated during
chronic treatment with fluoxetine, it should be used with caution in such
patients. </p><P></P>

<p>In patients with diabetes, Fluoxetine may alter glycemic control. Hypoglycemia
has occurred during therapy with Fluoxetine, and hyperglycemia has developed
following discontinuation of the drug. As is true with many other types
of medication when taken concurrently by patients with diabetes, insulin
and/or oral hypoglycemic dosage may need to be adjusted when therapy with
Fluoxetine is instituted or discontinued. </p><P></P>

<p>INTERFERENCE WITH COGNITIVE AND MOTOR PERFORMANCE--Any psychoactive
drug may impair judgment, thinking, or motor skills, and patients should
be cautioned about operating hazardous machinery, including automobiles,
until they are reasonably certain that the drug treatment does not affect
them adversely. Information For Patients--Physicians are advised to discuss
the following issues with patients for whom they prescribe Fluoxetine:
</p><P></P>

<p>Because Fluoxetine may impair judgment, thinking, or motor skills, patients
should be advised to avoid driving a car or operating hazardous machinery
until they are reasonably certain that their performance is not affected.
</p>
<P></P>
<p>Patients should be advised to inform their physician if they are taking
or plan to take any prescription or over-the-counter drugs, or alcohol.
</p><P></P>

<p>Patients should be advised to notify their physician if they become
pregnant or intend to become pregnant during therapy. </p>
<P></P>
<p>Patients should be advised to notify their physician if they are breast
feeding an infant. </p>
<P></P>
<p>Patients should be advised to notify their physician if they develop
a rash or hives. </p><P></P>

<p>Laboratory Tests--There are no specific laboratory tests recommended.
</p><P></P>

<p>Drug Interactions--As with all drugs, the potential for interaction
by a variety of mechanisms (eg, pharmacodynamic, pharmacokinetic drug inhibition
or enhancement, etc) is a possibility (See Accumulation and Slow Elimination
Under Clinical Pharmacology). </p><P></P>

<p>DRUGS METABOLIZED BY P450IID6--Approximately 3% to 10% of the normal
population has a genetic defect that leads to reduced levels of activity
of the cytochrome P450 isoenzyme P450IID6. Such individuals have been referred
to as &quot;poor metabolizers&quot; of drugs such as debrisoquin, dextromethorphan,
and tricyclic antidepressants. Many drugs, such as most antidepressants
including fluoxetine and other selective uptake inhibitors of serotonin,
are metabolized by this isoenzyme; thus, both the pharmacokinetic properties
and relative proportion of metabolites are altered in poor metabolizers.
However, for fluoxetine and its metabolite the sum of the plasma concentrations
of the 4 active enantiomers is comparable between poor and extensive metabolizers
(See Variability in Metabolism Under Clinical Pharmacology). </p>
<P></P>
<p>Fluoxetine, like other agents that are metabolized by P450IID6, inhibits
the activity of this isoenzyme, and thus may make normal metabolizers resemble
&quot;poor metabolizers.&quot; Therapy with medications that are predominantly
metabolized by the P450IID6 system and that have a relatively narrow therapeutic
index (see list below), should be initiated at the low end of the dose
range if a patient is receiving fluoxetine concurrently or have taken it
in the previous 5 weeks. Thus, his/her dosing requirements resemble standard
dosing practice used in 3% to 10% of the population designated as &quot;poor
metabolizers.&quot; Alternately, the addition of fluoxetine to the treatment
regimen of a patient already receiving a drug metabolized by P450IID6 raises
the possibility of the need for decreased dose of the original medication.
Drugs with a narrow therapeutic index represent the greatest concern (eg,
flecainide, encainide, vinblastine, carbamazepine, and tricyclic antidepressants).
TRYPTOPHAN--Five patients receiving Fluoxetine in combination with tryptophan
experienced adverse reactions, including agitation, restlessness, and gastrointestinal
distress. </p><P></P>

<p>MONOAMINE OXIDASE INHIBITORS--See Contraindications. </p>
<P></P>
<p>OTHER ANTIDEPRESSANTS--There have been greater than 2-fold increases
of previously stable plasma levels of other antidepressants when Fluoxetine
has been administered in combination with these agents (See Accumulation
and Slow Elimination Under Clinical Pharmacology). </p><P></P>

<p>LITHIUM--There have been reports of both increased and decreased lithium
levels when lithium was used concomitantly with fluoxetine. Cases of lithium
toxicity have been reported. Lithium levels should be monitored when these
drugs are administered concomitantly. </p><P></P>

<p>DIAZEPAM CLEARANCE--The half-life of concurrently administered diazepam
may be prolonged in some patients (See Accumulation and Slow Elimination
Under Clinical Pharmacology). </p>
<P></P>
<p>POTENTIAL EFFECTS OF COADMINISTRATION OF DRUGS TIGHTLY BOUND TO PLASMA
PROTEINS </p><P></P>

<p>Because fluoxetine is tightly bound to plasma protein, the administration
of fluoxetine to a patient taking another drug that is tightly bound to
protein (eg, Coumadin, digitoxin) may cause a shift in plasma concentrations
potentially resulting in an adverse effect. Conversely, adverse effects
may result from displacement of protein bound fluoxetine by other tightly
bound drugs (See Accumulation and Slow Elimination Under Clinical Pharmacology).
</p><P></P>

<p>CNS ACTIVE DRUGS--The risk of using Fluoxetine in combination with other
CNS active drugs has not been systematically evaluated. Consequently, caution
is advised if the concomitant administration of Fluoxetine and such drugs
is required (See Accumulation and Slow Elimination Under Clinical Pharmacology).
</p><P></P>

<p>ELECTROCONVULSIVE THERAPY--There are no clinical studies establishing
the benefit of the combined use of ECT and fluoxetine. There have been
rare reports of prolonged seizures in patients on fluoxetine receiving
ECT treatment. </p>
<P></P>
<p>Carcinogenesis, Mutagenesis, Impairment Of Fertility--There is no evidence
of carcinogenicity, mutagenicity, or impairment of fertility with Fluoxetine.
</p><P></P>

<p>The dietary administration of fluoxetine to rats and mice for 2 years
at levels equivalent to approximately 7.5 and 9.0 times the maximum human
dose (80 mg) respectively produced no evidence of carcinogenicity. </p>
<P></P>
<p>Fluoxetine and norfluoxetine have been shown to have no genotoxic effects
based on the following assays: bacterial mutation assay, DNA repair assay
in cultured rat hepatocytes, mouse lymphoma assay, and in vivo sister chromatid
exchange assay in Chinese hamster bone marrow cells. </p>
<P></P>
<p>Two fertility studies conducted in rats at doses of approximately 5
and 9 times the maximum human dose (80 mg) indicated that fluoxetine had
no adverse effects on fertility. A slight decrease in neonatal survival
was noted, but this was probably associated with depressed maternal food
consumption and suppressed weight gain. </p><P></P>

<p>Pregnancy--TERATOGENIC EFFECTS--PREGNANCY CATEGORY B: Reproduction studies
have been performed in rats and rabbits at doses 9 and 11 times the maximum
daily human dose (80 mg) respectively and have revealed no evidence of
harm to the fetus due to Fluoxetine. There are, however, no adequate and
well-controlled studies in pregnant women. Because animal reproduction
studies are not always predictive of human response, this drug should be
used during pregnancy only if clearly needed. </p>
<P></P>
<p>Labor And Delivery--The effect of Fluoxetine on labor and delivery in
humans is unknown. </p>
<P></P>
<p>Nursing Mothers--Because many drugs are excreted in human milk, caution
should be exercised when Fluoxetine is administered to a nursing woman.
In 1 breast milk sample, the concentration of fluoxetine plus norfluoxetine
was 70.4 ng/mL. The concentration in the mother's plasma was 295.0 ng/mL.
No adverse effects on the infant were reported. </p>
<P></P>
<p>Usage In Children--Safety and effectiveness in children have not been
established. </p>
<P></P>
<p>Usage In The Elderly--Fluoxetine has not been systematically evaluated
in older patients; however, several hundred elderly patients have participated
in clinical studies with Fluoxetine and no unusual adverse age-related
phenomena have been identified. However, these data are insufficient to
rule out possible age-related differences during chronic use, particularly
in elderly patients who have concomitant systemic illnesses or who are
receiving concomitant drugs. </p><P></P>

<p>Hyponatremia--Several cases of hyponatremia (some with serum sodium
lower than 110 mmol/L) have been reported. The hyponatremia appeared to
be reversible when Fluoxetine was discontinued. Although these cases were
complex with varying possible etiologies, some were possibly due to the
syndrome of inappropriate antidiuretic hormone secretion (SIADH). The majority
of these occurrences have been in older patients and in patients taking
diuretics or who were otherwise volume depleted. </p><P></P>

<p>Platelet Function--There have been rare reports of altered platelet
function and/or abnormal results from laboratory studies in patients taking
fluoxetine. </p><P></P>

<p>While there have been reports of abnormal bleeding in several patients
taking fluoxetine, it is unclear whether fluoxetine had a causative role.
</p><P></P>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>
<P></P>
<p>As with all drugs, the potential for interaction by a variety of mechanisms
(eg pharmacodynamic, pharmacokinetic drug inhibition or enhancement, etc)
is a possibility (See Accumulation and Slow Elimination Under Clinical
Pharmacology). </p>
<P></P>
<p>DRUGS METABOLIZED BY P450IID6--Approximately 3% to 10% of the normal
population has a genetic defect that leads to reduced levels of activity
of the cytochrome P450 isoenzyme P450IID6. Such individuals have been referred
to as &quot;poor metabolizers&quot; of drugs such as debrisoquin, dextromethorphan,
and tricyclic antidepressants. Many drugs, such as most antidepressants
including fluoxetine and other selective uptake inhibitors of serotonin,
are metabolized by this isoenzyme; thus, both the pharmacokinetic properties
and relative proportion of metabolites are altered in poor metabolizers.
However, for fluoxetine and its metabolite the sum of the plasma concentrations
of the 4 active enantiomers is comparable between poor and extensive metabolizers
(See Variability in Metabolism Under Clinical Pharmacology). </p><P></P>

<p>Fluoxetine, like other agents that are metabolized by P450IID6, inhibits
the activity of this isoenzyme, and thus may make normal metabolizers resemble
&quot;poor metabolizers.&quot; Therapy with medications that are predominantly
metabolized by the P450IID6 system and that have a relatively narrow therapeutic
index (see list below), should be initiated at the low end of the dose
range if a patient is receiving fluoxetine concurrently or have taken it
in the previous 5 weeks. Thus, his/her dosing requirements resemble standard
dosing practice used in 3% to 10% of the population designated as &quot;poor
metabolizers.&quot; Alternately, the addition of fluoxetine to the treatment
regimen of a patient already receiving a drug metabolized by P450IID6 raises
the possibility of the need for decreased dose of the original medication.
Drugs with a narrow therapeutic index represent the greatest concern (eg,
flecainide, encainide, vinblastine, carbamazepine, and tricyclic antidepressants).
</p>
<P></P>
<p>TRYPTOPHAN--Five patients receiving Fluoxetine in combination with tryptophan
experienced adverse reactions, including agitation, restlessness, and gastrointestinal
distress. </p><P></P>

<p>MONOAMINE OXIDASE INHIBITORS--See Contraindications. </p>
<P></P>
<p>OTHER ANTIDEPRESSANTS--There have been greater than 2-fold increases
of previously stable plasma levels of other antidepressants when Fluoxetine
has been administered in combination with these agents (See Accumulation
and Slow Elimination Under Clinical Pharmacology). </p>
<P></P>
<p>LITHIUM--There have been reports of both increased and decreased lithium
levels when lithium was used concomitantly with fluoxetine. Cases of lithium
toxicity have been reported. Lithium levels should be monitored when these
drugs are administered concomitantly. </p><P></P>

<p>DIAZEPAM CLEARANCE--The half-life of concurrently administered diazepam
may be prolonged in some patients (See Accumulation and Slow Elimination
Under Clinical Pharmacology). </p><P></P>

<p>POTENTIAL EFFECTS OF COADMINISTRATION OF DRUGS TIGHTLY BOUND TO PLASMA
PROTEINS </p>
<P></P>
<p>Because fluoxetine is tightly bound to plasma protein, the administration
of fluoxetine to a patient taking another drug that is tightly bound to
protein (eg, Coumadin, digitoxin) may cause a shift in plasma concentrations,
potentially resulting in an adverse effect. Conversely, adverse effects
may result from displacement of protein bound fluoxetine by other tightly
bound drugs (See Accumulation and Slow Elimination Under Clinical Pharmacology).
</p><P></P>

<p>CNS ACTIVE DRUGS--The risk of using Fluoxetine in combination with other
CNS active drugs has not been systematically evaluated. Consequently, caution
is advised if the concomitant administration of Fluoxetine and such drugs
is required (See Accumulation and Slow Elimination Under Clinical Pharmacology).
</p><P></P>

<p>ELECTROCONVULSIVE THERAPY--There are no clinical studies establishing
the benefit of the combined use of ECT and fluoxetine. There have been
rare reports of prolonged seizures in patients on fluoxetine receiving
ECT treatment. </p>
<P></P>
<p>(See Also PRECAUTIONS) </p>
<P></P>
<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>
<P></P>
<p>Commonly Observed--The most commonly observed adverse events associated
with the use of Fluoxetine and not seen at an equivalent incidence among
placebo-treated patients were: nervous system complaints, including anxiety,
nervousness, and insomnia; drowsiness and fatigue or asthenia; tremor;
sweating; gastrointestinal complaints, including anorexia, nausea, and
diarrhea; and dizziness or lightheadedness. </p><P></P>

<p>Associated With Discontinuation Of Treatment--Fifteen percent of approximately
4,000 patients who received Fluoxetine in US premarketing clinical trials
discontinued treatment due to an adverse event. The more common events
causing discontinuation included: psychiatric (5.3%), primarily nervousness,
anxiety, and insomnia; digestive (3.0%), primarily nausea; nervous system
(1.6%), primarily dizziness; body as a whole (1.5%), primarily asthenia
and headache; and skin (1.4%), primarily rash and pruritus. </p><P></P>

<p>Other Events Observed During Premarketing Evaluation Of Fluoxetine (Fluoxetine
Hydrochloride)--During clinical testing in the US, multiple doses of Fluoxetine
were administered to approximately 5,600 subjects. Untoward events associated
with this exposure were recorded by clinical investigators using descriptive
terminology of their own choosing. Consequently, it is not possible to
provide a meaningful estimate of the proportion of individuals experiencing
adverse events without first grouping similar types of untoward events
into a limited (ie, reduced) number of standardized event categories. </p>
<P></P>
<p>In the tabulations that follow, a standard COSTART Dictionary terminology
has been used to classify reported adverse events. The frequencies presented,
therefore, represent the proportion of the 5,600 individuals exposed to
Fluoxetine who experienced an event of the type cited on at least 1 occasion
while receiving Fluoxetine. COSTART terms are so general as to be uninformative,
and those events where a drug cause was remote. It is important to emphasize
that, although the events reported did occur during treatment with Fluoxetine,
they were not necessarily caused by it. </p><P></P>

<p>Events are further classified within body system categories and enumerated
in order of decreasing frequency using the following definitions: frequent
adverse events are defined as those occurring on 1 or more occasions in
at least 1/100 patients; infrequent adverse events are those occurring
in 1/100 to 1/1,000 patients; rare events are those occurring in less than
1/1,000 patients. </p><P></P>

<p>BODY AS A WHOLE--Frequent: chills; Infrequent: chills and fever, cyst,
face edema, hangover effect, jaw pain, malaise, neck pain, neck rigidity,
and pelvic pain; Rare: abdomen enlarged, cellulitis, hydrocephalus, hypothermia,
LE syndrome, moniliasis, and serum sickness. </p><P></P>

<p>CARDIOVASCULAR SYSTEM--Infrequent: angina pectoris, arrhythmia, hemorrhage,
hypertension, hypotension, migraine, postural hypotension, syncope, and
tachycardia; Rare: AV block first degree, bradycardia, bundle branch block,
cerebral ischemia, myocardial infarct, thrombophlebitis, vascular headache,
and ventricular arrhythmia. </p>
<P></P>
<p>DIGESTIVE SYSTEM--Frequent: increased appetite; Infrequent: aphthous
stomatitis, dysphagia, eructation, esophagitis, gastritis, gingivitis,
glossitis, liver function tests abnormal, melena, stomatitis, thirst; Rare:
bloody diarrhea, cholecystitis, cholelithiasis, colitis, duodenal ulcer,
enteritis, fecal incontinence, hematemesis, hepatitis, hepatomegaly, hyperchlorhydria,
increased salivation, jaundice, liver tenderness, mouth ulceration, salivary
gland enlargement, stomach ulcer, tongue discoloration, and tongue edema.
</p><P></P>

<p>ENDOCRINE SYSTEM--Infrequent: hypothyroidism; Rare: goiter and hyperthyroidism.
</p>
<P></P>
<p>HEMIC AND LYMPHATIC SYSTEM--Infrequent: anemia and lymphadenopathy;
Rare: bleeding time increased, blood dyscrasia, leukopenia, lymphocytosis,
petechia, purpura, sedimentation rate increased, and thrombocythemia. </p>
<P></P>
<p>METABOLIC AND NUTRITIONAL--Frequent: weight loss; Infrequent: generalized
edema, hypoglycemia, peripheral edema, and weight gain; Rare: dehydration,
gout hypercholesteremia, hyperglycemia, hyperlipemia, hypoglycemic reaction,
hypokalemia, hyponatremia, and iron deficiency anemia. </p>
<P></P>
<p>MUSCULOSKELETAL SYSTEM--Infrequent: arthritis, bone pain, bursitis,
tenosynovitis, and twitching; Rare: bone necrosis, chondrodystrophy, muscle
hemorrhage, myositis, osteoporosis, pathological fracture, and rheumatoid
arthritis. </p>
<P></P>
<p>NERVOUS SYSTEM--Frequent: abnormal dreams and agitation; Infrequent:
abnormal gait, acute brain syndrome, akathisia, amnesia, apathy, ataxia,
buccoglossal syndrome, CNS stimulation, convulsion, delusions, depersonalization,
emotional lability, euphoria, hallucinations, hostility, hyperkinesia,
hypesthesia, incoordination, libido increased, manic reaction, neuralgia,
neuropathy, paranoid reaction, psychosis, and vertigo; Rare: abnormal electroencephalogram,
antisocial reaction, chronic brain syndrome, circumoral paresthesia, CNS
depression, coma, dysarthria, dystonia, extrapyramidal syndrome, hypertonia,
hysteria, myoclonus, nystagmus, paralysis, reflexes decreased, stupor,
and torticollis. </p><P></P>

<p>RESPIRATORY SYSTEM--Frequent: bronchitis, rhinitis, and yawn; Infrequent:
asthma, epistaxis, hiccup, hyperventilation, and pneumonia; Rare: apnea,
hemoptysis, hypoxia, larynx edema, lung edema, lung fibrosis/alveolitis,
and pleural effusion. </p><P></P>

<p>SKIN AND APPENDAGES--Infrequent: acne, alopecia, contact dermatitis,
dry skin, herpes simplex, maculopapular rash, and urticaria; Rare: eczema,
erythema multiforme, fungal dermatitis, herpes zoster, hirsutism, psoriasis,
purpuric rash, pustular rash, seborrhea, skin discoloration, skin hypertrophy,
subcutaneous nodule, and vesiculobullous rash. </p><P></P>

<p>SPECIAL SENSES--Infrequent: amblyopia, conjunctivitis, ear pain, eye
pain, mydriasis, photophobia, and tinnitus; Rare: blepharitis, cataract,
corneal lesion, deafness, diplopia, eye hemorrhage, glaucoma, iritis, ptosis,
strabismus, and taste loss. </p><P></P>

<p>UROGENITAL SYSTEM--Infrequent: abnormal ejaculation, amenorrhea, breast
pain, cystitis, dysuria, fibrocystic breast, impotence, leukorrhea, menopause,
menorrhagia, ovarian disorder, urinary incontinence, urinary retention,
urinary urgency, urination impaired, and vaginitis; Rare: abortion, albuminuria,
breast enlargement, dyspareunia, epididymitis, female lactation, hematuria,
hypomenorrhea, kidney calculus, metrorrhagia, orchitis, polyuria, pyelonephritis,
pyuria, salpingitis, urethral pain, urethritis, urinary tract disorder,
urolithiasis, uterine hemorrhage, uterine spasm, and vaginal hemorrhage.
</p>
<P></P>
<p>Postintroduction Reports--Voluntary reports of adverse events temporally
associated with Fluoxetine that have been received since market introduction
and which may have no causal relationship with the drug include the following:
</p>
<P></P>
<p>Aplastic anemia, cerebral vascular accident, confusion, dyskinesia (including,
for example, a case of buccal-lingual-masticatory syndrome with involuntary
tongue protrusion reported to develop in a 77-year-old female after 5 weeks
of fluoxetine therapy and which completely resolved over the next few months
following drug discontinuation), ecchymoses, eosinophilic pneumonia, gastrointestinal
hemorrhage, hyperprolactinemia, immune-related hemolytic anemia, movement
disorders developing in patients with risk factors including drugs associated
with such events and worsening of preexisting movement disorders, neuroleptic
malignant syndrome-like events, pancreatitis, pancytopenia, suicidal ideation,
thrombocytopenia, thrombocytopenic purpura, vaginal bleeding after drug
withdrawal, and violent behaviors. </p><P></P>

<p>DRUG ABUSE AND DEPENDENCE </p>
<P></P>
<p>Controlled Substance Class--Fluoxetine is not a controlled substance.
Physical And Psychologic Dependence--Fluoxetine has not been systematically
studied in animals or humans, for its potential for abuse, tolerance, or
physical dependence. While the premarketing clinical experience with Fluoxetine
did not reveal any tendency for a withdrawal syndrome or any drug seeking
behavior, these observations were not systematic and it is not possible
to predict on the basis of this limited experience the extent to which
a CNS active drug will be misused, diverted, and/or abused once marketed.
Consequently, physicians should carefully evaluate patients for history
of drug abuse and follow such patients closely, observing them for signs
of misuse or abuse of Fluoxetine (eg, development of tolerance, incrementation
of dose, drug-seeking behavior). </p>
<P></P>
<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>
<P></P>
<p>Human Experience--As of December 1987, there were 2 deaths among approximately
38 reports of acute overdose with fluoxetine, either alone or in combination
with other drugs and/or alcohol. One death involved a combined overdose
with approximately 1,800 mg of fluoxetine and an undetermined amount of
maprotiline. Plasma concentrations of fluoxetine and maprotiline were 4.57
mg/L and 4.18 mg/L, respectively. A second death involved 3 drugs yielding
plasma concentrations as follows: fluoxetine, 1.93 mg/L; norfluoxetine,
1.10 mg/L; codeine, 1.80 mg/L; temazepam, 3.80 mg/L. </p>
<P></P>
<p>One other patient who reportedly took 3,000 mg of fluoxetine experienced
2 grand mal seizures that remitted spontaneously without specific anticonvulsant
treatment (See Management of Overdose). The actual amount of drug absorbed
may have been less due to vomiting. </p><P></P>

<p>Nausea and vomiting were prominent in overdoses involving higher fluoxetine
doses. Other prominent symptoms of overdose included agitation, restlessness,
hypomania, and other signs of CNS excitation. Except for the 2 deaths noted
above, all other overdose cases recovered without residua. </p>
<P></P>
<p>Since introduction, reports of death attributed to overdosage of fluoxetine
alone have been extremely rare. </p><P></P>

<p>Animal Experience--Studies in animals do not provide precise or necessarily
valid information about the treatment of human overdose. However, animal
experiments can provide useful insights into possible treatment strategies.
The oral median lethal dose in rats and mice was found to be 452 and 248
mg/kg respectively. Acute high oral doses produced hyperirritability and
convulsions in several animal species. </p><P></P>

<p>Among 6 dogs purposely overdosed with oral fluoxetine, 5 experienced
grand mal seizures. Seizures stopped immediately upon the bolus intravenous
administration of a standard veterinary dose of diazepam. In this short
term study, the lowest plasma concentration at which a seizure occurred
was only twice the maximum plasma concentration seen in humans taking 80
mg/day, chronically. </p>
<P></P>
<p>In a separate single-dose study, the ECG in dogs given high doses did
not reveal prolongation of the PR, QRS, or QT intervals. Tachycardia and
an increase in blood pressure were observed. Consequently, the value of
the ECG in predicting cardiac toxicity is unknown. Nonetheless, the ECG
should ordinarily be monitored in cases of human overdose (See Management
of Overdose). </p><P></P>

<p>Management Of Overdose--Establish and maintain an airway; ensure adequate
oxygenation and ventilation. Activated charcoal, which may be used with
sorbitol, may be as or more effective than emesis or lavage, and should
be considered in treating overdose. </p><P></P>

<p>Cardiac and vital signs monitoring is recommended, along with general
symptomatic and supportive measures. Based on experience in animals, which
may not be relevant to humans, fluoxetine-induced seizures that fail to
remit spontaneously may respond to diazepam. </p><P></P>

<p>There are no specific antidotes for Fluoxetine. </p>
<P></P>
<p>Due to the large volume of distribution of Fluoxetine, forced diuresis,
dialysis, hemoperfusion, and exchange transfusion are unlikely to be of
benefit. </p>
<P></P>
<p>In managing overdosage, consider the possibility of multiple drug involvement.
A specific caution involves patients taking or recently having taken fluoxetine
who might ingest by accident or intent, excessive quantities of a tricyclic
antidepressant. In such a case, accumulation of the parent tricyclic and
an active metabolite may increase the possibility of clinically significant
sequelae and extend the time needed for close medical observation (See
Other Antidepressants Under Precautions). </p><P></P>

<p>The physician should consider contacting a poison control center on
the treatment of any overdose. </p><P></P>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>
<P></P>
<p>Initial Treatment--In controlled trials used to support the efficacy
of fluoxetine, patients were administered morning doses ranging from 20
mg to 80 mg/day. Recent studies suggest that 20 mg/day may be sufficient
to obtain a satisfactory antidepressant response. Consequently, a dose
of 20 mg/day, administered in the morning, is recommended as the initial
dose. </p><P></P>

<p>A dose increase may be considered after several weeks if no clinical
improvement is observed. Doses above 20 mg/day should be administered on
a b.i.d. schedule (ie, morning and noon) and should not exceed a maximum
dose of 80 mg/day. </p><P></P>

<p>As with other antidepressants, the full antidepressant effect may be
delayed until 4 weeks of treatment or longer. </p><P></P>

<p>As with many other medications, a lower or less frequent dosage should
be used in patients with renal and/or hepatic impairment. A lower or less
frequent dosage should also be considered for patients, such as the elderly,
with concurrent disease or on multiple medications. </p>
<P></P>
<p>Maintenance/Continuation/Extended Treatment--There is no body of evidence
available to answer the question of how long the patient treated with fluoxetine
should remain on it. It is generally agreed among expert psychopharmacologists
(circa 1987) that acute episodes of depression require several months or
longer of sustained pharmacologic therapy. Whether the dose of antidepressant
needed to induce remission is identical to the dose needed to maintain
and/or sustain euthymia is unknown. </p>
<P></P>
<p>ANIMAL TOXICOLOGY: Phospholipids are increased in some tissues of mice,
rats, and dogs given fluoxetine chronically. This effect is reversible
after cessation of fluoxetine treatment. Phospholipid accumulation in animals
has been observed with many cationic amphiphilic drugs, including fenfluramine,
imipramine, and ranitidine. The significance of this effect in humans is
unknown. </p><P></P>

<p>
<hr></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-3</DOCNO>
<DOCOLDNO>IA018-000200-B033-77</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/top200a.htm 206.86.175.201 19970106223541 text/html 31965
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:29:26 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 31782
Last-modified: Mon, 28 Oct 1996 23:28:43 GMT
</DOCHDR>
<html>
<head>
   <title>The Top 200 Presciptions - RxListindications pharmacology precautions warnings side effectsadverse reactions drug interactions toxicity overdose dosing dose administration references patient informationcontraindications sex</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<h2><a href="http://www.rxlist.com"><img src="rx.gif" border=0 height=75 width=75></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Top 200 Prescriptions*&nbsp;Alpha/<a href="http://www.rxlist.com/top200.htm">Ranked</a>
</h2>

<pre><b>Brand Name               Manufacturer              Generic Name
<hr width="100%" >Accupril                 Parke-Davis               <a href="http://www.rxlist.com/cgi/generic/quinap.htm">Quinapril
</a>Accutane +               Roche                     <a href="http://www.rxlist.com/cgi/generic/isotret.htm">Isotretinoin
</a>Acetaminophen/Codeine    Lemmon                    <a href="http://www.rxlist.com/cgi/generic/acetcod.htm">Acetaminophen/Codeine
</a>Acetaminophen/Codeine    Purepac                   <a href="http://www.rxlist.com/cgi/generic/acetcod.htm">Acetaminophen/Codeine
</a>Adalat CC                Bayer                     <a href="http://www.rxlist.com/cgi/generic/nifedxl.htm">Nifedipine
</a>Adderall +               Richwood                  <a href="http://www.rxlist.com/cgi/generic/amphet.htm">Mixed Amphetamine Salts
</a>Albuterol                Lemmon                    <a href="http://www.rxlist.com/cgi/generic/albut1.htm">Albuterol
</a>Albuterol                Warrick                   <a href="http://www.rxlist.com/cgi/generic/albut1.htm">Albuterol
</a>Allegra +                Hoechst Marion Roussel    <a href="http://www.rxlist.com/cgi/generic/fexofen.htm">Fexofenadine
</a>Alprazolam               Geneva                    <a href="http://www.rxlist.com/cgi/generic/alpraz.htm">Alprazolam
</a>Alprazolam               Greenstone                <a href="http://www.rxlist.com/cgi/generic/alpraz.htm">Alprazolam
</a>Altace                   Hoechst-Roussel           <a href="http://www.rxlist.com/cgi/generic/ramipril.htm">Ramipril
</a>Ambien                   Searle                    <a href="http://www.rxlist.com/cgi/generic/zolpid.htm">Zolpidem
</a>Amitriptyline            Mylan                     <a href="http://www.rxlist.com/cgi/generic/amitrip.htm">Amitriptyline
</a>Amoxicillin Trihydrate   Novopharm                 <a href="http://www.rxlist.com/cgi/generic/amox.htm">Amoxicillin
</a>Amoxicillin Trihydrate   Warner Chilcott           <a href="http://www.rxlist.com/cgi/generic/amox.htm">Amoxicillin
</a>Amoxicillin              Biocraft                  <a href="http://www.rxlist.com/cgi/generic/amox.htm">Amoxicillin
</a>Amoxil                   SmithKline Beecham        <a href="http://www.rxlist.com/cgi/generic/amox.htm">Amoxicillin
</a>Aspirin +                Various                   <a href="http://www.rxlist.com/cgi/generic/asa.htm">Aspirin
</a>Atarax +                 Pfizer Roerig             <a href="http://www.rxlist.com/cgi/generic/hydrox.htm">Hydroxyzine
</a>Atenolol                 Geneva                    <a href="http://www.rxlist.com/cgi/generic/atenolol.htm">Atenolol
</a>Atenolol                 Lederie SP                <a href="http://www.rxlist.com/cgi/generic/atenolol.htm">Atenolol
</a>Atenolol                 Mylan                     <a href="http://www.rxlist.com/cgi/generic/atenolol.htm">Atenolol
</a>Atrovent                 Boehringer lngelheim      <a href="http://www.rxlist.com/cgi/generic/ipratrop.htm">Ipratropium
</a>Augmentin                SmithKline Beecham        <a href="http://www.rxlist.com/cgi/generic/amoxclav.htm">Amoxicillin/Clavulanate
</a>Axid                     Lilly                     <a href="http://www.rxlist.com/cgi/generic/nizat.htm">Nizatidine
</a>Azmacort                 Rhone-Poulenc Rorer       <a href="http://www.rxlist.com/cgi/generic/triamaer.htm">Triamcinolone aerosol
</a>Azulfidine +             Pharmacia                 <a href="http://www.rxlist.com/cgi/generic/sulfasal.htm">Sulfasalazine
</a>Bactroban                Smith Kline Beecham       <a href="http://www.rxlist.com/cgi/generic/mupi.htm">Mupirocin
</a>Beconase AQ              Allen &amp; Hanburys          <a href="http://www.rxlist.com/cgi/generic/beclo1.htm">Beclomethasone
</a>Benadryl +               Parke-Davis               <a href="http://www.rxlist.com/cgi/generic/dihydram.htm">Diphenhydramine
</a>Biaxin                   Abbott                    <a href="http://www.rxlist.com/cgi/generic/clarith.htm">Clarithromycin
</a>BuSpar                   Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/buspir.htm">Buspirone
</a>Calan SR                 Searle                    <a href="http://www.rxlist.com/cgi/generic/verapsr.htm">Verapamil
</a>Capoten                  Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/captop.htm">Captopril
</a>Carafate                 Marion Merrell Dow        <a href="http://www.rxlist.com/cgi/generic/sucral.htm">Sucralfate
</a>Cardizem CD              Marion Merrell Dow        <a href="http://www.rxlist.com/cgi/generic/diltiaz.htm">Diltiazem
</a>Cardura                  Roerig                    <a href="http://www.rxlist.com/cgi/generic/doxazo.htm">Doxazosin
</a>Carisoprodol             Schein                    <a href="http://www.rxlist.com/cgi/generic/carisop.htm">Carisoprodol
</a>Catapres +               Boehringer Ingelheim      <a href="http://www.rxlist.com/cgi/generic/clonidin.htm">Clonidine
</a>Ceclor                   Lilly                     <a href="http://www.rxlist.com/cgi/generic/cefaclor.htm">Cefaclor
</a>Cefaclor                 Mylan                     <a href="http://www.rxlist.com/cgi/generic/cefaclor.htm">Cefaclor
</a>Ceftin                   Burroughs Wellcome        <a href="http://www.rxlist.com/cgi/generic/cefurox.htm">Cefuroxime
</a>Cefzil                   Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/cefprozi.htm">Cefprozil
</a>Cephalexin               Zenith                    <a href="http://www.rxlist.com/cgi/generic/cephalex.htm">Cephalexin
</a>Cephalexin               Apothecon                 <a href="http://www.rxlist.com/cgi/generic/cephalex.htm">Cephalexin
</a>Cephalexin               Biocraft                  <a href="http://www.rxlist.com/cgi/generic/cephalex.htm">Cephalexin
</a>Children's Advil         Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/ibup.htm">Ibuprofen
</a>Cimetidine               Mylan                     <a href="http://www.rxlist.com/cgi/generic/cimet.htm">Cimetidine
</a>Cipro                    Bayer Pharm               <a href="http://www.rxlist.com/cgi/generic/cipro.htm">Ciprofloxacin
</a>Claritin                 Schering                  <a href="http://www.rxlist.com/cgi/generic/lorat.htm">Loratadine
</a>Claritin D               Schering                  <a href="http://www.rxlist.com/cgi/generic/loratd.htm">Loratidine/Pseudoephedrine
</a>Clomid +                 Marion Merrell Dow        <a href="http://www.rxlist.com/cgi/generic/clomiph.htm">Clomiphine
</a>Cocaine +                Various                   <a href="http://www.rxlist.com/cgi/generic/cocaine.htm">Cocaine
</a>Cotrim DS                Lemmon                    <a href="http://www.rxlist.com/cgi/generic/trisulf.htm">Trimeth/Sulfameth
</a>Coumadin                 Du Pont Pharm             <a href="http://www.rxlist.com/cgi/generic/warfarin.htm">Warfarin
</a>Cozaar +                 Merck                     <a href="http://www.rxlist.com/cgi/generic/losar.htm">Losartan
</a>Cyclobenzaprine HCI      Schein                    <a href="http://www.rxlist.com/cgi/generic/cyclobnz.htm">Cyclobenzaprine
</a>Cyclobenzaprine Hcl      Mylan                     <a href="http://www.rxlist.com/cgi/generic/cyclobnz.htm">Cyclobenzaprine
</a>Cycrin                   ESI Pharm                 <a href="http://www.rxlist.com/cgi/generic/medrox.htm">Medroxyprogesterone
</a>Cylert +                 Abbott                    <a href="http://www.rxlist.com/cgi/generic/pemoline.htm">Pemoline
</a>Cytotec +                Searle                    <a href="http://www.rxlist.com/cgi/generic/misopro.htm">Misoprostol
</a>Darvocet-N 100           Lilly                     <a href="http://www.rxlist.com/cgi/generic/propox.htm">Propoxyphene-N/APAP
</a>Darvon +                 Lilly                     <a href="http://www.rxlist.com/cgi/generic/propox2.htm">Propoxyphene
</a>Daypro                   Searle                    <a href="http://www.rxlist.com/cgi/generic/oxaproz.htm">Oxaprozin
</a>Deltasone                Upjohn                    <a href="http://www.rxlist.com/cgi/generic/pred.htm">Prednisone
</a>Demerol +                Sanofi Winthrop           <a href="http://www.rxlist.com/cgi/generic/meper.htm">Meperidine
</a>Demulen 1/35-28          Searle                    <a href="http://www.rxlist.com/cgi/generic/ethynoc.htm">Ethynodiol/Ethinyl Estradiol              
</a>Depakote                 Abbott                    <a href="http://www.rxlist.com/cgi/generic/dival.htm">Divalproex
</a>Desogen                  Organon                   <a href="http://www.rxlist.com/cgi/generic/desest.htm">Desogestrel/Ethinyl Estradiol
</a>Desyrel +                Bristol-Myers/Squibb      <a href="http://www.rxlist.com/cgi/generic/traz.htm">Trazodone
</a>DiaBeta                  Hoechst-Roussel           <a href="http://www.rxlist.com/cgi/generic/glybur.htm">Glyburide
</a>Diazepam                 Mylan                     <a href="http://www.rxlist.com/cgi/generic/diazepam.htm">Diazepam
</a>Dicyclomine HCI          Rugby                     <a href="http://www.rxlist.com/cgi/generic/dicyc.htm">Dicyclomine
</a>Diflucan                 Roerig                    <a href="http://www.rxlist.com/cgi/generic/flucon.htm">Fluconazole
</a>Dilacor XR               Rhone-Poulenc Rorer       <a href="http://www.rxlist.com/cgi/generic/diltiaz.htm">Diltiazem
</a>Dilantin                 Parke-Davis               <a href="http://www.rxlist.com/cgi/generic/phenyt.htm">Phenytoin
</a>Dipentum +               Pharmacia                 <a href="http://www.rxlist.com/cgi/generic/olsal.htm">Olsalazine
</a>Doxycycline Hyclate      Zenith                    <a href="http://www.rxlist.com/cgi/generic/doxycyc.htm">Doxycycline
</a>Duricef                  Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/cefadrox.htm">Cefadroxil
</a>Dyazide                  SmithKline Beecham        <a href="http://www.rxlist.com/cgi/generic/hctztri.htm">Hydrochlorothiazide/Triamterine
</a>E.E.S.                   Abbott                    <a href="http://www.rxlist.com/cgi/generic/ees.htm">Erythromycin
</a>Effexor                  Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/venlafax.htm">Venlafaxine
</a>Eldepryl +               Somerset                  <a href="http://www.rxlist.com/cgi/generic/seleg.htm">Selegiline
</a>Elocon                   Schering                  <a href="http://www.rxlist.com/cgi/generic/momet.htm">Mometasone
</a>Ery-Tab                  Abbott                    <a href="http://www.rxlist.com/cgi/generic/erythro.htm">Erythromycin
</a>Erythrocin Stearate      Abbott                    <a href="http://www.rxlist.com/cgi/generic/eryst.htm">Erythromycin
</a>Estrace                  Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/estrad.htm">Estradiol
</a>Estraderm                CIBA                      <a href="http://www.rxlist.com/cgi/generic/estratd.htm">Estradiol
</a>Fastin +                 Smith Kline Beecham       <a href="http://www.rxlist.com/cgi/generic/phenterm.htm">Phentermine
</a>Fiorinal/Codeine         Sandoz                    <a href="http://www.rxlist.com/cgi/generic/butalcod.htm">Butalbital/ASA/Caffeine/Codeine
</a>Flagyl +                 Searle                    <a href="http://www.rxlist.com/cgi/generic/metronid.htm">Metronidazole
</a>Flonase                  Allen &amp; Hanburys          <a href="http://www.rxlist.com/cgi/generic/flutic.htm">Fluticasone
</a>Florinef +               Bristol-Myers/Squibb      <a href="http://www.rxlist.com/cgi/generic/fludro.htm">Fludrocortisone
</a>Floxin                   Ortho Pharm               <a href="http://www.rxlist.com/cgi/generic/oflox.htm">Ofloxacin
</a>Fosamax +                Merck                     <a href="http://www.rxlist.com/cgi/generic/alendron.htm">Alendronate
</a>Furosmide                Mylan                     <a href="http://www.rxlist.com/cgi/generic/furos.htm">Furosemide
</a>Gemfibrozil              Warner Chilcott           <a href="http://www.rxlist.com/cgi/generic/gemfib.htm">Gemfibrozil 
</a>Glipizide                Mylan                     <a href="http://www.rxlist.com/cgi/generic/glip.htm">Glipizide
</a>Glucophage +             Bristol-Myers/Squibb      <a href="http://www.rxlist.com/cgi/generic/metformi.htm">Metformin
</a>Glucotrol                Pratt                     <a href="http://www.rxlist.com/cgi/generic/glip.htm">Glipizide
</a>Glucotrol XL             Pratt                     <a href="http://www.rxlist.com/cgi/generic/glipxl.htm">Glipizide  
</a>Glyburide                Geneva                    <a href="http://www.rxlist.com/cgi/generic/glybur.htm">Glyburide
</a>Glyburide                Greenstone                <a href="http://www.rxlist.com/cgi/generic/glybur.htm">Glyburide
</a>Glyburide                Copley                    <a href="http://www.rxlist.com/cgi/generic/glybur.htm">Glyburide
</a>Glynase Prestab          Upjohn                    <a href="http://www.rxlist.com/cgi/generic/glymic.htm">Glyburide
</a>Guaifenesin/PPA          Duramed                   <a href="http://www.rxlist.com/cgi/generic/guaiphen.htm">Guaifenesin/Phenylpropanolamine
</a>Hismanal                 Janssen                   <a href="http://www.rxlist.com/cgi/generic/astem.htm">Astemizole
</a>Humulin N                Lilly                     <a href="http://www.rxlist.com/cgi/generic/humnph.htm">Human Insulin-NPH
</a>Humulin 7O/30            Lilly                     <a href="http://www.rxlist.com/cgi/generic/hum7030.htm">Human Insulin 70/30
</a>Humulin R                Lilly                     <a href="http://www.rxlist.com/cgi/generic/huminsr.htm">Human Insulin Regular
</a>Hydrochlorothiazide      Zenith                    <a href="http://www.rxlist.com/cgi/generic/hctz.htm">Hydrochlorothiazide
</a>Hydrocodone w/APAP       Qualitest                 <a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">Hydrocodone w/APAP
</a>Hydrocodone/APAP         Watson                    <a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">Hydrocodone/APAP
</a>Hydrocodone/APAP         Rugby                     <a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">Hydrocodone/APAP
</a>Hydrocodone w/APAP       Warner Chilcott           <a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">Hydrocodone/APAP
</a>Hytrin                   Abbott                    <a href="http://www.rxlist.com/cgi/generic/teraz.htm">Terazosin
</a>lbuprofen                Knoll                     <a href="http://www.rxlist.com/cgi/generic/ibup.htm">Ibuprofen
</a>lmitrex                  Cerenex                   <a href="http://www.rxlist.com/cgi/generic/sumitr.htm">Sumatriptan
</a>Inderal +                Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/propran.htm">Propranolol
</a>Indocin +                Merck                     <a href="http://www.rxlist.com/cgi/generic/indometh.htm">Indomethacin
</a>K-Dur                    Key                       <a href="http://www.rxlist.com/cgi/generic/kclsr.htm">Potassium Chloride
</a>Klonopin                 Roche                     <a href="http://www.rxlist.com/cgi/generic/clonaz.htm">Clonazepam
</a>Klor-Con 10              Upsher-Smith              <a href="http://www.rxlist.com/cgi/generic/kclsr.htm">Potassium Chloride
</a>Lamisil +                Sandoz                    <a href="http://www.rxlist.com/cgi/generic/terbin.htm">Terbinafine
</a>Lanoxin                  Allen &amp; Hanburys          <a href="http://www.rxlist.com/cgi/generic/dig.htm">Digoxin
</a>Lasix                    Hoechst-Roussel           <a href="http://www.rxlist.com/cgi/generic/furos.htm">Furosemide
</a>Lescol                   Sandoz                    <a href="http://www.rxlist.com/cgi/generic/fluva.htm">Fluvastatin
</a>Levoxyl                  Daniels                   <a href="http://www.rxlist.com/cgi/generic/levothy.htm">Levothyroxine
</a>Lo/Ovral-28              Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/norgeth.htm">Norgestrel/Ethinyl Estradiol
</a>Loestrin-FE 1.5/30       Parke-Davis               <a href="http://www.rxlist.com/cgi/generic/norestoc.htm">Norethindrone/Ethinyl Estradiol
</a>Lodine                   Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/etodolac.htm">Etodolac
</a>Lopressor                Geigy                     <a href="http://www.rxlist.com/cgi/generic/metopro.htm">Metoprolol
</a>Lorabid                  Lilly                     <a href="http://www.rxlist.com/cgi/generic/loracarb.htm">Loracarbef
</a>Lorazepam                Purepac                   <a href="http://www.rxlist.com/cgi/generic/loraz.htm">Lorazepam
</a>Lorazepam                Mylan                     <a href="http://www.rxlist.com/cgi/generic/loraz.htm">Lorazepam
</a>Lorcet 10/650            Forest                    <a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">Hydrocodone/APAP
</a>Lotensin                 CIBA                      <a href="http://www.rxlist.com/cgi/generic/benaz.htm">Benazepril
</a>Lotrisone                Key                       <a href="http://www.rxlist.com/cgi/generic/clobet.htm">Clotrimoxazole/Betamethasone
</a>Lozol                    Rhone-Poulenc Rorer       <a href="http://www.rxlist.com/cgi/generic/indap.htm">Indapamide
</a>Luvox +                  Solvay                    <a href="http://www.rxlist.com/cgi/generic/fluvox.htm">Fluvoxamine
</a>Macrobid                 Procter &amp; Gamble          <a href="http://www.rxlist.com/cgi/generic/nitro25m.htm">Nitrofurantoin
</a>Medroxyprogesterone      Greenstone Ltd.           <a href="http://www.rxlist.com/cgi/generic/medrox.htm">Medroxyprogesterone
</a>Mesalamine +             Various                   <a href="http://www.rxlist.com/cgi/generic/mesal.htm">Mesalamine
</a>Methotrexate +           Various                   <a href="http://www.rxlist.com/cgi/generic/mtx.htm">Methotrexate
</a>Methylphenidate          MD Pharm                  <a href="http://www.rxlist.com/cgi/generic/methphen.htm">Methylphenidate
</a>Methylprednisolone       Duramed                   <a href="http://www.rxlist.com/cgi/generic/methprd.htm">Methylprednisolone
</a>Metoprolol Tartrate      Mylan                     <a href="http://www.rxlist.com/cgi/generic/metopro.htm">Metoprolol
</a>Metoprolol Tartrate      Geneva                    <a href="http://www.rxlist.com/cgi/generic/metopro.htm">Metoprolol
</a>Mevacor                  Merck                     <a href="http://www.rxlist.com/cgi/generic/lovastat.htm">Lovastatin
</a>Micronase                Upjohn                    <a href="http://www.rxlist.com/cgi/generic/glybur.htm">Glyburide
</a>Midrin +                 Carnrick                  <a href="http://www.rxlist.com/cgi/generic/midrin.htm">Isometheptene/Dichloralphenazone/APAP
</a>Monopril                 Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/fosinop.htm">Fosinopril
</a>Morphine +               Various                   <a href="http://www.rxlist.com/cgi/generic/ms.htm">Morphine
</a>Motrin                   McNeil-CPC                <a href="http://www.rxlist.com/cgi/generic/ibup.htm">Ibuprofen
</a>Naproxen                 Mylan                     <a href="http://www.rxlist.com/cgi/generic/naprox.htm">Naproxen
</a>Nasacort                 Rhone-Poulenc Rorer       <a href="http://www.rxlist.com/cgi/generic/triamnas.htm">Triamcinolone
</a>Nasalcrom +              Fisons                    <a href="http://www.rxlist.com/cgi/generic/cromnas.htm">Cromolyn
</a>Neomycin/Polymx/HC       Schein                    <a href="http://www.rxlist.com/cgi/generic/neopolhc.htm">Neomycin/Polymx/HC
</a>Neurontin +              Parke-Davis               <a href="http://www.rxlist.com/cgi/generic/gabapent.htm">Gabapentin
</a>Nitro-Dur                Key                       <a href="http://www.rxlist.com/cgi/generic/ntgtd.htm">Nitroglycerin
</a>Nitrostat                Parke-Davis               <a href="http://www.rxlist.com/cgi/generic/ntg.htm">Nitroglycerin
</a>Nizoral Cream            Janssen                   <a href="http://www.rxlist.com/cgi/generic/ketocon.htm">Ketoconazole
</a>Nortriptyline HCI        Schein                    <a href="http://www.rxlist.com/cgi/generic/nortrip.htm">Nortriptyline
</a>Norvasc                  Pfizer                    <a href="http://www.rxlist.com/cgi/generic/amlod2.htm">Amlodipine
</a>Ortho-Novum 7/7/7-28     Ortho Pharm               <a href="http://www.rxlist.com/cgi/generic/norestoc.htm">Norethindrone/Ethinyl Estradiol
</a>Ortho-Cept 28            Ortho Pharm               <a href="http://www.rxlist.com/cgi/generic/desest.htm">Desogestrel/Ethinyl Estradiol
</a>Ortho-Novum 1/35-28      Ortho Pharm               <a href="http://www.rxlist.com/cgi/generic/norestoc.htm">Norethindrone/Ethinyl Estradiol
</a>Oruvail                  Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/ketoprof.htm">Ketoprofen
</a>Paxil                    SmithKline Beecham        <a href="http://www.rxlist.com/cgi/generic/parox.htm">Paroxetine
</a>Penicillin VK            Mylan                     <a href="http://www.rxlist.com/cgi/generic/penvk.htm">Penicillin VK
</a>Pepcid                   Merck                     <a href="http://www.rxlist.com/cgi/generic/famot.htm">Famotidine
</a>Phenergan                Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/prometh.htm">Promethazine
</a>Pondimin +               A.H. Robins               <a href="http://www.rxlist.com/cgi/generic/fenflur.htm">Fenfluramine
</a>Potassium Chloride       Ethex                     <a href="http://www.rxlist.com/cgi/generic/kclsr.htm">Potassium Chloride
</a>Pravachol                Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/pravast.htm">Pravastatin
</a>Prednisone               Schein                    <a href="http://www.rxlist.com/cgi/generic/pred.htm">Prednisone
</a>Premarin                 Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/conest.htm">Conjugated Estrogens
</a>Prevacid                 Tap                       <a href="http://www.rxlist.com/cgi/generic/lansop.htm">Lansoprazole
</a>Prilosec                 Astra/Merck               <a href="http://www.rxlist.com/cgi/generic/omepra.htm">Omeprazole
</a>Prinivil                 Merck                     <a href="http://www.rxlist.com/cgi/generic/lisinop.htm">Lisinopril
</a>Procardia XL             Pratt                     <a href="http://www.rxlist.com/cgi/generic/nifedxl.htm">Nifedipine
</a>Promethazine/Codeine     Barre-National            <a href="http://www.rxlist.com/cgi/generic/promcod.htm">Promethazine/Codeine
</a>Propacet 100             Lemmon                    <a href="http://www.rxlist.com/cgi/generic/propox.htm">Propoxyphene N/APAP
</a>Propoxyphene N/APAP      Mylan                     <a href="http://www.rxlist.com/cgi/generic/propox.htm">Propoxyphene N/APAP
</a>Propulsid                Janssen                   <a href="http://www.rxlist.com/cgi/generic/cisap.htm">Cisapride
</a>Proscar +                Merck                     <a href="http://www.rxlist.com/cgi/generic/finas.htm">Finasteride
</a>Proventil Aerosol        Schering                  <a href="http://www.rxlist.com/cgi/generic/albut1.htm">Albuterol
</a><a href="http://www.rxlist.com/cgi/brand/provera.htm">Provera</a>                  Upjohn                    <a href="http://www.rxlist.com/cgi/generic/medrox.htm">Medroxyprogesterone
</a>Prozac                   Dista                     <a href="http://www.rxlist.com/cgi/generic/fluoxetine.htm">Fluoxetine
</a>Redux +                  Wyeth                     <a href="http://www.rxlist.com/cgi/generic/dexfen.htm">Dexfenfluramine
</a>Relafen                  SmithKline Beecham        <a href="http://www.rxlist.com/cgi/generic/nabume.htm">Nabumetone
</a>Retin-A                  Ortho Derm                <a href="http://www.rxlist.com/cgi/generic/tretinoin.htm">Tretinoin
</a>Risperdal +              Janssen                   <a href="http://www.rxlist.com/cgi/generic/risperid.htm">Risperidone
</a>Ritalin                  CIBA                      <a href="http://www.rxlist.com/cgi/generic/methphen.htm">Methylphenidate
</a>Roxicet                  Roxane                    <a href="http://www.rxlist.com/cgi/generic/oxyapap.htm">Oxycodone/APAP
</a>Seldane                  Marion Merrell Dow        <a href="http://www.rxlist.com/cgi/generic/terfen.htm">Terfenadine
</a>Seldane-D                Marion Merrell Dow        <a href="http://www.rxlist.com/cgi/generic/tersud.htm">Terfenadine/Pseudoephedrine
</a>Serevent                 Allen &amp; Hanburys          <a href="http://www.rxlist.com/cgi/generic/salmet.htm">Salmeterol
</a>Serzone +                Bristol Myers/Squibb      <a href="http://www.rxlist.com/cgi/generic/nefaz.htm">Nefazodone
</a>Sinequan +               Pfizer Roerig             <a href="http://www.rxlist.com/cgi/generic/doxepin.htm">Doxepin
</a>Skelaxin +               Carnrick                  <a href="http://www.rxlist.com/cgi/generic/metax.htm">Metaxalone
</a>Sumycin                  Apothecon                 <a href="http://www.rxlist.com/cgi/generic/tetcycl.htm">Tetracycline
</a>Suprax                   Lederie Rx                <a href="http://www.rxlist.com/cgi/generic/cefixime.htm">Cefixime
</a>Synthroid                Knoll                     <a href="http://www.rxlist.com/cgi/generic/levothy.htm">Levothyroxine
</a>Tegretol                 Basel                     <a href="http://www.rxlist.com/cgi/generic/carbam.htm">Carbamazepine
</a>Temazepam                Mylan                     <a href="http://www.rxlist.com/cgi/generic/temaz.htm">Temazepam
</a>Tenormin                 Zeneca                    <a href="http://www.rxlist.com/cgi/generic/atenolol.htm">Atenolol
</a>Terazol 7                Ortho Pharm               <a href="http://www.rxlist.com/cgi/generic/tercon.htm">Terconazole
</a>Theo-Dur                 Key                       <a href="http://www.rxlist.com/cgi/generic/theosr.htm">Theophylline
</a>Ticlid +                 Syntex                    <a href="http://www.rxlist.com/cgi/generic/ticlop.htm">Ticlopidine
</a>Timoptic                 Merck                     <a href="http://www.rxlist.com/cgi/generic/timolol.htm">Timolol
</a>Toprol-XL                Astra                     <a href="http://www.rxlist.com/cgi/generic/metopxl.htm">Metoprolol
</a>Toradol                  Roche                     <a href="http://www.rxlist.com/cgi/generic/ketor.htm">Ketorolac
</a>Trental                  Hoechst-Roussel           <a href="http://www.rxlist.com/cgi/generic/pentox.htm">Pentoxifylline
</a>Tri-Levlen 28            Berlex                    <a href="http://www.rxlist.com/cgi/generic/lngeed.htm">L-Norgestrel/Ethinyl Estradiol
</a>Triamterene/HCTZ         Geneva                    <a href="http://www.rxlist.com/cgi/generic/hctztri.htm">Triamterene/HCTZ
</a>Trimeth/Sulfameth        Mutual                    <a href="http://www.rxlist.com/cgi/generic/trisulf.htm">Trimeth/Sulfameth
</a>Trimeth/Sulfameth        Blocraft                  <a href="http://www.rxlist.com/cgi/generic/trisulf.htm">Trimeth/Sulfameth
</a>Trimox                   Apothecon                 <a href="http://www.rxlist.com/cgi/generic/amox.htm">Amoxicillin
</a>Triphasil-28             Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/lngeed.htm">L-Norgestrel/Ethinyl Estradiol
</a>Tylenol +                Mc Neil                   <a href="http://www.rxlist.com/cgi/generic/apap.htm">Acetaminophen
</a>Tylenol/Codeine          Mc Neil                   <a href="http://www.rxlist.com/cgi/generic/acetcod.htm">Acetaminophen/Codeine
</a>Ultram                   Mc Neil                   <a href="http://www.rxlist.com/cgi/generic/tramadol.htm">Tramadol
</a>Voltaren                 Geigy                     <a href="http://www.rxlist.com/cgi/generic/diclofen.htm">Diclofenac
</a>Valium                   Roche                     <a href="http://www.rxlist.com/cgi/generic/diazepam.htm">Diazepam
</a>Vancenase AQ             Schering                  <a href="http://www.rxlist.com/cgi/generic/beclo1.htm">Beclomethasone
</a>Vanceril                 Key                       <a href="http://www.rxlist.com/cgi/generic/beclo.htm">Beclomethasone
</a>Vasotec                  Merck                     <a href="http://www.rxlist.com/cgi/generic/enalap.htm">Enalapril
</a>Veetids                  Apothecon                 <a href="http://www.rxlist.com/cgi/generic/penvk.htm">Penicillin VK
</a>Ventolin Aerosol         Allen &amp; Hanburys          <a href="http://www.rxlist.com/cgi/generic/albut1.htm">Albuterol
</a>Verapamil SR             Goldline                  <a href="http://www.rxlist.com/cgi/generic/verapsr.htm">Verapamil
</a>Verelan                  Lederie Rx                <a href="http://www.rxlist.com/cgi/generic/verapsr.htm">Verapamil
</a>Vicodin                  Knoll                     <a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">Hydrocodone/APAP
</a>Wellbutrin +             Wellcome/Glaxo            <a href="http://www.rxlist.com/cgi/generic/buprop.htm">Bupropion
</a>Xanax                    Upjohn                    <a href="http://www.rxlist.com/cgi/generic/alpraz.htm">Alprazolam
</a>Yocon +                  Palisades                 <a href="http://www.rxlist.com/cgi/generic/yohimb.htm">Yohimbine
</a>Zantac                   Glaxo                     <a href="http://www.rxlist.com/cgi/generic/ranit.htm">Ranitidine
</a>Zestril                  Zeneca                    <a href="http://www.rxlist.com/cgi/generic/lisinop.htm">Lisinopril
</a>Zithromax Z-Pak          Pfizer                    <a href="http://www.rxlist.com/cgi/generic/azith.htm">Azithromycin
</a>Zocor                    Merck                     <a href="http://www.rxlist.com/cgi/generic/simva.htm">Simvastatin
</a>Zoloft                   Roerig                    <a href="http://www.rxlist.com/cgi/generic/sertral.htm">Sertraline
</a>Zovirax Tablets          Burroughs Wellcome        <a href="http://www.rxlist.com/cgi/generic/acyclo.htm">Acyclovir
</a>Zovirax Capsules         Burroughs Wellcome        <a href="http://www.rxlist.com/cgi/generic/acyclo.htm">Acyclovir
</a>Zyrtec +                 Pfizer                    <a href="http://www.rxlist.com/cgi/generic/cetiriz.htm">Cetirizine

</a></b><i>* source: Pharmacy Times, April 1996
+ Not in the Top 200 but heavily requested in the RxList database</i></pre>

<h2 align=center>
<hr width="100%" ></h2>

<h4 align=center><a href="http://www.rxlist.com/interact.htm">Search for
Interactions, Side Effects, Indications (etc.) with ALL Top 200 Drugs</a>
</h4>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;SearchRxList</a>
<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxlistHome
Page</a> &nbsp; </h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-4</DOCNO>
<DOCOLDNO>IA018-000200-B033-255</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/hydrocod.htm 206.86.175.201 19970106223942 text/html 16562
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:33:27 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 16379
Last-modified: Thu, 11 Jul 1996 06:07:50 GMT
</DOCHDR>
<html>
<head>
   <title> Acetaminophen with Hydrocodone - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Acetaminophen with Hydrocodone</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <P></P>
Each Acetaminophen with hydrocodone tablet contains:  
 <P></P>
Hydrocodone Bitartrate: 5 mg 
 <P></P>
(WARNING: May be habit forming.) 
 <P></P>
Acetaminophen: 500 mg 
 <P></P>
Hydrocodone bitartrate is an opioid analgesic and antitussive and occurs as
fine, white crystals or as a crystalline powder. It is affected by light. The
chemical name is: 4,5alpha epoxy-3-methoxy-17-methylmorphinan-6-one tartrate
(1:1) hydrate (2:5).  <P></P>
 
C18H21NO3C4H6O6.2 1/2H2O: M.W. 494.50 
 <P></P>
Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, nonsalicylate analgesic
and antipyretic which occurs as a white, odorless crystalline powder possessing 
a slightly bitter taste.  <P></P>
 
C8H9NO2: M.W. 151.16 
 <P></P>
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 
</b> <P></P>
Hydrocodone is a semisynthetic narcotic analgesic and antitussive with multiple 
actions qualitatively similar to those of codeine. Most of these involve the
central nervous system and smooth muscle. The precise mechamism of action of
hydrocodone and other opiates is not known, although it is believed to relate
to the existence of opiate receptors in the central nervous system. In addition 
to analgesia, narcotics may produce drowsiness, changes in mood and mental
clouding.  <P></P>
 
Radioimmunoassay techniques have recently been developed for the analysis of
hydrocodone in human plasma. After a 10 mg oral dose of hydrocodone bitartrate, 
a mean peak serum drug level of 23.6 ng/mL and an elimination half-life of 3.8
hours were found.  <P></P>
 
The analgesic action of acetaminophen involves peripheral and central
influences, but the specific mechanism is as yet undetermined. Antipyretic
activity is mediated through hypothalmic heat regulating centers. Acetaminophen 
inhibits prostaglandin synthetase. Therapeutic doses of acetaminophen have
negligible effects on the cardiovascular or respiratory systems; however, toxic 
doses may cause circulatory failure and rapid, shallow breathing. Acetaminophen 
is rapidly and almostly completely absorbed from the gastrointestinal tract,
producing maximum serum concentrations within 30 minutes to one hour. The
plasma half-life in adults and children ranges from 0.90 hours to 3.25 hours
with an average of approximately 2 hours. The drug distributes uniformly in
most body fluids and is approximately 25% protein bound. Acetaminophen is
conjugated in the liver, with less than 3% of the dose excreted unchanged in 24 
hours. The primary metabolic pathway is conjugation to sulfate and glucuronide
by-products.  A minor oxidative pathway forms cysteine and mercapturic acid.
These compounds are subsequently excreted by the kidneys into the urine.  
 <P></P>
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <P></P>
For the relief of moderate to moderately severe pain.  
 <P></P>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <P></P>
Hypersensitivity to acetaminophen or hydrocodone.  
 <P></P>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <P></P>
RESPIRATORY DEPRESSION: At high doses or in sensitive patients, hydrocodone may 
produce dose-related respiratory depression by acting directly on the brain
stem respiratory center. Hydrocodone also affects the center that controls
respiratory rhythm, and may produce irregular and periodic breathing.  
 <P></P>
HEAD INJURY AND INCREASED INTRACRANIAL PRESSURE: The respiratory depressant
effects of narcotics and their capacity to elevate cerebrospinal fluid pressure 
may be markedly exaggerated in the presence of head injury, other intracranial
lesions or a preexisting increase in intracranial pressure. Furthermore,
narcotics produce adverse reactions which may obscure the clinical course of
patients with head injuries.  <P></P>
 
ACUTE ABDOMINAL CONDITIONS: The administration of narcotics may obscure the
diagnosis or clinical course of patients with acute abdominal conditions.  
 <P></P>
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <P></P>
SPECIAL RISK PATIENTS: As with any narcotic analgesic agent, 
Acetaminophen with hydrocodone Tablets
should be used with caution in elderly or debilitated patients and those with
severe impairment of hepatic or renal function, hypothyroidism, Addison's
disease, prostatic hypertrophy or urethral stricture. The usual precautions
should be observed and the possibility of respiratory depression should be kept 
in mind.  <P></P>
 
INFORMATION FOR PATIENTS: Acetaminophen with hydrocodone Tablets, 
like all narcotics, may impair the
mental and/or physical abilities required for the performance of potentially
hazardous tasks such as driving a car or operating machinery; patients should
be cautioned accordingly.  <P></P>
 
COUGH REFLEX: Hydrocodone suppresses the cough reflex; as with all narcotics,
caution should be exercised when Acetaminophen with 
hydrocodone Tablets are used postoperatively and
in patients with pulmonary disease.  <P></P>
 
DRUG INTERACTIONS: Patients receiving other narcotic analgesics, antipsychotics 
<P></P>
antianxiety agents, or other CNS depressants (including alcohol) concomitantly
with Acetaminophen with hydrocodone Tablets 
may exhibit an additive CNS depression. When combined
therapy is contemplated, the dose of one or both agents should be reduced.  
 <P></P>
The use of MAO inhibitors or tricyclic antidepressants with hydrocodone
preparations may increase the effect of either the antidepressant or
hydrocodone.  <P></P>

The concurrent use of anticholinergics with hydrocodone may produce paralytic
ileus.  <P></P>
 
USAGE IN PREGNANCY 
 <P></P>
Teratogenic Effects: Pregnancy Category C. Hydrocodone has been shown to be
teratogenic in hamsters when given in doses 700 times the human dose. There are 
no adequate and well-controlled studies in pregnant women. 
Acetaminophen with hydrocodone Tablets
should be used during pregnancy only if the potential benefit justifies the
potential risk to the fetus.  <P></P>
 
Nonteratogenic Effects: Babies born to mothers who have been taking opioids
regularly prior to delivery will be physically dependent. The withdrawal signs
include irritability and excessive crying, tremors, hyperactive reflexes,
increased respiratory rate, increased stools, sneezing, yawning, vomiting, and
fever. The intensity of the syndrome does not always correlate with the
duration of maternal opioid use or dose. There is not consensus on the best
method of managing withdrawal. Chlorpromazine 0.7 to 1.0 mg/kg q6h, and
paregoric 2 to 4 drops/kg q4h, have been used to treat withdrawal symptoms in
infants. The duration of therapy is 4 to 28 days, with the dosage decreased as
tolerated.  <P></P>
 
LABOR AND DELIVERY: As with all narcotics, administration 
of Acetaminophen with hydrocodone Tablets to 
the mother shortly before delivery may result in some degree of respiratory
depression in the newborn, especially if higher doses are used. <P></P> 
 
NURSING MOTHERS: It is not known whether this drug is excreted in human milk. 
Because many drugs are excreted in human milk and because of the potential for
serious adverse reactions in nursing infants from Acetaminophen with hydrocodone Tablets, a
decision
should be made whether to discontinue nursing or to discontinue the drug,
taking into account the importance of the drug to the mother.  
 <P></P>
PEDIATRIC USE: Safety and effectiveness in children have not been established.  
 <P></P>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <P></P>
Patients receiving other narcotic analgesics, antipsychotics, antianxiety
agents, or other CNS depressants (including alcohol) concomitantly with Acetaminophen with
hydrocodone 
Tablets may exhibit an additive CNS depression. When combined therapy is
contemplated, the dose of one or both agents should be reduced.  
 <P></P>
The use of MAO inhibitors or tricyclic antidepressants with hydrocodone
preparations may increase the effect of either the antidepressant or
hydrocodone.  <P></P>
 
The concurrent use of anticholinergics with hydrocodone may produce paralytic
ileus.  <P></P>
 
(See Also PRECAUTIONS) 
 <P></P>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <P></P>
The most frequently observed adverse reactions include lightheadedness,
dizziness, sedation, nausea and vomiting. These effects seem to be more
prominent in ambulatory than in nonambulatory patients and some of these
adverse reactions may be aeviated if the patient lies down.
<P></P>
Other adverse reactions include:  
 <P></P>
CENTRAL NERVOUS SYSTEM: Drowsiness, mental clouding, lethargy, impairment of
mental and physical performance, anxiety, fear, dysphoria, psychic dependence,
mood changes.  <P></P>
 
GASTROINTESTINAL SYSTEM: The antiemetic phenothiazines are useful in
suppressing the nausea and vomiting which may occur (see above); however, some
phenothiazine derivatives seem to be antianalgesic and to increase the amount
of narcotic required to produce pain relief, while other phenothiazines reduce
the amount of narcotic required to produce a given level of analgesia.
Prolonged administration of Acetaminophen with hydrocodone 
Tablets may produce constipation. <P></P> 
 
GENITOURINARY SYSTEM: Ureteral spasm, spasm of vesical sphincters and urinary
retention have been reported.  <P></P>
 
RESPIRATORY DEPRESSION: Hydrocodone bitartrate may produce dose-related
respiratory depression by acting directly on the brain stem respiratory center. 
Hydrocodone also affects the center that controls respiratory rhythm, and may
produce irregular and periodic breathing. If significant respiratory depression 
occurs, it may be antagonized by the use of naloxone hydrochloride. Apply other 
supportive measures when indicated. <P></P> 
 
DRUG ABUSE AND DEPENDENCE 
 <P></P>
Acetaminophen with hydrocodone Tablets are subject to the 
Federal Controlled Substance Act (Schedule CIII).  
 <P></P>
Psychic dependence, physical dependence, and tolerance may develop upon
repeated administration of narcotics; therefore, 
Acetaminophen with hydrocodone Tablets should be
prescribed and administered with caution. However, psychic dependence is
unlikely to develop when Acetaminophen with hydrocodone 
Tablets are used for a short time for the treatment of pain.  
 <P></P>
Physical dependence, the condition in which continued administration of the
drug is required to prevent the appearance of a withdrawal syndrome, assumes
clinically significant proportions only after several weeks of continued
narcotic use, although some mild degree of physical dependence may develop
after a few days of narcotic therapy. Tolerance, in which increasingly large
doses are required in order to produce the same degree of analgesia, is
manifested initially by a shortened duration of analgesic effect, and
subsequently by decreases in the intensity of analgesia. The rate of
development of tolerance varies among patients.  <P></P>
 
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <P></P>
ACETAMINOPHEN:  
 <P></P>
SIGNS AND SYMPTOMS: In acute acetaminophen overdosage, dose-dependent,
potentially fatal hepatic necrosis is the most serious adverse effect. Renal
tubular necrosis, hypoglycemic coma, and thrombocytopenia may also occur.  
 <P></P>
In adults, hepatic toxicity has rarely been reported with acute overdoses of
less than 10 grams and fatalities with less than 15 grams. Importantly, young
children seem to be more resistant than adults to the hepatotoxic effect of an
acetaminophen overdose. Despite this, the measures outlined below should be
initiated in any adult or child suspected of having ingested an acetaminophen
overdose.  <P></P>
 
Early symptoms following a potentially hepatotoxic overdose may include: nausea 
vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of
hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.  
 <P></P>
TREATMENT: The stomach should be emptied promptly by lavage or by induction of
emesis with syrup of ipecac. Patients' estimates of the quantity of a drug
ingested are notoriously unreliable. Therefore, if an acetaminophen overdose is 
suspected, a serum acetaminophen assay should be obtained as early as possible, 
but no sooner than four hours following ingestion. Liver function studies
should be obtained initially and repeated at 24-hour intervals.  <P></P>
 
The antidote, N-acetylcysteine, should be administered as early as possible,
preferably within 16 hours of the overdose ingestion for optimal results, but
in any case, within 24 hours. Following recovery, there are no residual,
structural or functional hepatic abnormalities.  
 <P></P>
HYDROCODONE:  
 <P></P>
SIGNS AND SYMPTOMS: Serious overdose with hydrocodone is characterized by
respiratory depression (a decrease in respiratory rate and/or tidal volume,
Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor
or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes
bradycardia and hypotension. In severe overdosage, apnea, circular collapse,
cardiac arrest and death may occur.  <P></P>
 
TREATMENT: Primary attention should be given to the reestablishment of adequate 
respiratory exchange through provision of a patent airway and the institution
of assisted or controlled ventilation. The narcotic antagonist naloxone is a
specific antidote against respiratory depression which may result from
overdosage or unusual sensitivity to narcotics, including hydrocodone. 
Therefore, an appropriate dose of naloxone hydrochloride (see package insert)
should be administered, preferably by the intravenous route, and simultaneously 
with efforts at respiratory resuscitation.  <P></P>
 
Since the duration of action of hydrocodone may exceed that of the antagonist,
the patient should be kept under continued surveillance and repeated doses of
the antagonist should be administered as needed to maintain adequate
respiration.  <P></P>
 
An antagonist should not be administered in the absence of clinically
significant respiratory or cardiovascular depression. Oxygen, intravenous
fluids, vasopressors and other supportive measures should be employed as
indicated.  <P></P>
 
Gastric emptying may be useful in removing unabsorbed drug.  
 <P></P>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <P></P>
Dosage should be adjusted according to the severity of the pain and the
response of the patient. However, it should be kept in mind that tolerance to
hydrocodone can develop with continued use and that the incidence of untoward
effects is dose related.  <P></P>
 
The usual adult dosage is one or two tablets every four to six hours as needed
for pain. The total 24 hour dose should not exceed 8 tablets. <P></P>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-5</DOCNO>
<DOCOLDNO>IA018-000200-B041-231</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/antidepr.htm 206.86.175.201 19970106231104 text/html 6166
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:04:50 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5984
Last-modified: Sun, 30 Jun 1996 07:23:27 GMT
</DOCHDR>
<html>
<head>
   <title>Rxlist of Indications and Side Effects -  Antidepressant Drugs 
</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a>
<hr></p></center>

<h1 align=center>Antidepressant Medications</h1>

<h4>Medications included in this category primarily fall into the following
4 sub-categories A-D: </h4>

<li>Monoamine Oxidase (MAO) Inhibitors (A)</li>

<dl>
<dd> (examples: isocarboxazid, phenelzine, tranylcypromine) </dd>
</dl>

<li>Tricyclics (B)</li>

<dl>
<dd> (examples: amitriptyline, imipramine, doxepin) </dd>
</dl>

<li>Heterocyclics (C)</li>

<dl>
<dd> (examples: trazodone, maprotiline, bupropion) a sub-category of very
dissimilar medications </dd>
</dl>

<li>Seratonin-reuptake Inhibitors (D)</li>

<dl>
<dd> (examples: fluoxetine, paroxetine, sertraline) </dd>
</dl>

<p>These drugs selectively effect neurotransmitter mechanisms in the central
nervous system. 
<hr><a name="#TOP"></a></p>

<h3><a href="disclaim.htm">INDICATIONS</a></h3>

<p><b>A,B,C,D refer to sub-categories above</b> </p>

<li>alcoholism D+ </li>

<li>anorexia nervosa D+ </li>

<li>anxiety C+ </li>

<li>autism B+, D+ </li>

<li>attention-deficit hyperactivity disorder B+, C+ </li>

<li>bulimia B+, D+ </li>

<li>chronic obstructive pulmonary disease B+ </li>

<li>enuresis B </li>

<li>fibromyalgia B+ </li>

<li>depression A, B, C, D </li>

<li>diabetic neuropathy B+ </li>

<li>insomnia B+, C+ </li>

<li>migraine prophylaxis A+,B+ </li>

<li>obesity D+ </li>

<li>obsessive-compulsive disorder A+, B, D </li>

<li>orthostatic hypotension A+, D+ </li>

<li>pain B </li>

<li>panic disorder A+, B+, D+ </li>

<li>phobic disorder A+, B+ </li>

<li>post-traumatic stress disorder D+ </li>

<li>premenstrual syndrome (PMS) B+ </li>

<li>respiratory depression B+ </li>

<li>schizophrenia D+ </li>

<li>sleep apnea B+ </li>

<dl>
<dd>+ = not an FDA approved indication</dd>
</dl>

<p>
<hr><a href="#TOP">Return to Top</a> 
<hr></p>

<h3><a href="disclaim.htm">Side Effects and Adverse Reactions</a></h3>

<p><b>A,B,C,D refer to sub-categories above</b> </p>

<li>acne D </li>

<li>abdominal pain B, C, D </li>

<li>agitation D </li>

<li>agranulocytosis B </li>

<li>akathisia D </li>

<li>alopecia D </li>

<li>anemia B, D </li>

<li>angina A, D </li>

<li>angioedema D </li>

<li>anorexia B, C, D </li>

<li>anxiety B, C, D </li>

<li>appetite stimulation A </li>

<li>asthenia C, D </li>

<li>blurred vision A, B, C, D </li>

<li>breast enlargement B, C </li>

<li>confusion A, B, C, D </li>

<li>constipation B, C, D </li>

<li>contact dermatitis D </li>

<li>cough D </li>

<li>cycloplegia B, C </li>

<li>diaphoresis A, C, D </li>

<li>diarrhea A, B, C, D </li>

<li>diabetes mellitus A, B, C, D </li>

<li>dizziness A, B, C, D </li>

<li>drowsiness A, B, C, D </li>

<li>dysgeusia D </li>

<li>dyspepsia D </li>

<li>dyspnea D </li>

<li>dystonia D </li>

<li>dysuria D </li>

<li>eosinophilia B </li>

<li>EEG abnormalities B, D </li>

<li>EKG abnormalities B, C </li>

<li>erythema B, C, D </li>

<li>fatigue C, C </li>

<li>fever A, B, C </li>

<li>flatulance D </li>

<li>galactorrhea B, C </li>

<li>hallucinations C </li>

<li>heart failure A, B, C </li>

<li>headache A, D, C </li>

<li>hepatic enzyme elevation D </li>

<li>hepatitis A </li>

<li>hot flashes D </li>

<li>hyperglycemia D </li>

<li>hypertension A, B, C </li>

<li>hypertensive crisis A </li>

<li>hypoglycemia D </li>

<li>hyponatremia A, D </li>

<li>hypoosmolarity A, D </li>

<li>hypotension A, C, D </li>

<li>hypothyroidism D </li>

<li>impotence A, B, C, D </li>

<li>increased intraocular pressure B, C </li>

<li>intracranial hemorrhage A </li>

<li>insomnia C, D </li>

<li>jaundice A, B, C </li>

<li>leukopenia B </li>

<li>libido decrease B, C, D </li>

<li>mania D </li>

<li>myalgia D </li>

<li>myasthenia D </li>

<li>mydriasis A, B, C </li>

<li>myocardial infarction B, C </li>

<li>myopathy D </li>

<li>nasal congestion D </li>

<li>nausea &amp; vomiting A, B, C, D </li>

<li>orthostatic hypotension A, B, C, D </li>

<li>pain C, D </li>

<li>palpitations B, C, D </li>

<li>paresthesias D </li>

<li>parkinsonism B, C, D </li>

<li>peripheral edema A </li>

<li>pharyngitis D </li>

<li>photophobia A </li>

<li>photosensitivity B, C </li>

<li>polyuria D </li>

<li>premature ventricular contractions C </li>

<li>priapism A, C </li>

<li>pruritus B, C, D </li>

<li>psychosis C </li>

<li>purpura B </li>

<li>rash D </li>

<li>restlessness C </li>

<li>sedation B, C </li>

<li>seizures B, C, D </li>

<li>sexual dysfunction A, B, C, D </li>

<li>SIADH A, B, C, D </li>

<li>sinus bradycardia A, D </li>

<li>sinus tachycardia A </li>

<li>stroke B, C </li>

<li>suicidal ideation D </li>

<li>testicular swelling B, C </li>

<li>thrombocytopenia B </li>

<li>torsades de pointes B, C </li>

<li>toxic epidermal necrolysis D </li>

<li>tremor A, B, C, D </li>

<li>urinary retention A, B, C </li>

<li>urticaria B, C, D </li>

<li>vasculitis B, C </li>

<li>ventricular tachycardia B, C </li>

<li>visual impairment D </li>

<li>weakness A </li>

<li>weight gain A </li>

<li>weight loss D </li>

<li>xerosis D </li>

<li>xerostomia A, B, C, D 
<hr width="100%" ><a href="#top">Return to Top</a> 
<hr><font SIZE=+2><a href="http://www.rxlist.com/disclaim.htm">Important
- Please Read!</a> </font></li>

<h4 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">Search
RxList</a> <img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com/mono.htm">RxLists
of Indications and Side Effects</a> <img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">Rxlist
Home Page</a> </h4>

<center><p><font SIZE=-2>copyright 1996 Neil Sandow, Pharm.D. - all rights
reserved </font></p></center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-6</DOCNO>
<DOCOLDNO>IA018-000200-B041-52</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/fluvox.htm 206.86.175.201 19970106230812 text/html 60406
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:01:55 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 60223
Last-modified: Fri, 18 Oct 1996 21:45:12 GMT
</DOCHDR>
<html>
<head>
   <title>Fluvoxamine - RxList Generic Information</title>
   <meta name="keywords" content="Dumirox, Faverin, Fevarin, Floxyfral, Luvox, 
Maveral">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Fluvoxamine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Fluvoxamine maleate is a selective serotonin (5-HT) reuptake inhibitor
(SSRI) belonging to a new chemical series, the 2-aminoethyl oxime ethers
of aralkylketones. It is chemically unrelated to other SSRIs and clomipramine.
It is chemically designated as 5-methoxy- 4'-(trifluoromethyl)valerophenone-(E)-O-
(2-aminoethyl)oxime maleate (1:1) and has the empirical formula C15H21O2N2F3.C4H4O4.
Its molecular weight is 434.4. </p>

<p>Fluvoxamine maleate is a white or off white, odorless, crystalline powder
which is sparingly soluble in water, freely soluble in ethanol and chloroform
and practically insoluble in diethyl ether. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>PHARMACODYNAMICS </p>

<p>The mechanism of action of fluvoxamine maleate in Obsessive Compulsive
Disorder is presumed to be linked to its specific serotonin reuptake inhibition
in brain neurons. In preclinical studies, it was found that fluvoxamine
inhibited neuronal uptake of serotonin. </p>

<p>In In Vitro studies fluvoxamine maleate had no significant affinity
for histaminergic, alpha or beta adrenergic, muscarinic, or dopaminergic
receptors. Antagonism of some of these receptors is thought to be associated
with various sedative, cardiovascular, anticholinergic, and extrapyramidal
effects of some psychotropic drugs. </p>

<p>PHARMACOKINETICS </p>

<p>BIOAVAILABILITY: The absolute bioavailability of fluvoxamine maleate
is 53%. Oral bioavailability is not significantly affected by food. </p>

<p>In a dose proportionality study involving fluvoxamine maleate at 100,
200 and 300 mg/day for 10 consecutive days in 30 normal volunteers, steady
state was achieved after about a week of dosing. Maximum plasma concentrations
at steady state occurred within 3-8 hours of dosing and reached concentrations
averaging 88, 283 and 546 ng/mL, respectively. Thus, fluvoxamine had nonlinear
pharmacokinetics over this dose range, i.e., higher doses of fluvoxamine
maleate produced disproportionately higher concentrations than predicted
from the lower dose. </p>

<p>DISTRIBUTION/PROTEIN BINDING: The mean apparent volume of distribution
for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
Approximately 80% of fluvoxamine is bound to plasma protein, mostly albumin,
over a concentration range of 20 to 2000 ng/mL. </p>

<p>METABOLISM: Fluvoxamine maleate is extensively metabolized by the liver;
the main metabolic routes are oxidative demethylation and deamination.
Nine metabolites were identified following a 5 mg radiolabelled dose of
fluvoxamine maleate, constituting approximately 85% of the urinary excretion
products of fluvoxamine. The main human metabolite was fluvoxamine acid
which, together with its N- acetylated analog, accounted for about 60%
of the urinary excretion products. A third metabolite, fluvoxethanol, formed
by oxidative deamination, accounted for about 10%. Fluvoxamine acid and
fluvoxethanol were tested in an In Vitro assay of serotonin and norepinephrine
reuptake inhibition in rats; they were inactive except for a weak effect
of the former metabolite on inhibition of serotonin uptake (1-2 orders
of magnitude less potent than the parent compound). Approximately 2% of
fluvoxamine was excreted in urine unchanged. (See PRECAUTIONS--Drug Interactions)
</p>

<p>ELIMINATION: Following a 14C-labelled oral dose of fluvoxamine maleate
(5 mg), an average of 94% of drug-related products was recovered in the
urine within 71 hours. </p>

<p>The mean plasma half-life of fluvoxamine at steady state after multiple
oral doses of 100 mg/day in healthy, young volunteers was 15.6 hours. </p>

<p>ELDERLY SUBJECTS: In a study of Fluvoxamine Tablets at 50 and 100 mg
comparing elderly (aged 66-73) and young subjects (aged 19-35), mean maximum
plasma concentrations in the elderly were 40% higher. The multiple dose
elimination half-life of fluvoxamine was 17.4 and 25.9 hours in the elderly
compared to 13.6 and 15.6 hours in the young subjects at steady state for
50 and 100 mg doses, respectively. </p>

<p>In elderly patients, the clearance of fluvoxamine was reduced by about
50% and, therefore, Fluvoxamine Tablets should be slowly titrated during
initiation of therapy. </p>

<p>HEPATIC AND RENAL DISEASE: A cross study comparison (healthy subjects
vs. patients with hepatic dysfunction) suggested a 30% decrease in fluvoxamine
clearance in association with hepatic dysfunction. The mean minimum plasma
concentrations in renally impaired patients (creatinine clearance of 5
to 45 mL/min) after 4 and 6 weeks of treatment (50 mg bid, N=13) were comparable
to each other, suggesting no accumulation of fluvoxamine in these patients.
(See PRECAUTIONS--Use In Patients With Concomitant Illness) </p>

<p>CLINICAL STUDIES </p>

<p>CLINICAL TRIALS </p>

<p>The effectiveness of Fluvoxamine Tablets for the treatment of Obsessive
Compulsive Disorder (OCD) was demonstrated in two 10-week multicenter,
parallel group studies of adult outpatients. Patients in these trials were
titrated to a total daily fluvoxamine maleate dose of 150 mg/day over the
first two weeks of the trial, following which the dose was adjusted within
a range of 100-300 mg/day (on a bid schedule), on the basis of response
and tolerance. Patients in these studies had moderate to severe OCD (DSM-III-R),
with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale
(Y-BOCS), total score of 23. Patients receiving fluvoxamine maleate experienced
mean reductions of approximately 4 to 5 units on the Y-BOCS total score,
compared to a 2 unit reduction for placebo patients. </p>

<p>The following table provides the outcome classification by treatment
group on the Global Improvement item of the Clinical Global Impressions
(CGI) scale for both studies combined.</p>

<pre>
                     OUTCOME CLASSIFICATION (%) ON CGI-GLOBAL
                         IMPROVEMENT ITEM FOR COMPLETERS
                            IN POOL OF TWO OCD STUDIES
            Outcome                       Fluvoxamine               Placebo
         Classification                     (N=120)                 (N=134)
Worse                                          4%                      6%
No Change                                     31%                     51%
Minimally Improved                            22%                     32%
Much Improved                                 30%                     10%
Very Much Improved                            13%                      2%
Exploratory analyses for age and gender effects on outcomes did not suggest any
differential responsiveness on the basis of age or sex.</pre>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Fluvoxamine Tablets are indicated for the treatment of obsessions and
compulsions in patients with Obsessive Compulsive Disorder (OCD), as defined
in the DSM-III-R. The obsessions or compulsions cause marked distress,
are time-consuming, or significantly interfere with social or occupational
functioning. </p>

<p>The efficacy of Fluvoxamine Tablets was established in two 10-week trials
with obsessive compulsive outpatients with the diagnosis of Obsessive Compulsive
Disorder as defined in DSM-III-R. (See Clinical Trials under CLINICAL STUDIES.)
Obsessive Compulsive Disorder is characterized by recurrent and persistent
ideas, thoughts, impulses or images (obsessions) that are ego- dystonic
and/or repetitive, purposeful, and intentional behaviors (compulsions)
that are recognized by the person as excessive or unreasonable. </p>

<p>The effectiveness of Fluvoxamine Tablets for long-term use, i.e., for
more than 10 weeks, has not been systematically evaluated in placebo-controlled
trials. Therefore, the physician who elects to use Fluvoxamine Tablets
for extended periods should periodically re-evaluate the long-term usefulness
of the drug for the individual patient. (See DOSAGE AND ADMINISTRATION)
</p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Co-administration of terfenadine or astemizole with Fluvoxamine Tablets
is contraindicated (see WARNINGS and PRECAUTIONS). </p>

<p>Fluvoxamine Tablets are contraindicated in patients with a history of
hypersensitivity to fluvoxamine maleate. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>POTENTIAL FOR INTERACTION WITH MONOAMINE OXIDASE INHIBITORS IN PATIENTS
RECEIVING ANOTHER SEROTONIN REUPTAKE INHIBITOR DRUG IN COMBINATION WITH
MONOAMINE OXIDASE INHIBITORS (MAOI), </p>

<p>THERE HAVE BEEN REPORTS OF SERIOUS, SOMETIMES FATAL, REACTIONS INCLUDING
HYPERTHERMIA, RIGIDITY, MYOCLONUS, AUTONOMIC INSTABILITY WITH POSSIBLE
RAPID FLUCTUATIONS OF VITAL SIGNS, AND MENTAL STATUS CHANGES THAT INCLUDE
EXTREME AGITATION PROGRESSING TO DELIRIUM AND COMA. THESE REACTIONS HAVE
ALSO BEEN REPORTED IN PATIENTS WHO HAVE DISCONTINUED THAT DRUG AND HAVE
BEEN STARTED ON A MAOI. SOME CASES PRESENTED WITH FEATURES RESEMBLING NEUROLEPTIC
MALIGNANT SYNDROME. THEREFORE, IT IS RECOMMENDED THAT Fluvoxamine TABLETS
NOT BE USED IN COMBINATION WITH A MAOI, OR WITHIN 14 DAYS OF DISCONTINUING
TREATMENT WITH A MAOI. AFTER STOPPING Fluvoxamine TABLETS, AT LEAST 2 WEEKS
SHOULD BE ALLOWED BEFORE STARTING A MAOI. </p>

<p>POTENTIAL TERFENADINE AND ASTEMIZOLE INTERACTIONS : TERFENADINE AND
ASTEMIZOLE ARE BOTH METABOLIZED BY THE CYTOCHROME P450IIIA4 ISOZYME, AND
IT HAS BEEN DEMONSTRATED THAT KETOCONAZOLE, A POTENT INHIBITOR OF IIIA4,
BLOCKS THE METABOLISM OF TERFENADINE AND ASTEMIZOLE, RESULTING IN INCREASED
PLASMA CONCENTRATIONS OF PARENT DRUG. INCREASED PLASMA CONCENTRATIONS OF
TERFENADINE AND ASTEMIZOLE CAUSE QT PROLONGATION AND TORSADES DE POINTES-TYPE
VENTRICULAR TACHYCARDIA, SOMETIMES FATAL. AS NOTED ABOVE, A SUBSTANTIAL
PHARMACOKINETIC INTERACTION HAS BEEN OBSERVED FOR FLUVOXAMINE IN COMBINATION
WITH ALPRAZOLAM, A DRUG THAT IS KNOWN TO BE METABOLIZED BY THE IIIA4 ISOZYME.
</p>

<p>ALTHOUGH IT HAS NOT BEEN DEFINITIVELY DEMONSTRATED THAT FLUVOXAMINE
IS A POTENT IIIA4 INHIBITOR, IT IS LIKELY TO BE, GIVEN THE SUBSTANTIAL
INTERACTION OF FLUVOXAMINE WITH ALPRAZOLAM. CONSEQUENTLY, IT IS RECOMMENDED
THAT FLUVOXAMINE NOT BE USED IN COMBINATION WITH EITHER TERFENADINE OR
ASTEMIZOLE (SEE CONTRAINDICATIONS AND PRECAUTIONS). </p>

<p>OTHER POTENTIALLY IMPORTANT DRUG INTERACTIONS </p>

<p>(Also see PRECAUTIONS--Drug Interactions) </p>

<p>BENZODIAZEPINES: Benzodiazepines metabolized by hepatic oxidation (e.g.,
alprazolam, midazolam, triazolam, etc.) should be used with caution because
the clearance of these drugs is likely to be reduced by fluvoxamine. The
clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam,
oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </p>

<p>Alprazolam--When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg
qid) were co-administered to steady state, plasma concentrations and other
pharmacokinetic parameters (AUC, Cmax, T1/2) of alprazolam were approximately
twice those observed when alprazolam was administered alone; oral clearance
was reduced by about 50%. The elevated plasma alprazolam concentrations
resulted in decreased psychomotor performance and memory. This interaction,
which has not been investigated using higher doses of fluvoxamine, may
be more pronounced if a 300 mg daily dose is co-administered, particularly
since fluvoxamine exhibits non- linear pharmacokinetics over the dosage
range 100-300 mg. If alprazolam is co- administered with FluvoxamineTablets,
the initial alprazolam dosage should be at least halved and titration to
the lowest effective dose is recommended. No dosage adjustment is required
for FluvoxamineTablets. </p>

<p>Diazepam--The co-administration of FluvoxamineTablets and diazepam is
generally not advisable. Because fluvoxamine reduces the clearance of both
diazepam and its active metabolite, N- desmethyldiazepam, there is a strong
likelihood of substantial accumulation of both species during chronic co-administration.
Evidence supporting the conclusion that it is inadvisable to co-administer
fluvoxamine and diazepam is derived from a study in which healthy volunteers
taking 150 mg/day of fluvoxamine were administered a single oral dose of
10 mg of diazepam. In these subjects (N=8), the clearance of diazepam was
reduced by 65% and that of N- desmethyldiazepam to a level that was too
low to measure over the course of the 2 week long study. </p>

<p>It is likely that this experience significantly underestimates the degree
of accumulation that might occur with repeated diazepam administration.
Moreover, as noted with alprazolam, the effect of fluvoxamine may even
be more pronounced when it is administered at higher doses. </p>

<p>Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.
</p>

<p>THEOPHYLLINE: The effect of steady-state fluvoxamine (50 mg bid) on
the pharmacokinetics of a single dose of theophylline (375 mg as 442 mg
aminophylline) was evaluated in 12 healthy non-smoking, male volunteers.
The clearance of theophylline was decreased approximately 3-fold. Therefore,
if theophylline is co-administered with fluvoxamine maleate, its dose should
be reduced to one third of the usual daily maintenance dose and plasma
concentrations of theophylline should be monitored. No dosage adjustment
is required for FluvoxamineTablets. </p>

<p>WARFARIN: When fluvoxamine maleate (50 mg tid) was administered concomitantly
with warfarin for two weeks, warfarin plasma concentrations increased by
98% and prothrombin times were prolonged. Thus patients receiving oral
anticoagulants and FluvoxamineTablets should have their prothrombin time
monitored and their anticoagulant dose adjusted accordingly. No dosage
adjustment is required for FluvoxamineTablets. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL </p>

<p>ACTIVATION OF MANIA/HYPOMANIA: During premarketing studies involving
primarily depressed patients, hypomania or mania occurred in approximately
1% of patients treated with fluvoxamine. Activation of mania/hypomania
has also been reported in a small proportion of patients with major affective
disorder who were treated with other marketed antidepressants. As with
all antidepressants, FluvoxamineTablets should be used cautiously in patients
with a history of mania. </p>

<p>SEIZURES: During premarketing studies, seizures were reported in 0.2%
of fluvoxamine-treated patients. FluvoxamineTablets should be used cautiously
in patients with a history of seizures. It should be discontinued in any
patient who develops seizures. </p>

<p>SUICIDE: The possibility of a suicide attempt is inherent in patients
with depressive symptoms, whether these occur in primary depression or
in association with another primary disorder such as OCD. Close supervision
of high risk patients should accompany initial drug therapy. Prescriptions
for FluvoxamineTablets should be written for the smallest quantity of tablets
consistent with good patient management in order to reduce the risk of
overdose. </p>

<p>USE IN PATIENTS WITH CONCOMITANT ILLNESS: Closely monitored clinical
experience with FluvoxamineTablets in patients with concomitant systemic
illness is limited. Caution is advised in administering FluvoxamineTablets
to patients with diseases or conditions that could affect hemodynamic responses
or metabolism. </p>

<p>FluvoxamineTablets have not been evaluated or used to any appreciable
extent in patients with a recent history of myocardial infarction or unstable
heart disease. Patients with these diagnoses were systematically excluded
from many clinical studies during the product's premarketing testing. Evaluation
of the electrocardiograms for patients with depression or OCD who participated
in premarketing studies revealed no differences between fluvoxamine and
placebo in the emergence of clinically important ECG changes. </p>

<p>In patients with liver dysfunction, fluvoxamine clearance was decreased
by approximately 30%. FluvoxamineTablets should be slowly titrated in patients
with liver dysfunction during the initiation of treatment. </p>

<p>INFORMATION FOR PATIENTS </p>

<p>Physicians are advised to discuss the following issues with patients
for whom they prescribe FluvoxamineTablets: </p>

<p>INTERFERENCE WITH COGNITIVE OR MOTOR PERFORMANCE: Since any psychoactive
drug may impair judgment, thinking , or motor skills, patients should be
cautioned about operating hazardous machinery, including automobiles, until
they are certain that FluvoxamineTablets therapy does not adversely affect
their ability to engage in such activities. </p>

<p>PREGNANCY: Patients should be advised to notify their physicians if
they become pregnant or intend to become pregnant during therapy with FluvoxamineTablets.
NURSING: Patients receiving FluvoxamineTablets should be advised to notify
their physicians if they are breast feeding an infant. (See PRECAUTIONS-
-Nursing Mothers) </p>

<p>CONCOMITANT MEDICATION: Patients should be advised to notify their physicians
if they are taking, or plan to take, any prescription or over-the-counter
drugs, since there is a potential for clinically important interactions
with fluvoxamine Tablets. </p>

<p>ALCOHOL: As with other psychotropic medications, patients should be
advised to avoid alcohol while taking FluvoxamineTablets. </p>

<p>ALLERGIC REACTIONS: Patients should be advised to notify their physicians
if they develop a rash, hives, or a related allergic phenomenon during
therapy with FluvoxamineTablets. </p>

<p>LABORATORY TESTS </p>

<p>There are no specific laboratory tests recommended. </p>

<p>DRUG INTERACTIONS </p>

<p>POTENTIAL INTERACTIONS WITH DRUGS THAT INHIBIT OR ARE METABOLIZED BY
CYTOCHROME P450 ISOZYMES: Multiple hepatic cytochrome P450 (CYP450) enzymes
are involved in the oxidative biotransformation of a large number of structurally
different drugs and endogenous compounds. The available knowledge concerning
the relationship of fluvoxamine and the CYP450 enzyme system has been obtained
mostly from pharmacokinetic interaction studies conducted in healthy volunteers,
but some preliminary In Vitro data are also available. Based on a finding
of substantial interactions of fluvoxamine with certain of these drugs
(see later parts of this section and also WARNINGS for details) and limited
In Vitro data for the IIIA4 isozyme, it appears that fluvoxamine inhibits
the following isozymes that are known to be involved in the metabolism
of the listed drugs:</p>

<pre>

           IA2                         IIC9                     IIIA4
-----------------------------------------------------------------------------
     Warfarin                        Warfarin                 Alprazolam
-----------------------------------------------------------------------------
     Theophylline
-----------------------------------------------------------------------------
     Propranolol
</pre>

<p>In Vitro data suggest that fluvoxamine is a relatively weak inhibitor
of the IID6 isozyme. </p>

<p>None of the drugs studied for drug interactions significantly affected
the pharmacokinetics of fluvoxamine. However, the metabolism of fluvoxamine
has not been fully characterized and the effects of potent inhibitors of
IID6, such as quinidine, or of IIIA4 such as ketoconazole, on fluvoxamine
metabolism have not been studied. </p>

<p>A clinically significant fluvoxamine interaction is possible with drugs
having a narrow therapeutic ratio such as terfenadine or astemizole, warfarin,
theophylline, certain benzodiazepines and phenytoin. If FluvoxamineTablets
are to be administered together with a drug that is eliminated via oxidative
metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic
effects of the latter drug should be monitored closely, at least until
steady- state conditions are reached (See WARNINGS). </p>

<p>CNS ACTIVE DRUGS: Monoamine Oxidase Inhibitors: See WARNINGS </p>

<p>Alprazolam: See WARNINGS </p>

<p>Diazepam: See WARNINGS </p>

<p>Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg bid)
in healthy male volunteers (N=12) and a single dose of lorazepam (4 mg
single dose) indicated no significant pharmacokinetic interaction. On average,
both lorazepam alone and lorazepam with fluvoxamine produced substantial
decrements in cognitive functioning; however, the co-administration of
fluvoxamine and lorazepam did not produce larger mean decrements compared
to lorazepam alone. Lithium: As with other serotonergic drugs, lithium
may enhance the serotonergic effects of fluvoxamine and, therefore, the
combination should be used with caution. </p>

<p>Seizures have been reported with the co- administration of fluvoxamine
maleate and lithium. </p>

<p>Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine,
and the combination should, therefore, be used with caution. Severe vomiting
has been reported with the co-administration of fluvoxamine maleate and
tryptophan. Clozapine: Elevated serum levels of clozapine have been reported
in patients taking fluvoxamine maleate and clozapine. Since clozapine related
seizures and orthostatic hypotension appear to be dose related, the risk
of these adverse events may be higher when fluvoxamine and clozapine are
co-administered. Patients should be closely monitored when fluvoxamine
maleate and clozapine are used concurrently. </p>

<p>Alcohol: Studies involving single 40 g doses of ethanol (oral administration
in one study and intravenous in the other) and multiple dosing with fluvoxamine
maleate (50 mg bid) revealed no effect of either drug on the pharmacokinetics
or pharmacodynamics of the other. </p>

<p>Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA
levels have been reported with the co-administration of fluvoxamine maleate
and amitriptyline, clomipramine or imipramine. Caution is indicated with
the co- administration of FluvoxamineTablets and TCAs. </p>

<p>Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity
have been reported with the co-administration of fluvoxamine maleate and
carbamazepine. Methadone: Significantly increased methadone (plasma level:dose)
ratios have been reported when fluvoxamine maleate was administered to
patients receiving maintenance methadone treatment, with symptoms of opioid
intoxication in one patient. Opioid withdrawal symptoms were reported following
fluvoxamine maleate discontinuation in another patient. </p>

<p>OTHER DRUGS: </p>

<p>Theophylline: See WARNINGS </p>

<p>Propranolol And Other Beta-Blockers: Co- administration of fluvoxamine
maleate 100 mg per day and propranolol 160 mg per day in normal volunteers
resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol
plasma concentrations. In this study, there was a slight potentiation of
the propranolol-induced reduction in heart rate and reduction in the exercise
diastolic pressure. </p>

<p>One case of bradycardia and hypotension and a second case of orthostatic
hypotension have been reported with the co-administration of fluvoxamine
and metoprolol. </p>

<p>If propranolol or metoprolol is co-administered with FluvoxamineTablets,
a reduction in the initial beta-blocker dose and more cautious dose titration
is recommended. No dosage adjustment is required for FluvoxamineTablets.
Co-administration of fluvoxamine maleate 100 mg per day with atenolol 100
mg per day (N=6) did not affect the plasma concentrations of atenolol.
Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol
is eliminated primarily by renal excretion. </p>

<p>Warfarin: See WARNINGS </p>

<p>Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days
(N=8) did not significantly affect the pharmacokinetics of a 1.25 mg single
intravenous dose of digoxin. </p>

<p>Diltiazem: Bradycardia has been reported with the co-administration
of fluvoxamine maleate and diltiazem. </p>

<p>EFFECTS OF SMOKING ON FLUVOXAMINE METABOLISM: Smokers had a 25% increase
in the metabolism of fluvoxamine compared to nonsmokers. </p>

<p>ELECTROCONVULSIVE THERAPY (ECT): There are no clinical studies establishing
the benefits or risks of combined use of ECT and fluvoxamine maleate. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY </p>

<p>CARCINOGENESIS: There is no evidence of carcinogenicity, mutagenicity
or impairment of fertility with fluvoxamine maleate. </p>

<p>There was no evidence of carcinogenicity in rats treated orally with
fluvoxamine maleate for 30 months or hamsters treated orally with fluvoxamine
maleate for 20 (females) or 26 (males) months. The daily doses in the high
dose groups in these studies were increased over the course of the study
from a minimum of 160 mg/kg to a maximum of 240 mg/kg in rats, and from
a minimum of 135 mg/kg to a maximum of 240 mg/kg in hamsters. The maximum
dose of 240 mg/kg is approximately 6 times the maximum human daily dose
on a mg/M(squared) basis. </p>

<p>MUTAGENESIS: No evidence of mutagenic potential was observed in a mouse
micronucleus test, an In Vitro chromosome aberration test, or the Ames
microbial mutagen test with or without metabolic activation. </p>

<p>IMPAIRMENT OF FERTILITY: In fertility studies of male and female rats,
up to 80 mg/kg/day orally of fluvoxamine maleate, (approximately 2 times
the maximum human daily dose on a mg/M(squared) basis) had no effect on
mating performance, duration of gestation, or pregnancy rate. </p>

<p>PREGNANCY </p>

<p>TERATOGENIC EFFECTS--PREGNANCY CATEGORY C: In teratology studies in
rats and rabbits, daily oral doses of fluvoxamine maleate of up to 80 and
40 mg/kg, respectively (approximately 2 times the maximum human daily dose
on a mg/M(squared) basis) caused no fetal malformations. However, in other
reproduction studies in which pregnant rats were dosed through weaning
there was (1) an increase in pup mortality at birth (seen at 80 mg/kg and
above but not at 20 mg/kg), and (2) decreases in postnatal pup weights
(seen at 160 but not at 80 mg/kg) and survival (seen at all doses; lowest
dose tested = 5 mg/kg). (Doses of 5, 20, 80, and 160 mg/kg are approximately
0.1, 0.5, 2, and 4 times the maximum human daily dose on a mg/M(squared)
basis.) While the results of a cross- fostering study implied that at least
some of these results likely occurred secondarily to maternal toxicity,
the role of a direct drug effect on the fetuses or pups could not be ruled
out. There are no adequate and well- controlled studies in pregnant women.
Fluvoxamine maleate should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus. </p>

<p>LABOR AND DELIVERY </p>

<p>The effect of fluvoxamine on labor and delivery in humans is unknown.
</p>

<p>NURSING MOTHERS </p>

<p>As for many other drugs, fluvoxamine is secreted in human breast milk.
The decision of whether to discontinue nursing or to discontinue the drug
should take into account the potential for serious adverse effects from
exposure to fluvoxamine in the nursing infant as well as the potential
benefits of fluvoxamine (fluvoxamine maleate) Tablets therapy to the mother.
</p>

<p>PEDIATRIC USE </p>

<p>Safety and effectiveness of FluvoxamineTablets in individuals below
18 years of age have not been established. </p>

<p>GERIATRIC USE </p>

<p>Approximately 230 patients participating in controlled premarketing
studies with FluvoxamineTablets were 65 years of age or over. No overall
differences in safety were observed between these patients and younger
patients. Other reported clinical experience has not identified differences
in response between the elderly and younger patients. However, the clearance
of fluvoxamine is decreased by about 50% in elderly compared to younger
patients (see Pharmacokinetics under ACTIONS/CLINICAL PHARMACOLOGY), and
greater sensitivity of some older individuals also cannot be ruled out.
Consequently, FluvoxamineTablets should be slowly titrated during initiation
of therapy. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>POTENTIAL INTERACTIONS WITH DRUGS THAT INHIBIT OR ARE METABOLIZED BY
CYTOCHROME P450 ISOZYMES: </p>

<p>Multiple hepatic cytochrome P450 (CYP450) enzymes are involved in the
oxidative biotransformation of a large number of structurally different
drugs and endogenous compounds. The available knowledge concerning the
relationship of fluvoxamine and the CYP450 enzyme system has been obtained
mostly from pharmacokinetic interaction studies conducted in healthy volunteers,
but some preliminary In Vitro data are also available. Based on a finding
of substantial interactions of fluvoxamine with certain of these drugs
(see later parts of this section and also WARNINGS for details) and limited
In Vitro data for the IIIA4 isozyme, it appears that fluvoxamine inhibits
the following isozymes that are known to be involved in the metabolism
of the listed drugs: </p>

<pre>

           IA2                         IIC9                     IIIA4
-----------------------------------------------------------------------------
     Warfarin                        Warfarin                 Alprazolam
-----------------------------------------------------------------------------
     Theophylline
-----------------------------------------------------------------------------
     Propranolol
</pre>

<p>In Vitro data suggest that fluvoxamine is a relatively weak inhibitor
of the IID6 isozyme. </p>

<p>None of the drugs studied for drug interactions significantly affected
the pharmacokinetics of fluvoxamine. However, the metabolism of fluvoxamine
has not been fully characterized and the effects of potent inhibitors of
IID6, such as quinidine, or of IIIA4 such as ketoconazole, on fluvoxamine
metabolism have not been studied. </p>

<p>A clinically significant fluvoxamine interaction is possible with drugs
having a narrow therapeutic ratio such as terfenadine or astemizole, warfarin,
theophylline, certain benzodiazepines and phenytoin. If FluvoxamineTablets
are to be administered together with a drug that is eliminated via oxidative
metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic
effects of the latter drug should be monitored closely, at least until
steady- state conditions are reached (See WARNINGS). </p>

<p>CNS ACTIVE DRUGS: </p>

<p>Monoamine Oxidase Inhibitors: See WARNINGS </p>

<p>Alprazolam: See WARNINGS </p>

<p>Diazepam: See WARNINGS </p>

<p>Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg bid)
in healthy male volunteers (N=12) and a single dose of lorazepam (4 mg
single dose) indicated no significant pharmacokinetic interaction. On average,
both lorazepam alone and lorazepam with fluvoxamine produced substantial
decrements in cognitive functioning; however, the co-administration of
fluvoxamine and lorazepam did not produce larger mean decrements compared
to lorazepam alone. Lithium: As with other serotonergic drugs, lithium
may enhance the serotonergic effects of fluvoxamine and, therefore, the
combination should be used with caution. </p>

<p>Seizures have been reported with the co- administration of fluvoxamine
maleate and lithium. </p>

<p>Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine,
and the combination should, therefore, be used with caution. Severe vomiting
has been reported with the co-administration of fluvoxamine maleate and
tryptophan. Clozapine: Elevated serum levels of clozapine have been reported
in patients taking fluvoxamine maleate and clozapine. Since clozapine related
seizures and orthostatic hypotension appear to be dose related, the risk
of these adverse events may be higher when fluvoxamine and clozapine are
co-administered. Patients should be closely monitored when fluvoxamine
maleate and clozapine are used concurrently. </p>

<p>Alcohol: Studies involving single 40 g doses of ethanol (oral administration
in one study and intravenous in the other) and multiple dosing with fluvoxamine
maleate (50 mg bid) revealed no effect of either drug on the pharmacokinetics
or pharmacodynamics of the other. </p>

<p>Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA
levels have been reported with the co-administration of fluvoxamine maleate
and amitriptyline, clomipramine or imipramine. Caution is indicated with
the co- administration of FluvoxamineTablets and TCAs. </p>

<p>Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity
have been reported with the co-administration of fluvoxamine maleate and
carbamazepine. Methadone: Significantly increased methadone (plasma level:dose)
ratios have been reported when fluvoxamine maleate was administered to
patients receiving maintenance methadone treatment, with symptoms of opioid
intoxication in one patient. Opioid withdrawal symptoms were reported following
fluvoxamine maleate discontinuation in another patient. </p>

<p>OTHER DRUGS: </p>

<p>Theophylline: See WARNINGS </p>

<p>Propranolol And Other Beta-Blockers: Co- administration of fluvoxamine
maleate 100 mg per day and propranolol 160 mg per day in normal volunteers
resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol
plasma concentrations. In this study, there was a slight potentiation of
the propranolol-induced reduction in heart rate and reduction in the exercise
diastolic pressure. </p>

<p>One case of bradycardia and hypotension and a second case of orthostatic
hypotension have been reported with the co-administration of fluvoxamine
and metoprolol. </p>

<p>If propranolol or metoprolol is co-administered with FluvoxamineTablets,
a reduction in the initial beta-blocker dose and more cautious dose titration
is recommended. No dosage adjustment is required for FluvoxamineTablets.
Co-administration of fluvoxamine maleate 100 mg per day with atenolol 100
mg per day (N=6) did not affect the plasma concentrations of atenolol.
Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol
is eliminated primarily by renal excretion. </p>

<p>Warfarin: See WARNINGS </p>

<p>Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days
(N=8) did not significantly affect the pharmacokinetics of a 1.25 mg single
intravenous dose of digoxin. </p>

<p>Diltiazem: Bradycardia has been reported with the co-administration
of fluvoxamine maleate and diltiazem. </p>

<p>EFFECTS OF SMOKING ON FLUVOXAMINE METABOLISM: Smokers had a 25% increase
in the metabolism of fluvoxamine compared to nonsmokers. </p>

<p>ELECTROCONVULSIVE THERAPY (ECT): There are no clinical studies establishing
the benefits or risks of combined use of ECT and fluvoxamine maleate. (See
Also PRECAUTIONS and WARNINGS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>ASSOCIATED WITH DISCONTINUATION OF TREATMENT </p>

<p>Of the 1087 OCD and depressed patients treated with fluvoxamine maleate
in controlled clinical trials conducted in North America, 22% discontinued
treatment due to an adverse event. The most common events (&gt;/=1%) associated
with discontinuation and considered to be drug related (i.e., those events
associated with dropout at a rate at least twice that of placebo) included:</p>

<pre>
                                     TABLE 1
                          ADVERSE EVENTS ASSOCIATED WITH
                         DISCONTINUATION OF TREATMENT IN
                          OCD AND DEPRESSION POPULATIONS
-----------------------------------------------------------------------------
                                                        PERCENTAGE OF
BODY SYSTEM/                                               PATIENTS
ADVERSE EVENT                                FLUVOXAMINE           PLACEBO
-----------------------------------------------------------------------------
BODY AS A WHOLE
     Headache                                      3%                  1%
     Asthenia                                      2%                 &lt;1%
     Abdominal Pain                                1%                  0%
DIGESTIVE
     Nausea                                        9%                  1%
     Diarrhea                                      1%                 &lt;1%
     Vomiting                                      2%                 &lt;1%
     Anorexia                                      1%                 &lt;1%
     Dyspepsia                                     1%                 &lt;1%
NERVOUS SYSTEM
     Insomnia                                      4%                  1%
     Somnolence                                    4%                 &lt;1%
     Nervousness                                   2%                 &lt;1%
     Agitation                                     2%                 &lt;1%
     Dizziness                                     2%                 &lt;1%
     Anxiety                                       1%                 &lt;1%
     Dry Mouth                                     1%                 &lt;1%
</pre>

<p>INCIDENCE IN CONTROLLED TRIALS </p>

<p>COMMONLY OBSERVED ADVERSE EVENTS IN CONTROLLED CLINICAL TRIALS: </p>

<p>FluvoxamineTablets have been studied in controlled trials of OCD (N=320)
and depression (N=1350). In general, adverse event rates were similar in
the two data sets. The most commonly observed adverse events associated
with the use of FluvoxamineTablets and likely to be drug-related (incidence
of 5% or greater and at least twice that for placebo) derived from Table
2 were: Somnolence, Insomnia, Nervousness, Tremor, Nausea, Dyspepsia, Anorexia,
Vomiting, Abnormal Ejaculation, Asthenia, And Sweating. In a pool of two
studies involving only patients with OCD, the following additional events
were identified using the above rule: Dry Mouth, Decreased Libido, Urinary
Frequency, Anorgasmia, Rhinitis And Taste Perversion. </p>

<p>ADVERSE EVENTS OCCURRING AT AN INCIDENCE OF 1%: Table 2 enumerates adverse
events that occurred at a frequency of 1% or more, and were more frequent
than in the placebo group, among patients treated with FluvoxamineTablets
in two short- term placebo controlled OCD trials (10 week) and depression
trials (6 week) in which patients were dosed in a range of generally 100
to 300 mg/day. This table shows the percentage of patients in each group
who had at least one occurrence of an event at some time during their treatment.
Reported adverse events were classified using a standard COSTART-based
Dictionary terminology. The prescriber should be aware that these figures
cannot be used to predict the incidence of side effects in the course of
usual medical practice where patient characteristics and other factors
may differ from those that prevailed in the clinical trials. Similarly,
the cited frequencies cannot be compared with figures obtained from other
clinical investigations involving different treatments, uses, and investigators.
The cited figures, however, do provide the prescribing physician with some
basis for estimating the relative contribution of drug and non-drug factors
to the side-effect incidence rate in the population studied. </p>

<p>ADVERSE EVENTS IN OCD PLACEBO CONTROLLED STUDIES WHICH ARE MARKEDLY
DIFFERENT (DEFINED AS AT LEAST A TWO-FOLD DIFFERENCE) IN RATE FROM THE
POOLED EVENT RATES IN OCD AND DEPRESSION PLACEBO CONTROLLED STUDIES: The
events in OCD studies with a two-fold decrease in rate compared to event
rates in OCD and depression studies were dysphagia and amblyopia (mostly
blurred vision). Additionally, there was an approximate 25% decrease in
nausea. </p>

<p>The events in OCD studies with a two-fold increase in rate compared
to event rates in OCD and depression studies were: Asthenia, Abnormal Ejaculation
(Mostly Delayed Ejaculation), Anxiety, Infection, Rhinitis, Anorgasmia
(In Males), Depression, Libido Decreased, Pharyngitis, Agitation, Impotence,
Myoclonus/Twitch, Thirst, Weight Loss, Leg Cramps, Myalgia And Urinary
Retention. These events are listed in order of decreasing rates in the
OCD trials. </p>

<p>VITAL SIGN CHANGES </p>

<p>Comparisons of fluvoxamine maleate and placebo groups in separate pools
of short-term OCD and depression trials on (1) median change from baseline
on various vital signs variables and on (2) incidence of patients meeting
criteria for potentially important changes from baseline on various vital
signs variables revealed no important differences between fluvoxamine maleate
and placebo. </p>

<p>LABORATORY CHANGES </p>

<p>Comparisons of fluvoxamine maleate and placebo groups in separate pools
of short-term OCD and depression trials on (1) median change from baseline
on various serum chemistry, hematology, and urinalysis variables and on
(2) incidence of patients meeting criteria for potentially important changes
from baseline on various serum chemistry, hematology, and urinalysis variables
revealed no important differences between fluvoxamine maleate and placebo.
</p>

<p>ECG CHANGES </p>

<p>Comparisons of fluvoxamine maleate and placebo groups in separate pools
of short-term OCD and depression trials on (1) mean change from baseline
on various ECG variables and on (2) incidence of patients meeting criteria
for potentially important changes from baseline on various ECG variables
revealed no important differences between fluvoxamine maleate and placebo.</p>

<pre>
                                     TABLE 2
                         TREATMENT-EMERGENT ADVERSE EVENT
                          INCIDENCE RATES BY BODY SYSTEM
                              IN OCD AND DEPRESSION
                              POPULATIONS COMBINED1
-----------------------------------------------------------------------------
                                                  PERCENTAGE OF PATIENTS
                                                     REPORTING EVENT
BODY SYSTEM/                                 FLUVOXAMINE           PLACEBO
ADVERSE EVENT                                  N = 892             N = 778
-----------------------------------------------------------------------------
BODY AS WHOLE
     Headache                                      22                  20
     Asthenia                                      14                   6
     Flu Syndrome                                   3                   2
     Chills                                         2                   1
CARDIOVASCULAR
     Palpitations                                   3                   2
DIGESTIVE SYSTEM
     Nausea                                        40                  14
     Diarrhea                                      11                   7
     Constipation                                  10                   8
     Dyspepsia                                     10                   5
     Anorexia                                       6                   2
     Vomiting                                       5                   2
     Flatulence                                     4                   3
     Tooth Disorder2                                3                   1
     Dysphagia                                      2                   1
NERVOUS SYSTEM
     Somnolence                                    22                   8
     Insomnia                                      21                  10
     Dry Mouth                                     14                  10
     Nervousness                                   12                   5
     Dizziness                                     11                   6
     Tremor                                         5                   1
     Anxiety                                        5                   3
     Vasodilatation3                                3                   1
     Hypertonia                                     2                   1
     Agitation                                      2                   1
     Decreased Libido                               2                   1
     Depression                                     2                   1
     CNS Stimulation                                2                   1
RESPIRATORY SYSTEM
     Upper Respiratory
       Infection                                    9                   5
     Dyspnea                                        2                   1
     Yawn                                           2                   0
SKIN
     Sweating                                       7                   3
SPECIAL SENSES
     Taste Perversion                               3                   1
     Amblyopia4                                     3                   2
UROGENITAL
     Abnormal Ejaculation5,6                        8                   1
     Urinary Frequency                              3                   2
     Impotence6                                     2                   1
     Anorgasmia                                     2                   0
     Urinary Retention                              1                   0

1   Events for which fluvoxamine maleate incidence was equal to or less than
     placebo are not listed in the table above, but include the following:
     abdominal pain, abnormal dreams, appetite increase, back pain, chest
     pain, confusion, dysmenorrhea, fever, infection, leg cramps, migraine,
     myalgia, pain, paresthesia, pharyngitis, postural hypotension, pruritus,
     rash, rhinitis, thirst and tinnitus.
2   Includes &quot;toothache,&quot; &quot;tooth extraction and abscess,&quot; and &quot;caries.&quot;
3   Mostly feeling warm, hot, or flushed.
4   Mostly &quot;blurred vision.&quot;
5   Mostly &quot;delayed ejaculation.&quot;
6   Incidence based on number of male patients.</pre>

<p>OTHER EVENTS OBSERVED DURING THE PREMARKETING EVALUATION OF FluvoxamineTABLETS
</p>

<p>During premarketing clinical trials conducted in North America and Europe,
multiple doses of fluvoxamine maleate were administered for a combined
total of 2737 patient exposures in patients suffering OCD or Major Depressive
Disorder. Untoward events associated with this exposure were recorded by
clinical investigators using descriptive terminology of their own choosing.
Consequently, it is not possible to provide a meaningful estimate of the
proportion of individuals experiencing adverse events without first grouping
similar types of untoward events into a limited (i.e., reduced) number
of standard event categories. </p>

<p>In the tabulations which follow, a standard COSTART-based Dictionary
terminology has been used to classify reported adverse events. If the COSTART
term for an event was so general as to be uninformative, it was replaced
with a more informative term. The frequencies presented, therefore, represent
the proportion of the 2737 patient exposures to multiple doses of fluvoxamine
maleate who experienced an event of the type cited on at least one occasion
while receiving fluvoxamine maleate. All reported events are included in
the list below, with the following exceptions: 1) those events already
listed in Table 2, which tabulates incidence rates of common adverse experiences
in placebo- controlled OCD and depression clinical trials, are excluded;
2) those events for which a drug cause was considered remote (i.e., neoplasia,
gastrointestinal carcinoma, herpes simplex, herpes zoster, application
site reaction, and unintended pregnancy) are omitted; and 3) events which
were reported in only one patient and judged to not be potentially serious
are not included. It is important to emphasize that, although the events
reported did occur during treatment with fluvoxamine maleate, a causal
relationship to fluvoxamine maleate has not been established. </p>

<p>Events are further classified within body system categories and enumerated
in order of decreasing frequency using the following definitions: frequent
adverse events are defined as those occurring on one or more occasions
in at least 1/100 patients; infrequent adverse events are those occurring
between 1/100 and 1/1000 patients; and rare adverse events are those occurring
in less than 1/1000 patients. </p>

<p>BODY AS A WHOLE: Frequent: accidental injury, malaise; Infrequent: allergic
reaction, neck pain, neck rigidity, overdose, photosensitivity reaction,
suicide attempt; Rare: cyst, pelvic pain, sudden death. </p>

<p>CARDIOVASCULAR SYSTEM: Frequent: hypertension, hypotension, syncope,
tachycardia; Infrequent: angina pectoris, bradycardia, cardiomyopathy,
cardiovascular disease, cold extremities, conduction delay, heart failure,
myocardial infarction, pallor, pulse irregular, ST segment changes; Rare:
AV block, cerebrovascular accident, coronary artery disease, embolus, pericarditis,
phlebitis, pulmonary infarction, supraventricular extrasystoles. </p>

<p>DIGESTIVE SYSTEM: Frequent: elevated liver transaminases; Infrequent:
colitis, eructation, esophagitis, gastritis, gastroenteritis, gastrointestinal
hemorrhage, gastrointestinal ulcer, gingivitis, glossitis, hemorrhoids,
melena, rectal hemorrhage, stomatitis; Rare: biliary pain, cholecystitis,
cholelithiasis, fecal incontinence, hematemesis, intestinal obstruction,
jaundice. </p>

<p>ENDOCRINE SYSTEM: Infrequent: hypothyroidism; Rare: goiter. </p>

<p>HEMIC AND LYMPHATIC SYSTEMS: Infrequent: anemia, ecchymosis, leukocytosis,
lymphadenopathy, thrombocytopenia; Rare: leukopenia, purpura. </p>

<p>METABOLIC AND NUTRITIONAL SYSTEMS: Frequent: edema, weight gain, weight
loss; Infrequent: dehydration, hypercholesterolemia; Rare: diabetes mellitus,
hyperglycemia, hyperlipidemia, hypoglycemia, hypokalemia, lactate dehydrogenase
increased. </p>

<p>MUSCULOSKELETAL SYSTEM: Infrequent: arthralgia, arthritis, bursitis,
generalized muscle spasm, myasthenia, tendinous contracture, tenosynovitis;
Rare: arthrosis, myopathy, pathological fracture. </p>

<p>NERVOUS SYSTEM: Frequent: amnesia, apathy, hyperkinesia, hypokinesia,
manic reaction, myoclonus, psychotic reaction; Infrequent: agoraphobia,
akathisia, ataxia, CNS depression, convulsion, delirium, delusion, depersonalization,
drug dependence, dyskinesia, dystonia, emotional lability, euphoria, extrapyramidal
syndrome, gait unsteady, hallucinations, hemiplegia, hostility, hypersomnia,
hypochondriasis, hypotonia, hysteria, incoordination, increased salivation,
increased libido, neuralgia, paralysis, paranoid reaction, phobia, psychosis,
sleep disorder, stupor, twitching, vertigo; Rare: akinesia, coma, fibrillations,
mutism, obsessions, reflexes decreased, slurred speech, tardive dyskinesia,
torticollis, trismus, withdrawal syndrome. </p>

<p>RESPIRATORY SYSTEM: Frequent: cough increased, sinusitis; Infrequent:
asthma, bronchitis, epistaxis, hoarseness, hyperventilation; Rare: apnea,
congestion of upper airway, hemoptysis, hiccups, laryngismus, obstructive
pulmonary disease, pneumonia. </p>

<p>SKIN: Infrequent: acne, alopecia, dry skin, eczema, exfoliative dermatitis,
furunculosis, seborrhea, skin discoloration, urticaria. </p>

<p>SPECIAL SENSES: Infrequent: accommodation abnormal, conjunctivitis,
deafness, diplopia, dry eyes, ear pain, eye pain, mydriasis, otitis media,
parosmia, photophobia, taste loss, visual field defect; Rare: corneal ulcer,
retinal detachment. </p>

<p>UROGENITAL SYSTEM: Infrequent: anuria, breast pain, cystitis, delayed
menstruation1, dysuria, female lactation1, hematuria, menopause1, menorrhagia1,
metrorrhagia1, nocturia, polyuria, premenstrual syndrome1, urinary incontinence,
urinary tract infection, urinary urgency, urination impaired, vaginal hemorrhage1,
vaginitis1; Rare: kidney calculus, hematospermia2, oliguria. </p>

<p>1 Based on the number of females. </p>

<p>2 Based on the number of males. </p>

<p>NON-US POSTMARKETING REPORTS </p>

<p>Voluntary reports of adverse events in patients taking FluvoxamineTablets
that have been received since market introduction and are of unknown causal
relationship to FluvoxamineTablets use include: toxic epidermal necrolysis,
Stevens-Johnson syndrome, Henoch-Schoenlein purpura, bullous eruption,
priapism, agranulocytosis, neuropathy, aplastic anemia, anaphylactic reaction,
hyponatremia, acute renal failure, and severe akinesia with fever when
fluvoxamine was co- administered with antipsychotic medication. </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>CONTROLLED SUBSTANCE CLASS </p>

<p>FluvoxamineTablets are not controlled substances. </p>

<p>PHYSICAL AND PSYCHOLOGICAL DEPENDENCE </p>

<p>The potential for abuse, tolerance and physical dependence with fluvoxamine
maleate has been studied in a nonhuman primate model. No evidence of dependency
phenomena was found. The discontinuation effects of FluvoxamineTablets
were not systematically evaluated in controlled clinical trials. FluvoxamineTablets
were not systematically studied in clinical trials for potential for abuse,
but there was no indication of drug- seeking behavior in clinical trials.
It should be noted, however, that patients at risk for drug dependency
were systematically excluded from investigational studies of fluvoxamine
maleate. Generally, it is not possible to predict on the basis of preclinical
or premarketing clinical experience the extent to which a CNS active drug
will be misused, diverted, and/or abused once marketed. Consequently, physicians
should carefully evaluate patients for a history of drug abuse and follow
such patients closely, observing them for signs of fluvoxamine maleate
misuse or abuse (i.e., development of tolerance, incrementation of dose,
drug-seeking behavior). </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>HUMAN EXPERIENCE </p>

<p>Worldwide exposure to fluvoxamine maleate includes over 37,000 patients
treated in clinical trials and an estimated exposure of 4,500,000 patients
treated during foreign marketing experience (circa 1992). Of the 354 cases
of deliberate or accidental overdose involving fluvoxamine maleate reported
from this population, there were 19 deaths. Of the 19 deaths, 2 were in
patients taking fluvoxamine maleate alone and the remaining 17 were in
patients taking fluvoxamine maleate along with other drugs. In the remaining
335 patients, 309 had complete recovery after gastric lavage or symptomatic
treatment. One patient had persistent mydriasis after the event, and a
second patient had a bowel infarction requiring a hemicolectomy. In the
remaining 24 patients the outcome was unknown. The highest reported overdose
of fluvoxamine maleate involved a non-lethal ingestion of 10,000 mg (equivalent
of 1-3 months' dosage). The patient fully recovered with no sequelae. </p>

<p>Commonly observed adverse events associated with fluvoxamine maleate
overdose included drowsiness, vomiting, diarrhea, and dizziness. Other
notable signs and symptoms seen with fluvoxamine maleate overdose (single
or mixed drugs) included coma, tachycardia, bradycardia, hypotension, ECG
abnormalities, liver function abnormalities, convulsions, and symptoms
such as aspiration pneumonitis, respiratory difficulties or hypokalemia
that may occur secondary to loss of consciousness or vomiting. </p>

<p>MANAGEMENT OF OVERDOSE </p>

<p>1. An unobstructed airway should be established with maintenance of
respiration as required. Vital signs and ECG should be monitored. </p>

<p>2. Administration of activated charcoal may be as effective as emesis
or lavage and should be considered in treating overdose. Since absorption
with overdose may be delayed, measures to minimize absorption may be necessary
for up to 24 hours post-ingestion. </p>

<p>3. Maintain close observation as clinically indicated. </p>

<p>4. There are no specific antidotes for FluvoxamineTablets. </p>

<p>5. In managing overdosage, consider the possibility of multiple drug
involvement. The physician should consider contacting a poison control
center for additional information on the treatment of any overdosage. </p>

<p>6. Dialysis is not believed to be beneficial. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>The recommended starting dose for FluvoxamineTablets is 50 mg, administered
as a single daily dose at bedtime. In the controlled clinical trials establishing
the effectiveness of FluvoxamineTablets in OCD, patients were titrated
within a dose range of 100 to 300 mg/day. Consequently, the dose should
be increased in 50 mg increments every 4 to 7 days, as tolerated, until
maximum therapeutic benefit is achieved, not to exceed 300 mg per day.
It is advisable that a total daily dose of more than 100 mg should be given
in two divided doses. If the doses are not equal, the larger dose should
be given at bedtime. </p>

<p>DOSAGE FOR ELDERLY OR HEPATICALLY IMPAIRED PATIENTS </p>

<p>Elderly patients and those with hepatic impairment have been observed
to have a decreased clearance of fluvoxamine maleate. Consequently, it
may be appropriate to modify the initial dose and the subsequent dose titration
for these patient groups. </p>

<p>MAINTENANCE/CONTINUATION EXTENDED TREATMENT </p>

<p>Although the efficacy of FluvoxamineTablets beyond 10 weeks of dosing
for OCD has not been documented in controlled trials, OCD is a chronic
condition, and it is reasonable to consider continuation for a responding
patient. Dosage adjustments should be made to maintain the patient on the
lowest effective dosage, and patients should be periodically reassessed
to determine the need for continued treatment. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-7</DOCNO>
<DOCOLDNO>IA018-000200-B041-184</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/disclaim.htm 206.86.175.201 19970106231025 text/html 3271
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:04:11 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3089
Last-modified: Fri, 19 Jul 1996 03:42:33 GMT
</DOCHDR>
<html>
<head>
   <title>Rxlists of Indications and Side Effects Disclaimer</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=75 width=75></a>
<hr></p></center>

<h1 align=center>Important Information Regarding The RxLists of Indications
and Side Effects </h1>

<h3>INDICATIONS</h3>

<h4><a name="#USES"></a>This section of the RxList of Indications and Side
Effects is a complilation of the most commonly listed indications for all
the drugs within the category. Therefore, it may not be implied that all
of the indications (uses) apply to all of the individual drugs within the
category. In fact, it is unlikely that all of the indications apply to
any one drug. Indications that are followed by a plus sign (+) have not
been approved by the FDA (at the time the monograph was published) but
have been reported to have been used by some prescribers for those conditions
with one or more of the drugs within the category. Indications that are
not followed by a plus sign (+) are FDA approved but not necessarily for
all medications within the category.</h4>

<p> For further information on the actual indications of any individual
drug, please consult the full prescribing information for that drug, a
pharmacist, a physician, or other reliable source of drug information.
This information is supplied here for reference purposes only and should
not be solely relied upon for making therapeutic decisions regarding drug
therapy. 
<hr></p>

<h3>Side Effects and Adverse Reactions</h3>

<h4><a name="#SIDE"></a>This section of the RxList of Indications and Side
Effects is a compilation of the most commonly listed side effects and adverse
reactions for all the drugs within the category. Therefore, it may not
be implied that all of the side effects and adverse reactions apply to
all of the individual drugs within the category. In fact, it is unlikely
that all of the side effects and adverse reactions apply to any one drug.
</h4>

<p>For further information on the actual side effects and adverse reactions
of any individual drug, please consult the full prescribing information
for that drug, a pharmacist, a physician, or other reliable source of drug
information. This information is supplied here for reference purposes only
and should not be solely relied upon for making therapeutic decisions regarding
drug therapy. </p>

<center><p>
<hr></p></center>

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi">Search RxList</a>
<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com/mono.htm">RxLists
of Indications and Side Effects</a> <img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">Rxlist
Home Page</a> </p></center>

<center><p><font SIZE=-2>copyright 1996 Neil Sandow, Pharm.D. - all rights
reserved </font></p></center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-8</DOCNO>
<DOCOLDNO>IA018-000200-B039-138</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/guaiphen.htm 206.86.175.201 19970106230232 text/html 7483
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:56:18 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 7301
Last-modified: Tue, 23 Jul 1996 06:14:40 GMT
</DOCHDR>
<html>
<head>
   <title>Guaifenesin and Phenylpropanolamine - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Guaifenesin and Phenylpropanolamine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Each Guaifenesin/phenylpropanolamine <i>long-acting tablet</i> for oral
administration contains </p>

<p>phenylpropanolamine hydrochloride : 75 mg </p>

<p>guaifenesin : 400 mg </p>

<p>This product contains ingredients of the following therapeutic classes:</p>

<p> decongestant and expectorant.</p>

<p> Phenylpropanolamine hydrochloride is a decongestant having the chemical
name, benzenemethanol, alpha-(1-aminoethyl)-, hydrochloride (R*, S*), (+/-
). For chemical structure(s), click here, or use the button on the toolbar.
Guaifenesin is an expectorant having the chemical name, 1,2-propanediol,
3-(2- methoxyphenoxy)-.</p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p> Phenylpropanolamine hydrochloride is an alpha- adrenergic receptor
agonist (sympathomimetic) which produces vasoconstriction by stimulating
alpha-receptors within the mucosa of the respiratory tract. Clinically,
phenylpropanolamine shrinks swollen mucous membranes, reduces tissue hyperemia,
edema, and nasal congestion, and increases nasal airway patency. Guaifenesin
promotes lower respiratory tract drainage by thinning bronchial secretions,
lubricates irritated respiratory tract membranes through increased mucous
flow, and facilitates removal of viscous, inspissated mucus. As a result
of these drugs, sinus and bronchial drainage is improved, and dry, nonproductive
coughs become more productive and less frequent.</p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p> Guaifenesin/phenylpropanolamine is indicated for the symptomatic relief
of sinusitis, bronchitis, pharyngitis, and coryza when these conditions
are associated with nasal congestion and viscous mucus in the lower respiratory
tract.</p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p> Guaifenesin/phenylpropanolamine is contraindicated in individuals with
known hypersensitivity to sympathomimetics, severe hypertension, or in
patients receiving monoamine oxidase inhibitors.</p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p> Sympathomimetic amines should be used with caution in patients with
hypertension, diabetes mellitus, heart disease, peripheral vascular disease,
increased intraocular pressure, hyperthyroidism, or prostatic hypertrophy.</p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p> INFORMATION FOR PATIENTS: Do not crush or chew Guaifenesin/phenylpropanolamine
tablets prior to swallowing.</p>

<p> DRUG INTERACTIONS: Guaifenesin/phenylpropanolamine should not be used
in patients taking monoamine oxidase inhibitors or other sympathomimetics.</p>

<p> DRUG/LABORATORY TEST INTERACTIONS: Guaifenesin has been reported to
interfere with clinical laboratory determinations of urinary 5-hydroxyindoleacetic
acid (5-HIAA) and urinary vanillylmandelic acid (VMA).</p>

<p> PREGNANCY: Pregnancy Category C. Animal reproduction studies have not
been conducted with Guaifenesin/phenylpropanolamine. It is also not known
whether Guaifenesin/phenylpropanolamine can cause fetal harm when administered
to a pregnant woman or can affect reproduction capacity. Guaifenesin/phenylpropanolamine
should be given to a pregnant woman only if clearly needed. </p>

<p>NURSING MOTHERS: It is not known whether the drugs in Guaifenesin/phenylpropanolamine
are excreted in human milk. Because many drugs are excreted in human milk
and because of the potential for serious adverse reactions in nursing infants,
a decision should be made whether to discontinue nursing or to discontinue
the product, taking into account the importance of the drug to the mother.
</p>

<p>PEDIATRIC USE: Safety and effectiveness of Guaifenesin/phenylpropanolamine
tablets in pediatric patients below the age of 6 have not been established.</p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p> Guaifenesin/phenylpropanolamine should not be used in patients taking
monoamine oxidase inhibitors or other sympathomimetics.</p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p> Possible adverse reactions include nervousness, insomnia, restlessness,
headache, nausea, or gastric irritation. These reactions seldom, if ever,
require discontinuation of therapy. Urinary retention may occur in patients
with prostatic hypertrophy.</p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p> The treatment of overdosage should provide symptomatic and supportive
care. If the amount ingested is considered dangerous or excessive, induce
vomiting with ipecac syrup unless the patient is convulsing, comatose,
or has lost the gag reflex, in which case perform gastric lavage using
a large-bore tube. If indicated, follow with activated charcoal and a saline
cathartic. Since the effects of Guaifenesin/phenylpropanolamine may last
up to 12 hours, treatment should be continued for at least that length
of time.</p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p> ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER: one tablet
twice daily (every 12 hours),</p>

<p> CHILDREN 6 TO UNDER 12 YEARS: one-half (1/2) tablet twice daily (every
12 hours). Guaifenesin/phenylpropanolamine is not recommended for children
under 6 years of age. </p>

<p>Tablets may be broken in half for ease of administration without affecting
release of medication but should not be crushed or chewed prior to swallowing.
</p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-9</DOCNO>
<DOCOLDNO>IA018-000200-B034-183</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/parox.htm 206.86.175.201 19970106224338 text/html 59806
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:37:12 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 59623
Last-modified: Sun, 11 Aug 1996 03:46:14 GMT
</DOCHDR>
<html>
<head>
   <title>Paroxetine - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Paroxetine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

 <a name="DESCRIPTION"></a><b>DESCRIPTION 

</b> <p>

Paroxetine is an orally administered antidepressant with

a chemical structure unrelated to other selective serotonin reuptake inhibitors 

or to tricyclic, tetracyclic or other available antidepressant agents. It is

the hydrochloride salt of a phenylpiperidine compound identified chemically as

(-)- trans-4R-(4'-fluorophenyl)-3S-((3',4'-methylenedioxyphenoxy) methyl)

piperidine hydrochloride hemihydrate and has the empirical formula of

C19H20FNO3.HCl.1/2H2O. The molecular weight is 374.8 (329.4 as free base).  

 
<p>
Paroxetine hydrochloride is an odorless, off-white powder, having a melting

point range of 120 deg to 138 deg C and a solubility of 5.4 mg/mL in water.  

 <p>

<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 

</b> <p>

PHARMACODYNAMICS 

 
<p>
The antidepressant action of paroxetine is presumed to be linked to

potentiation of serotonergic activity in the central nervous system resulting

from inhibition of neuronal reuptake of serotonin (5-hydroxy-tryptamine, 5-HT). 

Studies at clinically relevant doses in humans have demonstrated that

paroxetine blocks the uptake of serotonin into human platelets. In Vitro

studies in animals also suggest that paroxetine is a potent and highly

selective inhibitor of neuronal serotonin reuptake and has only very weak

effects on norepinephrine and dopamine neuronal reuptake. In Vitro radioligand

binding studies indicate that paroxetine has little affinity for muscarinic,

alpha1-, alpha2-, beta-adrenergic-, dopamine (D2)-, 5-HT1-, 5-HT2- and

histamine (H1)-receptors; antagonism of muscarinic, histaminergic and alpha1

adrenergic receptors has been associated with various anticholinergic, sedative 

and cardiovascular effects for other psychotropic drugs.  

 
<p>
Because the relative potencies of paroxetine's major metabolites are at most

1/50 of the parent compound, they are essentially inactive.  
<p>
 

PHARMACOKINETICS 

 
<p>
Paroxetine hydrochloride is completely absorbed after oral dosing of a solution 

of the hydrochloride salt. In a study in which normal male subjects (n=15)

received 30 mg tablets daily for 30 days, steady-state paroxetine

concentrations were achieved by approximately 10 days for most subjects,

although it may take substantially longer in an occasional patient. At steady

state, mean values of Cmax, Tmax, Cmin and T1/2 were 61.7 ng/mL (CV 45%), 5.2

hr. (CV 10%), 30.7 ng/mL (CV 67%) and 21.0 hr. (CV 32%), respectively. The

steady-state Cmax and Cmin values were about 6 and 14 times what would be

predicted from single-dose studies. Steady-state drug exposure based on AUC0-24 

was about 8 times greater than would have been predicted from single-dose data

in these subjects. The excess accumulation is a consequence of the fact that

one of the enzymes that metabolizes paroxetine is readily saturable.  

<p>

In steady-state dose proportionality studies involving elderly and nonelderly

patients, at doses of 20 to 40 mg daily for the elderly and 20 to 50 mg daily

for the nonelderly, some nonlinearity was observed in both populations, again

reflecting a saturable metabolic pathway. In comparison to Cmin values after 20 

mg daily, values after 40 mg daily were only about 2 to 3 times greater than

doubled.  

 <p>

Paroxetine is extensively metabolized after oral administration. The principal

metabolites are polar and conjugated products of oxidation and methylation,

which are readily cleared. Conjugates with glucuronic acid and sulfate

predominate, and major metabolites have been isolated and identified. Data

indicate that the metabolites have no more than 1/50 the potency of the parent

compound at inhibiting serotonin uptake. The metabolism of paroxetine is

accomplished in part by cytochrome P450llD6. Saturation of this enzyme at

clinical doses appears to account for the nonlinearity of paroxetine kinetics

with increasing dose and increasing duration of treatment. The role of this

enzyme in paroxetine metabolism also suggests potential drug-drug interactions

(see PRECAUTIONS).  

 
<p>
Approximately 64% of a 30 mg oral solution dose of paroxetine was excreted in

the urine with 2% as the parent compound and 62% as metabolites over a 10-day

post-dosing period. About 36% was excreted in the feces (probably via the bile) 

mostly as metabolites and less than 1% as the parent compound over the 10-day

post-dosing period.  

 
<p>
DISTRIBUTION: Paroxetine distributes throughout the body, including the CNS,

with only 1% remaining in the plasma.  

 
<p>
PROTEIN BINDING: Approximately 95% and 93% of paroxetine is bound to plasma

protein at 100 ng/mL and 400 ng/mL, respectively. Under clinical conditions,

paroxetine concentrations would normally be less than 400 ng/mL. Paroxetine

does not alter the In Vitro protein binding of phenytoin or warfarin.  

 <p>

RENAL AND LIVER DISEASE:  Increased plasma concentrations of paroxetine occur

in subjects with renal and hepatic impairment. The mean plasma concentrations

in patients with creatinine clearance below 30 mL/min was approximately 4 times 

greater than seen in normal volunteers. Patients with creatinine clearance of

30 to 60 mL/min and patients with hepatic functional impairment had about a 2

fold increase in plasma concentrations (AUC, Cmax).  

 <p>

The initial dosage should therefore be reduced in patients with severe renal or 

hepatic impairment, and upward titration, if necessary, should be at increased

intervals (see DOSAGE AND ADMINISTRATION).  

 
<p>
ELDERLY PATIENTS:  In a multiple-dose study in the elderly at daily paroxetine

doses of 20, 30 and 40 mg, Cmin concentrations were about 70% to 80% greater

than the respective Cmin concentrations in nonelderly subjects. Therefore the

initial dosage in the elderly should be reduced. (See DOSAGE AND

ADMINISTRATION.) 

 <p>

CLINICAL TRIALS 

 <p>

The efficacy of Paroxetine as a treatment for depression has been established in 6

placebo-controlled studies of patients with depression (ages 18 to 73). In

these studies Paroxetine was shown to be significantly more effective than placebo

in treating depression by at least 2 of the following measures: Hamilton

Depression Rating Scale (HDRS), the Hamilton depressed mood item, and the

Clinical Global Impression (CGI)-Severity of Illness. Paroxetine was significantly

better than placebo in improvement of the HDRS sub-factor scores, including the 

depressed mood item, sleep disturbance factor and anxiety factor.  

 <p>

A study of depressed outpatients who had responded to Paroxetine (HDRS total score

&lt;8) during an initial 8-week open-treatment phase and were then randomized to

continuation on Paroxetine or placebo for 1 year demonstrated a significantly lower

relapse rate for patients taking Paroxetine (15%) compared to those on placebo

(39%).  Effectiveness was similar for male and female patients.  

 <p>

<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 

</b> <p>

Paroxetine is indicated for the treatment of depression.  

 <p>

The efficacy of Paroxetine in the treatment of a major depressive episode was

established in 6-week controlled trials of outpatients whose diagnoses

corresponded most closely to the DSM-III category of major depressive disorder

(see ACTIONS/CLINICAL PHARMACOLOGY).  

 <p>

A major depressive episode implies a prominent and relatively persistent

depressed or dysphoric mood that usually interferes with daily functioning

(nearly every day for at least 2 weeks); it should include at least 4 of the

following 8 symptoms: change in appetite, change in sleep, psychomotor

agitation or retardation, loss of interest in usual activities or decrease in

sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed

thinking or impaired concentration, and a suicide attempt or suicidal ideation. 

 
<p>
The antidepressant action of Paroxetine in hospitalized depressed patients has not

been adequately studied.  

 <p>

The efficacy of Paroxetine in maintaining an antidepressant response for up to 1

year was demonstrated in a placebo-controlled trial (see ACTIONS/CLINICAL

PHARMACOLOGY). Nevertheless, the physician who elects to use Paroxetine for extended 

periods should periodically re-evaluate the long-term usefulness of the drug

for the individual patient.  

 
<p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 

</b> 
<p>
Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs) is

contraindicated (see WARNINGS).  

 
<p>
<a name="WARNINGS"></a><b>WARNINGS 

</b> <p>

POTENTIAL FOR INTERACTION WITH MONOAMINE OXIDASE INHIBITORS 

 

IN PATIENTS RECEIVING ANOTHER SEROTONIN REUPTAKE INHIBITOR DRUG IN COMBINATION

WITH A MONOAMINE OXIDASE INHIBITOR (MAOI), THERE HAVE BEEN REPORTS OF SERIOUS,

SOMETIMES FATAL, REACTIONS INCLUDING HYPERTHERMIA, RIGIDITY, MYOCLONUS,

AUTONOMIC INSTABILITY WITH POSSIBLE RAPID FLUCTUATIONS OF VITAL SIGNS, AND

MENTAL STATUS CHANGES THAT INCLUDE EXTREME AGITATION PROGRESSING TO DELIRIUM

AND COMA. THESE REACTIONS HAVE ALSO BEEN REPORTED IN PATIENTS WHO HAVE RECENTLY 

DISCONTINUED THAT DRUG AND HAVE BEEN STARTED ON A MAOI. SOME CASES PRESENTED

WITH FEATURES RESEMBLING NEUROLEPTIC MALIGNANT SYNDROME. WHILE THERE ARE NO

HUMAN DATA SHOWING SUCH AN INTERACTION WITH PAROXETINE, LIMITED ANIMAL DATA ON THE

EFFECTS OF COMBINED USE OF PAROXETINE AND MAOIS SUGGEST THAT THESE DRUGS MAY

ACT SYNERGISTICALLY TO ELEVATE BLOOD PRESSURE AND EVOKE BEHAVIORAL EXCITATION.  



THEREFORE, IT IS RECOMMENDED THAT PAROXETINE NOT BE USED

IN COMBINATION WITH A MAOI, OR WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH A 

MAOI. AT LEAST 2 WEEKS SHOULD BE ALLOWED AFTER STOPPING Paroxetine BEFORE STARTING A 

MAOI.  

 <p>

<a name="PRECAUTIONS"></a><b>PRECAUTIONS 

</b> 
<p>
GENERAL 

 
<p>
ACTIVATION OF MANIA/HYPOMANIA:  During premarketing testing, hypomania or mania 

occurred in approximately 1.0% of Paroxetine-treated unipolar patients compared to

1.1% of active-control and 0.3% of placebo-treated unipolar patients. In a

subset of patients classified as bipolar, the rate of manic episodes was 2.2%

for Paroxetine and 11.6% for the combined active-control groups. As with all

antidepressants, Paroxetine should be used cautiously in patients with a history of

mania.  

 <p>

SEIZURES:  During premarketing testing, seizures occurred in 0.1% of Paroxetine-

treated patients, a rate similar to that associated with other antidepressants. 

Paroxetine should be used cautiously in patients with a history of seizures. It

should be discontinued in any patient who develops seizures.  

 
<p>
SUICIDE:  The possibility of a suicide attempt is inherent in depression and

may persist until significant remission occurs. Close supervision of high-risk

patients should accompany initial drug therapy. Prescriptions for Paroxetine should

be written for the smallest quantity of tablets consistent with good patient

management, in order to reduce the risk of overdose.  

 <p>

HYPONATREMIA:  Several cases of hyponatremia have been reported. The

hyponatremia appeared to be reversible when Paroxetine was discontinued. The

majority of these occurrences have been in elderly individuals, some in

patients taking diuretics or who were otherwise volume depleted.  

 <p>

USE IN PATIENTS WITH CONCOMITANT ILLNESS:  Clinical experience with Paroxetine in

patients with certain concomitant systemic illness is limited. Caution is

advisable in using Paroxetine in patients with diseases or conditions that could

affect metabolism or hemodynamic responses.  

 
<p>
Paroxetine has not been evaluated or used to any appreciable extent in patients with 

a recent history of myocardial infarction or unstable heart disease. Patients

with these diagnoses were excluded from clinical studies during the product's

premarket testing. Evaluation of electrocardiograms of 682 patients who

received Paroxetine in double-blind, placebo-controlled trials, however, did not

indicate that Paroxetine is associated with the development of significant ECG

abnormalities.  Similarly, Paroxetine does not cause any

clinically important changes in heart rate or blood pressure.  

 
<p>
Increased plasma concentrations of paroxetine occur in patients with severe

renal impairment (creatinine clearance &lt;30 mL/min.) or severe hepatic

impairment. A lower starting dose should be used in such patients (see DOSAGE

AND ADMINISTRATION).  

 
<p>
INFORMATION FOR PATIENTS 

 <p>

Physicians are advised to discuss the following issues with patients for whom

they prescribe Paroxetine:  
<p>
                               

INTERFERENCE WITH COGNITIVE AND MOTOR PERFORMANCE: Any psychoactive drug may

impair judgment, thinking or motor skills. Although in controlled studies Paroxetine 

has not been shown to impair psychomotor performance, patients should be

cautioned about operating hazardous machinery, including automobiles, until

they are reasonably certain that Paroxetine therapy does not affect their ability to 

engage in such activities.  

 
<p>
COMPLETING COURSE OF THERAPY:  While patients may notice improvement with Paroxetine 

therapy in 1 to 4 weeks, they should be advised to continue therapy as

directed.  

 
<p>
CONCOMITANT MEDICATION:  Patients should be advised to inform their physician

if they are taking, or plan to take, any prescription or over-the-counter drugs 

since there is a potential for interactions.  
<p>
 

ALCOHOL:  Although Paroxetine has not been shown to increase the impairment of

mental and motor skills caused by alcohol, patients should be advised to avoid

alcohol while taking Paroxetine.  

 
<p>
PREGNANCY:  Patients should be advised to notify their physician if they become 

pregnant or intend to become pregnant during therapy.  

 
<p>
NURSING:  Patients should be advised to notify their physician if they are

breast-feeding an infant. (See PRECAUTIONS--Nursing Mothers.) 

 
<p>
LABORATORY TESTS 
<p>
 

There are no specific laboratory tests recommended.  

 
<p>
DRUG INTERACTIONS 

 <p>

TRYPTOPHAN:  As with other serotonin reuptake inhibitors, an interaction

between paroxetine and tryptophan may occur when they are co-administered.

Adverse experiences, consisting primarily of headache, nausea, sweating and

dizziness, have been reported when tryptophan was administered to patients

taking Paroxetine. Consequently, concomitant use of Paroxetine 

with tryptophan is not recommended.  
<p>
 

MONOAMINE OXIDASE INHIBITORS:  See CONTRAINDICATIONS and WARNINGS.  

 <p>

WARFARIN:  Preliminary data suggest that there may be a pharmacodynamic

interaction (that causes an increased bleeding diathesis in the face of

unaltered prothrombin time) between paroxetine and warfarin. Since there is

little clinical experience, the concomitant administration of Paroxetine and

warfarin should be undertaken with caution.  

 <p>

DRUGS AFFECTING HEPATIC METABOLISM:  The metabolism and pharmacokinetics of

paroxetine may be affected by the induction or inhibition of drug-metabolizing

enzymes.  

 <p>

Cimetidine-Cimetidine inhibits many cytochrome P450 (oxidative) enzymes. In a

study where Paroxetine (30 mg q.d.) was dosed orally for 4 weeks, steady-state

plasma concentrations of paroxetine were increased by approximately 50% during

co- administration with oral cimetidine (300 mg t.i.d.) for the final week. 

Therefore, when these drugs are administered concurrently, dosage adjustment of 

Paroxetine after the 20 mg starting dose should be guided by clinical effect. The

effect of paroxetine on cimetidine's pharmacokinetics was not studied.  <p>

 

Phenobarbital-Phenobarbital induces many cytochrome P450 (oxidative) enzymes. 

When a single oral 30 mg dose of Paroxetine was administered at phenobarbital steady 

state (100 mg q.d. for 14 days), paroxetine AUC and T1/2 were reduced (by an

average of 25% and 38%, respectively) compared to paroxetine administered

alone.  The effect of paroxetine on phenobarbital pharmacokinetics was not

studied.  Since Paroxetine exhibits nonlinear pharmacokinetics, the results of this

study may not address the case where the 2 drugs are both being chronically

dosed. No initial Paroxetine dosage adjustment is considered necessary when co

administered with phenobarbital; any subsequent adjustment should be guided by

clinical effect.  

 
<p>
Phenytoin-When a single oral 30 mg dose of Paroxetine was administered at phenytoin

steady state (300 mg q.d. for 14 days), paroxetine AUC and T1/2 were reduced

(by an average of 50% and 35%, respectively) compared to Paroxetine administered

alone.  In a separate study, when a single oral 300 mg dose of phenytoin was

administered at paroxetine steady state (30 mg q.d. for 14 days), phenytoin AUC 

was slightly reduced (12% on average) compared to phenytoin administered alone. 

Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not

address the case where the 2 drugs are both being chronically dosed. No initial 

dosage adjustments are considered necessary when these drugs are co-

administered; any subsequent adjustments should be guided by clinical effect. 

 <p>

DRUGS METABOLIZED BY CYTOCHROME P450IID6: Concomitant use of Paroxetine with drugs

metabolized by cytochrome P450IID6 has not been formally studied but may

require lower doses than usually prescribed for either Paroxetine or the other drug. 

Many drugs, including most antidepressants (paroxetine, other SSRIs and many

tricyclics), are metabolized by the cytochrome P450 isozyme P450IID6. In most

patients (&gt;90%), this P450IID6 isozyme is saturated early during Paroxetine dosing.  

Like other agents that are metabolized by P450IID6, paroxetine may

significantly inhibit the activity of this isozyme.  

 
<p>
Therefore, co-administration of Paroxetine with other drugs that are metabolized by

this isozyme, including certain antidepressants (e.g., nortriptyline,

amitriptyline, imipramine, desipramine and fluoxetine), phenothiazines (e.g.,

thioridazine) and Type 1C antiarrhythmics (e.g., propafenone, flecainide and

encainide), or that inhibit this enzyme (e.g., quinidine), should be approached 

with caution.  

 
<p>
At steady state, when the P450IID6 pathway is essentially saturated, paroxetine 

clearance is governed by alternative P450 isozymes which, unlike P450IID6, show 

no evidence of saturation.  

 
<p>
DRUGS HIGHLY BOUND TO PLASMA PROTEIN:  Because paroxetine is highly bound to

plasma protein, administration of Paroxetine to a patient taking another drug that

is highly protein bound may cause increased free concentrations of the other

drug, potentially resulting in adverse events. Conversely, adverse effects

could result from displacement of paroxetine by other highly bound drugs.  

 <p>

ALCOHOL:  Although Paroxetine does not increase the impairment of mental and motor

skills caused by alcohol, patients should be advised to avoid alcohol while

taking Paroxetine.  

 
<p>
LITHIUM:  A multiple-dose study has shown that there is no pharmacokinetic

interaction between Paroxetine and lithium carbonate. However, since there is little 

clinical experience, the concurrent administration of paroxetine and lithium

should be undertaken with caution.  

 
<p>
DIGOXIN:  The steady-state pharmacokinetics of paroxetine was not altered when

administered with digoxin at steady state. Mean digoxin AUC at steady state

decreased by 15% in the presence of paroxetine. Since there is little clinical

experience, the concurrent administration of paroxetine and digoxin should be

undertaken with caution.  

 <p>

DIAZEPAM:  Under steady-state conditions, diazepam does not appear to affect

paroxetine kinetics. The effects of paroxetine on diazepam were not evaluated.  

 <p>

PROCYCLIDINE:  Daily oral dosing of Paroxetine (30 mg q.d.) increased steady-state

AUC0-24, Cmax and Cmin values of procyclidine (5 mg oral q.d.) by 35%, 37% and

67%, respectively, compared to procyclidine alone at steady state. If

anticholinergic effects are seen, the dose of procyclidine should be reduced. 

 
<p>
PROPRANOLOL:  In a study where propranolol (80 mg b.i.d.) was dosed orally for

18 days, the established steady-state plasma concentrations of propranolol were 

unaltered during co-administration with Paroxetine (30 mg q.d.) for the final 10

days. The effects of propranolol on paroxetine have not been evaluated.  

 <p>

ELECTROCONVULSIVE THERAPY (ECT):  There are no clinical studies of the combined 

use of ECT and Paroxetine.  <p>

 

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY <p>

 

CARCINOGENESIS:  Two-year carcinogenicity studies were conducted in mice and

rats given paroxetine in the diet at 1, 5 and 25 mg/kg/day (mice) and 1, 5 and

20 mg/kg/day (rats). The maximum doses in these studies were approximately 25

(mouse) and 20 (rat) times the maximum dose recommended for human use on a

mg/kg basis or 2.5 (mouse) and 5.8 (rat) times the maximum recommended human

dose on a mg/M(square) basis. There was a significantly greater number of male

rats in the high-dose group with reticulum cell sarcomas (1/100, 0/50, 0/50 and 

4/50 for control, low-, middle- and high-dose groups, respectively) and a

significantly increased linear trend across dose groups for the occurrence of

lymphoreticular tumors in male rats. Female rats were not affected. Although

there was a dose- related increase in the number of tumors in mice, there was

no drug-related increase in the number of mice with tumors. The relevance of

these findings to humans is unknown.  
<p>
 

MUTAGENESIS:  Paroxetine produced no genotoxic effects in a battery of 5 In

Vitro and 2 In Vivo assays that included the following: bacterial mutation

assay, mouse lymphoma mutation assay, unscheduled DNA synthesis assay, and

tests for cytogenetic aberrations In Vivo in mouse bone marrow and In Vitro in

human lymphocytes and in a dominant lethal test in rats.  

 <p>

IMPAIRMENT OF FERTILITY: Serotonergic compounds are known to affect

reproductive function in animals. Impaired reproductive function (i.e., reduced 

pregnancy rate, increased pre- and post-implantation losses, decreased

viability of pups) was found in reproduction studies in rats at doses of

paroxetine which were 15 or more times the highest recommended human dose on a

mg/kg basis, or 4.4 times on a mg/M(square) basis. Irreversible lesions

occurred in the reproductive tract of male rats after dosing in toxicity

studies for 2 to 52 weeks. These lesions, which consisted of vacuolation of

epididymal tubular epithelium and atrophic changes in the seminiferous tubules

of the testes with arrested spermatogenesis occurred at doses which were 25

times the highest recommended human dose on a mg/kg basis or 7.3 times on a

mg/M(square) basis.  

 <p>

PREGNANCY 

 <p>

TERATOGENIC EFFECTS--PREGNANCY CATEGORY B:  Reproduction studies performed in

rats and rabbits at doses up to 50 and 6 times the maximum recommended human

dose on a mg/kg basis or 10 and 2 times on a mg/M(square) basis, respectively,

have revealed no evidence of teratogenic effects. There are no adequate and

well-controlled studies in pregnant women. Because animal reproduction studies

are not always predictive of human response, this drug should be used during

pregnancy only if clearly needed.  

 
<p>
LABOR AND DELIVERY 

 <p>

The effect of paroxetine on labor and delivery in humans is unknown.  
<p>
 

NURSING MOTHERS 

 <p>

Like many other drugs, paroxetine is secreted in human milk, and caution should 

be exercised when Paroxetine is administered to a nursing 

woman.  

 <p>

USAGE IN CHILDREN 
<p>
 

Safety and effectiveness in children have not been established.  

 <p>

GERIATRIC USE 
<p>
 

In worldwide Paroxetine clinical trials, 17% of Paroxetine-treated patients

(approximately 700) were 65 years of age or older. Pharmacokinetic studies

revealed a decreased clearance in the elderly, and a lower starting dose is

recommended; there were, however, no overall differences in the adverse event

profile between elderly and younger patients, and effectiveness was similar in

younger and older patients.  (See ACTIONS/CLINICAL PHARMACOLOGY and DOSAGE AND

ADMINISTRATION.) 

 <p>

<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 

</b> <p>

TRYPTOPHAN:  As with other serotonin reuptake inhibitors, an interaction

between paroxetine and tryptophan may occur when they are co-administered.

Adverse experiences, consisting primarily of headache, nausea, sweating and

dizziness, have been reported when tryptophan was administered to patients

taking Paroxetine. Consequently, concomitant use of Paroxetine 

with tryptophan is not recommended.  

 <p>

MONOAMINE OXIDASE INHIBITORS:  See CONTRAINDICATIONS and WARNINGS.  

 <p>

WARFARIN:  Preliminary data suggest that there may be a pharmacodynamic

interaction (that causes an increased bleeding diathesis in the face of

unaltered prothrombin time) between paroxetine and warfarin. Since there is

little clinical experience, the concomitant administration of Paroxetine and

warfarin should be undertaken with caution.  

 <p>

DRUGS AFFECTING HEPATIC METABOLISM:  The metabolism and pharmacokinetics of

paroxetine may be affected by the induction or inhibition of drug-metabolizing

enzymes.  <p>

 

Cimetidine-Cimetidine inhibits many cytochrome P450 (oxidative) enzymes. In a

study where Paroxetine (30 mg q.d.) was dosed orally for 4 weeks, steady-state

plasma concentrations of paroxetine were increased by approximately 50% during

co- administration with oral cimetidine (300 mg t.i.d.) for the final week. 

Therefore, when these drugs are administered concurrently, dosage adjustment of 

Paroxetine after the 20 mg starting dose should be guided by clinical effect. The

effect of paroxetine on cimetidine's pharmacokinetics was not studied.  

 <p>

Phenobarbital-Phenobarbital induces many cytochrome P450 (oxidative) enzymes. 

When a single oral 30 mg dose of Paroxetine was administered at phenobarbital steady 

state (100 mg q.d. for 14 days), paroxetine AUC and T1/2 were reduced (by an

average of 25% and 38%, respectively) compared to paroxetine administered

alone.  The effect of paroxetine on phenobarbital pharmacokinetics was not

studied.  Since Paroxetine exhibits nonlinear pharmacokinetics, the results of this

study may not address the case where the 2 drugs are both being chronically

dosed. No initial Paroxetine dosage adjustment is considered necessary when co

administered with phenobarbital; any subsequent adjustment should be guided by

clinical effect.  
<p>
 

Phenytoin-When a single oral 30 mg dose of Paroxetine was administered at phenytoin

steady state (300 mg q.d. for 14 days), paroxetine AUC and T1/2 were reduced

(by an average of 50% and 35%, respectively) compared to Paroxetine administered

alone.  In a separate study, when a single oral 300 mg dose of phenytoin was

administered at paroxetine steady state (30 mg q.d. for 14 days), phenytoin AUC 

was slightly reduced (12% on average) compared to phenytoin administered alone. 

Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not

address the case where the 2 drugs are both being chronically dosed. No initial 

dosage adjustments are considered necessary when these drugs are co-

administered; any subsequent adjustments should be guided by clinical effect. 
<p>
 

DRUGS METABOLIZED BY CYTOCHROME P450IID6: Concomitant use of Paroxetine with drugs

metabolized by cytochrome P450IID6 has not been formally studied but may

require lower doses than usually prescribed for either Paroxetine or the other drug. 

Many drugs, including most antidepressants (paroxetine, other SSRIs and many

tricyclics), are metabolized by the cytochrome P450 isozyme P450IID6. In most

patients (&gt;90%), this P450IID6 isozyme is saturated early during Paroxetine dosing.  

Like other agents that are metabolized by P450IID6, paroxetine may

significantly inhibit the activity of this isozyme.  

 <p>

Therefore, co-administration of Paroxetine with other drugs that are metabolized by

this isozyme, including certain antidepressants (e.g., nortriptyline,

amitriptyline, imipramine, desipramine and fluoxetine), phenothiazines (e.g.,

thioridazine) and Type 1C antiarrhythmics (e.g., propafenone, flecainide and

encainide), or that inhibit this enzyme (e.g., quinidine), should be approached 

with caution.  

 
<p>
At steady state, when the P450IID6 pathway is essentially saturated, paroxetine 

clearance is governed by alternative P450 isozymes which, unlike P450IID6, show 

no evidence of saturation.  

 
<p>
DRUGS HIGHLY BOUND TO PLASMA PROTEIN:  Because paroxetine is highly bound to

plasma protein, administration of Paroxetine to a patient taking another drug that

is highly protein bound may cause increased free concentrations of the other

drug, potentially resulting in adverse events. Conversely, adverse effects

could result from displacement of paroxetine by other highly bound drugs.  

 <p>

ALCOHOL:  Although Paroxetine does not increase the impairment of mental and motor

skills caused by alcohol, patients should be advised to avoid alcohol while

taking Paroxetine.  

 <p>
LITHIUM:  A multiple-dose study has shown that there is no pharmacokinetic

interaction between Paroxetine and lithium carbonate. However, since there is little 

clinical experience, the concurrent administration of paroxetine and lithium

should be undertaken with caution.  

 <p>

DIGOXIN:  The steady-state pharmacokinetics of paroxetine was not altered when

administered with digoxin at steady state. Mean digoxin AUC at steady state

decreased by 15% in the presence of paroxetine. Since there is little clinical

experience, the concurrent administration of paroxetine and digoxin should be

undertaken with caution.  

 <p>

DIAZEPAM:  Under steady-state conditions, diazepam does not appear to affect

paroxetine kinetics. The effects of paroxetine on diazepam were not evaluated.  

 <p>

PROCYCLIDINE:  Daily oral dosing of Paroxetine (30 mg q.d.) increased steady-state

AUC0-24, Cmax and Cmin values of procyclidine (5 mg oral q.d.) by 35%, 37% and

67%, respectively, compared to procyclidine alone at steady state. If

anticholinergic effects are seen, the dose of procyclidine should be reduced. 

 <p>

PROPRANOLOL:  In a study where propranolol (80 mg b.i.d.) was dosed orally for

18 days, the established steady-state plasma concentrations of propranolol were 

unaltered during co-administration with Paroxetine (30 mg q.d.) for the final 10

days. The effects of propranolol on paroxetine have not been evaluated.  

 
<p>
ELECTROCONVULSIVE THERAPY (ECT):  There are no clinical studies of the combined 

use of ECT and Paroxetine.  

 
<p>
(See Also PRECAUTIONS).  

 <p>

<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 

</b> <p>

ASSOCIATED WITH DISCONTINUATION OF TREATMENT 

 <p>

Twenty-one percent (881/4,126) of Paroxetine patients in worldwide clinical trials

discontinued treatment due to an adverse event. The most common events (&gt;/=1%)

associated with discontinuation and considered to be drug related (i.e., those

events associated with dropout at a rate approximately twice or greater for

Paroxetine compared to placebo) included:  <p><pre>

 

CNS                                                                             

Somnolence                                                    2.3%              

Insomnia                                                      1.9%              

Agitation                                                     1.3%              

Tremor                                                        1.3%              

Anxiety                                                       1.1%              

GASTROINTESTINAL                                                                

Nausea                                                        3.4%              

Diarrhea                                                      1.0%              

Dry mouth                                                     1.0%              

Vomiting                                                      1.0%              

OTHER                                                                           

Asthenia                                                      1.7%              

Abnormal ejaculation                                          1.6%              

Sweating                                                      1.1%      </pre><p>        

INCIDENCE IN CONTROLLED TRIALS 

 <p>

COMMONLY OBSERVED ADVERSE EVENTS IN CONTROLLED CLINICAL TRIALS:  The most

commonly observed adverse events associated with the use of paroxetine

(incidence of 5% or greater and incidence for Paroxetine at least twice that for

placebo, derived from 1% table below) were: asthenia, sweating, nausea,

decreased appetite, somnolence, dizziness, insomnia, tremor, nervousness,

ejaculatory disturbance and other male genital disorders.  

 
<p>
ADVERSE EVENTS OCCURRING AT AN INCIDENCE OF 1% OR MORE AMONG PAROXETINE-TREATED 

PATIENTS:  The table that follows enumerates adverse events that occurred at an 

incidence of 1% or more among paroxetine-treated patients who participated in

short-term (6-week) placebo-controlled trials in which patients were dosed in a 

range of 20 to 50 mg/day. Reported adverse events were classified using a

standard COSTART-based Dictionary terminology.  

 <p>

The prescriber should be aware that these figures cannot be used to predict the 

incidence of side effects in the course of usual medical practice where patient 

characteristics and other factors differ from those which prevailed in the

clinical trials. Similarly, the cited frequencies cannot be compared with

figures obtained from other clinical investigations involving different

treatments, uses and investigators. The cited figures, however, do provide the

prescribing physician with some basis for estimating the relative contribution

of drug and nondrug factors to the side effect incidence rate in the population 

studied.  <p><pre>

 

                      TABLE 1. TREATMENT-EMERGENT ADVERSE                       

                   EXPERIENCE INCIDENCE IN PLACEBO-CONTROLLED                   

                                CLINICAL TRIALS                                

----------------------------------------------------------------------------    

BODY SYSTEM        PREFERRED TERM               Paroxetine           PLACEBO         

                                               (N=421)          (N=421)         

----------------------------------------------------------------------------    

Body as a Whole    Headache                     17.6%            17.3%          

                   Asthenia                     15.0%             5.9%          

                   Abdominal Pain                3.1%             4.0%          

                   Fever                         1.7%             1.7%          

                   Chest Pain                    1.4%             2.1%          

                   Trauma                        1.4%             0.5%          

                   Back Pain                     1.2%             2.4%          

Cardiovascular     Palpitation                   2.9%             1.4%          

                   Vasodilation                  2.6%             0.7%          

                   Postural Hypotension          1.2%             0.5%          

Dermatologic       Sweating                     11.2%             2.4%          

                   Rash                          1.7%             0.7%          

Gastrointestinal   Nausea                       25.7%             9.3%          

                   Dry Mouth                    18.1%            12.1%          

                   Constipation                 13.8%             8.6%          

                   Diarrhea                     11.6%             7.6%          

                   Decreased Appetite            6.4%             1.9%          

                   Flatulence                    4.0%             1.7%          

                   Vomiting                      2.4%             1.7%          

                   Oropharynx Disorder2          2.1%             0.0%          

                   Dyspepsia                     1.9%             1.0%          

                   Increased Appetite            1.4%             0.5%          

Musculoskeletal    Myopathy                      2.4%             1.4%          

                   Myalgia                       1.7%             0.7%          

                   Myasthenia                    1.4%             0.2%          

Nervous System     Somnolence                   23.3%             9.0%          

                   Dizziness                    13.3%             5.5%          

                   Insomnia                     13.3%             6.2%          

                   Tremor                        8.3%             1.9%          

                   Nervousness                   5.2%             2.6%          

                   Anxiety                       5.0%             2.9%          

                   Paresthesia                   3.8%             1.7%          

                   Libido Decreased              3.3%             0.0%          

                   Agitation                     2.1%             1.9%          

                   Drugged Feeling               1.7%             0.7%          

                   Myoclonus                     1.4%             0.7%          

                   CNS Stimulation               1.2%             3.6%          

                   Confusion                     1.2%             0.2%          

Respiration        Respiratory Disorder3         5.9%             6.4%          

                   Yawn                          3.8%             0.0%          

                   Pharyngitis                   2.1%             2.9%          

Special Senses     Blurred Vision                3.6%             1.4%          

                   Taste Perversion              2.4%             0.2%          

Urogenital System  Ejaculatory Disturbance4,5   12.9%             0.0%          

                   Other Male Genital           10.0%             0.0%          

                    Disorders4,6                                                

                   Urinary Frequency             3.1%             0.7%          

                   Urination Disorder7           2.9%             0.2%          

                   Female Genital Disorders4,8   1.8%             0.0%          

----------------------------------------------------------------------------    </pre><p>

1. Events reported by at least 1% of patients treated with Paroxetine (paroxetine    

    hydrochloride) are included. <p>                                      

2. Includes mostly &quot;lump in throat&quot; and &quot;tightness in throat.&quot; <p>       

3. Includes mostly &quot;cold symptoms&quot; or &quot;URI.&quot; <p>                  

4. Percentage corrected for gender. <p>                                  

5. Mostly &quot;ejaculatory delay.&quot; <p>           

6. Includes &quot;anorgasmia,&quot; &quot;erectile difficulties,&quot; &quot;delayed                     

    ejaculation/orgasm,&quot; and &quot;sexual dysfunction,&quot; and                          

   &quot;impotence.&quot; <p>                        

7. Includes mostly &quot;difficulty with micturition&quot; and &quot;urinary hesitancy.&quot; <p>  

8. Includes mostly &quot;anorgasmia&quot; and &quot;difficulty reaching climax/orgasm.&quot;        <p>



DOSE DEPENDENCY OF ADVERSE EVENTS:  A comparison of adverse event rates in a

fixed-dose study comparing Paroxetine 10, 20, 30 and 40 mg/day with placebo revealed 

a clear dose dependency for some of the more common adverse events associated

with Paroxetine use, as shown in the following table:  <p><pre>

 

                       TABLE 2. TREATMENT-EMERGENT ADVERSE                      

                            EXPERIENCE INCIDENCE IN A                           

                              DOSE-COMPARISON TRIAL*                            

                         PLACEBO                     Paroxetine                      

BODY SYSTEM/                           10 MG      20 MG      30 MG       40 MG  

PREFERRED TERM               N=51      N=102      N=104      N=101       N=102  

Body as a Whole                                                                 

  Asthenia                   0.0%       2.9%      10.6%      13.9%       12.7%  

Dermatology                                                                     

  Sweating                   2.0%       1.0%       6.7%       8.9%       11.8%  

Gastrointestinal                                                                

  Constipation               5.9%       4.9%       7.7%       9.9%       12.7%  

  Decreased                                                                     

    Appetite                 2.0%       2.0%       5.8%       4.0%        4.9%  

  Diarrhea                   7.8%       9.8%      19.2%       7.9%       14.7%  

  Dry Mouth                  2.0%      10.8%      18.3%      15.8%       20.6%  

  Nausea                    13.7%      14.7%      26.9%      34.7%       36.3%  

Nervous System                                                                  

  Anxiety                    0.0%       2.0%       5.8%       5.9%        5.9%  

  Dizziness                  3.9%       6.9%       6.7%       8.9%       12.7%  

  Nervousness                0.0%       5.9%       5.8%       4.0%        2.9%  

  Paresthesia                0.0%       2.9%       1.0%       5.0%        5.9%  

  Somnolence                 7.8%      12.7%      18.3%      20.8%       21.6%  

  Tremor                     0.0%       0.0%       7.7%       7.9%       14.7%  

Special Senses                                                                  

  Blurred Vision             2.0%       2.9%       2.9%       2.0%        7.8%  

Urogenital                                                                      

  Abnormal                                                                      

    Ejaculation              0.0%       5.8%       6.5%      10.6%       13.0%  

  Impotence                  0.0%       1.9%       4.3%       6.4%        1.9%  

  Male Genital                                                                  

    Disorders                0.0%       3.8%       8.7%       6.4%        3.7%  

*   Rule for including adverse events in table: incidence at least 5% for one   

     of paroxetine groups and &gt;/= twice the placebo incidence for at least one  

     paroxetine group.                </pre><p>                                          



ADAPTATION TO CERTAIN ADVERSE EVENTS:  Over a 4- to 6-week period, there was

evidence of adaptation to some adverse events with continued therapy (e.g.,

nausea and dizziness), but less to other effects (e.g., dry mouth, somnolence

and asthenia).  
<p>
 

WEIGHT AND VITAL SIGN CHANGES:  Significant weight loss may be an undesirable

result of treatment with Paroxetine for some patients but, on average, patients in

controlled trials had minimal (about 1 pound) weight loss vs. smaller changes

on placebo and active control. No significant changes in vital signs (systolic

and diastolic blood pressure, pulse and temperature) were observed in patients

treated with Paroxetine in controlled clinical trials.  
<p>
 

ECG CHANGES:  In an analysis of ECGs obtained in 682 patients treated with

Paroxetine and 415 patients treated with placebo in controlled clinical trials, no

clinically significant changes were seen in the ECGs of either group.  

 <p>

LIVER FUNCTION TESTS:  In placebo-controlled clinical trials, patients treated

with Paroxetine exhibited abnormal values on liver function tests at no greater rate 

than that seen in placebo-treated patients. In particular, the Paroxetine-vs.

placebo comparison for alkaline phosphatase was 0% vs. 0%, SGOT 0.3% vs. 0.3%,

SGPT 1% vs. 0.3% and bilirubin 0% vs. 0.8%.  

 <p>

OTHER EVENTS OBSERVED DURING THE PREMARKETING EVALUATION OF Paroxetine (PAROXETINE

HYDROCHLORIDE) <p>

 

During its premarketing assessment, multiple doses of Paroxetine were administered

to 4,126 patients in phase 2 and 3 studies. The conditions and duration of

exposure to Paroxetine varied greatly and included (in overlapping categories) open

and double-blind studies, uncontrolled and controlled studies, inpatient and

outpatient studies, and fixed-dose and titration studies. Untoward events

associated with this exposure were recorded by clinical investigators using

terminology of their own choosing. Consequently, it is not possible to provide

a meaningful estimate of the proportion of individuals experiencing adverse

events without first grouping similar types of untoward events into a smaller

number of standardized event categories.  

 <p>

In the tabulations that follow, reported adverse events were classified using a 

standard COSTART-based Dictionary terminology. The frequencies presented,

therefore, represent the proportion of the 4,126 patients exposed to multiple

doses of Paroxetine who experienced an event of the type

cited on at least one occasion while receiving Paroxetine. All reported events are

included except those already listed in Table 1, those reported in terms so

general as to be uninformative and those events where a drug cause was remote.  

It is important to emphasize that although the events reported occurred during

treatment with paroxetine, they were not necessarily caused by it.  

 

Events are further categorized by body system and listed in order of decreasing 

frequency according to the following definitions: frequent adverse events are

those occurring on one or more occasions in at least 1/100 patients (only those 

not already listed in the tabulated results from placebo-controlled trials

appear in this listing); infrequent adverse events are those occurring in 1/100 

to 1/1000 patients; rare events are those occurring in fewer than 1/1000

patients. Events of major clinical importance are also described in the

PRECAUTIONS section.  <p>

 

BODY AS A WHOLE:  Frequent: chills, malaise; Infrequent: allergic reaction,

carcinoma, face edema, moniliasis, neck pain; Rare: abscess, adrenergic

syndrome, cellulitis, neck rigidity, pelvic pain, peritonitis, ulcer.  

 <p>

CARDIOVASCULAR SYSTEM:  Frequent: hypertension, syncope, tachycardia;

Infrequent: bradycardia, conduction abnormalities, electrocardiogram abnormal,

hypotension, migraine, peripheral vascular disorder; Rare: angina pectoris,

arrhythmia, atrial fibrillation, bundle branch block, cerebral ischemia,

cerebrovascular accident, congestive heart failure, low cardiac output,

myocardial infarct, myocardial ischemia, pallor, phlebitis, pulmonary embolus,

supraventricular extrasystoles, thrombosis, varicose vein, vascular headache,

ventricular extrasystoles.  

 
<p>
DIGESTIVE SYSTEM:  Infrequent: bruxism, dysphagia, eructation, gastritis,

glossitis, increased salivation, liver function tests abnormal, mouth

ulceration, rectal hemorrhage; Rare: aphthous stomatitis, bloody diarrhea,

bulimia, colitis, duodenitis, esophagitis, fecal impactions, fecal incontinence 

gastritis, gastroenteritis, gingivitis, hematemesis, hepatitis, ileus,

jaundice, melena, peptic ulcer, salivary gland enlargement, stomach ulcer,

stomatitis, tongue edema, tooth caries.  

 <p>

ENDOCRINE SYSTEM:  Rare: diabetes mellitus, hyperthyroidism, hypothyroidism,

thyroiditis.  

 <p>

HEMIC AND LYMPHATIC SYSTEMS:  Infrequent: anemia, leukopenia, lymphadenopathy,

purpura; Rare: abnormal erythrocytes, eosinophilia, leukocytosis, lymphedema,

abnormal lymphocytes, lymphocytosis, microcytic anemia, monocytosis, normocytic 

anemia.  

 <p>

METABOLIC AND NUTRITIONAL:  Frequent: edema, weight gain, weight loss;

Infrequent: hyperglycemia, peripheral edema, thirst; Rare: alkaline phosphatase 

increased, bilirubinemia, dehydration, gout, hypercholesteremia, hypocalcemia,

hypoglycemia, hypokalemia, hyponatremia, SGOT increased, SGPT increased.  

 <p>

MUSCULOSKELETAL SYSTEM:  Infrequent: arthralgia, arthritis; Rare: arthrosis,

bursitis, myositis, osteoporosis, tetany.  

 <p>

NERVOUS SYSTEM:  Frequent: amnesia, CNS stimulation, concentration impaired,

depression, emotional lability, vertigo; Infrequent: abnormal thinking,

akinesia, alcohol abuse, ataxia, convulsion, depersonalization, hallucinations,

hyperkinesia, hypertonia, incoordination, lack of emotion, manic reaction,

paranoid reaction; Rare: abnormal electroencephalogram, abnormal gait,

antisocial reaction, choreoathetosis, delirium, delusions, diplopia, drug

dependence, dysarthria, dyskinesia, dystonia, euphoria, fasciculations, grand

mal convulsion, hostility, hyperalgesia, hypokinesia, hysteria, libido

increased, manic-depressive reaction, meningitis, myelitis, neuralgia,

neuropathy, nystagmus, paralysis, psychosis, psychotic depression, reflexes

increased, stupor, withdrawal syndrome.  

 <p>

RESPIRATORY SYSTEM:  Frequent: cough increased, rhinitis; Infrequent: asthma,

bronchitis, dyspnea, epistaxis, hyperventilation, pneumonia, respiratory flu,

sinusitis; Rare: carcinoma of lung, hiccups, lung fibrosis, sputum increased. 

 <p>

SKIN AND APPENDAGES:  Frequent: pruritus; Infrequent: acne, alopecia, dry skin, 

ecchymosis, eczema, furunculosis, urticaria; Rare: angioedema, contact

dermatitis, erythema nodosum, maculopapular rash, photosensitivity, skin

discoloration, skin melanoma.  

 <p>

SPECIAL SENSES:  Infrequent: abnormality of accommodation, ear pain, eye pain,

mydriasis, otitis media, taste loss, tinnitus; Rare: amblyopia, cataract,

conjunctivitis, corneal ulcer, exophthalmos, eye hemorrhage, glaucoma,

hyperacusis, otitis externa, photophobia.  

 <p>

UROGENITAL SYSTEM:  Infrequent: abortion, amenorrhea, breast pain, cystitis,

dysmenorrhea, dysuria, menorrhagia, nocturia, polyuria, urethritis, urinary

incontinence, urinary retention, urinary urgency, vaginitis; Rare: breast

atrophy, breast carcinoma, breast neoplasm, female lactation, hematuria, kidney 

calculus, kidney function abnormal, kidney pain, mastitis, nephritis, oliguria, 

prostatic carcinoma, vaginal moniliasis.  

 <p>

NON-U.S. POSTMARKETING REPORTS 
<p>
 

Voluntary reports of adverse events in patients taking Paroxetine that have been

received since market introduction and may have no causal relationship with the 

drug include elevated liver function tests (the most severe case was a death

due to liver necrosis, and one other case involved grossly elevated

transaminases associated with severe liver dysfunction).  

 <p>

DRUG ABUSE AND DEPENDENCE 
<p>
 

CONTROLLED SUBSTANCE CLASS: Paroxetine is not a&nbsp;controlled substance.  

 <p>

PHYSICAL AND PSYCHOLOGIC DEPENDENCE:  Paroxetine has not been systematically studied 

in animals or humans for its potential for abuse, tolerance or physical

dependence. While the clinical trials did not reveal any tendency for any drug- 

seeking behavior, these observations were not systematic and it is not possible 

to predict on the basis of this limited experience the extent to which a CNS-

active drug will be misused, diverted and/or abused once marketed. Consequently 

patients should be evaluated carefully for history of drug abuse, and such

patients should be observed closely for signs of Paroxetine misuse or abuse (e.g.,

development of tolerance, incrementations of dose, drug-seeking behavior).  

 <p>

<a name="OVERDOSAGE"></a><b>OVERDOSAGE 

</b> <p>

HUMAN EXPERIENCE:  No deaths were reported following acute overdose with Paroxetine

alone or in combination with other drugs and/or alcohol (18 cases, with doses

up to 850 mg) during premarketing clinical trials. Signs and symptoms of

overdose with Paroxetine included: nausea, vomiting, drowsiness, sinus tachycardia

and dilated pupils. There were no reports of ECG abnormalities, coma or

convulsions following overdosage with Paroxetine alone.  

 <p>

OVERDOSAGE MANAGEMENT:  Treatment should consist of those general measures

employed in the management of overdosage with any antidepressant. There are no

specific antidotes for paroxetine. Establish and maintain an airway; ensure adequate 

oxygenation and ventilation. Gastric evacuation either by the induction of

emesis or lavage or both should be performed. In most cases, following

evacuation, 20 to 30 grams of activated charcoal may be administered every 4 to 

6 hours during the first 24 to 48 hours after ingestion. An ECG should be taken 

and monitoring of cardiac function instituted if there is any evidence of

abnormality. Supportive care with frequent monitoring of vital signs and

careful observation is indicated. Due to the large volume of distribution of

Paroxetine, forced diuresis, dialysis, hemoperfusion and exchange transfusion are

unlikely to be of benefit.  

 <p>

A specific caution involves patients taking or recently having taken paroxetine 

who might ingest by accident or intent excessive quantities of a tricyclic

antidepressant. In such a case, accumulation of the parent tricyclic and its

active metabolite may increase the possibility of clinically significant

sequelae and extend the time needed for close medical observation.  

 
<p>
In managing overdosage, consider the possibility of multiple-drug involvement.  

The physician should consider contacting a poison control center for additional 

information on the treatment of any overdose. Telephone numbers for certified

poison control centers are listed in the Physicians' Desk Reference ().  

 <p>

<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 

</b> <p>

DEPRESSION 

 <p>

USUAL INITIAL DOSAGE:  Paroxetine should be administered

as a single daily dose, usually in the morning. The recommended initial dose is 

20 mg/day. Patients were dosed in a range of 20 to 50 mg/day in the clinical

trials demonstrating the antidepressant effectiveness of paroxetine. As with all

antidepressants, the full antidepressant effect may be delayed. Some patients

not responding to a 20 mg dose may benefit from dose increases, in 10 mg/day

increments, up to a maximum of 50 mg/day. Dose changes should occur at

intervals of at least 1 week.  

 <p>

DOSAGE FOR ELDERLY OR DEBILITATED, AND PATIENTS WITH SEVERE RENAL OR HEPATIC

IMPAIRMENT:  The recommended initial dose is 10 mg/day for elderly, debilitated 

patients, and/or patients with severe renal or hepatic impairment. Increases

may be made if indicated. Dosage should not exceed 40 mg/day.  

 
<p>
MAINTENANCE THERAPY:  There is no body of evidence available to answer the

question of how long the patient treated with paroxetine should remain on it. It is

generally agreed that acute episodes of depression require several months or

longer of sustained pharmacologic therapy. Whether the dose of an

antidepressant needed to induce remission is identical to the dose needed to

maintain and/or sustain euthymia is unknown.  

 <p>

Systematic evaluation of the efficacy of paroxetine has

shown that efficacy is maintained for periods of up to 1 year with doses that

averaged about 30 mg.  
<p>


SWITCHING PATIENTS TO OR FROM A MONOAMINE OXIDASE INHIBITOR:  At least 14 days

should elapse between discontinuation of a MAOI and initiation of paroxetine

therapy.  Similarly, at least 14 days should be allowed after stopping paroxetine

before starting a MAOI. 

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-10</DOCNO>
<DOCOLDNO>IA018-000200-B041-261</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/av3.htm 206.86.175.201 19970106231123 text/html 3270
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:05:09 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3088
Last-modified: Fri, 20 Dec 1996 18:08:16 GMT
</DOCHDR>
 <html>
<head>
<title>
RxList - The Internet Drug Index
</title>

</head>



<BODY Bgcolor="#ffffff">



<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi">
<img src="rx.gif" alt="click to search RxList" vspace=2 border=0
height=125 width=125 align=left>
</a><a href="http://www.reutershealth.com/ihw/reviews/rxint.html">                  
<img src="hi_rec.gif" height=38 width=25 align=right
border=0 alt="Reuter's review"></a>
</p></center>
<center>
<p><b><font SIZE=+3>RxList
<br>The Internet Drug Index </font></center></b></p>

<pre>
</pre><center>
<form method=post action="http://www.rxlist.com/cgi/rxlist.cgi">



<input name=drug size=25>

<input type=submit value="Search for Drug Name">

</dl></form><a href="http://www.pointcom.com">
<img src="5per.gif" alt="top 5%" vspace=1 border=0 height=65 width=65
align=left alt="Top5%">
</a>

<a href="http://www.arachnid.co.uk/award/health.html"><img src="med60.gif"        
align=right border=0 alt="Gold Medal"></a>
<h2><a href="http://www.rxlist.com/top200.htm">The Top 200
</a></h2>
<h5>[ <a href="http://www.rxlist.com/interact.htm"> Actions/Interactions ]</a>
| <a href="http://www.rxlist.com/rxlinks.htm">[ Links ]</a> | 
<a href="http://www.rxlist.com/about.htm">[ FAQ ]</a><br>[ <a href="http://www.rxlist.com/tempstat.htm">WWW Stats ]</a>  
[<a href="http://www.rxlist.com/stats.htm"> Stats ]</a> [<a href="#mini"> Mini-Survey ]</a><br>
<hr width=40%>
<a href="http://www.netmedicine.com"><img src="nm.gif"></a>
<hr></center>
<h2 align=center>
 
<a name="mini"></a><a href="http://www.rxlist.com/stats.htm#Results">RxList Wants to Know!</a></h2>
<form method="POST" action="formmail.cgi">
<input type=hidden name="recipient" value="survey@rxlist.com"><input type=hidden name="subject" value="Survey">
<input type=hidden name="redirect" value="http://www.rxlist.com">
<pre><ul><font size=4>
<b>Prescriber (i.e. MD, DDS,etc.)</b> <input name="pro" type="radio"
value="md"></pre>
</font><font size=4>

<pre><b>Pharmacist</b>                     <input name="pro" type="radio"
value="ph"></pre>
</font><font size=4>

<pre><b>Nurse</b>                          <input name="pro" type="radio"
value="rn"></pre>
</font><font size=4>

<pre><b>Other Health Professional</b>      <input name="pro" type="radio"
value="hp"></pre>
</font><font size=4>
<pre><b>Not a Health Professional</b>      <input name="pro" type="radio"
value="con"></pre></font>
</ul>
<center>
<p><b>Sex: <select NAME="Sex"><option>Male   <option>Female</select>   Age: <select NAME="Age"><option>Under 20<option>20-29<option>30-39<option>40-49<option>50-59<option>Over
60</select> </b><input type="submit" value="Submit Mini-Survey">
<hr><hr><a href="mailto:rx@rxlist.com">
<img src="mbox.gif" height=45 width=45 border=0 alt="e-mail"></a><br> <a 
href="mailto:rx@rxlist.com"><h4> E-mail Comments, 
Suggestions, & Corrections to </a><br>
 rx@rxlist.com </h4>
<h4>(707)746-8754 - Advertising, Press</h4>
<hr>
<hr>
<p>
<h5>
copyright 1996 - Neil Sandow, Pharm.D.
</h5></center>
<font COLOR="#FFFFFF">
<!--#counter file="rxcounter"--></font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-11</DOCNO>
<DOCOLDNO>IA018-000200-B039-207</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/phenterm.htm 206.86.175.201 19970106230326 text/html 11569
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:57:11 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 11386
Last-modified: Thu, 26 Sep 1996 05:04:19 GMT
</DOCHDR>
<html>
<head>
   <title>Phentermine - RxList Generic Information</title>
   <meta name="keywords" content="Adipex-P, Anoxine-Am, Atti-Plex P,
Bellapront, Curban, Dapex-37.5, Fastin, Fastophen, Ionamin, IFA-reducing,
Minobese-Forte, Mirapront, Obe-Mar, Obe-Nix, Obephen, Obermine, Obestin-30,
Oby-Cap, Oby-Trim, Ona-Mast, Panbesyl, Panshape M, Phentercot, Phentride,
Phentrol, Pro-Fast, Supramine, T-Diet, Tara-30, Teramin, Termene, Tora,
Umi-Pex 30, Zantryl">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Phentermine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Phentermine Hydrochloride USP has the chemical name of alpha, alpha-dimethylphenethylamine
hydrochloride .C10H15N.HCl : M.W. 185.7 </p>

<p>Phentermine hydrochloride USP is a white, odorless, hygroscopic, crystalline
powder which is soluble in water and lower alcohols, slightly soluble in
chloroform and insoluble in ether. </p>

<p>Phentermine, an anorectic agent for oral administration, is available
as a capsule or tablet containing 37.5 mg of phentermine hydrochloride
(equivalent to 30 mg of phentermine base). </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Phentermine hydrochloride is a sympathomimetic amine with pharmacologic
activity similar to the prototype drugs of this class used in obesity,
the amphetamines. Actions include central nervous system stimulation and
elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated
with all drugs of this class in which these phenomena have been looked
for. </p>

<p>Drugs of this class used in obesity are commonly known as &quot;anorectics&quot;
or &quot;anorexigenics&quot;. It has not been established, however, that
the action of such drugs in treating obesity is primarily one of appetite
suppression. Other central nervous system actions, or metabolic effects
may be involved, for example. Adult obese subjects instructed in dietary
management and treated with &quot;anorectic&quot; drugs, lose more weight
on the average than those treated with placebo and diet, as determined
in relatively short-term clinical trials. </p>

<p>The magnitude of increased weight loss of drug- treated patients over
placebo-treated patients is only a fraction of a pound a week. The rate
of weight loss is greatest in the first weeks of therapy for both drug
and placebo subjects and tends to decrease in succeeding weeks. The possible
origins of the increased weight loss due to the various drug effects are
not established. The amount of weight loss associated with the use of &quot;anorectic&quot;
drugs varies from trial to trial, and the increased weight loss appears
to be related in part to variables other than the drug prescribed, such
as the physician-investigator, the population treated, and the diet prescribed.
Studies do not permit conclusions as to the relative importance of the
drug and non-drug factors on weight loss. The natural history of obesity
is measured in years, whereas the studies cited are restricted to a few
weeks duration; thus, the total impact of drug-induced weight loss over
that of diet alone must be considered clinically limited. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Phentermine(R) (phentermine hydrochloride) is indicated in the management
of exogenous obesity as a short term adjunct (a few weeks) in a regimen
of weight reduction based on caloric restriction. </p>

<p>The limited usefulness of agents of this class (see ACTIONS/CLINICAL
PHARMACOLOGY) should be measured against possible risk factors inherent
in their use such as those described below. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate
to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy
to the sympathomimetic amines, glaucoma. </p>

<p>Agitated states. </p>

<p>Patients with a history of drug abuse. </p>

<p>During or within 14 days following the administration of monoamine oxidase
inhibitors (hypertensive crises may result). </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>Tolerance to the anorectic effect usually develops within a few weeks.
When this occurs, the recommended dose should not be exceeded in an attempt
to increase the effect; rather, the drug should be discontinued. </p>

<p>Phentermine hydrochloride may impair the ability of the patient to engage
in potentially hazardous activities such as operating machinery or driving
a motor vehicle; the patient should therefore be cautioned accordingly.
</p>

<p>USAGE IN PREGNANCY: Safe use in pregnancy has not been established.
Use of phentermine hydrochloride by women who are or who may become pregnant,
and those in the first trimester of pregnancy, requires that the potential
benefit be weighed against the possible hazard to mother and infant. </p>

<p>USAGE IN CHILDREN: Phentermine hydrochloride is not recommended for
use in children under 12 years of age. </p>

<p>USAGE WITH ALCOHOL: Concomitant use of alcohol with phentermine hydrochloride
may result in an adverse drug interaction. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>Caution is to be exercised in prescribing phentermine hydrochloride
for patients with even mild hypertension. </p>

<p>Insulin requirements in diabetes mellitus may be altered in association
with the use of phentermine hydrochloride and the concomitant dietary regimen.
Phentermine hydrochloride may decrease the hypotensive effect of guanethidine.
The least amount feasible should be prescribed or dispensed at one time
in order to minimize the possibility of overdosage. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>During or within 14 days following the administration of monoamine oxidase
inhibitors (hypertensive crises may result). </p>

<p>USAGE WITH ALCOHOL: Concomitant use of alcohol with phentermine hydrochloride
may result in an adverse drug interaction. </p>

<p>Insulin requirements in diabetes mellitus may be altered in association
with the use of phentermine hydrochloride and the concomitant dietary regimen.
Phentermine hydrochloride may decrease the hypotensive effect of guanethidine.
(See Also CONTRAINDICATIONS, WARNINGS, AND PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>CARDIOVASCULAR: Palpitation, tachycardia, elevation of blood pressure.
</p>

<p>CENTRAL NERVOUS SYSTEM: Overstimulation, restlessness, dizziness, insomnia,
euphoria, dysphoria, tremor, headache; rarely psychotic episodes at recommended
doses. </p>

<p>GASTROINTESTINAL: Dryness of the mouth, unpleasant taste, diarrhea,
constipation, other gastrointestinal disturbances. </p>

<p>ALLERGIC: Urticaria. </p>

<p>ENDOCRINE: Impotence, changes in libido. </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>Phentermine hydrochloride is a Schedule IV controlled substance. Phentermine
hydrochloride is related chemically and pharmacologically to the amphetamines.
Amphetamines and related stimulant drugs have been extensively abused,
and the possibility of abuse of phentermine hydrochloride should be kept
in mind when evaluating the desirability of including a drug as part of
a weight reduction program. Abuse of amphetamines and related drugs may
be associated with intense psychological dependence and severe social dysfunction.
There are reports of patients who have increased the dosage to many times
that recommended. Abrupt cessation following prolonged high dosage administration
results in extreme fatigue and mental depression; changes are also noted
on the sleep EEG. Manifestations of chronic intoxication with anorectic
drugs include severe dermatoses, marked insomnia, irritability, hyperactivity,
and personality changes. The most severe manifestation of chronic intoxication
is psychosis, often clinically indistinguishable from schizophrenia. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Manifestations of acute overdosage with phentermine hydrochloride include
restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness,
hallucinations, panic states. </p>

<p>Fatigue and depression usually follow the central stimulation. </p>

<p>Cardiovascular effects include arrhythmias, hypertension or hypotension
and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting,
diarrhea, and abdominal cramps. Fatal poisoning usually terminates in convulsions
and coma. </p>

<p>Management of acute phentermine hydrochloride intoxication is largely
symptomatic and includes lavage and sedation with a barbiturate. Experience
with hemodialysis or peritoneal dialysis is inadequate to permit recommendation
in this regard. Acidification of the urine increases phentermine excretion.
Intravenous phentolamine has been suggested for possible acute, severe
hypertension, if this complicates phentermine hydrochloride overdosage.
</p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Dosage should be individualized to obtain an adequate response with
the lowest effective dose. </p>

<p>The usual adult dose is one capsule or tablet (37.5 mg) daily, administered
before breakfast or 1-2 hours after breakfast. For tablets, the dosage
may be adjusted to the patient's need. For some patients 1/2 tablet (18.75
mg) daily may be adequate, while in some cases it may be desirable to give
1/2 tablet (18.75 mg) two times a day. </p>

<p>Late evening medication should be avoided because of the possibility
of resulting insomnia. </p>

<p>Phentermine hydrochloride is NOT recommended for use in children under
12 years of age. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-12</DOCNO>
<DOCOLDNO>IA018-000200-B041-290</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cardiova.htm 206.86.175.201 19970106231145 text/html 1728
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:05:31 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1546
Last-modified: Sun, 30 Jun 1996 07:23:34 GMT
</DOCHDR>
<html>
<head>
   <title>Rxlist of Indications and Side Effects - Cardiovascular and Anithypertensive 
Drugs </title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a>
<hr></p></center>

<h1 align=center>Cardiovascular and Antihypertensive Drugs </h1>

<h3>Due to the variety and complexity of the medications in these categories,
they have been further divided into the following sub-categories: </h3>

<p>
<hr></p>

<li>Alpha Blockers </li>

<li><a href="aceinh.htm">Angiotensin Converting Enzyme (ACE) Inhibitors</a>
</li>

<li>Anti-arrhythmics </li>

<li><a href="bblock.htm">Beta Blockers</a> </li>

<li><a href="calch.htm">Calcium Channel Blockers</a> </li>

<li>Centrally Acting Agents </li>

<li>Diuretics </li>

<li>Nitrates </li>

<li>Peripheral Vasodilators 
<hr><font SIZE=+2><a href="http://www.rxlist.com/disclaim.htm">Important
- Please Read!</a> </font></li>

<h4 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">Search
RxList</a> <img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com/mono.htm">RxLists
of Indications and Side Effects</a> <img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">Rxlist
Home Page</a> </h4>

<center><p><font SIZE=-2>copyright 1996 Neil Sandow, Pharm.D. - all rights
reserved </font></p></center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-13</DOCNO>
<DOCOLDNO>IA018-000200-B033-229</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/sertral.htm 206.86.175.201 19970106223914 text/html 47647
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:32:48 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 47464
Last-modified: Fri, 03 Jan 1997 00:11:08 GMT
</DOCHDR>
<html>
<head>
   <title>Sertraline - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Sertraline</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <p>
Sertraline  is an antidepressant for oral administration. It is chemically 
unrelated to tricylic, tetracyclic, or other available antidepressant agents. 
It has a molecular weight of 342.7. Sertraline hydrochloride has the following 
chemical name: (1S-cis)-4-(3,4-dichlorophenyl)- 
1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride. The empirical
formula C17H17NCl2.HCl.  <p>
 
Sertraline hydrochloride is a white crystalline powder that is slightly soluble 
in water and isopropyl alcohol, and sparingly soluble in ethanol.  
 <p>
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY <p>
</b> 
PHARMACODYNAMICS 
 <p>
The mechanism of action of sertraline is presumed to be linked to its
inhibition of CNS neuronal uptake of serotonin (5HT). Studies at clinically
relevant doses in man have demonstrated that sertraline blocks the uptake of
serotonin into human platelets. In Vitro studies in animals also suggest that
sertraline is a potent and selective inhibitor of neuronal serotonin reuptake
and has only very weak effects on norepinephrine and dopamine neuronal
reuptake. In Vitro studies have shown that sertraline has no significant
affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic 
histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors;
antagonism of such receptors has been hypothesized to be associated with
various anticholinergic, sedative, and cardiovascular effects for other
psychotropic drugs. The chronic administration of sertraline was found in
animals to downregulate brain norepinephrine receptors, as has been observed
with other clinically effective antidepressants. Sertraline does not inhibit
monoamine oxidase.  <p>
 
PHARMACOKINETICS 
 <p>
SYSTEMIC BIOAVAILABILITY--In man, following oral once-daily dosing over the
range of 50 to 200 mg for 14 days, mean peak plasma concentrations (Cmax) of
sertraline occurred between 4.5 to 8.4 hours postdosing. The average terminal
elimination half-life of plasma sertraline is about 26 hours. Based on this
pharmacokinetic parameter, steady-state sertraline plasma levels should be
achieved after approximately one week of once-daily dosing. Linear dose-
proportional pharmacokinetics were demonstrated in a single dose study in which 
the Cmax and area under the plasma concentration time curve (AUC) of sertraline 
were proportional to dose over a range of 50 to 200 mg. Consistent with the
terminal elimination half-life, there is an approximately two-fold accumulation 
compared to a single dose, of sertraline with repeated dosing over a 50 to 200
mg dose range. The single-dose bioavailability of sertraline tablets is
approximately equal to an equivalent dose of solution.  
<p>
The effects of food on the bioavailability of sertraline were studied in
subjects administered a single-dose with and without food. AUC was slightly
increased when drug was administered with food but the Cmax was 25% greater,
while the time to reach peak plasma concentration decreased from 8 hours post-
dosing to 5.5 hours.  
 <p>
METABOLISM--Sertraline undergoes extensive first pass metabolism. The principal 
initial pathway of metabolism for sertraline is N-demethylation. N-
desmethylsertraline has a plasma terminal elimination half-life of 62 to 104
hours. Both In Vitro biochemical and In Vivo pharmacological testing have shown 
N-desmethylsertraline to be substantially less active than sertraline. Both
sertraline and N-desmethylsertraline undergo oxidative deamination and
subsequent reduction, hydroxylation, and glucuronide conjugation. In a study of 
radiolabeled sertraline involving two healthy male subjects, sertraline
accounted for less than 5% of the plasma radioactivity. About 40-45% of the
administered radioactivity was recovered in urine in 9 days. Unchanged
sertraline was not detectable in the urine. For the same period, about 40-45%
of the administered radioactivity was accounted for in feces, including 12-14%
unchanged sertraline.  
 <p>
Desmethylsertraline exhibits time-related, dose dependent increases in AUC (0
24 hour), Cmax and Cmin, with about a 5-9 fold increase in these
pharmacokinetic parameters between day 1 and day 14.  
 <p>
PROTEIN BINDING--In Vitro protein binding studies performed with radiolabeled
3H-sertraline showed that sertraline is highly bound to serum proteins (98%) in 
the range of 20 to 500 ng/mL. However, at up to 300 and 200 ng/mL
concentrations, respectively, sertraline and N-desmethylsertraline did not
alter the plasma protein binding of two other highly protein bound drugs, viz., 
warfarin and propranolol (see Precautions).  
 <p>
AGE--Sertraline plasma clearance in a group of 16 (8 male, 8 female) elderly
patients treated for 14 days at dose of 100 mg/day was approximately 40% lower
than in a similarly studied group of younger (25 to 32 y.o.) individuals.
Steady state, therefore, should be achieved after 2 to 3 weeks in older
patients. The same study showed a decreased clearance of desmethylsertraline in 
older males, but not in older females.  
 <p>
LIVER DISEASE--As might be predicted from its primary site of metabolism, liver 
impairment can affect the elimination of sertraline. The elimination half-life
of sertraline was prolonged in a single dose study of patients with mild,
stable cirrhosis, with a mean of 52 hours compared to 22 hours seen in subjects 
without liver disease. This suggests that the use of sertraline in patients
with liver disease must be approached with caution. If sertraline is
administered to patients with liver disease, a lower or less frequent dose
should be used (see Precautions and Dosage and Administration).  
 <p>
RENAL DISEASE--The pharmacokinetics of sertraline in patients with significant
renal dysfunction have not been determined.  
 <p>
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
Sertraline is indicated for the treatment of depression. 
The efficacy of  sertraline in the treatment of a major depressive episode was
established in six to eight week controlled trials of outpatients whose
diagnoses corresponded most closely to the DSM-III category of major depressive 
disorder.  Sertraline is also indicated for obsessive-compulsive disorder.
 <p>
A major depressive episode implies a prominent and relatively persistent
depressed or dysphoric mood that usually interferes with daily functioning
(nearly every day for at least 2 weeks); it should include at least 4 of the
following 8 symptoms: change in appetite, change in sleep, psychomotor
agitation or retardation, loss of interest in usual activities or decrease in
sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed
thinking or impaired concentration, and a suicide attempt or suicidal ideation. 
 <p>
The antidepressant action of  sertraline in hospitalized depressed patients has not
been adequately studied.  
 <p>
A study of depressed outpatients who had responded to  sertraline during an initial
eight-week open treatment phase and were then randomized to continuation on
 sertraline or placebo demonstrated a significantly lower relapse rate over the next 
eight weeks for patients taking  sertraline compared to those on placebo. However,
the effectiveness of  sertraline in long-term use, that is, for more than 16 weeks,
has not been systematically evaluated in controlled trials. Therefore, the
physician who elects to use  sertraline for extended periods should periodically
reevaluate the long-term usefulness of the drug for the individual patient.  
 <p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <p>
None known.  
 <p>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <p>
CASES OF SERIOUS REACTIONS HAVE BEEN REPORTED IN PATIENTS RECEIVING SERTRALINE&nbsp;IN
COMBINATION WITH A MONOAMINE OXIDASE INHIBITOR (MAOI). THE SYMPTOMS HAVE
INCLUDED MENTAL STATUS CHANGES SUCH AS MEMORY CHANGES, CONFUSION AND
IRRITABILITY, CHILLS, PYREXIA AND MUSCLE RIGIDITY. IN PATIENTS RECEIVING
ANOTHER SEROTONIN REUPTAKE INHIBITOR DRUG IN COMBINATION WITH A MONOAMINE
OXIDASE INHIBITOR (MAOI), THERE HAVE BEEN REPORTS OF SERIOUS, SOMETIMES FATAL,
REACTIONS INCLUDING HYPERTHERMIA, RIGIDITY, MYOCLONUS, AUTONOMIC INSTABILITY
WITH POSSIBLE RAPID FLUCTUATIONS OF VITAL SIGNS, MENTAL STATUS CHANGES THAT
INCLUDE EXTREME AGITATION PROGRESSING TO DELIRIUM AND COMA. THESE REACTIONS
HAVE ALSO BEEN REPORTED IN PATIENTS WHO HAVE RECENTLY DISCONTINUED THAT DRUG
AND HAVE BEEN STARTED ON AN MAOI. SOME CASES PRESENTED WITH FEATURES RESEMBLING 
NEUROLEPTIC MALIGNANT SYNDROME. THEREFORE, IT IS RECOMMENDED THAT  sertraline
NOT BE USED IN COMBINATION WITH AN MAOI, OR WITHIN
14 DAYS OF DISCONTINUING TREATMENT WITH AN MAOI. SIMILARLY, AT LEAST 14 DAYS
SHOULD BE ALLOWED AFTER STOPPING  sertraline BEFORE STARTING AN MAOI.  <p>
 
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
GENERAL 
 <p>
ACTIVATION OF MANIA/HYPOMANIA--During premarketing testing, hypomania or mania
occurred in approximately 0.4% of  sertraline   treated
patients. Activation of mania/hypomania has also been reported in a small
proportion of patients with Major Affective Disorder treated with other
marketed antidepressants.  
 <p>
WEIGHT LOSS--Significant weight loss may be an undesirable result of treatment
with sertraline for some patients, but on average, patients in controlled
trials had minimal, 1 to 2 pound weight loss, versus smaller changes on
placebo. Only rarely have sertraline patients been discontinued for weight
loss.  
 <p>
SEIZURE-- sertraline has not been evaluated in patients with a seizure disorder. 
These patients were excluded from clinical studies during the product's
premarket testing. Accordingly, like other antidepressants,  sertraline should be
introduced with care in epileptic patients.  
 <p>
SUICIDE--The possibility of a suicide attempt is inherent in depression and may 
persist until significant remission occurs. Close supervision of high risk
patients should accompany initial drug therapy. Prescriptions for  sertraline should 
be written for the smallest quantity of tablets consistent with good patient
management, in order to reduce the risk of overdose.  
 <p>
WEAK URICOSURIC EFFECT-- sertraline is associated with a mean decrease in serum uric 
acid of approximately 7%. The clinical significance of this weak uricosuric
effect is unknown, and there have been no reports of acute renal failure with
 sertraline.  
 <p>
USE IN PATIENTS WITH CONCOMITANT ILLNESS--Clinical experience with  sertraline in
patients with certain concomitant systemic illness is limited. Caution is
advisable in using  sertraline in patients with diseases or conditions that could
affect metabolism or hemodynamic responses.  
 <p>
Sertraline has not been evaluated or used to any appreciable extent in patients
with a recent history of myocardial infarction or unstable heart disease.
Patients with these diagnoses were excluded from clinical studies during the
product's premarket testing. However, the electrocardiograms of 774 patients
who received  sertraline in double-blind trials were evaluated and the data indicate 
that  sertraline is not associated with the development of significant ECG
abnormalities.  
 <p>
Sertraline is extensively metabolized by the liver. In subjects with mild, stable
cirrhosis of the liver, the clearance of sertraline was decreased, thus
increasing the elimination half-life. A lower or less frequent dose should be
used in patients with cirrhosis.  
 <p>
Since  sertraline is extensively metabolized, excretion of unchanged drug in urine
is a minor route of elimination. However, until the pharmacokinetics of  sertraline
have been studied in patients with renal impairment and until adequate numbers
of patients with severe renal impairment have been evaluated during chronic
treatment with  sertraline, it should be used with caution in such patients.  
 <p>
INTERFERENCE WITH COGNITIVE AND MOTOR PERFORMANCE--In controlled studies,
sertraline did not cause sedation and did not interfere with psychomotor
performance.  
 <p>
HYPONATREMIA--Several cases of hyponatremia have been reported. The
hyponatremia appeared to be reversible when  sertraline was discontinued. The
majority of these occurrences have been in elderly individuals, some in
patients taking diuretics or who were otherwise volume depleted.  
 <p>
PLATELET FUNCTION--There have been rare reports of altered platelet function
and/or abnormal results from laboratory studies in patients taking  sertraline.
While there have been reports of abnormal bleeding or purpura in several
patients taking  sertraline, it is unclear whether  sertraline had a causative role.  
<p>
INFORMATION FOR PATIENTS 
 <p>
Physicians are advised to discuss the following issues with patients for whom
they prescribe  sertraline:  
 <p>
Patients should be told that although  sertraline has not been shown to impair the
ability of normal subjects to perform tasks requiring complex motor and mental
skills in laboratory experiments, drugs that act upon the central nervous
system may affect some individuals adversely.  
 <p>
Patients should be told that although  sertraline has not been shown in experiments
with normal subjects to increase the mental and motor skill impairments caused
by alcohol, the concomitant use of  sertraline and alcohol in depressed patients is
not advised.  <p>
 
Patients should be told that while no adverse interaction of  sertraline with over-
the-counter (OTC) drug products is known to occur, the potential for
interaction exists. Thus, the use of any OTC product should be initiated
cautiously according to the directions of use given for the OTC product.  
 <p>
Patients should be advised to notify their physician if they become pregnant or 
intend to become pregnant during therapy.  
 <p>
Patients should be advised to notify their physician if they are breast feeding 
an infant.  
 <p>
LABORATORY TESTS 
 <p>
None.  
 <p>
DRUG INTERACTIONS 
 <p>
POTENTIAL EFFECTS OF COADMINISTRATION OF DRUGS HIGHLY BOUND TO PLASMA PROTEINS- <p>
Because sertraline is tightly bound to plasma protein, the administration of
sertraline to a patient taking another drug which is
tightly bound to protein, (e.g., warfarin, digitoxin) may cause a shift in
plasma concentrations potentially resulting in an adverse effect. Conversely,
adverse effects may result from displacement of protein bound  sertraline by other
tightly bound drugs.  
 <p>
In a study comparing prothrombin time AUC (0-120 hr) following dosing with
warfarin (0.75 mg/kg) before and after 21 days of dosing with either  sertraline (50 
200 mg/day) or placebo, there was a mean increase in prothrombin time of 8%
relative to baseline for  sertraline compared to a 1% decrease for placebo (p&lt;0.02). 
The normalization of prothrombin time for the  sertraline group was delayed
compared to the placebo group. The clinical significance of this change is
unknown.  Accordingly, prothrombin time should be carefully monitored when
sertraline therapy is initiated or stopped.  <p>
 
CIMETIDINE--In a study assessing disposition of  sertraline (100mg) on the second of 
8 days of cimetidine administration (800mg daily), there were increases in
sertraline mean AUC (50%), Cmax (24%) and half-life (26%) compared to the placebo
group. The clinical significance of these changes is unknown.  
 <p>
CNS ACTIVE DRUGS--In a study comparing the disposition of intravenously
administered diazepam before and after 21 days of dosing with either  sertraline (50 
to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to 
baseline in diazepam clearance for the  sertraline group compared to a 19% decrease
relative to baseline for the placebo group (p&lt;0.03). There was a 23% increase
in Tmax for desmethyldiazepam in the  sertraline group compared to a 20% decrease in 
the placebo group (p&lt;0.03). The clinical significance of these changes is
unknown.  
 <p>
In a placebo-controlled trial in normal volunteers, the administration of two
doses of  sertraline did not significantly alter steady-state lithium levels or the
renal clearance of lithium.  <p>
 
Nonetheless, at this time, it is recommended that plasma lithium levels be
monitored following initiation of  sertraline therapy with appropriate adjustments
to the lithium dose.  
 <p>
The risk of using  sertraline in combination with other CNS active drugs has not
been systematically evaluated. Consequently, caution is advised if the
concomitant administration of  sertraline and such drugs is required.  
 <p>
There is limited controlled experience regarding the optimal timing of
switching from other antidepressants to  sertraline. Care and prudent medical
judgment should be exercised when switching, particularly from long-acting
agents. The duration of an appropriate washout period which should intervene
before switching from one selective serotonin reuptake inhibitor (SSRI) to
another has not been established.  
 <p>
HYPOGLYCEMIC DRUGS--In a placebo-controlled trial in normal volunteers,
administration of  sertraline for 22 days (including 200 mg/day for the final 13
days) caused a statistically significant 16% decrease from baseline in the
clearance of tolbutamide following an intravenous 1000 mg dose.  sertraline
administration did not noticeably change either the plasma protein binding or
the apparent volume of distribution of tolbutamide, suggesting that the
decreased clearance was due to a change in the metabolism of the drug. The
clinical significance of this decrease in tolbutamide clearance is unknown.  
 <p>
ATENOLOL-- sertraline (100 mg) when administered to 10 healthy male subjects had no
effect on the beta-adrenergic blocking ability of atenolol.  
 <p>
DIGOXIN--In a placebo-controlled trial in normal volunteers, administration of
sertraline for 17 days (including 200 mg/day for the last 10 days) did not change
serum digoxin levels or digoxin renal clearance.  <p>
 
MICROSOMAL ENZYME INDUCTION--Preclinical studies have shown  sertraline to induce
hepatic microsomal enzymes. In clinical studies,  sertraline was shown to induce
hepatic enzymes minimally as determined by a small (5%) but statistically
significant decrease in antipyrine half-life following administration of 200
mg/day for 21 days. This small change in antipyrine half-life reflects a
clinically insignificant change in hepatic metabolism.  
 <p>
ELECTROCONVULSIVE THERAPY--There are no clinical studies establishing the risks 
or benefits of the combined use of electroconvulsive therapy (ECT) and  sertraline.  
 <p>
ALCOHOL--Although  sertraline did not potentiate the cognitive and psychomotor
effects of alcohol in experiments with normal subjects, the concomitant use of
sertraline and alcohol in depressed patients is not recommended.  
 <p>
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY 
                               <p>
Lifetime carcinogenicity studies were carried out in CD-1 mice and Long-Evans
rats at doses up to 40 mg/kg in mice (10 times, on a mg/kg basis, and the same, 
on a mg/M(square) basis, as the maximum recommended human dose) and at doses up 
to 40 mg/kg in rats (10 times, on a mg/kg basis, and 2 times, on a mg/M(square) 
basis, the maximum recommended human dose). There was a dose-related increase
in the incidence of liver adenomas in male mice receiving sertraline at 10-40
mg/kg. No increase was seen in female mice or in rats of either sex receiving
the same treatments, nor was there an increase in hepatocellular carcinomas. 
Liver adenomas have a variable rate of spontaneous occurrence in the CD-1 mouse 
and are of unknown significance to humans. There was an increase in follicular
adenomas of the thyroid in female rats receiving sertraline at 40 mg/kg; this
was not accompanied by thyroid hyperplasia. While there was an increase in
uterine adenocarcinomas in rats receiving sertraline at 10-40 mg/kg compared to 
placebo controls, this effect was not clearly drug related.  
 <p>
Sertraline had no genotoxic effects, with or without metabolic activation,
based on the following assays: bacterial mutation assay; mouse lymphoma
mutation assay; and tests for cytogenetic aberrations In Vivo in mouse bone
marrow and In Vitro in human lymphocytes.  
 <p>
A decrease in fertility was seen in one of two rat studies at a dose of 80
mg/kg (20 times the maximum human dose on a mg/kg basis and 4 times on a
mg/M(square) basis).  
 <p>
PREGNANCY-PREGNANCY CATEGORY B 
 <p>
TERATOGENIC EFFECTS--Reproduction studies have been performed in rats and
rabbits at doses up to approximately 20 times and 10 times the maximum daily
human mg/kg dose (4 to 4.5 times the mg/M(square) dose), respectively.  
 <p>
There was no evidence of teratogenicity at any dose level. At doses
approximately 2.5-10 times the maximum daily human mg/kg dose, sertraline was
associated with delayed ossification in fetuses, probably secondary to effects
on the dams.  <p>
 
There are no adequate and well-controlled studies in pregnant women. Because
animal reproduction studies are not always predictive of human response, this
drug should be used during pregnancy only if clearly needed.  
 <p>
NON-TERATOGENIC EFFECTS--There was also decreased neonatal survival following
maternal administration of sertraline at doses as low as approximately 5 times
the maximum human mg/kg dose. The decrease in pup survival was shown to be most 
probably due to In Utero exposure to sertraline. The clinical significance of
these effects is unknown.  
 <p>
LABOR AND DELIVERY--The effect of  sertraline on labor and delivery in humans is
unknown.  <p>
 
NURSING MOTHERS--It is not known whether, and if so in what amount, sertraline
or its metabolites are excreted in human milk. Because many drugs are excreted
in human milk, caution should be exercised when  sertraline is administered to a
nursing woman.  
 <p>
PEDIATRIC USE--Safety and effectiveness in children have not been established.  
 <p>
GERIATRIC USE--Several hundred elderly patients have participated in clinical
studies with  sertraline. The pattern of adverse reactions in the elderly was
similar to that in younger patients.  <p>
 
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <p>
CASES OF SERIOUS REACTIONS HAVE BEEN REPORTED IN PATIENTS RECEIVING  sertraline IN
COMBINATION WITH A MONOAMINE OXIDASE INHIBITOR (MAOI). THE SYMPTOMS HAVE
INCLUDED MENTAL STATUS CHANGES SUCH AS MEMORY CHANGES, CONFUSION AND
IRRITABILITY, CHILLS, PYREXIA AND MUSCLE RIGIDITY. IN PATIENTS RECEIVING
ANOTHER SEROTONIN REUPTAKE INHIBITOR DRUG IN COMBINATION WITH A MONOAMINE
OXIDASE INHIBITOR (MAOI), THERE HAVE BEEN REPORTS OF SERIOUS, SOMETIMES FATAL,
REACTIONS INCLUDING HYPERTHERMIA, RIGIDITY, MYOCLONUS, AUTONOMIC INSTABILITY
WITH POSSIBLE RAPID FLUCTUATIONS OF VITAL SIGNS, MENTAL STATUS CHANGES THAT
INCLUDE EXTREME AGITATION PROGRESSING TO DELIRIUM AND COMA. THESE REACTIONS
HAVE ALSO BEEN REPORTED IN PATIENTS WHO HAVE RECENTLY DISCONTINUED THAT DRUG
AND HAVE BEEN STARTED ON AN MAOI. SOME CASES PRESENTED WITH FEATURES RESEMBLING 
NEUROLEPTIC MALIGNANT SYNDROME. THEREFORE, IT IS RECOMMENDED THAT  sertraline
NOT BE USED IN COMBINATION WITH AN MAOI, OR WITHIN
14 DAYS OF DISCONTINUING TREATMENT WITH AN MAOI. SIMILARLY, AT LEAST 14 DAYS
SHOULD BE ALLOWED AFTER STOPPING  sertraline BEFORE STARTING AN MAOI.  
 <p>
POTENTIAL EFFECTS OF COADMINISTRATION OF DRUGS HIGHLY BOUND TO PLASMA PROTEINS- <p>
Because sertraline is tightly bound to plasma protein, the administration of
sertraline to a patient taking another drug which is
tightly bound to protein, (e.g., warfarin, digitoxin) may cause a shift in
plasma concentrations potentially resulting in an adverse effect. Conversely,
adverse effects may result from displacement of protein bound  sertraline by other
tightly bound drugs.  <p>
 
In a study comparing prothrombin time AUC (0-120 hr) following dosing with
warfarin (0.75 mg/kg) before and after 21 days of dosing with either  sertraline (50 
200 mg/day) or placebo, there was a mean increase in prothrombin time of 8%
relative to baseline for  sertraline compared to a 1% decrease for placebo (p&lt;0.02). 
The normalization of prothrombin time for the  sertraline group was delayed
compared to the placebo group. The clinical significance of this change is
unknown.  Accordingly, prothrombin time should be carefully monitored when
 sertraline therapy is initiated or stopped.  
 <p>
CIMETIDINE--In a study assessing disposition of  sertraline (100mg) on the second of 
8 days of cimetidine administration (800mg daily), there were increases in
sertraline mean AUC (50%), Cmax (24%) and half-life (26%) compared to the placebo
group. The clinical significance of these changes is unknown.  
 <p>CNS ACTIVE DRUGS--In a study comparing the disposition of intravenously
administered diazepam before and after 21 days of dosing with either  sertraline (50 
to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to 
baseline in diazepam clearance for the  sertraline group compared to a 19% decrease
relative to baseline for the placebo group (p&lt;0.03). There was a 23% increase
in Tmax for desmethyldiazepam in the  sertraline group compared to a 20% decrease in 
the placebo group (p&lt;0.03). The clinical significance of these changes is
unknown.  <p>
 
In a placebo-controlled trial in normal volunteers, the administration of two
doses of  sertraline did not significantly alter steady-state lithium levels or the
renal clearance of lithium.  
 <p>
Nonetheless, at this time, it is recommended that plasma lithium levels be
monitored following initiation of  sertraline therapy with appropriate adjustments
to the lithium dose.  
 <p>
The risk of using  sertraline in combination with other CNS active drugs has not
been systematically evaluated. Consequently, caution is advised if the
concomitant administration of  sertraline and such drugs is required.  
 <p>
There is limited controlled experience regarding the optimal timing of
switching from other antidepressants to  sertraline. Care and prudent medical
judgment should be exercised when switching, particularly from long-acting
agents. The duration of an appropriate washout period which should intervene
before switching from one selective serotonin reuptake inhibitor (SSRI) to
another has not been established.  
 <p>
HYPOGLYCEMIC DRUGS--In a placebo-controlled trial in normal volunteers,
administration of  sertraline for 22 days (including 200 mg/day for the final 13
days) caused a statistically significant 16% decrease from baseline in the
clearance of tolbutamide following an intravenous 1000 mg dose.  sertraline
administration did not noticeably change either the plasma protein binding or
the apparent volume of distribution of tolbutamide, suggesting that the
decreased clearance was due to a change in the metabolism of the drug. The
clinical significance of this decrease in tolbutamide clearance is unknown.  
 <p>
ATENOLOL-- sertraline (100 mg) when administered to 10 healthy male subjects had no
effect on the beta-adrenergic blocking ability of atenolol.  
 <p>
DIGOXIN--In a placebo-controlled trial in normal volunteers, administration of
 sertraline for 17 days (including 200 mg/day for the last 10 days) did not change
serum digoxin levels or digoxin renal clearance.  
 <p>
MICROSOMAL ENZYME INDUCTION--Preclinical studies have shown  sertraline to induce
hepatic microsomal enzymes. In clinical studies,  sertraline was shown to induce
hepatic enzymes minimally as determined by a small (5%) but statistically
significant decrease in antipyrine half-life following administration of 200
mg/day for 21 days. This small change in antipyrine half-life reflects a
clinically insignificant change in hepatic metabolism.  
 <p>
ELECTROCONVULSIVE THERAPY--There are no clinical studies establishing the risks 
or benefits of the combined use of electroconvulsive therapy (ECT) and  sertraline.  
 <p>
ALCOHOL--Although  sertraline did not potentiate the cognitive and psychomotor
effects of alcohol in experiments with normal subjects, the concomitant use of
 sertraline and alcohol in depressed patients is not recommended.  
 <p>
(See Also WARNINGS and PRECAUTIONS) 
 <p>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
COMMONLY OBSERVED--The most commonly observed adverse events associated with
the use of  sertraline   and not seen at an equivalent
incidence among placebo treated patients were: gastrointestinal complaints,
including nausea, diarrhea/loose stools and dyspepsia; tremor; dizziness;
insomnia; somnolence; increased sweating; dry mouth; and male sexual
dysfunction (primarily ejaculatory delay).  
 <p>
ASSOCIATED WITH DISCONTINUATION OF TREATMENT--Fifteen percent of 2710 subjects
who received  sertraline in premarketing multiple dose clinical trials discontinued
treatment due to an adverse event. The more common events (reported by at least 
1% of subjects) associated with discontinuation included agitation, insomnia,
male sexual dysfunction (primarily ejaculatory delay), somnolence, dizziness,
headache, tremor, anorexia, diarrhea/loose stools, nausea, and fatigue.  
 <p>
INCIDENCE IN CONTROLLED CLINICAL TRIALS--The table that follows enumerates
adverse events that occurred at a frequency of 1% or more among  sertraline patients 
who participated in controlled trials comparing titrated  sertraline with placebo. 
Most patients received doses of 50 to 200 mg per day. The prescriber should be
aware that these figures cannot be used to predict the incidence of side
effects in the course of usual medical practice where patient characteristics
and other factors differ from those which prevailed in the clinical trials.
Similarly, the cited frequencies cannot be compared with figures obtained from
other clinical investigations involving different treatments, uses, and
investigators. The cited figures, however, do provide the prescribing physician 
with some basis for estimating the relative contribution of drug and non-drug
factors to the side effect incidence rate in the population studied.  <p>
 <pre>
                 TREATMENT-EMERGENT ADVERSE EXPERIENCE INCIDENCE                
                      IN PLACEBO-CONTROLLED CLINICAL TRIALS*                    
ADVERSE EXPERIENCE                                    (PERCENT OF PATIENTS      
                                                           REPORTING)           
                                                      sertraline         PLACEBO     
                                                    (N=861)         (N=853)     
AUTONOMIC NERVOUS SYSTEM DISORDERS                                              
Mouth Dry                                             16.3             9.3      
Sweating Increased                                     8.4             2.9      
CARDIOVASCULAR                                                                  
Palpitations                                           3.5             1.6      
Chest Pain                                             1.0             1.6      
CENTR. &amp; PERIPH. NERV. SYSTEM DISORDERS                                         
Headache                                              20.3            19.0      
Dizziness                                             11.7             6.7      
Tremor                                                10.7             2.7      
Paresthesia                                            2.0             1.8      
Hypoesthesia                                           1.7             0.6      
Twitching                                              1.4             0.1      
Hypertonia                                             1.3             0.4      
DISORDERS OF SKIN AND APPENDAGES                                                
Rash                                                   2.1             1.5      
GASTROINTESTINAL DISORDERS                                                      
Nausea                                                26.1            11.8      
Diarrhea/Loose Stools                                 17.7             9.3      
Constipation                                           8.4             6.3      
Dyspepsia                                              6.0             2.8      
Vomiting                                               3.8             1.8      
Flatulence                                             3.3             2.5      
Anorexia                                               2.8             1.6      
Abdominal Pain                                         2.4             2.2      
Appetite Increased                                     1.3             0.9      
GENERAL                                                                         
Fatigue                                               10.6             8.1      
Hot Flushes                                            2.2             0.5      
Fever                                                  1.6             0.6      
Back Pain                                              1.5             0.9      
METABOLIC AND NUTRITIONAL DISORDERS                                             
Thirst                                                 1.4             0.9      
MUSCULOSKELETAL SYSTEM DISORDERS                                                
Myalgia                                                1.7             1.5      
PSYCHIATRIC DISORDERS                                                           
Insomnia                                              16.4             8.8      
Sexual Dysfunction-Male (1)                           15.5             2.2      
Somnolence                                            13.4             5.9      
Agitation                                              5.6             4.0      
Nervousness                                            3.4             1.9      
Anxiety                                                2.6             1.3      
Yawning                                                1.9             0.2      
Sexual Dysfunction-Female (2)                          1.7             0.2      
Concentration Impaired                                 1.3             0.5      
REPRODUCTIVE                                                                    
Menstrual Disorder (2)                                 1.0             0.5      
RESPIRATORY SYSTEM DISORDERS                                                    
Rhinitis                                               2.0             1.5      
Pharyngitis                                            1.2             0.9      
SPECIAL SENSES                                                                  
Vision Abnormal                                        4.2             2.1      
Tinnitus                                               1.4             1.1      
Taste Perversion                                       1.2             0.7      
URINARY SYSTEM DISORDERS                                                        
Micturition Frequency                                  2.0             1.2      
Micturition Disorder                                   1.4             0.5      
*   Events reported by at least 1% of patients treated with  sertraline are          
     included.                                                                  
(1)--Primarily ejaculatory delay; % based on male patients only: 271  sertraline     
 and 271 placebo patients.                                                      
(2)--% based on female patients only: 590  sertraline and 582 placebo patients.      </pre><P>

OTHER EVENTS OBSERVED DURING THE PREMARKETING EVALUATION OF  sertraline (SERTRALINE
HYDROCHLORIDE): During its premarketing assessment, multiple doses of  sertraline
were administered to approximately 2700 subjects. The conditions and duration
of exposure to  sertraline varied greatly, and included (in overlapping categories)
clinical pharmacology studies, open and double-blind studies, uncontrolled and
controlled studies, inpatient and outpatient studies, fixed-dose and titration
studies, and studies for indications other than depression. Untoward events
associated with this exposure were recorded by clinical investigators using
terminology of their own choosing. Consequently, it is not possible to provide
a meaningful estimate of the proportion of individuals experiencing adverse
events without first grouping similar types of untoward events into a smaller
number of standardized event categories.  <p>
 
In the tabulations that follow, a World Health Organization dictionary of
terminology has been used to classify reported adverse events. The frequencies
presented, therefore, represent the proportion of the approximately 2700
individuals exposed to multiple doses of  sertraline who experienced an event of the 
type cited on at least one occasion while receiving  sertraline. All events are
included except those already listed in the previous table and those reported
in terms so general as to be uninformative. It is important to emphasize that
although the events reported occurred during treatment with  sertraline, they were
not necessarily caused by it.  
 <p>
Events are further categorized by body system and listed in order of decreasing 
frequency according to the following definitions: frequent adverse events are
those occurring on one or more occasions in at least 1/100 patients (only those 
not already listed in the tabulated results from placebo controlled trials
appear in this listing); infrequent adverse events are those occurring in 1/100 
to 1/1000 patients; rare events are those occurring in fewer than 1/1000
patients. Events of major clinical importance are also described in the
PRECAUTIONS section.  
 <p>
AUTONOMIC NERVOUS SYSTEM DISORDERS--Infrequent: flushing, mydriasis, increased
saliva, cold clammy skin; Rare: pallor.  <p>
 
CARDIOVASCULAR--Infrequent: postural dizziness, hypertension, hypotension,
postural hypotension, edema, dependent edema, periorbital edema, peripheral
edema, peripheral ischemia, syncope, tachycardia: Rare: precordial chest pain,
substernal chest pain, aggravated hypertension, myocardial infarction, varicose 
veins.  
 <p>
CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS-- Frequent: confusion;
Infrequent: ataxia, abnormal coordination, abnormal gait, hyperesthesia,
hyperkinesia, hypokinesia, migraine, nystagmus, vertigo; Rare: local anesthesia 
coma, convulsions, dyskinesia, dysphonia, hyporeflexia, hypotonia, ptosis.  
 <p>
DISORDERS OF SKIN AND APPENDAGES--Infrequent: acne, alopecia, pruritus,
erythematous rash, maculopapular rash, dry skin; Rare: bullous eruption,
dermatitis, erythema multiforme, abnormal hair texture, hypertrichosis,
photosensitivity reaction, follicular rash, skin discoloration, abnormal skin
odor, urticaria.  
 <p>
ENDOCRINE DISORDERS--Rare: exophthalmos, gynecomastia.  
 <p>
GASTROINTESTINAL DISORDERS--Infrequent: dysphagia, eructation; Rare: 
diverticulitis, fecal incontinence, gastritis, gastroenteritis, glossitis, gum
hyperplasia, hemorrhoids, hiccup, melena, hemorrhagic peptic ulcer, proctitis,
stomatitis, ulcerative stomatitis, tenesmus, tongue edema, tongue ulceration. 
 <p>
GENERAL--Frequent: asthenia; Infrequent: malaise, generalized edema, rigors,
weight decrease, weight increase; Rare: enlarged abdomen, halitosis, otitis
media, aphthous stomatitis.  
 <p>
HEMATOPOIETIC AND LYMPHATIC--Infrequent: lymphadenopathy, purpura; Rare: anemia 
anterior chamber eye hemorrhage.  
 <p>
METABOLIC AND NUTRITIONAL DISORDERS--Rare: dehydration, hypercholesterolemia,
hypoglycemia.  
 <p>
MUSCULOSKELETAL SYSTEM DISORDERS--Infrequent: arthralgia, arthrosis, dystonia,
muscle cramps, muscle weakness; Rare: hernia.  
 <p>
PSYCHIATRIC DISORDERS--Infrequent: abnormal dreams, aggressive reaction,
amnesia, apathy, delusion, depersonalization, depression, aggravated depression 
emotional lability, euphoria, hallucination, neurosis, paranoid reaction,
suicide ideation and attempt, teeth-grinding, abnormal thinking; Rare: hysteria 
somnambulism, withdrawal syndrome.  
 <p>
REPRODUCTIVE--Infrequent: dysmenorrhea (2), intermenstrual bleeding (2); Rare:  
amenorrhea (2), balanoposthitis (1), breast enlargement (2), female breast pain 
(2), leukorrhea (2), menorrhagia (2), atrophic vaginitis (2).  
 <p>
(1)--% based on male subjects only: 1005.  
 <p>
(2)--% based on female subjects only: 1705.  
                         <p>       
RESPIRATORY SYSTEM DISORDERS--Infrequent: bronchospasm, coughing, dyspnea,
epistaxis; Rare: bradypnea, hyperventilation, sinusitis, stridor.  
 <p>
SPECIAL SENSES--Infrequent: abnormal accommodation, conjunctivitis, diplopia,
earache, eye pain, xerophthalmia; Rare: abnormal lacrimation, photophobia,
visual field defect.  
 <p>
URINARY SYSTEM DISORDERS--Infrequent: dysuria, face edema, nocturia, polyuria,
urinary incontinence; Rare: oliguria, renal pain, urinary retention.  
 <p>
LABORATORY TESTS--In man, asymptomatic elevations in serum transaminases (SGOT
(or AST) and SGPT (or ALT)) have been reported infrequently (approximately
0.8%) in association with  sertraline administration. These hepatic enzyme
elevations usually occurred within the first 1 to 9 weeks of drug treatment and 
promptly diminished upon drug discontinuation.  
 <p>
Sertraline therapy was associated with small mean increases in total cholesterol
(approximately 3%) and triglycerides (approximately 5%), and a small mean
decrease in serum uric acid (approximately 7%) of no apparent clinical
importance.  
 <p>
DRUG ABUSE AND DEPENDENCE 
 <p>
CONTROLLED SUBSTANCE CLASS-- sertraline is not a controlled substance.  
 <p>
PHYSICAL AND PSYCHOLOGICAL DEPENDENCE-- sertraline has not been systematically
studied, in animals or humans, for its potential for abuse, tolerance, or
physical dependence. However, the premarketing clinical experience with  sertraline
did not reveal any tendency for a withdrawal syndrome or any drug-seeking
behavior. As with any new CNS active drug, physicians should carefully evaluate 
patients for history of drug abuse and follow such patients closely, observing
them for signs of  sertraline misuse or abuse (e.g., development of tolerance,
incrementation of dose, drug-seeking behavior).  <p>
 
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <p>
HUMAN EXPERIENCE--As of November, 1992, there were 79 reports of non-fatal
acute overdoses involving  sertraline, of which 28 were overdoses of  sertraline alone
and the remainder involved a combination of other drugs and/or alcohol in
addition to  sertraline. In those cases of overdose involving only  sertraline, the
reported doses ranged from 500mg to 6000mg. In a subset of 18 of these patients 
in whom  sertraline blood levels were determined, plasma concentrations ranged from
&lt;5ng/mL to 554ng/mL. Symptoms of overdose with  sertraline alone included somnolence 
nausea, vomiting, tachycardia, ECG changes, anxiety and dilated pupils.
Treatment was primarily supportive and included monitoring and use of activated 
charcoal, gastric lavage or cathartics and hydration. Although there were no
reports of death when  sertraline was taken alone, there were 4 deaths involving
overdoses of  sertraline in combination with other drugs and/or alcohol. Therefore,
any overdosage should be treated aggressively.  
 <p>
MANAGEMENT OF OVERDOSES--Establish and maintain an airway, insure adequate
oxygenation and ventilation. Activated charcoal, which may be used with
sorbitol, may be as or more effective than emesis or lavage, and should be
considered in treating overdose.  
 <p>
Cardiac and vital signs monitoring is recommended along with general
symptomatic and supportive measures.  
 <p>
There are no specific antidotes for sertraline.  
 <p>
Due to the large volume of distribution of  sertraline, forced diuresis, dialysis,
hemoperfusion, and exchange transfusion are unlikely to be of benefit.  
 <p>
In managing overdosage, consider the possibility of multiple drug involvement.  
The physician should consider contacting a poison control center on the
treatment of any overdose.  
 <p>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
INITIAL TREATMENT-- sertraline&nbsp;treatment should be
initiated with a dose of 50 mg once daily. While a relationship between dose
and antidepressant effect has not been established, patients were dosed in a
range of 50-200 mg/day in the clinical trials demonstrating the antidepressant
effectiveness of  sertraline. Consequently, patients not responding to a 50 mg dose
may benefit from dose increases up to a maximum of 200 mg/day. Given the 24
hour elimination half-life of  sertraline, dose changes should not occur at
intervals of less than 1 week.  
 <p>
Sertraline should be administered once daily, either in the morning or evening.  
 <p>
As indicated under Precautions, a lower or less frequent dosage should be used
in patients with hepatic impairment. In addition, particular care should be
used in patients with renal impairment.  
 <p>
MAINTENANCE/CONTINUATION/EXTENDED TREATMENT--There is evidence to suggest that
depressed patients responding during an initial 8 week treatment phase will
continue to benefit during an additional 8 weeks of treatment. While there are
insufficient data regarding any benefits from treatment beyond 16 weeks, it is
generally agreed among expert psychopharmacologists that acute episodes of
depression require several months or longer of sustained pharmacological
therapy. Whether the dose of antidepressant needed to induce remission is
identical to the dose needed to maintain and/or sustain euthymia is unknown. 

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-14</DOCNO>
<DOCOLDNO>IA018-000200-B034-243</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/cephalex.htm 206.86.175.201 19970106224435 text/html 18862
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:38:21 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 18679
Last-modified: Thu, 11 Jul 1996 06:06:49 GMT
</DOCHDR>
<html>
<head>
   <title>Cephalexin - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Cephalexin</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [drug-drug]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Cephalexin is a semisynthetic cephalosporin antibiotic intended for
oral administration. It is 7-(D-alpha-amino-alpha-phenylacetamido) 3-methyl-
3-cephem-4-carboxylic acid monohydrate. Cephalexin has the molecular formula
C16H17N3O4S.H2O and the molecular weight is 365.4. </p>

<p>The nucleus of cephalexin is related to that of other cephalosporin
antibiotics. The compound is a zwitterion; ie, the molecule contains both
a basic and an acidic group. The isoelectric point of cephalexin in water
is approximately 4.5 to 5. </p>

<p>The crystalline form of cephalexin which is available is a monohydrate.
It is a white crystalline solid having a bitter taste. Solubility in water
is low at room temperature; 1 or 2 mg/mL may be dissolved readily, but
higher concentrations are obtained with increasing difficulty. </p>

<p>The cephalosporins differ from penicillins in the structure of the bicyclic
ring system. Cephalexin has a D-phenylglycyl group as substituent at the
7 amino position and an unsubstituted methyl group at the 3-position. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Human Pharmacology--Cephalexin is acid stable and may be given without
regard to meals. It is rapidly absorbed after oral administration. Following
doses of 250 mg, 500 mg, and 1 g, average peak serum levels of approximately
9, 18, and 32 mcgm/mL respectively were obtained at 1 hour. Measurable
levels were present 6 hours after administration. Cephalexin is excreted
in the urine by glomerular filtration and tubular secretion. Studies showed
that over 90% of the drug was excreted unchanged in the urine within 8
hours. During this period, peak urine concentrations following the 250
mg, 500- mg, and 1-g doses were approximately 1,000, 2,200, and 5,000 mcgm/mL
respectively. </p>

<p>Microbiology--In Vitro tests demonstrate that the cephalosporins are
bactericidal because of their inhibition of cell-wall synthesis. Cephalexin
is active against the following organisms both In Vitro and in clinical
infections (see Indications and Usage): </p>

<p>Escherichia Coli </p>

<p>Haemophilus Influenzae </p>

<p>Klebsiella Pneumoniae </p>

<p>Moraxella (Branhamella) Catarrhalis </p>

<p>Proteus Mirabilis </p>

<p>Staphylococcus Aureus (including penicillinase-producing strains) </p>

<p>Staphylococcus Epidermidis (penicillinase-producing strains) </p>

<p>Streptococcus pneumoniae </p>

<p>Streptococcus pyogenes </p>

<p>Note--Methicillin-resistant staphylococci and most strains of enterococci
(Enterococcus Faecalis (formerly Streptococcus Faecalis)) are resistant
to cephalosporins, including cephalexin. It is not active against most
strains of Enterobacter spp, Morganella Morganii and Proteus Vulgaris.
It has no activity against Pseudomonas spp or Acinetobacter Calcoaceticus.
</p>

<p>Susceptibility Tests--DIFFUSION TECHNIQUES: Quantitative methods that
require measurement of zone diameters give the most precise estimate of
the susceptibility of bacteria to antimicrobial agents. One such standard
procedure* has been recommended for use with disks to test susceptibility
of organisms to cephalexin, using the 30-mcgm cephalothin disk. Interpretation
involves the correlation of the diameters obtained with the disk test with
the minimum inhibitory concentration (MIC) for cephalexin. </p>

<p>Reports from the laboratory giving results of the standard single-disk
susceptibility test with a 30-mcgm cephalothin disk should be interpreted
according to the following criteria: </p>

<p>Zone Diameter (mm) Interpretation &gt;/=18 (S) Susceptible 15-17 (MS)
Moderately Susceptible &lt; or =14 Resistant A report of &quot;Susceptible&quot;
indicates that the pathogen is likely to be inhibited by generally achievable
blood levels. A report of &quot;Moderately Susceptible&quot; suggests that
the organism would be susceptible if high dosage is used or if the infection
is confined to tissue and fluids in which high antibiotic levels are obtained.
A report of &quot;Resistant&quot; indicates that achievable concentrations
of the antibiotic are unlikely to be inhibitory and other therapy should
be selected. </p>

<p>Standardized procedures require the use of laboratory control organisms.
The 30 mcgm cephalothin disk should give the following zone diameters:
</p>

<p>Organism Zone Diameter (mm) E. Coli ATCC 25922 17-22 S. Aureus ATCC
25923 29-37 DILUTION TECHNIQUES: Use a standardized dilution method* (broth,
agar, microdilution) or equivalent with cephalothin powder. The MIC values
obtained should be interpreted according to the following criteria: </p>

<p>MIC (mcgm/mL) Interpretation &lt; or =8 (S) Susceptible 16 (MS) Moderately
Susceptible &gt;/=32 Resistant As with standard diffusion techniques, dilution
methods require the use of laboratory control organisms. Standard cephalothin
powder should provide the following MIC values: </p>

<pre>            Organism                             MIC (mcgm/mL)                  
E. Coli ATCC 25922                                  4.0-16.0                    
E. Faecalis ATCC 29212                              8.0-32.0                    
S. Aureus ATCC 29213                                0.12-0.5                    
----------- </pre>

<p>* Laboratory Standards: Performance standards for antimicrobial disk
susceptibility tests--4th ed. </p>

<p>Approved Standard NCCLS Document M2-A4, Vol 10, No 7, NCCLS, Villanova,
PA, 1990. </p>

<p>* National Committee for Clinical Laboratory Standards: Methods for
dilution antimicrobial susceptibility tests for bacteria that grow aerobically--2nd
ed. Approved Standard NCCLS Document M7-A2, Vol 10, No 8, NCCLS, Villanova,
PA, 1990. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Cephalexin is indicated for the treatment of the following infections
when caused by susceptible strains of the designated microorganisms: </p>

<p>Respiratory tract infections caused by S. Pneumoniae and S. Pyogenes
(Penicillin is the usual drug of choice in the treatment and prevention
of streptococcal infections, including the prophylaxis of rheumatic fever.
Cephalexin is generally effective in the eradication of streptococci from
the nasopharynx; however, substantial data establishing the efficacy of
Cephalexin in the subsequent prevention of rheumatic fever are not available
at present.) </p>

<p>Otitis media due to S. Pneumoniae, H. Influenzae, staphylococci, streptococci,
and M. Catarrhalis </p>

<p>Skin and skin structure infections caused by staphylococci and/or streptococci
</p>

<p>Bone infections caused by staphylococci and/or P. Mirabilis </p>

<p>Genitourinary tract infections, including acute prostatitis, caused
by E. Coli, P. Mirabilis, and K. Pneumoniae </p>

<p>Note--Culture and susceptibility tests should be initiated prior to
and during therapy. Renal function studies should be performed when indicated.
</p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Cephalexin is contraindicated in patients with known allergy to the
cephalosporin group of antibiotics. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>BEFORE CEPHALEXIN THERAPY IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE
CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO CEPHALOSPORINS AND PENICILLIN.
CEPHALOSPORIN C DERIVATIVES SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN-SENSITIVE
PATIENTS. </p>

<p>SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE EPINEPHRINE AND
OTHER EMERGENCY MEASURES. </p>

<p>There is some clinical and laboratory evidence of partial cross-allergenicity
of the penicillins and the cephalosporins. Patients have been reported
to have had severe reactions (including anaphylaxis) to both drugs. </p>

<p>Any patient who has demonstrated some form of allergy, particularly
to drugs, should receive antibiotics cautiously. No exception should be
made with regard to Cephalexin . </p>

<p>Pseudomembranous colitis has been reported with virtually all broad-spectrum
antibiotics (including macrolides, semisynthetic penicillins, and cephalosporins);
therefore, it is important to consider its diagnosis in patients who develop
diarrhea in association with the use of antibiotics. Such colitis may range
in severity from mild to life-threatening. </p>

<p>Treatment with broad-spectrum antibiotics alters the normal flora of
the colon and may permit overgrowth of clostridia. Studies indicate that
a toxin produced by Clostridium Difficile is a primary cause of antibiotic-associated
colitis. </p>

<p>Mild cases of pseudomembranous colitis usually respond to drug discontinuance
alone. In moderate to severe cases, management should include sigmoidoscopy,
appropriate bacteriologic studies, and fluid, electrolyte, and protein
supplementation. When the colitis does not improve after the drug has been
discontinued, or when it is severe, treatment with an oral antibacterial
drug effective against C. Difficile is recommended. Other causes of colitis
should be ruled out. </p>

<p>Usage In Pregnancy--Safety of this product for use during pregnancy
has not been established. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>General--Patients should be followed carefully so that any side effects
or unusual manifestations of drug idiosyncrasy may be detected. If an allergic
reaction to Cephalexin occurs, the drug should be discontinued and the
patient treated with the usual agents (eg, epinephrine or other pressor
amines, antihistamines, or corticosteroids). </p>

<p>Prolonged use of Cephalexin may result in the overgrowth of nonsusceptible
organisms. Careful observation of the patient is essential. If superinfection
occurs during therapy, appropriate measures should be taken. </p>

<p>Positive direct Coombs' tests have been reported during treatment with
the cephalosporin antibiotics. In hematologic studies or in transfusion
cross- matching procedures when antiglobulin tests are performed on the
minor side or in Coombs' testing of newborns whose mothers have received
cephalosporin antibiotics before parturition, it should be recognized that
a positive Coombs' test may be due to the drug. </p>

<p>Cephalexin should be administered with caution in the presence of markedly
impaired renal function. Under such conditions, careful clinical observation
and laboratory studies should be made because safe dosage may be lower
than that usually recommended. </p>

<p>Indicated surgical procedures should be performed in conjunction with
antibiotic therapy. </p>

<p>As a result of administration of Cephalexin, a false-positive reaction
for glucose in the urine may occur. This has been observed with Benedict's
and Fehling's solutions and also with Clinitest tablets but not with Tes-Tape
(Glucose Enzymatic Test Strip, USP). </p>

<p>Broad-spectrum antibiotics should be prescribed with caution in individuals
with a history of gastrointestinal disease, particularly colitis. </p>

<p>Usage In Pregnancy--Pregnancy Category B--The daily oral administration
of cephalexin to rats in doses of 250 or 500 mg/kg prior to and during
pregnancy, or to rats and mice during the period of organogenesis only,
had no adverse effect on fertility, fetal viability, fetal weight, or litter
size. Note that the safety of cephalexin during pregnancy in humans has
not been established. </p>

<p>Cephalexin showed no enhanced toxicity in weanling and newborn rats
as compared with adult animals. Nevertheless, because the studies in humans
cannot rule out the possibility of harm, Cephalexin should be used during
pregnancy only if clearly needed. </p>

<p>Nursing Mothers--The excretion of cephalexin in the milk increased up
to 4 hours after a 500-mg dose; the drug reached a maximum level of 4 mcgm/mL,
then decreased gradually, and had disappeared 8 hours after administration.
Caution should be exercised when Cephalexin is administered to a nursing
woman. </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Gastrointestinal--Symptoms of pseudomembranous colitis may appear either
during or after antibiotic treatment. Nausea and vomiting have been reported
rarely. The most frequent side effect has been diarrhea. It was very rarely
severe enough to warrant cessation of therapy. Dyspepsia, gastritis, and
abdominal pain have also occurred. As with some penicillins and some other
cephalosporins transient hepatitis and cholestatic jaundice have been reported
rarely. </p>

<p>Hypersensitivity--Allergic reactions in the form of rash, urticaria,
angioedema and, rarely, erythema multiforme, Stevens-Johnson syndrome,
or toxic epidermal necrolysis have been observed. These reactions usually
subsided upon discontinuation of the drug. In some of these reactions,
supportive therapy may be necessary. Anaphylaxis has also been reported.
</p>

<p>Other reactions have included genital and anal pruritus, genital moniliasis,
vaginitis and vaginal discharge, dizziness, fatigue, headache, agitation,
confusion, hallucinations, arthralgia, arthritis, and joint disorder. Reversible
interstitial nephritis has been reported rarely. Eosinophilia, neutropenia,
thrombocytopenia, and slight elevations in AST (SGOT) and ALT (SGPT) have
been reported. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Signs And Symptoms--Symptoms of oral overdose may include nausea, vomiting,
epigastric distress, diarrhea, and hematuria. If other symptoms are present,
it is probably secondary to an underlying disease state, an allergic reaction,
or toxicity due to ingestion of a second medication. </p>

<p>Treatment--To obtain up-to-date information about the treatment of overdose,
a good resource is your certified Regional Poison Control Center. Telephone
numbers of certified poison control centers are listed in the Physicians'
Desk Reference (). In managing overdosage, consider the possibility of
multiple drug overdoses, interaction among drugs, and unusual drug kinetics
in your patient. </p>

<p>Unless 5 to 10 times the normal dose of cephalexin has been ingested,
gastrointestinal decontamination should not be necessary. </p>

<p>Protect the patient's airway and support ventilation and perfusion.
Meticulously monitor and maintain, within acceptable limits, the patient's
vital signs, blood gases, serum electrolytes, etc. Absorption of drugs
from the gastrointestinal tract may be decreased by giving activated charcoal,
which, in many cases, is more effective than emesis or lavage; consider
charcoal instead of or in addition to gastric emptying. Repeated doses
of charcoal over time may hasten elimination of some drugs that have been
absorbed. Safeguard the patient's airway when employing gastric emptying
or charcoal. </p>

<p>Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion
have not been established as beneficial for an overdose of cephalexin;
however, it would be extremely unlikely that one of these procedures would
be indicated. </p>

<p>The oral median lethal dose of cephalexin in rats is 5,000 mg/kg. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Cephalexin is administered orally. </p>

<p>Adults--The adult dosage ranges from 1 to 4 g daily in divided doses.
The usual adult dose is 250 mg every 6 hours. For the following infections,
a dosage of 500 mg may be administered every 12 hours: streptococcal pharyngitis,
skin and skin-structure infections, and uncomplicated cystitis in patients
over 15 years of age. Cystitis therapy should be continued for 7 to 14
days. For more severe infections or those caused by less susceptible organisms,
larger doses may be needed. If daily doses of Cephalexin greater than 4
g are required, parenteral cephalosporins, in appropriate doses, should
be considered. </p>

<p>Children--The usual recommended daily dosage for children is 25 to 50
mg/kg in divided doses. For streptococcal pharyngitis in patients over
1 year of age and for skin and skin-structure infections, the total daily
dose may be divided and administered every 12 hours. </p>

<pre>Cephalexin SUSPENSION 
 
CHILD'S WEIGHT     125 MG/5 ML           250 MG/5 ML                            
10 kg (22 lb)   1/2 to 1 tsp q.i.d.   1/4 to 1/2 tsp q.i.d.                     
20 kg (44 lb)   1 to 2 tsp q.i.d.     1/2 to 1 tsp q.i.d.                       
40 kg (88 lb)   2 to 4 tsp q.i.d.     1 to 2 tsp q.i.d.                         
OR                                                                              
CHILD'S WEIGHT     125 MG/5 ML          250 MG/5 ML                             
10 kg (22 lb)   1 to 2 tsp b.i.d.   1/2 to 1 tsp b.i.d.                         
20 kg (44 lb)   2 to 4 tsp b.i.d.   1 to 2 tsp b.i.d.                           
40 kg (88 lb)   4 to 8 tsp b.i.d.   2 to 4 tsp b.i.d.                           </pre>

<p>In severe infections, the dosage may be doubled. In the therapy of otitis
media, clinical studies have shown that a dosage of 75 to 100 mg/kg/day
in 4 divided doses is required. </p>

<p>In the treatment of beta-hemolytic streptococcal infections, a therapeutic
dosage of Cephalexin should be administered for at least 10 days. </p>

<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-15</DOCNO>
<DOCOLDNO>IA018-000200-B034-205</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/alpraz.htm 206.86.175.201 19970106224357 text/html 60030
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:37:40 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 59847
Last-modified: Wed, 13 Nov 1996 00:01:00 GMT
</DOCHDR>
<html>
<head>
   <title>Alprazolam - RxList Generic Information</title>
<meta name="keywords" content="Alprax, Alprazolam, Intensol,
Alzolam, Constan, Solanax, Tafil, Trankimazin, Valeans, Xanax,
Xanor, Zenax, Zoldax"> </head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=148 width=150></a></p></center>

<h1 align=center>Alprazolam</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

 <a name="DESCRIPTION"></a><b>DESCRIPTION 

</b> <p>

Alprazolam Tablets contain alprazolam which is a triazolo analog of the 1,4

benzodiazepine class of central nervous system-active compounds.  

 <p>

The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo (4

3-alpha) (1,4) benzodiazepine.  
<p>
 

Alprazolam is a white crystalline powder, which is soluble in methanol or

ethanol but which has no appreciable solubility in water at physiological pH. 

 <p>

<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 

</b> <p>

CNS agents of the 1,4 benzodiazepine class presumably exert their effects by

binding at stereo specific receptors at several sites within the central

nervous system. Their exact mechanism of action is unknown. Clinically, all

benzodiazepines cause a dose-related central nervous system depressant activity 

varying from mild impairment of task performance to hypnosis.  

 <p>

Following oral administration, alprazolam is readily absorbed. Peak

concentrations in the plasma occur in one to two hours following

administration.  Plasma levels are proportionate to the dose given; over the

dose range of 0.5 to 3.0 mg, peak levels of 8.0 to 37 ng/ml were observed.

Using a specific assay methodology, the mean plasma elimination half-life of

alprazolam has been found to be about 11.2 hours (range: 6.3-26.9 hours) in

healthy adults.  

 <p>

The predominant metabolites are alpha-hydroxy-alprazolam and a benzophenone

derived from alprazolam. The biological activity of alpha-hydroxy-alprazolam is 

approximately one-half that of alprazolam. The benzophenone metabolite is

essentially inactive. Plasma levels of these metabolites are extremely low,

thus precluding precise pharmacokinetic description. However, their half-lives

appear to be of the same order of magnitude as that of alprazolam. Alprazolam

and its metabolites are excreted primarily in the urine.  

 <p>

The ability of alprazolam to induce human hepatic enzyme systems has not yet

been determined. However, this is not a property of benzodiazepines in general. 

Further, alprazolam did not affect the prothrombin or plasma warfarin levels

in male volunteers administered sodium warfarin orally.  
<p>
 

In Vitro, alprazolam is bound (80 percent) to human serum protein.  

 
<p>
Changes in the absorption, distribution, metabolism and excretion of

benzodiazepines have been reported in a variety of disease states including

alcoholism, impaired hepatic function and impaired renal function. Changes have 

also been demonstrated in geriatric patients. A mean half-life of alprazolam of 

16.3 hours has been observed in healthy elderly subjects (range: 9.0-26.9 hours 

n=16) compared to 11.0 hours (range: 6.3-15.8 hours, n=16) in healthy adult

subjects. The co-administration of oral contraceptives to healthy women

increased the half-life of alprazolam as compared to that in healthy control

women (mean: 12.4 hours, n=11 versus 9.6 hours, n=9). There was a prolongation

in the mean half-life of alprazolam from 12.4 hours (range: 7.2-18.4 hours,

n=9) to 16.6 hours (range: 10.0-24.3 hours, n=9) by the co-administration of

cimetidine to the same healthy adults. In patients with alcoholic liver disease 

the half-life of alprazolam ranged between 5.8 and 65.3 hours (mean: 19.7 hours 

n=17) as compared to between 6.3 and 26.9 hours (mean=11.4 hours, n=17) in

healthy subjects. In an obese group of subjects the half-life of alprazolam

ranged between 9.9 and 40.4 hours (mean=21.8 hours, n=12) as compared to

between 6.3 and 15.8 hours (mean=10.6 hours, n=12) in healthy subjects.  

 <p>

Because of its similarity to other benzodiazepines, it is assumed that

alprazolam undergoes transplacental passage and that it is excreted in human

milk.  <p>

 

<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 

</b> 
<p>
Alprazolam Tablets (alprazolam) are indicated for the management of anxiety disorder 

(a condition corresponding most closely to the APA Diagnostic and Statistical

Manual (DSM-III-R) diagnosis of generalized anxiety disorder) or the short-term 

relief of symptoms of anxiety. Anxiety or tension associated with the stress of 

everyday life usually does not require a treatment with an anxiolytic.  

 <p>

Generalized anxiety disorder is characterized by unrealistic or excessive

anxiety and worry (apprehensive expectation) about two or more life

circumstances, for a period of six months or longer, during which the person

has been bothered more days than not by these concerns. At least 6 of the

following 18 symptoms are often present in these patients: Motor Tension

(trembling, twitching, or feeling shaky; muscle tension, aches, or soreness;

restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath

or smothering sensations; palpitations or accelerated heart rate; sweating, or

cold clammy hands; dry mouth; dizziness or lightheadedness; nausea, diarrhea,

or other abdominal distress; flushes or chills; frequent urination; trouble

swallowing or &quot;lump in throat&quot;); Vigilance And Scanning (feeling keyed up or on 

edge; exaggerated startle response; difficulty concentrating or &quot;mind going

blank&quot; because of anxiety; trouble falling or staying asleep; irritability).

These symptoms must not be secondary to another psychiatric disorder or caused

by some organic factor.  

 <p>

Anxiety associated with depression is responsive to Alprazolam.  

 <p>
Alprazolam is also indicated for the treatment of panic disorder, with or without

agoraphobia.  

 <p>

Studies supporting this claim were conducted in patients whose diagnoses

corresponded closely to the DSM-III-R criteria for panic disorder (See CLINICAL 

STUDIES).  

 <p>

Panic disorder is an illness characterized by recurrent panic attacks. The

panic attacks, at least initially, are unexpected. Later in the course of this

disturbance certain situations, eg, driving a car or being in a crowded place,

may become associated with having a panic attack. These panic attacks are not

triggered by situations in which the person is the focus of others' attention

(as in social phobia). The diagnosis requires four such attacks within a four

week period, or one or more attacks followed by at least a month of persistent

fear of having another attack. The panic attacks must be characterized by at

least four of the following symptoms: dyspnea or smothering sensations;

dizziness, unsteady feelings, or faintness; palpitations or tachycardia;

trembling or shaking; sweating; choking; nausea or abdominal distress;

depersonalization or derealization; paresthesias; hot flashes or chills; chest

pain or discomfort; fear of dying; fear of going crazy or of doing something

uncontrolled. At least some of the panic attack symptoms must develop suddenly, 

and the panic attack symptoms must not be attributable to some known organic

factors. Panic disorder is frequently associated with some symptoms of

agoraphobia.  

 <p>

Demonstrations of the effectiveness of Alprazolam by systematic clinical study are

limited to four months duration for anxiety disorder and four to ten weeks

duration for panic disorder; however, patients with panic disorder have been

treated on an open basis for up to eight months without apparent loss of

benefit. The physician should periodically reassess the usefulness of the drug

for the individual patient.  

 <p>

<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 

</b> <p>

Alprazolam Tablets are contraindicated in patients with known sensitivity to this

drug or other benzodiazepines. Alprazolam may be used in patients with open angle

glaucoma who are receiving appropriate therapy, but is contraindicated in

patients with acute narrow angle glaucoma.  Alprazolam is contraindicated
in patients taking ketoconazole or itraconazole.

 <p>

<a name="WARNINGS"></a><b>WARNINGS 

</b> <p>

Dependence And Withdrawal Reactions, Including Seizures:  

 
<p>
Certain adverse clinical events, some life-threatening, are a direct

consequence of physical dependence to Alprazolam. These include a spectrum of

withdrawal symptoms; the most important is seizure (see DRUG ABUSE AND

DEPENDENCE). Even after relatively short-term use at the doses recommended for

the treatment of transient anxiety and anxiety disorder (ie, 0.75 to 4.0 mg per 

day), there is some risk of dependence. Post-marketing surveillance data

suggest that the risk of dependence and its severity appear to be greater in

patients treated with relatively high doses (above 4 mg per day) and for long

periods (more than 8-12 weeks).  

 <p>

The Importance Of Dose And The Risks Of Alprazolam As A Treatment For Panic 

Disorder 

 <p>

Because the management of panic disorder often requires the use of average

daily doses of Alprazolam above 4 mg, the risk of dependence among panic disorder

patients may be higher than that among those treated for less severe anxiety.

Experience in randomized placebo-controlled discontinuation studies of patients 

with panic disorder showed a high rate of rebound and withdrawal symptoms in

patients treated with Alprazolam compared to placebo treated patients.  

 <p>

Relapse or return of illness was defined as a return of symptoms characteristic 

of panic disorder (primarily panic attacks) to levels approximately equal to

those seen at baseline before active treatment was initiated. Rebound refers to 

a return of symptoms of panic disorder to a level substantially greater in

frequency, or more severe in intensity than seen at baseline. Withdrawal

symptoms were identified as those which were generally not characteristic of

panic disorder and which occurred for the first time more frequently during

discontinuation than at baseline.  

 <p>

In a controlled clinical trial in which 63 patients were randomized to alprazolam

and where withdrawal symptoms were specifically sought, the following were

identified as symptoms of withdrawal: heightened sensory perception, impaired

concentration, dysosmia, clouded sensorium, paresthesias, muscle cramps, muscle 

twitch, diarrhea, blurred vision, appetite decrease and weight loss. Other

symptoms, such as anxiety and insomnia, were frequently seen during

discontinuation, but it could not be determined if they were due to return of

illness, rebound or withdrawal.  

 <p>

In a larger database comprised of both controlled and uncontrolled studies in

which 641 patients received Alprazolam, discontinuation-emergent symptoms which

occurred at a rate of over 5% in patients treated with Alprazolam and at a greater

rate than the placebo treated group were as follows:  <p>

 

<pre>
                   DISCONTINUATION-EMERGENT SYMPTOM INCIDENCE                   

                   ------------------------------------------                   

PERCENTAGE OF 641 Alprazolam-TREATED PANIC DISORDER PATIENTS REPORTING EVENTS        

BODY SYSTEM/EVENT                                                               

NEUROLOGIC                                      GASTROINTESTINAL                
Insomnia                   29.5                 Nausea/Vomiting           16.5  
Lightheadedness            19.3                 Diarrhea                  13.6  
Abnormal involuntary                            Decreased salivation      10.6  
movement                   17.3                                                 
Headache                   17.0                 METABOLIC-NUTRITIONAL           
Muscular twitching          6.9                 Weight loss               13.3  
Impaired Coordination       6.6                 Decreased appetite        12.8  
Muscle tone disorders       5.9                                                 
Weakness                    5.8                 DERMATOLOGICAL                  
PSYCHIATRIC                                     Sweating                  14.4  
Anxiety                    19.2                                                 
Fatigue and Tiredness      18.4                 CARDIOVASCULAR                  
Irritability               10.5                 Tachycardia               12.2  
Cognitive disorder         10.3                                                 
Memory impairment           5.5                 SPECIAL SENSES                  
Depression                  5.1                 Blurred vision            10.0  
Confusional state           5.0                                                 
</pre><p>
From the studies cited, it has not been determined whether these symptoms are

clearly related to the dose and duration of therapy with Alprazolam in patients with 

panic disorder.  
<p>
 

In two controlled trials of six to eight weeks duration where the ability of

patients to discontinue medication was measured, 71%-93% of patients treated

with Alprazolam tapered completely off therapy compared to 89%-96% of placebo

treated patients. The ability of patients to completely discontinue therapy

with Alprazolam after long-term therapy has not been reliably determined.  

 
<p>
Seizures attributable to Alprazolam were seen after drug discontinuance or dose

reduction in 8 of 1980 patients with panic disorder or in patients

participating in clinical trials where doses of Alprazolam greater than 4 mg daily

for over 3 months were permitted. Five of these cases clearly occurred during

abrupt dose reduction, or discontinuation from daily doses of 2 to 10 mg. Three 

cases occurred in situations where there was not a clear relationship to abrupt 

dose reduction or discontinuation. In one instance, seizure occurred after

discontinuation from a single dose of 1 mg after tapering at a rate of 1 mg

every three days from 6 mg daily. In two other instances, the relationship to

taper is indeterminate; in both of these cases the patients had been receiving

doses of 3 mg daily prior to seizure. The duration of use in the above 8 cases

ranged from 4 to 22 weeks. There have been occasional voluntary reports of

patients developing seizures while apparently tapering gradually from Alprazolam.

The risk of seizure seems to be greatest 24-72 hours after discontinuation (see 

DOSAGE and ADMINISTRATION for recommended tapering and discontinuation

schedule).  

 <p>

Status Epilepticus And Its Treatment:  

 
<p>
The medical event voluntary reporting system shows that withdrawal seizures

have been reported in association with the discontinuation of Alprazolam. In most

cases, only a single seizure was reported; however, multiple seizures and

status epilepticus were reported as well. Ordinarily, the treatment of status

epilepticus of any etiology involves use of intravenous benzodiazepines plus

phenytoin or barbiturates, maintenance of a patent airway and adequate

hydration. For additional details regarding therapy, consultation with an

appropriate specialist may be considered.  

 
<p>
Interdose Symptoms:  
<p>
 

Early morning anxiety and emergence of anxiety symptoms between doses of Alprazolam

have been reported in patients with panic disorder taking prescribed

maintenance doses of Alprazolam. These symptoms may reflect the development of

tolerance or a time interval between doses which is longer than the duration of 

clinical action of the administered dose. In either case, it is presumed that

the prescribed dose is not sufficient to maintain plasma levels above those

needed to prevent relapse, rebound or withdrawal symptoms over the entire

course of the interdosing interval. In these situations, it is recommended that 

the same total daily dose be given divided as more frequent administrations

(See DOSAGE AND ADMINISTRATION).  

 
<p>
Risk Of Dose Reduction:  
<p>
 

Withdrawal reactions may occur when dosage reduction occurs for any reason.

This includes purposeful tapering, but also inadvertent reduction of dose (eg.

the patient forgets, the patient is admitted to a hospital, etc.). Therefore,

the dosage of Alprazolam should be reduced or discontinued gradually (See DOSAGE AND 

ADMINISTRATION).  

 <p>

Alprazolam Tablets are not of value in the treatment of psychotic patients and

should not be employed in lieu of appropriate treatment for psychosis. Because

of its CNS depressant effects, patients receiving Alprazolam should be cautioned

against engaging in hazardous occupations or activities requiring complete

mental alertness such as operating machinery or driving a motor vehicle. For

the same reason, patients should be cautioned about the simultaneous ingestion

of alcohol and other CNS depressant drugs during treatment with Alprazolam.  

 
<p>
Benzodiazepines can potentially cause fetal harm when administered to pregnant

women. If Alprazolam is used during pregnancy, or if the patient becomes pregnant

while taking this drug, the patient should be apprised of the potential hazard

to the fetus. Because of experience with other members of the benzodiazepine

class, Alprazolam is assumed to be capable of causing an increased risk of

congenital abnormalities when administered to a pregnant woman during the first 

trimester.  Because use of these drugs is rarely a matter of urgency, their use 

during the first trimester should almost always be avoided. The possibility

that a woman of childbearing potential may be pregnant at the time of

institution of therapy should be considered. Patients should be advised that if 

they become pregnant during therapy or intend to become pregnant they should

communicate with their physicians about the desirability of discontinuing the

drug.  
<p>
 

<a name="PRECAUTIONS"></a><b>PRECAUTIONS 

</b> 
<p>
GENERAL: If Alprazolam Tablets are to be combined with other psychotropic agents or

anticonvulsant drugs, careful consideration should be given to the pharmacology 

of the agents to be employed, particularly with compounds which might

potentiate the action of benzodiazepines (See DRUG INTERACTIONS).  

 
<p>
As with other psychotropic medications, the usual precautions with respect to

administration of the drug and size of the prescription are indicated for

severely depressed patients or those in whom there is reason to expect

concealed suicidal ideation or plans.  

 <p>

It is recommended that the dosage be limited to the smallest effective dose to

preclude the development of ataxia or oversedation which may be a particular

problem in elderly or debiliated patients. (See DOSAGE AND ADMINISTRATION). The 

usual precautions in treating patients with impaired renal, hepatic or

pulmonary function should be observed. There have been rare reports of death in 

patients with severe pulmonary disease shortly after the initiation of

treatment with Alprazolam. A decreased systemic alprazolam elimination rate (eg,

increased plasma half-life) has been observed in both alcoholic liver disease

patients and obese patients receiving Alprazolam (See CLINICAL PHARMACOLOGY) 

 
<p>
Episodes of hypomania and mania have been reported in association with the use

of Alprazolam in patients with depression.  

 
<p>
Alprazolam has a weak uricosuric effect. Although other medications with weak

uricosuric effect have been reported to cause acute renal failure, there have

been no reported instances of acute renal failure attributable to therapy with

Alprazolam.  

 
<p>
INFORMATION FOR PATIENTS:  
<p>
 

For All Users Of Alprazolam.  

 
<p>
To assure safe and effective use of benzodiazepines, all patients prescribed

Alprazolam should be provided with the following guidance. In addition, panic

disorder patients, for whom higher doses are typically prescribed, should be

advised about the risks associated with the use of higher doses.  

 <p>

1. Inform your physician about any alcohol consumption and medicine you are

taking now, including medication you may buy without a prescription. Alcohol

should generally not be used during treatment with benzodiazepines.  

 
<p>
2. Not recommended for use in pregnancy. Therefore, inform your physician if

you are pregnant, if you are planning to have a child, or if you become

pregnant while you are taking this medication.  


<p>
3. Inform your physician if you are nursing.  

 
<p>
4. Until you experience how this medication affects you, do not drive a car or

operate potentially dangerous machinery, etc.  
<p>
 

5. Do not increase the dose even if you think the medication &quot;does not work

anymore&quot; without consulting your physician. Benzodiazepines, even when used as

recommended, may produce emotional and/or physical dependence.  

 <p>

6. Do not stop taking the drug abruptly or decrease the dose without consulting 

your physician, since withdrawal symptoms can occur.  

 <p>

Additional Advice For Panic Disorder Patients:  

 <p>

The use of Alprazolam at the high doses (above 4 mg per day), often necessary to

treat panic disorder, is accompanied by risks that you may need to carefully

consider. When used at high doses for long intervals, which may or may not be

required for your treatment, Alprazolam has the potential to cause severe emotional

and physical dependence in some patients and these patients may find it

exceedingly difficult to terminate treatment. In two controlled trials of six

to eight weeks duration where the ability of patients to discontinue medication 

was measured, 7 to 29% of patients treated with Alprazolam did not completely taper

off therapy. The ability of patients to completely discontinue therapy with

Alprazolam after long-term therapy has not been reliably determined. In all cases,

it is important that your physician help you discontinue this medication in a

careful and safe manner to avoid overly extended use of Alprazolam.  

 
<p>
In addition, the extended use at high doses appears to increase the incidence

and severity of withdrawal reactions when Alprazolam is discontinued. These are

generally minor but seizure can occur, especially if you reduce the dose too

rapidly or discontinue the medication abruptly. Seizure can be life-

threatening.  
<p>
 

LABORATORY TESTS: Laboratory tests are not ordinarily required in otherwise

healthy patients.  

 
<p>
DRUG INTERACTIONS: The benzodiazepines, including alprazolam, produce additive

CNS depressant effects when co-administered with other psychotropic medications 

anticonvulsants, antihistaminics, ethanol and other drugs which themselves

produce CNS depression.  
<p>
 

The steady state plasma concentrations of imipramine and desipramine have been

reported to be increased an average of 31% and 20%, respectively, by the

concomitant administration of Alprazolam Tablets in doses up to 4 mg/day. The

clinical significance of these changes is unknown.  

 <p>

Pharmacokinetic interactions of benzodiazepines with other drugs have been

reported. For example, the clearance of alprazolam and certain other

benzodiazepines can be delayed by the co-administration of cimetidine. The

clearance of alprazolam can also be delayed by the co-administration of oral

contraceptives (See CLINICAL PHARMACOLOGY). The clinical significance of these

interactions is unclear.  

 <p>

DRUG/LABORATORY TEST INTERACTIONS: Although interactions between

benzodiazepines and commonly employed clinical laboratory tests have

occasionally been reported, there is no consistent pattern for a specific drug

or specific test.  

 <p>

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: No evidence of

carcinogenic potential was observed during 2-year bioassay studies of

alprazolam in rats at doses up to 30 mg/kg/day (150 times the maximum

recommended daily human dose of 10 mg/day) and in mice at doses up to 10

mg/kg/day (50 times the maximum recommended daily human dose).  

 <p>

Alprazolam was not mutagenic in the rat micronucleus test at doses up to 100

mg/kg, which is 500 times the maximum recommended daily human dose of 10

mg/day. Alprazolam also was not mutagenic In Vitro in the DNA Damage/Alkaline

Elution Assay or the Ames Assay.  

 
<p>
Alprazolam produced no impairment of fertility in rats at doses up to 5

mg/kg/day, which is 25 times the maximum recommended daily human dose of 10

mg/day.  
<p>
 

PREGNANCY: Teratogenic Effects: Pregnancy Category D: (See WARNINGS Section) 

 
<p>
Nonteratogenic Effects: It should be considered that the child born of a mother 

who is receiving benzodiazepines may be at some risk for withdrawal symptoms

from the drug during the postnatal period. Also, neonatal flaccidity and

respiratory problems have been reported in children born of mothers who have

been receiving benzodiazepines.  

 <p>

LABOR AND DELIVERY: Alprazolam has no established use in labor or delivery.  
<p>
 

NURSING MOTHERS: Benzodiazepines are known to be excreted in human milk. It

should be assumed that alprazolam is as well. Chronic administration of

diazepam to nursing mothers has been reported to cause their infants to become

lethargic and to lose weight. As a general rule, nursing should not be

undertaken by mothers who must use Alprazolam.  

 
<p>
PEDIATRIC USE: Safety and effectiveness in children below the age of 18 years

have not been established.  

 <p>

<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 

</b> 
<p>
The benzodiazepines, including alprazolam, produce additive CNS depressant

effects when co-administered with other psychotropic medications,

nticonvulsants, antihistaminics, ethanol and other drugs which themselves

produce CNS depression.  

 <p>

The steady state plasma concentrations of imipramine and desipramine have been

reported to be increased an average of 31% and 20%, respectively, by the

concomitant administration of Alprazolam Tablets in doses up to 4 mg/day. The

clinical significance of these changes is unknown.  
<p>
 

Pharmacokinetic interactions of benzodiazepines with other drugs have been

reported. For example, the clearance of alprazolam and certain other

benzodiazepines can be delayed by the co-administration of cimetidine. The

clearance of alprazolam can also be delayed by the co-administration of oral

contraceptives (See CLINICAL PHARMACOLOGY). The clinical significance of these

interactions is unclear.  

 <p>

(See Also PRECAUTIONS) 

 
<p>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 



</b><p>Side effects to Alprazolam Tablets, if they occur, are generally observed at the

beginning of therapy and usually disappear upon continued medication. In the

usual patient, the most frequent side effects are likely to be an extension of

the pharmacological activity of alprazolam, eg, drowsiness or lightheadedness.  

 
<p>
The data cited in the two tables below are estimates of untoward clinical event 

incidence among patients who participated under the following clinical

conditions: relatively short duration (ie, four weeks) placebo-controlled

clinical studies with dosages up to 4 mg/day of Alprazolam (for the management of

anxiety disorders or for the short-term relief of the symptoms of anxiety) and

short-term (up to ten weeks) placebo-controlled clinical studies with dosages

up to 10 mg/day of Alprazolam in patients with panic disorder, with or without

agoraphobia.  
<p>
 

These data cannot be used to predict precisely the incidence of untoward events 

in the course of usual medical practice where patient characteristics, and

other factors often differ from those in clinical trials. These figures cannot

be compared with those obtained from other clinical studies involving related

drug products and placebo as each group of drug trials are conducted under a

different set of conditions.  

 <p>

Comparison of the cited figures, however, can provide the prescriber with some

basis for estimating the relative contributions of drug and non-drug factors to 

the untoward event incidence in the population studied. Even this use must be

approached cautiously, as a drug may relieve a symptom in one patient but

induce it in others. (For example, an anxiolytic drug may relieve dry mouth (a

symptom of anxiety) in some subjects but induce it (an untoward event) in

others.) 

 
<p>
Additionally, for anxiety disorders the cited figures can provide the

prescriber with an indication as to the frequency with which physician

intervention (eg, increased surveillance, decreased dosage or discontinuation

of drug therapy) may be necessary because of the untoward clinical event.  

 
<p><pre>
-----------------------------------------------------------------------------   

                               ANXIETY DISORDERS                                

                                                                 INCIDENCE OF   

                                 TREATMENT-EMERGENT              INTERVENTION   

                                 SYMPTOM INCIDENCE**              BECAUSE OF    

                                                                   SYMPTOM      

                             Alprazolam             PLACEBO              Alprazolam       

                             -----             -------              -----       

NUMBER OF PATIENTS           565                 505                 565        

% of Patients Reporting:                                                        

CENTRAL NERVOUS SYSTEM                                                          

Drowsiness                  41.0                21.6                15.1        

Light-headedness            20.8                19.3                 1.2        

Depression                  13.9                18.1                 2.4        

Headache                    12.9                19.6                 1.1        

Confusion                    9.9                10.0                 0.9        

Insomnia                     8.9                18.4                 1.3        

Nervousness                  4.1                10.3                 1.1        

Syncope                      3.1                 4.0                   *        

Dizziness                    1.8                 0.8                 2.5        

Akathisia                    1.6                 1.2                   *        

Tiredness/Sleepiness           *                   *                 1.8        

GASTROINTESTINAL                                                                

Dry Mouth                   14.7                13.3                 0.7        

Constipation                10.4                11.4                 0.9        

Diarrhea                    10.1                10.3                 1.2        

Nausea/Vomiting              9.6                12.8                 1.7        

Increased Salivation         4.2                 2.4                   *        

CARDIOVASCULAR                                                                  

Tachycardia/Palpitations     7.7                15.6                 0.4        

Hypotension                  4.7                 2.2                   *        

SENSORY                                                                         

Blurred Vision               6.2                 6.2                 0.4        

MUSCULOSKELETAL                                                                 

Rigidity                     4.2                 5.3                   *        

Tremor                       4.0                 8.8                 0.4        

CUTANEOUS                                                                       

Dermatitis/Allergy           3.8                 3.1                 0.6        

OTHER                                                                           

Nasal                                                                           

Congestion                   7.3                 9.3                   *        

Weight Gain                  2.7                 2.7                   *        

Weight Loss                  2.3                 3.0                   *        

---------                                                                       

*  None Reported                                                                

** Events Reported By 1% Or More Of Patients On Alprazolam Are Included.             

------------------------------------------------------------------------------  </pre><p>

In addition to the relatively common (i.e., greater than 1%) untoward events

enumerated above, the following adverse events have been reported in

association with the use of benzodiazepines: dystonia, irritability,

concentration difficulties, anorexia, transient amnesia or memory impairment,

loss of coordination, fatigue, seizures, sedation, slurred speech, jaundice,

musculoskeletal weakness, pruritus, diplopia, dysarthria, changes in libido,

menstrual irregularities, incontinence and urinary retention.  

 <p><pre>

-------------------------------------------------                               

                  PANIC DISORDER                                                

                              TREATMENT-EMERGENT                                

                              SYMPTOM INCIDENCE*                                

                                Alprazolam   PLACEBO                                 

                                -----   -------                                 

NUMBER OF PATIENTS               1388     1231                                  

% OF PATIENTS REPORTING:                                                        

CENTRAL NERVOUS SYSTEM                                                          

Drowsiness                       76.8       42.7                                

Fatigue and Tiredness            48.6       42.3                                

Impaired Coordination            40.1       17.9                                

Irritability                     33.1       30.1                                

Memory Impairment                33.1       22.1                                

Lightheadedness/Dizziness        29.8       36.9                                

Insomnia                         29.4       41.8                                

Headache                         29.2       35.6                                

Cognitive Disorder               28.8       20.5                                

Dysarthria                       23.3        6.3                                

Anxiety                          16.6       24.9                                

Abnormal Involuntary                                                            

Movement                         14.8       21.0                                

Decreased Libido                 14.4        8.0                                

Depression                       13.8       14.0                                

Confusional State                10.4        8.2                                

Muscular Twitching                7.9       11.8                                

Increased Libido                  7.7        4.1                                

Change in Libido (Not Specified)  7.1        5.6                                

Weakness                          7.1        8.4                                

Muscle Tone Disorders             6.3        7.5                                

Syncope                           3.8        4.8                                

Akathisia                         3.0        4.3                                

Agitation                         2.9        2.6                                

Disinhibition                     2.7        1.5                                

Paresthesia                       2.4        3.2                                

Talkativeness                     2.2        1.0                                

Vasomotor Disturbances            2.0        2.6                                

Derealization                     1.9        1.2                                

Dream Abnormalities               1.8        1.5                                

Fear                              1.4        1.0                                

Feeling Warm                      1.3        0.5                                

GASTROINTESTINAL                                                                

Decreased Salivation             32.8       34.2                                

Constipation                     26.2       15.4                                

Nausea/Vomiting                  22.0       31.8                                

Diarrhea                         20.6       22.8                                

Abdominal Distress               18.3       21.5                                

Increased Salivation              5.6        4.4                                

CARDIO-RESPIRATORY                                                              

Nasal Congestion                 17.4       16.5                                

Tachycardia                      15.4       26.8                                

Chest Pain                       10.6       18.1                                

Hyperventilation                  9.7       14.5                                

Upper Respiratory Infection       4.3        3.7                                

SENSORY                                                                         

Blurred Vision                   21.0       21.4                                

Tinnitus                          6.6       10.4                                

MUSCULOSKELETAL                                                                 

Muscular Cramps                   2.4        2.4                                

Muscle Stiffness                  2.2        3.3                                

CUTANEOUS                                                                       

Sweating                         15.1       23.5                                

Rash                             10.8        8.1                                

OTHER                                                                           

Increased Appetite               32.7       22.8                                

Decreased Appetite               27.8       24.1                                

Weight Gain                      27.2       17.9                                

Weight Loss                      22.6       16.5                                

Micturition Difficulties         12.2        8.6                                

Menstrual Disorders              10.4        8.7                                

Sexual Dysfunction                7.4        3.7                                

Edema                             4.9        5.6                                

Incontinuence                     1.5        0.6                                

Infection                         1.3        1.7                                

* Events Reported By 1% Or More Of Patients On                                  

  Alprazolam Are Included.                                                           

-------------------------------------------------                  </pre><p>             

In addition to the relatively common (ie, greater than 1%) untoward events

enumerated in the table above, the following adverse events have been reported

in association with the use of Alprazolam: seizures, hallucinations,

depersonalization, taste alterations, diplopia, elevated bilirubin, elevated

hepatic enzymes, and jaundice.  

 <p>

There have also been reports of withdrawal seizures upon rapid decrease or

abrupt discontinuation of Alprazolam Tablets (See WARNINGS).  

 
<p>
To discontinue treatment in patients taking Alprazolam, the dosage should be reduced 

slowly in keeping with good medical practice. It is suggested that the daily

dosage of Alprazolam be decreased by no more than 0.5 mg every three days (See

DOSAGE AND ADMINISTRATION). Some patients may require an even slower dosage

reduction.  

 <p>

Panic disorder has been associated with primary and secondary major depressive

disorders and increased reports of suicide among untreated patients. Therefore, 

the same precaution must be exercised when using the higher doses of Alprazolam in

treating patients with panic disorder as is exercised with the use of any

psychotropic drug in treating depressed patients or those in whom there is

reason to expect concealed suicidal ideation or plans.  

 <p>
As with all benzodiazepines, paradoxical reactions such as stimulation,

increased muscle spasticity, sleep disturbances, hallucinations and other

adverse behavioral effects such as agitation, rage, irritability, and

aggressive or hostile behavior have been reported rarely. In many of the

spontaneous case reports of adverse behavioral effects, patients were receiving 

other CNS drugs concomitantly and/or were described as having underlying

psychiatric conditions.  Should any of the above events occur, alprazolam

should be discontinued.  Isolated published reports involving small numbers of

patients have suggested that patients who have borderline personality disorder, 

a prior history of violent or aggressive behavior, or alcohol or substance

abuse may be at risk for such events. Instances of irritability, hostility, and 

intrusive thoughts have been reported during discontinuation of alprazolam in

patients with posttraumatic stress disorder.  

 
<p>
Laboratory analyses were performed on all patients participating in the

clinical program for Alprazolam. The following incidences of abnormalities shown

below were observed in patients receiving Alprazolam and in patients in the

corresponding placebo group. Few of these abnormalities were considered to be

of physiological significance.  
<p><pre>

                        Alprazolam         PLACEBO                                   

                     LOW      HIGH  LOW      HIGH                               

HEMATOLOGY                                                                      

Hematocrit            *          *   *          *                               

Hemoglobin            *          *   *          *                               

Total WBC Count      1.4       2.3  1.0       2.0                               

Neutrophil Count     2.3       3.0  4.2       1.7                               

Lymphocyte Count     5.5       7.4  5.4       9.5                               

Monocyte Count       5.3       2.8  6.4         *                               

Eosinophil Count     3.2       9.5  3.3       7.2                               

Basophil Count        *          *   *          *                               

URINALYSIS                                                                      

Albumin               --         *   --         *                               

Sugar                 --         *   --         *                               

RBC/HPF               --       3.4   --       5.0                               

WBC/HPF               --      25.7   --      25.9                               

BLOOD CHEMISTRY                                                                 

Creatinine           2.2       1.9  3.5       1.0                               

Bilirubin             *        1.6   *          *                               

SGOT                  *        3.2  1.0       1.8                               

Alkaline                                                                        

Phosphatase           *        1.7   *        1.8                               

-----------                                                                     

* Less Than 1%                                                                  

-----------                                                                     
</pre><p>
When treatment with Alprazolam is protracted, periodic blood counts, urinalysis and

blood chemistry analyses are advisable.  

 
<p>
Minor changes in EEG patterns, usually low-voltage fast activity have been

observed in patients during therapy with Alprazolam and are of no known

significance.  

 <p>

POST INTRODUCTION REPORTS: Various adverse drug reactions have been reported in 

association with the use of Alprazolam since market introduction. The majority of

these reactions were reported through the medical event voluntary reporting

system. Because of the spontaneous nature of the reporting of medical events

and the lack of controls, a causal relationship to the use of Alprazolam cannot be

readily determined. Reported events include: liver enzyme elevations,

gynecomastia and galactorrhea.  

 <p>

DRUG ABUSE AND DEPENDENCE 

 <p>

PHYSICAL AND PSYCHOLOGICAL DEPENDENCE: Withdrawal symptoms similar in character 

to those noted with sedative/hypnotics and alcohol have occurred following

abrupt discontinuance of benzodiazepines, including Alprazolam. The symptoms can

range from mild dysphoria and insomnia to a major syndrome that may include

abdominal and muscle cramps, vomiting, sweating, tremors and convulsions. 

Distinguishing between withdrawal emergent signs and symptoms and the

recurrence of illness is often difficult in patients undergoing dose reduction. 

The long term strategy for treatment of these phenomena will vary with their

cause and the therapeutic goal. When necessary, immediate management of

withdrawal symptoms requires re-institution of treatment at doses of Alprazolam

sufficient to suppress symptoms. There have been reports of failure of other

benzodiazepines to fully suppress these withdrawal symptoms. These failures

have been attributed to incomplete cross-tolerance but may also reflect the use 

of an inadequate dosage regimen of the substituted benzodiazepine or the

effects of concomitant medications.  

 <p>

While it is difficult to distinguish withdrawal and recurrence for certain

patients, the time course and the nature of the symptoms may be helpful. A

withdrawal symdrome typically includes the occurence of new symptoms, tends to

appear toward the end of the taper or shortly after discontinuation, and will

decrease with time. In recurring panic disorder, symptoms similar to those

observed before treatment may recur either early or late, and they will

persist.  

 <p>

While the severity and incidence of withdrawal phenomena appear to be related

to dose and duration of treatment, withdrawal symptoms, including seizures,

have been reported after only brief therapy with Alprazolam at doses within the

recommended range for the treatment of anxiety (eg, 0.75 to 4 mg/day). Signs

and symptoms of withdrawal are often more prominent after rapid decrease of

dosage or abrupt discontinuance. The risk of withdrawal seizures may be

increased at doses above 4 mg/day (See WARNINGS).  

 <p>

Patients, especially individuals with a history of seizures or epilepsy, should 

not be abruptly discontinued from any CNS depressant agent, including Alprazolam. It

is recommended that all patients on Alprazolam who require a dosage reduction be

gradually tapered under close supervision (See WARNINGS and DOSAGE AND

ADMINISTRATION).  

 
<p>
Psychological dependence is a risk with all benzodiazepines, including Alprazolam. 

The risk of psychological dependence may also be increased at higher doses and

with longer term use, and this risk is further increased in patient with a

history of alcohol or drug abuse. Some patients have experienced considerable

difficulty in tapering and discontinuing from Alprazolam, especially those receiving 

higher doses for extended periods. Addiction-prone individuals should be under

careful surveillance when receiving Alprazolam. As with all anxiolytics, repeat

prescriptions should be limited to those who are under medical supervision.  

 
<p>
CONTROLLED SUBSTANCE CLASS: Alprazolam is a controlled substance under the

Controlled Substance Act by the Drug Enforcement Administration and Alprazolam

Tablets have been assigned to Schedule IV.  
<p>
 

<a name="OVERDOSAGE"></a><b>OVERDOSAGE 

</b> <p>
Manifestations of alprazolam overdosage include somnolence, confusion, impaired 

coordination, diminished reflexes and coma. Death has been reported in

association with overdoses of alprazolam by itself, as it has with other

benzodiazepines. In addition, fatalities have been reported in patients who

have overdosed with a combination of a single benzodiazepine, including

alprazolam, and alcohol; alcohol levels seen in some of these patients have

been lower than those usually associated with alcohol-induced fatality.  

 
<p>
The acute oral LD50 in rats is 331-2171 mg/kg. Other experiments in animals

have indicated that cardiopulmonary collapse can occur following massive

intravenous doses of alprazolam (over 195 mg/kg; 975 times the maximum

recommended daily human dose of 10 mg/day). Animals could be resuscitated with

positive mechanical ventilation and the intravenous infusion of norepinephrine

bitartrate.  

 <p>
Animal experiments have suggested that forced diuresis or hemodialysis are

probably of little value in treating overdosage.  

 <p>

GENERAL TREATMENT OF OVERDOSE: Overdosage reports with Alprazolam Tablets are

limited. As in all cases of drug overdosage, respiration, pulse rate, and blood 

pressure should be monitored. General supportive measures should be employed,

along with immediate gastric lavage. Intravenous fluids should be administered

and an adequate airway maintained. If hypotension occurs, it may be combated by 

the use of vasopressors. Dialysis is of limited value. As with the management

of intentional overdosing with any drug, it should be borne in mind that

multiple agents may have been ingested.  

 
<p>
Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the 

complete or partial reversal of the sedative effects of benzodiazepines and may 

be used in situations when an overdose with a benzodiazepine is known or

suspected. Prior to the administration of flumazenil, necessary measures should 

be instituted to secure airway, ventilation and intravenous access. Flumazenil

is intended as an adjunct to, not as a substitute for, proper management of

benzodiazepine overdose. Patients treated with flumazenil should be monitored

for re-sedation, respiratory depression, and other residual benzodiazepine

effects for an appropriate period after treatment. THE PRESCRIBER SHOULD BE

AWARE OF A RISK OF SEIZURE IN ASSOCIATION WITH FLUMAZENIL TREATMENT,

PARTICULARLY IN LONG-TERM BENZODIAZEPINE USERS AND IN CYCLIC ANTIDEPRESSANT

OVERDOSE. The complete flumazenil package insert including CONTRAINDICATIONS,

WARNINGS and PRECAUTIONS should be consulted prior to use.  

 <p>

<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 

</b> <p>

Dosage should be individualized for maximum beneficial effect. While the usual

daily dosages given below will meet the needs of most patients, there will be

some who require higher doses. In such cases, dosage should be increased

cautiously to avoid adverse effects.  
<p>
 

Anxiety Disorders And Transient Symptoms Of Anxiety:  

 <p>

Treatment for patients with anxiety should be initiated with a dose of 0.25 to

0.5 mg given three times daily. The dose may be increased to achieve a maximum

therapeutic effect, at intervals of 3 to 4 days, to a maximum daily dose of 4

mg, given in divided doses. The lowest possible effective dose should be

employed and the need for continued treatment reassessed frequently. The risk

of dependence may increase with dose and duration of treatment.  

 <p>

In elderly patients, in patients with advanced liver disease or in patients

with debilitating disease, the usual starting dose is 0.25 mg, given two or

three times daily. This may be gradually increased if needed and tolerated. The 

elderly may be especially sensitive to the effects of benzodiazepines.  

 <p>

If side effects occur at the recommended starting dose, the dose may be

lowered.  

 <p>

In all patients, dosage should be reduced gradually when discontinuing therapy

or when decreasing the daily dosage. Although there are no systematically

collected data to support a specific discontinuation schedule, it is suggested

that the daily dosage be decreased by no more than 0.5 mg every three days.

Some patients may require an even slower dosage reduction.  
<p>
 

Panic Disorder:  

 <p>

The successful treatment of many panic disorder patients has required the use

of Alprazolam at doses greater than 4 mg daily. In controlled trials conducted to

establish the efficacy of Alprazolam in panic disorder, doses in the range of 1 to

10 mg daily were used. The mean dosage employed was approximately 5 to 6 mg

daily. Among the approximately 1700 patients participating in the panic

disorder development program, about 300 received maximum Alprazolam dosages of

greater than 7 mg/day, including approximately 100 patients who received

maximum dosages of greater than 9 mg/day. Occasional patients required as much

as 10 mg a day to achieve a successful response.  

 <p>

However, in the absence of systematic studies evaluating the dose response

relationship, the dosing regimen for the administration of Alprazolam to patients

with panic disorder must be based on generic principles. Generally, therapy

should be initiated at a low dose to minimize the risk of adverse responses in

patients especially sensitive to the drug. Thereafter, the dose can be

increased at intervals equal to at least 5 times the elimination half-life

(about 11 hours in young patients, about 16 hours in elderly patients). Longer

titration intervals should probably be used because the maximum therapeutic

response may not occur until after the plasma levels achieve steady state. Dose 

should be advanced until an acceptable therapeutic response (ie, a substantial

reduction in or total elimination of panic attacks) is achieved, intolerance

occurs, or the maximum recommended dose is attained. Because of the danger of

withdrawal, abrupt discontinuation of treatment should be avoided (See WARNINGS 

PRECAUTIONS, DRUG ABUSE AND DEPENDENCE).  

 <p>

The Following Regimen Is One That Follows The Principles Outlined Above:  

 
<p>
Treatment may be initiated with a dose of 0.5 mg three times daily. Depending

on the response, the dose may be increased at intervals of 3 to 4 days in

increments of no more than 1 mg per day. Slower titration to the higher dose

levels may be advisable to allow full expression of the pharmacodynamic effect

of Alprazolam. To lessen the possibility of interdose symptoms, the times of

administration should be distributed as evenly as possible throughout the

waking hours, that is, on a three or four times per day schedule.  

 <p>

The necessary duration of treatment for panic disorder patients responding to

Alprazolam is unknown. After a period of extended freedom from attacks, a carefully

supervised tapered discontinuation may be attempted, but there is evidence that 

this may often be difficult to accomplish without recurrence of symptoms and/or 

the manifestation of withdrawal phenomena.  

 <p>

In any case, reduction of dose must be undertaken under close supervision and

must be gradual. If significant withdrawal symptoms develop, the previous

dosing schedule should be reinstituted and, only after stabilization, should a

less rapid schedule of discontinuation be attempted. Although no experimental

studies have been conducted to assess the comparative benefits of various

discontinuation regimens, a possible approach is to reduce the dose by no more

than 0.5 mg every three days, with the understanding that some patients may

require an even more gradual discontinuation. Some patients may prove resistant 

to all discontinuation regimens.  

 <p>

ANIMAL PHARMACOLOGY 
<p>
 

ANIMAL STUDIES 

 <p>

When rats were treated with alprazolam at 3, 10, and 30 mg/kg/day (15 to 150

times the maximum recommended human dose) orally for 2 years, a tendency for a

dose related increase in the number of cataracts was observed in females and a

tendency for a dose related increase in corneal vascularization was observed in 

males. These lesions did not appear until after 11 months of treatment.  

 <p>

CLINICAL STUDIES 

 <p>

Anxiety Disorders:  

 <p>

Alprazolam Tablets were compared to placebo in double blind clinical studies (doses

up to 4 mg/day) in patients with a diagnosis of anxiety or anxiety with

associated depressive symptomatology. Alprazolam was significantly better than

placebo at each of the evaluation periods of these four week studies as judged

by the following psychometric instruments: Physician's Global Impressions,

Hamilton Anxiety Rating Scale Target Symptoms, Patient's Global Impressions and 

Self-Rating Symptom Scale.  

 <p>

Panic Disorder:  

 <p>

Support for the effectiveness of Alprazolam in the treatment of panic disorder came

from three short-term, placebo controlled studies (up to 10 weeks) in patients

with diagnoses closely corresponding to DSM-III-R criteria for panic disorder.  

 <p>

The average dose of Alprazolam was 5-6 mg/day in two of the studies, and the doses

of Alprazolam were fixed at 2 and 6 mg/day in the third study. In all three studies, 

Alprazolam was superior to placebo on a variable defined as &quot;the number of patients

with zero panic attacks&quot; (range, 37-83% met this criterion), as well as on a

global improvement score. In two of the three studies, Alprazolam was superior to

placebo on a variable defined as &quot;change from baseline on the number of panic

attacks per week&quot; (range, 3.3-5.2), and also on a phobia rating scale. A

subgroup of patients who were improved on Alprazolam during short-term treatment in

one of these trials was continued on an open basis up to eight months, without

apparent loss of benefit. <p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-16</DOCNO>
<DOCOLDNO>IA018-000200-B033-107</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/amox.htm 206.86.175.201 19970106223617 text/html 16725
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:29:51 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 16542
Last-modified: Thu, 28 Nov 1996 18:50:07 GMT
</DOCHDR>
<html>
<head>
   <title>Amoxicillin  - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
   <meta name="KeyWords" content="A-Cillin, Acimox, Actimoxi, Agerpen, A-Gram, Alfamox,
Almodan, Aloxyn, Alphamox, AM 73, Amagesen Solutab, Amcill, Amoclen,
Amodex, Amo-flamsian, Amoflux, Amolin, Amorex, Amox, Amoxa, Amoxal,
Amoxapen, Amoxaren, Amoxcillin, Amoxi, Amoxi-basan, Amoxibiotic,
Amoxicilina, Amoxicillin Trihydrate, Amoxidal, Amoxiden, Amoxidin,
Amoxihexal, Amoxil, Amoxillin, Amoxin, Amoxipen, Amoxipenil, Amoxisol,
Amoxivan, Amoxivet, Amoxtrex, Amoxy, Amoxybid, Amoxycillin,
Amoxy-diolan, Amoxypen, Ampidroxyl, Anemol, Apitart, Apo-Amoxi, Ardine,
Aspenil, Audumic, Azillin, Bactamox, Bimox, Bintamox, Biomox, Bioxidona,
Bioxyllin, Bridopen, Bristamox, Cabermox, Cilamox, Clamox, Clamoxyl,
Clavoxilin, Coamoxin, Colmox, Comox, Comoxyl, Damoxicil, Delacillin,
Draximox, Efpinex, Entamox, Eupen, Excillin, Farconcil, Fisamox, Flemoxin,
Flenokin, Fullcilina, Gemox, Gimalxina, Gomcillin, Grinsul, Grunamox, Hiconcil,
Hidramox, Hipen, Hosboral, Ibiamox, Ikamoxil, Imacillin, Imaxilin, Imox,
Imoxil, Inmoxy, Intermox, Isimoxin, Izoltil, Jerramcil, Kamoxin, Kymoxin,
Lamoxy, Larocilin, Larotid, Limox, Majorpen, Matasedrin, Maxcil, Medimox,
Meixil, Mopen, Morgenxil, Mox, Moxacin, Moxaline, Moxarin, Moxcil,
Moxilen, Moxlin, Moxylin, Moxypen, Moxyvit, Novabritine, Novamoxin,
Novenzymin, Optium, Ospamox, Pamabiotico, Pambiotico, Pamocil, Pamoxin,
Pamoxicillin, Pasetocin, Penamox, Penbiosyn, Penmox, Pensyn, Piramox,
Polymox, Posmox, Protexillin, Rancil, Ranoxyl, Reloxyl, Rhamoxilina,
Robamox, Rocillin, Romoxil, Saltermox, Samosillin, Samthongcillin, Sawacillin,
Sawamezin, Senox, Servamox, Sia-mox, Sigmopen, Sil-A-mox, Simoxil,
Simplamox, Specillin, Supercillin, Superpeni, Supramox, Suprapen, Teramoxyl,
Tolodina, Triafamox, Triamoxil, Trilaxin, Trimox, Twicyl, Unicillin, Utimox,
Velamox, Virgoxillin, Widecillin, Winmox, Wymox, Yisulon, Zamocillin,
Zerrsox, Zimox">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Amoxicillin</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [drug-drug]
[<a href="#ADVERSE REACTIONS">side effects</a>] [toxicity] [<a href="#DOSAGE AND ADMINISTRATION">dosing</a>]
</font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION</b></p>

<p>Amoxicillin is a semisynthetic antibiotic, an analog of ampicillin,
with a broad spectrum of bactericidal activity against many gram-positive
and gram-negative microorganisms. Chemically it is D-(-)-alpha-amino-p
hydroxybenzyl penicillin trihydrate. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>PHARMACOLOGY </p>

<p>Amoxicillin is stable in the presence of gastric acid and may be given
without regard to meals. It is rapidly absorbed after oral administration.
It diffuses readily into most body tissues and fluids, with the exception
of brain and spinal fluid, except when meninges are inflamed. The half-life
of amoxicillin is 61.3 minutes. Most of the amoxicillin is excreted unchanged
in the urine; its excretion can be delayed by concurrent administration
of probenecid.</p>

<p>Amoxicillin is not highly protein-bound. In blood serum, amoxicillin
is approximately 20% protein-bound as compared to 60% for penicillin G.
</p>

<p>Orally administered doses of 250 mg and 500 mg amoxicillin capsules
result in average peak blood levels 1 to 2 hours after administration in
the range of 3.5 mcg/mL to 5.0 mcg/mL and 5.5 mcg/mL to 7.5 mcg/mL, respectively.
</p>

<p>Orally administered doses of amoxicillin suspension 125 mg/5 mL and
250 mg/5 mL result in average peak blood levels 1 to 2 hours after administration
in the range of 1.5 mcg/mL to 3.0 mcg/mL and 3.5 mcg/mL to 5.0 mcg/mL,
respectively. </p>

<p>Amoxicillin chewable tablets, 125 mg and 250 mg, produced blood levels
similar to those achieved with the corresponding doses of amoxicillin oral
suspensions. </p>

<p>Detectable serum levels are observed up to 8 hours after an orally administered
dose of amoxicillin. Following a 1 gram dose and utilizing a special skin
window technique to determine levels of the antibiotic, it was noted that
therapeutic levels were found in the interstitial fluid. Approximately
60% of an orally administered dose of amoxicillin is excreted in the urine
within 6 to 8 hours. </p>

<p>MICROBIOLOGY </p>

<p>Amoxicillin is similar to ampicillin in its bactericidal action against
susceptible organisms during the stage of active multiplication. It acts
through the inhibition of biosynthesis of cell wall mucopeptide. In Vitro
studies have demonstrated the susceptibility of most strains of the following
gram-positive bacteria: alpha- and beta-hemolytic streptococci, Diplococcus
Pneumoniae, nonpenicillinase-producing staphylococci, and Streptococcus
Faecalis. It is active In Vitro against many strains of Haemophilus Influenzae,
Neisseria Gonorrhoeae, Escherichia Coli and Proteus Mirabilis. </p>

<p>Because it does not resist destruction by penicillinase, it is not effective
against penicillinase-producing bacteria, particularly resistant staphylococci.
All strains of Pseudomonas and most strains of Klebsiella and Enterobacter
are resistant. </p>

<p>DISK SUSCEPTIBILITY TESTS: Quantitative methods that require measurement
of zone diameters give the most precise estimates of antibiotic susceptibility.
One such procedure* has been recommended for use with disks for testing
susceptibility to ampicillin-class antibiotics. Interpretations correlate
diameters of the disk test with MIC values for amoxicillin. With this procedure
a report from the laboratory of &quot;susceptible&quot; indicates that
the infecting organism is likely to respond to therapy. A report of &quot;resistant&quot;
indicates that the infecting organism is not likely to respond to therapy.
A report of &quot;intermediate susceptibility&quot; suggests that the organism
would be susceptible if high dosage is used, or if the infection is confined
to tissues and fluids (e.g., urine), in which high antibiotic levels are
attained. </p>

<p>* Bauer, A. W., Kirby, W. M. M., Sherris, J. C., and Turck, M.: Antibiotic
Testing by a Standardized Single Disc Method, Am. J. Clin. Pathol., 45:493,
1966. Standardized Disc Susceptibility Test, Federal Register 37:20527-29,
1972. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Amoxicillin is indicated in the treatment of infections due to susceptible
strains of the following: </p>

<p>GRAM-NEGATIVE ORGANISMS--H. Influenzae, E. Coli, P. Mirabilis and N.
Gonorrhoeae. </p>

<p>GRAM-POSITIVE ORGANISMS--Streptococci (including Streptococcus Faecalis),
D. Pneumoniae and nonpenicillinase-producing staphylococci. </p>

<p>Therapy may be instituted prior to obtaining results from bacteriological
and susceptibility studies to determine the causative organisms and their
susceptibility to amoxicillin. Indicated surgical procedures should be
performed. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>A history of allergic reaction to any of the penicillins is a contraindication.
</p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (anaphylactoid) REACTIONS
HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. THESE REACTIONS ARE
MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY
AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. BEFORE INITIATING
THERAPY WITH AMOXICILLIN, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS
HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS OR OTHER ALLERGENS.
IF AN ALLERGIC REACTION OCCURS, AMOXICILLIN SHOULD BE DISCONTINUED AND
APPROPRIATE THERAPY INSTITUTED. SERIOUS ANAPHYLACTIC REACTIONS REQUIRE
IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS
AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED
AS INDICATED. PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH NEARLY ALL
ANTI-BACTERIAL AGENTS, INCLUDING AMOXICILLIN, AND MAY RANGE IN SEVERITY
FROM MILD TO LIFE-THREATENING. THEREFORE, IT IS IMPORTANT TO CONSIDER THIS
DIAGNOSIS IN PATIENTS WHO PRESENT WITH DIARRHEA SUBSEQUENT TO THE ADMINISTRATION
OF ANTIBACTERIAL AGENTS </p>

<p>Treatment with antibacterial agents alters the normal flora of the colon
and may permit overgrowth of clostridia. Studies indicate that a toxin
produced by Clostridium Difficile is a primary cause of &quot;antibiotic-associated
colitis.&quot; After the diagnosis of pseudomembranous colitis has been
established, therapeutic measures should be initiated. Mild cases of pseudomembranous
colitis usually respond to drug discontinuation alone. In moderate to severe
cases, consideration should be given to management with fluids and electrolytes
protein supplementation and treatment with an antibacterial drug clinically
effective against C. Difficile colitis. </p>

<p>USAGE IN PREGNANCY </p>

<p>Safety for use in pregnancy has not been established. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>As with any potent drug, periodic assessment of renal, hepatic and hematopoietic
function should be made during prolonged therapy. The possibility of superinfections
with mycotic or bacterial pathogens should be kept in mind during therapy.
If superinfections occur (usually involving Enterobacter, Pseudomonas or
Candida), the drug should be discontinued and/or appropriate therapy instituted.
</p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>As with other penicillins, it may be expected that untoward reactions
will be essentially limited to sensitivity phenomena. They are more likely
to occur in individuals who have previously demonstrated hypersensitivity
to penicillins and in those with a history of allergy, asthma, hay fever
or urticaria. The following adverse reactions have been reported as associated
with the use of penicillins: </p>

<p>GASTROINTESTINAL: Nausea, vomiting and diarrhea. </p>

<p>HYPERSENSITIVITY REACTIONS: Erythematous maculopapular rashes, erythema
multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis and urticaria
have been reported. </p>

<p>NOTE: These hypersensitivity reactions may be controlled with antihistamines
and, if necessary, systemic corticosteroids. Whenever such reactions occur,
amoxicillin should be discontinued unless, in the opinion of the physician,
the condition being treated is life-threatening and amenable only to amoxicillin
therapy. </p>

<p>LIVER: A moderate rise in serum glutamic oxaloacetic transaminase (SGOT)
has been noted, but the significance of this finding is unknown. </p>

<p>HEMIC AND LYMPHATIC SYSTEMS: Anemia, thrombocytopenia, thrombocytopenic
purpura eosinophilia, leukopenia and agranulocytosis have been reported
during therapy with penicillins. These reactions are usually reversible
on discontinuation of therapy and are believed to be hypersensitivity phenomena.
</p>

<p>CENTRAL NERVOUS SYSTEM: Reversible hyperactivity, agitation, anxiety,
insomnia, confusion, behavioral changes, and/or dizziness have been reported
rarely. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>INFECTIONS OF THE EAR, NOSE AND THROAT due to streptococci, pneumococci,
nonpenicillinase-producing staphylococci and H. Influenzae; </p>

<p>INFECTIONS OF THE GENITOURINARY TRACT due to E. Coli, Proteus Mirabilis
and Streptococcus Faecalis; </p>

<p>INFECTIONS OF THE SKIN AND SOFT-TISSUES due to streptococci, susceptible
staphylococci and E. Coli: </p>

<p>USUAL DOSAGE: </p>

<p>Adults: 250 mg every 8 hours. </p>

<p>Children: 20 mg/kg/day in divided doses every 8 hours. </p>

<p>Children weighing 20 kg or more should be dosed according to the adult
recommendations. </p>

<p><b>In severe infections or those caused by less susceptible organisms:
</b></p>

<p>500 mg every 8 hours for adults and 40 mg/kg/day in divided doses every
8 hours for children may be needed. </p>

<p>INFECTIONS OF THE LOWER RESPIRATORY TRACT due to streptococci, pneumococci,
nonpenicillinase-producing staphylococci and H. Influenzae: </p>

<p>USUAL DOSAGE: </p>

<p>Adults: 500 mg every 8 hours. </p>

<p>Children: 40 mg/kg/day in divided doses every 8 hours. </p>

<p>Children weighing 20 kg or more should be dosed according to the adult
recommendations. </p>

<p>GONORRHEA, ACUTE UNCOMPLICATED ano-genital and urethral infections due
to N. Gonorrhoeae (males and females): </p>

<p>USUAL DOSAGE: </p>

<p>Adults: 3 grams as a single oral dose. </p>

<p>Prepubertal children: 50 mg/kg amoxicillin combined with 25 mg/kg probenecid
as a single dose. </p>

<p>NOTE: SINCE PROBENECID IS CONTRAINDICATED IN CHILDREN UNDER 2 YEARS,
THIS REGIMEN SHOULD NOT BE USED IN THESE CASES. </p>

<p>Cases of gonorrhea with a suspected lesion of syphilis should have dark-field
examinations before receiving amoxicillin, and monthly serological tests
for a minimum of 4 months. </p>

<p>Larger doses may be required for stubborn or severe infections. The
children's dosage is intended for individuals whose weight will not cause
a dosage to be calculated greater than that recommended for adults. </p>

<p>It should be recognized that in the treatment of chronic urinary tract
infections, frequent bacteriological and clinical appraisals are necessary.
Smaller doses than those recommended above should not be used. Even higher
doses may be needed at times. In stubborn infections, therapy may be required
for several weeks. It may be necessary to continue clinical and/or bacteriological
follow-up for several months after cessation of therapy. Except for gonorrhea,
treatment should be continued for a minimum of 48 to 72 hours beyond the
time that the patient becomes asymptomatic or evidence of bacterial eradication
has been obtained. It is recommended that there be at least 10 days' treatment
for any infection caused by hemolytic streptococci to prevent the occurrence
of acute rheumatic fever or glomerulonephritis. </p>

<p>DOSAGE AND ADMINISTRATION OF PEDIATRIC DROPS </p>

<p>Usual dosage for all indications except infections of the lower respiratory
tract: </p>

<p>Under 6 kg (13 lbs): 0.75 mL every 8 hours. </p>

<p>6 to 7 kg (13 to 15 lbs): 1.0 mL every 8 hours. </p>

<p>8 kg (16 to 18 lbs): 1.25 mL every 8 hours. </p>

<p>Infections of the lower respiratory tract: </p>

<p>Under 6 kg (13 lbs): 1.25 mL every 8 hours. </p>

<p>6 to 7 kg (13 to 15 lbs): 1.75 mL every 8 hours. </p>

<p>8 kg (16 to 18 lbs): 2.25 mL every 8 hours. </p>

<p>Children weighing more than 8 kg (18 lbs) should receive the appropriate
dose of the Oral Suspension 125 mg or 250 mg/5 mL. </p>

<p>After reconstitution, the required amount of suspension should be placed
directly on the child's tongue for swallowing. Alternate means of administration
are to add the required amount of suspension to formula, milk, fruit juice,
water, ginger ale or cold drinks. These preparations should then be taken
immediately. To be certain the child is receiving full dosage, such preparations
should be consumed in entirety. </p>

<p>
<hr></p>

<h2 align=center><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-17</DOCNO>
<DOCOLDNO>IA018-000200-B034-257</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/ibup.htm 206.86.175.201 19970106224451 text/html 36636
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:38:35 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 36453
Last-modified: Sun, 11 Aug 1996 03:45:03 GMT
</DOCHDR>
<html>
<head>
   <title>Ibuprofen - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Ibuprofen</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <p>
Ibuprofen Tablets contain the active ingredient ibuprofen, which is (+/-)-2-(p-
isobutylphenyl) propionic acid. Ibuprofen is a white powder with a melting
point of 74-77 deg C and is very slightly soluble in water (&lt;1 mg/ml) and
readily soluble in organic solvents such as ethanol and acetone.  
 <p>
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 
</b> <p>
Ibuprofen possesses analgesic and antipyretic activities. Its mode of action, like 
that of other nonsteroidal anti- inflammatory agents, is not completely understood,
 but may be related to prostaglandin synthetase inhibition.  
 <p>
In clinical studies in patients with rheumatoid arthritis and osteoarthritis,
Ibuprofen has been shown to be comparable to aspirin in controlling pain and
inflammation and to be associated with a statistically significant reduction in 
the milder gastrointestinal side effects (see ADVERSE REACTIONS). Ibuprofen may be 
well tolerated in some patients who have had gastrointestinal side effects with 
aspirin, but these patients when treated with Ibuprofen should be carefully
followed for signs and symptoms of gastrointestinal ulceration and bleeding. 
Although it is not definitely known whether Ibuprofen causes less peptic
ulceration than aspirin, in one study involving 885 patients with rheumatoid
arthritis treated for up to one year, there were no reports of gastric
ulceration with Ibuprofen whereas frank ulceration was reported in 13 patients in
the aspirin group (statistically significant p&lt; .001).  
 <p>
Gastroscopic studies at varying doses show an increased tendency toward gastric 
irritation at higher doses. However, at comparable doses, gastric irritation is 
approximately half that seen with aspirin. Studies using 51Cr-tagged red cells
indicate that fecal blood loss associated with Ibuprofen Tablets in doses up to
2400 mg daily did not exceed the normal range, and was significantly less than
that seen in aspirin-treated patients.  
 <p>
In clinical studies in patients with rheumatoid arthritis, Ibuprofen has been
shown to be comparable to indomethacin in controlling the signs and symptoms of 
disease activity and to be associated with a statistically significant
reduction of the milder gastrointestinal (see ADVERSE REACTIONS) and CNS side
effects.  
 <p>
Ibuprofen may be used in combination with gold salts and/or corticosteroids.  
 <p>
Controlled studies have demonstrated that Ibuprofen is a more effective analgesic
than propoxyphene for the relief of episiotomy pain, pain following dental
extraction procedures, and for the relief of the symptoms of primary
dysmenorrhea.  
 <p>
In patients with primary dysmenorrhea, Ibuprofen has been shown to reduce elevated 
levels of prostaglandin activity in the menstrual fluid and to reduce resting
and active intrauterine pressure, as well as the frequency of uterine
contractions. The probable mechanism of action is to inhibit prostaglandin
synthesis rather than simply to provide analgesia.  
 <p>
Ibuprofen is rapidly absorbed when administered orally. Peak
serum ibuprofen levels are generally attained one to two hours after
administration.  With single doses up to 800 mg, a linear relationship exists
between amount of drug administered and the integrated area under the serum
drug concentration vs time curve. Above 800 mg, however, the area under the
curve increases less than proportional to increases in dose. There is no
evidence of drug accumulation or enzyme induction.  
 <p>
The administration of Ibuprofen  either under fasting conditions or
immediately before meals yields quite similar serum ibuprofen concentration
time profiles. When Ibuprofen is administered immediately after a meal, there is a 
reduction in the rate of absorption but no appreciable decrease in the extent
of absorption. The bioavailability of the drug is minimally altered by the
presence of food.  
 <p>
A bioavailability study has shown that there was no interference with the
absorption of ibuprofen when Ibuprofen was given in conjunction with an antacid
containing both aluminum hydroxide and magnesium hydroxide.  
 <p>
Ibuprofen is rapidly metabolized and eliminated in the urine. The excretion of
ibuprofen is virtually complete 24 hours after the last dose. The serum half-
life is 1.8 to 2.0 hours.  
 <p>
Studies have shown that following ingestion of the drug, 45% to 79% of the dose 
was recovered in the urine within 24 hours as metabolite A (25%), (+)-2- (p
(2hydroxymethylpropyl)- phenyl) propionic acid and metabolite B (37%), (+)-2-
(p-(2carboxypropyl)-phenyl) propionic acid; the percentages of free and
conjugated ibuprofen were approximately 1% and 14%, respectively.  
 <p>
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
Ibuprofen Tablets are indicated for relief of the signs and symptoms
of rheumatoid arthritis and osteoarthritis.  
 <p>
Ibuprofen is indicated for relief of mild to moderate pain.  
 <p>
Ibuprofen is also indicated for the treatment of primary dysmenorrhea.  
 <p>
Since there have been no controlled clinical trials to demonstrate whether or
not there is any beneficial effect or harmful interaction with the use of
Ibuprofen in conjunction with aspirin, the combination cannot be recommended (see
DRUG INTERACTIONS).  
<p>
Controlled clinical trials to establish the safety and effectiveness of Ibuprofen
in children have not been conducted.  
 <p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <p>
Ibuprofen Tablets should not be used in patients who have previously
exhibited hypersensitivity to the drug, or in individuals with the syndrome of
nasal polyps, angioedema and bronchospastic reactivity to aspirin or other
nonsteroidal anti-inflammatory agents. Anaphylactoid reactions have occurred in 
such patients.  
 <p>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <p>
RISK OF GI ULCERATION, BLEEDING AND PERFORATION WITH NONSTEROIDAL ANTI-
INFLAMMATORY THERAPY:  
 <p>
Serious gastrointestinal toxicity such as bleeding, ulceration, and perforation 
can occur at any time, with or without warning symptoms, in patients treated
chronically with nonsteroidal anti-inflammatory drugs. Although minor upper
gastrointestinal problems, such as dyspepsia, are common, usually developing
early in therapy, physicians should remain alert for ulceration and bleeding in 
patients treated chronically with nonsteroidal anti-inflammatory drugs even in
the absence of previous GI tract symptoms. In patients observed in clinical
trials of several months to two years duration, symptomatic upper GI ulcers,
gross bleeding or perforation appear to occur in approximately 1% of patients
treated for 3-6 months, and in about 2-4% of patients treated for one year. 
Physicians should inform patients about the signs and/or symptoms of serious GI 
toxicity and what steps to take if they occur.  
 <p>
Studies to date have not identified any subset of patients not at risk of
developing peptic ulceration and bleeding. Except for a prior history of
serious GI events and other risk factors known to be associated with peptic
ulcer disease, such as alcoholism, smoking, etc., no risk factors (eg, age,
sex) have been associated with increased risk. Elderly or debilitated patients
seem to tolerate ulceration or bleeding less well than other individuals and
most spontaneous reports of fatal GI events are in this population. Studies to
date are inconclusive concerning the relative risk of various nonsteroidal anti 
inflammatory agents in causing such reactions. High doses of any such agents
probably carry a greater risk of these reactions, although controlled clinical
trials showing this do not exist in most cases. In considering the use of
relatively large doses (within the recommended dosage range), sufficient
benefit should be anticipated to offset the potential increased risk of GI
toxicity.  
 <p>
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
Blurred and/or diminished vision, scotomata, and/or changes in color vision
have been reported. If a patient develops such complaints while receiving
Ibuprofen Tablets, the drug should be discontinued and the patient
should have an ophthalmologic examination which includes central visual fields
and color vision testing.  
 <p>
Fluid retention and edema have been reported in association with Ibuprofen;
therefore, the drug should be used with caution in patients with a history of
cardiac decompensation or hypertension.  
                              <p>
Ibuprofen, like other nonsteroidal anti-inflammatory agents, can inhibit platelet
aggregation but the effect is quantitatively less and of shorter duration than
that seen with aspirin. Ibuprofen has been shown to prolong bleeding time (but
within the normal range) in normal subjects. Because this prolonged bleeding
effect may be exaggerated in patients with underlying hemostatic defects,
Ibuprofen should be used with caution in persons with intrinsic coagulation
defects and those on anticoagulant therapy.  
 <p>
Patients on Ibuprofen should report to their physicians signs or symptoms of
gastrointestinal ulceration or bleeding, blurred vision or other eye symptoms,
skin rash, weight gain, or edema.  
 <p>
In order to avoid exacerbation of disease or adrenal insufficiency, patients
who have been on prolonged corticosteroid therapy should have their therapy
tapered slowly rather than discontinued abruptly when Ibuprofen is added to the
treatment program.  
 <p>
The antipyretic and anti-inflammatory activity of ibuprofen may reduce fever
and inflammation, thus diminishing their utility as diagnostic signs in
detecting complications of presumed noninfectious noninflammatory painful
conditions.  
 <p>
As with other nonsteroidal anti-inflammatory drugs, borderline elevations of
one or more liver tests may occur in up to 15% of patients. These abnormalities 
may progress, may remain essentially unchanged, or may be transient with
continued therapy. The SGPT (ALT) test is probably the most sensitive indicator 
of liver dysfunction. Meaningful (3 times the upper limit of normal) elevations 
of SGPT or SGOT (AST) occurred in controlled clinical trials in less than 1% of 
patients. A patient with symptoms and/or signs suggesting liver dysfunction, or 
in whom an abnormal liver test has occurred, should be evaluated for evidence
of the development of more severe hepatic reaction while on therapy with
Ibuprofen.  Severe hepatic reactions, including jaundice and cases of fatal
hepatitis, have been reported with ibuprofen as with other nonsteroidal anti
inflammatory drugs.  Although such reactions are rare, if abnormal liver tests
persist or worsen, if clinical signs and symptoms consistent with liver disease 
develop, or if systemic manifestations occur (eg, eosinophilia, rash, etc.),
Ibuprofen should be discontinued.  
 <p>
In cross-study comparisons with doses ranging from 1200 mg to 3200 mg daily for 
several weeks, a slight dose-response decrease in hemoglobin/hematocrit was
noted. This has been observed with other nonsteroidal anti-inflammatory drugs;
the mechanism is unknown. With daily doses of 3200 mg, the total decrease in
hemoglobin may exceed 1 gram; if there are no signs of bleeding, it is probably 
not clinically important. In two postmarketing clinical studies the incidence
of a decreased hemoglobin level was greater than previously reported. Decrease
in hemoglobin of 1 gram or more was observed in 17.1% of 193 patients on 1600
mg ibuprofen daily (osteoarthritis), and in 22.8% of 189 patients taking 2400
mg of ibuprofen daily (rheumatoid arthritis). Positive stool occult blood tests 
and elevated serum creatinine levels were also observed in these studies.  
 <p>
ASEPTIC MENINGITIS: Aseptic meningitis with fever and coma has been observed on 
rare occasions in patients on ibuprofen therapy. Although it is probably more
likely to occur in patients with systemic lupus erythematosus and related
connective tissue diseases, it has been reported in patients who do not have an 
underlying chronic disease. If signs or symptoms of meningitis develop in a
patient on Ibuprofen, the possibility of its being related to Ibuprofen should be
considered.  
<p>
RENAL EFFECTS: As with other nonsteroidal anti-inflammatory drugs, long term
administration of ibuprofen to animals has resulted in renal papillary necrosis 
and other abnormal renal pathology. In humans, there have been reports of acute 
interstitial nephritis with hematuria, proteinuria, and occasionally nephrotic
syndrome.  
 <p>
A second form of renal toxicity has been seen in patients with prerenal
conditions leading to a reduction in renal blood flow or blood volume, where
the renal prostaglandins have a supportive role in the maintenance of renal
perfusion. In these patients administration of a nonsteroidal anti-inflammatory 
drug may cause a dose dependent reduction in prostaglandin formation and may
precipitate overt renal decompensation. Patients at greatest risk of this
reaction are those with impaired renal function, heart failure, liver
dysfunction, those taking diuretics and the elderly. Discontinuation of
nonsteroidal anti-inflammatory drug therapy is typically followed by recovery
to the pretreatment state. Those patients at high risk who chronically take
Ibuprofen should have renal function monitored if they have signs or symptoms
which may be consistent with mild azotemia, such as malaise, fatigue, loss of
appetite, etc.  Occasional patients may develop some elevation of serum
creatinine and BUN levels without signs or symptoms.  
 <p>
Since ibuprofen is eliminated primarily by the kidneys, patients with
significantly impaired renal function should be closely monitored; and a
reduction in dosage should be anticipated to avoid drug accumulation. 
Prospective studies on the safety of ibuprofen in patients with chronic renal
failure have not been conducted.  
 <p>
INFORMATION FOR PATIENTS 
 <p>
Ibuprofen, like other drugs of its class, is not free of side effects. The side
effects of these drugs can cause discomfort and, rarely, there are more serious 
side effects, such as gastrointestinal bleeding, which may result in
hospitalization and even fatal outcomes.  
 <p>
Nonsteroidal anti-inflammatory drugs are often essential agents in the
management of arthritis and have a major role in the treatment of pain, but
they also may be commonly employed for conditions which are less serious.  
 <p>
Physicians may wish to discuss with their patients the potential risks (see
WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS) and likely benefits of
nonsteroidal anti-inflammatory drug treatment, particularly when the drugs are
used for less serious conditions where treatment without such agents may
represent an acceptable alternative to both the patient and physician.  
 <p>
LABORATORY TESTS 
 <p>
Because serious GI tract ulcerations and bleeding can occur without warning
symptoms, physicians should follow chronically treated patients for the signs
and symptoms of ulcerations and bleeding and should inform them of importance
of this follow-up (see Risk of GI Ulceration, Bleeding and Perforation with
Nonsteroidal Anti-inflammatory therapy).  
 <p>
DRUG INTERACTIONS: Coumarin-Type Anticoagulants. Several short-term controlled
studies failed to show that Ibuprofen significantly affected prothrombin times or
a variety of other clotting factors when administered to individuals on
coumarin- type anticoagulants. However, because bleeding has been reported when 
Ibuprofen and other nonsteroidal anti-inflammatory agents have been administered
to patients on coumarin-type anticoagulants, the physician should be cautious
when administering Ibuprofen to patients on anticoagulants.  
 <p>
Aspirin: Animal studies show that aspirin given with nonsteroidal anti-
inflammatory agents, including Ibuprofen, yields a net decrease in anti-
inflammatory activity with lowered blood levels of the non-aspirin drug. Single 
dose bioavailability studies in normal volunteers have failed to show an effect 
of aspirin on ibuprofen blood levels. Correlative clinical studies have not
been done.  
 <p>
Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, 
probably reduces the tubular secretion of methotrexate based on In-Vitro
studies in rabbit kidney slices. This may indicate that ibuprofen could enhance 
the toxicity of methotrexate. Caution should be used if Ibuprofen is administered
concomitantly with methotrexate.  
 <p>
H-2 Antagonists: In studies with human volunteers, co-administration of
cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen
serum concentrations.  
 <p>
Furosemide: Clinical studies, as well as random observations, have shown that
ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some 
patients. This response has been attributed to inhibition of renal
prostaglandin synthesis. During concomitant therapy with ibuprofen, the patient 
should be observed closely for signs of renal failure (See PRECAUTIONS, RENAL
EFFECTS) as well as to assure diuretic efficacy.  
 <p>
Lithium: Ibuprofen produced an elevation of plasma lithium levels and a
reduction in renal lithium clearance in a study of eleven normal volunteers.
The mean minimum lithium concentration increased 15% and the renal clearance of 
lithium was decreased by 19% during this period of concomitant drug
administration. This effect has been attributed to inhibition of renal
prostaglandin synthesis by ibuprofen. Thus, when ibuprofen and lithium are
administered concurrently, subjects should be observed carefully for signs of
lithium toxicity. (Read circulars for lithium preparation before use of such
concurrent therapy.) 
 <p>
PREGNANCY: Reproductive studies conducted in rats and rabbits at doses somewhat 
less than the maximal clinical dose did not demonstrate evidence of
developmental abnormalities. However, animal reproduction studies are not
always predictive of human response. As there are no adequate and well
controlled studies in pregnant women, this drug should be used during pregnancy 
only if clearly needed. Because of the known effects of nonsteroidal anti
inflammatory drugs on the fetal cardiovascular system (closure of ductus
arteriosus), use during late pregnancy should be avoided. As with other drugs
known to inhibit prostaglandin synthesis, an increased incidence of dystocia
and delayed parturition occurred in rats. Administration of Ibuprofen is not
recommended during pregnancy.  
 <p>
NURSING MOTHERS: In limited studies, an assay capable of detecting 1 mcg/ml did 
not demonstrate ibuprofen in the milk of lactating mothers. However, because of 
the limited nature of the studies, and the possible adverse effects of
prostaglandin-inhibiting drugs on neonates, Ibuprofen is not recommended for use
in nursing mothers.  
 <p>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 

</b><p>Coumarin-Type Anticoagulants. Several short-term controlled studies failed to
show that Ibuprofen significantly affected prothrombin times or a variety of other 
clotting factors when administered to individuals on coumarin-type
anticoagulants. However, because bleeding has been reported when Ibuprofen and
other nonsteroidal anti-inflammatory agents have been administered to patients
on coumarin-type anticoagulants, the physician should be cautious when
administering Ibuprofen to patients on anticoagulants.  
 <p>
Aspirin: Animal studies show that aspirin given with nonsteroidal anti-
inflammatory agents, including Ibuprofen, yields a net decrease in anti-
inflammatory activity with lowered blood levels of the non-aspirin drug. Single 
dose bioavailability studies in normal volunteers have failed to show an effect 
of aspirin on ibuprofen blood levels. Correlative clinical studies have not
been done.  
 <p>
Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, 
probably reduces the tubular secretion of methotrexate based on In-Vitro
studies in rabbit kidney slices. This may indicate that ibuprofen could enhance 
the toxicity of methotrexate. Caution should be used if Ibuprofen is administered
concomitantly with methotrexate.  
 <p>
H-2 Antagonists: In studies with human volunteers, co-administration of
cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen
serum concentrations.  
 <p>
Furosemide: Clinical studies, as well as random observations, have shown that
ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some 
patients. This response has been attributed to inhibition of renal
prostaglandin synthesis. During concomitant therapy with ibuprofen, the patient 
should be observed closely for signs of renal failure (See PRECAUTIONS, RENAL
EFFECTS) as well as to assure diuretic efficacy.  
 <p>
Lithium: Ibuprofen produced an elevation of plasma lithium levels and a
reduction in renal lithium clearance in a study of eleven normal volunteers.
The mean minimum lithium concentration increased 15% and the renal clearance of 
lithium was decreased by 19% during this period of concomitant drug
administration. This effect has been attributed to inhibition of renal
prostaglandin synthesis by ibuprofen. Thus, when ibuprofen and lithium are
administered concurrently, subjects should be observed carefully for signs of
lithium toxicity. (Read circulars for lithium preparation before use of such
concurrent therapy.) 
 <p>
(See Also PRECAUTIONS) 
 <p>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
The most frequent type of adverse reaction occurring with ibuprofen is 
gastrointestinal. In controlled clinical trials the percentage
of patients reporting one or more gastrointestinal complaints ranged from 4% to 
16%.  
 <p>
In controlled studies when Ibuprofen was compared to aspirin and indomethacin in
equally effective doses, the overall incidence of gastrointestinal complaints
was about half that seen in either the aspirin- or indomethacin-treated
patients.  
 <p>
Adverse reactions observed during controlled clinical trials at an incidence
greater than 1% are listed in the table. Those reactions listed in Column one
encompass observations in approximately 3,000 patients. More than 500 of these
patients were treated for periods of at least 54 weeks.  
 <p>
Still other reactions occurring less frequently than 1 in 100 were reported in
controlled clinical trials and from marketing experience. These reactions have
been divided into two categories: Column two of the following table lists
reactions with therapy with Ibuprofen where the probability of a causal
relationship exists; for the reactions in Column three, a causal relationship
with Ibuprofen has not been established.  
 <p>
Reported side effects were higher at doses of 3200 mg/day than at doses of 2400 
mg or less per day in clinical trials of patients with rheumatoid arthritis.
The increases in incidence were slight and still within the ranges reported in
the following table.  <p><pre>
 
Ibuprofen                                                                          
                                                           PRECISE INCIDENCE    
INCIDENCE GREATER THAN 1%     PRECISE INCIDENCE UNKNOWN         UNKNOWN         
    (BUT LESS THAN 3%)            (BUT LESS THAN 1%)       (BUT LESS THAN 1%)   
     PROBABLE CAUSAL        PROBABLE CAUSAL RELATIONSHIP**       CAUSAL         
       RELATIONSHIP                                      RELATIONSHIP UNKNOWN** 
------------------------------------------------------------------------------  
GASTROINTESTINAL                                                                
Nausea*, epigastric pain*,      Gastric or duodenal ulcer                       
heartburn*, diarrhea,           with bleeding and/or                            
abdominal distress, nausea and  perforation, gastrointestinal                   
vomiting, indi-                 hemorrhage, melena,                             
gestion, constipation,          gastritis, hepatitis,                           
abdominal cramps or pain,       jaundice, abnormal liver                        
fullness of GI tract (bloating  function tests; pancreatitis                    
and flatulence)                                                                 
------------------------------------------------------------------------------  
CENTRAL NERVOUS SYSTEM                                                          
Dizziness*, headache,           Depression, insomnia,       Paresthesias,       
nervousness                     confusion, emotional        hallucinations,     
                                lability, somnolence,       dream               
                                aseptic meningitis with     abnormalities,      
                                fever and come              pseudo-             
                                                            tumor cerebri       
------------------------------------------------------------------------------  
DERMATOLOGIC                                                                    
Rash* (including maculopapular  Vesiculobullous eruptions,  Toxic epidermal     
type), pruritus                 urticaria, erythema         necrolysis,         
                                multiforme, Stevens-Johnson photoallergic skin  
                                syndrome, alopecia          reactions           
------------------------------------------------------------------------------  
SPECIAL SENSES                                                                  
Tinnitus                        Hearing loss, amblyopia     Conjunctivitis,     
                                (blurred and/or di-         diplopia, optic     
                                minished vision, scotomata  neuritis, cataracts 
                                and/or changes in                               
                                color vision) (see PRECAUTIONS)                 
------------------------------------------------------------------------------  
HEMATOLOGIC                     Neutropenia,                Bleeding episodes   
                                agranulocytosis, aplastic   (eg epistaxis,
                                anemia,                     menorrhagia)        
                                hemolytic anemia (sometimes                     
                                Coombs positive),                               
                                thrombocytopenia with or                        
                                without purpura, eosinophilia,                  
                                decreases in hemoglobin and                     
                                hematocrit (see PRECAUTIONS)                    
------------------------------------------------------------------------------  
METABOLIC/ENDOCRINE                                                             
Decreased appetite                                          Gynecomastia,       
                                                            hypoglycemic        
                                                            reaction, acidosis  
------------------------------------------------------------------------------  
CARDIOVASCULAR                                                                  
Edema, fluid retention          Congestive heart failure    Arrhythmias (sinus  
(generally responds             in patients with marginal   tachycardia,        
promptly to drug                cardiac function, elevated  sinus bradycardia)  
discontinuation; see PRECAU-    blood pressure, palpi-                          
TIONS)                          tations                                         
------------------------------------------------------------------------------  
ALLERGIC                        Syndrome of abdominal pain, Serum sickness,     
                                fever, chills, nausea       lupus erythe-       
                                and vomiting; anaphylaxis;  matosus syndrome,   
                                bronchospasm (see           Henoch-             
                                CONTRAINDICATIONS)          Schonlein           
                                                            vasculitis,         
                                                            angioedema          
------------------------------------------------------------------------------  
RENAL                           Acute renal failure (see    Renal papillary     
                                PRECAUTIONS), decreased     necrosis            
                                creatinine clearance,                           
                                polyuria, azotemia, cystitis,                   
                                hematuria                                       
------------------------------------------------------------------------------  
MISCELLANEOUS                   Dry eyes and mouth,                             
                                gingival ulcer, rhinitis                        
------------------------------------------------------------------------------  
*   Reactions occurring in 3% to 9% of patients treated with Ibuprofen. (Those     
    reactions occurring in less than 3% of the patients are unmarked).          
**  Reactions are classified under &quot;Probable Causal Relationship (PCR)&quot; if      
    there has been one positive rechallenge or if three or more cases occur     
    which might be causally related. Reactions are classified under &quot;Causal     
    Relationship Unknown&quot; if seven or more events have been reported but the    
    criteria for PCR have not been met.                                         
------------------------------------------------------------------------------  </pre><p>
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <p>
Approximately 1 1/2 hours after the reported ingestion of from 7 to 10 Ibuprofen
Tablets (400 mg), a 19-month old child weighing 12 kg was seen in
the hospital emergency room, apneic and cyanotic, responding only to painful
stimuli. This type of stimulus, however, was sufficient to induce respiration.  
Oxygen and parenteral fluids were given; a greenish-yellow fluid was aspirated
from the stomach with no evidence to indicate the presence of ibuprofen. Two
hours after ingestion the child's condition seemed stable; she still responded
only to painful stimuli and continued to have periods of apnea lasting from 5
to 10 seconds. She was admitted to intensive care and sodium bicarbonate was
administered as well as infusions of dextrose and normal saline. By four hours
post-ingestion she could be aroused easily, sit by herself and respond to
spoken commands. Blood level of ibuprofen was 102.9 mcgm/ml approximately 8 1/2 
hours after accidental ingestion. At 12 hours she appeared to be completely
recovered.  
 <p>
In two other reported cases where children (each weighing approximately 10 kg)
accidentally, acutely ingested approximately 120 mg/kg, there were no signs of
acute intoxication or late sequelae. Blood level in one child 90 minutes after
ingestion was 700 mcgm/ml--about 10 times the peak levels seen in absorption-
excretion studies.  
 <p>
A 19-year old male who had taken 8,000 mg of ibuprofen over a period of a few
hours complained of dizziness, and nystagmus was noted. After hospitalization,
parenteral hydration and three days' bed rest, he recovered with no reported
sequelae.  
 <p>
In cases of acute overdosage, the stomach should be emptied by vomiting or
lavage, though little drug will likely be recovered if more than an hour has
elapsed since ingestion. Because the drug is acidic and is excreted in the
urine, it is theoretically beneficial to administer alkali and induce diuresis. 
In addition to supportive measures the use of oral activated charcoal may help
to reduce the absorption and reabsorption of ibuprofen.  
 <p>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
Do not exceed 3200 mg total daily dose. If gastrointestinal complaints occur,
administer Ibuprofen Tablets with meals or milk.  
 <p>
RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS, INCLUDING FLARE-UPS OF CHRONIC
DISEASE:  
 <p>
Suggested Dosage: 1200 mg-3200 mg daily (300 mg qid; 400 mg, 600 mg or 800 mg
tid or qid). Individual patients may show a better response to 3200 mg daily,
as compared with 2400 mg, although in well-controlled clinical trials patients
on 3200 mg did not show a better mean response in terms of efficacy. Therefore, 
when treating patients with 3200 mg/day, the physician should observe
sufficient increased clinical benefits to offset potential increased risk.  
 <p>
The dose should be tailored to each patient, and may be lowered or raised
depending on the severity of symptoms either at time of initiating drug therapy 
or as the patient responds or fails to respond.  
 <p>
In general, patients with rheumatoid arthritis seem to require higher doses of
Ibuprofen than do patients with osteoarthritis.  
 <p>
The smallest dose of Ibuprofen that yields acceptable control should be employed.
A linear blood level dose-response relationship exists with single doses up to
800 mg (See ACTIONS/CLINICAL PHARMACOLOGY for effects of food on rate of
absorption).  
 <p>
The availability of four tablet strengths facilitates dosage adjustment.  
 <p>
In Chronic Conditions, a therapeutic response to therapy with Ibuprofen is
sometimes seen in a few days to a week but most often is observed by two weeks. 
After a satisfactory response has been achieved, the patient's dose should be
reviewed and adjusted as required.  
 <p>
MILD TO MODERATE PAIN:  
 <p>
400 mg every 4 to 6 hours as necessary for relief of pain.  
 <p>
In controlled analgesic clinical trials, doses of Ibuprofen greater than 400 mg
were no more effective than the 400 mg dose.  
 <p>
DYSMENORRHEA:  
 <p>
For the treatment of dysmenorrhea, beginning with the earliest onset of such
pain, Ibuprofen should be given in a dose of 400 mg every 4 hours as necessary for 
the relief of pain.  
<p>

<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-18</DOCNO>
<DOCOLDNO>IA018-000200-B041-192</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/mono.htm 206.86.175.201 19970106231031 text/html 1800
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:04:17 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1618
Last-modified: Sun, 30 Jun 1996 07:23:37 GMT
</DOCHDR>
<html>
<head>
   <title>Rxlists of Indications and Side Effects 
</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a>
<hr></p></center>

<h1 align=center>RxLists of Indications and Side Effects</h1>

<p>
<hr></p>

<li><a href="aceinh.htm">ACE Inhibitors</a> </li>

<li><a href="antidepr.htm">Antidepressants</a> </li>

<li><a href="bblock.htm">Beta Blockers</a> </li>

<li><a href="calch.htm">Calcium Channel Blockers</a> </li>

<li><a href="cardiova.htm">Cardiovasculars and Drugs For High Blood Pressure</a>
(sub-menu) </li>

<li><a href="nsaid.htm">Nonsteroidal Antiinflammatory Drugs</a> </li>

<li><a href="opiate.htm">Opiate Drugs (Narcotics) </a>
<hr></li>

<center><p><a href="http://www.rxlist.com/disclaim.htm">Important Information
About The RxLists of Indications and Side Effects!</a></p></center>

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></p></center>

<center><p><font SIZE=-2>copyright 1996 Neil Sandow, Pharm.D. - all rights
reserved </font></p></center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-19</DOCNO>
<DOCOLDNO>IA018-000200-B039-198</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/fenflur.htm 206.86.175.201 19970106230318 text/html 18034
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:57:04 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 17851
Last-modified: Thu, 26 Sep 1996 05:24:16 GMT
</DOCHDR>
<html>
<head>
   <title>Fenfluramine - RxList Generic Information</title>
   <meta name="Keywords" content="Adipomin, Deobesan, Dexfenfluramine,
Dietoff, Dima-Fen, Fendurin, Flabolin, Grazilan, Kataline, Obegon, Pesos,
Ponderal, Ponderamin, Ponderax, Ponderex, Pondimin, Poneral, Ponflural,
Slimerax">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Fenfluramine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Fenfluramine is an anorectic drug for oral administration. Fenfluramine
has the chemical name, N-ethyl-alpha- methyl-3-(trifluoromethyl) benzeneethanamine
hydrochloride. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Fenfluramine is a sympathomimetic amine, the pharmacologic activity
of which differs somewhat from that of the prototype drugs of this class
used in obesity, the amphetamines, in appearing to produce more central
nervous system depression than stimulation. </p>

<p>The mechanism of action of Fenfluramine is unclear but may be related
to brain levels (or turnover rates) of serotonin or to increased glucose
utilization. The antiappetite effects of Fenfluramine are suppressed by
serotonin-blocking drugs and by drugs that lower brain levels of the amine.
Furthermore, decreased serotonin levels produced by selective brain lesions
suppress the action of Fenfluramine. </p>

<p>In a study of 20 normal males, fenfluramine increased glucose utilization,
resulting in decreased blood glucose levels. Experimental work in animals
suggested that increased glucose utilization activated the satiety center
and decreased the activity of the feeding center. Perhaps by this mechanism
Fenfluramine inhibits appetite. The relationship between glucose utilization
and serotonin has not been clarified. </p>

<p>Fenfluramine is well-absorbed from the gastrointestinal tract, and a
maximal anorectic effect is generally seen after 2 to 4 hours. In man,
fenfluramine is de-ethylated to norfenfluramine which is subsequently oxidized
to m-trifluoromethyl benzoic acid and excreted as the glycine conjugate,
m-trifluoromethylhippuric acid. Other compounds found in the urine include
unchanged fenfluramine and norfenfluramine. </p>

<p>The rate of excretion of fenfluramine is pH dependent, with much smaller
amounts appearing in an alkaline than in an acid urine. </p>

<p>The half-life of fenfluramine is said to be about 20 hours, compared
with 5 hours for amphetamines; however, if urinary excretion is rapid and
the pH maintained in the acidic range (below pH 5), half-life can be reduced
to 11 hours. Fenfluramine and norfenfluramine reach steady state concentrations
in plasma within 3 to 4 days following chronic dosage. </p>

<p>The greatest weight loss is seen in those patients who maintain the
highest levels of Fenfluramine. A 2-to-3-kg weight loss over 6 weeks is
associated with a plasma level of 0.1 mcg/mL (or 10 mcg/100 mL). </p>

<p>Fenfluramine is widely distributed in almost all body tissues. It is
soluble in lipids and crosses the blood-brain barrier. Fenfluramine crosses
the placenta readily in monkeys. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Fenfluramine is indicated in the management of exogenous obesity as
a short-term (a few weeks) adjunct in a regimen of weight reduction based
on caloric restriction. </p>

<p>Drugs of this class used in obesity are commonly known as &quot;anorectics&quot;
or &quot;anorexigenics.&quot; It has not been established, however, that
the action of such drugs in treating obesity is primarily one of appetite
suppression. Other central nervous system actions or metabolic effects
may be involved. </p>

<p>Adult obese subjects instructed in dietary management and treated with
&quot;anorectic&quot; drugs, lose more weight on the average than those
treated with placebo and diet, as determined in relatively short-term trials.
</p>

<p>The average magnitude of increased weight loss of drug-treated patients
over placebo-treated is only a fraction of a pound a week. The rate of
weight loss is greatest in the first weeks of therapy for both drug and
placebo subjects and tends to decrease in succeeding weeks. The possible
origins of the increased weight loss due to the various drug effects are
not established. The average amount of weight loss associated with the
use of an &quot;anorectic&quot; drug varies from trial to trial, and the
increased weight loss appears to be related in part to variables other
than the drug prescribed such as the physician- investigator, the population
treated and the diet prescribed. Studies do not permit conclusions as to
the relative importance of the drug and non- drug factors on weight loss.
The natural history of obesity is measured in years, whereas the studies
cited are restricted to a few weeks duration; thus, the total impact of
drug-induced weight loss over that of diet alone must be considered clinically
limited. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Fenfluramine is contraindicated in patients with glaucoma or with hypersensitivity
to fenfluramine or other sympathomimetic amines. Do not administer fenfluramine
during or within 14 days following the administration of monoamine oxidase
inhibitors, since hypertensive crises may result. Patients with a history
of drug abuse should not receive this drug. </p>

<p>Do not administer fenfluramine to patients with alcoholism since psychiatric
symptoms (paranoia, depression, psychosis) have been reported in a few
such patients who had been administered this drug. </p>

<p>Fenfluramine should also generally be avoided in patients with psychotic
illness. There have been reports of schizophrenic patients who have become
agitated, delusional, and assaultive. </p>

<p>A fatal cardiac arrest has been reported shortly after the induction
of anesthesia in a patient who had been taking fenfluramine prior to surgery.
Fenfluramine may have a catecholamine- depleting effect when administered
for prolonged periods of time; therefore, potent anesthetic agents should
be administered with caution to patients taking fenfluramine. If general
anesthesia cannot be avoided, full cardiac monitoring and facilities for
instant resuscitative measures are a minimum necessity. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>When tolerance to the &quot;anorectic&quot; effect develops, the maximum
recommended dose should not be exceeded in an attempt to increase the effect;
rather, the drug should be discontinued. 
<br>
<br><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL. Fenfluramine differs in its pharmacological profile from other
&quot;anorectic&quot; drugs with which the prescribing practitioner may
be familiar. Correspondingly, there are possible adverse effects not associated
with other &quot;anorectics&quot;; such effects include those of diarrhea,
sedation, and depression. The possibility of these effects should be weighed
against the possible advantage of decreased central nervous system stimulation
and/or abuse potential. </p>

<p>There have been four cases of pulmonary hypertension reported in association
with fenfluramine use. Two cases were apparently reversible after discontinuation
of fenfluramine, but evidence of pulmonary hypertension recurred in one
of these patients upon rechallenge with fenfluramine. A third patient was
initially improved with nifedipine treatment, but was noted to have increased
pulmonary arterial pressure again at a four month follow up visit. Finally,
an irreversible and fatal case of pulmonary hypertension has been reported
in a patient who had seven 1-month courses of fenfluramine in the twelve
years prior to death. Patients taking fenfluramine should be advised to
report immediately any deterioration in exercise tolerance. </p>

<p>Use only with caution in hypertension, with monitoring of blood pressure,
since evidence is insufficient to rule out a possible adverse effect on
blood pressure in some hypertensive patients. The drug is not recommended
in severely hypertensive patients. The drug is not recommended for patients
with symptomatic cardiovascular disease including arrhythmias. </p>

<p>Caution should be exercised in prescribing fenfluramine for patients
with a history of mental depression. Further depression of mood may become
evident while the patient is on fenfluramine or following withdrawal of
fenfluramine. Symptoms of depression occurring immediately following abrupt
withdrawal can be readily controlled by reinstituting Fenfluramine, followed
by a gradual tapering off of the daily dose. </p>

<p>INFORMATION FOR PATIENTS. Fenfluramine may impair the ability of the
patient to engage in potentially hazardous activities such as operating
machinery or driving a motor vehicle (see &quot;Adverse Reactions&quot;);
the patient should be cautioned accordingly. Patient should also be advised
to avoid alcoholic beverages while taking Fenfluramine. </p>

<p>DRUG INTERACTIONS. Fenfluramine may increase slightly the effect of
antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine. Other
CNS depressant drugs should be used with caution in patients taking fenfluramine,
since the effects may be additive. </p>

<p>CARCINOGENESIS, MUTAGENESIS. No carcinogenic studies or mutagenic studies
have been undertaken with this drug. </p>

<p>PREGNANCY CATEGORY C. Fenfluramine was shown to produce a questionable
embryotoxic effect in rats and a reduced conception rate when given in
a dose of 20 times the human dose. However, additional reproduction studies
in rats, rabbits, mice, and monkeys at doses up to, respectively, 5 times,
20 times, 1 time, and 5 times the human dose yielded negative results.
</p>

<p>There are no adequate and well-controlled studies in pregnant women.
Fenfluramine should be used during pregnancy only if the potential benefit
justifies the potential risk to the fetus. </p>

<p>LABOR AND DELIVERY. The effect of fenfluramine during labor or delivery
on the mother and the fetus is unknown. The effect on later growth, development,
and functional maturation of the child is unknown. </p>

<p>NURSING MOTHERS. It is not known whether this drug is excreted in human
milk. Because many drugs are excreted in human milk, caution should be
exercised when fenfluramine is administered to a nursing mother. PEDIATRIC
USE. Safety and effectiveness in children below the age of 12 years have
not been established. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Fenfluramine may increase slightly the effect of antihypertensive drugs,
e.g., guanethidine, methyldopa, reserpine. </p>

<p>Other CNS depressant drugs should be used with caution in patients taking
fenfluramine, since the effects may be additive. (See Also PRECAUTIONS)
</p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The most common adverse reactions of fenfluramine are drowsiness, diarrhea,
and dry mouth. Less frequent adverse reactions reported in association
with fenfluramine are: </p>

<p>CENTRAL NERVOUS SYSTEM. Dizziness; confusion; incoordination; headache;
elevated mood; depression; anxiety, nervousness, or tension; insomnia;
weakness or fatigue; increased or decreased libido; agitation, dysarthria.
</p>

<p>GASTROINTESTINAL. Constipation; abdominal pain; nausea. </p>

<p>AUTONOMIC. Sweating; chills; blurred vision. </p>

<p>GENITOURINARY. Dysuria; urinary frequency. </p>

<p>CARDIOVASCULAR. Palpitation; hypotension; hypertension; fainting; pulmonary
hypertension. </p>

<p>SKIN. Rash; urticaria; burning sensation. </p>

<p>MISCELLANEOUS. Eye irritation; myalgia; fever; chest pain; bad taste.
</p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>Fenfluramine is a controlled substance in Schedule IV. Fenfluramine
is related chemically to the amphetamines, although it differs somewhat
pharmacologically. The amphetamines and related stimulant drugs have been
extensively abused and can produce tolerance and severe psychological dependence,
as well as other adverse organic and mental changes. In this regard, there
has been a report of abuse of fenfluramine by subjects with a history of
abuse of other drugs. Abuse of 80 to 400 milligrams of the drug has been
reported to be associated with euphoria, derealization, and perceptual
changes. Fenfluramine did not produce signs of dependence in animals and
appears to produce sedation more often than CNS stimulation at therapeutic
doses. Its abuse potential appears qualitatively different from that of
amphetamines. The possibility that fenfluramine may induce dependence should
be kept in mind when evaluating the desirability of including the drug
in the weight reduction programs of individual patients. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>SIGNS AND SYMPTOMS: Only limited data have been reported concerning
clinical effects and management of overdosage of fenfluramine. </p>

<p>Agitation and drowsiness, confusion, flushing, tremor (or shivering),
fever, sweating, abdominal pain, hyperventilation, and dilated non-reactive
pupils seem frequent in fenfluramine overdosage. Reflexes may be either
exaggerated or depressed and some patients may have rotary nystagmus. Tachycardia
may be present, but blood pressure may be normal or only slightly elevated.
Convulsions, coma, and ventricular extrasystoles, culminating in ventricular
fibrillation, and cardiac arrest, may occur at higher dosages. </p>

<p>HUMAN TOXICITY. Less than 5 mg/kg are toxic to humans. Five-ten mg/kg
may produce coma and convulsions. Reported single overdoses have ranged
from 300 to 2000 mg; the lowest reported fatal dose was a few hundred mg
in a small child, and the highest reported nonfatal dose was 1800 mg in
an adult. Most deaths were apparently due to respiratory failure and cardiac
arrest. </p>

<p>Toxic effects will appear within 30 to 60 minutes and may progress rapidly
to potentially fatal complications in 90 to 240 minutes. Symptoms may persist
for extended periods depending upon the dose ingested. </p>

<p>MANAGEMENT. After overdosage, only a small percentage of the drug is
excreted in the urine. Forced acid diuresis has been recommended only in
extreme cases in which the patient survives the early hours of intoxication
but fails to show decisive improvement from other measures. Hemodialysis
and peritoneal dialysis are of theoretical advantage but have not been
used clinically. </p>

<p>Reportedly the treatment of fenfluramine intoxication should include:
</p>

<p>--Gastric Lavage (but not drug-induced emesis because the patient may
become unconscious at a very early stage.) </p>

<p>--In the event that gastric lavage is not feasible due to trismus, consult
an anesthesiologist for endotracheal intubation after administration of
muscle relaxants; only then gastric evacuation should be tried. </p>

<p>--Administration of activated charcoal after emesis or lavage may reduce
absorption of drug. </p>

<p>--Monitoring Of Vital Functions. If necessary, mechanical respiration,
defibrillation, or &quot;cardioversion&quot; should be instituted. </p>

<p>--Drug Therapy. Diazepam or phenobarbital for convulsions or muscular
hyperactivity. In the presence of extreme tachycardia: propranolol; in
the presence of ventricular extrasystoles: lidocaine; in the presence of
hyperpyrexia: chlorpromazine. </p>

<p>Since fenfluramine has been shown to have a slight lowering effect on
blood sugar in some patients, the theoretical possibility of hypoglycemia
should be borne in mind although this effect has not been reported in cases
of clinical overdosage. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>The usual dose is one 20 mg tablet three times daily before meals. Depending
on the degree of effectiveness and side effects, the dosage may be increased
at weekly intervals by one tablet (20 mg) daily until a maximum dosage
of two tablets three times daily is attained. Total dosage of fenfluramine
should not exceed 120 mg per day. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-20</DOCNO>
<DOCOLDNO>IA018-000200-B044-20</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/nsaid.htm 206.86.175.201 19970106232052 text/html 5566
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:14:37 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5384
Last-modified: Sun, 30 Jun 1996 07:23:39 GMT
</DOCHDR>
<html>
<head>
   <title>Rxlist of Indications and Side Effects - Nonsteroidal Antiinflammatory Drugs
</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Nonsteroidal Antiinflammatory Drugs (NSAIDS)</h1>

<center><p align=center>
<hr width="100%" ></p></center>

<h3>As the name implies, the medications in this category are not steroids
but possess antiinflamatory actions as well as other properties. These
drugs inhibit the synthesis and actions of certain prostaglandins which
are widely distributed in body tissues and are integral to the inflammatory
process, platelet aggregation, and many more metabolic pathways. While
there are chemical differences between NSAIDS, they are clinically very
similar. The proper choice of agents is often determined by factors such
as the condition being treated, patient response, the dosing interval,
and cost, to name a few. </h3>

<p>
<hr></p>

<h3><a href="disclaim.htm#USES">INDICATIONS</a></h3>

<menu>
<li>ankylosing spondylitis </li>

<li>arterial thromboembolism prophylaxis </li>

<li>bursitis </li>

<li>conjunctivitis </li>

<li>corneal ulcer </li>

<li>cystic fibrosis+ </li>

<li>dysmenorrhea </li>

<li>fever </li>

<li>gouty arthritis </li>

<li>gout+ </li>

<li>headache </li>

<li>inflammation </li>

<li>juvenile rheumatoid arthritis </li>

<li>Kawasaki disease+ </li>

<li>keratoconjunctivitis </li>

<li>migraine </li>

<li>migraine prophylaxis+ </li>

<li>musculoskeletal inflammation </li>

<li>myocardial infarction prophylaxis </li>

<li>myocardial infarction </li>

<li>osteoarthritis </li>

<li>pain </li>

<li>patent ductus arteriosus </li>

<li>pericarditis+ </li>

<li>prosthetic heart valves </li>

<li>psoriatic arthritis+ </li>

<li>rheumatoid arthritis </li>

<li>seasonal allergic conjunctivitis </li>

<li>stroke prophylaxis </li>

<li>tendinitis </li>

<li>transient ischemic attacks </li>

<li>unstable angina </li>
</menu>

<dl>
<dd>+ = not an FDA approved indication</dd>
</dl>

<p>
<hr><a href="#top">Return to Top</a> 
<hr></p>

<h3><a href="disclaim.htm#SIDE">Side Effects and Adverse Reactions</a></h3>

<menu>
<li>abdominal pain </li>

<li>agranulocytosis </li>

<li>amblyopia </li>

<li>anemia </li>

<li>angioedema </li>

<li>anorexia </li>

<li>aplastic anemia </li>

<li>azotemia </li>

<li>bleeding </li>

<li>blurred vision </li>

<li>bronchospasm </li>

<li>bullous rash </li>

<li>cholestasis </li>

<li>constipation </li>

<li>corneal deposits </li>

<li>diarrhea </li>

<li>dizziness </li>

<li>drowsiness </li>

<li>dyspepsia </li>

<li>dyspnea </li>

<li>edema </li>

<li>elevated hepatic enzymes </li>

<li>erythema nodosum </li>

<li>exfoliative dermatitis </li>

<li>flatulence </li>

<li>gastritis </li>

<li>GI bleeding </li>

<li>GI perforation </li>

<li>granulocytopenia </li>

<li>headache </li>

<li>hearing loss </li>

<li>heart failure </li>

<li>hematuria </li>

<li>hemolysis </li>

<li>hepatic failure </li>

<li>hepatitis </li>

<li>hyperkalemia </li>

<li>hypertension </li>

<li>hyperuricemia </li>

<li>infection </li>

<li>insomnia </li>

<li>interstitial nephritis </li>

<li>intraventricular hemorrhage </li>

<li>jaundice </li>

<li>keratitis </li>

<li>lethargy </li>

<li>leukopenia </li>

<li>maculopapular rash </li>

<li>malaise </li>

<li>melena </li>

<li>musculoskeletal inflammation </li>

<li>nausea/vomiting </li>

<li>nephrotic syndrome </li>

<li>occult GI bleeding </li>

<li>ocular irritation </li>

<li>osteoarthritis </li>

<li>palpitations </li>

<li>pancreatitis </li>

<li>pancytopenia </li>

<li>peptic ulcer </li>

<li>peripheral edema </li>

<li>photosensitivity </li>

<li>platelet dysfunction </li>

<li>proteinuria </li>

<li>pruritus </li>

<li>pseudoporphyria </li>

<li>purpura </li>

<li>renal papillary necrosis </li>

<li>retinal hemorrhage </li>

<li>Reye's syndrome </li>

<li>rheumatoid arthritis </li>

<li>seizures </li>

<li>sinus tachycardia </li>

<li>Stevens-Johnson syndrome </li>

<li>tendinitis </li>

<li>thrombocytopenia </li>

<li>tinnitus </li>

<li>toxic epidermal necrolysis </li>

<li>urticaria </li>

<li>vasculitis </li>

<li>vertigo </li>

<li>visual impairment </li>
</menu>

<p><a href="nsaid.htm#top">Return to Top</a> 
<hr><font SIZE=+2><a href="http://www.rxlist.com/disclaim.htm">Important
- Please Read!</a> </font></p>

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"></a></p></center>

<h3 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h3>

<h4 align=center><a href="http://www.rxlist.com/mono.htm">RxLists of Indications
and Side Effects</a></h4>

<h4 align=center><a href="http://www.rxlist.com"></a></h4>

<center><p><font SIZE=-1>copyright 1996 Neil Sandow, Pharm.D. - all rights
reserved </font></p></center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-21</DOCNO>
<DOCOLDNO>IA018-000200-B033-68</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/stats.htm 206.86.175.201 19970106223533 text/html 2696
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:29:17 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2514
Last-modified: Mon, 06 Jan 1997 05:12:53 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
   <TITLE>RxList Statistics</TITLE>
   <META NAME="keywords" CONTENT="crack, rock, blow, snow">
   <META NAME="GENERATOR" CONTENT="Mozilla/3.01Gold (Win95; I) [Netscape]">
   <META NAME="KeyWords" CONTENT="crack, rock, blow, snow">
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000EE" VLINK="#551A8B" ALINK="#FF0000">

<CENTER><P><A HREF="http://www.rxlist.com"><IMG SRC="rx.gif" BORDER=0 HEIGHT=125 WIDTH=125></A></P></CENTER>

<H1 ALIGN=CENTER>RxList Statistics</H1>

<P>
<HR>January 6, 1997</P>

<P>RxList is currently visited by approximately 3,300 different visitors
daily. On a typical week day the RxList database is searched 5,000 times.
Each search produces an entry in a log file that helps to determine the
need for new monographs which are downloaded at the rate of 3,500 per day.
Activity drops by 30% on weekends and holidays. </P>

<P>View the most recent day's summary of <A HREF="http://www.rxlist.com/tempstat.htm">RxList
WWW Activity</A> updated daily at 7AM PST. Or, if you prefer, here's a
<A HREF="http://www.rxlist.com/aw/accesswatch-1.33/">recent graphical representation</A>
of a typical RxList Day. </P>

<H3 ALIGN=CENTER><A NAME="Results"></A>Current Results of <A HREF="http://www.rxlist.com/index.shtml#mini">Mini-Survey</A></H3>

<PRE><B>Number of Completed Surveys:        10,877

Not Health Professionals:            54.6%  

Health Professionals:                45.4%

   MD's &amp; Other Prescribers:         33.9%

   Pharmacists                       20.6%

   Nurses                            16.2%

   Other Health Professionals        29.3%

SEX
    Male                              66.5%

    Female                            33.5%

Age  
    Under 20                          6.0%
    20-29                            16.6%
    30-39                            24.4%
    40-49                            29.9%
    50-59                            15.5%
    60 and over                       7.6%</B></PRE>

<P>
<HR width="100%"></P>

<H2 ALIGN=CENTER><A HREF="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</A><A HREF="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <A HREF="http://www.rxlist.com/top200.htm"><IMG SRC="redball.gif" BORDER=0 HEIGHT=17 WIDTH=17></A></A><A HREF="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</A> &nbsp;&nbsp;<IMG SRC="redball.gif" HEIGHT=17 WIDTH=17><A HREF="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</A></H2>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B10-22</DOCNO>
<DOCOLDNO>IA018-000200-B035-230</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/pred.htm 206.86.175.201 19970106224929 text/html 27797
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:43:13 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 27614
Last-modified: Sun, 11 Aug 1996 03:46:42 GMT
</DOCHDR>
<html>
<head>
   <title>Prednisone - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Prednisone</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="pred.htm#DESCRIPTION">description</a>]
[<a href="pred.htm#ACTIONS/CLINICAL PHARMACOLOGY">action</a>] [<a href="pred.htm#INDICATIONS AND USAGE">use</a>]
[<a href="pred.htm#CONTRAINDICATIONS">contra</a>] [<a href="pred.htm#WARNINGS">warn!</a>]
[<a href="pred.htm#PRECAUTIONS">caution</a>] [<a href="pred.htm#DRUG INTERACTIONS">drug-drug</a>]
[<a href="pred.htm#ADVERSE REACTIONS">side effects</a>] [<a href="pred.htm#OVERDOSAGE">toxicity</a>]
[<a href="pred.htm#DOSAGE AND ADMINISTRATION">dosing</a>]</font> </p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION

</b><p>Prednisone is a glucocorticoid. Glucocorticoids  are adrenocortical steroids, 
both naturally occurring and synthetic, which are readily absorbed from the 
gastrointestinal tract. Prednisone is a white to practically white, odorless, 
crystalline powder. It is very slightly soluble in water; slightly soluble in alcohol, 
in chloroform, in dioxane, and in methanol. <p>
 
The chemical name for prednisone is pregna-1,4-diene-3,11,20-trione, 17,21-
dihydroxy- and its molecular weight is 358.43.  
 <p>
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY <p>
</b> 
Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also
have salt-retaining properties, are used as replacement therapy in
adrenocortical deficiency states. Their synthetic analogs are primarily used
for their potent anti-inflammatory effects in disorders of many organ systems.  
 <p>
Glucocorticoids cause profound and varied metabolic effects. In addition, they
modify the body's immune responses to diverse stimuli.  
 <p>
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
Prednisone Tablets are indicated in the following conditions:  
 <p>
1. ENDOCRINE DISORDERS 
 <p>
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone
is the first choice; synthetic analogs may be used in conjunction with
mineralocorticoids where applicable; in infancy mineralocorticoid
supplementation is of particular importance) 
 <p>
Congenital adrenal hyperplasia 
 <p>
Hypercalcemia associated with cancer 
 <p>
Nonsuppurative thyroiditis 
 <p>
2. RHEUMATIC DISORDERS 
 <p>
As adjunctive therapy for short-term administration (to tide the patient over
an acute episode or exacerbation) in:  
 <p>
Psoriatic arthritis 
 <p>
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases
may require low-dose maintenance therapy) 
 <p>
Ankylosing spondylitis 
 <p>
Acute and subacute bursitis 
 <p>
Acute nonspecific tenosynovitis 
 <p>
Acute gouty arthritis 
 <p>
Post-traumatic osteoarthritis 
 <p>
Synovitis of osteoarthritis 
 <p>
Epicondylitis 
 <p>
3. COLLAGEN DISEASES 
 <p>
During an exacerbation or as maintenance therapy in selected cases of:  
 <p>
Systemic lupus erythematosus 
 <p>
Systemic dermatomyositis (polymyositis) 
 <p>
Acute rheumatic carditis 
 <p>
4. DERMATOLOGIC DISEASES 
 <p>
Pemphigus 
 <p>
Bullous dermatitis herpetiformis 
 <p>
Severe erythema multiforme 
 <p>
(Stevens-Johnson syndrome) 
 <p>
Exfoliative dermatitis 
 <p>
Mycosis fungoides 
 <p>
Severe psoriasis 
 <p>
Severe seborrheic dermatitis 
 <p>
5. ALLERGIC STATES 
 <p>
Control of severe or incapacitating allergic conditions intractable to adequate 
trials of conventional treatment:  
 <p>
Seasonal or perennial allergic rhinitis 
 <p>
Bronchial asthma 
 <p>
Contact dermatitis 
 <p>
Atopic dermatitis 
 <p>
Serum sickness 
 <p>
Drug hypersensitivity reactions 
 <p>
6. OPHTHALMIC DISEASES 
 <p>
Severe acute and chronic allergic and inflammatory processes involving the eye
and its adnexa such as:  
 <p>
Allergic corneal marginal ulcers 
 <p>
Herpes zoster ophthalmicus 
 <p>
Anterior segment inflammation 
 <p>
Diffuse posterior uveitis and choroiditis 
 <p>
Sympathetic ophthalmia 
 <p>
Allergic conjunctivitis 
 <p>
Keratitis 
 <p>
Chorioretinitis 
 <p>
Optic neuritis 
 <p>
Iritis and iridocyclitis 
 <p>
7. RESPIRATORY DISEASES 
 <p>
Symptomatic sarcoidosis 
 <p>
Loeffler's syndrome not manageable by other means 
 <p>
Berylliosis 
 <p>
Fulminating or disseminated pulmonary tuberculosis when used concurrently with
appropriate antituberculous chemotherapy 
 <p>
Aspiration pneumonitis 
 <p>
8. HEMATOLOGIC DISORDERS 
 <p>
Idiopathic thrombocytopenic purpura in adults 
 <p>
Secondary thrombocytopenia in adults 
 <p>
Acquired (autoimmune) hemolytic anemia 
 <p>
Erythroblastopenia (RBC anemia) 
 <p>
Congenital (erythroid) hypoplastic anemia 
 <p>
9. NEOPLASTIC DISEASES 
 <p>
For palliative management of:  
 <p>
Leukemias and lymphomas in adults 
 <p>
Acute leukemia of childhood 
 <p>
10. EDEMATOUS STATES 
 <p>
To induce a diuresis or remission of proteinuria in the nephrotic syndrome,
without uremia, of the idiopathic type or that due to lupus erythematosus 
 <p>
11. GASTROINTESTINAL DISEASES 
 <p>
To tide the patient over a critical period of the disease in:  
 <p>
Ulcerative colitis 
 <p>
Regional enteritis 
 <p>
12. NERVOUS SYSTEM 
 <p>
Acute exacerbations of multiple sclerosis 
 <p>
13. MISCELLANEOUS 
 <p>
Tuberculous meningitis with subarachnoid block or impending block when used
concurrently with appropriate antituberculous chemotherapy 
 <p>
Trichinosis with neurologic or myocardial involvement 
 <p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <p>
Systemic fungal infections and known hypersensitivity to components.  
 <p>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <p>
In patients on corticosteroid therapy subjected to unusual stress, increased
dosage of rapidly acting corticosteroids before, during, and after the
stressful situation is indicated.  <p>
 
Corticosteroids may mask some signs of infection, and new infections may appear 
during their use. There may be decreased resistance and inability to localize
infection when corticosteroids are used.  <p>
 
Prolonged use of corticosteroids may produce posterior subcapsular cataracts,
glaucoma with possible damage to the optic nerves, and may enhance the
establishment of secondary ocular infections due to fungi or viruses.  
 <p>
Usage In Pregnancy: Since adequate human reproduction studies have not been
done with corticosteroids, the use of these drugs in pregnancy, nursing mothers 
or women of childbearing potential requires that the possible benefits of the
drug be weighed against the potential hazards to the mother and embryo or
fetus.  Infants born of mothers who have received substantial doses of
corticosteroids during pregnancy, should be carefully observed for signs of
hypoadrenalism.  
 <p>
Average and large doses of hydrocortisone or cortisone can cause elevation of
blood pressure, salt and water retention, and increased excretion of potassium. 
These effects are less likely to occur with the synthetic derivatives except
when used in large doses. Dietary salt restriction and potassium
supplementation may be necessary. All corticosteroids increase calcium
excretion.  <p>
 
WHILE ON CORTICOSTEROID THERAPY PATIENTS SHOULD NOT BE VACCINATED AGAINST
SMALLPOX. OTHER IMMUNIZATION PROCEDURES SHOULD NOT BE UNDERTAKEN IN PATIENTS
WHO ARE ON CORTICOSTEROIDS, ESPECIALLY ON HIGH DOSE, BECAUSE OF POSSIBLE
HAZARDS OF NEUROLOGICAL COMPLICATIONS AND A LACK OF ANTIBODY RESPONSE.  
 <p>
The use of Prednisone Tablets in active tuberculosis should be restricted to
those cases of fulminating or disseminated tuberculosis in which the
corticosteroid is used for the management of the disease in conjunction with an 
appropriate anti-tuberculous regimen.  
 <p>
If corticosteroids are indicated in patients with latent tuberculosis or
tuberculin reactivity, close observation is necessary as reactivation of the
disease may occur. During prolonged corticosteroid therapy, these patients
should receive chemoprophylaxis.  <p>
 
Persons who are on drugs which suppress the immune system are more susceptible
to infections than healthy individuals. Chicken pox and measles, for example,
can have a more serious or even fatal course in non-immune children or adults
on corticosteroids. In such children or adults who have not had these diseases, 
particular care should be taken to avoid exposure. How the dose, route and
duration of corticosteroid administration affects the risk of developing a
disseminated infection is not known. The contribution of the underlying disease 
and/or prior corticosteroid treatment to the risk is also not known. If exposed 
to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be 
indicated. If exposed to measles, prophylaxis with pooled intramuscular
immunoglobin (IG), may be indicated. (See the respective package inserts for
complete VZIG and IG prescribing information.) If chickenpox develops,
treatment with antiviral agents may be considered.  <p>
 
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
Drug-induced secondary adrenocortical insufficiency may be minimized by gradual 
reduction of dosage. This type of relative insufficiency may persist for months 
after discontinuation of therapy; therefore, in any situation of stress
occurring during that period, hormone therapy should be reinstituted. Since
mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid
should be administered concurrently.  
 <p>
There is an enhanced effect of corticosteroids on patients with hypothyroidism
and in those with cirrhosis.  
 <p>
Corticosteroids should be used cautiously in patients with ocular herpes
simplex because of possible corneal perforation.  
 <p>
The lowest possible dose of corticosteroid should be used to control the
condition under treatment, and when reduction in dosage is possible, the
reduction should be gradual.  
 <p>
Psychic derangements may appear when corticosteroids are used, ranging from
euphoria, insomnia, mood swings, personality changes, and severe depression, to 
frank psychotic manifestations. Also, existing emotional instability or
psychotic tendencies may be aggravated by corticosteroids.  
 <p>
Steroids should be used with caution in nonspecific ulcerative colitis, if
there is a probability of impending perforation, abscess or other pyogenic
infection; diverticulitis; fresh intestinal anastomoses; active or latent
peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia
gravis.  
 <p>
Growth and development of infants and children on prolonged corticosteroid
therapy should be carefully observed.  <p>
 
Although controlled clinical trials have shown corticosteroids to be effective
in speeding the resolution of acute exacerbations of multiple sclerosis, they
do not show that corticosteroids affect the ultimate outcome or natural history 
of the disease. The studies do show that relatively high doses of
corticosteroids are necessary to demonstrate a significant effect. (See DOSAGE
AND ADMINISTRATION).  <p>
 
Since complications of treatment with glucocorticoids are dependent on the size 
of the dose and the duration of treatment, a risk/benefit decision must be made 
in each individual case as to dose and duration of treatment and as to whether
daily or intermittent therapy should be used.  
                           <p>
Convulsions have been reported with concurrent use of methylprednisolone and
cyclosporin. Since concurrent use of these agents results in a mutual
inhibition of metabolism, it is possible that adverse events associated with
the individual use of either drug may be more apt to occur.  
 <p>
DRUG INTERACTIONS 
 <p>
The pharmacokinetic interactions listed below are potentially clinically
important. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin
and rifampin may increased the clearance of corticosteroids and may require
increases in corticosteroid dose to achieve the desired response. Drugs such as 
troleandomycin and ketoconazole may inhibit metabolism of cortocosteroids and
thus decrease their clearance. Therefore, the dose of corticosteroid should be
titrated to avoid steroid toxicity. Corticosteroids may increase the clearance
of high dose aspirin. This could lead to decreased salicylate serum levels or
increase the riskof salicylate toxicity when corticosteroid is withdrawn. 
Aspirin should be used cautiously in conjunction with corticosteroids in
patients suffering from hypoprothrombinemia. The effect of corticosteroids on
oral anticoagulants is variable. There are reports of enhanced as well as
diminished effects of anticoagulants when given concurrently with
corticosteroids. Therefore, coagulation indices should be monitored to maintain 
the desired anticoagulant effect.  <p>
 
INFORMATION FOR THE PATIENT 
 <p>
Persons who are on immunosuppressant doses of corticosteroids should be warned
to avoid exposure to chicken pox or measles.Patients should also be advised
that if they are exposed, medical advice should be sought without delay.  
 <p>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <p>
Aspirin should be used cautiously in conjunction with corticosteroids in
hypoprothrombinemia.  
 <p>
Convulsions have been reported with concurrent use of methylprednisolone and
cyclosporin. Since concurrent use of these agents results in a mutual
inhibition of metabolism, it is possible that adverse events associated with
the individual use of either drug may be more apt to occur.  
 <p>
The pharmacokinetic interactions listed below are potentially clinically
important. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin
and rifampin may increased the clearance of corticosteroids and may require
increases in corticosteroid dose to achieve the desired response. Drugs such as 
troleandomycin and ketoconazole may inhibit metabolism of cortocosteroids and
thus decrease their clearance. Therefore, the dose of corticosteroid should be
titrated to avoid steroid toxicity. Corticosteroids may increase the clearance
of high dose aspirin. This could lead to decreased salicylate serum levels or
increase the riskof salicylate toxicity when corticosteroid is withdrawn. 
Aspirin should be used cautiously in conjunction with corticosteroids in
patients suffering from hypoprothrombinemia. The effect of corticosteroids on
oral anticoagulants is variable. There are reports of enhanced as well as
diminished effects of anticoagulants when given concurrently with
corticosteroids. Therefore, coagulation indices should be monitored to maintain 
the desired anticoagulant effect.  
 <p>
(See Also PRECAUTIONS) 
 <p>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
FLUID AND ELECTROLYTE DISTURBANCES 
 <p>
Sodium retention 
 <p>
Fluid retention 
 
Congestive heart failure in susceptible patients <p>
 
Potassium loss <p>
 
Hypokalemic alkalosis <p>
 
Hypertension <p>
 
MUSCULOSKELETAL <p>
 
Muscle weakness <p>
 
Steroid myopathy <p>
 
Loss of muscle mass <p>
 
Osteoporosis <p>
 
Vertebral compression fractures <p>
 
Aseptic necrosis of femoral and humeral heads <p>
 
Pathologic fracture of long bones <p>
 
GASTROINTESTINAL <p>
 
Peptic ulcer with possible perforation and hemorrhage <p>
 
Pancreatitis <p>
 
Abdominal distention <p>
 
Ulcerative esophagitis 
 <p>
Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST,
SGOT) and alkaline phosphatase have been observed following corticosteroid
treatment. These changes are usually small, not associated with any clinical
syndrome and are reversible upon discontinuation.  <p>
 
DERMATOLOGIC <p>
 
Impaired wound healing <p>
 
Thin fragile skin <p>
 
Petechiae and ecchymoses <p>
 
Facial erythema <p>
 
Increased sweating <p>
 
May suppress reactions to skin tests <p>
 
METABOLIC <p>
 
Negative nitrogen balance due to protein catabolism <p>
 
NEUROLOGICAL <p>
 
Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually 
after treatment <p>
 
Convulsions 
 <p>
Vertigo 
 <p>
Headache 
 <p>
ENDOCRINE 
 <p>
Menstrual irregularities 
 <p>
Development of Cushingoid state 
 <p>
Secondary adrenocortical and pituitary unresponsiveness, particularly in times
of stress, as in trauma, surgery or illness.  
 <p>
Suppression of growth in children 
 <p>
Decreased carbohydrate tolerance 
 <p>
Manifestations of latent diabetes mellitus 
 <p>
Increased requirements for insulin or oral hypoglycemic agents in diabetics 
 <p>
OPHTHALMIC 
 <p>
Posterior subcapsular cataracts 
 <p>
Increased intraocular pressure 
 <p>
Glaucoma 
 <p>
Exophthalmos 
 <p>
ADDITIONAL REACTIONS 
 <p>
Urticaria and other allergic, anaphylactic or hypersensitivity reactions 
 <p>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
The initial dosage of Prednisone Tablets may vary from 5 mg to 60 mg of
prednisone per day depending on the specific disease entity being treated. In
situations of less severity lower doses will generally suffice while in
selected patients higher initial doses may be required. The initial dosage
should be maintained or adjusted until a satisfactory response is noted. If
after a reasonable period of time there is a lack of satisfactory clinical
response, Prednisone should be discontinued and the patient transferred to other 
appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE
VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT 
AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the
proper maintenance dosage should be determined by decreasing the initial drug
dosage in small decrements at appropriate time intervals until the lowest
dosage which will maintain an adequate clinical response is reached. It should
be kept in mind that constant monitoring is needed in regard to drug dosage.
Included in the situations which may make dosage adjustments necessary are
changes in clinical status secondary to remissions or exacerbations in the
disease process, the patient's individual drug responsiveness, and the effect
of patient exposure to stressful situations not directly related to the disease 
entity under treatment; in this latter situation, it may be necessary to
increase the dosage of Prednisone for a period of time consistent with the
patient's condition. If after long-term therapy the drug is to be stopped, it
is recommended that it be withdrawn gradually rather than abruptly.  
 <p>
MULTIPLE SCLEROSIS 
 <p>
In the treatment of acute exacerbations of multiple sclerosis daily doses of
200 mg of prednisolone for a week followed by 80 mg every other day for 1 month 
have been shown to be effective. (Dosage range is the same for prednisone and
prenisolone).  
 <p>
ADT (ALTERNATE DAY THERAPY) 
 <p>
ADT is a corticosteroid dosing regimen in which twice the usual daily dose of
corticoid is administered every other morning. The purpose of this mode of
therapy is to provide the patient requiring long-term pharmacologic dose
treatment with the beneficial effects of corticoids while minimizing certain
undesirable effects, including pituitary-adrenal suppression, the Cushingoid
state, corticoid withdrawal symptoms, and growth suppression in children.  
 <p>
The rationale for this treatment schedule is based on two major premises: (a)
the anti-inflammatory or therapeutic effect of corticoids persists longer than
their physical presence and metabolic effects and (b) administration of the
corticosteroid every other morning allows for re-establishment of more nearly
normal hypothalamic-pituitary-adrenal (HPA) activity on the off-steroid day.  
 <p>
A brief review of the HPA physiology may be helpful in understanding this
rationale. Acting primarily through the hypothalamus a fall in free cortisol
stimulates the pituitary gland to produce increasing amounts of corticotropin
(ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA
system is characterized by diurnal (circadian) rhythm. Serum levels of ACTH
rise from a low point about 10 pm to a peak level about 6 am. Increasing levels 
of ACTH stimulate adrenocortical activity resulting in a rise in plasma
cortisol with maximal levels occurring between 2 am and 8 am. This rise in
cortisol dampens ACTH production and in turn adrenocortical activity. There is
a gradual fall in plasma corticoids during the day with lowest levels occurring 
about midnight.  
 <p>
The diurnal rhythm of the HPA axis is lost in Cushing's disease, a syndrome of
adrenocortical hyperfunction characterized by obesity with centripetal fat
distribution, thinning of the skin with easy bruisability, muscle wasting with
weakness, hypertension, latent diabetes, osteoporosis, electrolyte imbalance,
etc. The same clinical findings of hyperadrenocorticism may be noted during
long-term pharmacologic dose corticoid therapy administered in conventional
daily divided doses. It would appear, then, that a disturbance in the diurnal
cycle with maintenance of elevated corticoid values during the night may play a 
significant role in the development of undesirable corticoid effects. Escape
from these constantly elevated plasma levels for even short periods of time may 
be instrumental in protecting against undesirable pharmacologic effects.  
 <p>
During conventional pharmacologic dose corticosteroid therapy, ACTH production
is inhibited with subsequent suppression of cortisol production by the adrenal
cortex. Recovery time for normal HPA activity is variable depending upon the
dose and duration of treatment. During this time the patient is vulnerable to
any stressful situation. Although it has been shown that there is considerably
less adrenal suppression following a single morning dose of prednisolone (10
mg) as opposed to a quarter of that dose administered every 6 hours, there is
evidence that some suppressive effect on adrenal activity may be carried over
into the following day when pharmacologic doses are used. Further, it has been
shown that a single dose of certain corticosteroids will produce adrenocortical 
suppression for two or more days. Other corticoids, including
methylprednisolone, hydrocortisone, prednisone, and prednisolone, are
considered to be short acting (producing adrenocortical suppression for 1 1/4
to 1 1/2 days following a single dose) and thus are recommended for alternate
day therapy.  
 <p>
The following should be kept in mind when considering alternate day therapy:  
 <p>
1) Basic principles and indications for corticosteroid therapy should apply.
The benefits of ADT should not encourage the indiscriminate use of steroids.  
<p>
 
2) ADT is a therapeutic technique primarily designed for patients in whom long- 
term pharmacologic corticoid therapy is anticipated.  
 <p>
3) In less severe disease processes in which corticoid therapy is indicated, it 
may be possible to initiate treatment with ADT. More severe disease states
usually will require daily divided high dose therapy for initial control of the 
disease process. The initial suppressive dose level should be continued until
satisfactory clinical response is obtained, usually four to ten days in the
case of many allergic and collagen diseases. It is important to keep the period 
of initial suppressive dose as brief as possible particularly when subsequent
use of alternate day therapy is intended.  
 <p>
Once control has been established, two courses are available: (a) change to ADT 
and then gradually reduce the amount of corticoid given every other day OR (b)
following control of the disease process reduce the daily dose of corticoid to
the lowest effective level as rapidly as possible and then change over to an
alternate day schedule. Theoretically, course (a) may be preferable.  
 <p>
4) Because of the advantages of ADT, it may be desirable to try patients on
this form of therapy who have been on daily corticoids for long periods of time 
(eg, patients with rheumatoid arthritis). Since these patients may already have 
a suppressed HPA axis, establishing them on ADT may be difficult and not always 
successful. However, it is recommended that regular attempts be made to change
them over. It may be helpful to triple or even quadruple the daily maintenance
dose and administer this every other day rather than just doubling the daily
dose if difficulty is encountered. Once the patient is again controlled, an
attempt should be made to reduce this dose to a minimum.  
 <p>
5) As indicated above, certain corticosteroids, because of their prolonged
suppressive effect on adrenal activity, are not recommended for alternate day
therapy (eg, dexamethasone and betamethasone).  
 <p>
6) The maximal activity of the adrenal cortex is between 2 am and 8 am, and it
is minimal between 4 pm and midnight. Exogenous corticosteroids suppress
adrenocortical activity the least, when given at the time of maximal activity
(am).  
 <p>
7) In using ADT it is important, as in all therapeutic situations to
individualize and tailor the therapy to each patient. Complete control of
symptoms will not be possible in all patients. An explanation of the benefits
of ADT will help the patient to understand and tolerate the possible flare-up
in symptoms which may occur in the latter part of the off-steroid day. Other
symptomatic therapy may be added or increased at this time if needed.  
 <p>
8) In the event of an acute flare-up of the disease process, it may be
necessary to return to a full suppressive daily corticoid dose for control.
Once control is again established alternate day therapy may be re-instituted. 
 <p>
9) Although many of the undesirable features of corticosteroid therapy can be
minimized by ADT, as in any therapeutic situation, the physician must carefully 
weigh the benefit-risk ratio for each patient in whom corticoid therapy is
being considered.  <p>
 


<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-23</DOCNO>
<DOCOLDNO>IA018-000200-B044-22</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/opiate.htm 206.86.175.201 19970106232059 text/html 3819
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:14:45 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3637
Last-modified: Sun, 30 Jun 1996 07:23:42 GMT
</DOCHDR>
<html>
<head>
   <title>Rxlist of Indications and Side Effects - Opiate Agonist Drugs
</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Opiate Agonists (Narcotics)</h1>

<center><p align=center>
<hr width="100%" ></p></center>

<h3>The opiate drugs are named after their natural source, the opium poppy.
The opium poppy contains several active chemicals such as morphine, codeine,
and papaverine. Other synthetic opiates' have been produced such as meperidine
and methadone. These drugs are often referred to as narcotics and are classfied
by the DEA according to their potential for abuse. Heroin, which readily
crosses the blood brain barrier, is classified as a C1 drug because of
its high potential for abuse. These drugs bind to opiate receptors' found
throughout the central nervous system which cause the release of endorphins
and encephalins, the bodies natural opiates'. </h3>

<p>
<hr></p>

<h3><a href="disclaim.htm">INDICATIONS</a></h3>

<li>agitation+ </li>

<li>cough </li>

<li>diarrhea+ </li>

<li>headache </li>

<li>migraine+ </li>

<li>myocardial infarction </li>

<li>opiate withdrawal </li>

<li>pain </li>

<li>post-operative shivering+ </li>

<li>pulmonary edema </li>

<li>sedation induction </li>

<li>shaking chills+ </li>

<dl>
<dd>+ = not an FDA approved indication</dd>
</dl>

<p>
<hr><a href="#top">Return to Top</a> 
<hr></p>

<h3><a href="disclaim.htm#side">Side Effects and Adverse Reactions</a></h3>

<li>anorexia </li>

<li>anxiety </li>

<li>asthenia </li>

<li>biliary obstruction </li>

<li>blurred vision </li>

<li>CNS depression </li>

<li>coma </li>

<li>confusion </li>

<li>constipation </li>

<li>depression </li>

<li>diaphoresis </li>

<li>dizziness </li>

<li>drowsiness </li>

<li>dysgeusia </li>

<li>dyspnea </li>

<li>epistaxis </li>

<li>erythema </li>

<li>euphoria </li>

<li>flushing </li>

<li>headache </li>

<li>hypertension </li>

<li>hypotension </li>

<li>insomnia </li>

<li>miosis </li>

<li>nasal congestion </li>

<li>nasal irritation </li>

<li>nausea/vomiting </li>

<li>orthostatic hypotension </li>

<li>palpitations </li>

<li>paresthesias </li>

<li>pharyngitis </li>

<li>physiological dependence </li>

<li>pruritus </li>

<li>respiratory depression </li>

<li>restlessness </li>

<li>rhinitis </li>

<li>sedation </li>

<li>seizures </li>

<li>SIADH </li>

<li>sinus tachycardia </li>

<li>sinus bradycardia </li>

<li>syncope </li>

<li>tinnitus </li>

<li>tremor </li>

<li>urinary retention </li>

<li>vertigo </li>

<li>withdrawal </li>

<li>xerostomia 
<hr width="100%" ><a href="#top">Return to Top</a> 
<hr><font SIZE=+2><a href="http://www.rxlist.com/disclaim.htm">Important
- Please Read!</a> </font></li>

<h3 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h3>

<h4 align=center><a href="http://www.rxlist.com/mono.htm">RxLists of Indications
and Side Effects</a></h4>

<center><p><font SIZE=-2>copyright 1996 Neil Sandow, Pharm.D. - all rights
reserved </font></p></center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-24</DOCNO>
<DOCOLDNO>IA018-000200-B035-116</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/erythro.htm 206.86.175.201 19970106224749 text/html 19190
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:41:34 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 19007
Last-modified: Thu, 11 Jul 1996 06:07:15 GMT
</DOCHDR>
<html>
<head>
   <title>Erythromycin - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Erythromycin</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Erythromycin is produced by a strain of Streptomyces Erythraeus and
belongs to the macrolide group of antibiotics. It is basic and readily
forms salts with acids. The base is white to off-white crystals or powder
slightly soluble in water, soluble in alcohol, in chloroform, and in ether.</p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>The mode of action of erythromycin is inhibition of protein synthesis
without affecting nucleic acid synthesis. Resistance to erythromycin of
some strains of Hemophilus Influenzae and staphylococci has been demonstrated.
Culture and susceptibility testing should be done. If the Kirby-Bauer method
of disc susceptibility is used, a 15 mcg erythromycin disc should give
a zone diameter of at least 18 mm when tested against an erythromycin susceptible
organism. </p>

<p>After absorption, erythromycin diffuses readily into most body fluids.
In the absence of meningeal inflammation, low concentrations are normally
achieved in the spinal fluid but passage of the drug across the blood-brain
barrier increases in meningitis. In the presence of normal hepatic function,
erythromycin is concentrated in the liver and excreted in the bile; the
effect of hepatic dysfunction on excretion of erythromycin by the liver
into the bile is not known. After oral administration, less than 5 percent
of the activity of the administered dose can be recovered in the urine.
</p>

<p>Erythromycin crosses the placental barrier but fetal plasma levels are
low. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Streptococcus Pyogenes (Group A beta hemolytic streptococcus): For upper
and lower respiratory tract, skin, and soft tissue infections of mild to
moderate severity. </p>

<p>Injectable benzathine penicillin G is considered by the American Heart
Association to be the drug of choice in the treatment and prevention of
streptococcal pharyngitis and in long-term prophylaxis of rheumatic fever.
</p>

<p>When oral medication is preferred for treatment of the above conditions,
penicillin G, V, or erythromycin are alternate drugs of choice. </p>

<p>When oral medication is given, the importance of strict adherence by
the patient to the prescribed dosage regimen must be stressed. A therapeutic
dose should be administered for at least 10 days. </p>

<p>Alpha-Hemolytic Streptococci (Viridans Group): Although no controlled
clinical efficacy trials have been conducted, oral erythromycin has been
suggested by the American Heart Association and American Dental Association
for use in a regimen for prophylaxis against bacterial endocarditis in
patients hypersensitive to penicillin who have congenital heart disease,
or rheumatic or other acquired valvular heart disease when they undergo
dental procedures and surgical procedures of the upper respiratory tract.
(REF.1) Erythromycin is not suitable prior to genitourinary or gastrointestinal
tract surgery. NOTE: When selecting antibiotics for the prevention of bacterial
endocarditis the physician or dentist should read the full joint statement
of the American Heart Association and the American Dental Association.
(REF.1) </p>

<p>Staphylococcus Aureus: For acute infections of skin and soft tissue
of mild to moderate severity. Resistant organisms may emerge during treatment.
</p>

<p>Streptococcus Pneumoniae (Diplococcus Pneumoniae): For upper respiratory
tract infections (e.g., otitis media, pharyngitis) and lower respiratory
tract infections (e.g., pneumonia) of mild to moderate degree. </p>

<p>Mycoplasma Pneumoniae (Eaton Agent, PPLO): For respiratory infections
due to this organism. </p>

<p>Hemophilus Influenzae: For upper respiratory tract infections of mild
to moderate severity when used concomitantly with adequate doses of sulfonamides.
Not all strains of this organism are susceptible at the erythromycin concentrations
ordinarily achieved (see appropriate sulfonamide labeling for prescribing
information). </p>

<p>Chlamydia Trachomatis: Erythromycin is indicated for treatment of the
following infections caused by Chlamydia Trachomatis: conjunctivitis of
the newborn, pneumonia of infancy and urogenital infections during pregnancy.
When tetracyclines are contraindicated or not tolerated, erythromycin is
indicated for the treatment of uncomplicated urethral, endocervical, or
rectal infections in adults due to Chlamydia Trachomatis. (REF.2) </p>

<p>Treponema Pallidum: Erythromycin is an alternate choice of treatment
for primary syphilis in patients allergic to the penicillins. In treatment
of primary syphilis, spinal fluid examinations should be done before treatment
and as part of follow-up after therapy. </p>

<p>Corynebacterium Diphtheriae And C. Minutissimum: As an adjunct to antitoxin,
to prevent establishment of carriers, and to eradicate the organism in
carriers. </p>

<p>In the treatment of erythrasma. </p>

<p>Entamoeba Histolytica: In the treatment of intestinal amebiasis only.
Extra enteric amebiasis requires treatment with other agents.</p>

<p>Listeria Monocytogenes: Infections due to this organism. </p>

<p>Neisseria Gonorrhoeae: Erythrocin(R) Lactobionate-I.V. (erythromycin
lactobionate for injection, USP) in conjunction with erythromycin base
orally, as an alternative drug in treatment of acute pelvic inflammatory
disease caused by N. Gonorrhoeae in female patients with a history of sensitivity
to penicillin. Before treatment of gonorrhea, patients who are suspected
of also having syphilis should have a microscopic examination for T. Pallidum
(by immunofluorescence or darkfield) before receiving erythromycin, and
monthly serologic tests for a minimum of 4 months. </p>

<p>Bordetella Pertussis: Erythromycin is effective in eliminating the organism
from the nasopharynx of infected individuals, rendering them non-infectious.
Some clinical studies suggest that erythromycin may be helpful in the prophylaxis
of pertussis in exposed susceptible individuals. </p>

<p>Legionnaires' Disease: Although no controlled clinical efficacy studies
have been conducted, In Vitro and limited preliminary clinical data suggest
that erythromycin can be effective in treating Legionnaires' Disease. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Erythromycin is contraindicated in patients with known hypersensitivity
to this antibiotic. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>There have been reports of hepatic dysfunction with or without jaundice,
occurring in patients receiving oral erythromycin products. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>General: Erythromycin is principally excreted by the liver. Caution
should be exercised when erythromycin is administered to patients with
impaired hepatic function. (See &quot;Actions/Clinical Pharmacology&quot;
and &quot;Warnings&quot; sections). </p>

<p>Prolonged or repeated use of erythromycin may result in an overgrowth
of nonsusceptible bacteria or fungi. If superinfection occurs, erythromycin
should be discontinued and appropriate therapy instituted. </p>

<p>When indicated, incision and drainage or other surgical procedures should
be performed in conjunction with antibiotic therapy. Laboratory Tests:
Erythromycin interferes with the fluorometric determination of urinary
catecholamines. </p>

<p>Drug Interactions: Erythromycin use in patients who are receiving high
doses of theophylline may be associated with an increase in serum theophylline
levels and potential theophylline toxicity. In case of theophylline toxicity
and/or elevated serum theophylline levels, the dose of theophylline should
be reduced while the patient is receiving concomitant erythromycin therapy.
</p>

<p>Concomitant administration of erythromycin and digoxin has been reported
to result in elevated digoxin serum levels. </p>

<p>There have been reports of increased anticoagulant effects when erythromycin
and oral anticoagulants were used concomitantly. </p>

<p>Concurrent use of erythromycin and ergotamine or dihydroergotamine has
been associated in some patients with acute ergot toxicity characterized
by severe peripheral vasospasm and dysesthesia. </p>

<p>Erythromycin has been reported to decrease the clearance of triazolam
and thus may increase the pharmacologic effect of triazolam.</p>

<p>The use of erythromycin in patients concurrently taking drugs metabolized
by the cytochrome P450 system may be associated with elevations in serum
erythromycin with carbamazepine, cyclosporine, hexobarbital and phenytoin.
Serum concentrations of drugs metabolized by the cytochrome P450 system
should be monitored closely in patients concurrently receiving erythromycin.
</p>

<p>Troleandomycin significantly alters the metabolism of terfenadine when
taken concomitantly; therefore, observe caution when erythromycin and terfenadine
are used concurrently. </p>

<p>Patients receiving concomitant lovastatin and erythromycin should be
carefully monitored; cases of rhabdomyolysis have been reported in seriously
ill patients. </p>

<p>Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term (2-year)
oral studies conducted in rats with erythromycin base did not provide evidence
of tumorigenicity. Mutagenicity studies have not been conducted. There
was no apparent effect on male or female fertility in rats fed erythromycin
(base) at levels up to 0.25 percent of diet. </p>

<p>Pregnancy: Pregnancy Category B: There is no evidence of teratogenicity
or any other adverse effect on reproduction in female rats fed erythromycin
base (up to 0.25 percent of diet) prior to and during mating, during gestation,
and through weaning of two successive litters. There are, however, no adequate
and well-controlled studies in pregnant women. Because animal reproduction
studies are not always predictive of human response, this drug should be
used during pregnancy only if clearly needed. Erythromycin has been reported
to cross the placental barrier in humans, but fetal plasma levels are generally
low. </p>

<p>Labor And Delivery: The effect of erythromycin on labor and delivery
is unknown. </p>

<p>Nursing Mothers: Erythromycin is excreted in breast milk, therefore,
caution should be exercised when erythromycin is administered to a nursing
woman. </p>

<p>Pediatric Use: See &quot;Indications and Usage&quot; and &quot;Dosage
and Administration&quot; sections. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Erythromycin use in patients who are receiving high doses of theophylline
may be associated with an increase in serum theophylline levels and potential
theophylline toxicity. In case of theophylline toxicity and/or elevated
serum theophylline levels, the dose of theophylline should be reduced while
the patient is receiving concomitant erythromycin therapy. </p>

<p>Concomitant administration of erythromycin and digoxin has been reported
to result in elevated digoxin serum levels. </p>

<p>There have been reports of increased anticoagulant effects when erythromycin
and oral anticoagulants were used concomitantly. </p>

<p>Concurrent use of erythromycin and ergotamine or dihydroergotamine has
been associated in some patients with acute ergot toxicity characterized
by severe peripheral vasospasm and dysesthesia. </p>

<p>Erythromycin has been reported to decrease the clearance of triazolam
and thus may increase the pharmacologic effect of triazolam. </p>

<p>The use of erythromycin in patients concurrently taking drugs metabolized
by the cytochrome P450 system may be associated with elevations in serum
erythromycin with carbamazepine, cyclosporine, hexobarbital and phenytoin.
Serum concentrations of drugs metabolized by the cytochrome P450 system
should be monitored closely in patients concurrently receiving erythromycin.
</p>

<p>Troleandomycin significantly alters the metabolism of terfenadine when
taken concomitantly; therefore, observe caution when erythromycin and terfenadine
are used concurrently. </p>

<p>Patients receiving concomitant lovastatin and erythromycin should be
carefully monitored; cases of rhabdomyolysis have been reported in seriously
ill patients. </p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The most frequent side effects of oral erythromycin preparations are
gastrointestinal and are dose-related. They include nausea, vomiting, abdominal
pain, diarrhea and anorexia. Symptoms of hepatic dysfunction and/or abnormal
liver function test results may occur (see &quot;Warnings&quot; section).
Pseudomembranous colitis has been rarely reported in association with erythromycin
therapy. </p>

<p>There have been isolated reports of transient central nervous system
side effects including confusion, hallucinations, seizures, and vertigo;
however, a cause and effect relationship has not been established. </p>

<p>Occasional case reports of cardiac arrhythmias such as ventricular tachycardia
have been documented in patients receiving erythromycin therapy. There
have been isolated reports of other cardiovascular symptoms such as chest
pain, dizziness, and palpitations; however, a cause and effect relationship
has not been established. </p>

<p>Allergic reactions ranging from urticaria and mild skin eruptions to
anaphylaxis have occurred. </p>

<p>There have been isolated reports of reversible hearing loss occurring
chiefly in patients with renal insufficiency and in patients receiving
high doses of erythromycin. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>In case of overdosage, erythromycin should be discontinued. Overdosage
should be handled with the prompt elimination of unabsorbed drug and all
other appropriate measures. </p>

<p>Erythromycin is not removed by peritoneal dialysis or hemodialysis.
</p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Adults: The usual dose is 250 mg four times daily in equally spaced
doses. The 333 mg tablet is recommended if dosage is desired every 8 hours.
If twice-a-day dosage is desired, the recommended dose is 500 mg every
12 hours. </p>

<p>Dosage may be increased up to 4 or more grams per day according to the
severity of the infection. Twice-a-day dosing is not recommended when doses
larger than 1 gram daily are administered. </p>

<p>Children: Age, weight, and severity of the infection are important factors
in determining the proper dosage. 30 to 50 mg/kg/day, in divided doses,
is the usual dose. For more severe infections, this dose may be doubled.
</p>

<p>In the treatment of streptococcal infections, a therapeutic dosage of
erythromycin should be administered for at least 10 days. In continuous
prophylaxis of streptococcal infections in persons with a history of rheumatic
heart disease, the dose is 250 mg twice a day. </p>

<p>For prophylaxis against bacterial endocarditis (REF.1) in patients with
congenital heart disease, or rheumatic or other acquired valvular heart
disease when undergoing dental procedures or surgical procedures of the
upper respiratory tract, give 1 g (20 mg/kg for children) orally 1 1/2
to 2 hours before the procedure, and then, 500 mg (10 mg/kg in children)
orally every 6 hours for 8 doses. </p>

<p>For conjunctivitis of the newborn caused by Chlamydia Trachomatis: Oral
erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 2
weeks. (REF.2) </p>

<p>For pneumonia of infancy caused by Chlamydia Trachomatis: Although the
optimal duration of therapy has not been established, the recommended therapy
is oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at
least 3 weeks. (REF.2) </p>

<p>For urogenital infections during pregnancy due to Chlamydia trachomatis:
Although the optimal dose and duration of therapy have not been established,
the suggested treatment is erythromycin 500 mg, by mouth, 4 times a day
for at least 7 days. For women who cannot tolerate this regimen, a decreased
dose of 250 mg, by mouth, 4 times a day should be used for at least 14
days. (REF.2) </p>

<p>For adults with uncomplicated urethral, endocervical, or rectal infections
caused by Chlamydia Trachomatis in whom tetracyclines are contraindicated
or not tolerated: 500 mg, by mouth, 4 times a day for at least 7 days.
(REF.2) </p>

<p>For treatment of primary syphilis: 30 to 40 grams given in divided doses
over a period of 10 to 15 days. </p>

<p>For treatment of acute pelvic inflammatory disease caused by N. Gonorrhoeae:
After initial treatment withmerythromycin lactobionate I.V. 500 mg every
6 hours for 3 days, the oral dosage recommendation is 250 mg every 6 hours
for 7 days. </p>

<p>For dysenteric amebiasis: 250 mg four times daily for 10 to 14 days,
for adults; 30 to 50 mg/kg/day in divided doses for 10 to 14 days, for
children. </p>

<p>For use in pertussis: Although optimal dosage and duration have not
been established, doses of erythromycin utilized in reported clinical studies
were 40 to 50 mg/kg/day, given in divided doses for 5 to 14 days. </p>

<p>For treatment of Legionnaires' Disease: Although optimal doses have
not been established, doses utilized in reported clinical data were 1 to
4 grams erythromycin base daily in divided doses. </p>

<p>REFERENCES </p>

<p>1. American Heart Association, 1977. Prevention of bacterial endocarditis,
Circulation 56: 139A-143A. </p>

<p>2. CDC Sexually Transmitted Diseases Treatment Guidelines 1982. </p>

<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-25</DOCNO>
<DOCOLDNO>IA018-000200-B035-36</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/clonaz.htm 206.86.175.201 19970106224601 text/html 15058
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:39:46 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 14875
Last-modified: Sun, 11 Aug 1996 03:43:31 GMT
</DOCHDR>
<html>
<head>
   <title>Clonazepam - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Clonazepam</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION 

</b> <p>

Chemically, clonazepam is 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-

benzodiazepin-2-one. It is a light yellow crystalline powder. It has a

molecular weight of 315.7.  

 <p>

<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 

</b> <p>

In laboratory animals, Clonazepam exhibits several pharmacologic properties which 

are characteristic of the benzodiazepine class of drugs. Convulsions produced

in rodents by pentylenetetrazol or electrical stimulation are antagonized, as

are convulsions produced by photic stimulation in susceptible baboons. A taming 

effect in aggressive primates, muscle weakness and hypnosis are likewise

produced by Clonazepam. In humans it is capable of suppressing the spike and wave 

discharge in absence seizures (petit mal) and decreasing the frequency,

amplitude, duration and spread of discharge in minor motor seizures.  

 <p>

Single oral dose administration of Clonazepam to humans gave maximum blood levels 

of drug, in most cases, within one to two hours. The half-life of the parent

compound varied from approximately 18 to 50 hours, and the major route of

excretion was in the urine. In humans, five metabolites have been identified.

In general, the biotransformation of clonazepam followed two pathways:

oxidative hydroxylation at the C-3 position and reduction of the 7-nitro

function to form 7-amino and/or 7-acetyl-amino derivatives.  

 <p>

<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 

</b> <p>

Clonazepam is useful alone or as an adjunct in the treatment of the Lennox

Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In

patients with absence seizures (petit mal) who have failed to respond to

succinimides, Clonazepam may be useful.  

 <p>

In some studies, up to 30% of patients have shown a loss of anticonvulsant

activity, often within three months of administration. In some cases, dosage

adjustment may reestablish efficacy.  

 
<p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 

</b> <p>

Clonazepam should not be used in patients with a history of sensitivity to

benzodiazepines, nor in patients with clinical or biochemical evidence of

significant liver disease. It may be used in patients with open angle glaucoma

who are receiving appropriate therapy, but is contraindicated in acute narrow

angle glaucoma.  

<p>

<a name="WARNINGS"></a><b>WARNINGS 

</b> <p>

Since Clonazepam produces CNS depression, patients receiving this drug should be

cautioned against engaging in hazardous occupations requiring mental alertness, 

such as operating machinery or driving a motor vehicle. They should also be

warned about the concomitant use of alcohol or other CNS-depressant drugs

during Clonazepam therapy (see Drug Interactions).  

 <p>

Usage In Pregnancy: The effects of Clonazepam in human pregnancy and nursing

infants are unknown.  

 
<p>
Recent reports suggest an association between the use of anticonvulsant drugs

by women with epilepsy and an elevated incidence of birth defects in children

born to these women. Data are more extensive with respect to diphenylhydantoin

and phenobarbital, but these are also the most commonly prescribed

anticonvulsants; less systematic or anecdotal reports suggest a possible

similar association with the use of all known anticonvulsant drugs.  

 <p>

The reports suggesting an elevated incidence of birth defects in children of

drug-treated epileptic women cannot be regarded as adequate to prove a definite 

cause and effect relationship. There are intrinsic methodologic problems in

obtaining adequate data on drug teratogenicity in humans; the possibility also

exists that other factors, e.g., genetic factors or the epileptic condition

itself, may be more important than drug therapy in leading to birth defects.

The great majority of mothers on anticonvulsant medication deliver normal

infants.  It is important to note that anticonvulsant drugs should not be

discontinued in patients in whom the drug is administered to prevent seizures

because of the strong possibility of precipitating status epilepticus with

attendant hypoxia and threat to life. In individual cases where the severity

and frequency of the seizure disorder are such that the removal of medication

does not pose a serious threat to the patient, discontinuation of the drug may

be considered prior to and during pregnancy, although it cannot be said with

any confidence that even mild seizures do not pose some hazards to the

developing embryo or fetus.  
<p>
 

These considerations should be weighed in treating or counseling epileptic

women of childbearing potential.  
<p>
 

Use of Clonazepam in women of childbearing potential should be considered only

when the clinical situation warrants the risk. Mothers receiving Clonazepam

should not breast feed their infants.  

 <p>

In a two-generation reproduction study with Clonazepam given orally to rats at 10 

or 100 mg/kg/day, there was a decrease in the number of pregnancies and a

decrease in the number of offspring surviving until weaning. When Clonazepam was

administered orally to pregnant rabbits at 0.2, 1.0, 5.0 or 10.0 mg/kg/day, a

nondose-related incidence of cleft palates, open eyelids, fused sternebrae and

limb defects was observed at the 0.2 and 5.0 mg/kg/day levels. Nearly all of

the malformations were seen from one dam in each of the affected dosages.  



Usage In Children: Because of the possibility that adverse effects on physical

or mental development could become apparent only after many years, a benefit

risk consideration of the long-term use of Clonazepam is important in pediatric

patients.  

<p> 

Withdrawal symptoms of the barbiturate type have occurred after the

discontinuation of benzodiazepines. (See DRUG ABUSE AND DEPENDENCE section.) 

 <p>

<a name="PRECAUTIONS"></a><b>PRECAUTIONS 

</b> <p>

When used in patients in whom several different types of seizure disorders

coexist, Clonazepam may increase the incidence or precipitate the onset of

generalized tonic-clonic seizures (grand mal). This may require the addition of 

appropriate anticonvulsants or an increase in their dosages. The concomitant

use of valproic acid and clonazepam may produce absence status.  

 <p>

Periodic blood counts and liver function tests are advisable during long-term

therapy with Clonazepam.  

 <p>

The abrupt withdrawal of Clonazepam, particularly in those patients on long-term, 

high-dose therapy, may precipitate status epilepticus. Therefore, when

discontinuing Clonazepam, gradual withdrawal is essential. While Clonazepam is

being gradually withdrawn, the simultaneous substitution of another

anticonvulsant may be indicated. Metabolites of Clonazepam are excreted by the

kidneys; to avoid their excess accumulation, caution should be exercised in the 

administration of the drug to patients with impaired renal function.  
<p>
 

Clonazepam may produce an increase in salivation. This should be considered

before giving the drug to patients who have difficulty handling secretions.

Because of this and the possibility of respiratory depression, Clonazepam should

be used with caution in patients with chronic respiratory diseases.  

 <p>

Information For Patients: To assure the safe and effective use of

benzodiazepines, patients should be informed that, since benzodiazepines may

produce psychological and physical dependence, it is advisable that they

consult with their physician before either increasing the dose or abruptly

discontinuing this drug.  

 <p>

<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 

</b> <p>

The CNS-depressant action of the benzodiazepine class of drugs may be

potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics,

antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes

of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic

antidepressants, and by other anticonvulsant drugs.  

 <p>

<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 

</b> 
<p>
The most frequently occurring side effects of Clonazepam are referable to CNS

depression. Experience to date has shown that drowsiness has occurred in

approximately 50% of patients and ataxia in approximately 30%. In some cases,

these may diminish with time; behavior problems have been noted in

approximately 25% of patients. Others, listed by system, are:  

 <p>

Neurologic: Abnormal eye movements, aphonia, choreiform movements, coma,

diplopia, dysarthria, dysdiadochokinesis, &quot;glassy-eyed&quot; appearance, headache,

hemiparesis, hypotonia, nystagmus, respiratory depression, slurred speech,

tremor, vertigo.  <p>

 

Psychiatric: Confusion, depression, amnesia, hallucinations, hysteria,

increased libido, insomnia, psychosis, suicidal attempt (the behavior effects

are more likely to occur in patients with a history of psychiatric

disturbances).  
<p>
 

Respiratory: Chest congestion, rhinorrhea, shortness of breath, hypersecretion

in upper respiratory passages.  

 <p>

Cardiovascular: Palpitations.  
<p>
 

Dermatologic: Hair loss, hirsutism, skin rash, ankle and facial edema.  <p>

 

Gastrointestinal: Anorexia, coated tongue, constipation, diarrhea, dry mouth,

encopresis, gastritis, hepatomegaly, increased appetite, nausea, sore gums.  

 
<p>
Genitourinary: Dysuria, enuresis, nocturia, urinary retention.  

 <p>

Musculoskeletal: Muscle weakness, pains.  
<p>
 

Miscellaneous: Dehydration, general deterioration, fever, lymphadenopathy,

weight loss or gain.  
<p>
 

Hematopoietic: Anemia, leukopenia, thrombocytopenia, eosinophilia.  

 <p>

Hepatic: Transient elevations of serum transaminases and alkaline phosphatase.  

 <p>

DRUG ABUSE AND DEPENDENCE 

 <p>

Withdrawal symptoms, similar in character to those noted with barbiturates and

alcohol (e.g., convulsions, psychosis, hallucinations, behavioral disorder,

tremor, abdominal and muscle cramps) have occurred following abrupt

discontinuance of clonazepam. The more severe withdrawal symptoms have usually

been limited to those patients who received excessive doses over an extended

period of time. Generally milder withdrawal symptoms (e.g., dysphoria and

insomnia) have been reported following abrupt discontinuance of benzodiazepines 

taken continuously at therapeutic levels for several months. Consequently,

after extended therapy, abrupt discontinuation should generally be avoided and

a gradual dosage tapering schedule followed. Addiction-prone individuals (such

as drug addicts or alcoholics) should be under careful surveillance when

receiving clonazepam or other psychotropic agents because of the predisposition 

of such patients to habituation and dependence.  

 <p>

<a name="OVERDOSAGE"></a><b>OVERDOSAGE 



</b><p>Symptoms of Clonazepam overdosage, like those produced by other CNS depressants,

include somnolence, confusion, coma and diminished reflexes. Treatment includes 

monitoring of respiration, pulse and blood pressure, general supportive

measures and immediate gastric lavage. Intravenous fluids should be

administered and an adequate airway maintained. Hypotension may be combated by

the use of levarterenol or metaraminol. Methylphenidate or caffeine and sodium

benzoate may be given to combat CNS depression. Dialysis is of no known value.  

 <p>

<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 

</b> <p>

Infants And Children: Clonazepam is administered orally. In order to minimize

drowsiness, the initial dose for infants and children (up to 10 years of age or 

30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day but not to

exceed 0.05 mg/kg/day given in two or three divided doses. Dosage should be

increased by no more than 0.25 to 0.5 mg every third day until a daily

maintenance dose of 0.1 to 0.2 mg/kg of body weight has been reached unless

seizures are controlled or side effects preclude further increase. Whenever

possible, the daily dose should be divided into three equal doses. If doses are 

not equally divided, the largest dose should be given before retiring.  

 
<p>
Adults: The initial dose for adults should not exceed 1.5 mg/day divided into

three doses. Dosage may be increased in increments of 0.5 to 1 mg every three

days until seizures are adequately controlled or until side effects preclude

any further increase. Maintenance dosage must be individualized for each

patient depending upon response. Maximum recommended daily dose is 20 mg.  

 <p>

The use of multiple anticonvulsants may result in an increase of depressant

adverse effects. This should be considered before adding Clonazepam to an

existing anticonvulsant regimen.  

<p>
<hr width="100%" ></p>

<ul>
<ul>
<h3 align=center><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h3>
</ul>
</ul>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-26</DOCNO>
<DOCOLDNO>IA018-000200-B034-161</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/brand/provera.htm 206.86.175.201 19970106224309 text/html 18635
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:36:51 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 18452
Last-modified: Fri, 20 Sep 1996 20:55:48 GMT
</DOCHDR>
<html>
<head>
   <title>Provera - RxList Product Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<h1><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif"
border=0 height=50
width=50></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provera 
&reg; </h1>
<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [drug-drug]
[<a href="#ADVERSE REACTIONS">side effects</a>] [toxicity] [<a href="#DOSAGE AND ADMINISTRATION">dosing</a>]
</font></p>

<p>PROVERA brand of medroxyprogesterone acetate tablets, USP </p>

<p>WARNING </p>

<p>THE USE OF PROVERA (MEDROXYPROGESTERONE ACETATE) DURING THE FIRST FOUR
MONTHS OF PREGNANCY IS NOT RECOMMENDED.</p>

<p>Progestational agents have been used beginning with the first trimester
of pregnancy in an attempt to prevent habitual abortion. There is no adequate
evidence that such use is effective when such drugs are given during the
first four months of pregnancy. Furthermore, in the vast majority of women,
the cause of abortion is a defective ovum, which progestational agents
could not be expected to influence. In addition, the use of progestational
agents, with their uterine-relaxant properties, in patients with fertilized
defective ova may cause a delay in spontaneous abortion. Therefore, the
use of such drugs during the first four months of pregnancy is not recommended.</p>

<p>Several reports suggest an association between intrauterine exposure
to progestational drugs in the first trimester of pregnancy and genital
abnormalities in male and female fetuses. The risk of hypospadias, 5 to
8 per 1,000 male births in the general population, may be approximately
doubled with exposure to these drugs. There are insufficient data to quantify
the risk to exposed female fetuses, but insofar as some of these drugs
induce mild virilization of the external genitalia of the female fetus,
and because of the increased association of hypospadias in the male fetus,
it is prudent to avoid the use of these drugs during the first trimester
of pregnancy.</p>

<p>If the patient is exposed to PROVERA Tablets (medroxyprogesterone acetate)
during the first four months of pregnancy or if she becomes pregnant while
taking this drug, she should be apprised of the potential risks to the
fetus.</p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>PROVERA Tablets contain medroxyprogesterone acetate, which is a derivative
of progesterone. It is a white to off-white, odorless crystalline powder,
stable in air, melting between 200 and 210 C. It is freely soluble in
chloroform, soluble in acetone and in dioxane, sparingly soluble in alcohol
and in methanol, slightly soluble in ether, and insoluble in water.</p>

<p>The chemical name for medroxyprogesterone acetate is Pregn-4-ene-3,20-dione,
17-(acetyloxy)-6-methyl-, (6a)-. The structural formula is:</p>

<center><p><img src="http://www.rxlist.com/cgi/brand/image/provera.gif"
border=0 height=200 width=200></p></center>

<p>Each PROVERA tablet for oral administration contains 2.5 mg, 5 mg or
10 mg of medroxy-progesterone acetate. Inactive ingredients: calcium stearate,
corn starch, lactose, mineral oil, sorbic acid, sucrose, talc. The 2.5
mg tablet contains FD&amp;C Yellow no. 6.</p>

<p><a name="ACTIONS"></a><b>ACTIONS </b></p>

<p>Medroxyprogesterone acetate, administered orally or parenterally in
the recommended doses to women with adequate endogenous estrogen, transforms
proliferative into secretory endometrium. Androgenic and anabolic effects
have been noted, but the drug is apparently devoid of significant estrogenic
activity. While parenterally administered medroxyprogesterone acetate inhibits
gonadotropin production, which in turn prevents follicular maturation and
ovulation, available data indicate that this does not occur when the usually
recommended oral dosage is given as single daily doses.</p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Secondary amenorrhea; abnormal uterine bleeding due to hormonal imbalance
in the absence of organic pathology, such as fibroids or uterine cancer.</p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>1.Thrombophlebitis, thromboembolic disorders, cerebral apoplexy or patients
with a past history of these conditions.</p>

<p>2.Liver dysfunction or disease.</p>

<p>3.Known or suspected malignancy of breast or genital organs.</p>

<p>4.Undiagnosed vaginal bleeding.</p>

<p>5.Missed abortion.</p>

<p>6.As a diagnostic test for pregnancy.</p>

<p>7.Known sensitivity to PROVERA Tablets.</p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>1.The physician should be alert to the earliest manifestations of thrombotic
disorders (thrombophlebitis, cerebrovascular disorders, pulmonary embolism,
and retinal thrombosis). Should any of these occur or be suspected, the
drug should be discontinued immediately.</p>

<p>2.Beagle dogs treated with medroxyprogesterone acetate developed mammary
nodules some of which were malignant. Although nodules occasionally appeared
in control animals, they were intermittent in nature, whereas the nodules
in the drug-treated animals were larger, more numerous, persistent, and
there were some breast malignancies with metastases. Their significance
with respect to humans has not been established.</p>

<p>3.Discontinue medication pending examination if there is sudden partial
or complete loss of vision, or if there is a sudden onset of proptosis,
diplopia or migraine. If examination reveals papilledema or retinal vascular
lesions, medication should be withdrawn.</p>

<p>4.Detectable amounts of progestin have been identified in the milk of
mothers receiving the drug. The effect of this on the nursing infant has
not been determined.</p>

<p>5.Usage in pregnancy is not recommended (See WARNING Box).</p>

<p>6.Retrospective studies of morbidity and mortality in Great Britain
and studies of morbidity in the United States have shown a statistically
significant association between thrombophlebitis, pulmonary embolism, and
cerebral thrombosis and embolism and the use of oral contraceptives.1-4
The estimate of the relative risk of thromboembolism in the study by Vessey
and Doll3 was about sevenfold, while Sartwell and associates4 in the United
States found a relative risk of 4.4, meaning that the users are several
times as likely to undergo thromboembolic disease without evident cause
as nonusers. The American study also indicated that the risk did not persist
after discontinuation of administration, and that it was not enhanced by
long continued administration. The American study was not designed to evaluate
a difference between products.</p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>1. The pretreatment physical examination should include special reference
to breast and pelvic organs, as well as Papanicolaou smear.</p>

<p>2. Because progestogens may cause some degree of fluid retention, conditions
which might be influenced by this factor, such as epilepsy, migraine, asthma,
cardiac or renal dysfunction, require careful observation.</p>

<p>3. In cases of breakthrough bleeding, as in all cases of irregular bleeding
per vaginum, nonfunctional causes should be borne in mind. In cases of
undiagnosed vaginal bleeding, adequate diagnostic measures are indicated.</p>

<p>4. Patients who have a history of psychic depression should be carefully
observed and the drug discontinued if the depression recurs to a serious
degree.</p>

<p>5. Any possible influence of prolonged progestin therapy on pituitary,
ovarian, adrenal, hepatic or uterine functions awaits further study.</p>

<p>6. A decrease in glucose tolerance has been observed in a small percentage
of patients on estrogen-progestin combination drugs. The mechanism of this
decrease is obscure. For this reason, diabetic patients should be carefully
observed while receiving progestin therapy.</p>

<p>7. The age of the patient constitutes no absolute limiting factor although
treatment with progestins may mask the onset of the climacteric.</p>

<p>8. The pathologist should be advised of progestin therapy when relevant
specimens are submitted.</p>

<p>9. Because of the occasional occurrence of thrombotic disorders, (thrombophlebitis,
pulmonary embolism, retinal thrombosis, and cerebrovascular disorders)
in patients taking estrogen-progestin combinations and since the mechanism
is obscure, the physician should be alert to the earliest manifestation
of these disorders.</p>

<p>10. Studies of the addition of a progestin product to an estrogen replacement
regimen for seven or more days of a cycle of estrogen administration have
reported a lowered incidence of endometrial hyperplasia. Morphological
and biochemical studies of endometrium suggest that 10-13 days of a progestin
are needed to provide maximal maturation of the endometrium and to eliminate
any hyperplastic changes. Whether this will provide protection from endometrial
carcinoma has not been clearly established. There are possible additional
risks which may be associated with the inclusion of progestin in estrogen
replacement regimen. The potential risks include adverse effects on carbohydrate
and lipid metabolism. The dosage used may be important in minimizing these
adverse effects.</p>

<p>11. Aminoglutethimide administered concomitantly with PROVERA may significantly
depress the bioavailability of PROVERA.</p>

<p>Carcinogenesis, Mutagenesis, Impairment of Fertility.</p>

<p>Long-term intramuscular administration of PROVERA has been shown to
produce mammary tumors in beagle dogs (see WARNINGS). There was no evidence
of a carcinogenic effect associated with the oral administration of PROVERA
to rats and mice. Medroxyprogesterone acetate was not mutagenic in a battery
of in vitro or in vivo genetic toxicity assays.</p>

<p>Medroxyprogesterone acetate at high doses is an antifertility drug and
high doses would be expected to impair fertility until the cessation of
treatment.</p>

<p>Information for the Patient </p>

<p>See Patient Information at end of insert.</p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Pregnancy-(See WARNING Box for possible adverse effects on the fetus).</p>

<p>Breast-Breast tenderness or galactorrhea has been reported rarely. Skin-Sensitivity
reactions consisting of urticaria, pruritus, edema and generalized rash
have occurred in an occasional patient. Acne, alopecia and hirsutism have
been reported in a few cases.</p>

<p>Thromboembolic Phenomena-Thromboembolic phenomena including thrombophlebitis
and pulmonary embolism have been reported.</p>

<p>The following adverse reactions have been observed in women taking progestins
including PROVERA Tablets: breakthrough bleeding, spotting, change in menstrual
flow, amenorrhea, edema, change in weight (increase or decrease), changes
in cervical erosion and cervical secretions, cholestatic jaundice, anaphylactoid
reactions and anaphylaxis, rash (allergic) with and without pruritus, mental
depression, pyrexia, insomnia, nausea, somnolence.</p>

<p>A statistically significant association has been demonstrated between
use of estrogen-progestin combination drugs and the following serious adverse
reactions: thrombophlebitis; pulmonary embolism and cerebral thrombosis
and embolism. For this reason patients on progestin therapy should be carefully
observed.</p>

<p>Although available evidence is suggestive of an association, such a
relationship has been neither confirmed nor refuted for the following serious
adverse reactions: neuro-ocular lesions, eg, retinal thrombosis and optic
neuritis. </p>

<p>The following adverse reactions have been observed in patients receiving
estrogen-progestin combination drugs: rise in blood pressure in susceptible
individuals, fatigue, backache, hirsutism, premenstrual-like syndrome,
loss of scalp hair, erythema multiforme, changes in libido, erythema nodosum,
changes in appetite, hemorrhagic eruption, cystitis-like syndrome, headache,
itching, nervousness, dizziness.</p>

<p>In view of these observations, patients on progestin therapy should
be carefully observed.</p>

<p>The following laboratory results may be altered by the use of estrogen-progestin
combination drugs: Increased sulfobromophthalein retention and other hepatic
function tests. Coagulation tests: increase in prothrombin factors VII,
VIII, IX and X. Metyrapone test. Pregnanediol determination. Thyroid function:
increase in PBI, and butanol extractable protein bound iodine and decrease
in T3 uptake values.</p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Secondary Amenorrhea-PROVERA Tablets may be given in dosages of 5 to
10 mg daily for from 5 to 10 days. A dose for inducing an optimum secretory
transformation of an endometrium that has been adequately primed with either
endogenous or exogenous estrogen is 10 mg of PROVERA daily for 10 days.
In cases of secondary amenorrhea, therapy may be started at any time. Progestin
withdrawal bleeding usually occurs within three to seven days after discontinuing
PROVERA therapy.</p>

<p>Abnormal Uterine Bleeding Due to Hormonal Imbalance in the Absence of
Organic Pathology-Beginning on the calculated 16th or 21st day of the menstrual
cycle, 5 to 10 mg of medroxyprogesterone acetate may be given daily for
from 5 to 10 days. To produce an optimum secretory transformation of an
endometrium that has been adequately primed with either endogenous or exogenous
estrogen, 10 mg of medroxyprogesterone acetate daily for 10 days beginning
on the 16th day of the cycle is suggested. Progestin withdrawal bleeding
usually occurs within three to seven days after discontinuing therapy with
PROVERA. Patients with a past history of recurrent episodes of abnormal
uterine bleeding may benefit from planned menstrual cycling with PROVERA.</p>

<p>HOW SUPPLIED </p>

<p>PROVERA Tablets are available in the following strengths and package
sizes:</p>

<p>2.5 mg (scored, round, orange)</p>

<p>Bottles of 30 NDC 0009-0064-06 </p>

<p>Bottles of 100 NDC 0009-0064-04 </p>

<p>5 mg (scored, hexagonal, white)</p>

<p>Bottles of 30 NDC 0009-0286-32 </p>

<p>Bottles of 100 NDC 0009-0286-03 </p>

<p>10 mg (scored, round, white)</p>

<p>Bottles of 30 NDC 0009-0050-09 </p>

<p>Bottles of 100 NDC 0009-0050-02 </p>

<p>Bottles of 500 NDC 0009-0050-11 </p>

<p>DOSEPAK-3 Unit of Use (10) NDC 0009-0050-12 </p>

<p>Store at controlled room temperature 15-30 C (59-86 F).</p>

<p>REFERENCES </p>

<p>1.Royal College of General Practitioners: Oral contraception and thromboembolic
disease. J Coll Gen Pract 13:267-279, 1967.</p>

<p>2.Inman WHW, Vessey MP: Investigation of deaths from pulmonary, coronary,
and cerebral thrombosis and embolism in women of child- bearing age. Br
Med J 2:193-199, 1968.</p>

<p>3.Vessey MP, Doll R: Investigation of relation between use of oral contraceptives
and thromboembolic disease. A further report. Br Med J 2:651-657, 1969.</p>

<p>4.Sartwell PE, Masi AT, Arthes FG, et al: Thromboembolism and oral contraceptives:
An epidemiological case-control study. Am J Epidemiol 90:365-380, 1969.</p>

<p>The text of the patient insert for progesterone and progesterone-like
drugs is set forth below.</p>

<p>PATIENT INFORMATION </p>

<p>PROVERA Tablets contain medroxyprogesterone acetate a progesterone.
The information below is that which the U.S. Food and Drug Administration
requires be provided for all patients taking progesterones. The information
below relates only to the risk to the unborn child associated with use
of progesterone during pregnancy. For further information on the use, side
effects and other risks associated with this product, ask your doctor.</p>

<p>WARNING FOR WOMEN </p>

<p>Progesterone or progesterone-like drugs have been used to prevent miscarriage
in the first few months of pregnancy. No adequate evidence is available
to show that they are effective for this purpose. Furthermore, most cases
of early miscarriage are due to causes which could not be helped by these
drugs.</p>

<p>There is an increased risk of minor birth defects in children whose
mothers take this drug during the first 4 months of pregnancy. Several
reports suggest an association between mothers who take these drugs in
the first trimester of pregnancy and genital abnormalities in male and
female babies. The risk to the male baby is the possibility of being born
with a condition in which the opening of the penis is on the underside
rather than the tip of the penis (hypospadias). Hypospadias occurs in about
5 to 8 per 1,000 male births and is about doubled with exposure to these
drugs. There is not enough information to quantify the risk to exposed
female fetuses, but enlargement of the clitoris and fusion of the labia
may occur, although rarely.</p>

<p>Therefore, since drugs of this type may induce mild masculinization
of the external genitalia of the female fetus, as well as hypospadias in
the male fetus, it is wise to avoid using the drug during the first trimester
of pregnancy.</p>

<p>These drugs have been used as a test for pregnancy but such use is no
longer considered safe because of possible damage to a developing baby.
Also, more rapid methods for testing for pregnancy are now available.</p>

<p>If you take PROVERA and later find you were pregnant when you took it,
be sure to discuss this with your doctor as soon as possible.</p>

<p>Caution: Federal law prohibits dispensing without prescription.</p>

<p>The Upjohn Company </p>

<p>Kalamazoo, MI 49001, USA </p>

<p>Revised January 1992 812 584 409 </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-27</DOCNO>
<DOCOLDNO>IA018-000200-B033-274</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/lisinop.htm 206.86.175.201 19970106224009 text/html 55190
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:33:49 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 55007
Last-modified: Sun, 11 Aug 1996 03:45:16 GMT
</DOCHDR>
<html>
<head>
   <title>Lisinopril - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Lisinopril</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <p>
 
USE IN PREGNANCY 
 <p>
WHEN USED IN PREGNANCY DURING THE SECOND AND THIRD TRIMESTERS, ACE INHIBITORS
CAN CAUSE INJURY AND EVEN DEATH TO THE DEVELOPING FETUS. When pregnancy is
detected, lisinopril should be discontinued as soon as possible. See WARNINGS,
Fetal/Neonatal Morbidity and Mortality.  
 <p>
Lisinopril, a synthetic peptide derivative, is an oral long-acting 
angiotensin converting enzyme inhibitor. Lisinopril is chemically described as
(S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline dihydrate. Its
empirical formula is C21H31N3O5.2H2O 
 <p>
Lisinopril is a white to off-white, crystalline powder, with a molecular weight 
of 441.53. It is soluble in water and sparingly soluble in methanol and
practically insoluble in ethanol.  
 
<p>
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 
</b> <p>
MECHANISM OF ACTION:  Lisinopril inhibits angiotensin converting enzyme (ACE)
in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the 
conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. 
Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The 
beneficial effects of lisinopril in hypertension and heart failure appear to
result primarily from suppression of the renin-angiotensin-aldosterone system.  
Inhibition of ACE results in decreased plasma angiotensin II which leads to
decreased vasopressor activity and to decreased aldosterone secretion. The
latter decrease may result in a small increase of serum potassium. In
hypertensive patients with normal renal function treated with Lisinopril alone for 
up to 24 weeks, the mean increase in serum potassium was approximately 0.1
mEq/L; however, approximately 15% of patients had increases greater than 0.5
mEq/L and approximately 6% had a decrease greater than 0.5 mEq/L. In the same
study, patients treated with Lisinopril and hydrochlorothiazide for up to 24 weeks 
had a mean decrease in serum potassium of 0.1 mEq/L; approximately 4% of
patients had increases greater than 0.5 mEq/L and approximately 12% had a
decrease greater than 0.5 mEq/L. (See PRECAUTIONS.) Removal of angiotensin II
negative feedback on renin secretion leads to increased plasma renin activity.  
 <p>
ACE is identical to kininase, an enzyme that degrades bradykinin. Whether
increased levels of bradykinin, a potent vasodepressor peptide, play a role in
the therapeutic effects of Lisinopril remains to be elucidated.  
<p>
While the mechanism through which Lisinopril lowers blood pressure is believed to
be primarily suppression of the renin-angiotensin-aldosterone system, Lisinopril
is antihypertensive even in patients with low-renin hypertension. Although
Lisinopril was antihypertensive in all races studied, black hypertensive patients
(usually a low-renin hypertensive population) had a smaller average response to 
monotherapy than nonblack patients.  
 <p>
Concomitant administration of Lisinopril and hydrochlorothiazide further reduced
blood pressure in black and nonblack patients and any racial differences in
blood pressure response were no longer evident.  
 <p>
PHARMACOKINETICS AND METABOLISM:  Following oral administration of Lisinopril,
peak serum concentrations of lisinopril occur within about 7 hours. Declining
serum concentrations exhibit a prolonged terminal phase which does not
contribute to drug accumulation. This terminal phase probably represents
saturable binding to ACE and is not proportional to dose.  
 <p>
Lisinopril does not appear to be bound to other serum proteins. Lisinopril does 
not undergo metabolism and is excreted unchanged entirely in the urine. Based
on urinary recovery, the mean extent of absorption of lisinopril is
approximately 25%, with large intersubject variability (6%-60%) at all doses
tested (5-80 mg).  Lisinopril absorption is not influenced by the presence of
food in the gastrointestinal tract. The absolute bioavailability of lisinopril
is reduced to 16% in patients with stable NYHA Class II-IV congestive heart
failure, and the volume of distribution appears to be slightly smaller than
that in normal subjects.  
 <p>
Upon multiple dosing, lisinopril exhibits an effective half-life of
accumulation of 12 hours.  
 <p>
Impaired renal function decreases elimination of lisinopril, which is excreted
principally through the kidneys, but this decrease becomes clinically important 
only when the glomerular filtration rate is below 30 mL/min. Above this
glomerular filtration rate, the elimination half-life is little changed. With
greater impairment, however, peak and trough lisinopril levels increase, time
to peak concentration increases and time to attain steady state is prolonged.
Older patients, on average, have (approximately doubled) higher blood levels
and the area under the plasma concentration time curve (AUC) than younger
patients. (See DOSAGE AND ADMINISTRATION.) Lisinopril can be removed by
hemodialysis.  
 <p>
Studies in rats indicate that lisinopril crosses the blood-brain barrier
poorly.  Multiple doses of lisinopril in rats do not result in accumulation in
any tissues. Milk of lactating rats contains radioactivity following
administration of 14C lisinopril. By whole body autoradiography, radioactivity
was found in the placenta following administration of labeled drug to pregnant
rats, but none was found in the fetuses.  
 <p>
PHARMACODYNAMICS AND CLINICAL EFFECTS 
 <p>
HYPERTENSION:  Administration of Lisinopril to patients with hypertension results
in a reduction of both supine and standing blood pressure to about the same
extent with no compensatory tachycardia. Symptomatic postural hypotension is
usually not observed although it can occur and should be anticipated in volume
and/or salt-depleted patients. (See WARNINGS.) When given together with
thiazide-type diuretics, the blood pressure lowering effects of the two drugs
are approximately additive.  
 <p>
In most patients studied, onset of antihypertensive activity was seen at one
hour after oral administration of an individual dose of Lisinopril, with peak
reduction of blood pressure achieved by 6 hours. Although an antihypertensive
effect was observed 24 hours after dosing with recommended single daily doses,
the effect was more consistent and the mean effect was considerably larger in
some studies with doses of 20 mg or more than with lower doses. However, at all 
doses studied, the mean antihypertensive effect was substantially smaller 24
hours after dosing than it was 6 hours after dosing.  
 <p>
In some patients, achievement of optimal blood pressure reduction may require
two to four weeks of therapy.  
 <p>
The antihypertensive effects of Lisinopril are maintained during long-term
therapy.  Abrupt withdrawal of Lisinopril has not been associated with a rapid
increase in blood pressure, or a significant increase in blood pressure
compared to pretreatment levels.  <p>
 
Two dose-response studies utilizing a once-daily regimen were conducted in 438
mild to moderate hypertensive patients not on a diuretic. Blood pressure was
measured 24 hours after dosing. An antihypertensive effect of Lisinopril was seen
with 5 mg in some patients. However, in both studies blood pressure reduction
occurred sooner and was greater in patients treated with 10, 20 or 80 mg of
Lisinopril. In controlled clinical studies, Lisinopril 20-80 mg has been compared in
patients with mild to moderate hypertension to hydrochlorothiazide 12.5-50 mg
and with atenolol 50-200 mg; and in patients with moderate to severe
hypertension to metoprolol 100-200 mg. It was superior to hydrochlorothiazide
in effects on systolic and diastolic pressure in a population that was 3/4
Caucasian. Lisinopril was approximately equivalent to atenolol and metoprolol in
effects on diastolic blood pressure, and had somewhat greater effects on
systolic blood pressure.  
 <p>
Lisinopril had similar effectiveness and adverse effects in younger and older (&gt;
65 years) patients. It was less effective in blacks than in Caucasians.  
 <p>
In hemodynamic studies in patients with essential hypertension, blood pressure
reduction was accompanied by a reduction in peripheral arterial resistance with 
little or no change in cardiac output and in heart rate. In a study in nine
hypertensive patients, following administration of Lisinopril, there was an
increase in mean renal blood flow that was not significant. Data from several
small studies are inconsistent with respect to the effect of lisinopril on
glomerular filtration rate in hypertensive patients with normal renal function, 
but suggest that changes, if any, are not large.  
 <p>
In patients with renovascular hypertension Lisinopril has been shown to be well
tolerated and effective in controlling blood pressure. (See PRECAUTIONS.) 
 <p>
HEART FAILURE:  During baseline-controlled clinical trials, in patients
receiving digitalis and diuretics, single doses of Lisinopril resulted in
decreases in pulmonary capillary wedge pressure, systemic vascular resistance
and blood pressure accompanied by an increase in cardiac output and no change
in heart rate.  
 <p>
In two placebo controlled, 12-week clinical studies, Lisinopril as adjunctive
therapy to digitalis and diuretics improved the following signs and symptoms
due to congestive heart failure: edema, rales, paroxysmal nocturnal dyspnea and
jugular venous distention. In one of the studies, beneficial response was also
noted for: orthopnea, presence of third heart sound and the number of patients
classified as NYHA Class III and IV. Exercise tolerance was also improved in
this one study. The effect of lisinopril on mortality in patients with heart
failure has not been evaluated.  
 <p>
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
HYPERTENSION:  Lisinopril is indicated for the treatment of hypertension. It may
be used alone as initial therapy or concomitantly with other classes of
antihypertensive agents.  
 <p>
HEART FAILURE:  Lisinopril is indicated as adjunctive therapy in the management of 
heart failure in patients who are not responding adequately to diuretics and
digitalis.  
 <p>
In using Lisinopril, consideration should be given to the fact that another
angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, 
particularly in patients with renal impairment or collagen vascular disease,
and that available data are insufficient to show that Lisinopril does not have a
similar risk. (See WARNINGS.) 
 <p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <p>
Lisinopril is contraindicated in patients who are hypersensitive to this product
and in patients with a history of angioedema related to previous treatment with 
an angiotensin converting enzyme inhibitor.  
 <p>
<a name="WARNINGS"></a><b>WARNINGS 
</b> 
 <p>
USE IN PREGNANCY 
 <p>
WHEN USED IN PREGNANCY DURING THE SECOND AND THIRD TRIMESTERS, ACE INHIBITORS
CAN CAUSE INJURY AND EVEN DEATH TO THE DEVELOPING FETUS. When pregnancy is
detected, Lisinopril should be discontinued as soon as possible. See WARNINGS,
Fetal/Neonatal Morbidity and Mortality.  
 
 <p>
ANGIOEDEMA:  Angioedema of the face, extremities, lips, tongue, glottis and/or
larynx has been reported in patients treated with angiotensin converting enzyme 
inhibitors, including Lisinopril. In such cases, Lisinopril should be promptly
discontinued and appropriate therapy and monitoring should be provided until
complete and sustained resolution of signs and symptoms has occurred. In
instances where swelling has been confined to the face and lips the condition
has generally resolved without treatment, although antihistamines have been
useful in relieving symptoms. Angioedema associated with laryngeal edema may be 
fatal. WHERE THERE IS INVOLVEMENT OF THE TONGUE, GLOTTIS OR LARYNX, LIKELY TO
CAUSE AIRWAY OBSTRUCTION, APPROPRIATE THERAPY, EG, SUBCUTANEOUS EPINEPHRINE
SOLUTION 1:1000 (0.3 ML TO 0.5 ML) AND/OR MEASURES NECESSARY TO ENSURE A PATENT 
AIRWAY SHOULD BE PROMPTLY ADMINISTERED. (SEE ADVERSE REACTIONS.) 
 <p>
HYPOTENSION:  Excessive hypotension is rare in patients with uncomplicated
hypertension treated with Lisinopril alone.  
 <p>
Patients with heart failure given Lisinopril commonly have some reduction in blood 
pressure, with peak blood pressure reduction occurring 6 to 8 hours postdose,
but discontinuation of therapy because of continuing symptomatic hypotension
usually is not necessary when dosing instructions are followed; caution should
be observed when initiating therapy. (See DOSAGE AND ADMINISTRATION.) 
 <p>
Patients at risk of excessive hypotension, sometimes associated with oliguria
and/or progressive azotemia, and rarely with acute renal failure and/or death,
include those with the following conditions or characteristics: heart failure
with systolic blood pressure below 100 mm Hg, hyponatremia, high dose diuretic
therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis 
or severe volume and/or salt depletion of any etiology. It may be advisable to
eliminate the diuretic (except in patients with heart failure), reduce the
diuretic dose or increase salt intake cautiously before initiating therapy with 
Lisinopril in patients at risk for excessive hypotension who are able to tolerate
such adjustments. (See PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS.) 
 <p>
In patients at risk of excessive hypotension, therapy should be started under
very close medical supervision and such patients should be followed closely for 
the first two weeks of treatment and whenever the dose of Lisinopril and/or
diuretic is increased. Similar considerations may apply to patients with
ischemic heart or cerebrovascular disease, in whom an excessive fall in blood
pressure could result in a myocardial infarction or cerebrovascular accident. 
 <p>
If excessive hypotension occurs, the patients should be placed in supine
position and, if necessary, receive an intravenous infusion of normal saline. A 
transient hypotensive response is not a contraindication to further doses of
Lisinopril which usually can be given without difficulty once the blood pressure
has stabilized. If symptomatic hypotension develops, a dose reduction or
discontinuation of Lisinopril or concomitant diuretic may be necessary.  
 <p>
NEUTROPENIA/AGRANULOCYTOSIS:  Another angiotensin converting enzyme inhibitor,
captopril, has been shown to cause agranulocytosis and bone marrow depression,
rarely in uncomplicated patients but more frequently in patients with renal
impairment especially if they also have a collagen vascular disease. Available
data from clinical trials of Lisinopril are insufficient to show that Lisinopril does 
not cause agranulocytosis at similar rates. Marketing experience has revealed
rare cases of neutropenia and bone marrow depression in which a causal
relationship to lisinopril cannot be excluded. Periodic monitoring of white
blood cell counts in patients with collagen vascular disease and renal disease
should be considered.  
 <p>
FETAL/NEONATAL MORBIDITY AND MORTALITY:  ACE inhibitors can cause fetal and
neonatal morbidity and death when administered to pregnant women. Several dozen 
cases have been reported in the world literature. When pregnancy is detected,
ACE inhibitors should be discontinued as soon as possible.  
 <p>
The use of ACE inhibitors during the second and third trimesters of pregnancy
has been associated with fetal and neonatal injury, including hypotension,
neonatal skull hypoplasia, anuria, reversible or irreversible renal failure,
and death. Oligohydramnios has also been reported, presumably resulting from
decreased fetal renal function; oligohydramnios in this setting has been
associated with fetal limb contractures, craniofacial deformation, and
hypoplastic lung development. Prematurity, intrauterine growth retardation, and 
patent ductus arteriosus have also been reported, although it is not clear
whether these occurrences were due to the ACE-inhibitor exposure.  
 <p>
These adverse effects do not appear to have resulted from intrauterine ACE-
inhibitor exposure that has been limited to the first trimester. Mothers whose
embryos and fetuses are exposed to ACE inhibitors only during the first
trimester should be so informed. Nonetheless, when patients become pregnant,
physicians should make every effort to discontinue the use of Lisinopril as soon
as possible.  
 <p>
Rarely (probably less often than once in every thousand pregnancies), no
alternative to ACE inhibitors will be found. In these rare cases, the mothers
should be apprised of the potential hazards to their fetuses, and serial
ultrasound examinations should be performed to assess the intra-amniotic
environment.  
 <p>
If oligohydramnios is observed, Lisinopril should be discontinued unless it is
considered lifesaving for the mother. Contraction stress testing (CST), a
nonstress test (NST), or biophysical profiling (BPP) may be appropriate,
depending upon the week of pregnancy. Patients and physicians should be aware,
however, that oligohydramnios may not appear until after the fetus has
sustained irreversible injury.  
 <p>
Infants with histories of in utero exposure to ACE inhibitors should be closely 
observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs,
attention should be directed toward support of blood pressure and renal
perfusion. Exchange transfusion or dialysis may be required as means of
reversing hypotension and/or substituting for disordered renal function. 
Lisinopril, which crosses the placenta, has been removed from neonatal
circulation by peritoneal dialysis with some clinical benefit, and
theoretically may be removed by exchange transfusion, although there is no
experience with the latter procedure.  
 <p>
No teratogenic effects of lisinopril were seen in studies of pregnant rats,
mice, and rabbits. On a mg/kg basis, the doses used were up to 625 times (in
mice), 188 times (in rats), and 0.6 times (in rabbits) the maximum recommended
human dose.  
 <p>
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
GENERAL 
 <p>
IMPAIRED RENAL FUNCTION:  As a consequence of inhibiting the renin-angiotensin- 
aldosterone system, changes in renal function may be anticipated in susceptible 
individuals. In patients with severe congestive heart failure whose renal
function may depend on the activity of the renin-angiotensin-aldosterone system 
treatment with angiotensin converting enzyme inhibitors, including Lisinopril,
may be associated with oliguria and/or progressive azotemia and rarely with
acute renal failure and/or death.  
 <p>
In hypertensive patients with unilateral or bilateral renal artery stenosis,
increases in blood urea nitrogen and serum creatinine may occur. Experience
with another angiotensin converting enzyme inhibitor suggests that these
increases are usually reversible upon discontinuation of Lisinopril and/or
diuretic therapy.  In such patients, renal function should be monitored during
the first few weeks of therapy.  
 <p>
Some patients with hypertension or heart failure with no apparent pre-existing
renal vascular disease have developed increases in blood urea nitrogen and
serum creatinine, usually minor and transient, especially when Lisinopril has been 
given concomitantly with a diuretic. This is more likely to occur in patients
with pre-existing renal impairment. Dosage reduction and/or discontinuation of
the diuretic and/or Lisinopril may be required.  
 <p>
EVALUATION OF PATIENTS WITH HYPERTENSION OR HEART FAILURE SHOULD ALWAYS INCLUDE 
ASSESSMENT OF RENAL FUNCTION. (SEE DOSAGE AND ADMINISTRATION.) 
 <p>
HEMODIALYSIS PATIENTS:  Sudden and potentially life-threatening anaphylactoid
reactions have been reported in some patients dialyzed with high-flux membranes 
(eg, AN69*) and treated concomitantly with an ACE inhibitor. In such patients,
dialysis must be stopped immediately, and aggressive therapy for anaphylactoid
reactions be initiated. Symptoms have not been relieved by antihistamines in
these situations. In these patients, consideration should be given to using a
different type of dialysis membrane or a different class of antihypertensive
agent.  
 <p>
HYPERKALEMIA:  In clinical trials hyperkalemia (serum potassium greater than
5.7 mEq/L) occurred in approximately 2.2% of hypertensive patients and 4.8% of
patients with heart failure. In most cases these were isolated values which
resolved despite continued therapy. Hyperkalemia was a cause of discontinuation 
of therapy in approximately 0.1% of hypertensive patients and 0.6% of patients
with heart failure. Risk factors for the development of hyperkalemia include
renal insufficiency, diabetes mellitus, and the concomitant use of potassium-
sparing diuretics, potassium supplements and/or potassium-containing salt
substitutes, which should be used cautiously, if at all, with Lisinopril. (See
Drug Interactions.) 
 <p>
COUGH:  Cough has been reported with the use of ACE inhibitors. 
Characteristically, the cough is nonproductive, persistent and resolves after
discontinuation of therapy. ACE inhibitor-induced cough should be considered as 
part of the differential diagnosis of cough.  
 <p>
SURGERY/ANESTHESIA:  In patients undergoing major surgery or during anesthesia
with agents that produce hypotension, Lisinopril may block angiotensin II
formation secondary to compensatory renin release. If hypotension occurs and is 
considered to be due to this mechanism, it can be corrected by volume
expansion.  
 <p>
INFORMATION FOR PATIENTS 
 <p>
ANGIOEDEMA:  Angioedema, including laryngeal edema, may occur especially
following the first dose of Lisinopril. Patients should be so advised and told to
report immediately any signs or symptoms suggesting angioedema (swelling of
face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing)
and to take no more drug until they have consulted with the prescribing
physician.  
 <p>
SYMPTOMATIC HYPOTENSION:  Patients should be cautioned to report
lightheadedness especially during the first few days of therapy. If actual
syncope occurs, the patient should be told to discontinue the drug until they
have consulted with the prescribing physician.  
 <p>
All patients should be cautioned that excessive perspiration and dehydration
may lead to an excessive fall in blood pressure because of reduction in fluid
volume. Other causes of volume depletion such as vomiting or diarrhea may also
lead to a fall in blood pressure; patients should be advised to consult with
their physician.  
 <p>
HYPERKALEMIA:  Patients should be told not to use salt substitutes containing
potassium without consulting their physician.  
 <p>
NEUTROPENIA:  Patients should be told to report promptly any indication of
infection (eg, sore throat, fever) which may be a sign of neutropenia.  
 <p>
PREGNANCY:  Female patients of childbearing age should be told about the
consequences of second- and third-trimester exposure to ACE inhibitors, and
they should also be told that these consequences do not appear to have resulted 
from intrauterine ACE-inhibitor exposure that has been limited to the first
trimester. These patients should be asked to report pregnancies to their
physicians as soon as possible.  
 <p>
NOTE:  As with many other drugs, certain advice to patients being treated with
Lisinopril is warranted. This information is intended to aid in the safe and
effective use of this medication. It is not a disclosure of all possible
adverse or intended effects.  
 <p>
DRUG INTERACTIONS 
 <p>
HYPOTENSION--PATIENTS ON DIURETIC THERAPY:  Patients on diuretics and
especially those in whom diuretic therapy was recently instituted, may
occasionally experience an excessive reduction of blood pressure after
initiation of therapy with Lisinopril. The possibility of hypotensive effects with 
Lisinopril can be minimized by either discontinuing the diuretic or increasing the 
salt intake prior to initiation of treatment with Lisinopril. If it is necessary
to continue the diuretic, initiate therapy with Lisinopril at a dose of 5 mg daily 
and provide close medical supervision after the initial dose until blood
pressure has stabilized. (See WARNINGS, and DOSAGE AND ADMINISTRATION.) When a
diuretic is added to the therapy of a patient receiving Lisinopril, an additional
antihypertensive effect is usually observed. Studies with ACE inhibitors in
combination with diuretics indicate that the dose of the ACE inhibitor can be
reduced when it is given with a diuretic. (See DOSAGE AND ADMINISTRATION.) 
 <p>
INDOMETHACIN:  In a study in 36 patients with mild to moderate hypertension
where the antihypertensive effects of Lisinopril alone were compared to Lisinopril
given concomitantly with indomethacin, the use of indomethacin was associated
with a reduced effect, although the difference between the two regimens was not 
significant.  
 <p>
OTHER AGENTS:  Lisinopril has been used concomitantly with nitrates and/or digoxin 
without evidence of clinically significant adverse interactions. No clinically
important pharmacokinetic interactions occurred when Lisinopril was used
concomitantly with propranolol or hydrochlorothiazide. The presence of food in
the stomach does not alter the bioavailability of Lisinopril.  
 <p>
AGENTS INCREASING SERUM POTASSIUM:  Lisinopril attenuates potassium loss caused by 
thiazide-type diuretics. Use of Lisinopril with potassium-sparing diuretics (eg,
spironolactone, triamterene or amiloride), potassium supplements, or potassium- 
containing salt substitutes may lead to significant increases in serum
potassium. Therefore, if concomitant use of these agents is indicated because
of demonstrated hypokalemia, they should be used with caution and with frequent 
monitoring of serum potassium. Potassium-sparing agents should generally not be 
used in patients with heart failure who are receiving Lisinopril.  
 <p>
LITHIUM:  Lithium toxicity has been reported in patients receiving lithium with 
drugs which cause elimination of sodium, including ACE inhibitors. Lithium
toxicity was usually reversible upon discontinuation of both drugs. It is
recommended that serum lithium levels be monitored frequently if Lisinopril is
administered concomitantly with lithium.  
 <p>
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: There was no evidence of
a tumorigenic effect when lisinopril was administered for 105 weeks to male and 
female rats at doses up to 90 mg/kg/day (about 56 or 9 times* the maximum
recommended daily human dose, based on body weight and body surface area,
respectively). There was no evidence of carcinogenicity) when lisinopril was
administered for 92 weeks to (male and female) mice at doses up to 135
mg/kg/day (about 84 times* the maximum recommended daily human dose). This dose 
was 6.8 times the maximum human dose based on body surface area in mice.  
 <p>
* Calculations assume a human weight of 50 kg and human body surface area of
1.62 M(square).  
<p>
Lisinopril was not mutagenic in the Ames microbial mutagen test with or without 
metabolic activation. It was also negative in a forward mutation assay using
Chinese hamster lung cells. Lisinopril did not produce single strand DNA breaks 
in an in vitro alkaline elution rat hepatocyte assay. In addition, lisinopril
did not produce increases in chromosomal aberrations in an in vitro test in
Chinese hamster ovary cells or in an in vivo study in mouse bone marrow.  
 <p>
There were no adverse effects on reproductive performance in male and female
rats treated with up to 300 mg/kg/day of lisinopril. This dose is 188 times and 
30 times the maximum human dose when based on mg/kg and mg/M(square),
respectively.  
 <p>
PREGNANCY 
 <p>
PREGNANCY CATEGORIES C (FIRST TRIMESTER) AND D (SECOND AND THIRD TRIMESTERS). 
(See WARNINGS, Fetal/Neonatal Morbidity and Mortality.  
 <p>
NURSING MOTHERS:  Milk of lactating rats contains radioactivity following
administration of 14C lisinopril. It is not known whether this drug is excreted 
in human milk. Because many drugs are excreted in human milk, and because of
the potential for serious adverse reactions in nursing infants from ACE
inhibitors, a decision should be made whether to discontinue nursing and/or
discontinue Lisinopril, taking into account the importance of the drug to the
mother.  
 <p>
PEDIATRIC USE:  Safety and effectiveness in children have not been established. 
 <p>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <p>
HYPOTENSION--PATIENTS ON DIURETIC THERAPY:  Patients on diuretics and
especially those in whom diuretic therapy was recently instituted, may
occasionally experience an excessive reduction of blood pressure after
initiation of therapy with Lisinopril. The possibility of hypotensive effects with 
Lisinopril can be minimized by either discontinuing the diuretic or increasing the 
salt intake prior to initiation of treatment with Lisinopril. If it is necessary
to continue the diuretic, initiate therapy with Lisinopril at a dose of 5 mg daily 
and provide close medical supervision after the initial dose until blood
pressure has stabilized. (See WARNINGS, and DOSAGE AND ADMINISTRATION.) When a
diuretic is added to the therapy of a patient receiving Lisinopril, an additional
antihypertensive effect is usually observed. Studies with ACE inhibitors in
combination with diuretics indicate that the dose of the ACE inhibitor can be
reduced when it is given with a diuretic. (See DOSAGE AND ADMINISTRATION.) 
 <p>
INDOMETHACIN:  In a study in 36 patients with mild to moderate hypertension
where the antihypertensive effects of Lisinopril alone were compared to Lisinopril
given concomitantly with indomethacin, the use of indomethacin was associated
with a reduced effect, although the difference between the two regimens was not 
significant.  
 <p>
OTHER AGENTS:  Lisinopril has been used concomitantly with nitrates and/or digoxin 
without evidence of clinically significant adverse interactions. No clinically
important pharmacokinetic interactions occurred when Lisinopril was used
concomitantly with propranolol or hydrochlorothiazide. The presence of food in
the stomach does not alter the bioavailability of Lisinopril.  
 <p>
AGENTS INCREASING SERUM POTASSIUM:  Lisinopril attenuates potassium loss caused by 
thiazide-type diuretics. Use of Lisinopril with potassium-sparing diuretics (eg,
spironolactone, triamterene or amiloride), potassium supplements, or potassium- 
containing salt substitutes may lead to significant increases in serum
potassium. Therefore, if concomitant use of these agents is indicated because
of demonstrated hypokalemia, they should be used with caution and with frequent 
monitoring of serum potassium. Potassium-sparing agents should generally not be 
used in patients with heart failure who are receiving Lisinopril.  
 <p>
LITHIUM:  Lithium toxicity has been reported in patients receiving lithium with 
drugs which cause elimination of sodium, including ACE inhibitors. Lithium
toxicity was usually reversible upon discontinuation of both drugs. It is
recommended that serum lithium levels be monitored frequently if Lisinopril is
administered concomitantly with lithium.  
 <p>
(See Also PRECAUTIONS) 
 <p>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
Lisinopril has been found to be generally well tolerated in controlled clinical
trials involving 1969 patients. For the most part, adverse experiences were
mild and transient.  
 <p>
In clinical trials in patients with hypertension treated with Lisinopril,
discontinuation of therapy due to clinical adverse experiences occurred in 5.7% 
of patients. The overall frequency of adverse experiences could not be related
to total daily dosage within the recommended therapeutic dosage range.  
 <p>
In patients with heart failure treated with Lisinopril for up to four years,
discontinuation of therapy due to clinical adverse experiences occurred in
11.0% of patients. In controlled studies in patients with heart failure,
therapy was discontinued in 8.1% of patients treated with Lisinopril for 12 weeks, 
compared to 7.7% of patients treated with placebo for 12 weeks.  
 <p>
HYPERTENSION 
 <p>
For adverse experiences occurring in greater than 1% of patients with
hypertension treated with Lisinopril or Lisinopril plus hydrochlorothiazide in
controlled clinical trials, comparative incidence data are listed in the table
below:  <p><pre>
                   PERCENT OF PATIENTS IN CONTROLLED STUDIES                    
                                                 Lisinopril                        
                           Lisinopril         Hydrochlorothiazide     PLACEBO      
                           (n=1349)              (n=629)           (n=207)      
                          Incidence             Incidence         Incidence     
                      (discontinuation)   (discontinuation)   (discontinuation) 
----------------------------------------------------------------------------    
BODY AS A WHOLE                                                                 
    Fatigue              2.5 (0.3)              4.0 (0.5)          1.0 (0.0)    
    Asthenia             1.3 (0.5)              2.1 (0.2)          1.0 (0.0)    
    Chest Pain           1.2 (0.1)              1.3 (0.2)          1.4 (0.0)    
    Orthostatic Effects  1.2 (0.0)              3.5 (0.2)          1.0 (0.0)    
CARDIOVASCULAR                                                                  
    Hypotension          1.2 (0.5)              1.6 (0.5)          0.5 (0.5)    
DIGESTIVE                                                                       
    Diarrhea             2.7 (0.2)              2.7 (0.3)          2.4 (0.0)    
    Nausea               2.0 (0.4)              2.5 (0.2)          2.4 (0.0)    
    Vomiting             1.1 (0.2)              1.4 (0.1)          0.5 (0.0)    
    Dyspepsia            0.9 (0.0)              1.9 (0.0)          0.0 (0.0)    
MUSCULOSKELETAL                                                                 
    Back Pain            0.6 (0.0)              1.1 (0.1)          1.4 (0.0)    
    Muscle Cramps        0.5 (0.0)              2.9 (0.8)          0.5 (0.0)    
NERVOUS/PSYCHIATRIC                                                             
    Headache             5.7 (0.2)              4.5 (0.5)          1.9 (0.0)    
    Dizziness            5.4 (0.4)              9.2 (1.0)          1.9 (0.0)    
    Paresthesia          0.8 (0.1)              2.1 (0.2)          0.0 (0.0)    
    Decreased Libido     0.4 (0.1)              1.3 (0.1)          0.0 (0.0)    
    Vertigo              0.2 (0.1)              1.1 (0.2)          0.0 (0.0)    
RESPIRATORY                                                                     
    Cough                3.5 (0.7)              4.6 (0.8)          1.0 (0.0)    
    Upper Respiratory                                                           
    Infection            2.1 (0.1)              2.7 (0.1)          0.0 (0.0)    
    Common Cold          1.1 (0.1)              1.3 (0.1)          0.0 (0.0)    
    Nasal Congestion     0.4 (0.1)              1.3 (0.1)          0.0 (0.0)    
    Influenza            0.3 (0.1)              1.1 (0.1)          0.0 (0.0)    
SKIN                                                                            
    Rash                 1.3 (0.4)              1.6 (0.2)          0.5 (0.5)    
UROGENITAL                                                                      
    Impotence            1.0 (0.4)              1.6 (0.5)          0.0 (0.0)    
HEART FAILURE 
 
The following table lists those adverse experiences which occurred in greater
than 1% of patients with heart failure treated with Lisinopril or placebo for up
to 12 weeks in controlled clinical trials. Also listed are those adverse
experiences occurring in greater than 1% of patients with heart failure treated 
with Lisinopril for up to four years.  
 
                                Controlled Trials                 All Trials    
                           Lisinopril            Placebo              Lisinopril      
                           (n=407)            (n=155)              (n=620)      
                          Incidence          Incidence            Incidence     
                      (discontinuation)  (discontinuation)   (discontinuation)  
                           12 weeks           12 weeks          up to 4 years   
----------------------------------------------------------------------------    
BODY AS A WHOLE                                                                 
    Chest Pain           3.4 (0.2)              1.3 (0.0)          7.3 (0.3)    
    Asthenia             3.2 (0.2)              3.2 (0.0)          6.9 (0.3)    
    Abnormal Pain        2.2 (0.7)              1.9 (0.0)          4.0 (0.5)    
    Edema                1.0 (0.0)              0.6 (0.0)          2.4 (0.2)    
    Syncope              1.0 (0.0)              0.6 (0.6)          1.8 (0.0)    
    Orthostatic Effects  1.0 (0.2)              0.0 (0.0)          1.1 (0.2)    
    Fever                0.5 (0.0)              0.6 (0.0)          1.1 (0.0)    
    Malaise              1.0 (0.2)              0.0 (0.0)          1.1 (0.3)    
CARDIOVASCULAR                                                                  
    Hypotension          4.4 (1.7)              0.6 (0.6)          5.3 (1.8)    
    Angina Pectoris      1.5 (0.2)              3.2 (1.3)          3.7 (0.3)    
    Worsening of         0.0 (0.0)              3.2 (1.3)          2.9 (0.6)    
      Heart Failure                                                             
    Orthostatic          1.0 (0.2)              0.0 (0.0)          1.9 (0.3)    
     Hypotension                                                                
    Palpitation          1.0 (0.0)              0.0 (0.0)          1.9 (0.0)    
    CVA                  0.2 (0.0)              0.0 (0.0)          1.6 (0.2)    
    Myocardial           0.5 (0.2)              0.6 (0.0)          1.3 (0.5)    
      Infarction                                                                
DIGESTIVE                                                                       
    Diarrhea             3.7 (0.5)              1.9 (0.0)          6.1 (0.6)    
    Nausea               2.7 (0.5)              5.2 (0.0)          5.0 (0.5)    
    Vomiting             1.0 (0.5)              0.6 (0.0)          2.4 (0.3)    
    Dyspepsia            0.2 (0.2)              0.0 (0.0)          1.8 (0.2)    
    Anorexia             0.7 (0.2)              1.3 (0.0)          1.5 (0.3)    
    Increased Salivation 0.0 (0.0)              1.3 (0.0)          0.2 (0.0)    
METABOLIC                                                                       
    Gout                 0.5 (0.2)              0.0 (0.0)          1.5 (0.2)    
MUSCULOSKELETAL                                                                 
    Muscle Cramps        0.5 (0.0)              1.3 (0.0)          2.1 (0.0)    
    Back Pain            0.5 (0.0)              1.9 (0.0)          1.6 (0.0)    
    Leg Pain             0.5 (0.0)              0.6 (0.0)          1.3 (0.2)    
    Myalgia              0.5 (0.0)              1.9 (0.6)          0.6 (0.0)    
NERVOUS/PSYCHIATRIC                                                             
    Dizziness           11.8 (1.2)              4.5 (1.3)         14.0 (1.8)    
    Headache             4.4 (0.2)              3.9 (0.0)          4.5 (0.2)    
    Paresthesia          1.0 (0.0)              0.0 (0.0)          2.6 (0.0)    
    Insomnia             0.7 (0.0)              0.6 (0.0)          2.3 (0.0)    
    Depression           0.0 (0.0)              1.3 (0.0)          1.1 (0.0)    
RESPIRATORY                                                                     
    Dyspnea              2.7 (0.2)              4.5 (0.6)          7.6 (0.3)    
    Cough                1.7 (0.0)              2.6 (0.0)          6.1 (0.2)    
    Upper Respiratory                                                           
    Infection            1.5 (0.0)              1.3 (0.0)          4.5 (0.0)    
    Bronchitis           0.5 (0.0)              0.0 (0.0)          1.6 (0.0)    
    Chest Sound                                                                 
    Abnormalities        0.0 (0.0)              1.3 (0.0)          0.3 (0.0)    
    Pulmonary Edema      0.2 (0.0)              1.3 (0.0)          0.3 (0.0)    
SKIN                                                                            
    Rash                 1.7 (0.5)              0.6 (0.6)          4.8 (1.0)    
    Pruritus             1.2 (0.2)              1.9 (0.6)          1.5 (0.5)    
UROGENITAL                                                                      
    Urinary Tract                                                               
    Infection            0.5 (0.0)              0.0 (0.0)          1.5 (0.0) </pre><p>
   
Other clinical adverse experiences occurring in 0.3% to 1.0% of patients with
hypertension or heart failure treated with Lisinopril in controlled clinical
trials and rarer, serious, possibly drug-related events reported in
uncontrolled studies or marketing experience are listed below, and within each
category, are in order of decreasing severity.  
 <p>
BODY AS A WHOLE:  Anaphylactoid reactions (see PRECAUTIONS, Hemodialysis
Patients), chest discomfort, pain, pelvic pain, flank pain, facial edema,
peripheral edema, virus infection, chills.  
 <p>
CARDIOVASCULAR:  Cardiac arrest; myocardial infarction or cerebrovascular
accident, possibly secondary to excessive hypotension in high risk patients
(see WARNINGS, Hypotension); pulmonary embolism and infarction, arrhythmias
(including ventricular tachycardia, atrial tachycardia, atrial fibrillation,
bradycardia and premature ventricular contractions), transient ischemic attacks 
paroxysmal nocturnal dyspnea, decreased blood pressure, peripheral edema,
vasculitis.  
 <p>
DIGESTIVE:  Pancreatitis, hepatitis (hepatocellular or cholestatic jaundice),
gastritis, heartburn, gastrointestinal cramps, constipation, flatulence, dry
mouth.  
 <p>
HEMATOLOGIC:  Rare cases of bone marrow depression, neutropenia and
thrombocytopenia.  
 <p>
ENDOCRINE:  Diabetes mellitus.  
 <p>
METABOLIC:  Weight loss, dehydration, fluid overload, weight gain.  
 <p>
MUSCULOSKELETAL:  Arthritis, arthralgia, neck pain, hip pain, low back pain,
joint pain, knee pain, shoulder pain, arm pain, lumbago.  
 <p>
NERVOUS SYSTEM/PSYCHIATRIC:  Stroke, ataxia, memory impairment, tremor, spasm,
confusion, somnolence, hypersomnia, irritability and nervousness.  
 <p>
RESPIRATORY SYSTEM:  Malignant lung neoplasms, hemoptysis, asthma, pleural
effusion, pneumonia, wheezing, orthopnea, painful respiration, epistaxis,
laryngitis, sinusitis, pharyngeal pain, pharyngitis, rhinitis, rhinorrhea.  
 <p>
SKIN:  Urticaria, alopecia, herpes zoster, photosensitivity, skin lesions, skin 
infections, erythema, flushing, diaphoresis.  
 <p>
SPECIAL SENSES:  Visual loss, diplopia, blurred vision, tinnitus, photophobia.  
 <p>
UROGENITAL SYSTEM:  Acute renal failure, oliguria, anuria, uremia, progressive
azotemia, renal dysfunction, (see PRECAUTIONS and DOSAGE AND ADMINISTRATION),
pyelonephritis, dysuria, breast pain.  
 <p>
MISCELLANEOUS:  A symptom complex has been reported which may include a
positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, 
myalgia, fever, vasculitis, eosinophilia and leukocytosis. Rash,
photosensitivity or other dermatological manifestations may occur alone or in
combination with these symptoms.  
 <p>
ANGIOEDEMA:  Angioedema has been reported in patients receiving Lisinopril (0.1%). 
Angioedema associated with laryngeal edema may be fatal. If angioedema of the
face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with
Lisinopril should be discontinued and appropriate therapy instituted immediately.  
(See WARNINGS.) 
 <p>
HYPOTENSION:  In hypertensive patients, hypotension occurred in 1.2% and
syncope occurred in 0.1% of patients. Hypotension or syncope was a cause of
discontinuation of therapy in 0.5% of hypertensive patients. In patients with
heart failure, hypotension occurred in 5.3% and syncope occurred in 1.8% of
patients. These adverse experiences were causes for discontinuation of therapy
in 1.8% of these patients. (See WARNINGS.) 
 <p>
FETAL/NEONATAL MORBIDITY AND MORTALITY:  See WARNINGS, Fetal/Neonatal Morbidity 
and Mortality.  
 <p>
COUGH:  See PRECAUTIONS--Cough 
 <p>
CLINICAL LABORATORY TEST FINDINGS 
 <p>
SERUM ELECTROLYTES:  Hyperkalemia (See PRECAUTIONS.) 
 <p>
CREATININE, BLOOD UREA NITROGEN:  Minor increases in blood urea nitrogen and
serum creatinine, reversible upon discontinuation of therapy, were observed in
about 2.0% of patients with essential hypertension treated with Lisinopril alone.  
Increases were more common in patients receiving concomitant diuretics and in
patients with renal artery stenosis. (See PRECAUTIONS.) Reversible minor
increases in blood urea nitrogen and serum creatinine were observed in
approximately 11.6% of patients with congestive heart failure on concomitant
diuretic therapy. Frequently, these abnormalities resolved when the dosage of
the diuretic was decreased.  
 <p>
HEMOGLOBIN AND HEMATOCRIT:  Small decreases in hemoglobin and hematocrit (mean
decreases of approximately 0.4 g% and 1.3 vol%, respectively) occurred
frequently in patients treated with Lisinopril but were rarely of clinical
importance in patients without some other cause of anemia. In clinical trials,
less than 0.1% of patients discontinued therapy due to anemia.  
 <p>
LIVER FUNCTION TESTS:  Rarely, elevations of liver enzymes and/or serum
bilirubin have occurred.  
 <p>
In hypertensive patients, 2.0% discontinued therapy due to laboratory adverse
experiences, principally elevations in blood urea nitrogen (0.6%), serum
creatinine (0.5%) and serum potassium (0.4%).  
 <p>
In the heart failure trials, 3.4% of patients discontinued therapy due to
laboratory adverse experiences: 1.8% due to elevations in blood urea nitrogen
and/or creatinine and 0.6% due to elevations in serum potassium.  
 <p>
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <p>
Following a single oral dose of 20 g/kg no lethality occurred in rats, and
death occurred in one of 20 mice receiving the same dose. The most likely
manifestation of overdosage would be hypotension, for which the usual treatment 
would be intravenous infusion of normal saline solution.  
 <p>
Lisinopril can be removed by hemodialysis.  
 <p>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
HYPERTENSION 
 <p>
INITIAL THERAPY:  In patients with uncomplicated essential hypertension not on
diuretic therapy, the recommended initial dose is 10 mg once a day. Dosage
should be adjusted according to blood pressure response. The usual dosage range 
is 20-40 mg per day administered in a single daily dose. The antihypertensive
effect may diminish toward the end of the dosing interval regardless of the
administered dose, but most commonly with a dose of 10 mg daily. This can be
evaluated by measuring blood pressure just prior to dosing to determine whether 
satisfactory control is being maintained for 24 hours. If it is not, an
increase in dose should be considered. Doses up to 80 mg have been used but do
not appear to give greater effect. If blood pressure is not controlled with
Lisinopril alone, a low dose of a diuretic may be added. Hydrochlorothiazide, 12.5 
mg has been shown to provide an additive effect. After the addition of a
diuretic, it may be possible to reduce the dose of Lisinopril.  
 <p>
DIURETIC TREATED PATIENTS:  In hypertensive patients who are currently being
treated with a diuretic, symptomatic hypotension may occur occasionally
following the initial dose of Lisinopril. The diuretic should be discontinued, if
possible, for two to three days before beginning therapy with Lisinopril to reduce 
the likelihood of hypotension. (See WARNINGS.) The dosage of Lisinopril should be
adjusted according to blood pressure response. If the patient's blood pressure
is not controlled with Lisinopril alone, diuretic therapy may be resumed as
described above.  
 <p>
If the diuretic cannot be discontinued, an initial dose of 5 mg should be used
under medical supervision for at least two hours and until blood pressure has
stabilized for at least an additional hour. (See WARNINGS and PRECAUTIONS, Drug 
Interactions.) 
 <p>
Concomitant administration of Lisinopril with potassium supplements, potassium
salt substitutes, or potassium-sparing diuretics may lead to increases of serum 
potassium. (See PRECAUTIONS.) 
 <p>
DOSAGE ADJUSTMENT IN RENAL IMPAIRMENT:  The usual dose of Lisinopril (10 mg) is
recommended for patients with creatinine clearance &gt; 30 mL/min (serum
creatinine of up to approximately 3 mg/dL). For patients with creatinine
clearance &gt;/= 10 mL/min &lt; or = 30 mL/min (serum creatinine &gt;/= 3 mg/dL), the first 
dose is 5 mg once daily. For patients with creatinine clearance &lt; 10 mL/min
(usually on hemodialysis) the recommended initial dose is 2.5 mg. The dosage
may be titrated upward until blood pressure is controlled or to a maximum of 40 
mg daily.  
 <p><pre>
-----------------------------------------------------------------------------   
                                             Creatinine             Initial     
                                             Clearance                Dose      
Renal Status                                   mL/min                mg/day     
-----------------------------------------------------------------------------   
Normal Renal Function                                                           
     to Mild Impairment                         &gt;30                    10       
Moderate to Severe                                                              
     Impairment                              &gt;/=10&lt; or =30              5       
Dialysis Patients*                              &lt;10                   2.5**     
-----------------------------------------------------------------------------   
*   See PRECAUTIONS, Hemodialysis Patients.                                     
**  Dosage interval should be adjusted depending on the blood pressure          
     response.    </pre><p>                                                              
HEART FAILURE 
 <p>
Lisinopril is indicated as adjunctive therapy with diuretics and digitalis. The
recommended starting dose is 5 mg once a day. When initiating treatment with
lisinopril in patients with heart failure, the initial dose should be
administered under medical observation, especially in those patients with low
blood pressure (systolic blood pressure below 100 mm Hg). The mean peak blood
pressure lowering occurs six to eight hours after dosing. Observation should
continue until blood pressure is stable. The concomitant diuretic dose should
be reduced, if possible, to help minimize hypovolemia which may contribute to
hypotension. (See WARNINGS and PRECAUTIONS, Drug Interactions.) The appearance
of hypotension after the initial dose of Lisinopril does not preclude subsequent
careful dose titration with the drug, following effective management of the
hypotension.  
 <p>
The usual effective dosage range is 5 to 20 mg per day administered as a single 
daily dose.  
 <p>
DOSAGE ADJUSTMENT IN PATIENTS WITH HEART FAILURE AND RENAL IMPAIRMENT OR
HYPONATREMIA:  In patients with heart failure who have hyponatremia (serum
sodium &lt; 130 mEq/L) or moderate to severe renal impairment (creatinine
clearance &lt; or = 30 mL/min or serum creatinine &gt; 3 mg/dL), therapy with Lisinopril
should be initiated at a dose of 2.5 mg once a day under close medical
supervision. (See WARNINGS and PRECAUTIONS, Drug Interactions.) 
 <p>
USE IN ELDERLY:  In general, blood pressure response and adverse experiences
were similar in younger and older patients given similar doses of Lisinopril. 
Pharmacokinetic studies, however, indicate that maximum blood levels and area
under the plasma concentration time curve (AUC) are doubled in older patients,
so that dosage adjustments should be made with particular caution. 

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-28</DOCNO>
<DOCOLDNO>IA018-000200-B040-111</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/traz.htm 206.86.175.201 19970106230601 text/html 23288
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:59:45 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 23105
Last-modified: Fri, 11 Oct 1996 05:52:13 GMT
</DOCHDR>
<html>
<head>
   <title>Trazodone - RxList Generic Information</title>
   <meta name="keywords" content="Desyrel, Beneficat, Bimaran, Deprax, Desirel,
Manegan, Molipaxin, Pragmarel, Sideril, Taxagon, Thombran, Trazalon, Trazolan, Trazon-150,
Trazonil, Trittico">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Trazodone</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Trazodone is an antidepressant chemically unrelated to tricyclic, tetracyclic,
or other known antidepressant agents. It is a triazolopyridine derivative
designated as 2-(3-(4-(3-chlorophenyl)-1- piperazinyl) propyl)-1,2,4-triazolo(4,
3-a)pyridin-3(2H)-one hydrochloride. It is a white odorless crystalline
powder which is freely soluble in water. Its molecular weight is 408.3.
The empirical formula is C19H22ClN5O.HCl. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>The mechanism of Trazodone's antidepressant action in man is not fully
understood. In animals, Trazodone selectively inhibits serotonin uptake
by brain synaptosomes and potentiates the behavioral changes induced by
the serotonin precursor, 5- hydroxytryptophan. Cardiac conduction effects
of Trazodone in the anesthetized dog are qualitatively dissimilar and quantitatively
less pronounced than those seen with tricyclic antidepressants. Trazodone
is not a monoamine oxidase inhibitor and, unlike amphetamine-type drugs,
does not stimulate the central nervous system. </p>

<p>In man, Trazodone is well absorbed after oral administration without
selective localization in any tissue. When Trazodone is taken shortly after
ingestion of food, there may be an increase in the amount of drug absorbed,
a decrease in maximum concentration, and a lengthening in the time to maximum
concentration. Peak plasma levels occur approximately one hour after dosing
when Trazodone is taken on an empty stomach or two hours after dosing when
taken with food. 
<br>
<br>Elimination of Trazodone is biphasic, consisting of an initial phase
(half-life 3- 6 hours) followed by a slower phase (half-life 5-9 hours),
and is unaffected by the presence or absence of food. Since the clearance
of Trazodone from the body is sufficiently variable, in some patients Trazodone
may accumulate in the plasma. For those patients who responded to Trazodone,
one- third of the inpatients and one-half of the outpatients had a significant
therapeutic response by the end of the first week of treatment. Three-fourths
of all responders demonstrated a significant therapeutic effect by the
end of the second week. One-fourth of responders required 2-4 weeks for
a significant therapeutic response. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Trazodone is indicated for the treatment of depression. The efficacy
of Trazodone has been demonstrated in both inpatient and outpatient settings
and for depressed patients with and without prominent anxiety. The depressive
illness of patients studied corresponds to the Major Depressive Episode
criteria of the American Psychiatric Association's Diagnostic and Statistical
Manual, III. (REF. a) </p>

<p>Major Depressive Episode implies a prominent and relatively persistent
(nearly every day for at least two weeks) depressed or dysphoric mood that
usually interferes with daily functioning, and includes at least four of
the following eight symptoms: change in appetite, change in sleep, psychomotor
agitation or retardation, loss of interest in usual activities or decrease
in sexual drive, increased fatigability, feelings of guilt or worthlessness,
slowed thinking or impaired concentration, and suicidal ideation or attempts.
</p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Trazodone is contraindicated in patients hypersensitive to Trazodone.
</p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>TRAZODONE HAS BEEN ASSOCIATED WITH THE OCCURRENCE OF PRIAPISM. IN MANY
OF THE CASES REPORTED, SURGICAL INTERVENTION WAS REQUIRED AND, IN SOME
OF THESE CASES, PERMANENT IMPAIRMENT OF ERECTILE FUNCTION OR IMPOTENCE
RESULTED. MALE PATIENTS WITH PROLONGED OR INAPPROPRIATE ERECTIONS SHOULD
IMMEDIATELY DISCONTINUE THE DRUG AND CONSULT THEIR PHYSICIAN. </p>

<p>The detumescence of priapism and drug-induced penile erections has been
accomplished by both pharmacologic, e.g., the intracavernosal injection
of alpha-adrenergic stimulants such as epinephrine and norepinephrine,
as well as surgical procedures. (REF. b-g) </p>

<p>Any pharmacologic or surgical procedure utilized in the treatment of
priapism should be performed under the supervision of a urologist or a
physician familiar with the procedure and should not be initiated without
urologic consultation if the priapism has persisted for more than 24 hours.
</p>

<p>Trazodone is not recommended for use during the initial recovery phase
of myocardial infarction. </p>

<p>Caution should be used when administering Trazodone to patients with
cardiac disease, and such patients should be closely monitored, since antidepressant
drugs (including Trazodone) have been associated with the occurrence of
cardiac arrhythmias. Recent clinical studies in patients with pre-existing
cardiac disease indicate that Trazodone may be arrhythmogenic in some patients
in that population. Arrhythmias identified include isolated PVCs, ventricular
couplets, and in two patients short episodes (3-4 beats) of ventricular
tachycardia. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL </p>

<p>The possibility of suicide in seriously depressed patients is inherent
in the illness and may persist until significant remission occurs. Therefore,
prescriptions should be written for the smallest number of tablets consistent
with good patient management. </p>

<p>Hypotension, including orthostatic hypotension and syncope, has been
reported to occur in patients receiving Trazodone. Concomitant administration
of antihypertensive therapy with Trazodone may require a reduction in the
dose of the antihypertensive drug. </p>

<p>Little is known about the interaction between Trazodone and general
anesthetics; therefore, prior to elective surgery, Trazodone should be
discontinued for as long as clinically feasible. </p>

<p>As with all antidepressants, the use of Trazodone should be based on
the consideration of the physician that the expected benefits of therapy
outweigh potential risk factors. </p>

<p>INFORMATION FOR PATIENTS </p>

<p>Because priapism has been reported to occur in patients receiving Trazodone,
patients with prolonged or inappropriate penile erection should immediately
discontinue the drug and consult with the physician (see WARNINGS). Antidepressants
may impair the mental and/or physical ability required for the performance
of potentially hazardous tasks, such as operating an automobile or machinery;
the patient should be cautioned accordingly. </p>

<p>Trazodone may enhance the response to alcohol, barbiturates, and other
CNS depressants. </p>

<p>Trazodone should be given shortly after a meal or light snack. Within
any individual patient, total drug absorption may be up to 20% higher when
the drug is taken with food rather than on an empty stomach. The risk of
dizziness/lightheadedness may increase under fasting conditions. </p>

<p>LABORATORY TESTS </p>

<p>Occasional low white blood cell and neutrophil counts have been noted
in patients receiving Trazodone. These were not considered clinically significant
and did not necessitate discontinuation of the drug; however, the drug
should be discontinued in any patient whose white blood cell count or absolute
neutrophil count falls below normal levels. White blood cell and differential
counts are recommended for patients who develop fever and sore throat (or
other signs of infection) during therapy. </p>

<p>DRUG INTERACTIONS </p>

<p>Increased serum digoxin or phenytoin levels have been reported to occur
in patients receiving Trazodone concurrently with either of those two drugs.
It is not known whether interactions will occur between monoamine oxidase
(MAO) inhibitors and Trazodone. Due to the absence of clinical experience,
if MAO inhibitors are discontinued shortly before or are to be given concomitantly
with Trazodone, therapy should be initiated cautiously with gradual increase
in dosage until optimum response is achieved. </p>

<p>THERAPEUTIC INTERACTIONS </p>

<p>Concurrent administration with electroshock therapy should be avoided
because of the absence of experience in this area. </p>

<p>There have been reports of increased and decreased prothrombin time
occurring in warfarinized patients who take Trazodone. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY </p>

<p>No drug- or dose-related occurrence of carcinogenesis was evident in
rats receiving Trazodone in daily oral doses up to 300 mg/kg for 18 months.
</p>

<p>PREGNANCY CATEGORY C </p>

<p>Trazodone has been shown to cause increased fetal resorption and other
adverse effects on the fetus in two studies using the rat when given at
dose levels approximately 30-50 times the proposed maximum human dose.
There was also an increase in congenital anomalies in one of three rabbit
studies at approximately 15-50 times the maximum human dose. There are
no adequate and well- controlled studies in pregnant women. Trazodone should
be used during pregnancy only if the potential benefit justifies the potential
risk to the fetus. </p>

<p>NURSING MOTHERS </p>

<p>Trazodone and/or its metabolites have been found in the milk of lactating
rats, suggesting that the drug may be secreted in human milk. Caution should
be exercised when Trazodone is administered to a nursing woman. </p>

<p>PEDIATRIC USE </p>

<p>Safety and effectiveness in children below the age of 18 have not been
established. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Increased serum digoxin or phenytoin levels have been reported to occur
in patients receiving Trazodone concurrently with either of those two drugs.
It is not known whether interactions will occur between monoamine oxidase
(MAO) inhibitors and Trazodone. Due to the absence of clinical experience,
if MAO inhibitors are discontinued shortly before or are to be given concomitantly
with Trazodone, therapy should be initiated cautiously with gradual increase
in dosage until optimum response is achieved. (See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Because the frequency of adverse drug effects is affected by diverse
factors (eg, drug dose, method of detection, physician judgment, disease
under treatment, etc.), a single meaningful estimate of adverse event incidence
is difficult to obtain. This problem is illustrated by the variation in
adverse event incidence observed and reported from the inpatients and outpatients
treated with Trazodone. It is impossible to determine precisely what accounts
for the differences observed. </p>

<p>CLINICAL TRIAL REPORTS </p>

<p>The table below is presented solely to indicate the relative frequency
of adverse events reported in representative controlled clinical studies
conducted to evaluate the safety and efficacy of Trazodone. </p>

<p>The figures cited cannot be used to predict precisely the incidence
of untoward events in the course of usual medical practice where patient
characteristics and other factors often differ from those which prevailed
in the clinical trials. These incidence figures, also, cannot be compared
with those obtained from other clinical studies involving related drug
products and placebo as each group of drug trials is conducted under a
different set of conditions. </p>

<pre>
                                               Treatment-Emergent
                                                Symptom Incidence
                                        --------------------------------
                                            Inpts.            Outpts.
                                            ------            -------
                                          D        P         D       P
-----------------------------------      ---      ---       ---     ---
Number of Patients                       142       95       157     158
% of Patients Reporting
Allergic
   Skin Condition/Edema                  2.8      1.1       7.0     1.3
Autonomic
  Blurred Vision                         6.3      4.2      14.7     3.8
  Constipation                           7.0      4.2       7.6     5.7
  Dry Mouth                             14.8      8.4      33.8    20.3
Cardiovascular
  Hypertension                           2.1      1.1       1.3       *
  Hypotension                            7.0      1.1       3.8     0.0
  Shortness of Breath                      *      1.1       1.3     0.0
  Syncope                                2.8      2.1       4.5     1.3
  Tachycardia/Palpitations               0.0      0.0       7.0     7.0
CNS
  Anger/Hostility                        3.5      6.3       1.3     2.5
  Confusion                              4.9      0.0       5.7     7.6
  Decreased Concentration                2.8      2.1       1.3     0.0
  Disorientation                         2.1      0.0         *     0.0
  Dizziness/Lightheadedness             19.7      5.3      28.0    15.2
  Drowsiness                            23.9      6.3      40.8    19.6
  Excitement                             1.4      1.1       5.1     5.7
  Fatigue                               11.3      4.2       5.7     2.5
  Headache                               9.9      5.3      19.8    15.8
  Insomnia                               9.9     10.5       6.4    12.0
  Impaired Memory                        1.4      0.0         *       *
  Nervousness                           14.8     10.5       6.4     8.2
Gastrointestinal
  Abdominal/Gastric Disorder             3.5      4.2       5.7     4.4
  Bad Taste in Mouth                     1.4      0.0       0.0     0.0
  Diarrhea                               0.0      1.1       4.5     1.9
  Nausea/Vomiting                        9.9      1.1      12.7     9.5
Musculoskeletal
  Musculoskeletal Aches/Pains            5.6      3.2       5.1     2.5
Neurological
  Incoordination                         4.9      0.0       1.9     0.0
  Paresthesia                            1.4      0.0       0.0       *
  Tremors                                2.8      1.1       5.1     3.8
Sexual Function
  Decreased Libido                         *      1.1       1.3       *
Other
  Decreased Appetite                     3.5      5.3       0.0       *
  Eyes Red/Tired/Itching                 2.8      0.0       0.0     0.0
  Head Full-Heavy                        2.8      0.0       0.0     0.0
  Malaise                                2.8      0.0       0.0     0.0
  Nasal/Sinus Congestion                 2.8      0.0       5.7     3.2
  Nightmares/Vivid Dreams                  *      1.1       5.1     5.7
  Sweating/Clamminess                    1.4      1.1         *       *
  Tinnitus                               1.4      0.0       0.0       *
  Weight Gain                            1.4      0.0       4.5     1.9
  Weight Loss                              *      3.2       5.7     2.5
-----------
*Incidence less than 1%
-----------
                                      D = Trazodone               P = Placebo</pre>

<p>Occasional sinus bradycardia has occurred in long-term studies. In addition
to the relatively common (ie, greater than 1%) untoward events enumerated
above, the following adverse events have been reported to occur in association
with the use of Trazodone in the controlled clinical studies: akathisia,
allergic reaction, anemia, chest pain, delayed urine flow, early menses,
flatulence, hallucinations/delusions, hematuria, hypersalivation, hypomania,
impaired speech, impotence, increased appetite, increased libido, increased
urinary frequency, missed periods, muscle twitches, numbness, and retrograde
ejaculation. </p>

<p>POSTINTRODUCTION REPORTS: </p>

<p>Although the following adverse reactions have been reported in Trazodone
users, the causal association has neither been confirmed nor refuted. </p>

<p>Voluntary reports received since market introduction include the following:
abnormal dreams, agitation, alopecia, anxiety, aphasia, apnea, ataxia,
breast enlargement or engorgement, cardiospasms, cerebrovascular accident,
chills, cholestatis, clitorism, congestive heart failure, diplopia, edema,
extrapyramidal symptoms, grand mal seizures, hallucinations, hemolytic
anemia, hirsutism, hyperbilirubinemia, increased amylase, increased salivation,
insomnia, leukocytosis, leukonychia, jaundice, lactation, liver enzyme
alterations, methemoglobinemia, nausea/vomiting (most frequently), paresthesia,
paranoid reaction, priapism (see WARNINGS and PRECAUTIONS, INFORMATION
FOR PATIENTS; some patients have required surgical intervention), pruritus,
psoriasis, psychosis, rash, stupor, inappropriate ADH syndrome, tardive
dyskinesia, unexplained death, urinary incontinence, urinary retention,
urticaria, vasodilation, vertigo, and weakness. </p>

<p>Cardiovascular system effects which have been reported include the following:
conduction block, orthostatic hypotension and syncope, palpitations, bradycardia,
atrial fibrillation, myocardial infarction, cardiac arrest, arrhythmia,
and ventricular ectopic activity, including ventricular tachycardia (see
WARNINGS). </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>ANIMAL ORAL LD50 </p>

<p>The oral LD50 of the drug is 610 mg/kg in mice, 486 mg/kg in rats, and
560 mg/kg in rabbits. </p>

<p>SIGNS AND SYMPTOMS </p>

<p>Death from overdose has occurred in patients ingesting Trazodone (trazodone
hydrochloride) and other drugs concurrently (namely, alcohol; alcohol +
chloral hydrate + diazepam; amobarbital; chlordiazepoxide; or meprobamate).
The most severe reactions reported to have occurred with overdose of Trazodone
alone have been priapism, respiratory arrest, seizures, and EKG changes.
The reactions reported most frequently have been drowsiness and vomiting.
Overdosage may cause an increase in incidence or severity of any of the
reported adverse reactions (see ADVERSE REACTIONS). </p>

<p>TREATMENT </p>

<p>There is no specific antidote for Trazodone. Treatment should be symptomatic
and supportive in the case of hypotension or excessive sedation. Any patient
suspected of having taken an overdose should have the stomach emptied by
gastric lavage. Forced diuresis may be useful in facilitating elimination
of the drug. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>The dosage should be initiated at a low level and increased gradually,
noting the clinical response and any evidence of intolerance. Occurrence
of drowsiness may require the administration of a major portion of the
daily dose at bedtime or a reduction of dosage. Trazodone should be taken
shortly after a meal or light snack. Symptomatic relief may be seen during
the first week, with optimal antidepressant effects typically evident within
two weeks. Twenty-five percent of those who respond to Trazodone require
more than two weeks (up to four weeks) of drug administration. </p>

<p>USUAL ADULT DOSAGE </p>

<p>An initial dose of 150 mg/day in divided doses is suggested. The dose
may be increased by 50 mg/day every three to four days. The maximum dose
for outpatients usually should not exceed 400 mg/day in divided doses.
Inpatients (i.e., more severely depressed patients) may be given up to
but not in excess of 600 mg/day in divided doses. </p>

<p>MAINTENANCE </p>

<p>Dosage during prolonged maintenance therapy should be kept at the lowest
effective level. Once an adequate response has been achieved, dosage may
be gradually reduced, with subsequent adjustment depending on therapeutic
response. Although there has been no systematic evaluation of the efficacy
of Trazodone beyond six weeks, it is generally recommended that a course
of antidepressant drug treatment should be continued for several months.
</p>

<p>REFERENCES </p>

<p>a. Williams JBW, Ed: Diagnostic and Statistical Manual of Mental Disorders-III,
American Psychiatric Association, May 1980. </p>

<p>b. Lue TF, Physiology of erection and pathophysiology of impotence.
In: Wash PC, Retik AB, Stamey TA, Vaughan ED, eds. Campbell's Urology,
Sixth edition. Philadelphia: W.B.Saunders; 1992: 722-725. </p>

<p>c. Goldstein I, Krane RJ, Diagnosis and therapy of erectile dysfunction.
In: Wash PC, Retik AB, Stamey TA, Vaughan ED, eds. Campbell's Urology.
Sixth edition. Philadelphia: W.B. Saunders; 1992: 3071-3072. </p>

<p>d. Yealy DM, Hogya PT: Priapism. Emerg Med Clin North Am. 1988; 6:509-520.
</p>

<p>e. Banos JE, Bosch F, Farre M, Drug-induced priapism. Its aetiology,
incidence, and treatment. Med Toxicol Adverse Drug Exp. 1989: 4:46-58.
</p>

<p>f. O'Brien WM, O'Connor KP, Lynch JH. Priapism: current concepts. Ann
Emerg Med. 1989: 980-983. </p>

<p>g. Bardin ED, Krieger JN. Pharmacological priapism: comparison of trazodone-and
papaverine- associated cases. Int Urol Nephrol. 1990: 22:147-152. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-29</DOCNO>
<DOCOLDNO>IA018-000200-B035-87</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/amitrip.htm 206.86.175.201 19970106224718 text/html 24035
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:41:02 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 23852
Last-modified: Thu, 11 Jul 1996 06:18:26 GMT
</DOCHDR>
<html>
<head>
   <title>Amitriptyline - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Amitriptyline</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Amitriptyline HCl is 3-(10,11-dihydro-5H-dibenzo(a,d)cycloheptene-5-ylidene)-
N N-dimethyl-1-propanamine hydrochloride. Its empirical formula is C20H23N.HCl.
</p>

<p>Amitriptyline HCl, a dibenzocycloheptadiene derivative, has a molecular
weight of 313.87. It is a white, odorless, crystalline compound which is
freely soluble in water. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Amitriptyline is an antidepressant with sedative effects. Its mechanism
of action in man is not known. It is not a monoamine oxidase inhibitor
and it does not act primarily by stimulation of the central nervous system.
</p>

<p>Amitriptyline inhibits the membrane pump mechanism responsible for uptake
of norepinephrine and serotonin in adrenergic and serotonergic neurons.
Pharmacologically this action may potentiate or prolong neuronal activity
since reuptake of these biogenic amines is important physiologically in
terminating transmitting activity. This interference with the reuptake
of norepinephrine and/or serotonin is believed by some to underlie the
antidepressant activity of amitriptyline. </p>

<p>METABOLISM </p>

<p>Studies in man following oral administration of 14C-labeled drug indicated
that amitriptyline is rapidly absorbed and metabolized. Radioactivity of
the plasma was practically negligible, although significant amounts of
radioactivity appeared in the urine by 4 to 6 hours and one-half to one-third
of the drug was excreted within 24 hours. </p>

<p>Amitriptyline is metabolized by N-demethylation and bridge hydroxylation
in man rabbit, and rat. Virtually the entire dose is excreted as glucuronide
or sulfate conjugate of metabolites, with little unchanged drug appearing
in the urine. Other metabolic pathways may be involved. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>For the relief of symptoms of depression. Endogenous depression is more
likely to be alleviated than are other depressive states. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Amitriptyline is contraindicated in patients who have shown prior hypersensitivity
to it. </p>

<p>It should not be given concomitantly with monoamine oxidase inhibitors.
</p>

<p>Hyperpyretic crises, severe convulsions, and deaths have occurred in
patients receiving tricyclic antidepressant and monoamine oxidase inhibiting
drugs simultaneously. When it is desired to replace a monoamine oxidase
inhibitor with Amitriptyline, a minimum of 14 days should be allowed to
elapse after the former is discontinued. Amitriptyline should then be initiated
cautiously with gradual increase in dosage until optimum response is achieved.
</p>

<p>This drug is not recommended for use during the acute recovery phase
following myocardial infarction. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>Amitriptyline may block the antihypertensive action of guanethidine
or similarly acting compounds. </p>

<p>It should be used with caution in patients with a history of seizures
and, because of its atropine-like action, in patients with a history of
urinary retention, angle-closure glaucoma or increased intraocular pressure.
In patients with angle-closure glaucoma, even average doses may precipitate
an attack. </p>

<p>Patients with cardiovascular disorders should be watched closely. Tricyclic
antidepressant drugs, including Amitriptyline, particularly when given
in high doses, have been reported to produce arrhythmias, sinus tachycardia,
and prolongation of the conduction time. Myocardial infarction and stroke
have been reported with drugs of this class. </p>

<p>Close supervision is required when Amitriptyline is given to hyperthyroid
patients or those receiving thyroid medication. </p>

<p>Amitriptyline may enhance the response to alcohol and the effects of
barbiturates and other CNS depressants. In patients who may use alcohol
excessively, it should be borne in mind that the potentiation may increase
the danger inherent in any suicide attempt or overdosage. Delirium has
been reported with concurrent administration of amitriptyline and disulfiram.
</p>

<p>USAGE IN PREGNANCY:Teratogenic effects were not observed in mice, rats,
or rabbits when amitriptyline was given orally at doses of 2 to 40 mg/kg/day
(up to 13 times the maximum recommended human dose**). Studies in the literature
have shown amitriptyline to be teratogenic in mice and hamsters when given
by various routes of administration at doses of 28 to 100 mg/kg/day (9
to 33 times the maximum recommended human dose), producing multiple malformations.
Another study in the rat reported that an oral dose of 25 mg/kg/day (8
times the maximum recommended human dose) produced delays in ossification
of fetal vertebral bodies without other signs of embryotoxicity. In rabbits,
an oral dose of 60 mg/ kg/day (20 times the maximum recommended human dose)
was reported to cause incomplete ossification of the cranial bones. </p>

<p>Amitriptyline has been shown to cross the placenta. Although a causal
relationship has not been established, there have been a few reports of
adverse events, including CNS effects, limb deformities, or developmental
delay, in infants whose mothers had taken amitriptyline during pregnancy.
</p>

<p>There are no adequate or well-controlled studies in pregnant women.
Amitriptyline should be used during pregnancy only if the potential benefit
to the mother justifies the potential risk to the fetus. </p>

<p>NURSING MOTHERS: Amitriptyline is excreted into breast milk. In one
report in which a patient received amitriptyline 100 mg/day while nursing
her infant, levels of 83-141 ng/mL were detected in the mother's serum.
Levels of 135-151 ng/mL were found in the breast milk, but no trace of
the drug could be detected in the infant's serum. </p>

<p>Because of the potential for serious adverse reactions in nursing infants
from amitriptyline, a decision should be made whether to discontinue nursing
or to discontinue the drug, taking into account the importance of the drug
to the mother. </p>

<p>USAGE IN CHILDREN:In view of the lack of experience with the use of
this drug in children, it is not recommended at the present time for patients
under 12 years of age. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>Schizophrenic patients may develop increased symptoms of psychosis;
patients with paranoid symptomatology may have an exaggeration of such
symptoms. Depressed patients, particularly those with known manic-depressive
illness, may experience a shift to mania or hypomania. In these circumstances
the dose of amitriptyline may be reduced or a major tranquilizer such as
perphenazine may be administered concurrently. </p>

<p>When Amitriptyline is given with anticholinergic agents or sympathomimetic
drugs, including epinephrine combined with local anesthetics, close supervision
and careful adjustment of dosages are required. </p>

<p>Hyperpyrexia has been reported when Amitriptyline is administered with
anticholingeric agents or with neuroleptic drugs, particularly during hot
weather. Paralytic ileus may occur in patients taking tricyclic antidepressants
in combination with anticholinergic-type drugs. </p>

<p>Cimetidine is reported to reduce hepatic metabolism of certain tricyclic
antidepressants, thereby delaying elimination and increasing steady-state
concentrations of these drugs. Clinically significant effects have been
reported with the tricyclic antidepressants when used concomitantly with
cimetidine. Increases in plasma levels of tricyclic antidepressants, and
in the frequency and severity of side effects, particularly anticholinergic,
have been reported when cimetidine was added to the drug regimen. Discontinuation
of cimetidine in well-controlled patients receiving tricyclic antidepressants
and cimetidine may decrease the plasma levels and efficacy of the antidepressants.
</p>

<p>Caution is advised if patients receive large doses of ethchlorvynol
concurrently. Transient delirium has been reported in patients who were
treated with one gram of ethchlorvynol and 75-150 mg of Amitriptyline.
</p>

<p>The possibility of suicide in depressed patients remains until significant
remission occurs. Potentially suicidal patients should not have access
to large quantities of this drug. Prescriptions should be written for the
smallest amount feasible. </p>

<p>Concurrent administration of Amitriptyline and electroshock therapy
may increase the hazards associated with such therapy. Such treatment should
be limited to patients for whom it is essential. </p>

<p>When possible, the drug should be discontinued several days before elective
surgery. </p>

<p>Both elevation and lowering of blood sugar levels have been reported.
</p>

<p>Amitriptyline should be used with caution in patients with impaired
liver function. </p>

<p>INFORMATION FOR PATIENTS: While on therapy with Amitriptyline, patients
should be advised as to the possible impairment of mental and/or physical
abilities required for performance of hazardous tasks, such as operating
machinery or driving a motor vehicle. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>It should not be given concomitantly with monoamine oxidase inhibitors.
</p>

<p>Hyperpyretic crises, severe convulsions, and deaths have occurred in
patients receiving tricyclic antidepressant and monoamine oxidase inhibiting
drugs simultaneously. When it is desired to replace a monoamine oxidase
inhibitor with Amitriptyline, a minimum of 14 days should be allowed to
elapse after the former is discontinued. Amitriptyline should then be initiated
cautiously with gradual increase in dosage until optimum response is achieved.
</p>

<p>Amitriptyline may block the antihypertensive action of guanethidine
or similarly acting compounds. </p>

<p>Close supervision is required when Amitriptyline is given to hyperthyroid
patients or those receiving thyroid medication. </p>

<p>Amitriptyline may enhance the response to alcohol and the effects of
barbiturates and other CNS depressants. In patients who may use alcohol
excessively, it should be borne in mind that the potentiation may increase
the danger inherent in any suicide attempt or overdosage. Delirium has
been reported with concurrent administration of amitriptyline and disulfiram.
</p>

<p>When Amitriptyline is given with anticholinergic agents or sympathomimetic
drugs, including epinephrine combined with local anesthetics, close supervision
and careful adjustment of dosages are required. </p>

<p>Hyperpyrexia has been reported when Amitriptyline is administered with
anticholingeric agents or with neuroleptic drugs, particularly during hot
weather. </p>

<p>Paralytic ileus may occur in patients taking tricyclic antidepressants
in combination with anticholinergic-type drugs. </p>

<p>Cimetidine is reported to reduce hepatic metabolism of certain tricyclic
antidepressants, thereby delaying elimination and increasing steady-state
concentrations of these drugs. Clinically significant effects have been
reported with the tricyclic antidepressants when used concomitantly with
cimetidine. Increases in plasma levels of tricyclic antidepressants, and
in the frequency and severity of side effects, particularly anticholinergic,
have been reported when cimetidine was added to the drug regimen. Discontinuation
of cimetidine in well-controlled patients receiving tricyclic antidepressants
and cimetidine may decrease the plasma levels and efficacy of the antidepressants.
</p>

<p>Caution is advised if patients receive large doses of ethchlorvynol
concurrently. Transient delirium has been reported in patients who were
treated with one gram of ethchlorvynol and 75-150 mg of Amitriptyline.
</p>

<p>(See Also CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Within each category the following adverse reactions are listed in order
of decreasing severity. Included in the listing are a few adverse reactions
which have not been reported with this specific drug. However, pharmacological
similarities among the tricyclic antidepressant drugs require that each
of the reactions be considered when amitriptyline is administered. </p>

<p>CARDIOVASCULAR: Myocardial infarction; stroke; nonspecific ECG changes
and changes in AV conductor; heart block; arrhythmias; hypotension, particularly
orthostatic hypotension; syncope; hypertension; tachycardia; palpitation.
</p>

<p>CNS AND NEUROMUSCULAR: Coma; seizures; hallucinations; delusions; confusional
states; disorientation; incoordination; ataxia; tremors; peripheral neuropathy;
numbness, tingling, and paresthesias of the extremities; extrapyramidal
symptoms including abnormal involuntary movements and tardive dyskinesia;
dysarthria; disturbed concentration; excitement; anxiety; insomnia; restlessness;
nightmares; drowsiness; dizziness; weakness; fatigue; headache; syndrome
of inappropriate ADH (antidiuretic hormone) secretion; tinnitus; alteration
in EEG patterns. </p>

<p>ANTICHOLINERGIC: Paralytic ileus; hyperpyrexia; urinary retention, dilatation
of the urinary tract; constipation; blurred vision, disturbance of accommodation,
increased intraocular pressure, mydriasis; dry mouth. </p>

<p>ALLERGIC: Skin rash; urticaria; photosensitization; edema of face and
tongue. </p>

<p>HEMATOLOGIC: Bone marrow depression including agranulocytosis, leukopenia,
thrombocytopenia; purpura; eosinophilia. </p>

<p>GASTROINTESTINAL: Rarely hepatitis (including altered liver function
and jaundice); nausea; epigastric distress; vomiting; anorexia; stomatitis;
peculiar taste; diarrhea; parotid swelling; black tongue. </p>

<p>ENDOCRINE: Testicular swelling and gynecomastia in the male; breast
enlargement and galactorrhea in the female; increased or decreased libido;
impotence; elevation and lowering of blood sugar levels. </p>

<p>OTHER: Alopecia; edema; weight gain or loss; urinary frequency; increased
perspiration. </p>

<p>WITHDRAWAL SYMPTOMS: After prolonged administration, abrupt cessation
of treatment may produce nausea, headache, and malaise. Gradual dosage
reduction has been reported to produce, within two weeks, transient symptoms
including irritability, restlessness, and dream and sleep disturbance.
These symptoms are not indicative of addiction. Rare instances have been
reported of mania or hypomania occurring within 2-7 days following cessation
of chronic therapy with tricyclic antidepressants. </p>

<p>CAUSAL RELATIONSHIP UNKNOWN: Other reactions, reported under circumstances
where a causal relationship could not be established, are listed to serve
as alerting information to physicians: </p>

<p>BODY AS A WHOLE: Lupus-like syndrome (migratory arthritis, positive
ANA and rheumatoid factor). </p>

<p>DIGESTIVE: Hepatic failure, ageusia. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>MANIFESTATIONS: High doses may cause temporary confusion, disturbed
concentration, or transient visual hallucinations. Overdosage may cause
drowsiness; hypothermia; tachycardia and other arrhythmic abnormalities,
such as bundle branch block; ECG evidence of impaired conduction; congestive
heart failure; dilated pupils; disorders of ocular motility; convulsions;
severe hypotension; stupor; coma; and polyradiculoneuropathy. Other symptoms
may be agitation, hyperactive reflexes, muscle rigidity, vomiting, hyperpyrexia,
or any of those listed under ADVERSE REACTIONS. </p>

<p>There has been a report of fatal dysrhythmia occurring as late as 56
hours after amitriptyline overdose. </p>

<p>All patients suspected of having taken an overdosage should be admitted
to a hospital as soon as possible. Treatment is symptomatic and supportive.
Empty the stomach as quickly as possible by emesis followed by gastric
lavage upon arrival at the hospital. Following gastric lavage, activated
charcoal may be administered. Twenty to 30 g of activated charcoal may
be given every four to six hours during the first 24 to 48 hours after
ingestion. An ECG should be taken and close monitoring of cardiac function
instituted if there is any sign of abnormality. Maintain an open airway
and adequate fluid intake; regulate body temperature. </p>

<p>The intravenous administration of 1-3 mg of physostigmine salicylate
is reported to reverse the symptoms of tricyclic antidepressant poisoning.
Because physostigmine is rapidly metabolized, the dosage of physostigmine
should be repeated as required particularly if life threatening signs such
as arrhythmias convulsions, and deep coma recur or persist after the initial
dosage of physostigmine. Because physostigmine itself may be toxic, it
is not recommended for routine use. </p>

<p>Standard measures should be used to manage circulatory shock and metabolic
acidosis. Cardiac arrhythmias may be treated with neostigmine, pyridostigmine,
or propranolol. Should cardiac failure occur, the use of digitalis should
be considered. Close monitoring of cardiac function for not less than five
days is advisable. </p>

<p>Anticonvulsants may be given to control convulsions. Amitriptyline increases
the CNS depressant action but not the anticonvulsant action of barbiturates;
therefore, an inhalation anesthetic, diazepam, or paraldehyde is recommended
for control of convulsions. </p>

<p>Dialysis is of no value because of low plasma concentrations of the
drug. </p>

<p>Since overdosage is often deliberate, patients may attempt suicide by
other means during the recovery phase. </p>

<p>Deaths by deliberate or accidental overdosage have occurred with this
class of drugs. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>ORAL DOSAGE Dosage should be initiated at a low level and increased
gradually, noting carefully the clinical response and any evidence of intolerance.
</p>

<p>INITIAL DOSAGE FOR ADULTS--For outpatients 75 mg of amitriptyline HCl
a day in divided doses is usually satisfactory. If necessary, this may
be increased to a total of 150 mg per day. Increases are made preferably
in the late afternoon and/or bedtime doses. A sedative effect may be apparent
before the antidepressant effect is noted, but an adequate therapeutic
effect may take as long as 30 days to develop. </p>

<p>An alternate method of initiating therapy in outpatients is to begin
with 50 to 100 mg amitriptyline HCl at bedtime. This may be increased by
25 or 50 mg as necessary in the bedtime dose to a total of 150 mg per day.</p>

<p>Hospitalized patients may require 100 mg a day initially. This can be
increased gradually to 200 mg a day if necessary. A small number of hospitalized
patients may need as much as 300 mg a day. </p>

<p>ADOLESCENT AND ELDERLY PATIENTS--In general, lower dosages are recommended
for these patients. Ten mg 3 times a day with 20 mg at bedtime may be satisfactory
in adolescent and elderly patients who do not tolerate higher dosages.
</p>

<p>MAINTENANCE--The usual maintenance dosage of amitriptyline HCl is 50
to 100 mg per day. In some patients 40 mg per day is sufficient. For maintenance
therapy the total daily dosage may be given in a single dose preferably
at bedtime. When satisfactory improvement has been reached, dosage should
be reduced to the lowest amount that will maintain relief of symptoms.
It is appropriate to continue maintenance therapy 3 months or longer to
lessen the possibility of relapse. </p>

<p>INTRAMUSCULAR DOSAGE </p>

<p>Initially, 20 to 30 mg (2 to 3 mL) four times a day. </p>

<p>When Amitriptyline Injection is administered intramuscularly, the effects
may appear more rapidly than with oral administration. </p>

<p>When Amitriptyline Injection is used for initial therapy in patients
unable or unwilling to take Amitriptyline tablets, the tablets should replace
the injection as soon as possible. </p>

<p>USAGE IN CHILDREN </p>

<p>In view of the lack of experience with the use of this drug in children,
it is not recommended at the present time for patients under 12 years of
age. </p>

<p>PLASMA LEVELS </p>

<p>Because of the wide variation in the absorption and distribution of
tricyclic antidepressants in body fluids, it is difficult to directly correlate
plasma levels and therapeutic effect. However, determination of plasma
levels may be useful in identifying patients who appear to have toxic effects
and may have excessively high levels, or those in whom lack of absorption
or noncompliance is suspected. Adjustments in dosage should be made according
to the patient's clinical response and not on the basis of plasma levels.*/*
</p>

<p><i>REFERENCES </i></p>

<p>Ayd FJ Jr: Amitriptyline (Amitriptyline) therapy for depressive reactions.
Psychosomatics 1960;1:320-325. </p>

<p>Diamond S: Human metabolization of amitriptyline tagged with carbon
14. Curr Ther Res, Mar 1965, pp 170-175. </p>

<p>Dorfman W: Clinical experiences with amitriptyline (Amitriptyline):
A preliminary report. Psychosomatics 1960;1:153-155. </p>

<p>Fallette JM, Stasney CR, Mintz AA: Amitriptyline poisoning treated with
physostigmine. South Med J 1970; 63:1492-1493. </p>

<p>Hollister LE, Overall JE, Johnson M, et al: Controlled comparison of
amitriptyline, imipramine and placebo in hospitalized depressed patients.
J Nerv Ment Dis 1964; 139:370-375. </p>

<p>Hordern A, Burt CG, Holt NF: Depressive states: A pharmacotherapeutic
study, Springfield study. Springfield, Ill, Charles C. Thomas, 1965.</p>

<p>Klerman GL, Cole JO: Clinical pharmacology of imipramine and related
antidepressant compounds. Int J Psychiatry 1976;3:267-304. </p>

<p>McConaghy N, Joffe AD, Kingston WR, et al: Correlation of clinical features
of depressed out-patients with response to amitriptyline and protriptyline.
Br J Psychiatry 1968; 114:103-106. </p>

<p>McDonald IM, Perkins M, Marjerrison G, et al: A controlled comparison
of amitriptyline and electroconvulsive therapy in the treatment of depression.
Am J Psychiatry 1966;122: 1427-1431. </p>

<p>Slovis T, Ott J, Teitelbaum, et al: Physostigmine therapy in acute tricyclic
antidepressant poisoning. Clin Toxicol 1971;4: 451-459. </p>

<p>Symposium on depression with special studies of a new antidepressant,
amitriptyline. Dis Nerv Syst, (Sect 2) May 1961, pp 5-56. </p>

<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-30</DOCNO>
<DOCOLDNO>IA018-000200-B039-172</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/buprop.htm 206.86.175.201 19970106230302 text/html 44452
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:56:43 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 44269
Last-modified: Wed, 25 Sep 1996 22:25:10 GMT
</DOCHDR>
<html>
<head>
   <title>Bupropion - RxList Generic Information</title>
   <meta name="keywords" content="Wellbutrin">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Bupropion</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Bupropion, an antidepressant of the aminoketone class, is chemically
unrelated to tricyclic, tetracyclic, or other known antidepressant agents.
Its structure closely resembles that of diethylpropion; it is related to
phenylethylamines. It is designated as (+/-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)am
ino)-1-propanone hydrochloride. The molecular weight is 276.2. The empirical
formula is C13H18ClNO.HCl. Bupropion powder is white, crystalline, and
highly soluble in water. It has a bitter taste and produces the sensation
of local anesthesia on the oral mucosa. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>PHARMACODYNAMICS AND PHARMACOLOGICAL ACTIONS: The neurochemical mechanism
of the antidepressant effect of bupropion is not known. Bupropion does
not inhibit monoamine oxidase. Compared to classical tricyclic antidepressants,
it is a weak blocker of the neuronal uptake of serotonin and norepinephrine;
it also inhibits the neuronal re- uptake of dopamine to some extent. </p>

<p>Bupropion produces dose-related CNS stimulant effects in animals, as
evidenced by increased locomotor activity, increased rates of responding
in various schedule-controlled operant behavior tasks, and, at high doses,
induction of mild stereotyped behavior. </p>

<p>Bupropion causes convulsions in rodents and dogs at doses approximately
tenfold the dose recommended as the human antidepressant dose. </p>

<p>ABSORPTION, DISTRIBUTION, PHARMACOKINETICS, METABOLISM, AND ELIMINATION:
</p>

<p>ORAL BIOAVAILABILITY AND SINGLE-DOSE PHARMACOKINETICS: In humans, following
oral administration of Bupropion, peak plasma bupropion concentrations
are usually achieved within 2 hours, followed by a biphasic decline. The
average half-life of the second (post- distributional) phase is approximately
14 hours, with a range of 8 to 24 hours. Six hours after a single dose,
plasma bupropion concentrations are approximately 30% of peak concentrations.
Plasma bupropion concentrations are dose-proportional following single
doses of 100 to 250 mg; however, it is not known if the proportionality
between dose and plasma level is maintained in chronic use. </p>

<p>The absolute bioavailability of Bupropion tablets in humans has not
been determined because an intravenous formulation for human use is not
available. However, it appears likely that only a small proportion of any
orally administered dose reaches the systemic circulation intact. For example,
the absolute bioavailability of bupropion in animals (rats and dogs) ranges
from 5% to 20%. </p>

<p>METABOLISM: Following oral administration of 200 mg of 14C-bupropion,
87% and 10% of the radioactive dose were recovered in the urine and feces,
respectively. However, the fraction of the oral dose of Bupropion excreted
unchanged was only 0.5%, a finding documenting the extensive metabolism
of bupropion. </p>

<p>Several of the known metabolites of bupropion are pharmacologically
active, but their potency and toxicity relative to bupropion have not been
fully characterized. However, because of their longer elimination half-lives,
the plasma concentrations of at least two of the known metabolites can
be expected, especially in chronic use, to be very much higher than the
plasma concentration of bupropion. This is of potential clinical importance
because factors or conditions altering metabolic capacity (e.g., liver
disease, congestive heart failure, age, concomitant medications, etc.)
or elimination may be expected to influence the degree and extent of accumulation
of these active metabolites. </p>

<p>Furthermore, bupropion has been shown to induce its own metabolism in
three animal species (mice, rats, and dogs) following subchronic administration.
If induction also occurs in humans, the relative contribution of bupropion
and its metabolites to the clinical effects of Bupropion may be changed
in chronic use. Plasma and urinary metabolites so far identified include
biotransformation products formed via reduction of the carbonyl group and/or
hydroxylation of the Tert-butyl group of bupropion. Four basic metabolites
have been identified. They are the Erythro- and Threo- amino alcohols of
bupropion, the Erythro- amino diol of bupropion, and a morpholinol metabolite
(formed from hydroxylation of the Tert- butyl group of bupropion). </p>

<p>The morpholinol metabolite appears in the systemic circulation almost
as rapidly as the parent drug following a single oral dose. Its peak level
is three times the peak level of the parent drug; it has a half-life on
the order of 24 hours; and its AUC 0 to 60 hrs is about 15 times that of
bupropion. </p>

<p>The Threo- amino alcohol metabolite has a plasma concentration-time
profile similar to that of the morpholinol metabolite. The Erythro- amino
alcohol and the Erythro- amino diol metabolites generally cannot be detected
in the systemic circulation following a single oral dose of the parent
drug. </p>

<p>The morpholinol and the Threo- amino alcohol metabolites have been found
to be half as potent as bupropion in animal screening tests for antidepressant
drugs. During a chronic dosing study in 14 depressed patients with left
ventricular dysfunction, it was found that there was substantial interpatient
variability (two- to fivefold) in the trough steady-state concentrations
of bupropion and the morpholinol and Threo- amino alcohol metabolites.
In addition, the steady-state plasma concentrations of these metabolites
were 10 to 100 times the steady- state concentrations of the parent drug.
</p>

<p>The effect of other disease states and altered organ function on the
metabolism and/or elimination of bupropion has not been studied in detail.
However, the elimination of the major metabolites of bupropion may be affected
by reduced renal or hepatic function because they are moderately polar
compounds and are likely to undergo conjugation in the liver prior to urinary
excretion. The preliminary results of a comparative single-dose pharmacokinetic
study in normal versus cirrhotic patients indicated that half-lives of
the metabolites were prolonged by cirrhosis and that the metabolites accumulated
to levels two to three times those in normals. </p>

<p>The effect of age on plasma concentrations of bupropion and its metabolites
has not been characterized. </p>

<p>In vitro tests show that bupropion is 80% or more bound to human albumin
at plasma concentrations up to 800 micromolar (200 mcgm/mL). </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Bupropion is indicated for the treatment of depression. A physician
considering Bupropion for the management of a patient's first episode of
depression should be aware that the drug may cause generalized seizures
with an approximate incidence of 0.4% (4/1000). This incidence of seizures
may exceed that of other marketed antidepressants by as much as fourfold.
This relative risk is only an approximate estimate because no direct comparative
studies have been conducted. The efficacy of Bupropion has been established
in three placebo-controlled trials, including two of approximately 3 weeks
duration in depressed inpatients, and one of approximately 6 weeks duration
in depressed outpatients. The depressive disorder of the patients studied
corresponds most closely to the Major Depression category of the APA Diagnostic
and Statistical Manual III. </p>

<p>Major Depression implies a prominent and relatively persistent depressed
or dysphoric mood that usually interferes with daily functioning (nearly
every day for at least two weeks); it should include at least four of the
following eight symptoms: change in appetite, change in sleep, psychomotor
agitation or retardation, loss of interest in usual activities or decrease
in sexual drive, increased fatigability, feelings of guilt or worthlessness,
slowed thinking or impaired concentration, and suicidal ideation or attempts.
</p>

<p>Effectiveness of Bupropion in long-term use, that is, for more than
6 weeks, has not been systematically evaluated in controlled trials. Therefore,
the physician who elects to use Bupropion for extended periods should periodically
re-evaluate the long-term usefulness of the drug for the individual patient.
</p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Bupropion is contraindicated in patients with a seizure disorder. Bupropion
is also contraindicated in patients with a current or prior diagnosis of
bulimia or anorexia nervosa because of a higher incidence of seizures noted
in such patients treated with Bupropion. The concurrent administration
of Bupropion and a monoamine oxidase (MAO) inhibitor is contraindicated.
At least 14 days should elapse between discontinuation of an MAO inhibitor
and initiation of treatment with Bupropion. Bupropion is contraindicated
in patients who have shown an allergic response to it. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>SEIZURES: Bupropion IS ASSOCIATED WITH SEIZURES IN APPROXIMATELY 0.4%
(4/1000) OF PATIENTS TREATED AT DOSES UP TO 450 MG/DAY. THIS INCIDENCE
OF SEIZURES MAY EXCEED THAT OF OTHER MARKETED ANTIDEPRESSANTS BY AS MUCH
AS FOURFOLD. THIS RELATIVE RISK IS ONLY AN APPROXIMATE ESTIMATE BECAUSE
NO DIRECT COMPARATIVE STUDIES HAVE BEEN CONDUCTED. THE ESTIMATED SEIZURE
INCIDENCE FOR Bupropion INCREASES ALMOST TENFOLD BETWEEN 450 AND 600 MG/DAY,
WHICH IS TWICE THE USUALLY REQUIRED DAILY DOSE (300 MG) AND ONE AND ONE-
THIRD THE MAXIMUM RECOMMENDED DAILY DOSE (450 MG). GIVEN THE WIDE VARIABILITY
AMONG INDIVIDUALS AND THEIR CAPACITY TO METABOLIZE AND ELIMINATE DRUGS,
THIS DISPROPORTIONATE INCREASE IN SEIZURE INCIDENCE WITH DOSE INCREMENTATION
CALLS FOR CAUTION IN DOSING. </p>

<p>DURING THE INITIAL DEVELOPMENT, 25 AMONG APPROXIMATELY 2400 PATIENTS
TREATED WITH Bupropion EXPERIENCED SEIZURES. AT THE TIME OF SEIZURE, SEVEN
PATIENTS WERE RECEIVING DAILY DOSES OF 450 MG OR BELOW, FOR AN INCIDENCE
OF 0.33% (3/1000) WITHIN THE RECOMMENDED DOSE RANGE. TWELVE PATIENTS EXPERIENCED
SEIZURES AT 600 MG PER DAY (2.3% INCIDENCE); SIX ADDITIONAL PATIENTS HAD
SEIZURES AT DAILY DOSES BETWEEN 600 AND 900 MG (2.8% INCIDENCE). </p>

<p>A SEPARATE, PROSPECTIVE STUDY WAS CONDUCTED TO DETERMINE THE INCIDENCE
OF SEIZURE DURING AN 8-WEEK TREATMENT EXPOSURE IN APPROXIMATELY 3200 ADDITIONAL
PATIENTS WHO RECEIVED DAILY DOSES OF UP TO 450 MG. PATIENTS WERE PERMITTED
TO CONTINUE TREATMENT BEYOND 8 WEEKS IF CLINICALLY INDICATED. EIGHT SEIZURES
OCCURRED DURING THE INITIAL 8-WEEK TREATMENT PERIOD AND FIVE SEIZURES WERE
REPORTED IN PATIENTS CONTINUING TREATMENT BEYOND 8 WEEKS, RESULTING IN
A TOTAL SEIZURE INCIDENCE OF 0.4%. </p>

<p>THE RISK OF SEIZURE APPEARS TO BE STRONGLY ASSOCIATED WITH DOSE AND
THE PRESENCE OF PREDISPOSING FACTORS. A SIGNIFICANT PREDISPOSING FACTOR
(E.G., HISTORY OF HEAD TRAUMA OR PRIOR SEIZURE, CNS TUMOR, CONCOMITANT
MEDICATIONS THAT LOWER SEIZURE THRESHOLD, ETC.) WAS PRESENT IN APPROXIMATELY
ONE-HALF OF THE PATIENTS EXPERIENCING A SEIZURE. SUDDEN AND LARGE INCREMENTS
IN DOSE MAY CONTRIBUTE TO INCREASED RISK. WHILE MANY SEIZURES OCCURRED
EARLY IN THE COURSE OF TREATMENT, SOME SEIZURES DID OCCUR AFTER SEVERAL
WEEKS AT FIXED DOSE. </p>

<p>RECOMMENDATIONS FOR REDUCING THE RISK OF SEIZURE: RETROSPECTIVE ANALYSIS
OF CLINICAL EXPERIENCE GAINED DURING THE DEVELOPMENT OF Bupropion SUGGESTS
THAT THE RISK OF SEIZURE MAY BE MINIMIZED IF (1) THE TOTAL DAILY DOSE OF
Bupropion DOES NOT EXCEED 450 MG, (2) THE DAILY DOSE IS ADMINISTERED T.I.D.,
WITH EACH SINGLE DOSE NOT TO EXCEED 150 MG TO AVOID HIGH PEAK CONCENTRATIONS
OF BUPROPION AND/OR ITS METABOLITES, AND (3) THE RATE OF INCREMENTATION
OF DOSE IS VERY GRADUAL. EXTREME CAUTION SHOULD BE USED WHEN Bupropion
IS (1) ADMINISTERED TO PATIENTS WITH A HISTORY OF SEIZURE, CRANIAL TRAUMA,
OR OTHER PREDISPOSITION(S) TOWARD SEIZURE, OR (2) PRESCRIBED WITH OTHER
AGENTS (E.G., ANTIPSYCHOTICS, OTHER ANTIDEPRESSANTS, ETC.) OR TREATMENT
REGIMENS (E.G., ABRUPT DISCONTINUATION OF A BENZODIAZEPINE) THAT LOWER
SEIZURE THRESHOLD. </p>

<p>POTENTIAL FOR HEPATOTOXICITY: In rats receiving large doses of bupropion
chronically, there was an increase in incidence of hepatic hyperplastic
nodules and hepatocellular hypertrophy. In dogs receiving large doses of
bupropion chronically, various histologic changes were seen in the liver,
and laboratory tests suggesting mild hepatocellular injury were noted.
Although scattered abnormalities in liver function tests were detected
in patients participating in clinical trials, there is no clinical evidence
that bupropion acts as a hepatotoxin in humans. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL: </p>

<p>AGITATION AND INSOMNIA: A substantial proportion of patients treated
with Bupropion experience some degree of increased restlessness, agitation,
anxiety, and insomnia, especially shortly after initiation of treatment.
In clinical studies, these symptoms were sometimes of sufficient magnitude
to require treatment with sedative/hypnotic drugs. In approximately 2%
of patients, symptoms were sufficiently severe to require discontinuation
of treatment with Bupropion. PSYCHOSIS, CONFUSION, AND OTHER NEUROPSYCHIATRIC
PHENOMENA: Patients treated with Bupropion have been reported to show a
variety of neuropsychiatric signs and symptoms including delusions, hallucinations,
psychotic episodes, confusion, and paranoia. Because of the uncontrolled
nature of many studies, it is impossible to provide a precise estimate
of the extent of risk imposed by treatment with Bupropion. In several cases,
neuropsychiatric phenomena abated upon dose reduction and/or withdrawal
of treatment. </p>

<p>ACTIVATION OF PSYCHOSIS AND/OR MANIA: Antidepressants can precipitate
manic episodes in Bipolar Manic Depressive patients during the depressed
phase of their illness and may activate latent psychosis in other susceptible
patients. Bupropion is expected to pose similar risks. </p>

<p>ALTERED APPETITE AND WEIGHT: A weight loss of greater than 5 pounds
occurred in 28% of Bupropion patients. This incidence is approximately
double that seen in comparable patients treated with tricyclics or placebo.
Furthermore, while 34.5% of patients receiving tricyclic antidepressants
gained weight, only 9.4% of patients treated with Bupropion did. Consequently,
if weight loss is a major presenting sign of a patient's depressive illness,
the anorectic and/or weight reducing potential of Bupropion should be considered.
</p>

<p>SUICIDE: The possibility of a suicide attempt is inherent in depression
and may persist until significant remission occurs. Accordingly, prescriptions
for Bupropion should be written for the smallest number of tablets consistent
with good patient management. </p>

<p>USE IN PATIENTS WITH SYSTEMIC ILLNESS: There is no clinical experience
establishing the safety of Bupropion in patients with a recent history
of myocardial infarction or unstable heart disease. Therefore, care should
be exercised if it is used in these groups. Bupropion was well tolerated
in patients who had previously developed orthostatic hypotension while
receiving tricyclic antidepressants. </p>

<p>Because bupropion HCl and its metabolites are almost completely excreted
through the kidney and metabolites are likely to undergo conjugation in
the liver prior to urinary excretion, treatment of patients with renal
or hepatic impairment should be initiated at reduced dosage as bupropion
and its metabolites may accumulate in such patients beyond concentrations
expected in patients without renal or hepatic impairment. The patient should
be closely monitored for possible toxic effects of elevated blood and tissue
levels of drug and metabolites. INFORMATION FOR PATIENTS: Physicians are
advised to discuss the following issues with patients: </p>

<p>Patients should be instructed to take Bupropion in equally divided doses
three or four times a day to minimize the risk of seizure. Patients should
be told that any CNS-active drug like Bupropion may impair their ability
to perform tasks requiring judgment or motor and cognitive skills. Consequently,
until they are reasonably certain that Bupropion does not adversely affect
their performance, they should refrain from driving an automobile or operating
complex, hazardous machinery. </p>

<p>Patients should be told that the use and cessation of use of alcohol
may alter the seizure threshold, and, therefore, that the consumption of
alcohol should be minimized, and, if possible, avoided completely. </p>

<p>Patients should be advised to inform their physician if they are taking
or plan to take any prescription or over-the-counter drugs. Concern is
warranted because Bupropion and other drugs may affect each other's metabolism.
</p>

<p>Patients should be advised to notify their physician if they become
pregnant or intend to become pregnant during therapy. </p>

<p>DRUG INTERACTIONS: No systematic data have been collected on the consequences
of the concomitant administration of Bupropion and other drugs. </p>

<p>However, animal data suggest that Bupropion may be an inducer of drug-metabolizing
enzymes. This may be of potential clinical importance because the blood
levels of co-administered drugs may be altered. </p>

<p>Alternatively, because bupropion is extensively metabolized, the co-administration
of other drugs may affect its clinical activity. In particular, care should
be exercised when administering drugs known to affect hepatic drug-metabolizing
enzyme systems (e.g., carbamazepine, cimetidine, phenobarbital, phenytoin).
</p>

<p>Studies in animals demonstrate that the acute toxicity of bupropion
is enhanced by the MAO inhibitor phenelzine (see CONTRAINDICATIONS). </p>

<p>Limited clinical data suggest a higher incidence of adverse experiences
in patients receiving concurrent administration of Bupropion and L- dopa.
Administration of Bupropion to patients receiving L-dopa concurrently should
be undertaken with caution, using small initial doses and small gradual
dose increases. </p>

<p>Concurrent administration of Bupropion and agents which lower seizure
threshold should be undertaken only with extreme caution (see WARNINGS).
Low initial dosing and small gradual dose increases should be employed.
</p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Lifetime carcinogenicity
studies were performed in rats and mice at doses up to 300 and 150 mg/kg/day,
respectively. In the rat study there was an increase in nodular proliferative
lesions of the liver at doses of 100 to 300 mg/kg/day; lower doses were
not tested. The question of whether or not such lesions may be precursors
of neoplasms of the liver is currently unresolved. Similar liver lesions
were not seen in the mouse study, and no increase in malignant tumors of
the liver and other organs was seen in either study. </p>

<p>Bupropion produced a borderline positive response (2 to 3 times control
mutation rate) in some strains in the Ames bacterial mutagenicity test,
and a high oral dose (300, but not 100 or 200 mg/kg) produced a low incidence
of chromosomal aberrations in rats. The relevance of these results in estimating
the risk of human exposure to therapeutic doses is unknown. </p>

<p>A fertility study was performed in rats; no evidence of impairment of
fertility was encountered at oral doses up to 300 mg/kg/day. </p>

<p>PREGNANCY: TERATOGENIC EFFECTS: Pregnancy Category B: Reproduction studies
have been performed in rabbits and rats at doses up to 15 to 45 times the
human daily dose and have revealed no definitive evidence of impaired fertility
or harm to the fetus due to bupropion. (In rabbits, a slightly increased
incidence of fetal abnormalities was seen in two studies, but there was
no increase in any specific abnormality). There are no adequate and well-
controlled studies in pregnant women. Because animal reproduction studies
are not always predictive of human response, this drug should be used during
pregnancy only if clearly needed. LABOR AND DELIVERY: The effect of Bupropion
on labor and delivery in humans is unknown. </p>

<p>NURSING MOTHERS: Because of the potential for serious adverse reactions
in nursing infants from Bupropion, a decision should be made whether to
discontinue nursing or to discontinue the drug, taking into account the
importance of the drug to the mother. </p>

<p>PEDIATRIC USE: The safety and effectiveness of Bupropion in individuals
under 18 years old have not been established. </p>

<p>USE IN THE ELDERLY: Bupropion has not been systematically evaluated
in older patients. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>No systematic data have been collected on the consequences of the concomitant
administration of Bupropion and other drugs. </p>

<p>However, animal data suggest that Bupropion may be an inducer of drug
metabolizing enzymes. This may be of potential clinical importance because
the blood levels of co-administered drugs may be altered. </p>

<p>Alternatively, because bupropion is extensively metabolized, the co-administration
of other drugs may affect its clinical activity. In particular, care should
be exercised when administering drugs known to affect hepatic drug-metabolizing
enzyme systems (e.g., carbamazepine, cimetidine, phenobarbital, phenytoin).
</p>

<p>Studies in animals demonstrate that the acute toxicity of bupropion
is enhanced by the MAO inhibitor phenelzine (see CONTRAINDICATIONS). </p>

<p>Limited clinical data suggest a higher incidence of adverse experiences
in patients receiving concurrent administration of Bupropion and L- dopa.
Administration of Bupropion to patients receiving L-dopa concurrently should
be undertaken with caution, using small initial doses and small gradual
dose increases. </p>

<p>Concurrent administration of Bupropion and agents which lower seizure
threshold should be undertaken only with extreme caution (see WARNINGS).
Low initial dosing and small gradual dose increases should be employed.
</p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>(See also WARNINGS and PRECAUTIONS) Adverse events commonly encountered
in patients treated with Bupropion are agitation, dry mouth, insomnia,
headache/migraine, nausea/vomiting, constipation, and tremor. </p>

<p>Adverse events were sufficiently troublesome to cause discontinuation
of treatment with Bupropion in approximately 10% of the 2400 patients and
volunteers who participated in clinical trials during the product's initial
development. The more common events causing discontinuation include neuropsychiatric
disturbances (3.0%), primarily agitation and abnormalities in mental status;
gastrointestinal disturbances (2.1%), primarily nausea and vomiting; neurological
disturbances (1.7%), primarily seizures, headaches, and sleep disturbances;
and dermatologic problems (1.4%), primarily rashes. It is important to
note, however, that many of these events occurred at doses that exceed
the recommended daily dose. </p>

<p>Accurate estimates of the incidence of adverse events associated with
the use of any drug are difficult to obtain. Estimates are influenced by
drug dose, detection technique, setting, physician judgments, etc. Consequently,
the table below is presented solely to indicate the relative frequency
of adverse events reported in representative controlled clinical studies
conducted to evaluate the safety and efficacy of Bupropion under relatively
similar conditions of daily dosage (300 to 600 mg), setting, and duration
(3 to 4 weeks). The figures cited cannot be used to predict precisely the
incidence of untoward events in the course of usual medical practice where
patient characteristics and other factors must differ from those which
prevailed in the clinical trials. These incidence figures also cannot be
compared with those obtained from other clinical studies involving related
drug products as each group of drug trials is conducted under a different
set of conditions. </p>

<p>Finally, it is important to emphasize that the tabulation does not reflect
the relative severity and/or clinical importance of the events. A better
perspective on the serious adverse events associated with the use of Bupropion
is provided in WARNINGS and PRECAUTIONS. </p>

<pre>
                  TREATMENT EMERGENT ADVERSE EXPERIENCE INCIDENCE             
                       IN PLACEBO-CONTROLLED CLINICAL TRIALS*                 
                           (PERCENT OF PATIENTS REPORTING)                    
                 ---------------------------------------------------          
                                         Bupropion     PLACEBO               
                                         PATIENTS       PATIENTS              
                 ADVERSE EXPERIENCE      (N = 323)      (N = 185)             
                 CARDIOVASCULAR                                               
                 Cardiac Arrhythmias         5.3            4.3               
                 Dizziness                  22.3           16.2               
                 Hypertension                4.3            1.6               
                 Hypotension                 2.5            2.2               
                 Palpitations                3.7            2.2               
                 Syncope                     1.2            0.5               
                 Tachycardia                10.8            8.6               
                 DERMATOLOGIC                                                 
                 Pruritus                    2.2            0.0               
                 Rash                        8.0            6.5               
                 GASTROINTESTINAL                                             
                 Anorexia                   18.3           18.4               
                 Appetite Increase           3.7            2.2               
                 Constipation               26.0           17.3               
                 Diarrhea                    6.8            8.6               
                 Dyspepsia                   3.1            2.2               
                 Nausea/Vomiting            22.9           18.9               
                 Weight Gain                13.6           22.7               
                 Weight Loss                23.2           23.2               
                 GENITOURINARY                                                
                 Impotence                   3.4            3.1               
                 Menstrual Complaints        4.7            1.1               
                 Urinary Frequency           2.5            2.2               
                 Urinary Retention           1.9            2.2               
                 MUSCULOSKELETAL                                              
                 Arthritis                   3.1            2.7               
                 NEUROLOGICAL                                                 
                 Akathisia                   1.5            1.1               
                 Akinesia/Bradykinesia       8.0            8.6               
                 Cutaneous Temperature                                        
                 Disturbance                 1.9            1.6               
                 Dry Mouth                  27.6           18.4               
                 Excessive Sweating         22.3           14.6               
                 Headache/Migraine          25.7           22.2               
                 Impaired Sleep Quality      4.0            1.6               
                 Increased Salivary Flow     3.4            3.8               
                 Insomnia                   18.6           15.7               
                 Muscle Spasms               1.9            3.2               
                 Pseudoparkinsonism          1.5            1.6               
                 Sedation                   19.8           19.5               
                 Sensory Disturbance         4.0            3.2               
                 Tremor                     21.1            7.6               
                 NEUROPSYCHIATRIC                                             
                 Agitation                  31.9           22.2               
                 Anxiety                     3.1            1.1               
                 Confusion                   8.4            4.9               
                 Decreased Libido            3.1            1.6               
                 Delusions                   1.2            1.1               
                 Disturbed Concentration     3.1            3.8               
                 Euphoria                    1.2            0.5               
                 Hostility                   5.6            3.8               
                 NONSPECIFIC                                                  
                 Fatigue                     5.0            8.6               
                 Fever/Chills                1.2            0.5               
                 RESPIRATORY                                                  
                 Upper Respiratory                                            
                 Complaints                  5.0           11.4               
                 SPECIAL SENSES                                               
                 Auditory Disturbance        5.3            3.2               
                 Blurred Vision             14.6           10.3               
                 Gustatory Disturbance       3.1            1.1               
                                                  
                 *Events reported by at least 1% of Bupropion                
                 patients are included. </pre>

<p>OTHER EVENTS OBSERVED DURING THE DEVELOPMENT OF Bupropion: The conditions
and duration of exposure to Bupropion varied greatly and a substantial
proportion of the experience was gained in open and uncontrolled clinical
settings. During this experience, numerous adverse events were reported;
however, without appropriate controls, it is impossible to determine with
certainty which events were or were not caused by Bupropion. The following
enumeration is organized by organ system and describes events in terms
of their relative frequency of reporting in the data base. Events of major
clinical importance are also described in WARNINGS and PRECAUTIONS. </p>

<p>The following definitions of frequency are used: Frequent adverse events
are defined as those occurring in at least 1/100 patients. Infrequent adverse
events are those occurring in 1/100 to 1/1000 patients, while rare events
are those occurring in less than 1/1000 patients. </p>

<p>CARDIOVASCULAR: Frequent was edema; infrequent were chest pain, EKG
abnormalities (premature beats and nonspecific ST-T changes), and shortness
of breath/dyspnea; rare were flushing, pallor, phlebitis, and myocardial
infarction. DERMATOLOGIC: Frequent were nonspecific rashes; infrequent
were alopecia and dry skin; rare were change in hair color, hirsutism,
and acne. ENDOCRINE: Infrequent was gynecomastia; rare were glycosuria
and hormone level change. </p>

<p>GASTROINTESTINAL: Infrequent were dysphagia, thirst disturbance, and
liver damage/jaundice; rare were rectal complaints, colitis, G.I. bleeding,
intestinal perforation, and stomach ulcer. </p>

<p>GENITOURINARY: Frequent was nocturia; infrequent were vaginal irritation,
testicular swelling, urinary tract infection, painful erection, and retarded
ejaculation; rare were dysuria, enuresis, urinary incontinence, menopause,
ovarian disorder, pelvic infection, cystitis, dyspareunia, and painful
ejaculation. </p>

<p>HEMATOLOGIC/ONCOLOGIC: Rare were lymphadenopathy, anemia, and pancytopenia.
</p>

<p>MUSCULOSKELETAL: Rare was musculoskeletal chest pain. </p>

<p>NEUROLOGICAL: (see WARNINGS) Frequent were ataxia/incoordination, seizure,
myoclonus, dyskinesia, and dystonia; infrequent were mydriasis, vertigo,
and dysarthria; rare were EEG abnormality, abnormal neurological exam,
impaired attention, sciatica, and aphasia. </p>

<p>NEUROPSYCHIATRIC: (see PRECAUTIONS) Frequent were mania/hypomania, increased
libido, hallucinations, decrease in sexual function, and depression; infrequent
were memory impairment, depersonalization, psychosis, dysphoria, mood instability,
paranoia, formal thought disorder, and frigidity; rare was suicidal ideation.
</p>

<p>ORAL COMPLAINTS: Frequent was stomatitis; infrequent were toothache,
bruxism, gum irritation, and oral edema; rare was glossitis. </p>

<p>RESPIRATORY: Infrequent were bronchitis and shortness of breath/dyspnea;
rare were epistaxis, rate or rhythm disorder, pneumonia, and pulmonary
embolism. </p>

<p>SPECIAL SENSES: Infrequent was visual disturbance; rare was diplopia.
</p>

<p>NONSPECIFIC: Frequent were flu-like symptoms; infrequent was nonspecific
pain; rare were body odor, surgically related pain, infection, medication
reaction, and overdose. </p>

<p>POSTINTRODUCTION REPORTS: Voluntary reports of adverse events temporally
associated with Bupropion that have been received since market introduction
and which may have no causal relationship with the drug include the following:
CARDIOVASCULAR: orthostatic hypotension, third degree heart block ENDOCRINE:
syndrome of inappropriate antidiuretic hormone secretion GASTROINTESTINAL:
esophagitis, hepatitis </p>

<p>HEMIC AND LYMPHATIC: ecchymosis, leukocytosis, leukopenia </p>

<p>MUSCULOSKELETAL: arthralgia, myalgia, muscle rigidity/fever/rhabdomyolysis
NERVOUS: coma, delirium, dream abnormalities, paresthesia, unmasking of
tardive dyskinesia </p>

<p>SKIN AND APPENDAGES: Stevens-Johnson syndrome, angioedema, exfoliative
dermatitis, urticaria </p>

<p>SPECIAL SENSES: tinnitus </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>HUMANS: Controlled clinical studies conducted in normal volunteers,
in subjects with a history of multiple drug abuse, and in depressed patients
showed some increase in motor activity and agitation/excitement. </p>

<p>In a population of individuals experienced with drugs of abuse, a single
dose of 400 mg Bupropion produced mild amphetamine-like activity as compared
to placebo on the morphine- benzedrine subscale of the Addiction Research
Center Index (ARCI) and a score intermediate between placebo and amphetamine
on the Liking Scale of the ARCI. These scales measure general feelings
of euphoria and drug desirability. </p>

<p>Findings in clinical trials, however, are not known to predict the abuse
potential of drugs reliably. Nonetheless, evidence from single-dose studies
does suggest that the recommended daily dosage of bupropion when administered
in divided doses is not likely to be especially reinforcing to amphetamine
or stimulant abusers. However, higher doses, which could not be tested
because of the risk of seizure, might be modestly attractive to those who
abuse stimulant drugs. </p>

<p>ANIMALS: Studies in rodents have shown that bupropion exhibits some
pharmacologic actions common to psychostimulants, including increases in
locomotor activity and the production of a mild stereotyped behavior and
increases in rates of responding in several schedule-controlled behavior
paradigms. Drug discrimination studies in rats showed stimulus generalization
between bupropion and amphetamine and other psychostimulants. Rhesus monkeys
have been shown to self-administer bupropion intravenously. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>LETHAL DOSES IN ANIMALS: In rats, the acute oral LD50 values were 607
mg/kg (males) and 482 mg/kg (females). Respective values for mice were
544 mg/kg and 636 mg/kg. Signs of acute toxicity included labored breathing,
salivation, arched back, ptosis, ataxia, and convulsions. </p>

<p>HUMAN OVERDOSE EXPERIENCE: There has been limited clinical experience
with overdosage of Bupropion. Thirteen overdoses occurred during clinical
trials. Twelve patients ingested 850 to 4200 mg and recovered without significant
sequelae. Another patient who ingested 9000 mg of Bupropion and 300 mg
of tranylcypromine experienced a grand mal seizure and recovered without
further sequelae. </p>

<p>Since introduction, Bupropion overdoses up to 17,500 mg have been reported.
Seizure was reported in approximately one-third of all cases. Other serious
reactions reported with overdoses of Bupropion alone included hallucinations,
loss of consciousness, and tachycardia. Fever, muscle rigidity, rhabdomyolysis,
hypotension, stupor, coma, and respiratory failure have been reported when
Bupropion was part of multiple drug overdoses. </p>

<p>Although most patients recovered without sequelae, deaths associated
with overdoses of Bupropion alone have been reported rarely in patients
ingesting massive doses of Bupropion. Multiple uncontrolled seizures, bradycardia,
cardiac failure, and cardiac arrest prior to death were reported in these
patients. MANAGEMENT OF OVERDOSE: Following suspected overdose, hospitalization
is advised. If the patient is conscious, vomiting should be induced by
syrup of ipecac. Activated charcoal also may be administered every 6 hours
during the first 12 hours after ingestion. Baseline laboratory values should
be obtained. Electrocardiogram and EEG monitoring also are recommended
for the next 48 hours. Adequate fluid intake should be provided. </p>

<p>If the patient is stuporous, comatose, or convulsing, airway intubation
is recommended prior to undertaking gastric lavage. Although there is little
clinical experience with lavage following an overdose of Bupropion, it
is likely to be of benefit within the first 12 hours after ingestion since
absorption of the drug may not yet be complete. </p>

<p>While diuresis, dialysis, or hemoperfusion are sometimes used to treat
drug overdosage, there is no experience with their use in the management
of overdoses of Bupropion. Because diffusion of Bupropion from tissue to
plasma may be slow, dialysis may be of minimal benefit several hours after
overdose. </p>

<p>Based on studies in animals, it is recommended that seizures be treated
with an intravenous benzodiazepine preparation and other supportive measures,
as appropriate. </p>

<p>Further information about the treatment of overdoses may be available
from a poison control center. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>GENERAL DOSING CONSIDERATIONS: It is particularly important to administer
Bupropion in a manner most likely to minimize the risk of seizure (see
WARNINGS). Increases in dose should not exceed 100 mg/day in a 3-day period.
Gradual escalation in dosage is also important if agitation, motor restlessness,
and insomnia, often seen during the initial days of treatment, are to be
minimized. If necessary, these effects may be managed by temporary reduction
of dose or the short-term administration of an intermediate to long-acting
sedative hypnotic. A sedative hypnotic usually is not required beyond the
first week of treatment. Insomnia may also be minimized by avoiding bedtime
doses. If distressing, untoward effects supervene, dose escalation should
be stopped. </p>

<p>No single dose of Bupropion should exceed 150 mg. Bupropion should be
administered t.i.d., preferably with at least 6 hours between successive
doses. USUAL DOSAGE FOR ADULTS: The usual adult dose is 300 mg/day, given
t.i.d. Dosing should begin at 200 mg/day, given as 100 mg b.i.d. Based
on clinical response, this dose may be increased to 300 mg/day, given as
100 mg t.i.d., no sooner than 3 days after beginning therapy (see table
below). </p>

<pre>

                            DOSING REGIMEN                                    
                                                 Number of Tablets            
Treatment        Total       Tablet           
   Day        Daily Dose    Strength     Morning     Midday     Evening       
------------------------------------------------------------------------      
   1           200 mg        100 mg         1          0          1           
   4           300 mg        100 mg         1          1          1           
------------------------------------------------------------------------      
</pre>

<p>INCREASING THE DOSAGE ABOVE 300 MG/DAY: As with other antidepressants,
the full antidepressant effect of Bupropion may not be evident until 4
weeks of treatment or longer. An increase in dosage, up to a maximum of
450 mg/day, given in divided doses of not more than 150 mg each, may be
considered for patients in whom no clinical improvement is noted after
several weeks of treatment at 300 mg/day. Dosing above 300 mg/day may be
accomplished using the 75 or 100 mg tablets. The 100 mg tablet must be
administered q.i.d. with at least 4 hours between successive doses, in
order not to exceed the limit of 150 mg in a single dose. Bupropion should
be discontinued in patients who do not demonstrate an adequate response
after an appropriate period of treatment at 450 mg/day. </p>

<p>ELDERLY PATIENTS: In general, older patients are known to metabolize
drugs more slowly and to be more sensitive to the anticholinergic, sedative,
and cardiovascular side effects of antidepressant drugs. Clinical trials
enrolled several hundred patients 60 years of age and older. The experience
with these patients and younger ones was similar. </p>

<p>MAINTENANCE: The lowest dose that maintains remission is recommended.
Although it is not known how long the patient should remain on Bupropion,
it is generally recognized that acute episodes of depression require several
months or longer of antidepressant drug treatment. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-31</DOCNO>
<DOCOLDNO>IA018-000200-B033-50</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/tempstat.htm 206.86.175.201 19970106223516 text/html 87031
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:29:00 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 86848
Last-modified: Mon, 06 Jan 1997 14:59:11 GMT
</DOCHDR>
<html>
<body bgcolor="#ffffff">
<a href="http://www.rxlist.com">
<img src="rx.gif" height=50 width=50 border=0></a>
</body>
</html>
<HTML><HEAD>
<TITLE>World Wide Web Access Statistics for www.rxlist.com</TITLE>
</HEAD><BODY>
<H1>World Wide Web Access Statistics for www.rxlist.com</H1>
<EM>Last updated: Mon, 06 Jan 1997 06:55:03 (GMT -0800)</EM>
<UL>
<LI><A HREF="#Daily">Total Transfers by Request Date</A>
<LI><A HREF="#Hourly">Total Transfers by Request Hour</A>
<LI><A HREF="#Domain">Total Transfers by Client Domain</A>
<LI><A HREF="#Subdomain">Total Transfers by Reversed Subdomain</A>
<LI><A HREF="#Archive">Total Transfers by URL/Archive Section</A>
<LI><A HREF="stats-1996/Dec.monthstat.htm.gz">Previous Full Summary Period (.gz)</A>
</UL>
<H2>Totals:3AM-3AM(24 Hr): Jan  5 1997 to Jan  6 1997</H2>
<PRE>
Requests Received During Summary Period           20198
Bytes Transmitted During Summary Period       118578135
Half-Day Average Hits                             10099
Half-Day Average Bytes                         59289068
</PRE>
<HR>
<H2><A NAME="Daily">Total Transfers by Request Date</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Date
----- ----- ------------ -------- |------------
95.04 94.73    112325479    19196 | Jan  5 1997
 4.96  5.27      6252656     1002 | Jan  6 1997
</PRE>
<HR>
<H2><A NAME="Hourly">Total Transfers by Request Hour</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Time
----- ----- ------------ -------- |-----
 1.70  1.88      2225729      344 |  00
 1.40  1.47      1747327      282 |  01
 1.24  1.23      1453144      250 |  02
 1.33  1.29      1534184      268 |  03
 1.50  1.36      1607400      302 |  04
 2.00  1.81      2150529      403 |  05
 2.99  2.73      3238014      604 |  06
 4.28  4.96      5881346      865 |  07
 3.87  3.70      4388631      782 |  08
 4.98  5.21      6178464     1006 |  09
 4.77  4.99      5919659      964 |  10
 6.17  5.52      6542163     1246 |  11
 5.62  5.37      6372330     1136 |  12
 5.44  5.20      6161169     1098 |  13
 4.86  5.07      6006440      982 |  14
 5.81  6.06      7181432     1174 |  15
 6.63  6.17      7316022     1339 |  16
 6.89  6.57      7784686     1391 |  17
 6.59  6.20      7348874     1332 |  18
 7.48  7.31      8672666     1511 |  19
 4.86  5.28      6264711      982 |  20
 4.58  4.68      5548773      925 |  21
 2.95  3.81      4519597      596 |  22
 2.06  2.14      2534845      416 |  23
</PRE>
<HR>
<H2><A NAME="Domain">Total Transfers by Client Domain</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Domain
----- ----- ------------ -------- |------------------------------------
 0.01  0.05        63406        3 | ar    Argentina
 0.92  1.20      1420968      186 | au    Australia
 0.14  0.11       134028       29 | be    Belgium
 0.02  0.04        48053        4 | bh    Bahrain
 0.16  0.24       285990       33 | br    Brazil
 3.22  3.10      3674546      650 | ca    Canada
 0.27  0.41       487633       54 | ch    Switzerland
 0.01  0.01        16784        2 | cn    China
 0.01  0.01         7461        3 | cy    Cyprus
 0.08  0.06        71411       17 | cz    Czech Republic
 0.28  0.25       301907       56 | de    Germany
 0.24  0.08        90161       49 | dk    Denmark
 0.07  0.04        43924       15 | es    Spain
 0.20  0.13       158899       40 | fi    Finland
 0.11  0.07        77345       22 | fr    France
 0.08  0.03        33792       16 | hu    Hungary
 0.13  0.12       147857       27 | ie    Ireland
 0.19  0.23       272836       39 | il    Israel
 0.03  0.19       230187        7 | in    India
 0.24  0.19       220676       48 | it    Italy
 0.33  0.24       278887       67 | jp    Japan
 0.08  0.08        95657       16 | mx    Mexico
 0.20  0.13       159478       40 | nl    Netherlands
 0.10  0.13       155395       20 | no    Norway
 0.05  0.09       101668       10 | nz    New Zealand (Aotearoa)
 0.03  0.02        17878        7 | pe    Peru
 0.01  0.05        57794        2 | pk    Pakistan
 0.16  0.25       302258       33 | pl    Poland
 0.01  0.02        20071        3 | pt    Portugal
 0.36  0.33       393853       73 | se    Sweden
 0.23  0.22       260814       46 | sg    Singapore
 0.08  0.08        93666       17 | th    Thailand
 0.05  0.03        39843       11 | tw    Taiwan
 0.49  0.39       460443       99 | uk    United Kingdom
 0.75  0.69       816957      152 | us    United States
 0.05  0.03        29872       10 | za    South Africa
35.44 35.43     42009796     7159 | com   Commercial
 3.25  4.27      5067053      656 | edu   Educational
 0.40  0.28       336628       80 | gov   Government
36.75 36.28     43023835     7422 | net   Network
 0.51  0.50       594045      102 | org   Non-Profit Organization
14.22 13.89     16474380     2873 | unresolved 
</PRE>
<HR>
<H2><A NAME="Subdomain">Total Transfers by Reversed Subdomain</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Reversed Subdomain
----- ----- ------------ -------- |------------------------------------
14.22 13.89     16474380     2873 | Unresolved
 0.01  0.05        63406        3 | ar.retina.rcac4
 0.03  0.03        35316        6 | au.com.connect
 0.03  0.02        17878        7 | au.com.intercoast
 0.03  0.07        86835        6 | au.com.mpx
 0.00  0.04        52585        1 | au.com.netconnect
 0.01  0.00         5563        3 | au.com.onthenet
 0.01  0.01        11023        3 | au.com.ozemail
 0.12  0.11       125535       24 | au.com.southcom
 0.06  0.12       146236       12 | au.com.wantree
 0.02  0.04        44570        5 | au.com.wr
 0.04  0.01        14234        8 | au.edu.adelaide.services
 0.02  0.09       111375        4 | au.edu.latrobe
 0.06  0.03        38622       12 | au.edu.monash
 0.01  0.01        10589        3 | au.edu.unimelb.its
 0.08  0.05        62486       17 | au.gov.ansto.tandem
 0.03  0.02        17967        7 | au.gov.antdiv
 0.01  0.01        17723        3 | au.gov.qld.citec
 0.06  0.12       139437       13 | au.net.aone.canberra.cpe
 0.03  0.18       214667        7 | au.net.aone.melbourne
 0.05  0.01        10440       11 | au.net.aone.perth.cpe
 0.00  0.03        32605        1 | au.net.aone.syd
 0.01  0.03        40260        3 | au.net.iinet
 0.01  0.03        37023        3 | au.net.mpx.gw
 0.01  0.02        20071        3 | au.net.netspace.melbourne
 0.07  0.04        48939       14 | au.net.ois
 0.00  0.01         8392        1 | au.net.shepparton
 0.01  0.02        23459        3 | au.net.tmns
 0.03  0.04        47138        6 | au.oz.su.medlib
 0.01  0.02        29301        2 | be.eunet
 0.03  0.00         5379        7 | be.innet
 0.01  0.03        31064        3 | be.skynet
 0.08  0.06        68284       17 | be.unicall
 0.02  0.04        48053        4 | bh.com.batelco
 0.03  0.05        65189        7 | br.com.iaccess
 0.01  0.02        19232        2 | br.com.ism
 0.06  0.05        62362       12 | br.com.matrix.ppp
 0.04  0.07        85080        9 | br.com.nutecnet
 0.01  0.05        54127        3 | br.com.secrel
 0.06  0.04        50342       13 | ca.ab.compusmart
 0.09  0.15       175255       18 | ca.aecl
 0.17  0.25       295494       35 | ca.bc.gov.dial
 0.01  0.01         7461        3 | ca.bc.intergate
 0.05  0.03        35469       10 | ca.bctel
 0.01  0.01         6114        2 | ca.carleton
 0.01  0.05        64006        3 | ca.carleton.ccs
 0.07  0.04        45034       14 | ca.cyberstore
 0.18  0.14       169321       36 | ca.cyberus
 0.21  0.16       193240       42 | ca.direct
 0.04  0.02        21938        8 | ca.escape
 0.01  0.02        20071        3 | ca.inasec
 0.07  0.06        66467       14 | ca.istar.ant
 0.10  0.15       173826       20 | ca.istar.kit
 0.14  0.13       151112       29 | ca.istar.ott
 0.06  0.06        74267       13 | ca.istar.tor
 0.10  0.03        33274       20 | ca.magic
 0.14  0.10       115396       29 | ca.mb.mbnet
 0.02  0.07        85149        4 | ca.nb.nbnet
 0.16  0.09       109120       33 | ca.netcom
 0.16  0.05        59558       33 | ca.nf.nlnet
 0.01  0.01        13234        3 | ca.on.cois
 0.08  0.03        39891       16 | ca.on.npiec
 0.03  0.02        17878        7 | ca.on.odyssey
 0.01  0.03        33230        3 | ca.on.wchat
 0.02  0.10       122105        5 | ca.qc.rocler
 0.01  0.03        36055        3 | ca.recorder.ipad2
 0.02  0.00         1915        5 | ca.ryerson.scs
 0.03  0.05        63269        7 | ca.sympatico.ns
 0.20  0.15       178998       41 | ca.sympatico.on
 0.16  0.13       148840       32 | ca.sympatico.qc
 0.10  0.12       147190       21 | ca.sympatico.sk
 0.01  0.04        51395        3 | ca.ubc.net.annex7
 0.08  0.08       100233       16 | ca.ubc.net.netinf1
 0.01  0.04        47150        3 | ca.ucalgary.kin
 0.00  0.01        11358        1 | ca.unb.csd.sun
 0.11  0.17       205256       22 | ca.utoronto.chass
 0.12  0.13       151361       24 | ca.uwo.slip
 0.28  0.30       353274       56 | ca.yorku.slip
 0.01  0.02        29072        2 | ch.access
 0.01  0.05        54433        2 | ch.hon
 0.02  0.03        30456        4 | ch.iprolink
 0.05  0.13       149091       10 | ch.span
 0.11  0.14       165312       22 | ch.swissonline
 0.07  0.05        59269       14 | ch.worldcom
 0.01  0.01        16784        2 | cn.net.bta
 0.03  0.06        76633        7 | com.3-cities
 0.01  0.05        64006        3 | com.a-o
 0.05  0.05        53933       10 | com.abbott
 0.07  0.07        79808       15 | com.abstractsoft
 0.07  0.03        30410       14 | com.accessone
 0.06  0.09       102680       12 | com.accsyst
 0.06  0.07        88510       13 | com.adsnet
 0.14  0.17       197515       29 | com.aicom.tc3.ns
 0.06  0.04        42541       13 | com.alaweb
 0.11  0.13       158292       22 | com.amaonline
 0.02  0.02        23128        5 | com.amp
 0.34  0.36       426872       68 | com.aol.ipt
 9.45  9.59     11366158     1908 | com.aol.proxy
 0.03  0.05        54862        7 | com.aonline
 0.06  0.06        72162       12 | com.aracnet
 0.02  0.04        43780        4 | com.ark
 0.03  0.05        56380        6 | com.atcon.stv
 0.04  0.03        39211        9 | com.atext
 0.01  0.02        22322        3 | com.aug
 0.07  0.09       101040       15 | com.awanet
 0.01  0.04        51247        3 | com.awinc.abc
 0.08  0.06        65821       16 | com.azstarnet
 0.01  0.03        36055        3 | com.ballistic
 0.03  0.02        17878        7 | com.batnet
 0.05  0.02        24057       10 | com.bd
 0.39  0.30       355824       79 | com.bdsi
 0.06  0.04        44691       13 | com.bdsnet
 0.34  0.60       713057       68 | com.best.vip
 0.03  0.02        17878        7 | com.bmnet
 0.05  0.02        24452       10 | com.brokersys
 0.01  0.03        38784        3 | com.bt.access
 0.01  0.04        51247        3 | com.btinternet
 0.15  0.12       145242       31 | com.cadvision
 0.06  0.05        54305       13 | com.california
 0.07  0.05        62284       15 | com.calweb
 0.06  0.01        15291       13 | com.canuck
 0.08  0.13       150338       17 | com.carelife
 0.06  0.10       122337       13 | com.carlsbadnm
 0.03  0.00         5379        7 | com.ccia
 0.01  0.03        32067        3 | com.ccis
 0.08  0.11       131792       17 | com.ccnet
 0.01  0.02        23459        3 | com.centtech
 0.01  0.02        27635        3 | com.cerfnet.usa
 0.06  0.02        26980       12 | com.cet
 0.03  0.01        15563        7 | com.cfanet
 0.05  0.02        25607       11 | com.chatlink
 0.01  0.05        63630        3 | com.cinetwork
 0.19  0.21       249000       38 | com.cisco
 0.06  0.07        86279       13 | com.clandjop
 0.08  0.06        68045       17 | com.coastalnet
 0.96  1.10      1309013      194 | com.compuserve
 0.04  0.02        21600        9 | com.connecti
 0.03  0.02        17878        7 | com.connectnet
 0.03  0.00         2094        6 | com.cowland
 0.00  0.03        30678        1 | com.craftech
 0.06  0.05        56275       13 | com.cruzio
 0.14  0.13       151726       29 | com.cswnet
 0.02  0.03        33145        4 | com.ctaz
 0.06  0.09       104552       12 | com.cts
 0.06  0.08        96542       13 | com.curved-logic
 0.08  0.07        82809       17 | com.cwo
 0.17  0.23       273843       35 | com.cyberg8t
 0.03  0.06        71270        6 | com.cybergate
 0.03  0.02        17878        7 | com.daktel
 0.01  0.03        38908        3 | com.dancris
 0.15  0.08        91275       31 | com.datalytics
 0.15  0.08        93953       30 | com.datasync
 0.03  0.01        16400        7 | com.deltanet
 0.09  0.14       170926       18 | com.dmv.easton
 0.07  0.07        87074       14 | com.dopamine
 0.01  0.04        42776        3 | com.dungeon
 0.01  0.02        20325        3 | com.eburg
 0.01  0.01        14758        3 | com.empirenet
 1.23  1.21      1430322      249 | com.erols
 0.01  0.00          999        3 | com.esper
 0.07  0.03        31931       15 | com.eurekanet
 0.32  0.36       422087       64 | com.execpc
 0.08  0.08        96709       17 | com.exit109
 0.02  0.01         7677        4 | com.ezl
 0.06  0.06        73607       13 | com.fcs-net
 0.09  0.05        62671       19 | com.ffni
 0.01  0.02        20262        3 | com.firstsol
 0.08  0.05        63554       17 | com.flinet
 0.10  0.10       113909       21 | com.frazmtn
 0.09  0.05        53672       18 | com.gaffaneys
 0.01  0.01        13234        3 | com.galstar
 0.07  0.06        65613       15 | com.getnet
 0.24  0.36       429951       49 | com.gnn.proxy
 0.21  0.20       239915       43 | com.gnp
 0.05  0.09       109530       11 | com.goldrush
 0.24  0.19       221277       48 | com.goodnet
 0.23  0.14       169433       47 | com.halcyon
 0.09  0.03        30324       19 | com.hamptons
 0.02  0.01        11699        5 | com.harborside.coos0
 0.08  0.09       102632       17 | com.harborside.rs0
 0.06  0.03        36623       13 | com.harris.semi.mis
 0.01  0.01        14758        3 | com.hcil
 0.05  0.05        60772       10 | com.hevanet
 0.06  0.04        43594       12 | com.hidesert
 0.18  0.05        54056       37 | com.hkstar
 0.07  0.05        60323       14 | com.hollinet
 0.07  0.03        31489       14 | com.hollyberry.abq-dialin2
 0.13  0.09       101905       26 | com.iafrica
 0.03  0.12       144968        6 | com.ibm.us.ca
 0.01  0.04        50780        3 | com.ibm.us.ny
 0.00  0.00         3381        1 | com.ibm.watson
 0.01  0.02        26888        3 | com.iceonline
 0.10  0.08       100609       21 | com.idcomm
 0.03  0.02        17878        7 | com.idirect
 0.02  0.01         8469        4 | com.idsonline
 0.01  0.02        21634        3 | com.ieway
 0.10  0.07        83247       20 | com.ihot
 0.01  0.04        50780        3 | com.iinc
 0.02  0.05        63362        4 | com.iisc
 0.01  0.01        11083        3 | com.ims-bmt
 0.09  0.10       123972       18 | com.inch.dialup
 0.10  0.14       167368       20 | com.inetnebr
 0.03  0.08        94681        6 | com.infoseek
 0.06  0.05        57605       12 | com.infowest
 0.07  0.05        58167       14 | com.injersey
 0.02  0.00         2835        4 | com.innercite
 0.03  0.08        99301        6 | com.innovsoftd
 0.06  0.04        47662       13 | com.inow
 0.07  0.01         8875       15 | com.insnet
 0.01  0.03        34078        3 | com.intel.fm
 0.07  0.06        65670       15 | com.intel.rr
 0.13  0.17       197200       27 | com.intellinet.lit
 0.19  0.19       225257       39 | com.intercall
 0.01  0.03        33615        3 | com.interlog
 0.09  0.08        95470       19 | com.interlog.cc
 0.07  0.03        32031       15 | com.internorth.yt
 0.00  0.00          911        1 | com.intralaw
 0.06  0.06        75647       13 | com.invlogic
 0.05  0.02        22737       10 | com.io.austin
 0.00  0.03        35508        1 | com.ios
 0.00  0.00          333        1 | com.isomedia
 0.00  0.00         3381        1 | com.itis
 0.01  0.06        66087        3 | com.javanet
 0.05  0.05        56480       10 | com.jnj
 0.07  0.10       118000       14 | com.jumppoint
 0.01  0.02        22322        3 | com.kern
 0.00  0.00         1080        1 | com.ko
 0.01  0.02        22462        3 | com.kwic
 0.05  0.01        14213       10 | com.largoent
 0.03  0.06        69133        6 | com.lgc.zycor
 0.00  0.00          333        1 | com.li
 0.07  0.01        11772       15 | com.lilly.d48
 0.00  0.00          382        1 | com.localnet.syr
 0.06  0.07        85462       12 | com.lotus
 0.00  0.02        20190        1 | com.lrun
 0.01  0.05        61700        3 | com.lucent.proxy
 0.01  0.00          999        3 | com.macomb.dialup0
 0.01  0.05        54564        3 | com.macomb.dialup1
 0.01  0.04        50780        3 | com.magiccarpet
 0.01  0.03        37632        3 | com.map
 0.06  0.09       105328       13 | com.matnet
 0.15  0.08       100449       30 | com.memphisonline.tch3nsc
 0.08  0.09       112071       17 | com.metronet
 0.08  0.03        31962       16 | com.mich.dialip
 0.53  0.39       466654      108 | com.mindspring.dialup
 0.06  0.03        30366       13 | com.minot
 0.06  0.02        27653       12 | com.misnet
 0.03  0.02        17878        7 | com.mixcom
 0.03  0.02        17878        7 | com.mnsinc
 0.08  0.05        58577       16 | com.monmouth
 0.08  0.01        14117       17 | com.monsanto
 0.21  0.12       136741       42 | com.montana
 0.01  0.09       103903        3 | com.mosby
 0.13  0.20       242331       27 | com.mosquitonet
 0.06  0.06        71610       12 | com.mother.dav
 0.01  0.02        19232        2 | com.mozcom
 0.08  0.06        68008       17 | com.mrj.dial
 0.01  0.04        51247        3 | com.mv
 0.08  0.05        59033       16 | com.mwmc
 0.13  0.18       211619       27 | com.mwweb
 0.01  0.01        15293        3 | com.myna.rn2
 0.04  0.11       126920        8 | com.n-jcenter
 0.05  0.02        22420       10 | com.n-link
 0.05  0.04        46442       11 | com.naplesnet
 0.04  0.12       142740        8 | com.nbn
 0.03  0.02        17878        7 | com.ncfcomm
 0.09  0.07        83241       19 | com.ncweb
 0.12  0.04        46362       24 | com.neosoft
 0.09  0.06        69378       18 | com.neosoft.no
 0.01  0.02        22462        3 | com.neta
 0.02  0.04        44960        5 | com.netaxis
 3.47  3.85      4561684      700 | com.netcom.ix
 0.06  0.06        72640       13 | com.netcom.slip
 0.08  0.03        39037       17 | com.netdoor.hat
 0.12  0.13       150652       25 | com.netime
 0.01  0.00         4469        3 | com.netscape
 0.06  0.07        81243       13 | com.nettally.ppp
 0.01  0.07        77667        3 | com.niagara
 0.12  0.06        65778       25 | com.nitco
 0.01  0.00         4222        3 | com.nlbbs
 0.03  0.02        17878        7 | com.nque
 0.18  0.26       314196       36 | com.nucleus
 0.12  0.05        57513       25 | com.nytimes
 0.14  0.17       206941       29 | com.onr
 0.10  0.11       128390       20 | com.owt
 0.03  0.04        49080        6 | com.pacifier.van5
 0.03  0.05        54511        6 | com.pathcom
 0.13  0.10       115908       26 | com.pcix
 0.01  0.05        55535        3 | com.pcnet
 0.06  0.05        62368       13 | com.pdnt
 0.07  0.05        56718       15 | com.penn
 0.01  0.03        34277        3 | com.pepper
 0.08  0.11       127439       16 | com.pipex.du
 0.00  0.00         1080        1 | com.pipex.msn-uk.max16
 0.03  0.05        63690        6 | com.pipex.msn-uk.max18
 0.01  0.03        37760        3 | com.pipex.msn-uk.max19
 0.01  0.04        41724        3 | com.pipex.msn-uk.max21
 0.15  0.09       107216       31 | com.pipex.msn-uk.max9
 0.02  0.09       108719        5 | com.pjm
 0.10  0.04        50487       21 | com.po
 0.09  0.13       159747       19 | com.pond.vf
 0.10  0.08        97312       20 | com.preferred
 0.04  0.16       191627        9 | com.primenet.elp
 0.11  0.07        87990       22 | com.primenet.phx
 0.13  0.10       123796       27 | com.primenet.tus
 0.03  0.02        17878        7 | com.proaxis
 0.61  0.71       836360      123 | com.prodigy
 0.01  0.02        20262        3 | com.ptw
 0.00  0.00          316        1 | com.qni
 0.14  0.05        65148       29 | com.qns
 0.07  0.09       107014       15 | com.quebectel.f112
 0.07  0.02        28482       14 | com.quik.reno
 0.06  0.03        32563       13 | com.rapidcity
 0.05  0.04        52294       11 | com.rapidnet
 0.03  0.02        17878        7 | com.rmii
 0.04  0.01         8864        9 | com.ro
 0.01  0.04        51395        3 | com.rose
 0.01  0.03        37993        3 | com.rrd
 0.03  0.01         6498        6 | com.rt66
 0.08  0.06        66755       17 | com.rxlist
 0.01  0.02        25188        3 | com.sanders
 0.01  0.01        15604        3 | com.sbi
 0.10  0.16       187754       21 | com.scruznet.pa
 0.06  0.06        73607       13 | com.seanet.dialup
 0.01  0.00          632        2 | com.series2000
 0.09  0.10       119922       19 | com.shellus
 0.12  0.09       102579       24 | com.sisna
 0.06  0.03        39161       12 | com.ska.na
 0.01  0.00         4222        3 | com.slic
 0.06  0.05        63878       13 | com.smartec.pm1_ny
 0.01  0.02        19800        3 | com.sojourn
 0.07  0.05        62195       15 | com.spherenet
 0.03  0.04        49624        6 | com.staffnet
 0.05  0.02        29620       11 | com.std
 0.01  0.04        50780        3 | com.stlnet
 0.02  0.03        39303        5 | com.summer
 0.07  0.08        92549       14 | com.sun
 0.00  0.00         3381        1 | com.sunalliance
 0.02  0.03        41141        4 | com.sureste
 0.00  0.02        24235        1 | com.taligent
 0.06  0.01        16064       13 | com.tcac
 0.06  0.02        28952       12 | com.tconl
 0.08  0.03        37558       16 | com.tctc
 0.03  0.07        87302        6 | com.tde
 0.03  0.05        54936        6 | com.teleport
 0.12  0.13       152361       25 | com.televar
 0.04  0.07        86890        8 | com.telia
 0.02  0.03        32141        4 | com.the-spa
 0.01  0.03        34524        3 | com.thecore
 0.09  0.07        79145       18 | com.ti
 0.03  0.06        66741        6 | com.tiac.dc.washi.ts1
 0.01  0.00          766        2 | com.tiac.ma.ashbu.gw2
 0.21  0.62       737410       42 | com.tiac.ma.athol.gw1
 0.08  0.08        97720       17 | com.tiac.ma.bedfo.ts10
 0.06  0.06        72914       13 | com.tiac.ma.bedfo.ts3
 0.01  0.01         7461        3 | com.tiac.ma.littl.gw3
 0.06  0.07        84020       13 | com.tiac.ma.metro.ts17
 0.07  0.03        35906       15 | com.tidepool
 0.09  0.11       135347       19 | com.tir
 0.07  0.08        91650       15 | com.trader.pm2
 0.09  0.08        89609       19 | com.trader.pm5
 0.05  0.01        14310       11 | com.trailer-sales
 0.01  0.04        48723        3 | com.transport
 0.17  0.20       239364       35 | com.trib
 0.01  0.02        18658        3 | com.trilli
 0.01  0.03        38297        3 | com.trw.stdppp
 0.02  0.02        21265        4 | com.tstonramp
 0.09  0.05        54254       19 | com.ultranet
 0.10  0.09       109166       20 | com.unnet
 0.03  0.02        17878        7 | com.v-wave
 0.14  0.13       158211       29 | com.vivanet
 0.00  0.00         3381        1 | com.vividnet
 0.43  0.28       335029       87 | com.voicenet
 0.02  0.03        38190        5 | com.vvm
 0.03  0.05        56380        6 | com.wazoo.pm2
 0.08  0.11       126381       16 | com.westol
 0.01  0.03        38784        3 | com.wiltel
 0.06  0.02        26341       12 | com.wingsbbs
 0.01  0.01         7754        2 | com.winternet.dialup
 0.02  0.01        11766        4 | com.wko
 0.01  0.02        21634        3 | com.wport
 0.06  0.07        78920       12 | com.wvin
 0.12  0.09       104160       24 | com.wwa
 0.07  0.04        52443       15 | com.wwdc
 0.05  0.00         3476       11 | com.wwics
 0.07  0.03        36370       14 | com.wwisp
 0.01  0.02        21516        3 | com.wwnet
 0.02  0.03        38426        5 | com.xerox.parc
 0.01  0.05        64006        3 | com.xetron
 0.11  0.11       136113       23 | com.xfalcon
 0.06  0.04        44594       13 | com.xtdl.bedford
 0.01  0.01         7461        3 | cy.com.cytanet
 0.08  0.06        71411       17 | cz.cuni.lfhk
 0.09  0.10       114946       18 | de.baden-online
 0.10  0.13       150338       21 | de.dtag.btx
 0.05  0.01         8087       10 | de.eunet.m
 0.03  0.02        28536        7 | de.uni-sb
 0.00  0.00         3381        1 | dk.cybercity
 0.08  0.03        39304       17 | dk.dk-online.c17
 0.05  0.02        22421       10 | dk.novo
 0.02  0.00         5265        5 | dk.tele.abc
 0.08  0.02        19790       16 | dk.tele.arh
 0.01  0.05        62807        2 | edu.asu
 0.08  0.14       161213       17 | edu.asu.inre
 0.01  0.05        57663        3 | edu.bradley.slip
 0.01  0.03        34524        3 | edu.buffalo.ppp-net
 0.06  0.03        35243       13 | edu.cmu.andrew.slip
 0.13  0.07        82762       26 | edu.cornell.cit
 0.01  0.03        31520        2 | edu.creighton
 0.06  0.13       150560       13 | edu.dartmouth
 0.00  0.00          316        1 | edu.emory.mathcs
 0.01  0.04        51395        3 | edu.fau.math
 0.02  0.05        59163        4 | edu.fsu.scri
 0.02  0.09       105461        4 | edu.gatech.res
 0.07  0.11       127736       15 | edu.gmu
 0.01  0.03        41473        3 | edu.harvard.mgh
 0.01  0.01        14145        3 | edu.harvard.student
 0.07  0.08        93258       15 | edu.harvard.tch
 0.02  0.05        55614        4 | edu.humboldt
 0.01  0.03        32439        3 | edu.ilstu.ras
 0.00  0.00         3381        1 | edu.loras
 0.01  0.02        27635        3 | edu.maine.caps.ts-p-caps3
 0.01  0.01         8905        2 | edu.mec.randolph
 0.00  0.02        28667        1 | edu.missouri.coin
 0.01  0.03        40412        3 | edu.mssm
 0.12  0.08        95070       24 | edu.msstate.ts1
 0.01  0.00          999        3 | edu.msstate.ts2
 0.09  0.24       282486       18 | edu.nlu
 0.00  0.00         2648        1 | edu.nodak.ndsu.pt2
 0.01  0.02        19232        2 | edu.nyu.med
 0.01  0.03        39906        3 | edu.orst.usda-ars
 0.00  0.00          382        1 | edu.pitt.net.rmt
 0.01  0.04        50780        3 | edu.rice
 0.06  0.01        13481       12 | edu.rit.isc
 0.02  0.03        38788        4 | edu.rutgers
 0.03  0.05        62407        6 | edu.stanford
 0.17  0.18       211881       34 | edu.syr
 0.10  0.07        88042       20 | edu.syr.npac
 0.07  0.05        58930       15 | edu.temple.ppp
 0.07  0.03        39278       14 | edu.toronto.ecf
 0.01  0.03        34524        3 | edu.tulane.tcs
 0.00  0.01        10528        1 | edu.uah.hh
 0.05  0.02        24009       10 | edu.ucdavis.ucdmc
 0.01  0.01         6762        2 | edu.ucla.ts.wla
 0.05  0.02        22223       10 | edu.uconn.ppp
 0.18  0.21       245738       37 | edu.ucsd
 0.01  0.01        13221        3 | edu.ucsd.extern
 0.01  0.06        67314        3 | edu.ufl.nerdc
 0.16  0.10       117225       33 | edu.uic.dialin
 0.01  0.05        64006        3 | edu.uic.phyb
 0.03  0.06        69285        6 | edu.uiuc.ncsa
 0.07  0.03        33511       14 | edu.uky.pharm
 0.03  0.02        17878        7 | edu.umass.ecs
 0.06  0.02        27092       12 | edu.umass.remote
 0.05  0.09       112073       11 | edu.umd
 0.16  0.19       228329       32 | edu.umn.dialup
 0.13  0.07        85488       26 | edu.unt.dialup
 0.02  0.01        14475        5 | edu.uoregon
 0.00  0.00          316        1 | edu.usc
 0.03  0.02        17878        7 | edu.usd.med
 0.05  0.05        55007       11 | edu.usf.med
 0.01  0.03        36404        3 | edu.utah.lib
 0.10  0.13       154591       21 | edu.utexas.ots
 0.10  0.13       150811       20 | edu.utk.rmt
 0.01  0.04        50780        3 | edu.uwm.fa
 0.01  0.05        63406        3 | edu.washington.orthop
 0.12  0.14       171821       25 | edu.washington.u
 0.00  0.01         9821        1 | edu.wisc.net
 0.00  0.59       699619        1 | edu.wpi
 0.07  0.03        36841       14 | edu.wright.suao
 0.07  0.04        47569       15 | edu.wustl
 0.04  0.06        67906        9 | edu.wvnet.dialup
 0.07  0.04        43924       15 | es.intercom.accessnet
 0.10  0.06        73823       20 | fi.clinet.pp
 0.07  0.05        57404       14 | fi.joensuu
 0.01  0.00         4604        2 | fi.oulu
 0.02  0.02        23068        4 | fi.weppi
 0.00  0.00          333        1 | fr.cea.alpes
 0.05  0.02        23079       11 | fr.club-internet.neuilly
 0.03  0.02        17878        7 | fr.nctech
 0.01  0.03        36055        3 | fr.wanadoo
 0.03  0.01        12910        7 | gov.bnl.ccd
 0.02  0.05        53795        4 | gov.bnl.idas
 0.06  0.05        53650       13 | gov.doe.fe
 0.06  0.02        26316       12 | gov.ncifcrf
 0.22  0.16       189957       44 | gov.usps
 0.08  0.03        33792       16 | hu.iif.dial
 0.10  0.10       118413       20 | ie.iol.cache
 0.03  0.02        29444        7 | ie.iol.dublin
 0.07  0.14       162193       14 | il.ac
 0.00  0.02        23983        1 | il.co.orbotech
 0.05  0.02        22295       11 | il.net.netmedia
 0.06  0.05        64365       13 | il.net.netvision.pop3b
 0.01  0.07        80921        2 | in.net.vsnl
 0.02  0.13       149266        5 | in.nic
 0.11  0.09       101254       22 | it.askesis
 0.05  0.02        25634       11 | it.indi
 0.02  0.06        68322        4 | it.iol
 0.05  0.02        25466       11 | it.programatic
 0.09  0.11       130034       18 | jp.co.chugai-pharm
 0.03  0.02        17878        7 | jp.co.tanabe
 0.04  0.04        50533        8 | jp.co.yokogawa
 0.06  0.03        35862       12 | jp.or.highway
 0.11  0.04        44580       22 | jp.or.medbank.in
 0.06  0.07        83068       13 | mx.com.spin
 0.01  0.01        12589        3 | mx.net.data
 0.06  0.02        27161       13 | net.3rivers
 0.06  0.02        27139       12 | net.accessus
 0.01  0.03        30861        3 | net.adams
 0.03  0.02        17878        7 | net.agate.sdi
 0.12  0.11       134513       25 | net.agt
 0.06  0.01        12930       12 | net.aisp
 0.13  0.15       182280       26 | net.alaska
 0.06  0.05        63086       12 | net.alltel
 0.01  0.06        65260        2 | net.aloha
 0.13  0.15       177015       27 | net.aloha.u
 0.03  0.07        83556        7 | net.alphacom
 0.06  0.06        74378       13 | net.ap.portal-01
 0.02  0.04        50549        4 | net.apci
 0.07  0.10       113120       15 | net.apk.medina
 0.18  0.18       218420       36 | net.arctic
 0.02  0.01        11169        4 | net.argo
 0.13  0.22       262432       26 | net.aristotle
 0.21  0.13       154950       42 | net.arn
 0.08  0.05        60067       17 | net.aros.slc
 0.10  0.13       150637       20 | net.atmnet
 0.07  0.06        68573       15 | net.att.dial-access.ca.los-angeles-001
 0.09  0.08        89758       18 | net.att.dial-access.ca.san-diego-001
 0.12  0.08        99060       24 | net.att.dial-access.ca.san-francisco-002
 0.00  0.00          316        1 | net.att.dial-access.ca.san-francisco-004
 0.11  0.08        92278       23 | net.att.dial-access.ca.san-francisco-005
 0.04  0.02        20949        9 | net.att.dial-access.ca.san-francisco-025
 0.03  0.02        17878        7 | net.att.dial-access.ca.santa-ana-002
 0.16  0.26       308959       32 | net.att.dial-access.co.denver-001
 0.09  0.13       154209       19 | net.att.dial-access.fl.miami-001
 0.00  0.02        28872        1 | net.att.dial-access.fl.orlando-002
 0.10  0.10       112990       20 | net.att.dial-access.fl.orlando-004
 0.08  0.06        71132       17 | net.att.dial-access.fl.orlando-005
 0.01  0.02        27635        3 | net.att.dial-access.fl.orlando-006
 0.05  0.06        72033       10 | net.att.dial-access.fl.tampa-002
 0.07  0.03        32555       14 | net.att.dial-access.ga.atlanta-002
 0.09  0.03        31503       19 | net.att.dial-access.ga.atlanta-003
 0.01  0.03        33552        3 | net.att.dial-access.ga.atlanta-005
 0.05  0.04        49300       10 | net.att.dial-access.ga.atlanta-035
 0.08  0.09       105989       17 | net.att.dial-access.ga.atlanta-09
 0.01  0.04        50780        3 | net.att.dial-access.il.chicago-002
 0.02  0.06        66932        4 | net.att.dial-access.il.chicago-033
 0.05  0.02        23931       10 | net.att.dial-access.mo.bridgeton-001
 0.18  0.20       234897       37 | net.att.dial-access.mo.bridgeton-002
 0.04  0.11       135521        8 | net.att.dial-access.mo.bridgeton-051
 0.01  0.03        36055        3 | net.att.dial-access.mo.bridgeton-052
 0.06  0.04        41937       13 | net.att.dial-access.mo.bridgeton-053
 0.07  0.08        93106       15 | net.att.dial-access.mo.bridgeton-055
 0.08  0.09       103316       16 | net.att.dial-access.mo.bridgeton-056
 0.01  0.03        35161        3 | net.att.dial-access.mo.bridgeton-058
 0.10  0.08        98155       20 | net.att.dial-access.mo.bridgeton-065
 0.01  0.03        31520        2 | net.att.dial-access.mo.kansas-city-001
 0.03  0.03        35579        7 | net.att.dial-access.mo.st-louis-002
 0.01  0.02        18658        3 | net.att.dial-access.mo.st-louis-006
 0.10  0.08        90390       20 | net.att.dial-access.mo.st-louis-011
 0.23  0.15       172834       47 | net.att.dial-access.ny.new-york-003
 0.01  0.02        24719        3 | net.att.dial-access.ny.new-york-004
 0.08  0.08        95877       17 | net.att.dial-access.ny.new-york-006
 0.06  0.03        40640       13 | net.att.dial-access.ny.new-york-007
 0.01  0.04        50780        3 | net.att.dial-access.ny.new-york-008
 0.01  0.03        34078        3 | net.att.dial-access.ny.new-york-013
 0.00  0.00         3381        1 | net.att.dial-access.tx.houston-002
 0.01  0.00          999        3 | net.att.dial-access.unused-207-116-177
 0.06  0.02        26333       13 | net.att.dial-access.va.arlington-002
 0.16  0.15       182377       33 | net.att.dial-access.va.arlington-008
 0.06  0.07        78113       13 | net.att.dial-access.va.middletown-53
 0.08  0.09       110329       16 | net.att.dial-access.va.middletown-54
 0.13  0.13       155447       26 | net.att.dial-access.wa.seattle-001
 0.11  0.06        74974       23 | net.att.dial-access.wa.seattle-002
 0.10  0.11       130874       20 | net.att.dial-access.wa.seattle-003
 0.01  0.02        22671        3 | net.att.ico
 0.06  0.06        68053       12 | net.avalon.icwest
 0.03  0.13       148813        7 | net.bayarea
 0.01  0.06        75142        3 | net.baynet
 0.10  0.19       226288       20 | net.bbssys
 0.01  0.00         3697        2 | net.bellatlantic
 0.22  0.15       175729       45 | net.bellsouth.atl
 0.07  0.04        48914       15 | net.bellsouth.mem
 0.36  0.37       439323       72 | net.bellsouth.mia
 0.08  0.08        92715       17 | net.berkshire
 0.10  0.23       270848       20 | net.bright.dial
 0.01  0.04        50780        3 | net.brightok
 0.18  0.13       153856       36 | net.buffnet
 0.01  0.02        22790        3 | net.bway
 0.03  0.05        55042        6 | net.cableol.tch
 0.10  0.08        99593       20 | net.capecod
 0.05  0.08        97808       10 | net.cardina
 0.01  0.02        19261        3 | net.carib-link
 0.05  0.02        22093       10 | net.caribe
 0.01  0.01         9657        3 | net.castle
 0.06  0.06        71689       13 | net.cdsnet.dip
 0.02  0.05        54161        4 | net.cei.fs
 0.01  0.00         3813        2 | net.cei.pb
 0.09  0.05        55180       18 | net.centuryinter.ob
 0.09  0.09       110436       18 | net.clark
 0.05  0.04        43139       10 | net.clic.qbc
 0.06  0.05        58274       13 | net.cloud9.dialup
 0.12  0.11       134590       24 | net.cmc.novato
 0.04  0.01         8760        8 | net.communique.msy4
 0.10  0.11       129139       21 | net.communique.sli2
 0.03  0.02        17878        7 | net.community.coco
 0.07  0.08        96295       14 | net.comsource
 1.13  1.08      1278997      229 | net.concentric
 0.04  0.01        13028        8 | net.connect
 0.08  0.12       142002       17 | net.connex.orillia
 0.04  0.06        74387        8 | net.crosslink.us.va.colonial-beach.pm1
 0.00  0.00          316        1 | net.csra
 0.08  0.07        77668       17 | net.cybernex
 0.03  0.02        17878        7 | net.cyberramp
 0.10  0.04        43525       21 | net.datasys
 0.06  0.01         9240       12 | net.davlin
 0.07  0.14       160879       15 | net.dbtech
 0.03  0.07        82621        7 | net.dca
 0.10  0.10       113931       20 | net.dcache
 0.00  0.03        32655        1 | net.demon.www
 0.48  0.46       545122       97 | net.dialsprint
 0.01  0.02        20162        3 | net.digital
 0.05  0.02        22435       10 | net.digitalexp.fl.marianna
 0.06  0.02        26226       13 | net.dpc
 0.11  0.15       179374       23 | net.earthlink
 0.02  0.03        39918        4 | net.earthlink.dialup.la-ca-us
 0.06  0.09       102954       13 | net.earthlink.dynip.us.ca.agoura.maxa
 0.01  0.02        27577        3 | net.eau
 0.16  0.14       168810       33 | net.ebtech
 0.06  0.05        64159       13 | net.ee.marietta
 0.00  0.02        24776        1 | net.egyptian
 0.08  0.14       165369       17 | net.emi
 0.02  0.01        14475        5 | net.en
 0.01  0.01         8268        3 | net.enter
 0.10  0.20       242167       21 | net.epix
 0.01  0.03        34764        3 | net.eri.troy
 0.01  0.03        36404        3 | net.eskimo.ndip
 0.01  0.03        35113        3 | net.etv
 0.22  0.11       131215       45 | net.evansville
 0.05  0.02        22366       11 | net.fastlane
 0.07  0.07        80793       14 | net.fgi
 0.02  0.04        41588        4 | net.fia
 0.08  0.09       103877       17 | net.fix.dialup.snlo
 0.54  0.46       543045      110 | net.flash
 0.02  0.01        10480        4 | net.frontiercomm.dialup
 0.13  0.16       191267       26 | net.frontiernet.roc.dial
 0.08  0.05        53812       16 | net.ftn
 0.18  0.15       172864       36 | net.fuse
 0.01  0.04        42776        3 | net.futuris
 0.01  0.05        64006        3 | net.fyi
 0.02  0.00         4872        5 | net.galaxy.ry
 0.18  0.11       130255       36 | net.gate
 0.01  0.00         1577        3 | net.gdipartners
 0.04  0.05        56965        9 | net.ghg
 0.02  0.01        17027        4 | net.gis
 0.01  0.02        22322        3 | net.global2000
 0.12  0.14       164397       24 | net.globalserve
 0.15  0.15       176328       31 | net.golden
 0.07  0.02        29570       14 | net.got
 0.02  0.05        58852        4 | net.grid.dlls
 0.42  0.18       215449       85 | net.gte
 0.03  0.02        17878        7 | net.gtn
 0.04  0.12       137486        8 | net.guernsey
 0.08  0.10       119620       16 | net.gulf.pcola
 0.01  0.03        36055        3 | net.gvi
 0.12  0.03        35418       25 | net.gwi
 0.10  0.07        88323       21 | net.hiwaay
 0.06  0.05        57663       13 | net.hookup.hfx
 0.09  0.07        78403       18 | net.hookup.van
 0.03  0.02        17878        7 | net.hula
 0.07  0.03        33641       15 | net.i-cafe
 0.05  0.02        25515       11 | net.i-link-2
 0.32  0.45       532466       65 | net.iadfw.ppp
 0.19  0.12       146941       38 | net.iamerica
 0.11  0.11       134367       22 | net.ibm.ca.on
 0.01  0.02        27635        3 | net.ibm.us
 0.06  0.05        58974       13 | net.ibm.us.al
 0.03  0.05        61575        7 | net.ibm.us.ca
 0.00  0.00          382        1 | net.ibm.us.dc
 0.01  0.06        66227        3 | net.ibm.us.fl
 0.11  0.13       159939       23 | net.ibm.us.mi
 0.07  0.07        86071       14 | net.ibm.us.ms
 0.08  0.07        77993       16 | net.ibm.us.nj
 0.25  0.25       296120       50 | net.ibm.us.ny
 0.00  0.00          316        1 | net.ibm.us.oh
 0.11  0.11       126330       23 | net.ibm.us.tn
 0.06  0.04        44790       13 | net.ibm.us.wa
 0.03  0.02        23461        6 | net.ica
 0.10  0.06        71891       20 | net.ican.barrie-01
 0.01  0.00         4325        3 | net.ican.stcatherines-01
 0.01  0.03        40236        3 | net.ican.syracuse-02
 0.02  0.04        51332        4 | net.ici
 0.09  0.06        68168       18 | net.icsi
 0.05  0.00         4867       10 | net.idt.ana.is-1
 0.03  0.02        17878        7 | net.idt.cle.ts-1
 0.01  0.04        48378        3 | net.idt.hck.ts-10
 0.09  0.15       180435       18 | net.idt.hob.ts-1
 0.06  0.03        33668       13 | net.idt.hp.ts-1
 0.02  0.01        12932        5 | net.idt.mvl.ts-1
 0.01  0.03        41036        3 | net.idt.nyc.ts-10
 0.08  0.04        52129       16 | net.idt.nyc.ts-14
 0.03  0.02        17878        7 | net.idt.nyc.ts-9
 0.01  0.04        50780        3 | net.ies
 0.03  0.02        17878        7 | net.igcom.ppp
 0.02  0.04        50967        4 | net.igs.ott
 0.14  0.13       155846       29 | net.igs.windsor
 0.05  0.12       141669       10 | net.ime
 0.22  0.26       305507       45 | net.imperium
 0.05  0.02        22887       10 | net.inav
 0.00  0.00          300        1 | net.incentre.edm
 0.05  0.02        22076       10 | net.indy
 0.17  0.14       167346       35 | net.indy.ts
 0.08  0.09       112043       17 | net.infi.avp
 0.08  0.03        34161       16 | net.infi.bgr
 0.04  0.06        75682        8 | net.infi.crp
 0.07  0.05        60593       14 | net.infi.lex
 0.06  0.05        56720       13 | net.infi.orf
 0.01  0.02        27424        2 | net.infi.pot
 0.01  0.01        10549        3 | net.infi.richmond
 0.07  0.05        61050       14 | net.infoave.ncelrb.r01
 0.06  0.02        29541       13 | net.infoave.sclncs.r1
 0.08  0.08        97291       17 | net.infoave.scmbch.r03
 0.00  0.00          382        1 | net.infoave.tnpkvl.r2
 0.01  0.01        17428        3 | net.infocom
 0.03  0.05        57744        6 | net.infonline
 0.14  0.20       243051       28 | net.interconnect
 0.17  0.21       254805       35 | net.intrepid
 0.03  0.02        17878        7 | net.inw
 0.01  0.01         9766        3 | net.inx
 0.12  0.06        74380       24 | net.ionet
 0.06  0.13       159417       12 | net.iquest
 0.01  0.03        31520        2 | net.ismi
 0.06  0.07        81623       13 | net.iu
 0.13  0.14       162562       27 | net.ivic
 0.06  0.07        80910       13 | net.jersey
 0.03  0.02        17878        7 | net.kersur
 0.07  0.03        40961       15 | net.kingston
 0.01  0.03        35303        2 | net.lava
 0.07  0.10       114509       15 | net.lax
 0.06  0.02        29413       13 | net.leba
 0.02  0.02        26470        4 | net.li
 0.11  0.14       163517       22 | net.lightspeed
 0.17  0.16       189485       35 | net.linknet
 0.01  0.02        23459        3 | net.loop.hwts14
 0.07  0.03        40614       14 | net.ltec
 0.08  0.03        37984       16 | net.maas
 0.06  0.05        55331       13 | net.magick.gp.p2
 0.07  0.05        54539       14 | net.mastnet
 0.02  0.06        75513        5 | net.maz
 0.07  0.03        37321       14 | net.mc
 0.03  0.01        16269        7 | net.mci.bloomington
 0.01  0.05        54127        3 | net.mci.bloomington.mix1
 0.01  0.02        22462        3 | net.mci.boston
 0.06  0.08        95410       12 | net.mci.boston.mix2
 0.11  0.11       126518       23 | net.mci.campus.auburn
 0.12  0.04        51636       25 | net.mci.campus.austel
 0.06  0.09       104516       12 | net.mci.campus.snaustel
 0.06  0.03        36748       12 | net.mci.campus.ucr
 0.01  0.04        50780        3 | net.mci.campus.weber
 0.06  0.02        25110       12 | net.mci.losangeles
 0.12  0.03        38805       25 | net.mci.newyork
 0.12  0.10       117686       24 | net.mci.willowsprings.mix1
 0.07  0.09       110785       15 | net.mcn
 0.05  0.05        62484       10 | net.meganet
 0.06  0.02        28435       13 | net.megsinet
 0.50  0.55       655698      100 | net.mich.dialip
 0.07  0.09       109138       14 | net.microgate
 0.06  0.06        68681       13 | net.micron.boi
 0.02  0.03        36737        4 | net.midusa.homecity
 0.01  0.02        20359        3 | net.midusa.mcpherson
 0.03  0.05        64184        7 | net.midusa.salina
 0.21  0.13       150332       43 | net.midwest
 0.07  0.12       147376       15 | net.mindlink.nwm
 0.06  0.02        28868       13 | net.mindport
 0.16  0.11       131633       33 | net.mis
 0.03  0.04        42804        6 | net.miworld
 0.10  0.08        91784       20 | net.mnsi.win
 0.05  0.02        24975       11 | net.moa.ouhub
 0.01  0.03        32067        3 | net.monad.top
 0.03  0.05        57689        6 | net.mountain-inter
 0.07  0.07        83240       14 | net.mr.nas
 0.05  0.12       139721       11 | net.mwt.sabin
 0.06  0.04        52996       13 | net.nai
 0.19  0.11       125911       38 | net.nb
 0.01  0.03        36055        3 | net.nceye
 0.13  0.07        77930       26 | net.ncn
 0.03  0.02        17878        7 | net.netacc
 0.01  0.05        57816        3 | net.netins.dialup
 0.01  0.03        40236        3 | net.netmagic.sj
 0.05  0.03        40601       11 | net.netroute.nebula
 0.06  0.05        64516       13 | net.netshop
 0.10  0.08        98422       20 | net.niia
 0.01  0.03        36055        3 | net.nl.arnhem
 0.06  0.03        34796       13 | net.norlight.dul
 0.04  0.02        18261        8 | net.nortel
 0.00  0.03        41160        1 | net.nortexinfo
 0.06  0.04        52945       13 | net.norwich
 0.04  0.02        21259        8 | net.nothinbut
 0.09  0.09       112336       18 | net.novia
 0.05  0.07        81369       10 | net.ns
 0.01  0.00         3982        3 | net.odyssee
 0.17  0.08        98991       34 | net.olympus
 0.24  0.36       429176       49 | net.one.access
 0.25  0.14       170403       51 | net.onramp.hstntx
 0.16  0.11       131030       33 | net.oz
 0.05  0.08        98647       10 | net.p3
 0.08  0.06        75283       17 | net.pacbell.anhm01
 0.05  0.07        81884       10 | net.pacbell.frsn01
 0.08  0.07        87216       17 | net.pacbell.irvn11
 0.07  0.09       106254       14 | net.pacbell.lsan03
 0.03  0.05        55365        6 | net.pacbell.nhwd02
 0.01  0.01        12589        3 | net.pacbell.okld03
 0.08  0.06        76799       16 | net.pacbell.rdcy01
 0.04  0.08        89357        9 | net.pacbell.scrm01
 0.12  0.07        88614       25 | net.pacbell.sndg02
 0.03  0.07        84107        6 | net.pacbell.snfc21
 0.01  0.02        23590        3 | net.pacbell.vntrcs
 0.01  0.04        48052        3 | net.pacbell.wnck11
 0.14  0.20       232976       29 | net.pe
 0.00  0.01         8392        1 | net.peoples
 0.02  0.06        76412        4 | net.pi
 0.06  0.03        38594       13 | net.pitnet
 0.03  0.07        85573        6 | net.port
 0.08  0.05        59984       16 | net.powerweb
 0.01  0.04        50780        3 | net.premier1
 0.01  0.00          764        2 | net.premiernet
 0.06  0.02        25694       12 | net.primary
 0.15  0.05        58398       30 | net.priority
 0.03  0.03        30145        7 | net.probe
 0.09  0.09       101201       19 | net.prodigy.la
 0.10  0.07        87661       20 | net.prodigy.nyc
 0.13  0.14       168046       27 | net.prodigy.ykt
 0.06  0.07        85968       13 | net.promedia
 0.01  0.03        39906        3 | net.psi.pub-ip.al.birmingham
 0.11  0.07        86546       23 | net.psi.pub-ip.az.phoenix2
 0.06  0.03        33621       13 | net.psi.pub-ip.az.tucson
 0.03  0.01        10100        6 | net.psi.pub-ip.ca.santa-ana
 0.01  0.03        37023        3 | net.psi.pub-ip.ct.harford3
 0.01  0.02        17992        3 | net.psi.pub-ip.md.annapolis2
 0.07  0.04        46612       15 | net.psi.pub-ip.md.baltimore
 0.01  0.02        19573        2 | net.psi.pub-ip.ny.an10-new-york4
 0.23  0.23       277560       46 | net.psi.pub-ip.ny.an13-new-york4
 0.06  0.08        89499       13 | net.psi.pub-ip.ny.garden-city2
 0.04  0.05        55648        8 | net.psi.pub-ip.ny.syracuse
 0.09  0.04        46759       18 | net.psi.pub-ip.pa.philadelphia2
 0.05  0.01         8951       10 | net.ptd.cli
 0.12  0.16       191580       25 | net.ptd.leh
 0.19  0.20       242773       38 | net.ptd.mil
 0.01  0.04        50780        3 | net.ptd.str
 0.12  0.09       100937       24 | net.ptialaska.juneau
 0.01  0.02        26888        3 | net.ptialaska.sitka
 0.11  0.14       162100       23 | net.radiks
 0.08  0.07        84431       16 | net.radix.annex4
 0.08  0.21       246376       17 | net.revealed
 0.05  0.06        68658       10 | net.rica
 0.06  0.05        65068       13 | net.rochelle
 0.04  0.04        51285        9 | net.rose
 0.07  0.03        34590       14 | net.saturn
 0.13  0.09       104529       26 | net.scott
 0.17  0.03        39949       35 | net.scsn
 0.08  0.09       102671       16 | net.sgi.mcm
 0.01  0.02        23459        3 | net.sky
 0.06  0.02        24902       12 | net.skyenet
 0.03  0.01        12635        6 | net.skyinet
 0.19  0.27       322792       38 | net.snet
 0.09  0.14       170651       18 | net.socketis
 0.05  0.02        22361       10 | net.southeast
 0.01  0.05        61700        3 | net.sover.rut
 0.02  0.05        56153        5 | net.sover.wrj
 0.01  0.04        50780        3 | net.sowega
 0.04  0.11       124929        9 | net.speed
 0.01  0.02        22881        3 | net.spokane
 0.10  0.09       110453       21 | net.srv
 0.05  0.14       166405       11 | net.star
 0.05  0.02        23919       10 | net.startext
 0.03  0.03        34438        7 | net.stic
 0.01  0.05        56608        2 | net.sunlink
 0.05  0.05        62801       10 | net.superior
 0.03  0.05        56380        6 | net.superiway
 0.14  0.11       134779       29 | net.swbell.hstntx
 0.12  0.07        82502       25 | net.swva
 0.07  0.07        85416       15 | net.tbaytel
 0.08  0.06        70105       16 | net.tcccom
 0.03  0.00         1998        6 | net.tcimet
 0.07  0.08        91916       14 | net.tco
 0.01  0.02        17992        3 | net.tdi
 0.01  0.03        36404        3 | net.tds.oakman
 0.02  0.02        18569        5 | net.teclink
 0.01  0.03        31344        3 | net.terranet
 0.10  0.06        65497       21 | net.tetranet
 0.01  0.08        92661        2 | net.tfs.lake
 0.01  0.02        22462        3 | net.thefuture
 0.01  0.04        50780        3 | net.themall
 0.02  0.06        71239        5 | net.tiac
 0.01  0.03        38784        3 | net.tis.hsv
 0.02  0.10       116573        5 | net.toolcity
 0.10  0.12       147918       21 | net.top
 0.05  0.02        25132       11 | net.total.mtl
 0.06  0.06        69730       13 | net.tvs
 0.03  0.02        17878        7 | net.tvs.hope
 0.02  0.02        19893        5 | net.twave
 0.01  0.01        13025        3 | net.txdirect
 0.07  0.08        93739       15 | net.tyrell.tyrell
 0.05  0.02        23735       10 | net.ultra
 0.01  0.03        35616        2 | net.ultra.ma.ltn
 0.01  0.01         9657        3 | net.unicom.access
 0.11  0.09       104318       22 | net.up
 0.01  0.03        40260        3 | net.usaor
 0.14  0.23       273679       28 | net.usit.dynamic
 0.01  0.02        22462        3 | net.uswest.utah
 0.09  0.10       115866       18 | net.uu.ms.az.phoenix.max2
 0.06  0.02        27976       13 | net.uu.ms.ca.los-angeles.max10
 0.01  0.02        22790        3 | net.uu.ms.ca.los-angeles.max11
 0.06  0.02        27553       13 | net.uu.ms.ca.los-angeles.max12
 0.03  0.02        17878        7 | net.uu.ms.ca.los-angeles.max22
 0.10  0.11       126362       20 | net.uu.ms.ca.los-angeles.max68
 0.01  0.03        38784        3 | net.uu.ms.ca.los-angeles.max73
 0.07  0.03        37013       15 | net.uu.ms.ca.los-angeles.max78
 0.01  0.09       103987        2 | net.uu.ms.ca.san-diego.max16
 0.05  0.02        25691       11 | net.uu.ms.ca.san-diego.max5
 0.09  0.08        90983       19 | net.uu.ms.ca.san-francisco.max20
 0.01  0.02        18802        3 | net.uu.ms.ca.santa-clara.max13
 0.01  0.02        17890        3 | net.uu.ms.ca.santa-clara.max6
 0.08  0.09       107596       17 | net.uu.ms.co.denver.max2
 0.05  0.07        79229       10 | net.uu.ms.dc.washington.max14
 0.08  0.10       117796       16 | net.uu.ms.dc.washington.max20
 0.01  0.05        58777        3 | net.uu.ms.dc.washington.max3
 0.06  0.04        43696       13 | net.uu.ms.dc.washington.max9
 0.03  0.02        17878        7 | net.uu.ms.fl.miami.max1
 0.08  0.08        96030       17 | net.uu.ms.fl.orlando.max15
 0.08  0.07        81685       16 | net.uu.ms.fl.orlando.max18
 0.07  0.06        75678       15 | net.uu.ms.fl.orlando.max2
 0.01  0.00          999        3 | net.uu.ms.fl.orlando.max7
 0.10  0.11       129909       20 | net.uu.ms.ga.atlanta.max30
 0.06  0.04        52022       13 | net.uu.ms.ga.atlanta.max4
 0.03  0.15       182523        6 | net.uu.ms.ga.atlanta.max7
 0.02  0.11       128774        4 | net.uu.ms.il.chicago.max5
 0.06  0.04        52056       13 | net.uu.ms.il.chicago.max7
 0.07  0.03        30928       14 | net.uu.ms.il.chicago.max8
 0.01  0.01         9657        3 | net.uu.ms.in.indianapolis.max15
 0.01  0.01        12589        3 | net.uu.ms.in.indianapolis.max9
 0.01  0.04        50780        3 | net.uu.ms.ma.boston.max12
 0.01  0.05        63406        3 | net.uu.ms.ma.boston.max25
 0.01  0.03        35616        2 | net.uu.ms.ma.boston.max27
 0.07  0.03        31618       14 | net.uu.ms.ma.boston.max30
 0.03  0.04        49563        6 | net.uu.ms.ma.boston.max4
 0.03  0.02        17878        7 | net.uu.ms.mn.minneapolis.max8
 0.05  0.03        34737       10 | net.uu.ms.mo.kansas-city.max12
 0.09  0.05        64746       19 | net.uu.ms.mo.kansas-city.max8
 0.06  0.05        53623       12 | net.uu.ms.mo.kansas-city2.max3
 0.05  0.02        21975       10 | net.uu.ms.mo.st-louis.max2
 0.06  0.04        42712       13 | net.uu.ms.nc.raleigh.max12
 0.01  0.02        20870        3 | net.uu.ms.nc.raleigh.max17
 0.00  0.02        23750        1 | net.uu.ms.nc.raleigh.max9
 0.05  0.08        98104       11 | net.uu.ms.nj.newark.max10
 0.17  0.18       214943       35 | net.uu.ms.nv.las-vegas.max2
 0.07  0.05        63700       15 | net.uu.ms.nv.las-vegas.max3
 0.03  0.04        51879        7 | net.uu.ms.ny.new-york.max10
 0.08  0.03        35662       16 | net.uu.ms.ny.new-york.max12
 0.01  0.06        75987        2 | net.uu.ms.ny.new-york.max2
 0.03  0.09       112078        7 | net.uu.ms.ny.new-york.max22
 0.01  0.03        32439        3 | net.uu.ms.ny.new-york.max27
 0.07  0.08        97436       15 | net.uu.ms.ny.new-york.max34
 0.12  0.08        94957       24 | net.uu.ms.ny.new-york.max38
 0.01  0.04        47526        3 | net.uu.ms.oh.cleveland.max14
 0.01  0.01         9657        3 | net.uu.ms.oh.cleveland.max17
 0.01  0.01        15169        3 | net.uu.ms.oh.cleveland.max19
 0.01  0.01        14114        3 | net.uu.ms.oh.cleveland.max28
 0.01  0.04        45486        3 | net.uu.ms.oh.cleveland.max6
 0.08  0.09       108660       16 | net.uu.ms.oh.cleveland.max7
 0.03  0.07        86954        6 | net.uu.ms.or.portland.max1
 0.03  0.02        17878        7 | net.uu.ms.pa.philadelphia.max13
 0.01  0.02        20325        3 | net.uu.ms.sc.columbia.max7
 0.08  0.08        94058       16 | net.uu.ms.tx.dallas.max19
 0.23  0.54       636619       46 | net.uu.ms.tx.dallas.max20
 0.07  0.06        71743       15 | net.uu.ms.tx.dallas.max6
 0.12  0.10       116860       24 | net.uu.ms.tx.houston.max2
 0.01  0.02        22462        3 | net.uu.ms.tx.houston.max5
 0.01  0.01        15169        3 | net.uu.ms.tx.houston2.max7
 0.08  0.05        59902       17 | net.uu.ms.tx.irving.max1
 0.01  0.01        12589        3 | net.uu.ms.ut.salt-lake-city.max1
 0.05  0.04        48976       10 | net.uu.ms.ut.salt-lake-city.max5
 0.01  0.02        26888        3 | net.uu.ms.wa.seattle.max1
 0.10  0.09       106364       21 | net.uu.ms.wa.seattle.max17
 0.06  0.06        72914       13 | net.uu.ms.wa.seattle.max45
 0.06  0.03        39411       12 | net.uu.ms.wa.seattle.max9
 0.01  0.02        20882        2 | net.vais
 0.03  0.01        15892        6 | net.venus
 0.12  0.06        74195       25 | net.vicon
 0.01  0.04        42863        3 | net.videotron.mmtl.162
 0.04  0.11       124656        8 | net.videotron.mque.229
 0.15  0.14       160904       30 | net.virgin.tch
 0.03  0.05        60662        6 | net.visi.nn
 0.05  0.02        22380       10 | net.voyager
 0.18  0.12       144796       36 | net.voyager.dial
 0.08  0.07        86523       16 | net.warwick
 0.03  0.03        35072        7 | net.webgate
 0.16  0.24       279598       33 | net.webtv.alma.iap
 0.45  0.50       597441       91 | net.webtv.alma.isp
 0.90  1.11      1313062      181 | net.webtv.bryant.iap
 0.01  0.04        50780        3 | net.weir
 0.06  0.06        74095       13 | net.wenet.ppp
 0.11  0.07        87945       22 | net.which.tch
 0.01  0.02        20162        3 | net.wil
 0.05  0.02        22350       10 | net.willinet
 0.01  0.01        12589        3 | net.wilmington.wisedial
 0.16  0.08       100543       32 | net.win
 0.07  0.08        92092       15 | net.wiscasset
 0.03  0.06        75585        6 | net.world-net
 0.16  0.16       185211       33 | net.wt
 0.03  0.06        71155        7 | net.xanadu2
 0.02  0.03        38788        4 | net.xsite
 0.16  0.14       171370       33 | net.zebra
 0.21  0.19       221765       42 | net.zoomnet.jackson
 0.01  0.00          999        3 | nl.introweb
 0.00  0.02        23750        1 | nl.tudelft
 0.03  0.04        42185        7 | nl.vu.med
 0.08  0.03        36658       16 | nl.xs4all
 0.06  0.05        55886       13 | nl.xs4all.dial
 0.01  0.02        22790        3 | no.hint.stud
 0.04  0.03        32992        8 | no.ntnu.itea
 0.01  0.03        38784        3 | no.sn.ppp
 0.01  0.00         1148        3 | no.telenor
 0.01  0.05        59681        3 | no.telepost
 0.00  0.00         2648        1 | nz.ac.waikato
 0.02  0.02        19354        4 | nz.co.es
 0.01  0.07        77667        3 | nz.co.xtra
 0.01  0.00         1999        2 | nz.govt.natlib
 0.07  0.06        65773       15 | org.amug
 0.00  0.03        36506        1 | org.ap
 0.08  0.03        36932       16 | org.bluecrab
 0.00  0.03        34897        1 | org.capaccess
 0.01  0.03        36404        3 | org.cedarnet
 0.03  0.02        17878        7 | org.eee
 0.08  0.04        46481       17 | org.hal-pc
 0.06  0.05        54231       12 | org.hslc
 0.00  0.00          316        1 | org.michiana
 0.00  0.03        40725        1 | org.morris
 0.01  0.04        48052        3 | org.northnet.canton
 0.07  0.07        80305       15 | org.open
 0.03  0.02        17878        7 | org.ruralhealth
 0.01  0.07        77667        3 | org.win
 0.03  0.02        17878        7 | pe.net.unired
 0.01  0.05        57794        2 | pk.net.brain
 0.12  0.18       215337       25 | pl.gda.amg.farmacja
 0.04  0.07        86921        8 | pl.tpnet.lodz
 0.01  0.02        20071        3 | pt.telepac
 0.07  0.08        90147       15 | se.algonet.ppp
 0.08  0.06        69099       16 | se.ki.it
 0.19  0.15       183212       39 | se.swipnet
 0.01  0.04        51395        3 | se.umu.sn
 0.01  0.01         7189        3 | sg.ac.np
 0.01  0.03        37760        3 | sg.com.cyberway
 0.15  0.09       109931       30 | sg.net.pacific
 0.05  0.09       105934       10 | sg.nus
 0.01  0.05        64348        3 | th.ac.mahidol
 0.07  0.02        29318       14 | th.net.ksc
 0.02  0.02        21965        4 | tw.edu.ccu
 0.03  0.02        17878        7 | tw.edu.nthu.ab.hung
 0.08  0.08        96493       16 | uk.ac.srf.pact
 0.00  0.02        23750        1 | uk.ac.susx.central
 0.06  0.06        75647       13 | uk.co.demon
 0.02  0.00         4861        4 | uk.co.dircon
 0.09  0.06        67548       19 | uk.co.ednet
 0.11  0.06        65429       23 | uk.co.idiscover.nexus
 0.10  0.10       113770       20 | uk.co.pol.c1r5
 0.01  0.01        12945        3 | uk.co.rcp
 0.06  0.02        27663       13 | us.al.mobile.maf
 0.00  0.00          383        1 | us.ca.cc.elcamino
 0.04  0.02        23315        8 | us.ca.k12.porterville
 0.03  0.02        17878        7 | us.ca.k12.sbceo
 0.09  0.06        66423       19 | us.ca.ridgecrest
 0.00  0.03        33562        1 | us.co.lib.pueblo
 0.04  0.08        98519        9 | us.fl.k12.pinellas.baypt
 0.04  0.04        51285        9 | us.la.lib.beau
 0.14  0.12       140373       28 | us.md.lib.bcpl
 0.01  0.02        27788        3 | us.mi.lib.shl
 0.11  0.11       136104       23 | us.mi.newaygo
 0.09  0.07        84155       19 | us.or.coos.cb
 0.04  0.04        41867        8 | us.tn.cc.jscc
 0.00  0.01        16862        1 | us.tn.k12.ten
 0.01  0.04        50780        3 | us.wi.k12.wausau
 0.03  0.02        17878        7 | za.co.aztec
 0.01  0.01        11994        3 | za.pix.ptb
</PRE>
<HR>
<H2><A NAME="Archive">Total Transfers by URL/Archive Section</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Archive Section
----- ----- ------------ -------- |------------------------------------
 8.10  4.54      5383796     1636 | <a href="/">/</a>
 5.47  3.10      3673481     1104 | <a href="/5per.gif">/5per.gif</a>
 0.00  0.00         4008        1 | <a href="/ImageTape.class">/ImageTape.class</a>
 0.10  0.07        77314       21 | <a href="/about.htm">/about.htm</a>
 0.05  0.03        33979       11 | <a href="/aceinh.htm">/aceinh.htm</a>
 0.20  0.20       236541       40 | <a href="/antidepr.htm">/antidepr.htm</a>
 0.10  0.03        32285       21 | <a href="/av.htm">/av.htm</a>
 0.08  0.02        21062       16 | <a href="/av2.htm">/av2.htm</a>
 0.19  0.07        84952       38 | <a href="/av3.htm">/av3.htm</a>
 0.10  0.07        77492       20 | <a href="/bblock.htm">/bblock.htm</a>
 0.10  0.06        65628       20 | <a href="/calch.htm">/calch.htm</a>
 0.23  0.06        76310       47 | <a href="/cardiova.htm">/cardiova.htm</a>
 0.01  0.00         1212        3 | <a href="/cgi/">/cgi/</a>
 0.02  0.03        38772        4 | <a href="/cgi/brand/image/ogen.gif">/cgi/brand/image/ogen.gif</a>
 0.10  0.13       156865       21 | <a href="/cgi/brand/image/provera.gif">/cgi/brand/image/provera.gif</a>
 0.02  0.11       129267        4 | <a href="/cgi/brand/ogen.htm">/cgi/brand/ogen.htm</a>
 0.10  0.28       337445       20 | <a href="/cgi/brand/provera.htm">/cgi/brand/provera.htm</a>
 0.10  0.01        14535       21 | <a href="/cgi/brand/redball.gif">/cgi/brand/redball.gif</a>
 0.12  0.05        56607       24 | <a href="/cgi/brand/rx.gif">/cgi/brand/rx.gif</a>
 0.02  0.00         1674        4 | <a href="/cgi/brand/tm.gif">/cgi/brand/tm.gif</a>
 5.06  0.35       410256     1022 | <a href="/cgi/count.gif">/cgi/count.gif</a>
 0.01  0.01         6942        2 | <a href="/cgi/disclaim.htm">/cgi/disclaim.htm</a>
 0.05  0.15       179568       11 | <a href="/cgi/generic/">/cgi/generic/</a>
 0.11  0.30       350757       23 | <a href="/cgi/generic/acetcod.htm">/cgi/generic/acetcod.htm</a>
 0.05  0.25       291579       11 | <a href="/cgi/generic/acyclo.htm">/cgi/generic/acyclo.htm</a>
 0.10  0.23       271474       20 | <a href="/cgi/generic/albut1.htm">/cgi/generic/albut1.htm</a>
 0.03  0.14       162081        6 | <a href="/cgi/generic/alendron.htm">/cgi/generic/alendron.htm</a>
 0.04  0.21       244945        9 | <a href="/cgi/generic/allopur.htm">/cgi/generic/allopur.htm</a>
 0.13  1.15      1367219       26 | <a href="/cgi/generic/alpraz.htm">/cgi/generic/alpraz.htm</a>
 0.14  0.57       678913       29 | <a href="/cgi/generic/amitrip.htm">/cgi/generic/amitrip.htm</a>
 0.02  0.12       138070        5 | <a href="/cgi/generic/amlod2.htm">/cgi/generic/amlod2.htm</a>
 0.13  0.34       406525       26 | <a href="/cgi/generic/amox.htm">/cgi/generic/amox.htm</a>
 0.06  0.30       352648       13 | <a href="/cgi/generic/amoxclav.htm">/cgi/generic/amoxclav.htm</a>
 0.04  0.16       195437        9 | <a href="/cgi/generic/amphet.htm">/cgi/generic/amphet.htm</a>
 0.03  0.05        57300        6 | <a href="/cgi/generic/apap.htm">/cgi/generic/apap.htm</a>
 0.03  0.09       104664        6 | <a href="/cgi/generic/asa.htm">/cgi/generic/asa.htm</a>
 0.01  0.04        46622        2 | <a href="/cgi/generic/astem.htm">/cgi/generic/astem.htm</a>
 0.08  0.53       634098       17 | <a href="/cgi/generic/atenolol.htm">/cgi/generic/atenolol.htm</a>
 0.09  0.47       554618       18 | <a href="/cgi/generic/azith.htm">/cgi/generic/azith.htm</a>
 0.00  0.02        22871        1 | <a href="/cgi/generic/beclo.htm">/cgi/generic/beclo.htm</a>
 0.02  0.08        93335        5 | <a href="/cgi/generic/beclo1.htm">/cgi/generic/beclo1.htm</a>
 0.01  0.01        14298        2 | <a href="/cgi/generic/benzon.htm">/cgi/generic/benzon.htm</a>
 0.01  0.10       120182        2 | <a href="/cgi/generic/bishctz.htm">/cgi/generic/bishctz.htm</a>
 0.10  0.64       760083       20 | <a href="/cgi/generic/buprop.htm">/cgi/generic/buprop.htm</a>
 0.03  0.14       163873        6 | <a href="/cgi/generic/buspir.htm">/cgi/generic/buspir.htm</a>
 0.05  0.23       271458       10 | <a href="/cgi/generic/butalcod.htm">/cgi/generic/butalcod.htm</a>
 0.05  0.29       339243       11 | <a href="/cgi/generic/captop.htm">/cgi/generic/captop.htm</a>
 0.08  0.50       588081       17 | <a href="/cgi/generic/carbam.htm">/cgi/generic/carbam.htm</a>
 0.06  0.10       115500       12 | <a href="/cgi/generic/carisop.htm">/cgi/generic/carisop.htm</a>
 0.11  0.29       344812       22 | <a href="/cgi/generic/cefaclor.htm">/cgi/generic/cefaclor.htm</a>
 0.01  0.04        48918        3 | <a href="/cgi/generic/cefadrox.htm">/cgi/generic/cefadrox.htm</a>
 0.01  0.06        66268        2 | <a href="/cgi/generic/cefixime.htm">/cgi/generic/cefixime.htm</a>
 0.03  0.12       143898        6 | <a href="/cgi/generic/cefurox.htm">/cgi/generic/cefurox.htm</a>
 0.01  0.11       126258        3 | <a href="/cgi/generic/cemp.htm">/cgi/generic/cemp.htm</a>
 0.16  0.48       572393       32 | <a href="/cgi/generic/cephalex.htm">/cgi/generic/cephalex.htm</a>
 0.01  0.03        33168        2 | <a href="/cgi/generic/certriz.htm">/cgi/generic/certriz.htm</a>
 0.02  0.07        88504        4 | <a href="/cgi/generic/cetiriz.htm">/cgi/generic/cetiriz.htm</a>
 0.01  0.03        32360        2 | <a href="/cgi/generic/chlordia.htm">/cgi/generic/chlordia.htm</a>
 0.02  0.14       163188        4 | <a href="/cgi/generic/cimet.htm">/cgi/generic/cimet.htm</a>
 0.11  0.73       867999       23 | <a href="/cgi/generic/cipro.htm">/cgi/generic/cipro.htm</a>
 0.02  0.07        82628        4 | <a href="/cgi/generic/cisap.htm">/cgi/generic/cisap.htm</a>
 0.10  0.45       530034       21 | <a href="/cgi/generic/clarith.htm">/cgi/generic/clarith.htm</a>
 0.01  0.03        35746        2 | <a href="/cgi/generic/clobet.htm">/cgi/generic/clobet.htm</a>
 0.04  0.27       318456        9 | <a href="/cgi/generic/clomiph.htm">/cgi/generic/clomiph.htm</a>
 0.01  0.04        41826        3 | <a href="/cgi/generic/clomipr.htm">/cgi/generic/clomipr.htm</a>
 0.11  0.27       321084       23 | <a href="/cgi/generic/clonaz.htm">/cgi/generic/clonaz.htm</a>
 0.06  0.17       203891       13 | <a href="/cgi/generic/clonidin.htm">/cgi/generic/clonidin.htm</a>
 0.03  0.04        46416        6 | <a href="/cgi/generic/cocaine.htm">/cgi/generic/cocaine.htm</a>
 0.07  0.31       363174       14 | <a href="/cgi/generic/conest.htm">/cgi/generic/conest.htm</a>
 0.08  0.25       301218       16 | <a href="/cgi/generic/cortisne.htm">/cgi/generic/cortisne.htm</a>
 0.01  0.02        29463        3 | <a href="/cgi/generic/cromnas.htm">/cgi/generic/cromnas.htm</a>
 0.05  0.18       208140       11 | <a href="/cgi/generic/cyclobnz.htm">/cgi/generic/cyclobnz.htm</a>
 0.02  0.19       227524        4 | <a href="/cgi/generic/desest.htm">/cgi/generic/desest.htm</a>
 0.46  3.06      3628259       93 | <a href="/cgi/generic/dexfen.htm">/cgi/generic/dexfen.htm</a>
 0.01  0.00         3495        3 | <a href="/cgi/generic/dexfenx.htm">/cgi/generic/dexfenx.htm</a>
 0.04  0.01        14064        8 | <a href="/cgi/generic/dhea.htm">/cgi/generic/dhea.htm</a>
 0.07  0.16       192077       14 | <a href="/cgi/generic/diazepam.htm">/cgi/generic/diazepam.htm</a>
 0.04  0.25       292429        9 | <a href="/cgi/generic/diclofen.htm">/cgi/generic/diclofen.htm</a>
 0.03  0.12       143997        7 | <a href="/cgi/generic/dicyc.htm">/cgi/generic/dicyc.htm</a>
 0.05  0.39       456876       10 | <a href="/cgi/generic/dig.htm">/cgi/generic/dig.htm</a>
 0.10  0.18       214790       21 | <a href="/cgi/generic/dihydram.htm">/cgi/generic/dihydram.htm</a>
 0.03  0.16       191898        6 | <a href="/cgi/generic/diltiaz.htm">/cgi/generic/diltiaz.htm</a>
 0.07  0.37       443952       14 | <a href="/cgi/generic/dival.htm">/cgi/generic/dival.htm</a>
 0.05  0.17       203843       10 | <a href="/cgi/generic/doxazo.htm">/cgi/generic/doxazo.htm</a>
 0.04  0.13       157230        9 | <a href="/cgi/generic/doxepin.htm">/cgi/generic/doxepin.htm</a>
 0.04  0.23       271792        9 | <a href="/cgi/generic/doxycyc.htm">/cgi/generic/doxycyc.htm</a>
 0.01  0.05        62907        3 | <a href="/cgi/generic/ees.htm">/cgi/generic/ees.htm</a>
 0.06  0.53       625620       12 | <a href="/cgi/generic/enalap.htm">/cgi/generic/enalap.htm</a>
 0.01  0.04        42638        2 | <a href="/cgi/generic/eryst.htm">/cgi/generic/eryst.htm</a>
 0.08  0.26       310573       17 | <a href="/cgi/generic/erythro.htm">/cgi/generic/erythro.htm</a>
 0.04  0.29       346656        8 | <a href="/cgi/generic/estrad.htm">/cgi/generic/estrad.htm</a>
 0.02  0.18       207968        5 | <a href="/cgi/generic/estratd.htm">/cgi/generic/estratd.htm</a>
 0.01  0.08       100758        2 | <a href="/cgi/generic/ethynoc.htm">/cgi/generic/ethynoc.htm</a>
 0.05  0.29       345354       10 | <a href="/cgi/generic/etodolac.htm">/cgi/generic/etodolac.htm</a>
 0.02  0.12       143860        5 | <a href="/cgi/generic/famot.htm">/cgi/generic/famot.htm</a>
 0.17  0.52       620339       35 | <a href="/cgi/generic/fenflur.htm">/cgi/generic/fenflur.htm</a>
 0.01  0.04        41872        2 | <a href="/cgi/generic/fexofen.htm">/cgi/generic/fexofen.htm</a>
 0.03  0.20       233944        6 | <a href="/cgi/generic/finas.htm">/cgi/generic/finas.htm</a>
 0.01  0.06        65618        2 | <a href="/cgi/generic/flucon.htm">/cgi/generic/flucon.htm</a>
 0.02  0.07        79316        4 | <a href="/cgi/generic/fludro.htm">/cgi/generic/fludro.htm</a>
 0.23  1.71      2032191       47 | <a href="/cgi/generic/fluoxetine.htm">/cgi/generic/fluoxetine.htm</a>
 0.02  0.09       108400        4 | <a href="/cgi/generic/flutic.htm">/cgi/generic/flutic.htm</a>
 0.01  0.10       124179        3 | <a href="/cgi/generic/fluva.htm">/cgi/generic/fluva.htm</a>
 0.14  1.32      1566970       28 | <a href="/cgi/generic/fluvox.htm">/cgi/generic/fluvox.htm</a>
 0.01  0.08        89152        2 | <a href="/cgi/generic/fosinop.htm">/cgi/generic/fosinop.htm</a>
 0.06  0.25       294408       12 | <a href="/cgi/generic/furos.htm">/cgi/generic/furos.htm</a>
 0.03  0.27       325346        7 | <a href="/cgi/generic/gabapent.htm">/cgi/generic/gabapent.htm</a>
 0.02  0.15       181292        4 | <a href="/cgi/generic/gemfib.htm">/cgi/generic/gemfib.htm</a>
 0.02  0.07        83511        4 | <a href="/cgi/generic/glip.htm">/cgi/generic/glip.htm</a>
 0.04  0.18       211000        8 | <a href="/cgi/generic/glybur.htm">/cgi/generic/glybur.htm</a>
 0.02  0.10       118012        4 | <a href="/cgi/generic/glymic.htm">/cgi/generic/glymic.htm</a>
 0.05  0.05        59773       11 | <a href="/cgi/generic/guaicod.htm">/cgi/generic/guaicod.htm</a>
 0.14  0.18       207774       28 | <a href="/cgi/generic/guaiphen.htm">/cgi/generic/guaiphen.htm</a>
 0.02  0.11       126852        4 | <a href="/cgi/generic/haloper.htm">/cgi/generic/haloper.htm</a>
 0.02  0.05        62568        4 | <a href="/cgi/generic/hctz.htm">/cgi/generic/hctz.htm</a>
 0.03  0.15       181170        6 | <a href="/cgi/generic/hctztri.htm">/cgi/generic/hctztri.htm</a>
 0.01  0.06        70212        3 | <a href="/cgi/generic/hquine.htm">/cgi/generic/hquine.htm</a>
 0.00  0.00          333        1 | <a href="/cgi/generic/hum7030.htm">/cgi/generic/hum7030.htm</a>
 0.00  0.02        20661        1 | <a href="/cgi/generic/humnph.htm">/cgi/generic/humnph.htm</a>
 0.18  0.37       439142       36 | <a href="/cgi/generic/hydrocod.htm">/cgi/generic/hydrocod.htm</a>
 0.06  0.10       114540       12 | <a href="/cgi/generic/hydrox.htm">/cgi/generic/hydrox.htm</a>
 0.04  0.13       151758        9 | <a href="/cgi/generic/hyoscy.htm">/cgi/generic/hyoscy.htm</a>
 0.10  0.59       700550       21 | <a href="/cgi/generic/ibup.htm">/cgi/generic/ibup.htm</a>
 0.03  0.15       174400        7 | <a href="/cgi/generic/imip.htm">/cgi/generic/imip.htm</a>
 0.01  0.05        55861        2 | <a href="/cgi/generic/indap.htm">/cgi/generic/indap.htm</a>
 0.03  0.21       254341        6 | <a href="/cgi/generic/indometh.htm">/cgi/generic/indometh.htm</a>
 0.01  0.02        28066        2 | <a href="/cgi/generic/ipratrop.htm">/cgi/generic/ipratrop.htm</a>
 0.01  0.05        55730        2 | <a href="/cgi/generic/isomono.htm">/cgi/generic/isomono.htm</a>
 0.07  0.41       481373       15 | <a href="/cgi/generic/isotret.htm">/cgi/generic/isotret.htm</a>
 0.02  0.06        74136        4 | <a href="/cgi/generic/kclsr.htm">/cgi/generic/kclsr.htm</a>
 0.05  0.08        94534       11 | <a href="/cgi/generic/ketocon.htm">/cgi/generic/ketocon.htm</a>
 0.02  0.17       200480        4 | <a href="/cgi/generic/ketoprof.htm">/cgi/generic/ketoprof.htm</a>
 0.03  0.24       283178        6 | <a href="/cgi/generic/ketor.htm">/cgi/generic/ketor.htm</a>
 0.05  0.33       385467       10 | <a href="/cgi/generic/lansop.htm">/cgi/generic/lansop.htm</a>
 0.11  0.43       509108       23 | <a href="/cgi/generic/levothy.htm">/cgi/generic/levothy.htm</a>
 0.09  0.72       850254       18 | <a href="/cgi/generic/lisinop.htm">/cgi/generic/lisinop.htm</a>
 0.03  0.19       228771        7 | <a href="/cgi/generic/lngeed.htm">/cgi/generic/lngeed.htm</a>
 0.01  0.04        42403        3 | <a href="/cgi/generic/loracarb.htm">/cgi/generic/loracarb.htm</a>
 0.07  0.23       274133       15 | <a href="/cgi/generic/lorat.htm">/cgi/generic/lorat.htm</a>
 0.04  0.22       263984        8 | <a href="/cgi/generic/loratd.htm">/cgi/generic/loratd.htm</a>
 0.03  0.07        84168        6 | <a href="/cgi/generic/loraz.htm">/cgi/generic/loraz.htm</a>
 0.02  0.09       106189        5 | <a href="/cgi/generic/losar.htm">/cgi/generic/losar.htm</a>
 0.01  0.14       168843        3 | <a href="/cgi/generic/losarhct.htm">/cgi/generic/losarhct.htm</a>
 0.05  0.51       609480       10 | <a href="/cgi/generic/lovastat.htm">/cgi/generic/lovastat.htm</a>
 0.05  0.05        57343       11 | <a href="/cgi/generic/mecliz.htm">/cgi/generic/mecliz.htm</a>
 0.06  0.19       224726       12 | <a href="/cgi/generic/medrox.htm">/cgi/generic/medrox.htm</a>
 0.05  0.17       199276       11 | <a href="/cgi/generic/meper.htm">/cgi/generic/meper.htm</a>
 0.02  0.08        96355        5 | <a href="/cgi/generic/mesal.htm">/cgi/generic/mesal.htm</a>
 0.01  0.01        17712        3 | <a href="/cgi/generic/metax.htm">/cgi/generic/metax.htm</a>
 0.08  0.83       983565       16 | <a href="/cgi/generic/metformi.htm">/cgi/generic/metformi.htm</a>
 0.00  0.02        24395        1 | <a href="/cgi/generic/methdone.htm">/cgi/generic/methdone.htm</a>
 0.02  0.02        28085        5 | <a href="/cgi/generic/methocar.htm">/cgi/generic/methocar.htm</a>
 0.07  0.18       213866       15 | <a href="/cgi/generic/methphen.htm">/cgi/generic/methphen.htm</a>
 0.02  0.11       134492        4 | <a href="/cgi/generic/methprd.htm">/cgi/generic/methprd.htm</a>
 0.04  0.18       214086        8 | <a href="/cgi/generic/metopro.htm">/cgi/generic/metopro.htm</a>
 0.04  0.22       258003        9 | <a href="/cgi/generic/metopxl.htm">/cgi/generic/metopxl.htm</a>
 0.08  0.39       462772       16 | <a href="/cgi/generic/metronid.htm">/cgi/generic/metronid.htm</a>
 0.05  0.04        51060       10 | <a href="/cgi/generic/midrin.htm">/cgi/generic/midrin.htm</a>
 0.01  0.11       130614        3 | <a href="/cgi/generic/mirtaz.htm">/cgi/generic/mirtaz.htm</a>
 0.01  0.06        71684        2 | <a href="/cgi/generic/misopro.htm">/cgi/generic/misopro.htm</a>
 0.01  0.04        42969        3 | <a href="/cgi/generic/momet.htm">/cgi/generic/momet.htm</a>
 0.05  0.12       144096       10 | <a href="/cgi/generic/ms.htm">/cgi/generic/ms.htm</a>
 0.12  1.26      1494053       24 | <a href="/cgi/generic/mtx.htm">/cgi/generic/mtx.htm</a>
 0.01  0.01        13839        3 | <a href="/cgi/generic/mupi.htm">/cgi/generic/mupi.htm</a>
 0.06  0.31       368469       13 | <a href="/cgi/generic/nabume.htm">/cgi/generic/nabume.htm</a>
 0.06  0.32       373821       13 | <a href="/cgi/generic/naprox.htm">/cgi/generic/naprox.htm</a>
 0.09  0.84       994640       18 | <a href="/cgi/generic/nefaz.htm">/cgi/generic/nefaz.htm</a>
 0.01  0.03        32235        3 | <a href="/cgi/generic/neopolhc.htm">/cgi/generic/neopolhc.htm</a>
 0.05  0.30       357230       10 | <a href="/cgi/generic/nifedxl.htm">/cgi/generic/nifedxl.htm</a>
 0.04  0.14       160500        8 | <a href="/cgi/generic/nitro25m.htm">/cgi/generic/nitro25m.htm</a>
 0.01  0.07        88671        3 | <a href="/cgi/generic/nizat.htm">/cgi/generic/nizat.htm</a>
 0.08  0.62       732394       16 | <a href="/cgi/generic/norestoc.htm">/cgi/generic/norestoc.htm</a>
 0.01  0.07        82754        2 | <a href="/cgi/generic/norgeth.htm">/cgi/generic/norgeth.htm</a>
 0.05  0.14       160512       11 | <a href="/cgi/generic/nortrip.htm">/cgi/generic/nortrip.htm</a>
 0.02  0.02        25071        4 | <a href="/cgi/generic/ntg.htm">/cgi/generic/ntg.htm</a>
 0.02  0.17       200186        5 | <a href="/cgi/generic/oflox.htm">/cgi/generic/oflox.htm</a>
 0.00  0.02        19786        1 | <a href="/cgi/generic/olsal.htm">/cgi/generic/olsal.htm</a>
 0.08  0.49       584096       16 | <a href="/cgi/generic/omepra.htm">/cgi/generic/omepra.htm</a>
 0.01  0.02        22545        3 | <a href="/cgi/generic/orphen.htm">/cgi/generic/orphen.htm</a>
 0.01  0.06        65970        2 | <a href="/cgi/generic/oxaproz.htm">/cgi/generic/oxaproz.htm</a>
 0.05  0.09       101810       10 | <a href="/cgi/generic/oxyapap.htm">/cgi/generic/oxyapap.htm</a>
 0.04  0.06        69171        8 | <a href="/cgi/generic/oxyasa.htm">/cgi/generic/oxyasa.htm</a>
 0.17  1.50      1774208       34 | <a href="/cgi/generic/parox.htm">/cgi/generic/parox.htm</a>
 0.03  0.06        75116        7 | <a href="/cgi/generic/pemoline.htm">/cgi/generic/pemoline.htm</a>
 0.01  0.03        35679        3 | <a href="/cgi/generic/penvk.htm">/cgi/generic/penvk.htm</a>
 0.21  0.38       448554       42 | <a href="/cgi/generic/phenterm.htm">/cgi/generic/phenterm.htm</a>
 0.09  0.31       372634       18 | <a href="/cgi/generic/phenyt.htm">/cgi/generic/phenyt.htm</a>
 0.03  0.23       277124        6 | <a href="/cgi/generic/pravast.htm">/cgi/generic/pravast.htm</a>
 0.08  0.33       392624       16 | <a href="/cgi/generic/pred.htm">/cgi/generic/pred.htm</a>
 0.04  0.28       331740        9 | <a href="/cgi/generic/prochlr.htm">/cgi/generic/prochlr.htm</a>
 0.02  0.09       106196        4 | <a href="/cgi/generic/promcod.htm">/cgi/generic/promcod.htm</a>
 0.02  0.07        85220        5 | <a href="/cgi/generic/prometh.htm">/cgi/generic/prometh.htm</a>
 0.07  0.29       338478       14 | <a href="/cgi/generic/propox.htm">/cgi/generic/propox.htm</a>
 0.02  0.09       108940        5 | <a href="/cgi/generic/propox2.htm">/cgi/generic/propox2.htm</a>
 0.08  0.41       489895       17 | <a href="/cgi/generic/propran.htm">/cgi/generic/propran.htm</a>
 0.01  0.00         3374        2 | <a href="/cgi/generic/q">/cgi/generic/q</a>
 0.02  0.15       181135        4 | <a href="/cgi/generic/quinap.htm">/cgi/generic/quinap.htm</a>
 0.08  0.38       453558       16 | <a href="/cgi/generic/ranit.htm">/cgi/generic/ranit.htm</a>
 6.04  0.71       836859     1220 | <a href="/cgi/generic/redball.gif">/cgi/generic/redball.gif</a>
 0.03  0.37       438809        7 | <a href="/cgi/generic/risperid.htm">/cgi/generic/risperid.htm</a>
 6.25  2.44      2890684     1263 | <a href="/cgi/generic/rx.gif">/cgi/generic/rx.gif</a>
 0.03  0.02        26369        7 | <a href="/cgi/generic/rx.jpg">/cgi/generic/rx.jpg</a>
 0.02  0.18       215225        5 | <a href="/cgi/generic/salmet.htm">/cgi/generic/salmet.htm</a>
 0.00  0.03        31235        1 | <a href="/cgi/generic/seleg.htm">/cgi/generic/seleg.htm</a>
 0.19  1.41      1675644       38 | <a href="/cgi/generic/sertral.htm">/cgi/generic/sertral.htm</a>
 0.03  0.27       315843        7 | <a href="/cgi/generic/simva.htm">/cgi/generic/simva.htm</a>
 0.03  0.17       198247        7 | <a href="/cgi/generic/sinemet.htm">/cgi/generic/sinemet.htm</a>
 0.02  0.05        63596        4 | <a href="/cgi/generic/sucral.htm">/cgi/generic/sucral.htm</a>
 0.07  0.12       137835       15 | <a href="/cgi/generic/sudafed.htm">/cgi/generic/sudafed.htm</a>
 0.05  0.20       237500       10 | <a href="/cgi/generic/sulfasal.htm">/cgi/generic/sulfasal.htm</a>
 0.02  0.14       166748        4 | <a href="/cgi/generic/sumitr.htm">/cgi/generic/sumitr.htm</a>
 0.02  0.16       194916        5 | <a href="/cgi/generic/tamox.htm">/cgi/generic/tamox.htm</a>
 0.02  0.05        57960        4 | <a href="/cgi/generic/temaz.htm">/cgi/generic/temaz.htm</a>
 0.03  0.22       258661        6 | <a href="/cgi/generic/teraz.htm">/cgi/generic/teraz.htm</a>
 0.00  0.02        18846        1 | <a href="/cgi/generic/terbin.htm">/cgi/generic/terbin.htm</a>
 0.00  0.01        10349        1 | <a href="/cgi/generic/tercon.htm">/cgi/generic/tercon.htm</a>
 0.04  0.23       268496        8 | <a href="/cgi/generic/terfen.htm">/cgi/generic/terfen.htm</a>
 0.03  0.19       227418        6 | <a href="/cgi/generic/tersud.htm">/cgi/generic/tersud.htm</a>
 0.03  0.08        98686        7 | <a href="/cgi/generic/test.htm">/cgi/generic/test.htm</a>
 0.04  0.23       275688        9 | <a href="/cgi/generic/testos.htm">/cgi/generic/testos.htm</a>
 0.05  0.13       158610       10 | <a href="/cgi/generic/tetcycl.htm">/cgi/generic/tetcycl.htm</a>
 0.01  0.06        67108        2 | <a href="/cgi/generic/theosr.htm">/cgi/generic/theosr.htm</a>
 0.02  0.13       153629        5 | <a href="/cgi/generic/ticlop.htm">/cgi/generic/ticlop.htm</a>
 0.01  0.08        95283        3 | <a href="/cgi/generic/timolol.htm">/cgi/generic/timolol.htm</a>
 0.00  0.01         8392        1 | <a href="/cgi/generic/top200.htm">/cgi/generic/top200.htm</a>
 0.07  0.36       423301       14 | <a href="/cgi/generic/tramadol.htm">/cgi/generic/tramadol.htm</a>
 0.04  0.16       188237        9 | <a href="/cgi/generic/traz.htm">/cgi/generic/traz.htm</a>
 0.01  0.03        32142        3 | <a href="/cgi/generic/tretinoin.htm">/cgi/generic/tretinoin.htm</a>
 0.02  0.10       116120        5 | <a href="/cgi/generic/triamaer.htm">/cgi/generic/triamaer.htm</a>
 0.02  0.07        84404        4 | <a href="/cgi/generic/triamnas.htm">/cgi/generic/triamnas.htm</a>
 0.09  0.47       561868       19 | <a href="/cgi/generic/trisulf.htm">/cgi/generic/trisulf.htm</a>
 0.07  0.77       915476       15 | <a href="/cgi/generic/venlafax.htm">/cgi/generic/venlafax.htm</a>
 0.03  0.24       285075        7 | <a href="/cgi/generic/verapsr.htm">/cgi/generic/verapsr.htm</a>
 0.07  0.35       420040       14 | <a href="/cgi/generic/warfarin.htm">/cgi/generic/warfarin.htm</a>
 0.09  0.09       106702       18 | <a href="/cgi/generic/yohimb.htm">/cgi/generic/yohimb.htm</a>
 0.07  0.59       693729       14 | <a href="/cgi/generic/zolpid.htm">/cgi/generic/zolpid.htm</a>
 0.01  0.01         8038        2 | <a href="/cgi/opiate.htm">/cgi/opiate.htm</a>
 0.02  0.00         3008        4 | <a href="/cgi/redball.gif">/cgi/redball.gif</a>
 5.21  1.87      2218521     1052 | <a href="/cgi/rx.gif">/cgi/rx.gif</a>
15.26 11.37     13484425     3082 | <a href="/cgi/rxlist.cgi">/cgi/rxlist.cgi</a>
 0.29  0.16       185961       59 | <a href="/disclaim.htm">/disclaim.htm</a>
 0.81  0.05        55442      163 | <a href="/formmail.cgi">/formmail.cgi</a>
 0.00  0.00          490        1 | <a href="/generic/">/generic/</a>
 0.01  0.03        41379        3 | <a href="/generic/amox.htm">/generic/amox.htm</a>
 0.05  0.03        35033       11 | <a href="/hb.htm">/hb.htm</a>
 5.33  0.85      1009145     1077 | <a href="/hi_rec.gif">/hi_rec.gif</a>
 0.02  0.01        13524        4 | <a href="/index.shtml">/index.shtml</a>
 0.69  0.28       336785      139 | <a href="/interact.htm">/interact.htm</a>
 5.32  1.22      1446877     1075 | <a href="/mbox.gif">/mbox.gif</a>
 5.48  2.56      3037786     1106 | <a href="/med60.gif">/med60.gif</a>
 0.18  0.06        68999       37 | <a href="/mono.htm">/mono.htm</a>
 0.01  1.18      1399238        2 | <a href="/monthstat.htm">/monthstat.htm</a>
 5.36  1.42      1680260     1083 | <a href="/nm.gif">/nm.gif</a>
 0.14  0.13       156015       28 | <a href="/nsaid.htm">/nsaid.htm</a>
 0.17  0.11       133160       35 | <a href="/opiate.htm">/opiate.htm</a>
 2.74  0.31       369766      553 | <a href="/redball.gif">/redball.gif</a>
 0.00  0.24       288967        1 | <a href="/restricted/temp.gz">/restricted/temp.gz</a>
 6.53  2.45      2900072     1319 | <a href="/rx.gif">/rx.gif</a>
 0.01  0.07        80460        3 | <a href="/rxlink2.htm">/rxlink2.htm</a>
 0.50  2.16      2564046      100 | <a href="/rxlinks.htm">/rxlinks.htm</a>
 0.08  0.03        32453       17 | <a href="/scoutsel.gif">/scoutsel.gif</a>
 0.00  0.14       161787        1 | <a href="/stats-1996/Dec.monthstat.htm.gz">/stats-1996/Dec.monthstat.htm.gz</a>
 0.11  0.06        66642       23 | <a href="/stats.htm">/stats.htm</a>
 0.00  0.10       115154        1 | <a href="/temphtm.htm">/temphtm.htm</a>
 0.10  1.24      1468094       21 | <a href="/tempstat.htm">/tempstat.htm</a>
 0.00  0.01         7624        1 | <a href="/ticker.class">/ticker.class</a>
 0.00  0.01        10528        1 | <a href="/ticker.txt">/ticker.txt</a>
 2.03  8.48     10051127      411 | <a href="/top200.htm">/top200.htm</a>
 0.17  0.68       807792       34 | <a href="/top200a.htm">/top200a.htm</a>
 0.04  0.01         6900        9 | Code 302 Moved Temporarily
 0.00  0.00          584        1 | Code 401 Unauthorized
 0.17  0.02        18947       35 | Code 404 Not Found
</PRE>
<HR>
<ADDRESS>This summary was generated by 
<A HREF="http://www.ics.uci.edu/pub/websoft/wwwstat/">wwwstat-2.0</A>
</ADDRESS>
<hr>
<ADDRESS>Return to 
<a href="http://www.rxlist.com/stats.htm">RxList Stats</a>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B10-32</DOCNO>
<DOCOLDNO>IA018-000200-B033-121</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/levothy.htm 206.86.175.201 19970106223629 text/html 29630
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:30:10 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 29447
Last-modified: Thu, 11 Jul 1996 06:08:03 GMT
</DOCHDR>
<html>
<head>
   <title>Levothyroxine - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Levothyroxine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <P></P>
Levothyroxine TABLETS and INJECTION contain synthetic
crystalline L-3,3',5,5'-tetraiodothyronine sodium salt (levothyroxine (T4)
sodium). Synthetic T4 is similar to that produced in the human thyroid gland.
T4 contains four iodine atoms and is formed by the coupling of two molecules of 
diiodotyrosine (DIT).  <P></P>
 
Levothyroxine (T4) Sodium has an empirical formula of C15H10I4NNaO4xH2O,
molecular weight of 798.86 (anhydrous), and structural formula as shown:  
 <P></P>
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 
</b> <P></P>
The steps in the synthesis of thyroid hormones are controlled by thyrotropin
(Thyroid Stimulating Hormone, TSH) secreted by the anterior pituitary. This
hormone's secretion is in turn controlled by a feedback mechanism effected by
the thyroid hormones themselves and by thyrotropin releasing hormone (TRH), a
tripeptide of hypothalamic origin. Endogenous thyroid hormone secretion is
suppressed when exogenous thyroid hormones are administered to euthyroid
individuals in excess of the normal gland's secretion.  
 <P></P>
The mechanisms by which thyroid hormones exert their physiologic action are not 
well understood. These hormones enhance oxygen consumption by most tissues of
the body and increase the basal metabolic rate and the metabolism of
carbohydrates, lipids, and proteins. Thus they exert a profound influence on
every organ system in the body and are of particular importance in the
development of the central nervous system.  <P></P>
 
The normal thyroid gland contains approximately 200 mcg of levothyroxine (T4)
per gram of gland, and 15 mcg of triiodothyronine (T3) per gram. The ratio of
these two hormones in the circulation does not represent the ratio in the
thyroid gland, since about 80 percent of peripheral triiodothyronine comes from 
monodeiodination of levothyroxine at the 5 position (outer ring). Peripheral
monodeiodination of levothyroxine at the 5 position (inner ring) results in the 
formation of reverse triiodothyronine (rT3), which is calorigenically inactive. 
These facts would seem to advocate levothyroxine as the treatment of choice
for the hypothyroid patient and to militate against the administration of
hormone combinations which, while normalizing thyroxine levels may produce
triiodothyronine levels in the thyrotoxic range.  <P></P>
 
Triiodothyronine (T3) level is low in the fetus and newborn, in old age, in
chronic caloric deprivation, hepatic cirrhosis, renal failure, surgical stress, 
and chronic illnesses representing what has been called the &quot;low
triiodothyronine syndrome.&quot; <P></P>
 
PHARMACOKINETICS 
 <P></P>
Animal studies have shown that T4 is only partially absorbed from the
gastrointestinal tract. The degree of absorption is dependent on the vehicle
used for its administration and by the character of the intestinal contents,
the intestinal flora, including plasma protein, soluble dietary factors, all of 
which bind thyroid and thereby make it unavailable for diffusion.  <P></P>
 
Depending on other factors, absorption has varied from 48 to 79 percent of the
administered dose. Fasting increases absorption. Malabsorption syndromes, as
well as dietary factors, (children's soybean formula, concomitant use of
anionic exchange resins such as cholestyramine) cause excessive fecal loss.  
 <P></P>
More than 99 percent of circulating hormones are bound to serum proteins,
including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA) 
and albumin (TBa), whose capacities and affinities vary for the hormones. The
higher affinity of levothyroxine (T4) for both TBG and TBPA as compared to
triiodothyronine (T3) partially explains the higher serum levels and longer
half-life of the former hormone. Both protein-bound hormones exist in
equilibrium with minute amounts of free hormone, the latter accounting for the
metabolic activity.  
<P></P>
Deiodination of levothyroxine (T4) occurs at a number of sites, including liver 
kidney, and other tissues. The conjugated hormone, in the form of glucuronide
or sulfate, is found in the bile and gut where it may complete an enterohepatic 
circulation. Eighty-five percent of levothyroxine (T4) metabolized daily is
deiodinated.  <P></P>
 
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <P></P>
Levothyroxine is indicated:  
 <P></P>
1. As replacement or supplemental therapy in patients with hypothyroidism of
any etiology, except transient hypothyroidism during the recovery phase of
subacute thyroiditis. This category includes cretinism, myxedema, and ordinary
hypothyroidism in patients of any age (children, adults, the elderly), or state 
(including pregnancy); primary hypothyroidism resulting from functional
deficiency, primary atrophy, partial or total absence of thyroid gland, or the
effects of surgery, radiation, or drugs, with or without the presence of
goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism
(See CONTRAINDICATIONS and PRECAUTIONS). Levothyroxine INJECTION can be used
intravenously whenever a rapid onset of effect is critical and either
intravenously or intramuscularly in hypothyroid patients whenever the oral
route is precluded for long periods of time.  <P></P>
 
2. As a pituitary TSH suppressant, in the treatment or prevention of various
types of euthyroid goiters, including thyroid nodules, subacute or chronic
lymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the
management of thyroid cancer.  <P></P>
 
3. As a diagnostic agent in suppression tests to aid in the diagnosis of
suspected mild hyperthyroidism or thyroid gland autonomy.  
 <P></P>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <P></P>
Thyroid hormone preparations are generally contraindicated in patients with
diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated
thyrotoxicosis, and apparent hypersensitivity to any of their active or
extraneous constituents. There is no well documented evidence from the
literature, however, of true allergic or idiosyncratic reactions to thyroid
hormone.  <P></P>
 
<a name="WARNINGS"></a><b>WARNINGS 
</b> <P></P>
Drugs with thyroid hormone activity, alone or together with other therapeutic
agents, have been used for the treatment of obesity. In euthyroid patients,
doses within the range of daily hormonal requirements are ineffective for
weight reduction. Larger doses may produce serious or even life threatening
manifestations of toxicity, particularly when given in association with
sympathomimetic amines such as those used for their anorectic effects.  
 <P></P>
The use of thyroid hormones in the therapy of obesity, alone or combined with
other drugs, is unjustified and has been shown to be ineffective. Neither is
their use justified for the treatment of male or female infertility unless this 
condition is accompanied by hypothyroidism.  
 <P></P>
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <P></P>
GENERAL:  Thyroid hormones should be used with great caution in a number of
circumstances where the integrity of the cardiovascular system, particularly
the coronary arteries, is suspected. These include patients with angina
pectoris or the elderly, who have a greater likelihood of occult cardiac
disease. In these patients, therapy should be initiated with low doses, i.e.,
25-50 mcg levothyroxine (T4). When, in such patients, a euthyroid state can
only be reached at the expense of an aggravation of the cardiovascular disease, 
thyroid hormone dosage should be reduced.  <P></P>
 
Thyroid hormone therapy in patients with concomitant diabetes mellitus or
insipidus or adrenal cortical insufficiency aggravates the intensity of their
symptoms. Appropriate adjustments of the various therapeutic measures directed
at these concomitant endocrine diseases are required. The therapy of myxedema
coma may require simultaneous administration of glucocorticoids (See DOSAGE AND 
ADMINISTRATION).  
 <P></P>
Hypothyroidism decreases and hyperthyroidism increases the sensitivity to oral
anticoagulants. Prothrombin time should be closely monitored in thyroid treated 
patients on oral anticoagulants and dosage of the latter agents adjusted on the 
basis of frequent prothrombin time determinations. In infants, excessive doses
of thyroid hormone preparations may produce craniosynostosis.  <P></P>
 
INFORMATION FOR THE PATIENT:  Patients on thyroid hormone preparations and
parents of children on thyroid therapy should be informed that: <P></P> 
 
1. Replacement therapy is to be taken essentially for life, with the exception
of cases of transient hypothyroidism, usually associated with thyroiditis, and
in those patients receiving a therapeutic trial of the drug. <P></P> 
 
2. They should immediately report during the course of therapy any signs or
symptoms of thyroid hormone toxicity, e.g., chest pain, increased pulse rate,
palpitations, excessive sweating, heat intolerance, nervousness, or any other
unusual event.  
 <P></P>
3. In case of concomitant diabetes mellitus, the daily dosage of antidiabetic
medication may need readjustment as thyroid hormone replacement is achieved. If 
thyroid medication is stopped, a downward readjustment of the dosage of insulin 
or oral hypoglycemic agent may be necessary to avoid hypoglycemia. At all times 
close monitoring of blood or urinary glucose levels is mandatory in such
patients.  
 <P></P>
4. In case of concomitant oral anticoagulant therapy, the prothrombin time
should be measured frequently to determine if the dosage of oral anticoagulants 
is to be readjusted. <P></P>
 
5. Partial loss of hair may be experienced by children in the first few months
of thyroid therapy, but this is usually a transient phenomenon and later
recovery is usually the rule.  <P></P>
 
LABORATORY TESTS:  Treatment of patients with thyroid hormones requires the
periodic assessment of thyroid status by means of appropriate laboratory tests, 
by full clinical evaluation, or both. The TSH suppression test can be used to
test the effectiveness of any thyroid preparation bearing in mind the relative
insensitivity of the infant pituitary to the negative feedback effect of
thyroid hormones. Serum T4 levels can be used to test the effectiveness of
levothyroxine sodium. When the total serum T4 is low but TSH is normal, a test
specific to assess unbound (free) T4 levels is warranted. Specific measurements 
of T4 and T3 by competitive protein binding or radioimmunoassay are not
influenced by blood levels of organic or inorganic iodine and have essentially
replaced older tests of thyroid hormone measurements, i.e., PBI, BEI, and T4 by 
column.  <P></P>
 
DRUG INTERACTIONS:  Oral Anticoagulants--Thyroid hormones appear to increase
catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are
also being given, compensatory increases in clotting factor synthesis are
impaired. Patients stabilized on oral anticoagulants who are found to require
thyroid replacement therapy should be watched very closely when thyroid is
started. If a patient is truly hypothyroid, it is likely that a reduction in
anticoagulant dosage will be required. No special precautions appear to be
necessary when oral anticoagulant therapy is begun in a patient already
stabilized on maintenance thyroid replacement therapy.  <P></P>
 
Insulin Or Oral Hypoglycemics--Initiating thyroid replacement therapy may cause 
increases in insulin or oral hypoglycemic requirements. The effects seen are
poorly understood and depend upon a variety of factors such as dose and type of 
thyroid preparations and endocrine status of the patient. Patients receiving
insulin or oral hypoglycemics should be closely watched during initiation of
thyroid replacement therapy.  <P></P>
 
Cholestyramine--Cholestyramine binds both T4 and T3 in the intestine, thus
impairing absorption of these thyroid hormones. In Vitro studies indicate that
the binding is not easily reversed. Therefore, four to five hours should elapse 
between administration of cholestyramine and thyroid hormones. <P></P> 
 
Estrogen, Oral Contraceptives--Estrogens tend to increase serum thyroxine-
binding globulin (TBG). In a patient with a nonfunctioning thyroid gland who is 
receiving thyroid replacement therapy, free levothyroxine may be decreased when 
estrogens are started thus increasing thyroid requirements. However, if the
patient's thyroid gland has sufficient function, the decreased free thyroxine
will result in a compensatory increase in thyroxine output by the thyroid. 
Therefore, patients without a functioning thyroid gland who are on thyroid
replacement therapy may need to increase their thyroid dose if estrogens or
estrogen-containing oral contraceptives are given.  <P></P>
 
DRUG/LABORATORY TEST INTERACTIONS:  The following drugs or moieties are known
to interfere with some laboratory tests performed in patients on thyroid
hormone therapy: Androgens, corticosteroids, estrogens, oral contraceptives
containing estrogens, iodine-containing preparations, and the numerous
preparations containing salicylates.  <P></P>
 
1. Changes in TBG concentration should be taken into consideration in the
interpretation of T4 and T3 values. Pregnancy, estrogens, and estrogen-
containing oral contraceptives increase TBG concentrations. TBG may also be
increased during infectious hepatitis. Decreases in TBG concentrations are
observed in nephrosis, acromegaly, and after androgen or corticosteroid
therapy.  Familial hyper- or hypo-thyroxine-binding-globulinemias have been
described. The incidence of TBG deficiency approximates 1 in 9000. The binding
of thyroxine by TBPA is inhibited by salicylates. In such cases, the unbound
(free) hormone should be measured. Alternatively, an indirect measure of free
thyroxine, such as the Free Thyroxine Index (FTI) may be used.  <P></P>
 
2. Medicinal or dietary iodine interferes with all In Vivo tests of radioiodine 
uptake, producing low uptakes which may not indicate a true decrease in hormone 
synthesis.  
 <P></P>
3. The persistence of clinical and laboratory evidence of hypothyroidism in
spite of adequate dosage replacement indicates either poor patient compliance,
poor absorption, or inactivity of the preparation. Intracellular resistance to
thyroid hormone is quite rare, and is suggested by clinical signs and symptoms
of hypothyroidism in the presence of high serum T4 levels.  <P></P>
 
CARCINOGENESIS, MUTAGENESIS, AND IMPAIRMENT OF FERTILITY:  A reported
association between prolonged thyroid therapy and breast cancer has not been
confirmed and patients on thyroid therapy for established indications should
not discontinue therapy. No confirmatory long-term studies in animals have been 
performed to evaluate carcinogenic potential, mutagenicity, or impairment of
fertility in either males or females.  <P></P>
 
PREGNANCY:  Pregnancy category A. Thyroid hormones do not readily cross the
placental barrier. The clinical experience to date does not indicate any
adverse effect on fetuses when thyroid hormones are administered to pregnant
women. On the basis of current knowledge, thyroid replacement therapy to
hypothyroid women should not be discontinued during pregnancy. <P></P> 
 
NURSING MOTHERS:  Minimal amounts of thyroid hormones are excreted in human
milk. Thyroid is not associated with serious adverse reactions and does not
have known tumorigenic potential. While caution should be exercised when
thyroid is administered to a nursing woman, adequate replacement doses of
levothyroxine are generally needed to maintain normal lactation.  
 <P></P>
PEDIATRIC USE:  Pregnant mothers provide little or no thyroid hormone to the
fetus. The incidence of congenital hypothyroidism is relatively high (1 in 4
000) and the hypothyroid fetus would not derive any benefit from the small
amounts of hormone crossing the placental barrier. Routine determinations of
serum T4 and/or TSH is strongly advised in neonates in view of the deleterious
effects of thyroid deficiency on growth and development.  
<P></P>
Treatment should be initiated immediately upon diagnosis, and maintained for
life, unless transient hypothyroidism is suspected; in which case, therapy may
be interrupted for 2 to 8 weeks after the age of 3 years to reassess the
condition. Cessation of therapy is justified in patients who have maintained a
normal TSH during those 2 to 8 weeks.  <P></P>
 
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <P></P>
Oral Anticoagulants--Thyroid hormones appear to increase catabolism of vitamin
K-dependent clotting factors. If oral anticoagulants are also being given,
compensatory increases in clotting factor synthesis are impaired. Patients
stabilized on oral anticoagulants who are found to require thyroid replacement
therapy should be watched very closely when thyroid is started. If a patient is 
truly hypothyroid, it is likely that a reduction in anticoagulant dosage will
be required. No special precautions appear to be necessary when oral
anticoagulant therapy is begun in a patient already stabilized on maintenance
thyroid replacement therapy.  <P></P>
 
Insulin Or Oral Hypoglycemics--Initiating thyroid replacement therapy may cause 
increases in insulin or oral hypoglycemic requirements. The effects seen are
poorly understood and depend upon a variety of factors such as dose and type of 
thyroid preparations and endocrine status of the patient. Patients receiving
insulin or oral hypoglycemics should be closely watched during initiation of
thyroid replacement therapy.  
 <P></P>
Cholestyramine--Cholestyramine binds both T4 and T3 in the intestine, thus
impairing absorption of these thyroid hormones. In Vitro studies indicate that
the binding is not easily reversed. Therefore, four to five hours should elapse 
between administration of cholestyramine and thyroid hormones.  
 <P></P>
Estrogen, Oral Contraceptives--Estrogens tend to increase serum thyroxine-
binding globulin (TBG). In a patient with a nonfunctioning thyroid gland who is 
receiving thyroid replacement therapy, free levothyroxine may be decreased when 
estrogens are started thus increasing thyroid requirements. However, if the
patient's thyroid gland has sufficient function, the decreased free thyroxine
will result in a compensatory increase in thyroxine output by the thyroid. 
Therefore, patients without a functioning thyroid gland who are on thyroid
replacement therapy may need to increase their thyroid dose if estrogens or
estrogen-containing oral contraceptives are given.  <P></P>
 
(See Also PRECAUTIONS) 
<P></P>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <P></P>
Adverse reactions other than those indicative of hyperthyroidism because of
therapeutic overdosage, either initially or during the maintenance periods, are 
rare (see OVERDOSAGE).  <P></P>
 
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <P></P>
SIGNS AND SYMPTOMS:  Excessive doses of thyroid result in hypermetabolic state
resembling in every respect the condition of endogenous origin. The condition
may be self-induced.  <P></P>
 
TREATMENT OF OVERDOSAGE:  Dosage should be reduced or therapy temporarily
discontinued if signs and symptoms of overdosage appear. Treatment may be
reinstated at a lower dosage. In normal individuals, normal hypothalamic-
pituitary-thyroid axis function is restored in 6 to 8 weeks after thyroid
suppression.  <P></P>
 
Treatment of acute massive thyroid hormone overdosage is aimed at reducing
gastrointestinal absorption of the drugs and counteracting central and
peripheral effects, mainly those of increased sympathetic activity. Vomiting
may be induced initially if further gastrointestinal absorption can reasonably
be prevented and barring contraindications such as coma, convulsions, or loss
of the gagging reflex. Treatment is symptomatic and supportive. Oxygen may be
administered and ventilation maintained. Cardiac glycosides may be indicated if 
congestive heart failure develops. Measures to control fever, hypoglycemia, or
fluid loss should be instituted if needed. Antiadrenergic agents, particularly
propranolol, have been used advantageously in the treatment of increased
sympathetic activity. Propranolol may be administered intravenously at a dosage 
of 1 to 3 mg over a 10 minute period or orally, 80 to 160 mg/day, especially
when no contraindications exist for its use. Other adjunctive measures may
include administration of cholestyramine to interfere with thyroxine absorption 
and glucocorticoids to inhibit conversion of T4 to T3.  <P></P>
 
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <P></P>
The dosage and rate of administration of Levothyroxine (Levothyroxine Sodium,
USP) is determined by the indication and must in every case be individualized
according to patient response and laboratory findings.  
 <P></P>
HYPOTHYROIDISM:  Levothyroxine TABLETS are usually instituted using low doses, with 
increments which depend on the cardiovascular status of the patient. The usual
starting dose is 50 mcg, with increments of 25 mcg every 2 to 3 weeks. A lower
starting dosage, 25 mcg/day or less, is recommended in patients with long
standing hypothyroidism, particularly if cardiovascular impairment is suspected 
in which case extreme caution is recommended. The appearance of angina is an
indication for a reduction in dosage. Most patients require not more than 200
mcg/day. Failure to respond to doses of 300 mcg suggests lack of compliance or
malabsorption. Adequate therapy usually results in normal TSH and T4 levels
after 2 to 3 weeks of the maintenance dose.  <P></P>
 
Readjustment of Levothyroxine TABLET dosage should be made within the first four
weeks of therapy, after proper clinical and laboratory evaluations.  
 <P></P>
Levothyroxine INJECTION by intravenous or intramuscular routes can be substituted
for the oral dosage form when ingestion of Levothyroxine TABLETS is precluded for
long periods of time. The initial parenteral dosage should be approximately one 
half of the previously established oral dosage of levothyroxine sodium tablets. 
Close observation of the patient, with individual adjustment of the dosage as
needed, is recommended.  <P></P>

MYXEDEMA COMA:  Myxedema coma is usually precipitated in the hypothyroid
patient by intercurrent illness or drugs such as sedatives and anesthetics and
should be considered a medical emergency. Therapy should be directed at the
correction of electrolyte disturbances and possible infection besides the
administration of thyroid hormones. Corticosteroids should be administered
routinely. T4 may be administered via a nasogastric tube but the preferred
route of administration is intravenous. Sodium levothyroxine (T4) is given at a 
starting dose of 400 mcg (100 mcg/mL) given rapidly, and is usually well
tolerated, even in the elderly.  In the presence of concomitant heart disease,
the sudden administration of such large doses of L-thyroxine intravenously is
clearly not without its cardiovascular risks. Under such circumstances,
intravenous therapy should not be undertaken without weighing the alternative
risks of the myxedema coma and the cardiovascular disease. Clinical judgement
in this situation may dictate smaller intravenous doses of Levothyroxine INJECTION. 
The initial dose is followed by daily supplements of 100 to 200 mcg given
intravenously. Normal T4 levels are achieved in 24 hours followed in 3 days by
threefold evaluation of T3. Continued daily administration of lesser amounts
parenterally should be maintained until the patient is fully capable of
accepting a daily oral dose. A daily maintenance dose of 50 to 100 mcg
parenterally should suffice to maintain the euthyroid state, once established.
Oral therapy would be resumed as soon as the clinical situation has been
stabilized and the patient is able to take oral medication.  <P></P>
 
TSH SUPPRESSION IN THYROID CANCER, NODULES, AND EUTHYROID GOITERS:  Exogenous
thyroid hormone may produce regression of metastases from follicular and
papillary carcinoma of the thyroid and is used as ancillary therapy of these
conditions following surgery or radioactive iodine. Medullary carcinoma of the
thyroid is usually unresponsive to this therapy. TSH should be suppressed to
low or undetectable levels. Therefore, larger amounts of thyroid hormone than
those used for replacement therapy are frequently required. This therapy is
also used in treating nontoxic solitary nodules and multinodular goiters, and
to prevent thyroid enlargement in chronic (Hashimoto's) thyroiditis.  
 <P></P>
THYROID SUPPRESSION THERAPY:  Administration of thyroid hormone in doses higher 
than those produced physiologically by the gland results in suppression of the
production of endogenous hormone. This is the basis for the thyroid suppression 
test and is used as an aid in the diagnosis of patients with signs of mild
hyperthyroidism in whom base line laboratory tests appear normal, or to
demonstrate thyroid gland autonomy in patients with Graves' ophthalmopathy.
131I uptake is determined before and after the administration of the exogenous
hormone. A fifty percent or greater suppression of uptake indicates a normal
thyroid-pituitary axis and thus rules out thyroid gland autonomy.  
 <P></P>
For adults, the average suppressive dose of levothyroxine (T4) is 2.6 mcg/kg of 
body weight per day given for 7 to 10 days. These doses usually yield normal
serum T4 and T3 levels and lack of response to TSH.  <P></P>
 
Levothyroxine sodium should be administered cautiously to patients in whom
there is a strong suspicion of thyroid gland autonomy, in view of the fact that 
the exogenous hormone effects will be additive to the endogenous source.  
<P></P>
PEDIATRIC DOSAGE:  Pediatric dosage should follow the recommendations
summarized in Table I. In infants with congenital hypothyroidism, therapy with
full doses should be instituted as soon as the diagnosis has been made.
Levothyroxine TABLETS may be given to infants and children who cannot swallow
intact tablets by crushing the proper dose tablet and suspending the FRESHLY
CRUSHED tablet in a small amount of water or formula. The suspension can be
given by spoon or dropper. DO NOT STORE THE SUSPENSION FOR ANY PERIOD OF TIME.
The crushed tablet may also be sprinkled over a small amount of food, such as
cooked cereal or apple sauce.  <P></P>
 <PRE>
                               Table I                                          
                      RECOMMENDED PEDIATRIC DOSAGE                              
                      FOR CONGENITAL HYPOTHYROIDISM*                            
------------------------------------------------------------------------------- 
                  Levothyroxine (Levothyroxine Sodium Tablets, USP)                 
                -------------------------------------------------               
Age              Dose per day               Daily dose per kg                   
                                            of body weight                      
                -------------------------------------------------               
0- 6 mos          25- 50 mcg                    8-10 mcg                        
6-12 mos          50- 75 mcg                    6- 8 mcg                        
1- 5 yrs          75-100 mcg                    5- 6 mcg                        
6-12 yrs         100-150 mcg                    4- 5 mcg                        
------------------------------------------------                                
* To be adjusted on the basis of clinical response and laboratory tests         
 (see LABORATORY TESTS).                                                        
</PRE><P></P>
CAUTION:  Federal (USA) law prohibits dispensing without a prescription.  </pre>
<P></P>
<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-33</DOCNO>
<DOCOLDNO>IA018-000200-B041-222</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/aceinh.htm 206.86.175.201 19970106231058 text/html 2889
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:04:43 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2707
Last-modified: Sun, 30 Jun 1996 07:23:24 GMT
</DOCHDR>
<html>
<head>
   <title>RxList of Indications and Side Effects - Angiotensin Converting Enzyme (ACE) Inhibitors
</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a>
<hr></p></center>

<h1 align=center>Angiotensin Converting Enzyme (ACE) Inhibitors </h1>

<h3>ACE Inhibitors (examples: capoten, enalapril, lisinopril) reduce the
enzymatic conversion of angiotensin I to angiotensin II. Angiotensin II
is a potent vasoconstrictor that causes blood pressure to increase. Many
of the generic names for ACE inhibitors end in &quot;pril&quot;. </h3>

<p>
<hr></p>

<h3><a href="disclaim.htm">INDICATIONS</a></h3>

<li>diabetic nephropathy+ </li>

<li>heart failure </li>

<li>hypertension </li>

<li>hypertensive emergency+ </li>

<li>hypertensive urgency+ </li>

<li>myocardial infarction+ </li>

<li>proteinuria </li>

<li>scleroderma renal crisis + </li>

<dl>
<dd>+ = not an FDA approved indication</dd>
</dl>

<p>
<hr><a href="#top">Return to Top</a> 
<hr></p>

<h3><a href="disclaim.htm#side">Side Effects and Adverse Reactions</a></h3>

<li>agranulocytosis </li>

<li>angina </li>

<li>angioedema </li>

<li>aplastic anemia </li>

<li>azotemia </li>

<li>back pain </li>

<li>conjunctivitis </li>

<li>cough </li>

<li>diarrhea </li>

<li>dizziness </li>

<li>dysgeusia </li>

<li>dyspepsia </li>

<li>fatigue </li>

<li>flushing </li>

<li>glomerulonephritis </li>

<li>headache </li>

<li>hyperkalemia </li>

<li>hypotension </li>

<li>infection </li>

<li>insomnia </li>

<li>interstitial nephritis </li>

<li>maculopapular rash </li>

<li>muscle cramping </li>

<li>myalgia </li>

<li>nasal congestion </li>

<li>nephrotic syndrome </li>

<li>neutropenia </li>

<li>orthostatic hypotension </li>

<li>palpitations </li>

<li>pancytopenia </li>

<li>paresthesias </li>

<li>renal tubular necrosis </li>

<li>sinusitis </li>

<li>sinus tachycardia </li>

<li>syncope 
<hr width="100%" ><a href="#top">Return to Top</a> 
<hr><font SIZE=+2><a href="http://www.rxlist.com/disclaim.htm">Important
- Please Read!</a> </font></li>

<h4 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">Search
RxList</a> <img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com/mono.htm">RxLists
of Indications and Side Effects</a> <img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">Rxlist
Home Page</a> </h4>

<center><p><font SIZE=-2>copyright 1996 Neil Sandow, Pharm.D. - all rights
reserved </font></p></center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-34</DOCNO>
<DOCOLDNO>IA018-000200-B033-241</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/clarith.htm 206.86.175.201 19970106223929 text/html 29952
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:33:09 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 29769
Last-modified: Thu, 11 Jul 1996 06:06:57 GMT
</DOCHDR>
<html>
<head>
   <title>Clarithromycin - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Clarithromycin</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [toxicity] [<a href="#DOSAGE AND ADMINISTRATION">dosing</a>]
</font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION</b> 
 <P></P>
Clarithromycin  is a semi-synthetic macrolide antibiotic. Chemically,
it is 6-0-Methylerythromycin. The molecular formula is C38H69NO13, and the
molecular weight is 747.96.  <P></P>
 
  
 
Clarithromycin is a white to off-white crystalline powder. It is soluble in
acetone, slightly soluble in methanol, ethanol and acetonitrile, and
practically insoluble in water.  
 <P></P>
 
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY</b> 
 <P></P>
Clarithromycin is rapidly absorbed from the gastrointestinal tract after oral
administration. The absolute bioavailability of 250 mg clarithromycin tablets
was approximately 50%. Food slightly delays both the onset of clarithromycin
absorption and the formation of the antimicrobially active metabolite, 14-OH
clarithromycin, but does not affect the extent of bioavailability. Therefore,
Clarithromycin tablets may be given without regard to meals.  
 <P></P>
In fasting healthy human subjects, peak serum concentrations were attained
within 2 hours after oral dosing. Steady-state peak serum clarithromycin
concentrations were attained in 2 to 3 days and were approximately 1 mcg/mL
with a 250 mg dose administered every 12 hours and 2 to 3 mcg/mL with a 500 mg
dose administered every 12 hours. The elimination half-life of clarithromycin
was about 3 to 4 hours with 250 mg administered every 12 hours but increased to 
5 to 7 hours with 500 mg administered every 12 hours. The nonlinearity of
clarithromycin pharmacokinetics is slight at the recommended doses of 250 mg
and 500 mg administered every 12 hours. With a 250 mg every 12 hours dosing,
the principal metabolite, 14-OH clarithromycin, attains a peak steady-state
concentration of about 0.6 mcg/mL and has an elimination half-life of 5 to 6
hours. With a 500 mg every 12 hours dosing, the peak steady-state
concentrations of 14-OH clarithromycin are slightly higher (up to 1 mcg/ mL),
and its elimination half-life is about 7 hours. With either dose, the steady
state concentration of this metabolite is generally attained within 2 to 3
days.  <P></P>
 
After a 250 mg every 12 hours oral dose, approximately 20% of the dose is
excreted in the urine as the unchanged parent drug, clarithromycin. After a 500 
mg every 12 hours dosing, the urinary excretion of clarithromycin is somewhat
greater, approximately 30%. The renal clearance of clarithromycin is, however,
<P></P>
relatively independent of the dose size and approximates the normal glomerular
filtration rate. The major metabolite found in the urine is 14-OH
clarithromycin which accounts for an additional 10% to 15% of the dose with
either 250 mg or 500 mg administered every 12 hours.  <P></P>
 
The steady-state concentrations of clarithromycin in subjects with impaired
hepatic function did not differ from those in normal subjects; however, the 14- 
OH clarithromycin concentrations were lower in the hepatically impaired
subjects. The decreased formation of 14-OH clarithromycin was at least
partially offset by an increase in renal clearance of clarithromycin in the
subjects with impaired hepatic function when compared to healthy subjects.  
 <P></P>
The pharmacokinetics of clarithromycin were also altered in subjects with
impaired renal function. (See PRECAUTIONS and DOSAGE AND ADMINISTRATION.) 
 <P></P>
Clarithromycin and the 14-OH clarithromycin metabolite distribute readily into
body tissues and fluids. There are no data available on cerebrospinal fluid
penetration. Because of high intracellular concentrations, tissue
concentrations are higher than serum concentrations. Examples from tissue and
serum concentrations are presented below.  <P></P>
 
              <PRE>                 CONCENTRATION                                    
                            (after 250 mg q 12h)                                
TISSUE TYPE                      TISSUE                    SERUM                
                                 (mcg/g)                   (mcg/mL)             
-------------------------------------------------------------------------       
Tonsil                           1.6                       0.8                  
Lung                             8.8                       1.7                  
-------------------------------------------------------------------------       </PRE><P></P>
MICROBIOLOGY:  
 
Clarithromycin exerts its antibacterial action by binding to the 50S ribosomal
subunit of susceptible organisms and inhibiting protein synthesis.  
 <P></P>
Clarithromycin is active In Vitro against a variety of aerobic and anaerobic
gram-positive and gram-negative organisms.  
 <P></P>
Additionally, the 14-OH clarithromycin metabolite also has clinically
significant antimicrobial activity. Against Haemophilus Influenzae, 14-OH
clarithromycin is twice as active as the parent compound.  <P></P>
 
Clarithromycin has been shown to be active against most strains of the
following organisms both In Vitro and in clinical infections: (See INDICATIONS
AND USAGE.) <P></P>
 
GRAM-POSITIVE AEROBES 
 <P></P>
Staphylococcus Aureus 
 <P></P>
Streptococcus Pneumoniae 
 <P></P>
Streptococcus Pyogenes 
 <P></P>
GRAM-NEGATIVE AEROBES 
 <P></P>
Haemophilus Influenzae 
Moraxella (Branhamella) Catarrhalis 
 <P></P>
OTHER AEROBES 
 <P></P>
Mycoplasma Pneumoniae 
 <P></P>
Beta-lactamase production should have no effect on clarithromycin activity.  
 <P></P>
NOTE: Most strains of methicillin-resistant and oxacillin-resistant
staphylococci are resistant to clarithromycin.  
 <P></P>
Clarithromycin has been shown to be active In Vitro against most strains of the 
following organisms. The following In Vitro data are available; however, their
clinical significance is unknown.  <P></P>
 
GRAM-POSITIVE AEROBES 
 <P></P>
Listeria Monocytogenes 
 <P></P>
Streptococcus Agalactiae 
 <P></P>
Streptococci (Groups C, F, G) 
 <P></P>
Viridans Group Streptococci 
 <P></P>
GRAM-NEGATIVE AEROBES 
 <P></P>
Bordetella Pertussis 
 <P></P>
Campylobacter Jejuni 
 <P></P>
Legionella Pneumophila 
 <P></P>
Neisseria Gonorrhoeae 
 <P></P>
Pasteurella Multocida 
 <P></P>
OTHER AEROBES 
 <P></P>
Chlamydia Trachomatis 
 <P></P>
Mycobacterium Kansasii 
 <P></P>
GRAM-POSITIVE ANAEROBES 
 <P></P>
Clostridium Perfringens 
 <P></P>
Peptococcus Niger 
 <P></P>
Propionibacterium Acnes 
 <P></P>
GRAM-NEGATIVE ANAEROBES 
 <P></P>
Bacteroides Melaninogenicus 
 <P></P>
SUSCEPTIBILITY TESTS:  
DIFFUSION TECHNIQUES:  
 <P></P>
Quantitative methods that require measurement of zone diameters give the most
precise estimate of the susceptibility of bacteria to antimicrobial agents. One 
such standard procedure (REF. 1) which has been recommended for use with disks
to test susceptibility of organisms to clarithromycin, uses the 15-mcg disk. 
Interpretation involves the correlation of the diameter obtained in the disk
test with minumum inhibitory concentration (MIC) for clarithromycin.  
 <P></P>
Reports from the laboratory giving results of the standard single-disk
susceptibility test with a 15-mcg clarithromycin disk should be interpreted
according to the following criteria:  <P></P>
 <PRE>
ZONE DIAMETER (MM)                                  INTERPRETATION              
-------------------------------------------------------------------------       
&gt;/=  18                                             (S) Susceptible             
     14-17                                          (I) Intermediate            
&lt; or =  13                                          (R) Resistant               
------------------------------------------------------------------------- </PRE> <P></P>     
A report of 'Susceptible' indicates that the pathogen is likely to respond to
monotherapy with clarithromycin.  <P></P>
 
A report of 'Intermediate' indicates that the result be considered equivocal
and, if the organism is not fully susceptible to alternative clinically
feasible drugs, the test should be repeated. This category provides a buffer
zone which prevents small uncontrolled technical factors from causing major
discrepancies in interpretations.  <P></P>
 
However, standardized diffusion methods for routine In Vitro susceptibility
testing, using the 15-mcg clarithromycin disk, do not measure the additive
antimicrobial activity of the 14-OH metabolite and thus may underestimate the
drug's potential activity against Haemophilus Influenzae. Haemophilus
Influenzae isolates falling into the 'Intermediate' category often respond to
treatment.  <P></P>
 
A report of 'Resistant' indicates that achievable drug concentrations are
unlikely to be inhibitory, and other therapy should be selected.  
 <P></P>
Standardized procedures require the use of laboratory control organisms. The 15 
mcg clarithromycin disk should give the following zone diameters:  <P></P>
<PRE> 
ORGANISM                                      ZONE DIAMETER (MM)                
-------------------------------------------------------------------------       
S. Aureus       ATCC 25923                               23-30                  
-------------------------------------------------------------------------       
DILUTION TECHNIQUES:  
 
Use a standardized dilution method (REF. 2) (broth, agar, microdilution) or
equivalent with clarithromycin powder. The MIC values obtained should be
interpreted according to the following criteria:  
 
MIC (MCG/ML)                                        INTERPRETATION              
-------------------------------------------------------------------------       
&lt; or =  2.0                                         (S) Susceptible             
     4.0                                            (I) Intermediate            
&gt;/=  8.0                                            (R) Resistant               
-------------------------------------------------------------------------       
</PRE><P></P>

                              
As with standard diffusion techniques, dilution methods require the use of
laboratory control organisms. Standard clarithromycin powder should provide the 
following MIC values:  <P></P>
<PRE> 
ORGANISM                                           MIC (MCG/ML)                 
-------------------------------------------------------------------------       
S. Aureus        ATCC 29213                             0.06-0.25               
E. Faecalis      ATCC 29212                              0.25-1.0               
-------------------------------------------------------------------------       </PRE><P></P>
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <P></P>
Clarithromycin  is indicated for the treatment of mild to moderate
infections caused by susceptible strains of the designated microorganisms in
the conditions listed below:  <P></P>
 
Upper Respiratory Tract Infections 
 <P></P>
Pharyngitis/Tonsillitis due to Streptococcus Pyogenes 
 <P></P>
Acute maxillary sinusitis due to Streptococcus Pneumoniae 
 <P></P>
Lower Respiratory Tract Infections 
 <P></P>
Acute bacterial exacerbation of chronic bronchitis due to Haemophilus
Influenzae, Moraxella Catarrhalis, or Streptococcus Pneumoniae 
 <P></P>
Pneumonia due to Myocoplasma Pneumoniae, or Streptococcus Pneumoniae 
 <P></P>
Uncomplicated Skin and Skin Structure Infections due to Staphylococcus Aureus,
or Streptococcus Pyogenes. Abscesses usually require surgical drainage. 
<P></P>
Disseminated mycobacterial infections due to Mycobacterium avium or Mycobacterium 
intracellulare.<P></P>

Clarithromycin tablets in combination with omeprazole capsules is indicated for the 
treatment of patients with an active duodenal ulcer associated with H. pylori 
infection.  The eradication of H. pylori has been demonstrated to reduce the risk of 
duodenal ulcer recurrence.<P></P>

In patients who fail therapy, suceptibility testing should be done if possible.  
If resistance is demonstrated, alternative therapy is reommended.
 <P></P>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <P></P>
Clarithromycin is contraindicated in patients with known hypersensitivity to
clarithromycin, erythromycin, or any of the macrolide antibiotics.  
 <P></P>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <P></P>
CLARITHROMYCIN SHOULD NOT BE USED IN PREGNANT WOMEN EXCEPT IN CLINICAL
CIRCUMSTANCES WHERE NO ALTERNATIVE THERAPY IS APPROPRIATE. IF PREGNANCY OCCURS
WHILE TAKING THIS DRUG, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD
TO THE FETUS. CLARITHROMYCIN HAS DEMONSTRATED ADVERSE EFFECTS ON PREGNANCY
OUTCOME AND/OR EMBRYO-FETAL DEVELOPMENT IN MONKEYS, RATS, MICE, AND RABBITS AT
DOSES THAT PRODUCED PLASMA LEVELS 2 TO 17 TIMES THE SERUM LEVELS ACHIEVED IN
HUMANS TREATED AT THE MAXIMUM RECOMMENDED HUMAN DOSES. (SEE PREGNANCY.) 
 <P></P>
PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH NEARLY ALL ANTIBACTERIAL AGENTS 
INCLUDING MACROLIDES, AND MAY RANGE IN SEVERITY FROM MILD TO LIFE THREATENING.
THEREFORE, IT IS IMPORTANT TO CONSIDER THIS DIAGNOSIS IN PATIENTS WHO PRESENT
WITH DIARRHEA SUBSEQUENT TO THE ADMINISTRATION OF ANTIBACTERIAL AGENTS.  
 <P></P>
Treatment with antibacterial agents alters the normal flora of the colon and
may permit overgrowth of clostridia. Studies indicate that a toxin produced by
Clostridium Difficile is a primary cause of 'antibiotic-associated colitis.' 
 <P></P>
After the diagnosis of pseudomembranous colitis has been established,
therapeutic measures should be initiated. Mild cases of pseudomembranous
<P></P>
colitis usually respond to discontinuation of the drug alone. In moderate to
severe cases, consideration should be given to management with fluids and
electrolytes, protein supplementation, and treatment with an antibacterial drug 
effective against Clostridium Difficile.  <P></P>
 
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <P></P>
General: Clarithromycin is principally excreted via the liver and kidney. 
Clarithromycin may be administered without dosage adjustment to patients with
hepatic impairment and normal renal function. However, in the presence of
severe renal impairment with or without coexisting hepatic impairment,
decreased dosage or prolonged dosing intervals may be appropriate.  
 <P></P>
Drug Interactions: Clarithromycin use in patients who are receiving
theophylline may be associated with an increase of serum theophylline
concentrations. Monitoring of serum theophylline concentrations should be
considered for patients receiving high doses of theophylline or with baseline
concentrations in the upper therapeutic range. In two studies in which
theophylline was administered with clarithromycin (a theophylline sustained-
release formulation was dosed at either 6.5 mg/kg or 12 mg/kg together with 250 
mg or 500 mg q 12 h clarithromycin), the steady-state levels of Cmax. Cmin. 
and the area under the serum concentration time curve (AUC) increased about
20%.  <P></P>
 
Single-dose administration of clarithromycin has been shown to result in
increased concentrations of carbamazepine. Blood level monitoring of
carbamazepine may be considered.  <P></P>
 
The following drug interactions have not been reported in clinical trials with
clarithromycin; however, they have been observed with erythromycin products:  
 <P></P>
Concomitant administration of erythromycin and digoxin has been reported to
result in elevated digoxin levels.  <P></P>
 
There have been reports of increased anticoagulant effects when erythromycin
and oral anticoagulants were used concomitantly.  <P></P>
 
Concurrent use of erythromycin and ergotamine or dihydroergotamine has been
associated in some patients with acute ergot toxicity characterized by severe
peripheral vasospasm and dysesthesia.  <P></P>
 
Erythromycin has been reported to decrease the clearance of triazolam and thus
may increase the pharmacologic effect of triazolam.<P></P>  
 
The use of erythromycin in patients concurrently taking drugs metabolized by
the cytochrome P450 system may be associated with elevations in serum levels of 
these other drugs. There have been reports of interactions of erythromycin with 
carbamazepine, cyclosporine, hexobarbital, and phenytoin. Serum concentrations
of drugs metabolized by the cytochrome P450 system should be monitored closely
in patients concurrently receiving erythromycin.  <P></P>
 
Carcinogenesis, Mutagenesis, Impairment Of Fertility: The following In Vitro
mutagenicity tests have been conducted with clarithromycin:  <P></P>
 
Salmonella/Mammalian Microsome Test 
 <P></P>
Bacterial Induced Mutation Frequency Test 
<P></P>

In Vitro Chromosome Aberration Test 
 <P></P>
Rat Hepatocyte DNA Synthesis Assay 
 <P></P>
Mouse Lymphoma Assay 
 <P></P>
Mouse Dominant Lethal Study 
 <P></P>
Mouse Micronucleus Test 
 <P></P>
All tests had negative results except the In Vitro Chromosome Aberration Test
which was weakly positive in one test and negative in another.  <P></P>
 
In addition, a Bacterial Reserve-Mutation Test (Ames Test) has been performed
on clarithromycin metabolites with negative results.  <P></P>
 
Fertility and reproduction studies have shown that daily doses of 150-160
mg/kg/day to male and female rats caused no adverse effects on the estrous
cycle, fertility, parturition, or number and viability of offspring. Plasma
levels in rats after 150 mg/kg/day were 2 times the human serum levels.  
 <P></P>
In the 150 mg/kg/day monkey studies, plasma levels were 3 times the human serum 
levels. When given orally after the 150 mg/kg/day, clarithromycin was shown to
produce embryonic loss in monkeys. This effect has been attributed to marked
maternal toxicity of the drug at this high dose.  <P></P>
 
In rabbits, In Utero fetal loss occurred at an intravenous dose of 33 mg/sq m,
which is 17 times less than the maximum proposed human oral daily dose of 618
mg/sq m.  <P></P>
 
Long-term studies in animals have not been performed to evaluate carcinogenic
potential.  
 <P></P>
Pregnancy:  Teratogenic Effects: Pregnancy Category C. Four teratogenicity
studies in rats (three with oral doses and one with intravenous doses up to 160 
mg/kg/day administered during the period of major organogenesis) and two in
rabbits (at oral doses up to 125 mg/kg/day or intravenous doses of 30 mg/kg/day 
administered during gestation days 6 to 18) failed to demonstrate any
teratogenicity from clarithromycin. Two additional oral studies in a different
rat strain at similar doses and similar conditions demonstrated a low incidence 
of cardiovascular anomalies at doses of 150 mg/kg/day administered during
gestation days 6 to 15. Plasma levels after 150 mg/kg/day were 2 times the
human serum levels. Four studies in mice revealed a variable incidence of cleft 
palate following oral doses of 1000 mg/kg/day during gestation days 6 to 15. 
Cleft palate was also seen at 500 mg/kg/day. The 1000 mg/kg/day exposure
resulted in plasma levels 17 times the human serum levels. In monkeys, an oral
dose of 70 mg/kg/day produced fetal growth retardation at plasma levels that
were 2 times the human serum levels.  <P></P>
 
There are no adequate and well-controlled studies in pregnant women. 
Clarithromycin should be used during pregnancy only if the potential benefit
justifies the potential risk to the fetus. (SEE WARNINGS.) <P></P>
 
Nursing Mothers: It is not known whether clarithromycin is excreted in human
milk. Because many drugs are excreted in human milk, caution should be
exercised when clarithromycin is administered to a nursing woman. It is known
<P></P>
that clarithromycin is excreted in the milk of lactating animals and that other 
drugs of this class are excreted in human milk.  
 <P></P>
Pediatric Use: Safety and effectiveness of clarithromycin in children under 12
years of age have not been established.  
 <P></P>
Geriatric Use: In a steady-state study in which healthy elderly subjects (age
65 to 81 years old) were given 500 mg every 12 hours, the maximum
concentrations of clarithromycin and 14-OH clarithromycin were increased. The
AUC was also increased. These changes in pharmacokinetics parallel known age
related decreases in renal function. In clinical trials, elderly patients did
not have an increased incidence of adverse events when compared to younger
patients.  Dosage adjustment should be considered in the elderly patients with
severe renal impairment.  <P></P>
 
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <P></P>
Clarithromycin use in patients who are receiving theophylline may be associated 
with an increase of serum theophylline concentrations. Monitoring of serum
theophylline concentrations should be considered for patients receiving high
doses of theophylline or with baseline concentrations in the upper therapeutic
range. In two studies in which theophylline was administered with
clarithromycin (a theophylline sustained-release formulation was dosed at
either 6.5 mg/kg or 12 mg/kg together with 250 mg or 500 mg q 12 h
clarithromycin), the steady-state levels of Cmax. Cmin. and the area under the
serum concentration time curve (AUC) increased about 20%.  <P></P>
 
Single-dose administration of clarithromycin has been shown to result in
increased concentrations of carbamazepine. Blood level monitoring of
carbamazepine may be considered.  <P></P>
 
The following drug interactions have not been reported in clinical trials with
clarithromycin; however, they have been observed with erythromycin products:  
 <P></P>
Concomitant administration of erythromycin and digoxin has been reported to
result in elevated digoxin levels.  <P></P>
 
There have been reports of increased anticoagulant effects when erythromycin
and oral anticoagulants were used concomitantly.  <P></P>
 
Concurrent use of erythromycin and ergotamine or dihydroergotamine has been
associated in some patients with acute ergot toxicity characterized by severe
peripheral vasospasm and dysesthesia.  <P></P>
 
Erythromycin has been reported to decrease the clearance of triazolam and thus
may increase the pharmacologic effect of triazolam. <P></P> 
 
The use of erythromycin in patients concurrently taking drugs metabolized by
the cytochrome P450 system may be associated with elevations in serum levels of 
these other drugs. There have been reports of interactions of erythromycin with 
carbamazepine, cyclosporine, hexobarbital, and phenytoin. Serum concentrations
of drugs metabolized by the cytochrome P450 system should be monitored closely
in patients concurrently receiving erythromycin.  <P></P>
 
(See Also PRECAUTIONS) 
 <P></P>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
<P></P>

</b>The majority of side effects observed in clinical trials were of a mild and
transient nature. Fewer than 3% of patients discontinued therapy because of
drug-related side effects.  <P></P>
 
The most frequently reported events, whether drug-related or not, were diarrhea 
(3%), nausea (3%), abnormal taste (3%), dyspepsia (2%), abdominal
pain/discomfort (2%), and headache (2%). Most of these events were described as 
mild or moderate in severity. Of the reported adverse events, only 1% were
described as severe.  <P></P>
 
In studies of pneumonia comparing clarithromycin to erythromycin base or
erythromycin stearate, there were fewer adverse events involving the digestive
system in clarithromycin-treated patients compared to erythyromycin-treated
patients (13% vs 32%; p&lt;0.01). Twenty percent of erythromycin-treated patients
discontinued therapy due to adverse events compared to 4% of clarithromycin-
treated patients.  <P></P>
 
The following adverse events have been reported with erythromycin products but
not in clinical trials of clarithromycin:  <P></P>
 
Rarely, erythromycin has been associated with ventricular arrhythmias,
including ventricular tachycardia, and torsades de pointes, in individuals with 
prolonged QT intervals.  <P></P>
 
Changes In Laboratory Values:  Changes in laboratory values with possible
clinical significance were as follows:  <P></P>
 
Hepatic--Elevated SGPT (ALT) &lt;1%, SGOT (AST) &lt;1%, GGT &lt;1%, alkaline phosphatase 
&lt;1%, LDH &lt;1%, and total bilirubin &lt;1%.  <P></P>
 
Hematologic--Decreased WBC &lt;1%, and elevated prothrombin time 1%.  
 <P></P>
Renal--Elevated BUN 4%, and elevated serum creatinine &lt;1%.  
 <P></P>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <P></P>
Clarithromycin  tablets may be given with or without meals.  
 <P></P>
                       <PRE>      DOSAGE GUIDELINES                                  
------------------------------------------------------------------------        
INFECTION                             DOSAGE               NORMAL DURATION      
                                      (Q 12 H)                  (DAYS)          
------------------------------------------------------------------------        
Upper respiratory tract               250-500 mg                10-14           
   Pharyngitis/Tonsillitis            250 mg                      10            
   Acute maxillary sinusitis          500 mg                      14            
Lower respiratory tract               250-500 mg                 7-14           
   Acute exacerbation of                                                        
   chronic bronchitis due to:                                                   
     S. Pneumoniae                    250 mg                     7-14           
     M. Catarrhalis                   250 mg                     7-14           
     H. Influenzae                    500 mg                     7-14           
   Pneumonia due to:                                                            
     S. Pneumoniae                    250 mg                     7-14           
     M. Pneumoniae                    250 mg                     7-14           
Uncomplicated skin and                                                          

skin structure                        250 mg                     7-14           
------------------------------------------------------------------------   </PRE>  <P></P>   
Beta-lactamase production should have no effect on clarithromycin activity.  
 <P></P>
Clarithromycin may be administered without dosage adjustment in the presence of 
hepatic impairment if there is normal renal function. However, in the presence
of severe renal impairment with or without coexisting hepatic impairment,
decreased doses or prolongation of dosing intervals may be appropriate.  
 <P></P>
ANIMAL PHARMACOLOGY 
 <P></P>
Clarithromycin is rapidly and well-absorbed with dose-linear kinetics, low
protein binding, and a high volume of distribution. Plasma half-life ranged
from 1-6 hours and was species dependent. High tissue concentrations were
achieved, but negligible accumulation was observed. Fecal clearance
predominated.  Hepatotoxicity occurred in all species tested (i.e., in rats and 
monkeys at doses 2 times greater than and in dogs at doses comparable to the
maximum human daily dose, based on a mg/sq m basis). Renal tubular degeneration 
(calculated on a mg/sq m basis) occurred in rats at doses 2 times, in monkeys
at doses 8 times, and in dogs at doses 12 times greater than the maximum human
daily dose.  Testicular atrophy (on a mg/sq m basis) occurred in rats at doses
7 times, in dogs at doses 3 times, and in monkeys at doses 8 times greater than 
the maximum human daily dose. Corneal opacity (on a mq/sq m basis) occurred in
dogs at doses 12 times and in monkeys at doses 8 times greater than the maximum 
human daily dose. Lymphoid depletion (on a mg/sq m basis) occurred in dogs at
doses 3 times greater than and in monkeys at doses 2 times greater than the
maximum human daily dose. These adverse events were absent during clinical
trials.  <P></P>
 
REFERENCES 
 <P></P>
1.  National Committee for Clinical Laboratory Standards. Performance Standards 
For Antimicrobial Disk Susceptibility Tests--Fourth Edition. Approved Standard
NCCLS Document M2-A4, Vol. 10, No. 7, NCCLS, Villanova, PA, 1990.  
 <P></P>
2.  National Committee for Clinical Laboratory Standards. Methods For Dilution
Antimicrobial Susceptibility Tests For Bacteria That Grow Aerobically--Second
Edition. Approved Standard NCCLS Document M7-A2, Vol. 10, No. 8, NCCLS,
Villanova, PA, 1990.  <P></P>
 


<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search


RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-35</DOCNO>
<DOCOLDNO>IA018-000200-B036-9</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/atenolol.htm 206.86.175.201 19970106225012 text/html 43568
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:43:56 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 43385
Last-modified: Sun, 11 Aug 1996 03:42:36 GMT
</DOCHDR>
<html>
<head>
   <title>Atenolol - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Atenolol</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

 <a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <p>
Atenolol, a synthetic, beta1-selective (cardioselective)
adrenoreceptor blocking agent, may be chemically described as benzeneacetamide, 
4-(2'-hydroxy-3'-((1-methylethyl)amino)propoxy)-.  (C14H22N2O3)
 <p>
Atenolol (free base) has a molecular weight of 266. It is a relatively polar
hydrophilic compound with a water solubility of 26.5 mg/mL at 37 deg C and a
log partition coefficient (octanol/ water) of 0.23. It is freely soluble in 1N
HCl (300 mg/mL at 25 deg C) and less soluble in chloroform (3 mg/mL at 25 deg
C).  
 <p>
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 
</b> <p>
Atenolol is a beta1-selective (cardioselective) beta-adrenergic receptor
blocking agent without membrane stabilizing or intrinsic sympathomimetic
(partial agonist) activities. This preferential effect is not absolute, however 
and at higher doses, Atenolol inhibits beta2-adrenoreceptors, chiefly located
in the bronchial and vascular musculature.  
 <p>
PHARMACOKINETICS AND METABOLISM:  In man, absorption of an oral dose is rapid
and consistent but incomplete. Approximately 50% of an oral dose is absorbed
from the gastrointestinal tract, the remainder being excreted unchanged in the
feces. Peak blood levels are reached between two (2) and four (4) hours after
ingestion. Unlike propranolol or metoprolol, but like nadolol, Atenolol
undergoes little or no metabolism by the liver, and the absorbed portion is
eliminated primarily by renal excretion. Over 85% of an intravenous dose is
excreted in urine within 24 hours compared with approximately 50% for an oral
dose. Atenolol also differs from propranolol in that only a small amount (6%-
16%) is bound to proteins in the plasma. This kinetic profile results in
relatively consistent plasma drug levels with about a fourfold interpatient
variation.  
 <p>
The elimination half-life of oral Atenolol is approximately 6 to 7 hours, and
there is no alteration of the kinetic profile of the drug by chronic
administration. Following intravenous administration, peak plasma levels are
reached within 5 minutes. Declines from peak levels are rapid (5- to 10-fold)
during the first 7 hours; thereafter, plasma levels decay with a half-life
similar to that of orally administered drug. Following oral doses of 50 mg or
100 mg, both beta-blocking and antihypertensive effects persist for at least 24 
hours. When renal function is impaired, elimination of Atenolol is closely
related to the glomerular filtration rate; significant accumulation occurs when 
the creatinine clearance falls below 35 mL/min/1.73M(square). (See DOSAGE AND
ADMINISTRATION).  
 <p>
PHARMACODYNAMICS:  In standard animal or human pharmacological tests, beta-
adrenoreceptor blocking activity of Atenolol has been demonstrated by: (1)
reduction in resting and exercise heart rate and cardiac output, (2) reduction
of systolic and diastolic blood pressure at rest and on exercise, (3)
inhibition of isoproterenol induced tachycardia, and (4) reduction in reflex
orthostatic tachycardia.  
 <p>
A significant beta-blocking effect of Atenolol, as measured by reduction of
exercise tachycardia, is apparent within one hour following oral administration 
of a single dose. This effect is maximal at about 2 to 4 hours, and persists
for at least 24 hours. Maximum reduction in exercise tachycardia occurs within
5 minutes of an intravenous dose. For both orally and intravenously
administered drug, the duration of action is dose related and also bears a
linear relationship to the logarithm of plasma Atenolol concentration. The
effect on exercise tachycardia of a single 10 mg intravenous dose is largely
dissipated by 12 hours, whereas beta-blocking activity of single oral doses of
50 mg and 100 mg is still evident beyond 24 hours following administration.
However, as has been shown for all beta-blocking agents, the antihypertensive
effect does not appear to be related to plasma level.  
 <p>
In normal subjects, the beta1-selectivity of Atenolol has been shown by its
reduced ability to reverse the beta2-mediated vasodilating effect of
isoproterenol as compared to equivalent beta-blocking doses of propranolol. In
asthmatic patients, a dose of Atenolol producing a greater effect on resting
heart rate than propranolol resulted in much less increase in airway
resistance.  In a placebo controlled comparison of approximately equipotent
oral doses of several beta blockers, Atenolol produced a significantly smaller
decrease of FEV1 than nonselective beta blockers such as propranolol and,
unlike those agents, did not inhibit bronchodilation in response to
isoproterenol.  
 <p>
Consistent with its negative chronotropic effect due to beta blockade of the SA 
node, Atenolol increases sinus cycle length and sinus node recovery time. 
Conduction in the AV node is also prolonged. Atenolol is devoid of membrane
stabilizing activity, and increasing the dose well beyond that producing beta
blockade does not further depress myocardial contractility. Several studies
have demonstrated a moderate (approximately 10%) increase in stroke volume at
rest and during exercise.  
 <p>
In controlled clinical trials, Atenolol, given as a single daily oral dose, was 
an effective antihypertensive agent providing 24-hour reduction of blood
pressure. Atenolol has been studied in combination with thiazide-type diuretics 
and the blood pressure effects of the combination are approximately additive. 
Atenolol is also compatible with methyldopa, hydralazine, and prazosin, each
combination resulting in a larger fall in blood pressure than with the single
agents. The dose range of Atenolol is narrow and increasing the dose beyond 100 
mg once daily is not associated with increased antihypertensive effect. The
mechanisms of the antihypertensive effects of beta-blocking agents have not
been established. Several possible mechanisms have been proposed and include:
(1) competitive antagonism of catecholamines at peripheral (especially cardiac) 
adrenergic neuron sites, leading to decreased cardiac output, (2) a central
effect leading to reduced sympathetic outflow to the periphery, and (3)
suppression of renin activity. The results from long-term studies have not
shown any diminution of the antihypertensive efficacy of Atenolol with
prolonged use.  
 <p>
By blocking the positive chronotropic and inotropic effects of catecholamines
and by decreasing blood pressure, atenolol generally reduces the oxygen
requirements of the heart at any given level of effort, making it useful for
many patients in the long-term management of angina pectoris. On the other hand 
atenolol can increase oxygen requirements by increasing left ventricular fiber
length and end diastolic pressure, particularly in patients with heart failure. 
 <p>
In a multicenter clinical trial (ISIS-1) conducted in 16,027 patients with
suspected myocardial infarction, patients presenting within 12 hours (mean = 5
hours) after the onset of pain were randomized to either conventional therapy
plus Atenolol (n = 8,037), or conventional therapy alone (n = 7,990). Patients
with a heart rate of &lt;50 bpm or systolic blood pressure &lt;100 mm Hg, or with
other contraindications to beta blockade, were excluded. Thirty-eight percent
of each group were treated within 4 hours of onset of pain. The mean time from
onset of pain to entry was 5.0 +/- 2.7 hours in both groups. Patients in the
Atenolol group were to receive Atenolol I.V. Injection 5-10 mg given over 5
minutes plus Atenolol Tablets 50 mg every 12 hours orally on the first study
day (the first oral dose administered about 15 minutes after the IV dose)
followed by either Atenolol Tablets 100 mg once daily or Atenolol Tablets 50 mg 
twice daily on days 2-7. The groups were similar in demographic and medical
history characteristics and in electrocardiographic evidence of myocardial
infarction, bundle branch block, and first degree atrioventricular block at
entry.  
 <p>
During the treatment period (days 0-7), the vascular mortality rates were 3.89% 
in the Atenolol group (313 deaths) and 4.57% in the control group (365 deaths). 
This absolute difference in rates, 0.68%, is statistically significant at the
P &lt;0.05 level. The absolute difference translates into a proportional reduction 
of 15% (3.89-4.57/4.57 = -0.15). The 95% confidence limits are 1%-27%. Most of
the difference was attributed to mortality in days 0-1 (Atenolol-- 121 deaths;
control--171 deaths).  
 <p>
Despite the large size of the ISIS-1 trial, it is not possible to identify
clearly subgroups of patients most likely or least likely to benefit from early 
treatment with atenolol. Good clinical judgment suggests, however, that
patients who are dependent on sympathetic stimulation for maintenance of
adequate cardiac output and blood pressure are not good candidates for beta
blockade. Indeed, the trial protocol reflected that judgment by excluding
patients with blood pressure consistently below 100 mm Hg systolic. The overall 
results of the study are compatible with the possibility that patients with
borderline blood pressure (less than 120 mm Hg systolic), especially if over 60 
years of age, are less likely to benefit.  
 <p>
The mechanism through which atenolol improves survival in patients with
definite or suspected acute myocardial infarction is unknown, as is the case
for other beta blockers in the postinfarction setting. Atenolol, in addition to 
its effects on survival, has shown other clinical benefits including reduced
frequency of ventricular premature beats, reduced chest pain, and reduced
enzyme elevation.  
 <p>
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
HYPERTENSION:  Atenolol is indicated in the management of hypertension. It may
be used alone or concomitantly with other antihypertensive agents, particularly 
with a thiazide-type diuretic.  
 <p>
ANGINA PECTORIS DUE TO CORONARY ATHEROSCLEROSIS: Atenolol is indicated for the
long-term management of patients with angina pectoris.  
 <p>
ACUTE MYOCARDIAL INFARCTION:  Atenolol is indicated in the management of
hemodynamically stable patients with definite or suspected acute myocardial
infarction to reduce cardiovascular mortality. Treatment can be initiated as
soon as the patient's clinical condition allows. (See DOSAGE AND ADMINISTRATION 
CONTRAINDICATIONS, AND WARNINGS.) In general, there is no basis for treating
patients like those who were excluded from the ISIS-1 trial (blood pressure
less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other
reasons to avoid beta blockade. As noted above, some subgroups (eg, elderly
patients with systolic blood pressure below 120 mm Hg) seemed less likely to
benefit.  
 <p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <p>
Atenolol is contraindicated in sinus bradycardia, heart block greater than
first degree, cardiogenic shock, and overt cardiac failure. (See WARNINGS.) 
 <p>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <p>
CARDIAC FAILURE:  Sympathetic stimulation is necessary in supporting
circulatory function in congestive heart failure, and beta blockade carries the 
potential hazard of further depressing myocardial contractility and
precipitating more severe failure. In patients who have congestive heart
failure controlled by digitalis and/or diuretics, Atenolol should be
administered cautiously. Both digitalis and atenolol slow AV conduction.  
 <p>
In patients with acute myocardial infarction, cardiac failure which is not
promptly and effectively controlled by 80 mg of intravenous furosemide or
equivalent therapy is a contraindication to beta-blocker treatment.  
 <p>
IN PATIENTS WITHOUT A HISTORY OF CARDIAC FAILURE:  Continued depression of the
myocardium with beta-blocking agents over a period of time can, in some cases,
lead to cardiac failure. At the first sign or symptom of impending cardiac
failure, patients should be fully digitalized and/or be given a diuretic and
the response observed closely. If cardiac failure continues despite adequate
digitalization and diuresis, Atenolol should be withdrawn. (SEE DOSAGE AND
ADMINISTRATION.) 
 <p>
 
CESSATION OF THERAPY WITH Atenolol:  Patients with coronary artery disease, who 
are being treated with Atenolol, should be advised against abrupt
discontinuation of therapy. Severe exacerbation of angina and the occurrence of 
myocardial infarction and ventricular arrhythmias have been reported in angina
patients following the abrupt discontinuation of therapy with beta blockers.
The last two complications may occur with or without preceding exacerbation of
the angina pectoris. As with other beta blockers, when discontinuation of
Atenolol is planned, the patients should be carefully observed and advised to
limit physical activity to a minimum. If the angina worsens or acute coronary
insufficiency develops, it is recommenced that Atenolol be promptly
reinstituted, at least temporarily. Because coronary artery disease is common
and may be unrecognized, it may be prudent not to discontinue Atenolol therapy
abruptly even in patients treated only for hypertension. (See DOSAGE AND
ADMINISTRATION.) 
 <p>
 
CONCOMITANT USE OF CALCIUM CHANNEL BLOCKERS: When calcium channel blockers are
coadministered with beta-blockers, bradycardia and heart block can occur and
the left ventricular end diastolic pressure can rise. Patients with pre
existing conduction abnormalities or left ventricular dysfunction are
particularly susceptible. (See PRECAUTIONS.) 
 <p>
BRONCHOSPASTIC DISEASES:  PATIENTS WITH BRONCHOSPASTIC DISEASE SHOULD, IN
GENERAL, NOT RECEIVE BETA BLOCKERS. BECAUSE OF ITS RELATIVE BETA1 SELECTIVITY,
HOWEVER, Atenolol MAY BE USED WITH CAUTION IN PATIENTS WITH BRONCHOSPASTIC
DISEASE WHO DO NOT RESPOND TO, OR CANNOT TOLERATE, OTHER ANTIHYPERTENSIVE
TREATMENT. SINCE BETA1 SELECTIVITY IS NOT ABSOLUTE, THE LOWEST POSSIBLE DOSE OF 
Atenolol SHOULD BE USED WITH THERAPY INITIATED AT 50 MG AND A BETA2-STIMULATING 
AGENT (BRONCHODILATOR) SHOULD BE MADE AVAILABLE. IF DOSAGE MUST BE INCREASED,
DIVIDING THE DOSE SHOULD BE CONSIDERED IN ORDER TO ACHIEVE LOWER PEAK BLOOD
LEVELS.  
 <p>
ANESTHESIA AND MAJOR SURGERY:  It is not advisable to withdraw beta-
adrenoreceptor blocking drugs prior to surgery in the majority of patients. 
However, care should be taken when using anesthetic agents such as those which
may depress the myocardium. Vagal dominance, if it occurs, may be corrected
with atropine (1-2 mg IV).  
 <p>
Additionally, caution should be used when Atenolol I.V. Injection is
administered concomitantly with such agents.  
 <p>
Atenolol, like other beta blockers, is a competitive inhibitor of beta-receptor 
agonists and its effects on the heart can be reversed by administration of such 
agents: eg, dobutamine or isoproterenol with caution (see section on
OVERDOSAGE).  
 <p>
DIABETES AND HYPOGLYCEMIA:  Atenolol should be used with caution in diabetic
patients if a beta-blocking agent is required. Beta blockers may mask
tachycardia occurring with hypoglycemia, but other manifestations such as
dizziness and sweating may not be significantly affected. At recommended doses
Atenolol does not potentiate insulin-induced hypoglycemia and, unlike
nonselective beta blockers, does not delay recovery of blood glucose to normal
levels.  
 <p>
THYROTOXICOSIS:  Beta-adrenergic blockade may mask certain clinical signs (eg,
tachycardia) of hyperthyroidism. Patients suspected of having thyroid disease
should be monitored closely when administering Atenolol I.V. Injection. Abrupt
withdrawal of beta blockade might precipitate a thyroid storm; therefore,
patients suspected of developing thyrotoxicosis from whom Atenolol therapy is
to be withdrawn should be monitored closely. (See DOSAGE AND ADMINISTRATION.) 
 <p>
WARNINGS 
 <p>
PREGNANCY AND FETAL INJURY:  Atenolol can cause fetal harm when administered to 
a pregnant woman. Atenolol crosses the placental barrier and appears in cord
blood. Administration of atenolol, starting in the second trimester of
pregnancy, has been associated with the birth of infants that are small for
gestational age. No studies have been performed on the use of atenolol in the
first trimester and the possibility of fetal injury cannot be excluded. If this 
drug is used during pregnancy, or if the patient becomes pregnant while taking
this drug, the patient should be apprised of the potential hazard to the fetus. 
 <p>
Atenolol has been shown to produce a dose-related increase in embryo/fetal
resorptions in rats at doses equal to or greater than 50 mg/kg/day or 25 or
more times the maximum recommended human antihypertensive dose*. Although
similar effects were not seen in rabbits, the compound was not evaluated in
rabbits at doses above 25 mg/kg/day or 12.5 times the maximum recommended human 
antihypertensive dose*.  
 <p>
---------- 
 <p>
* Based on the maximum dose of 100 mg/day in a 50 kg patient.  
 <p>
---------- 
 <p><a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
GENERAL:  Patients already on a beta blocker must be evaluated carefully before 
Atenolol is administered. Initial and subsequent Atenolol dosages can be
adjusted downward depending on clinical observations including pulse and blood
pressure. Atenolol may aggravate peripheral arterial circulatory disorders.  
 <p>
IMPAIRED RENAL FUNCTION:  The drug should be used with caution in patients with 
impaired renal function. (See DOSAGE AND ADMINISTRATION.) 
                            <p>
DRUG INTERACTIONS:  Catecholamine-depleting drugs (eg, reserpine) may have an
additive effect when given with beta-blocking agents. Patients treated with
Atenolol plus a catecholamine depletor should therefore be closely observed for 
evidence of hypotension and/or marked bradycardia which may produce vertigo,
syncope or postural hypotension.  
 <p>
Calcium channel blockers may also have an additive effect when given with
Atenolol (See WARNINGS.) 
 <p>
Beta blockers may exacerbate the rebound hypertension which can follow the
withdrawal of clonidine. If the two drugs are coadministered, the beta blocker
should be withdrawn several days before the gradual withdrawal of clonidine. If 
replacing clonidine by beta-blocker therapy, the introduction of beta blockers
should be delayed for several days after clonidine administration has stopped.  
 <p>
Caution should be exercised with Atenolol I.V. Injection when given in close
proximity with drugs that may also have a depressant effect on myocardial
contractility. On rare occasions, concomitant use of intravenous beta blockers
and intravenous verapamil has resulted in serious adverse reactions, especially 
in patients with severe cardiomyopathy, congestive heart failure, or recent
myocardial infarction.  
 <p>
Information on concurrent usage of atenolol and aspirin is limited. Data from
several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical
interaction between aspirin and beta blockers in the acute myocardial
infarction setting.  
 <p>
While taking beta blockers, patients with a history of anaphylactic reaction to 
a variety of allergens may have a more severe reaction on repeated challenge,
either accidental, diagnostic or therapeutic. Such patients may be unresponsive 
to the usual doses of epinephrine used to treat the allergic reaction.  
 <p>
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY:  Two long-term (maximum
dosing duration of 18 or 24 months) rat studies and one long-term (maximum
dosing duration of 18 months) mouse study, each employing dose levels as high
as 300 mg/kg/day or 150 times the maximum recommended human antihypertensive
dose,* did not indicate a carcinogenic potential of atenolol. A third (24
month) rat study, employing doses of 500 and 1,500 mg/kg/day (250 and 750 times 
the maximum recommended human antihypertensive dose*) resulted in increased
incidences of benign adrenal medullary tumors in males and females, mammary
fibroadenomas in females, and anterior pituitary adenomas and thyroid
parafollicular cell carcinomas in males. No evidence of a mutagenic potential
of atenolol was uncovered in the dominant lethal test (mouse), in vivo
cytogenetics test (Chinese hamster) or Ames test (S Typhimurium).  
 <p>
Fertility of male or female rats (evaluated at dose levels as high as 200
mg/kg/day or 100 times the maximum recommended human dose*) was unaffected by
atenolol administration.  
 <p>
ANIMAL TOXICOLOGY:  Chronic studies employing oral atenolol performed in
animals have revealed the occurrence of vacuolation of epithelial cells of
Brunner's glands in the duodenum of both male and female dogs at all tested
dose levels of atenolol (starting at 15 mg/kg/day or 7.5 times the maximum
recommended human antihypertensive dose*) and increased incidence of atrial
degeneration of hearts of male rats at 300 but not 150 mg atenolol/kg/day (150
and 75 times the maximum recommended human antihypertensive dose,*
respectively).  
 <p>
---------- 
 <p>
*Based on the maximum dose of 100 mg/day in a 50 kg patient.  
 <p>
---------- 
 <p>
USAGE IN PREGNANCY:  PREGNANCY CATEGORY D: SEE WARNINGS--PREGNANCY AND FETAL
INJURY.  
 <p>
NURSING MOTHERS:  Atenolol is excreted in human breast milk at a ratio of 1.5
to 6.8 when compared to the concentration in plasma. Caution should be
exercised when Atenolol is administered to a nursing woman. Clinically
significant bradycardia has been reported in breast fed infants. Premature
infants, or infants with impaired renal function, may be more likely to develop 
adverse effects.  
 <p>
PEDIATRIC USE:  Safety and effectiveness in children have not been established. 
 <p>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <p>
Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when
given with beta-blocking agents. Patients treated with Atenolol plus a
catecholamine depletor should therefore be closely observed for evidence of
hypotension and/or marked bradycardia which may produce vertigo, syncope or
postural hypotension.  
 <p>
Calcium channel blockers may also have an additive effect when given with
Atenolol (See WARNINGS.) 
 <p>
Beta blockers may exacerbate the rebound hypertension which can follow the
withdrawal of clonidine. If the two drugs are coadministered, the beta blocker
should be withdrawn several days before the gradual withdrawal of clonidine. If 
replacing clonidine by beta-blocker therapy, the introduction of beta blockers
should be delayed for several days after clonidine administration has stopped.  
 <p>
Caution should be exercised with Atenolol I.V. Injection when given in close
proximity with drugs that may also have a depressant effect on myocardial
contractility. On rare occasions, concomitant use of intravenous beta blockers
and intravenous verapamil has resulted in serious adverse reactions, especially 
in patients with severe cardiomyopathy, congestive heart failure, or recent
myocardial infarction.  
 <p>
Information on concurrent usage of atenolol and aspirin is limited. Data from
several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical
interaction between aspirin and beta blockers in the acute myocardial
infarction setting.  
 <p>
While taking beta blockers, patients with a history of anaphylactic reaction to 
a variety of allergens may have a more severe reaction on repeated challenge,
either accidental, diagnostic or therapeutic. Such patients may be unresponsive 
to the usual doses of epinephrine used to treat the allergic reaction.  
 <p>
(See Also PRECAUTIONS) 
 <p>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
Most adverse effects have been mild and transient.  
 <p>
The frequency estimates in the following table were derived from controlled
studies in hypertensive patients in which adverse reactions were either
volunteered by the patient (US studies) or elicited, eg, by checklist (foreign
studies). The reported frequency of elicited adverse effects was higher for
both Atenolol and placebo-treated patients than when these reactions were
volunteered. Where frequency of adverse effects of Atenolol and placebo is
similar, causal relationship to Atenolol is uncertain.  <p><pre>
 
                                                          Total--Volunteered    
                                    Volunteered              and Elicited       
                                    (US Studies)        (Foreign +US Studies)   
                                Atenolol    Placebo     Atenolol     Placebo    
                               (n = 164)   (n = 206)   (n = 399)    (n = 407)   
                                   %           %           %            %       
----------------------------------------------------------------------------    
CARDIOVASCULAR                                                                  
  Bradycardia                     3           0            3           0        
  Cold Extremities                0           0.5          12          5        
  Postural Hypotension            2           1            4           5        
  Leg Pain                        0           0.5          3           1        
CENTRAL NERVOUS                                                                 
SYSTEM/NEUROMUSCULAR                                                            
  Dizziness                       4           1            13          6        
  Vertigo                         2           0.5          2           0.2      
  Light-headedness                1           0            3           0.7      
  Tiredness                       0.6         0.5          26          13       
  Fatigue                         3           1            6           5        
  Lethargy                        1           0            3           0.7      
  Drowsiness                      0.6         0            2           0.5      
  Depression                      0.6         0.5          12          9        
  Dreaming                        0           0            3           1        
GASTROINTESTINAL                                                                
  Diarrhea                        2           0            3           2        
  Nausea                          4           1            3           1        
RESPIRATORY (see WARNINGS)                                                      
  Wheeziness                      0           0            3           3        
  Dyspnea                         0.6         1            6           4        
</pre><p>
ACUTE MYOCARDIAL INFARCTION:  In a series of investigations in the treatment of 
acute myocardial infarction, bradycardia and hypotension occurred more commonly 
as expected for any beta blocker, in atenolol-treated patients than in control
patients. However, these usually responded to atropine and/ or to withholding
further dosage of atenolol. The incidence of heart failure was not increased by 
atenolol. Inotropic agents were infrequently used. The reported frequency of
these and other events occurring during these investigations is given in the
following table.  
 <p>
In a study of 477 patients, the following adverse events were reported during
either intravenous and/or oral atenolol administration:  
 <pre>
                                       Conventional              Conventional   
                                       Therapy Plus                Therapy      
                                         Atenolol                   Alone       
                                         (n=244)                   (n=233)      
----------------------------------------------------------------------------    
Bradycardia                             43  (18%)                  24   (10%)   
Hypotension                             60  (25%)                  34   (15%)   
Bronchospasm                             3 (1.2%)                   2  (0.9%)   
Heart Failure                           46  (19%)                  56   (24%)   
Heart Block                             11 (4.5%)                  10  (4.3%)   
BBB +Major Axis Deviation               16 (6.6%)                  28   (12%)   
Supraventricular Tachycardia            28 (11.5%)                 45   (19%)   
  Atrial Fibrillation                   12   (5%)                  29   (11%)   
  Atrial Flutter                         4 (1.6%)                   7    (3%)   
Ventricular Tachycardia                 39  (16%)                  52   (22%)   
Cardiac Reinfarction                     0   (0%)                   6  (2.6%)   
Total Cardiac Arrests                    4 (1.6%)                  16  (6.9%)   
Nonfatal Cardiac Arrests                 4 (1.6%)                  12  (5.1%)   
Deaths                                   7 (2.9%)                  16  (6.9%)   
Cardiogenic Shock                        1 (0.4%)                   4  (1.7%)   
Development of Ventricular                                                      
Septal Defect                            0   (0%)                   2  (0.9%)   
Development of Mitral                                                           
Regurgitation                            0   (0%)                   2  (0.9%)   
Renal Failure                            1 (0.4%)                   0    (0%)   
Pulmonary Emboli                         3 (1.2%)                   0    (0%)   
In the subsequent International Study of Infarct Survival (ISIS-1) including
over 16,000 patients of whom 8,037 were randomized to receive Atenolol
treatment, the dosage of intravenous and subsequent oral Atenolol was either
discontinued or reduced for the following reasons:  
 
                           Reasons for Reduced Dosage                           
                                       IV Atenolol                   Oral       
                                       Reduced Dose              Partial Dose   
                                         (&lt;5 mg)*                               
----------------------------------------------------------------------------    
Hypotension/Bradycardia                105 (1.3%)                  1168 (14.5   
                                                                           %)   
Cardiogenic Shock                        4 (.04%)                    35 (.44%)  
Reinfarction                             0   (0%)                     5 (.06%)  
Cardiac Arrest                           5 (.06%)                    28 (.34%)  
Heart Block (&gt; first degree)             5 (.06%)                   143 (1.7%)  
Cardiac Failure                          1 (.01%)                   233 (2.9%)  
Arrhythmias                              3 (.04%)                    22 (.27%)  
Bronchospasm                             1 (.01%)                    50 (.62%)  
----------------------------------------------------------------------------    
*  Full dosage was 10 mg and some patients received less than 10 mg but more    
    than 5 mg.                                                                  </pre><p>
During postmarketing experience with Atenolol, the following have been reported 
in temporal relationship to the use of the drug: elevated liver enzymes and/or
bilirubin, hallucinations, headache, impotence, Peyronie's disease, postural
hypotension which may be associated with syncope, psoriasiform rash or
exacerbation of psoriasis, psychoses, purpura, reversible alopecia,
thrombocytopenia and visual disturbances. Atenolol, like other beta blockers,
has been associated with the development of antinuclear antibodies (ANA) and
lupus syndrome.  
 <p>
POTENTIAL ADVERSE EFFECTS 
 <p>
In addition, a variety of adverse effects have been reported with other beta-
adrenergic blocking agents, and may be considered potential adverse effects of
Atenolol.  
 <p>
HEMATOLOGIC:  Agranulocytosis.  
 <p>
ALLERGIC:  Fever, combined with aching and sore throat, laryngospasm, and
respiratory distress.  
 <p>
CENTRAL NERVOUS SYSTEM:  Reversible mental depression progressing to catatonia; 
an acute reversible syndrome characterized by disorientation of time and place; 
short-term memory loss; emotional lability with slightly clouded sensorium; and 
decreased performance on neuropsychometrics.  
 <p>
GASTROINTESTINAL:  Mesenteric arterial thrombosis, ischemic colitis.  
 <p>
OTHER:  Erythematous rash, Raynaud's phenomenon.  
 <p>
MISCELLANEOUS:  There have been reports of skin rashes and/or dry eyes
associated with the use of beta-adrenergic blocking drugs. The reported
incidence is small, and in most cases, the symptoms have cleared when treatment 
was withdrawn. Discontinuance of the drug should be considered if any such
reaction is not otherwise explicable. Patients should be closely monitored
following cessation of therapy. (See DOSAGE AND ADMINISTRATION.) 
 <p>
The oculomucocutaneous syndrome associated with the beta blocker practolol has
not been reported with Atenolol. Furthermore, a number of patients who had
previously demonstrated established practolol reactions were transferred to
Atenolol therapy with subsequent resolution or quiescence of the reaction.  
 <p>
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b><p> 
Overdosage with Atenolol has been reported with patients surviving acute doses
as high as 5 g. One death was reported in a man who may have taken as much as
10 g acutely.  
 <p>
The predominant symptoms reported following Atenolol overdose are lethargy,
disorder of respiratory drive, wheezing, sinus pause and bradycardia. 
Additionally, common effects associated with overdosage of any beta-adrenergic
blocking agent and which might also be expected in Atenolol overdose are
congestive heart failure, hypotension, bronchospasm and/or hypoglycemia.  
 <p>
Treatment of overdose should be directed to the removal of any unabsorbed drug
by induced emesis, gastric lavage, or administration of activated charcoal. 
Atenolol can be removed from the general circulation by hemodialysis. Other
treatment modalities should be employed at the physician's discretion and may
include:  
 <p>
BRADYCARDIA: Atropine intravenously. If there is no response to vagal blockade, 
give isoproterenol cautiously. In refractory cases, a transvenous cardiac
pacemaker may be indicated.  
 <p>
HEART BLOCK (SECOND OR THIRD DEGREE): Isoproterenol or transvenous cardiac
pacemaker.  
 <p>
CARDIAC FAILURE: Digitalize the patient and administer a diuretic. Glucagon has 
been reported to be useful.  
 <p>
HYPOTENSION: Vasopressors such as dopamine or norepinephrine (levarterenol). 
Monitor blood pressure continuously.  
 <p>
BRONCHOSPASM: A beta2 stimulant such as isoproterenol or terbutaline and/or
aminophylline.  
 <p>
HYPOGLYCEMIA: Intravenous glucose.  
 <p>
Based on the severity of symptoms, management may require intensive support
care and facilities for applying cardiac and respiratory support.  
 <p>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b><p> 
HYPERTENSION:  The initial dose of Atenolol is 50 mg given as one tablet a day
either alone or added to diuretic therapy. The full effect of this dose will
usually be seen within one to two weeks. If an optimal response is not achieved 
the dosage should be increased to Atenolol 100 mg given as one tablet a day. 
Increasing the dosage beyond 100 mg a day is unlikely to produce any further
benefit.  
 <p>
Atenolol may be used alone or concomitantly with other antihypertensive agents
including thiazide-type diuretics, hydralazine, prazosin, and alpha-methyldopa. 
 <p>
ANGINA PECTORIS:  The initial dose of Atenolol is 50 mg given as one tablet a
day. If an optimal response is not achieved within one week, the dosage should
be increased to Atenolol 100 mg given as one tablet a day. Some patients may
require a dosage of 200 mg once a day for optimal effect.  
 <p>
Twenty-four hour control with once daily dosing is achieved by giving doses
larger than necessary to achieve an immediate maximum effect. The maximum early 
effect on exercise tolerance occurs with doses of 50 to 100 mg, but at these
doses the effect at 24 hours is attenuated, averaging about 50% to 75% of that
observed with once a day oral doses of 200 mg.  
 <p>
ACUTE MYOCARDIAL INFARCTION:  In patients with definite or suspected acute
myocardial infarction, treatment with Atenolol I.V. Injection should be
initiated as soon as possible after the patient's arrival in the hospital and
after eligibility is established. Such treatment should be initiated in a
coronary care or similar unit immediately after the patient's hemodynamic
condition has stabilized. Treatment should begin with the intravenous
administration of 5 mg Atenolol over 5 minutes followed by another 5 mg
intravenous injection 10 minutes later. Atenolol I.V. Injection should be
administered under carefully controlled conditions including monitoring of
blood pressure, heart rate, and electrocardiogram. Dilutions of Atenolol I.V. 
Injection in Dextrose Injection USP, Sodium Chloride Injection USP, or Sodium
Chloride and Dextrose Injection may be used. These admixtures are stable for 48 
hours if they are not used immediately.  
 <p>
In patients who tolerate the full intravenous dose (10 mg), Atenolol Tablets 50 
mg should be initiated 10 minutes after the last intravenous dose followed by
another 50 mg oral dose 12 hours later. Thereafter, Atenolol can be given
orally either 100 mg once daily or 50 mg twice a day for a further 6-9 days or
until discharge from the hospital. If bradycardia or hypotension requiring
treatment or any other untoward effects occur, Atenolol should be discontinued. 
 <p>
Data from other beta blocker trials suggest that if there is any question
concerning the use of IV beta blocker or clinical estimate that there is a
contraindication, the IV beta blocker may be eliminated and patients fulfilling 
the safety criteria may be given Atenolol Tablets 50 mg twice daily or 100 mg
once a day for at least seven days (if the IV dosing is excluded).  
 <p>
Although the demonstration of efficacy of Atenolol is based entirely on data
from the first seven postinfarction days, data from other beta blocker trials
suggest that treatment with beta blockers that are effective in the
postinfarction setting may be continued for one to three years if there are no
contraindications.  
 <p>
Atenolol is an additional treatment to standard coronary care unit therapy.  
 <p>
ELDERLY PATIENTS OR PATIENTS WITH RENAL IMPAIRMENT: Atenolol is excreted by the 
kidneys; consequently dosage should be adjusted in cases of severe impairment
of renal function. Some reduction in dosage may also be appropriate for the
elderly, since decreased kidney function is a physiologic consequence of aging. 
Atenolol excretion would be expected to decrease with advancing age.  
       <p>                     
No significant accumulation of Atenolol occurs until creatinine clearance falls 
below 35 mL/min/1.73 M(square). Accumulation of atenolol and prolongation of
its half-life were studied in subjects with creatinine clearance between 5 and
105 mL/min. Peak plasma levels were significantly increased in subjects with
creatinine clearances below 30 mL/min.  
 <p>
The following maximum oral dosages are recommended for elderly, renally
impaired patients and for patients with renal impairment due to other causes: 
 <p><pre>
                                         Atenolol                               
        Creatinine Clearance           Elimination              Maximum         
       (mL/min/1.73M(square))         Half-Life (h)              Dosage         
-----------------------------------------------------------------------------   
               15-35                      16-27               50 mg daily       
                &lt;15                        &gt;27                25 mg daily       
Some renally-impaired or elderly patients being treated for hypertension may
require a lower starting dose of Atenolol: 25 mg given as one tablet a day. If
this 25 mg dose is used, assessment of efficacy must be made carefully. This
should include measurement of blood pressure just prior to the next dose
(&quot;trough&quot; blood pressure) to ensure that the treatment effect is present for a
full 24 hours.  
 </pre><p>
Although a similar dosage reduction may be considered for elderly and/or
renally-impaired patients being treated for indications other than hypertension 
data are not available for these patient populations.  
 <p>
Patients on hemodialysis should be given 25 mg or 50 mg after each dialysis;
this should be done under hospital supervision as marked falls in blood
pressure can occur.  
 <p>
CESSATION OF THERAPY IN PATIENTS WITH ANGINA PECTORIS:  If withdrawal of
Atenolol therapy is planned, it should be achieved gradually and patients
should be carefully observed and advised to limit physical activity to a
minimum.  
 
 <p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-36</DOCNO>
<DOCOLDNO>IA018-000200-B034-102</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/propox.htm 206.86.175.201 19970106224154 text/html 23977
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:35:39 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 23794
Last-modified: Sun, 11 Aug 1996 03:46:50 GMT
</DOCHDR>
<html>
<head>
   <title>Propoxyphene with acetaminophen - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Propoxyphene with acetaminophen</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION 

</b><p>
Propoxyphene Napsylate  is an odorless, white crystalline

powder with a bitter taste. It is very slightly soluble in water and soluble in 

methanol, ethanol, chloroform, and acetone. Chemically, it is (alphaS,1R)-

alpha-(2-Dimethylamino)-1-methylethyl)-alpha-phenylphenethyl propionate

compound with 2-naphthalenesulfonic acid (1:1) monohydrate. Its molecular

weight is 565.72.  <p>

 



Propoxyphene napsylate differs from propoxyphene hydrochloride in that it

allows more stable liquid dosage forms and tablet formulations. Because of

differences in molecular weight, a dose of 100 mg (176.8 micromol) of

propoxyphene napsylate is required to supply an amount of propoxyphene

equivalent to that present in 65 mg (172.9 micromol) of propoxyphene

hydrochloride.  
<p>
 

<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 

</b> 
<p>
Propoxyphene is a centrally acting narcotic analgesic agent. Equimolar doses of 

propoxyphene hydrochloride or napsylate provide similar plasma concentrations.  

Following administration of 65, 130, or 195 mg of propoxyphene hydrochloride,

the bioavailability of propoxyphene is equivalent to that of 100, 200, or 300

mg respectively of propoxyphene napsylate. Peak plasma concentrations of

propoxyphene are reached in 2 to 2 1/2 hours. After a 100-mg oral dose of

propoxyphene napsylate, peak plasma levels of 0.05 to 0.1 mcgm/mL are achieved. 

<p>

The napsylate salt tends to be absorbed more slowly than the hydrochloride. 

At or near therapeutic doses, this absorption difference is small 

when compared with that among subjects and among doses.

 <p>

Because of this several hundredfold difference in solubility, the absorption

rate of very large doses of the napsylate salt is significantly lower than that 

of equimolar doses of the hydrochloride.  

 
<p>
Repeated doses of propoxyphene at 6-hour intervals lead to increasing plasma

concentrations, with a plateau after the ninth dose at 48 hours.  

 <p>

Propoxyphene is metabolized in the liver to yield norpropoxyphene. Propoxyphene 

has a half-life of 6 to 12 hours, whereas that of norpropoxyphene is 30 to 36

hours.  

 <p>

Norpropoxyphene has substantially less central-nervous-system-depressant effect 

than propoxyphene but a greater local anesthetic effect, which is similar to

that of amitriptyline and antiarrhythmic agents, such as lidocaine and

quinidine.  

 <p>

In animal studies in which propoxyphene and norpropoxyphene were continuously

infused in large amounts, intracardiac conduction time (PR and QRS intervals)

was prolonged. Any intracardiac conduction delay attributable to high

concentrations of norpropoxyphene may be of relatively long duration.  

 <p>

ACTIONS 

 <p>

Propoxyphene is a mild narcotic analgesic structurally related to methadone.

The potency of propoxyphene napsylate is from two-thirds to equal that of

codeine.  

 <p>

The combination of propoxyphene and acetaminophen produces greater analgesia

than that produced by either propoxyphene or acetaminophen administered alone.  
<p>
 

<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 

</b> 
<p>
propoxyphene napsylate and acetaminophen tablets are indicated for the 

relief of mild to moderate pain, either when pain is present alone or when it 

is accompanied by fever.  
<p>
 

Propoxyphene napsylate) is indicated for the relief of mild to moderate pain.  

 <p>

<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 

</b> 
<p>
Hypersensitivity to propoxyphene or acetaminophen.  

 
<p>
 

<a name="WARNINGS"></a><b>WARNINGS 

</b> <p>

--DO NOT PRESCRIBE PROPOXYPHENE FOR PATIENTS WHO ARE SUICIDAL OR ADDICTION

PRONE.  
<p>
 

--PRESCRIBE PROPOXYPHENE WITH CAUTION FOR PATIENTS TAKING TRANQUILIZERS OR

ANTIDEPRESSANT DRUGS AND PATIENTS WHO USE ALCOHOL IN EXCESS.  

 <p>

--TELL YOUR PATIENTS NOT TO EXCEED THE RECOMMENDED DOSE AND TO LIMIT THEIR

INTAKE OF ALCOHOL.  

<p>

Propoxyphene products in excessive doses, either alone or in combination with

other CNS depressants, including alcohol, are a major cause of drug-related

deaths. Fatalities within the first hour of overdosage are not uncommon. In a

survey of deaths due to overdosage conducted in 1975, in approximately 20% of

the fatal cases, death occurred within the first hour (5% occurred within 15

minutes). Propoxyphene should not be taken in doses higher than those

recommended by the physician. The judicious prescribing of propoxyphene is

essential to the safe use of this drug. With patients who are depressed or

suicidal, consideration should be given to the use of non-narcotic analgesics.  

Patients should be cautioned about the concomitant use of propoxyphene products 

and alcohol because of potentially serious CNS-additive effects of these

agents.  Because of its added depressant effects, propoxyphene should be

prescribed with caution for those patients whose medical condition requires the 

concomitant administration of sedatives, tranquilizers, muscle relaxants,

antidepressants, or other CNS-depressant drugs. Patients should be advised of

the additive depressant effects of these combinations.  

 <p>

Many of the propoxyphene-related deaths have occurred in patients with previous 

histories of emotional disturbances or suicidal ideation or attempts as well as 

histories of misuse of tranquilizers, alcohol, and other CNS-active drugs. Some 

deaths have occurred as a consequence of the accidental ingestion of excessive

quantities of propoxyphene alone or in combination with other drugs. Patients

taking propoxyphene should be warned not to exceed the dosage recommended by

the physician.  

 

 <p>

Drug Dependence--Propoxyphene, when taken in higher-than-recommended doses over 

long periods of time, can produce drug dependence characterized by psychic

dependence and, less frequently, physical dependence and tolerance.

Propoxyphene will only partially suppress the withdrawal syndrome in

individuals physically dependent on morphine or other narcotics. The abuse

liability of propoxyphene is qualitatively similar to that of codeine although

quantitatively less, and propoxyphene should be prescribed with the same degree 

of caution appropriate to the use of codeine.  
<p>

Usage In Ambulatory Patients--Propoxyphene may impair the mental and/or

physical abilities required for the performance of potentially hazardous tasks, 

such as driving a car or operating machinery. The patient should be cautioned

accordingly.  

 <p>

<a name="PRECAUTIONS"></a><b>PRECAUTIONS 

</b> <p>

General--Propoxyphene should be administered with caution to patients with

hepatic or renal impairment, since higher serum concentrations or delayed

elimination may occur.  

 <p>

Drug Interactions--The CNS-depressant effect of propoxyphene is additive with

that of other CNS depressants, including alcohol.  
<p>
 

As is the case with many medicinal agents, propoxyphene may slow the metabolism 

of a concomitantly administered drug. Should this occur, the higher serum

concentrations of that drug may result in increased pharmacologic or adverse

effects of that drug. Such occurrences have been reported when propoxyphene was 

administered to patients on antidepressants, anticonvulsants, or warfarin-like

drugs. Severe neurologic signs, including coma, have occurred with concurrent

use of carbamazepine.  

<p>

Usage In Pregnancy--Safe use in pregnancy has not been established relative to

possible adverse effects on fetal development. Instances of withdrawal symptoms 

in the neonate have been reported following usage during pregnancy. Therefore,

propoxyphene should not be used in pregnant women unless, in the judgment of

the physician, the potential benefits outweigh the possible hazards.  

 <p>

Usage In Nursing Mothers--Low levels of propoxyphene have been detected in

human milk. In postpartum studies involving nursing mothers who were given

propoxyphene, no adverse effects were noted in infants receiving mother's milk. 

 <p>

Usage In Children--Propoxyphene is not recommended for use in children, because 

documented clinical experience has been insufficient to establish safety and a

suitable dosage regimen in the pediatric age group.  

 <p>

Usage In The Elderly--The rate of propoxyphene metabolism may be reduced in

some patients. Increased dosing interval should be considered.  

 
<p>
A Patient Information Sheet is available for these products. See text following 

&quot;How Supplied&quot; section below.  

 <p>

<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 

</b> <p>

The CNS-depressant effect of propoxyphene is additive with that of other CNS

depressants, including alcohol.  
<p>
 

As is the case with many medicinal agents, propoxyphene may slow the metabolism 

of a concomitantly administered drug. Should this occur, the higher serum

concentrations of that drug may result in increased pharmacologic or adverse

effects of that drug. Such occurrences have been reported when propoxyphene was 

administered to patients on antidepressants, anticonvulsants, or warfarin-like

drugs. Severe neurologic signs, including coma, have occurred with concurrent

use of carbamazepine.  

 

(See Also PRECAUTIONS) 

 <p>

<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 

</b> <p>

In a survey conducted in hospitalized patients, less than 1% of patients taking 

propoxyphene hydrochloride at recommended doses experienced side effects. The

most frequently reported were dizziness, sedation, nausea, and vomiting. Some

of these adverse reactions may be alleviated if the patient lies down.  

 <p>

Other adverse reactions include constipation, abdominal pain, skin rashes,

lightheadedness, headache, weakness, euphoria, dysphoria, hallucinations, and

minor visual disturbances.  

 <p>

Liver dysfunction has been reported in association with both active components

of propoxyphene napsylate and acetaminophen tablets.  

 <p>

Propoxyphene therapy has been associated with abnormal liver function tests and 

more rarely, with instances of reversible jaundice (including cholestatic

jaundice). Hepatic necrosis may result from acute overdose of acetaminophen

(See Management of Overdosage). In chronic ethanol abusers, this has been

reported rarely with short-term use of acetaminophen doses of 2.5 to 10 g/day.

Fatalities have occurred.  

<p>

Renal papillary necrosis may result from chronic acetaminophen use,

particularly when the dosage is greater than recommended and when combined with 

aspirin.  

 <p>

Subacute painful myopathy has occurred following chronic propoxyphene

overdosage.  

 <p>

DRUG ABUSE AND DEPENDENCE 

 <p>

SEE WARNINGS 
<p>
 

<a name="OVERDOSAGE"></a><b>OVERDOSAGE 

</b> <p>

MANAGEMENT OF OVERDOSAGE 

 <p>

In all cases of suspected overdosage, call your regional Poison Control Center

to obtain the most up-to-date information about the treatment of overdose. This 

recommendation is made because, in general, information regarding the treatment 

of overdosage may change more rapidly than do package inserts.  

 
<p>
Initial consideration should be given to the management of the CNS effects of

propoxyphene overdosage. Resuscitative measures should be initiated promptly. 
<p>

Symptoms Of Propoxyphene Overdosage--The manifestations of acute overdosage

with propoxyphene are those of narcotic overdosage. The patient is usually

somnolent but may be stuporous or comatose and convulsing. Respiratory

depression is characteristic. The ventilatory rate and/or tidal volume is

decreased, which results in cyanosis and hypoxia. Pupils, initially pinpoint,

may become dilated as hypoxia increases. Cheyne-Stokes respiration and apnea

may occur. Blood pressure and heart rate are usually normal initially, but

blood pressure falls and cardiac performance deteriorates, which ultimately

results in pulmonary edema and circulatory collapse, unless the respiratory

depression is corrected and adequate ventilation is restored promptly. Cardiac

arrhythmias and conduction delay may be present. A combined respiratory

metabolic acidosis occurs owing to retained CO2 (hypercapnia) and to lactic

acid formed during anaerobic glycolysis. Acidosis may be severe if large

amounts of salicylates have also been ingested. Death may occur.  
<p>
 

Treatment Of Propoxyphene Overdosage--Attention should be directed first to

establishing a patent airway and to restoring ventilation. Mechanically

assisted ventilation, with or without oxygen, may be required, and positive

pressure respiration may be desirable if pulmonary edema is present. The

narcotic antagonist naloxone will markedly reduce the degree of respiratory

depression, and 0.4 to 2 mg should be administered promptly, preferably

intravenously. If the desired degree of counteraction with improvement in

respiratory functions is not obtained, naloxone should be repeated at 2- to 3

minute intervals. The duration of action of the antagonist may be brief. If no

response is observed after 10 mg of naloxone have been administered, the

diagnosis of propoxyphene toxicity should be questioned. Naloxone may also be

administered by continuous intravenous infusion.  

 <p>

Treatment Of Propoxyphene Overdosage In Children--The usual initial dose of

naloxone in children is 0.01 mg/kg body weight given intravenously. If this

dose does not result in the desired degree of clinical improvement, a

subsequent increased dose of 0.1 mg/kg body weight may be administered. If an

IV route of administration is not available, naloxone may be administered IM or

subcutaneously in divided doses. If necessary, naloxone can be diluted with

Sterile Water for Injection.  
<p>
 

Blood gases, pH, and electrolytes should be monitored in order that acidosis

and any electrolyte disturbance present may be corrected promptly. Acidosis,

hypoxia, and generalized CNS depression predispose to the development of

cardiac arrhythmias. Ventricular fibrillation or cardiac arrest may occur and

necessitate the full complement of cardiopulmonary resuscitation (CPR)

measures.  Respiratory acidosis rapidly subsides as ventilation is restored and 

hypercapnia eliminated, but lactic acidosis may require intravenous bicarbonate 

for prompt correction.  

 <p>

Electrocardiographic monitoring is essential. Prompt correction of hypoxia,

acidosis, and electrolyte disturbance (when present) will help prevent these

cardiac complications and will increase the effectiveness of agents

administered to restore normal cardiac function.  

 <p>

In addition to the use of a narcotic antagonist, the patient may require

careful titration with an anticonvulsant to control convulsions. Analeptic

drugs (for example, caffeine or amphetamine) should not be used because of

their tendency to precipitate convulsions.  

 <p>

General supportive measures, in addition to oxygen, include, when necessary,

intravenous fluids, vasopressor-inotropic compounds, and, when infection is

likely, anti-infective agents. Gastric lavage may be useful, and activated

charcoal can adsorb a significant amount of ingested propoxyphene. Dialysis is

of little value in poisoning due to propoxyphene. Efforts should be made to

determine whether other agents, such as alcohol, barbiturates, tranquilizers,

or other CNS depressants, were also ingested, since these increase CNS

depression as well as cause specific toxic effects.  

 
<p>
Symptoms Of Acetaminophen Overdosage--Shortly after oral ingestion of an

overdose of acetaminophen and for the next 24 hours, anorexia, nausea, vomiting 

diaphoresis, general malaise, and abdominal pain have been noted. The patient

may then present no symptoms, but evidence of liver dysfunction may become

apparent up to 72 hours after ingestion, with elevated serum transaminase and

lactic dehydrogenase levels, an increase in serum bilirubin concentrations, and 

a prolonged prothrombin time. Death from hepatic failure may result 3 to 7 days 

after overdosage.  

 <p>

Acute renal failure may accompany the hepatic dysfunction and has been noted in 

patients who do not exhibit signs of fulminant hepatic failure. Typically,

renal impairment is more apparent 6 to 9 days after ingestion of the overdose.  

 <p>

Treatment Of Acetaminophen Overdosage--Acetaminophen in massive overdosage may

cause hepatic toxicity in some patients. In All Cases Of Suspected Overdose,

Immediately Call Your Regional Poison Center Or The Rocky Mountain Poison

Center's Toll-Free Number (800-525-6115) for assistance in diagnosis and for

directions in the use of N-acetylcysteine as an antidote.  

 <p>

In adults, hepatic toxicity has rarely been reported with acute overdoses of

less than 10 g and fatalities with less than 15 g. Importantly, young children

seem to be more resistant than adults to the hepatotoxic effect of an

acetaminophen overdose. Despite this, the measures outlined below should be

initiated in any adult or child suspected of having ingested an acetaminophen

overdose.  
<p>


Because clinical and laboratory evidence of hepatic toxicity may not be

apparent until 48 to 72 hours postingestion, liver function studies should be

obtained initially and repeated at 24-hour intervals.  

 <p>

Consider emptying the stomach promptly by lavage or by induction of emesis with 

syrup of ipecac. Patients' estimates of the quantity of a drug ingested are

notoriously unreliable. Therefore, if an acetaminophen overdose is suspected, a 

serum acetaminophen assay should be obtained as early as possible, but no

sooner than 4 hours following ingestion. The antidote, N-acetylcysteine, should 

be administered as early as possible, and within 16 hours of the overdose

ingestion for optimal results. Following recovery, there are no residual,

structural, or functional hepatic abnormalities.  

 <p>

<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 

</b> <p>

These products are given orally. The usual dosage of propoxyphene napsylate and 

acetaminophen tablets is 100 mg propoxyphene napsylate and 650 mg acetaminophen 

every 4 hours as needed for pain.  

 <p>

The maximum recommended dose of propoxyphene napsylate is 600 mg/day.  

 <p>

Consideration should be given to a reduced total daily dosage in patients with

hepatic or renal impairment.  

 <p>

<b><i>ANIMAL PHARMACOLOGY</i></b> 

 <p>

ANIMAL TOXICOLOGY 

 <p>

The acute lethal doses of the hydrochloride and napsylate salts of propoxyphene 

were determined in 4 species. The results shown in Figure 1 indicate that, on a 

molar basis, the napsylate salt is less toxic than the hydrochloride. This may

be due to the relative insolubility and retarded absorption of propoxyphene

napsylate.  <p>

 
<pre>
---------------------------------------------------------------------           

            Figure 1. Acute oral toxicity of propoxyphene                       

---------------------------------------------------------------------           

                      LD50(mg/kg) (+/-) SE                                      

                 ------------------------------                                 

                         LD50 (mmol/kg)                                         

---------------------------------------------------------------------           

                Propoxyphene                  Propoxyphene                      

Species         Hydrochloride                  Napsylate                        

---------------------------------------------------------------------           

Mouse            282 (+/-) 39                  915 (+/-) 163                    

                 ------------                  -------------                    

                     0.75                           1.62                        

Rat              230 (+/-) 44                  647 (+/-) 95                     

                 -------------                 -------------                    

                     0.61                           1.14                        

Rabbit               Ca. 82                         &gt;183                        

                 -------------                 -------------                    

                      0.22                          &gt;0.32                       

Dog                  Ca. 100                        &gt;183                        

                 -------------                 -------------                    

                      0.27                          &gt;0.32                       

---------------------------------------------------------------------   </pre><p>

        

Some indication of the relative insolubility and retarded absorption of

propoxyphene napsylate was obtained by measuring plasma propoxyphene levels in

2 groups of 4 dogs following oral administration of equimolar doses of the 2

salts. 
 <p>

Although none of the animals in this experiment died, 3 of the 4 dogs given

propoxyphene hydrochloride exhibited convulsive seizures during the time

interval corresponding to the peak plasma levels. The 4 animals receiving the

napsylate salt were mildly ataxic but not acutely ill. <p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-37</DOCNO>
<DOCOLDNO>IA018-000200-B041-14</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/yohimb.htm 206.86.175.201 19970106230734 text/html 6057
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:01:20 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5875
Last-modified: Wed, 16 Oct 1996 23:49:45 GMT
</DOCHDR>
<html>
<head>
   <title>Yohimbine - RxList Generic Information</title>
   <meta name="keywords" content="Actibine, Aphrodyne, Dayto-Himbin, Erex, Thybine,
Yocon, Yohimbine Hcl, Yohimex, Yomax">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Yohimbine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="yohimb.htm#WARNINGS">caution</a>]
[<a href="#DRUG INTERACTIONS">drug-drug</a>] [<a href="#ADVERSE REACTIONS">side
effects</a>] [toxicity] [<a href="#DOSAGE AND ADMINISTRATION">dosing</a>]
</font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Yohimbine is a 3alpha-15alpha-20beta-17alpha- hydroxy Yohimbine-16alpha-
carboxylic acid methyl ester. The alkaloid is found in Rubaceae and related
trees. Also in Rauwolfia Serpentina (L) Benth. Yohimbine is an indolalkylamine
alkaloid with chemical similarity to reserpine. It is a crystalline powder,
odorless. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Yohimbine blocks presynaptic alpha-2 adrenergic receptors. Its actions
on peripheral blood vessels resembles that of reserpine, though it is weaker
and of short duration. Yohimbine's peripheral autonomic nervous system
effect is to increase parasympathetic (cholinergic) and decrease sympathetic
(adrenergic) activity. It is to be noted that in male sexual performance,
erection is linked to cholinergic activity and to alpha-2 adrenergic blockade
which may theoretically result in increased penile inflow, decreased penile
outflow or both. </p>

<p>Yohimbine exerts a stimulating action on the mood and may increase anxiety.
Such actions have not been adequately studied or related to dosage although
they appear to require high doses of the drug. Yohimbine has a mild anti-diuretic
action, probably via stimulation of hypothalamic centers and release of
posterior pituitary hormone. </p>

<p>Reportedly, Yohimbine exerts no significant influence on cardiac stimulation
and other effects mediated by beta-adrenergic receptors, its effect on
blood pressure, if any, would be to lower it; however, no adequate studies
are at hand to quantitate this effect in terms of Yohimbine dosage. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Yohimbine is indicated as a sympathicolytic and mydriatic. It may have
activity as an aphrodisiac. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Renal diseases, and patients sensitive to the drug. In view of the limited
and inadequate information at hand, no precise tabulation can be offered
of additional contraindications. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>Generally, this drug is not proposed for use in females and certainly
must not be used during pregnancy. Neither is this drug proposed for use
in pediatric, geriatric or cardio-renal patients with gastric or duodenal
ulcer history. Nor should it be used in conjunction with mood- modifying
drugs such as antidepressants, or in psychiatric patients in general. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>SEE <a href="yohimb.htm#WARNINGS">WARNINGS</a> </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Yohimbine readily penetrates the (CNS) and produces a complex pattern
of responses in lower doses than required to produce peripheral alpha-
adrenergic blockade. These include, anti- diuresis, a general picture of
central excitation including elevation of blood pressure and heart rate
increased motor activity, irritability and tremor. Sweating, nausea and
vomiting are common after parenteral administration of the drug. (REF.
1,2) Also dizziness, headache, skin flushing reported when used orally.
(REF. 1,3) </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Experimental dosage reported in treatment of erectile impotence: (REF.
1,3,4,) 1 tablet (5.4 mg) 3 times a day, to adult males taken orally. Occasional
side effects reported with this dosage are nausea, dizziness or nervousness.
In the event of side effects dosage is to be reduced to 1/2 tablet 3 times
a day, followed by gradual increases to 1 tablet 3 times a day. Reported
therapy not more than 10 weeks. (REF. 3) </p>

<p>REFERENCES </p>

<p>1. A. Morales et al., New England Journal of Medicine:1221. November
12, 1981. </p>

<p>2. Goodman, Gilman--The Pharmacological basis of Therapeutics 6th ed.,
p. 176- 188, McMillan </p>

<p>3. Weekly Urological Clinical letter, 27:2, July 4, 1983. </p>

<p>4. A. Morales et al., The Journal of Urology 128: 45-47, 1982. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-38</DOCNO>
<DOCOLDNO>IA018-000200-B041-269</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/bblock.htm 206.86.175.201 19970106231129 text/html 3861
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:05:16 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3679
Last-modified: Sun, 30 Jun 1996 07:23:30 GMT
</DOCHDR>
<html>
<head>
   <title>Rxlist of Indications and Side Effects - Beta Blocker Drugs
</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a>
<hr></p></center>

<h1 align=center>Beta Blocker Drugs </h1>

<h3>The beta blockers (examples: atenolol, metoprolol, propranolol) act
as competitive antagonists at the adrenergic beta receptors. The newer
agents tend to be more selective for the cardiac (beta-1) receptors which
allows for decreased systemic side effects. Most of the generic names for
beta blockers end with &quot;olol&quot;.</h3>

<p>
<hr></p>

<h3><a href="disclaim.htm">INDICATIONS</a></h3>

<li>angina </li>

<li>anxiety+ </li>

<li>atrial fibrillation </li>

<li>atrial flutter </li>

<li>esophageal varices+ </li>

<li>ethanol withdrawal+ </li>

<li>glaucoma </li>

<li>hypertension </li>

<li>hypertensive emergency+ </li>

<li>hypotension induction+ </li>

<li>idiopathic hypertrophic subaortic stenosis </li>

<li>migraine prophylaxis </li>

<li>myocardial infarction prophylaxis </li>

<li>myocardial infarction </li>

<li>ocular hypertension </li>

<li>paroxysmal supraventricular tachycardia </li>

<li>perioperative hypertension+ </li>

<li>pheochromocytoma </li>

<li>portal hypertension+ </li>

<li>scleroderma renal crisis + </li>

<li>thyrotoxicosis </li>

<li>tremor </li>

<li>variceal bleeding prophylaxis+ </li>

<li>ventricular arrhythmias </li>

<dl>
<dd>+ = not an FDA approved indication</dd>
</dl>

<p>
<hr><a href="#top">Return to Top</a> 
<hr></p>

<h3><a href="disclaim.htm#side">Side Effects and Adverse Reactions</a></h3>

<li>agranulocytosis </li>

<li>alopecia </li>

<li>angina </li>

<li>arthralgias </li>

<li>asthenia </li>

<li>AV block </li>

<li>bronchospasm </li>

<li>cardiac arrest </li>

<li>depression </li>

<li>diaphoresis </li>

<li>diarrhea </li>

<li>dizziness </li>

<li>dyspepsia </li>

<li>dyspnea </li>

<li>edema </li>

<li>ejaculation dysfunction </li>

<li>elevated hepatic enzymes </li>

<li>exfoliative dermatitis </li>

<li>fatigue </li>

<li>hallucinations </li>

<li>headache </li>

<li>heart failure </li>

<li>hepatic necrosis </li>

<li>hyperglycemia </li>

<li>hypoglycemia </li>

<li>hypotension </li>

<li>impotence </li>

<li>insomnia </li>

<li>jaundice </li>

<li>lacrimation </li>

<li>libido decrease </li>

<li>myalgia </li>

<li>nausea/vomiting </li>

<li>nightmares </li>

<li>ocular irritation </li>

<li>orthostatic hypotension </li>

<li>paresthesias </li>

<li>peripheral vasoconstriction </li>

<li>peripheral edema </li>

<li>pharyngitis </li>

<li>priapism </li>

<li>pruritus </li>

<li>QT prolongation </li>

<li>sinus bradycardia </li>

<li>skin hyperpigmentation </li>

<li>syncope </li>

<li>torsade de pointes </li>

<li>urinary retention </li>

<li>ventricular fibrillation </li>

<li>ventricular tachycardia </li>

<li>wheezing </li>

<li>xerosis 
<hr width="100%" ><a href="#top">Return to Top</a> 
<hr><font SIZE=+2><a href="http://www.rxlist.com/disclaim.htm">Important
- Please Read!</a> </font></li>

<h4 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">Search
RxList</a> <img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com/mono.htm">RxLists
of Indications and Side Effects</a> <img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">Rxlist
Home Page</a> </h4>

<center><p><font SIZE=-2>copyright 1996 Neil Sandow, Pharm.D. - all rights
reserved </font></p></center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-39</DOCNO>
<DOCOLDNO>IA018-000200-B036-34</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/oxyapap.htm 206.86.175.201 19970106225026 text/html 12443
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:44:12 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 12260
Last-modified: Sun, 11 Aug 1996 03:45:59 GMT
</DOCHDR>
<html>
<head>
   <title>Oxycodone and Acetaminophen - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Oxycodone and Acetaminophen</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

 <a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <p>
Acetaminophen occurs as a white, odorless, crystalline powder, possessing a
slightly bitter taste.  
 <p>
The oxycodone component is 14-hydroxydihydrocodeinone, a white, odorless,
crystalline powder having a saline, bitter taste. It is derived from the opium
alkaloid thebaine.  
 <p>
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 
</b> <p>
The principal ingredient, oxycodone, is a semisynthetic narcotic analgesic with 
multiple actions qualitatively similar to those of morphine; the most prominent 
of these involve the central nervous system and organs composed of smooth
muscle. The principal actions of therapeutic value of the oxycodone in Oxycodone 
and acetaminophen are analgesia and sedation.  
 <p>
Oxycodone is similar to codeine and methadone in that it retains at least one
half of its analgesic activity when administered orally.  
 <p>
Acetaminophen is a non-opiate, non-salicylate analgesic and antipyretic.  
 <p>
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
Oxycodone and acetaminophen is indicated for the relief of moderate to moderately severe pain.  
 <p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <p>
Oxycodone and acetaminophen should not be administered to patients who are hypersensitive to
oxycodone or acetaminophen.  
 <p>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <p>
DRUG DEPENDENCE: Oxycodone can produce drug dependence of the morphine type and 
therefore, has the potential for being abused. Psychic dependence, physical
dependence and tolerance may develop upon repeated administration of Oxycodone and
acetaminophen, and it should be prescribed and administered with the same degree of caution
appropriate to the use of other oral narcotic-containing medications. Like
other narcotic-containing medications, Oxycodone and acetaminophen is subject to the Federal
Controlled Substances Act (Schedule II).  
 <p>
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
GENERAL 
 <p>
HEAD INJURY AND INCREASED INTRACRANIAL PRESSURE: The respiratory depressant
effects of narcotics and their capacity to elevate cerebrospinal fluid pressure 
may be markedly exaggerated in the presence of head injury, other intracranial
lesions or a pre-existing increase in intracranial pressure. Furthermore,
narcotics produce adverse reactions which may obscure the clinical course of
patients with head injuries.  
 <p>
ACUTE ABDOMINAL CONDITIONS: The administration of Oxycodone and acetaminophen or other narcotics
may obscure the diagnosis or clinical course in patients with acute abdominal
conditions.  
 <p>
SPECIAL RISK PATIENTS: Oxycodone and acetaminophen should be given with caution to certain
patients such as the elderly or debilitated, and those with severe impairment
of hepatic or renal function, hypothyroidism, Addison's disease, and prostatic
hypertrophy or urethral stricture.  
 <p>
INFORMATION FOR PATIENTS Oxycodone may impair the mental and/or physical
abilities required for the performance of potentially hazardous tasks such as
driving a car or operating machinery. The patient using Oxycodone and acetaminophen should be
cautioned accordingly.  
 <p>
DRUG INTERACTIONS Patients receiving other narcotic analgesics, general
anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics or other
CNS depressants (including alcohol) concomitantly with Oxycodone and acetaminophen may exhibit
an additive CNS depression. When such combined therapy is contemplated, the dose
of one or both agents should be reduced.  
 <p>
The use of MAO inhibitors or tricyclic antidepressants with oxycodone
preparations may increase the effect of either the antidepressant or oxycodone. 
 <p>
The concurrent use of anticholinergics with narcotics may produce paralytic
ileus.  
 <p>
USAGE IN PREGNANCY Pregnancy Category C: Animal reproductive studies have not
been conducted with Oxycodone and acetaminophen. It is also not known whether Oxycodone and
acetaminophen can cause fetal harm when administered to a pregnant woman or can affect 
reproductive capacity. Oxycodone and acetaminophen should not be given to a pregnant woman 
unless in the judgment of the physician, the potential benefits outweigh the possible
hazards.  
                            <p>
Nonteratogenic Effects: Use of narcotics during pregnancy may produce physical
dependence in the neonate.  
 <p>
Labor and Delivery: As with all narcotics, administration of Oxycodone and acetaminophen to the
mother shortly before delivery may result in some degree of respiratory
depression in the newborn and the mother, especially if higher doses are used.  
 <p>
NURSING MOTHERS It is not known whether Oxycodone and acetaminophen is excreted in human milk. 
Because many drugs are excreted in human milk, caution should be exercised when 
Oxycodone and acetaminophen is administered to a nursing woman.  
 <p>
PEDIATRIC USE Safety and effectiveness in children have not been established. 
 <p>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <p>
Patients receiving other narcotic analgesics, general anesthetics,
phenothiazines, other tranquilizers, sedative-hypnotics or other CNS
depressants (including alcohol) concomitantly with Oxycodone and acetaminophen may exhibit an
additive CNS depression. When such combined therapy is contemplated, the dose
of one or both agents should be reduced.  
 <p>
The use of MAO inhibitors or tricyclic antidepressants with oxycodone
preparations may increase the effect of either the antidepressant or oxycodone. 
 <p>
The concurrent use of anticholinergics with narcotics may produce paralytic
ileus.  
 
(See Also PRECAUTIONS) <p>
 
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
The most frequently observed adverse reactions include lightheadedness,
dizziness, sedation, nausea and vomiting. These effects seem to be more
prominent in ambulatory than in nonambulatory patients, and some of these
adverse reactions may be alleviated if the patient lies down.  
 <p>
Other adverse reactions include euphoria, dysphoria, constipation, skin rash
and pruritus. At higher doses, oxycodone has most of the disadvantages of
morphine including respiratory depression.  
 <p>
DRUG ABUSE AND DEPENDENCE 
 <p>
Oxycodone and acetaminophen Tablets are a Schedule II controlled substance.  
 <p>
Oxycodone can produce drug dependence and has the potential for being abused. 
(See WARNINGS.) 
 <p>
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <p>
ACETAMINOPHEN 
                            <p>
SIGNS AND SYMPTOMS: In acute acetaminophen overdosage, dose-dependent,
potentially fatal hepatic necrosis is the most serious adverse effect. Renal
tubular necrosis, hypoglycemic coma and thrombocytopenia may also occur.  
 <p>
In adults, hepatic toxicity has rarely been reported with acute overdoses of
less than 10 grams and fatalities with less than 15 grams. Importantly, young
children seem to be more resistant than adults to the hepatotoxic effect of an
acetaminophen overdose. Despite this, the measures outlined below should be
initiated in any adult or child suspected of having ingested an acetaminophen
overdose.  
 <p>
Early symptoms following a potentially hepatotoxic overdose may include: nausea 
vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of
hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.  
 <p>
TREATMENT: The stomach should be emptied promptly by lavage or by induction of
emesis with syrup of ipecac. Patient's estimates of the quantity of a drug
ingested are notoriously unreliable. Therefore, if an acetaminophen overdose is 
suspected, a serum acetaminophen assay should be obtained as early as possible, 
but no sooner than four hours following ingestion. Liver function studies
should be obtained initially and repeated at 24-hour intervals.  
 <p>
The antidote, N-acetylcysteine, should be administered as early as possible,
preferably within 16 hours of the overdose ingestion for optimal results, but
in any case, within 24 hours. Following recovery, there are no residual,
structural, or functional hepatic abnormalities.  
 <p>
OXYCODONE 
 <p>
SIGNS AND SYMPTOMS: Serious overdosage with oxycodone is characterized by
respiratory depression (a decrease in respiratory rate and or tidal volume,
Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor
or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes
bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, 
cardiac arrest and death may occur.  
 <p>
TREATMENT: Primary attention should be given to the reestablishment of adequate 
respiratory exchange through provision of a patent airway and the institution
of assisted or controlled ventilation. The narcotic antagonist naloxone
hydrochloride (Narcan(R)) is a specific antidote against respiratory depression 
which may result from overdosage or unusual sensitivity to narcotics, including 
oxycodone. Therefore, an appropriate dose of naloxone hydrochloride (usual
initial adult dose 0.4 mg to 2 mg) should be administered preferably by the
intravenous route, and simultaneously with efforts at respiratory resuscitation 
(see package insert). Since the duration of action of oxycodone may exceed that 
of the antagonist, the patient should be kept under continued surveillance and
repeated doses of the antagonist should be administered as needed to maintain
adequate respiration.  
 <p>
An antagonist should not be administered in the absence of clinically
significant respiratory or cardiovascular depression. Oxygen, intravenous
fluids, vasopressors and other supportive measures should be employed as
indicated.  
 <p>
Gastric emptying may be useful in removing unabsorbed drug.  
 <p>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
Dosage should be adjusted according to the severity of the pain and the
response of the patient. It may occasionally be necessary to exceed the usual
dosage recommended below in cases of more severe pain or in those patients who
have become tolerant to the analgesic effect of narcotics. Oxycodone and acetaminophen
is given orally. The usual adult dosage is one tablet every 6 hours as needed for pain.  
 
<p>
<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-40</DOCNO>
<DOCOLDNO>IA018-000200-B039-190</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/nefaz.htm 206.86.175.201 19970106230312 text/html 58100
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:56:56 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 57917
Last-modified: Tue, 01 Oct 1996 06:21:16 GMT
</DOCHDR>
<html>
<head>
   <title>Nefazodone - RxList Generic Information</title>
   <meta name="keywords" content="Serzone">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Nefazodone</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Nefazodone is an antidepressant for oral administration with a chemical
structure unrelated to selective serotonin reuptake inhibitors, tricyclics,
tetracyclics, or monoamine oxidase inhibitors (MAOI). Nefazodone hydrochloride
is a synthetically derived phenylpiperazine antidepressant. The chemical
name for nefazodone hydrochloride is 2-(3-(4-(3- chlorophenyl)-1-piperazinyl)-propyl)-5
-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-- 3H- 1,2,4-triazol-3-one monohydrochloride.
The molecular formula is C25H32CIN5O2.HCl, which corresponds to a molecular
weight of 506.5. </p>

<p>Nefazodone hydrochloride is a nonhygroscopic, white crystalline solid.
It is freely soluble in chloroform, soluble in propylene glycol, and slightly
soluble in polyethylene glycol and water. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>PHARMACODYNAMICS </p>

<p>The mechanism of action of nefazodone, as with other antidepressants,
is unknown. </p>

<p>Preclinical studies have shown that nefazodone inhibits neuronal uptake
of serotonin and norepinephrine. </p>

<p>Nefazodone occupies central 5-HT2 receptors at nanomolar concentrations,
and acts as an antagonist at this receptor. Nefazodone was shown to antagonize
alpha1-adrenergic receptors, a property which may be associated with postural
hypotension. In Vitro binding studies showed that nefazodone had no significant
affinity for the following receptors: alpha2 and beta adrenergic, 5-HT1A,
cholinergic, dopaminergic, or benzodiazepine. </p>

<p>PHARMACOKINETICS </p>

<p>Nefazodone hydrochloride is rapidly and completely absorbed but is subject
to extensive metabolism, so that its absolute bioavailability is low, about
20%, and variable. Peak plasma concentrations occur at about one hour and
the half- life of nefazodone is 2-4 hours. </p>

<p>Both nefazodone and its pharmacologically similar metabolite, hydroxynefazodone,
exhibit nonlinear kinetics for both dose and time, with AUC and Cmax increasing
more than proportionally with dose increases and more than expected upon
multiple dosing over time, compared to single dosing. For example, in a
multiple-dose study involving BID dosing with 50, 100, and 200 mg, the
AUC for nefazodone and hydroxynefazodone increased by about 4-fold with
an increase in dose from 200 to 400 mg per day; Cmax increased by about
3-fold with the same dose increase. In a multiple-dose study involving
BID dosing with 25, 50, 100, and 150 mg, the accumulation ratios for nefazodone
and hydroxynefazodone AUC, after 5 days of BID dosing relative to the first
dose, ranged from approximately 3 to 4 at the lower doses (50-100 mg/day)
and from 5 to 7 at the higher doses (200-300 mg/day); there were also approximately
2- to 4-fold increases in Cmax after 5 days of BID dosing relative to the
first dose, suggesting extensive and greater than predicted accumulation
of nefazodone and its hydroxy metabolite with multiple dosing. Steady-
state plasma nefazodone and metabolite concentrations are attained within
4 to 5 days of initiation of BID dosing or upon dose increase or decrease.
</p>

<p>Nefazodone is extensively metabolized after oral administration by n-
dealkylation and aliphatic and aromatic hydroxylation, and less than 1%
of administered nefazodone is excreted unchanged in urine. Attempts to
characterize three metabolites identified in plasma, hydroxynefazodone
(HO-NEF), meta- chlorophenylpiperazine (mCPP), and a triazole-dione metabolite,
have been carried out. The AUC (expressed as a multiple of the AUC for
nefazodone dosed at 100 mg BID) and elimination half-lives for these three
metabolites were as follows: </p>

<pre>-----------------------------------------------------------------------------
         AUC Multiples and T1/2 for
Three Metabolites of Nefazodone (100 mg BID)
-----------------------------------------------------------------------------
Metabolite      AUC Multiple      T1/2
-----------------------------------------------------------------------------
  HO-NEF            0.4        1.5-4 hrs
-----------------------------------------------------------------------------
   mCPP             0.07         4-8 hrs
-----------------------------------------------------------------------------
Triazole-dione      4.0           18 hrs
-----------------------------------------------------------------------------</pre>

<p>HO-NEF possesses a pharmacological profile qualitatively and quantitatively
similar to that of nefazodone. mCPP has some similarities to nefazodone,
but also has agonist activity at some serotonergic receptor subtypes. The
pharmacological profile of the triazole-dione metabolite has not yet been
well characterized. In addition to the above compounds, several other metabolites
were present in plasma but have not been tested for pharmacological activity.
After oral administration of radiolabelled nefazodone, the mean half-life
of total label ranged between 11 and 24 hours. Approximately 55% of the
administered radioactivity was detected in urine and about 20-30% in feces.
Distribution--Nefazodone is widely distributed in body tissues, including
the central nervous system (CNS). In humans the volume of distribution
of nefazodone ranges from 0.22 to 0.87 l/kg. </p>

<p>Protein Binding--At concentrations of 25-2500 ng/mL nefazodone is extensively
(&gt;99%) bound to human plasma proteins In Vitro. While nefazodone did
not alter the In Vitro protein binding of chlorpromazine, desipramine,
diazepam, diphenylhydantoin, lidocaine, prazosin, propranolol, verapamil,
or warfarin, it is unknown whether or not displacement of either nefazodone
or other drugs occurs In Vivo. There was a 5% decrease in the protein binding
of haloperidol; this is probably of no clinical significance. </p>

<p>Effect Of Food--Food delays the absorption of nefazodone and decreases
the bioavailability of nefazodone by approximately 20%. </p>

<p>Renal Disease--In studies involving 29 renally- impaired patients, renal
impairment (creatinine clearances ranging from 7 to 60 mL/min/1.73M(squared))
had no effect on steady-state nefazodone plasma concentrations. Liver Disease--In
a multiple-dose study of patients with liver cirrhosis, the AUC values
for nefazodone and HO-NEF at steady state were approximately 25% greater
than those observed in normal volunteers. </p>

<p>Age/Gender Effects--After single doses of 300 mg to younger and older
patients, Cmax and AUC for nefazodone and hydroxynefazodone were up to
twice as high in the older patients. With multiple doses, however, differences
were much smaller, 10-20%. A similar result was seen for gender, with a
higher Cmax and AUC in women after single doses but no difference after
multiple doses. </p>

<p>Treatment with Nefazodone should be initiated at half the usual dose
in elderly patients, especially women (see DOSAGE AND ADMINISTRATION Section),
but the therapeutic dose range is similar in younger and older patients.
</p>

<p>CLINICAL TRIALS SUPPORTING THE EFFECTIVENESS CLAIM </p>

<p>The efficacy of Nefazodone as a treatment for depression was established
in two placebo-controlled, short-term trials in outpatients meeting DSM-III
or DSM-IIIR criteria for major depression. One was a 6-week dose-titration
study comparing Nefazodone in two dose ranges (up to 300 mg/day and up
to 600 mg/day (mean modal dose for this group was about 400 mg/day), on
a BID schedule) and placebo. The other was an 8-week dose-titration study
comparing Nefazodone (up to 600 mg/day; mean modal dose was 375 mg/day),
imipramine (up to 300mg/day), and placebo, all on a BID schedule. Overall,
these studies demonstrated Nefazodone, at doses titrated up to 600 mg/day,
to be superior to placebo on at least three of the following four measures:
17-Item Hamilton Depression Rating Scale or HDRS (total score), Hamilton
Depressed Mood item, CGI Severity score, and CGI Improvement score. Significant
differences were also found for certain factors of the HDRS (e.g., anxiety
factor, sleep disturbance factor, and retardation factor). Two other 6-8
week placebo- and imipramine- controlled studies in depressed outpatients
provided additional support for the superiority of nefazodone (titrated
up to 500 or 600 mg/day; mean modal doses of 462 mg/day and 363 mg/day)
over placebo. </p>

<p>There were no efficacy studies focusing specifically on the elderly
or on men and women separately. Overall, approximately two-thirds of patients
in these trials were women, and an analysis of the effects of gender on
outcome did not suggest any differential responsiveness on the basis of
sex. There were too few elderly patients in these trials to reveal possible
age- related differences in response. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Nefazodone is indicated for the treatment of depression. </p>

<p>The efficacy of Nefazodone in the treatment of depression was established
in 6-8 week controlled trials of outpatients whose diagnoses corresponded
most closely to the DSM-III or DSM- IIIR category of major depressive disorder
(see CLINICAL PHARMACOLOGY Section). </p>

<p>A major depressive episode implies a prominent and relatively persistent
depressed or dysphoric mood that usually interferes with daily functioning
(nearly every day for at least 2 weeks). It must include either depressed
mood or loss of interest or pleasure and at least 5 of the following 9
symptoms: depressed mood, loss of interest in usual activities, significant
change in weight and/or appetite, insomnia or hypersomnia, psychomotor
agitation or retardation, increased fatigue, feelings of guilt or worthlessness,
slowed thinking or impaired concentration, a suicide attempt or suicidal
ideation. The antidepressant effectiveness of Nefazodone in hospitalized
depressed patients has not been adequately studied. </p>

<p>The effectiveness of Nefazodone in long-term use, that is, for more
than 6 to 8 weeks, has not been systematically evaluated in controlled
trials. Therefore, the physician who elects to use Nefazodone for extended
periods should periodically re-evaluate the long-term usefulness of the
drug for the individual patient. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Coadministration of terfenadine or astemizole with Nefazodone (nefazodone
hydrochloride) is contraindicated (see WARNINGS and PRECAUTIONS Sections).
Nefazodone is contraindicated in patients with known hypersensitivity to
nefazodone or other phenylpiperazine antidepressants. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>POTENTIAL FOR INTERACTION WITH MONOAMINE OXIDASE INHIBITORS IN PATIENTS
RECEIVING ANTIDEPRESSANTS WITH PHARMACOLOGICAL PROPERTIES SIMILAR TO NEFAZODONE
IN COMBINATION WITH A MONOAMINE OXIDASE INHIBITOR (MAOI), THERE HAVE BEEN
REPORTS OF SERIOUS, SOMETIMES FATAL, REACTIONS. FOR A SELECTIVE SEROTONIN
REUPTAKE INHIBITOR, THESE REACTIONS HAVE INCLUDED HYPERTHERMIA, RIGIDITY,
MYOCLONUS, AUTONOMIC INSTABILITY WITH POSSIBLE RAPID FLUCTUATIONS OF VITAL
SIGNS, AND MENTAL STATUS CHANGES THAT INCLUDE EXTREME AGITATION PROGRESSING
TO DELIRIUM AND COMA. THESE REACTIONS HAVE ALSO BEEN REPORTED IN PATIENTS
WHO HAVE RECENTLY DISCONTINUED THAT DRUG AND HAVE BEEN STARTED ON A MAOI.
SOME CASES PRESENTED WITH FEATURES RESEMBLING NEUROLEPTIC MALIGNANT SYNDROME.
SEVERE HYPERTHERMIA AND SEIZURES, SOMETIMES FATAL, HAVE BEEN REPORTED IN
ASSOCIATION WITH THE COMBINED USE OF TRICYCLIC ANTIDEPRESSANTS AND MAOIS.
THESE REACTIONS HAVE ALSO BEEN REPORTED IN PATIENTS WHO HAVE RECENTLY DISCONTINUED
THESE DRUGS AND HAVE BEEN STARTED ON AN MAOI. ALTHOUGH THE EFFECTS OF COMBINED
USE OF NEFAZODONE AND MAOI HAVE NOT BEEN EVALUATED IN HUMANS OR ANIMALS,
BECAUSE NEFAZODONE IS AN INHIBITOR OF BOTH SEROTONIN AND NOREPINEPHRINE
REUPTAKE, IT IS RECOMMENDED THAT NEFAZODONE NOT BE USED IN COMBINATION
WITH AN MAOI, OR WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH AN MAOI.
AT LEAST 1 WEEK SHOULD BE ALLOWED AFTER STOPPING NEFAZODONE BEFORE STARTING
A MAOI. </p>

<p>INTERACTION WITH TRIAZOLOBENZODIAZEPINES </p>

<p>Interaction studies of nefazodone with two triazolobenzodiazepines,
i.e., triazolam and alprazolam, metabolized by cytochrome P450IIIA4, have
revealed substantial and clinically important increases in plasma concentrations
of these compounds when administered concomitantly with nefazodone. </p>

<p>Triazolam </p>

<p>When a single oral 0.25-mg dose of triazolam was coadministered with
nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased
4-fold and peak concentrations increased 1.7-fold. Nefazodone plasma concentrations
were unaffected by triazolam. COADMINISTRATION OF NEFAZODONE POTENTIATED
THE EFFECTS OF TRIAZOLAM ON PSYCHOMOTOR PERFORMANCE TESTS. If triazolam
is coadministered with Nefazodone, a 75% reduction in the initial triazolam
dosage is recommended. </p>

<p>For many patients, e.g., the elderly, it is recommended that triazolam
not be used in combination with nefazodone. No dosage adjustment is required
for Nefazodone. </p>

<p>Alprazolam </p>

<p>When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered,
steady-state peak concentrations, AUC and half-life values for alprazolam
increased by approximately 2-fold. Nefazodone plasma concentrations were
unaffected by alprazolam. If alprazolam is coadministered with Nefazodone,
a 50% reduction in the initial alprazolam dosage is recommended. No dosage
adjustment is required for Nefazodone. </p>

<p>POTENTIAL TERFENADINE AND ASTEMIZOLE INTERACTIONS TERFENADINE AND ASTEMIZOLE
ARE BOTH METABOLIZED BY THE CYTOCHROME P450IIIA4 ISOZYME, AND IT HAS BEEN
DEMONSTRATED THAT KETOCONAZOLE, ERYTHROMYCIN, AND OTHER INHIBITORS OF IIIA4
CAN BLOCK THE METABOLISM OF TERFENADINE AND ASTEMIZOLE, RESULTING IN INCREASED
PLASMA CONCENTRATIONS OF PARENT DRUG. INCREASED PLASMA CONCENTRATIONS OF
TERFENADINE AND ASTEMIZOLE ARE ASSOCIATED WITH QT PROLONGATION AND WITH
RARE CASES OF SERIOUS CARDIOVASCULAR ADVERSE EVENTS, INCLUDING DEATH, DUE
PRINCIPALLY TO VENTRICULAR TACHYCARDIA OF THE TORSADES DE POINTES TYPE.
NEFAZODONE HAS BEEN SHOWN In Vitro TO BE AN INHIBITOR OF IIIA4. CONSEQUENTLY,
IT IS RECOMMENDED THAT NEFAZODONE NOT BE USED IN COMBINATION WITH EITHER
TERFENADINE OR ASTEMIZOLE (SEE CONTRAINDICATIONS AND PRECAUTIONS SECTIONS).
</p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL </p>

<p>Postural Hypotension </p>

<p>A pooled analysis of the vital signs monitored during placebo-controlled
premarketing studies revealed that 5.1% of nefazodone patients compared
to 2.5% of placebo patients (p &lt; or = 0.01) met criteria for a potentially
important decrease in blood pressure at some time during treatment (systolic
blood pressure &lt; or = 90 mmHg And a change from baseline of &gt;/=20
mmHg). While there was no difference in the proportion of nefazodone and
placebo patients having adverse events characterized as 'syncope' (nefazodone,
0.2%; placebo, 0.3%), the rates for adverse events characterized as 'postural
hypotension' were as follows: nefazodone (2.8%), tricyclic antidepressants
(10.9%), SSRI (1.1%), and placebo (0.8%). Thus, the prescriber should be
aware that there is some risk of postural hypotension in association with
nefazodone use. Nefazodone should be used with caution in patients with
known cardiovascular or cerebrovascular disease that could be exacerbated
by hypotension (history of myocardial infarction, angina, or ischemic stroke)
and conditions that would predispose patients to hypotension (dehydration,
hypovolemia, and treatment with antihypertensive medication). </p>

<p>Activation Of Mania/Hypomania </p>

<p>During premarketing testing, hypomania or mania occurred in 0.3% of
nefazodone- treated unipolar patients, compared to 0.3% of tricyclic- and
0.4% of placebo- treated patients. In patients classified as bipolar the
rate of manic episodes was 1.6% for nefazodone, 5.1% for the combined tricyclic-treated
groups, and 0% for placebo- treated patients. Activation of mania/hypomania
is a known risk in a small proportion of patients with major affective
disorder treated with other marketed antidepressants. As with all antidepressants,
Nefazodone (nefazodone hydrochloride) should be used cautiously in patients
with a history of mania. Suicide The possibility of a suicide attempt is
inherent in depression and may persist until significant remission occurs.
Close supervision of high risk patients should accompany initial drug therapy.
Prescriptions for Nefazodone should be written for the smallest quantity
of tablets consistent with good patient management in order to reduce the
risk of overdose. </p>

<p>Seizures </p>

<p>During premarketing testing, a recurrence of a petit mal seizure was
observed in a patient receiving nefazodone who had a history of such seizures.
One nonstudy participant took 2000-3000mg of nefazodone with methocarbamol
and alcohol; this person reportedly experienced a convulsion (type not
documented). </p>

<p>Priapism </p>

<p>While priapism did not occur during premarketing experience with nefazodone,
priapism has been reported with a structurally related drug, trazodone.
If patients present with prolonged or inappropriate erections, they should
discontinue therapy immediately and consult their physicians. If the condition
persists for more than 24 hours, a urologist should be consulted to determine
appropriate management. </p>

<p>Use In Patients With Concomitant Illness </p>

<p>Nefazodone has not been evaluated or used to any appreciable extent
in patients with a recent history of myocardial infarction or unstable
heart disease. Patients with these diagnoses were systematically excluded
from clinical studies during the product's premarketing testing. Evaluation
of electrocardiograms of 1153 patients who received nefazodone in 6- to
8-week, double- blind, placebo- controlled trials did not indicate that
nefazodone is associated with the development of clinically important ECG
abnormalities. However, sinus bradycardia, defined as heart rate &lt; or
= 50 bpm and a decrease of at least 15 bpm from baseline, was observed
in 1.5% of nefazodone-treated patients compared to 0.4% of placebo-treated
patients (p &lt; or = 0.05). Because patients with a recent history of
myocardial infarction or unstable heart disease were excluded from clinical
trials, such patients should be treated with caution. In patients with
cirrhosis of the liver, the AUC values of nefazodone and HO-NEF were increased
by approximately 25%. </p>

<p>INFORMATION FOR PATIENTS </p>

<p>Physicians are advised to discuss the following issues with patients
for whom they prescribe Nefazodone: </p>

<p>Time To Response/Continuation </p>

<p>As with all antidepressants, several weeks on treatment may be required
to obtain the full antidepressant effect. Once improvement is noted, it
is important for patients to continue drug treatment as directed by their
physician. </p>

<p>Interference With Cognitive And Motor Performance </p>

<p>Since any psychoactive drug may impair judgment, thinking, or motor
skills, patients should be cautioned about operating hazardous machinery,
including automobiles, until they are reasonably certain that Nefazodone
therapy does not adversely affect their ability to engage in such activities.
</p>

<p>Pregnancy </p>

<p>Patients should be advised to notify their physician if they become
pregnant or intend to become pregnant during therapy. </p>

<p>Nursing </p>

<p>Patients should be advised to notify their physician if they are breast-feeding
an infant (see PRECAUTIONS Section, NURSING MOTHERS Subsection). </p>

<p>Concomitant Medication </p>

<p>Patients should be advised to inform their physicians if they are taking,
or plan to take, any prescription or over-the-counter drugs, since there
is a potential for interactions. Significant caution is indicated if Nefazodone
is to be used in combination with either Halcion or Xanax, and concomitant
use with Seldane or Hismanal is contraindicated (see CONTRAINDICATIONS
and WARNINGS Sections). </p>

<p>Alcohol </p>

<p>Patients should be advised to avoid alcohol while taking Nefazodone.
</p>

<p>Allergic Reactions </p>

<p>Patients should be advised to notify their physician if they develop
a rash, hives, or a related allergic phenomenon. </p>

<p>LABORATORY TESTS </p>

<p>There are no specific laboratory tests recommended. </p>

<p>DRUG INTERACTIONS </p>

<p>Drugs Highly Bound To Plasma Protein </p>

<p>Because nefazodone is highly bound to plasma protein (see CLINICAL PHARMACOLOGY
Section, PHARMACOKINETICS Subsection), administration of Nefazodone to
a patient taking another drug that is highly protein bound may cause increased
free concentrations of the other drug, potentially resulting in adverse
events. Conversely, adverse effects could result from displacement of nefazodone
by other highly bound drugs. </p>

<p>CNS Active Drugs </p>

<p>Monoamine Oxidase Inhibitors--See WARNINGS Section </p>

<p>Haloperidol--When a single oral 5-mg dose of haloperidol was coadministered
with nefazodone (200 mg BID) at steady state, haloperidol apparent clearance
decreased by 35% with no significant increase in peak haloperidol plasma
concentrations or time of peak. This change is of unknown clinical significance.
Pharmacodynamic effects of haloperidol were generally not altered significantly.
There were no changes in the pharmacokinetic parameters for nefazodone.
Dosage adjustment of haloperidol may be necessary when coadministered with
nefazodone. </p>

<p>Lorazepam--When lorazepam (2 mg BID) and nefazodone (200 mg BID) were
coadministered to steady state, there was no change in any pharmacokinetic
parameter for either drug compared to each drug administered alone. Therefore,
dosage adjustment is not necessary for either drug when coadministered.
Triazolam/Alprazolam--See WARNINGS Section </p>

<p>Alcohol--Although nefazodone did not potentiate the cognitive and psychomotor
effects of alcohol in experiments with normal subjects, the concomitant
use of Nefazodone and alcohol in depressed patients is not advised. </p>

<p>General Anesthetics--Little is known about the potential for interaction
between nefazodone and general anesthetics; therefore, prior to elective
surgery, Nefazodone should be discontinued for as long as clinically feasible.
</p>

<p>Other CNS Active Drugs--The use of nefazodone in combination with other
CNS- active drugs has not been systematically evaluated. Consequently,
caution is advised if concomitant administration of Nefazodone and such
drugs is required. </p>

<p>Cimetidine </p>

<p>When nefazodone (200 mg BID) and cimetidine (300 mg QID) were coadministered
for one week, no change in the steady-state pharmacokinetics of either
nefazodone or cimetidine was observed compared to each dosed alone. Therefore,
dosage adjustment is not necessary for either drug when coadministered.
</p>

<p>Cardiovascular Active Drugs </p>

<p>Digoxin--When nefazodone (200 mg BID) and digoxin (0.2 mg QD) were coadministered
for 9 days to healthy male volunteers (n=18) who were phenotyped as P450IID6
extensive metabolizers, Cmax, Cmin, and AUC of digoxin were increased by
29%, 27%, and 15%, respectively. Digoxin had no effects on the pharmacokinetics
of nefazodone and its active metabolites. Because of the narrow therapeutic
index of digoxin, caution should be exercised when nefazodone and digoxin
are coadministered; plasma level monitoring for digoxin is recommended.
</p>

<p>Propranolol--The coadministration of nefazodone (200 mg BID) and propranolol
(40 mg BID) for 5.5 days to healthy male volunteers (n=18), including 3
poor and 15 extensive P450IID6 metabolizers, resulted in 30% and 14% reductions
in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax
for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone,
and triazole-dione were not affected by coadministration of propranolol.
However, Cmax, Cmin, and AUC of m- chlorophenylpiperazine were increased
by 23%, 54%, and 28%, respectively. No change in initial dose of either
drug is necessary and dose adjustments should be made on the basis of clinical
response. </p>

<p>Pharmacokinetics Of Nefazodone In 'Poor Metabolizers' And Potential
Interaction With Drugs That Inhibit And/Or Are Metabolized By Cytochrome
P450 Isozymes IIIA4 Isozyme--Nefazodone has been shown In Vitro to be an
inhibitor of cytochrome P450IIIA4. This is consistent with the interaction
observed between nefazodone and the benzodiazepines triazolam and alprazolam,
drugs metabolized by this isozyme. Consequently, caution is indicated in
the combined use of nefazodone with any drugs known to be metabolized by
the IIIA4 isozyme. In particular, the combined use of nefazodone with either
terfenadine or astemizole is contraindicated (see CONTRAINDICATIONS and
WARNINGS Sections). </p>

<p>IID6 Isozyme--A subset (3% to 10%) of the population has reduced activity
of the drug- metabolizing enzyme cytochrome P450IID6. Such individuals
are referred to commonly as &quot;poor metabolizers&quot; of drugs such
as debrisoquin, dextromethorphan, and the tricyclic antidepressants. The
pharmacokinetics of nefazodone and its major metabolites are not altered
in these &quot;poor metabolizers.&quot; Plasma concentrations of one minor
metabolite (mCPP) are increased in this population; the adjustment of Nefazodone
dosage is not required when administered to &quot;poor metabolizers.&quot;
Nefazodone and its metabolites have been shown In Vitro to be extremely
weak inhibitors of P450IID6. Thus, it is not likely that nefazodone will
decrease the metabolic clearance of drugs metabolized by this isozyme.
IA2 Isozyme--Nefazodone and its metabolites have been shown In Vitro not
to inhibit cytochrome P450IA2. Thus, metabolic interactions between nefazodone
and drugs metabolized by this isozyme are unlikely. </p>

<p>Electro-Convulsive Therapy (ECT) </p>

<p>There are no clinical studies of the combined use of ECT and nefazodone.
</p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY </p>

<p>Carcinogenesis </p>

<p>There is no evidence of carcinogenicity with nefazodone. The dietary
administration of nefazodone to rats and mice for 2 years at daily doses
of up to 200 mg/kg and 800 mg/kg, respectively, which are approximately
3 and 6 times, respectively, the maximum human daily dose on a mg/M(squared)
basis, produced no increase in tumors. </p>

<p>Mutagenesis </p>

<p>Nefazodone has been shown to have no genotoxic effects based on the
following assays: bacterial mutation assays, a DNA repair assay in cultured
rat hepatocytes, a mammalian mutation assay in Chinese hamster ovary cells,
an In Vivo cytogenetics assay in rat bone marrow cells, and a rat dominant
lethal study. </p>

<p>Impairment Of Fertility </p>

<p>A fertility study in rats showed a slight decrease in fertility at 200
mg/kg/day (approximately three times the maximum human daily dose on a
mg/M(squared) basis) but not at 100 mg/kg/day (approximately 1.5 times
the maximum human daily dose on a mg/M(squared) basis). </p>

<p>PREGNANCY </p>

<p>Teratogenic Effects--Pregnancy Category C </p>

<p>Reproduction studies have been performed in pregnant rabbits and rats
at daily doses up to 200 and 300 mg/kg, respectively (approximately 6 and
5 times, respectively, the maximum human daily dose on a mg/M(squared)
basis). No malformations were observed in the offspring as a result of
nefazodone treatment. However, increased early pup mortality was seen in
rats at a dose approximately five times the maximum human dose, and decreased
pup weights were seen at this and lower doses, when dosing began during
pregnancy and continued until weaning. The cause of these deaths is not
known. The no-effect dose for rat pup mortality was 1.3 times the human
dose on a mg/M(squared) basis. There are no adequate and well-controlled
studies in pregnant women. Nefazodone should be used during pregnancy only
if the potential benefit justifies the potential risk to the fetus. </p>

<p>LABOR AND DELIVERY </p>

<p>The effect of Nefazodone on labor and delivery in humans is unknown.
</p>

<p>NURSING MOTHERS </p>

<p>It is not known whether Nefazodone or its metabolites are excreted in
human milk. Because many drugs are excreted in human milk, caution should
be exercised when Nefazodone is administered to a nursing woman. </p>

<p>PEDIATRIC USE </p>

<p>Safety and effectiveness in individuals below 18 years of age have not
been established. GERIATRIC USE </p>

<p>Over 500 elderly (&gt;/=65 years) individuals participated in clinical
studies with nefazodone. No unusual adverse age-related phenomena were
identified in this cohort of elderly patients treated with nefazodone.
Due to the increased systemic exposure to nefazodone seen in single dose
studies in elderly patients (see CLINICAL PHARMACOLOGY Section, PHARMACOKINETICS
Subsection), treatment should be initiated at half the usual dose, but
titration upward should take place over the same range as in younger patients
(see DOSAGE AND ADMINISTRATION Section). The usual precautions should be
observed in elderly patients who have concomitant medical illnesses or
who are receiving concomitant drugs. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Drugs Highly Bound To Plasma Protein </p>

<p>Because nefazodone is highly bound to plasma protein (see CLINICAL PHARMACOLOGY
Section, PHARMACOKINETICS Subsection), administration of Nefazodone to
a patient taking another drug that is highly protein bound may cause increased
free concentrations of the other drug, potentially resulting in adverse
events. Conversely, adverse effects could result from displacement of nefazodone
by other highly bound drugs. </p>

<p>CNS Active Drugs </p>

<p>Monoamine Oxidase Inhibitors--See WARNINGS Section </p>

<p>Haloperidol--When a single oral 5-mg dose of haloperidol was coadministered
with nefazodone (200 mg BID) at steady state, haloperidol apparent clearance
decreased by 35% with no significant increase in peak haloperidol plasma
concentrations or time of peak. This change is of unknown clinical significance.
Pharmacodynamic effects of haloperidol were generally not altered significantly.
There were no changes in the pharmacokinetic parameters for nefazodone.
Dosage adjustment of haloperidol may be necessary when coadministered with
nefazodone. </p>

<p>Lorazepam--When lorazepam (2 mg BID) and nefazodone (200 mg BID) were
coadministered to steady state, there was no change in any pharmacokinetic
parameter for either drug compared to each drug administered alone. Therefore,
dosage adjustment is not necessary for either drug when coadministered.
</p>

<p>Triazolam/Alprazolam--See WARNINGS Section </p>

<p>Alcohol--Although nefazodone did not potentiate the cognitive and psychomotor
effects of alcohol in experiments with normal subjects, the concomitant
use of Nefazodone and alcohol in depressed patients is not advised. </p>

<p>General Anesthetics--Little is known about the potential for interaction
between nefazodone and general anesthetics; therefore, prior to elective
surgery, Nefazodone should be discontinued for as long as clinically feasible.
</p>

<p>Other CNS Active Drugs--The use of nefazodone in combination with other
CNS- active drugs has not been systematically evaluated. Consequently,
caution is advised if concomitant administration of Nefazodone and such
drugs is required. </p>

<p>Cimetidine </p>

<p>When nefazodone (200 mg BID) and cimetidine (300 mg QID) were coadministered
for one week, no change in the steady-state pharmacokinetics of either
nefazodone or cimetidine was observed compared to each dosed alone. Therefore,
dosage adjustment is not necessary for either drug when coadministered.
</p>

<p>Cardiovascular Active Drugs </p>

<p>Digoxin--When nefazodone (200 mg BID) and digoxin (0.2 mg QD) were coadministered
for 9 days to healthy male volunteers (n=18) who were phenotyped as P450IID6
extensive metabolizers, Cmax, Cmin, and AUC of digoxin were increased by
29%, 27%, and 15%, respectively. Digoxin had no effects on the pharmacokinetics
of nefazodone and its active metabolites. Because of the narrow therapeutic
index of digoxin, caution should be exercised when nefazodone and digoxin
are coadministered; plasma level monitoring for digoxin is recommended.
</p>

<p>Propranolol--The coadministration of nefazodone (200 mg BID) and propranolol
(40 mg BID) for 5.5 days to healthy male volunteers (n=18), including 3
poor and 15 extensive P450IID6 metabolizers, resulted in 30% and 14% reductions
in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax
for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone,
and triazole-dione were not affected by coadministration of propranolol.
However, Cmax, Cmin, and AUC of m- chlorophenylpiperazine were increased
by 23%, 54%, and 28%, respectively. No change in initial dose of either
drug is necessary and dose adjustments should be made on the basis of clinical
response. Pharmacokinetics Of Nefazodone In 'Poor Metabolizers' And Potential
Interaction With Drugs That Inhibit And/or Are Metabolized By Cytochrome
P450 Isozymes IIIA4 Isozyme--Nefazodone has been shown In Vitro to be an
inhibitor of cytochrome P450IIIA4. This is consistent with the interaction
observed between nefazodone and the benzodiazepines triazolam and alprazolam,
drugs metabolized by this isozyme. Consequently, caution is indicated in
the combined use of nefazodone with any drugs known to be metabolized by
the IIIA4 isozyme. In particular, the combined use of nefazodone with either
terfenadine or astemizole is contraindicated (see CONTRAINDICATIONS and
WARNINGS Sections). </p>

<p>IID6 Isozyme--A subset (3% to 10%) of the population has reduced activity
of the drug- metabolizing enzyme cytochrome P450IID6. Such individuals
are referred to commonly as &quot;poor metabolizers&quot; of drugs such
as debrisoquin, dextromethorphan, and the tricyclic antidepressants. The
pharmacokinetics of nefazodone and its major metabolites are not altered
in these &quot;poor metabolizers.&quot; Plasma concentrations of one minor
metabolite (mCPP) are increased in this population; the adjustment of Nefazodone
dosage is not required when administered to &quot;poor metabolizers.&quot;
Nefazodone and its metabolites have been shown In Vitro to be extremely
weak inhibitors of P450IID6. Thus, it is not likely that nefazodone will
decrease the metabolic clearance of drugs metabolized by this isozyme.
IA2 Isozyme--Nefazodone and its metabolites have been shown In Vitro not
to inhibit cytochrome P450IA2. Thus, metabolic interactions between nefazodone
and drugs metabolized by this isozyme are unlikely. </p>

<p>Electro-Convulsive Therapy (ECT) </p>

<p>There are no clinical studies of the combined use of ECT and nefazodone.
(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>ASSOCIATED WITH DISCONTINUATION OF TREATMENT </p>

<p>Approximately 16% of the 3496 patients who received Nefazodone (nefazodone
hydrochloride) in worldwide premarketing clinical trials discontinued treatment
due to an adverse experience. The more common (&gt;/=1%) events in clinical
trials associated with discontinuation and considered to be drug related
(i.e., those events associated with dropout at a rate approximately twice
or greater for Nefazodone compared to placebo) included: nausea (3.5%),
dizziness (1.9%), insomnia (1.5%), asthenia (1.3%), and agitation (1.2%).
</p>

<p>INCIDENCE IN CONTROLLED TRIALS </p>

<p>Commonly Observed Adverse Events In Controlled Clinical Trials: </p>

<p>The most commonly observed adverse events associated with the use of
Nefazodone (incidence of 5% or greater) and not seen at an equivalent incidence
among placebo-treated patients (i.e., significantly higher incidence for
Nefazodone compared to placebo, p &lt; or = 0.05), derived from the table
below, were: somnolence, dry mouth, nausea, dizziness, constipation, asthenia,
lightheadedness, blurred vision, confusion, and abnormal vision. Adverse
Events Occurring At An Incidence Of 1% Or More Among Nefazodone-Treated
Patients: </p>

<p>The table that follows enumerates adverse events that occurred at an
incidence of 1% or more and were more frequent than in the placebo group,
among Nefazodone- treated patients who participated in short-term (6- to
8-week) placebo- controlled trials in which patients were dosed with Nefazodone
to ranges of 300 to 600 mg/day. This table shows the percentage of patients
in each group who had at least one episode of an event at some time during
their treatment. Reported adverse events were classified using a standard
COSTART-based Dictionary terminology. </p>

<p>The prescriber should be aware that these figures cannot be used to
predict the incidence of side effects in the course of usual medical practice
where patient characteristics and other factors differ from those which
prevailed in the clinical trials. Similarly, the cited frequencies cannot
be compared with figures obtained from other clinical investigations involving
different treatments, uses, and investigators. The cited figures, however,
do provide the prescribing physician with some basis for estimating the
relative contribution of drug and nondrug factors to the side-effect incidence
rate in the population studied. </p>

<pre>            Treatment-Emergent Adverse Experience Incidence in
             6- to 8-Week Placebo-Controlled Clinical Trials(1)
                   Nefazodone 300 to 600 mg/day Dose Range
                                                 Nefazodone         Placebo
Body System           Preferred Term            (n = 393)       (n = 394)
-----------------------------------------------------------------------------
Body as a Whole       Headache                      36%              33%
                      Asthenia                      11%               5%
                      Infection                      8%               6%
                      Flu syndrome                   3%               2%
                      Chills                         2%               1%
                      Fever                          2%               1%
                      Neck Rigidity                  1%               0
Cardiovascular        Postural hypotension           4%               1%
                      Hypotension                    2%               1%
Dermatological        Pruritus                       2%               1%
                      Rash                           2%               1%
Gastrointestinal      Dry mouth                     25%              13%
                      Nausea                        22%              12%
                      Constipation                  14%               8%
                      Dyspepsia                      9%               7%
                      Diarrhea                       8%               7%
                      Increased appetite             5%               3%
                      Nausea &amp; Vomiting              2%               1%
Metabolic             Peripheral edema               3%               2%
                      Thirst                         1%              &lt;1%
Musculoskeletal       Arthralgia                     1%              &lt;1%
Nervous               Somnolence                    25%              14%
                      Dizziness                     17%               5%
                      Insomnia                      11%               9%
                      Lightheadedness               10%               3%
                      Confusion                      7%               2%
                      Memory impairment              4%               2%
                      Paresthesia                    4%               2%
                      Vasodilatation(2)              4%               2%
                      Abnormal dreams                3%               2%
                      Concentration decreased        3%               1%
                      Ataxia                         2%               0
                      Incoordination                 2%               1%
                      Psychomotor retardation        2%               1%
                      Tremor                         2%               1%
                      Hypertonia                     1%               0
                      Libido decreased               1%              &lt;1%
Respiratory           Pharyngitis                    6%               5%
                      Cough increased                3%               1%
Special Senses        Blurred vision                 9%               3%
                      Abnormal vision(3)             7%               1%
                      Tinnitus                       2%               1%
                      Taste perversion               2%               1%
                      Visual field defect            2%               0
Urogenital            Urinary frequency              2%               1%
                      Urinary tract infection        2%               1%
                      Urinary retention              2%               1%
                      Vaginitis(4)                   2%               1%
                      Breast pain(4)                 1%              &lt;1%
-----------------------------------------------------------------------------
(1)Events reported by at least 1% of patients treated with Nefazodone and more
    frequent than the placebo group are included; incidence is rounded to the
    nearest 1% (&lt;1% indicates an incidence less than 0.5%). Events for which
    the Nefazodone incidence was equal to or less than placebo are not listed in
    the table, but included the following: abdominal pain, pain, back pain,
    accidental injury, chest pain, neck pain, palpitation, migraine, sweating,
    flatulence, vomiting, anorexia, tooth disorder, weight gain, edema,
    myalgia, cramp, agitation, anxiety, depression, hypesthesia, CNS,
    stimulation, dysphoria, emotional lability, sinusitis, rhinitis,
    dysmenorrhea(4), dysuria.
(2)Vasodilatation--flushing, feeling warm.
(3)Abnormal vision--scotoma, visual trails.
(4)Incidence adjusted for gender.</pre>

<p>Dose Dependency Of Adverse Events </p>

<p>The table that follows enumerates adverse events that were more frequent
in the Nefazodone dose range of 300 to 600 mg/day than in the Nefazodone
dose range of up to 300 mg/day. This table shows only those adverse events
for which there was a statistically significant difference (p &lt; or =
0.05) in incidence between the Nefazodone dose ranges as well as a difference
between the high dose range and placebo. </p>

<pre>     Dose Dependency of Adverse Events in Placebo-Controlled Trials(1)
                                      Nefazodone        Nefazodone
                                   300-600 mg/day &lt; or = 300 mg/day Placebo

Body System        Preferred Term    (n = 209)      (n = 211)  (n = 212)

-----------------------------------------------------------------------------

Gastrointestinal   Nausea               23%            14%         12%

                   Constipation         17%            10%          9%

Nervous            Somnolence           28%            16%         13%

                   Dizziness            22%            11%          4%

                   Confusion             8%             2%          1%

Special Senses     Abnormal vision      10%             0           2%

                   Blurred vision        9%             3%          2%

                   Tinnitus              3%             0           1%

-----------------------------------------------------------------------------

(1)Events for which there was a statistically significant difference

    (p &lt; or = 0.05) between the nefazodone dose groups.</pre>

<p>Vital Sign Changes </p>

<p>(See PRECAUTIONS Section, Postural Hypotension Subsection) Weight Changes
</p>

<p>In a pooled analysis of placebo-controlled premarketing studies, there
were no differences between nefazodone and placebo groups in the proportions
of patients meeting criteria for potentially important increases or decreases
in body weight (a change of &gt;/=7%). </p>

<p>Laboratory Changes </p>

<p>Of the serum chemistry, serum hematology, and urinalysis parameters
monitored during placebo- controlled premarketing studies with nefazodone,
a pooled analysis revealed a statistical trend between nefazodone and placebo
for hematocrit, i.e., 2.8% of nefazodone patients met criteria for a potentially
important decrease in hematocrit (&lt; or = 37% male or &lt; or = 32% female)
compared to 1.5% of placebo patients (0.05 </p>

<p>ECG Changes </p>

<p>Of the ECG parameters monitored during placebo- controlled premarketing
studies with nefazodone, a pooled analysis revealed a statistically significant
difference between nefazodone and placebo for sinus bradycardia, i.e.,
1.5% of nefazodone patients met criteria for a potentially important decrease
in heart rate (&lt; or = 50 bpm and a decrease of &gt;/=15 bpm) compared
to 0.4% of placebo patients (p &lt;0.05). There was no obvious clinical
significance of the observed changes in the few patients meeting these
criteria. </p>

<p>OTHER EVENTS OBSERVED DURING THE PREMARKETING EVALUATION OF Nefazodone
During its premarketing assessment, multiple doses of Nefazodone were administered
to 3496 patients in clinical studies, including more than 250 patients
treated for at least one year. The conditions and duration of exposure
to Nefazodone varied greatly, and included (in overlapping categories)
open and double-blind studies, uncontrolled and controlled studies, inpatient
and outpatient studies, fixed- dose and titration studies. Untoward events
associated with this exposure were recorded by clinical investigators using
terminology of their own choosing. Consequently, it is not possible to
provide a meaningful estimate of the proportion of individuals experiencing
adverse events without first grouping similar types of untoward events
into a smaller number of standardized event categories. </p>

<p>In the tabulations that follow, reported adverse events were classified
using a standard COSTART- based Dictionary terminology. The frequencies
presented, therefore, represent the proportion of the 3496 patients exposed
to multiple doses of Nefazodone who experienced an event of the type cited
on at least one occasion while receiving Nefazodone. All reported events
are included except those already listed in the Treatment-Emergent Adverse
Experience Incidence table, those events listed in other safety-related
sections of this insert, those adverse experiences subsumed under COSTART
terms that are either overly general or excessively specific so as to be
uninformative, those events for which a drug cause was very remote, and
those events which were not serious and occurred in fewer than two patients.
</p>

<p>It is important to emphasize that, although the events reported occurred
during treatment with Nefazodone, they were not necessarily caused by it.
Events are further categorized by body system and listed in order of decreasing
frequency according to the following definitions: frequent adverse events
are those occurring on one or more occasions in at least 1/100 patients
(only those not already listed in the tabulated results from placebo-controlled
trials appear in this listing); infrequent adverse events are those occurring
in 1/100 to 1/1000 patients; rare events are those occurring in fewer than
1/1000 patients. </p>

<p>Body As A Whole--Infrequent: allergic reaction, malaise, photosensitivity
reaction, face edema, hangover effect, abdomen enlarged, hernia, pelvic
pain, and halitosis. Rare: cellulitis. </p>

<p>Cardiovascular System--Infrequent: tachycardia, hypertension, syncope,
ventricular extrasystoles, and angina pectoris. Rare: AV block, congestive
heart failure, hemorrhage, pallor, and varicose vein. </p>

<p>Dermatologic System--Infrequent: dry skin, acne, alopecia, urticaria,
maculopapular rash, vesiculobullous rash, and eczema. </p>

<p>Gastrointestinal System--Frequent: gastroenteritis. Infrequent: eructation,
periodontal abscess, abnormal liver function tests, gingivitis, colitis,
gastritis, mouth ulceration, stomatitis, esophagitis, peptic ulcer, and
rectal hemorrhage. Rare: glossitis, hepatitis, dysphagia, gastrointestinal
hemorrhage, oral moniliasis, and ulcerative colitis. </p>

<p>Hemic And Lymphatic System--Infrequent: ecchymosis, anemia, leukopenia,
and lymphadenopathy. </p>

<p>Metabolic And Nutritional System--Infrequent: weight loss, gout, dehydration,
lactic dehydrogenase increased, SGOT increased, and SGPT increased. Rare:
hypercholesteremia and hypoglycemia. </p>

<p>Musculoskeletal System--Infrequent: arthritis, tenosynovitis, muscle
stiffness, and bursitis. Rare: tendinous contracture. </p>

<p>Nervous System--Infrequent: vertigo, twitching, depersonalization, hallucinations,
suicide attempt, apathy, euphoria, hostility, suicidal thoughts, abnormal
gait, thinking abnormal, attention decreased, derealization, neuralgia,
paranoid reaction, dysarthria, increased libido, suicide, and myoclonus.
Rare: hyperkinesia, increased salivation, cerebrovascular accident, hyperesthesia,
hypotonia, ptosis, and neuroleptic malignant syndrome. </p>

<p>Respiratory System--Frequent: dyspnea and bronchitis. Infrequent: asthma,
pneumonia, laryngitis, voice alteration, epistaxis, hiccup. Rare: hyperventilation
and yawn. </p>

<p>Special Senses--Frequent: eye pain. Infrequent: dry eye, ear pain, abnormality
of accommodation, diplopia, conjunctivitis, mydriasis, keratoconjunctivitis,
hypercusis, and photophobia. Rare: deafness, glaucoma, night blindness,
and taste loss. </p>

<p>Urogenital System--Frequent: impotence.(a) Infrequent: cystitis, urinary
urgency, metrorrhagia(a), amenorrhea(a), polyuria, vaginal hemorrhage(a),
breast enlargement(a), menorrhagia(a), urinary incontinence, abnormal ejaculation(a),
hematuria, nocturia, and kidney calculus. Rare: uterine fibroids enlarged(a),
uterine hemorrhage(a), anorgasmia, and oliguria. </p>

<p>(a) Adjusted for gender. </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>CONTROLLED SUBSTANCE CLASS </p>

<p>Nefazodone is not a controlled substance. </p>

<p>PHYSICAL AND PSYCHOLOGICAL DEPENDENCE </p>

<p>In animal studies, nefazodone did not act as a reinforcer for intravenous
self- administration in monkeys trained to self-administer cocaine, suggesting
no abuse liability. In a controlled study of abuse liability in human subjects,
nefazodone showed no potential for abuse. </p>

<p>Nefazodone has not been systematically studied in humans for its potential
for tolerance, physical dependence, or withdrawal. While the premarketing
clinical experience with nefazodone did not reveal any tendency for a withdrawal
syndrome or any drug-seeking behavior, it is not possible to predict on
the basis of this limited experience the extent to which a CNS-active drug
will be misused, diverted, and/or abused once marketed. Consequently, physicians
should carefully evaluate patients for a history of drug abuse and follow
such patients closely, observing them for signs of misuse or abuse of Nefazodone
(e.g., development of tolerance, dose escalation, drug- seeking behavior).
</p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE &nbsp;</b></p>

<p>HUMAN EXPERIENCE </p>

<p>There is very limited experience with nefazodone overdose. In premarketing
clinical studies, there were seven reports of nefazodone overdose alone
or in combination with other pharmacological agents. The amount of nefazodone
ingested ranged from 1000 mg to 11,200 mg. Commonly reported symptoms from
overdose of nefazodone included nausea, vomiting, and somnolence. One nonstudy
participant took 2000-3000 mg of nefazodone with methocarbanol and alcohol;
this person reportedly experienced a convulsion (type not documented).
None of the patients died. </p>

<p>OVERDOSE MANAGEMENT </p>

<p>Overdosage may cause an increase in incidence or severity of any of
the reported adverse reactions (see ADVERSE REACTIONS Section). </p>

<p>There is no specific antidote for Nefazodone (nefazodone hydrocholoride).
Treatment should be symptomatic and supportive in the case of hypotension
or excessive sedation. Any patient suspected of having taken an overdose
should have the stomach emptied by gastric lavage. </p>

<p>In managing overdosage, consider the possibility of multiple drug involvement.
The physician should consider contacting a poison control center on the
treatment of any overdose. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
&nbsp;</b></p>

<p>INITIAL TREATMENT </p>

<p>The recommended starting dose for Nefazodone is 200 mg/day, administered
in two divided doses (BID). In the controlled trials establishing the antidepressant
efficacy of Nefazodone, the effective dose range was generally 300 to 600
mg/day. Consequently, most patients, depending on tolerability and the
need for further clinical effect, should have dose increased. Dose increases
should occur in increments of 100 mg/day to 200 mg/day, again on a BID
schedule, at intervals of no less than 1 week. As with all antidepressants,
several weeks on treatment may be required to obtain a full antidepressant
response. </p>

<p>DOSAGE FOR ELDERLY OR DEBILITATED PATIENTS </p>

<p>The recommended initial dose for elderly or debilitated patients is
100 mg/day on a BID schedule. These patients often have reduced nefazodone
clearance and/or increased sensitivity to the side effects of CNS-active
drugs. It may also be appropriate to modify the rate of subsequent dose
titration. As steady-state plasma levels do not change with age, the final
target dose based on a careful assessment of the patient's clinical response
may be similar in healthy younger and older patients. </p>

<p>MAINTENANCE/CONTINUATION/EXTENDED TREATMENT </p>

<p>There is no body of evidence available from controlled trials to indicate
how long the depressed patient should be treated with Nefazodone. It is
generally agreed, however, that pharmacological treatment for acute episodes
of depression should continue for up to six months or longer. Whether the
dose of antidepressant needed to induce remission is identical to the dose
needed to maintain euthymia is unknown. Although there are no efficacy
data that specifically address maintenance antidepressant treatment with
Nefazodone, the safety of nefazodone in long-term use is supported by data
from both double- blind and open-label trials involving more than 250 patients
treated for at least one year. </p>

<p>SWITCHING PATIENTS TO OR FROM A MONOAMINE OXIDASE INHIBITOR </p>

<p>At least 14 days should elapse between discontinuation of an MAOI and
initiation of therapy with Nefazodone. In addition, at least 7 days should
be allowed after stopping Nefazodone before starting an MAOI. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-41</DOCNO>
<DOCOLDNO>IA018-000200-B037-95</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/dival.htm 206.86.175.201 19970106225519 text/html 34032
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:49:04 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 33849
Last-modified: Tue, 20 Aug 1996 22:50:21 GMT
</DOCHDR>
<html>
<head>
   <title>Divalproex - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Divalproex</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>WARNINGS: </p>

<p>HEPATIC FAILURE RESULTING IN FATALITIES HAS OCCURRED IN PATIENTS RECEIVING
VALPROIC ACID AND ITS DERIVATIVES. EXPERIENCE HAS INDICATED THAT CHILDREN
UNDER THE AGE OF TWO YEARS ARE AT A CONSIDERABLY INCREASED RISK OF DEVELOPING
FATAL HEPATOTOXICITY, ESPECIALLY THOSE ON MULTIPLE ANTICONVULSANTS, THOSE
WITH CONGENITAL METABOLIC DISORDERS, THOSE WITH SEVERE SEIZURE DISORDERS
ACCOMPANIED BY MENTAL RETARDATION, AND THOSE WITH ORGANIC BRAIN DISEASE.
WHEN DIVALPROEX IS USED IN THIS PATIENT GROUP, IT SHOULD BE USED WITH EXTREME
CAUTION AND AS A SOLE AGENT. THE BENEFITS OF SEIZURE CONTROL SHOULD BE
WEIGHED AGAINST THE RISKS. ABOVE THIS AGE GROUP, EXPERIENCE HAS INDICATED
THAT THE INCIDENCE OF FATAL HEPATOTOXICITY DECREASES CONSIDERABLY IN PROGRESSIVELY
OLDER PATIENT GROUPS. </p>

<p>THESE INCIDENTS USUALLY HAVE OCCURRED DURING THE FIRST SIX MONTHS OF
TREATMENT. SERIOUS OR FATAL HEPATOTOXICITY MAY BE PRECEDED BY NON-SPECIFIC
SYMPTOMS SUCH AS LOSS OF SEIZURE CONTROL, MALAISE, WEAKNESS, LETHARGY,
FACIAL EDEMA, ANOREXIA AND VOMITING. PATIENTS SHOULD BE MONITORED CLOSELY
FOR APPEARANCE OF THESE SYMPTOMS. LIVER FUNCTION TESTS SHOULD BE PERFORMED
PRIOR TO THERAPY AND AT FREQUENT INTERVALS THEREAFTER, ESPECIALLY DURING
THE FIRST SIX MONTHS. </p>

<p>Divalproex sodium is a stable co-ordination compound comprised of sodium
valproate and valproic acid in a 1:1 molar relationship and formed during
the partial neutralization of valproic acid with 0.5 equivalent of sodium
hydroxide. Chemically it is designated as sodium hydrogen bis (2 propylpentanoate).
</p>

<p>Divalproex sodium occurs as a white powder with a characteristic odor.
</p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Divalproex sodium is an antiepileptic agent which dissociates to the
valproate ion in the gastrointestinal tract. The mechanism by which valproate
exerts its antiepileptic effects has not been established. It has been
suggested that its activity is related to increased brain levels of gamma-aminobutyric
acid (GABA). </p>

<p>Equivalent oral doses of Divalproex (divalproex sodium) products and
DEPAKENE (valproic acid) capsules deliver equivalent quantities of valproate
ion systemically. However, the rate of valproate ion absorption may vary
with the conditions of use (eg, fasting or postprandial) and the method
of administration (eg, whether the contents of the capsule are sprinkled
on food or the capsule is taken intact). </p>

<p>When subjects are in a fasting state, peak plasma concentrations of
valproate ion are observed approximately 3 to 4 hours following administration
of all Divalproex products. </p>

<p>Experiments indicate that feeding can influence the rate of systemic
absorption of valproate. In studies in which the contents of Divalproex
(divalproex sodium) Sprinkle capsules were sprinkled on applesauce, feeding
was found to delay the time to peak plasma concentration by approximately
1.5 hours. </p>

<p>Compared to Divalproex tablets, however, Divalproex Sprinkle capsules
(in the fasting state) exhibit a slower rate of absorption, resulting in
lower peak plasma concentrations (ie, fluctuations between minimum and
maximum plasma valproate concentrations are attentuated). </p>

<p>While absorption rate from the GI tract and fluctuation in valproate
plasma concentrations vary with dosing regimen and formulation, the efficacy
of valproate in chronic use is not affected. Experience employing dosing
regimens from once-a-day to four-times-a-day, as well as studies in primate
epilepsy models involving constant rate infusion, indicate that total daily
systemic bioavailability (extent of absorption) is the primary determinant
of seizure control and that differences in the ratios of plasma peak to
trough concentrations between valproate formulations are inconsequential
from a practical clinical standpoint. </p>

<p>Accordingly, coadministration of oral valproate products with food and
substitution among the various Divalproex and DEPAKENE formulations should
cause no clinical problems (see DOSAGE AND ADMINISTRATION). Nonetheless,
any changes in dosage administration, or the addition or discontinuance
of concomitant drugs should ordinarily be accompanied by close monitoring
of clinical status and valproate plasma concentrations. </p>

<p>The plasma half-life of valproate is typically in the range of 6 to
16 hours. Half-lives in the lower part of the range are usually found in
patients taking other antiepileptic drugs capable of enzyme induction.
</p>

<p>Valproate is primarily metabolized in the liver. The major metabolic
routes are glucuronidation, mitochondrial beta oxidation, and microsomal
oxidation. The major metabolites formed are the glucuronide conjugate,
2-propyl-3-keto- pentanoic acid, and 2-propylhydroxypentanoic acids. Other
unsaturated metabolites have been reported. The major route of elimination
of these metabolites is in the urine. </p>

<p>Patients on monotherapy will generally have longer half-lives and higher
concentrations of valproate at a given dosage than patients receiving polytherapy.
This is primarily due to enzyme induction caused by other antiepileptics,
which results in enhanced clearance of valproate by glucuronidation and
microsomal oxidation. Because of these changes in valproate clearance,
monitoring of antiepileptic concentrations should be intensified whenever
concomitant antiepileptics are introduced or withdrawn. </p>

<p>The therapeutic range is commonly considered to be 50 to 100 mcg/ml
of total valproate, although some patients may be controlled with lower
or higher plasma concentrations. (REF.5) Valproate is highly bound (90%)
to plasma proteins in the therapeutic range; however, protein binding is
concentration-dependent and decreases at high valproate concentrations.
The binding is variable among patients and may be affected by fatty acids
or by highly bound drugs such as salicylate. Some clinicians favor monitoring
free valproate concentrations, which may more accurately reflect CNS penetration
of valproate. As yet, a consensus on the therapeutic range of free concentrations
has not been established; however, monitoring total and free valproate
may be informative when there are changes in clinical status, concomitant
medication, or valproate dosage. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Divalproex (divalproex sodium) is indicated for use as sole and adjunctive
therapy in the treatment of simple and complex absence seizures, and adjunctively
in patients with multiple seizure types that include absence seizures.
</p>

<p>Simple absence is defined as very brief clouding of the sensorium or
loss of consciousness accompanied by certain generalized epileptic discharges
without other detectable clinical signs. Complex absence is the term used
when other signs are also present. </p>

<p>June 24, 1996 -- Divalproex sodium is now indicated
for treatment of
complex partial seizures
(CPS), a common type of epilepsy. This new indication increases the
breadth of seizure coverage
provided by the established anti-epilepsy agent.  May be used for this 
indication as a sole agent or as an adjunct to other forms of therapy.
<p>
Divalproex is also indicated for the prevention of migraine headaches.
<p>
<p>SEE WARNINGS FOR STATEMENT REGARDING FATAL HEPATIC DYSFUNCTION. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>DIVALPROEX SODIUM SHOULD NOT BE ADMINISTERED TO PATIENTS WITH HEPATIC
DISEASE OR SIGNIFICANT DYSFUNCTION. </p>

<p>Divalproex sodium is contraindicated in patients with known hypersensitivity
to the drug. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>HEPATIC FAILURE RESULTING IN FATALITIES HAS OCCURRED IN PATIENTS RECEIVING
VALPROIC ACID AND ITS DERIVATIVES. EXPERIENCE HAS INDICATED THAT CHILDREN
UNDER THE AGE OF TWO YEARS ARE AT A CONSIDERABLY INCREASED RISK OF DEVELOPING
FATAL HEPATOTOXICITY, ESPECIALLY THOSE ON MULTIPLE ANTICONVULSANTS, THOSE
WITH CONGENITAL METABOLIC DISORDERS, THOSE WITH SEVERE SEIZURE DISORDERS
ACCOMPANIED BY MENTAL RETARDATION, AND THOSE WITH ORGANIC BRAIN DISEASE.
WHEN Divalproex IS USED IN THIS PATIENT GROUP, IT SHOULD BE USED WITH EXTREME
CAUTION AND AS A SOLE AGENT. THE BENEFITS OF SEIZURE CONTROL SHOULD BE
WEIGHED AGAINST THE RISKS. ABOVE THIS AGE GROUP, EXPERIENCE HAS INDICATED
THAT THE INCIDENCE OF FATAL HEPATOTOXICITY DECREASES CONSIDERABLY IN PROGRESSIVELY
OLDER PATIENT GROUPS. </p>

<p>THESE INCIDENTS USUALLY HAVE OCCURRED DURING THE FIRST SIX MONTHS OF
TREATMENT. SERIOUS OR FATAL HEPATOTOXICITY MAY BE PRECEDED BY NON-SPECIFIC
SYMPTOMS SUCH AS LOSS OF SEIZURE CONTROL, MALAISE, WEAKNESS, LETHARGY,
FACIAL EDEMA, ANOREXIA AND VOMITING. PATIENTS SHOULD BE MONITORED CLOSELY
FOR APPEARANCE OF THESE SYMPTOMS. LIVER FUNCTION TESTS SHOULD BE PERFORMED
PRIOR TO THERAPY AND AT FREQUENT INTERVALS THEREAFTER, ESPECIALLY DURING
THE FIRST SIX MONTHS. </p>

<p>HEPATIC FAILURE RESULTING IN FATALITIES HAS OCCURRED IN PATIENTS RECEIVING
VALPROIC ACID. THESE INCIDENTS USUALLY HAVE OCCURRED DURING THE FIRST SIX
MONTHS OF TREATMENT. SERIOUS OR FATAL HEPATOTOXICITY MAY BE PRECEDED BY
NONSPECIFIC SYMPTOMS SUCH AS LOSS OF SEIZURE CONTROL, MALAISE, WEAKNESS,
LETHARGY, FACIAL EDEMA, ANOREXIA, AND VOMITING. PATIENTS SHOULD BE MONITORED
CLOSELY FOR APPEARANCE OF THESE SYMPTOMS. LIVER FUNCTION TESTS SHOULD BE
PERFORMED PRIOR TO THERAPY AND AT FREQUENT INTERVALS THEREAFTER, ESPECIALLY
DURING THE FIRST SIX MONTHS. HOWEVER, PHYSICIANS SHOULD NOT RELY TOTALLY
ON SERUM BIOCHEMISTRY SINCE THESE TESTS MAY NOT BE ABNORMAL IN ALL INSTANCES,
BUT SHOULD ALSO CONSIDER THE RESULTS OF CAREFUL INTERIM MEDICAL HISTORY
AND PHYSICAL EXAMINATION. CAUTION SHOULD BE OBSERVED WHEN ADMINISTERING
Divalproex PRODUCTS TO PATIENTS WITH A PRIOR HISTORY OF HEPATIC DISEASE.
PATIENTS ON MULTIPLE ANTICONVULSANTS, CHILDREN, THOSE WITH CONGENITAL METABOLIC
DISORDERS, THOSE WITH SEVERE SEIZURE DISORDERS ACCOMPANIED BY MENTAL RETARDATION,
AND THOSE WITH ORGANIC BRAIN DISEASE MAY BE AT PARTICULAR RISK. EXPERIENCE
HAS INDICATED THAT CHILDREN UNDER THE AGE OF TWO YEARS ARE AT CONSIDERABLY
INCREASED RISK OF DEVELOPING FATAL HEPATOTOXICITY, ESPECIALLY THOSE WITH
THE AFOREMENTIONED CONDITIONS. WHEN Divalproex IS USED IN THIS PATIENT
GROUP, IT SHOULD BE USED WITH EXTREME CAUTION AND AS A SOLE AGENT. THE
BENEFITS OF SEIZURE CONTROL SHOULD BE WEIGHED AGAINST THE RISKS. ABOVE
THIS AGE GROUP, EXPERIENCE HAS INDICATED THAT THE INCIDENCE OF FATAL HEPATOTOXICITY
DECREASES CONSIDERABLY IN PROGRESSIVELY OLDER PATIENT GROUPS. </p>

<p>THE DRUG SHOULD BE DISCONTINUED IMMEDIATELY IN THE PRESENCE OF SIGNIFICANT
HEPATIC DYSFUNCTION, SUSPECTED OR APPARENT. IN SOME CASES, HEPATIC DYSFUNCTION
HAS PROGRESSED IN SPITE OF DISCONTINUATION OF DRUG. </p>

<p>The frequency of adverse effects (particularly elevated liver enzymes)
may be dose-related. The benefit of improved seizure control which may
accompany the higher doses should therefore be weighed against the possibility
of a greater incidence of adverse effects. </p>

<p>USAGE IN PREGNANCY: ACCORDING TO PUBLISHED AND UNPUBLISHED REPORTS,
VALPROIC ACID MAY PRODUCE TERATOGENIC EFFECTS IN THE OFFSPRING OF HUMAN
FEMALES RECEIVING THE DRUG DURING PREGNANCY. </p>

<p>THERE ARE MULTIPLE REPORTS IN THE CLINICAL LITERATURE WHICH INDICATE
THAT THE USE OF ANTIEPILEPTIC DRUGS DURING PREGNANCY RESULTS IN AN INCREASED
INCIDENCE OF BIRTH DEFECTS IN THE OFFSPRING. ALTHOUGH DATA ARE MORE EXTENSIVE
WITH RESPECT TO TRIMETHADIONE, PARAMETHADIONE, PHENYTOIN, AND PHENOBARBITAL,
REPORTS INDICATE A POSSIBLE SIMILAR ASSOCIATION WITH THE USE OF OTHER ANTIEPILEPTIC
DRUGS. THEREFORE, ANTIEPILEPTIC DRUGS SHOULD BE ADMINISTERED TO WOMEN OF
CHILDBEARING POTENTIAL ONLY IF THEY ARE CLEARLY SHOWN TO BE ESSENTIAL IN
THE MANAGEMENT OF THEIR SEIZURES. </p>

<p>THE INCIDENCE OF NEURAL TUBE DEFECTS IN THE FETUS MAY BE INCREASED IN
MOTHERS RECEIVING VALPROATE DURING THE FIRST TRIMESTER OF PREGNANCY. THE
CENTERS FOR DISEASE CONTROL (CDC) HAS ESTIMATED THE RISK OF VALPROIC ACID
EXPOSED WOMEN HAVING CHILDREN WITH SPINA BIFIDA TO BE APPROXIMATELY 1 to
2%. (REF.1) </p>

<p>OTHER CONGENITAL ANOMALIES (EG, CRANIOFACIAL DEFECTS, CARDIOVASCULAR
MALFORMATIONS AND ANOMALIES INVOLVING VARIOUS BODY SYSTEMS), COMPATIBLE
AND INCOMPATIBLE WITH LIFE, HAVE BEEN REPORTED. SUFFICIENT DATA TO DETERMINE
THE INCIDENCE OF THESE CONGENITAL ANOMALIES IS NOT AVAILABLE. </p>

<p>THE HIGHER INCIDENCE OF CONGENITAL ANOMALIES IN ANTIEPILEPTIC DRUG-TREATED
WOMEN WITH SEIZURE DISORDERS CANNOT BE REGARDED AS A CAUSE AND EFFECT RELATIONSHIP.
THERE ARE INTRINSIC METHODOLOGIC PROBLEMS IN OBTAINING ADEQUATE DATA ON
DRUG TERATOGENICITY IN HUMANS; GENETIC FACTORS OR THE EPILEPTIC CONDITION
ITSELF, MAY BE MORE IMPORTANT THAN DRUG THERAPY IN CONTRIBUTING TO CONGENITAL
ANOMALIES. </p>

<p>PATIENTS TAKING VALPROATE MAY DEVELOP CLOTTING ABNORMALITIES. A PATIENT
WHO HAD LOW FIBRINOGEN WHEN TAKING MULTIPLE ANTICONVULSANTS INCLUDING VALPROATE
GAVE BIRTH TO AN INFANT WITH AFIBRINOGENEMIA WHO SUBSEQUENTLY DIED OF HEMORRHAGE.
IF VALPROATE IS USED IN PREGNANCY, THE CLOTTING PARAMETERS SHOULD BE MONITORED
CAREFULLY. </p>

<p>HEPATIC FAILURE, RESULTING IN THE DEATH OF A NEWBORN AND OF AN INFANT,
HAVE BEEN REPORTED FOLLOWING THE USE OF VALPROATE DURING PREGNANCY. </p>

<p>ANIMAL STUDIES ALSO HAVE DEMONSTRATED VALPROATE INDUCED TERATOGENICITY.
Studies in rats and human females demonstrated placental transfer of the
drug. Doses greater than 65 mg/kg/day given to pregnant rats and mice produced
skeletal abnormalities in the offspring, primarily involving ribs and vertebrae;
doses greater than 150 mg/kg/day given to pregnant rabbits produced fetal
resorptions and (primarily) soft-tissue abnormalities in the offspring.
In rats a dose- related delay in the onset of parturition was noted. Postnatal
growth and survival of the progeny were adversely affected, particularly
when drug administration spanned the entire gestation and early lactation
period. </p>

<p>Antiepileptic drugs should not be discontinued in patients in whom the
drug is administered to prevent major seizures because of the strong possibility
of precipitating status epilepticus with attendant hypoxia and threat to
life. In individual cases where the severity and frequency of the seizure
disorder are such that the removal of medication does not pose a serious
threat to the patient, discontinuation of the drug may be considered prior
to and during pregnancy, although it cannot be said with any confidence
that even minor seizures do not pose some hazard to the developing embryo
or fetus. </p>

<p>The prescribing physician will wish to weigh these considerations in
treating or counseling epileptic women of childbearing potential. </p>

<p>Tests to detect neural tube and other defects using current accepted
procedures should be considered a part of routine prenatal care in childbearing
women receiving valproate. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>Hepatic Dysfunction: See WARNING, CONTRAINDICATIONS AND WARNINGS. </p>

<p>General: Because of reports of thrombocytopenia, inhibition of the secondary
phase of platelet aggregation, and abnormal coagulation parameters (eg.
low fibrinogen), platelet counts and coagulation tests are recommended
before initiating therapy and at periodic intervals. It is recommended
that patients receiving Divalproex (divalproex sodium) be monitored for
platelet count and coagulation parameters prior to planned surgery. Evidence
of hemorrhage, bruising, or a disorder of hemostasis/coagulation is an
indication for reduction of the dosage or withdrawal of therapy. </p>

<p>Hyperammonemia with or without lethargy or coma has been reported and
may be present in the absence of abnormal liver function tests. Asympatomatic
elevations of ammonia are more common and when present require more frequent
monitoring. If clinically significant symptoms occur, Divalproex therapy
should be modified or discontinued. </p>

<p>Since valproate may interact with concurrently administered antiepileptic
drugs periodic plasma concentration determinations of concomitant antiepileptic
drugs are recommended during the early course of therapy. (See DRUG INTERACTIONS).
</p>

<p>Valproate is partially eliminated in the urine as a keto-metabolite
which may lead to a false interpretation of the urine ketone test. </p>

<p>There have been reports of altered thyroid function tests associated
with valproate. The clinical significance of these is unknown. </p>

<p>Information For Patients: Since Divalproex products may produce CNS
depression, especially when combined with CNS depressants (eg, alcohol),
patients should be advised not to engage in hazardous activities, such
as driving an automobile or operating dangerous machinery, until it is
known that they do not become drowsy from the drug. </p>

<p>The specially coated particles in Divalproex Sprinkle capsules have
been observed in the stool, but this occurrence has not been associated
with clinically significant effects. </p>

<p>Drug Interactions: Valproate may potentiate the action of CNS depressants
(ie, alcohol, benzodiazepines, etc). </p>

<p>The concomitant administration of valproate with drugs that exhibit
extensive protein binding (eg, aspirin, carbamazepine, dicumarol, and phenytoin)
may result in alteration of serum drug concentrations. </p>

<p>There is evidence that valproate can cause an increase in serum phenobarbital
concentrations by impairment of nonrenal clearance. This pnenomenon can
result in severe CNS depression. The combination of valproate and phenobarbital
has also beeen reported to produce CNS depression without significant elevations
of barbiturate or valproate serum concentrations. All patients receiving
concomitant barbiturate therapy should be closely monitored for neurological
toxicity. Serum barbiturate levels should be obtained, if possible, and
the barbiturate dosage decreased, if appropriate. </p>

<p>Primidone is metabolized to a barbiturate and, therefore, may also be
involved in a similar or identical interaction. </p>

<p>There have been reports of breakthrough seizures occurring with the
combination of valproate and phenytoin. Most reports have noted a decrease
in total plasma phenytoin concentration. However, increases in total phenytoin
serum concentration have been reported. An initial fall with subsequent
increase in total phenytoin concentrations has also been reported. In addition,
a decrease in total serum phenytoin with an increase in the free vs. protein
bound phenytoin concentrations has been reported. The dosage of phenytoin
should be adjusted as required by the clinical situation. </p>

<p>The concomitant use of valproic acid and clonazepam may induce absence
status in patients with a history of absence type seizures. </p>

<p>There is inconclusive evidence regarding the effect of valproate on
serum ethosuximide concentrations. Patients receiving valproate and ethosuximide,
especially along with other anticonvulsants, should be monitored for alterations
in serum concentrations of both drugs. </p>

<p>Caution is recommended when valproate is used with drugs affecting coagulation,
(eg, aspirin, warfarin). See ADVERSE REACTIONS. </p>

<p>Evidence suggests that there is an association between the use of certain
antiepileptics and failure of oral contraceptives. One explanation for
this interaction is that enzyme-inducing antiepileptics effectively lower
plasma concentrations of the relevant steroid hormones, resulting in unimpaired
ovulation. However, other mechanisms, not related to enzyme induction,
may contribute to the failure of oral contraceptives. While valproate is
not a significant enzyme inducer, and, therefore, would not be expected
to decrease concentrations of steroid hormones, clinical data about the
interaction of valproate with oral contraceptives is minimal. (REF. 2)
</p>

<p>Carcinogenesis: Valproic acid was administered to Sprague Dawley rats
and ICR (HA /ICR) mice at doses of 0, 80, and 170 mg/kg/day for two years.
A variety of neoplasms were observed in both species. The chief findings
were a statistically significant increase in the incidence of subcutaneous
fibrosarcomas in high dose male rats receiving valproic acid and a statistically
significant dose-related trend for benign pulmonary adenomas in male mice
receiving valproic acid. The significance of these findings for humans
is unknown. </p>

<p>Mutagenesis: Studies of valproate have been performed using bacterial
and mammalian systems. These studies have provided no evidence of a mutagenic
potential for valproate. </p>

<p>Fertility: Chronic toxicity studies in juvenile and adult rats and dogs
demonstrated reduced spermatogenesis and testicular atrophy at doses greater
than 200 mg/kg/day in rats and greater than 90 mg/kg/day in dogs. Segment
I fertility studies in rats have shown doses up to 350 mg/kg/day for 60
days to have no effect on fertility. THE EFFECT OF VALPROATE ON TESTICULAR
DEVELOPMENT AND ON SPERM PRODUCTION AND FERTILITY IN HUMANS IS UNKNOWN.
</p>

<p>Pregnancy: Pregnancy Category D: See WARNINGS. </p>

<p>Nursing Mothers: Valproate is excreted in breast milk. Concentrations
in breast milk have been reported to be 1-10% of serum concentrations.
It is not known what effect this would have on a nursing infant. Caution
should be exercised when divalproex sodium is administered to a nursing
woman. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Valproate may potentiate the action of CNS depressants (ie, alcohol,
benzodiazepines, etc). </p>

<p>The concomitant administration of valproate with drugs that exhibit
extensive protein binding (eg, aspirin, carbamazepine, dicumarol, and phenytoin)
may result in alteration of serum drug concentrations. </p>

<p>There is evidence that valproate can cause an increase in serum phenobarbital
concentrations by impairment of nonrenal clearance. This pnenomenon can
result in severe CNS depression. The combination of valproate and phenobarbital
has also beeen reported to produce CNS depression without significant elevations
of barbiturate or valproate serum concentrations. All patients receiving
concomitant barbiturate therapy should be closely monitored for neurological
toxicity. Serum barbiturate levels should be obtained, if possible, and
the barbiturate dosage decreased, if appropriate. </p>

<p>Primidone is metabolized to a barbiturate and, therefore, may also be
involved in a similar or identical interaction. </p>

<p>There have been reports of breakthrough seizures occurring with the
combination of valproate and phenytoin. Most reports have noted a decrease
in total plasma phenytoin concentration. However, increases in total phenytoin
serum concentration have been reported. An initial fall with subsequent
increase in total phenytoin concentrations has also been reported. In addition,
a decrease in total serum phenytoin with an increase in the free vs. protein
bound phenytoin concentrations has been reported. The dosage of phenytoin
should be adjusted as required by the clinical situation. </p>

<p>The concomitant use of valproic acid and clonazepam may induce absence
status in patients with a history of absence type seizures. </p>

<p>There is inconclusive evidence regarding the effect of valproate on
serum ethosuximide concentrations. Patients receiving valproate and ethosuximide,
especially along with other anticonvulsants, should be monitored for alterations
in serum concentrations of both drugs. </p>

<p>Caution is recommended when valproate is used with drugs affecting coagulation,
(eg, aspirin, warfarin). See ADVERSE REACTIONS. </p>

<p>Evidence suggests that there is an association between the use of certain
antiepileptics and failure of oral contraceptives. One explanation for
this interaction is that enzyme-inducing antiepileptics effectively lower
plasma concentrations of the relevant steroid hormones, resulting in unimpaired
ovulation. However, other mechanisms, not related to enzyme induction,
may contribute to the failure of oral contraceptives. While valproate is
not a significant enzyme inducer, and, therefore, would not be expected
to decrease concentrations of steroid hormones, clinical data about the
interaction of valproate with oral contraceptives is minimal. (REF.2) </p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Since divalproex sodium has usually been used with other antiepileptic
drugs, it is not possible, in most cases, to determine whether the following
adverse reactions can be ascribed to divalproex sodium alone, or the combination
of drugs. </p>

<p>Gastrointestinal: The most commonly reported side effects at the initiation
of therapy are nausea, vomiting and indigestion. These effects are usually
transient and rarely require discontinuation of therapy. Diarrhea, abdominal
cramps, and constipation have been reported. Both anorexia with some weight
loss and increased appetite with weight gain have also been reported. The
administration of delayed-release divalproex sodium may result in reduction
of gastrointestinal side effects in some patients. (REF.3) </p>

<p>CNS Effects: Sedative effects have occurred in patients receiving valproate
alone but occur most often in patients receiving combination therapy. Sedation
usually abates upon reduction of other antiepileptic medication. Tremor
(may be dose-related), hallucinations, ataxia, headache, nystagmus, diplopia,
asterixis &quot;spots before eyes&quot;, dysarthria, dizziness, and incoordination.
Rare cases of coma have occurred in patients receiving valproate alone
or in conjunction with phenobarbital. In rare instances encephalopathy
with fever has developed shortly after the introduction of valproate monotherapy
without evidence of hepatic dysfunction or inappropriate plasma levels;
all patients recovered after the drug was withdrawn. </p>

<p>Dermatologic: Transient hair loss, skin rash, photosensitivity, generalized
pruritus, erythema multiforme, and Stevens-Johnson syndrome. A case of
fatal epidermal necrolysis has been reported in a 6 month old infant taking
valproate and several other concomitant medications. </p>

<p>Psychiatric: Emotional upset, depression, psychosis, aggression, hyperactivity
and behavioral deterioration. </p>

<p>Musculoskeletal: Weakness. </p>

<p>Hematologic: Thrombocytopenia and inhibition of the secondary phase
of platelet aggregation may be reflected in altered bleeding time, petechiae,
bruising, hematoma formation, and frank hemorrhage (see PRECAUTIONS--General
and Drug Interactions). Relative lymphocytosis, macrocytosis, hypofibrinogenemia,
leukopenia, eosinophilia, anemia including macrocytic with or without folate
deficiency, bone marrow suppression, and acute intermittent porphyria.
</p>

<p>Hepatic: Minor elevations of transaminases (eg, SGOT and SGPT) and LDH
are frequent and appear to be dose-related. Occasionally, laboratory test
results include increases in serum bilirubin and abnormal changes in other
liver function tests. These results may reflect potentially serious hepatotoxicity
(see WARNINGS). </p>

<p>Endocrine: Irregular menses and secondary amenorrhea, breast enlargement,
galactorrhea and parotid gland swelling. Abnormal thyroid function tests
(see PRECAUTIONS). </p>

<p>Pancreatic: Acute pancreatitis including fatalities. </p>

<p>Metabolic: Hyperammonemia (see PRECAUTIONS), hyponatremia, and inappropriate
ADH secretion. </p>

<p>Decreased carnitine concentrations have been reported although the clinical
relevance is undetermined. </p>

<p>Hyperglycinemia has occurred and was associated with a fatal outcome
in a patient with preexistent nonketotic hyperglycinemia. </p>

<p>Genitourinary: Enuresis. </p>

<p>Special Senses: Hearing loss, either reversible or irreversible, has
been reported; however, a cause and effect relationship has not been established.
</p>

<p>Other: Edema of the extremities, lupus erythematosus, and fever. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Overdosage with valproate may result in somnolence, heart block, and
deep coma. Fatalities have been reported. </p>

<p>The benefit of gastric lavage or emesis will vary with the time since
ingestion. General supportive measures should be applied with particular
attention to the maintenance of adequate urinary output. </p>

<p>Naloxone has been reported to reverse the CNS depressant effects of
valproate overdosage. Because naloxone could theoretically also reverse
the antiepileptic effects of valproate, it should be used with caution.
</p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Divalproex tablets and Sprinkle capsules are administered orally. The
recommended initial dose is 15 mg/kg/day, increasing at one week intervals
by 5 to 10 mg/kg/day until seizures are controlled or side effects preclude
further increases. The maximum recommended dosage is 60 mg/kg/day. If the
total daily dose exceeds 250 mg, it should be given in a divided regimen.
</p>

<p>Administration Of Sprinkle Capsule: Divalproex Sprinkle capsules may
be swallowed whole or may be administered by carefully opening the capsule
and sprinkling the entire contents on a small amount (teaspoonful) of soft
food such as applesauce or pudding. The drug/food mixture should be swallowed
immediately (avoid chewing) and not stored for future use. Each capsule
is oversized to allow ease of opening. </p>

<p>Conversion From valproic acid To Divalproex: In patients previously
receiving valproic acid therapy, Divalproex products should be initiated
at the same daily dose and dosing schedule. After the patient is stabilized
on a Divalproex product, a dosing schedule of two or three times a day
may be elected in selected patients. (REF.4) </p>

<p>Prevention of migraine headaches: 250mg bid titrated up to 1000 mg/day
if necessary.<p>
<p>Divalproex products provide equal extents of absorption, although they
may not produce identical trough and peak valproate concentrations. Divalproex
tablets produce slightly higher peak concentrations than Divalproex Sprinkle
capsules. Such differences in the maximum and minimum valproate plasma
concentrations are unlikely to be of clinical significance; however, changes
in dosage administration of valproate or concomitant medications should
be accompanied by increased monitoring of plasma concentrations of valproate
and other medications, as well as the patient's clinical status. </p>

<p>The frequency of adverse effects (particularly elevated liver enzymes)
may be dose-related. The benefit of improved seizure control with higher
doses should be weighed against the possibility of a greater incidence
of adverse reactions. </p>

<p>A good correlation has not been established between daily dose, serum
concentration and therapeutic effect. However, therapeutic valproate serum
concentrations for most patients will range from 50 to 100 mcg/mL. Some
patients may be controlled with lower or higher serum concentrations (see
ACTIONS/CLINICAL PHARMACOLOGY). </p>

<p>As the Divalproex dosage is titrated upward, blood concentrations of
phenobarbital and/or phenytoin may be affected. (See PRECAUTIONS). </p>

<p>Patients who experience G. I. irritation may benefit from administration
of the drug with food or by slowly building up the dose from an initial
low level. </p>

<p>REFERENCES </p>

<p>1. Centers for Disease Control, valproate: a new cause of birth defects--report
from Italy and follow-up from France. Morbidity And Mortality Weekly Report.
1983; 32(33); 438-439. </p>

<p>2. Mattson RH, et al. Use of oral contraceptives by women with epilepsy.
JAMA. 1986; 256(2): 238-240. </p>

<p>3. Wilder, BJ, et al. Gastrointestinal tolerance of divalproex sodium.
Neurology. 1983; 33: 808-811. </p>

<p>4. Wilder BJ, et al. Twice-daily dosing of valproate with divalproex,
Clin Pharmacol Ther. 1983; 34(4): 501-504. </p>

<p>5. Hurst DL. Expanded therapeutic range of valproate. Pediatr Neurol.
1987; 3:342-344. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-42</DOCNO>
<DOCOLDNO>IA018-000200-B034-24</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/cipro.htm 206.86.175.201 19970106224043 text/html 43926
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:34:16 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 43743
Last-modified: Sun, 11 Aug 1996 03:43:20 GMT
</DOCHDR>
<html>
<head>
   <title>Ciprofloxacin - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Ciprofloxacin</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

 <a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <p>
Ciprofloxacin  is a synthetic broad spectrum antibacterial agent for oral administration. 
Ciprofloxacin, a fluoroquinolone, is available as the monohydrochloride monohydrate salt 
of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. 
It is a faintly yellowish to light yellow crystalline substance with a molecular weight 
of 385.8. Its empirical formula is C17H18FN3O3.HCl.H2O.  
  <p>
 
Ciprofloxacin differs from other quinolones in that it has a fluorine atom at the 6-position, 
a piperazine moiety at the 7-position, and a cyclopropyl ring at the 1-position.  
 <p>
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 
</b> <p>
Ciprofloxacinfloxacin tablets are rapidly and well absorbed from the gastrointestinal tract
after oral administration. The absolute bioavailability is approximately 70%
with no substantial loss by first pass metabolism. Serum concentrations
increase proportionately with the dose as shown:  <p><pre>
 
                           MAXIMUM                            AREA              
DOSE                 SERUM CONCENTRATION               UNDER CURVE (AUC)        
(MG)                      (MCGM/ML)                      (MCGM .HR/ML)          
 250                         1.2                               4.8              
 500                         2.4                              11.6              
 750                         4.3                              20.2              
1000                         5.4                              30.8     </pre><p>

       
Maximum serum concentrations are attained 1 to 2 hours after oral dosing. Mean
concentrations 12 hours after dosing with 250, 500, or 750 mg are 0.1, 0.2, and 
0.4 mcgm/mL, respectively. The serum elimination half-life in subjects with
normal renal function is approximately 4 hours.  <p>
 
Approximately 40 to 50% of an orally administered dose is excreted in the urine 
as unchanged drug. After a 250 mg oral dose, urine concentrations of
ciprofloxacin usually exceed 200 mcgm/mL during the first two hours and are
approximately 30 mcgm/mL at 8 to 12 hours after dosing. The urinary excretion
of ciprofloxacin is virtually complete within 24 hours after dosing. The renal
clearance of ciprofloxacin, which is approximately 300 mL/minute, exceeds the
normal glomerular filtration rate of 120 mL/minute. Thus, active tubular
secretion would seem to play a significant role in its elimination. Co-
administration of probenecid with ciprofloxacin results in about a 50%
reduction in the ciprofloxacin renal clearance and a 50% increase in its
concentration in the systemic circulation. Although bile concentrations of
ciprofloxacin are several fold higher than serum concentrations after oral
dosing, only a small amount of the dose administered is recovered from the bile 
as unchanged drug. An additional 1-2% of the dose is recovered from the bile in 
the form of metabolites. Approximately 20 to 35% of an oral dose is recovered
from the feces within 5 days after dosing. This may arise from either biliary
clearance or transintestinal elimination. Four metabolites have been identified 
in human urine which together account for approximately 15% of an oral dose.
The metabolites have antimicrobial activity, but are less active than unchanged 
ciprofloxacin.  
 <p>
When Ciprofloxacinfloxacin is given concomitantly with food, there is a delay in the
absorption of the drug, resulting in peak concentrations that are closer to 2
hours after dosing rather than 1 hour. The overall absorption, however, is not
substantially affected. Concurrent administration of antacids containing
magnesium hydroxide or aluminum hydroxide may reduce the bioavailability of
ciprofloxacin by as much as 90% (See PRECAUTIONS).  
 <p>
Concomitant administration of ciprofloxacin with theophylline decreases the
clearance of theophylline resulting in elevated serum theophylline levels, and
increased risk of a patient developing CNS or other adverse reactions. 
Ciprofloxacin also decreases caffeine clearance and inhibits the formation of
paraxanthine after caffeine administration. (See PRECAUTIONS).  
 <p>
In patients with reduced renal function, the half-life of ciprofloxacin is
slightly prolonged. Dosage adjustments may be required (See DOSAGE AND
ADMINISTRATION).  
 <p>
In preliminary studies in patients with stable chronic liver cirrhosis, no
significant changes in ciprofloxacin pharmacokinetics have been observed. The
kinetics of ciprofloxacin in patients with acute hepatic insufficiency, however 
have not been fully elucidated.  
 <p>
The binding of ciprofloxacin to serum proteins is 20 to 40% which is not likely 
to be high enough to cause significant protein binding interactions with other
drugs.  
 <p>
After oral administration ciprofloxacin is widely distributed throughout the
body. Tissue concentrations often exceed serum concentrations in both men and
women, particularly in genital tissue including the prostate. Ciprofloxacin is
present in active form in the saliva, nasal and bronchial secretions, sputum,
skin blister fluid, lymph, peritoneal fluid, bile and prostatic secretions. 
Ciprofloxacin has also been detected in lung, skin, fat, muscle, cartilage, and 
bone. The drug diffuses into the cerebrospinal fluid (CSF); however, CSF
concentrations are generally less than 10% of peak serum concentrations. Low
levels of the drug have been detected in the aqueous and vitreous humors of the 
eye.  <p>
 
MICROBIOLOGY: Ciprofloxacin has In Vitro activity against a wide range of gram- 
negative and gram-positive organisms. The bactericidal action of ciprofloxacin
results from interference with the enzyme DNA gyrase which is needed for the
synthesis of bacterial DNA.  <p>
 
Ciprofloxacin has been shown to be active against most strains of the following 
organisms both In Vitro and in clinical infections (See INDICATIONS AND USAGE
section):  
 <p>
GRAM-POSITIVE BACTERIA 
 <p>
Enterococcus Faecalis: Staphylococcus Aureus 
 <p>
(Many strains are : Staphylococcus epidermidis 
 <p>
only moderately : Streptococcus Pneumoniae 
 <p>
susceptible) : Streptococcus Pyogenes 
<p>
GRAM-NEGATIVE BACTERIA 
 <p>
Campylobacter Jejuni: Proteus Mirabilis 
 <p>
Citrobacter Diversus: Proteus Vulgaris 
 <p>
Citrobacter Freundii: Providencia Rettgeri 
 <p>
Enterobacter Cloacae: Providencia Stuartii 
 <p>
Escherichia Coli: Pseudomonas Aeruginosa 
 <p>
Haemophilus Influenzae: Serratia Marcescens 
 <p>
Haemophilus Parainfluenzae: Shigella Flexneri 
 <p>
Klebsiella Pneumoniae: Shigella Sonnei 
 <p>
Morganella Morganii 
 <p>
Ciprofloxacin has been shown to be active In Vitro against most strains of the
following organisms; however, The Clinical Significance Of These Data Is
Unknown.  <p>
 
GRAM-POSITIVE BACTERIA 
 <p>
Staphylococcus Haemolyticus: Staphylococcus Saprophyticus 
 <p>
Staphylococcus Hominis 
 <p>
GRAM-NEGATIVE BACTERIA 
 <p>
Acinetobacter Calcoaceticus : Legionella Pneumophila 
 <p>
subs. Anitrastus : Moraxella (Branhamella) 
 <p>
Acinetobacter Calcoaceticus : Catarrhalis 
 <p>
subs. Iwoffi : Neisseria Gonorrhoeae 
 <p>
Aeromonas Caviae: Neisseria Meningitidis 
 <p>
Aeromonas Hydrophila: Pasteurella Multocida 
 <p>
Brucella Melitensis: Salmonella Enteritidis 
 <p>
Campylobacter Coli: Salmonella Typhi 
 <p>
Edwardsiella Tarda: Vibrio Cholerae 
 <p>
Enterobacter Aerogenes: Vibrio Parahaemolyticus 
 <p>
Haemophilus Ducreyi: Vibrio Vulnificus 
 <p>
Klebsiella Oxytoca: Yersinia Enterocolitica 
<p>
OTHER ORGANISMS 
 <p>
Chlamydia Trachomatis (only moderately susceptible) 
 <p>
Mycobacterium Tuberculosis (only moderately susceptible) 
 <p>
Most strains of Pseudomonas Cepacia and some strains of Xanthomonas
(Pseudomonas) Maltophilia are resistant to ciprofloxacin as are most anaerobic
bacteria, including Bacteroides Fragilis and Clostridium Difficile.  
 <p>
Ciprofloxacin is slightly less active when tested at acidic pH. The inoculum
size has little effect when tested In Vitro. The minimum bactericidal
concentration (MBC) generally does not exceed the minimum inhibitory
concentration (MIC) by more than a factor of 2. Resistance to ciprofloxacin In
Vitro develops slowly (multiple-step mutation).  
 <p>
Ciprofloxacin does not cross-react with other antimicrobial agents such as beta 
lactams or aminoglycosides; therefore, organisms resistant to these drugs may
be susceptible to ciprofloxacin.  
 <p>
In Vitro studies have shown that additive activity often results when
ciprofloxacin is combined with other antimicrobial agents such as beta-lactams, 
aminoglycosides, clindamycin, or metronidazole. Synergy has been reported
particularly with the combination of ciprofloxacin and a beta-lactam;
antagonism is observed only rarely.  
 <p>
SUSCEPTIBILITY TESTS 
 <p>
DIFFUSION TECHNIQUES:  Quantitative methods that require measurement of zone
diameters give the most precise estimates of susceptibility of bacteria to
antimicrobial agents. One such standardized procedure (REF. 1) which has been
recommended for use with disks to test susceptibility of organisms to
ciprofloxacin uses the 5-mcgm ciprofloxacin disk. Interpretation involves
correlation of the diameters obtained in the disk test with the minimum
inhibitory concentrations (MICs) for ciprofloxacin.  
 <p>
Reports from the laboratory giving results of the standard single-disk
susceptibility test with a 5-mcgm ciprofloxacin disk should be interpreted
according to the following criteria:  
 <p><pre>
ZONE DIAMETER (MM)    INTERPRETATION                                            
   &gt;/=21              (S) Susceptible                                           
   16-20              (I) Intermediate (Moderately                              
                             Susceptible)                                       
   &lt;/=15               Resistant                                             
A report of &quot;Susceptible&quot; indicates that the pathogen is likely to be inhibited 
by generally achievable blood levels. A report of &quot;Intermediate (Moderately
Susceptible)&quot; suggests that the organism would be susceptible if high dosage is 
used or if the infection is confined to tissues and fluids in which high
antimicrobial levels are attained. A report of &quot;Resistant&quot; indicates that
achievable drug concentrations are unlikely to be inhibitory and other therapy
should be selected.  
 
DILUTION TECHNIQUES: Use a standardized dilution method (REF. 2) (broth, agar,
microdilution) or equivalent with ciprofloxacin powder. The MIC values obtained 
should be interpreted according to the following criteria:
  
MIC (MCGM/ML)     INTERPRETATION                                                
   &lt;/=1           (S) Susceptible                                               
      2           (I) Intermediate (Moderately                                  
                       Susceptible)                                             
   &gt;/=4            Resistant                                                 
Standardized procedures require the use of laboratory control organisms. This
is true for both standardized diffusion techniques and standardized dilution
techniques. The 5-mcgm ciprofloxacin disk should give the following zone
diameters and the standard ciprofloxacin powder should provide the following
MIC values:  
 
                                    DISK ZONE DIAMETER                          
             QC STRAINS                    (MM)              MIC (MCGM/ML)      
S. Aureus (ATCC 25923)                    22-30                    --           
S. Aureus (ATCC 29213)                      --                  0.12-0.5        
E. Coli (ATCC 25922)                      30-40               0.004-0.015       
P. Aeruginosa (ATCC 27853)                25-33                 0.25-1.0        
E. Faecalis (ATCC 29212)                    --                  0.25-2.0        
For anaerobic bacteria the MIC of ciprofloxacin can be determined by agar or
broth dilution (including microdilution) techniques (REF. 3).  </pre><p>
 
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
Ciprofloxacinfloxacin is indicated for the treatment of infections caused by susceptible
strains of the designated microorganisms in the conditions listed below. Please 
see DOSAGE AND ADMINISTRATION for specific recommendations.  
 <p>
LOWER RESPIRATORY INFECTIONS caused by Escherichia Coli, Klebsiella Pneumoniae, 
Enterobacter Cloacae, Proteus Mirabilis, Pseudomonas Aeruginosa, Haemophilus
Influenzae, Haemophilus Parainfluenzae, or Streptococcus Pneumoniae.  
 <p>
SKIN AND SKIN STRUCTURE INFECTIONS caused by Escherichia Coli, Klebsiella
Pneumoniae, Enterobacter Cloacae, Proteus Mirabilis, Proteus Vulgaris,
Providencia Stuartii, Morganella Morganii, Citrobacter Freundii, Pseudomonas
Aeruginosa, Staphylococcus Aureus, Staphylococcus Epidermidis, or Streptococcus 
Pyogenes.  <p>
 
BONE AND JOINT INFECTIONS caused by Enterobacter Cloacae, Serratia Marcescens,
or Pseudomonas Aeruginosa.  
 <p>
URINARY TRACT INFECTIONS caused by Escherichia Coli, Klebsiella Pneumoniae,
Enterobacter Cloacae, Serratia Marcescens, Proteus Mirabilis, Providencia
Rettgeri, Morganella Morganii, Citrobacter Diversus, Citrobacter Freundii,
Pseudomonas Aeruginosa, Staphylococcus Epidermidis, or Enterococcus Faecalis. 
 <p>
INFECTIOUS DIARRHEA caused by Escherichia Coli (enterotoxigenic strains),
Campylobacter Jejuni, Shigella Flexneri* or Shigella Sonnei* when antibacterial 
therapy is indicated.  
 <p>
* Although treatment of infections due to this organism in this organ system
demonstrated a clinically significant outcome, efficacy was studied in fewer
than 10 patients.  
 <p>
If anaerobic organisms are suspected of contributing to the infection,
appropriate therapy should be administered.  <p>
 
Appropriate culture and susceptibility tests should be performed before
treatment in order to isolate and identify organisms causing infection and to
determine their susceptibility to ciprofloxacin. Therapy with Ciprofloxacinfloxacin may be
initiated before results of these tests are known; once results become
available appropriate therapy should be continued. As with other drugs, some
strains of Pseudomonas Aeruginosa may develop resistance fairly rapidly during
treatment with ciprofloxacin. Culture and susceptibility testing performed
periodically during therapy will provide information not only on the
therapeutic effect of the antimicrobial agent but also on the possible
emergence of bacterial resistance.  
 <p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <p>
Ciprofloxacinfloxacin  is contraindicated in persons with a
history of hypersensitivity to ciprofloxacin or any member of the quinolone
class of antimicrobial agents.  
 <p>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <p>
THE SAFETY AND EFFECTIVENESS OF Ciprofloxacin IN CHILDREN, ADOLESCENTS (LESS
THAN 18 YEARS OF AGE), PREGNANT WOMEN, AND LACTATING WOMEN HAVE NOT BEEN
ESTABLISHED. (SEE PRECAUTIONS--PEDIATRIC USE, PREGNANCY AND NURSING MOTHERS
SUBSECTIONS.) The oral administration of ciprofloxacin caused lameness in
immature dogs. Histopathological examination of the weight-bearing joints of
these dogs revealed permanent lesions of the cartilage. Related quinolone-class 
drugs also produce erosions of cartilage of weight-bearing joints and other
signs of arthropathy in immature animals of various species. (See ANIMAL
PHARMACOLOGY.) 
 <p>
Convulsions have been reported in patients receiving ciprofloxacin. Convulsions 
increased intracranial pressure, and toxic psychosis have been reported in
patients receiving drugs in this class. Quinolones may also cause central
nervous system (CNS) stimulation which may lead to tremors, restlessness,
lightheadedness, confusion and hallucinations. If these reactions occur in
patients receiving ciprofloxacin, the drug should be discontinued and
appropriate measures instituted. As with all quinolones, ciprofloxacin should
be used with caution in patients with known or suspected CNS disorders, such as 
severe cerebral arteriosclerosis, epilepsy, and other factors that predispose
to seizures. (See ADVERSE REACTIONS.) 
 <p>
SERIOUS AND FATAL REACTIONS HAVE BEEN REPORTED IN PATIENTS RECEIVING CONCURRENT 
ADMINISTRATION OF Ciprofloxacin AND THEOPHYLLINE. These reactions have included 
cardiac arrest, seizure, status epilepticus and respiratory failure. Although
similar serious adverse events have been reported in patients receiving
theophylline alone, the possibility that these reactions may be potentiated by
ciprofloxacin cannot be eliminated. If concomitant use cannot be avoided, serum 
levels of theophylline should be monitored and dosage adjustments made as
appropriate.  
 <p>
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some
following the first dose, have been reported in patients receiving quinolone
therapy. Some reactions were accompanied by cardiovascular collapse, loss of
consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and
itching. Only a few patients had a history of hypersensitivity reactions. 
Serious anaphylactic reactions require immediate emergency treatment with
epinephrine. Oxygen, intravenous steroids, and airway management, including
intubation, should be administered as indicated.  
Severe hypersensitivity reactions characterized by rash, fever, eosinophilia,
jaundice, and hepatic necrosis with fatal outcome have also been rarely
reported in patients receiving ciprofloxacin along with other drugs. The
possibility that these reactions were related to ciprofloxacin cannot be
excluded. Ciprofloxacin should be discontinued at the first appearance of a
skin rash or any other sign of hypersensitivity.  <p>
 
PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH NEARLY ALL ANTIBACTERIAL AGENTS 
INCLUDING Ciprofloxacin, AND MAY RANGE IN SEVERITY FROM MILD TO LIFE-
THREATENING. THEREFORE, IT IS IMPORTANT TO CONSIDER THIS DIAGNOSIS IN PATIENTS
WHO PRESENT WITH DIARRHEA SUBSEQUENT TO THE ADMINISTRATION OF ANTIBACTERIAL
AGENTS.  <p>
 
Treatment with antibacterial agents alters the normal flora of the colon and
may permit overgrowth of clostridia. Studies indicate that a toxin produced by
Clostridium Difficile is one primary cause of &quot;antibiotic-associated colitis&quot;.  
 <p>
After the diagnosis of pseudomembranous colitis has been established,
therapeutic measures should be initiated. Mild cases of pseudomembranous
colitis usually respond to drug discontinuation alone. In moderate to severe
cases, consideration should be given to management with fluids and electrolytes 
protein supplementation and treatment with an antibacterial drug clinically
effective against C. Difficile colitis.  
 <p>
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
GENERAL:  Crystals of ciprofloxacin have been observed rarely in the urine of
human subjects but more frequently in the urine of laboratory animals, which is 
usually alkaline. (See ANIMAL PHARMACOLOGY.) Crystalluria related to
ciprofloxacin has been reported only rarely in humans because human urine is
usually acidic. Alkalinity of the urine should be avoided in patients receiving 
ciprofloxacin. Patients should be well hydrated to prevent the formation of
highly concentrated urine.  
 <p>
Alteration of the dosage regimen is necessary for patients with impairment of
renal function. (See DOSAGE AND ADMINISTRATION.) 
 <p>
Moderate to severe phototoxicity manifested by an exaggerated sunburn reaction
has been observed in patients who are exposed to direct sunlight while
receiving some members of the quinolone class of drugs. Excessive sunlight
should be avoided. Therapy should be discontinued if phototoxicity occurs.  
 <p>
As with any potent drug, periodic assessment of organ system functions,
including renal, hepatic, and hematopoietic function, is advisable during
prolonged therapy.  
 <p>
<b>INFORMATION FOR PATIENTS:</b>  Patients should be advised that ciprofloxacin may be 
taken with or without meals. The preferred time of dosing is two hours after a
meal. Patients should also be advised to drink fluids liberally and not take
antacids containing magnesium, aluminum, or calcium, products containing iron,
or multivitamins containing zinc. However, usual dietary intake of calcium has
not been shown to alter the absorption of ciprofloxacin.  
 <p>
Patients should be advised that ciprofloxacin may be associated with
hypersensitivity reactions, even following a single dose, and to discontinue
the drug at the first sign of a skin rash or other allergic reaction.  
<p>
Patients should be advised to avoid excessive sunlight or artificial
ultraviolet light while receiving ciprofloxacin and to discontinue therapy if
phototoxicity occurs.  <p>
 
Ciprofloxacin may cause dizziness and lightheadedness; therefore patients
should know how they react to this drug before they operate an automobile or
machinery or engage in activities requiring mental alertness or coordination. 
 <p>
Patients should be advised that ciprofloxacin may increase the effects of
theophylline and caffeine. There is a possibility of caffeine accumulation when 
products containing caffeine are consumed while taking quinolones.  
 <p>
<b>DRUG INTERACTIONS:</b>  As with some other quinolones, concurrent administration of 
ciprofloxacin with theophylline may lead to elevated serum concentrations of
theophylline and prolongation of its elimination half-life. This may result in
increased risk of theophylline-related adverse reactions. (See WARNINGS.) If
concomitant use cannot be avoided, serum levels of theophylline should be
monitored and dosage adjustments made as appropriate.  <p>
 
Some quinolones, including ciprofloxacin, have also been shown to interfere
with the metabolism of caffeine. This may lead to reduced clearance of caffeine 
and a prolongation of its serum half-life.  <p>
 
Concurrent administration of ciprofloxacin with antacids containing magnesium,
aluminum, or calcium; with sucralfate or divalent and trivalent cations such as 
iron may substantially interfere with the absorption of ciprofloxacin,
resulting in serum and urine levels considerably lower than desired. To a
lesser extent this effect is demonstrated with zinc-containing multivitamins.
(See DOSAGE AND ADMINISTRATION for concurrent administration of these agents
with ciprofloxacin.) <p>
 
Some quinolones, including ciprofloxacin, have been associated with transient
elevations in serum creatinine in patients receiving cyclosporine
concomitantly.  <p>
 
Quinolones have been reported to enhance the effects of the oral anticoagulant
warfarin or its derivatives. When these products are administered concomitantly 
prothrombin time or other suitable coagulation tests should be closely
monitored.  
 <p>
Probenecid interferes with renal tubular secretion of ciprofloxacin and
produces an increase in the level of ciprofloxacin in the serum. This should be 
considered if patients are receiving both drugs concomitantly.  
 <p>
As with other broad spectrum antimicrobial agents, prolonged use of
ciprofloxacin may result in overgrowth of nonsusceptible organisms. Repeated
evaluation of the patient's condition and microbial susceptibility testing is
essential. If superinfection occurs during therapy, appropriate measures should 
be taken.  <p>
 
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Eight In Vitro
mutagenicity tests have been conducted with ciprofloxacin and the test results
are listed below:  <p>
 
Salmonella/Microsome Test (Negative) 
 <p>
E. Coli DNA Repair Assay (Negative) 
<p>
Mouse Lymphoma Cell Forward Mutation Assay 
 <p>
(Positive) 
 <p>
Chinese Hamster V79 Cell HGPRT Test (Negative) 
 <p>
Syrian Hamster Embryo Cell Transformation Assay 
 <p>
(Negative) 
 <p>
Saccharomyces Cerevisiae Point Mutation Assay (Negative) 
 <p>
Saccharomyces Cerevisiae Mitotic Crossover and Gene 
 <p>
Conversion Assay (Negative) 
 <p>
Rat Hepatocyte DNA Repair Assay (Positive) 
 <p>
Thus 2 of the 8 tests were positive but results of the following 3 In Vivo test 
systems gave negative results:  
 <p>
Rat Hepatocyte DNA Repair Assay 
 <p>
Micronucleus Test (Mice) 
 <p>
Dominant Lethal Test (Mice) 
 <p>
Long term carcinogenicity studies in mice and rats have been completed. After
daily oral dosing for up to 2 years, there is no evidence that ciprofloxacin
had any carcinogenic or tumorigenic effects in these species.  
 <p>
PREGNANCY: TERATOGENIC EFFECTS. PREGNANCY CATEGORY C: Reproduction studies have 
been performed in rats and mice at doses up to 6 times the usual daily human
dose and have revealed no evidence of impaired fertility or harm to the fetus
due to ciprofloxacin. In rabbits, as with most antimicrobial agents,
ciprofloxacin (30 and 100 mg/kg orally) produced gastrointestinal disturbances
resulting in maternal weight loss and an increased incidence of abortion. No
teratogenicity was observed at either dose. After intravenous administration,
at doses up to 20 mg/kg, no maternal toxicity was produced, and no
embryotoxicity or teratogenicity was observed. There are, however, no adequate
and well- controlled studies in pregnant women. Ciprofloxacin should be used
during pregnancy only if the potential benefit justifies the potential risk to
the fetus. (See WARNINGS.) <p>
 
NURSING MOTHERS:  Ciprofloxacin is excreted in human milk. Because of the
potential for serious adverse reactions in infants nursing from mothers taking
ciprofloxacin, a decision should be made either to discontinue nursing or to
discontinue the drug, taking into account the importance of the drug to the
mother.  
 <p>
PEDIATRIC USE:  Safety and effectiveness in children and adolescents less than
18 years of age have not been established. Ciprofloxacin causes arthropathy in
juvenile animals. (See WARNINGS.) 
 <p>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b>
 <p>

 As with some other quinolones, concurrent administration of ciprofloxacin with
theophylline may lead to elevated serum concentrations of theophylline and
prolongation of its elimination half-life. This may result in increased risk of 
theophylline-related adverse reactions. (See WARNINGS.) If concomitant use
cannot be avoided, serum levels of theophylline should be monitored and dosage
adjustments made as appropriate.  
 <p>
Some quinolones, including ciprofloxacin, have also been shown to interfere
with the metabolism of caffeine. This may lead to reduced clearance of caffeine 
and a prolongation of its serum half-life.  
 <p>
Concurrent administration of ciprofloxacin with antacids containing magnesium,
aluminum, or calcium; with sucralfate or divalent and trivalent cations such as 
iron may substantially interfere with the absorption of ciprofloxacin,
resulting in serum and urine levels considerably lower than desired. To a
lesser extent this effect is demonstrated with zinc-containing multivitamins.
(See DOSAGE AND ADMINISTRATION for concurrent administration of these agents
with ciprofloxacin.) 
 <p>
Some quinolones, including ciprofloxacin, have been associated with transient
elevations in serum creatinine in patients receiving cyclosporine
concomitantly.  
 <p>
Quinolones have been reported to enhance the effects of the oral anticoagulant
warfarin or its derivatives. When these products are administered concomitantly 
prothrombin time or other suitable coagulation tests should be closely
monitored.  <p>
 
Probenecid interferes with renal tubular secretion of ciprofloxacin and
produces an increase in the level of ciprofloxacin in the serum. This should be 
considered if patients are receiving both drugs concomitantly.  
 <p>
As with other broad spectrum antimicrobial agents, prolonged use of
ciprofloxacin may result in overgrowth of nonsusceptible organisms. Repeated
evaluation of the patient's condition and microbial susceptibility testing is
essential. If superinfection occurs during therapy, appropriate measures should 
be taken.  <p>
 
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
During clinical investigation, 2,799 patients received 2,868 courses of the
drug. Adverse events that were considered likely to be drug related occurred in 
7.3% of patients treated, possibly related in 9.2%, (total of 16.5% thought to
be possibly or probably related to drug therapy), and remotely related in 3.0%. 
Ciprofloxacin was discontinued because of an adverse event in 3.5% of patients
treated, primarily involving the gastrointestinal system (1.5%), skin (0.6%),
and central nervous system (0.4%).  
 <p>
The most frequently reported events, drug related or not, were nausea (5.2%),
diarrhea (2.3%), vomiting (2.0%), abdominal pain/discomfort (1.7%), headache
(1.2%), restlessness (1.1%), and rash (1.1%).  
 <p>
Additional events that occurred in less than 1% of ciprofloxacin treated
patients are listed below.  
 <p>
CARDIOVASCULAR: palpitation, atrial flutter, ventricular ectopy, syncope,
hypertension, angina pectoris, myocardial infarction, cardiopulmonary arrest,
cerebral thrombosis 
 <p>
CENTRAL NERVOUS SYSTEM: dizziness, lightheadedness, insomnia, nightmares,
hallucinations, manic reaction, irritability, tremor, ataxia, convulsive
seizures, lethargy, drowsiness, weakness, malaise, anorexia, phobia,
depersonalization, depression, paresthesia (See above.) (See PRECAUTIONS.) 
 <p>
GASTROINTESTINAL: painful oral mucosa, oral candidiasis, dysphagia, intestinal
perforation, gastrointestinal bleeding (See above.) Cholestatic jaundice has
been reported.  
 <p>
MUSCULOSKELETAL: joint or back pain, joint stiffness, achiness, neck or chest
pain, flare up of gout <p>
 
RENAL/UROGENITAL: interstitial nephritis, nephritis, renal failure, polyuria,
urinary retention, urethral bleeding, vaginitis, acidosis 
 <p>
RESPIRATORY: dyspnea, epistaxis, laryngeal or pulmonary edema, hiccough,
hemoptysis, bronchospasm, pulmonary embolism 
 <p>
SKIN/HYPERSENSITIVITY: pruritus, urticaria, photosensitivity, flushing, fever,
chills, angioedema, edema of the face, neck, lips, conjunctivae or hands,
cutaneous candidiasis, hyperpigmentation, erythema nodosum (See above.) 
 <p>
Allergic reactions ranging from urticaria to anaphylactic reactions have been
reported. (See WARNINGS).  <p>
 
SPECIAL SENSES: blurred vision, disturbed vision (change in color perception,
overbrightness of lights), decreased visual acuity, diplopia, eye pain,
tinnitus, hearing loss, bad taste 
 <p>
Most of the adverse events reported were described as only mild or moderate in
severity, abated soon after the drug was discontinued, and required no
treatment.  
 <p>
In several instances nausea, vomiting, tremor, irritability or palpitation were 
judged by investigators to be related to elevated serum levels of theophylline
possibly as a result of drug interaction with ciprofloxacin.  
 <p>
Other adverse events reported in the postmarketing phase include anaphylactic
reactions, erythema multiforme/Stevens-Johnson syndrome, exfoliative dermatitis 
toxic epidermal necrolysis, vasculitis, jaundice, hepatic necrosis, toxic
psychosis, postural hypotension, possible exacerbation of myasthenia gravis,
anosmia, confusion, dysphasia, nystagmus, pseudomembranous colitis,
pancreatitis, dyspepsia, flatulence, and constipation. Also reported were
hemolytic anemia; agranulocytosis; elevation of serum triglycerides, serum
cholesterol, blood glucose, serum potassium; prolongation of prothrombin time;
albuminuria; candiduria, vaginal candidiasis; renal calculi; and change in
serum phenytoin. (See PRECAUTIONS).  <p>
 
ADVERSE LABORATORY CHANGES:  Changes in laboratory parameters listed as adverse 
events without regard to drug relationship:  
 <p>
Hepatic--Elevations of: ALT (SGPT) (1.9%), AST (SGOT) (1.7%), alkaline
phosphatase (0.8%), LDH (0.4%), serum bilirubin (0.3%).  
 <p>
Hematologic--Eosinophilia (0.6%), leukopenia (0.4%), decreased blood platelets
(0.1%), elevated blood platelets (0.1%), pancytopenia (0.1%).  
 <p>
Renal--Elevations of: Serum creatinine (1.1%), BUN (0.9%).  
 <p>
CRYSTALLURIA, CYLINDRURIA AND HEMATURIA HAVE BEEN REPORTED.  
 <p>
Other changes occurring in less than 0.1% of patients treated were: Elevation
of serum gammaglutamyl transferase, elevation of serum amylase, reduction in
blood glucose, elevated uric acid, decrease in hemoglobin, anemia, bleeding
diathesis, increase in blood monocytes, leukocytosis.  
 <p>
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <p>
In the event of acute overdosage, the stomach should be emptied by inducing
vomiting or by gastric lavage. The patient should be carefully observed and
given supportive treatment. Adequate hydration must be maintained. Only a small 
amount of ciprofloxacin (&lt;10%) is removed from the body after hemodialysis or
peritoneal dialysis.  
 <p>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
The usual adult dosage for patients with urinary tract infections is 250 mg
every 12 hours. For patients with complicated infections caused by organisms
not highly susceptible, 500 mg may be administered every 12 hours.  
 <p>
Lower respiratory tract infections, skin and skin structure infections, and
bone and joint infections may be treated with 500 mg every 12 hours. For more
severe or complicated infections, a dosage of 750 mg may be given every 12
hours.  <p>
 
The recommended dosage for Infectious Diarrhea is 500 mg every 12 hours.  
 <p><pre>
                                DOSAGE GUIDELINES                               
LOCATION OF INFECTION  TYPE OR SEVERITY     UNIT DOSE   FREQUENCY      DAILY    
                                                                        DOSE    
-----------------------------------------------------------------------------   
Urinary Tract          Mild/Moderate          250 mg      q 12 h       500 mg   
                       -------------------------------------------------------  
                       Severe/Complicated     500 mg      q 12 h      1000 mg   
-----------------------------------------------------------------------------   
Lower Respiratory      Mild/Moderate          500 mg      q 12 h      1000 mg   
 Tract;                                                                         
Bone and Joint;        -------------------------------------------------------  
Skin &amp; Skin Structure  Severe/Complicated     750 mg      q 12 h      1500 mg   
-----------------------------------------------------------------------------   
Infectious Diarrhea    Mild/Moderate/Severe   500 mg      q 12 h      1000 mg 
</pre><p>
 
The determination of dosage for any particular patient must take into
consideration the severity and nature of the infection, the susceptibility of
the causative organism, the integrity of the patient's host-defense mechanisms, 
and the status of renal function and hepatic function.  
 <p>
The duration of treatment depends upon the severity of infection. Generally
ciprofloxacin should be continued for at least 2 days after the signs and
symptoms of infection have disappeared. The usual duration is 7 to 14 days;
however, for severe and complicated infections more prolonged therapy may be
required. Bone and joint infections may require treatment for 4 to 6 weeks or
longer. Infectious Diarrhea may be treated for 5-7 days.  <p>
CONCURRENT USE WITH ANTACIDS OR MULTIVALENT CATIONS: Concurrent administration
of ciprofloxacin with sucralfate or divalent and trivalent cations such as iron 
or antacids containing magnesium, aluminum, or calcium may substantially
interfere with the absorption of ciprofloxacin, resulting in serum and urine
levels considerably lower than desired. Therefore, concurrent administration of 
these agents with ciprofloxacin should be avoided. However, usual dietary
intake of calcium has not been shown to alter the bioavailability of
ciprofloxacin.  Single dose bioavailability studies have shown that antacids
may be administered either 2 hours after or 6 hours before ciprofloxacin dosing 
without a significant decrease in bioavailability. Histamine H2-receptor
antagonists appear to have no significant effect on the bioavailability of
ciprofloxacin.  <p>
 
IMPAIRED RENAL FUNCTION:  Ciprofloxacin is eliminated primarily by renal
excretion; however, the drug is also metabolized and partially cleared through
the biliary system of the liver and through the intestine. These alternate
pathways of drug elimination appear to compensate for the reduced renal
excretion in patients with renal impairment. Nonetheless, some modification of
dosage is recommended, particularly for patients with severe renal dysfunction. 
The following table provides dosage guidelines for use in patients with renal
impairment; however, monitoring of serum drug levels provides the most reliable 
basis for dosage adjustment:  <p><pre>
 
                       RECOMMENDED STARTING AND MAINTENANCE                     
                         DOSES FOR PATIENTS WITH IMPAIRED                       
                                  RENAL FUNCTION                                
CREATININE CLEARANCE (ML/MIN)                           DOSE                    
                  &gt;50                             See Usual Dosage              
                 30-50                           250-500 mg q 12 h              
                  5-29                           250-500 mg q 18 h              
        Patients on hemodialysis                 250-500 mg q 24 h              
         or Peritoneal dialysis                   (after dialysis)              
When only the serum creatinine concentration is known, the following formula
may be used to estimate creatinine clearance.  
 
Men: Creatinine clearance                                                       
                     (mL/min)                      Weight (kg) X (140 - age)    
                               =   -------------------------------------------  
                                                 72 X serum creatinine (mg/dL)  
Women: 0.85 X the value calculated for men.                                     
The serum creatinine should represent a steady state of renal function.  
 </pre><p>
In patients with severe infections and severe renal impairment, a unit dose of
750 mg may be administered at the intervals noted above; however, patients
should be carefully monitored and the serum ciprofloxacin concentration should
be measured periodically. Peak concentrations (1-2 hours after dosing) should
generally range from 2 to 4 mcgm/mL.  
 <p>
For patients with changing renal function or for patients with renal impairment 
and hepatic insufficiency, measurement of serum concentrations of ciprofloxacin 
will provide additional guidance for adjusting dosage.  
 <p>
ANIMAL PHARMACOLOGY 
 <p>
Ciprofloxacin and other quinolones have been shown to cause arthropathy in
immature animals of most species tested (See WARNINGS). Damage of weight
bearing joints was observed in juvenile dogs and rats. In young beagles 100
mg/kg ciprofloxacin given daily for 4 weeks, caused degenerative articular
changes of the knee joint. At 30 mg/kg the effect on the joint was minimal. In
a subsequent study in beagles removal of weight bearing from the joint reduced
the lesions but did not totally prevent them.  
 <p>
Crystalluria, sometimes associated with secondary nephropathy, occurs in
laboratory animals dosed with ciprofloxacin. This is primarily related to the
reduced solubility of ciprofloxacin under alkaline conditions, which
predominate in the urine of test animals; in man, crystalluria is rare since
human urine is typically acidic. In rhesus monkeys, crystalluria without
nephropathy has been noted after single oral doses as low as 5 mg/kg. After 6
months of intravenous dosing at 10 mg/kg/day, no nephropathological changes
were noted; however, nephropathy was observed after dosing at 20 mg/kg/day for
the same duration.  <p>
In dogs, ciprofloxacinfloxacin at 3 and 10 mg/kg by rapid IV injection (15 sec.)
produces pronounced hypotensive effects. These effects are considered to be
related to histamine release since they are partially antagonized by pyrilamine 
an antihistamine. In rhesus monkeys, rapid IV injection also produces
hypotension but the effect in this species is inconsistent and less pronounced. 
 <p>
In mice, concomitant administration of nonsteroidal anti-inflammatory drugs
such as fenbufen, phenylbutazone and indomethacin with quinolones has been
reported to enhance the CNS stimulatory effect of quinolones.  
 <p>
Ocular toxicity seen with some related drugs has not been observed in
ciprofloxacin-treated animals.  
 <p>
REFERENCES 
 <p>
1. National Committee for Clinical Laboratory Standards, PERFORMANCE STANDARDS
FOR ANTIMICROBIAL DISK SUSCEPTIBILITY TESTS--Fourth Edition. Approved Standard
NCCLS Document M2-A4, Vol. 10, No. 7, NCCLS, Villanova, PA, April, 1990. 2. 
National Committee for Clinical Laboratory Standards, METHODS FOR DILUTION
ANTIMICROBIAL SUSCEPTIBLITY TESTS FOR BACTERIA THAT GROW AEROBICALLY-- Second
Edition. Approved Standard NCCLS Document M7-A2, Vol. 10, No. 8, NCCLS,
Villanova, PA, April, 1990. 3. National Committee 
<p>
<h3 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h3>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-43</DOCNO>
<DOCOLDNO>IA018-000200-B033-92</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/conest.htm 206.86.175.201 19970106223549 text/html 32725
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:29:34 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 32542
Last-modified: Sat, 06 Jul 1996 07:11:44 GMT
</DOCHDR>
<html>
<head>
   <title>Conjugated Estrogens - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Conjugated Estrogens</h1>

<p>
<hr><font COLOR="#0000FF">
[<a href="#DESCRIPTION">description</a>] 
[<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>]
[<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] 
[<a href="#PRECAUTIONS">caution</a>]
[<!a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>]
[<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>]</font> </p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION 
<P></P>
</b> 
<P></P>
Caution: Federal law prohibits dispensing without prescription.  
<P></P>
 

 

1. ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA

IN POSTMENOPAUSAL WOMEN.  
<P></P>
 

Close clinical surveillance of all women taking estrogens is important.

Adequate diagnostic measures, including endometrial sampling when indicated,

should be undertaken to rule out malignancy in all cases of undiagnosed

persistent or recurring abnormal vaginal bleeding. There is currently no

evidence that &quot;natural&quot; estrogens are more or less hazardous than &quot;synthetic&quot;

estrogens at equiestrogenic doses.  
<P></P>
 

2. ESTROGENS SHOULD NOT BE USED DURING PREGNANCY.  

 <P></P>

Estrogen therapy during pregnancy is associated with an increased risk of

congenital defects in the reproductive organs of the male and female fetus, an

increased risk of vaginal adenosis, squamous-cell dysplasia of the uterine

cervix, and vaginal cancer in the female later in life. The 1985 DES Task Force 

concluded that women who used DES during their pregnancies may subsequently

experience an increased risk of breast cancer. However, a causal relationship

is still unproven, and the observed level of risk is similar to that for a

number of other breast-cancer risk factors.  
<P></P>
 

There is no indication for estrogen therapy during pregnancy. Estrogens are

ineffective for the prevention or treatment of threatened or habitual abortion. 

 <P></P>

 

Conjugated estrogens tablets for oral administration contain a 

mixture of estrogens obtained exclusively from natural sources, occurring as

the sodium salts of water-soluble estrogen sulfates blended to represent the

average composition of material derived from pregnant mares' urine. It contains 

estrone, equilin, and 17 alpha-dihydroequilin, together with smaller amounts of 

17 alpha- estradiol, equilenin, and 17 alpha-dihydroequilenin as salts of their 

sulfate esters.
<P></P>


<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 

</b> <P></P>

Estrogens are important in the development and maintenance of the female

reproductive system and secondary sex characteristics. They promote growth and

development of the vagina, uterus, and fallopian tubes, and enlargement of the

breasts. Indirectly, they contribute to the shaping of the skeleton,

maintenance of tone and elasticity of urogenital structures, changes in the

epiphyses of the long bones that allow for the pubertal growth spurt and its

termination, growth of axillary and pubic hair, and pigmentation of the nipples 

and genitals.  Decline of estrogenic activity at the end of the menstrual cycle 

can bring on menstruation, although the cessation of progesterone secretion is

the most important factor in the mature ovulatory cycle. However, in the

preovulatory or nonovulatory cycle, estrogen is the primary determinant in the

onset of menstruation. Estrogens also affect the release of pituitary

gonadotropins.  
<P></P>
 

The pharmacologic effects of conjugated estrogens are similar to those of

endogenous estrogens. They are soluble in water and are well absorbed from the

gastrointestinal tract.  

 
<P></P>
In responsive tissues (female genital organs, breasts, hypothalamus, pituitary) 

estrogens enter the cell and are transported into the nucleus. As a result of

estrogen action, specific RNA and protein synthesis occurs.  

 <P></P>

Metabolism and inactivation occur primarily in the liver. Some estrogens are

excreted into the bile; however, they are reabsorbed from the intestine and

returned to the liver through the portal venous system. Water-soluble estrogen

conjugates are strongly acidic and are ionized in body fluids, which favor

excretion through the kidneys since tubular reabsorption is minimal.  

 <P></P>

<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
<P></P>
</b> 

Conjugated estrogens are indicated in the treatment of:  
<P></P>
 

1. Moderate to severe vasomotor symptoms associated with the menopause. There

is no adequate evidence that estrogens are effective for nervous symptoms or

depression which might occur during menopause and they should not be used to

treat these conditions.  <P></P>

 

2. Atrophic vaginitis.  

 <P></P>

3. Osteoporosis (loss of bone mass). The mainstays of prevention and management 

of osteoporosis are estrogen and calcium; exercise and nutrition may be

important adjuncts.  

<P></P>

Estrogen replacement therapy is the most effective single modality for the

prevention of osteoporosis in women. Estrogen reduces bone resorption and

retards or halts postmenopausal bone loss. Case-controlled studies have shown

an approximately 60-percent reduction in hip and wrist fractures in women whose 

estrogen replacement was begun within a few years of menopause. Studies also

suggest that estrogen reduces the rate of vertebral fractures. Even when

started as late as 6 years after menopause, estrogen prevents further loss of

bone mass but does not restore it to premenopausal levels. The lowest effective 

dose for prevention and treatment of osteoporosis should be utilized. (See

DOSAGE AND ADMINISTRATION.) 

 <P></P>

Woman are at higher risk than men because they have less bone mass, and for

several years following natural or induced menopause, the rate of bone mass

decline is accelerated. Early menopause is one of the strongest predictors for

the development of osteoporosis. White women are at higher risk than black

women, and white men are at higher risk than black men. Women who are

underweight also have osteoporosis more often than overweight women. Cigarette

smoking may be an additional factor in increasing risk. Calcium deficiency has

been implicated in the pathogenesis of the disease. Therefore, when not

contraindicated, it is recommended that postmenopausal women receive an

elemental calcium intake of 1000 to 1500 mg/day.  
<P></P>
 

Immobilization and prolonged bed rest produce rapid bone loss, while weight-

bearing exercise has been shown both to reduce bone loss and to increase bone

mass. The optimal type and amount of physical activity that would prevent

osteoporosis have not been established.  

 <P></P>

4. Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. 
<P></P>
 

5. Breast cancer (for palliation only) in appropriately selected women and men

with metastatic disease.  

 <P></P>

6. Advanced androgen-dependent carcinoma of the prostate (for palliation only). 

 <P></P>

<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
<P></P>
</b> 

Estrogens should not be used in women (or men) with any of the following

conditions:  

 <P></P>

1. Known or suspected pregnancy (see Boxed Warning). Estrogen may cause fetal

harm when administered to a pregnant woman.  
<P></P>
 

2. Known or suspected cancer of the breast except in appropriately selected

patients being treated for metastatic disease.  

 <P></P>

3. Known or suspected estrogen-dependent neoplasia.  

 <P></P>

4. Undiagnosed abnormal genital bleeding.  

 <P></P>

5. Active thrombophlebitis or thromboembolic disorders.  

                    <P></P>

6. Women on estrogen replacement therapy have not been reported to have an

increased risk of thrombophlebitis and/or thromboembolic disease. However,

there is insufficient information regarding women who have had previous

thromboembolic disease.  

 <P></P>

Conjugated estrogens Tablets should not be used in patients hypersensitive to their

ingredients.  

 <P></P>

<a name="WARNINGS"></a><b>WARNINGS 

</b> 
<P></P>
 

1. ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA

IN POSTMENOPAUSAL WOMEN.  

 <P></P>

Close clinical surveillance of all women taking estrogens is important.

Adequate diagnostic measures, including endometrial sampling when indicated,

should be undertaken to rule out malignancy in all cases of undiagnosed

persistent or recurring abnormal vaginal bleeding. There is currently no

evidence that &quot;natural&quot; estrogens are more or less hazardous than &quot;synthetic&quot;

estrogens at equiestrogenic doses.  

 <P></P>

2. ESTROGENS SHOULD NOT BE USED DURING PREGNANCY.  
<P></P>
 

Estrogen therapy during pregnancy is associated with an increased risk of

congenital defects in the reproductive organs of the male and female fetus, an

increased risk of vaginal adenosis, squamous-cell dysplasia of the uterine

cervix, and vaginal cancer in the female later in life. The 1985 DES Task Force 

concluded that women who used DES during their pregnancies may subsequently

experience an increased risk of breast cancer. However, a causal relationship

is still unproven, and the observed level of risk is similar to that for a

number of other breast-cancer risk factors.  

 <P></P>

There is no indication for estrogen therapy during pregnancy. Estrogens are

ineffective for the prevention or treatment of threatened or habitual abortion. 

 <P></P>

 

1. Induction Of Malignant Neoplasms. Some studies have suggested a possible

increased incidence of breast cancer in those women on estrogen therapy taking

higher doses for prolonged periods of time. The majority of studies, however,

have not shown an association with the usual doses used for estrogen

replacement therapy. Women on this therapy should have regular breast

examinations and should be instructed in breast self-examination. The reported

endometrial cancer risk among estrogen users was about 4-fold or greater than

in nonusers and appears dependent on duration of treatment and on estrogen

dose. There is no significant increased risk associated with the use of

estrogens for less than one year. The greatest risk appears associated with

prolonged use--five years or more. In one study, persistence of risk was

demonstrated for 10 years after cessation of estrogen treatment. In another

study, a significant decrease in the incidence of endometrial cancer occurred

six months after estrogen withdrawal.  

 <P></P>

Estrogen therapy during pregnancy is associated with an increased risk of fetal 

congenital reproductive-tract disorders. In females there is an increased risk

of vaginal adenosis, squamous-cell dysplasia of the cervix, and cancer later in 

life; in the male, urogenital abnormalities. Although some of these changes are 

benign, it is not known whether they are precursors of malignancy.  

 <P></P>

2. Gallbladder Disease. A recent study has reported a 2.5-fold increase in the

risk of surgically confirmed gallbladder disease in women receiving

postmenopausal estrogens.  <P></P>

 

3. Cardiovascular Disease. Large doses of estrogen (5 mg conjugated estrogens

per day), comparable to those used to treat cancer of the prostate and breast,

have been shown in a large prospective clinical trial in men to increase the

risk of nonfatal myocardial infarction, pulmonary embolism, and

thrombophlebitis. It cannot necessarily be extrapolated from men to women. 

However, to avoid the theoretical cardiovascular risk caused by high estrogen

doses, the doses for estrogen replacement therapy should not exceed the

recommended dose.  
<P></P>
 

4. Elevated Blood Pressure. There is no evidence that this may occur with use

of estrogens in the menopause. However, blood pressure should be monitored with 

estrogen use, especially if high doses are used.  

 <P></P>

5. Hypercalcemia. Administration of estrogen may lead to severe hypercalcemia

in patients with breast cancer and bone metastases. If this occurs, the drug

should be stopped and appropriate measures taken to reduce the serum calcium

level.  

 <P></P>

<a name="PRECAUTIONS"></a><b>PRECAUTIONS 

</b> <P></P>

A. General.  

 <P></P>

1. Addition Of A Progestin. Studies of the addition of a progestin for seven or 

more days of a cycle of estrogen administration have reported a lowered

incidence of endometrial hyperplasia. Morphological and biochemical studies of

endometrium suggest that 10 to 13 days of progestin are needed to provide

maximal maturation of the endometrium and to eliminate any hyperplastic

changes.  Whether this will provide protection from endometrial carcinoma has

not been clearly established. There are possible additional risks which may be

associated with the inclusion of progestin in estrogen replacement regimens.

The potential risks include adverse effects on carbohydrate and lipid

metabolism. The choice of progestin and dosage may be important in minimizing

these adverse effects.  

 <P></P>

2. Physical Examination. A complete medical and family history should be taken

prior to the initiation of any estrogen therapy. The pretreatment and periodic

physical examinations should include special reference to blood pressure,

breasts, abdomen, and pelvic organs, and should include a Papanicolaou smear.

As a general rule, estrogen should not be prescribed for longer than one year

without another physical examination being performed.  

<P></P>

3. Fluid Retention. Because estrogens may cause some degree of fluid retention, 

conditions which might be influenced by this factor, such as asthma, epilepsy,

migraine, and cardiac or renal dysfunction, require careful observation.  

 <P></P>

4. Uterine Bleeding And Mastodynia. Certain patients may develop undesirable

manifestations of estrogenic stimulation, such as abnormal uterine bleeding and 

mastodynia.  <P></P>

 

5. Uterine Fibroids. Preexisting uterine leiomyomata may increase in size

during prolonged high-dose estrogen use.  
<P></P>
 

6. Impaired Liver Function. Estrogens may be poorly metabolized in patients

with impaired liver function and should be administered with caution.  
<P></P>
 

7. Hypercalcemia And Renal Insufficiency. Prolonged use of estrogens can alter

the metabolism of calcium and phosphorus. Estrogens should be used with caution 

in patients with metabolic bone disease.  

 <P></P>

B. Information for the Patient.  
<P>
 </P>

See text of Patient Package Insert which appears after the HOW SUPPLIED

section.  

 <P></P>

C. Laboratory Tests.  

 <P></P>

Clinical response at the smallest dose should generally be the guide to

estrogen administration for relief of symptoms for those indications in which

symptoms are observable. However, for prevention and treatment of osteoporosis

see DOSAGE AND ADMINISTRATION section. Tests used to measure adequacy of

estrogen replacement therapy include serum estrone and estradiol levels and

suppression of serum gonadotrophin levels.  

 
<P></P>
D. Drug/Laboratory Test Interactions.  

 <P></P>

Some of these drug/laboratory test interactions have been observed only with

estrogen-progestin combinations (oral contraceptives):  

 <P></P>

1. Increased prothrombin and factors VII, VIII, IX and X; decreased

antithrombin 3; increased norepinephrine-induced platelet aggregability,

decreased fibrinolysis.  
<P></P>
 

2. Increased thyroid-binding globulin (TBG) leading to increased circulating

total thyroid hormone, as measured by T4 levels determined either by column or

by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated 

TBG; free T4 concentration is unaltered.  

 <P></P>

3. Impaired glucose tolerance.  
<P></P>
 

4. Reduced response to metyrapone test.  
<P></P>
 

5. Reduced serum folate concentration.  

<P></P>

E. Mutagenesis and Carcinogenesis.  
<P></P>
 

Long-term, continuous administration of natural and synthetic estrogens in

certain animal species increases the frequency of carcinomas of the breast,

cervix, vagina, and liver.  

 <P></P>

F. Pregnancy Caterogy X.  

 <P></P>

Estrogens should not be used during pregnancy. See CONTRAINDICATIONS and Boxed

Warning.  

 <P></P>

G. Nursing Mothers.  

 <P></P>

As a general principle, the administration of any drug to nursing mothers

should be done only when clearly necessary since many drugs are excreted in

human milk.  

 
<P></P>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 

</b> <P></P>

(See WARNINGS regarding induction of neoplasia, adverse effects on the fetus,

increased incidence of gallbladder disease.) The following additional adverse

reactions have been reported with estrogenic therapy.  

 <P></P>

1. Genitourinary System. Changes in vaginal bleeding pattern and abnormal

withdrawal bleeding or flow. Breakthrough bleeding, spotting. Increase in size

of uterine fibromyomata. Vaginal candidiasis. Change in amount of cervical

secretion.  <P></P>

 

2. Breasts. Tenderness, enlargement.  
<P></P>
 

3. Gastrointestinal. Nausea, vomiting; abdominal cramps, bloating; cholestatic

jaundice.  
<P></P>
 

4. Skin. Chloasma or melasma that may persist when drug is discontinued;

erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp

hair; hirsutism.  

 <P></P>

5. Eyes. Steepening of corneal curvature; intolerance of contact lenses.  

 <P></P>

6. CNS. Headache, migraine, dizziness; mental depression; chorea.  

 <P></P>

7. Miscellaneous. Increase or decrease in weight; reduced carbohydrate

tolerance; aggravation of porphyria; edema; changes in libido.  

 <P></P>

<b>ACUTE <a name="OVERDOSAGE"></a>OVERDOSAGE 

</b> 
<P></P>
Numerous reports of ingestion of large doses of estrogen-containing oral

contraceptives by young children indicate that acute serious ill effects do not 

occur. Overdosage of estrogen may cause nausea and vomiting.  
<P></P>
                    

<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 

</b> 
<P></P>
1. For treatment of moderate to severe vasomotor symptoms, atrophic vaginitis,

and atrophic urethritis associated with the menopause. The lowest dose that

will control symptoms should be chosen, and medication should be discontinued

as promptly as possible.  

 
<P></P>
Attempts to discontinue or taper medication should be made at 3-month to 6

month intervals.  

 <P></P>

Usual dosage ranges:  

 <P></P>

Vasomotor symptoms--1.25 mg daily. If the patient has not menstruated within

the last two months or more, cyclic administration is started arbitrarily. If

the patient is menstruating, cyclic (e.g., three weeks on and one week off)

administration is started on day 5 of bleeding.  

 <P></P>

Atrophic vaginitis and Atrophic urethritis--0.3 mg to 1.25 mg or more daily,

depending upon the tissue response of the individual patient. Administer

cyclically.  

 <P></P>

2. Hypoestrogenism due to:  

 
<P></P>
a. Female hypogonadism--2.5 mg to 7.5 mg daily, in divided doses for 20 days,

followed by a rest period of 10 days' duration. If bleeding does not occur by

the end of this period, the same dosage schedule is repeated. The number of

courses of estrogen therapy necessary to produce bleeding may vary depending on 

the responsiveness of the endometrium.  
<P></P>
 

If bleeding occurs before the end of the 10-day period, begin a 20-day estrogen 

progestin cyclic regimen with Conjugated estrogens, 2.5 mg to 7.5 mg daily in divided

doses, for 20 days. During the last five days of estrogen therapy, give an oral 

progestin. If bleeding occurs before this regimen is concluded, therapy is

discontinued and may be resumed on the fifth day of bleeding.  

 <P></P>

b. Female castration or primary ovarian failure--1.25 mg daily, cyclically. 

Adjust dosage, upward or downward, according to severity of symptoms and

response of the patient. For maintenance, adjust dosage to lowest level that

will provide effective control.  
<P></P>
 

3. Osteoporosis (loss of bone mass)--0.625 mg daily. Administration should be

cyclic (e.g., three weeks on and one week off).  

 <P></P>

4. Advanced androgen-dependent carcinoma of the prostate, for palliation only-- 

1.25 mg to 2.5 mg three times daily. The effectiveness of therapy can be judged 

by phosphatase determinations as well as by symptomatic improvement of the

patient.  

 <P></P>

5. Breast cancer (for palliation only) in appropriately selected women and men

with metastatic disease. Suggested dosage is 10 mg three times daily for a

period of at least three months.  

 <P></P>

Treated patients with an intact uterus should be monitored closely for signs of 

endometrial cancer, and appropriate diagnostic measures should be taken to rule 

out malignancy in the event of persistent or recurring abnormal vaginal

bleeding.  

 <P></P>

<b><i>PATIENT PACKAGE INSERT 

 <P></P>

INFORMATION FOR THE PATIENT 
<P></P>
 

</i></b>This leaflet describes when and how to use estrogens and the risks of estrogen

treatment.  

 <P></P>

ESTROGEN DRUGS 

 <P></P>

Estrogens have several important uses but also some risks. You must decide,

with your doctor, whether the risks of estrogens are acceptable in view of

their benefits. If you decide to start taking estrogens, check with your doctor 

to make sure you are using the lowest possible effective dose. The length of

treatment with estrogens will depend upon the reason for use. This should also

be discussed with your doctor.  

 <P></P>

USES OF ESTROGEN 

 <P></P>

To Reduce Menopausal Symptoms. Estrogens are hormones produced by the ovaries.  

The decrease in the amount of estrogen that occurs in all women, usually

between ages 45 and 55, causes the menopause. Sometimes the ovaries are removed 

by an operation, causing &quot;surgical menopause.&quot; When the amount of estrogen

begins to decrease, some women develop very uncomfortable symptoms, such as

feelings of warmth in the face, neck and chest or sudden intense episodes of

heat and sweating (&quot;hot flashes&quot;). The use of drugs containing estrogens can

help the body adjust to lower estrogen levels.  

 <P></P>

Most women have none or only mild menopausal symptoms and do not need

estrogens.  Other women may need estrogens for a few months while their bodies

adjust to lower estrogen levels. The majority of women do not need estrogen

replacement for longer than six months for these symptoms.  
<P></P>
 

To Prevent Brittle Bones. After age 40, and especially after menopause, some

women develop osteoporosis. This is a thinning of the bones that makes them

weaker and more likely to break, often leading to fractures of vertebrae, hip,

and wrist bones. Taking estrogens after the menopause slows down bone loss and

may prevent bones from breaking. Eating foods that are high in calcium (such as 

milk products) or taking calcium supplements (1,000 to 1,500 milligrams per

day) and certain types of exercise may also help prevent osteoporosis.  

 <P></P>

Since estrogen use is associated with some risk, its use in the prevention of

osteoporosis should be confined to women who appear to be susceptible to this

condition. The following characteristics are often present in women who are

likely to develop osteoporosis: white race, thinness, and cigarette smoking.  

 
<P></P>
Women who had their menopause by the surgical removal of their ovaries at a

relatively young age are good candidates for estrogen replacement therapy to

prevent osteoporosis.  
<P></P>
 

To Treat Certain Types Of Abnormal Uterine Bleeding Due To Hormonal Imbalance.  

 <P></P>

To Treat Atrophic Vaginitis (itching, burning, dryness in or around the vagina) 

and Atrophic Urethritis (which may cause difficulty or burning on urination). 

 <P></P>

To Treat Certain Cancers.  

 
<P></P>
WHEN ESTROGENS SHOULD NOT BE USED 

 <P></P>

Estrogens should not be used:  

 <P></P>

During Pregnancy. Although the possibility is fairly small, there is a greater

risk of having a child born with a birth defect if you take estrogens during

pregnancy. A male child may have an increased risk of developing abnormalities

of the urinary system and sex organs. A female child may have an increased risk 

of developing cancer of the vagina or cervix in her teens or twenties. Estrogen 

is not effective in preventing miscarriage (abortion).  
<P></P>
 

If You Have Had Any Heart Or Circulation Problems. Estrogen therapy should be

used only after consultation with your physician and only in recommended doses. 

Patients with a tendency for abnormal blood clotting should avoid estrogen use

(see below).  <P></P>

 

If You Have Had Cancer. Since estrogens increase the risk of certain cancers,

you should not take estrogens if you have ever had cancer of the breast or

uterus. In certain situations, your doctor may choose to use estrogen in the

treatment of breast cancer.  
<P></P>
 

When They Are Ineffective. Sometimes women experience nervous symptoms or

depression during menopause. There is no evidence that estrogens are effective

for such symptoms. You may have heard that taking estrogens for long periods

(years) after menopause will keep your skin soft and supple and keep you

feeling young. There is no evidence that this is so and such long-term

treatment may carry serious risks.  

 <P></P>

DANGERS OF ESTROGENS 
<P></P>
 

Cancer Of The Uterus. The risk of cancer of the uterus increases the longer

estrogens are used and when larger doses are taken. One study showed that when

estrogens are discontinued, this increased risk of cancer seems to fall off

quickly. In another study, the persistence of risk was demonstrated for 10

years after stopping estrogen treatment. Because of this risk, It Is Important

To Take The Lowest Dose Of Estrogen That Will Control Your Symptoms And To Take 

It Only As Long As You Need It. There is a higher risk of cancer of the uterus

if you are overweight, diabetic, or have high blood pressure.  
<P></P>
 

If you have had your uterus removed (total hysterectomy), there is no danger of 

developing cancer of the uterus.  
<P>
 </P>

Cancer Of The Breast. The majority of studies have shown no association with

the usual doses used for estrogen replacement therapy and breast cancer. Some

studies have suggested a possible increased incidence of breast cancer in those 

women taking estrogens for prolonged periods of time and especially if higher

doses are used.  

 <P></P>

Regular breast examinations by a health professional and self-examination are

recommended for women receiving estrogen therapy, as they are for all women.  
<P></P>
 

Gallbladder Disease. Women who use estrogens after menopause are more likely to 

develop gallbladder disease needing surgery than women who do not use

estrogens.  

 <P></P>

Abnormal Blood Clotting. Taking estrogens may increase the risk of blood clots. 

These clots can cause a stroke, heart attack or pulmonary embolus, any of

which may be fatal.  
<P></P>
                    

SIDE EFFECTS:  

 
<P></P>
In addition to the risk listed above, the following side effects have been

reported with estrogen use:  

 
<P></P>
--Nausea and vomiting.  

 <P></P>

--Breast tenderness or enlargement.  
<P></P>
 

--Enlargement of benign tumors of the uterus.  

 <P></P>

--Retention of excess fluid. This may make some conditions worsen, such as

asthma, epilepsy, migraine, heart disease, or kidney disease.  

 <P></P>

--A spotty darkening of the skin, particularly on the face.  

 <P></P>

REDUCING RISK OF ESTROGEN USE 
<P></P>
 

If you decide to take estrogens, you can reduce your risks by carefully

monitoring your treatment.  

 <P></P>

See Your Doctor Regularly. While you are taking estrogens, it is important that 

you visit your doctor at least once a year for a physical examination. If

members of your family have had breast cancer or if you have ever had breast

nodules or an abnormal mammogram (breast X ray), you may need to have more

frequent breast examinations.  
<P></P>
 

Reevaluate Your Need For Estrogens. You and your doctor should reevaluate your

need for estrogens at least every six months.  

 <P></P>

Be Alert For Signs Of Trouble. Report these or any other unusual side effects

to your doctor immediately:  
<P></P>
 

--Abnormal bleeding from the vagina.  
<P></P>
 

--Pains in the calves or chest, a sudden shortness of breath or coughing blood

(indicating possible clots in the legs, heart, or lungs).  

 <P></P>

--Severe headache, dizziness, faintness, or changes in vision, indicating

possible clots in the brain or eye.  

 <P></P>

--Breast lumps.  

 <P>
</P>
--Yellowing of the skin.  

 <P></P>

--Pain, swelling, or tenderness in the abdomen.  

 <P></P>

OTHER INFORMATION 

 <P></P>

Some physicians may choose to prescribe another hormonal drug to be used in

association with estrogen treatment. These drugs, progestins, have been

reported to lower the frequency of occurrence of a possible precancerous

condition of the uterine lining. Whether this will provide protection from

uterine cancer has not been clearly established. There are possible additional

risks that may be associated with the inclusion of a progestin in estrogen

treatment. The possible risks include unfavorable effects on blood fats and

sugars. The choice of progestin and its dosage may be important in minimizing

these effects.  
<P></P>
 

Your doctor has prescribed this drug for you and you alone. Do not give the

drug to anyone else.  

 <P></P>

If you will be taking calcium supplements as part of the treatment to help

prevent osteoporosis, check with your doctor about the amounts recommended.  

 <P></P>

Keep this and all drugs out of the reach of children. In case of overdose, call 

your doctor, hospital, or poison control center immediately.  

 <P></P>

This leaflet provides the most important information about estrogens. If you

want to read more, ask your doctor or pharmacist to let you read the

professional labeling. <P></P> 

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-44</DOCNO>
<DOCOLDNO>IA018-000200-B042-198</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/dhea.htm 206.86.175.201 19970106231525 text/html 1558
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:09:10 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1376
Last-modified: Tue, 01 Oct 1996 21:14:23 GMT
</DOCHDR>
<html>
<head>
   <title>Dehydroepiandrosterone (DHEA)- RxList Generic Information</title>
   <meta name="keywords" content="DHEA, hormone, aging">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Dehydroepiandrosterone (DHEA)</h1>

<p>
<pre>
NAME OF PRODUCT:
Generic - dehydroepiandrosterone (DHEA)
Trade -not established
DESIGNATED USE:  Treatment of SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
and the reduction in the use of steroids in steroid-dependent
SLE patients.
DATE DESIGNATED AN ORPHAN PRODUCT:  07/13/94
MARKETING APPROVAL DATE:  Not approved for marketing
SPONSOR NAME AND ADDRESS:
Genlabs Technologies, Incorporated
505 Penobscot Drive
Redwood City, CA 94063
(415) 369-9500
</pre><p> 
<hr width="100%" ></p>

<h3 align=center><a
href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h3>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-45</DOCNO>
<DOCOLDNO>IA018-000200-B033-263</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/amoxclav.htm 206.86.175.201 19970106223953 text/html 27464
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:33:38 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 27281
Last-modified: Tue, 12 Nov 1996 23:51:58 GMT
</DOCHDR>
<html>
<head>
   <title>Amoxicillin/clavulanate - RxList Generic Information</title>
<meta name="keywords" content="Augmentan, Augmentin, Clavulin, Clavumox">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Amoxicillin/clavulanate</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>


<a name="DESCRIPTION"></a><b>DESCRIPTION</b> 
 <p>
Amoxicillin/clavulanate is an oral antibacterial combination consisting of the semisynthetic
antibiotic amoxicillin and the beta-lactamase inhibitor, clavulanate potassium
(the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin 
derived from the basic penicillin nucleus, 6-aminopenicillanic acid.
Chemically, amoxicillin is D-(-)-alpha-amino-p-hydroxybenzyl-penicillin
trihydrate.  
 <p>
Clavulanic acid is produced by the fermentation of Streptomyces Clavuligerus.
It is a beta-lactam structurally related to the penicillins and possesses the
ability to inactivate a wide variety of beta-lactamases by blocking the active
sites of these enzymes. Clavulanic acid is particularly active against the
clinically important plasmid mediated beta-lactamases frequently responsible
for transferred drug resistance to penicillins and cephalosporins. Chemically
clavulanate potassium is potassium Z-(3R, 5R)-2-(beta-hydroxyethylidene) clavam 
3-carboxylate.  
 
 <p>
 
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 
</b><p> 
Amoxicillin and clavulanate potassium are well absorbed from the
gastrointestinal tract after oral administration of Amoxicillin/clavulanate. Amoxicillin/clavulanate is
stable in the presence of gastric acid and may be given without regard to
meals.  
<p> 
Oral administration of 1 Amoxicillin/clavulanate 250 mg or Amoxicillin/clavulanate 500 mg tablet provides
average peak serum concentrations 1 to 2 hours after dosing of 4.4 mcg/mL and
7.6 mcg/mL, respectively, for amoxicillin and 2.3 mcg/mL for clavulanic acid.
The areas under the serum concentration curves obtained during the first 6

hours after dosing were 11.4 mcg/mL.hr. and 20.2 mcg/mL.hr. for amoxicillin,
respectively, when 1 Amoxicillin/clavulanate 250 mg or 500 mg tablet was administered to
adult volunteers. The corresponding area under the serum concentration curve
for clavulanic acid was 5 mcg/mL.hr. Oral administration of 5 mL of Amoxicillin/clavulanate
250 mg/5 mL suspension or the equivalent dose of 10 mL Amoxicillin/clavulanate 125 mg/5 mL
suspension provides average peak serum concentrations approximately 1 hour
after dosing of 6.9 mcg/mL for amoxicillin and 1.6 mcg/mL for clavulanic acid.  
The areas under the serum concentration curves obtained during the first 6
hours after dosing were 12.6 mcg/mL.hr. for amoxicillin and 2.9 mcg/mL.hr. for
clavulanic acid when 5 mL of Amoxicillin/clavulanate 250 mg/5 mL suspension or equivalent
dose of 10 mL of Amoxicillin/clavulanate 125 mg/5 mL suspension was administered to adult
volunteers. One Amoxicillin/clavulanate 250 mg chewable tablet or 2 Amoxicillin/clavulanate 125 mg chewable 
tablets are equivalent to 5 mL of Amoxicillin/clavulanate 250 mg/5 mL suspension and provide
similar serum levels of amoxicillin and clavulanic acid.  
<p> 
Amoxicillin serum concentrations achieved with Amoxicillin/clavulanate are similar to those
produced by the oral administration of equivalent doses of amoxicillin alone. 
The half-life of amoxicillin after the oral administration of Amoxicillin/clavulanate is 1.3
hours and that of clavulanic acid is 1.0 hour.  
 <p>
Approximately 50% to 70% of the amoxicillin and approximately 25% to 40% of the 
clavulanic acid are excreted unchanged in urine during the first 6 hours after
administration of a single Amoxicillin/clavulanate 250 mg or 500 mg tablet or 10 mL of
Amoxicillin/clavulanate 250 mg/5 mL suspension.  
 <p>
Concurrent administration of probenecid delays amoxicillin excretion but does
not delay renal excretion of clavulanic acid.  
 <p>
Neither component in Amoxicillin/clavulanate is highly protein-bound; clavulanic acid has
been found to be approximately 30% bound to human serum and amoxicillin
approximately 20% bound.  
 <p>
Amoxicillin diffuses readily into most body tissues and fluids with the
exception of the brain and spinal fluids. The results of experiments involving
the administration of clavulanic acid to animals suggest that this compound,
like amoxicillin, is well distributed in body tissues.  
 <p>
Two hours after oral administration of a single 35 mg/kg dose of Amoxicillin/clavulanate
suspension to fasting children, average concentrations of 3.0 mcg/mL of
amoxicillin and 0.5 mcg/mL of clavulanic acid were detected in middle ear
effusions.  
 <p>
Microbiology: Amoxicillin is a semisynthetic antibiotic with a broad spectrum
of bactericidal activity against many gram-positive and gram-negative
microorganisms. Amoxicillin is, however, susceptible to degradation by beta-
lactamases and therefore the spectrum of activity does not include organisms
which produce these enzymes. Clavulanic acid is a beta-lactam, structurally
related to the penicillins, which possesses the ability to inactivate a wide
range of beta-lactamase enzymes commonly found in microorganisms resistant to
penicillins and cephalosporins. In particular, it has good activity against the 
clinically important plasmid mediated beta-lactamases frequently responsible
for transferred drug resistance.  
 <p>
The formulation of amoxicillin with clavulanic acid in Amoxicillin/clavulanate protects
amoxicillin from degradation by beta-lactamase enzymes and effectively extends
the antibiotic spectrum of amoxicillin to include many bacteria normally
resistant to amoxicillin and other beta-lactam antibiotics. Thus Amoxicillin/clavulanate
possesses the distinctive properties of a broad-spectrum antibiotic and a beta- 
lactamase inhibitor.  
 <p>
While In Vitro studies have demonstrated the susceptibility of most strains of
the following organisms, clinical efficacy for infections other than those
included in the INDICATIONS AND USAGE section has not been documented:  
 <p>
GRAM-POSITIVE BACTERIA: Staphylococcus Aureus (beta-lactamase and non-beta-
lactamase producing), Staphylococcus Epidermidis (beta-lactamase and non-beta-
lactamase producing), Staphylococcus Saprophyticus (beta-lactamase and non-beta 
lactamase producing), Streptococcus Faecalis* (Enterococcus), Streptococcus
Pneumoniae* (D. Pneumoniae), Streptococcus Pyogenes*, Streptococcus Viridans* 
 <p>
ANAEROBES: Clostridium species*, Peptococcus species*, Peptostreptococcus
species* 
 
       <p>     
 
*These are non-beta-lactamase-producing strains and therefore are susceptible
to amoxicillin alone.  
 
<p>            
 
GRAM-NEGATIVE BACTERIA: Hemophilus Influenzae (beta-lactamase and non-beta-
lactamase producing), Moraxella (Branhamella) Catarrhalis (beta-lactamase and
non-beta-lactamase producing); Escherichia Coli (beta-lactamase and non-beta-
lactamase producing), Klebsiella species (All known strains are beta-lactamase
producing), Enterobacter species (Although most strains of Enterobacter species 
are resistant In Vitro, clinical efficacy has been demonstrated with Amoxicillin/clavulanate
in urinary tract infections caused by these organisms.), Proteus Mirabilis
(beta-lactamase and non-beta-lactamase producing), Proteus Vulgaris (beta-
lactamase and non-beta-lactamase producing), Neisseria Gonorrhoeae (beta-
lactamase and non-beta-lactamase producing), Legionella species (beta-lactamase 
and non-beta-lactamase producing).  
 <p>
ANAEROBES: Bacteroides species, including B. Fragilis (beta-lactamase and non-
beta-lactamase producing).  
 <p>
SUSCEPTIBILITY TESTING 
 <p>
DIFFUSION TECHNIQUE: For Kirby-Bauer method of susceptibility testing, a 30 mcg 
Amoxicillin/clavulanate (20 mcg amoxicillin + 10 mcg clavulanic acid) diffusion disk should
be used. With this procedure, a report from the laboratory of &quot;Susceptible&quot;
indicates that the infecting organism is likely to respond to Amoxicillin/clavulanate therapy 
and a report of &quot;Resistant&quot; indicates that the infecting organism is not likely 
to respond to therapy. An &quot;intermediate susceptibility&quot; report suggests that
the infecting organism would be susceptible to Amoxicillin/clavulanate if the higher dosage
is used or if the infection is confined to tissues or fluids (e.g., urine) in
which high antibiotic levels are attained.  
 <p>
DILUTION TECHNIQUES: Broth or agar dilution methods may be used to determine
the minimal inhibitory concentration (MIC) value for susceptibility of
bacterial isolates to Amoxicillin/clavulanate. Tubes should be inoculated to contain 10
(raised to the power of 4) to 10 (raised to the power of 5) organisms/mL or
plates &quot;spotted&quot; with 10(cube) to 10 (raised to the power of 4) organisms.  
 <p>
The recommended dilution method employs a constant amoxicillin/clavulanic acid
ratio of 2 to 1 in all tubes with increasing concentrations of amoxicillin.
MICs are reported in terms of amoxicillin concentration in the presence of
clavulanic acid at a constant 2 parts amoxicillin to 1 part clavulanic acid.  
 <p>
Recommended Amoxicillin/clavulanate Susceptibility Ranges(1,2)          
<pre>                      
------------------------------------------------------------------------------  
                                                                   MIC(3)       
ORGANISMS           RESISTANT   INTERMEDIATE     SUSCEPTIBLE     CORRELATES     
                                                                   MCG/ML       
------------------------------------------------------------------------------  
                                                               R          S     
Gram-Negative                                                                   
Enteric              &lt;/=13 mm    14 to 17 mm       &gt;/=18 mm   &gt;/=32/16  &lt;/=8/4  
Bacteria                                                                        
Staphylococcus(4)                                                               
and                  &lt;/=19 mm          --          &gt;/=20 mm             &lt;/=4/2  
Hemophilus spp.                                                         &lt;/=4/2  
------------------------------------------------------------------------------- 
1The non-beta-lactamase-producing organisms which are normally susceptible to   
 ampicillin, such as streptococci, will have similar zone sizes as for          
 ampicillin disks.                                                              
2The quality control cultures should have the following assigned daily ranges   
 for Amoxicillin/clavulanate:                                                                 
                                                                                
                                                                                
                          Disks       MIC Range (mcg/ml)                        
E. Coli   (ATCC 25922)  19 to 25 mm       2/1 to 8/4                            
                                                                                
S. Aureus (ATCC 25923)  28 to 36 mm    0.25/0.12 to                             
                                         0.5/0.25                               
E. Coli   (ATCC 35218)  18 to 22 mm     4/2 to 16/8                             


3Expressed as concentration of amoxicillin/clavulanic acid.                     
4Organisms which show susceptibility to Amoxicillin/clavulanate but are resistant to          
    methicillin/oxacillin should be considered resistant.                       
-------------------------------------------------------------------------------</pre><p> 
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
Amoxicillin/clavulanate is indicated in the treatment of infections caused by susceptible
strains of the designated organisms in the conditions listed below:  
 <p>
LOWER RESPIRATORY TRACT INFECTIONS--caused by beta-lactamase-producing strains
of Hemophilus Influenzae and Moraxella (Branhamella) Catarrhalis.  
 <p>
OTITIS MEDIA--caused by beta-lactamase-producing strains of Hemophilus
Influenzae and Moraxella (Branhamella) Catarrhalis.  
 <p>
SINUSITIS--caused by beta-lactamase-producing strains of Hemophilus Influenzae
and Moraxella (Branhamella) Catarrhalis.  
 <p>
SKIN AND SKIN STRUCTURE INFECTIONS--caused by beta-lactamase-producing strains
of Staphylococcus Aureus, Escherichia Coli and Klebsiella spp.  
 <p>
URINARY TRACT INFECTIONS--caused by beta-lactamase-producing strains of
Escherichia Coli, Klebsiella spp. and Enterobacter spp.  
 <p>
While Amoxicillin/clavulanate is indicated only for the conditions listed above, infections
caused by ampicillin-susceptible organisms are also amenable to Amoxicillin/clavulanate
treatment due to its amoxicillin content. Therefore, mixed infections caused by 
ampicillin-susceptible organisms and beta-lactamase-producing organisms
susceptible to Amoxicillin/clavulanate should not require the addition of another antibiotic. 
 <p>
Bacteriological studies, to determine the causative organisms and their
susceptibility to Amoxicillin/clavulanate, should be performed together with any indicated
surgical procedures.  
 <p>
Therapy may be instituted prior to obtaining the results from bacteriological
and susceptibility studies to determine the causative organisms and their
susceptibility to Amoxicillin/clavulanate when there is reason to believe the infection may
involve any of the beta-lactamase-producing organisms listed above. Once the
results are known, therapy should be adjusted, if appropriate.  
 <p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b><p> 
A history of allergic reactions to any penicillin is a contraindication.  
 <p>
<a name="WARNINGS"></a><b>WARNINGS 
</b><p> 
SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTOID) REACTIONS HAVE
BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. ALTHOUGH ANAPHYLAXIS IS MORE
FREQUENT FOLLOWING PARENTERAL THERAPY, IT HAS OCCURRED IN PATIENTS ON ORAL
PENICILLINS. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A
HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO
MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF
PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED
WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH ANY PENICILLIN, CAREFUL
INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO
PENICILLINS, CEPHALOSPORINS OR OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS, 
Amoxicillin/clavulanate SHOULD BE DISCONTINUED AND THE APPROPRIATE THERAPY INSTITUTED.
SERIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH
EPINEPHRINE.  OXYGEN, INTRAVENOUS STEROIDS AND AIRWAY MANAGEMENT, INCLUDING
INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.  
 <p>
PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH NEARLY ALL ANTIBACTERIAL AGENTS 
INCLUDING Amoxicillin/clavulanate, AND HAS RANGED IN SEVERITY FROM MILD TO LIFE-THREATENING.
THEREFORE, IT IS IMPORTANT TO CONSIDER THIS DIAGNOSIS IN PATIENTS WHO PRESENT
WITH DIARRHEA SUBSEQUENT TO THE ADMINISTRATION OF ANTIBACTERIAL AGENTS.  
 <p>
Treatment with antibacterial agents alters the normal flora of the colon and
may permit overgrowth of clostridia. Studies indicate that a toxin produced by
Clostridium Difficile is 1 primary cause of &quot;antibiotic associated colitis.&quot; 
 <p>
Mild cases of pseudomembranous colitis usually respond to drug discontinuation
alone. In moderate to severe cases, consideration should be given to management 
with fluids and electrolytes, protein supplementation and treatment with an
antibacterial drug clinically effective against C. Difficile colitis.  
 <p>
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b><p> 
General: While Amoxicillin/clavulanate possesses the characteristic low toxicity of the
penicillin group of antibiotics, periodic assessment of organ system functions, 
including renal, hepatic and hematopoietic function, is advisable during
prolonged therapy.  
 <p>
A high percentage of patients with mononucleosis who receive ampicillin develop 
a skin rash. Thus, ampicillin class antibiotics should not be administered to
patients with mononucleosis.  <p>
The possibility of superinfections with mycotic or bacterial pathogens should
be kept in mind during therapy. If superinfections occur (usually involving
Pseudomonas or Candida), the drug should be discontinued and/or appropriate
therapy instituted.  
 <p>
Drug Interactions: Probenecid decreases the renal tubular secretion of
amoxicillin. Concurrent use with Amoxicillin/clavulanate may result in increased and
prolonged blood levels of amoxicillin.  
 <p>
The concurrent administration of allopurinol and ampicillin increases
substantially the incidence of rashes in patients receiving both drugs as
compared to patients receiving ampicillin alone. It is not known whether this
potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia
present in these patients. There are no data with Amoxicillin/clavulanate and allopurinol
administered concurrently.  
 <p>
Amoxicillin/clavulanate should not be co-administered with Antabuse (disulfiram).  
 <p>
Drug/Laboratory Test Interactions: Oral administration of Amoxicillin/clavulanate will result 
in high urine concentrations of amoxicillin. High urine concentrations of
ampicillin may result in false-positive reactions when testing for the presence 
of glucose in urine using Clinitest, Benedict's Solution or Fehling's
Solution. Since this effect may also occur with amoxicillin and therefore
Amoxicillin/clavulanate, it is recommended that glucose tests based on enzymatic glucose
oxidase reactions (such as Clinistix or Tes-Tape) be used.  
 <p>
Following administration of ampicillin to pregnant women a transient decrease
in plasma concentration of total conjugated estriol, estriol-glucuronide,
conjugated estrone and estradiol has been noted. This effect may also occur
with amoxicillin and therefore Amoxicillin/clavulanate.  
 <p>
Carcinogenesis, Mutagenesis, Impairment Of Fertility: Long-term studies in
animals have not been performed to evaluate carcinogenic or mutagenic
potential.  
 <p>
Pregnancy (Category B): Reproduction studies have been performed in mice and
rats at doses up to ten (10) times the human dose and have revealed no evidence 
of impaired fertility or harm to the fetus due to Amoxicillin/clavulanate. There are, however 
no adequate and well-controlled studies in pregnant women. Because animal
reproduction studies are not always predictive of human response, this drug
should be used during pregnancy only if clearly needed.  
 <p>
Labor And Delivery: Oral ampicillin class antibiotics are generally poorly
absorbed during labor. Studies in guinea pigs have shown that intravenous
administration of ampicillin decreased the uterine tone, frequency of
contractions, height of contractions and duration of contractions. However, it
is not known whether the use of Amoxicillin/clavulanate in humans during labor or delivery
has immediate or delayed adverse effects on the fetus, prolongs the duration of 
labor, or increases the likelihood that forceps delivery or other obstetrical
intervention or resuscitation of the newborn will be necessary.  
 <p>
Nursing Mothers: Ampicillin class antibiotics are excreted in the milk;
therefore, caution should be exercised when Amoxicillin/clavulanate is administered to a
nursing woman.
<p>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <p>
Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use 
with Amoxicillin/clavulanate may result in increased and prolonged blood levels of
amoxicillin.  
 <p>
The concurrent administration of allopurinol and ampicillin increases
substantially the incidence of rashes in patients receiving both drugs as
compared to patients receiving ampicillin alone. It is not known whether this
potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia
present in these patients. There are no data with Amoxicillin/clavulanate and allopurinol
administered concurrently.  
 <p>
Amoxicillin/clavulanate should not be co-administered with Antabuse (disulfiram).  
 
(See Also PRECAUTIONS) 
 <p>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
Amoxicillin/clavulanate is generally well tolerated. The majority of side effects observed in 
clinical trials were of a mild and transient nature and less than 3% of
patients discontinued therapy because of drug-related side effects. The most
frequently reported adverse effects were diarrhea/loose stools (9%), nausea
(3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%). The
overall incidence of side effects, and in particular diarrhea, increased with
the higher recommended dose. Other less frequently reported reactions include:
abdominal discomfort, flatulence and headache.  
 <p>
The following adverse reactions have been reported for ampicillin class
antibiotics:  
 <p>
Gastrointestinal: Diarrhea, nausea, vomiting, indigestion, gastritis,
stomatitis, glossitis, black &quot;hairy&quot; tongue, enterocolitis and pseudomembranous 
colitis. Onset of pseudomembranous colitis symptoms may occur during or after
antibiotic treatment (see WARNINGS).  
 <p>
Hypersensitivity Reactions: Skin rashes, urticaria, angioedema, serum sickness- 
like reactions (urticaria or skin rash accompanied by arthritis, arthralgia,
myalgia and frequently fever), erythema multiforme (rarely Stevens-Johnson
Syndrome) and an occasional case of exfoliative dermatitis have been reported.  
These reactions may be controlled with antihistamines and, if necessary,
systemic corticosteroids. Whenever such reactions occur, the drug should be
discontinued, unless the opinion of the physician dictates otherwise. Serious
and occasional fatal hypersensitivity (anaphylactic) reactions can occur with
oral penicillin (see WARNINGS).  
 <p>
Liver: A moderate rise in AST (SGOT) and/or ALT (SGPT) has been noted in
patients treated with ampicillin class antibiotics but the significance of
these findings is unknown. Hepatic dysfunction, including increases in serum
transaminases (AST and/or ALT), serum bilirubin and/or alkaline phosphatase,
has been infrequently reported with Amoxicillin/clavulanate. The histologic findings on liver 
biopsy have consisted of predominantly cholestatic, hepatocellular or mixed
cholestatic-hepatocellular changes. The onset of signs/symptoms of hepatic
dysfunction may occur during or after therapy. Complete resolution has occurred 
with time.  <p>
Hemic And Lymphatic Systems: Anemia, thrombocytopenia, thrombocytopenic purpura 
eosinophilia, leukopenia and agranulocytosis have been reported during therapy
with penicillins. These reactions are usually reversible on discontinuation of
therapy and are believed to be hypersensitivity phenomena. A slight
thrombocytosis was noted in less than 1% of the patients treated with
Amoxicillin/clavulanate.  
 <p>
Central Nervous System: Reversible hyperactivity, agitation, anxiety, insomnia, 
confusion, behavioral changes, and/or dizziness have been reported rarely.  
 <p>
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <p>
Amoxicillin may be removed from circulation by hemodialysis.  
 
The molecular weight, degree of protein binding and pharmacokinetic profile of
clavulanic acid together with information from a single patient with renal
insufficiency all suggest that this compound may also be removed by
hemodialysis.  <p>
 
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
THE Amoxicillin/clavulanate 250 MG TABLET AND THE 250 MG CHEWABLE TABLET DO NOT CONTAIN THE
SAME AMOUNT OF CLAVULANIC ACID (AS THE POTASSIUM SALT). THE Amoxicillin/clavulanate 250 MG
TABLET CONTAINS 125 MG OF CLAVULANIC ACID, WHEREAS THE 250 MG CHEWABLE TABLET
CONTAINS 62.5 MG OF CLAVULANIC ACID. THEREFORE, THE Amoxicillin/clavulanate 250 MG TABLET AND 
THE 250 MG CHEWABLE TABLET SHOULD NOT BE SUBSTITUTED FOR EACH OTHER, AS THEY
ARE NOT INTERCHANGEABLE.  
 <p>
SINCE BOTH THE Amoxicillin/clavulanate 250 MG AND 500 MG TABLETS CONTAIN THE SAME AMOUNT OF
CLAVULANIC ACID (125 MG, AS THE POTASSIUM SALT), 2 Amoxicillin/clavulanate 250 MG TABLETS ARE 
NOT EQUIVALENT TO 1 Amoxicillin/clavulanate 500 MG TABLET. THEREFORE, 2 Amoxicillin/clavulanate 250 MG
TABLETS SHOULD NOT BE SUBSTITUTED FOR 1 Amoxicillin/clavulanate 500 MG TABLET FOR TREATMENT
OF MORE SEVERE INFECTIONS.  
 <p>
DOSAGE:  
 <p>
ADULTS: The usual adult dose is 1 Amoxicillin/clavulanate 250 mg tablet every 8 hours.  For
more severe infections and infections of the respiratory tract, the dose should 
be 1 Amoxicillin/clavulanate 500 mg tablet every 8 hours.  
 <p>
CHILDREN: The usual dose is 20 mg/kg/day, based on amoxicillin component, in
divided doses every 8 hours. For otitis media, sinusitis and lower respiratory
tract infections, the dose should be 40 mg/kg/day, based on the amoxicillin
component, in divided doses every 8 hours. Severe infections should be treated
with the higher recommended dose.  
 <p>
Children weighing 40 kg and more should be dosed according to the adult
recommendations.  
 <p>
DUE TO THE DIFFERENT AMOXICILLIN TO CLAVULANIC ACID RATIOS IN THE Amoxicillin/clavulanate 250 
MG TABLET (250/125) VERSUS THE Amoxicillin/clavulanate 250 MG CHEWABLE TABLET (250/62.5), THE 
Amoxicillin/clavulanate 250 MG TABLET SHOULD NOT BE USED UNTIL THE CHILD WEIGHS AT LEAST 40
KG AND MORE.  
 <p>
NOTE: SHAKE ORAL SUSPENSION WELL BEFORE USING.  
 <p>
RECONSTITUTED SUSPENSION MUST BE STORED UNDER REFRIGERATION AND DISCARDED AFTER 
10 DAYS.  
 <p>
ADMINISTRATION: The absorption of Amoxicillin/clavulanate is unaffected by food. Therefore,
Amoxicillin/clavulanate may be administered without regard to meals.  
 <p>


<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-46</DOCNO>
<DOCOLDNO>IA018-000200-B039-1</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/venlafax.htm 206.86.175.201 19970106230049 text/html 63714
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:54:33 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 63531
Last-modified: Sun, 14 Jul 1996 21:20:53 GMT
</DOCHDR>
<html>
<head>
   <title>Venlafaxine - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Venlafaxine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Venlafaxine is a structurally novel antidepressant for oral administration.
It is chemically unrelated to tricyclic, tetracyclic, or other available
antidepressant agents. It is designated (R/S)-1-(2- (dimethylamino)-1-(4-methoxyphenyl)ethyl)
cyclohexanol hydrochloride or (+/- )- 1-(alpha-((dimethylamino)methyl)-p-methoxybenzyl)
cyclohexanol hydrochloride and has the empirical formula of C17H27NO2HCl.
Its molecular weight is 313.87. </p>

<p>Venlafaxine hydrochloride is a white to off-white crystalline solid
with a solubility of 572 mg/mL in water (adjusted to ionic strength of
0.2 M with sodium chloride). Its octanol: water (0.2 M sodium chloride)
partition coefficient is 0.43. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>PHARMACODYNAMICS </p>

<p>The mechanism of the antidepressant action of venlafaxine in humans
is believed to be associated with its potentiation of neurotransmitter
activity in the CNS. Preclinical studies have shown that venlafaxine and
its active metabolite, O- desmethylvenlafaxine (ODV), are potent inhibitors
of neuronal serotonin and norepinephrine reuptake and weak inhibitors of
dopamine reuptake. Venlafaxine and ODV have no significant affinity for
muscarinic, histaminergic, or alpha-1 adrenergic receptors In Vitro. Pharmacologic
activity at these receptors is hypothesized to be associated with the various
anticholinergic, sedative, and cardiovascular effects seen with other psychotropic
drugs. Venlafaxine and ODV do not possess monoamine oxidase (MAO) inhibitory
activity. </p>

<p>PHARMACOKINETICS </p>

<p>Venlafaxine is well absorbed and extensively metabolized in the liver.
O- desmethylvenlafaxine (ODV) is the only major active metabolite. On the
basis of mass balance studies, at least 92% of a single dose of venlafaxine
is absorbed. Approximately 87% of a venlafaxine dose is recovered in the
urine within 48 hours as either unchanged venlafaxine (5%), unconjugated
ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%).
Renal elimination of venlafaxine and its metabolites is the primary route
of excretion. The relative bioavailability of venlafaxine from a tablet
was 100% when compared to an oral solution. Food has no significant effect
on the absorption of venlafaxine or on the formation of ODV. </p>

<p>The degree of binding of venlafaxine to human plasma is 27% +/- 2% at
concentrations ranging from 2.5 to 2215 ng/mL. The degree of ODV binding
to human plasma is 30% +/- 12% at concentrations ranging from 100 to 500
ng/mL. Protein-binding-induced drug interactions with venlafaxine are not
expected. </p>

<p>Steady-state concentrations of both venlafaxine and ODV in plasma were
attained within 3 days of multiple-dose therapy. Venlafaxine and ODV exhibited
linear kinetics over the dose range of 75 to 450 mg total dose per day
(administered on a q8h schedule). Plasma clearance, elimination half-life
and steady-state volume of distribution were unaltered for both venlafaxine
and ODV after multiple- dosing. Mean +/- SD steady-state plasma clearance
of venlafaxine and ODV is 1.3 +/- 0.6 and 0.4 +/- 0.2 L/h/kg, respectively;
elimination half-life is 5 +/- 2 and 11 +/- 2 hours, respectively; and
steady-state volume of distribution is 7.5 +/- 3.7 L/kg and 5.7 +/- 1.8
L/kg, respectively. When equal daily doses of venlafaxine were administered
as either b.i.d. or t.i.d. regimens, the drug exposure (AUC) and fluctuation
in plasma levels of venlafaxine and ODV were comparable following both
regimens. </p>

<p>Age And Gender </p>

<p>A pharmacokinetic analysis of 404 venlafaxine-treated patients from
two studies involving both b.i.d. and t.i.d. regimens showed that dose-normalized
trough plasma levels of either venlafaxine or ODV were unaltered due to
age or gender differences. Dosage adjustment based upon the age or gender
of a patient is generally not necessary (see &quot;DOSAGE AND ADMINISTRATION&quot;).
</p>

<p>Liver Disease </p>

<p>In 9 patients with hepatic cirrhosis, the pharmacokinetic disposition
of both venlafaxine and ODV was significantly altered after oral administration
of venlafaxine. Venlafaxine elimination half-life was prolonged by about
30%, and clearance decreased by about 50% in cirrhotic patients compared
to normal subjects. ODV elimination half-life was prolonged by about 60%
and clearance decreased by about 30% in cirrhotic patients compared to
normal subjects. A large degree of intersubject variability was noted.
Three patients with more severe cirrhosis had a more substantial decrease
in venlafaxine clearance (about 90%) compared to normal subjects. </p>

<p>Dosage adjustment is necessary in these patients (see &quot;DOSAGE AND
ADMINISTRATION&quot;). </p>

<p>Renal Disease </p>

<p>In a renal impairment study, venlafaxine elimination half-life after
administration was prolonged by about 50% and clearance was reduced by
about 24% in renally impaired patients (GFR =10-70 mL/min), compared to
normal subjects. In dialysis patients, venlafaxine elimination half-life
was prolonged by about 180% and clearance was reduced by about 57% compared
to normal subjects. Similarly, ODV elimination half-life was prolonged
by about 40% although clearance was unchanged in patients with renal impairment
(GFR =10 70 mL/min) compared to normal subjects. In dialysis patients,
ODV elimination half-life was prolonged by about 142% and clearance was
reduced by about 56%, compared to normal subjects. A large degree of intersubject
variability was noted. </p>

<p>Dosage adjustment is necessary in these patients (see &quot;DOSAGE AND
ADMINISTRATION&quot;). </p>

<p>CLINICAL TRIALS </p>

<p>The efficacy of Venlafaxine as a treatment for depression was established
in 5 placebo-controlled, short-term trials. Four of these were 6-week trials
in outpatients meeting DSM-III or DSM-III-R criteria for major depression:
two involving dose titration with Venlafaxine in a range of 75 to 225 mg/day
(t.i.d. schedule), the third involving fixed Venlafaxine doses of 75, 225,
and 375 mg/day (t.i.d. schedule), and the fourth involving doses of 25,
75, and 200 mg/day (b.i.d. schedule). The fifth was a 4-week study of inpatients
meeting DSM-III-R criteria for major depression with melancholia whose
Venlafaxine doses were titrated in a range of 150 to 375 mg/day (t.i.d
schedule). In these 5 studies, Venlafaxine was shown to be significantly
superior to placebo on at least 2 of the following 3 measures: Hamilton
Depression Rating Scale (total score), Hamilton depressed mood item, and
Clinical Global Impression--Severity of Illness rating. Doses from 75 to
225 mg/day were superior to placebo in outpatient studies and a mean dose
of about 350 mg/day was effective in inpatients. Data from the 2 fixed-dose
outpatient studies were suggestive of a dose-response relationship in the
range of 75 to 225 mg/day. There was no suggestion of increased response
with doses greater than 225 mg/day. </p>

<p>While there were no efficacy studies focusing specifically on an elderly
population, elderly patients were included among the patients studied.
Overall, approximately 2/3 of all patients in these trials were women.
Exploratory analyses for age and gender effects on outcome did not suggest
any differential responsiveness on the basis of age or sex. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Venlafaxine is indicated for the treatment of depression. </p>

<p>The efficacy of Venlafaxine in the treatment of depression was established
in 6 week controlled trials of outpatients whose diagnoses corresponded
most closely to the DSM-III or DSM-III-R category of major depressive disorder
and in a 4 week controlled trial of inpatients meeting diagnostic criteria
for major depressive disorder with melancholia (see &quot;CLINICAL PHARMACOLOGY&quot;).
</p>

<p>A major depressive episode implies a prominent and relatively persistent
depressed or dysphoric mood that usually interferes with daily functioning
(nearly every day for at least 2 weeks); it should include 4 of the following
8 symptoms: change in appetite, change in sleep, psychomotor agitation
or retardation, loss of interest in usual activities or decrease in sexual
drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking
or impaired concentration, and a suicide attempt or suicidal ideation.
</p>

<p>The effectiveness of Venlafaxine in long-term use, that is, for more
than 4 to 6 weeks, has not been systematically evaluated in controlled
trials. Therefore, the physician who elects to use Venlafaxine for extended
periods should periodically re-evaluate the long-term usefulness of the
drug for the individual patient. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>None known. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>POTENTIAL FOR INTERACTION WITH MONOAMINE OXIDASE INHIBITORS </p>

<p>IN PATIENTS RECEIVING ANTIDEPRESSANTS WITH PHARMACOLOGICAL PROPERTIES
SIMILAR TO VENLAFAXINE IN COMBINATION WITH A MONOAMINE OXIDASE INHIBITOR
(MAOI), THERE HAVE BEEN REPORTS OF SERIOUS, SOMETIMES FATAL, REACTIONS.
FOR A SELECTIVE SEROTONIN REUPTAKE INHIBITOR, THESE REACTIONS HAVE INCLUDED
HYPERTHERMIA, RIGIDITY, MYOCLONUS, AUTONOMIC INSTABILITY WITH POSSIBLE
RAPID FLUCTUATIONS OF VITAL SIGNS, AND MENTAL STATUS CHANGES THAT INCLUDE
EXTREME AGITATION PROGRESSING TO DELIRIUM AND COMA. SOME CASES PRESENTED
WITH FEATURES RESEMBLING NEUROLEPTIC MALIGNANT SYNDROME. SEVERE HYPERTHERMIA
AND SEIZURES, SOMETIMES FATAL, HAVE BEEN REPORTED IN ASSOCIATION WITH THE
COMBINED USE OF TRICYCLIC ANTIDEPRESSANTS AND MAOIS. THESE REACTIONS HAVE
ALSO BEEN REPORTED IN PATIENTS WHO HAVE RECENTLY DISCONTINUED THESE DRUGS
AND HAVE BEEN STARTED ON AN MAOI. THE EFFECTS OF COMBINED USE OF Venlafaxine
AND MAOIS HAVE NOT BEEN EVALUATED IN HUMANS OR ANIMALS. THEREFORE, BECAUSE
Venlafaxine IS AN INHIBITOR OF BOTH NOREPINEPHRINE AND SEROTONIN REUPTAKE,
IT IS RECOMMENDED THAT Venlafaxine NOT BE USED IN COMBINATION WITH AN MAOI,
OR WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH AN MAOI. BASED ON THE
HALF-LIFE OF Venlafaxine, AT LEAST 7 DAYS SHOULD BE ALLOWED AFTER STOPPING
Venlafaxine BEFORE STARTING AN MAOI. </p>

<p>SUSTAINED HYPERTENSION </p>

<p>Venlafaxine treatment is associated with sustained increases in blood
pressure. (1) In a premarketing study comparing three fixed doses of venlafaxine
(75, 225, and 375 mg/day) and placebo, a mean increase in supine diastolic
blood pressure (SDBP) of 7.2 mm Hg was seen in the 375 mg/day group at
week 6 compared to essentially no changes in the 75 and 225 mg/day groups
and a mean decrease in SDBP of 2.2 mm Hg in the placebo group. (2) An analysis
for patients meeting criteria for sustained hypertension (defined as treatment
emergent SDBP &gt;/= 90 mm Hg And &gt;/= 10 mm Hg above baseline for 3
consecutive visits) revealed a dose- dependent increase in the incidence
of sustained hypertension for venlafaxine: </p>

<pre>                    Probability of Sustained Elevation in SDBP                  
                    (Pool of Premarketing Venlafaxine Studies)                  
------------------------------------------------------------------------        
         Treatment Group                    Incidence of Sustained              
                                              Elevation in SDBP                 
------------------------------------------------------------------------        
Venlafaxine                                                                     
------------------------------------------------------------------------        
      &lt;100 mg/day                                     3%                        
------------------------------------------------------------------------        
      101-200 mg/day                                  5%                        
------------------------------------------------------------------------        
      201-300 mg/day                                  7%                        
------------------------------------------------------------------------        
      &gt;300 mg/day                                    13%                        
------------------------------------------------------------------------        
Placebo                                               2%                        
------------------------------------------------------------------------</pre>

<p>An analysis of the patients with sustained hypertension and the 19 venlafaxine
patients who were discontinued from treatment because of hypertension (&lt;1%
of total venlafaxine-treated group) revealed that most of the blood pressure
increases were in a modest range (10-15 mm Hg, SDBP). Nevertheless, sustained
increases of this magnitude could have adverse consequences. Therefore,
it is recommended that patients receiving venlafaxine have regular monitoring
of blood pressure. For patients who experience a sustained increase in
blood pressure while receiving venlafaxine, either dose reduction or discontinuation
should be considered. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL </p>

<p>Anxiety And Insomnia </p>

<p>Treatment-emergent anxiety, nervousness, and insomnia were more commonly
reported for venlafaxine-treated patients compared to placebo-treated patients
in a pooled analysis of short-term, double-blind, placebo-controlled depression
studies: </p>

<pre>                                 VENLAFAXINE                     PLACEBO        
SYMPTOM                            n = 1033                      n = 609        
Anxiety                                  6%                           3%        
Nervousness                             13%                           6%        
Insomnia                                18%                          10% </pre>

<p>Anxiety, nervousness, and insomnia led to drug discontinuation in 2%,
2%, and 3%, respectively, of the patients treated with venlafaxine in the
phase 2--3 depression studies. </p>

<p>Changes In Appetite And Weight </p>

<p>Treatment-emergent anorexia was more commonly reported for venlafaxine-treated
(11%) than placebo-treated patients (2%) in the pool of short-term, double-
blind, placebo-controlled depression studies. A dose-dependent weight loss
was often noted in patients treated with venlafaxine for several weeks.
Significant weight loss, especially in underweight depressed patients,
may be an undesirable result of venlafaxine treatment. A loss of 5% or
more of body weight occurred in 6% of patients treated with venlafaxine
compared with 1% of patients treated with placebo and 3% of patients treated
with another antidepressant. However, discontinuation for weight loss associated
with venlafaxine was uncommon (0.1% of venlafaxine-treated patients in
the phase 2-3 depression trials). </p>

<p>Activation Of Mania/Hypomania </p>

<p>During phase 2-3 trials, hypomania or mania occurred in 0.5% of patients
treated with venlafaxine. Activation of mania/hypomania has also been reported
in a small proportion of patients with major affective disorder who were
treated with other marketed antidepressants. As with all antidepressants,
Venlafaxine should be used cautiously in patients with a history of mania.
</p>

<p>Seizures </p>

<p>During premarketing testing, seizures were reported in 0.26% (8/3082)
of venlafaxine-treated patients. Most seizures (5 of 8) occurred in patients
receiving doses of 150 mg/day or less. Venlafaxine should be used cautiously
in patients with a history of seizures. It should be discontinued in any
patient who develops seizures. </p>

<p>Suicide </p>

<p>The possibility of a suicide attempt is inherent in depression and may
persist until significant remission occurs. Close supervision of high-risk
patients should accompany initial drug therapy. Prescriptions for Venlafaxine
should be written for the smallest quantity of tablets consistent with
good patient management in order to reduce the risk of overdose. </p>

<p>Use In Patients With Concomitant Illness </p>

<p>Clinical experience with Venlafaxine in patients with concomitant systemic
illness is limited. Caution is advised in administering Venlafaxine to
patients with diseases or conditions that could affect hemodynamic responses
or metabolism. </p>

<p>Venlafaxine has not been evaluated or used to any appreciable extent
in patients with a recent history of myocardial infarction or unstable
heart disease. Patients with these diagnoses were sytematically excluded
from many clinical studies during the product's premarketing testing. Evaluation
of the electrocardiograms for 769 patients who received Venlafaxine in
4- to 6-week double blind placebo-controlled trials, however, showed that
the incidence of trial- emergent conduction abnormalities did not differ
from that with placebo. The mean heart rate in Venlafaxine-treated patients
was increased relative to baseline by about 4 beats per minute. </p>

<p>In patients with renal impairment (GFR=10-70 mL/min) or cirrhosis of
the liver, the clearances of venlafaxine and its active metabolite were
decreased, thus prolonging the elimination half-lives of these substances.
A lower dose may be necessary (see &quot;DOSAGE AND ADMINISTRATION&quot;).
Venlafaxine, like all antidepressants, should be used with caution in such
patients. </p>

<p>INFORMATION FOR PATIENTS </p>

<p>Physicians are advised to discuss the following issues with patients
for whom they prescribe Venlafaxine: </p>

<p>Interference With Cognitive And Motor Performance </p>

<p>Clinical studies were performed to examine the effects of venlafaxine
on behavioral performance of healthy individuals. The results revealed
no clinically significant impairment of psychomotor, cognitive, or complex
behavior performance. However, since any psychoactive drug may impair judgment,
thinking, or motor skills, patients should be cautioned about operating
hazardous machinery, including automobiles, until they are reasonably certain
that Venlafaxine therapy does not adversely affect their ability to engage
in such activities. </p>

<p>Pregnancy </p>

<p>Patients should be advised to notify their physician if they become
pregnant or intend to become pregnant during therapy. </p>

<p>Nursing </p>

<p>Patients should be advised to notify their physician if they are breast-feeding
an infant. </p>

<p>Concomitant Medication </p>

<p>Patients should be advised to inform their physicians if they are taking,
or plan to take, any prescription or over-the-counter drugs, since there
is a potential for interactions. </p>

<p>Alcohol </p>

<p>Although Venlafaxine has not been shown to increase the impairment of
mental and motor skills caused by alcohol, patients should be advised to
avoid alcohol while taking Venlafaxine. </p>

<p>Allergic Reactions </p>

<p>Patients should be advised to notify their physician if they develop
a rash, hives, or a related allergic phenomenon. </p>

<p>LABORATORY TESTS </p>

<p>There are no specific laboratory tests recommended. </p>

<p>DRUG INTERACTIONS </p>

<p>As with all drugs, the potential for interaction by a variety of mechanisms
is a possibility. </p>

<p>Drugs Highly Bound To Plasma Protein </p>

<p>Venlafaxine is not highly bound to plasma proteins; therefore, administration
of Venlafaxine to a patient taking another drug that is highly protein
bound should not cause increased free concentrations of the other drug.
</p>

<p>Lithium </p>

<p>The steady-state pharmacokinetics of venlafaxine administered as 50
mg every 8 hours were not affected when a single 600 mg oral dose of lithium
was administered to 12 healthy male subjects. O-desmethylvenlafaxine (ODV)
was also unaffected. Venlafaxine had no effect on the pharmacokinetics
of lithium. </p>

<p>Diazepam </p>

<p>Under steady-state conditions for venlafaxine administered as 50 mg
every 8 hours, a single 10 mg dose of diazepam did not appear to affect
the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.
Venlafaxine also did not have any effect on the pharmacokinetics of diazepam
or its active metabolite, desmethyldiazepam. </p>

<p>Administration of Venlafaxine did not affect the psychomotor and psychometric
effects induced by diazepam. </p>

<p>Cimetidine </p>

<p>Concomitant administration of cimetidine and Venlafaxine in a steady-state
study for both drugs resulted in inhibition of first-pass metabolism of
venlafaxine in 18 healthy subjects. The oral clearance of venlafaxine was
reduced by about 43%, and the exposure (AUC) and maximum concentration
(Cmax) of the drug were increased by about 60%. However, co-administration
of cimetidine had no apparent effect on the pharmacokinetics of ODV, which
is present in much greater quantity in the circulation than is venlafaxine.
Consequently, the overall pharmacological activity of venlafaxine plus
ODV is expected to increase only slightly, and no dosage adjustment should
be necessary for most normal adults. However, for patients with pre-existing
hypertension, and for elderly patients or patients with hepatic dysfunction,
the interaction associated with the concomitant use of Venlafaxine and
cimetidine is not known and potentially could be more pronounced. Therefore,
caution is advised with such patients. </p>

<p>Alcohol </p>

<p>A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics
of venlafaxine or ODV when venlafaxine was administered as a 50 mg dose
every 8 hours in 15 healthy male subjects. The administration of Venlafaxine
in a stable regimen did not exaggerate the psychomotor and psychometric
effects induced by ethanol in these same subjects when they were not receiving
Venlafaxine. </p>

<p>Drugs That Inhibit Cytochrome P450IID6 Metabolism </p>

<p>In Vitro studies indicate that venlafaxine is metabolized to its active
metabolite, ODV, by cytochrome P450IID6, the isoenzyme that is responsible
for the genetic polymorphism seen in the metabolism of many antidepressants.
Therefore, the potential exists for a drug interaction between Venlafaxine
and drugs that inhibit cytochrome P450IID6 metabolism. Drug interactions
that reduce the metabolism of venlafaxine to ODV could potentially increase
the plasma concentrations of venlafaxine and lower the concentrations of
the active metabolite. </p>

<p>Drugs Metabolized By Cytochrome P450IID6 </p>

<p>In Vitro studies indicate that venlafaxine is a relatively weak inhibitor
of cytochrome P450IID6. However, the clinical significance of this finding
is unknown. </p>

<p>Monoamine Oxidase Inhibitors </p>

<p>See &quot;WARNINGS.&quot; </p>

<p>CNS-Active Drugs </p>

<p>The risk of using venlafaxine in combination with other CNS-active drugs
has not been systematically evaluated (except in the case of lithium and
diazepam, as noted above). Consequently, caution is advised if the concomitant
administration of venlafaxine and such drugs is required. </p>

<p>Electroconvulsive Therapy </p>

<p>There are no clinical data establishing the benefit of electroconvulsive
therapy combined with Venlafaxine treatment. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY </p>

<p>Carcinogenesis </p>

<p>Venlafaxine was given by oral gavage to mice for 18 months at doses
of 120 mg/kg per day, which was 16 times, on a mg/kg basis, and 1.7 times
on a mg/M(square) basis, the maximum recommended human dose. Venlafaxine
was also given to rats by oral gavage for 24 months at doses up to 120
mg/kg per day. In rats receiving the 120 mg/kg dose, plasma levels of venlafaxine
were 1 times (male rats) and 6 times (female rats) the plasma levels of
patients receiving the maximum recommended human dose. Plasma levels of
the O-desmethyl metabolite were lower in rats than in patients receiving
the maximum recommended dose. Tumors were not increased by venlafaxine
treatment in mice or rats. </p>

<p>Mutagenicity </p>

<p>Venlafaxine and the major human metabolite, O-desmethylvenlafaxine (ODV),
were </p>

<p>not mutagenic in the Ames reverse mutation assay in Salmonella bacteria
or the CHO/HGPRT mammalian cell forward gene mutation assay. Venlafaxine
was also not mutagenic in the In Vitro BALB/c-3T3 mouse cell transformation
assay, the sister chromatid exchange assay in cultured CHO cells, or the
In Vivo chromosomal aberration assay in rat bone marrow. ODV was not mutagenic
in the In Vitro CHO cell chromosomal aberration assay. There was a clastogenic
response in the In Vivo chromosomal aberration assay in rat bone marrow
in male rats receiving 200 times, on a mg/kg basis, or 50 times, on a mg/M(square)
basis, the maximum human daily dose. The no effect dose was 67 times (mg/kg)
or 17 times (mg/M(square)) the human dose. </p>

<p>Impairment Of Fertility </p>

<p>Reproduction and fertility studies in rats showed no effects on male
or female fertility at oral doses of up to 8 times the maximum recommended
human daily dose on a mg/kg basis, or up to 2 times on a mg/M(square) basis.
</p>

<p>PREGNANCY </p>

<p>Teratogenic Effects--Pregnancy Category C </p>

<p>Venlafaxine did not cause malformations in offspring of rats or rabbits
given doses up to 11 times (rat) or 12 times (rabbit) the maximum recommended
human daily dose on a mg/kg basis, or 2.5 times (rat) and 4 times (rabbit)
the human daily dose on a mg/M(square) basis. However, in rats, there was
a decrease in pup weight, an increase in stillborn pups, and an increase
in pup deaths during the first 5 days of lactation, when dosing began during
pregnancy and continued until weaning. The cause of these deaths is not
known. These effects occurred at 10 times (mg/kg) or 2.5 times (mg/M(square))
the maximum human daily dose. The no effect dose for rat pup mortality
was 1.4 times the human dose on a mg/kg basis or 0.25 times the human dose
on a mg/M(square) basis. There are no adequate and well-controlled studies
in pregnant women. Because animal reproduction studies are not always predictive
of human response, this drug should be used during pregnancy only if clearly
needed. </p>

<p>LABOR AND DELIVERY </p>

<p>The effect of Venlafaxine on labor and delivery in humans is unknown.
</p>

<p>NURSING MOTHERS </p>

<p>It is not known whether venlafaxine hydrochloride or its metabolites
are excreted in human milk. Because many drugs are excreted in human milk,
caution should be exercised when Venlafaxine is administered to a nursing
woman. </p>

<p>USAGE IN CHILDREN </p>

<p>Safety and effectiveness in individuals below 18 years of age have not
been established. </p>

<p>GERIATRIC USE </p>

<p>Of the 2,897 patients in phase 2-3 depression studies with Venlafaxine,
12% (357) were 65 years of age or over. No overall differences in effectiveness
or safety were observed between these patients and younger patients, and
other reported clinical experience has not identified differences in response
between the elderly and younger patients. However, greater sensitivity
of some older individuals cannot be ruled out. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>As with all drugs, the potential for interaction by a variety of mechanisms
is a possibility. </p>

<p>Drugs Highly Bound To Plasma Protein </p>

<p>Venlafaxine is not highly bound to plasma proteins; therefore, administration
of Venlafaxine to a patient taking another drug that is highly protein
bound should not cause increased free concentrations of the other drug.
</p>

<p>Lithium </p>

<p>The steady-state pharmacokinetics of venlafaxine administered as 50
mg every 8 hours were not affected when a single 600 mg oral dose of lithium
was administered to 12 healthy male subjects. O-desmethylvenlafaxine (ODV)
was also unaffected. Venlafaxine had no effect on the pharmacokinetics
of lithium. </p>

<p>Diazepam </p>

<p>Under steady-state conditions for venlafaxine administered as 50 mg
every 8 hours, a single 10 mg dose of diazepam did not appear to affect
the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects.
Venlafaxine also did not have any effect on the pharmacokinetics of diazepam
or its active metabolite, desmethyldiazepam. </p>

<p>Administration of Venlafaxine did not affect the psychomotor and psychometric
effects induced by diazepam. </p>

<p>Cimetidine </p>

<p>Concomitant administration of cimetidine and Venlafaxine in a steady-state
study for both drugs resulted in inhibition of first-pass metabolism of
venlafaxine in 18 healthy subjects. The oral clearance of venlafaxine was
reduced by about 43%, and the exposure (AUC) and maximum concentration
(Cmax) of the drug were increased by about 60%. However, co-administration
of cimetidine had no apparent effect on the pharmacokinetics of ODV, which
is present in much greater quantity in the circulation than is venlafaxine.
Consequently, the overall pharmacological activity of venlafaxine plus
ODV is expected to increase only slightly, and no dosage adjustment should
be necessary for most normal adults. However, for patients with pre-existing
hypertension, and for elderly patients or patients with hepatic dysfunction,
the interaction associated with the concomitant use of Venlafaxine and
cimetidine is not known and potentially could be more pronounced. Therefore,
caution is advised with such patients. </p>

<p>Alcohol </p>

<p>A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics
of venlafaxine or ODV when venlafaxine was administered as a 50 mg dose
every 8 hours in 15 healthy male subjects. The administration of Venlafaxine
in a stable regimen did not exaggerate the psychomotor and psychometric
effects induced by ethanol in these same subjects when they were not receiving
Venlafaxine. </p>

<p>Drugs That Inhibit Cytochrome P450IID6 Metabolism </p>

<p>In Vitro studies indicate that venlafaxine is metabolized to its active
metabolite, ODV, by cytochrome P450IID6, the isoenzyme that is responsible
for the genetic polymorphism seen in the metabolism of many antidepressants.
Therefore, the potential exists for a drug interaction between Venlafaxine
and drugs that inhibit cytochrome P450IID6 metabolism. Drug interactions
that reduce the metabolism of venlafaxine to ODV could potentially increase
the plasma concentrations of venlafaxine and lower the concentrations of
the active metabolite. </p>

<p>Drugs Metabolized By Cytochrome P450IID6 </p>

<p>In Vitro studies indicate that venlafaxine is a relatively weak inhibitor
of cytochrome P450IID6. However, the clinical significance of this finding
is unknown. </p>

<p>Monoamine Oxidase Inhibitors </p>

<p>See &quot;WARNINGS.&quot; </p>

<p>CNS-Active Drugs </p>

<p>The risk of using venlafaxine in combination with other CNS-active drugs
has not been systematically evaluated (except in the case of lithium and
diazepam, as noted above). Consequently, caution is advised if the concomitant
administration of venlafaxine and such drugs is required. </p>

<p>Electroconvulsive Therapy </p>

<p>There are no clinical data establishing the benefit of electroconvulsive
therapy combined with Venlafaxine treatment. </p>

<p>(See Also PRECAUTIONS)</p>

<p><a name="ADVERSE REACTIONS"></a><b> ADVERSE REACTIONS </b></p>

<p>ASSOCIATED WITH DISCONTINUATION OF TREATMENT </p>

<p>Nineteen percent (537/2897) of venlafaxine patients in phase 2-3 depression
studies discontinued treatment due to an adverse event. The more common
events (&gt;/=1%) associated with discontinuation and considered to be
drug-related (i.e. those events associated with dropout at a rate approximately
twice or greater for venlafaxine compared to placebo) included: </p>

<pre>CNS                                    VENLAFAXINE                PLACEBO       
Somnolence                                   3%                    1%           
Insomnia                                     3%                    1%           
Dizziness                                    3%                    --           
Nervousness                                  2%                    --           
Dry mouth                                    2%                    --           
Anxiety                                      2%                    1%           
GASTROINTESTINAL                                                                
Nausea                                       6%                    1%           
UROGENITAL                                                                      
Abnormal ejaculation*                        3%                    --           
OTHER                                                                           
Headache                                     3%                    1%           
Asthenia                                     2%                    --           
Sweating                                     2%                    --           
-----------------------------------------------------------------------------   
*    Percentages based on the number of males.                                  
--   Less than 1%                                 </pre>

<p>INCIDENCE IN CONTROLLED TRIALS </p>

<p>Commonly Observed Adverse Events In Controlled Clinical Trials </p>

<p>The most commonly observed adverse events associated with the use of
Venlafaxine (incidence of 5% or greater) and not seen at an equivalent
incidence among placebo-treated patients (i.e., incidence for Venlafaxine
at least twice that for placebo), derived from the 1% incidence table below,
were asthenia, sweating, nausea, constipation, anorexia, vomiting, somnolence,
dry mouth, dizziness, nervousness, anxiety, tremor, and blurred vision
as well as abnormal ejaculation/orgasm and impotence in men. </p>

<p>Adverse Events Occurring At An Incidence Of 1% Or More Among Venlafaxine-Treated
Patients </p>

<p>The table that follows enumerates adverse events that occurred at an
incidence of 1% or more, and were more frequent than in the placebo group,
among Venlafaxine- treated patients who participated in short-term (4-
to 8-week) placebo- controlled trials in which patients were administered
doses in a range of 75 to 375 mg/day. This table shows the percentage of
patients in each group who had at least one episode of an event at some
time during their treatment. Reported adverse events were classified using
a standard COSTART-based Dictionary terminology. </p>

<p>The prescriber should be aware that these figures cannot be used to
predict the incidence of side effects in the course of usual medical practice
where patient characteristics and other factors differ from those which
prevailed in the clinical trials. Similarly, the cited frequencies cannot
be compared with figures obtained from other clinical investigations involving
different treatments, uses and investigators. The cited figures, however,
do provide the prescribing physician with some basis for estimating the
relative contribution of drug and nondrug factors to the side effect incidence
rate in the population studied. </p>

<pre>                                 TABLE 1                                        
            TREATMENT-EMERGENT ADVERSE EXPERIENCE INCIDENCE IN                  
             4- TO 8-WEEK PLACEBO-CONTROLLED CLINICAL TRIALS1                   
----------------------------------------------------------------------------    
BODY SYSTEM           PREFERRED TERM             Venlafaxine        PLACEBO         
                                                 (N=1033)       (N=609)         
----------------------------------------------------------------------------    
Body as a Whole       Headache                      25%          24%            
                      Asthenia                      12%           6%            
                      Infection                      6%           5%            
                      Chills                         3%           --            
                      Chest pain                     2%           1%            
                      Trauma                         2%           1%            
Cardiovascular        Vasodilatation                 4%           3%            
                      Increased blood                2%           --            
                       pressure/hypertension                                    
                      Tachycardia                    2%           --            
                      Postural hypotension           1%           --            
Dermatological        Sweating                      12%           3%            
                      Rash                           3%           2%            
                      Pruritus                       1%           --            
Gastrointestinal      Nausea                        37%          11%            
                      Constipation                  15%           7%            
                      Anorexia                      11%           2%            
                      Diarrhea                       8%           7%            
                      Vomiting                       6%           2%            
                      Dyspepsia                      5%           4%            
                      Flatulence                     3%           2%            
Metabolic             Weight loss                    1%           --            
Nervous System        Somnolence                    23%           9%            
                      Dry mouth                     22%          11%            
                      Dizziness                     19%           7%            
                      Insomnia                      18%          10%            
                      Nervousness                   13%           6%            
                      Anxiety                        6%           3%            
                      Tremor                         5%           1%            
                      Abnormal dreams                4%           3%            
                      Hypertonia                     3%           2%            
                      Paresthesia                    3%           2%            
                      Libido decreased               2%           --            
                      Agitation                      2%           --            
                      Confusion                      2%           1%            
                      Thinking abnormal              2%           1%            
                      Depersonalization              1%           --            
                      Depression                     1%           --            
                      Urinary retention              1%           --            
                      Twitching                      1%           --            
Respiration           Yawn                           3%           --            
Special Senses        Blurred vision                 6%           2%            
                      Taste perversion               2%           --            
                      Tinnitus                       2%           --            
                      Mydriasis                      2%           --            
Urogenital System     Abnormal ejaculation/orgasm   12%2          --2           
                      Impotence                      6%2          --2           
                      Urinary frequency              3%           2%            
                      Urination impaired             2%           --            
                      Orgasm disturbance             2%3          --3           
                      Menstrual disorder             1%3          --3           
----------------------------------------------------------------------------    
1   Events reported by at least 1% of patients treated with Venlafaxine are         
     included, and are rounded to the nearest %. Events for which the Venlafaxine   
     incidence was equal to or less than placebo are not listed in the table,   
     but included the following: abdominal pain, pain, back pain, flu           
     syndrome, fever, palpitation, increased appetite, myalgia, arthralgia,     
     amnesia, hypesthesia, rhinitis, pharyngitis, sinusitis, cough increased,   
     urinary tract infection, and dysmenorrhea3.                                
--  Incidence less than 1%.                                                     
2   Incidence based on number of male patients.                                 
3   Incidence based on number of female patients.     </pre>

<p>Dose Dependency Of Adverse Events </p>

<p>A comparison of adverse event rates in a fixed-dose study comparing
Venlafaxine 75, 225, and 375 mg/day with placebo revealed a dose dependency
for some of the more common adverse events associated with Venlafaxine
use, as shown in the table that follows. The rule for including events
was to enumerate those that occurred at an incidence of 5% or more for
at least one of the venlafaxine groups and for which the incidence was
at least twice the placebo incidence for at least one Venlafaxine group.
Tests for potential dose relationships for these events (Cochran- Armitage
Test, with a criterion of exact 2-sided p-value &lt; or =0.05) suggested
a dose-dependency for several adverse events in this list, including chills,
hypertension, anorexia, nausea, agitation, dizziness, somnolence, tremor,
yawning, sweating, and abnormal ejaculation. </p>

<pre>                                 TABLE 2                                        
               TREATMENT-EMERGENT EXPERIENCE INCIDENCE IN A                     
                          DOSE COMPARISON TRIAL                                 
----------------------------------------------------------------------------    
                                              Venlafaxine (MG/DAY)                  
       BODY SYSTEM/                                                             
         PREFERRED TERM      PLACEBO       75       225       375               
                              (N=92)     (N=89)    (N=89)    (N=88)             
----------------------------------------------------------------------------    
       BODY AS A WHOLE                                                          
         Abdominal pain          3.3%    3.4%      2.2%      8.0%               
         Asthenia                3.3%   16.9%     14.6%     14.8%               
         Chills                  1.1%    2.2%      5.5%      6.8%               
         Infection               2.2%    2.2%      5.6%      2.3%               
       CARDIOVASCULAR SYSTEM                                                    
         Hypertension            1.1%    1.5%      2.2%      4.5%               
         Vasodilatation          0.0%    4.5%      5.6%      2.3%               
       DIGESTIVE SYSTEM                                                         
         Anorexia                2.2%   14.6%     13.5%     17.0%               
         Dyspepsia               2.2%    6.7%      6.7%      4.5%               
         Nausea                 14.1%   32.6%     38.2%     58.0%               
         Vomiting                1.1%    7.9%      3.4%      6.8%               
       NERVOUS SYSTEM                                                           
         Agitation               0.0%    1.1%      2.2%      4.5%               
         Anxiety                 4.3%   11.2%      4.5%      2.3%               
         Dizziness               4.3%   19.1%     22.5%     23.9%               
         Insomnia                9.8%   22.5%     20.2%     13.6%               
         Libido decreased        1.1%    2.2%      1.1%      5.7%               
         Nervousness             4.3%   21.3%     13.5%     12.5%               
         Somnolence              4.3%   16.9%     18.0%     26.1%               
         Tremor                  0.0%    1.1%      2.2%     10.2%               
       RESPIRATORY SYSTEM                                                       
         Yawn                    0.0%    4.5%      5.6%      8.0%               
       SKIN AND APPENDAGES                                                      
         Sweating                5.4%    6.7%     12.4%     19.3%               
       SPECIAL SENSES                                                           
         Abnormality of          0.0%    9.1%      7.9%      5.6%               
          accommodation                                                         
       UROGENITAL SYSTEM                                                        
         Abnormal                0.0%    4.5%      2.2%     12.5%               
          ejaculation/orgasm                                                    
         Impotence               0.0%    5.8%      2.1%      3.6%               
          (Number of men)      (n=63)  (n=52)    (n=48)    (n=56)               
</pre>

<p>Adaptation To Certain Adverse Events </p>

<p>Over a 6-week period, there was evidence of adaptation to some adverse
events with continued therapy (e.g., dizziness and nausea), but less to
other effects (e.g., abnormal ejaculation and dry mouth). </p>

<p>Vital Sign Changes </p>

<p>Venlafaxine treatment (averaged over all dose groups) in clinical trials
was associated with a mean increase in pulse rate of approximately 3 beats
per minute, compared to no change for placebo. It was associated with mean
increases in diastolic blood pressure ranging from 0.7 to 2.5 mm Hg averaged
over all dose groups, compared to mean decreases ranging from 0.9 to 3.8
mm Hg for placebo. However, there is a dose dependency for blood pressure
increase (see &quot;WARNINGS&quot;). </p>

<p>Laboratory Changes </p>

<p>Of the serum chemistry and hematology parameters monitored during clinical
trials with Venlafaxine, a statistically significant difference with placebo
was seen only for serum cholesterol, i.e., patients treated with Venlafaxine
had mean increases from baseline of 3 mg/dL, a change of unknown clinical
significance. </p>

<p>ECG Changes </p>

<p>In an analysis of ECGs obtained in 769 patients treated with Venlafaxine
and 450 patients treated with placebo in controlled clinical trials, the
only statistically significant difference observed was for heart rate,
i.e., a mean increase from baseline of 4 beats per minute for Venlafaxine.
</p>

<p>OTHER EVENTS OBSERVED DURING THE PREMARKETING EVALUATION OF VENLAFAXINE
</p>

<p>During its premarketing assessment, multiple doses of Venlafaxine were
administered to 2181 patients in phase 2 and 3 studies. The conditions
and duration of exposure to Venlafaxine varied greatly, and included (in
overlapping categories) open and double-blind studies, uncontrolled and
controlled studies, inpatient and outpatient studies, fixed-dose and titration
studies. Untoward events associated with this exposure were recorded by
clinical investigators, using terminology of their own choosing. Consequently,
it is not possible to provide a meaningful estimate of the proportion of
individuals experiencing adverse events without first grouping similar
types of untoward events into a smaller number of standardized event categories.
</p>

<p>In the tabulations that follow, reported adverse events were classified
using a standard COSTART-based Dictionary terminology. The frequencies
presented, therefore, represent the proportion of the 2181 patients exposed
to multiple doses of Venlafaxine who experienced an event of the type cited
on at least one occasion while receiving Venlafaxine. All reported events
are included except those already listed in Table 1 and those events for
which a drug cause was remote. If the COSTART term for an event was so
general as to be uninformative, it was replaced with a more informative
term. It is important to emphasize that, although the events reported occurred
during treatment with Venlafaxine, they were not necessarily caused by
it. </p>

<p>Events are further categorized by body system and listed in order of
decreasing frequency according to the following definitions: frequent adverse
events are those occurring on one or more occasions in at least 1/100 patients
(only those not already listed in the tabulated results from placebo-controlled
trials appear in this listing); infrequent adverse events are those occurring
in 1/100 to 1/1000 patients; rare events are those occurring in fewer than
1/1000 patients. </p>

<p>BODY AS A WHOLE--FREQUENT: accidental injury, malaise, neck pain; INFREQUENT:
abdomen enlarged, allergic reaction, cyst, face edema, generalized edema,
hangover effect, hernia, intentional injury, moniliasis, neck rigidity,
overdose, chest pain substernal, pelvic pain, photosensitivity reaction,
suicide attempt; RARE: appendicitis, body odor, carcinoma, cellulitis,
halitosis, ulcer, withdrawal syndrome. </p>

<p>CARDIOVASCULAR SYSTEM--FREQUENT: migraine; INFREQUENT: angina pectoris,
extrasystoles, hypotension, peripheral vascular disorder (mainly cold feet
and/or cold hands), syncope, thrombophlebitis; RARE: arrhythmia, first-degree
atrioventricular block, bradycardia, bundle branch block, mitral valve
disorder mucocutaneous hemorrhage, sinus bradycardia, varicose vein. </p>

<p>DIGESTIVE SYSTEM--FREQUENT: dysphagia, eructation; INFREQUENT: colitis,
tongue edema, esophagitis, gastritis, gastroenteritis, gingivitis, glossitis,
rectal hemorrhage, hemorrhoids, melena, stomatitis, stomach ulcer, mouth
ulceration; RARE: cheilitis, cholecystitis, cholelithiasis, hematemesis,
gum hemorrhage, hepatitis, ileitis, jaundice, oral moniliasis, intestinal
obstruction, proctitis, increased salivation, soft stools, tongue discoloration,
esophageal ulcer, peptic ulcer syndrome. </p>

<p>ENDOCRINE SYSTEM--RARE: goiter, hyperthyroidism, hypothyroidism. </p>

<p>HEMIC AND LYMPHATIC SYSTEM--FREQUENT: ecchymosis; INFREQUENT: anemia,
leukocytosis, leukopenia, lymphadenopathy, lymphocytosis, thrombocythemia,
thrombocytopenia, WBC abnormal; RARE: basophilia, cyanosis eosinophilia,
erythrocytes abnormal. </p>

<p>METABOLIC AND NUTRITIONAL--FREQUENT: peripheral edema, weight gain;
INFREQUENT: alkaline phosphatase increased, creatinine increased, diabetes
mellitus, edema glycosuria, hypercholesteremia, hyperglycemia, hyperlipemia,
hyperuricemia, hypoglycemia, hypokalemia, SGOT increased, thirst; RARE:
alcohol intolerance, bilirubinemia, BUN increased, gout, hemochromatosis,
hyperkalemia, hyperphosphatemia, hypoglycemic reaction, hyponatremia, hypophosphatemia,
hypoproteinemia, SGPT increased, uremia. </p>

<p>MUSCULOSKELETAL SYSTEM--INFREQUENT: arthritis, arthrosis, bone pain,
bone spurs bursitis, joint disorder, myasthenia, tenosynovitis; RARE: osteoporosis.
</p>

<p>NERVOUS SYSTEM--FREQUENT: emotional lability, trismus, vertigo; INFREQUENT:
apathy, ataxia, circumoral paresthesia, CNS stimulation, euphoria, hallucinations,
hostility, hyperesthesia, hyperkinesia, hypertonia, hypotonia, incoordination,
libido increased, myoclonus, neuralgia, neuropathy, paranoid reaction,
psychosis, psychotic depression, sleep disturbance, abnormal speech, stupor,
torticollis; RARE: akathisia, akinesia, alcohol abuse, aphasia, bradykinesia,
cerebrovascular accident, loss of consciousness, delusions, dementia, dystonia,
hypokinesia, neuritis, nystagmus, reflexes increased. </p>

<p>RESPIRATORY SYSTEM--FREQUENT: bronchitis, dyspnea; INFREQUENT: asthma,
chest congestion, epistaxis, hyperventilation, laryngismus, laryngitis,
pneumonia, voice alteration; RARE: atelectasis, hemoptysis, hypoxia, pleurisy,
pulmonary embolus, sleep apnea, sputum increased. </p>

<p>SKIN AND APPENDAGES--INFREQUENT: acne, alopecia, brittle nails, contact
dermatitis, dry skin, herpes simplex, herpes zoster, maculopapular rash,
urticaria; RARE: skin atrophy, exfoliative dermatitis, fungal dermatitis,
lichenoid dermatitis, hair discoloration, eczema, furunculosis, hirsutism,
skin hypertrophy, leukoderma, psoriasis, pustular rash, vesiculobullous
rash. </p>

<p>SPECIAL SENSES--FREQUENT: abnormal vision, ear pain; INFREQUENT: cataract,
conjunctivitis, corneal lesion, diplopia, dry eyes, exophthalmos, eye pain,
otitis media, parosmia, photophobia, subconjunctival hemorrhage, taste
loss, visual field defect; RARE: blepharitis, chromatopsia, conjunctival
edema, deafness, glaucoma, hyperacusis, keratitis, labyrinthitis, miosis,
papilledema, decreased pupillary reflex, scleritis. </p>

<p>UROGENITAL SYSTEM--FREQUENT: anorgasmia, dysuria, hematuria, metrorrhagia*,
urination impaired, vaginitis*; INFREQUENT: albuminuria, amenorrhea*, kidney
calculus, cystitis, leukorrhea, menorrhagia*, nocturia, bladder pain, breast
pain, kidney pain, polyuria, prostatitis*, pyelonephritis, pyuria, urinary
incontinence, urinary urgency, uterine fibroids enlarged*, uterine hemorrhage*,
vaginal hemorrhage*, vaginal moniliasis*, RARE: abortion*, breast engorgement,
breast enlargement, calcium crystalluria, female lactation*, hypomenorrhea*,
menopause*, prolonged erection*, uterine spasm*. </p>

<p>* Based on the number of male or female patients as appropriate. </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>CONTROLLED SUBSTANCE CLASS </p>

<p>Venlafaxine is not a controlled substance. </p>

<p>PHYSICAL AND PSYCHOLOGICAL DEPENDENCE </p>

<p>In Vitro studies revealed that venlafaxine has virtually no affinity
for opiate benzodiazepine, phencyclidine (PCP), or N-methyl-D-aspartic
acid (NMDA) receptors. </p>

<p>Venlafaxine was not found to have any significant CNS stimulant activity
in rodents. In primate drug discrimination studies, venlafaxine showed
no significant stimulant or depressant abuse liability. </p>

<p>While the discontinuation effects of Venlafaxine have not been systematically
evaluated in controlled clinical trials, a retrospective survey of new
events occurring during taper or following discontinuation revealed the
following six events that occurred at an incidence of at least 5% and for
which the incidence for Venlafaxine was at least twice the placebo incidence:
asthenia, dizziness, headache, insomnia, nausea, and nervousness. Therefore,
it is recommended that the dosage be tapered gradually and the patient
monitored (see &quot;DOSAGE AND ADMINISTRATION&quot;). </p>

<p>While Venlafaxine has not been systematically studied in clinical trials
for its potential for abuse, there was no indication of drug-seeking behavior
in the clinical trials. However, it is not possible to predict on the basis
of premarketing experience the extent to which a CNS active drug will be
misused, diverted, and/or abused once marketed. Consequently, physicians
should carefully evaluate patients for history of drug abuse and follow
such patients closely, observing them for signs of misuse or abuse of Venlafaxine
(e.g., development of tolerance, incrementation of dose, drug-seeking behavior).
</p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>HUMAN EXPERIENCE </p>

<p>There were 14 reports of acute overdose with Venlafaxine (venlafaxine
hydrochloride), either alone or in combination with other drugs and/or
alcohol, among the patients included in the premarketing evaluation. The
majority of the reports involved ingestions in which the total dose of
Venlafaxine taken was estimated to be no more than several-fold higher
than the usual therapeutic dose. The 3 patients who took the highest doses
were estimated to have ingested approximately 6.75 g, 2.75 g, and 2.5 g.
The resultant peak plasma levels of venlafaxine for the latter 2 patients
were 6.24 and 2.35 mcgm/mL, respectively, and the peak plasma levels of
O-desmethylvenlafaxine were 3.37 and 1.30 mcgm/mL respectively. Plasma
venlafaxine levels were not obtained for the patient who ingested 6.75
g of venlafaxine. All 14 patients recovered without sequelae. Most patients
reported no symptoms. Among the remaining patients, somnolence was the
most commonly reported symptom. The patient who ingested 2.75 g of venlafaxine
was observed to have 2 generalized convulsions and a prolongation of QTc
to 500 msec, compared with 405 msec at baseline. Mild sinus tachycardia
was reported in 2 of the other patients. </p>

<p>OVERDOSAGE MANAGEMENT </p>

<p>Treatment should consist of those general measures employed in the management
of overdosage with any antidepressant. Ensure an adequate airway, oxygenation,
and ventilation. Monitoring of cardiac rhythm and vital signs is recommended.
General supportive and symptomatic measures are also recommended. Use of
activated charcoal, induction of emesis, or gastric lavage should be considered.
Due to the large volume of distribution of venlafaxine hydrochloride, forced
diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely
to be of benefit. No specific antidotes for Venlafaxine are known. </p>

<p>In managing overdosage, consider the possibility of multiple drug involvement.
The physician should consider contacting a poison control center on the
treatment of any overdose. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>INITIAL TREATMENT </p>

<p>The recommended starting dose for Venlafaxine is 75 mg/day, administered
in two or three divided doses, taken with food. Depending on tolerability
and the need for further clinical effect, the dose may be increased to
150 mg/day. If needed the dose should be further increased up to 225 mg/day.
When increasing the dose, increments of up to 75 mg/day should be made
at intervals of no less than 4 days. In outpatient settings there was no
evidence of usefulness of doses greater than 225 mg/day for moderately
depressed patients, but more severely depressed inpatients responded to
a mean dose of 350 mg/day. Certain patients, including more severely depressed
patients, may therefore respond more to higher doses, up to a maximum of
375 mg/day, generally in three divided doses. </p>

<p>DOSAGE FOR PATIENTS WITH HEPATIC IMPAIRMENT </p>

<p>Given the decrease in clearance and increase in elimination half-life
for both venlafaxine and ODV that is observed in patients with hepatic
cirrhosis compared to normal subjects (see &quot;CLINICAL PHARMACOLOGY&quot;),
it is recommended that the total daily dose be reduced by 50% in patients
with moderate hepatic impairment. Since there was much individual variability
in clearance between patients with cirrhosis, it may be necessary to reduce
the dose even more than 50%, and individualization of dosing may be desirable
in some patients. </p>

<p>DOSAGE FOR PATIENTS WITH RENAL IMPAIRMENT </p>

<p>Given the decrease in clearance for venlafaxine and the increase in
elimination half-life for both venlafaxine and ODV that is observed in
patients with renal impairment (GFR = 10-70 mL/min) compared to normals
(see &quot;CLINICAL PHARMACOLOGY&quot;), it is recommended that the total
daily dose be reduced by 25% in patients with mild to moderate renal impairment.
It is recommended that the total daily dose be reduced by 50% and the dose
be withheld until the dialysis treatment is completed (4 hrs) in patients
undergoing hemodialysis. Since there was much individual variability in
clearance between patients with renal impairment, individualization of
dosing may be desirable in some patients. </p>

<p>DOSAGE FOR ELDERLY PATIENTS </p>

<p>No dose adjustment is recommended for elderly patients on the basis
of age. As with any antidepressant, however, caution should be exercised
in treating the elderly. When individualizing the dosage, extra care should
be taken when increasing the dose. </p>

<p>MAINTENANCE/CONTINUATION/EXTENDED TREATMENT </p>

<p>There is no body of evidence available to answer the question of how
long a patient should continue to be treated with Venlafaxine. It is generally
agreed that acute episodes of major depression require several months or
longer of sustained pharmacologic therapy. Whether the dose of antidepressant
needed to induce remission is identical to the dose needed to maintain
and/or sustain euthymia is unknown. </p>

<p>DISCONTINUING Venlafaxine </p>

<p>When discontinuing Venlafaxine after more than 1 week of therapy, it
is generally recommended that the dose be tapered to minimize the risk
of discontinuation symptoms. Patients who have received Venlafaxine for
6 weeks or more should have their dose tapered gradually over a 2-week
period. </p>

<p>SWITCHING PATIENTS TO OR FROM A MONOAMINE OXIDASE INHIBITOR </p>

<p>At least 14 days should elapse between discontinuation of an MAOI and
initiation of therapy with Venlafaxine. In addition, at least 7 days should
be allowed after stopping Venlafaxine before starting an MAOI. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-47</DOCNO>
<DOCOLDNO>IA018-000200-B041-42</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/doxepin.htm 206.86.175.201 19970106230759 text/html 17270
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:01:45 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 17087
Last-modified: Fri, 18 Oct 1996 22:05:28 GMT
</DOCHDR>
<html>
<head>
   <title>Doxepin - RxList Generic Information</title>
   <meta name="keywords" content="Adapin, Alopam, Aponal, Deptran, Doxetar, Doxin, Gilex,
Quitaxon, Sinequan, Sinquane, Spectra, Triadapin, Xepin, Zonalon">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Doxepin</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p><a name="DESCRIPTION"></a>
<hr width="100%" ></p>

<p><b>DESCRIPTION </b></p>

<p>Doxepin is one of a class of psychotherapeutic agents known as dibenzoxepin
tricyclic compounds. The molecular formula of the compound is C19H21NO.HCl
having a molecular weight of 316. It is a white crystalline solid readily
soluble in water, lower alcohols and chloroform. Doxepin (doxepin HCl)
is a dibenzoxepin derivative and is the first of a family of tricyclic
psychotherapeutic agents. Specifically, it is an isomeric mixture of: 1-Propanamine,3-dibenz(b,e)oxepin-11(6H)ylidene-
N,N-dimethyl-, hydrochloride. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>The mechanism of action of Doxepin is not definitely known. It is not
a central nervous system stimulant nor a monoamine oxidase inhibitor. The
current hypothesis is that the clinical effects are due, at least in part,
to influences on the adrenergic activity at the synapses so that deactivation
of norepinephrine by reuptake into the nerve terminals is prevented. Animal
studies suggest that doxepin HCl does not appreciably antagonize the antihypertensive
action of guanethidine. In animal studies anticholinergic, antiserotonin
and antihistamine effects on smooth muscle have been demonstrated. At higher
than usual clinical doses, norepinephrine response was potentiated in animals.
This effect was not demonstrated in humans. </p>

<p>At clinical dosages up to 150 mg per day, Doxepin can be given to man
concomitantly with guanethidine and related compounds without blocking
the antihypertensive effect. At dosages above 150 mg per day blocking of
the antihypertensive effect of these compounds has been reported. </p>

<p>Doxepin is virtually devoid of euphoria as a side effect. Characteristic
of this type of compound, Doxepin has not been demonstrated to produce
the physical tolerance or psychological dependence associated with addictive
compounds. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Doxepin is recommended for the treatment of: </p>

<p>1. Psychoneurotic patients with depression and/or anxiety. </p>

<p>2. Depression and/or anxiety associated with alcoholism (not to be taken
concomitantly with alcohol). </p>

<p>3. Depression and/or anxiety associated with organic disease (the possibility
of drug interaction should be considered if the patient is receiving other
drugs concomitantly). </p>

<p>4. Psychotic depressive disorders with associated anxiety including
involutional depression and manic-depressive disorders. </p>

<p>The target symptoms of psychoneurosis that respond particularly well
to Doxepin include anxiety, tension, depression, somatic symptoms and concerns,
sleep disturbances, guilt, lack of energy, fear, apprehension and worry.
</p>

<p>Clinical experience has shown that Doxepin is safe and well tolerated
even in the elderly patient. Owing to lack of clinical experience in the
pediatric population, Doxepin is not recommended for use in children under
12 years of age. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Doxepin is contraindicated in individuals who have shown hypersensitivity
to the drug. Possibility of cross sensitivity with other dibenzoxepines
should be kept in mind. </p>

<p>Doxepin is contraindicated in patients with glaucoma or a tendency to
urinary retention. These disorders should be ruled out, particularly in
older patients. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>The once-a-day dosage regimen of Doxepin in patients with intercurrent
illness or patients taking other medications should be carefully adjusted.
This is especially important in patients receiving other medications with
anticholinergic effects. </p>

<p>Usage In Geriatrics </p>

<p>The use of Doxepin on a once-a-day dosage regimen in geriatric patients
should be adjusted carefully based on the patient's condition. </p>

<p>Usage In Pregnancy </p>

<p>Reproduction studies have been performed in rats, rabbits, monkeys and
dogs and there was no evidence of harm to the animal fetus. The relevance
to humans is not known. Since there is no experience in pregnant women
who have received this drug, safety in pregnancy has not been established.
There has been a report of apnea and drowsiness occurring in a nursing
infant whose mother was taking Doxepin. </p>

<p>Usage In Children </p>

<p>The use of Doxepin in children under 12 years of age is not recommended
because safe conditions for its use have not been established. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>DROWSINESS </p>

<p>Since drowsiness may occur with the use of this drug, patients should
be warned of the possibility and cautioned against driving a car or operating
dangerous machinery while taking the drug. Patients should also be cautioned
that their response to alcohol may be potentiated. </p>

<p>SUICIDE </p>

<p>Since suicide is an inherent risk in any depressed patient and may remain
so until significant improvement has occurred, patients should be closely
supervised during the early course of therapy. Prescriptions should be
written for the smallest feasible amount. </p>

<p>PSYCHOSIS </p>

<p>Should increased symptoms of psychosis or shift to manic symptomatology
occur, it may be necessary to reduce dosage or add a major tranquilizer
to the dosage regimen. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Drugs Metabolized By P450 206: The biochemical activity of the drug
metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced
in a subset of the caucasian population (about 7-10% of caucasians are
so-called &quot;poor metabolizers&quot;); reliable estimates of the prevalence
of reduced P450 2D6 isozyme activity among Asian, African and other populations
are not yet available. Poor metabolizers have higher than expected plasma
concentrations of tricyclic antidepressants (TCAs) when given usual doses.
Depending on the fraction of drug metabolized by P450 2D6, the increase
in plasma concentration may be small, or quite large (8-fold increase in
plasma AUC of the TCA). </p>

<p>In addition, certain drugs inhibit the activity of this isozyme and
make normal metabolizers resemble poor metabolizers. An individual who
is stable on a given dose of TCA may become abruptly toxic when given one
of these inhibiting drugs as concomitant therapy. The drugs that inhibit
cytochrome P450 2D6 include some that are not metabolized by the enzyme
(quinidine: cimetidine) and many that are substrates for P450 2D6 (many
other antidepressants, phenothiazines, and the Type 1C antiarrhythmics
propafenone and flecainide). While all the selective serotonin reuptake
inhibitors (SSRIs) e.g., fluoxetine sertraline, and paroxetine, inhibit
P450 2D6, they may vary in the extent of inhibition. The extent to which
SSRI-TCA interactions may pose clinical problems will depend on the degree
of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless,
caution is indicated in the coadministration of TCAs with any of the SSRIs
and also in switching from one class to the other. Of particular importance,
sufficient time must elapse before initiating TCA treatment in a patient
being withdrawn from fluoxetine, given the long half-life of the parent
and active metabolite (at least 5 weeks may be necessary). </p>

<p>Concomitant use of tricyclic antidepressants with drugs that can inhibit
cytochrome P450 2D6 may require lower doses than usually prescribed for
either the tricyclic antidepressant or the other drug. Furthermore, whenever
one of these drugs is withdrawn from cotherapy, an increased dose of tricyclic
antidepressant may be required. It is desirable to monitor TCA plasma levels
whenever a TCA is going to be coadministered with another drug known to
be an inhibitor of P450 2D6. </p>

<p>MAO Inhibitors: Serious side effects and even death have been reported
following the concomitant use of certain drugs with MAO inhibitors. Therefore,
MAO inhibitors should be discontinued at least two weeks prior to the cautious
initiation of therapy with Doxepin. The exact length of time may vary and
is dependent upon the particular MAO inhibitor being used, the length of
time it has been administered, and the dosage involved. </p>

<p>Cimetidine: Cimetidine has been reported to produce clinically significant
fluctuations in steady-state serum concentrations of various tricyclic
antidepressants. Serious anticholinergic symptoms (i.e., severe dry mouth,
urinary retention and blurred vision) have been associated with elevations
in the serum levels of tricyclic antidepressant when cimetidine therapy
is initiated. Additionally, higher than expected tricyclic antidepressant
levels have been observed when they are begun in patients already taking
cimetidine. In patients who have been reported to be well controlled on
tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation
of cimetidine has been reported to decrease established steady-state serum
tricyclic antidepressant levels and compromise their therapeutic effects.
</p>

<p>Alcohol: It should be borne in mind that alcohol ingestion may increase
the danger inherent in any intentional or unintentional Doxepin overdosage.
This is especially important in patients who may use alcohol excessively.
</p>

<p>Tolazamide: A case of severe hypoglycemia has been reported in a type
II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the
addition of doxepin (75 mg/day). </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>NOTE: Some of the adverse reactions noted below have not been specifically
reported with Doxepin use. However, due to the close pharmacological similarities
among the tricyclics, the reactions should be considered when prescribing
Doxepin (doxepin HCl). </p>

<p>Anticholinergic Effects: Dry mouth, blurred vision, constipation, and
urinary retention have been reported. If they do not subside with continued
therapy, or become severe, it may be necessary to reduce the dosage. </p>

<p>Central Nervous System Effects: Drowsiness is the most commonly noticed
side effect. This tends to disappear as therapy is continued. Other infrequently
reported CNS side effects are confusion, disorientation, hallucinations,
numbness, paresthesias, ataxia, extrapyramidal symptoms, seizures, tardive
dyskinesia, and tremor. </p>

<p>Cardiovascular: Cardiovascular effects including hypotension, hypertension,
and tachycardia have been reported occasionally. </p>

<p>Allergic: Skin rash, edema, photosensitization, and pruritus have occasionally
occurred. </p>

<p>Hematologic: Eosinophilia has been reported in a few patients. There
have been occasional reports of bone marrow depression manifesting as agranulocytosis,
leukopenia, thrombocytopenia, and purpura. </p>

<p>Gastrointestinal: Nausea, vomiting, indigestion, taste disturbances,
diarrhea, anorexia, and aphthous stomatitis have been reported. (See anticholinergic
effects.) </p>

<p>Endocrine: Raised or lowered libido, testicular swelling, gynecomastia
in males, enlargement of breasts and galactorrhea in the female, raising
or lowering of blood sugar levels, and syndrome of inappropriate antidiuretic
hormone secretion have been reported with tricyclic administration. </p>

<p>Other: Dizziness, tinnitus, weight gain, sweating, chills, fatigue,
weakness, flushing, jaundice, alopecia, headache, exacerbation of asthma,
and hyperpyrexia (in association with chlorpromazine) have been occasionally
observed as adverse effects. </p>

<p>Withdrawal Symptoms: The possibility of development of withdrawal symptoms
upon abrupt cessation of treatment after prolonged Doxepin administration
should be borne in mind. These are not indicative of addiction and gradual
withdrawal of medication should not cause these symptoms. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>A. Signs and Symptoms </p>

<p>1. Mild: Drowsiness, stupor, blurred vision, excessive dryness of mouth.
</p>

<p>2. Severe: Respiratory depression, hypotension, coma, convulsions, cardiac
arrhythmias and tachycardias. </p>

<p>Also: urinary retention (bladder atony), decreased gastrointestinal
motility (paralytic ileus), hyperthermia (or hypothermia), hypertension,
dilated pupils, hyperactive reflexes. </p>

<p>B. Management and Treatment </p>

<p>1. Mild: Observation and supportive therapy is all that is usually necessary.
</p>

<p>2. Severe: Medical management of severe Doxepin overdosage consists
of aggressive supportive therapy. If the patient is conscious, gastric
lavage, with appropriate precautions to prevent pulmonary aspiration, should
be performed even though Doxepin is rapidly absorbed. The use of activated
charcoal has been recommended, as has been continuous gastric lavage with
saline for 24 hours or more. An adequate airway should be established in
comatose patients and assisted ventilation used if necessary. EKG monitoring
may be required for several days, since relapse after apparent recovery
has been reported. Arrhythmias should be treated with the appropriate antiarrhythmic
agent. It has been reported that many of the cardiovascular and CNS symptoms
of tricyclic antidepressant poisoning in adults may be reversed by the
slow intravenous administration of 1 mg to 3 mg of physostigmine salicylate.
Because physostigmine is rapidly metabolized, the dosage should be repeated
as required. Convulsions may respond to standard anticonvulsant therapy;
however, barbiturates may potentiate any respiratory depression. Dialysis
and forced diuresis generally are not of value in the management of overdosage
due to high tissue and protein binding of Doxepin. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>For most patients with illness of mild to moderate severity, a starting
daily dose of 75 mg is recommended. Dosage may subsequently be increased
or decreased at appropriate intervals and according to individual response.
The usual optimum dose range is 75 mg/day to 150 mg/day. </p>

<p>In more severely ill patients higher doses may be required with subsequent
gradual increase to 300 mg/day if necessary. Additional therapeutic effect
is rarely to be obtained by exceeding a dose of 300 mg/day. </p>

<p>In patients with very mild symptomatology or emotional symptoms accompanying
organic disease, lower doses may suffice. Some of these patients have been
controlled on doses as low as 25-50 mg/day. </p>

<p>The total daily dosage of Doxepin may be given on a divided or once-a-day
dosage schedule. If the once-a-day schedule is employed the maximum recommended
dose is 150 mg/day. This dose may be given at bedtime. </p>

<p>THE 150 MG CAPSULE STRENGTH IS INTENDED FOR MAINTENANCE THERAPY ONLY
AND IS NOT RECOMMENDED FOR INITIATION OF TREATMENT. </p>

<p>Anti-anxiety effect is apparent before the antidepressant effect. Optimal
antidepressant effect may not be evident for two to three weeks. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-48</DOCNO>
<DOCOLDNO>IA018-000200-B033-136</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/ranit.htm 206.86.175.201 19970106223647 text/html 30015
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:30:28 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 29832
Last-modified: Sat, 06 Jul 1996 07:46:03 GMT
</DOCHDR>
<html>
<head>
   <title>Ranitidine - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Ranitidine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[warn!] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>The active ingredient in Ranitidine is ranitidine hydrochloride (HCl),
a histamine H2-receptor antagonist. Chemically it is N(2-(((5-((dimethylamino)methyl)-2-
furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine, HCl. </p>

<p>The empirical formula is C13H22N4O3S.HCl, representing a molecular weight
of 350.87. </p>

<p>Ranitidine HCl is a white to pale yellow, granular substance that is
soluble in water. It has a slightly bitter taste and sulfurlike odor. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Ranitidine (ranitidine HCl) is a competitive, reversible inhibitor of
the action of histamine at the histamine H2-receptors, including receptors
on the gastric cells. Ranitidine does not lower serum Ca++ in hypercalcemic
states. Ranitidine is not an anticholinergic agent. </p>

<p>ANTISECRETORY ACTIVITY: 1. EFFECTS ON ACID SECRETION: Ranitidine inhibits
both daytime and nocturnal basal gastric acid secretions as well as gastric
acid secretion stimulated by food, betazole, and pentagastrin, as shown
in the following table: </p>

<pre><font SIZE=-1>                 EFFECT OF ORAL Ranitidine ON GASTRIC ACID SECRETION                

------------------------------------------------------------------------------  

              Time after Dose, h     % Inhibition of Gastric Acid Output by     

                                                    Dose, mg                    

                                   -------------------------------------------- 

                                     75-80       100         150       200      

              ----------------------------------------------------------------- 

Basal                Up to 4                      99          95                

Nocturnal            Up to 13          95         96          92                

Betazole             Up to 3                      97          99                

Pentagastrin         Up to 5           58         72          72        80      

Meal                 Up to 3                      73          79        95     </font>
</pre>

<p>It appears that basal-, nocturnal-, and betazole-stimulated secretions
are most sensitive to inhibition by Ranitidine, responding almost completely
to doses of 100 mg or less, while pentagastrin- and food-stimulated secretions
are more difficult to suppress. </p>

<p>2. EFFECTS ON OTHER GASTROINTESTINAL SECRETIONS: </p>

<p>PEPSIN: Oral Ranitidine does not affect pepsin secretion. Total pepsin
output is reduced in proportion to the decrease in volume of gastric juice.
</p>

<p>INTRINSIC FACTOR: Oral Ranitidine has no significant effect on pentagastrin-
stimulated intrinsic factor secretion. </p>

<p>SERUM GASTRIN: Ranitidine has little or no effect on fasting or postprandial
serum gastrin. </p>

<p>OTHER PHARMACOLOGIC ACTIONS: </p>

<p>A. Gastric bacterial flora--increase in nitrate-reducing organisms,
significance not known. </p>

<p>B. Prolactin levels--no effect in recommended oral or intravenous (IV)
dosage, but small, transient, dose-related increases in serum prolactin
have been reported after IV bolus injections of 100 mg or more. </p>

<p>C. Other pituitary hormones--no effect on serum gonadotropins, TSH,
or GH. Possible impairment of vasopressin release. </p>

<p>D. No change in cortisol, aldosterone, androgen, or estrogen levels.
</p>

<p>E. No antiandrogenic action. </p>

<p>F. No effect on count, motility, or morphology of sperm. </p>

<p>PHARMACOKINETICS: Ranitidine is 50% absorbed after oral administration,
compared to an IV injection with mean peak levels of 440-545 ng/mL occurring
at 2-3 hours after a 150-mg dose. The tablet and syrup formulations are
bioequivalent, and the capsule and tablet are bioequivalent. The elimination
half-life is 2.5-3 hours. </p>

<p>Absorption is not significantly impaired by the administration of food
or antacids. Propantheline slightly delays and increases peak blood levels
of Ranitidine, probably by delaying gastric emptying and transit time.
In one study, simultaneous administration of high-potency antacid (150
mmol) in fasting subjects has been reported to decrease the absorption
of Ranitidine. </p>

<p>Serum concentrations necessary to inhibit 50% of stimulated gastric
acid secretion are estimated to be 36-94 ng/mL. Following a single oral
dose of 150 mg, serum concentrations of Ranitidine are in this range up
to 12 hours. However, blood levels bear no consistent relationship to dose
or degree of acid inhibition. </p>

<p>The principal route of excretion is the urine, with approximately 30%
of the orally administered dose collected in the urine as unchanged drug
in 24 hours. Renal clearance is about 410 mL per minute, indicating active
tubular excretion. Four patients with clinically significant renal function
impairment (creatinine clearance 25-35 mL per minute) administered 50 mg
of ranitidine IV had an average plasma half-life of 4.8 hours, a ranitidine
clearance of 29 mL per minute, and a volume of distribution of 1.76 L/kg.
In general, these parameters appear to be altered in proportion to creatinine
clearance (see DOSAGE AND ADMINISTRATION). </p>

<p>In man, the N-oxide is the principal metabolite in the urine; however,
this amounts to less than 4% of the dose. Other metabolites are the S-oxide
(1%) and the desmethyl ranitidine (1%). The remainder of the administered
dose is found in the stool. Studies in patients with hepatic dysfunction
(compensated cirrhosis) indicate that there are minor, but clinically insignificant,
alterations in ranitidine half-life, distribution, clearance, and bioavailability.
</p>

<p>The volume of distribution is about 1.4 L/kg. Serum protein binding
averages 15%. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Ranitidine (ranitidine HCl) is indicated in: </p>

<p>1. Short-term treatment of active duodenal ulcer. Most patients heal
within 4 weeks. Studies available to date have not assessed the safety
of ranitidine in uncomplicated duodenal ulcer for periods of more than
8 weeks. </p>

<p>2. Maintenance therapy for duodenal ulcer patients at reduced dosage
after healing of acute ulcers. No placebo-controlled comparative studies
have been carried out for periods of longer than 1 year. </p>

<p>3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-
Ellison syndrome and systemic mastocytosis). </p>

<p>4. Short-term treatment of active, benign gastric ulcer. Most patients
heal within 6 weeks and the usefulness of further treatment has not been
demonstrated. Studies available to date have not assessed the safety of
ranitidine in uncomplicated, benign gastric ulcer for periods of more than
6 weeks. </p>

<p>5. Treatment of GERD. Symptomatic relief commonly occurs within 1 or
2 weeks after starting therapy with Ranitidine 150 mg b.i.d. </p>

<p>6. Treatment of endoscopically diagnosed erosive esophagitis. Healing
of endoscopically diagnosed erosive esophagitis occurs at 4 weeks (47%),
8 weeks (71%), and 12 weeks (84%) of therapy with Ranitidine 150 mg q.i.d.
Symptomatic relief of heartburn commonly occurs within 24 hours of therapy
initiation with Ranitidine. </p>

<p>Concomitant antacids should be given as needed for pain relief to patients
with active duodenal ulcer; active, benign gastric ulcer; hypersecretory
states; GERD; and erosive esophagitis. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Ranitidine (ranitidine HCl) is contraindicated for patients known to
have hypersensitivity to the drug or any of the ingredients. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL: 1. Symptomatic response to Ranitidine (ranitidine HCl) therapy
does not preclude the presence of gastric malignancy. </p>

<p>2. Since Ranitidine is excreted primarily by the kidney, dosage should
be adjusted in patients with impaired renal function (see DOSAGE AND ADMINISTRATION).
Caution should be observed in patients with hepatic dysfunction since Ranitidine
is metabolized in the liver. </p>

<p>3. Rare reports suggest that Ranitidine may precipitate acute porphyria
attacks in patients with acute porphyria. Ranitidine should therefore be
avoided in patients with a history of acute porphyria. </p>

<p>LABORATORY TESTS: False-positive tests for urine protein with Multistix
may occur during Ranitidine therapy, and therefore testing with sulfosalicylic
acid is recommended. </p>

<p>DRUG INTERACTIONS: Although Ranitidine has been reported to bind weakly
to cytochrome P-450 In Vitro, recommended doses of the drug do not inhibit
the action of the cytochrome P-450--linked oxygenase enzymes in the liver.
However, there have been isolated reports of drug interactions that suggest
that Ranitidine may affect the bioavailability of certain drugs by some
mechanism as yet unidentified (e.g., a pH-dependent effect on absorption
or a change in volume of distribution). </p>

<p>Increased or decreased prothrombin times have been reported during concurrent
use of ranitidine and warfarin. However, in human pharmacokinetic studies
with dosages of ranitidine up to 400 mg per day, no interaction occurred;
ranitidine had no effect on warfarin clearance or prothrombin time. The
possibility of an interaction with warfarin at dosages of ranitidine higher
than 400 mg per day has not been investigated. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: There was no indication
of tumorigenic or carcinogenic effects in life-span studies in mice and
rats at dosages up to 2,000 mg/kg per day. </p>

<p>Ranitidine was not mutagenic in standard bacterial tests (Salmonella,
Escherichia Coli) for mutagenicity at concentrations up to the maximum
recommended for these assays. </p>

<p>In a dominant lethal assay, a single oral dose of 1,000 mg/kg to male
rats was without effect on the outcome of two matings per week for the
next 9 weeks. </p>

<p>PREGNANCY: Teratogenic Effects: Pregnancy Category B: Reproduction studies
have been performed in rats and rabbits at doses up to 160 times the human
dose and have revealed no evidence of impaired fertility or harm to the
fetus due to Ranitidine. There are, however, no adequate and well-controlled
studies in pregnant women. Because animal reproduction studies are not
always predictive of human response, this drug should be used during pregnancy
only if clearly needed. </p>

<p>NURSING MOTHERS: Ranitidine is secreted in human milk. Caution should
be exercised when Ranitidine is administered to a nursing mother. </p>

<p>PEDIATRIC USE: Safety and effectiveness in children have not been established.
</p>

<p>USE IN ELDERLY PATIENTS: Ulcer healing rates in elderly patients (65-82
years of age) were no different from those in younger age-groups. The incidence
rates for adverse events and laboratory abnormalities were also not different
from those seen in other age-groups. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Although Ranitidine has been reported to bind weakly to cytochrome P-450
In Vitro, recommended doses of the drug do not inhibit the action of the
cytochrome P-450 linked oxygenase enzymes in the liver. However, there
have been isolated reports of drug interactions that suggest that Ranitidine
may affect the bioavailability of certain drugs by some mechanism as yet
unidentified (e.g., a pH-dependent effect on absorption or a change in
volume of distribution). </p>

<p>Increased or decreased prothrombin times have been reported during concurrent
use of ranitidine and warfarin. However, in human pharmacokinetic studies
with dosages of ranitidine up to 400 mg per day, no interaction occurred;
ranitidine had no effect on warfarin clearance or prothrombin time. The
possibility of an interaction with warfarin at dosages of ranitidine higher
than 400 mg per day has not been investigated. </p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The following have been reported as events in clinical trials or in
the routine management of patients treated with Ranitidine (ranitidine
HCl). The relationship to Ranitidine therapy has been unclear in many cases.
Headache, sometimes severe, seems to be related to Ranitidine administration.
</p>

<p>CENTRAL NERVOUS SYSTEM: Rarely, malaise, dizziness, somnolence, insomnia,
and vertigo. Rare cases of reversible mental confusion, agitation, depression,
and hallucinations have been reported, predominantly in severely ill elderly
patients. Rare cases of reversible blurred vision suggestive of a change
in accommodation have been reported. Rare reports of reversible involuntary
motor disturbances have been received. </p>

<p>CARDIOVASCULAR: As with other H2-blockers, rare reports of arrhythmias
such as tachycardia, bradycardia, atrioventricular block, and premature
ventricular beats. </p>

<p>GASTROINTESTINAL: Constipation, diarrhea, nausea/vomiting, abdominal
discomfort/pain, and rare reports of pancreatitis. </p>

<p>HEPATIC: In normal volunteers, SGPT values were increased to at least
twice the pretreatment levels in 6 of 12 subjects receiving 100 mg q.i.d.
IV for 7 days, and in 4 of 24 subjects receiving 50 mg q.i.d. IV for 5
days. There have been occasional reports of hepatitis, hepatocellular or
hepatocanalicular or mixed, with or without jaundice. In such circumstances,
ranitidine should be immediately discontinued. These events are usually
reversible, but in exceedingly rare circumstances death has occurred. </p>

<p>MUSCULOSKELETAL: Rare reports of arthralgias and myalgias. </p>

<p>HEMATOLOGIC: Blood count changes (leukopenia, granulocytopenia, and
thrombocytopenia) have occurred in a few patients. These were usually reversible.
Rare cases of agranulocytosis, pancytopenia, sometimes with marrow hypoplasia,
and aplastic anemia and exceedingly rare cases of acquired immune hemolytic
anemia have been reported. </p>

<p>ENDOCRINE: Controlled studies in animals and man have shown no stimulation
of any pituitary hormone by Ranitidine and no antiandrogenic activity,
and cimetidine- induced gynecomastia and impotence in hypersecretory patients
have resolved when Ranitidine has been substituted. However, occasional
cases of gynecomastia, impotence, and loss of libido have been reported
in male patients receiving Ranitidine, but the incidence did not differ
from that in the general population. </p>

<p>INTEGUMENTARY: Rash, including rare cases suggestive of mild erythema
multiforme, and, rarely, alopecia. </p>

<p>OTHER: Rare cases of hypersensitivity reactions (e.g.. bronchospasm,
fever, rash, eosinophilia), anaphylaxis, angioneurotic edema, and small
increases in serum creatinine. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>There has been limited experience with overdosage. Reported acute ingestions
of up to 18 g orally have been associated wtih transient adverse effects
similar to those encountered in normal clinical experience (see ADVERSE
REACTIONS). In addition, abnormalities of gait and hypotension have been
reported. </p>

<p>When overdosage occurs, the usual measures to remove unabsorbed material
from the gastrointestinal tract, clinical monitoring, and supportive therapy
should be employed. </p>

<p>Studies in dogs receiving dosages of Ranitidine (ranitidine HCl) in
excess of 225 mg/kg per day have shown muscular tremors, vomiting, and
rapid respiration. Single oral doses of 1,000 mg/kg in mice and rats were
not lethal. Intravenous LD50 values in mice and rats were 77 and 83 mg/kg,
respectively. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>ACTIVE DUODENAL ULCER: The current recommended adult oral dosage of
Ranitidine (ranitidine HCl) for duodenal ulcer is 150 mg or 10 mL (2 teaspoonfuls
equivalent to 150 mg of ranitidine) twice daily. An alternative dosage
of 300 mg or 20 mL (4 teaspoonfuls equivalent to 300 mg of ranitidine)
once daily after the evening meal or at bedtime can be used for patients
in whom dosing convenience is important. The advantages of one treatment
regimen compared to the other in a particular patient population have yet
to be demonstrated (see Clinical Trials: Active Duodenal Ulcer). Smaller
doses have been shown to be equally effective in inhibiting gastric acid
secretion in US studies, and several foreign trials have shown that 100
mg b.i.d. is as effective as the 150 mg dose. </p>

<p>Antacid should be given as needed for relief of pain (see ACTIONS/CLINICAL
PHARMACOLOGY: Pharmacokinetics). </p>

<p>MAINTENANCE THERAPY: The current recommended adult oral dosage is 150
or 10 mL (2 teaspoonfuls equivalent to 150 mg of ranitidine) at bedtime.
</p>

<p>PATHOLOGICAL HYPERSECRETORY CONDITIONS (SUCH AS ZOLLINGER-ELLISON SYNDROME):
The current recommended adult oral dosage is 150 mg or 10 mL (2 teaspoonfuls
equivalent to 150 mg of ranitidine) twice a day. In some patients it may
be necessary to administer Ranitidine 150-mg doses more frequently. Dosages
should be adjusted to individual patient needs, and should continue as
long as clinically indicated. Dosages up to 6 g per day have been employed
in patients with severe disease. </p>

<p>BENIGN GASTRIC ULCER: The current recommended adult oral dosage is 150
mg or 10 mL (2 teaspoonfuls equivalent to 150 mg of ranitidine) twice a
day. </p>

<p>GERD: The current recommended adult oral dosage is 150 mg or 10 mL (2
teaspoonfuls equivalent to 150 mg of ranitidine) twice a day. </p>

<p>EROSIVE ESOPHAGITIS: The current recommended adult oral dosage is 150
mg or 10 mL(2 teaspoonfuls equivalent to 150 mg of ranitidine) four times
a day. </p>

<p>DOSAGE ADJUSTMENT FOR PATIENTS WITH IMPAIRED RENAL FUNCTION: On the
basis of experience with a group of subjects with severely impaired renal
function treated with Ranitidine, the recommended dosage in patients with
a creatinine clearance less than 50 mL per minute is 150 mg or 10 mL (2
teaspoonfuls equivalent to 150 mg of ranitidine) every 24 hours. Should
the patient's condition require, the frequency of dosing may be increased
to every 12 hours or even further with caution. Hemodialysis reduces the
level of circulating ranitidine. Ideally, the dosing schedule should be
adjusted so that the timing of a scheduled dose coincides with the end
of hemodialysis. </p>

<p><b><i>CLINICAL STUDIES </i></b></p>

<p>CLINICAL TRIALS: ACTIVE DUODENAL ULCER: In a multicenter, double-blind,
controlled, US study of endoscopically diagnosed duodenal ulcers, earlier
healing was seen in the patients treated with Ranitidine as shown in Table
I: </p>

<pre><font SIZE=-1> 

Table I           ------------------------------------------------------------- 

                              Ranitidine*                       Placebo*            

                  ------------------------------------------------------------- 

                        Number        Healed/         Number        Healed/     

                       Entered       Evaluable       Entered       Evaluable    

------------------------------------------------------------------------------  

    Outpatients                                                                 

    Week 2               195        69/182 (38%)**     188        31/164 (19%)  

    Week 4                         137/187 (73%)**                76/168 (45%)  

------------------------------------------------------------------------------  

*All patients were permitted p.r.n. antacids for          **p &lt;0.0001.          

relief of pain.                                                                 

In these studies patients treated with Ranitidine reported a reduction in both

daytime and nocturnal pain, and they also consumed less antacid than the

placebo-treated patients.  

 

Table II                    --------------------------------------------------- 

                                        MEAN DAILY DOSES OF ANTACID             

                            --------------------------------------------------- 

                                    Ulcer Healed           Ulcer Not Healed     

------------------------------------------------------------------------------  

         Ranitidine                         0.06                     0.71           

         Placebo                            0.71                     1.43   

        </font>
</pre>

<p>Foreign studies have shown that patients heal equally well with 150
mg b.i.d. and 300 mg h.s. (85% versus 84%, respectively) during a usual
4-week course of therapy. If patients require extended therapy of 8 weeks,
the healing rate may be higher for 150 mg b.i.d. as compared to 300 mg
h.s. (92% versus 87%, respectively). </p>

<p>Studies have been limited to short-term treatment of acute duodenal
ulcer. Patients whose ulcers healed during therapy had recurrences of ulcers
at the usual rates. There have been no systematic studies to evaluate whether
continued treatment with Ranitidine alters recurrence rates. </p>

<p>MAINTENANCE THERAPY IN DUODENAL ULCER: Ranitidine has been found to
be effective as maintenance therapy for patients following healing of acute
duodenal ulcers. In two independent, double-blind, multicenter, controlled
trials, the number of duodenal ulcers observed was significantly less in
patients treated with Ranitidine (150 mg h.s.) than in patients treated
with placebo over a 12-month period. </p>

<pre><font SIZE=-1> 

          DUODENAL ULCER PREVALENCE                                             

-------------------------------------------------                               

  Double-blind, Multicenter, Placebo-Controlled                                 

                      Trials                                                    

-------------------------------------------------                               

Multicenter                                No. of                               

Trial   Drug  Duodenal Ulcer Prevalence  Patients                               

-------------------------------------------------                               

                    0-4    0-8     0-12                                         

                   Months Months  Months                                        

                  -------------------------------                               

          RAN        20%*   24%*    35%*   138                                  

USA       PLC        44%    54%     59%    139                                  

-------------------------------------------------                               

          RAN        12%*   21%*    28%*   174                                  

Foreign   PLC        56%    64%     68%    165                                  

-------------------------------------------------           </font></pre>

<p>% = Life table estimate. 
<br>* = p&lt;0.05 (Ranitidine versus comparator). 
<br>RAN = ranitidine (Ranitidine). 
<br>PLC = placebo. 
<br></p>

<p>As with other H2-antagonists, the factors responsible for the significant
reduction in the prevalence of duodenal ulcers include prevention of recurrence
of ulcers, more rapid healing of ulcers that may occur during maintenance
therapy, or both. </p>

<p>GASTRIC ULCER: In a multicenter, double-blind, controlled, US study
of endoscopically diagnosed gastric ulcers, earlier healing was seen in
the patients treated with Ranitidine as shown in the following table: </p>

<pre><font SIZE=-1> 

             ------------------------------------                               

                 Ranitidine*           Placebo*                                     

             ------------------------------------                               

              Number  Healed/  Number   Healed/                                 

             Entered Evaluable Entered  Evaluable

-------------------------------------------------                               

Outpatients                                                                     

Week 2                 16/83             10/83                                  

                92     (19%)      94     (12%)                                  

Week 6                 50/73             35/69                                  

                       (68%)**           (51%)                                  

-------------------------------------------------         </font></pre>

<p>* All patients were permitted p.r.n. antacids for relief of pain. 
<br>**p = 0.009. </p>

<p>In this multicenter trial, significantly more patients treated with
Ranitidine became pain-free during therapy. </p>

<p>PATHOLOGICAL HYPERSECRETORY CONDITIONS (SUCH AS ZOLLINGER-ELLISON SYNDROME):
Ranitidine inhibits gastric acid secretion and reduces occurrence of diarrhea,
anorexia, and pain in patients with pathological hypersecretion associated
with Zollinger-Ellison syndrome, systemic mastocytosis, and other pathological
hypersecretory conditions (e.g., postoperative, &quot;short-gut&quot; syndrome,
idiopathic). Use of Ranitidine was followed by healing of ulcers in 8 of
19 (42%) patients who were intractable to previous therapy. </p>

<p>GASTROESOPHAGEAL REFLUX DISEASE (GERD): In two multicenter, double-blind,
placebo-controlled, 6-week trials performed in the United States and Europe,
Ranitidine 150 mg b.i.d. was more effective than placebo for the relief
of heartburn and other symptoms associated with GERD. Ranitidine-treated
patients consumed significantly less antacid than did placebo-treated patients.
</p>

<p>The US trial indicated that Ranitidine 150 mg b.i.d. significantly reduced
the frequency of heartburn attacks and severity of heartburn pain within
1-2 weeks after starting therapy. The improvement was maintained throughout
the 6-week trial period. Moreover, patient response rates demonstrated
that the effect on heartburn extends through both the day and night time
periods. </p>

<p>EROSIVE ESOPHAGITIS: In two multicenter, double-blind, randomized, placebo-
controlled, 12-week trials performed in the United States, Ranitidine (ranitidine
HCl) 150 mg q.i.d. was significantly more effective than placebo in healing
endoscopically diagnosed erosive esophagitis and in relieving associated
heartburn. The erosive esophagitis healing rates were as follows: </p>

<pre>
<font SIZE=-1>          EROSIVE ESOPHAGITIS PATIENT HEALING RATES                             

            _____________________________________                               

            ]       Healed/Evaluable            ]                               

            ]___________________________________]                               

            ]              ]     Ranitidine     ]                               

            ]  Placebo*    ]  150 mg q.i.d.*    ]                               

            ]   n = 229    ]    n = 215         ]                               

]-----------]-----------------------------------]                               

]Week 4     ] 43/198 (22%) ]  96/206 (47%)**    ]                               

]Week 8     ] 63/176 (36%) ] 142/200 (71%)**    ]                               

]Week 12    ] 92/159 (58%) ] 162/192 (84%)**    ]                               

]-----------]-----------------------------------]  </font>
</pre>

<p>*All patients were permitted p.r.n. antacids for relief of pain. 
<br>**p&lt;0.001 versus placebo. </p>

<p>No additional benefit in healing of esophagitis or in relief of heartburn
was seen with a ranitidine dose of 300 mg q.i.d. 
<br></p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-49</DOCNO>
<DOCOLDNO>IA018-000200-B035-216</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/verapsr.htm 206.86.175.201 19970106224920 text/html 40525
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:43:05 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 40342
Last-modified: Sun, 11 Aug 1996 03:48:00 GMT
</DOCHDR>
<html>


<head>


   <title>Verapamil (SR) - RxList Generic Information</title>


   <meta name="Author" content="">


   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">


</head>


<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">





<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>





<h1 align=center>Verapamil (SR)</h1>





<p>


<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="verapsr.htm#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]


[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]


[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG 



INTERACTIONS">drug-drug</a>]


[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]


[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>]</font> </p>





<p><b>This is NOT the official FDA approved material for this drug. Therefore,


please consult the appropriate FDA approved package insert for additional


information!</b></p>





<p>


<hr width="100%" ></p>





<a name="DESCRIPTION"></a><b>DESCRIPTION <p>


</b> 


Verapamil (SR) is a calcium ion influx inhibitor (slow-


channel blocker or calcium ion antagonist). Verapamil chemically is benzeneacetonitrile,


alpha-(3-((2-(3,4-dimethoxyphenyl) ethyl) methylamino)propyl)-3,4-dimethoxy-alpha-


(1-methylethyl) hydrochloride <p>


 


Verapamil HCl is an almost white, crystalline powder, practically free of odor, 


with a bitter taste. It is soluble in water, chloroform, and methanol.


Verapamil HCl is not chemically related to other cardioactive drugs.  <p>


 


<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY <p>


</b> 


Verapamil  (verapamil HCl) is a calcium ion influx inhibitor (slow-channel blocker


or calcium ion antagonist) that exerts its pharmacologic effects by modulating


the influx of ionic calcium across the cell membrane of the arterial smooth


muscle as well as in conductile and contractile myocardial cells.  <p>


 


MECHANISM OF ACTION <p>


 


ESSENTIAL HYPERTENSION: Verapamil exerts antihypertensive effects by decreasing 


systemic vascular resistance, usually without orthostatic decreases in blood


pressure or reflex tachycardia; bradycardia (rate less than 50 beats/min) is


uncommon (1.4%). During isometric or dynamic exercise Verapamil  does not alter


systolic cardiac function in patients with normal ventricular function.  


 


Verapamil  does not alter total serum calcium levels. However, one report suggested


that calcium levels above the normal range may alter the therapeutic effect of


Verapamil .  <p>


 


Other pharmacologic actions of Verapamil  include the following:  <p>


 


Verapamil  dilates the main coronary arteries and coronary arterioles, both in


normal and ischemic regions, and is a potent inhibitor of coronary artery spasm 


whether spontaneous or ergonovine-induced. This property increases myocardial


oxygen delivery in patients with coronary artery spasm and is responsible for


the effectiveness of Verapamil  in vasospastic (Prinzmetal's or variant) as well as


unstable angina at rest. Whether this effect plays any role in classical effort 


angina is not clear, but studies of exercise tolerance have not shown an


increase in the maximum exercise rate-pressure product, a widely accepted


measure of oxygen utilization. This suggests that, in general, relief of spasm


or dilation of coronary arteries is not an important factor in classical


angina.  <p>


 


Verapamil  regularly reduces the total systemic resistance (afterload) against which 


the heart works both at rest and at a given level of exercise by dilating


peripheral arterioles.  <p>


 


Electrical activity through the AV node depends, to a significant degree, upon


calcium influx through the slow channel. By decreasing the influx of calcium,


Verapamil  prolongs the effective refractory period within the AV node and slows AV


conduction in a rate-related manner.  <p>


 


Normal sinus rhythm is usually not affected, but in patients with sick sinus


syndrome, Verapamil  may interfere with sinus-node impulse generation and may induce 


sinus arrest or sinoatrial block. Atrioventricular block can occur in patients


without preexisting conduction defects (see Warnings).  <p>


 


Verapamil  does not alter the normal atrial action potential or intraventricular


conduction time, but depresses amplitude, velocity of depolarization, and


conduction in depressed atrial fibers. Verapamil  may shorten the antegrade


effective refractory period of the accessory bypass tract. Acceleration of


ventricular rate and/or ventricular fibrillation has been reported in patients


with atrial flutter or atrial fibrillation and a coexisting accessory AV


pathway following administration of verapamil (see Warnings).  
<p>

 


Verapamil  has a local anesthetic action that is 1.6 times that of procaine on an


equimolar basis. It is not known whether this action is important at the doses


used in man.  <p>


 


PHARMACOKINETICS AND METABOLISM: With the immediate-release formulation, more


than 90% of the orally administered dose of Verapamil  is absorbed. Because of rapid 


biotransformation of verapamil during its first pass through the portal


circulation, bioavailability ranges from 20% to 35%. Peak plasma concentrations 


are reached between 1 and 2 hours after oral administration. Chronic oral


administration of 120 mg of verapamil HCl every 6 hours resulted in plasma


levels of verapamil ranging from 125 to 400 ng/ml, with higher values reported


occasionally. A nonlinear correlation between the verapamil dose administered


and verapamil plasma level does exist. In early dose titration with verapamil a 


relationship exists between verapamil plasma concentration and prolongation of


the PR interval. However, during chronic administration this relationship may


disappear. The mean elimination half-life in single-dose studies ranged from


2.8 to 7.4 hours. In these same studies, after repetitive dosing, the half-life 


increased to a range from 4.5 to 12.0 hours (after less than 10 consecutive


doses given 6 hours apart). Half-life of verapamil may increase during


titration. No relationship has been established between the plasma


concentration of verapamil and a reduction in blood pressure.  <p>


 


Aging may affect the pharmacokinetics of verapamil. Elimination half-life may


be prolonged in the elderly. In multiple-dose studies under fasting conditions, 


the bioavailability, measured by AUC, of Verapamil (SR) was similar to Verapamil 


(immediate release); rates of absorption were of course different.  <p>


 


In a randomized, single-dose, crossover study using healthy volunteers,


administration of 240 mg Verapamil (SR) with food produced peak plasma verapamil


concentrations of 79 ng/ml; time to peak plasma verapamil concentration of 7.71 


hours; and AUC (0-24 hr) of 841 ng.hr/ml. When Verapamil (SR) was administered to


fasting subjects, peak plasma verapamil concentration was 164 ng/ml; time to


peak plasma verapamil concentration was 5.21 hours; and AUC (0-24 hr) was 1,478 


ng.hr/ml. Similar results were demonstrated for plasma norverapamil. Food thus


produces decreased bioavailability (AUC) but a narrower peak-to-trough ratio.


Good correlation of dose and response is not available, but controlled studies


of Verapamil (SR) have shown effectiveness of doses similar to the effective doses of 


Verapamil  (immediate release).  <p>


 


In healthy men, orally administered Verapamil  undergoes extensive metabolism in the 


liver. Twelve metabolites have been identified in plasma; all except


norverapamil are present in trace amounts only. Norverapamil can reach steady-


state plasma concentrations approximately equal to those of verapamil itself. 


The cardiovascular activity of norverapamil appears to be approximately 20%


that of verapamil. Approximately 70% of an administered dose is excreted as


metabolites in the urine and 16% or more in the feces within 5 days. About 3%


to 4% is excreted in the urine as unchanged drug. Approximately 90% is bound to 


plasma proteins. In patients with hepatic insufficiency, metabolism of


immediate-release verapamil is delayed and elimination half-life prolonged up


to 14 to 16 hours (see Precautions); the volume of distribution is increased


and plasma clearance reduced to about 30% of normal. Verapamil clearance values 


suggest that patients with liver dysfunction may attain therapeutic verapamil


plasma concentrations with one third of the oral daily dose required for


patients with normal liver function.  <p>


 


After four weeks of oral dosing (120 mg q.i.d.), verapamil and norverapamil


levels were noted in the cerebrospinal fluid with estimated partition


coefficient of 0.06 for verapamil and 0.04 for norverapamil.  <p>


 


HEMODYNAMICS AND MYOCARDIAL METABOLISM: Verapamil  reduces afterload and myocardial


contractility. Improved left ventricular diastolic function in patients with


IHSS and those with coronary heart disease has also been observed with Verapamil .


In most patients, including those with organic cardiac disease, the negative


inotropic action of Verapamil  is countered by reduction of afterload, and cardiac


index is usually not reduced. However, in patients with severe left ventricular 


dysfunction (eg, pulmonary wedge pressure above 20 mm Hg or ejection fraction


less than 30%), or in patients taking beta-adrenergic blocking agents or other


cardiodepressant drugs, deterioration of ventricular function may occur (see


Drug Interactions).  <p>


 


PULMONARY FUNCTION: Verapamil  does not induce bronchoconstriction and, hence, does


not impair ventilatory function.  <p>


 


<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE <p>


</b> 


Verapamil (SR) is indicated for the management of essential hypertension.  <p>


 


<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 


</b> <p>


Verapamil HCl tablets are contraindicated in:  <p>


 


1. Severe left ventricular dysfunction (see Warnings) <p>


 


2. Hypotension (systolic pressure less than 90 mm Hg) or cardiogenic shock <p>


 


3. Sick sinus syndrome (except in patients with a functioning artificial


ventricular pacemaker) <p>


 


4. Second- or third-degree AV block (except in patients with a functioning


artificial ventricular pacemaker) <p>


 


5. Patients with atrial flutter or atrial fibrillation and an accessory bypass


tract (eg, Wolff-Parkinson-White, Lown-Ganong-Levine syndromes). (See


Warnings.) <p>


 


6. Patients with known hypersensitivity to verapamil hydrochloride.  <p>


 


<a name="WARNINGS"></a><b>WARNINGS <p>


</b> 


HEART FAILURE: Verapamil has a negative inotropic effect, which in most


patients is compensated by its afterload reduction (decreased systemic vascular 


resistance) properties without a net impairment of ventricular performance. In


clinical experience with 4,954 patients, 87 (1.8%) developed congestive heart


failure or pulmonary edema. Verapamil should be avoided in patients with severe 


left ventricular dysfunction (eg, ejection fraction less than 30%) or moderate


to severe symptoms of cardiac failure and in patients with any degree of


ventricular dysfunction if they are receiving a beta-adrenergic blocker (see


Drug Interactions). Patients with milder ventricular dysfunction should, if


possible, be controlled with optimum doses of digitalis and/or diuretics before 


verapamil treatment. (NOTE INTERACTIONS WITH DIGOXIN UNDER PRECAUTIONS.) <p>


 


HYPOTENSION: Occasionally, the pharmacologic action of verapamil may produce a


decrease in blood pressure below normal levels, which may result in dizziness


or symptomatic hypotension. The incidence of hypotension observed in 4,954


patients enrolled in clinical trials was 2.5%. In hypertensive patients,


decreases in blood pressure below normal are unusual. Tilt-table testing (60


degrees) was not able to induce orthostatic hypotension.  <p>


 


ELEVATED LIVER ENZYMES: Elevations of transaminases with and without


concomitant elevations in alkaline phosphatase and bilirubin have been


reported. Such elevations have sometimes been transient and may disappear even


in the face of continued verapamil treatment. Several cases of


injury related to verapamil have been proven by rechallenge; half of these had


clinical symptoms (malaise, fever, and/or right upper quadrant pain) in


addition to elevation of SGOT, SGPT, and alkaline phosphatase. Periodic


monitoring of liver function in patients receiving verapamil is therefore


prudent.  <p>


 


ACCESSORY BYPASS TRACT (WOLFF-PARKINSON-WHITE OR LOWN-GANONG-LEVINE): Some


patients with paroxysmal and/or chronic atrial fibrillation or atrial flutter


and a coexisting accessory AV pathway have developed increased antegrade


conduction across the accessory pathway bypassing the AV node, producing a very 


rapid ventricular response or ventricular fibrillation after receiving


intravenous verapamil (or digitalis). Although a risk of this occurring with


oral verapamil has not been established, such patients receiving oral verapamil 


may be at risk and its use in these patients is contraindicated (see


Contraindications). Treatment is usually DC-cardioversion. Cardioversion has


been used safely and effectively after oral Verapamil .  <p>


 


ATRIOVENTRICULAR BLOCK: The effect of verapamil on AV conduction and the SA


node may cause asymptomatic first-degree AV block and transient bradycardia,


sometimes accompanied by nodal escape rhythms. PR-interval prolongation is


correlated with verapamil plasma concentrations, especially during the early


titration phase of therapy. Higher degrees of AV block, however, were


infrequently (0.8%) observed. Marked first-degree block or progressive


development to second- or third-degree AV block requires a reduction in dosage


or, in rare instances, discontinuation of verapamil HCl and institution of


appropriate therapy, depending upon the clinical situation.  <p>


 


PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY (IHSS): In 120 patients with


hypertrophic cardiomyopathy (most of them refractory or intolerant to


propranolol) who received therapy with verapamil at doses up to 720 mg/day, a


variety of serious adverse effects were seen. Three patients died in pulmonary


edema; all had severe left ventricular outflow obstruction and a past history


of left ventricular dysfunction. Eight other patients had pulmonary edema


and/or severe hypotension; abnormally high (greater than 20 mm Hg) pulmonary


wedge pressure and a marked left ventricular outflow obstruction were present


in most of these patients. Concomitant administration of quinidine (see Drug


Interactions) preceded the severe hypotension in 3 of the 8 patients (2 of whom 


developed pulmonary edema). Sinus bradycardia occurred in 11% of the patients,


second-degree AV block in 4%, and sinus arrest in 2%. It must be appreciated


that this group of patients had a serious disease with a high mortality rate. 


Most adverse effects responded well to dose reduction, and only rarely did


verapamil use have to be discontinued.  
<p>

 


<a name="PRECAUTIONS"></a><b>PRECAUTIONS 


</b> <p>


GENERAL 

<p>
 


USE IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION: Since verapamil is highly


metabolized by the liver, it should be administered cautiously to patients with 


impaired hepatic function. Severe liver dysfunction prolongs the elimination


half-life of immediate-release verapamil to about 14 to 16 hours; hence


approximately 30% of the dose given to patients with normal liver function


should be administered to these patients. Careful monitoring for abnormal


prolongation of the PR interval or other signs of excessive pharmacologic


effects (see Overdosage) should be carried out.  


 <p>


USE IN PATIENTS WITH ATTENUATED (DECREASED) NEUROMUSCULAR TRANSMISSION: It has


been reported that verapamil decreases neuromuscular transmission in patients


with Duchenne's muscular dystrophy, and that verapamil prolongs recovery from


the neuromuscular blocking agent vecuronium. It may be necessary to decrease


the dosage of verapamil when it is administered to patients with attenuated


neuromuscular transmission.  

<p>
 


USE IN PATIENTS WITH IMPAIRED RENAL FUNCTION: About 70% of an administered dose 


of verapamil is excreted as metabolites in the urine. Verapamil is not removed


by hemodialysis. Until further data are available, verapamil should be


administered cautiously to patients with impaired renal function. These


patients should be carefully monitored for abnormal prolongation of the PR


interval or other signs of overdosage (see Overdosage).  


 
<p>

DRUG INTERACTIONS 


 <p>


BETA-BLOCKERS: Concomitant therapy with beta-adrenergic blockers and verapamil


may result in additive negative effects on heart rate, atrioventricular


conduction and/or cardiac contractility. The combination of sustained-release


verapamil and beta-adrenergic blocking agents has not been studied. However,


there have been reports of excessive bradycardia and AV block, including


complete heart block, when the combination has been used for the treatment of


hypertension. For hypertensive patients, the risks of combined therapy may


outweigh the potential benefits. The combination should be used only with


caution and close monitoring.  


 <p>


Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has


been observed in a patient receiving concomitant timolol (a beta-adrenergic


blocker) eyedrops and oral verapamil.  


 
<p>

A decrease in metoprolol and propranolol clearance has been observed when


either drug is administered concomitantly with verapamil. A variable effect has 


been seen when verapamil and atenolol were given together.  


 
<p>

DIGITALIS: Clinical use of verapamil in digitalized patients has shown the


combination to be well tolerated if digoxin doses are properly adjusted. 


However, chronic verapamil treatment can increase serum digoxin levels by 50%


to 75% during the first week of therapy, and this can result in digitalis


toxicity.  In patients with hepatic cirrhosis the influence of verapamil on


digoxin kinetics is magnified. Verapamil may reduce total body clearance and


extrarenal clearance of digitoxin by 27% and 29%, respectively. Maintenance


digitalis doses should be reduced when verapamil is administered, and the


patient should be carefully monitored to avoid over- or underdigitalization.


Whenever overdigitalization is suspected, the daily dose of digitalis should be 


reduced or temporarily discontinued. On discontinuation of Verapamil  use, the


patient should be reassessed to avoid underdigitalization.  


 <p>


ANTIHYPERTENSIVE AGENTS: Verapamil administered concomitantly with oral


antihypertensive agents (eg, vasodilators, angiotensin-converting enzyme


inhibitors, diuretics, beta-blockers) will usually have an additive effect on


lowering blood pressure. Patients receiving these combinations should be


appropriately monitored. Concomitant use of agents that attenuate alpha-


adrenergic function with verapamil may result in a reduction in blood pressure


that is excessive in some patients. Such an effect was observed in one study


following the concomitant administration of verapamil and prazosin.  


 

<p>
ANTIARRHYTHMIC AGENTS:  


 <p>


DISOPYRAMIDE: Until data on possible interactions between verapamil and


disopyramide phosphate are obtained, disopyramide should not be administered


within 48 hours before or 24 hours after verapamil administration.  


 
<p>

FLECAINIDE: A study in healthy volunteers showed that the concomitant


administration of flecainide and verapamil may have additive effects on


myocardial contractility, AV conduction, and repolarization. Concomitant


therapy with flecainide and verapamil may result in additive negative inotropic 


effect and prolongation of atrioventricular conduction.  


 
<p>

QUINIDINE: In a small number of patients with hypertrophic cardiomyopathy


(IHSS), concomitant use of verapamil and quinidine resulted in significant


hypotension. Until further data are obtained, combined therapy of verapamil and 


quinidine in patients with hypertrophic cardiomyopathy should probably be


avoided.  


 <p>


The electrophysiologic effects of quinidine and verapamil on AV conduction were 


studied in 8 patients. Verapamil significantly counteracted the effects of


quinidine on AV conduction. There has been a report of increased quinidine


levels during verapamil therapy.  


 

<p>
OTHER:  


 <p>


NITRATES: Verapamil has been given concomitantly with short- and long-acting


nitrates without any undesirable drug interactions. The pharmacologic profile


of both drugs and the clinical experience suggest beneficial interactions.  


 
<p>

CIMETIDINE: The interaction between cimetidine and chronically administered


verapamil has not been studied. Variable results on clearance have been


obtained in acute studies of healthy volunteers; clearance of verapamil was


either reduced or unchanged.  

<p>
 


LITHIUM: Increased sensitivity to the effects of lithium (neurotoxicity) has


been reported during concomitant verapamil-lithium therapy with either no


change or an increase in serum lithium levels. However, the addition of


verapamil has also resulted in the lowering of serum lithium levels in patients 


receiving chronic stable oral lithium. Patients receiving both drugs must be


monitored carefully.  


      <p>                      


CARBAMAZEPINE: Verapamil therapy may increase carbamazepine concentrations


during combined therapy. This may produce carbamazepine side effects such as


diplopia, headache, ataxia, or dizziness.  


 <p>


RIFAMPIN: Therapy with rifampin may markedly reduce oral verapamil


bioavailability.  


 <p>


PHENOBARBITAL: Phenobarbital therapy may increase verapamil clearance.  


 
<p>

CYCLOSPORINE: Verapamil therapy may increase serum levels of cyclosporine.  

<p>
 


THEOPHYLLINE: Verapamil may inhibit the clearance and increase the plasma


levels of theophylline.  
<p>

 


INHALATION ANESTHETICS: Animal experiments have shown that inhalation


anesthetics depress cardiovascular activity by decreasing the inward movement


of calcium ions. When used concomitantly, inhalation anesthetics and calcium


antagonists, such as verapamil, should each be titrated carefully to avoid


excessive cardiovascular depression.  
<p>

 


NEUROMUSCULAR BLOCKING AGENTS: Clinical data and animal studies suggest that


verapamil may potentiate the activity of neuromuscular blocking agents (curare- 


like and depolarizing). It may be necessary to decrease the dose of verapamil


and/or the dose of the neuromuscular blocking agent when the drugs are used


concomitantly.  

<p>
 


CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: An 18-month toxicity


study in rats, at a low multiple (6-fold) of the maximum recommended human dose 


and not the maximum tolerated dose, did not suggest a tumorigenic potential.


There was no evidence of a carcinogenic potential of verapamil administered in


the diet of rats for two years at doses of 10, 35, and 120 mg/kg/day or


approximately 1, 3.5, and 12 times, respectively, the maximum recommended human 


daily dose (480 mg/day or 9.6 mg/kg/day).  


 <p>


Verapamil was not mutagenic in the Ames test in 5 test strains at 3 mg per


plate with or without metabolic activation.  


 <p>


Studies in female rats at daily dietary doses up to 5.5 times (55 mg/kg/day)


the maximum recommended human dose did not show impaired fertility. Effects on


male fertility have not been determined.  


 
<p>

PREGNANCY: Pregnancy Category C. Reproduction studies have been performed in


rabbits and rats at oral doses up to 1.5 (15 mg/kg/day) and 6 (60 mg/kg/day)


times the human oral daily dose, respectively, and have revealed no evidence of 


teratogenicity. In the rat, however, this multiple of the human dose was


embryocidal and retarded fetal growth and development, probably because of


adverse maternal effects reflected in reduced weight gains of the dams. This


oral dose has also been shown to cause hypotension in rats. There are no


adequate and well-controlled studies in pregnant women. Because animal


reproduction studies are not always predictive of human response, this drug


should be used during pregnancy only if clearly needed. Verapamil crosses the


placental barrier and can be detected in umbilical vein blood at delivery.  


 

<p>
LABOR AND DELIVERY: It is not known whether the use of verapamil during labor


or delivery has immediate or delayed adverse effects on the fetus, or whether


it prolongs the duration of labor or increases the need for forceps delivery or 


other obstetric intervention. Such adverse experiences have not been reported


in the literature, despite a long history of use of verapamil in Europe in the


treatment of cardiac side effects of beta-adrenergic agonist agents used to


treat premature labor.  


 <p>


NURSING MOTHERS: Verapamil is excreted in human milk. Because of the potential


for adverse reactions in nursing infants from verapamil, nursing should be


discontinued while verapamil is administered.  


 <p>


PEDIATRIC USE: Safety and efficacy of Verapamil (SR) in children below the age of 18


years have not been established.  


 
<p>

ANIMAL PHARMACOLOGY AND/OR ANIMAL TOXICOLOGY: In chronic animal toxicology


studies verapamil caused lenticular and/or suture line changes at 30 mg/kg/day


or greater, and frank cataracts at 62.5 mg/kg/day or greater in the beagle dog


but not in the rat. Development of cataracts due to verapamil has not been


reported in man.  


 
<p>

<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 


</b> <p>


BETA-BLOCKERS: Concomitant therapy with beta-adrenergic blockers and verapamil


may result in additive negative effects on heart rate, atrioventricular


conduction and/or cardiac contractility. The combination of sustained-release


verapamil and beta-adrenergic blocking agents has not been studied. However,


there have been reports of excessive bradycardia and AV block, including


complete heart block, when the combination has been used for the treatment of


hypertension. For hypertensive patients, the risks of combined therapy may


outweigh the potential benefits. The combination should be used only with


caution and close monitoring.  

<p>
 


Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has


been observed in a patient receiving concomitant timolol (a beta-adrenergic


blocker) eyedrops and oral verapamil.  


 <p>


A decrease in metoprolol and propranolol clearance has been observed when


either drug is administered concomitantly with verapamil. A variable effect has 


been seen when verapamil and atenolol were given together.  


 <p>


DIGITALIS: Clinical use of verapamil in digitalized patients has shown the


combination to be well tolerated if digoxin doses are properly adjusted. 


However, chronic verapamil treatment can increase serum digoxin levels by 50%


to 75% during the first week of therapy, and this can result in digitalis


toxicity.  In patients with hepatic cirrhosis the influence of verapamil on


digoxin kinetics is magnified. Verapamil may reduce total body clearance and


extrarenal clearance of digitoxin by 27% and 29%, respectively. Maintenance


digitalis doses should be reduced when verapamil is administered, and the


patient should be carefully monitored to avoid over- or underdigitalization.


Whenever overdigitalization is suspected, the daily dose of digitalis should be 


reduced or temporarily discontinued. On discontinuation of Verapamil  use, the


patient should be reassessed to avoid underdigitalization.  

<p>
 


ANTIHYPERTENSIVE AGENTS: Verapamil administered concomitantly with oral


antihypertensive agents (eg, vasodilators, angiotensin-converting enzyme


inhibitors, diuretics, beta-blockers) will usually have an additive effect on

 
lowering blood pressure. Patients receiving these combinations should be


appropriately monitored. Concomitant use of agents that attenuate alpha-


adrenergic function with verapamil may result in a reduction in blood pressure


that is excessive in some patients. Such an effect was observed in one study


following the concomitant administration of verapamil and prazosin.  


 
<p>

ANTIARRHYTHMIC AGENTS:  


 <p>


DISOPYRAMIDE: Until data on possible interactions between verapamil and


disopyramide phosphate are obtained, disopyramide should not be administered


within 48 hours before or 24 hours after verapamil administration.  


 

<p>
FLECAINIDE: A study in healthy volunteers showed that the concomitant


administration of flecainide and verapamil may have additive effects on


myocardial contractility, AV conduction, and repolarization. Concomitant


therapy with flecainide and verapamil may result in additive negative inotropic 


effect and prolongation of atrioventricular conduction.  

<p>
 


QUINIDINE: In a small number of patients with hypertrophic cardiomyopathy


(IHSS), concomitant use of verapamil and quinidine resulted in significant


hypotension. Until further data are obtained, combined therapy of verapamil and 


quinidine in patients with hypertrophic cardiomyopathy should probably be


avoided.  

<p>
 


The electrophysiologic effects of quinidine and verapamil on AV conduction were 


studied in 8 patients. Verapamil significantly counteracted the effects of


quinidine on AV conduction. There has been a report of increased quinidine


levels during verapamil therapy.  


 

<p>
OTHER:  


 <p>


NITRATES: Verapamil has been given concomitantly with short- and long-acting


nitrates without any undesirable drug interactions. The pharmacologic profile


of both drugs and the clinical experience suggest beneficial interactions.  


 

<p>
CIMETIDINE: The interaction between cimetidine and chronically administered


verapamil has not been studied. Variable results on clearance have been


obtained in acute studies of healthy volunteers; clearance of verapamil was


either reduced or unchanged.  


 <p>


LITHIUM: Increased sensitivity to the effects of lithium (neurotoxicity) has


been reported during concomitant verapamil-lithium therapy with either no


change or an increase in serum lithium levels. However, the addition of


verapamil has also resulted in the lowering of serum lithium levels in patients 


receiving chronic stable oral lithium. Patients receiving both drugs must be


monitored carefully.  

<p>
 


CARBAMAZEPINE: Verapamil therapy may increase carbamazepine concentrations


during combined therapy. This may produce carbamazepine side effects such as


diplopia, headache, ataxia, or dizziness.  


 <p>


RIFAMPIN: Therapy with rifampin may markedly reduce oral verapamil


bioavailability.  


 <p>


PHENOBARBITAL: Phenobarbital therapy may increase verapamil clearance.  


 
<p>

CYCLOSPORINE: Verapamil therapy may increase serum levels of cyclosporine.  

<p>
 


THEOPHYLLINE: Verapamil may inhibit the clearance and increase the plasma


levels of theophylline.  

<p>
 


INHALATION ANESTHETICS: Animal experiments have shown that inhalation


anesthetics depress cardiovascular activity by decreasing the inward movement


of calcium ions. When used concomitantly, inhalation anesthetics and calcium


antagonists, such as verapamil, should each be titrated carefully to avoid


excessive cardiovascular depression.  

<p>
 


NEUROMUSCULAR BLOCKING AGENTS: Clinical data and animal studies suggest that


verapamil may potentiate the activity of neuromuscular blocking agents (curare- 


like and depolarizing). It may be necessary to decrease the dose of verapamil


and/or the dose of the neuromuscular blocking agent when the drugs are used


concomitantly.  


 


(See Also PRECAUTIONS) 

<p>
 


<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 


</b><p> 


Serious adverse reactions are uncommon when verapamil therapy is initiated with 


upward dose titration within the recommended single and total daily dose. See


Warnings for discussion of heart failure, hypotension, elevated liver enzymes,


AV block, and rapid ventricular response. Reversible (upon discontinuation of


verapamil) non-obstructive, paralytic ileus has been infrequently reported in


association with the use of verapamil. The following reactions to orally


administered verapamil occurred at rates greater than 1.0% or occurred at lower 


rates but appeared clearly drug-related in clinical trials in 4,954 patients: 


 <pre>
<p>

Constipation        7.3%    Dyspnea          1.4%                               


Dizziness           3.3%    Bradycardia                                         


Nausea              2.7%     (HR&lt;50/min)     1.4%                               


Hypotension         2.5%    AV block total                                      


Headache            2.2%     (1 deg, 2 deg,                                     


Edema               1.9%      3 deg)         1.2%                               


                             2 deg and 3 deg 0.8%                               


CHF, Pulmonary              Rash             1.2%                               


edema               1.8%    Flushing         0.6%                               


Fatigue             1.7%                                                        

</pre><p>
Elevated liver enzymes (see Warnings)                                           
<p>

In clinical trials related to the control of ventricular response in


digitalized patients who had atrial fibrillation or flutter, ventricular rates


below 50/min at rest occurred in 15% of patients and asymptomatic hypotension


occurred in 5% of patients.  

<p>
 


The following reactions, reported in 1% or less of patients, occurred under


conditions (open trials, marketing experience) where a causal relationship is


uncertain; they are listed to alert the physician to a possible relationship: 


 
<p>

Cardiovascular: angina pectoris, atrioventricular dissociation, chest pain,


claudication, myocardial infarction, palpitations, purpura (vasculitis),


syncope.  


 
<p>

Digestive System: diarrhea, dry mouth, gastrointestinal distress, gingival


hyperplasia.  

<p>
 


Hemic And Lymphatic: ecchymosis or bruising.  


 

<p>
Nervous System: cerebrovascular accident, confusion, equilibrium disorders,


insomnia, muscle cramps, paresthesia, psychotic symptoms, shakiness,


somnolence.  
<p>

 


Skin: arthralgia and rash, exanthema, hair loss, hyperkeratosis, macules,


sweating, urticaria, Stevens-Johnson syndrome, erythema multiforme.  


 
<p>

Special Senses: blurred vision.  


 <p>


Urogenital: gynecomastia, galactorrhea/hyperprolactinemia, increased urination, 


spotty menstruation, impotence.  

<p>
 


TREATMENT OF ACUTE CARDIOVASCULAR ADVERSE REACTIONS: The frequency of


cardiovascular adverse reactions that require therapy is rare; hence,


experience with their treatment is limited. Whenever severe hypotension or


complete AV block occurs following oral administration of verapamil, the


appropriate emergency measures should be applied immediately; eg, intravenously 


administered norepinephrine bitartrate, atropine sulfate, isoproterenol HCl


(all in the usual doses), or calcium gluconate (10% solution). In patients with 


hypertrophic cardiomyopathy (IHSS), alpha-adrenergic agents (phenylephrine HCl, 


metaraminol bitartrate, or methoxamine HCl) should be used to maintain blood


pressure, and isoproterenol and norepinephrine should be avoided. If further


support is necessary, dopamine HCl or dobutamine HCl may be administered.


Actual treatment and dosage should depend on the severity of the clinical


situation and the judgment and experience of the treating physician.  


 <p>


<a name="OVERDOSAGE"></a><b>OVERDOSAGE 


</b> <p>


Overdose with verapamil may lead to pronounced hypotension, bradycardia, and


conduction system abnormalities (eg, junctional rhythm with AV dissociation and 


high degree AV block, including asystole). Other symptoms secondary to


hypoperfusion (eg, metabolic acidosis, hyperglycemia, hyperkalemia, renal


dysfunction, and convulsions) may be evident.  


 <p>


Treat all verapamil overdoses as serious and maintain observation for at least


48 hours (especially Verapamil (SR)), preferably under continuous hospital care. 


Delayed pharmacodynamic consequences may occur with the sustained-release


formulation. Verapamil is known to decrease gastrointestinal transit time. 


Verapamil cannot be removed by hemodialysis.  


 <p>


Treatment of overdosage should be supportive. Beta-adrenergic stimulation or


parenteral administration of calcium solutions may increase calcium ion flux


across the slow channel and has been used effectively in treatment of


deliberate overdose of verapamil. The following measures may be considered:  


 
<p>

BRADYCARDIA AND CONDUCTION SYSTEM ABNORMALITIES: Atropine, isoproterenol, and


cardiac pacing.  


 
<p>

HYPOTENSION: Intravenous fluids, vasopressors (eg, dopamine, dobutamine),


calcium solutions (eg, 10% calcium chloride solution).  


 <p>


CARDIAC FAILURE: Inotropic agents (eg, isoproterenol, dopamine, dobutamine),


diuretics.  
<p>

 


Asystole should be handled by the usual measures including cardiopulmonary


resuscitation.  

<p>
 


<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 


</b> 
<p>

ESSENTIAL HYPERTENSION: The dose of Verapamil (SR) should be individualized by


titration and the drug should be administered with food. Initiate therapy with


180 mg of sustained-release verapamil HCl, Verapamil (SR), given in the morning.


Lower initial doses of 120 mg a day may be warranted in patients who may have


an increased response to verapamil (eg, the elderly or small people). Upward


titration should be based on therapeutic efficacy and safety evaluated weekly


and approximately 24 hours after the previous dose. The antihypertensive


effects of Verapamil (SR) are evident within the first week of therapy.  


 

<p>
If adequate response is not obtained with 180 mg of Verapamil (SR), the dose may be


titrated upward in the following manner:  


 <p>


a) 240 mg each morning, 


 
<p>

b) 180 mg each morning plus 

<p>
 


180 mg each evening; or 


 
<p>

240 mg each morning plus 


 
<p>

120 mg each evening, 


         <p>                   


c)  240 mg every 12 hours.  


 <p>


When switching from immediate-release Verapamil  to Verapamil (SR) the total daily dose in 


milligrams may remain the same.  

<p>
 


 


ANIMAL PHARMACOLOGY 


 <p>


ANIMAL PHARMACOLOGY AND/OR ANIMAL TOXICOLOGY: In chronic animal toxicology


studies verapamil caused lenticular and/or suture line changes at 30 mg/kg/day


or greater, and frank cataracts at 62.5 mg/kg/day or greater in the beagle dog


but not in the rat. Development of cataracts due to verapamil has not been


reported in man.  


 


(See Also PRECAUTIONS) 

<p>
 








<h2 align=center>


<hr width="100%" ></h2>





<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top


200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search


RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList


Home Page</a></h2>





</body>


</html>




</DOC>
<DOC>
<DOCNO>WT08-B10-50</DOCNO>
<DOCOLDNO>IA018-000200-B038-56</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/doxycyc.htm 206.86.175.201 19970106225854 text/html 30677
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:52:37 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 30494
Last-modified: Sat, 13 Jul 1996 08:50:30 GMT
</DOCHDR>
<html>
<head>
   <title>Doxycycline - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Doxycycline</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Doxycycline is a broad-spectrum antibiotic synthetically derived from
oxytetracycline. It has a molecular formula of C22H24N2O8.H2O and a molecular
weight of 462.46. The chemical designation for doxycycline is 4-(Dimethylamino)-1,
4, 4a, 5, 5a, 6, 11, 12a-octahydro-3, 5, 10, 12, 12a-pentahydroxy-6-methyl-1,
11-dioxo-2- naphthacenecarboxamide monohydrate. The molecular formula for
doxycycline hydrochloride hemiethanolate hemihydrate is (C22H24N2O8.HCl)2.C2H6O.H2O
and the molecular weight is 1025.89. Doxycycline is a light-yellow crystalline
powder. Doxycycline hyclate is soluble in water, while doxycycline monohydrate
is very slightly soluble in water. </p>

<p>Doxycycline has a high degree of lipoid solubility and a low affinity
for calcium binding. It is highly stable in normal human serum. Doxycycline
will not degrade into an epianhydro form. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Tetracyclines are readily absorbed and are bound to plasma proteins
in varying degree. They are concentrated by the liver in the bile, and
excreted in the urine and feces at high concentrations and in a biologically
active form. Doxycycline is virtually completely absorbed after oral administration.
</p>

<p>Following a 200 mg dose, normal adult volunteers averaged peak serum
levels of 2.6 mcg/mL of doxycycline at 2 hours decreasing to 1.45 mcg/mL
at 24 hours. </p>

<p>Excretion of doxycycline by the kidney is about 40%/72 hours in individuals
with normal function (creatinine clearance about 75 mL/ min.). This percentage
excretion may fall as low as 1-5%/72 hours in individuals with severe renal
insufficiency (creatinine clearance below 10 mL/min.). Studies have shown
no significant difference in serum half-life of doxycycline (range 18-22
hours) in individuals with normal and severely impaired renal function.
</p>

<p>Hemodialysis does not alter serum half-life. </p>

<p>Results of animal studies indicate that tetracyclines cross the placenta
and are found in fetal tissues. </p>

<p>MICROBIOLOGY </p>

<p>The tetracyclines are primarily bacteriostatic and are thought to exert
their antimicrobial effect by the inhibition of protein synthesis. The
tetracyclines, including doxycycline, have a similar antimicrobial spectrum
of activity against a wide range of gram-positive and gram-negative organisms.
Cross resistance of these organisms to tetracyclines is common. </p>

<p>GRAM-NEGATIVE BACTERIA </p>

<p>Neisseria Gonorrhoeae </p>

<p>Calymmatobacterium Granulomatis </p>

<p>Haemophilus Ducreyi </p>

<p>Haemophilus Influenzae </p>

<p>Yersinia Pestis (formerly Pasteurella Pestis) </p>

<p>Francisella Tularensis (formerly Pasteurella Tularensis) </p>

<p>Vibrio Cholera (formerly Vibrio Comma) </p>

<p>Bartonella Bacilliformis </p>

<p>Brucella species </p>

<p>Because many strains of the following groups of gram-negative microorganisms
have been shown to be resistant to tetracyclines, culture and susceptibility
testing are recommended: </p>

<p>Escherichia Coli </p>

<p>Klebsiella species </p>

<p>Enterobacter Aerogenes </p>

<p>Shigella species </p>

<p>Acinetobacter species (formerly Mima species and Herellea species) </p>

<p>Bacteroides species </p>

<p>GRAM-POSITIVE BACTERIA </p>

<p>Because many strains of the following groups of gram-positive microorganisms
have been shown to be resistant to tetracycline, culture and susceptibility
testing are recommended. Up to 44 percent of strains of Streptococcus Pyogenes
and 74 percent of Streptococcus Faecalis have been found to be resistant
to tetracycline drugs. Therefore, tetracycline should not be used for streptococcal
disease unless the organism has been demonstrated to be susceptible. </p>

<p>Streptococcus Pyogenes </p>

<p>Streptococcus Pneumoniae </p>

<p>Enterococcus group (Streptococcus Faecalis and Streptococcus Faecium)
</p>

<p>Alpha-hemolytic streptococci (viridans group) </p>

<p>OTHER MICROORGANISMS </p>

<p>Rickettsiae </p>

<p>Chlamydia Psittaci </p>

<p>Chlamydia Trachomatis </p>

<p>Mycoplasma Pneumoniae </p>

<p>Ureaplasma Urealyticum </p>

<p>Borrelia Recurrentis </p>

<p>Treponema Pallidum </p>

<p>Treponema Pertenue </p>

<p>Clostridium species </p>

<p>Fusobacterium Fusiforme </p>

<p>Actinomyces species </p>

<p>Bacillus Anthracis </p>

<p>Propionbacterium Acnes </p>

<p>Entamoeba species </p>

<p>Balantidium Coli </p>

<p>Plasmodium Falciparum </p>

<p>Doxycycline has been found to be active against the asexual erythrocytic
forms of Plasmodium Falciparum but not against the gametocytes of P. Falciparum.
The precise mechanism of action of the drug is not known. </p>

<p>SUSCEPTIBILITY TESTS: DIFFUSION TECHNIQUES: Quantitative methods that
require measurement of zone diameters give the most precise estimate of
the susceptibility of bacteria to antimicrobial agents. One such standard
procedure (REF. 1) which has been recommended for use with disks to test
susceptibility of organisms to doxycycline uses the 30-mcg tetracycline-class
disk or the 30 mcg doxycycline disk. Interpretation involves the correlation
of the diameter obtained in the disk test with the minimum inhibitory concentration
(MIC) for tetracycline or doxycycline, respectively.</p>

<p> Reports from the laboratory giving results of the standard single-disk
susceptibility test with a 30-mcg tetracycline-class disk or the 30-mcg
doxycycline disk should be interpreted according to the following criteria:
</p>

<pre>                      ZONE DIAMETER (MM)                INTERPRETATION          
        tetracycline             doxycycline                                    
           &gt;/=19                    &gt;/=16                Susceptible            
           15-18                    13-15                Intermediate           
           &lt; or =14                 &lt; or =12             Resistant  </pre>

<p>A report of &quot;Susceptible&quot; indicates that the pathogen is likely
to be inhibited by generally achievable blood levels. A report of &quot;Intermediate&quot;
suggests that the organism would be susceptible if a high dosage is used
or if the infection is confined to tissues and fluids in which high antimicrobial
levels are attained. A report of &quot;Resistant&quot; indicates that achievable
concentrations are unlikely to be inhibitory, and other therapy should
be selected. </p>

<p>Standardized procedures require the use of laboratory control organisms.
The 30 mcg tetracycline-class disk or the 30-mcg doxycycline disk should
give the following zone diameters: </p>

<pre><font SIZE=-1>                ORGANISM                        ZONE DIAMETER (MM)              
                                         tetracycline         doxycycline       
           E. Coli ATCC 25922               18-25                18-24          
          S. Aureus ATCC 25923              19-28                23-29          

DILUTION TECHNIQUES: Use a standardized dilution method (REF. 2) (broth, agar,
microdilution) or equivalent with tetracycline powder. The MIC values obtained
should be interpreted according to the following criteria:  
 
                    MIC (MCG/ML)                         INTERPRETATION         
                        &lt; or =4                           Susceptible           
                         8                                Intermediate          
                       &gt;/=16                              Resistant            

As with standard diffusion techniques, dilution methods require the use of
laboratory control organisms. Standard tetracycline powder should provide the
following MIC values:  
 
                      ORGANISM                            MIC (MCG/ML)          
                 E. Coli ATCC 25922                         1.0-4.0             
                S. Aureus ATCC 29213                        0.25-1.0            
               E. Faecalis ATCC 29212                         8-32              
              P. Aeruginosa ATCC 27853                        8-32  </font></pre>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>TREATMENT: </p>

<p>Doxycycline is indicated for the treatment of the following infections:
</p>

<p>Rocky mountain spotted fever, typhus fever and the typhus group, Q fever,
rickettsialpox, and tick fevers caused by Rickettsiae. </p>

<p>Respiratory tract infections caused by Mycoplasma Pneumoniae. </p>

<p>Lymphogranuloma venereum caused by Chlamydia Trachomatis. </p>

<p>Psittacosis (ornithosis) caused by Chlamydia Psittaci. </p>

<p>Trachoma caused by Chlamydia Trachomatis, although the infectious agent
is not always eliminated as judged by immunofluorescence. </p>

<p>Inclusion conjunctivitis caused by Chlamydia Trachomatis. </p>

<p>Uncomplicated urethral, endocervical or rectal infections in adults
caused by Chlamydia Trachomatis. </p>

<p>Nongonococcal urethritis caused by Ureaplasma Urealyticum. </p>

<p>Relapsing fever due to Borrelia Recurrentis. </p>

<p>Doxycycline is also indicated for the treatment of infections caused
by the following gram-negative microorganisms: </p>

<p>Chancroid caused by Haemophilus Ducreyi. </p>

<p>Plague due to Yersinia Pestis (formerly Pasteurella Pestis). </p>

<p>Tuleremia due to Francisella Tulerensis (formerly Pasteurella Tulerensis).
</p>

<p>Cholera caused by Vibrio Cholerae (formerly Vibrio Comma). </p>

<p>Campylobacter fetus infections caused by Campylobacter Fetus (formerly
Vibrio Fetus). </p>

<p>Brucellosis due to Brucella species (in conjunction with streptomycin).
</p>

<p>Bartonellosis due to Bartonella Bacilliformis. </p>

<p>Granuloma inguinale caused by Calymmatobacterium Granulomatis. </p>

<p>Because many strains of the following groups of microorganisms have
been shown to be resistant to doxycycline, culture and susceptibility testing
are recommended. </p>

<p>Doxycycline is indicated for treatment of infections caused by the following
gram-negative microorganisms, when bacteriologic testing indicates appropriate
susceptibility to the drug: </p>

<p>Escherichia Coli. </p>

<p>Enterobacter Aerogenes (formerly Aerobacter Aerogenes). </p>

<p>Shigella species. </p>

<p>Acinetobacter species (formerly Mima species and Herellea species).
</p>

<p>Respiratory tract infections caused by Haemophilus Influenzae. </p>

<p>Respiratory tract and urinary tract infections caused by Klebsiella
species. </p>

<p>Doxycycline is indicated for treatment of infections caused by the following
gram-positive microorganisms when bacteriologic testing indicates appropriate
susceptibility to the drug: </p>

<p>Upper respiratory infections caused by Streptococcus Pneumoniae (formerly
Diplococcus Pneumoniae). </p>

<p>When penicillin is contraindicated, doxycycline is an alternative drug
in the treatment of the following infections: </p>

<p>Uncomplicated gonorrhea caused by Neisseria Gonorrhoeae. </p>

<p>Syphilis caused by Treponema Pallidum. </p>

<p>Yaws caused by Treponema Pertenue. </p>

<p>Listeriosis due to Listeria Monocytogenes. </p>

<p>Anthrax due to Bacillus Anthracis. </p>

<p>Vincent's infection caused by Fusobacterium Fusiforme. </p>

<p>Actinomycosis caused by Actinomyces Israelii. </p>

<p>Infections caused by Clostridium species. </p>

<p>In acute intestinal amebiasis, doxycycline may be a useful adjunct to
amebicides. </p>

<p>In severe acne, doxycycline may be useful adjunctive therapy. </p>

<p>PROPHYLAXIS: </p>

<p>Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium
Falciparum in short-term travelers (&lt;4 months) to areas with chloroquine
and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION
section and Information for Patients subsection of the PRECAUTIONS section.
</p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>This drug is contraindicated in persons who have shown hypersensitivity
to any of the tetracyclines. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT
(LAST HALF OF PREGNANCY, INFANCY AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY
CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse
reaction is more common during long-term use of the drugs, but has been
observed following repeated short-term courses. Enamel hypoplasia has also
been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS
AGE GROUP UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED.
</p>

<p>All tetracyclines form a stable calcium complex in any bone-forming
tissue. A decrease in fibula growth rate has been observed in prematures
given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction
was shown to be reversible when the drug was discontinued. </p>

<p>Results of animal studies indicate that tetracyclines cross the placenta,
are found in fetal tissues, and can have toxic effects on the developing
fetus (often related to retardation of skeletal development). Evidence
of embryotoxicity has also been noted in animals treated early in pregnancy.
If any tetracycline is used during pregnancy or if the patient becomes
pregnant while taking this drug, the patient should be apprised of the
potential hazard to the fetus. </p>

<p>The antianabolic action of the tetracyclines may cause an increase in
BUN. Studies to date indicate that this does not occur with the use of
doxycycline in patients with impaired renal function. </p>

<p>Photosensitivity manifested by an exaggerated sunburn reaction has been
observed in some individuals taking tetracyclines. Patients apt to be exposed
to direct sunlight or ultraviolet light should be advised that this reaction
can occur with tetracycline drugs, and treatment should be discontinued
at the first evidence of skin erythema. </p>

<p>Doxycycline Syrup contains sodium metabisulfite, a sulfite that may
cause allergic-type reactions including anaphylactic symptoms and life-threatening
or less severe asthmatic episodes in certain susceptible people. The over-all
prevalence of sulfite sensitivity in the general population is unknown
and probably low. Sulfite sensitivity is seen more frequently in asthmatic
than in non-asthmatic people. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL </p>

<p>As with other antibiotic preparations, use of this drug may result in
overgrowth of nonsusceptible organisms, including fungi. If superinfection
occurs, the antibiotic should be discontinued and appropriate therapy instituted.
</p>

<p>Bulging fontanels in infants and benign intracranial hypertension in
adults have been reported in individuals receiving tetracyclines. These
conditions disappeared when the drug was discontinued. </p>

<p>Incision and drainage or other surgical procedures should be performed
in conjunction with antibiotic therapy, when indicated. </p>

<p>Doxycycline offers substantial but not complete suppression of the asexual
blood stages of Plasmodium strains. </p>

<p>Doxycycline does not suppress P. Falciparum'S sexual blood stage gametocytes.
Subjects completing this prophylactic regimen may still transmit the infection
to mosquitoes outside endemic areas. </p>

<p>INFORMATION FOR PATIENTS </p>

<p>Patients taking doxycycline for malaria prophylaxis should be advised:
</p>

<p>--that no present-day antimalarial agent, including doxycycline, guarantees
protection against malaria. </p>

<p>--to avoid being bitten by mosquitoes by using personal protective measures
that help avoid contact with mosquitoes, especially from dusk to dawn (e.g.,
staying in well-screened areas, using mosquito nets, covering the body
with clothing, and using an effective insect repellent.) </p>

<p>--that doxycycline prophylaxis: </p>

<p>--should begin 1-2 days before travel to the malarious area, </p>

<p>--should be continued daily while in the malarious area and after leaving
the malarious area, </p>

<p>--should be continued for 4 further weeks to avoid development of malaria
after returning from an endemic area, </p>

<p>--should not exceed 4 months. </p>

<p>All patients taking doxycycline should be advised: </p>

<p>--to avoid excessive sunlight or artificial ultraviolet light while
receiving doxycycline and to discontinue therapy if phototoxicity (e.g.,
skin eruption, etc.) occurs. Sunscreen or sunblock should be considered.
(See WARNINGS.) </p>

<p>--to drink fluids liberally along with doxycycline to reduce the risk
of esophageal irritation and ulceration. (See ADVERSE REACTIONS.) </p>

<p>--that the absorption of tetracyclines is reduced when taken with foods,
especially those which contain calcium. However, the absorption of doxycycline
is not markedly influenced by simultaneous ingestion of food or milk. (See
DRUG INTERACTIONS.) </p>

<p>--that the absorption of tetracyclines is reduced when taking bismuth
subsalicylate. (See DRUG INTERACTIONS.) </p>

<p>--that the use of doxycycline might increase the incidence of vaginal
candidiasis. </p>

<p>LABORATORY TESTS </p>

<p>In venereal disease, when co-existent syphilis is suspected, dark field
examinations should be done before treatment is started and the blood serology
repeated monthly for at least 4 months. </p>

<p>In long-term therapy, periodic laboratory evaluation of organ systems,
including hematopoietic, renal, and hepatic studies, should be performed.
</p>

<p>DRUG INTERACTIONS </p>

<p>Because tetracyclines have been shown to depress plasma prothrombin
activity, patients who are on anticoagulant therapy may require downward
adjustment of their anticoagulant dosage. </p>

<p>Since bacteriostatic drugs may interfere with the bactericidal action
of penicillin, it is advisable to avoid giving tetracyclines in conjunction
with penicillin. </p>

<p>Absorption of tetracyclines is impaired by antacids containing aluminum,
calcium, or magnesium, and iron-containing preparations. </p>

<p>Absorption of tetracyclines is impaired by bismuth subsalicylate. </p>

<p>Barbiturates, carbamazepine, and phenytoin decrease the half-life of
doxycycline. </p>

<p>The concurrent use of tetracycline and Penthrane (methoxyflurane) has
been reported to result in fatal renal toxicity. </p>

<p>Concurrent use of tetracycline may render oral contraceptives less effective.
</p>

<p>DRUG/LABORATORY TEST INTERACTIONS </p>

<p>False elevations of urinary catecholamine levels may occur due to interference
with the fluorescence test. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY </p>

<p>Long-term studies in animals to evaluate carcinogenic potential of doxycycline
have not been conducted. However, there has been evidence of oncogenic
activity in rats in studies with the related antibiotics, oxytetracycline
(adrenal and pituitary tumors), and minocycline (thyroid tumors). </p>

<p>Likewise, although mutagenicity studies of doxycycline have not been
conducted, positive results in In Vitro mammalian cell assays have been
reported for related antibiotics (tetracycline, oxytetracycline). </p>

<p>Doxycycline administered orally at dosage levels as high as 250 mg/kg/day
had no apparent effect on the fertility of female rats. Effect on male
fertility has not been studied. </p>

<p>PREGNANCY CATEGORY </p>

<p>Teratogenic effects: Category &quot;D&quot; -- (See WARNINGS). </p>

<p>Nonteratogenic effects: (See WARNINGS). </p>

<p>LABOR AND DELIVERY </p>

<p>The effect of tetracyclines on labor and delivery is unknown. </p>

<p>NURSING MOTHERS </p>

<p>Tetracyclines are excreted in human milk. Because of the potential for
serious adverse reactions in nursing infants from doxycycline, a decision
should be made whether to discontinue nursing or to discontinue the drug,
taking into account the importance of the drug to the mother. (See WARNINGS).
</p>

<p>PEDIATRIC USE </p>

<p>See WARNINGS and DOSAGE AND ADMINISTRATION. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Because tetracyclines have been shown to depress plasma prothrombin
activity, patients who are on anticoagulant therapy may require downward
adjustment of their anticoagulant dosage. </p>

<p>Since bacteriostatic drugs may interfere with the bactericidal action
of penicillin, it is advisable to avoid giving tetracyclines in conjunction
with penicillin. </p>

<p>Absorption of tetracyclines is impaired by antacids containing aluminum,
calcium, or magnesium, and iron-containing preparations. </p>

<p>Absorption of tetracyclines is impaired by bismuth subsalicylate. </p>

<p>Barbiturates, carbamazepine, and phenytoin decrease the half-life of
doxycycline. </p>

<p>The concurrent use of tetracycline and Penthrane (methoxyflurane) has
been reported to result in fatal renal toxicity. </p>

<p>Concurrent use of tetracycline may render oral contraceptives less effective.
</p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Due to oral doxycycline's virtually complete absorption, side effects
of the lower bowel, particularly diarrhea, have been infrequent. The following
adverse reactions have been observed in patients receiving tetracyclines:
</p>

<p>Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia,
enterocolitis, and inflammatory lesions (with monilial overgrowth) in the
anogenital region. Hepatotoxicity has been reported rarely. These reactions
have been caused by both the oral and parenteral administration of tetracyclines.
Rare instances of esophagitis and esophageal ulcerations have been reported
in patients receiving capsule and tablet forms of the drugs in the tetracycline
class. Most of these patients took medications immediately before going
to bed. (See DOSAGE AND ADMINISTRATION.) </p>

<p>Skin: maculopapular and erythematous rashes. Exfoliative dermatitis
has been reported but is uncommon. Photosensitivity is discussed above.
(See WARNINGS.) </p>

<p>Renal toxicity: Rise in BUN has been reported and is apparently dose
related. (See WARNINGS.) </p>

<p>Hypersensitivity reactions: urticaria, angioneurotic edema, anaphylaxis,
anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of
systemic lupus erythematosus. </p>

<p>Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia
have been reported. </p>

<p>Other: bulging fontanels in infants and intracranial hypertension in
adults. (See PRECAUTIONS--General.) </p>

<p>When given over prolonged periods, tetracyclines have been reported
to produce brown-black microscopic discoloration of the thyroid gland.
No abnormalities of thyroid function studies are known to occur. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>In case of overdosage, discontinue medication, treat symptomatically
and institute supportive measures. Dialysis does not alter serum half-life
and thus would not be of benefit in treating cases of overdosage. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS
FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE
MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS. </p>

<p>Adults: The usual dose of oral doxycycline is 200 mg on the first day
of treatment (administered 100 mg every 12 hours) followed by a maintenance
dose of 100 mg/day. The maintenance dose may be administered as a single
dose or as 50 mg every 12 hours. </p>

<p>In the management of more severe infections (particularly chronic infections
of the urinary tract), 100 mg every 12 hours is recommended. </p>

<p>For children above eight years of age: The recommended dosage schedule
for children weighing 100 pounds or less is 2 mg/lb of body weight divided
into two doses on the first day of treatment, followed by 1 mg/lb of body
weight given as a single daily dose or divided into two doses, on subsequent
days. For more severe infections up to 2 mg/lb of body weight may be used.
For children over 100 lbs the usual adult dose should be used. </p>

<p>The therapeutic antibacterial serum activity will usually persist for
24 hours following recommended dosage. </p>

<p>When used in streptococcal infections, therapy should be continued for
10 days. </p>

<p>Administration of adequate amounts of fluid along with capsule and tablet
forms of drugs in the tetracycline class is recommended to wash down the
drugs and reduce the risk of esophageal irritation and ulceration. (See
ADVERSE REACTIONS.) </p>

<p>If gastric irritation occurs, it is recommended that doxycycline be
given with food or milk. The absorption of doxycycline is not markedly
influenced by simultaneous ingestion of food or milk. </p>

<p>Studies to date have indicated that administration of doxycycline at
the usual recommended doses does not lead to excessive accumulation of
the antibiotic in patients with renal impairment. </p>

<p>Uncomplicated gonococcal infections in adults (except anorectal infections
in men): 100 mg, by mouth, twice a day for 7 days. As an alternate single
visit dose, administer 300 mg stat followed in one hour by a second 300
mg dose. The dose may be administered with food, including milk or carbonated
beverage, as required. </p>

<p>Uncomplicated urethral, endocervical, or rectal infection in adults
caused by Chlamydia Trachomatis: 100 mg by mouth twice a day for 7 days.
</p>

<p>Nongonococcal urethritis (NGU) caused by C. Trachomatis or U. Urealyticum:
100 mg by mouth twice a day for 7 days. </p>

<p>Syphilis--early: Patients who are allergic to penicillin should be treated
with doxycycline 100 mg by mouth twice a day for 2 weeks. </p>

<p>Syphilis of more than one year's duration: Patients who are allergic
to penicillin should be treated with doxycycline 100 mg by mouth twice
a day for 4 weeks. </p>

<p>Acute epididymo-orchitis caused by N. Gonorrhoeae: 100 mg, by mouth,
twice a day for at least 10 days. </p>

<p>Acute epididymo-orchitis caused by C. Trachomatis: 100 mg, by mouth,
twice a day for at least 10 days. </p>

<p>For prophylaxis of malaria: For adults, the recommended dose is 100
mg daily. For children over 8 years of age, the recommended dose is 2 mg/kg
given once daily up to the adult dose. Prophylaxis should begin 1-2 days
before travel to the malarious area. Prophylaxis should be continued daily
during travel in the malarious area and for 4 weeks after the traveler
leaves the malarious area. </p>

<p>ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY </p>

<p>Hyperpigmentation of the thyroid has been produced by members of the
tetracycline class in the following species: in rats by oxytetracycline,
doxycycline, tetracycline PO4, and methacycline; in minipigs by doxycycline,
minocycline, tetracycline PO4, and methacycline; in dogs by doxycycline
and minocycline; in monkeys by minocycline.</p>

<p> Minocycline, tetracycline PO4, methacycline, doxycycline, tetracycline
base, oxytetracycline HCl, and tetracycline HCl were goitrogenic in rats
fed a low iodine diet. This goitrogenic effect was accompanied by high
radioactive iodine uptake. Administration of minocycline also produced
a large goiter with high radioiodine uptake in rats fed a relatively high
iodine diet. </p>

<p>Treatment of various animal species with this class of drugs has also
resulted in the induction of thyroid hyperplasia in the following: in rats
and dogs (minocycline); in chickens (chlortetracycline); and in rats and
mice (oxytetracycline). Adrenal gland hyperplasia has been observed in
goats and rats treated with oxytetracycline. </p>

<p>REFERENCES </p>

<p>1. National Committee for Clinical Laboratory Standards, Performance
Standards For Antimicrobial Disk Susceptibility Tests, Fourth Edition.
Approved Standard NCCLS Document M2-A4, Vol. 10, No. 7 NCCLS, Villanova,
PA, April 1990. </p>

<p>2. National Committee for Clinical Laboratory Standards, Methods For
Dilution Antimicrobial Susceptibility Tests For Bacteria That Grow Aerobically,
Second Edition. Approved Standard NCCLS Document M7-A2, Vol. 10, No. 8
NCCLS, Villanova, PA, April 1990. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-51</DOCNO>
<DOCOLDNO>IA018-000200-B036-61</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/trisulf.htm 206.86.175.201 19970106225046 text/html 31615
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:44:30 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 31432
Last-modified: Sun, 11 Aug 1996 03:47:50 GMT
</DOCHDR>
<html>
<head>
   <title>Trimethoprim and Sulfamethoxazole - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Trimethoprim and Sulfamethoxazole</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION <p>
</b> 
Trimethoprim and sulfamethoxazole is a synthetic antibacterial
combination product.<p>

Trimethoprim is 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine. It is a
white to light yellow, odorless, bitter compound with a molecular weight of
290.3.  <p>
 
Sulfamethoxazole is N1-(5-methyl-3-isoxazolyl) sulfanilamide. It is an almost
white, odorless, tasteless compound with a molecular weight of 253.28.  <p>
 
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY <p>
</b> 
Trimethoprim and sulfamethoxazole is rapidly absorbed following oral administration. Both
sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound
and metabolized forms; sulfamethoxazole also exists as the conjugated form. The 
metabolism of sulfamethoxazole occurs predominately by N4-acetylation, although 
the glucuronide conjugate has been identified. The principal metabolites of
trimethoprim are the 1- and 3-oxides and the 3'- and 4'-hydroxy derivatives.
The free forms of sulfamethoxazole and trimethoprim are considered to be the
therapeutically active forms. Approximately 44% of trimethoprim and 70% of
sulfamethoxazole are bound to plasma proteins. The presence of 10 mg percent
sulfamethoxazole in plasma decreases the protein binding of trimethoprim by an
insignificant degree; trimethoprim does not influence the protein binding of
sulfamethoxazole.  
 <p>
Peak blood levels for the individual components occur 1 to 4 hours after oral
administration. The mean serum half-lives of sulfamethoxazole and trimethoprim
are 10 and 8 to 10 hours, respectively. However, patients with severely
impaired renal function exhibit an increase in the half-lives of both
components, requiring dosage regimen adjustment (see DOSAGE AND ADMINISTRATION
section).  Detectable amounts of trimethoprim and sulfamethoxazole are present
in the blood 24 hours after drug administration. During administration of 160
mg trimethoprim and 800 mg sulfamethoxazole B.I.D., the mean steady-state
plasma concentration of trimethoprim was 1.72 mcgm/mL. The steady-state mean
plasma levels of free and total sulfamethoxazole were 57.4 mcgm/mL and 68.0
mcgm/mL, respectively.  These steady-state levels were achieved after three
days of drug administration. (REF. 1) 
 <p>
Excretion of sulfamethoxazole and trimethoprim is primarily by the kidneys
through both glomerular filtration and tubular secretion. Urine concentrations
of both sulfamethoxazole and trimethoprim are considerably higher than are the
concentrations in the blood. The average percentage of the dose recovered in
urine from 0 to 72 hours after a single oral dose of Trimethoprim and 
sulfamethoxazole is 84.5% for total sulfonamide and 66.8% for free trimethoprim. 
Thirty percent of the total sulfonamide is excreted as free sulfamethoxazole, 
with the remaining as N4 acetylated metabolite. (REF. 2) When administered 
together as Trimethoprim and sulfamethoxazole, neither sulfamethoxazole nor 
trimethoprim affects the urinary excretion pattern of the other.  
 <p>
Both trimethoprim and sulfamethoxazole distribute to sputum, vaginal fluid and
middle ear fluid; trimethoprim also distributes to bronchial secretion, and
both pass the placental barrier and are excreted in breast milk.  
 <p>
MICROBIOLOGY:  Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic
acid by competing with Para-aminobenzoic acid (PABA). Trimethoprim blocks the
production of tetrahydrofolic acid from dihydrofolic acid by binding to and
reversibly inhibiting the required enzyme, dihydrofolate reductase. Thus,
Trimethoprim and sulfamethoxazole blocks two consecutive steps in the biosynthesis of nucleic
acids and proteins essential to many bacteria.  <p>
 
In Vitro studies have shown that bacterial resistance develops more slowly with 
Trimethoprim and sulfamethoxazole than with either trimethoprim or sulfamethoxazole alone.  
 <p>
In Vitro serial dilution tests have shown that the spectrum of antibacterial
activity of Trimethoprim and sulfamethoxazole includes the common urinary tract pathogens with
the exception of Pseudomonas Aeruginosa. The following organisms are usually
susceptible: Escherichia Coli, Klebsiella species, Enterobacter species,
Morganella Morganii, Proteus Mirabilis, and indole-positive Proteus species
including Proteus Vulgaris. The usual spectrum of antimicrobial activity of
Trimethoprim and sulfamethoxazole includes the following bacterial pathogens isolated from
middle ear exudate and from bronchial secretions: Haemophilus Influenzae, including
ampicillin-resistant strains, and Streptococcus Pneumoniae. Shigella Flexneri
and Shigella Sonnei are usually susceptible. The usual spectrum also includes
enterotoxigenic strains of Escherichia Coli (ETEC) causing bacterial
gastroenteritis.  <p><pre>
 
            REPRESENTATIVE MINIMUM INHIBITORY CONCENTRATION VALUES FOR          
                          Trimethoprim and sulfamethoxazole-SUSCEPTIBLE ORGANISMS                
        
                                  (MIC--mcgm/mL)                                
------------------------------------------------------------------------------  
                       TMP              SMX            TMP/SMX (1:20)           
Bacteria              alone            alone         TMP            SMX         
------------------------------------------------------------------------------  
Escherichia Coli     0.05-1.5         1.0-245      0.05-0.5       0.95-9.5      
Escherichia Coli                                                                
  (enterotoxigenic  0.015-0.15      0.285-&gt;950    0.005-0.15     0.095-2.85     
 strains)                                                                       
Proteus species                                                                 
  (indole positive)   0.5-5.0        7.35-300      0.05-1.5       0.95-28.5     
Morganella Morganii   0.5-5.0        7.35-300      0.05-1.5       0.95-28.5     
Proteus Mirabilis     0.5-1.5        7.35-30       0.05-0.15      0.95-2.85     
Klebsiella species   0.15-5.0        2.45-245      0.05-1.5       0.95-28.5     
Enterobacter species 0.15-5.0        2.45-245      0.05-1.5       0.95-28.5     
Haemophilus          0.15-1.5        2.85-95      0.015-0.15     0.285-2.85     
 Influenzae                                                                     
Streptococcus        0.15-1.5        7.35-24.5     0.05-0.15      0.95-2.85     
 Pneumoniae                                                                     
Shigella Flexneri*  &lt;0.01-0.04      &lt;0.16-&gt;320   &lt;0.002-0.03      0.04-0.625    
Shigella Sonnei*     0.02-0.08      0.625-&gt;320    0.004-0.06      0.08-1.25     
------------------------------------------------------------------------------  
TMP = trimethoprim                                     SMX = sulfamethoxazole   
----------- 
 
* Rudoy RC, Nelson JD, Haltalin KC. Antimicrob Agents Chemother 5:439-443, May
1974; 
 
</pre><p>
 
The recommended quantitative disc susceptibility method may be used for
estimating the susceptibility of bacteria to Trimethoprim and sulfamethoxazole. (REF. 3,4) With
this procedure, a report from the laboratory of &quot;Susceptible to trimethoprim and
sulfamethoxazole&quot; indicates that the infection is likely to respond to therapy
with Trimethoprim and sulfamethoxazole. If the infection is confined to the urine, a report of
&quot;Intermediate susceptibility to trimethoprim and sulfamethoxazole&quot; also
indicates that the infection is likely to respond. A report of &quot;Resistant to
trimethoprim and sulfamethoxazole&quot; indicates that the infection is unlikely to
respond to therapy with Trimethoprim and sulfamethoxazole.  <p>
 
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
Urinary Tract Infections:  For the treatment of urinary tract infections due to 
susceptible strains of the following organisms: Escherichia Coli, Klebsiella
species, Enterobacter species, Morganella Morganii, Proteus Mirabilis and
Proteus Vulgaris. It is recommended that initial episodes of uncomplicated
urinary tract infections be treated with a single effective antibacterial agent 
rather than the combination.  <p>
 
Acute Otitis Media:  For the treatment of acute otitis media in children due to 
susceptible strains of Streptococcus Pneumoniae or Haemophilus Influenzae when
in the judgment of the physician Trimethoprim and sulfamethoxazole offers some advantage over
the use of other antimicrobial agents. To date, there are limited data on the safety of
repeated use of Trimethoprim and sulfamethoxazole in children under two years of age.
Trimethoprim and sulfamethoxazole is not
indicated for prophylactic or prolonged administration in otitis media at any
age.  
 <p>
Acute Exacerbations Of Chronic Bronchitis In Adults:  For the treatment of
acute exacerbations of chronic bronchitis due to susceptible strains of
Streptococcus Pneumoniae or Haemophilus Influenzae when in the judgment of the
physician Trimethoprim and sulfamethoxazole offers some advantage over the use of a single
antimicrobial
agent.  
 <p>
Shigellosis:  For the treatment of enteritis caused by susceptible strains of
Shigella Flexneri and Shigella Sonnei when antibacterial therapy is indicated.  
 <p>
Pneumocystis Carinii Pneumonia:  For the treatment of documented Pneumocystis
Carinii pneumonia.  
 <p>
Travelers' Diarrhea In Adults:  For the treatment of travelers' diarrhea due to 
susceptible strains of enterotoxigenic E. Coli.  
 <p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <p>
Hypersensitivity to trimethoprim or sulfonamides. Patients with documented
megaloblastic anemia due to folate deficiency. Pregnancy at term and during the 
nursing period, because sulfonamides pass the placenta and are excreted in the
milk and may cause kernicterus. Infants less than two months of age.  <p>
 
<a name="WARNINGS"></a><b>WARNINGS 
</b> <p>
FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE,
HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING STEVENS-JOHNSON SYNDROME,
TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS,
APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS.  
 <p>
TRIMETHOPRIM AND SULFAMETHOXAZOLE SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF SKIN RASH OR
ANY SIGN OF ADVERSE REACTION.  Clinical signs, such as rash, sore throat, fever,
arthralgia, cough, shortness of breath, pallor, purpura or jaundice may be
early indications of serious reactions. In rare instances a skin rash may be
followed by more severe reactions, such as Stevens-Johnson syndrome, toxic
epidermal necrolysis, hepatic necrosis or serious blood disorder. Complete
blood counts should be done frequently in patients receiving sulfonamides.  
 <p>
Trimethoprim and sulfamethoxazole SHOULD NOT BE USED IN THE TREATMENT OF STREPTOCOCCAL
PHARYNGITIS. 
<p>
Clinical studies have documented that patients with group A beta-hemolytic
streptococcal tonsillopharyngitis have a greater incidence of bacteriologic
failure when treated with Trimethoprim and sulfamethoxazole than do those patients treated with
penicillin, as evidenced by failure to eradicate this organism from the
tonsillopharyngeal area.  
 <p>
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
GENERAL:  Trimethoprim and sulfamethoxazole should be given with caution to patients with
impaired renal or hepatic function, to those with possible folate deficiency (E.G., the
elderly, chronic alcoholics, patients receiving anticonvulsant therapy,
patients with malabsorption syndrome, and patients in malnutrition states) and
to those with severe allergies or bronchial asthma. In glucose-6-phosphate
dehydrogenase deficient individuals, hemolysis may occur. This reaction is
frequently dose-related.  
   <p>
USE IN THE ELDERLY:  There may be an increased risk of severe adverse reactions 
in elderly patients, particularly when complicating conditions exist, E.G.,
impaired kidney and/or liver function, or concomitant use of other drugs.
Severe skin reactions, generalized bone marrow suppression (see WARNINGS and
ADVERSE REACTIONS sections) or a specific decrease in platelets (with or
without purpura) are the most frequently reported severe adverse reactions in
elderly patients. In those concurrently receiving certain diuretics, primarily
thiazides, an increased incidence of thrombocytopenia with purpura has been
reported. Appropriate dosage adjustments should be made for patients with
impaired kidney function (see DOSAGE AND ADMINISTRATION section).  
 <p>
USE IN THE TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA IN PATIENTS WITH
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS): AIDS patients may not tolerate or
respond to Trimethoprim and sulfamethoxazole in the same manner as non-AIDS patients. The
incidence of side effects, particularly rash, fever, leukopenia and elevated
aminotransferase (transaminase) values, with Trimethoprim and sulfamethoxazole therapy in AIDS
patients who are being treated for Pneumocystis Carinii pneumonia has been reported to
be greatly increased compared with the incidence normally associated with the
use of Trimethoprim and sulfamethoxazole in non-AIDS patients.  
 <p>
INFORMATION FOR PATIENTS:  Patients should be instructed to maintain an
adequate fluid intake in order to prevent crystalluria and stone formation.  
 <p>
LABORATORY TESTS:  Complete blood counts should be done frequently in patients
receiving Trimethoprim and sulfamethoxazole; if a significant reduction in the count of any
formed blood element is noted, Trimethoprim and sulfamethoxazole should be discontinued.
Urinalyses with careful microscopic examination and renal function tests should be performed
during therapy, particularly for those patients with impaired renal function.  
 <p>
DRUG INTERACTIONS:  In elderly patients concurrently receiving certain
diuretics, primarily thiazides, an increased incidence of thrombocytopenia with 
purpura has been reported.  
 <p>It has been reported that Trimethoprim and sulfamethoxazole may prolong the prothrombin time in
patients who are receiving the anticoagulant warfarin. This interaction should be kept
in mind when Trimethoprim and sulfamethoxazole is given to patients already on anticoagulant
therapy, and the coagulation time should be reassessed.  
 <p>
Trimethoprim and sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. Trimethoprim
and sulfamethoxazole, given at a
common clinical dosage, increased the phenytoin half-life by 39% and decreased
the phenytoin metabolic clearance rate by 27%. When administering these drugs
concurrently, one should be alert for possible excessive phenytoin effect.  
 <p>
Sulfonamides can also displace methotrexate from plasma protein binding sites,
thus increasing free methotrexate concentrations.  
 <p>
DRUG/LABORATORY TEST INTERACTIONS: Trimethoprim and sulfamethoxazole, specifically the
trimethoprim component, can interfere with a serum methotrexate assay as determined by the
competitive binding protein technique (CBPA) when a bacterial dihydrofolate
reductase is used as the binding protein. No interference occurs, however, if
methotrexate is measured by a radioimmunoassay (RIA).  
 <p>
The presence of trimethoprim and sulfamethoxazole may also interfere with the
Jaffe alkaline picrate reaction assay for creatinine, resulting in
overestimations of about 10% in the range of normal values.  
 <p>
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY:  
 <p>
Carcinogenesis: Long-term studies in animals to evaluate carcinogenic potential 
have not been conducted with Trimethoprim and sulfamethoxazole.  
 <p>
Mutagenesis: Bacterial mutagenic studies have not been performed with
sulfamethoxazole and trimethoprim in combination. Trimethoprim was demonstrated 
to be nonmutagenic in the Ames assay. No chromosomal damage was observed in
human leukocytes In Vitro with sulfamethoxazole and trimethoprim alone or in
combination; the concentrations used exceeded blood levels of these compounds
following therapy with Trimethoprim and sulfamethoxazole. Observations of leukocytes obtained
from
patients treated with Trimethoprim and sulfamethoxazole revealed no chromosomal abnormalities.  
 <p>
Impairment Of Fertility: No adverse effects on fertility or general
reproductive performance were observed in rats given oral dosages as high as 70 
mg/kg/day trimethoprim plus 350 mg/kg/day sulfamethoxazole.  
 <p>
PREGNANCY: Teratogenic Effects: Pregnancy Category C. In rats, oral doses of
533 mg/kg sulfamethoxazole or 200 mg/kg trimethoprim produced teratologic
effects manifested mainly as cleft palates.  
 <p>
The highest dose which did not cause cleft palates in rats was 512 mg/kg
sulfamethoxazole or 192 mg/kg trimethoprim when administered separately. In two 
studies in rats, no teratology was observed when 512 mg/kg of sulfamethoxazole
was used in combination with 128 mg/kg of trimethoprim. In one study, however,
cleft palates were observed in one litter out of 9 when 355 mg/kg of
sulfamethoxazole was used in combination with 88 mg/kg of trimethoprim.  
 <p>
In some rabbit studies, an overall increase in fetal loss (dead and resorbed
and malformed conceptuses) was associated with doses of trimethoprim 6 times
the human therapeutic dose.  
 <p>
While there are no large, well-controlled studies on the use of trimethoprim
and sulfamethoxazole in pregnant women, Brumfitt and Pursell, (REF. 5) in a
retrospective study, reported the outcome of 186 pregnancies during which the
mother received either placebo or trimethoprim and sulfamethoxazole. The
incidence of congenital abnormalities was 4.5% (3 of 66) in those who received
placebo and 3.3% (4 of 120) in those receiving trimethoprim and
sulfamethoxazole. There were no abnormalities in the 10 children whose mothers
received the drug during the first trimester. In a separate survey, Brumfitt
and Pursell also found no congenital abnormalities in 35 children whose mothers 
had received oral trimethoprim and sulfamethoxazole at the time of conception
or shortly thereafter.  
 <p>
Because trimethoprim and sulfamethoxazole may interfere with folic acid
metabolism, Trimethoprim and sulfamethoxazole should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus.  
 <p>
NONTERATOGENIC EFFECTS:  See CONTRAINDICATIONS section.  
 <p>
NURSING MOTHERS: See CONTRAINDICATIONS section.  
 <p>PEDIATRIC USE: Trimethoprim and sulfamethoxazole is not recommended for infants younger than two
months of age (see INDICATIONS and CONTRAINDICATIONS sections).  
 <p>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <p>
In elderly patients concurrently receiving certain diuretics, primarily
thiazides, an increased incidence of thrombocytopenia with purpura has been
reported.  
 <p>
It has been reported that Trimethoprim and sulfamethoxazole may prolong the prothrombin time in
patients who are receiving the anticoagulant warfarin. This interaction should be kept
in mind when Trimethoprim and sulfamethoxazole is given to patients already on anticoagulant
therapy, and the coagulation time should be reassessed.  
 <p>
Trimethoprim and sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. Trimethoprim
and sulfamethoxazole, given at a common clinical dosage, increased the phenytoin half-life by
39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs
concurrently, one should be alert for possible excessive phenytoin effect.  
 <p>
Sulfonamides can also displace methotrexate from plasma protein binding sites,
thus increasing free methotrexate concentrations.  
 <p>
(See also PRECAUTIONS) 
 <p>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
The most common adverse effects are gastrointestinal disturbances (nausea,
vomiting, anorexia) and allergic skin reactions (such as rash and urticaria). 
FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE,
HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING STEVENS-JOHNSON SYNDROME,
TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS,
APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS (SEE WARNINGS SECTION).  
 <p>
Hematologic: Agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia,
neutropenia, hemolytic anemia, megaloblastic anemia, hypoprothrombinemia,
methemoglobinemia, eosinophilia.  
 <p>
Allergic Reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis,
anaphylaxis, allergic myocarditis, erythema multiforme, exfoliative dermatitis, 
angioedema, drug fever, chills, Henoch-Schoenlein purpura, serum sickness-like
syndrome, generalized allergic reactions, generalized skin eruptions,
photosensitivity, conjunctival and scleral injection, pruritus, urticaria and
rash. In addition, periarteritis nodosa and systemic lupus erythematosus have
been reported.  
 <p>
Gastrointestinal: Hepatitis (including cholestatic jaundice and hepatic
necrosis), elevation of serum transaminase and bilirubin, pseudomembranous
enterocolitis, pancreatitis, stomatitis, glossitis, nausea, emesis, abdominal
pain, diarrhea, anorexia.  
 <p>
Genitourinary: Renal failure, interstitial nephritis, BUN and serum creatinine
elevation, toxic nephrosis with oliguria and anuria, and crystalluria.  
 <p>Neurologic: Aseptic meningitis, convulsions, peripheral neuritis, ataxia,
vertigo, tinnitus, headache.  
 <p>
Psychiatric: Hallucinations, depression, apathy, nervousness.  
 <p>Endocrine: The sulfonamides bear certain chemical similarities to some
goitrogens, diuretics (acetazolamide and the thiazides) and oral hypoglycemic
agents. Cross-sensitivity may exist with these agents. Diuresis and
hypoglycemia have occurred rarely in patients receiving sulfonamides.  
 <p>
Musculoskeletal: Arthralgia and myalgia.  
 <p>
Respiratory: Pulmonary infiltrates.  
 <p>
Miscellaneous: Weakness, fatigue, insomnia.  
 <p>
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <p>
ACUTE: The amount of a single dose of Trimethoprim and sulfamethoxazole that is either
associated with symptoms of overdosage or is likely to be life-threatening has not been
reported. Signs and symptoms of overdosage reported with sulfonamides include
anorexia, colic, nausea, vomiting, dizziness, headache, drowsiness and
unconsciousness. Pyrexia, hematuria and crystalluria may be noted. Blood
dyscrasias and jaundice are potential late manifestations of overdosage.  
 <p>
Signs of acute overdosage with trimethoprim include nausea, vomiting, dizziness 
headache, mental depression, confusion and bone marrow depression.  
 <p>
General principles of treatment include the institution of gastric lavage or
emesis, forcing oral fluids, and the administration of intravenous fluids if
urine output is low and renal function is normal. Acidification of the urine
will increase renal elimination of trimethoprim. The patient should be
monitored with blood counts and appropriate blood chemistries, including
electrolytes. If a significant blood dyscrasia or jaundice occurs, specific
therapy should be instituted for these complications. Peritoneal dialysis is
not effective and hemodialysis is only moderately effective in eliminating
trimethoprim and sulfamethoxazole.  
 <p>
CHRONIC:  Use of Trimethoprim and sulfamethoxazole at high doses and/or for extended periods of
time may cause bone marrow depression manifested as thrombocytopenia, leukopenia and/or
megaloblastic anemia. If signs of bone marrow depression occur, the patient
should be given leucovorin 5 to 15 mg daily until normal hematopoiesis is
restored.  
 <p>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
NOT RECOMMENDED FOR USE IN INFANTS LESS THAN TWO MONTHS OF AGE.  
 <p>
Urinary Tract Infections And Shigellosis In Adults And Children And Acute
Otitis Media In Children:  
 <p>
Adults:  The usual adult dosage in the treatment of urinary tract infections is 
one Trimethoprim and sulfamethoxazole DS (double strength) tablet, two Trimethoprim and
sulfamethoxazole tablets or four teaspoonfuls (20 mL) of Trimethoprim and sulfamethoxazole
Pediatric Suspension every 12 hours for 10 to 14 days. An identical daily dosage is used for 5
days in the treatment of shigellosis.  
 <p>
Children:  The recommended dose for children with urinary tract infections or
acute otitis media is 8 mg/kg trimethoprim and 40 mg/kg sulfamethoxazole per 24 
hours, given in two divided doses every 12 hours for 10 days. An identical
daily dosage is used for 5 days in the treatment of shigellosis. The following
table is a guideline for the attainment of this dosage:  
 <p><pre>
Children Two Months Of Age Or Older:                                            
------------------------------------------------------------------------------  
     Weight                          Dose--every 12 hours                       
------------------------------------------------------------------------------  
lb          kg               Teaspoonfuls               Tablets                 
------------------------------------------------------------------------------  
22          10             1 teasp.  (5 mL)                --                   
44          20             2 teasp. (10 mL)                1 tablet             
66          30             3 teasp. (15 mL)            1 1/2 tablets            
88          40             4 teasp. (20 mL)                2 tablets or         
                                                        1 DS tablet             
------------------------------------------------------------------------------  
For Patients With Impaired Renal Function: When renal function is impaired, a
reduced dosage should be employed using the following table:  
 
------------------------------------------------------------------------------  
           Creatinine                                                           
           Clearance                            Recommended                     
            (mL/min)                           Dosage Regimen                   
------------------------------------------------------------------------------  
            Above 30                       Usual standard regimen               
             15-30                         1/2 the usual regimen                
            Below 15                        Use not recommended                 
------------------------------------------------------------------------------  </pre><p>
Acute Exacerbations Of Chronic Bronchitis In Adults:  
 <p>
The usual adult dosage in the treatment of acute exacerbations of chronic
bronchitis is one Trimethoprim and sulfamethoxazole DS (double strength) tablet, two
Trimethoprim and sulfamethoxazole tablets or four teaspoonfuls (20 mL) of Trimethoprim and
sulfamethoxazole Pediatric Suspension every 12 hours for 14 days.  
 <p>
Pneumocystis Carinii Pneumonia:  
 <p>
The recommended dosage for patients with documented Pneumocystis Carinii
pneumonia is 20 mg/kg trimethoprim and 100 mg/kg sulfamethoxazole per 24 hours
given in equally divided doses every 6 hours for 14 days. The following table
is a guideline for the attainment of this dosage in children:  <pre>
 
------------------------------------------------------------------------------  
     Weight                            Dose--every six hours                    
------------------------------------------------------------------------------  
lb          kg               Teaspoonfuls               Tablets                 
------------------------------------------------------------------------------  
18          8              1 teasp.  (5 mL)                --                   
35          16             2 teasp. (10 mL)                1 tablet             
53          24             3 teasp. (15 mL)            1 1/2 tablets            
70          32             4 teasp. (20 mL)                2 tablets or         
                                                        1 DS tablet             
------------------------------------------------------------------------------  </pre><p>
Travelers' Diarrhea In Adults:  
 <p>
For the treatment of travelers' diarrhea, the usual adult dosage is one Trimethoprim and
sulfamethoxazole DS (double strength) tablet; two Trimethoprim and sulfamethoxazole tablets or
four teaspoonfuls (20 mL) of Pediatric Suspension every 12 hours for 5 days.  
 <p>
REFERENCES 
 <p>
1. Kremers P, Duvivier J, Heusghem C. Pharmacokinetic Studies of Co-Trimoxazole 
in Man after Single and Repeated Doses. J Clin Pharmacol 14:112-117, Feb-Mar
1974. 2. Kaplan SA, Et Al. Pharmacokinetic Profile of Trimethoprim-
Sulfamethoxazole in Man. J Infect Dis 128 (Suppl): S547-S555, Nov 1973. 3. 
Federal Register 37: 20527-20529, 1972. 4. Bauer AW, Kirby WMM, Sherris JC,
Turck M: Antibiotic Susceptibility Testing by a Standardized Single Disk
Method.  Am J Clin Path 45:493-496, Apr 1966. 5. Brumfitt W, Pursell R: 
Trimethoprim/Sulfamethoxazole in the Treatment of Bacteriuria in Women. J
Infect Dis 128 (Suppl): S657-S663, Nov 1973.  
 
<p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-52</DOCNO>
<DOCOLDNO>IA018-000200-B041-238</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/av.htm 206.86.175.201 19970106231110 text/html 3270
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:04:56 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3088
Last-modified: Fri, 20 Dec 1996 18:08:09 GMT
</DOCHDR>
 <html>
<head>
<title>
RxList - The Internet Drug Index
</title>

</head>



<BODY Bgcolor="#ffffff">



<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi">
<img src="rx.gif" alt="click to search RxList" vspace=2 border=0
height=125 width=125 align=left>
</a><a href="http://www.reutershealth.com/ihw/reviews/rxint.html">                  
<img src="hi_rec.gif" height=38 width=25 align=right
border=0 alt="Reuter's review"></a>
</p></center>
<center>
<p><b><font SIZE=+3>RxList
<br>The Internet Drug Index </font></center></b></p>

<pre>
</pre><center>
<form method=post action="http://www.rxlist.com/cgi/rxlist.cgi">



<input name=drug size=25>

<input type=submit value="Search for Drug Name">

</dl></form><a href="http://www.pointcom.com">
<img src="5per.gif" alt="top 5%" vspace=1 border=0 height=65 width=65
align=left alt="Top5%">
</a>

<a href="http://www.arachnid.co.uk/award/health.html"><img src="med60.gif"        
align=right border=0 alt="Gold Medal"></a>
<h2><a href="http://www.rxlist.com/top200.htm">The Top 200
</a></h2>
<h5>[ <a href="http://www.rxlist.com/interact.htm"> Actions/Interactions ]</a>
| <a href="http://www.rxlist.com/rxlinks.htm">[ Links ]</a> | 
<a href="http://www.rxlist.com/about.htm">[ FAQ ]</a><br>[ <a href="http://www.rxlist.com/tempstat.htm">WWW Stats ]</a>  
[<a href="http://www.rxlist.com/stats.htm"> Stats ]</a> [<a href="#mini"> Mini-Survey ]</a><br>
<hr width=40%>
<a href="http://www.netmedicine.com"><img src="nm.gif"></a>
<hr></center>
<h2 align=center>
 
<a name="mini"></a><a href="http://www.rxlist.com/stats.htm#Results">RxList Wants to Know!</a></h2>
<form method="POST" action="formmail.cgi">
<input type=hidden name="recipient" value="survey@rxlist.com"><input type=hidden name="subject" value="Survey">
<input type=hidden name="redirect" value="http://www.rxlist.com">
<pre><ul><font size=4>
<b>Prescriber (i.e. MD, DDS,etc.)</b> <input name="pro" type="radio"
value="md"></pre>
</font><font size=4>

<pre><b>Pharmacist</b>                     <input name="pro" type="radio"
value="ph"></pre>
</font><font size=4>

<pre><b>Nurse</b>                          <input name="pro" type="radio"
value="rn"></pre>
</font><font size=4>

<pre><b>Other Health Professional</b>      <input name="pro" type="radio"
value="hp"></pre>
</font><font size=4>
<pre><b>Not a Health Professional</b>      <input name="pro" type="radio"
value="con"></pre></font>
</ul>
<center>
<p><b>Sex: <select NAME="Sex"><option>Male   <option>Female</select>   Age: <select NAME="Age"><option>Under 20<option>20-29<option>30-39<option>40-49<option>50-59<option>Over
60</select> </b><input type="submit" value="Submit Mini-Survey">
<hr><hr><a href="mailto:rx@rxlist.com">
<img src="mbox.gif" height=45 width=45 border=0 alt="e-mail"></a><br> <a 
href="mailto:rx@rxlist.com"><h4> E-mail Comments, 
Suggestions, & Corrections to </a><br>
 rx@rxlist.com </h4>
<h4>(707)746-8754 - Advertising, Press</h4>
<hr>
<hr>
<p>
<h5>
copyright 1996 - Neil Sandow, Pharm.D.
</h5></center>
<font COLOR="#FFFFFF">
<!--#counter file="rxcounter"--></font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-53</DOCNO>
<DOCOLDNO>IA018-000200-B043-85</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/mirtaz.htm 206.86.175.201 19970106231721 text/html 43338
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:11:05 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 43155
Last-modified: Wed, 18 Dec 1996 23:36:14 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
   <TITLE>Mirtazapine - RxList Generic Information</TITLE>
   <META NAME="keywords" CONTENT="Remeron">
   <META NAME="GENERATOR" CONTENT="Mozilla/3.01Gold (Win95; I) [Netscape]">
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000EE" VLINK="#551A8B" ALINK="#FF0000">

<CENTER><P><A HREF="http://www.rxlist.com/cgi/rxlist.cgi"><IMG SRC="rx.gif" BORDER=0 HEIGHT=125 WIDTH=125></A></P></CENTER>

<H1 ALIGN=CENTER>Mirtazapine</H1>

<P>
<HR><FONT COLOR="#0000FF">[<A HREF="#DESCRIPTION">description</A>] [<A HREF="#ACTIONS/CLINICAL PHARMACOLOGY">action</A>]
[<A HREF="#INDICATIONS AND USAGE">use</A>] [<A HREF="#CONTRAINDICATIONS">contra</A>]
[<A HREF="#WARNINGS">warn!</A>] [<A HREF="#PRECAUTIONS">caution</A>] [<A HREF="#DRUG INTERACTIONS">drug-drug</A>]
[<A HREF="#ADVERSE REACTIONS">side effects</A>] [<A HREF="#OVERDOSAGE">toxicity</A>]
[<A HREF="#DOSAGE AND ADMINISTRATION">dosing</A>] </FONT></P>

<P><B>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</B></P>

<P>
<HR width="100%"></P>

<P><A NAME="DESCRIPTION"></A><B>DESCRIPTION </B></P>

<P>Mirtazapine is an antidepressant for oral administration. It has a tetracyclic
chemical structure unrelated to selective serotonin reuptake inhibitors,
tricyclics or monoamine oxidase inhibitors (MAOI). Mirtazapine belongs
to the piperazino-azepine group of compounds. It is designated 1,2,3,4,10,14b-hexahydro-2-methylpyrazino
(2,1-a)pyrido (2,3-c)benzazepine and has the empirical formula of C17H19N3.
Its molecular weight is 265.36. Mirtazapine is a white to creamy white
crystalline powder which is slightly soluble in water. </P>

<P><A NAME="ACTIONS/CLINICAL PHARMACOLOGY"></A><B>ACTIONS/CLINICAL PHARMACOLOGY
</B></P>

<P>PHARMACODYNAMICS </P>

<P>The mechanism of action of Mirtazapine , as with other antidepressants,
is unknown. </P>

<P>Evidence gathered in preclinical studies suggests that mirtazapine enhances
central noradrenergic and serotonergic activity. These studies have shown
that mirtazapine acts as an antagonist at central presynaptic alpha2 adrenergic
inhibitory autoreceptors and heteroreceptors, an action that is postulated
to result in an increase in central noradrenergic and serotonergic activity.
</P>

<P>Mirtazapine is a potent antagonist of 5-HT2 and 5-HT3 receptors. Mirtazapine
has no significant affinity for the 5-HT1A and 5-HT1B receptors. </P>

<P>Mirtazapine is a potent antagonist of histamine (H1) receptors, a property
that may explain its prominent sedative effects. </P>

<P>Mirtazapine is a moderate peripheral alpha1 adrenergic antagonist, a
property that may explain the occasional orthostatic hypotension reported
in association with its use. </P>

<P>Mirtazapine is a moderate antagonist at muscarinic receptors, a property
that may explain the relatively low incidence of anticholinergic side effects
associated with its use. </P>

<P>PHARMACOKINETICS </P>

<P>Mirtazapine is rapidly and completely absorbed following oral administration
and has a half-life of about 20-40 hours. Peak plasma concentrations are
reached within about 2 hours following an oral dose. The presence of food
in the stomach has a minimal effect on both the rate and extent of absorption
and does not require a dosage adjustment. </P>

<P>Mirtazapine is extensively metabolized after oral administration. Major
pathways of biotransformation are demethylation and hydroxylation followed
by glucuronide conjugation. In vitro data from human liver microsomes indicate
that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy
metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible
for the formation of the N-desmethyl and N-oxide metabolite. Mirtazapine
has an absolute bioavailability of about 50%. It is eliminated predominantly
via urine (75%) with 15% in feces. Several unconjugated metabolites possess
pharmacological activity but are present in the plasma at very low levels.
The (-) enantiomer has an elimination half-life that is approximately twice
as long as the (+) enantiomer and therefore achieves plasma levels that
are about three times as high as that of the (+) enantiomer. </P>

<P>Plasma levels are linearly related to dose over a dose range of 15 to
80 mg. The mean elimination half-life of mirtazapine after oral administration
ranges from approximately 20-40 hours across age and gender subgroups,
with females of all ages exhibiting significantly longer elimination half-lives
than males (mean half-life of 37 hours for females Vs. 26 hours for males).
Steady state plasma levels of mirtazapine are attained within 5 days, with
about 50% accumulation (accumulation ratio = 1.5). </P>

<P>Mirtazapine is approximately 85% bound to plasma proteins over a concentration
range of 0.01 to 10 &micro;/mL. </P>

<P>POPULATION SUBGROUPS </P>

<P>Liver Disease--Following a single 15 mg oral dose of mirtazapine, the
oral clearance of mirtazapine was decreased by approximately 30% in hepatically
impaired patients compared to subjects with normal hepatic function. Caution
is indicated in administering Mirtazapine to patients with compromised
hepatic function (see PRECAUTIONS and DOSAGE AND ADMINISTRATION). </P>

<P>Renal Disease--Following a single 15 mg oral dose of mirtazapine, patients
with moderate (glomerular filtration rate (GFR) = 11-39 mL/min/1.73 M(squared))
and severe (GFR &lt;10 mL/min/1.73 M(squared)) renal impairment had reductions
in mean oral clearance of mirtazapine of about 30% and 50%, respectively,
compared to normal subjects. Caution is indicated in administering Mirtazapine
to patients with compromised renal function (see PRECAUTIONS and DOSAGE
AND ADMINISTRATION). </P>

<P>Elderly Patients--Following oral administration of mirtazapine 20 mg/day
for 7 days to subjects of varying ages (range, 25-74), oral clearance of
mirtazapine was reduced in the elderly compared to the younger subjects.
The differences were most striking in males, with a 40% lower clearance
in elderly males compared to younger males, while the clearance in elderly
females was only 10% lower compared to younger females. Caution is indicated
in administering Mirtazapine to elderly patients (see PRECAUTIONS and DOSAGE
AND ADMINISTRATION). </P>

<P>CLINICAL TRIALS SHOWING EFFECTIVENESS </P>

<P>The efficacy of Mirtazapine as a treatment for depression was established
in four placebo-controlled, 6-week trials in adult outpatients meeting
DSM-III criteria for major depression. Patients were titrated with mirtazapine
from a dose range of 5 mg up to 35 mg/day. Overall, these studies demonstrated
mirtazapine to be superior to placebo on at least three of the following
four measures: 21-Item Hamilton Depression Rating Scale (HDRS) total score;
HDRS Depressed Mood Item; CGI Severity score; and Montgomery and Asberg
Depression Rating Scale (MADRS). Superiority of mirtazapine over placebo
was also found for certain factors of the HDRS including anxiety/somatization
factor and sleep disturbance factor. The mean mirtazapine dose for patients
who completed these four studies ranged from 21 to 32 mg/day. A fifth study
of similar design utilized a higher dose (up to 50 mg) per day and also
showed effectiveness. </P>

<P>Examination of age and gender subsets of the population did not reveal
any differential responsiveness on the basis of these subgroupings. </P>

<P><A NAME="INDICATIONS AND USAGE"></A><B>INDICATIONS AND USAGE </B></P>

<P>Mirtazapine Tablets are indicated for the treatment of depression. </P>

<P>The efficacy of Mirtazapine in the treatment of depression was established
in six week controlled trials of outpatients whose diagnoses corresponded
most closely to the Diagnostic and Statistical Manual of Mental Disorders-3rd
edition (DSM-III) category of major depressive disorder (see ACTIONS/CLINICAL
PHARMACOLOGY). </P>

<P>A major depressive episode (DSM-IV) implies a prominent and relatively
persistent (nearly every day for at least 2 weeks) depressed or dysphoric
mood that usually interferes with daily functioning, and includes at least
five of the following nine symptoms: depressed mood, loss of interest in
usual activities, significant change in weight and/or appetite, insomnia
or hypersomnia, psychomotor agitation or retardation, increased fatigue,
feelings of guilt or worthlessness, slowed thinking or impaired concentration,
a suicide attempt or suicidal ideation. </P>

<P>The antidepressant effectiveness of Mirtazapine in hospitalized depressed
patients has not been adequately studied. </P>

<P>The effectiveness of Mirtazapine in long-term use, that is, for more
than 6 weeks, has not been systematically evaluated in controlled trials.
Therefore, the physician who elects to use Mirtazapine for extended periods
should periodically evaluate the long-term usefulness of the drug for the
individual patient. </P>

<P><A NAME="CONTRAINDICATIONS"></A><B>CONTRAINDICATIONS </B></P>

<P>Mirtazapine Tablets are contraindicated in patients with a known hypersensitivity
to mirtazapine. </P>

<P><A NAME="WARNINGS"></A><B>WARNINGS </B></P>

<P>AGRANULOCYTOSIS </P>

<P>IN PREMARKETING CLINICAL TRIALS, TWO (ONE WITH SJOGREN'S SYNDROME) OUT
OF 2,796 PATIENTS TREATED WITH Mirtazapine TABLETS DEVELOPED AGRANULOCYTOSIS
(ABSOLUTE NEUTROPHIL COUNT (ANC) &lt;500/MM(CUBED) WITH ASSOCIATED SIGNS
AND SYMPTOMS, E.G., FEVER, INFECTION, ETC.) AND A THIRD PATIENT DEVELOPED
SEVERE NEUTROPENIA (ANC &lt;500/MM(CUBED) WITHOUT ANY ASSOCIATED SYMPTOMS).
FOR THESE THREE PATIENTS, ONSET OF SEVERE NEUTROPENIA WAS DETECTED ON DAYS
61, 9, AND 14 OF TREATMENT, RESPECTIVELY. ALL THREE PATIENTS RECOVERED
AFTER Mirtazapine WAS STOPPED. THESE THREE CASES YIELD A CRUDE INCIDENCE
OF SEVERE NEUTROPENIA (WITH OR WITHOUT ASSOCIATED INFECTION) OF APPROXIMATELY
1.1 PER THOUSAND PATIENTS EXPOSED, WITH A VERY WIDE 95% CONFIDENCE INTERVAL,
I.E., 2.2 CASES PER 10,000 TO 3.1 CASES PER 1000. IF A PATIENT DEVELOPS
A SORE THROAT, FEVER, STOMATITIS OR OTHER SIGNS OF INFECTION, ALONG WITH
A LOW WBC COUNT, TREATMENT WITH Mirtazapine SHOULD BE DISCONTINUED AND
THE PATIENT SHOULD BE CLOSELY MONITORED. </P>

<P>MAO INHIBITORS </P>

<P>IN PATIENTS RECEIVING OTHER ANTIDEPRESSANTS IN COMBINATION WITH A MONOAMINE
OXIDASE INHIBITOR (MAOI) AND IN PATIENTS WHO HAVE RECENTLY DISCONTINUED
AN ANTIDEPRESSANT DRUG AND THEN ARE STARTED ON AN MAOI, THERE HAVE BEEN
REPORTS OF SERIOUS, AND SOMETIMES FATAL, REACTIONS, E.G., INCLUDING NAUSEA,
VOMITING, FLUSHING, DIZZINESS, TREMOR, MYOCLONUS, RIGIDITY, DIAPHORESIS,
HYPERTHERMIA, AUTONOMIC INSTABILITY WITH RAPID FLUCTUATIONS OF VITAL SIGNS,
SEIZURES, AND MENTAL STATUS CHANGES RANGING FROM AGITATION TO COMA. ALTHOUGH
THERE ARE NO HUMAN DATA PERTINENT TO SUCH AN INTERACTION WITH Mirtazapine
, IT IS RECOMMENDED THAT Mirtazapine NOT BE USED IN COMBINATION WITH AN
MAOI, OR WITHIN 14 DAYS OF INITIATING OR DISCONTINUING THERAPY WITH AN
MAOI. </P>

<P><A NAME="PRECAUTIONS"></A><B>PRECAUTIONS </B></P>

<P>GENERAL </P>

<P>SOMNOLENCE </P>

<P>In U.S. controlled studies, somnolence was reported in 54% of patients
treated with Mirtazapine , compared to 18% for placebo and 60% for amitriptyline.
In these studies, somnolence resulted in discontinuation for 10.4% of Mirtazapine
treated patients, compared to 2.2% for placebo. It is unclear whether or
not tolerance develops to the somnolent effects of Mirtazapine. Because
of Mirtazapine's potentially significant effects on impairment of performance,
patients should be cautioned about engaging in activities requiring alertness
until they have been able to assess the drug's effect on their own psychomotor
performance (see Information for Patients). </P>

<P>DIZZINESS </P>

<P>In U.S. controlled studies, dizziness was reported in 7% of patients
treated with Mirtazapine , compared to 3% for placebo and 14% for amitriptyline.
It is unclear whether or not tolerance develops to the dizziness observed
in association with the use of Mirtazapine. </P>

<P>INCREASED APPETITE/WEIGHT GAIN </P>

<P>In U.S. controlled studies, appetite increase was reported in 17% of
patients treated with Mirtazapine , compared to 2% for placebo and 6% for
amitriptyline. In these same trials, weight gain of &gt;/=7% of body weight
was reported in 7.5% of patients treated with mirtazapine, compared to
0% for placebo and 5.9% for amitriptyline. In a pool of premarketing U.S.
studies, including many patients in long-term, open label treatment, 8%
of patients receiving Mirtazapine discontinued for weight gain. </P>

<P>CHOLESTEROL/TRIGLYCERIDES </P>

<P>In U.S. controlled studies, nonfasting cholesterol increases to &gt;/=20%
above the upper limits of normal were observed in 15% of patients treated
with Mirtazapine , compared to 7% for placebo and 8% for amitriptyline.
In these same studies, nonfasting triglyceride increases to &gt;/=500 mg/dL
were observed in 6% of patients treated with mirtazapine, compared to 3%
for placebo and 3% for amitriptyline. </P>

<P>TRANSAMINASE ELEVATIONS </P>

<P>Clinically significant ALT (SGPT) elevations (&gt;/=3 times the upper
limit of the normal range) were observed in 2.0% (8/424) of patients exposed
to Mirtazapine in a pool of short-term U.S. controlled trials, compared
to 0.3% (1/328) of placebo patients and 2.0% (3/181) of amitriptyline patients.
Most of these patients with ALT increases did not develop signs or symptoms
associated with compromised liver function. While some patients were discontinued
for the ALT increases, in other cases, the enzyme levels returned to normal
despite continued Mirtazapine treatment. Mirtazapine should be used with
caution in patients with impaired hepatic function (see Pharmacokinetics
section of ACTIONS/CLINICAL PHARMACOLOGY, and DOSAGE AND ADMINISTRATION).
</P>

<P>ACTIVATION OF MANIA/HYPOMANIA </P>

<P>Mania/hypomania occurred in approximately 0.2% (3/1,299 patients) of
Mirtazapine treated patients in U.S. studies. Although the incidence of
mania/hypomania was very low during treatment with mirtazapine, it should
be used carefully in patients with a history of mania/hypomania. </P>

<P>SEIZURE </P>

<P>In premarketing clinical trials only one seizure was reported among
the 2,796 U.S. and non-U.S. patients treated with Mirtazapine . However,
no controlled studies have been carried out in patients with a history
of seizures. Therefore, care should be exercised when mirtazapine is used
in these patients. </P>

<P>SUICIDE </P>

<P>Suicidal ideation is inherent in depression and may persist until significant
remission occurs. As with any patient receiving antidepressants, high-risk
patients should be closely supervised during initial drug therapy. Prescriptions
of Mirtazapine should be written for the smallest quantity consistent with
good patient management, in order to reduce the risk of overdose. </P>

<P>USE IN PATIENTS WITH CONCOMITANT ILLNESS </P>

<P>Clinical experience with Mirtazapine in patients with concomitant systemic
illness is limited. Accordingly, care is advisable in prescribing mirtazapine
for patients with diseases or conditions that affect metabolism or hemodynamic
responses. </P>

<P>Mirtazapine has not been systematically evaluated or used to any appreciable
extent in patients with a recent history of myocardial infarction or other
significant heart disease. Mirtazapine was not associated with clinically
significant ECG abnormalities in U.S. and non-U.S. placebo controlled trials.
Mirtazapine was associated with significant orthostatic hypotension in
early clinical pharmacology trials with normal volunteers. Orthostatic
hypotension was infrequently observed in clinical trials with depressed
patients. Mirtazapine should be used with caution in patients with known
cardiovascular or cerebrovascular disease that could be exacerbated by
hypotension (history of myocardial infarction, angina, or ischemic stroke)
and conditions that would predispose patients to hypotension (dehydration,
hypovolemia, and treatment with antihypertensive medication). </P>

<P>Mirtazapine clearance is decreased in patients with moderate (glomerular
filtration rate (GFR) = 11-39 mL/min/1.73 M(squared)) and severe (GFR &lt;10
mL/min/1.73 M(squared)) renal impairment, and also in patients with hepatic
impairment (see Pharmacokinetics subsection of ACTIONS/CLINICAL PHARMACOLOGY).
Caution is indicated in administering Mirtazapine to such patients (see
DOSAGE AND ADMINISTRATION). </P>

<P>INFORMATION FOR PATIENTS </P>

<P>Physicians are advised to discuss the following issues with patients
for whom they prescribe Mirtazapine : </P>

<P>AGRANULOCYTOSIS </P>

<P>Patients who are to receive Mirtazapine should be warned about the risk
of developing agranulocytosis. Patients should be advised to contact their
physician if they experience any indication of infection such as fever,
chills, sore throat, mucous membrane ulceration or other possible signs
of infection. Particular attention should be paid to any flu-like complaints
or other symptoms that might suggest infection. </P>

<P>INTERFERENCE WITH COGNITIVE AND MOTOR PERFORMANCE </P>

<P>Mirtazapine may impair judgement, thinking, and, particularly, motor
skills, because of its prominent sedative effect. The drowsiness associated
with mirtazapine use may impair a patient's ability to drive, use machines
or perform tasks that require alertness. Thus, patients should be cautioned
about engaging in hazardous activities until they are reasonably certain
that Mirtazapine therapy does not adversely affect their ability to engage
in such activities. </P>

<P>COMPLETING COURSE OF THERAPY </P>

<P>While patients may notice improvement with Mirtazapine therapy in 1
to 4 weeks, they should be advised to continue therapy as directed. </P>

<P>CONCOMITANT MEDICATION </P>

<P>Patients should be advised to inform their physician if they are taking,
or intend to take, any prescription or over-the-counter drugs since there
is a potential for Mirtazapine to interact with other drugs. </P>

<P>ALCOHOL </P>

<P>The impairment of cognitive and motor skills produced by Mirtazapine
has been shown to be additive with those produced by alcohol. Accordingly,
patients should be advised to avoid alcohol while taking mirtazapine. </P>

<P>PREGNANCY </P>

<P>Patients should be advised to notify their physician if they become
pregnant or intend to become pregnant during Mirtazapine therapy. </P>

<P>NURSING </P>

<P>Patients should be advised to notify their physician if they are breast-feeding
an infant. </P>

<P>LABORATORY TESTS </P>

<P>There are no routine laboratory tests recommended. </P>

<P>DRUG INTERACTIONS </P>

<P>As with other drugs, the potential for interaction by a variety of mechanisms
(e.g., pharmacodynamic, pharmacokinetic inhibition or enhancement, etc.)
is a possibility (see ACTIONS/CLINICAL PHARMACOLOGY). </P>

<P>DRUGS AFFECTING HEPATIC METABOLISM </P>

<P>The metabolism and pharmacokinetics of Mirtazapine may be affected by
the induction or inhibition of drug-metabolizing enzymes. </P>

<P>DRUGS THAT ARE METABOLIZED BY AND/OR INHIBIT CYTOCHROME P450 ENZYMES
</P>

<P>Many drugs are metabolized by and/or inhibit various cytochrome P450
enzymes, e.g., 2D6, 1A2, 3A4, etc. In vitro studies have shown that Mirtazapine
is a substrate for several of these enzymes, including 2D6, 1A2, and 3A4.
While in vitro studies have shown that mirtazapine is not a potent inhibitor
of any of these enzymes, an indication that mirtazapine is not likely to
have a clinically significant inhibitory effect on the metabolism of other
drugs that are substrates for these cytochrome P450 enzymes, the concomitant
use of mirtazapine with most other drugs metabolized by these enzymes has
not been formally studied. Consequently, it is not possible to make any
definitive statements about the risks of coadministration of mirtazapine
with such drugs. </P>

<P>ALCOHOL </P>

<P>Concomitant administration of alcohol (equivalent to 60 g) had a minimal
effect on plasma levels of Mirtazapine (15 mg) in 6 healthy male subjects.
However, the impairment of cognitive and motor skills produced by Mirtazapine
were shown to be additive with those produced by alcohol. Accordingly,
patients should be advised to avoid alcohol while taking Mirtazapine. </P>

<P>DIAZEPAM </P>

<P>Concomitant administration of diazepam (15 mg) had a minimal effect
on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. However,
the impairment of motor skills produced by Mirtazapine has been shown to
be additive with those caused by diazepam. Accordingly, patients should
be advised to avoid diazepam and other similar drugs while taking Mirtazapine.
</P>

<P>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY </P>

<P>CARCINOGENESIS </P>

<P>Carcinogenicity studies were conducted with Mirtazapine given in the
diet at doses of 2, 20, and 200 mg/kg/day to mice and 2, 20, and 60 mg/kg/day
to rats. The highest doses used are approximately 20 and 12 times the maximum
recommended human dose (MRHD) of 45 mg/day on a mg/M(squared) basis in
mice and rats, respectively. There was an increased incidence of hepatocellular
adenoma and carcinoma in male mice at the high dose. In rats, there was
an increase in hepatocellular adenoma in females at the mid and high doses
and in hepatocellular tumors and thyroid follicular adenoma/cystadenoma
and carcinoma in males at the high dose. The data suggest that the above
effects could possibly be mediated by non-genotoxic mechanisms, the relevance
of which to humans is not known. </P>

<P>The doses used in the mouse study may not have been high enough to fully
characterize the carcinogenic potential of Mirtazapine. </P>

<P>MUTAGENESIS </P>

<P>Mirtazapine was not mutagenic or clastogenic and did not induce general
DNA damage as determined in several genotoxicity tests: Ames test, IN VITRO
gene mutation assay in Chinese hamster V 79 cells, IN VITRO sister chromatid
exchange assay in cultured rabbit lymphocytes, IN VIVO bone marrow micronucleus
test in rats, and unscheduled DNA synthesis assay in HeLa cells. </P>

<P>IMPAIRMENT OF FERTILITY </P>

<P>In a fertility study in rats, Mirtazapine was given at doses up to 100
mg/kg (20 times the maximum recommended human dose (MRHD) on a mg/M(squared)
basis). Mating and conception were not affected by the drug, but estrous
cycling was disrupted at doses that were 3 or more times the MRHD and pre-implantation
losses occurred at 20 times the MRHD. </P>

<P>PREGNANCY </P>

<P>TERATOGENIC EFFECTS-PREGNANCY CATEGORY C </P>

<P>Reproduction studies in pregnant rats and rabbits at doses up to 100
mg/kg and 40 mg/kg, respectively (20 and 17 times the maximum recommended
human dose (MRHD) on a mg/M(squared) basis, respectively), have revealed
no evidence of teratogenic effects. However, in rats, there was an increase
in post- implantation losses in dams treated with Mirtazapine . </P>

<P>There was an increase in pup deaths during the first 3 days of lactation
and a decrease in pup birth weights. The cause of these deaths is not known.
These effects occurred at doses that were 20 times the MRHD, but not at
3 times the MRHD, on a mg/M(squared) basis. There are no adequate and well
controlled studies in pregnant women. Because animal reproduction studies
are not always predictive of human response, this drug should be used during
pregnancy only if clearly needed. </P>

<P>NURSING MOTHERS </P>

<P>It is not known whether mirtazapine is excreted in human milk. Because
many drugs are excreted in human milk, caution should be exercised when
Mirtazapine Tablets are administered to nursing women. </P>

<P>PEDIATRIC USE </P>

<P>Safety and effectiveness in children have not been established. </P>

<P>GERIATRIC USE </P>

<P>Approximately 190 elderly individuals (&gt;/=65 years of age) participated
in clinical studies with Mirtazapine . No unusual adverse age-related phenomena
were identified in this group. Pharmacokinetic studies revealed a decreased
clearance in the elderly. Caution is indicated in administering Mirtazapine
to elderly patients (see ACTIONS/CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).
</P>

<P><A NAME="DRUG INTERACTIONS"></A><B>DRUG INTERACTIONS </B></P>

<P>As with other drugs, the potential for interaction by a variety of mechanisms
(e.g., pharmacodynamic, pharmacokinetic inhibition or enhancement, etc.)
is a possibility (see ACTIONS/CLINICAL PHARMACOLOGY). </P>

<P>DRUGS AFFECTING HEPATIC METABOLISM </P>

<P>The metabolism and pharmacokinetics of Mirtazapine may be affected by
the induction or inhibition of drug-metabolizing enzymes. </P>

<P>DRUGS THAT ARE METABOLIZED BY AND/OR INHIBIT CYTOCHROME P450 ENZYMES
</P>

<P>Many drugs are metabolized by and/or inhibit various cytochrome P450
enzymes, e.g., 2D6, 1A2, 3A4, etc. In vitro studies have shown that Mirtazapine
is a substrate for several of these enzymes, including 2D6, 1A2, and 3A4.
While in vitro studies have shown that mirtazapine is not a potent inhibitor
of any of these enzymes, an indication that mirtazapine is not likely to
have a clinically significant inhibitory effect on the metabolism of other
drugs that are substrates for these cytochrome P450 enzymes, the concomitant
use of mirtazapine with most other drugs metabolized by these enzymes has
not been formally studied. Consequently, it is not possible to make any
definitive statements about the risks of coadministration of mirtazapine
with such drugs. </P>

<P>ALCOHOL </P>

<P>Concomitant administration of alcohol (equivalent to 60 g) had a minimal
effect on plasma levels of Mirtazapine (15 mg) in 6 healthy male subjects.
However, the impairment of cognitive and motor skills produced by Mirtazapine
were shown to be additive with those produced by alcohol. Accordingly,
patients should be advised to avoid alcohol while taking Mirtazapine. </P>

<P>DIAZEPAM </P>

<P>Concomitant administration of diazepam (15 mg) had a minimal effect
on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. However,
the impairment of motor skills produced by Mirtazapine has been shown to
be additive with those caused by diazepam. Accordingly, patients should
be advised to avoid diazepam and other similar drugs while taking Mirtazapine.
</P>

<P>(See Also PRECAUTIONS) </P>

<P><A NAME="ADVERSE REACTIONS"></A><B>ADVERSE REACTIONS </B></P>

<P>ASSOCIATED WITH DISCONTINUATION OF TREATMENT </P>

<P>Approximately 16 percent of the 453 patients who received Mirtazapine
in U.S. 6-week controlled clinical trials discontinued treatment due to
an adverse experience, compared to 7 percent of 361 placebo-treated patients
in those studies. The most common events (&gt;/=1%) associated with discontinuation
and considered to be drug related (i.e., those events associated with dropout
at a rate at least twice that of placebo) included:</P>

<PRE>

                    Common Adverse Events Associated with
                    Discontinuation of Treatment in 6-Week
                           U.S. Mirtazapine Trials

                                            Percentage of Patients
                                              Discontinuing with
                                                Adverse Event
 Adverse                             
 Event                                   Mirtazapine              Placebo
                                           (n=453)                 (n=361)
 Somnolence                                 10.4%                 2.2%
 Nausea                                      1.5%                   0%
</PRE>

<P>COMMONLY OBSERVED ADVERSE EVENTS IN U.S. CONTROLLED CLINICAL TRIALS
</P>

<P>The most commonly observed adverse events associated with the use of
Mirtazapine (incidence of 5% or greater) and not observed at an equivalent
incidence among placebo-treated patients (Mirtazapine incidence at least
twice that for placebo) were:</P>

<PRE>

                      Common Treatment-Emergent Adverse
                      Events Associated with the Use of
                      Mirtazapine in 6-Week U.S. Trials

                                          Percentage of Patients Reporting
                                                Adverse Event
 Adverse                             
 Event                                   Mirtazapine              Placebo
                                           (n=453)                 (n=361)
 Somnolence                                   54%                  18%
 Increased Appetite                           17%                   2%
 Weight Gain                                  12%                   2%
 Dizziness                                     7%                   3%
</PRE>

<P>ADVERSE EVENTS OCCURRING AT AN INCIDENCE OF 1% OR MORE AMONG Mirtazapine
TREATED PATIENTS </P>

<P>The table that follows enumerates adverse events that occurred at an
incidence of 1% or more, and were more frequent than in the placebo group,
among Mirtazapine -treated patients who participated in short-term U.S.
placebo-controlled trials in which patients were dosed in a range of 5
to 60 mg/day. This table shows the percentage of patients in each group
who had at least one episode of an event at some time during their treatment.
Reported adverse events were classified using a standard COSTART-based
dictionary terminology. </P>

<P>The prescriber should be aware that these figures cannot be used to
predict the incidence of side effects in the course of usual medical practice
where patient characteristics and other factors differ from those which
prevailed in the clinical trials. Similarly, the cited frequencies cannot
be compared with figures obtained from other investigations involving different
treatments, uses and investigators. The cited figures, however, do provide
the prescribing physician with some basis for estimating the relative contribution
of drug and non-drug factors to the side effect incidence rate in the population
studied. </P>

<PRE>
                             INCIDENCE OF ADVERSE
                        CLINICAL EXPERIENCES(1) (&gt;/=1%)
                    IN SHORT-TERM U.S. CONTROLLED STUDIES

 Body System
     Adverse Clinical                    Mirtazapine              Placebo
     Experience                            (n=453)                 (n=361)

 BODY AS A WHOLE
     Asthenia                                  8%                   5%
     Flu Syndrome                              5%                   3%
     Back Pain                                 2%                   1%
 DIGESTIVE SYSTEM
     Dry Mouth                                25%                  15%
     Increased Appetite                       17%                   2%
     Constipation                             13%                   7%
 METABOLIC AND
 NUTRITIONAL DISORDERS
     Weight Gain                              12%                   2%
     Peripheral Edema                          2%                   1%
     Edema                                     1%                   0%
 MUSCULOSKELETAL SYSTEM
     Myalgia                                   2%                   1%
 NERVOUS SYSTEM
     Somnolence                               54%                  18%
     Dizziness                                 7%                   3%
     Abnormal Dreams                           4%                   1%
     Thinking Abnormal                         3%                   1%
     Tremor                                    2%                   1%
     Confusion                                 2%                   0%
 RESPIRATORY SYSTEM
     Dyspnea                                   1%                   0%
 UROGENITAL SYSTEM
     Urinary Frequency                         2%                   1%

 (1)  Events reported by at least 1% of patients treated with Mirtazapine
       are included, except the following events which had an
      incidence on placebo &gt;/=Mirtazapine: headache, infection, pain, chest
      pain, palpitation, tachycardia, postural hypotension, nausea, dyspepsia,
      diarrhea, flatulence, insomnia, nervousness, libido decreased,
      hypertonia, pharyngitis, rhinitis, sweating, amblyopia, tinnitus, taste
      perversion.</PRE>

<P>ECG CHANGES </P>

<P>In an analysis of ECGs obtained in U.S. placebo-controlled clinical
trials, Mirtazapine and placebo-treated patients had a similar incidence
of abnormal changes from baseline at 6-8 weeks of approximately 3%. The
abnormalities were generally not considered clinically significant. </P>

<P>OTHER ADVERSE EVENTS OBSERVED DURING THE PREMARKETING EVALUATION OF
Mirtazapine </P>

<P>During its premarketing assessment, multiple doses of Mirtazapine were
administered to 2,796 patients in clinical studies. The conditions and
duration of exposure to mirtazapine varied greatly, and included (in overlapping
categories) open and double-blind studies, uncontrolled and controlled
studies, inpatient and outpatient studies, fixed dose and titration studies.
Untoward events associated with this exposure were recorded by clinical
investigators using terminology of their own choosing. Consequently, it
is not possible to provide a meaningful estimate of the proportion of individuals
experiencing adverse events without first grouping similar types of untoward
events into a smaller number of standardized event categories. </P>

<P>In the tabulations that follow, reported adverse events were classified
using a standard COSTART-based dictionary terminology. The frequencies
presented, therefore, represent the proportion of the 2,796 patients exposed
to multiple doses of Mirtazapine who experienced an event of the type cited
on at least one occasion while receiving Mirtazapine. All reported events
are included except those already listed in the previous table, those adverse
experiences subsumed under COSTART terms that are either overly general
or excessively specific so as to be uninformative, and those events for
which a drug cause was very remote. </P>

<P>It is important to emphasize that, although the events reported occurred
during treatment with Mirtazapine, they were not necessarily caused by
it. </P>

<P>Events are further categorized by body system and listed in order of
decreasing frequency according to the following definitions: frequent adverse
events are those occurring on one or more occasions in at least 1/100 patients;
infrequent adverse events are those occurring in 1/100 to 1/1000 patients;
rare events are those occurring in fewer than 1/1000 patients. Only those
events not already listed in the previous table appear in this listing.
Events of major clinical importance are also described in the WARNINGS
and PRECAUTIONS sections. </P>

<P>BODY AS A WHOLE: frequent: malaise, abdominal pain, abdominal syndrome
acute; Infrequent: chills, fever, face edema, ulcer, photosensitivity reaction,
neck rigidity, neck pain, abdomen enlarged; Rare: cellulitis, chest pain
substernal. </P>

<P>CARDIOVASCULAR SYSTEM: frequent: hypertension, vasodilatation; Infrequent:
angina pectoris, myocardial infarction, bradycardia, ventricular extrasystoles,
syncope, migraine, hypotension; Rare: atrial arrhythmia, bigeminy, vascular
headache, pulmonary embolus, cerebral ischemia, cardiomegaly, phlebitis,
left heart failure. </P>

<P>DIGESTIVE SYSTEM: frequent: vomiting, anorexia; Infrequent: eructation,
glossitis, cholecystitis, nausea and vomiting, gum hemorrhage, stomatitis,
colitis, liver function tests abnormal; Rare: tongue discoloration, ulcerative
stomatitis, salivary gland enlargement, increased salivation, intestinal
obstruction, pancreatitis, aphthous stomatitis, cirrhosis of liver, gastritis,
gastroenteritis, oral moniliasis, tongue edema. </P>

<P>ENDOCRINE SYSTEM: rare: goiter, hypothyroidism. </P>

<P>HEMIC AND LYMPHATIC SYSTEM: rare: lymphadenopathy, leukopenia, petechia,
anemia, thrombocytopenia, lymphocytosis, pancytopenia. </P>

<P>METABOLIC AND NUTRITIONAL DISORDERS: frequent: thirst; Infrequent: dehydration,
weight loss; Rare: gout, SGOT increased, healing abnormal, acid phosphatase
increased, SGPT increased, diabetes mellitus. </P>

<P>MUSCULOSKELETAL SYSTEM: frequent: myasthenia, arthralgia; Infrequent:
arthritis, tenosynovitis; Rare: pathological fracture, osteoporosis fracture,
bone pain, myositis, tendon rupture, arthrosis, bursitis. </P>

<P>NERVOUS SYSTEM: frequent: hypesthesia, apathy, depression, hypokinesia,
vertigo, twitching, agitation, anxiety, amnesia, hyperkinesia, paresthesia;
Infrequent: ataxia, delirium, delusions, depersonalization, dyskinesia,
extrapyramidal syndrome, libido increased, coordination abnormal, dysarthria,
hallucinations, manic reaction, neurosis, dystonia, hostility, reflexes
increased, emotional lability, euphoria, paranoid reaction; Rare: aphasia,
nystagmus, akathisia, stupor, dementia, diplopia, drug dependence, paralysis,
grand mal convulsion, hypotonia, myoclonus, psychotic depression, withdrawal
syndrome. </P>

<P>RESPIRATORY SYSTEM: frequent: cough increased, sinusitis; Infrequent:
epistaxis, bronchitis, asthma, pneumonia; Rare: asphyxia, laryngitis, pneumothorax,
hiccup. </P>

<P>SKIN AND APPENDAGES: frequent: pruritus, rash; Infrequent: acne exfoliative
dermatitis, dry skin, herpes simplex, alopecia; Rare: urticaria, herpes
zoster, skin hypertrophy, seborrhea, skin ulcer. </P>

<P>SPECIAL SENSES: infrequent: eye pain, abnormality of accommodation,
conjunctivitis, deafness, keratoconjunctivitis, lacrimation disorder, glaucoma,
hyperacusis, ear pain; Rare: blepharitis, partial transitory deafness,
otitis media, taste loss, parosmia. </P>

<P>UROGENITAL SYSTEM: frequent: urinary tract infection; Infrequent: kidney
calculus, cystitis, dysuria, urinary incontinence, urinary retention, vaginitis,
hematuria, breast pain, amenorrhea, dysmenorrhea, leukorrhea, impotence;
Rare: polyuria, urethritis, metrorrhagia, menorrhagia, abnormal ejaculation,
breast engorgement, breast enlargement, urinary urgency. </P>

<P>DRUG ABUSE AND DEPENDENCE: </P>

<P>CONTROLLED SUBSTANCE CLASS </P>

<P>Mirtazapine Tablets are not a controlled substance. </P>

<P>PHYSICAL AND PSYCHOLOGICAL DEPENDENCE </P>

<P>Mirtazapine has not been systematically studied in animals or humans
for its potential for abuse, tolerance or physical dependence. While clinical
trials did not reveal any tendency for any drug-seeking behavior, these
observations were not systematic and it is not possible to predict on the
basis of this limited experience the extent to which a CNS-active drug
will be misused, diverted and/or abused once marketed. Consequently, patients
should be evaluated carefully for history of drug abuse, and such patients
should be observed closely for signs of mirtazapine misuse or abuse (e.g.,
development of tolerance, incrementations of dose, drug-seeking behavior).
</P>

<P><A NAME="OVERDOSAGE"></A><B>OVERDOSAGE </B></P>

<P>HUMAN EXPERIENCE </P>

<P>There is very limited experience with Mirtazapine overdose. In premarketing
clinical studies, there were eight reports of mirtazapine overdose alone
or in combination with other pharmacological agents. The only drug overdose
death reported while taking Mirtazapine Tablets was in combination with
amitriptyline and chlorprothixene in a non-U.S. clinical study. Based on
plasma levels, the Mirtazapine dose taken was 30-45 mg, while plasma levels
of amitriptyline and chlorprothixene were found to be at toxic levels.
All other premarketing overdose cases resulted in full recovery. Signs
and symptoms reported in association with overdose included disorientation,
drowsiness, impaired memory, and tachycardia. There were no reports of
ECG abnormalities, coma or convulsions following overdose with Mirtazapine
alone. </P>

<P>OVERDOSE MANAGEMENT </P>

<P>Treatment should consist of those general measures employed in the management
of overdose with any antidepressant. There are no specific antidotes for
Mirtazapine . If the patient is unconscious, establish and maintain an
airway to ensure adequate oxygenation and ventilation. Gastric evacuation
either by the induction of emesis or lavage or both should be considered.
Activated charcoal should also be considered in treatment of overdose.
Cardiac and vital signs monitoring is recommended along with general symptomatic
and supportive measures. </P>

<P>In managing overdosage, consider the possibility of multiple-drug involvement.
The physician should consider contacting a poison control center for additional
information on the treatment of any overdose. </P>

<P><A NAME="DOSAGE AND ADMINISTRATION"></A><B>DOSAGE AND ADMINISTRATION
</B></P>

<P>INITIAL TREATMENT </P>

<P>The recommended starting dose for Mirtazapine is 15 mg/day, administered
in a single dose, preferably in the evening prior to sleep. In the controlled
clinical trials establishing the antidepressant efficacy of Mirtazapine,
the effective dose range was generally 15-45 mg/day. While the relationship
between dose and antidepressant response for Mirtazapine has not been adequately
explored, patients not responding to the initial 15 mg dose may benefit
from dose increases up to a maximum of 45 mg/day. Mirtazapine has an elimination
half-life of approximately 20-40 hours; therefore, dose changes should
not be made at intervals of less than one to two weeks in order to allow
sufficient time for evaluation of the therapeutic response to a given dose.
</P>

<P>ELDERLY AND PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT </P>

<P>The clearance of mirtazapine is reduced in elderly patients and in patients
with moderate to severe renal or hepatic impairment. Consequently, the
prescriber should be aware that plasma mirtazapine levels may be increased
in these patient groups, compared to levels observed in younger adults
without renal or hepatic impairment (see Pharmacokinetics subsection of
ACTIONS/CLINICAL PHARMACOLOGY). </P>

<P>MAINTENANCE/EXTENDED TREATMENT </P>

<P>There is no body of evidence available from controlled trials to indicate
how long the depressed patient should be treated with Mirtazapine . It
is generally agreed, however, that pharmacological treatment for acute
episodes of depression should continue for up to six months or longer.
Whether the dose of antidepressant needed to induce remission is identical
to the dose needed to maintain euthymia is unknown. </P>

<P>SWITCHING PATIENTS TO OR FROM A MONOAMINE OXIDASE INHIBITOR </P>

<P>At least 14 days should elapse between discontinuation of an MAOI and
initiation of therapy with Mirtazapine . In addition, at least 14 days
should be allowed after stopping Mirtazapine before starting an MAOI. </P>

<P>
<HR width="100%"></P>

<H2 ALIGN=CENTER><A HREF="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</A><A HREF="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <A HREF="http://www.rxlist.com/top200.htm"><IMG SRC="redball.gif" BORDER=0 HEIGHT=17 WIDTH=17></A></A><A HREF="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</A> &nbsp;&nbsp;<IMG SRC="redball.gif" HEIGHT=17 WIDTH=17><A HREF="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</A></H2>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B10-54</DOCNO>
<DOCOLDNO>IA018-000200-B037-252</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/cyclobnz.htm 206.86.175.201 19970106225731 text/html 21047
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:51:10 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 20864
Last-modified: Tue, 12 Nov 1996 23:40:31 GMT
</DOCHDR>
<html>
<head>
   <title>Cyclobenzaprine - RxList Generic Information</title>
   <meta name="keywords" content="Flexeril">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Cyclobenzaprine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Cyclobenzaprine hydrochloride is a white, crystalline tricyclic amine
salt with the empirical formula C20H21N.HCl and a molecular weight of 311.9.
It has a melting point of 217 deg C, and a pKa of 8.47 at 25 deg C. It
is freely soluble in water and alcohol, sparingly soluble in isopropanol,
and insoluble in hydrocarbon solvents. If aqueous solutions are made alkaline,
the free base separates. Cyclobenzaprine HCl is designated chemically as
3-(5H- dibenzo(a d)cyclohepten-5-ylidene)-N, N-dimethyl-1-propanamine hydrochloride.
</p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Cyclobenzaprine HCl relieves skeletal muscle spasm of local origin without
interfering with muscle function. It is ineffective in muscle spasm due
to central nervous system disease. </p>

<p>Cyclobenzaprine reduced or abolished skeletal muscle hyperactivity in
several animal models. Animal studies indicate that cyclobenzaprine does
not act at the neuromuscular junction or directly on skeletal muscle. Such
studies show that cyclobenzaprine acts primarily within the central nervous
system at brain stem as opposed to spinal cord levels, although its action
on the latter may contribute to its overall skeletal muscle relaxant activity.
Evidence suggests that the net effect of cyclobenzaprine is a reduction
of tonic somatic motor activity, influencing both gamma (gamma) and alpha
(alpha) motor systems.</p>

<p> Pharmacological studies in animals showed a similarity between the
effects of cyclobenzaprine and the structurally related tricyclic antidepressants,
including reserpine antagonism, norepinephrine potentiation, potent peripheral
and central anticholinergic effects, and sedation. Cyclobenzaprine caused
slight to moderate increase in heart rate in animals. </p>

<p>Cyclobenzaprine is well absorbed after oral administration, but there
is a large intersubject variation in plasma levels. Cyclobenzaprine is
eliminated quite slowly with a half-life as long as one to three days.
It is highly bound to plasma proteins, is extensively metabolized primarily
to glucuronide-like conjugates, and is excreted primarily via the kidneys.
</p>

<p>No significant effect on plasma levels or bioavailability of Cyclobenzaprine
or aspirin was noted when single or multiple doses of the two drugs were
administered concomitantly. Concomitant administration of Cyclobenzaprine
and aspirin is usually well tolerated and no unexpected or serious clinical
or laboratory adverse effects have been observed. No studies have been
performed to indicate whether Cyclobenzaprine enhances the clinical effect
of aspirin or other analgesics, or whether analgesics enhance the clinical
effect of Cyclobenzaprine in acute musculoskeletal conditions. </p>

<p>CLINICAL STUDIES: </p>

<p>Controlled clinical studies show that Cyclobenzaprine significantly
improves the signs and symptoms of skeletal muscle spasm as compared with
placebo. The clinical responses include improvement in muscle spasm as
determined by palpation, reduction in local pain and tenderness, increased
range of motion, and less restriction in activities of daily living. When
daily observations were made, clinical improvement was observed as early
as the first day of therapy. </p>

<p>Eight double-blind controlled clinical studies were performed in 642
patients comparing Cyclobenzaprine, diazepam, and placebo. Muscle spasm,
local pain and tenderness, limitation of motion, and restriction in activities
of daily living were evaluated. In three of these studies there was a significantly
greater improvement with Cyclobenzaprine than with diazepam, while in the
other studies the improvement following both treatments was comparable.
</p>

<p>Although the frequency and severity of adverse reactions observed in
patients treated with Cyclobenzaprine were comparable to those observed
in patients treated with diazepam, dry mouth was observed more frequently
in patients treated with Cyclobenzaprine and dizziness more frequently
in those treated with diazepam. The incidence of drowsiness, the most frequent
adverse reaction, was similar with both drugs. </p>

<p>Analysis of the data from controlled studies shows that Cyclobenzaprine
produces clinical improvement whether or not sedation occurs. </p>

<p>Surveillance Program </p>

<p>A post-marketing surveillance program was carried out in 7607 patients
with acute musculoskeletal disorders, and included 297 patients treated
for 30 days or longer. The overall effectiveness of Cyclobenzaprine was
similar to that observed in the double-blind controlled studies; the overall
incidence of adverse effects was less (see ADVERSE REACTIONS). </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Cyclobenzaprine is indicated as an adjunct to rest and physical therapy
for relief of muscle spasm associated with acute, painful musculoskeletal
conditions. </p>

<p>Improvement is manifested by relief of muscle spasm and its associated
signs and symptoms, namely, pain, tenderness, limitation of motion, and
restriction in activities of daily living. </p>

<p>Cyclobenzaprine (Cyclobenzaprine HCl) Should Be Used Only For Short
Periods (Up To Two Or Three Weeks) Because Adequate Evidence Of Effectiveness
For More Prolonged Use Is Not Available And Because Muscle Spasm Associated
With Acute, Painful Musculoskeletal Conditions Is Generally Of Short Duration
And Specific Therapy For Longer Periods Is Seldom Warranted. </p>

<p>Cyclobenzaprine has not been found effective in the treatment of spasticity
associated with cerebral or spinal cord disease, or in children with cerebral
palsy. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS</b></p>

<p> Hypersensitivity to the drug. </p>

<p>Concomitant use of monoamine oxidase inhibitors or within 14 days after
their discontinuation. </p>

<p>Acute recovery phase of myocardial infarction, and patients with arrhythmias,
heart block or conduction disturbances, or congestive heart failure. </p>

<p>Hyperthyroidism. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>Cyclobenzaprine is closely related to the tricyclic antidepressants,
e.g., amitriptyline and imipramine. In short term studies for indications
other than muscle spasm associated with acute musculoskeletal conditions,
and usually at doses somewhat greater than those recommended for skeletal
muscle spasm, some of the more serious central nervous system reactions
noted with the tricyclic antidepressants have occurred (see WARNINGS, below,
and ADVERSE REACTIONS). </p>

<p>Cyclobenzaprine may interact with monoamine oxidase (MAO) inhibitors.
Hyperpyretic crisis, severe convulsions, and deaths have occurred in patients
receiving tricyclic antidepressants and MAO inhibitor drugs. </p>

<p>Tricyclic antidepressants have been reported to produce arrhythmias,
sinus tachycardia, prolongation of the conduction time leading to myocardial
infarction and stroke. </p>

<p>Cyclobenzaprine may enhance the effects of alcohol, barbiturates, and
other CNS depressants. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>General </p>

<p>Because of its atropine-like action, Cyclobenzaprine should be used
with caution in patients with a history of urinary retention, angle-closure
glaucoma, increased intraocular pressure, and in patients taking anticholinergic
medication. </p>

<p>Information For Patients </p>

<p>Cyclobenzaprine may impair mental and/or physical abilities required
for performance of hazardous tasks, such as operating machinery or driving
a motor vehicle. </p>

<p>Drug Interactions </p>

<p>Cyclobenzaprine may enhance the effects of alcohol, barbiturates, and
other CNS depressants. </p>

<p>Tricyclic antidepressants may block the antihypertensive action of guanethidine
and similarly acting compounds. </p>

<p>Carcinogenesis, Mutagenesis, Impairment Of Fertility </p>

<p>In rats treated with Cyclobenzaprine for up to 67 weeks at doses of
approximately 5 to 40 times the maximum recommended human dose, pale, sometimes
enlarged, livers were noted and there was a dose-related hepatocyte vacuolation
with lipidosis. In the higher dose groups this microscopic change was seen
after 26 weeks and even earlier in rats which died prior to 26 weeks; at
lower doses, the change was not seen until after 26 weeks. </p>

<p>Cyclobenzaprine did not affect the onset, incidence or distribution
of neoplasia in an 81-week study in the mouse or in a 105-week study in
the rat. </p>

<p>At oral doses of up to 10 times the human dose, cyclobenzaprine did
not adversely affect the reproductive performance or fertility of male
or female rats. Cyclobenzaprine did not demonstrate mutagenic activity
in the male mouse at dose levels of up to 20 times the human dose. </p>

<p>Pregnancy </p>

<p>Pregnancy Category B: Reproduction studies have been performed in rats,
mice and rabbits at doses up to 20 times the human dose, and have revealed
no evidence of impaired fertility or harm to the fetus due to Cyclobenzaprine.
There are, however, no adequate and well-controlled studies in pregnant
women. Because animal reproduction studies are not always predictive of
human response, this drug should be used during pregnancy only if clearly
needed. </p>

<p>Nursing Mothers </p>

<p>It is not known whether this drug is excreted in human milk. Because
cyclobenzaprine is closely related to the tricyclic antidepressants, some
of which are known to be excreted in human milk, caution should be exercised
when Cyclobenzaprine is administered to a nursing woman. </p>

<p>Pediatric Use </p>

<p>Safety and effectiveness of Cyclobenzaprine in children below the age
of 15 have not been established. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Concomitant use of monoamine oxidase inhibitors or within 14 days after
their discontinuation. Cyclobenzaprine may enhance the effects of alcohol,
barbiturates, and other CNS depressants. </p>

<p>Tricyclic antidepressants may block the antihypertensive action of guanethidine
and similarly acting compounds. </p>

<p>(See Also CONTRAINDICATIONS and PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The following list of adverse reactions is based on the experience in
473 patients treated with Cyclobenzaprine in controlled clinical studies,
7607 patients in the post-marketing surveillance program, and reports received
since the drug was marketed. The overall incidence of adverse reactions
among patients in the surveillance program was less than the incidence
in the controlled clinical studies. </p>

<p>The adverse reactions reported most frequently with Cyclobenzaprine
were drowsiness, dry mouth and dizziness. The incidence of these common
adverse reactions was lower in the surveillance program than in the controlled
clinical studies: </p>

<pre>                 Clinical    Surveillance                                      
                  Studies       Program                                         
drowsiness          39%           16%                                           
dry mouth           27%            7%                                           
dizziness           11%            3%    </pre>

<p>Among the less frequent adverse reactions, there was no appreciable
difference in incidence in controlled clinical studies or in the surveillance
program. Adverse reactions which were reported in 1% to 3% of the patients
were: fatigue/tiredness, asthenia, nausea, constipation, dyspepsia, unpleasant
taste, blurred vision, headache, nervousness, and confusion. </p>

<p>Incidence Less Than 1 In 100 </p>

<p>The following adverse reactions have been reported at an incidence of
less than 1 in 100: </p>

<p>Body As A Whole: Syncope; malaise. </p>

<p>Cardiovascular: Tachycardia; arrhythmia; vasodilatation; palpitation;
hypotension. </p>

<p>Digestive: Vomiting; anorexia; diarrhea; gastrointestinal pain; gastritis;
thirst; flatulence; edema of the tongue; abnormal liver function and rare
reports of hepatitis, jaundice and cholestasis. </p>

<p>Hypersensitivity: Anaphylaxis; angioedema; pruritus; facial edema; urticaria;
rash. </p>

<p>Musculoskeletal: Local weakness. </p>

<p>Nervous System And Psychiatric: Ataxia; vertigo; dysarthria; tremors;
hypertonia; convulsions; muscle twitching; disorientation; insomnia; depressed
mood; abnormal sensations; anxiety; agitation; abnormal thinking and dreaming;
hallucinations; excitement; paresthesia; diplopia. </p>

<p>Skin: Sweating. </p>

<p>Special Senses: Ageusia; tinnitus. </p>

<p>Urogenital: Urinary frequency and/or retention. </p>

<p>Causal Relationship Unknown </p>

<p>Other reactions, reported rarely for Cyclobenzaprine under circumstances
where a causal relationship could not be established or reported for other
tricyclic drugs, are listed to serve as alerting information to physicians:
</p>

<p>Body As A Whole: Chest pain; edema. </p>

<p>Cardiovascular: Hypertension; myocardial infarction; heart block; stroke.
</p>

<p>Digestive: Paralytic ileus; tongue discoloration; stomatitis; parotid
swelling. </p>

<p>Endocrine: Inappropriate ADH syndrome. </p>

<p>Hematic And Lymphatic: Purpura; bone marrow depression; leukopenia;
eosinophilia; thrombocytopenia. </p>

<p>Metabolic, Nutritional And Immune: Elevation and lowering of blood sugar
levels; weight gain or loss. </p>

<p>Musculoskeletal: Myalgia. </p>

<p>Nervous System And Psychiatric: Decreased or increased libido; abnormal
gait; delusions; peripheral neuropathy; Bell's palsy; alteration in EEG
patterns; extrapyramidal symptoms. </p>

<p>Respiratory: Dyspnea. </p>

<p>Skin: Photosensitization; alopecia. </p>

<p>Urogenital: Impaired urination; dilatation of urinary tract; impotence;
testicular swelling; gynecomastia; breast enlargement; galactorrhea. </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>Pharmacologic similarities among the tricyclic drugs require that certain
withdrawal symptoms be considered when Cyclobenzaprine is administered,
even though they have not been reported to occur with this drug. Abrupt
cessation of treatment after prolonged administration may produce nausea,
headache, and malaise. These are not indicative of addiction. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Manifestations: High doses may cause temporary confusion, disturbed
concentration, transient visual hallucinations, agitation, hyperactive
reflexes muscle rigidity, vomiting, or hyperpyrexia, in addition to anything
listed under ADVERSE REACTIONS. Based on the known pharmacologic actions
of the drug, overdosage may cause drowsiness, hypothermia, tachycardia
and other cardiac rhythm abnormalities such as bundle branch block, ECG
evidence of impaired conduction, and congestive heart failure. Other manifestations
may be dilated pupils, convulsions, severe hypotension, stupor, and coma.
</p>

<p>The acute oral LD50 of Cyclobenzaprine is approximately 338 and 425
mg/kg in mice and rats, respectively. </p>

<p>Treatment: Treatment is symptomatic and supportive. Empty the stomach
as quickly as possible by emesis, followed by gastric lavage. After gastric
lavage activated charcoal may be administered. Twenty to 30 g of activated
charcoal may be given every four to six hours during the first 24 to 48
hours after ingestion. An ECG should be taken and close monitoring of cardiac
function must be instituted if there is any evidence of dysrhythmia. Maintenance
of an open airway, adequate fluid intake, and regulation of body temperature
are necessary. </p>

<p>The intravenous administration of 1-3 mg of physostigmine salicylate
is reported to reverse symptoms of poisoning by atropine and other drugs
with anticholinergic activity. Physostigmine may be helpful in the treatment
of cyclobenzaprine overdose. Because physostigmine is rapidly metabolized,
the dosage of physostigmine should be repeated as required, particularly
if life- threatening signs such as arrhythmias, convulsions, and deep coma
recur or persist after the initial dosage of physostigmine. Because physostigmine
itself may be toxic, it is not recommended for routine use. </p>

<p>Standard medical measures should be used to manage circulatory shock
and metabolic acidosis. Cardiac arrhythmias may be treated with neostigmine,
pyridostigmine, or propranolol. When signs of cardiac failure occur, the
use of a short-acting digitalis preparation should be considered. Close
monitoring of cardiac function for not less than five days is advisable.
</p>

<p>Anticonvulsants may be given to control seizures. </p>

<p>Dialysis is probably of no value because of low plasma concentrations
of the drug. </p>

<p>Since overdosage is often deliberate, patients may attempt suicide by
other means during the recovery phase. Deaths by deliberate or accidental
overdosage have occurred with this class of drugs. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>The usual dosage of Cyclobenzaprine is 10 mg three times a day, with
a range of 20 to 40 mg a day in divided doses. Dosage should not exceed
60 mg a day. Use of Cyclobenzaprine for periods longer than two or three
weeks is not recommended. (See INDICATIONS AND USAGE.) </p>

<p>CLINICAL STUDIES </p>

<p>Controlled clinical studies show that Cyclobenzaprine significantly
improves the signs and symptoms of skeletal muscle spasm as compared with
placebo. The clinical responses include improvement in muscle spasm as
determined by palpation, reduction in local pain and tenderness, increased
range of motion, and less restriction in activities of daily living. When
daily observations were made, clinical improvement was observed as early
as the first day of therapy. </p>

<p>Eight double-blind controlled clinical studies were performed in 642
patients comparing Cyclobenzaprine, diazepam, and placebo. Muscle spasm,
local pain and tenderness, limitation of motion, and restriction in activities
of daily living were evaluated. In three of these studies there was a significantly
greater improvement with Cyclobenzaprine than with diazepam, while in the
other studies the improvement following both treatments was comparable.
</p>

<p>Although the frequency and severity of adverse reactions observed in
patients treated with Cyclobenzaprine were comparable to those observed
in patients treated with diazepam, dry mouth was observed more frequently
in patients treated with Cyclobenzaprine and dizziness more frequently
in those treated with diazepam. The incidence of drowsiness, the most frequent
adverse reaction, was similar with both drugs. </p>

<p>Analysis of the data from controlled studies shows that Cyclobenzaprine
produces clinical improvement whether or not sedation occurs. </p>

<p>Surveillance Program </p>

<p>A post-marketing surveillance program was carried out in 7607 patients
with acute musculoskeletal disorders, and included 297 patients treated
for 30 days or longer. The overall effectiveness of Cyclobenzaprine was
similar to that observed in the double-blind controlled studies; the overall
incidence of adverse effects was less (see ADVERSE REACTIONS). </p>

<p>(See Also ACTIONS/CLINICAL PHARMACOLOGY) </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-55</DOCNO>
<DOCOLDNO>IA018-000200-B036-331</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/naprox.htm 206.86.175.201 19970106225421 text/html 30924
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:48:04 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 30741
Last-modified: Tue, 09 Jul 1996 23:02:29 GMT
</DOCHDR>
<html>
<head>
   <title>Naproxen - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Naproxen</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a>DESCRIPTION </p>

<p>Naproxen is a member of the arylacetic acid group of nonsteroidal anti-inflammatory
drugs. </p>

<p>The chemical name for naproxen is 2-naphthaleneacetic acid, 6-methoxy-alpha-
methyl-,(+). </p>

<p>Naproxen is an odorless, white to off-white crystalline substance. It
is lipid soluble, practically insoluble in water at low pH and freely soluble
in water at high pH. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Naproxen is a nonsteroidal anti-inflammatory drug with analgesic and
antipyretic properties. Naproxen sodium, the sodium salt of naproxen, has
been developed as an analgesic because it is more rapidly absorbed. The
naproxen anion inhibits prostaglandin synthesis but beyond this its mode
of action is unknown. </p>

<p>Naproxen is rapidly and completely absorbed from the gastrointestinal
tract. After administration of naproxen, peak plasma levels of naproxen
anion are attained in 2 to 4 hours, with steady-state conditions normally
achieved after 4-5 doses. The mean biological half-life of the anion in
humans is approximately 13 hours, and at therapeutic levels it is greater
than 99% albumin bound. At doses of naproxen greater than 500 mg/day there
is a lack of dose proportionality due to an increase in clearance caused
by saturation of proteins at higher doses. Approximately 95% of the dose
is excreted in the urine, primarily as naproxen, 6-0-desmethyl naproxen
or their conjugates. The rate of excretion has been found to coincide closely
with the rate of drug disappearance from the plasma. The drug does not
induce metabolizing enzymes. </p>

<p>In children of 5 to 16 years of age with arthritis, plasma naproxen
levels following a 5 mg/kg single dose of suspension were found to be similar
to those found in normal adults following a 500 mg dose. The terminal half-life
appears to be similar in children and adults. Pharmacokinetic studies of
naproxen were not performed in children of less than 5 years of age. </p>

<p>The drug was studied in patients with rheumatoid arthritis, osteoarthritis,
juvenile arthritis, ankylosing spondylitis, tendinitis and bursitis, and
acute gout. It is not a corticosteroid. Improvement in patients treated
for rheumatoid arthritis has been demonstrated by a reduction in joint
swelling, a reduction in pain, a reduction in duration of morning stiffness,
a reduction in disease activity as assessed by both the investigator and
patient, and by increased mobility as demonstrated by a reduction in walking
time. </p>

<p>In patients with osteoarthritis, the therapeutic action of the drug
has been shown by a reduction in joint pain or tenderness, an increase
in range of motion in knee joints, increased mobility as demonstrated by
a reduction in walking time, and improvement in capacity to perform activities
of daily living impaired by the disease. </p>

<p>In clinical studies in patients with rheumatoid arthritis, osteoarthritis,
and juvenile arthritis, the drug has been shown to be comparable to aspirin
and indomethacin in controlling the aforementioned measures of disease
activity, but the frequency and severity of the milder gastrointestinal
adverse effects (nausea, dyspepsia, heartburn) and nervous system adverse
effects (tinnitus, dizziness, lightheadedness) were less than in both the
aspirin- and indomethacin-treated patients. It is not known whether the
drug causes less peptic ulceration than aspirin. </p>

<p>In patients with ankylosing spondylitis, the drug has been shown to
decrease night pain, morning stiffness and pain at rest. In double-blind
studies the drug was shown to be as effective as aspirin, but with fewer
side effects. </p>

<p>In patients with acute gout, a favorable response to the drug was shown
by significant clearing of inflammatory changes (e.g., decrease in swelling,
heat) within 24-48 hours, as well as by relief of pain and tenderness.
</p>

<p>The drug may be used safely in combination with gold salts and/or corticosteroids;
however, in controlled clinical trials, when added to the regimen of patients
receiving corticosteroids it did not appear to cause greater improvement
over that seen with corticosteroids alone. Whether the drug could be used
in conjunction with partially effective doses of corticosteroid for a &quot;steroid-sparing&quot;
effect has not been adequately studied. When added to the regimen of patients
receiving gold salts the drug did result in greater improvement. Its use
in combination with salicylates is not recommended because data are inadequate
to demonstrate that the drug produces greater improvement over that achieved
with aspirin alone. Further, there is some evidence that aspirin increases
the rate of excretion of the drug. </p>

<p>Generally, improvement due to the drug has not been found to be dependent
on age, sex, severity or duration of disease. </p>

<p>In clinical trials in patients with osteoarthritis and rheumatoid arthritis
comparing treatments of 750 mg per day with 1,500 mg per day, there were
trends toward increased efficacy with the higher dose and a more clearcut
increase in adverse reactions, particularly gastrointestinal reactions
severe enough to cause the patient to leave the trial, which approximately
doubled. </p>

<p>The drug was studied in patients with mild to moderate pain, and pain
relief was obtained within 1 hour. It is not a narcotic and is not a CNS-acting
drug. Controlled double-blind studies have demonstrated the analgesic properties
of the drug in, for example, post-operative, post-partum, orthopedic and
uterine contraction pain and dysmenorrhea. In dysmenorrheic patients, the
drug reduces the level of prostaglandins in the uterus, which correlates
with a reduction in the frequency and severity of uterine contractions.
Analgesic action has been shown by such measures as a reduction of pain
intensity scores, increase in pain relief scores, decrease in numbers of
patients requiring additional analgesic medication, and delay in time for
required remedication. The analgesic effect has been found to last for
up to 7 hours. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Naproxen is indicated for the treatment of rheumatoid arthritis, osteoarthritis,
juvenile arthritis, ankylosing spondylitis, tendinitis and bursitis, and
acute gout. </p>

<p>It is also indicated in the relief of mild to moderate pain and for
the treatment of primary dysmenorrhea. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>The drug is contraindicated in patients who have had allergic reactions
to Naproxen or naproxen sodium. It is also contraindicated in patients
in whom aspirin or other nonsteroidal anti-inflammatory/analgesic drugs
induce the syndrome of asthma, rhinitis, and nasal polyps. Both types of
reactions have the potential of being fatal. Anaphylactoid reactions to
Naproxen, or Naproxen sodium whether of the true allergic type or the pharmacologic
idiosyncratic (e.g., aspirin syndrome) type, usually but not always occur
in patients with a known history of such reactions. Therefore, careful
questioning of patients for such things as asthma, nasal polyps, urticaria,
and hypotension associated with nonsteroidal anti-inflammatory drugs before
starting therapy is important. In addition, if such symptoms occur during
therapy, treatment should be discontinued. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>RISK OF GI ULCERATION, BLEEDING AND PERFORATION WITH NSAID THERAPY:
</p>

<p>Serious gastrointestinal toxicity such as bleeding, ulceration, and
perforation can occur at any time, with or without warning symptoms, in
patients treated chronically with NSAID therapy. Although minor upper gastrointestinal
problems, such as dyspepsia, are common, usually developing early in therapy,
physicians should remain alert for ulceration and bleeding in patients
treated chronically with NSAIDs even in the absence of previous GI tract
symptoms. In patients observed in clinical trials of several months to
two years duration, symptomatic upper GI ulcers, gross bleeding or perforation
appear to occur in approximately 1% of patients treated for 3-6 months,
and in about 2-4% of patients treated for one year. Physicians should inform
patients about the signs and/or symptoms of serious GI toxicity and what
steps to take if they occur. </p>

<p>Studies to date have not identified any subset of patients not at risk
of developing peptic ulceration and bleeding. Except for a prior history
of serious GI events and other risk factors known to be associated with
peptic ulcer disease, such as alcoholism, smoking, etc., no risk factors
(e.g., age, sex) have been associated with increased risk. Elderly or debilitated
patients seem to tolerate ulceration or bleeding less well than other individuals
and most spontaneous reports of fatal GI events are in this population.
Studies to date are inconclusive concerning the relative risk of various
NSAIDs in causing such reactions. High doses of any NSAID probably carry
a greater risk of these reactions, although controlled clinical trials
showing this do not exist in most cases. In considering the use of relatively
large doses (within the recommended dosage range), sufficient benefit should
be anticipated to offset the potential increased risk of GI toxicity. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL: </p>

<p>NAPROXEN SHOULD NOT BE USED CONCOMITANTLY WITH THE RELATED DRUG NAPROXEN
SODIUM SINCE THEY BOTH CIRCULATE IN PLASMA AS THE NAPROXEN ANION. </p>

<p>Renal Effects: As with other nonsteroidal anti-inflammatory drugs, long-term
administration of naproxen to animals has resulted in renal papillary necrosis
and other abnormal renal pathology. In humans, there have been reports
of acute interstitial nephritis with hematuria, proteinuria, and occasionally
nephrotic syndrome. </p>

<p>A second form of renal toxicity has been seen in patients with prerenal
conditions leading to the reduction in renal blood flow or blood volume,
where the renal prostaglandins have a supportive role in the maintenance
of renal perfusion. In these patients, administration of a nonsteroidal
anti inflammatory drug may cause a dose-dependent reduction in prostaglandin
formation and may precipitate overt renal decompensation. Patients at greatest
risk of this reaction are those with impaired renal function, heart failure,
liver dysfunction, those taking diuretics, and the elderly. Discontinuation
of nonsteroidal anti-inflammatory therapy is typically followed by recovery
to the pretreatment state. </p>

<p>Naproxen and its metabolites are eliminated primarily by the kidneys,
therefore the drug should be used with great caution in patients with significantly
impaired renal function and the monitoring of serum creatinine and/or creatinine
clearance is advised in these patients. Caution should be used if the drug
is given to patients with creatinine clearance of less than 20 mL/minute
because accumulation of naproxen metabolites has been seen in such patients.
</p>

<p>Chronic alcoholic liver disease and probably other forms of cirrhosis
reduce the total plasma concentration of naproxen, but the plasma concentration
of unbound naproxen is increased. Caution is advised when high doses are
required and some adjustment of dosage may be required in these patients.
It is prudent to use the lowest effective dose. </p>

<p>Studies indicate that although total plasma concentration of naproxen
is unchanged, the unbound plasma fraction of naproxen is increased in the
elderly. Caution is advised when high doses are required and some adjustment
of dosage may be required in elderly patients. As with other drugs used
in the elderly, it is prudent to use the lowest effective dose. </p>

<p>As with other nonsteroidal anti-inflammatory drugs, borderline elevations
of one or more liver tests may occur in up to 15% of patients. These abnormalities
may progress, may remain essentially unchanged, or may be transient with
continued therapy. The SGPT (ALT) test is probably the most sensitive indicator
of liver dysfunction. Meaningful (3 times the upper limit of normal) elevations
of SGPT or SGOT (AST) occurred in controlled clinical trials in less than
1% of patients. A patient with symptoms and/or signs suggesting liver dysfunction,
or in whom an abnormal liver test has occurred, should be evaluated for
evidence of the development of more severe hepatic reaction while on therapy
with this drug. Severe hepatic reactions, including jaundice and cases
of fatal hepatitis, have been reported with this drug as with other nonsteroidal
anti inflammatory drugs. Although such reactions are rare, if abnormal
liver tests persist or worsen, if clinical signs and symptoms consistent
with liver disease develop, or if systemic manifestations occur (e.g. eosinophilia,
rash, etc.), this drug should be discontinued. </p>

<p>If steroid dosage is reduced or eliminated during therapy, the steroid
dosage should be reduced slowly and the patients must be observed closely
for any evidence of adverse effects, including adrenal insufficiency and
exacerbation of symptoms of arthritis. </p>

<p>Patients with initial hemoglobin values of 10 grams or less who are
to receive long-term therapy should have hemoglobin values determined periodically.
</p>

<p>Peripheral edema has been observed in some patients. For this reason,
the drug should be used with caution in patients with fluid retention,
hypertension or heart failure. </p>

<p>Naproxen suspension contains 8 mg/mL of sodium. This should be considered
in patients whose overall intake of sodium must be restricted. </p>

<p>The antipyretic and anti-inflammatory activities of the drug may reduce
fever and inflammation, thus diminishing their utility as diagnostic signs
in detecting complications of presumed non-infectious, non-inflammatory
painful Because of adverse eye findings in animal studies with drugs of
this class, it is recommended that ophthalmic studies be carried out if
any change or disturbance in vision occurs. </p>

<p>INFORMATION FOR PATIENTS: </p>

<p>Naproxen, like other drugs of its class, is not free of side effects.
The side effects of these drugs can cause discomfort and, rarely, there
are more serious side effects, such as gastrointestinal bleeding, which
may result in hospitalization and even fatal outcomes. </p>

<p>NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) are often essential agents
in the management of arthritis and have a major role in the treatment of
pain, but they also may be commonly employed for conditions which are less
serious. </p>

<p>Physicians may wish to discuss with their patients the potential risks
(see Warnings, Precautions, and Adverse Reactions sections) and likely
benefits of NSAID treatment, particularly when the drugs are used for less
serious conditions where treatment without NSAIDs may represent an acceptable
alternative to both the patient and physician. </p>

<p>Caution should be exercised by patients whose activities require alertness
if they experience drowsiness, dizziness, vertigo or depression during
therapy with the drug. </p>

<p>LABORATORY TESTS: </p>

<p>Because serious GI tract ulceration and bleeding can occur without warning
symptoms, physicians should follow chronically treated patients for the
signs and symptoms of ulceration and bleeding and should inform them of
the importance of this follow-up (see Risk of GI Ulcerations, Bleeding
and Perforation with NSAID Therapy). </p>

<p>DRUG INTERACTIONS: </p>

<p>In Vitro studies have shown that naproxen anion, because of its affinity
for protein, may displace from their binding sites other drugs which are
also albumin-bound. Theoretically, the naproxen anion itself could likewise
be displaced. Short-term controlled studies failed to show that taking
the drug significantly affects prothrombin times when administered to individuals
on coumarin-type anticoagulants. Caution is advised nonetheless, since
interactions have been seen with other nonsteroidal agents of this class.
Similarly, patients receiving the drug and a hydantoin, sulfonamide or
sulfonylurea should be observed for signs of toxicity to these drugs. </p>

<p>The natriuretic effect of furosemide has been reported to be inhibited
by some drugs of this class. Inhibition of renal lithium clearance leading
to increases in plasma lithium concentrations has also been reported. </p>

<p>This and other nonsteroidal anti-inflammatory drugs can reduce the antihypertensive
effect of propranolol and other beta-blockers. </p>

<p>Probenecid given concurrently increases naproxen anion plasma levels
and extends its plasma half-life significantly. </p>

<p>Caution should be used if this drug is administered concomitantly with
methotrexate. Naproxen and other nonsteroidal anti-inflammatory drugs have
been reported to reduce the tubular secretion of methotrexate in an animal
model, possibly enhancing the toxicity of that drug. </p>

<p>DRUG/LABORATORY TEST INTERACTIONS: </p>

<p>The drug may decrease platelet aggregation and prolong bleeding time.
This effect should be kept in mind when bleeding times are determined.
</p>

<p>The administration of the drug may result in increased urinary values
for 17 ketogenic steroids because of an interaction between the drug and/or
its metabolites with m-dinitrobenzene used in this assay. Although 17-hydroxy-
corticosteroid measurements (Porter-Silber test) do not appear to be artifactually
altered, it is suggested that therapy with the drug be temporarily discontinued
72 hours before adrenal function tests are performed. </p>

<p>The drug may interfere with some urinary assays of 5-hydroxy indoleacetic
acid (5HIAA). </p>

<p>CARCINOGENESIS: </p>

<p>A two-year study was performed in rats to evaluate the carcinogenic
potential of the drug. No evidence of carcinogenicity was found. </p>

<p>PREGNANCY: </p>

<p>Teratogenic Effects: Pregnancy Category B. Reproduction studies have
been performed in rats, rabbits and mice at doses up to six times the human
dose and have revealed no evidence of impaired fertility or harm to the
fetus due to the drug. There are, however, no adequate and well-controlled
studies in pregnant women. Because animal reproduction studies are not
always predictive of human response, the drug should not be used during
pregnancy unless clearly needed. Because of the known effect of drugs of
this class on the human fetal cardiovascular system (closure of ductus
arteriosus), use during late pregnancy should be avoided. </p>

<p>Non-teratogenic Effects: As with other drugs known to inhibit prostaglandin
synthesis, an increased incidence of dystocia and delayed parturition occurred
in rats. </p>

<p>NURSING MOTHERS: </p>

<p>The naproxen anion has been found in the milk of lactating women at
a concentration of approximately 1% of that found in the plasma. Because
of the possible adverse effects of prostaglandin-inhibiting drugs on neonates,
use in nursing mothers should be avoided. </p>

<p>PEDIATRIC USE: </p>

<p>Safety and effectiveness in children below the age of 2 years have not
been established. Pediatric dosing recommendations for juvenile arthritis
are based on well-controlled studies (see Dosage and Administration). There
are no adequate effectiveness or dose-response data for other pediatric
conditions, but the experience in juvenile arthritis and other use experience
have established that single doses of 2.5-5 mg/kg, with total daily dose
not exceeding 15 mg/kg/day, are safe in children over 2 years of age. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>In Vitro studies have shown that naproxen anion, because of its affinity
for protein, may displace from their binding sites other drugs which are
also albumin-bound. Theoretically, the naproxen anion itself could likewise
be displaced. Short-term controlled studies failed to show that taking
the drug significantly affects prothrombin times when administered to individuals
on coumarin-type anticoagulants. Caution is advised nonetheless, since
interactions have been seen with other nonsteroidal agents of this class.
Similarly, patients receiving the drug and a hydantoin, sulfonamide or
sulfonylurea should be observed for signs of toxicity to these drugs. </p>

<p>The natriuretic effect of furosemide has been reported to be inhibited
by some drugs of this class. Inhibition of renal lithium clearance leading
to increases in plasma lithium concentrations has also been reported. </p>

<p>This and other nonsteroidal anti-inflammatory drugs can reduce the antihypertensive
effect of propranolol and other beta-blockers. </p>

<p>Probenecid given concurrently increases naproxen anion plasma levels
and extends its plasma half-life significantly. </p>

<p>Caution should be used if this drug is administered concomitantly with
methotrexate. Naproxen and other nonsteroidal anti-inflammatory drugs have
been reported to reduce the tubular secretion of methotrexate in an animal
model, possibly enhancing the toxicity of that drug. </p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The following adverse reactions are divided into 3 parts based on frequency
and likelihood of causal relationship to naproxen. </p>

<p>INCIDENCE GREATER THAN 1% </p>

<p>PROBABLE CAUSAL RELATIONSHIP: </p>

<p>Adverse reactions reported in controlled clinical trials in 960 patients
treated for rheumatoid arthritis or osteoarthritis are listed below. In
general these reactions were reported 2 to 10 times more frequently than
they were in studies in the 962 patients treated for mild to moderate pain
or for dysmenorrhea. </p>

<p>A clinical study found gastrointestinal reactions to be more frequent
and more severe in rheumatoid arthritis patients taking 1,500 mg naproxen
daily compared to those taking 750 mg daily (see Actions/Clinical Pharmacology).
</p>

<p>In controlled clinical trials with about 80 children and in well-monitored
open studies with about 400 children with juvenile arthritis, the incidences
of rash and prolonged bleeding times were increased, the incidences of
gastrointestinal and central nervous system reactions were about the same,
and the incidences of other reactions were lower in children than in adults.
</p>

<p>GASTROINTESTINAL: The most frequent complaints reported related to the
gastrointestinal tract. They were: constipation*, heartburn*, abdominal
pain*, nausea*, dyspepsia, diarrhea, stomatitis. </p>

<p>CENTRAL NERVOUS SYSTEM: Headache*, dizziness*, drowsiness*, lightheadedness,
vertigo. </p>

<p>DERMATOLOGIC: Itching (pruritus)*, skin eruptions*, ecchymoses*, sweating,
purpura. </p>

<p>SPECIAL SENSES: Tinnitus*, hearing disturbances, visual disturbances.
</p>

<p>CARDIOVASCULAR: Edema*, dyspnea*, palpitations. </p>

<p>GENERAL: Thirst. </p>

<p>*Incidence of reported reactions between 3% and 9%. Those reactions
occurring in less than 3% of the patients are unmarked. </p>

<p>INCIDENCE LESS THAN 1% </p>

<p>PROBABLE CAUSAL RELATIONSHIP: </p>

<p>The following adverse reactions were reported less frequently than 1%
during controlled clinical trials and through voluntary reports since marketing.
The probability of a causal relationship exists between the drug and these
adverse reactions: </p>

<p>GASTROINTESTINAL: Abnormal liver function tests, colitis, gastrointestinal
bleeding and/or perforation, hematemesis, jaundice, melena, peptic ulceration
with bleeding and/or perforation, vomiting. </p>

<p>RENAL: Glomerular nephritis, hematuria, hyperkalemia, interstitial nephritis,
nephrotic syndrome, renal disease, renal failure, renal papillary necrosis.
</p>

<p>HEMATOLOGIC: Agranulocytosis, eosinophilia, granulocytopenia, leukopenia,
thrombocytopenia. </p>

<p>CENTRAL NERVOUS SYSTEM: Depression, dream abnormalities, inability to
concentrate, insomnia, malaise, myalgia and muscle weakness. </p>

<p>DERMATOLOGIC: Alopecia, photosensitive dermatitis, skin rashes. </p>

<p>SPECIAL SENSES: Hearing impairment. </p>

<p>CARDIOVASCULAR: Congestive heart failure. </p>

<p>RESPIRATORY: Eosinophilic pneumonitis. </p>

<p>GENERAL: Anaphylactoid reactions, menstrual disorders, pyrexia (chills
and fever). </p>

<p>CAUSAL RELATIONSHIP UNKNOWN: </p>

<p>Other reactions have been reported in circumstances in which a causal
relationship could not be established. However, in these rarely reported
events the possibility cannot be excluded. Therefore, these observations
are being listed to serve as alerting information to the physicians: </p>

<p>HEMATOLOGIC: Aplastic anemia, hemolytic anemia. </p>

<p>CENTRAL NERVOUS SYSTEM: Aseptic meningitis, cognitive dysfunction. </p>

<p>DERMATOLOGIC: Epidermal necrolysis, erythema multiforme, photosensitivity
reactions resembling porphyria cutanea tarda and epidermolysis bullosa,
Stevens Johnson syndrome, urticaria. </p>

<p>GASTROINTESTINAL: Non-peptic gastrointestinal ulceration, ulcerative
stomatitis. </p>

<p>CARDIOVASCULAR: Vasculitis. </p>

<p>GENERAL: Angioneurotic edema, hyperglycemia, hypoglycemia. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Significant overdosage may be characterized by drowsiness, heartburn,
indigestion, nausea or vomiting. A few patients have experienced seizures,
but it is not clear whether or not these were drug related. It is not known
what dose of the drug would be life threatening. The oral LD50 of the drug
is 543 mg/kg in rats, 1234 mg/kg in mice, 4110 mg/kg in hamsters and greater
than 1000 mg/kg in dogs. </p>

<p>Should a patient ingest a large number of tablets or a large volume
of suspension, accidentally or purposefully, the stomach may be emptied
and usual supportive measures employed. In animals 0.5 g/kg of activated
charcoal was effective in reducing plasma levels of naproxen. Hemodialysis
does not decrease the plasma concentration of naproxen because of the high
degree of its protein binding. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>A measuring cup marked in 1/2 teaspoon and 2.5 milliliter increments
is provided with the suspension. This cup or a teaspoon may be used to
measure the appropriate dose. </p>

<p>FOR RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, AND ANKYLOSING SPONDYLITIS:
</p>

<p>The recommended dose of Naproxen in adults is 250 mg (10 mL or 2 tsp
of suspension), 375 mg (15 mL or 3 tsp), or 500 mg (20 mL or 4 tsp) twice
daily (morning and evening). During long-term administration, the dose
may be adjusted up or down depending on the clinical response of the patient.
A lower daily dose may suffice for long-term administration. The morning
and evening doses do not have to be equal in size and the administration
of the drug more frequently than twice daily is not necessary. In patients
who tolerate lower doses well, the dose may be increased to 1,500 mg per
day for limited periods when a higher level of anti-inflammatory/analgesic
activity is required. When treating such patients with the 1,500 mg/day
dose, the physician should observe sufficient increased clinical benefits
to offset the potential increased risk (see Actions/Clinical Pharmacology).
</p>

<p>Symptomatic improvement in arthritis usually begins within 2 weeks.
However, if improvement is not seen within this period, a trial for an
additional 2 weeks should be considered. </p>

<p>FOR JUVENILE ARTHRITIS: </p>

<p>The recommended total daily dose of Naproxen is approximately 10 mg/kg
given in 2 divided doses. One half of the 250 mg tablet may be used to
approximate this dose. The following table may be used as a guide for the
suspension: </p>

<pre>CHILD'S WEIGHT                                              DOSE                
13 kg (29 lb)                                     2.5 mL (1/2 tsp) b.i.d.       
25 kg (55 lb)                                     5 mL (1 tsp) b.i.d.           
38 kg (84 lb)                                     7.5 mL (1 1/2 tsp) b.i.d.</pre>

<p>FOR ACUTE GOUT: </p>

<p>The recommended starting dose of Naproxen is 750 mg (30 mL or 6 tsp),
followed by 250 mg (10 mL or 2 tsp) every 8 hours until the attack has
subsided. </p>

<p>FOR MILD TO MODERATE PAIN, PRIMARY DYSMENORRHEA AND ACUTE TENDINITIS
AND BURSITIS: </p>

<p>The recommended starting dose of Naproxen is 500 mg (20 mL or 4 tsp),
followed by 250 mg (10 mL or 2 tsp) every 6 to 8 hours as required. The
total daily dose should not exceed 1,250 mg (50 mL or 10 tsp). </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-56</DOCNO>
<DOCOLDNO>IA018-000200-B033-37</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/about.htm 206.86.175.201 19970106223508 text/html 4037
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:28:52 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3855
Last-modified: Mon, 11 Nov 1996 19:14:47 GMT
</DOCHDR>
<html>
<head>
   <title>About RxList - The Internet Drug Index
</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">


<center><p><a href="http://www.rxlist.com">                      
<img src="rx.gif" alt="click to search RxList" vspace=2 border=0
height=125 width=125 align=left>
</a><a href="http://www.pointcom.com">
<img src="5per.gif" alt="top 5%" vspace=2 border=0 height=72 width=72
align=right>
</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<a href="http://rs.internic.net/scout/report">
<img src="scoutsel.gif" alt="Scout Report" border=0 height=29 width=100
align=right>
</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<a href="http://www.reutershealth.com/ihw/reviews/rxint.html">
<img src="hi_rec.gif" height=38 width=25 align=right
border=0></a></p></center>
<pre>


</pre><center>
<h1>About RxList</H1></center><hr>
<h4>Note: This <a href="http://www.lpage.com/cgi/" TARGET="NEW">'Fuzzy'
Search</a> Assumes
Your Input May Be Spelled Incorrectly and Attempts to Find Close Matches.
'Fuzzy' Results May Appear Nonsensical, at Times, but Reflect Certain Similar
Patterns to Allow For a Range of Spelling Probabilities. You May Turn Off
This Feature With the Use of <font SIZE=+1>*</font> as a Wildcard.
To Search on a Category You MUST Use an Asterisk (i.e., Antidep*,
Antibiot*, Antineoplastic*, etc.) With a VALID RxList Category Name. </h4>

<p>** RxList is a Free Service to the Internet Community. The RxList Database
Consists Primarily of Products Currently on the US Market or close to approval.
Every Attempt has Been Made to Assure The Accuracy of RxList. RxList Does
Not Offer Any Guarantees Regarding the Accuracy or Completeness of This
Data. Use RxList, Therefore, at Your Own Risk! ** </p>

<p>General Drug Information Questions Cannot be Supported at This Time.
Further Information on Any of the More Than 4000 US Products Listed Here
Can Be Obtained Through Your Local Pharmacist or Physician. You will also
find a wealth of information from the Internet Resources which have created
<a href="http://www.rxlist.com/rxlinks.htm">links</a> to this site. <b>Please
Read the Separate Description and <a href="http://www.rxlist.com/disclaim.htm">Disclaimer</a>
before using </b><a href="http://www.rxlist.com/mono.htm">RxLists of Indications
and Side Effects.</a> RxLists of Indications and Side Effects May Cause
the Lynx Browser to Crash. </p>

<p>The <a href="http://www.rxlist.com/top200.htm">Top 200</a> Prescriptions
(1995) was recently added with hypertext links to generic prescribing information.
These 200 products represent nearly 2/3 of all prescriptions filled in
the United States and the majority of searches of the RxList database. 
 Using the power of the Alta Vista Database, you can now
<a href="http://www.rxlist.com/interact.htm"> search all Top 200
Prescriptions</a> simultaneously for potential drug interactions, side 
effects, indications, etc.</p>

<p>Neil Sandow, Pharm.D. has been a hospital pharmacy director in the SF
Bay Area for the past twelve years and an Internet enthusiast since
1994.</p>

<center><p>
<hr><img src="mbox.gif" border=0 height=34 width=29>
<br><a href="mailto:rx@rxlist.com">E-mail to 
<br></a>rx@rxlist.com </p></center>

<center><p>
<hr></p></center>

<h2 align=center>
<br><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

<h2 align=center>
<br>
<hr width="100%" ></h2>

<h5 align=center>copyright 1995 - Neil Sandow, Pharm.D. </h5>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-57</DOCNO>
<DOCOLDNO>IA018-000200-B035-46</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/cefaclor.htm 206.86.175.201 19970106224609 text/html 19990
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:39:54 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 19807
Last-modified: Thu, 11 Jul 1996 06:06:26 GMT
</DOCHDR>
<html>
<head>
   <title>Cefaclor - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Cefaclor</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration.
It is chemically designated as 3-chloro-7-D-(2- phenylglycinamido)-3-cephem-4-carboxylic
acid monohydrate. The chemical formula for cefaclor is C15H14CIN3O4S.H2O
and the molecular weight is 385.82. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Cefaclor is well absorbed after oral administration to fasting subjects.
Total absorption is the same whether the drug is given with or without
food; however, when it is taken with food, the peak concentration achieved
is 50% to 75% of that observed when the drug is administered to fasting
subjects and generally appears from three fourths to 1 hour later. Following
administration of 250-mg, 500-mg, and 1-g doses to fasting subjects, average
peak serum levels of approximately 7, 13, and 23 mcgm/mL respectively were
obtained within 30 to 60 minutes. Approximately 60% to 85% of the drug
is excreted unchanged in the urine within 8 hours, the greater portion
being excreted within the first 2 hours. During this 8-hour period, peak
urine concentrations following the 250 mg, 500-mg, and 1-g doses were approximately
600, 900, and 1,900 mcgm/mL respectively. The serum half-life in normal
subjects is 0.6 to 0.9 hour. In patients with reduced renal function, the
serum half-life of cefaclor is slightly prolonged. In those with complete
absence of renal function, the plasma half-life of the intact molecule
is 2.3 to 2.8 hours. Excretion pathways in patients with markedly impaired
renal function have not been determined. Hemodialysis shortens the half-life
by 25% to 30%. </p>

<p>Microbiology--In vitro tests demonstrate that the bactericidal action
of the cephalosporins results from inhibition of cell-wall synthesis. Cefaclor
is active in vitro against most strains of clinical isolates of the following
organisms: </p>

<p>Staphylococci, including coagulase-positive, coagulase-negative, and
penicillinase-producing strains (when tested by in vitro methods), exhibit
cross-resistance between cefaclor and methicillin </p>

<p>Streptococcus Pyogenes (group A beta-hemolytic streptococci) </p>

<p>Streptococcus Pneumoniae </p>

<p>Moraxella (Branhamella) Catarrhalis </p>

<p>Haemophilus Influenzae, including beta-lactamase-producing ampicillin-resistant
strains </p>

<p>Escherichia Coli </p>

<p>Proteus Mirabilis </p>

<p>Klebsiella sp </p>

<p>Citrobacter Diversus </p>

<p>Neisseria Gonorrhoeae </p>

<p>Propionibacterium Acnes and Bacteroides sp (excluding Bacteroides Fragilis)
</p>

<p>Peptococci </p>

<p>Peptostreptococci </p>

<p>Note: Pseudomonas sp, Acinetobacter Calcoaceticus (formerly Mima sp
and Herellea sp), and most strains of enterococci (Enterococcus Faecalis
(formerly Streptococcus Faecalis), group D streptococci), Enterobacter
sp, indole positive Proteus, and Serratia sp are resistant to cefaclor.
When tested by in vitro methods, staphylococci exhibit cross-resistance
between cefaclor and methicillin-type antibiotics. </p>

<p>Disk Susceptibility Tests--Quantitative methods that require measurement
of zone diameters give the most precise estimates of antibiotic susceptibility.
One such procedure (REF. 1) has been recommended for use with disks for
testing susceptibility to cephalothin. The currently accepted zone diameter
interpretative criteria for the cephalothin disk are appropriate for determining
bacterial susceptibility to cefaclor. With this procedure, a report from
the laboratory of &quot;resistant&quot; indicates that the infecting organism
is not likely to respond to therapy. A report of &quot;intermediate susceptibility&quot;
suggests that the organism would be susceptible if the infection is confined
to tissues and fluids (eg, urine) in which high antibiotic levels can be
obtained or if high dosage is used. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Cefaclor is indicated in the treatment of the following infections when
caused by susceptible strains of the designated microorganisms: </p>

<p>OTITIS MEDIA caused by S. Pneumoniae, H. Influenzae, staphylococci,
and S. Pyogenes (group A beta-hemolytic streptococci) </p>

<p>LOWER RESPIRATORY INFECTIONS, including pneumonia, caused by S. Pneumoniae,
H. Influenzae, and S. Pyogenes (group A beta-hemolytic streptococci) </p>

<p>UPPER RESPIRATORY INFECTIONS, including pharyngitis and tonsillitis,
caused by S. Pyogenes (group A beta-hemolytic streptococci) </p>

<p>Note: Penicillin is the usual drug of choice in the treatment and prevention
of streptococcal infections, including the prophylaxis of rheumatic fever.
Cefaclor is generally effective in the eradication of streptococci from
the nasopharynx; however, substantial data establishing the efficacy of
Cefaclor in the subsequent prevention of rheumatic fever are not available
at present. </p>

<p>URINARY TRACT INFECTIONS, including pyelonephritis and cystitis, caused
by E. Coli, P. Mirabilis, Klebsiella sp, and coagulase-negative staphylococci
</p>

<p>SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus Aureus and
S. Pyogenes (group A beta-hemolytic streptococci) </p>

<p>Appropriate culture and susceptibility studies should be performed to
determine susceptibility of the causative organism to Cefaclor. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Cefaclor is contraindicated in patients with known allergy to the cephalosporin
group of antibiotics. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>IN PENICILLIN-SENSITIVE PATIENTS, CEPHALOSPORIN ANTIBIOTICS SHOULD BE
ADMINISTERED CAUTIOUSLY. THERE IS CLINICAL AND LABORATORY EVIDENCE OF PARTIAL
CROSS-ALLERGENICITY OF THE PENICILLINS AND THE CEPHALOSPORINS, AND THERE
ARE INSTANCES IN WHICH PATIENTS HAVE HAD REACTIONS, INCLUDING ANAPHYLAXIS,
TO BOTH DRUG CLASSES. </p>

<p>Antibiotics, including Cefaclor , should be administered cautiously
to any patient who has demonstrated some form of allergy, particularly
to drugs. </p>

<p>Pseudomembranous colitis has been reported with virtually all broad-spectrum
antibiotics (including macrolides, semisynthetic penicillins, and cephalosporins);
therefore, it is important to consider its diagnosis in patients who develop
diarrhea in association with the use of antibiotics. Such colitis may range
in severity from mild to life threatening. </p>

<p>Treatment with broad-spectrum antibiotics alters the normal flora of
the colon and may permit overgrowth of clostridia. Studies indicate that
a toxin produced by Clostridium Difficile is a primary cause of antibiotic-associated
colitis. </p>

<p>Mild cases of pseudomembranous colitis usually respond to drug discontinuance
alone. In moderate to severe cases, management should include sigmoidoscopy,
appropriate bacteriologic studies, and fluid, electrolyte, and protein
supplementation. When the colitis does not improve after the drug has been
discontinued, or when it is severe, oral vancomycin is the drug of choice
for antibiotic-associated pseudomembranous colitis produced by C. Difficile.
Other causes of colitis should be ruled out. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>General--If an allergic reaction to Cefaclor occurs, the drug should
be discontinued, and, if necessary, the patient should be treated with
appropriate agents, eg, pressor amines, antihistamines, or corticosteroids.
</p>

<p>Prolonged use of Cefaclor may result in the overgrowth of nonsusceptible
organisms. Careful observation of the patient is essential. If superinfection
occurs during therapy, appropriate measures should be taken. </p>

<p>Positive direct Coombs' tests have been reported during treatment with
the cephalosporin antibiotics. In hematologic studies or in transfusion
cross matching procedures when antiglobulin tests are performed on the
minor side or in Coombs' testing of newborns whose mothers have received
cephalosporin antibiotics before parturition, it should be recognized that
a positive Coombs' test may be due to the drug. </p>

<p>Cefaclor should be administered with caution in the presence of markedly
impaired renal function. Since the half-life of cefaclor in anuria is 2.3
to 2.8 hours, dosage adjustments for patients with moderate or severe renal
impairment are usually not required. Clinical experience with cefaclor
under such conditions is limited; therefore, careful clinical observation
and laboratory studies should be made. </p>

<p>As with other B-lactam antibiotics, the renal excretion of cefaclor
is inhibited by probenecid. </p>

<p>As a result of administration of Cefaclor, a false-positive reaction
for glucose in the urine may occur. This has been observed with Benedict's
and Fehling's solutions and also with Clinitest tablets but not with Tes-Tape
(Glucose Enzymatic Test Strip, USP). </p>

<p>Broad-spectrum antibiotics should be prescribed with caution in individuals
with a history of gastrointestinal disease, particularly colitis. </p>

<p>Pregnancy--Pregnancy Category B--Reproduction studies have been performed
in mice and rats at doses up to 12 times the human dose and in ferrets
given 3 times the maximum human dose and have revealed no evidence of impaired
fertility or harm to the fetus due to Cefaclor. There are, however, no
adequate and well- controlled studies in pregnant women. Because animal
reproduction studies are not always predictive of human response, this
drug should be used during pregnancy only if clearly needed. </p>

<p>Nursing Mothers--Small amounts of Cefaclor have been detected in mother's
milk following administration of single 500-mg doses. Average levels were
0.18, 0.20 0.21, and 0.16 mcgm/mL at 2, 3, 4, and 5 hours respectively.
Trace amounts were detected at 1 hour. The effect on nursing infants is
not known. Caution should be exercised when Cefaclor is administered to
a nursing woman. </p>

<p>Pediatric Use--Safety and effectiveness of this product for use in infants
less than 1 month of age have not been established. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>SEE WARNINGS </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Adverse effects considered related to therapy with Cefaclor are listed
below: </p>

<p>Hypersensitivity reactions have been reported in about 1.5% of patients
and include morbilliform eruptions (1 in 100). Pruritus, urticaria, and
positive Coombs' tests each occur in less than 1 in 200 patients. </p>

<p>Cases of SERUM-SICKNESS-LIKE reactions have been reported with the use
of Cefaclor. These are characterized by findings of erythema multiforme,
rashes, and other skin manifestations accompanied by arthritis/arthralgia,
with or without fever, and differ from classic serum sickness in that there
is infrequently associated lymphadenopathy and proteinuria, no circulating
immune complexes, and no evidence to date of sequelae of the reaction.
While further investigation is ongoing, SERUM-SICKNESS-LIKE reactions appear
to be due to hypersensitivity and more often occur during or following
a second (or subsequent) course of therapy with Cefaclor. Such reactions
have been reported more frequently in children than in adults with an overall
occurrence ranging from 1 in 200 (0.5%) in one focused trial to 2 in 8,346
(0.024%) in overall clinical trials (with an incidence in children in clinical
trials of 0.055%) to 1 in 38,000 (0.003%) in spontaneous event reports.
Signs and symptoms usually occur a few days after initiation of therapy
and subside within a few days after cessation of therapy; occasionally
these reactions have resulted in hospitalization, usually of short duration
(median hospitalization = two to three days, based on postmarketing surveillance
studies). In those requiring hospitalization, the symptoms have ranged
from mild to severe at the time of admission with more of the severe reactions
occurring in children. Antihistamines and glucocorticoids appear to enhance
resolution of the signs and symptoms. No serious sequelae have been reported.
</p>

<p>More severe hypersensitivity reactions, including Stevens-Johnson syndrome,
toxic epidermal necrolysis, and anaphylaxis, have been reported rarely.
Anaphylaxis may be more common in patients with a history of penicillin
allergy. </p>

<p>Gastrointestinal symptoms occur in about 2.5% of patients and include
diarrhea (1 in 70). </p>

<p>Symptoms of pseudomembranous colitis may appear either during or after
antibiotic treatment. Nausea and vomiting have been reported rarely. As
with some penicillins and some other cephalosporins, transient hepatitis
and cholestatic jaundice have been reported rarely. </p>

<p>Other effects considered related to therapy included eosinophilia (1
in 50 patients), genital pruritus or vaginitis (less than 1 in 100 patients),
and, rarely, thrombocytopenia or reversible interstitial nephritis. </p>

<p>Causal Relationship Uncertain--CNS--Rarely, reversible hyperactivity,
nervousness, insomnia, confusion, hypertonia, dizziness, and somnolence
have been reported. </p>

<p>Transitory abnormalities in clinical laboratory test results have been
reported. Although they were of uncertain etiology, they are listed below
to serve as alerting information for the physician. </p>

<p>Hepatic--Slight elevations of AST (SGOT), ALT (SGPT), or alkaline phosphatase
values (1 in 40). </p>

<p>Hematopoietic--As has also been reported with other beta-lactam antibiotics,
transient lymphocytosis, leukopenia, and, rarely, hemolytic anemia and
reversible neutropenia of possible clinical significance. </p>

<p>There have been rare reports of increased prothrombin time with or without
clinical bleeding in patients receiving Cefaclor and Coumadin concomitantly.
</p>

<p>Renal--Slight elevations in BUN or serum creatinine (less than 1 in
500) or abnormal urinalysis (less than 1 in 200). </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Signs And Symptoms--The toxic symptoms following an overdose of cefaclor
may include nausea, vomiting, epigastric distress, and diarrhea. The severity
of the epigastric distress and the diarrhea are dose related. If other
symptoms are present, it is probable that they are secondary to an underlying
disease state, an allergic reaction, or the effects of other intoxication.
</p>

<p>Treatment--To obtain up-to-date information about the treatment of overdose,
a good resource is your certified Regional Poison Control Center. In managing
overdosage, consider the possibility of multiple drug overdoses, interaction
among drugs, and unusual drug kinetics in your patient. </p>

<p>Unless 5 times the normal dose of cefaclor has been ingested, gastrointestinal
decontamination will not be necessary. </p>

<p>Protect the patient's airway and support ventilation and perfusion.
Meticulously monitor and maintain, within acceptable limits, the patient's
vital signs, blood gases, serum electrolytes, etc. Absorption of drugs
from the gastrointestinal tract may be decreased by giving activated charcoal,
which, in many cases, is more effective than emesis or lavage; consider
charcoal instead of or in addition to gastric emptying. Repeated doses
of charcoal over time may hasten elimination of some drugs that have been
absorbed. Safeguard the patient's airway when employing gastric emptying
or charcoal. </p>

<p>Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion
have not been established as beneficial for an overdose of cefaclor. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Cefaclor is administered orally. </p>

<p>Adults--The usual adult dosage is 250 mg every 8 hours. </p>

<p>For more severe infections (such as pneumonia) or those caused by less
susceptible organisms, doses may be doubled. </p>

<p>Children--The usual recommended daily dosage for children is 20 mg/kg/day
in divided doses every 8 hours. </p>

<p>In more serious infections, otitis media, and infections caused by less
susceptible organisms, 40 mg/kg/day are recommended, with a maximum dosage
of 1 g/day. </p>

<pre>                           Cefaclor Suspension                                    
                             20 MG/KG/DAY                                       
Child's Weight       125 mg/5 mL       250 mg/5 mL          .                   
---------------------------------------------------                             
        9 kg       1/2 tsp t.i.d.                                               
       18 kg         1 tsp t.i.d.      1/2 tsp t.i.d.                           
                             40 MG/KG/DAY                                       
        9 kg         1 tsp t.i.d.      1/2 tsp t.i.d.       .                   
       18 kg                             1 tsp t.i.d.           
  </pre>

<p>B.I.D. Treatment Option--For the treatment of otitis media and pharyngitis,
the total daily dosage may be divided and administered every 12 hours.
</p>

<pre>      
                           Cefaclor Suspension                                    
                             20 MG/KG/DAY   
                             (PHARYNGITIS)                                      
Child's Weight       187 mg/5 mL       375 mg/5 mL          .                   
---------------------------------------------------                             
        9 kg       1/2 tsp b.i.d.                                               
       18 kg         1 tsp b.i.d.      1/2 tsp b.i.d.                           
                             40 MG/KG/DAY                                       
                             (OTITIS MEDIA)                                     
        9 kg         1 tsp b.i.d.      1/2 tsp b.i.d.       .                   
       18 kg                             1 tsp b.i.d.   
</pre>

<p>Cefaclor may be administered in the presence of impaired renal function.
Under such a condition, the dosage usually is unchanged (See Precautions).
</p>

<p>In the treatment of beta-hemolytic streptococcal infections, a therapeutic
dosage of Cefaclor should be administered for at least 10 days.</p>

<p>REFERENCES 1. Am J Clin Pathol 1966;45:493; Federal Register 1974;39:19182-19184.
</p>

<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-58</DOCNO>
<DOCOLDNO>IA018-000200-B041-128</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/hydrox.htm 206.86.175.201 19970106230933 text/html 9345
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:03:08 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 9163
Last-modified: Tue, 22 Oct 1996 06:30:21 GMT
</DOCHDR>
<html>
<head>
   <title>Hydroxyzine - RxList Generic Information</title>
   <meta name="keywords" content="Adroxazine, Anxanil, Atarax, Atazina, Aterax,
Bobsule, Calmofilase, Cedar, Disron, E-Vista, Hiderax, Histan,
Hizin, Hydroxacen, Hyzine, Iterax, Masmoran, Multipax, Neucalm 50,
Novohydroxyzin, Orgatrax, Otarex, Paxistil, Postarax, Quiess, Rezine,
Tranquijust, Ultramax, Visrex, Vista-Plex 50, Vistacon-50, Vistacot,
Vistaject, Vistaril, Vistazine">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Hydroxyzine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Hydroxyzine hydrochloride is designated chemically as 1-(p-chlorobenzhydryl)
4- (2-(2-hydroxyethoxy)-ethyl) piperazine dihydrochloride. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Hydroxyzine is unrelated chemically to the phenothiazines, reserpine,
meprobamate, or the benzodiazepines. </p>

<p>Hydroxyzine is not a cortical depressant, but its action may be due
to a suppression of activity in certain key regions of the subcortical
area of the central nervous system. Primary skeletal muscle relaxation
has been demonstrated experimentally. Bronchodilator activity, and antihistaminic
and analgesic effects have been demonstrated experimentally and confirmed
clinically. An antiemetic effect, both by the apomorphine test and the
veriloid test, has been demonstrated. Pharmacological and clinical studies
indicate that hydroxyzine in therapeutic dosage does not increase gastric
secretion or acidity and in most cases has mild antisecretory activity.
Hydroxyzine is rapidly absorbed from the gastrointestinal tract and Hydroxyzine's
clinical effects are usually noted within 15 to 30 minutes after oral administration.
</p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>For symptomatic relief of anxiety and tension associated with psychoneurosis
and as an adjunct in organic disease states in which anxiety is manifested.
Useful in the management of pruritus due to allergic conditions such as
chronic urticaria and atopic and contact dermatoses, and in histamine-
mediated pruritus. </p>

<p>As a sedative when used as premedication and following general anesthesia,
HYDROXYZINE MAY POTENTIATE MEPERIDINE (DEMEROL(R)) AND BARBITURATES, so
their use in pre-anesthetic adjunctive therapy should be modified on an
individual basis. Atropine and other belladonna alkaloids are not affected
by the drug. Hydroxyzine is not known to interfere with the action of digitalis
in any way and it may be used concurrently with this agent. </p>

<p>The effectiveness of hydroxyzine as an antianxiety agent for long term
use, that is more than 4 months, has not been assessed by systematic clinical
studies. The physician should reassess periodically the usefulness of the
drug for the individual patient. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit,
induced fetal abnormalities in the rat and mouse at doses substantially
above the human therapeutic range. Clinical data in human beings are inadequate
to establish safety in early pregnancy. Until such data are available,
hydroxyzine is contraindicated in early pregnancy. </p>

<p>Hydroxyzine is contraindicated for patients who have shown a previous
hypersensitivity to it. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>NURSING MOTHERS: It is not known whether this drug is excreted in human
milk. Since many drugs are so excreted, hydroxyzine should not be given
to nursing mothers. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG
IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS
NARCOTICS, NON- NARCOTIC ANALGESICS AND BARBITURATES. Therefore when central
nervous system depressants are administered concomitantly with hydroxyzine
their dosage should be reduced. Since drowsiness may occur with use of
this drug, patients should be warned of this possibility and cautioned
against driving a car or operating dangerous machinery while taking Hydroxyzine.
Patients should be advised against the simultaneous use of other CNS depressant
drugs, and cautioned that the effect of alcohol may be increased. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG
IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS
NARCOTICS, NON- NARCOTIC ANALGESICS AND BARBITURATES. Therefore when central
nervous system depressants are administered concomitantly with hydroxyzine
their dosage should be reduced. (See Also PRECAUTIONS.) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Side effects reported with the administration of Hydroxyzine (hydroxyzine
hydrochloride) are usually mild and transitory in nature. </p>

<p>ANTICHOLINERGIC: Dry mouth. </p>

<p>CENTRAL NERVOUS SYSTEM: Drowsiness is usually transitory and may disappear
in a few days of continued therapy or upon reduction of the dose. Involuntary
motor activity including rare instances of tremor and convulsions have
been reported, usually with doses considerably higher than those recommended.
Clinically significant respiratory depression has not been reported at
recommended doses. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>The most common manifestation of Hydroxyzine overdosage is hypersedation.
As in the management of overdosage with any drug, it should be borne in
mind that multiple agents may have been taken. </p>

<p>If vomiting has not occurred spontaneously, it should be induced. Immediate
gastric lavage is also recommended. General supportive care, including
frequent monitoring of the vital signs and close observation of the patient,
is indicated. Hypotension, though unlikely, may be controlled with intravenous
fluids and Levophed(R) (levarterenol), or Aramine(R) (metaraminol). Do
not use epinephrine as Hydroxyzine counteracts its pressor action. </p>

<p>There is no specific antidote. It is doubtful that hemodialysis would
be of any value in the treatment of overdosage with hydroxyzine. However,
if other agents such as barbiturates have been ingested concomitantly,
hemodialysis may be indicated. There is no practical method to quantitate
hydroxyzine in body fluids or tissue after its ingestion or administration.
</p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>For symptomatic relief of anxiety and tension associated with psychoneurosis
and as an adjunct in organic disease states in which anxiety is manifested:
in adults, 50-100 mg q.i.d.; children under 6 years, 50 mg daily in divided
doses and over 6 years, 50-100 mg daily in divided doses. </p>

<p>For use in the management of pruritus due to allergic conditions such
as chronic urticaria and atopic and contact dermatoses, and in histamine-
mediated pruritus: in adults, 25 mg t.i.d. or q.i.d.; children under 6
years, 50 mg daily in divided doses and over 6 years, 50-100 mg daily in
divided doses. As a sedative when used as a premedication and following
general anesthesia: 50- 100 mg in adults, and 0.6 mg/kg in children. </p>

<p>When treatment is initiated by the intramuscular route of administration,
subsequent doses may be administered orally. As with all medications, the
dosage should be adjusted according to the patient's response to therapy.
</p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-59</DOCNO>
<DOCOLDNO>IA018-000200-B036-196</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/buspir.htm 206.86.175.201 19970106225237 text/html 32508
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:46:16 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 32325
Last-modified: Mon, 08 Jul 1996 21:19:54 GMT
</DOCHDR>
<html>
<head>
   <title>Buspirone - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Buspirone</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Buspirone is an antianxiety agent that is not chemically or pharmacologically
related to the benzodiazepines, barbiturates, or other sedative/anxiolytic
drugs. </p>

<p>Buspirone hydrochloride is a white crystalline, water soluble compound
with a molecular weight of 422.0. Chemically, buspirone hydrochloride is
8- (4-(4-(2 pyrimidinyl)-1-piperazinyl)butyl)-8-azaspiro(4.5)decane-7,9-dione
monohydrochloride. The empirical formula is C21H31N5O2.HCl. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>The mechanism of action of buspirone is unknown. Buspirone differs from
typical benzodiazepine anxiolytics in that it does not exert anticonvulsant
or muscle relaxant effects. It also lacks the prominent sedative effect
that is associated with more typical anxiolytics. In Vitro preclinical
studies have shown that buspirone has a high affinity for serotonin (5-HT1A)
receptors. Buspirone has no significant affinity for benzodiazepine receptors
and does not affect GABA binding In Vitro or In Vivo when tested in preclinical
models. </p>

<p>Buspirone has moderate affinity for brain D2-dopamine receptors. Some
studies do suggest that buspirone may have indirect effects on other neurotransmitter
systems. </p>

<p>Buspirone is rapidly absorbed in man and undergoes extensive first pass
metabolism. In a radiolabeled study, unchanged buspirone in the plasma
accounted for only about 1% of the radioactivity in the plasma. Following
oral administration, plasma concentrations of unchanged buspirone are very
low and variable between subjects. Peak plasma levels of 1 to 6 ng/mL have
been observed 40 to 90 minutes after single oral doses of 20 mg. The single-dose
bioavailability of unchanged buspirone when taken as a tablet is on the
average about 90% of an equivalent dose of solution, but there is large
variability. </p>

<p>The effects of food upon the bioavailability of Buspirone have been
studied in eight subjects. They were given a 20-mg dose with and without
food; the area under the plasma concentration-time curve (AUC) and peak
plasma concentration (Cmax) of unchanged buspirone increased by 84% and
116% respectively, but the total amount of buspirone immunoreactive material
did not change. This suggests that food may decrease the extent of presystemic
clearance of buspirone, but the clinical significance of these findings
is unknown. </p>

<p>A multiple-dose study conducted in 15 subjects suggests that buspirone
has nonlinear pharmacokinetics. Thus, dose increases and repeated dosing
may lead to somewhat higher blood levels of unchanged buspirone than would
be predicted from results of single-dose studies. </p>

<p>In man, approximately 95% of buspirone is plasma protein bound, but
other highly bound drugs, eg, phenytoin, propranolol, and warfarin are
not displaced by buspirone from plasma protein In Vitro. However, In Vitro
binding studies show that buspirone does displace digoxin. </p>

<p>Buspirone is metabolized primarily by oxidation producing several hydroxylated
derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine
(1-PP). In animal models predictive of anxiolytic potential, 1-PP has about
one quarter of the activity of buspirone, but is present in up to 20-fold
greater amounts. However, this is probably not important in humans: blood
samples from humans chronically exposed to Buspirone do not exhibit high
levels of 1-PP; mean values are approximately 3 ng/mL and the highest human
blood level recorded among 108 chronically dosed patients was 17 ng/mL,
less than 1/200th of 1-PP levels found in animals given large doses of
buspirone without signs of toxicity. </p>

<p>In a single-dose study using 14C-labeled buspirone, 29% to 63% of the
dose was excreted in the urine within 24 hours, primarily as metabolites;
fecal excretion accounted for 18 to 38% of the dose. The average elimination
half life of unchanged buspirone after single doses of 10 to 40 mg is about
2 to 3 hours. </p>

<p>The pharmacokinetics of Buspirone in patients with hepatic or renal
dysfunction has not been determined, nor has the effect of age. The effect
of Buspirone on drug metabolism or concomitant drug disposition has not
been investigated. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Buspirone is indicated for the management of anxiety disorders or the
short-term relief of the symptoms of anxiety. Anxiety or tension associated
with the stress of everyday life usually does not require treatment with
an anxiolytic. </p>

<p>The efficacy of Buspirone has been demonstrated in controlled clinical
trials of outpatients whose diagnosis roughly corresponds to Generalized
Anxiety Disorder (GAD). Many of the patients enrolled in these studies
also had coexisting depressive symptoms and Buspirone relieved anxiety
in the presence of these coexisting depressive symptoms. The patients evaluated
in these studies had experienced symptoms for periods of 1 month to over
1 year prior to the study, with an average symptom duration of 6 months.
Generalized Anxiety Disorder (300.02) is described in the American Psychiatric
Association's Diagnostic and Statistical Manual, III (REF. 1) as follows:
</p>

<p>Generalized, persistent anxiety (of at least 1 month continual duration),
manifested by symptoms from three of the four following categories. </p>

<p>1. Motor tension: shakiness, jitteriness, jumpiness, trembling, tension,
muscle aches, fatigability, inability to relax, eyelid twitch, furrowed
brow, strained face, fidgeting, restlessness, easy startle. </p>

<p>2. Autonomic hyperactivity: sweating, heart pounding or racing, cold,
clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling
in hands or feet), upset stomach, hot or cold spells, frequent urination,
diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing,
pallor, high resting pulse, and respiration rate. </p>

<p>3. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation
of misfortune to self or others. </p>

<p>4. Vigilance and scanning: hyperattentiveness resulting in distractibility,
difficulty in concentrating, insomnia, feeling &quot;on edge,&quot; irritability,
impatience. </p>

<p>The above symptoms would not be due to another mental disorder, such
as a depressive disorder or schizophrenia. However, mild depressive symptoms
are common in GAD. </p>

<p>The effectiveness of Buspirone in long-term use, that is, for more than
3 to 4 weeks, has not been demonstrated in controlled trials. There is
no body of evidence available that systematically addresses the appropriate
duration of treatment for GAD. However, in a study of long-term use, 264
patients were treated with Buspirone for 1 year without ill effect. Therefore,
the physician who elects to use Buspirone for extended periods should periodically
reassess the usefulness of the drug for the individual patient. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Buspirone is contraindicated in patients hypersensitive to buspirone
hydrochloride. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>THE ADMINISTRATION OF Buspirone TO A PATIENT TAKING A MONOAMINE OXIDASE
INHIBITOR (MAOI) MAY POSE A HAZARD. There have been reports of the occurrence
of elevated blood pressure when Buspirone has been added to a regimen including
an MAOI. Therefore, it is recommended that Buspirone not be used concomitantly
with an MAOI. </p>

<p>Because Buspirone has no established antipsychotic activity, it should
not be employed in lieu of appropriate antipsychotic treatment. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL: </p>

<p>INTERFERENCE WITH COGNITIVE AND MOTOR PERFORMANCE: </p>

<p>Studies indicate that Buspirone is less sedating than other anxiolytics
and that it does not produce significant functional impairment. However,
its CNS effects in any individual patient may not be predictable. Therefore,
patients should be cautioned about operating an automobile or using complex
machinery until they are reasonably certain that buspirone treatment does
not affect them adversely. </p>

<p>While formal studies of the interaction of Buspirone with alcohol indicate
that buspirone does not increase alcohol-induced impairment in motor and
mental performance, it is prudent to avoid concomitant use of alcohol and
buspirone. </p>

<p>POTENTIAL FOR WITHDRAWAL REACTIONS IN SEDATIVE/HYPNOTIC/ANXIOLYTIC DRUG
DEPENDENT PATIENTS: </p>

<p>Because Buspirone does not exhibit cross-tolerance with benzodiazepines
and other common sedative/hypnotic drugs, it will not block the withdrawal
syndrome often seen with cessation of therapy with these drugs. Therefore,
before starting therapy with Buspirone, it is advisable to withdraw patients
gradually, especially patients who have been using a CNS-depressant drug
chronically, from their prior treatment. Rebound or withdrawal symptoms
may occur over varying time periods, depending in part on the type of drug,
and its effective half-life of elimination. </p>

<p>The syndrome of withdrawal from sedative/hypnotic/anxiolytic drugs can
appear as any combination of irritability, anxiety, agitation, insomnia,
tremor, abdominal cramps, muscle cramps, vomiting, sweating, flu-like symptoms
without fever, and occasionally, even as seizures. </p>

<p>POSSIBLE CONCERNS RELATED TO BUSPIRONE'S BINDING TO DOPAMINE RECEPTORS:
</p>

<p>Because buspirone can bind to central dopamine receptors, a question
has been raised about its potential to cause acute and chronic changes
in dopamine mediated neurological function (eg, dystonia, pseudoparkinsonism,
akathisia, and tardive dyskinesia). Clinical experience in controlled trials
has failed to identify any significant neuroleptic-like activity; however,
a syndrome of restlessness, appearing shortly after initiation of treatment,
has been reported in some small fraction of buspirone-treated patients.
The syndrome may be explained in several ways. For example, buspirone may
increase central noradrenergic activity; alternatively, the effect may
be attributable to dopaminergic effects (ie, represent akathisia). Obviously,
the quesion cannot be totally resolved at this point in time. Generally,
long-term sequelae of any drug's use can be identified only after several
years of marketing. </p>

<p>INFORMATION FOR PATIENTS: </p>

<p>To assure safe and effective use of Buspirone, the following information
and instructions should be given to patients: </p>

<p>1. Inform your physician about any medications, prescription or nonprescription
alcohol, or drugs that you are now taking or plan to take during your treatment
with Buspirone. </p>

<p>2. Inform your physician if you are pregnant, or if you are planning
to become pregnant, or if you become pregnant while you are taking Buspirone.
</p>

<p>3. Inform your physician if you are breastfeeding an infant. </p>

<p>4. Until you experience how this medication affects you, do not drive
a car or operate potentially dangerous machinery. </p>

<p>LABORATORY TESTS: </p>

<p>There are no specific laboratory tests recommended. </p>

<p>DRUG INTERACTIONS: </p>

<p>It is recommended that Buspirone Not be used concomitantly with MAO
inhibitors (See WARNINGS). Because the effects of concomitant administration
of Buspirone with most other psychotropic drugs have not been studied,
the concomitant use of Buspirone with other CNS-active drugs should be
approached with caution. </p>

<p>There is one report suggesting that the concomitant use of Desyrel (trazodone
hydrochloride) and Buspirone may have caused 3- to 6-fold elevations on
SGPT (ALT) in a few patients. In a similar study, attempting to replicate
this finding, no interactive effect on hepatic transaminases was identified.
</p>

<p>In a study in normal volunteers, concomitant administration of Buspirone
and haloperidol resulted in increased serum haloperidol concentrations.
The clinical significance of this finding is not clear. </p>

<p>In Vitro, buspirone does not displace tightly bound drugs like phenytoin,
propranolol, and warfarin from serum proteins. However, there has been
one report of prolonged prothrombin time when buspirone was added to the
regimen of a patient treated with warfarin. The patient was also chronically
receiving phenytoin, phenobarbital, digoxin, and Synthroid. </p>

<p>In Vitro, buspirone may displace less firmly bound drugs like digoxin.
The clinical significance of this property is unknown. </p>

<p>DRUG/LABORATORY TEST INTERACTIONS: </p>

<p>Buspirone is not known to interfere with commonly employed clinical
laboratory tests. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: </p>

<p>No evidence of carcinogenic potential was observed in rats during a
24-month study at approximately 133 times the maximum recommended human
oral dose; or in mice, during an 18-month study at approximately 167 times
the maximum recommended human oral dose. </p>

<p>With or without metabolic activation, buspirone did not induce point
mutations in five strains of Salmonella Typhimurium (Ames Test) or mouse
lymphoma L5178YTK + cell cultures, nor was DNA damage observed with buspirone
in Wi-38 human cells. Chromosomal aberrations or abnormalities did not
occur in bone marrow cells of mice given one or five daily doses of buspirone.
</p>

<p>PREGNANCY: TERATOGENIC EFFECTS: </p>

<p>Pregnancy Category B: No fertility impairment or fetal damage was observed
in reproduction studies performed in rats and rabbits at buspirone doses
of approximately 30 times the maximum recommended human dose. In humans,
however, adequate and well-controlled studies during pregnancy have Not
been performed. Because animal reproduction studies are not always predictive
of human response this drug should be used during pregnancy only if clearly
needed. </p>

<p>LABOR AND DELIVERY: </p>

<p>The effect of Buspirone on labor and delivery in women is unknown. No
adverse effects were noted in reproduction studies in rats. </p>

<p>NURSING MOTHERS: </p>

<p>The extent of the excretion in human milk of buspirone or its metabolites
is not known. In rats, however, buspirone and its metabolites are excreted
in milk. Buspirone administration to nursing women should be avoided if
clinically possible. </p>

<p>PEDIATRIC USE: </p>

<p>The safety and effectiveness of Buspirone have not been determined in
individuals below 18 years of age. </p>

<p>USE IN THE ELDERLY: </p>

<p>Buspirone has not been systematically evaluated in older patients; however,
several hundred elderly patients have participated in clinical studies
with Buspirone and no unusual adverse age-related phenomena have been identified.
In 87 elderly patients for whom dosage data were available, the modal total
daily dose of Buspirone was 15 mg per day, the same as that in the total
sample of patients treated with Buspirone. </p>

<p>USE IN PATIENTS WITH IMPAIRED HEPATIC OR RENAL FUNCTION: </p>

<p>Since Buspirone is metabolized by the liver and excreted by the kidneys,
its administration to patients with severe hepatic or renal impairment
cannot be recommended. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Because the effects of concomitant administration of Buspirone with
most other psychotropic drugs have not been studied, the concomitant use
of Buspirone with other CNS-active drugs should be approached with caution
(see WARNINGS). </p>

<p>There is one report suggesting that the concomitant use of Desyrel (trazodone
hydrochloride) and Buspirone may have caused 3- to 6-fold elevations on
SGPT (ALT) in a few patients. In a similar study, attempting to replicate
this finding, no interactive effect on hepatic transaminases was identified.
</p>

<p>In a study in normal volunteers, concomitant administration of Buspirone
and haloperidol resulted in increased serum haloperidol concentrations.
The clinical significance of this finding is not clear. </p>

<p>In Vitro, buspirone does not displace tightly bound drugs like phenytoin,
propranolol, and warfarin from serum proteins. However, there has been
one report of prolonged prothrombin time when buspirone was added to the
regimen of a patient treated with warfarin. The patient was also chronically
receiving phenytoin, phenobarbital, digoxin, and Synthroid. </p>

<p>In Vitro, buspirone may displace less firmly bound drugs like digoxin.
The clinical significance of this property is unknown. </p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>(SEE ALSO PRECAUTIONS) </p>

<p>COMMONLY OBSERVED: </p>

<p>The more commonly observed untoward events associated with the use of
Buspirone not seen at an equivalent incidence among placebo-treated patients
include dizziness, nausea, headache, nervousness, lightheadedness, and
excitement. </p>

<p>ASSOCIATED WITH DISCONTINUATION OF TREATMENT: </p>

<p>One guide to the relative clinical importance of adverse events associated
with Buspirone is provided by the frequency with which they caused drug
discontinuation during clinical testing. Approximately 10% of the 2200
anxious patients who participated in the Buspirone premarketing clinical
efficacy trials in anxiety disorders lasting 3 to 4 weeks discontinued
treatment due to an adverse event. The more common events causing discontinuation
included: central nervous system disturbances (3.4%), primarily dizziness,
insomnia, nervousness, drowsiness and lightheaded feeling; gastrointestinal
disturbances (1.2%), primarily nausea; and miscellaneous disturbances (1.1%),
primarily headache and fatigue. In addition, 3.4% of patients had multiple
complaints, none of which could be characterized as primary. </p>

<p>INCIDENCE IN CONTROLLED CLINICAL TRIALS: </p>

<p>The table that follows enumerates adverse events that occurred at a
frequency of 1% or more among Buspirone patients who participated in 4-week,
controlled trials comparing Buspirone with placebo. The frequencies were
obtained from pooled data for 17 trials. The prescriber should be aware
that these figures cannot be used to predict the incidence of side effects
in the course of usual medical practice where patient characteristics and
other factors differ from those which prevailed in the clinical trials.
Similarly, the cited frequencies cannot be compared with figures obtained
from other clinical investigations involving different treatments, uses,
and investigators. Comparison of the cited figures, however, does provide
the prescribing physician with some basis for estimating the relative contribution
of drug and nondrug factors to the side-effect incidence rate in the population
studied. </p>

<pre>      TREATMENT-EMERGENT ADVERSE EXPERIENCE                                    

         INCIDENCE IN PLACEBO-CONTROLLED                                       

                 CLINICAL TRIALS*                                              

         (PERCENT OF PATIENTS REPORTING)                                       

                               Buspirone    PLACEBO                            
   
ADVERSE EXPERIENCE            (N = 477) (N = 464)                              

Cardiovascular                                                                 

 Tachycardia/Palpitations         1         1                                  

CNS                                                                            

 Dizziness                       12         3                                  

 Drowsiness                      10         9                                  

 Nervousness                      5         1                                  

 Insomnia                         3         3                                  

 Lightheadedness                  3        --                                  

 Decreased Concentration          2         2                                  

 Excitement                       2        --                                  

 Anger/Hostility                  2        --                                  

 Confusion                        2        --                                  

 Depression                       2         2                                  

EENT                                                                           

 Blurred Vision                   2        --                                  

Gastrointestinal                                                               

 Nausea                           8         5                                  

 Dry Mouth                        3         4                                  

 Abdominal/Gastric Distress       2         2                                  

 Diarrhea                         2        --                                  

 Constipation                     1         2                                  

 Vomiting                         1         2                                  

Musculoskeletal                                                                

 Musculoskeletal Aches/Pains      1        --                                  

Neurological                                                                   

 Numbness                         2        --                                  

 Paresthesia                      1        --                                  

 Incoordination                   1        --                                  

 Tremor                           1        --                                  

Skin                                                                           

 Skin Rash                        1        --                                  

Miscellaneous                                                                  

 Headache                         6         3                                  

 Fatigue                          4         4                                  

 Weakness                         2        --                                  

 Sweating/Clamminess              1        --                                  

------------                                                                   

* Events reported by at least 1% of Buspirone                                  
   
  patients are included.                                                       

--Incidence less than 1%.                                                      

------------                                                                   </pre>

<p>OTHER EVENTS OBSERVED DURING THE ENTIRE PREMARKETING EVALUATION OF Buspirone:
</p>

<p>During its premarketing assessment, Buspirone was evaluated in over
3500 subjects. </p>

<p>This section reports event frequencies for adverse events occurring
in approximately 3000 subjects from this group who took multiple doses
of Buspirone in the dose range for which Buspirone is being recommended
(ie, the modal daily dose of Buspirone fell between 10 and 30 mg for 70%
of the patients studied) and for whom safety data were systematically collected.
The conditions and duration of exposure to Buspirone varied greatly, involving
well-controlled studies as well as experience in open and uncontrolled
clinical settings. As part of the total experience gained in clinical studies,
various adverse events were reported. In the absence of appropriate controls
in some of the studies, a causal relationship to Buspirone treatment cannot
be determined. The list includes all undesirable events reasonably associated
with the use of the drug. </p>

<p>The following enumeration by organ system describes events in terms
of their relative frequency of reporting in this data base. Events of major
clinical importance are also described in the PRECAUTIONS section. </p>

<p>The following definitions of frequency are used: Frequent adverse events
are defined as those occurring in at least 1/100 patients. Infrequent adverse
events are those occurring in 1/100 to 1/1000 patients, while rare events
are those occurring in less than 1/1000 patients. </p>

<p>CARDIOVASCULAR: </p>

<p>Frequent was nonspecific chest pain; infrequent were syncope, hypotension
and hypertension; rare were cerebrovascular accident, congestive heart
failure, myocardial infarction, cardiomyopathy and bradycardia. </p>

<p>CENTRAL NERVOUS SYSTEM: </p>

<p>Frequent were dream disturbances; infrequent were depersonalization,
dysphoria, noise intolerance, euphoria, akathisia, fearfulness, loss of
interest, dissociative reaction, hallucinations, suicidal ideation and
seizures; rare were feelings of claustrophobia, cold intolerance, stupor,
and slurred speech and psychosis. </p>

<p>EENT: </p>

<p>Frequent were tinnitus, sore throat, and nasal congestion. Infrequent
were redness and itching of the eyes, altered taste, altered smell, and
conjunctivitis; rare were inner ear abnormality, eye pain, photophobia,
and pressure on eyes. </p>

<p>ENDOCRINE: </p>

<p>Rare were galactorrhea and thyroid abnormality. </p>

<p>GASTROINTESTINAL: </p>

<p>Infrequent were flatulence, anorexia, increased appetite, salivation,
irritable colon and rectal bleeding; rare was burning of the tongue. </p>

<p>GENITOURINARY: </p>

<p>Infrequent were urinary frequency, urinary hesitancy, menstrual irregularity
and spotting, and dysuria; rare were amenorrhea, pelvic inflammatory disease,
enuresis, and nocturia. </p>

<p>MUSCULOSKELETAL: </p>

<p>Infrequent were muscle cramps, muscle spasms, rigid/stiff muscles, and
arthralgias. </p>

<p>NEUROLOGICAL: </p>

<p>Infrequent were involuntary movements and slowed reaction time; rare
was muscle weakness. </p>

<p>RESPIRATORY: </p>

<p>Infrequent were hyperventilation, shortness of breath, and chest congestion;
rare was epistaxis. </p>

<p>SEXUAL FUNCTION: </p>

<p>Infrequent were decreased or increased libido; rare were delayed ejaculation
and impotence. </p>

<p>SKIN: </p>

<p>Infrequent were edema, pruritus, flushing, easy bruising, hair loss,
dry skin, facial edema and blisters; rare were acne and thinning of nails.
</p>

<p>CLINICAL LABORATORY: </p>

<p>Infrequent were increases in hepatic aminotransferases (SGOT, SGPT);
rare were eosinophilia, leukopenia, and thrombocytopenia. </p>

<p>MISCELLANEOUS: </p>

<p>Infrequent were weight gain, fever, roaring sensation in the head, weight
loss, and malaise; rare were alcohol abuse, bleeding disturbance, loss
of voice, and hiccoughs. </p>

<p>POSTINTRODUCTION CLINICAL EXPERIENCE </p>

<p>Postmarketing experience has shown an adverse experience profile similar
to that given above. Voluntary reports since introduction have included
rare occurrences of allergic reactions, cogwheel rigidity, dystonic reactions,
ecchymosis, emotional lability, tunnel vision, and urinary retention. Because
of the uncontrolled nature of these spontaneous reports, a causal relationship
to Buspirone treatment has not been determined. </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>CONTROLLED SUBSTANCE CLASS: </p>

<p>Buspirone is not a controlled substance. </p>

<p>PHYSICAL AND PSYCHOLOGICAL DEPENDENCE: </p>

<p>In human and animal studies, buspirone has shown no potential for abuse
or diversion and there is no evidence that it causes tolerance, or either
physical or psychological dependence. Human volunteers with a history of
recreational drug or alcohol usage were studied in two double-blind clinical
investigations. None of the subjects were able to distinguish between Buspirone
and placebo. By contrast, subjects showed a statistically significant preference
for methaqualone and diazepam. Studies in monkeys, mice, and rats have
indicated that buspirone lacks potential for abuse. </p>

<p>Following chronic administration in the rat, abrupt withdrawal of buspirone
did not result in the loss of body weight commonly observed with substances
that cause physical dependency. </p>

<p>Although there is no direct evidence that Buspirone causes physical
dependence or drug-seeking behavior, it is difficult to predict from experiments
the extent to which a CNS-active drug will be misused, diverted, and/or
abused once marketed. Consequently, physicians should carefully evaluate
patients for a history of drug abuse and follow such patients closely,
observing them for signs of Buspirone misuse or abuse (eg, development
of tolerance, incrementation of dose, drug- seeking behavior). </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>SIGNS AND SYMPTOMS: </p>

<p>In clinical pharmacology trials, doses as high as 375 mg/day were administered
to healthy male volunteers. As this dose was approached, the following
symptoms were observed: nausea, vomiting, dizziness, drowsiness, miosis,
and gastric distress. No deaths have been reported in humans either with
deliberate or accidental overdosage of Buspirone. Toxicology studies of
buspirone yielded the following LD50 values: mice, 655 mg/kg; rats, 196
mg/kg; dogs, 586 mg/kg; and monkeys, 356 mg/kg. These dosages are 160-550
times the recommended human daily dose. </p>

<p>RECOMMENDED OVERDOSE TREATMENT: </p>

<p>General symptomatic and supportive measures should be used along with
immediate gastric lavage. Respiration, pulse, and blood pressure should
be monitored as in all cases of drug overdosage. No specific antidote is
known to buspirone, and dialyzability of buspirone has not been determined.
</p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>The recommended initial dose is 15 mg daily (5 mg three times a day).
To achieve an optimal therapeutic response, at intervals of 2 to 3 days
the dosage may be increased 5 mg per day, as needed. The maximum daily
dosage should not exceed 60 mg per day. In clinical trials allowing dose
titration, divided doses of 20 to 30 mg per day were commonly employed.
</p>

<p>REFERENCES </p>

<p>1. American Psychiatric Association, Ed.: Diagnostic and Statistical
Manual of Mental Disorders--III, American Psychiatric Association, May
1980. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-60</DOCNO>
<DOCOLDNO>IA018-000200-B042-209</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/guaicod.htm 206.86.175.201 19970106231531 text/html 5744
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:09:17 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5562
Last-modified: Tue, 12 Nov 1996 08:09:30 GMT
</DOCHDR>
<html>
<head>
   <title>Guaifenesin With Codeine - RxList Generic Information</title>
   <meta name="keywords" content="Baytussin A.C., Biotussin Ac, Bitex, Bron-Tuss, Brontex, 
Cheracol, Cheratussin Ac, Cherospect, Cherralex W/Codeine, Codefen,
Codesia, Gani-Tuss Nr, Glyatuss Ac, Glydeine, Guaifen-C, Guaifenesin Ac, 
Guaifenesin W/Codeine, Guaituss Ac, Guiatuss Ac, Guiatussin Ac, Guiatussin 
W/Codeine, Halotussin-Dac, Iofen-C Nf, Marcof, Medi-Tuss W/Codeine,
Mytussin Ac, Nortussin, Robafen Ac, Robichem Ac, Robitussin-Ac, 
Robolene Ac, Tolu-Sed, Tussi-Organidin Nr, Tussi-Organidin-S Nr, Tussidin 
Nr, Tussin Ac">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Guaifenesin With Codeine (Syrup)</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [contra] [<a href="#WARNINGS">warn!</a>]
[caution] [<a href="#DRUG INTERACTIONS">drug-drug</a>] [side effects] [toxicity]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<pre>
Guaifenesin and Codeine

Each 5 ml (1 teaspoonful) contains:

Guaifenesin, USP:  100 mg

Codeine Phosphate, USP:  10 mg

(Warning: May be habit forming)

Alcohol 3.5 percent </pre>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>This syrup preparation combines the expectorant, guaifenesin, with the
cough suppressant, codeine. Guaifenesin enhances the output of lower respiratory
tract fluid. The enhanced flow of less viscid secretions promotes and facilitates
the removal of mucus. Codeine is a centrally acting agent which elevates
the threshold for cough. As a result, dry, unproductive coughs become more
productive and less frequent. </p>

<p>Under Federal law, this preparation is available without a prescription.
Certain state laws may differ. The container label contains the following
indications, warnings and drug interaction precaution statements and directions:
</p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Temporarily controls cough due to minor throat and bronchial irritation
as may occur with the common cold or inhaled irritants. Helps loosen phlegm
(mucus) and thin bronchial secretions to make coughs more productive. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>A persistent cough may be a sign of a serious condition. If cough persists
for more than 1 week, tends to recur, or is accompanied by fever, rash,
or persistent headache, consult a doctor. Do not take this product for
persistent or chronic cough such as occurs with smoking, asthma, chronic
bronchitis, emphysema, or if cough is accompanied by excessive phlegm (mucus)
unless directed by a doctor. Adults and children who have a chronic pulmonary
disease or shortness of breath, or children who are taking other drugs,
should not take this product unless directed by a doctor. May cause or
aggravate constipation. As with any drug, if you are pregnant or nursing
a baby, seek the advice of a health professional before using this product.
</p>

<p>Professional Note: Guaifenesin has been shown to produce a color interference
with certain clinical laboratory determinations of 5-hydroxyindoleacetic
acid (5-HIAA) and vanillylmandelic acid (VMA). </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Caution should be used when taking this product with sedatives, tranquilizers
and drugs used for depression, especially monoamine oxidase inhibitors
(MAOIs). These combinations may cause greater sedation (drowsiness) than
is caused by the products used alone. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Take orally as stated below or use as directed by a doctor. Adults and
children 12 years of age and over: 2 teaspoonfuls every 4 hours, not to
exceed 12 teaspoonfuls in a 24-hour period; children 6 to under 12 years:
1 teaspoonful every 4 hours, not to exceed 6 teaspoonfuls in a 24-hour
period; children under 6 years: consult a doctor. A special measuring device
should be used to give an accurate dose of this product to children under
6 years of age. Giving a higher dose than recommended by a doctor could
result in serious side effects for a child. Use of codeine-containing preparations
is not recommended for children under 2 years of age. Do not exceed recommended
dosage. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-61</DOCNO>
<DOCOLDNO>IA018-000200-B035-13</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/simva.htm 206.86.175.201 19970106224520 text/html 52385
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:39:03 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 52202
Last-modified: Sun, 11 Aug 1996 03:47:19 GMT
</DOCHDR>
<html>
<head>
   <title>Simvastatin - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Simvastatin</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION <p>
</b> 
Simvastatin  is a cholesterol lowering agent that is derived
synthetically from a fermentation product of Aspergillus Terreus. After oral
ingestion, simvastatin, which is an inactive lactone, is hydrolyzed to the
corresponding beta-hydroxyacid form. This is an inhibitor of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the
conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step
in the biosynthesis of cholesterol.  <p>
 
Simvastatin is butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-
dimethyl- 8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl) ethyl)-1-napthalenyl
ester, (1S-(1alpha,3alpha,7beta, 8beta(2S*, 4S*),-8abeta)). The empirical
formula of simvastatin is C25H38O5 and its molecular weight is 418.57.  <p>
 
Simvastatin is a white to off-white, nonhygroscopic, crystalline powder that is 
practically insoluble in water, and freely soluble in chloroform, methanol and
ethanol.  <p>
 
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 
</b> <p>
The involvement of low-density lipoprotein (LDL) cholesterol in atherogenesis
has been well-documented in clinical and pathological studies, as well as in
many animal experiments.  
 <p>
Epidemiological studies have established that high LDL (low-density
lipoprotein) cholesterol and low HDL (high-density lipoprotein) cholesterol are 
both risk factors for coronary heart disease. The Lipid Research Clinics
Coronary Primary Prevention Trial (LRC-CPPT), coordinated by the National
Institutes of Health (NIH), studied men aged 35-59 with total cholesterol
levels of 265 mg/dL (6.8 mmol/L) or greater, LDL cholesterol values 175 mg/dL
(4.5 mmol/L) or greater, and triglyceride levels not more than 300 mg/dL (3.4
mmol/L). This seven-year, double-blind, placebo-controlled study demonstrated
that lowering LDL cholesterol with diet and cholestyramine decreased the
combined rate of coronary heart disease death plus non-fatal myocardial
infarction.  
 <p>
Simvastatin has been shown to reduce both normal and elevated LDL cholesterol
concentrations. The effect of simvastatin-induced changes in lipoprotein levels 
including reduction of serum cholesterol, on cardiovascular morbidity or
mortality has not been established.  
 <p>
LDL is formed from very-low-density lipoprotein (VLDL) and is catabolized
predominantly by the high affinity LDL receptor. The mechanism of the LDL-
lowering effect of Simvastatin may involve both reduction of VLDL cholesterol
concentration, and induction of the LDL receptor, leading to reduced production 
and/or increased catabolism of LDL cholesterol. Apolipoprotein B also falls
substantially during treatment with Simvastatin. Since each LDL particle contains one 
molecule of apolipoprotein B, and since little apolipoprotein B is found in
other lipoproteins, this strongly suggests that Simvastatin does not merely cause
cholesterol to be lost from LDL, but also reduces the concentration of
circulating LDL particles. In addition, Simvastatin modestly reduces VLDL cholesterol 
and plasma triglycerides and can produce increases of variable magnitude in HDL 
cholesterol. The effects of Simvastatin on Lp(a), fibrinogen, and certain other
independent biochemical risk markers for coronary heart disease are unknown.  
 <p>
Simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme that catalyzes
the conversion of HMG-CoA to mevalonate. The conversion of HMG-CoA to
mevalonate is an early step in the biosynthetic pathway for cholesterol.  
 <p>
Pharmacokinetics 
 <p>
Simvastatin is a lactone that is readily hydrolyzed In Vivo to the
corresponding beta-hydroxyacid, a potent inhibitor of HMG-CoA reductase.
Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic
studies of the beta- hydroxyacid metabolites (active inhibitors) and, following 
base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma
following administration of simvastatin.  
 <p>
Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was
excreted in urine and 60% in feces. The latter represents absorbed drug
equivalents excreted in bile, as well as any unabsorbed drug. Plasma
concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked 
at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose. 
Absorption of simvastatin, estimated relative to an intravenous reference dose, 
in each of two animal species tested, averaged about 85% of an oral dose. In
animal studies, after oral dosing, simvastatin achieved substantially higher
concentrations in the liver than in nontarget tissues. Simvastatin undergoes
extensive first-pass extraction in the liver, its primary site of action, with
subsequent excretion of drug equivalents in the bile. As a consequence of
extensive hepatic extraction of simvastatin (estimated to be &gt; 60% in man), the 
availability of drug to the general circulation is low. In a single-dose study
in nine healthy subjects, it was estimated that less than 5% of an oral dose of 
simvastatin reaches the general circulation as active inhibitors. Following
administration of simvastatin tablets, the coefficient of variation, based on
between-subject variability, was approximately 48% for the area under the
concentration-time curve (AUC) for total inhibitory activity in the general
circulation.  
 <p>
Both simvastatin and its beta-hydroxyacid metabolite are highly bound
(approximately 95%) to human plasma proteins. Animal studies have not been
performed to determine whether simvastatin crosses the blood-brain and
placental barriers. However, when radiolabeled simvastatin was administered to
rats, simvastatin-derived radioactivity crossed the blood-brain barrier.  
 <p>
The major active metabolites of simvastatin present in human plasma are the
beta-hydroxyacid of simvastatin and its 6'-hydroxy, 6'-hydroxy methyl, and 6'-
exomethylene derivatives. Peak plasma concentrations of both active and total
inhibitors were attained within 1.3 to 2.4 hours postdose. While the
recommended therapeutic dose range is 5 to 40 mg/day, there was no substantial
deviation from linearity of AUC of inhibitors in the general circulation with
an increase in dose to as high as 120 mg. Relative to the fasting state, the
plasma profile of inhibitors was not affected when simvastatin was administered 
immediately before an A.H.A. recommended low-fat meal.  
 <p>
Kinetic studies with another reductase inhibitor, having a similar principal
route of elimination, have suggested that for a given dose level higher
systemic exposure may be achieved in patients with severe renal insufficiency
(as measured by creatinine clearance).  
 <p>
Clinical Studies <p>
 
Simvastatin has been shown to be highly effective in reducing total and LDL
cholesterol in heterozygous familial and non-familial forms of
hypercholesterolemia and in mixed hyperlipidemia. A marked response was seen
within 2 weeks, and the maximum therapeutic response occurred within 4-6 weeks. 
The response was maintained during chronic therapy.  
 <p>
In a multicenter, double-blind, placebo-controlled, dose-response study in
patients with familial or non-familial hypercholesterolemia, Simvastatin given as a
single-dose in the evening (the recommended dosing) was similarly effective as
when given on a twice-daily basis. Simvastatin consistently and significantly
decreased total plasma cholesterol (TOTAL-C), LDL cholesterol (LDL-C), total
cholesterol/HDL cholesterol (TOTAL-C/HDL-C) ratio, and LDL cholesterol/HDL
cholesterol (LDL-C/HDL-C) ratio. Simvastatin also modestly decreased triglycerides
(TRIG) and produced increases of variable magnitude in HDL cholesterol (HDL-C). 
 <p>
The results of a dose response study in patients with primary
hypercholesterolemia are presented in Table I.  <p>
 
                             <pre>       TABLE I                                     
          DOSE RESPONSE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA           
               (Mean Percent Change from Baseline After 8 Weeks)                
                                                  LDL-C/     TOTAL-C/           
TREATMENT       N    TOTAL-C    LDL-C    HDL-C    HDL-C       HDL-C     TRIG.   
PLACEBO         28      -3        -4       +2        -4          -3       +7    
Simvastatin                                                                           
5 mg q.p.m.     28     -17       -24       +7       -27         -22      -10    
10 mg q.p.m.    27     -24       -33       +9       -37         -29      -10    
20 mg q.p.m.    26     -25       -33      +11       -36         -30      -19    
40 mg q.p.m.    29     -28       -40      +12       -46         -36      -19    </pre><p>
Simvastatin was compared to cholestyramine, probucol, or gemfibrozil, respectively,
in double-blind parallel studies involving 1102 patients. All studies were
performed in patients who were at moderate to high risk of coronary events
based on serum cholesterol levels. At all dosage levels tested, Simvastatin produced
a significantly greater reduction of total plasma cholesterol, LDL cholesterol, 
VLDL cholesterol, triglycerides, and total cholesterol/HDL cholesterol ratio
when compared to cholestyramine or probucol. The increase in HDL seen with
Simvastatin was not significantly greater than the increase seen with cholestyramine
but was significantly different from the decrease seen with probucol (see
Tables II and III). <p>
 
                   <pre>                 TABLE II                                    
                            Simvastatin VS. CHOLESTYRAMINE                            
                 (Percent Change from Baseline After 12 Weeks)                  
                                            LDL-C/   TOTAL-C/                   
TREATMENT     N   TOTAL-C   LDL-C   HDL-C   HDL-C     HDL-C    VLDL-C   TRIG.   
                   (mean)   (mean)  (mean)  (mean)    (mean)  (median)  (mean)  
Simvastatin                                                                           
20 mg q.p.m.  84     -27     -32      +10     -36      -31       -8      -13    
40 mg q.p.m.  82     -33     -41      +10     -45      -38      -28      -21    
CHOLESTYRAMINE                                                                  
4-24 g/day*   85     -15     -21       +8     -25      -19       +7      +15    
*maximum tolerated dose (mean dose taken, 18 g/day)                             
                                   TABLE III                                    
                               Simvastatin VS. PROBUCOL                               
                 (Percent Change from Baseline After 12 Weeks)                  
                                            LDL-C/   TOTAL-C/                   
TREATMENT     N   TOTAL-C   LDL-C   HDL-C   HDL-C     HDL-C    VLDL-C   TRIG.   
                   (mean)   (mean)  (mean)  (mean)    (mean)  (median)  (mean)  
Simvastatin                                                                           
20 mg q.p.m.  82     -27     -34      +10     -39      -34      -18      -17    
40 mg q.p.m.  80     -30     -40      +13     -45      -37      -14      -19    
PROBUCOL                                                                        
500 mg b.i.d. 81     -13      -8      -27     +31      +25      +11     -0.4    </pre><p>

In a study designed to evaluate the possible effects of simvastatin on
reproductive hormones and sperm characteristics in men with familial
hypercholesterolemia, there was a small decrease in the mean percentage of
vital sperm and a small increase in the mean percentage of abnormal forms, with 
these changes achieving statistical significance at week 14. However, there was 
no effect on numbers or concentration of motile sperm. Simvastatin had no
effect on basal reproductive hormone levels (prolactin, luteinizing hormone,
follicle- stimulating hormone, and plasma testosterone). Provocative testing
(HCG stimulation) was not done. Treatment with another HMG-CoA reductase
inhibitor resulted in a statistically significant decrease in plasma
testosterone response to HCG.  
 <p>
In a study to evaluate the effect of simvastatin on adrenocortical function in
patients with Type II hypercholesterolemia, simvastatin had no effect on basal
adrenocortical function as assessed by determination of morning plasma cortisol 
levels, urine free cortisol, and urinary excretion of 17-hydroxy steroids. 
Simvastatin also had no effect on adrenocortical reserve as evaluated by the
plasma cortisol response to ACTH stimulation and insulin-induced hypoglycemia.  
 <p>
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
Therapy with lipid-altering agents should be a component of multiple risk
factor intervention in those individuals at significantly increased risk for
atherosclerotic vascular disease due to hypercholesterolemia. Simvastatin is
indicated as an adjunct to diet for the reduction of elevated total and LDL
cholesterol levels in patients with primary hypercholesterolemia (Types IIa and 
IIb(1)), when the response to a diet restricted in saturated fat and
cholesterol and other nonpharmacological measures alone has been inadequate.  
 <p>
Prior to initiating therapy with simvastatin, secondary causes for
hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism 
nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug
therapy, alcoholism) should be excluded, and a lipid profile performed to
measure TOTAL-C, HDL-C, and triglycerides (TG). For patients with TG less than
400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: 
 <p>
LDL-C = Total cholesterol - (0.20 X (triglycerides) +HDL-C) <p>
 
For TG levels &gt;400 mg/dL (&gt;4.5 mmol/L), this equation is less accurate and LDL
C concentrations should be determined by ultracentrifugation. In many
hypertriglyceridemic patients, LDL-C may be low or normal despite elevated
TOTAL-C. In such cases, Simvastatin is not indicated.  
 <p>
Lipid determinations should be performed at intervals of no less than four
weeks and dosage adjusted according to the patient's response to therapy.  
 <p>
The National Cholesterol Education Program (NCEP) Treatment Guidelines are
summarized below: <p>
 <pre>
                                       LDL-Cholesterol                          
                                       mg/dL (mmol/L)                           
                                                                                
Definite            Two or More                                                 
Atherosclerotic     Other Risk        Initiation                                
Disease*            Factors**         Level               Goal                  
------------------------------------------------------------------------------- 
NO                  NO                  &gt;/=190            &lt;160                  
                                        (&gt;/=4.9)          (&lt;4.1)                
NO                  YES                 &gt;/=160            &lt;130                  
                                        (&gt;/=4.1)          (&lt;3.4)                
YES                 YES or NO           &gt;/=130            &lt; or =100                
                                        (&gt;/=3.4)          (&lt; or =2.6)              
*Coronary heart disease or peripheral vascular disease (including symptomatic   
carotid artery disease).                    </pre><p>                                    
**Other risk factors for coronary heart disease (CHD) include: age (males:      
&gt;/=45 years; females: &gt;/=55 years or premature menopause without estrogen       
replacement therapy); family history of premature CHD; current cigarette        
smoking; hypertension; confirmed HDL-C &lt;35 mg/dL (&lt;0.91 mmol/L); and diabetes   
mellitus. Subtract one risk factor if HDL-C is &gt;/=60 mg/dL (&gt;/=1.6 mmol/L).     
Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C
levels be used to initiate and assess treatment response. Only if LDL-C levels
are not available, should the TOTAL-C be used to monitor therapy.  <p>
 
Although Simvastatin may be useful to reduce elevated LDL cholesterol levels in
patients with combined hypercholesterolemia and hypertriglyceridemia where
hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia),
it has not been studied in conditions where the major abnormality is elevation
of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or
V).(1) 
 <p>
The effect of simvastatin-induced changes in lipoprotein levels, including
reduction of serum cholesterol, on cardiovascular morbidity or mortality has
not been established.  
 
<p>
 
      <pre>             (1)CLASSIFICATION OF HYPERLIPOPROTEINEMIAS                   
                                                                 Lipid          
                                  Lipoproteins                 Elevations       
          TYPE                      ELEVATED              MAJOR        MINOR    
          I (rare)      chylomicrons                        TG           up     
                                                                         &gt; C   
        IIa             LDL                                 C            --     
        IIb             LDL, VLDL                           C            TG     
        III (rare)      IDL                                C/TG          --     
         IV             VLDL                                TG           up     
                                                                         &gt; C   
          V (rare)      chylomicrons, VLDL                  TG           up     
                                                                         &gt; C   
C = cholesterol, TG = triglycerides,                                            
LDL = low-density lipoprotein,                                                  
VLDL = very-low-density lipoprotein,                                            
IDL = intermediate-density lipoprotein.                                         
---------- </pre>
 <p>
**For adult diabetics, a modification of these guidelines is recommended--see:  
American Diabetes Association Consensus Statement: Role of cardiovascular risk
factors in prevention and treatment of macrovascular disease in diabetes,
Diabetes Care 12(8): 573-79, 1989. <p>
 

 
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <p>
Hypersensitivity to any component of this medication.  
 <p>
Active liver disease or unexplained persistent elevations of serum
transaminases (see WARNINGS). <p>
 
Pregnancy And Lactation. Atherosclerosis is a chronic process and the
discontinuation of lipid-lowering drugs during pregnancy should have little
impact on the outcome of long-term therapy of primary hypercholesterolemia. 
Moreover, cholesterol and other products of the cholesterol biosynthesis
pathway are essential components for fetal development, including synthesis of
steroids and cell membranes. Because of the ability of inhibitors of HMG-CoA
reductase such as Simvastatin to decrease the synthesis of cholesterol and possibly
other products of the cholesterol biosynthesis pathway, Simvastatin may cause fetal
harm when administered to a pregnant woman. Therefore, simvastatin is
contraindicated during pregnancy and in nursing mothers. SIMVASTATIN SHOULD BE
ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY
UNLIKELY TO CONCEIVE. If the patient becomes pregnant while taking this drug,
simvastatin should be discontinued and the patient should be apprised of the
potential hazard to the fetus. <p>
 
<a name="WARNINGS"></a><b>WARNINGS 
</b> <p>
Liver Dysfunction 
 <p>
PERSISTENT INCREASES (TO MORE THAN 3 TIMES THE UPPER LIMIT OF NORMAL) IN SERUM
TRANSAMINASES HAVE OCCURRED IN 1% OF PATIENTS WHO RECEIVED SIMVASTATIN IN
CLINICAL TRIALS. When drug treatment was interrupted or discontinued in these
patients, the transaminase levels usually fell slowly to pretreatment levels. 
The increases were not associated with jaundice or other clinical signs or
symptoms. There was no evidence of hypersensitivity.  
 <p>
IT IS RECOMMENDED THAT LIVER FUNCTION TESTS BE PERFORMED DURING THERAPY WITH
SIMVASTATIN. SERUM TRANSAMINASE LEVELS, INCLUDING ALT (SGPT), SHOULD BE
MONITORED BEFORE TREATMENT BEGINS, EVERY SIX WEEKS FOR THE FIRST THREE MONTHS,
EVERY EIGHT WEEKS DURING THE REMAINDER OF THE FIRST YEAR, AND PERIODICALLY
THEREAFTER (E.G., AT APPROXIMATELY 6 MONTH INTERVALS). Special attention should 
be paid to patients who develop elevated serum transaminase levels, and in
these patients, measurements should be repeated promptly and then performed
more frequently. If the transaminase levels show evidence of progression,
particularly if they rise to three times the upper limit of normal and are
persistent, the drug should be discontinued. Liver biopsy should be considered
if elevations persist beyond discontinuation of drug.  <p>
 
The drug should be used with caution in patients who consume substantial
quantities of alcohol and/or have a past history of liver disease. Active liver 
diseases or unexplained transaminase elevations are contraindications to the
use of simvastatin.  
 <p>
As with other lipid-lowering agents, moderate (less than three times the upper
limit of normal) elevations of serum transaminases have been reported following 
therapy with simvastatin. These changes appeared soon after initiation of
therapy with simvastatin, were often transient, were not accompanied by any
symptoms and did not require interruption of treatment.  <p>
 
Skeletal Muscle 
 <p>
Rare cases of rhabdomyolysis with acute renal failure secondary to
myoglobinuria have been associated with simvastatin therapy. Rhabdomyolysis has 
also been associated with other HMG-CoA reductase inhibitors when they were
administered alone or concomitantly with 1) immunosuppressive therapy,
including cyclosporine in cardiac transplant patients; 2) gemfibrozil or lipid
lowering doses (&gt;/= 1 g/day) of nicotinic acid in non-transplant patients, or
3) erythromycin in seriously ill patients. Some of the patients who had
rhabdomyolysis in association with the reductase inhibitors had preexisting
renal insufficiency, usually as a consequence of long-standing diabetes. In
most subjects who have had an unsatisfactory lipid response to either
simvastatin or gemfibrozil alone, the possible benefits of combined therapy
with these drugs are not considered to outweigh the risk of severe myopathy,
rhabdomyolysis, and acute renal failure.  While it is not known whether this
interaction occurs with fibrates other than gemfibrozil, myopathy and
rhabdomyolysis have occasionally been associated with the use of other fibrates 
alone, including clofibrate. Therefore, the combined use of simvastatin with
other fibrates should generally be avoided.  
 <p>
Physicians contemplating combined therapy with simvastatin and lipid-lowering
doses of nicotinic acid, or with immunosuppressive drugs should carefully weigh 
the potential benefits and risks and should carefully monitor patients for any
signs and symptoms of muscle pain, tenderness, or weakness, particularly during 
the initial months of therapy and during any periods of upward dosage titration 
of either drug. Periodic creatine phosphokinase (CPK) determinations may be
considered in such situations, but there is no assurance that such monitoring
will prevent the occurrence of severe myopathy.  
 <p>
Because of an apparent relationship between increased plasma levels of active
metabolites derived from other HMG-CoA reductase inhibitors and myopathy, in
patients taking cyclosporine, the daily dosage should not exceed 10 mg/day (see 
DOSAGE AND ADMINISTRATION).  <p>
 
SIMVASTATIN THERAPY SHOULD BE TEMPORARILY WITHHELD OR DISCONTINUED IN ANY
PATIENT WITH AN ACUTE, SERIOUS CONDITION SUGGESTIVE OF A MYOPATHY OR HAVING A
RISK FACTOR PREDISPOSING TO THE DEVELOPMENT OF RENAL FAILURE SECONDARY TO
RHABDOMYOLYSIS, (E.G., SEVERE ACUTE INFECTION, HYPOTENSION, MAJOR SURGERY,
TRAUMA, SEVERE METABOLIC, ENDOCRINE AND ELECTROLYTE DISORDERS, AND UNCONTROLLED 
SEIZURES).  
 <p>
Myopathy should be considered in any patient with diffuse myalgias, muscle
tenderness or weakness, and/or marked elevation of CPK. Patients should be
advised to report promptly unexplained muscle pain, tenderness or weakness,
particularly if accompanied by malaise or fever. Simvastatin therapy should be
discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or
suspected.  
 <p>
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
General 
 <p>
Before instituting therapy with Simvastatin, an attempt should be made to control
hypercholesterolemia with appropriate diet, exercise, and weight reduction in
obese patients, and to treat other underlying medical problems (see INDICATIONS 
AND USAGE).  
 <p>
Simvastatin may cause elevation of creatine phosphokinase and transaminase
levels (see WARNINGS and ADVERSE REACTIONS). This should be considered in the
differential diagnosis of chest pain in a patient on therapy with simvastatin.  
 <p>
Homozygous Familial Hypercholesterolemia 
 <p>
Simvastatin is less effective in patients with the rare homozygous familial
hypercholesterolemia, possibly because these patients have few functional LDL
receptors.  
 <p>
Information For Patients 
 <p>
Patients should be advised to report promptly unexplained muscle pain,
tenderness, or weakness, particularly if accompanied by malaise or fever.  
 <p>
Drug Interactions 
 <p>
Immunosuppressive Drugs, Gemfibrozil, Niacin (Nicotinic Acid), Erythromycin:
See WARNINGS, Skeletal Muscle.  
 <p>
Antipyrine: Because simvastatin had no effect on the pharmocokinetics of
antipyrine, interactions with other drugs metabolized via the same cytochrome
isozymes are not expected.  
 <p>
Propranolol: In healthy male volunteers there was a significant decrease in
mean Cmax, but no change in AUC, for simvastatin total and active inhibitors
with concomitant administration of single doses of Simvastatin and propranolol. The
clinical relevance of this finding is unclear. The pharmacokinetics of the
enantiomers of propranolol were not affected.  
 <p>
Digoxin: Concomitant administration of a single dose of digoxin in healthy male 
volunteers receiving simvastatin resulted in a slight elevation (less than 0.3
ng/mL) in digoxin concentrations in plasma (as measured by a radioimmunoassay)
compared to concomitant administration of placebo and digoxin. Patients taking
digoxin should be monitored appropriately when simvastatin is initiated.  
 <p>
Warfarin: Simvastatin therapy appeared to enhance slightly the anticoagulant
effect of warfarin (mean changes in prothrombin time less than two seconds) in
normal volunteers maintained in a state of low therapeutic anticoagulation.
With other reductase inhibitors, clinically evident bleeding and/or increased
prothrombin time has been reported in a few patients taking coumarin
anticoagulants concomitantly. In such patients, prothrombin time should be
determined before starting simvastatin and frequently enough during early
therapy to insure that no significant alteration of prothrombin time occurs. 
Once a stable prothrombin time has been documented, prothrombin times can be
monitored at the intervals usually recommended for patients on coumarin
anticoagulants. If the dose of simvastatin is changed, the same procedure
should be repeated. Simvastatin therapy has not been associated with bleeding
or with changes in prothrombin time in patients not taking anticoagulants.  
 <p>
Other Concomitant Therapy: Although specific interaction studies were not
performed, in clinical studies, simvastatin was used concomitantly with
angiotensin-converting enzyme (ACE) inhibitors, beta blockers, calcium-channel
blockers, diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs) without
evidence of clinically significant adverse interactions. The effect of
cholestyramine on the absorption and kinetics of simvastatin has not been
determined.  
 <p>
Endocrine Function <p>
 
HMG-CoA reductase inhibitors interfere with cholesterol synthesis and as such
might theoretically blunt adrenal and/or gonadal steroid production. However,
clinical studies have shown that simvastatin does not reduce basal plasma
cortisol concentration or impair adrenal reserve, and does not reduce basal
plasma testosterone concentration (see ACTIONS/CLINICAL PHARMACOLOGY, Clinical
Studies). Another HMG-CoA reductase inhibitor has been shown to reduce the
plasma testosterone response to HCG; the effect of simvastatin on HCG
stimulated testosterone secretion has not been studied.  
 <p>
Results of clinical trials with drugs in this class have been inconsistent with 
regard to drug effects on basal and reserve steroid levels. The effects of HMG- 
CoA reductase inhibitors on male fertility have not been studied in adequate
numbers of male patients. The effects, if any, on the pituitary-gonadal axis in 
pre-menopausal women are unknown. Patients treated with simvastatin who develop 
clinical evidence of endocrine dysfunction should be evaluated appropriately. 
Caution should also be exercised if an HMG-CoA reductase inhibitor or other
agent used to lower cholesterol levels is administered to patients also
receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may 
decrease the levels or activity of endogenous steroid hormones.  <p>
 
CNS Toxicity 
 <p>
Optic nerve degeneration was seen in clinically normal dogs treated with
simvastatin for 14 weeks at 180 mg/kg/day, a dose that produced mean plasma
drug levels about 44 times higher than the mean drug level in humans taking 40
mg/ day.  
 <p>
CNS vascular lesions, characterized by perivascular hemorrhage and edema,
mononuclear cell infiltration of perivascular spaces, perivascular fibrin
deposits and necrosis of small vessels were seen in dogs treated with
simvastatin at a dose of 360 mg/kg/day, a dose that produced plasma drug levels 
that were about 50 times higher than the mean drug levels in humans taking 40
mg/day. Similar CNS vascular lesions have been observed with several other
drugs of this class.  
 <p>
A chemically similar drug in this class also produced optic nerve degeneration
(Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs
in a dose-dependent fashion starting at 60 mg/kg/day, a dose that produced mean 
plasma drug levels about 30 times higher than the mean drug level in humans
taking the highest recommended dose (as measured by total enzyme inhibitory
activity). This same drug also produced vestibulocochlear Wallerian-like
degeneration and retinal ganglion cell chromatolysis in dogs treated for 14
weeks at 180 mg/kg/day, a dose that resulted in a mean plasma drug level
similar to that seen with the 60 mg/kg/day dose.  
 <p>
Carcinogenesis, Mutagenesis, Impairment Of Fertility 
 <p>
In a 72-week carcinogenicity study, mice were administered daily doses of
simvastatin of 25, 100, and 400 mg/kg body weight, which resulted in mean
plasma drug levels approximately 3, 15, and 33 times higher than the mean human 
plasma drug concentration (as total inhibitory activity) after a 40 mg oral
dose. Liver carcinomas were significantly increased in high-dose females and
mid- and high- dose males with a maximum incidence of 90 percent in males. The
incidence of adenomas of the liver was significantly increased in mid- and high 
dose females.  Drug treatment also significantly increased the incidence of
lung adenomas in mid- and high-dose males and females. Adenomas of the
Harderian gland (a gland of the eye of rodents) were significantly higher in
high-dose mice than in controls. No evidence of a tumorigenic effect was
observed at 25 mg/kg/day.  Although mice were given up to 500 times the human
dose (HD) on a mg/kg/body weight basis, blood levels of HMG-CoA reductase
inhibitory activity were only 3- 33 times higher in mice than in humans given
40 mg of Simvastatin.  <p>
 
In a separate 92-week carcinogenicity study in mice at doses up to 25 mg/kg/day 
no evidence of a tumorigenic effect was observed. Although mice were given up
to 31 times the human dose on a mg/kg basis, plasma drug levels were only 2-4
times higher than humans given 40 mg simvastatin as measured by AUC.  
 <p>
In a two-year study in rats, there was a statistically significant increase in
the incidence of thyroid follicular adenomas in female rats exposed to
approximately 45 times higher levels of simvastatin than humans given 40 mg
simvastatin (as measured by AUC). Preliminary results from a second two-year
rat study indicate an increase in the incidence of thyroid and liver tumors in
male and female rats at doses that produce exposure levels &gt;/=29 times (based
on AUC) that achieved in humans at a dosage of 40 mg/day. Liver tumors are
found in rodents with all the chemically similar drugs of this class. No
increased incidence of tumors was observed at doses that produce exposure
levels 15 times (based on AUC) those seen in man.  <p>
 
No evidence of mutagenicity was observed in a microbial mutagen test using
mutant strains of Salmonella Typhimurium with or without rat or mouse liver
metabolic activation. In addition, no evidence of damage to genetic material
was noted in an In Vitro alkaline elution assay using rat hepatocytes, a V-79
mammalian cell forward mutation study, an In Vitro chromosome aberration study
in CHO cells, or an In Vivo chromosomal aberration assay in mouse bone marrow.  
 <p>
There was decreased fertility in male rats treated with simvastatin for 34
weeks at 25 mg/kg body weight (15 times the maximum human exposure level, based 
on AUC, in patients receiving 40 mg/day); however, this effect was not observed 
during a subsequent fertility study in which simvastatin was administered at
this same dose level to male rats for 11 weeks (the entire cycle of
spermatogenesis including epididymal maturation). No microscopic changes were
observed in the testes of rats from either study. At 180 mg/kg/day, (which
produces exposure levels 44 times higher than those in humans taking 40 mg/day) 
seminiferous tubule degeneration (necrosis and loss of spermatogenic
epithelium) was observed. In dogs, there was drug-related testicular atrophy,
decreased spermatogenesis, spermatocytic degeneration and giant cell formation
at 10 mg/kg/day (approximately 7 times the human exposure level, based on AUC,
at 40 mg/day). The clinical significance of these findings is unclear.  <p>
 
Pregnancy <p>
 
Pregnancy Category X <p>
 
See CONTRAINDICATIONS.  
 <p>
Safety in pregnant women has not been established. Simvastatin was not
teratogenic in rats at doses of 25 mg/kg/day or in rabbits at doses up to 10
mg/kg daily. These doses resulted in 6 times (rat) or 4 times (rabbit) the
human exposure based on mg/M(square) surface area. However, in studies with
another structurally-related HMG-CoA reductase inhibitor, skeletal
malformations were observed in rats and mice. Rare reports of congenital
anomalies have been received following intrauterine exposure to HMG-CoA
reductase inhibitors. There has been one report of severe congenital bony
deformity, tracheo-esophageal fistula, and anal atresia (VATER) association) in 
a baby born to a woman who took another HMG-CoA reductase inhibitor with
dextroamphetamine sulfate during the first trimester of pregnancy. Simvastatin
should be administered to women of child-bearing potential only when such
patients are highly unlikely to conceive and have been informed of the
potential hazards. If the woman becomes pregnant while taking simvastatin, it
should be discontinued and the patient advised again as to the potential
hazards to the fetus.  <p>
 
Nursing Mothers 
 <p>
It is not known whether simvastatin is excreted in human milk. Because a small
amount of another drug in this class is excreted in human milk and because of
the potential for serious adverse reactions in nursing infants, women taking
simvastatin should not nurse their infants (see CONTRAINDICATIONS).  
 <p>
Pediatric Use 
 <p>
Safety and effectiveness in children and adolescents have not been established. 
Because children and adolescents are not likely to benefit from cholesterol
lowering for at least a decade and because experience with this drug is limited 
(no studies in subjects below the age of 20 years), treatment of children or
adolescents with simvastatin is not recommended at this time.  
 <p>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <p>
Immunosuppressive Drugs, Gemfibrozil, Niacin (Nicotinic Acid), Erythromycin:
See WARNINGS, Skeletal Muscle.  
 <p>
Antipyrine: Because simvastatin had no effect on the pharmocokinetics of
antipyrine, interactions with other drugs metabolized via the same cytochrome
isozymes are not expected.  
 <p>
Propranolol: In healthy male volunteers there was a significant decrease in
mean Cmax, but no change in AUC, for simvastatin total and active inhibitors
with concomitant administration of single doses of Simvastatin and propranolol. The
clinical relevance of this finding is unclear. The pharmacokinetics of the
enantiomers of propranolol were not affected.  
<p>
Digoxin: Concomitant administration of a single dose of digoxin in healthy male 
volunteers receiving simvastatin resulted in a slight elevation (less than 0.3
ng/mL) in digoxin concentrations in plasma (as measured by a radioimmunoassay)
compared to concomitant administration of placebo and digoxin. Patients taking
digoxin should be monitored appropriately when simvastatin is initiated.  
<p> 
Warfarin: Simvastatin therapy appeared to enhance slightly the anticoagulant
effect of warfarin (mean changes in prothrombin time less than two seconds) in
normal volunteers maintained in a state of low therapeutic anticoagulation.
With other reductase inhibitors, clinically evident bleeding and/or increased
prothrombin time has been reported in a few patients taking coumarin
anticoagulants concomitantly. In such patients, prothrombin time should be
determined before starting simvastatin and frequently enough during early
therapy to insure that no significant alteration of prothrombin time occurs. 
Once a stable prothrombin time has been documented, prothrombin times can be
monitored at the intervals usually recommended for patients on coumarin
anticoagulants. If the dose of simvastatin is changed, the same procedure
should be repeated. Simvastatin therapy has not been associated with bleeding
or with changes in prothrombin time in patients not taking anticoagulants.  <p>
 
Other Concomitant Therapy: Although specific interaction studies were not
performed, in clinical studies, simvastatin was used concomitantly with
angiotensin-converting enzyme (ACE) inhibitors, beta blockers, calcium-channel
blockers, diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs) without
evidence of clinically significant adverse interactions. The effect of
cholestyramine on the absorption and kinetics of simvastatin has not been
determined.  
 <p>
Endocrine Function <p>
 
HMG-CoA reductase inhibitors interfere with cholesterol synthesis and as such
might theoretically blunt adrenal and/or gonadal steroid production. However,
clinical studies have shown that simvastatin does not reduce basal plasma
cortisol concentration or impair adrenal reserve, and does not reduce basal
plasma testosterone concentration (see ACTIONS/CLINICAL PHARMACOLOGY, Clinical
Studies). Another HMG-CoA reductase inhibitor has been shown to reduce the
plasma testosterone response to HCG; the effect of simvastatin on HCG
stimulated testosterone secretion has not been studied.  <p>
 
Results of clinical trials with drugs in this class have been inconsistent with 
regard to drug effects on basal and reserve steroid levels. The effects of HMG- 
CoA reductase inhibitors on male fertility have not been studied in adequate
numbers of male patients. The effects, if any, on the pituitary-gonadal axis in 
pre-menopausal women are unknown. Patients treated with simvastatin who develop 
clinical evidence of endocrine dysfunction should be evaluated appropriately. 
Caution should also be exercised if an HMG-CoA reductase inhibitor or other
agent used to lower cholesterol levels is administered to patients also
receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may 
decrease the levels or activity of endogenous steroid hormones.  
 <p>
CNS Toxicity 
 <p>
Optic nerve degeneration was seen in clinically normal dogs treated with
simvastatin for 14 weeks at 180 mg/kg/day, a dose that produced mean plasma
drug levels about 44 times higher than the mean drug level in humans taking 40
mg/ day.  
<p>
CNS vascular lesions, characterized by perivascular hemorrhage and edema,
mononuclear cell infiltration of perivascular spaces, perivascular fibrin
deposits and necrosis of small vessels were seen in dogs treated with
simvastatin at a dose of 360 mg/kg/day, a dose that produced plasma drug levels 
that were about 50 times higher than the mean drug levels in humans taking 40
mg/day. Similar CNS vascular lesions have been observed with several other
drugs of this class.  
 <p>
A chemically similar drug in this class also produced optic nerve degeneration
(Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs
in a dose-dependent fashion starting at 60 mg/kg/day, a dose that produced mean 
plasma drug levels about 30 times higher than the mean drug level in humans
taking the highest recommended dose (as measured by total enzyme inhibitory
activity). This same drug also produced vestibulocochlear Wallerian-like
degeneration and retinal ganglion cell chromatolysis in dogs treated for 14
weeks at 180 mg/kg/day, a dose that resulted in a mean plasma drug level
similar to that seen with the 60 mg/kg/day dose.  
 <p>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
In the controlled clinical studies and their open extensions (2423 patients
with mean duration of follow-up of approximately 18 months), 1.4% of patients
were discontinued due to adverse experiences attributable to Simvastatin. Adverse
reactions have usually been mild and transient. Simvastatin has been evaluated for
serious adverse reactions in more than 21,000 patients and is generally well
tolerated.  
 <p>
Clinical Adverse Experiences 
 <p>
Adverse experiences occurring at an incidence of 1 percent or greater in
patients treated with Simvastatin, regardless of causality, in controlled clinical
studies are shown in the table below: <p>
 <pre>
                            Simvastatin       Placebo     Cholestyramine     Probucol 
                           (N=1583)     (N=157)        (N=179)          (N=81)  
                              %            %              %               %     
Body As A Whole                                                                 
   Abdominal pain            3.2          3.2             8.9            2.5    
   Asthenia                  1.6          2.5             1.1            1.2    
Gastrointestinal                                                                
   Constipation              2.3          1.3            29.1            1.2    
   Diarrhea                  1.9          2.5             7.8            3.7    
   Dyspepsia                 1.1           --             4.5            3.7    
   Flatulence                1.9          1.3            14.5            6.2    
   Nausea                    1.3          1.9            10.1            2.5    
Nervous System/Psychiatric                                                      
   Headache                  3.5          5.1             4.5            3.7    
Respiratory                                                                     
   Upper respiratory                                                            
    infection                2.1          1.9             3.4            6.2    </pre><p>
The following effects have been reported with drugs in this class. Not all
effects listed below have necessarily been associated with simvastatin therapy. <p>
 
Skeletal: myopathy, rhabdomyolysis, arthralgias.  
 <p>
Neurological: dysfunction of certain cranial nerves (including alteration of
taste, impairment of extra-ocular movement, facial paresis), tremor, vertigo,
memory loss, paresthesia, peripheral neuropathy, peripheral nerve palsy,
anxiety, insomnia, depression.  
 <p>
Hypersensitivity Reactions: An apparent hypersensitivity syndrome has been
reported rarely which has included one or more of the following features: 
anaphylaxis, angioedema, lupus erythematous-like syndrome, polymyalgia
rheumatica, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia 
positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria,
asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic
epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome.  
 <p>
Gastrointestinal: pancreatitis, hepatitis, including chronic active hepatitis,
cholestatic jaundice, fatty change in liver, and, rarely, cirrhosis, fulminant
hepatic necrosis, and hepatoma; anorexia, vomiting.  
 <p>
Skin: alopecia, pruritus. A variety of skin changes (e.g., nodules,
discoloration, dryness of skin/mucous membranes, changes to hair/nails) has
been reported.  
 <p>
Reproductive: gynecomastia, loss of libido, erectile dysfunction.  <p>
 
Eye: progression of cataracts (lens opacities), ophthalmoplegia.  
 <p>
Laboratory Abnormalities: elevated transaminases, alkaline phosphatase, and
bilirubin; thyroid function abnormalities.  
 <p>
Laboratory Tests <p>
 
Marked persistent increases of serum transaminases have been noted (see
WARNINGS, Liver Dysfunction). About 5% of patients had elevations of creatine
phosphokinase (CPK) levels of 3 or more times the normal value on one or more
occasions. This was attributable to the noncardiac fraction of CPK. Muscle pain 
or dysfunction usually was not reported (see WARNINGS, Skeletal Muscle).  
 <p>
Concomitant Therapy 
 <p>
In controlled clinical studies in which simvastatin was administered
concomitantly with cholestyramine, no adverse reactions peculiar to this
concomitant treatment were observed. The adverse reactions that occurred were
limited to those reported previously with simvastatin or cholestyramine. The
combined use of simvastatin with fibrates should generally be avoided (see
WARNINGS, Skeletal Muscle).  <p>
 
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <p>
Significant lethality was observed in mice after a single oral dose of 9
g/M(square). No evidence of lethality was observed in rats or dogs treated with 
doses of 30 and 100 g/M(square), respectively. No specific diagnostic signs
were observed in rodents. At these doses the only signs seen in dogs were
emesis and mucoid stools.  
 <p>
A few cases of overdosage with Simvastatin have been reported; no patients had any
specific symptoms, and all patients recovered without sequelae. The maximum
dose taken was 450 mg. Until further experience is obtained, no specific
treatment of overdosage with Simvastatin can be recommended.  
 <p>
The dialyzability of simvastatin and its metabolites in man is not known at
present.  
 <p>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
The patient should be placed on a standard cholesterol-lowering diet before
receiving Simvastatin and should continue on this diet during treatment with Simvastatin
(see NCEP Treatment Guidelines for details on dietary therapy). <p>
 
The recommended starting dose is 5-10 mg once a day in the evening. The
recommended dosing range is 5-40 mg/day as a single dose in the evening; the
maximum recommended dose is 40 mg/day. Doses should be individualized according 
to baseline LDL-C levels, the recommended goal of therapy (see NCEP Guidelines) 
and the patient's response. A starting dose of 5 mg/day should be considered
for patients with LDL-C (on diet) of &lt; or =190 mg/dL (4.9 mmol/L) and for the
elderly.  Patients with LDL-C levels &gt;190 mg/dL (4.9 mmol/L) should be started
on 10 mg/day. Adjustments of dosage should be made at intervals of 4 weeks or
more. <p>
 
In the elderly, maximum reductions in LDL cholesterol may be achieved with
daily doses of 20 mg or less.  
 <p>
Cholesterol levels should be monitored periodically and consideration should be 
given to reducing the dosage of Simvastatin if cholesterol falls below the targeted
range.  
 <p>
Concomitant Therapy 
 <p>
Simvastatin is effective alone or when used concomitantly with bile-acid
sequestrants.  Use of Simvastatin with fibrate-type drugs such as gemfibrozil or
clofibrate should generally be avoided (see WARNINGS, Skeletal Muscle).  
 
In patients taking immunosuppressive drugs concomitantly with simvastatin (see
WARNINGS, Skeletal Muscle), therapy should begin with 5 mg of Simvastatin and should
not exceed 10 mg/day.  
 <p>
Dosage In Patients With Renal Insufficiency 
 <p>
Because Simvastatin does not undergo significant renal excretion, modification of
dosage should not be necessary in patients with mild to moderate renal
insufficiency. However, caution should be exercised when Simvastatin is administered
to patients with severe renal insufficiency; such patients should be started at 
5 mg/day and be closely monitored (see ACTIONS/CLINICAL PHARMACOLOGY,
Pharmacokinetics). <p>

<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-62</DOCNO>
<DOCOLDNO>IA018-000200-B038-90</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/diazepam.htm 206.86.175.201 19970106225918 text/html 14738
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:53:02 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 14555
Last-modified: Sun, 11 Aug 1996 03:43:50 GMT
</DOCHDR>
<html>
<head>
   <title>Diazepam - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Diazepam</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [action]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

 <a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <p>
Diazepam  is a benzodiazepine derivative developed through original
Roche research. Chemically, diazepam is 7-chloro-1,3-dihydro-1-methyl-5-phenyl- 
2H-1,4-benzodiazepin-2-one. It is a colorless crystalline compound, insoluble
in water and has a molecular weight of 284.74.  <p>
 
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
Diazepam is indicated for the management of anxiety disorders or for the short
term relief of the symptoms of anxiety. Anxiety or tension associated with the
stress of everyday life usually does not require treatment with an anxiolytic.  
 <p>
In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of
acute agitation, tremor, impending or acute delirium tremens and hallucinosis.  
 <p>
Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to
reflex spasm to local pathology (such as inflammation of the muscles or joints, 
or secondary to trauma); spasticity caused by upper motor neuron disorders
(such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.  
 <p>
Oral Diazepam may be used adjunctively in convulsive disorders, although it has
not proved useful as the sole therapy. The effectiveness of Diazepam in long-term 
use, that is, more than 4 months, has not been assessed by systematic clinical
studies. The physician should periodically reassess the usefulness of the drug
for the individual patient.  
 <p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <p>
Diazepam is contraindicated in patients with a known hypersensitivity to this
drug and, because of lack of sufficient clinical experience, in children under
6 months of age. It may be used in patients with open angle glaucoma who are
receiving appropriate therapy, but is contraindicated in acute narrow angle
glaucoma.  
 <p>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <p>
Diazepam is not of value in the treatment of psychotic patients and should not be 
employed in lieu of appropriate treatment.  <p>
 
As is true of most preparations containing CNS-acting drugs, patients receiving 
Diazepam should be cautioned against engaging in hazardous occupations requiring
complete mental alertness such as operating machinery or driving a motor
vehicle.  <p>
 
As with other agents which have anticonvulsant activity, when Diazepam is used as 
an adjunct in treating convulsive disorders, the possibility of an increase in
the frequency and/or severity of grand mal seizures may require an increase in
the dosage of standard anticonvulsant medication. Abrupt withdrawal of Diazepam
in such cases may also be associated with a temporary increase in the frequency 
and/or severity of seizures.  <p>
 
Since Diazepam has a central nervous system depressant effect, patients should be 
advised against the simultaneous ingestion of alcohol and other CNS-depressant
drugs during Diazepam therapy.  
 <p>
USAGE IN PREGNANCY: AN INCREASED RISK OF CONGENITAL MALFORMATIONS ASSOCIATED
WITH THE USE OF MINOR TRANQUILIZERS (DIAZEPAM, MEPROBAMATE AND
CHLORDIAZEPOXIDE) DURING THE FIRST TRIMESTER OF PREGNANCY HAS BEEN SUGGESTED IN 
SEVERAL STUDIES.  BECAUSE USE OF THESE DRUGS IS RARELY A MATTER OF URGENCY,
THEIR USE DURING THIS PERIOD SHOULD ALMOST ALWAYS BE AVOIDED. THE POSSIBILITY
THAT A WOMAN OF CHILDBEARING POTENTIAL MAY BE PREGNANT AT THE TIME OF
INSTITUTION OF THERAPY SHOULD BE CONSIDERED. PATIENTS SHOULD BE ADVISED THAT IF 
THEY BECOME PREGNANT DURING THERAPY OR INTEND TO BECOME PREGNANT THEY SHOULD
COMMUNICATE WITH THEIR PHYSICIANS ABOUT THE DESIRABILITY OF DISCONTINUING THE
DRUG.  <p>
 
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
If Diazepam is to be combined with other psychotropic agents or anticonvulsant
drugs, careful consideration should be given to the pharmacology of the agents
to be employed--particularly with known compounds which may potentiate the
action of Diazepam, such as phenothiazines, narcotics, barbiturates, MAO
inhibitors and other antidepressants. The usual precautions are indicated for
severely depressed patients or those in whom there is any evidence of latent
depression; particularly the recognition that suicidal tendencies may be
present and protective measures may be necessary. The usual precautions in
treating patients with impaired renal or hepatic function should be observed. 
 <p>
In elderly and debilitated patients, it is recommended that the dosage be
limited to the smallest effective amount to preclude the development of ataxia
or oversedation (2 mg to 2 1/2 mg once or twice daily, initially, to be
increased gradually as needed and tolerated).  <p>
 
The clearance of Diazepam and certain other benzodiazepines can be delayed in
association with cimetidine administration. The clinical significance 
of this is unclear.  <p>
 
Information For Patients: To assure the safe and effective use of
benzodiazepines, patients should be informed that, since benzodiazepines may
produce psychological and physical dependence, it is advisable that they
consult with their physician before either increasing the dose or abruptly
discontinuing this drug.  <p>
 
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <p>
SEE PRECAUTIONS 
 <p>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
Side effects most commonly reported were drowsiness, fatigue and ataxia. 
Infrequently encountered were confusion, constipation, depression, diplopia,
dysarthria, headache, hypotension, incontinence, jaundice, changes in libido,
nausea, changes in salivation, skin rash, slurred speech, tremor, urinary
retention, vertigo and blurred vision. Paradoxical reactions such as acute
hyperexcited states, anxiety, hallucinations, increased muscle spasticity,
insomnia, rage, sleep disturbances and stimulation have been reported; should
these occur, use of the drug should be discontinued.  
 <p>
Because of isolated reports of neutropenia and jaundice, periodic blood counts
and liver function tests are advisable during long-term therapy. Minor changes
in EEG patterns, usually low-voltage fast activity, have been observed in
patients during and after Diazepam therapy and are of no known significance.  
 <p>
DRUG ABUSE AND DEPENDENCE <p>
 
Withdrawal symptoms, similar in character to those noted with barbiturates and
alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and
sweating), have occurred following abrupt discontinuance of diazepam. The more
severe withdrawal symptoms have usually been limited to those patients who had
received excessive doses over an extended period of time. Generally milder
withdrawal symptoms (eg, dysphoria and insomnia) have been reported following
abrupt discontinuation of benzodiazepines taken continuously at therapeutic
levels for several months. Consequently, after extended therapy, abrupt
discontinuation should generally be avoided and a gradual dosage tapering
schedule followed. Addiction-prone individuals (such as drug addicts or
alcoholics) should be under careful surveillance when receiving diazepam or
other psychotropic agents because of the predisposition of such patients to
habituation and dependence.  
 <p>
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <p>
Management Of Overdosage: Manifestations of Diazepam overdosage include
somnolence, confusion, coma and diminished reflexes. Respiration, pulse and
blood pressure should be monitored, as in all cases of drug overdosage,
although, in general, these effects have been minimal following overdosage. 
General supportive measures should be employed, along with immediate gastric
lavage. Intravenous fluids should be administered and an adequate airway
maintained. Hypotension may be combated by the use of Levophed(R)
(levarterenol) or Aramine (metaraminol). Dialysis is of limited value. As with
the management of intentional overdosage with any drug, it should be borne in
mind that multiple agents may have been ingested.  
 <p>
Flumazenil, a specific benzodiazepine-receptor antagonist, is indicated for the 
complete or partial reversal of the sedative effects of benzodiazepines and may 
be used in situations when an overdose with a benzodiazepine is known or
suspected. Prior to the administration of flumazenil, necessary measures should 
be instituted to secure airway, ventilation and intravenous access.  Flumazenil 
is intended as an adjunct to, not as a substitute for, proper management of
benzodiazepine overdose. Patients treated with flumazenil should be monitored
for resedation, respiratory depression and other residual benzodiazepine
effects for an appropriate period after treatment. THE PRESCRIBER SHOULD BE
AWARE OF A RISK OF SEIZURE IN ASSOCIATION WITH FLUMAZENIL TREATMENT,
PARTICULARLY IN LONG-TERM BENZODIAZEPINE USERS AND IN CYCLIC ANTIDEPRESSANT
OVERDOSE. The complete flumazenil package insert, including CONTRAINDICATIONS,
WARNINGS and PRECAUTIONS, should be consulted prior to use.  
 <p>
Withdrawal symptoms of the barbiturate type have occurred after the
discontinuation of benzodiazepines. (See DRUG ABUSE AND DEPENDENCE section.) 
 <p>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
Dosage should be individualized for maximum beneficial effect. While the usual
daily dosages given below will meet the needs of most patients, there will be
some who may require higher doses. In such cases dosage should be increased
cautiously to avoid adverse effects.  
 <p><pre>
ADULTS:                   USUAL DAILY DOSE                                      
Management Of Anxiety     Depending upon severity of                            
Disorders And Relief      symptoms--2 mg to 10 mg,                              
Of Symptoms Of Anxiety.   2 to 4 times daily                                    
Symptomatic Relief        10 mg, 3 or 4 times                                   
In Acute Alcohol          during the first 24 hours,                            
Withdrawal.               reducing to 5 mg, 3 or 4                              
                          times daily as needed                                 
Adjunctively For Relief   2 mg to 10 mg, 3 or 4                                 
Of Skeletal Muscle Spasm. times daily                                           
Adjunctively In           2 mg to 10 mg, 2 to 4                                 
Convulsive Disorders.     times daily                                           
Geriatric Patients, or    2 mg to 2 1/2 mg, 1 or 2                              
in the presence of        times daily initially;                                
debilitating disease.     increase gradually as                                 
                          needed and tolerated                                  
CHILDREN:                                                                       
Because of varied         1 mg to 2 1/2 mg, 3 or 4                              
responses to CNS-acting   times daily initially;                                
drugs, initiate therapy   increase gradually as                                 
with lowest dose and      needed and tolerated                                  
increase as required.                                                           
Not for use in children                                                         
under 6 months.                          </pre><p>                                       
 
<i>ANIMAL PHARMACOLOGY 
</i> <p>
In animals, Diazepam appears to act on parts of the limbic system, the thalamus
and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine
and reserpine, has no demonstrable peripheral autonomic blocking action, nor
does it produce extrapyramidal side effects; however, animals treated with
Diazepam do have a transient ataxia at higher doses. Diazepam was found to have
transient cardiovascular depressor effects in dogs. Long-term experiments in
rats revealed no disturbances of endocrine function.  
 <p>
Oral LD50 of diazepam is 720 mg/kg in mice and 1240 mg/kg in rats. 
Intraperitoneal administration of 400 mg/kg to a monkey resulted in death on
the sixth day.  <p>
 
Reproduction Studies: A series of rat reproduction studies was performed with
diazepam in oral doses of 1, 10, 80 and 100 mg/kg. At 100 mg/kg there was a
decrease in the number of pregnancies and surviving offspring in these rats. 
Neonatal survival of rats at doses lower than 100 mg/kg was within normal
limits. Several neonates in these rat reproduction studies showed skeletal or
other defects. Further studies in rats at doses up to and including 80
mg/kg/day did not reveal teratological effects on the offspring.  
 <p>
In humans, measurable blood levels of Diazepam were obtained in maternal and cord 
blood, indicating placental transfer of the drug.  
<p>

<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-63</DOCNO>
<DOCOLDNO>IA018-000200-B033-147</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/dig.htm 206.86.175.201 19970106223700 text/html 50527
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:30:43 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 50344
Last-modified: Sat, 06 Jul 1996 08:04:54 GMT
</DOCHDR>
<html>
<head>
   <title>Digoxin - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Digoxin</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <P></P>
Digoxin is one of the cardiac (or digitalis) glycosides, a closely related
group of drugs having in common specific effects on the myocardium. These drugs 
are found in a number of plants. Digoxin is extracted from the leaves of
Digitalis Lanata. The term &quot;digitalis&quot; is used to designate the whole group.
The glycosides are composed of two portions: a sugar and a cardenolide (hence
&quot;glycosides&quot;).  
 <P></P>
Digoxin has the molecular formula C41H64O14, a molecular weight of 780.95 and
melting and decomposition points above 235 deg C. The drug is practically
insoluble in water and in ether; slightly soluble in diluted (50%) alcohol and
in chloroform; and freely soluble in pyridine. Digoxin powder is composed of
odorless white crystals.  
 <P></P>
Digoxin has the chemical name: 3beta-((O-2,6-dideoxy-beta-D-Ribo  -
hexopyranosyl-(1 right arrow 4)-O-2,  6-dideoxy-beta-D-Ribo  -hexopyranosyl-(1
right arrow 4)-2,  6-dideoxy-beta-D-Ribo-hexopyranosyl)oxy)-12beta,14-
dihydroxy-5beta-card-20(22)-enolide.  <P></P>
 
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 
</b> <P></P>
MECHANISM OF ACTION: The influence of digitalis glycosides on the myocardium is 
dose-related, and involves both a direct action on cardiac muscle and the
specialized conduction system, and indirect actions on the cardiovascular
system mediated by the autonomic nervous system. The indirect actions mediated
by the autonomic nervous system involve a vagomimetic action, which is
responsible for the effects of digitalis on the sino-atrial (SA) and
atrioventricular (AV) nodes; and also a baroreceptor sensitization which
results in increased carotid sinus nerve activity and enhanced sympathetic
withdrawal for any given increment in mean arterial pressure. The pharmacologic 
consequences of these direct and indirect effects are: 1) an increase in the
force and velocity of myocardial systolic contraction (positive inotropic
action); 2) a slowing of heart rate (negative chronotropic effect); and 3)
decreased conduction velocity through the AV node. In higher doses, digitalis
increases sympathetic outflow from the central nervous system (CNS) to both
cardiac and peripheral sympathetic nerves.  This increase in sympathetic
activity may be an important factor in digitalis cardiac toxicity. Most of the
extracardiac manifestations of digitalis toxicity are also mediated by the CNS. 
 <P></P>
PHARMACOKINETICS:  
 <P></P>
ABSORPTION--Gastrointestinal absorption of digoxin is a passive process. 
Absorption of digoxin from the Digoxin tablet formulation has been demonstrated 
to be 60 to 80% complete compared to an identical intravenous dose of digoxin
(absolute bioavailability). When digoxin tablets are taken after meals, the
rate of absorption is slowed, but the total amount of digoxin absorbed is
usually unchanged. When taken with meals high in bran fiber, however, the
amount absorbed from an oral dose may be reduced. Comparison of the systemic
availability and equivalent doses for digoxin preparations are shown in the
following table: <P></P> 
 
<PRE>------------------------------------------------------------------------        
                            ABSOLUTE             EQUIVALENT DOSES               
   PRODUCT               BIOAVAILABILITY             (IN MG*)                   
------------------------------------------------------------------------        
Digoxin(R) Tablet             60-80%        0.125        0.25        0.5        
Digoxin Elixir                70-85%        0.125        0.25        0.5        
Digoxin Injection/I.M.        70-85%        0.125        0.25        0.5        
Digoxin Injection/I.V.         100%         0.1          0.2         0.4        
       
------------------------------------------------------------------------        
*1 mg = 1000 mcgm                                                               
------------------------------------------------------------------------        </PRE><P></P>
In some patients, orally administered digoxin is converted to cardioinactive
reduction products (e.g., dihydrodigoxin) by colonic bacteria in the gut. Data
suggest that one in ten patients treated with digoxin tablets will degrade 40%
or more of the ingested dose.  
 <P></P>
DISTRIBUTION--Following drug administration, a 6 to 8 hour distribution phase
is observed. This is followed by a much more gradual serum concentration
decline, which is dependent on digoxin elimination from the body. The peak
height and slope of the early portion (absorption/distribution phases) of the
serum concentration-time curve are dependent upon the route of administration
and the absorption characteristics of the formulation. Clinical evidence
indicates that the early high serum concentrations do not reflect the
concentration of digoxin at its site of action, but that with chronic use, the
steady-state post-distribution serum levels are in equilibrium with tissue
levels and correlate with pharmacologic effects. In individual patients, these
post- distribution serum concentrations are linearly related to maintenance
dosage and may be useful in evaluating therapeutic and toxic effects (see Serum 
Digoxin Concentrations in DOSAGE AND ADMINISTRATION section).  
 <P></P>
Digoxin is concentrated in tissues and therefore has a large apparent volume of 
distribution. Digoxin crosses both the blood-brain barrier and the placenta. At 
delivery, serum digoxin concentration in the newborn is similar to the serum
level in the mother. Approximately 20 to 25% of plasma digoxin is bound to
protein. Serum digoxin concentrations are not significantly altered by large
changes in fat tissue weight, so that its distribution space correlates best
with lean (ideal) body weight, not total body weight.  
 <P></P>
PHARMACOLOGIC RESPONSE--The approximate times to onset of effect and to peak
effect of all the Digoxin preparations are given in the following table:  <P></P>
 
<PRE>----------------------------------------------------------------------          
                                 TIME TO ONSET              TIME TO             
PRODUCT                            OF EFFECT*             PEAK EFFECT*          
----------------------------------------------------------------------          
Digoxin Tablet                    0.5-2 hours               2-6 hours           
Digoxin Elixir                    0.5-2 hours               2-6 hours           
Digoxin Injection/I.M.            0.5-2 hours               2-6 hours           
Digoxin Injection/I.V.            5-30 minutes**            1-4 hours           
----------------------------------------------------------------------   </PRE> <BR>      
*Documented for ventricular response rate in atrial fibrillation,               
inotropic effect and electrocardiographic changes.   <BR>                           
**Depending upon rate of infusion.   <BR>                                           
------------------------------------------------------------------------   <P></P>     
EXCRETION--Elimination of digoxin follows first-order kinetics (that is, the
quantity of digoxin eliminated at any time is proportional to the total body
content). Following intravenous administration to normal subjects, 50 to 70% of 
a digoxin dose is excreted unchanged in the urine. Renal excretion of digoxin
is proportional to glomerular filtration rate and is largely independent of
urine flow. In subjects with normal renal function, digoxin has a half-life of
1.5 to 2.0 days. The half-life in anuric patients is prolonged to 4 to 6 days.
Digoxin is not effectively removed from the body by dialysis, exchange
transfusion or during cardiopulmonary by-pass because most of the drug is in
tissue rather than circulating in the blood.  <P></P>
 
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <P></P>
HEART FAILURE: The increased cardiac output resulting from the inotropic action 
of digoxin ameliorates the disturbances characteristic of heart failure (venous 
congestion, edema, dyspnea, orthopnea and cardiac asthma).  
 <P></P>
Digoxin is more effective in &quot;low output&quot; (pump) failure than in &quot;high output&quot;
heart failure secondary to arteriovenous fistula, anemia, infection or
hyperthyroidism.  
 <P></P>
Digoxin is usually continued after failure is controlled, unless some known
precipitating factor is corrected. Studies have shown, however, that even
though hemodynamic effects can be demonstrated in almost all patients,
corresponding improvement in the signs and symptoms of heart failure is not
necessarily apparent. Therefore, in patients in whom digoxin may be difficult
to regulate, or in whom the risk of toxicity may be great (e.g., patients with
unstable renal function or whose potassium levels tend to fluctuate) a cautious 
withdrawal of digoxin may be considered. If digoxin is discontinued, the
patient should be regularly monitored for clinical evidence of recurrent heart
failure.<P></P>
ATRIAL FIBRILLATION: Digoxin reduces ventricular rate and thereby improves
hemodynamics. Palpitation, precordial distress or weakness are relieved and
concomitant congestive failure ameliorated. Digoxin should be continued in
doses necessary to maintain the desired ventricular rate.  
 <P></P>
ATRIAL FLUTTER: Digoxin slows the heart and regular sinus rhythm may appear. 
Frequently the flutter is converted to atrial fibrillation with a controlled
ventricular response. Digoxin treatment should be maintained if atrial
fibrillation persists. (Electrical cardioversion is often the treatment of
choice for atrial flutter. See discussion of cardioversion in PRECAUTIONS
section.) 
 <P></P>
PAROXYSMAL ATRIAL TACHYCARDIA (PAT): Digoxin may convert PAT to sinus rhythm by 
slowing conduction through the AV node. If heart failure has ensued or
paroxysms recur frequently, digoxin should be continued. In infants, digoxin is 
usually continued for 3 to 6 months after a single episode of PAT to prevent
recurrence.  <P></P>
 
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <P></P>
Digitalis glycosides are contraindicated in ventricular fibrillation.  
 <P></P>
In a given patient, an untoward effect requiring permanent discontinuation of
other digitalis preparations usually constitutes a contraindication to digoxin. 
Hypersensitivity to digoxin itself is a contraindication to its use. Allergy
to digoxin, though rare, does occur. It may not extend to all such preparations 
and another digitalis glycoside may be tried with caution.  
 <P></P>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <P></P>
Digitalis alone or with other drugs has been used in the treatment of obesity.  
This use of digoxin or other digitalis glycosides is unwarranted. Moreover,
since they may cause potentially fatal arrhythmias or other adverse effects,
the use of these drugs solely for the treatment of obesity is dangerous. <P></P> 
 
Anorexia, nausea, vomiting and arrhythmias may accompany heart failure or may
be indications of digitalis intoxication. Clinical evaluation of the cause of
these symptoms should be attempted before further digitalis administration. In
such circumstances determination of the serum digoxin concentration may be an
aid in deciding whether or not digitalis toxicity is likely to be present. If
the possibility of digitalis intoxication cannot be excluded, cardiac
glycosides should be temporarily withheld, if permitted by the clinical
situation.  
 <P></P>
Patients with renal insufficiency require smaller than usual maintenance doses
of digoxin (see DOSAGE AND ADMINISTRATION section).  
 <P></P>
Heart failure accompanying acute glomerulonephritis requires extreme care in
digitalization. Relatively low loading and maintenance doses and concomitant
use of antihypertensive drugs may be necessary and careful monitoring is
essential.  Digoxin should be discontinued as soon as possible.  
 <P></P>
Patients with severe carditis, such as carditis associated with rheumatic fever 
or viral myocarditis, are especially sensitive to digoxin-induced disturbances
of rhythm.  
 <P></P>
Newborn infants display considerable variability in their tolerance to digoxin. 
Premature and immature infants are particularly sensitive, and dosage must not
only be reduced but must be individualized according to their degree of
maturity.  
 <P></P>
Note: Digitalis glycosides are an important cause of accidental poisoning in
children.  
 <P></P>
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <P></P>
GENERAL: Digoxin toxicity develops more frequently and lasts longer in patients 
with renal impairment because of the decreased excretion of digoxin. Therefore, 
it should be anticipated that dosage requirements will be decreased in patients 
with moderate to severe renal disease (see DOSAGE AND ADMINISTRATION section).  
Because of the prolonged half-life, a longer period of time is required to
achieve an initial or new steady-state concentration in patients with renal
impairment than in patients with normal renal function.  
 <P></P>
In patients with hypokalemia, toxicity may occur despite serum digoxin
concentrations within the &quot;normal range,&quot; because potassium depletion
sensitizes the myocardium to digoxin. Therefore, it is desirable to maintain
normal serum potassium levels in patients being treated with digoxin.
Hypokalemia may result from diuretic, amphotericin B or corticosteroid therapy, 
and from dialysis or mechanical suction of gastrointestinal secretions. It may
also accompany malnutrition, diarrhea, prolonged vomiting, old age and long
standing heart failure. In general, rapid changes in serum potassium or other
electrolytes should be avoided, and intravenous treatment with potassium should 
be reserved for special circumstances as described below (see TREATMENT OF
ARRHYTHMIAS PRODUCED BY OVERDOSAGE section).  
 <P></P>
Calcium, particularly when administered rapidly by the intravenous route, may
produce serious arrhythmias in digitalized patients. Hypercalcemia from any
cause predisposes the patient to digitalis toxicity. On the other hand,
hypocalcemia can nullify the effects of digoxin in man; thus, digoxin may be
ineffective until serum calcium is restored to normal. These interactions are
related to the fact that calcium affects contractility and excitability of the
heart in a manner similar to digoxin.  
 <P></P>
Hypomagnesemia may predispose to digitalis toxicity. If low magnesium levels
are detected in a patient on digoxin, replacement therapy should be instituted. 
 <P></P>
Quinidine, verapamil, amiodarone, propafenone, indomethacin and itraconazole
cause a rise in serum digoxin concentration, with the implication that
digitalis intoxication may result. This rise appears to be proportional to the
dose. The effect is mediated by a reduction in the digoxin clearance and, in
the case of quinidine, decreased volume of distribution as well.  
 <P></P>
Certain antibiotics may increase digoxin absorption in patients who convert
digoxin to inactive metabolites in the gut (see Pharmacokinetics portion of the 
ACTIONS/CLINICAL PHARMACOLOGY section). Recent studies have shown that specific 
colonic bacteria in the lower gastrointestinal tract convert digoxin to
cardioinactive reduction products, thereby reducing its bioavailability. 
Although inactivation of these bacteria by antibiotics is rapid, the serum
digoxin concentration will rise at a rate consistent with the elimination half
life of digoxin. The magnitude of rise in serum digoxin concentration relates
to the extent of bacterial inactivation, and may be as much as two-fold in some 
cases. Patients with acute myocardial infarction or severe pulmonary disease
may be unusually sensitive to digoxin-induced disturbances of rhythm.  
 <P></P>
Atrial arrhythmias associated with hypermetabolic states (e.g. hyperthyroidism) 
are particularly resistant to digoxin treatment. Large doses of digoxin are not 
recommended as the only treatment of these arrhythmias and care must be taken
to avoid toxicity if large doses of digoxin are required. In hypothyroidism,
the digoxin requirements are reduced. Digoxin responses in patients with
compensated thyroid disease are normal.  
 <P></P>
Reduction of digoxin dosage may be desirable prior to electrical cardioversion
to avoid induction of ventricular arrhythmias, but the physician must consider
the consequences of rapid increase in ventricular response to atrial
fibrillation if digoxin is withheld 1 to 2 days prior to cardioversion. If
there is a suspicion that digitalis toxicity exists, elective cardioversion
should be delayed. If it is not prudent to delay cardioversion, the energy
level selected should be minimal at first and carefully increased in an attempt 
to avoid precipitating ventricular arrhythmias.  
 <P></P>
Incomplete AV block, especially in patients with Stokes-Adams attacks, may
progress to advanced or complete heart block if digoxin is given.  
 <P></P>
In some patients with sinus node disease (i.e., Sick Sinus Syndrome), digoxin
may worsen sinus bradycardia or sino-atrial block.  
 <P></P>
In patients with Wolff-Parkinson-White Syndrome and atrial fibrillation,
digoxin can enhance transmission of impulses through the accessory pathway.
This effect may result in extremely rapid ventricular rates and even
ventricular fibrillation.  
 <P></P>
Digoxin may worsen the outflow obstruction in patients with idiopathic
hypertrophic subaortic stenosis (IHSS). Unless cardiac failure is severe, it is 
doubtful whether digoxin should be employed.  
 <P></P>
Patients with chronic constrictive pericarditis may fail to respond to digoxin. 
In addition, slowing of the heart rate by digoxin in some patients may further
decrease cardiac output.  
 <P></P>
Patients with heart failure from amyloid heart disease or constrictive
cardiomyopathies respond poorly to treatment with digoxin.
Digoxin is not indicated for the treatment of sinus tachycardia unless it is
associated with heart failure.  
 <P></P>
Digoxin may produce false positive ST-T changes in the electrocardiogram during 
exercise testing.  
 <P></P>
Intramuscular injection of digoxin is extremely painful and offers no
advantages unless other routes of administration are contraindicated.  
 <P></P>
LABORATORY TESTS: Patients receiving digoxin should have their serum
electrolytes and renal function (BUN and/or serum creatinine) assessed
periodically; the frequency of assessments will depend on the clinical setting. 
For discussion of serum digoxin concentrations, see DOSAGE AND ADMINISTRATION
section.  
 <P></P>
DRUG INTERACTIONS: Potassium-depleting Corticosteroids and Diuretics may be
major contributing factors to digitalis toxicity. Calcium, particularly if
administered rapidly by the intravenous route, may produce serious arrhythmias
in digitalized patients. Quinidine, Verapamil, Amiodarone, Propafenone,
Indomethacin And Itraconazole cause a rise in serum digoxin concentration, with 
the implication that digitalis intoxication may result. Certain Antibiotics
increase digoxin absorption in patients who inactivate digoxin by bacterial
metabolism in the lower intestine, so that digitalis intoxication may result. 
Propantheline and Diphenoxylate, by decreasing gut motility, may increase
digoxin absorption. Antacids, Kaolin-Pectin, Sulfasalazine, Neomycin,
Cholestyramine, certain Anticancer Drugs, and Metoclopramide may reduce
intestinal digoxin absorption, resulting in unexpectedly low serum
concentrations. There have been inconsistent reports regarding the effects of
other drugs on the serum digoxin concentration. Thyroid administration to a
digitalized, hypothyroid patient may increase the dose requirement of digoxin.  
Concomitant use of digoxin and Sympathomimetics increases the risk of cardiac
arrhythmias because both enhance ectopic pacemaker activity. Succinylcholine
may cause a sudden extrusion of potassium from muscle cells, and may thereby
cause arrhythmias in digitalized patients. Although beta adrenergic blockers or 
calcium channel blockers and digoxin may be useful in combination to control
atrial fibrillation, their additive effects on AV node conduction can result in 
complete heart block.  
 <P></P>
Due to the considerable variability of these interactions, digoxin dosage
should be carefully individualized when patients receive coadministered
medications.  Furthermore, caution should be exercised when combining digoxin
with any drug that may cause a significant deterioration in renal function,
since this may impair the excretion of digoxin.  
 <P></P>
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY:  
 <P></P>
There have been no long-term studies performed in animals to evaluate
carcinogenic potential.  <P></P>
 
PREGNANCY: TERATOGENIC EFFECTS: Pregnancy Category C. Animal reproduction
studies have not been conducted with digoxin. It is also not known whether
digoxin can cause fetal harm when administered to a pregnant woman or can
affect reproduction capacity. Digoxin should be given to a pregnant woman only
if clearly needed.  <P></P>
 
NURSING MOTHERS: Studies have shown that digoxin concentrations in the mother's 
serum and milk are similar. However, the estimated daily dose to a nursing
infant will be far below the usual infant maintenance dose. Therefore, this
amount should have no pharmacologic effect upon the infant. Nevertheless,
caution should be exercised when digoxin is administered to a nursing woman.  
 <P></P>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <P></P>
Potassium-depleting Corticosteroids and Diuretics may be major contributing
factors to digitalis toxicity. Calcium, particularly if administered rapidly by 
the intravenous route, may produce serious arrhythmias in digitalized patients. 
Quinidine, Verapamil, Amiodarone, Propafenone, Indomethacin And Itraconazole
cause a rise in serum digoxin concentration, with the implication that
digitalis intoxication may result. Certain Antibiotics increase digoxin
absorption in patients who inactivate digoxin by bacterial metabolism in the
lower intestine, so that digitalis intoxication may result. Propantheline and
Diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
Antacids, Kaolin- Pectin, Sulfasalazine, Neomycin, Cholestyramine, certain
Anticancer Drugs, and Metoclopramide may reduce intestinal digoxin absorption,
resulting in unexpectedly low serum concentrations. There have been
inconsistent reports regarding the effects of other drugs on the serum digoxin
concentration. Thyroid administration to a digitalized, hypothyroid patient may 
increase the dose requirement of digoxin. Concomitant use of digoxin and
Sympathomimetics increases the risk of cardiac arrhythmias because both enhance 
ectopic pacemaker activity. Succinylcholine may cause a sudden extrusion of
potassium from muscle cells, and may thereby cause arrhythmias in digitalized
patients. Although beta adrenergic blockers or calcium channel blockers and
digoxin may be useful in combination to control atrial fibrillation, their
additive effects on AV node conduction can result in complete heart block.  
 <P></P>
Due to the considerable variability of these interactions, digoxin dosage
should be carefully individualized when patients receive coadministered
medications.  Furthermore, caution should be exercised when combining digoxin
with any drug that may cause a significant deterioration in renal function,
since this may impair the excretion of digoxin.  
 <P></P>
(See Also PRECAUTIONS) <P></P>
 
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <P></P>
The frequency and severity of adverse reactions to digoxin depend on the dose
and route of administration, as well as on the patient's underlying disease or
concomitant therapies (see PRECAUTIONS section and Serum Digoxin Concentrations 
subsection of DOSAGE AND ADMINISTRATION). The overall incidence of adverse
reactions has been reported as 5 to 20%, with 15 to 20% of them being
considered serious (one to four percent of patients receiving digoxin).
Evidence suggests that the incidence of toxicity has decreased since the
introduction of the serum digoxin assay and improved standardization of digoxin 
tablets. Cardiac toxicity accounts for about one-half, gastrointestinal
disturbances for about one-fourth, and CNS and other toxicity for about one
fourth of these adverse reactions.  
 <P></P>
ADULTS:  
 <P></P>
CARDIAC--Unifocal or multiform ventricular premature contractions, especially
in bigeminal or trigeminal patterns, are the most common arrhythmias associated 
with digoxin toxicity in adults with heart disease.  
 <P></P>
Ventricular tachycardia may result from digitalis toxicity. Atrioventricular
(AV) dissociation, accelerated junctional (nodal) rhythm and atrial tachycardia 
with block are also common arrhythmias caused by digoxin overdosage.  
 <P></P>
Excessive slowing of the pulse is a clinical sign of digoxin overdosage. AV
block (Wenckebach) of increasing degree may proceed to complete heart block.  
 <P></P>
Note: The electrocardiogram is fundamental in determining the presence and
nature of these cardiac disturbances. Digoxin may also induce other changes in
the ECG (e.g., PR prolongation, ST depression), which represent digoxin effect
and may or may not be associated with digitalis toxicity.  
 <P></P>
GASTROINTESTINAL--Anorexia, nausea, vomiting and less commonly diarrhea are
common early symptoms of overdosage. However, uncontrolled heart failure may
also produce such symptoms. Digitalis toxicity very rarely may cause abdominal
pain and hemorrhagic necrosis of the intestines.  
 <P></P>
CNS--Visual disturbances (blurred or yellow vision), headache, weakness,
dizziness, apathy and psychosis can occur.  
 <P></P>
OTHER--Gynecomastia is occasionally observed. Maculopapular rash or other skin
reactions are rarely observed.  
<P></P> 
INFANTS AND CHILDREN: Toxicity differs from the adult in a number of respects.  
Anorexia, nausea, vomiting, diarrhea and CNS disturbances may be present but
are rare as initial symptoms in infants. Cardiac arrhythmias are more reliable
signs of toxicity. Digoxin in children may produce any arrhythmia. The most
commonly encountered are conduction disturbances or supraventricular
tachyarrhythmias, such as atrial tachycardia with or without block and
junctional (nodal) tachycardia. Ventricular arrhythmias are less common. Sinus
bradycardia may also be a sign of impending digoxin intoxication, especially in 
infants, even in the absence of first degree heart block. Any arrhythmia or
alteration in cardiac conduction that develops in a child taking digoxin should 
initially be assumed to be a consequence of digoxin intoxication.  
 <P></P>
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <P></P>
TREATMENT OF ARRHYTHMIAS PRODUCED BY OVERDOSAGE:
<P></P>
ADULTS: Digoxin should be discontinued until all signs of toxicity are gone. 
Discontinuation may be all that is necessary if toxic manifestations are not
severe and appear only near the expected time for maximum effect of the drug. 
 <P></P>
Correction of factors that may contribute to toxicity such as electrolyte
disturbances, hypoxia, acid-base disturbances and removal of aggravating agents 
such as catecholamines, should also be considered. Potassium salts may be
indicated, particularly if hypokalemia is present. Potassium administration may 
be dangerous in the setting of massive digitalis overdosage (see Massive
Digitalis Overdosage subsection below). Potassium chloride in divided oral
doses totaling 3 to 6 grams of the salt (40 to 80 mEq K+) for adults may be
given provided renal function is adequate (see below for potassium
recommendations in Infants and Children).  
 <P></P>
When correction of the arrhythmia is urgent and the serum potassium
concentration is low or normal, potassium should be administered intravenously
in 5% dextrose injection. For adults, a total of 40 to 80 mEq (diluted to a
concentration of 40 mEq per 500 mL) may be given at a rate not exceeding 20 mEq 
per hour, or slower if limited by pain due to local irritation. Additional
amounts may be given if the arrhythmia is uncontrolled and potassium well
tolerated. ECG monitoring should be performed to watch for any evidence of
potassium toxicity (e.g., peaking of T waves) and to observe the effect on the
arrhythmia. The infusion may be stopped when the desired effect is achieved.  
 <P></P>
Note: Potassium should not be used and may be dangerous in heart block due to
digoxin, unless primarily related to supraventricular tachycardia.  
 <P></P>
Other agents that have been used for the treatment of digoxin intoxication
include lidocaine, procainamide, propranolol and phenytoin, although use of the 
latter must be considered experimental. In advanced heart block, atropine
and/or temporary ventricular pacing may be beneficial. Digibind(R), Digoxin
Immune Fab (Ovine), can be used to reverse potentially life-threatening digoxin 
(or digitoxin) intoxication. Improvement in signs and symptoms of digitalis
toxicity usually begins within 1/2 hour of Digibind administration. Each 40 mg
vial of Digibind will neutralize 0.6 mg of digoxin (which is a usual body store 
of an adequately digitalized 70 kg patient).  
 <P></P>
INFANTS AND CHILDREN: See Adult section for general recommendations for the
treatment of arrhythmias produced by overdosage and for cautions regarding the
use of potassium.  <P></P>
 
If a potassium preparation is used to treat toxicity, it may be given orally in 
divided doses totaling 1 to 1.5 mEq K+ per kilogram (kg) body weight (1 gram of 
potassium chloride contains 13.4 mEq K+).  
 <P></P>
When correction of the arrhythmia with potassium is urgent, approximately 0.5
mEq/kg of potassium per hour may be given intravenously, with careful ECG
monitoring. The intravenous solution of potassium should be dilute enough to
avoid local irritation; however, especially in infants, care must be taken to
avoid intravenous fluid overload.
<P></P>
MASSIVE DIGITALIS OVERDOSAGE: Manifestations of life-threatening toxicity
include severe ventricular arrhythmias such as ventricular tachycardia or
ventricular fibrillation, or progressive bradyarrhythmias such as severe sinus
bradycardia or second or third degree heart block not responsive to atropine.
An overdosage of more than 10 mg of digoxin in previously healthy adults or 4
mg in previously healthy children or overdosage resulting in steady-state serum 
concentrations greater than 10 ng/mL, often results in cardiac arrest.  
 <P></P>
Severe digitalis intoxication can cause life-threatening elevation in serum
potassium concentration by shifting potassium from inside to outside the cell
resulting in hyperkalemia. Administration of potassium supplements in the
setting of massive intoxication may be hazardous.  
 <P></P>
Digibind, Digoxin Immune Fab (Ovine), may be used at a dose equimolar to
digoxin in the body to reverse the effects of ingestion of a massive overdose.  
The decision to administer Digibind before the onset of toxic manifestations
will depend on the likelihood that life-threatening toxicity will occur (see
above).  
 <P></P>
Patients with massive digitalis ingestion should receive large doses of
activated charcoal to prevent absorption and bind digoxin in the gut during
enteroenteric recirculation. Emesis of gastric lavage may be indicated
especially if ingestion has occurred within 30 minutes of the patient's
presentation at the hospital. Emesis should not be induced in patients who are
obtunded. If a patient presents more than 2 hours after ingestion or already
has toxic manifestations, it may be unsafe to induce vomiting or attempt
passage of a gastric tube, because such maneuvers may induce an acute vagal
episode that can worsen digitalis-toxic arrhythmias.  
 <P></P>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <P></P>
RECOMMENDED DOSAGES ARE AVERAGE VALUES THAT MAY REQUIRE CONSIDERABLE
MODIFICATION BECAUSE OF INDIVIDUAL SENSITIVITY OR ASSOCIATED CONDITIONS. 
Diminished renal function is the most important factor requiring modification
of recommended doses.  
 <P></P>
In deciding the dose of digoxin, several factors must be considered:  
 <P></P>
1. The disease being treated. Atrial arrhythmias may require larger doses than
heart failure.  
 <P></P>
2. The body weight of the patient. Doses should be calculated based upon lean
or ideal body weight.  
 <P></P>
3. The patient's renal function, preferably evaluated on the basis of
creatinine clearance.  
 <P></P>
4. Age is an important factor in infants and children.  
 <P></P>
5. Concomitant disease states, drugs or other factors likely to alter the
expected clinical response to digoxin (see PRECAUTIONS and Drug Interactions
sections).  
 <P></P>
Digitalization may be accomplished by either of two general approaches that
vary in dosage and frequency of administration, but reach the same endpoint in
terms of total amount of digoxin accumulated in the body.  
 <P></P>
1. Rapid digitalization may be achieved by administering a loading dose based
upon projected peak body digoxin stores, then calculating the maintenance dose
as a percentage of the loading dose.  
 <P></P>
2. More gradual digitalization may be obtained by beginning an appropriate
maintenance dose, thus allowing digoxin body stores to accumulate slowly. 
Steady-state serum digoxin concentrations will be achieved in approximately 5
half-lives of the drug for the individual patient. Depending upon the patient's 
renal function, this will take between one and three weeks.  
 <P></P>
ADULTS:  
 <P></P>
ADULTS--RAPID DIGITALIZATION WITH A LOADING DOSE. Peak body digoxin stores of 8 
to 12 mcgm/kg should provide therapeutic effect with minimum risk of toxicity
in most patients with heart failure and normal sinus rhythm. Larger stores (10
to 15 mcgm/kg) are often required for adequate control of ventricular rate in
patients with atrial flutter or fibrillation. Because of altered digoxin
distribution and elimination, projected peak body stores for patients with
renal insufficiency should be conservative (i.e., 6 to 10 mcgm/kg) (see
PRECAUTIONS section).  
 <P></P>
The loading dose should be based on the projected peak body stores and
administered in several portions, with roughly half the total given as the
first dose. Additional fractions of this planned total dose may be given at 6
to 8 hour intervals, WITH CAREFUL ASSESSMENT OF CLINICAL RESPONSE BEFORE EACH
ADDITIONAL DOSE.  
 <P></P>
If the patient's clinical response necessitates a change from the calculated
dose of digoxin, then calculation of the maintenance dose should be based upon
the amount actually given.  
 <P></P>
In previously undigitalized patients, a single initial Digoxin Tablet dose of
500 to 750 mcgm (0.5 to 0.75 mg) usually produces a detectable effect in 0.5 to 
2 hours that becomes maximal in 2 to 6 hours. Additional doses of 125 to 375
mcgm (0.125 to 0.375 mg) may be given cautiously at 6 to 8 hour intervals until 
clinical evidence of an adequate effect is noted. The usual amount of Digoxin
Tablets that a 70 kg patient requires to achieve 8 to 15 mcgm/kg peak body
stores is 750 to 1250 mcgm (0.75 to 1.25 mg).  
 <P></P>
Although peak body stores are mathematically related to loading doses and are
utilized to calculate maintenance doses, they do not correlate with measured
serum concentrations. This discrepancy is caused by digoxin distribution within 
the body during the first 6 to 8 hours following a dose. Serum concentrations
drawn during this time are usually not interpretable.<P></P>
The maintenance dose should be based upon the percentage of the peak body
stores lost each day through elimination. The following formula has had wide
clinical use:  <P></P>
 
 <PRE>Maintenance Dose = Peak Body Stores (i.e., Loading Dose) x % Daily Loss        
                                                           ------------         
                                                              100               
                          Where: % Daily Loss = 14 + Ccr/5                      </PRE>
<BR>Ccr is creatinine clearance, corrected to 70 kg body weight or 1.73 m(square)
body surface area. For Adults, if only serum creatinine concentrations (Scr)
are available, a Ccr (corrected to 70 kg body weight) may be estimated in men
as (140 - Age)/Scr. For women, this result should be multiplied by 0.85.  
 <P></P>
Note: This equation cannot be used for estimating creatinine clearance in
infants or children.  
 <P></P>
A common practice involves the use of Digoxin Injection to achieve rapid
digitalization, with conversion to Digoxin Tablets or Digoxin Liquid Capsules for
maintenance therapy. If patients are switched from intravenous to oral digoxin
formulations, allowances must be made for differences in bioavailability when
calculating maintenance dosages (see table, ACTIONS/CLINICAL PHARMACOLOGY
section).  
 <P></P>
ADULTS--GRADUAL DIGITALIZATION WITH A MAINTENANCE DOSE: The following table
provides average Digoxin Tablet daily maintenance dose requirements for
patients with heart failure based upon lean body weight and renal function:<P></P>  
 <PRE>
------------------------------------------------------------------------        
           Usual Digoxin Daily Maintenance Dose Requirements (mcgm)             
                 For Estimated Peak Body Stores of 10 mcgm/kg                   
           ---------------------------------------------------                  
                         LEAN BODY WEIGHT (KG/LBS)                              
                  50/      60/    70/   80/   90/    100/                       
                  110      132    154   176   198    220                        
           ---------------------------------------------------                  
             0    *63**    125    125   125   188*/* 188   22                   
            10    125      125    125   188   188    188   19                   
            20    125      125    188   188   188    250   16                   
Corrected   30    125      188    188   188   250    250   14   Number          
   Ccr      40    125      188    188   250   250    250   13     of            
(mL/min     50    188      188    250   250   250    250   12    Days           
per 70 kg)  60    188      188    250   250   250    375   11   Before          
            70    188      250    250   250   250    375   10   Steady-         
            80    188      250    250   250   375    375    9   State           
            90    188      250    250   250   375    500    8   Achieved        
           100    250      250    250   375   375    500    7                   
           -----------------------------------------        </PRE> <BR>                   
*  63 mcgm = 0.063 mg <BR>                                                          
** 1/2 of 125 mcgm tablet or 125 mcgm every other day    <BR>                       
*/*1 1/2 of 125 mcgm tablet.    <BR>                                                
EXAMPLE--based on the above table, a patient in heart failure with an estimated   
lean body weight of 70 kg and a Ccr of 60 mL/min, should be given a 250 mcgm
(0.25 mg) Digoxin Tablet each day, usually taken after the morning meal. 
Steady-state serum concentrations should not be anticipated before 11 days.  
 <P></P>
INFANTS AND CHILDREN: Digitalization must be individualized. Divided daily
dosing is recommended for infants and young children. Children over 10 years of 
age require adult dosages in proportion to their body weight.  
 <P></P>
In the newborn period, renal clearance of digoxin is diminished and suitable
dosage adjustments must be observed. This is especially pronounced in the
premature infant. Beyond the immediate newborn period, children generally
require proportionally larger doses than adults on the basis of body weight or
body surface area.  <P></P>
 
Digoxin Injection Pediatric can be used to achieve rapid digitalization, with
conversion to an oral Digoxin formulation for maintenance therapy. If patients
are switched from intravenous to oral digoxin tablets or elixir, allowances
must be made for differences in bioavailability when calculating maintenance
dosages (see bioavailability table in ACTIONS/CLINICAL PHARMACOLOGY section and 
dosing table below).  <P></P>
 
Intramuscular injection of digoxin is extremely painful and offers no
advantages unless other routes of administration are contraindicated.  
 <P></P>
Digitalizing and daily maintenance doses for each age group are given below and 
should provide therapeutic effect with minimum risk of toxicity in most
patients with heart failure and normal sinus rhythm. Larger doses are often
required for adequate control of ventricular rate in patients with atrial
flutter or fibrillation.  <P></P>
 
The loading dose should be administered in several portions, with roughly half
the total given as the first dose. Additional fractions of this planned total
dose may be given at 6 to 8 hour intervals, WITH CAREFUL ASSESSMENT OF CLINICAL 
RESPONSE BEFORE EACH ADDITIONAL DOSE. If the patient's clinical response
necessitates a change from the calculated dose of digoxin, then calculation of
the maintenance dose should be based upon the amount actually given.  <P></P>
 
<PRE>-------------------------------------------------------------------------       
     Usual Digitalizing and Maintenance Dosages for Digoxin Tablets             
   in Children WITH NORMAL RENAL FUNCTION BASED ON LEAN BODY WEIGHT             
-------------------------------------------------------------------------       
                   Digitalizing*              DAILY** MAINTENANCE               
   Age             Dose (mcgm/kg)               Dose (mcgm/kg)                  
-------------------------------------------------------------------------       
2 to 5 Years          30 to 40                                                  
5 to 10 Years         20 to 35           25 to 35% of Oral loading dose*/*      
Over 10 Years         10 to 15                                                  
------------------------------------------------------------------------        </PRE><BR>
*  I.V. digitalizing doses are 80% of oral digitalizing doses.   <BR>               
** Divided daily dosing is recommended for children under 10 years              
   of age.<BR>
*/*Projected or actual digitalizing dose providing clinical response. <BR>          
------------------------------------------------------------------------  <P></P>      
More gradual digitalization can also be accomplished by beginning an
appropriate maintenance dose. The range of percentages provided above can be
used in calculating this dose for patients with normal renal function. In
children with renal disease, digoxin dosing must be carefully titrated based
upon clinical response.  
 <P></P>
Long-term use of digoxin is indicated in many children who have been
digitalized for acute heart failure, unless the cause is transient. Children
with severe congenital heart disease, even after surgery, may require digoxin
for prolonged periods.  
 <P></P>
IT CANNOT BE OVEREMPHASIZED THAT BOTH THE ADULT AND PEDIATRIC DOSAGE GUIDELINES 
PROVIDED ARE BASED UPON AVERAGE PATIENT RESPONSE AND SUBSTANTIAL INDIVIDUAL
VARIATION CAN BE EXPECTED. ACCORDINGLY, ULTIMATE DOSAGE SELECTION MUST BE BASED 
UPON CLINICAL ASSESSMENT OF THE PATIENT.  
 <P></P>
SERUM DIGOXIN CONCENTRATIONS: Measurement of serum digoxin concentrations can
be helpful to the clinician in determining the state of digitalization and in
assigning certain probabilities to the likelihood of digoxin intoxication. 
Studies in adults considered adequately digitalized (without evidence of
toxicity) show that about two-thirds of such patients have serum digoxin levels 
ranging from 0.8 to 2.0 ng/mL. Patients with atrial fibrillation or atrial
flutter require and appear to tolerate higher levels than do patients with
other indications. On the other hand, in adult patients with clinical evidence
of digoxin toxicity, about two-thirds will have serum digoxin levels greater
than 2.0 ng/mL. Thus, whereas levels less than 0.8 ng/mL are infrequently
associated with toxicity, levels greater than 2.0 ng/mL are often associated
with toxicity.  Values in between are not very helpful in deciding whether a
certain sign or symptom is more likely caused by digoxin toxicity or by
something else. There are rare patients who are unable to tolerate digoxin even 
at serum concentrations below 0.8 ng/mL. Some researchers suggest that infants
and young children tolerate slightly higher serum concentrations than do
adults.  
 <P></P>
To allow adequate time for equilibration of digoxin between serum and tissue,
SAMPLING OF SERUM CONCENTRATIONS FOR CLINICAL USE SHOULD BE AT LEAST 6 TO 8
HOURS AFTER THE LAST DOSE, regardless of the route of administration or
formulation used. On a twice daily dosing schedule, there will be only minor
differences in serum digoxin concentrations whether sampling is done at 8 or 12 
hours after a dose. After a single daily dose, the concentration will be 10 to
25% lower when sampled at 24 versus 8 hours, depending upon the patient's renal 
function. Ideally, sampling for assessment of steady-state concentrations
should be done just before the next dose.  
 <P></P>
If a discrepancy exists between the reported serum concentration and the
observed clinical response, the clinician should consider the following
possibilities:  <P></P>
 
1. Analytical problems in the assay procedure.
<P></P>
2. Inappropriate serum sampling time.  
 <P></P>
3. Administration of a digitalis glycoside other than digoxin.  
 <P></P>
4. Conditions (described in WARNINGS and PRECAUTIONS sections) causing an
alteration in the sensitivity of the patient to digoxin.  
 <P></P>
5. The patient falls outside the norm in his response to or handling of
digoxin.  This decision should only be reached after exclusion of the other
possibilities and generally should be confirmed by additional correlations of
clinical observations with serum digoxin concentrations.  
 <P></P>
The serum concentration data should always be interpreted in the overall
clinical context and an isolated serum concentration value should not be used
alone as a basis for increasing or decreasing digoxin dosage.  
 <P></P>
ADJUSTMENT OF MAINTENANCE DOSE IN PREVIOUSLY DIGITALIZED PATIENTS:  
 <P></P>
Digoxin Tablet maintenance doses in individual patients on steady-state digoxin 
can be adjusted upward or downward in proportion to the ratio of the desired
versus the measured serum concentration. For example, a patient at steady-state 
on 125 mcgm (0.125 mg) of Digoxin Tablets per day with a measured serum
concentration of 0.7 ng/mL, should have the dose increased to 250 mcgm (0.25
mg) per day to achieve a steady-state serum concentration of 1.4 ng/mL,
ASSUMING THE SERUM DIGOXIN CONCENTRATION MEASUREMENT IS CORRECT, RENAL FUNCTION 
REMAINS STABLE DURING THIS TIME AND THE NEEDED ADJUSTMENT IS NOT THE RESULT OF
A PROBLEM WITH COMPLIANCE.  
 <P></P>
DOSAGE ADJUSTMENT WHEN CHANGING PREPARATIONS: The difference in bioavailability 
between injectable Digoxin or Digoxin liquid capsules and Digoxin Elixir Pediatric or
Digoxin Tablets must be considered when changing patients from one dosage form
to another.  
 <P></P>
Digoxin Injection and digoxin liquid capsules doses of 100 mcgm (0.1 mg) and 200 mcgm (0.2
mg) are approximately equivalent to 125 mcgm (0.125 mg) and 250 mcgm (0.25 mg)
doses of Digoxin Tablets and Elixir Pediatric (see table in ACTIONS/CLINICAL
PHARMACOLOGY section). Intramuscular injection of digoxin is extremely painful
and offers no advantages unless other routes of administration are
contraindicated.  <P></P>
 

<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-64</DOCNO>
<DOCOLDNO>IA018-000200-B040-158</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/metronid.htm 206.86.175.201 19970106230641 text/html 32804
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:00:26 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 32621
Last-modified: Mon, 14 Oct 1996 04:38:13 GMT
</DOCHDR>
<html>
<head>
   <title>Metronidazole - RxList Generic Information</title>
   <meta name="keywords" content="Acromona, Amibazol, Amiyodazol, Arcazol, Asiazole,



Asuzol, Clont, Debetrol, Deflamon, Elyzol, Fladex, Flagenase, Flagyl, Flagyl 375, Fossyol,



Fulikan, Fuzuzin, Klion, Medai, Melis, Metarsal, Metizol, Metro IV, Metrocream, Metrogel,



Metrogyl, Metrolag, Metrolex, Metroxyn, Metrozin, Metryl, Nalox, Nitrozol,



Norstene, Novonidazole, Protostat, Satric, Servizol, Takimetol, Trichozole, Tricowas-B,



Trikacide, Trofonil, Vaginyl, Vagitrix, Vagyl, Zadstat">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B"
alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0
height=125 width=125></a></p></center>

<h1 align=center>Metronidazole</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a
href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a
href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a
href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a
href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION</b></p>

<pre>                   *************************************************
                   *                                               *
                   *  WARNING                                      *
                   *  Metronidazole has been shown to be           *
                   *  carcinogenic in mice and rats. (See          *
                   *  PRECAUTIONS.) Unnecessary use of the drug    *
                   *  should be avoided. Its use should be         *
                   *  reserved for the conditions described in     *
                   *  the INDICATIONS AND USAGE section below.     *
                   *                                               *
                   *************************************************</pre>

<p>Metronidazole is an oral synthetic antiprotozoal and antibacterial agent,
2- Methyl- 5-nitroimidazole 1-ethanol. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL
PHARMACOLOGY
</b></p>

<p>Disposition of metronidazole in the body is similar for both oral and
intravenous dosage forms, with an average elimination half-life in healthy
humans of 8 hours. </p>

<p>The major route of elimination of metronidazole and its metabolites
is via the urine (60% to 80% of the dose), with fecal excretion accounting
for 6% to 15% of the dose. The metabolites that appear in the urine result
primarily from side- chain oxidation (1-(beta- hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole
and 2- methyl-5-nitroimidazole-1-yl-acetic acid) and glucuronide conjugation,
with unchanged metronidazole accounting for approximately 20% of the total.
Renal clearance of metronidazole is approximately 10 mL/min/1.73M(squared).
Metronidazole is the major component appearing in the plasma, with lesser
quantities of the 2-hydroxymethyl metabolite also being present. Less than
20% of the circulating metronidazole is bound to plasma proteins. Both
the parent compound and the metabolite possess In Vitro bactericidal activity
against most strains of anaerobic bacteria and In Vitro trichomonacidal
activity. </p>

<p>Metronidazole appears in cerebrospinal fluid, saliva, and human milk
in concentrations similar to those found in plasma. Bactericidal concentrations
of metronidazole have also been detected in pus from hepatic abscesses.
</p>

<p>Metronidazole 375 capsules have been shown to have a rate and extent
of absorption similar to metronidazole tablets and were bioequivalent at
an equal single dose of 750 mg. In a study conducted with 23 adult, healthy,
female volunteers, oral administration of two 375-mg Metronidazole capsules
under fasted conditions produced a mean (+/- 1 SD) peak plasma concentration
(Cmax) of 21.4 (+/- 2.8) mcg/mL with a mean Tmax of 1.6 (+/- 0.7) hours
and a mean area under the plasma concentration-time curve (AUC) of 223
(+/- 44) mcg.hr/mL. In the same study, three 250-mg Metronidazole tablets
produced a mean Cmax of 20.4 (+/- 3.8) mcg/mL with a mean Tmax of 1.4 (+/-
0.4) hours and a mean AUC of 218 (+/- 50) mcg.hr/mL. </p>

<p>Administration of Metronidazole 375 capsules with food does not affect
the extent of absorption of metronidazole; however, the presence of food
results in a lower Cmax and a delayed Tmax compared to fasted conditions.
In a study of 14 healthy, adult, female volunteers, administration of Metronidazole
375 capsules under fasting conditions produced a mean Cmax of 10.9 (+/-
1.5) mcg/mL, a mean Tmax of 1.5 (+/- 1.4) hours, and a mean AUC of 110
(+/- 34) mcg.hr/mL compared to a mean Cmax of 8.6 (+/- 1.6) mcg/mL, a mean
Tmax of 4.2 (+/- 1.7) hours, and a mean AUC of 99 (+/- 14) mcg.hr/mL under
fed conditions. </p>

<p>Decreased renal function does not alter the single-dose pharmacokinetics
of metronidazole. However, plasma clearance of metronidazole is decreased
in patients with decreased liver function. </p>

<p>MICROBIOLOGY: </p>

<p>Metronidazole exerts antimicrobial effects in an anaerobic environment
by the following possible mechanism: Once metronidazole enters the organism,
the drug is reduced by intracellular electron transport proteins. Because
of this alteration to the metronidazole molecule, a concentration gradient
is maintained which promotes the drug's intracellular transport. Presumably,
free radicals are formed which, in turn, react with cellular components
resulting in death of the microorganism. </p>

<p>Metronidazole has been shown to be active against most strains of the
following microorganisms both In Vitro and in clinical infections as described
in the INDICATIONS AND USAGE section. </p>

<p>GRAM-POSITIVE ANAEROBES: </p>

<p>Clostridium species </p>

<p>Eubacterium species </p>

<p>Peptococcus Niger </p>

<p>Peptostreptococcus species </p>

<p>GRAM-NEGATIVE ANAEROBES: </p>

<p>Bacteroides Fragilis group (B. Fragilis, B. Distasonis, B. Ovatus, B.
</p>

<p>Thetaiotaomicron, B. Vulgatus) </p>

<p>Fusobacterium species </p>

<p>PROTOZOAL PARASITES: </p>

<p>Entamoeba Histolytica </p>

<p>Trichomonas Vaginalis </p>

<p>The following In Vitro data are available, BUT THEIR CLINICAL SIGNIFICANCE
IS UNKNOWN: </p>

<p>Metronidazole exhibits In Vitro minimal inhibitory concentrations (MIC's)
of 8 mcgm/mL or less against most (&gt;/= 90%) strains of the following
microorganisms; however, the safety and effectiveness of metronidazole
in treating clinical infections due to these microorganisms have not been
established in adequate and well- controlled clinical trials. </p>

<p>GRAM-NEGATIVE ANAEROBES: </p>

<p>Bacteroides Fragilis group (B. Caccae, B. Uniformis) </p>

<p>Prevotella species (P. Bivia, P. Buccae, P. Disiens) </p>

<p>Metronidazole is active against most obligate anaerobes, but does not
possess any clinically relevant activity against facultative anaerobes
or obligate aerobes. </p>

<p>SUSCEPTIBILITY TESTS: </p>

<p>DILUTION TECHNIQUES: </p>

<p>Quantitative methods that are used to determine minimum inhibitory concentrations
provide reproducible estimates of the susceptibility of bacteria to antimicrobial
compounds. For anaerobic bacteria, the susceptibility to metronidazole
can be determined by the reference agar dilution method or by alternate
standardized test methods (REF. 1). The MIC values obtained should be interpreted
according to the following criteria: </p>

<pre>MIC (MCGM/ML)                           INTERPRETATION
-----------------------------------------------------------------------------
           &lt; or =  8                   &nbsp;Susceptible (S)
              16                        Intermediate (I)
          &gt;/= 32                        Resistant 
-----------------------------------------------------------------------------</pre>

<p>For protozoal parasites: Standardized tests do not exist for use in
clinical microbiology laboratories. </p>

<p>A report of &quot;Susceptible&quot; indicates that the pathogen is likely
to be inhibited by usually achievable concentrations of the antimicrobial
compound in the blood. A report of &quot;Intermediate&quot; indicates that
the result should be considered equivocal, and if the microorganism is
not fully susceptible to alternative, clinically feasible drugs, the test
should be repeated. This category implies possible clinical applicability
in body sites where the drug is physiologically concentrated or in situations
where high dosage of drug can be used. This category also provides a buffer
zone which prevents small uncontrolled technical factors from causing major
discrepancies in interpretation. A report of &quot;Resistant&quot; indicates
that usually achievable concentrations of the antimicrobial compound in
the blood are unlikely to be inhibitory and other therapy should be selected.
</p>

<p>Standardized susceptibility test procedures require the use of laboratory
control microorganisms that are used to control the technical aspects of
the laboratory procedures. Standard metronidazole powder should provide
the following MIC values: </p>

<pre>MICROORGANISM                                         MIC (MCGM/ML)
-----------------------------------------------------------------------------
Bacteroides Fragilis
  ATCC 25285                                             0.25-1.0
Bacteroides Thetaiotaomicron
  ATCC 29741                                             0.5-2.0
-----------------------------------------------------------------------------</pre>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE
</b></p>

<p>Symptomatic Trichomoniasis. Metronidazole 375 capsules are indicated
for the treatment of symptomatic trichomoniasis in females and males when
the presence of the trichomonad has been confirmed by appropriate laboratory
procedures (wet smears and/or cultures). </p>

<p>Asymptomatic Trichomoniasis. Metronidazole 375 capsules are indicated
in the treatment of asymptomatic females when the organism is associated
with endocervicitis, cervicitis, or cervical erosion. Since there is evidence
that presence of the trichomonad can interfere with accurate assessment
of abnormal cytological smears, additional smears should be performed after
eradication of the parasite. </p>

<p>Treatment Of Asymptomatic Consorts. T. Vaginalis infection is a venereal
disease. Therefore, asymptomatic sexual partners of treated patients should
be treated simultaneously if the organism has been found to be present,
in order to prevent reinfection of the partner. The decision as to whether
to treat an asymptomatic male partner who has a negative culture or one
for whom no culture has been attempted is an individual one. In making
this decision, it should be noted that there is evidence that a woman may
become reinfected if her consort is not treated. Also, since there can
be considerable difficulty in isolating the organism from the asymptomatic
male carrier, negative smears and cultures cannot be relied upon in this
regard. In any event, the consort should be treated with metronidazole
in cases of reinfection. </p>

<p>Amebiasis. Metronidazole 375 capsules are indicated in the treatment
of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess.
In amebic liver abscess, metronidazole therapy does not obviate the need
for aspiration or drainage of pus. </p>

<p>Anaerobic Bacterial Infections. Metronidazole 375 capsules are indicated
in the treatment of serious infections caused by susceptible anaerobic
bacteria. Indicated surgical procedures should be performed in conjunction
with metronidazole therapy. In a mixed aerobic and anaerobic infection,
antimicrobials appropriate for the treatment of the aerobic infection should
be used in addition to Metronidazole 375 capsules. </p>

<p>In the treatment of most serious anaerobic infections, intravenous metronidazole
is usually administered initially. This may be followed by oral therapy
with Metronidazole 375 capsules at the discretion of the physician. </p>

<p>INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess,
and liver abscess, caused by Bacteroides species including the B. Fragilis
group (B. Fragilis, B. Distasonis, B. Ovatus, B. Thetaiotaomicron, B. Vulgatus),
Clostridium species, Eubacterium species, Peptococcus Niger, or Peptostreptococcus
species. </p>

<p>SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including
the B. Fragilis group, Clostridium species, Peptococcus Niger, Peptostreptococcus
species, or Fusobacterium species. </p>

<p>GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian
abscess, and postsurgical vaginal cuff infection, caused by Bacteroides
species including the B. Fragilis group, Clostridium species, Peptococcus
Niger, or Peptostreptococcus species. </p>

<p>BACTERIAL SEPTICEMIA caused by Bacteroides species including the B.
Fragilis group or Clostridium species. </p>

<p>BONE AND JOINT INFECTIONS (as adjunctive therapy) caused by Bacteroides
species including the B. Fragilis group. </p>

<p>CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain
abscess, caused by Bacteroides species including the B. Fragilis group.
</p>

<p>LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and
lung abscess, caused by Bacteroides species including the B. Fragilis group.
</p>

<p>ENDOCARDITIS caused by Bacteroides species including the B. Fragilis
group. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Metronidazole 375 capsules are contraindicated in patients with a prior
history of hypersensitivity to metronidazole or other nitroimidazole derivatives.
</p>

<p>In patients with trichomoniasis, Metronidazole 375 capsules are contraindicated
during the first trimester of pregnancy. (See PRECAUTIONS.) </p>

<p><a name="WARNINGS"></a><b>WARNINGS  </b><p>
<pre>                   *************************************************
                   *                                               *
                   *  WARNING                                      *
                   *  Metronidazole has been shown to be           *
                   *  carcinogenic in mice and rats. (See          *
                   *  PRECAUTIONS.) Unnecessary use of the drug    *
                   *  should be avoided. Its use should be         *
                   *  reserved for the conditions described in     *
                   *  the INDICATIONS AND USAGE section below.     *
                   *                                               *
                   *************************************************</pre>


<p>Convulsive Seizures And Peripheral Neuropathy: Convulsive seizures and
peripheral neuropathy, the latter characterized mainly by numbness or paresthesia
of an extremity, have been reported in patients treated with metronidazole.
The appearance of abnormal neurologic signs demands the prompt discontinuation
of metronidazole therapy. Metronidazole should be administered with caution
to patients with central nervous system diseases. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL: Patients with severe hepatic disease metabolize metronidazole
slowly, with resultant accumulation of metronidazole and its metabolites
in the plasma. Accordingly, for such patients, doses below those usually
recommended should be administered cautiously. Known or previously unrecognized
candidiasis may present more prominent symptoms during therapy with metronidazole
and requires treatment with a candidacidal agent. </p>

<p>INFORMATION FOR PATIENTS: Alcoholic beverages should be avoided while
taking Metronidazole 375 capsules and for at least three days afterward.
(See DRUG INTERACTIONS.) </p>

<p>LABORATORY TESTS: Metronidazole is a nitroimidazole and should be used
with caution in patients with evidence of or history of blood dyscrasia.
A mild leukopenia has been observed during its administration; however,
no persistent hematologic abnormalities attributable to metronidazole have
been observed in clinical studies. Total and differential leukocyte counts
are recommended before and after therapy for trichomoniasis and amebiasis,
especially if a second course of therapy is necessary, and before and after
therapy for anaerobic infections. </p>

<p>DRUG INTERACTIONS: Metronidazole has been reported to potentiate the
anticoagulant effect of warfarin and other oral coumarin anticoagulants,
resulting in a prolongation of prothrombin time. This possible drug interaction
should be considered when metronidazole is prescribed for patients on this
type of anticoagulant therapy. </p>

<p>The simultaneous administration of drugs that induce microsomal liver
enzymes, such as phenytoin or phenobarbital, may accelerate the elimination
of metronidazole, resulting in reduced plasma levels; impaired clearance
of phenytoin has also been reported. </p>

<p>The simultaneous administration of drugs that decrease microsomal liver
enzyme activity, such as cimetidine, may prolong the half-life and decrease
plasma clearance of metronidazole. In patients stabilized on relatively
high doses of lithium, short-term metronidazole therapy has been associated
with elevation of serum lithium and, in a few cases, signs of lithium toxicity.
Serum lithium and serum creatinine levels should be obtained several days
after beginning metronidazole to detect any increase that may precede clinical
symptoms of lithium intoxication. </p>

<p>Alcoholic beverages should not be consumed during metronidazole therapy
and for at least three days afterward because abdominal cramps, nausea,
vomiting, headaches, and flushing may occur. </p>

<p>Psychotic reactions have been reported in alcoholic patients who are
using metronidazole and disulfiram concurrently. Metronidazole should not
be given to patients who have taken disulfiram within the last 2 weeks.
</p>

<p>DRUG/LABORATORY TEST INTERACTIONS: Metronidazole may interfere with
certain types of determinations of serum chemistry values, such as aspartate
aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate
dehydrogenase (LDH), triglycerides, and hexokinase glucose. Values of zero
may be observed. All of the assays in which interference has been reported
involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide
adenine dinucleotide (NAD+ right arrow left arrow NADH). Interference is
due to the similarity in absorbance peaks of NADH (340 nm) and metronidazole
(322 nm) at pH 7. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Metronidazole
has shown evidence of carcinogenic activity in a number of studies involving
chronic, oral administration in mice and rats, but similar studies in the
hamster gave negative results. </p>

<p>Prominent among the effects in the mouse was the promotion of pulmonary
tumorigenesis. This has been observed in all six reported studies in that
species, including one study in which the animals were dosed on an intermittent
schedule (administration during every fourth week only). At very high dose
levels (approximately 1500 mg/M(squared) which is approximately 3 times
the most frequently recommended human dose for a 50 kg adult based on mg/M(squared))
there was a statistically significant increase in the incidence of malignant
liver tumors in males. Also, the published results of one of the mouse
studies indicate an increase in the incidence of malignant lymphomas as
well as pulmonary neoplasms associated with lifetime feeding of the drug.
All these effects are statistically significant. </p>

<p>Several long-term, oral-dosing studies in the rat have been completed.
There were statistically significant increases in the incidence of various
neoplasms, particularly in mammary and hepatic tumors, among female rats
administered metronidazole over those noted in the concurrent female control
groups. Two lifetime tumorigenicity studies in hamsters have been performed
and reported to be negative. </p>

<p>Metronidazole has shown mutagenic activity in a number of In Vitro assay
systems. In Vivo studies have failed to demonstrate a potential for genetic
damage. </p>

<p>Fertility studies have been performed in mice at doses up to six times
the maximum recommended human dose based on mg/M(squared) and have revealed
no evidence of impaired fertility. </p>

<p>PREGNANCY: </p>

<p>TERATOGENIC EFFECTS: PREGNANCY CATEGORY B. Metronidazole crosses the
placental barrier and enters the fetal circulation rapidly. Reproduction
studies have been performed in rats at doses up to five times the human
dose and have revealed no evidence of impaired fertility or harm to the
fetus due to metronidazole. No fetotoxicity was observed when metronidazole
was administered orally to pregnant mice at 60 mg/M(squared)/day, which
is approximately 10% of the human dose when expressed as mg/M(squared).
However, in a single small study where the drug was administered intraperitoneally,
some intrauterine deaths were observed. The relationship of these findings
to the drug is unknown. There are, however, no adequate and well-controlled
studies in pregnant women. Because animal reproduction studies are not
always predictive of human response, and because metronidazole is a carcinogen
in rodents, this drug should be used during pregnancy only if clearly needed.
(See CONTRAINDICATIONS.) </p>

<p>Metronidazole use in the second and third trimesters of pregnancy should
be restricted to those patients in whom alternative treatment has been
inadequate. Use of metronidazole in the first trimester should be carefully
evaluated because metronidazole crosses the placental barrier and its effects
on human fetal organogenesis are not known. (See above.) </p>

<p>NURSING MOTHERS: Because of the potential for tumorigenicity shown for
metronidazole in mouse and rat studies, a decision should be made whether
to discontinue nursing or to discontinue the drug, taking into account
the importance of the drug to the mother. Metronidazole is secreted in
human milk in concentrations similar to those found in plasma. </p>

<p>GERIATRIC USE: Decreased renal function does not alter the single-dose
pharmacokinetics of metronidazole. However, plasma clearance of metronidazole
is decreased in patients with decreased liver function. Therefore, in elderly
patients, monitoring of serum levels may be necessary to adjust the metronidazole
dosage accordingly. </p>

<p>PEDIATRIC USE: Safety and effectiveness in children have not been established,
except in the treatment of amebiasis. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Metronidazole has been reported to potentiate the anticoagulant effect
of warfarin and other oral coumarin anticoagulants, resulting in a prolongation
of prothrombin time. This possible drug interaction should be considered
when metronidazole is prescribed for patients on this type of anticoagulant
therapy. The simultaneous administration of drugs that induce microsomal
liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination
of metronidazole, resulting in reduced plasma levels; impaired clearance
of phenytoin has also been reported. </p>

<p>The simultaneous administration of drugs that decrease microsomal liver
enzyme activity, such as cimetidine, may prolong the half-life and decrease
plasma clearance of metronidazole. In patients stabilized on relatively
high doses of lithium, short-term metronidazole therapy has been associated
with elevation of serum lithium and, in a few cases, signs of lithium toxicity.
Serum lithium and serum creatinine levels should be obtained several days
after beginning metronidazole to detect any increase that may precede clinical
symptoms of lithium intoxication. </p>

<p>Alcoholic beverages should not be consumed during metronidazole therapy
and for at least three days afterward because abdominal cramps, nausea,
vomiting, headaches, and flushing may occur. </p>

<p>Psychotic reactions have been reported in alcoholic patients who are
using metronidazole and disulfiram concurrently. Metronidazole should not
be given to patients who have taken disulfiram within the last 2 weeks.
(See Also PRECAUTIONS.) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The following reactions have also been reported during treatment with
metronidazole: </p>

<p>Central Nervous System: Two serious adverse reactions reported in patients
treated with metronidazole have been convulsive seizures and peripheral
neuropathy, the latter characterized mainly by numbness or paresthesia
of an extremity. Since persistent peripheral neuropathy has been reported
in some patients receiving prolonged administration of metronidazole, patients
should be specifically warned about these reactions and should be told
to stop the drug and report immediately to their physicians if any neurologic
symptoms occur. In addition, patients have reported dizziness, vertigo,
incoordination, ataxia, confusion, irritability, depression, weakness,
and insomnia. (See WARNINGS.) </p>

<p>Gastrointestinal: The most common adverse reactions reported have been
referable to the gastrointestinal tract, particularly nausea reported by
about 12% of patients, sometimes accompanied by headache, anorexia, and
occasionally vomiting; diarrhea; epigastric distress; and abdominal cramping.
Constipation has also been reported. </p>

<p>A sharp, unpleasant metallic taste is not unusual. Furry tongue, glossitis,
and stomatitis have occurred; these may be associated with a sudden overgrowth
of Candida which may occur during therapy. Rare cases of pancreatitis,
which generally abated on withdrawal of the drug, have been reported. </p>

<p>Hematopoietic: Reversible neutropenia (leukopenia); rarely, reversible
thrombocytopenia. </p>

<p>Cardiovascular: Flattening of the T-wave may be seen in electrocardiographic
tracings. </p>

<p>Hypersensitivity: Urticaria, erythematous rash, flushing, nasal congestion,
dryness of the mouth (or vagina or vulva), and fever. </p>

<p>Renal: Dysuria, cystitis, polyuria, incontinence, and a sense of pelvic
pressure. Instances of darkened urine have been reported by approximately
one patient in 100,000. Although the pigment which is probably responsible
for this phenomenon has not been positively identified, it is almost certainly
a metabolite of metronidazole and seems to have no clinical significance.
</p>

<p>Other: Proliferation of Candida in the vagina, dyspareunia, decrease
of libido, proctitis, and fleeting joint pains sometimes resembling &quot;serum
sickness.&quot; If patients receiving metronidazole drink alcoholic beverages,
they may experience abdominal distress, nausea, vomiting, flushing, or
headache. A modification of the taste of alcoholic beverages has also been
reported. </p>

<p>Patients with Crohn's disease are known to have an increased incidence
of gastrointestinal and certain extraintestinal cancers. There have been
some reports in the medical literature of breast and colon cancer in Crohn's
disease patients who have been treated with metronidazole at high doses
for extended periods of time. A cause and effect relationship has not been
established. Crohn's disease is not an approved indication for Metronidazole
375 capsules. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Single oral doses of metronidazole, up to 15 g, have been reported in
suicide attempts and accidental overdoses. Symptoms reported include nausea,
vomiting, and ataxia. </p>

<p>Oral metronidazole has been studied as a radiation sensitizer in the
treatment of malignant tumors. Neurotoxic effects, including seizures and
peripheral neuropathy, have been reported after 5 to 7 days of doses of
6 to 10.4 g every other day. </p>

<p>Treatment: There is no specific antidote for metronidazole overdose;
therefore, management of the patient should consist of symptomatic and
supportive therapy. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND
ADMINISTRATION
</b></p>

<p>In elderly patients, the pharmacokinetics of metronidazole may be altered,
and, therefore, monitoring of serum levels may be necessary to adjust the
metronidazole dosage accordingly. </p>

<p>TRICHOMONIASIS: </p>

<p>In The Female: </p>

<p>Seven-Day Course Of Treatment--375 mg two times daily for seven consecutive
days. </p>

<p>A seven-day course of treatment may minimize reinfection by protecting
the patient long enough for the sexual contacts to obtain treatment. Pregnant
patients should not be treated during the first trimester. (See CONTRAINDICATIONS
and PRECAUTIONS.) </p>

<p>When repeat courses of the drug are required, it is recommended that
an interval of four to six weeks elapse between courses and that the presence
of the trichomonad be reconfirmed by appropriate laboratory measures. Total
and differential leukocyte counts should be made before and after re-treatments.
</p>

<p>In The Male: Treatment should be individualized as for the female. </p>

<p>AMEBIASIS: </p>

<p>Adults: </p>

<p>For Acute Intestinal Amebiasis (Acute Amebic Dysentery): 750 mg orally
three times daily for 5 to 10 days. </p>

<p>For Amebic Liver Abscess: 750 mg orally three times daily for 5 to 10
days. </p>

<p>Children: 35 to 50 mg/kg/24 hours, divided into three doses, orally
for 10 days. </p>

<p>ANAEROBIC BACTERIAL INFECTIONS: In the treatment of most serious anaerobic
infections, intravenous metronidazole is usually administered initially.
</p>

<p>The usual adult oral dosage is 7.5 mg/kg every 6 hours. A maximum of
4 g should not be exceeded during a 24-hour period. </p>

<p>The usual duration of therapy is 7 to 10 days; however, infections of
the bone and joint, lower respiratory tract, and endocardium may require
longer treatment. </p>

<p>Patients with severe hepatic disease metabolize metronidazole slowly,
with resultant accumulation of metronidazole and its metabolites in the
plasma. Accordingly, for such patients, doses below those usually recommended
should be administered cautiously. Close monitoring of plasma metronidazole
levels (REF. 2) and toxicity is recommended. </p>

<p>The dose of metronidazole should not be specifically reduced in anuric
patients because accumulated metabolites may be rapidly removed by dialysis.
</p>

<p><i>REFERENCES </i></p>

<p><i>1. National Committee for Clinical Laboratory Standards, Methods
for Antimicrobial Susceptibility Testing of Anaerobic Bacteria- -Third
Edition. Approved Standard NCCLS Document M11-A3, Vol. 13, No. 26, NCCLS,
Villanova, PA, December, 1993. </i></p>

<p><i>2. Ralph ED, Kirby WMM. Bioassay of metronidazole with either anaerobic
or aerobic incubation, J. Infect. Dis. 1975; 132(Nov): 587-591 or Gulaid
et al. Determination of metronidazole and its major metabolites in biological
fluids by high pressure liquid chromatography, Br. J. Clin. Pharmacol.
1978; 6:430-432. </i></p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a
href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0
height=17 width=17></a></a><a
href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a
href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-65</DOCNO>
<DOCOLDNO>IA018-000200-B034-33</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/omepra.htm 206.86.175.201 19970106224058 text/html 36306
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:34:40 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 36123
Last-modified: Thu, 11 Jul 1996 06:08:54 GMT
</DOCHDR>
<html>
<head>
   <title>Omeprazole - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">
` 
<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Omeprazole</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>The active ingredient in omeprazole Delayed-Release Capsules is a substituted
benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)
sulfinyl)-1H-benzimidazole, a compound that inhibits gastric acid secretion.
Its empirical formula is C17H19N3O3S, with a molecular weight of 345.42.
</p>

<p>Omeprazole is a white to off-white crystalline powder which melts with
decomposition at about 155 deg C. It is a weak base, freely soluble in
ethanol and methanol, and slightly soluble in acetone and isopropanol and
very slightly soluble in water. The stability of omeprazole is a function
of pH; it is rapidly degraded in acid media, but has acceptable stability
under alkaline conditions. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Pharmacokinetics And Metabolism </p>

<p>Omeprazole Delayed-Release Capsules contain an enteric-coated granule
formulation of omeprazole (because omeprazole is acid-labile), so that
absorption of omeprazole begins only after the granules leave the stomach.
Absorption is rapid, with peak plasma levels of omeprazole occurring within
0.5 to 3.5 hours. Peak plasma concentrations of omeprazole and AUC are
approximately proportional to doses up to 40 mg, but because of a saturable
first-pass effect a greater than linear response in peak plasma concentration
and AUC occurs with doses greater than 40 mg. Absolute bioavailability
(compared to intravenous administration) is about 30-40% at doses of 20-40
mg, due in large part to presystemic metabolism. In healthy subjects the
plasma half-life is 0.5 to 1 hour, and the total body clearance is 500-600
mL/min. Protein binding is approximately 95%. </p>

<p>The bioavailability of omeprazole increases slightly upon repeated administration
of Omeprazole Delayed-Release Capsules. </p>

<p>Following single dose oral administration of a buffered solution of
omeprazole, little if any unchanged drug was excreted in urine. The majority
of the dose (about 77%) was eliminated in urine as at least six metabolites.
Two were identified as hydroxyomeprazole and the corresponding carboxylic
acid. The remainder of the dose was recoverable in feces. This implies
a significant biliary excretion of the metabolites of omeprazole. Three
metabolites have been identified in plasma--the sulfide and sulfone derivatives
of omeprazole, and hydroxyomeprazole. These metabolites have very little
or no antisecretory activity. </p>

<p>In patients with chronic hepatic disease, the bioavailability increased
to approximately 100% compared to an I.V. dose, reflecting decreased first-pass
effect, and the plasma half-life of the drug increased to nearly 3 hours
compared to the half-life in normals of 0.5-1 hour. Plasma clearance averaged
70 mL/min, compared to a value of 500-600 mL/min in normal subjects. </p>

<p>In patients with chronic renal impairment, whose creatinine clearance
ranged between 10 and 62 mL/min/1.73 M(square), the disposition of omeprazole
was very similar to that in healthy volunteers, although there was a slight
increase in bioavailability. Because urinary excretion is a primary route
of excretion of omeprazole metabolites, their elimination slowed in proportion
to the decreased creatinine clearance. </p>

<p>The elimination rate of omeprazole was somewhat decreased in the elderly,
and bioavailability was increased. Omeprazole was 76% bioavailable when
a single 40 mg oral dose of omeprazole (buffered solution) was administered
to healthy elderly volunteers, versus 58% in young volunteers given the
same dose. Nearly 70% of the dose was recovered in urine as metabolites
of omeprazole and no unchanged drug was detected. The plasma clearance
of omeprazole was 250 mL/min (about half that of young volunteers) and
its plasma half-life averaged one hour, about twice that of young healthy
volunteers. </p>

<p>Pharmacodynamics </p>

<p>Mechanism Of Action </p>

<p>Omeprazole belongs to a new class of antisecretory compounds, the substituted
benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic
properties, but that suppress gastric acid secretion by specific inhibition
of the H+/K+ ATPase enzyme system at the secretory surface of the gastric
parietal cell. Because this enzyme system is regarded as the acid (proton)
pump within the gastric mucosa, omeprazole has been characterized as a
gastric acid-pump inhibitor, in that it blocks the final step of acid production.
This effect is dose-related and leads to inhibition of both basal and stimulated
acid secretion irrespective of the stimulus. Animal studies indicate that
after rapid disappearance from plasma, omeprazole can be found within the
gastric mucosa for a day or more. </p>

<p>Antisecretory Activity </p>

<p>After oral administration, the onset of the antisecretory effect of
omeprazole occurs within one hour, with the maximum effect occurring within
two hours. Inhibition of secretion is about 50% of maximum at 24 hours
and the duration of inhibition lasts up to 72 hours. The antisecretory
effect thus lasts far longer than would be expected from the very short
(less than one hour) plasma half- life, apparently due to prolonged binding
to the parietal H+/K+ ATPase enzyme. When the drug is discontinued, secretory
activity returns gradually, over 3 to 5 days. The inhibitory effect of
omeprazole on acid secretion increases with repeated once-daily dosing,
reaching a plateau after four days. </p>

<p>Results from numerous studies of the antisecretory effect of multiple
doses of 20 mg and 40 mg of omeprazole in normal volunteers and patients
are shown below. The &quot;max&quot; value represents determinations at
a time of maximum effect (2-6 hours after dosing), while &quot;min&quot;
values are those 24 hours after the last dose of omeprazole. </p>

<pre>   Range of Mean Values from Multiple Studies                                   
of the Mean Antisecretory Effects of Omeprazole                                 
       AFTER MULTIPLE DAILY DOSING                                              
                      Omeprazole     Omeprazole                                 
    PARAMETER           20 MG          40 MG                                    
% Decrease in        MAX     MIN    MAX     MIN                                 
Basal Acid Output    78    58-80   94    80-93                                
-------------------------------------------------                               
% Decrease in                                                                   
Peak Acid Output     79    50-59   88    62-68                                
-------------------------------------------------                               
% Decrease in                                                                   
24-hr. Intragastric         80-97          92-94                                
Acidity                                                                         
-------------------------------------------------                               </pre>

<p>Single Studies Single daily oral doses of omeprazole ranging from a
dose of 10 mg to 40 mg have produced 100% inhibition of 24-hour intragastric
acidity in some patients. </p>

<p>Enterochromaffin-like (ECL) Cell Effects </p>

<p>In 24-month carcinogenicity studies in rats, a dose-related significant
increase in gastric carcinoid tumors and ECL cell hyperplasia was observed
in both male and female animals (see PRECAUTIONS, Carcinogenesis, Mutagenesis,
Impairment Of Fertility). Hypergastrinemia secondary to prolonged and sustained
hypochlorhydria has been postulated to be the mechanism by which ECL cell
hyperplasia and gastric carcinoid tumors develop. Omeprazole may also affect
other cells in the gastrointestinal tract (e.g., G cells), either directly
or by inducing sustained hypochlorhydria, but this possibility has not
been extensively studied. </p>

<p>Human gastric biopsy specimens from about 200 patients treated continuously
with omeprazole for an average of over 12 months have not detected ECL
cell effects of omeprazole similar to those seen in rats. Longer term data
are needed to rule out the possibility of an increased risk for the development
of gastric tumors in patients receiving long-term therapy with omeprazole.
</p>

<p>Serum Gastrin Effects </p>

<p>In studies involving more than 200 patients, serum gastrin levels increased
during the first 1 to 2 weeks of once-daily administration of therapeutic
doses of omeprazole in parallel with inhibition of acid secretion. No further
increase in serum gastrin occurred with continued treatment. In comparison
with histamine H2-receptor antagonists, the median increases produced by
20 mg doses of omeprazole were higher (1.3 to 3.6 fold vs. 1.1 to 1.8 fold
increase). Gastrin values returned to pretreatment levels, usually within
1 to 2 weeks after discontinuation of therapy. </p>

<p>Other Effects </p>

<p>Systemic effects of omeprazole in the CNS, cardiovascular and respiratory
systems have not been found to date. Omeprazole, given in oral doses of
30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate
metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol,
testosterone, prolactin, cholecystokinin or secretin. </p>

<p>No effect on gastric emptying of the solid and liquid components of
a test meal was demonstrated after a single dose of omeprazole 90 mg. In
healthy subjects, a single I.V. dose of omeprazole (0.35 mg/kg) had no
effect on intrinsic factor secretion. No systematic dose-dependent effect
has been observed on basal or stimulated pepsin output in humans. </p>

<p>However, when intragastric pH is maintained at 4.0 or above, basal pepsin
output is low, and pepsin activity is decreased. </p>

<p>As do other agents that elevate intragastric pH, omeprazole administered
for 14 days in healthy subjects produced a significant increase in the
intragastric concentrations of viable bacteria. The pattern of the bacterial
species was unchanged from that commonly found in saliva. All changes resolved
within three days of stopping treatment. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Short-Term Treatment Of Active Duodenal Ulcer </p>

<p>Omeprazole Delayed-Release Capsules are indicated for short-term treatment
of active duodenal ulcer. Most patients heal within four weeks. Some patients
may require an additional four weeks of therapy. </p>

<p>Omeprazole SHOULD NOT BE USED AS MAINTENANCE THERAPY FOR TREATMENT OF
PATIENTS WITH DUODENAL ULCER DISEASE. (See boxed WARNING.) </p>

<p>Gastroesophageal Reflux Disease (GERD) </p>

<p>Severe Erosive Esophagitis Omeprazole Delayed-Release Capsules are indicated
for the short-term treatment (4 8 weeks) of severe erosive esophagitis
(grade 2 or above) which has been diagnosed by endoscopy (see ACTIONS/CLINICAL
PHARMACOLOGY, Clinical Studies). </p>

<p>Poorly Responsive Symptomatic GERD </p>

<p>Omeprazole Delayed-Release Capsules are also indicated for the short-term
treatment (4-8 weeks) of symptomatic gastroesophageal reflux disease (esophagitis)
poorly responsive to customary medical treatment, usually including an
adequate course of a histamine H2-receptor antagonist. </p>

<p>The efficacy of Omeprazole used for longer than 8 weeks in these patients
has not been established. In the rare instance of a patient not responding
to 8 weeks of treatment, it may be helpful to give up to an additional
4 weeks of treatment. If there is recurrence of severe or symptomatic GERD
poorly responsive to customary medical treatment, additional 4-8 week courses
of omeprazole may be considered. THE DRUG SHOULD NOT BE USED AS MAINTENANCE
THERAPY. (See boxed WARNING.) </p>

<p>Pathological Hypersecretory Conditions </p>

<p>Omeprazole Delayed-Release Capsules are indicated for the long-term
treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison
syndrome, multiple endocrine adenomas and systemic mastocytosis). </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Omeprazole Delayed-Release Capsules are contraindicated in patients
with known hypersensitivity to any component of the formulation. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>IN LONG-TERM (2 YEAR) STUDIES IN RATS, OMEPRAZOLE PRODUCED A DOSE-RELATED
INCREASE IN GASTRIC CARCINOID TUMORS (SEE PRECAUTIONS, CARCINOGENESIS,
MUTAGENESIS, IMPAIRMENT OF FERTILITY). WHILE AVAILABLE ENDOSCOPIC EVALUATIONS
AND HISTOLOGIC EXAMINATIONS OF BIOPSY SPECIMENS FROM HUMAN STOMACHS HAVE
NOT DETECTED A RISK FROM SHORT-TERM EXPOSURE TO Omeprazole, FURTHER HUMAN
DATA ON THE EFFECT OF SUSTAINED HYPOCHLORHYDRIA AND HYPERGASTRINEMIA ARE
NEEDED TO RULE OUT THE POSSIBILITY OF AN INCREASED RISK FOR THE DEVELOPMENT
OF TUMORS IN HUMANS RECEIVING LONG-TERM THERAPY WITH Omeprazole. Omeprazole
SHOULD BE PRESCRIBED ONLY FOR THE CONDITIONS, DOSAGE AND DURATION DESCRIBED
(SEE INDICATIONS AND USAGE AND DOSAGE AND ADMINISTRATION). </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>General </p>

<p>Symptomatic response to therapy with omeprazole does not preclude the
presence of gastric malignancy. </p>

<p>Information For Patients </p>

<p>Omeprazole Delayed-Release Capsules should be taken before eating. Patients
should be cautioned that the Omeprazole Delayed-Release Capsule should
not be opened, chewed or crushed, and should be swallowed whole. </p>

<p>Drug Interactions </p>

<p>Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin,
drugs that are metabolized by oxidation in the liver. Although in normal
subjects no interaction with theophylline or propranolol was found, there
have been clinical reports of interaction with other drugs metabolized
via the cytochrome P-450 system (e.g., cyclosporine, disulfiram, benzodiazepines).
Patients should be monitored to determine if it is necessary to adjust
the dosage of these drugs when taken concomitantly with Omeprazole. </p>

<p>Because of its profound and long lasting inhibition of gastric acid
secretion, it is theoretically possible that omeprazole may interfere with
absorption of drugs where gastric pH is an important determinant of their
bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).
In the clinical trials antacids were used concomitantly with the administration
of Omeprazole. </p>

<p>Carcinogenesis, Mutagenesis, Impairment Of Fertility </p>

<p>In two 24-month carcinogenicity studies in rats, omeprazole at daily
doses of 1.7, 3.4, 13.8, 44.0 and 140.8 mg/kg/day (approximately 4 to 352
times the human dose, based on a patient weight of 50 kg and a human dose
of 20 mg) produced gastric ECL cell carcinoids in a dose-related manner
in both male and female rats; the incidence of this effect was markedly
higher in female rats, which had higher blood levels of omeprazole. Gastric
carcinoids seldom occur in the untreated rat. In addition, ECL cell hyperplasia
was present in all treated groups of both sexes. In one of these studies,
female rats were treated with 13.8 mg omeprazole/kg/day (approximately
35 times the human dose) for one year, then followed for an additional
year without the drug. No carcinoids were seen in these rats. An increased
incidence of treatment-related ECL cell hyperplasia was observed at the
end of one year (94% treated vs 10% controls). By the second year the difference
between treated and control rats was much smaller (46% vs 26%) but still
showed more hyperplasia in the treated group. An unusual primary malignant
tumor in the stomach was seen in one rat (2%). No similar tumor was seen
in male or female rats treated for two years. For this strain of rat no
similar tumor has been noted historically, but a finding involving only
one tumor is difficult to interpret. A 78-week mouse carcinogenicity study
of omeprazole did not show increased tumor occurrence, but the study was
not conclusive. </p>

<p>Omeprazole was not mutagenic in an In Vitro Ames Salmonella Typhimurium
assay, an In Vitro mouse lymphoma cell assay and an In Vivo rat liver DNA
damage assay. A mouse micronucleus test at 625 and 6250 times the human
dose gave a borderline result, as did an In Vivo bone marrow chromosome
aberration test. A second mouse micronucleus study at 2000 times the human
dose, but with different (suboptimal) sampling times, was negative. </p>

<p>In a rat fertility and general reproductive performance test, omeprazole
in a dose range of 13.8 to 138.0 mg/kg/day (approximately 35 to 345 times
the human dose) was not toxic or deleterious to the reproductive performance
of parental animals. </p>

<p>Pregnancy </p>

<p>Pregnancy Category C </p>

<p>Teratology studies conducted in pregnant rats at doses up to 138 mg/kg/day
(approximately 345 times the human dose) and in pregnant rabbits at doses
up to 69 mg/kg/day (approximately 172 times the human dose) did not disclose
any evidence for a teratogenic potential of omeprazole. </p>

<p>In rabbits, omeprazole in a dose range of 6.9 to 69.1 mg/kg/day (approximately
17 to 172 times the human dose) produced dose-related increases in embryo-
lethality, fetal resorptions and pregnancy disruptions. In rats, dose-related
embryo/fetal toxicity and postnatal developmental toxicity were observed
in offspring resulting from parents treated with omeprazole 13.8 to 138.0
mg/kg/day (approximately 35 to 345 times the human dose). There are no
adequate or well- controlled studies in pregnant women. Omeprazole should
be used during pregnancy only if the potential benefit justifies the potential
risk to the fetus. </p>

<p>Nursing Mothers </p>

<p>It is not known whether omeprazole is excreted in human milk. In rats,
omeprazole administration during late gestation and lactation at doses
of 13.8 to 138 mg/kg/day (35 to 345 times the human dose) resulted in decreased
weight gain in pups. Because many drugs are excreted in human milk, because
of the potential for serious adverse reactions in nursing infants from
omeprazole, and because of the potential for tumorigenicity shown for omeprazole
in rat carcinogenicity studies, a decision should be made whether to discontinue
nursing or to discontinue the drug, taking into account the importance
of the drug to the mother. Pediatric Use </p>

<p>Safety and effectiveness in children have not been established. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin,
drugs that are metabolized by oxidation in the liver. Although in normal
subjects no interaction with theophylline or propranolol was found, there
have been clinical reports of interaction with other drugs metabolized
via the cytochrome P-450 system (e.g., cyclosporine, disulfiram, benzodiazepines).
Patients should be monitored to determine if it is necessary to adjust
the dosage of these drugs when taken concomitantly with Omeprazole. </p>

<p>Because of its profound and long lasting inhibition of gastric acid
secretion, it is theoretically possible that omeprazole may interfere with
absorption of drugs where gastric pH is an important determinant of their
bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).
In the clinical trials antacids were used concomitantly with the administration
of Omeprazole. </p>

<p>(See Also PRECAUTIONS) <a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS
</b></p>

<p>Omeprazole Delayed-Release Capsules were generally well tolerated during
domestic and international clinical trials in 3096 patients. </p>

<p>In the U.S. clinical trial population of 465 patients (including duodenal
ulcer Zollinger-Ellison syndrome and resistant ulcer patients), the following
adverse experiences were reported to occur in 1% or more of patients on
therapy with Omeprazole. Numbers in parentheses indicate percentages of
the adverse experiences considered by investigators as possibly, probably
or definitely related to the drug: </p>

<pre>                 Omeprazole  Placebo   Ranitidine                               
                 (N = 465)   (N = 64)  (N = 195)                                
                 ----------  --------  ----------                               
Headache          6.9 (2.4)  6.3        7.7 (2.6)                               
Diarrhea          3.0 (1.9)  3.1 (1.6)  2.1 (0.5)                               
Abdominal Pain    2.4 (0.4)  3.1        2.1                                     
Nausea            2.2 (0.9)  3.1        4.1 (0.5)                               
URI               1.9        1.6        2.6                                     
Dizziness         1.5 (0.6)  0.0        2.6 (1.0)                               
Vomiting          1.5 (0.4)  4.7        1.5 (0.5)                               
Rash              1.5 (1.1)  0.0        0.0                                     
Constipation      1.1 (0.9)  0.0        0.0                                     
Cough             1.1        0.0        1.5                                     
Asthenia          1.1 (0.2)  1.6 (1.6)  1.5 (1.0)                               
Back Pain         1.1        0.0        0.5                                     </pre>

<p>The following adverse reactions which occurred in 1% or more of omeprazole-
treated patients have been reported in international double-blind, and
open- label, clinical trials in which 2,631 patients and subjects received
omeprazole. </p>

<pre>                           Incidence of Adverse                                 
                            Experiences &gt; or = 1%                                   
                           Causal Relationship                                  
                             not Assessed                                       
                           Omeprazole    Placebo                                
                           ----------    -------                                
                           (n = 2631)  (n = 120)                                
Body As A Whole, Site                                                           
Unspecified                                                                     
 Abdominal pain               5.2           3.3                                 
 Asthenia                     1.3           0.8                                 
Digestive System                                                                
 Constipation                 1.5           0.8                                 
 Diarrhea                     3.7           2.5                                 
 Flatulence                   2.7           5.8                                 
 Nausea                       4.0           6.7                                 
 Vomiting                     3.2          10.0                                 
 Acid regurgitation           1.9           3.3                                 
Nervous System/Psychiatric                                                      
 Headache                     2.9           2.5  </pre>

<p>Additional adverse experiences occurring in &lt;1% of patients or subjects
in domestic and/or international trials, or occurring since the drug was
marketed, are shown below within each body system. In many instances, the
relationship to Omeprazole was unclear. </p>

<p>Body As A Whole: Fever, pain, fatigue, malaise, abdominal swelling </p>

<p>Cardiovascular: Chest pain or angina, tachycardia, bradycardia, palpitation,
elevated blood pressure, peripheral edema </p>

<p>Digestive: Hepatitis including hepatic failure (rarely), pancreatitis,
elevated ALT (SGPT), elevated AST (SGOT), elevated gamma-glutamyl transpeptidase,
elevated alkaline phosphatase, elevated bilirubin (jaundice), anorexia,
irritable colon, flatulence, fecal discoloration, esophageal candidiasis,
mucosal atrophy of the tongue, dry mouth </p>

<p>Metabolic/Nutritional: Hypoglycemia, weight gain </p>

<p>Musculoskeletal: Muscle cramps, myalgia, muscle weakness, joint pain,
leg pain </p>

<p>Nervous System/Psychiatric: Psychic disturbances including depression,
aggression, hallucinations, confusion, insomnia, nervousness, tremors,
apathy, somnolence, anxiety, dream abnormalities; vertigo; paresthesia;
hemifacial dysesthesia </p>

<p>Respiratory: Epistaxis, pharyngeal pain </p>

<p>Skin: Rash and, very rarely, cases of severe generalized skin reactions
including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, and
erythema multiforme, skin inflammation, urticaria, angioedema, pruritus,
alopecia, dry skin, hyperhidrosis </p>

<p>Special Senses: Tinnitus, taste perversion </p>

<p>Urogenital: Interstitial nephritis, urinary tract infection, microscopic
pyuria urinary frequency, elevated serum creatinine, proteinuria, hematuria,
glycosuria, testicular pain, gynecomastia </p>

<p>Hematologic: Agranulocytosis has been reported in a 65 year old diabetic
male on several drugs in addition to omeprazole; the relationship of the
agranulocytosis to omeprazole is uncertain. Pancytopenia, thrombocytopenia,
neutropenia, anemia, leucocytosis, hemolytic anemia. </p>

<p>The incidence of clinical adverse experiences in patients greater than
65 years of age was similar to that in patients 65 years of age or less.
</p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>There is no experience to date with deliberate overdosage. Dosages of
up to 360 mg/day have been well tolerated. No specific antidote is known.
Omeprazole is extensively protein bound and is, therefore, not readily
dialyzable. In the event of overdosage, treatment should be symptomatic
and supportive. </p>

<p>Lethal doses of omeprazole after single oral administration are about
1500 mg/kg in mice and greater than 4000 mg/kg in rats, and about 100 mg/kg
in mice and greater than 40 mg/kg in rats given single intravenous injections.
Animals given these doses showed sedation, ptosis, convulsions, and decreased
activity, body temperature, and respiratory rate and increased depth of
respiration. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Short-Term Treatment Of Active Duodenal Ulcer </p>

<p>The recommended adult oral dose is 20 mg once daily. Most patients heal
within four weeks. Some patients may require an additional four weeks of
therapy. (See INDICATIONS AND USAGE.) </p>

<p>Severe Erosive Esophagitis Or Poorly Responsive Gastroesophageal Reflux
Disease (GERD) </p>

<p>The recommended adult oral dose is 20 mg daily for 4 to 8 weeks (see
INDICATIONS AND USAGE). </p>

<p>Pathological Hypersecretory Conditions </p>

<p>The dosage of Omeprazole in patients with pathological hypersecretory
conditions varies with the individual patient. The recommended adult oral
starting dose is 60 mg once a day. Doses should be adjusted to individual
patient needs and should continue for as long as clinically indicated.
Doses up to 120 mg t.i.d. have been administered. Daily dosages of greater
than 80 mg should be administered in divided doses. Some patients with
Zollinger-Ellison syndrome have been treated continuously with Omeprazole
for more than 5 years. </p>

<p>No dosage adjustment is necessary for patients with renal impairment,
hepatic dysfunction or for the elderly. </p>

<p>Omeprazole Delayed-Release Capsules should be taken before eating. In
the clinical trials, antacids were used concomitantly with Omeprazole.</p>

<p>Patients should be cautioned that the Omeprazole Delayed-Release Capsule
should not be opened, chewed or crushed, and should be swallowed whole.
</p>

<p>CLINICAL STUDIES </p>

<p>Duodenal Ulcer Disease </p>

<p>Active Duodenal Ulcer: In a multicenter, double-blind, placebo-controlled
study of 147 patients with endoscopically documented duodenal ulcer, the
percentage of patients healed (per protocol) at 2 and 4 weeks was significantly
higher with Omeprazole 20 mg once a day than with placebo (p&lt; or = 0.01).
</p>

<pre> Treatment of Active Duodenal Ulcer                                          
          % of Patients Healed                                                  
                    Omeprazole             Placebo                                
                   20 mg a.m.              a.m.                                 
                     (n=99)               (n=48)                                
                     ------               ------                                
Week 2                41                   13                                  
Week 4                75                   27                                  
----------                                                                      </pre>

<p>(p&lt; or =0.01) Complete daytime and nighttime pain relief occurred
significantly (p&lt; or = 0.01) in patients treated with Omeprazole 20
mg than in patients treated with placebo. At the end of the study, significantly
more patients who had received Omeprazole had complete relief of daytime
pain (p&lt; or = 0.05) and nighttime pain (p&lt; or = 0.01). </p>

<p>In a multicenter, double-blind study of 293 patients with endoscopically
documented duodenal ulcer, the percentage of patients healed (per protocol)
at 4 weeks was significantly higher with Omeprazole 20 mg once a day than
with ranitidine 150 mg b.i.d. (p&lt;0.01). </p>

<pre>       Treatment of Active Duodenal Ulcer                                       
             % of Patients Healed                                               
                 Omeprazole                 Ranitidine                            
                20 mg a.m.              150 mg b.i.d.                           
                 (n=145)                   (n=148)                              
                 -------                   -------                              
Week 2              42                        34                                
Week 4             82                        63                                
----------                                                                      </pre>

<p>(p&lt;0.01) </p>

<pre>Healing occurred significantly faster in patients treated with Omeprazole than in 
those treated with ranitidine 150 mg b.i.d. (p&lt;0.01).  </pre>

<p>In a foreign multinational randomized, double-blind study of 105 patients
with endoscopically documented duodenal ulcer, 20 mg and 40 mg of Omeprazole
were compared to 150 mg b.i.d. of ranitidine at 2, 4 and 8 weeks. At 2
and 4 weeks both doses of Omeprazole were statistically superior (per protocol)
to ranitidine but 40 mg was not superior to 20 mg of Omeprazole, and at
8 weeks there was no significant difference between any of the active drugs.
</p>

<pre>          Treatment of Active Duodenal Ulcer                                    
                % of Patients Healed                                            
                 Omeprazole                 Ranitidine                            
            20 mg       40 mg           150 mg b.i.d.                           
            (n=34)      (n=36)              (n=35)                              
            ------      ------              ------                              
Week 2       83          83                 53                                
Week 4       97         100                 82                                
Week 8       100        100                 94                                
----------                                                                      </pre>

<p>(p&lt; or = 0.01) Gastroesophageal Reflux Disease (GERD) In a U.S. multicenter
double-blind placebo controlled study of 20 mg or 40 mg of Omeprazole Delayed-Release
Capsules in patients with symptomatic esophagitis and endoscopically diagnosed
erosive esophagitis of grade 2 or above, the percentage healing rates (per
protocol) were as follows: </p>

<pre>              20 mg         40 mg                                               
             Omeprazole      Omeprazole      Placebo                                
Week          (n=83)        (n=87)        (n=43)                                
-------------------------------------------------                               
4              39          45            7                                  
8              74          75           14                                  
-----------                                                                     </pre>

<p>(p&lt;0.01) Omeprazole versus placebo. </p>

<pre>In this study, the 40 mg dose was not superior to the 20 mg dose of Omeprazole in 
the percentage healing rate. Other controlled clinical trials have also shown
that Omeprazole is effective in severe GERD. In comparisons with histamine H2-
receptor antagonists in patients with erosive esophagitis, grade 2 or above,
Omeprazole in a dose of 20 mg was significantly more effective than the active
controls. Complete daytime and nighttime heartburn relief occurred
significantly faster (p&lt;0.01) in patients treated with Omeprazole than in those
taking placebo or histamine H2-receptor antagonists.  </pre>

<p>Pathological Hypersecretory Conditions </p>

<p>In open studies of 136 patients with pathological hypersecretory conditions,
such as Zollinger-Ellison (ZE) syndrome with or without multiple endocrine
adenomas, Omeprazole Delayed-Release Capsules significantly inhibited gastric
acid secretion and controlled associated symptoms of diarrhea, anorexia,
and pain. Doses ranging from 20 mg every other day to 360 mg per day maintained
basal acid secretion below 10 mEq/hr in patients without prior gastric
surgery, and below 5 mEq/hr in patients with prior gastric surgery. </p>

<p>Initial doses were titrated to the individual patient need, and adjustments
were necessary with time in some patients (see DOSAGE AND ADMINISTRATION).
Omeprazole was well tolerated at these high dose levels for prolonged periods
(&gt;5 years in some patients). In most ZE patients, serum gastrin levels
were not modified by Omeprazole. However, in some patients serum gastrin
increased to levels greater than those present prior to initiation of omeprazole
therapy. At least 2 patients with ZE syndrome on long-term treatment with
Omeprazole developed gastric carcinoids. This finding was believed to be
a manifestation of the underlying condition, which is known to be associated
with such tumors, rather than the result of the administration of Omeprazole.
</p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-66</DOCNO>
<DOCOLDNO>IA018-000200-B042-73</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/ 206.86.175.201 19970106231313 text/html 16676
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:06:58 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HEAD><TITLE>Index of /cgi/generic/</TITLE></HEAD><BODY>
<H1>Index of /cgi/generic/</H1>
<PRE>
<HR>
<A HREF="q">q</A>                             size   1308
<A HREF="tar/">tar/</A>                           
<A HREF="metopro.htm">metopro.htm</A>                   size  35187
<A HREF="imip.htm">imip.htm</A>                      size  28656
<A HREF="ibup.htm">ibup.htm</A>                      size  36453
<A HREF="glip.htm">glip.htm</A>                      size  27343
<A HREF="apap.htm">apap.htm</A>                      size   9168
<A HREF="cemp.htm">cemp.htm</A>                      size  41703
<A HREF="misopro.htm">misopro.htm</A>                   size  35459
<A HREF="seleg.htm">seleg.htm</A>                     size  30852
<A HREF="augmentin.htm">augmentin.htm</A>                 size  26015
<A HREF="fluoxetine.htm">fluoxetine.htm</A>                size  47612
<A HREF="diclofen.htm">diclofen.htm</A>                  size  36129
<A HREF="ketoprof.htm">ketoprof.htm</A>                  size  49737
<A HREF="clonidin.htm">clonidin.htm</A>                  size  16576
<A HREF="alendron.htm">alendron.htm</A>                  size  37956
<A HREF="midrin.htm">midrin.htm</A>                    size   4724
<A HREF="guaiphen.htm">guaiphen.htm</A>                  size   7301
<A HREF="trisulf.htm">trisulf.htm</A>                   size  31432
<A HREF="ketocon.htm">ketocon.htm</A>                   size   8212
<A HREF="dhea.htm">dhea.htm</A>                      size   1376
<A HREF="asa.htm">asa.htm</A>                       size  19539
<A HREF="acyclo.htm">acyclo.htm</A>                    size  47911
<A HREF="orphen.htm">orphen.htm</A>                    size   7133
<A HREF="isomono.htm">isomono.htm</A>                   size  27482
<A HREF="fexofen.htm">fexofen.htm</A>                   size  20553
<A HREF="doxepin.htm">doxepin.htm</A>                   size  17087
<A HREF="conest_t.htm">conest_t.htm</A>                  size   1552
<A HREF="desest.htm">desest.htm</A>                    size  56498
<A HREF="eryst.htm">eryst.htm</A>                     size  20936
<A HREF="tersud.htm">tersud.htm</A>                    size  37520
<A HREF="cortisne.htm">cortisne.htm</A>                  size  19676
<A HREF="redball.gif">redball.gif</A>                   size    371
<A HREF="nifedxl.htm">nifedxl.htm</A>                   size  35340
<A HREF="famot.htm">famot.htm</A>                     size  28389
<A HREF="butalcod.htm">butalcod.htm</A>                  size  35125
<A HREF="lovastat.htm">lovastat.htm</A>                  size  60565
<A HREF="hquine.htm">hquine.htm</A>                    size  23021
<A HREF="gabapent.htm">gabapent.htm</A>                  size  46095
<A HREF="pravast.htm">pravast.htm</A>                   size  47629
<A HREF="cimet.htm">cimet.htm</A>                     size  40414
<A HREF="momet.htm">momet.htm</A>                     size  13940
<A HREF="timolol.htm">timolol.htm</A>                   size  31378
<A HREF="tramadol.htm">tramadol.htm</A>                  size  32153
<A HREF="lorat.htm">lorat.htm</A>                     size  19098
<A HREF="glipxl.htm">glipxl.htm</A>                    size  38141
<A HREF="promcod.htm">promcod.htm</A>                   size  26166
<A HREF="zolpid.htm">zolpid.htm</A>                    size  54994
<A HREF="loratd.htm">loratd.htm</A>                    size  32615
<A HREF="atenolol.htm">atenolol.htm</A>                  size  43385
<A HREF="nizat.htm">nizat.htm</A>                     size  29174
<A HREF="lngeed.htm">lngeed.htm</A>                    size  37690
<A HREF="ntgtd.htm">ntgtd.htm</A>                     size  18398
<A HREF="nsaid.htm">nsaid.htm</A>                     size   5384
<A HREF="ramipril.htm">ramipril.htm</A>                  size  38877
<A HREF="phenyt.htm">phenyt.htm</A>                    size  26903
<A HREF="diazepam.htm">diazepam.htm</A>                  size  14555
<A HREF="sucral.htm">sucral.htm</A>                    size  15516
<A HREF="metopxl.htm">metopxl.htm</A>                   size  28284
<A HREF="tetcycl.htm">tetcycl.htm</A>                   size  15478
<A HREF="nabume.htm">nabume.htm</A>                    size  30295
<A HREF="carbam.htm">carbam.htm</A>                    size  34210
<A HREF="ms.htm">ms.htm</A>                        size  15019
<A HREF="ees.htm">ees.htm</A>                       size  20586
<A HREF="metronid.htm">metronid.htm</A>                  size  32621
<A HREF="hydrocod.htm">hydrocod.htm</A>                  size  16379
<A HREF="ranit.htm">ranit.htm</A>                     size  29832
<A HREF="sertral.htm">sertral.htm</A>                   size  47464
<A HREF="phenterm.htm">phenterm.htm</A>                  size  11386
<A HREF="cefixime.htm">cefixime.htm</A>                  size  32751
<A HREF="methdone.htm">methdone.htm</A>                  size  24012
<A HREF="amoxclav.htrm.txt">amoxclav.htrm.txt</A>             size  27712
<A HREF="mecliz.htm">mecliz.htm</A>                    size   5319
<A HREF="loracarb.htm">loracarb.htm</A>                  size  41354
<A HREF="cefaclor.htm">cefaclor.htm</A>                  size  19807
<A HREF="test.htm">test.htm</A>                      size  13715
<A HREF="post.htm">post.htm</A>                      size   1128
<A HREF="pred.htm">pred.htm</A>                      size  27614
<A HREF="meper.htm">meper.htm</A>                     size  17733
<A HREF="clonaz.htm">clonaz.htm</A>                    size  14875
<A HREF="allopur.htm">allopur.htm</A>                   size  34514
<A HREF="losar.htm">losar.htm</A>                     size  34758
<A HREF="cyclobnz.htm">cyclobnz.htm</A>                  size  20864
<A HREF="diltiaz.htm">diltiaz.htm</A>                   size  37930
<A HREF="alpraz.htm">alpraz.htm</A>                    size  59847
<A HREF="clomipr.htm">clomipr.htm</A>                   size  53033
<A HREF="prochlr.htm">prochlr.htm</A>                   size  36477
<A HREF="propox2.htm">propox2.htm</A>                   size  21405
<A HREF="antidepr.htm">antidepr.htm</A>                  size   5984
<A HREF="mirtaz.htm">mirtaz.htm</A>                    size  43155
<A HREF="methocar.htm">methocar.htm</A>                  size   5235
<A HREF="theosr.htm">theosr.htm</A>                    size  33171
<A HREF="ketor.htm">ketor.htm</A>                     size  56186
<A HREF="kclsr.htm">kclsr.htm</A>                     size  18151
<A HREF="norestoc.htm">norestoc.htm</A>                  size  54033
<A HREF="testos.htm">testos.htm</A>                    size  30981
<A HREF="buspir.htm">buspir.htm</A>                    size  32325
<A HREF="dicyc.htm">dicyc.htm</A>                     size  20188
<A HREF="cetiriz.htm">cetiriz.htm</A>                   size  21743
<A HREF="finas.htm">finas.htm</A>                     size  38993
<A HREF="furos.htm">furos.htm</A>                     size  24151
<A HREF="pre.htm">pre.htm</A>                       size   1492
<A HREF="bishctz.htm">bishctz.htm</A>                   size  59708
<A HREF="certriz.htm">certriz.htm</A>                   size  21743
<A HREF="flutic.htm">flutic.htm</A>                    size  26717
<A HREF="cromnas.htm">cromnas.htm</A>                   size   9439
<A HREF="ethynoc.htm">ethynoc.htm</A>                   size  49996
<A HREF="medrox.htm">medrox.htm</A>                    size  18539
<A HREF="hctztri.htm">hctztri.htm</A>                   size  29812
<A HREF="levothy.htm">levothy.htm</A>                   size  29447
<A HREF="cefurox.htm">cefurox.htm</A>                   size  23600
<A HREF="cefur0x.htm">cefur0x.htm</A>                   size  23637
<A HREF="lansop.htm">lansop.htm</A>                    size  40604
<A HREF="ipratrop.htm">ipratrop.htm</A>                  size  13650
<A HREF="simva.htm">simva.htm</A>                     size  52202
<A HREF="cisap.htm">cisap.htm</A>                     size  20274
<A HREF="aceinh.htm">aceinh.htm</A>                    size   2707
<A HREF="top200.htm">top200.htm</A>                    size  26181
<A HREF="indap.htm">indap.htm</A>                     size  30702
<A HREF="ticlop.htm">ticlop.htm</A>                    size  37941
<A HREF="beclo1.htm">beclo1.htm</A>                    size  18284
<A HREF="buprop.htm">buprop.htm</A>                    size  44269
<A HREF="cardiova.htm">cardiova.htm</A>                  size   1546
<A HREF="fluva.htm">fluva.htm</A>                     size  41010
<A HREF="ntg.htm">ntg.htm</A>                       size   7864
<A HREF="dig.htm">dig.htm</A>                       size  50344
<A HREF="norgeth.htm">norgeth.htm</A>                   size  40994
<A HREF="chlordia.htm">chlordia.htm</A>                  size  15797
<A HREF="oxyapap.htm">oxyapap.htm</A>                   size  12260
<A HREF="dexfenx.htm">dexfenx.htm</A>                   size    784
<A HREF="benzon.htm">benzon.htm</A>                    size   6767
<A HREF="dexfen.htm">dexfen.htm</A>                    size  46997
<A HREF="terfen.htm">terfen.htm</A>                    size  33179
<A HREF="terbin.htm">terbin.htm</A>                    size  18463
<A HREF="tercon.htm">tercon.htm</A>                    size   9967
<A HREF="warfarin.htm">warfarin.htm</A>                  size  36979
<A HREF="amox.htm">amox.htm</A>                      size  16542
<A HREF="rx.gif">rx.gif</A>                        size   2266
<A HREF="rx.jpg">rx.jpg</A>                        size   3384
<A HREF="mtx.htm">mtx.htm</A>                       size  73884
<A HREF="flucon.htm">flucon.htm</A>                    size  32426
<A HREF="propran.htm">propran.htm</A>                   size  37253
<A HREF="tretinoin.htm">tretinoin.htm</A>                 size  10331
<A HREF="erythro.htm">erythro.htm</A>                   size  19007
<A HREF="methphen.htm">methphen.htm</A>                  size  16017
<A HREF="mupi.htm">mupi.htm</A>                      size   6371
<A HREF="cipro.htm">cipro.htm</A>                     size  43743
<A HREF="beclo.htm">beclo.htm</A>                     size  22488
<A HREF="fludro.htm">fludro.htm</A>                    size  19446
<A HREF="doxazo.htm">doxazo.htm</A>                    size  29295
<A HREF="amoxclav.htm">amoxclav.htm</A>                  size  27281
<A HREF="acetcod.htm">acetcod.htm</A>                   size  16288
<A HREF="dival.htm">dival.htm</A>                     size  33849
<A HREF="sudafed.htm">sudafed.htm</A>                   size   8807
<A HREF="sulfasal.htm">sulfasal.htm</A>                  size  23367
<A HREF="salmet.htm">salmet.htm</A>                    size  42662
<A HREF="guaicod.htm">guaicod.htm</A>                   size   5562
<A HREF="losarhct.htm">losarhct.htm</A>                  size  55898
<A HREF="opiate.htm">opiate.htm</A>                    size   3637
<A HREF="hctz.htm">hctz.htm</A>                      size  20362
<A HREF="traz.htm">traz.htm</A>                      size  23105
<A HREF="index.html.sav">index.html.sav</A>                size     71
<A HREF="nitro25m.htm">nitro25m.htm</A>                  size  26256
<A HREF="amox_t.htm">amox_t.htm</A>                    size   3048
<A HREF="mesal.htm">mesal.htm</A>                     size  18888
<A HREF="amphet.htm">amphet.htm</A>                    size  24005
<A HREF="clobet.htm">clobet.htm</A>                    size  17490
<A HREF="olsal.htm">olsal.htm</A>                     size  19403
<A HREF="conest.htm">conest.htm</A>                    size  32542
<A HREF="isotret.htm">isotret.htm</A>                   size  33977
<A HREF="sinemet.htm">sinemet.htm</A>                   size  27938
<A HREF="dihydram.htm">dihydram.htm</A>                  size  10975
<A HREF="methprd.htm">methprd.htm</A>                   size  33240
<A HREF="estratd.htm">estratd.htm</A>                   size  43367
<A HREF="astem.htm">astem.htm</A>                     size  22928
<A HREF="risperid.htm">risperid.htm</A>                  size  62304
<A HREF="cocaine.htm">cocaine.htm</A>                   size   7354
<A HREF="estrad.htm">estrad.htm</A>                    size  42949
<A HREF="erytst.htm">erytst.htm</A>                    size  20936
<A HREF="pemoline.htm">pemoline.htm</A>                  size  14487
<A HREF="gemfib.htm">gemfib.htm</A>                    size  44940
<A HREF="index.shtml.sav">index.shtml.sav</A>               size   2058
<A HREF="triamaer.htm">triamaer.htm</A>                  size  22841
<A HREF="oxaproz.htm">oxaproz.htm</A>                   size  32602
<A HREF="neopolhc.htm">neopolhc.htm</A>                  size  10362
<A HREF="penvk.htm">penvk.htm</A>                     size  11510
<A HREF="benaz.htm">benaz.htm</A>                     size  40948
<A HREF="amlod2.htm">amlod2.htm</A>                    size  27231
<A HREF="isomono2.htm">isomono2.htm</A>                  size  22623
<A HREF="huminsr.htm">huminsr.htm</A>                   size   4466
<A HREF="haloper.htm">haloper.htm</A>                   size  31330
<A HREF="loraz.htm">loraz.htm</A>                     size  13645
<A HREF="glybur.htm">glybur.htm</A>                    size  25992
<A HREF="yohimb.htm">yohimb.htm</A>                    size   5875
<A HREF="nefaz.htm">nefaz.htm</A>                     size  57917
<A HREF="fenflur.htm">fenflur.htm</A>                   size  17851
<A HREF="doxycyc.htm">doxycyc.htm</A>                   size  30494
<A HREF="sumitr.htm">sumitr.htm</A>                    size  41304
<A HREF="etodolac.htm">etodolac.htm</A>                  size  42703
<A HREF="temaz.htm">temaz.htm</A>                     size  14107
<A HREF="teraz.htm">teraz.htm</A>                     size  55957
<A HREF="triamnas.htm">triamnas.htm</A>                  size  20718
<A HREF="bblock.htm">bblock.htm</A>                    size   3679
<A HREF="blank.htm">blank.htm</A>                     size    898
<A HREF="verapsr.htm">verapsr.htm</A>                   size  40342
<A HREF="glymic.htm">glymic.htm</A>                    size  29120
<A HREF="pentox.htm">pentox.htm</A>                    size  17690
<A HREF="cefadrox.htm">cefadrox.htm</A>                  size  17832
<A HREF="azith.htm">azith.htm</A>                     size  32222
<A HREF="captop.htm">captop.htm</A>                    size  55880
<A HREF="naprox.htm">naprox.htm</A>                    size  30741
<A HREF="clarith.htm">clarith.htm</A>                   size  29769
<A HREF="cefprozi.htm">cefprozi.htm</A>                  size  32135
<A HREF="calch.htm">calch.htm</A>                     size   3227
<A HREF="metax.htm">metax.htm</A>                     size   5522
<A HREF="hum7030.htm">hum7030.htm</A>                   size  19214
<A HREF="venlafax.htm">venlafax.htm</A>                  size  63531
<A HREF="fluvox.htm">fluvox.htm</A>                    size  60223
<A HREF="clomiph.htm">clomiph.htm</A>                   size  35001
<A HREF="prometh.htm">prometh.htm</A>                   size  16661
<A HREF="indometh.htm">indometh.htm</A>                  size  50781
<A HREF="oflox.htm">oflox.htm</A>                     size  53880
<A HREF="enalap.htm">enalap.htm</A>                    size  51752
<A HREF="hyoscy.htm">hyoscy.htm</A>                    size  16479
<A HREF="amitrip.htm">amitrip.htm</A>                   size  23852
<A HREF="cephalex.htm">cephalex.htm</A>                  size  18679
<A HREF="oxyasa.htm">oxyasa.htm</A>                    size   9452
<A HREF="humnph.htm">humnph.htm</A>                    size  20278
<A HREF="quinap.htm">quinap.htm</A>                    size  44910
<A HREF="tamox.htm">tamox.htm</A>                     size  39080
<A HREF="metformi.htm">metformi.htm</A>                  size  62444
<A HREF="mono.htm">mono.htm</A>                      size   1618
<A HREF="parox.htm">parox.htm</A>                     size  59623
<A HREF="fosinop.htm">fosinop.htm</A>                   size  44193
<A HREF="lisinop.htm">lisinop.htm</A>                   size  55007
<A HREF="propox.htm">propox.htm</A>                    size  23794
<A HREF="carisop.htm">carisop.htm</A>                   size   9243
<A HREF="nortrip.htm">nortrip.htm</A>                   size  14209
<A HREF="omepra.htm">omepra.htm</A>                    size  36123
<A HREF="albut1.htm">albut1.htm</A>                    size  17067
<A HREF="hydrox.htm">hydrox.htm</A>                    size   9163
</PRE>
</BODY>
</DOC>
<DOC>
<DOCNO>WT08-B10-67</DOCNO>
<DOCOLDNO>IA018-000200-B036-217</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/loraz.htm 206.86.175.201 19970106225301 text/html 13828
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:46:47 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 13645
Last-modified: Mon, 08 Jul 1996 21:41:21 GMT
</DOCHDR>
<html>
<head>
   <title>Lorazepam - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Lorazepam</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Lorazepam , an antianxiety agent, has the chemical formula, 7-chloro-5-
(O-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one. It is
a nearly white powder almost insoluble in water. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Studies in healthy volunteers show that in single high doses Lorazepam
has a tranquilizing action on the central nervous system with no appreciable
effect on the respiratory or cardiovascular systems. </p>

<p>Lorazepam is readily absorbed with an absolute bioavailability of 90
percent. Peak concentrations in plasma occur approximately 2 hours following
administration. The peak plasma level of lorazepam from a 2 mg dose is
approximately 20 ng/mL. </p>

<p>The mean half-life of unconjugated lorazepam in human plasma is about
12 hours and for its major metabolite, lorazepam glucuronide, about 18
hours. At clinically relevant concentrations, lorazepam is approximately
85% bound to plasma proteins. Lorazepam is rapidly conjugated at its 3-hydroxy
group into lorazepam glucuronide which is then excreted in the urine. Lorazepam
glucuronide has no demonstrable CNS activity in animals. </p>

<p>The plasma levels of lorazepam are proportional to the dose given. There
is no evidence of accumulation of lorazepam on administration up to six
months. </p>

<p>Studies comparing young and elderly subjects have shown that the pharmacokinetics
of lorazepam remain unaltered with advancing age. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Lorazepam is indicated for the management of anxiety disorders or for
the short-term relief of the symptoms of anxiety or anxiety associated
with depressive symptoms. Anxiety or tension associated with the stress
of everyday life usually does not require treatment with an anxiolytic.
</p>

<p>The effectiveness of Lorazepam in long-term use, that is, more than
4 months, has not been assessed by systematic clinical studies. The physician
should periodically reassess the usefulness of the drug for the individual
patient. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Lorazepam is contraindicated in patients with known sensitivity to the
benzodiazepines or with acute narrow-angle glaucoma. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>Lorazepam is not recommended for use in patients with a primary depressive
disorder or psychosis. As with all patients on CNS-acting drugs, patients
receiving lorazepam should be warned not to operate dangerous machinery
or motor vehicles and that their tolerance for alcohol and other CNS depressants
will be diminished. </p>

<p>PHYSICAL AND PSYCHOLOGICAL DEPENDENCE </p>

<p>Withdrawal symptoms, similar in character to those noted with barbiturates
and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting,
and sweating), have occurred following abrupt discontinuance of lorazepam.
The more severe withdrawal symptoms have usually been limited to those
patients who received excessive doses over an extended period of time.
Generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have
been reported following abrupt discontinuance of benzodiazepines taken
continuously at therapeutic levels for several months. Consequently, after
extended therapy, abrupt discontinuation should generally be avoided and
a gradual dosage-tapering schedule followed. Addiction-prone individuals
(such as drug addicts or alcoholics) should be under careful surveillance
when receiving lorazepam or other psychotropic agents because of the predisposition
of such patients to habituation and dependence. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>In patients with depression accompanying anxiety, a possibility for
suicide should be borne in mind. </p>

<p>For elderly or debilitated patients, the initial daily dosage should
not exceed 2 mg in order to avoid oversedation. </p>

<p>The usual precautions for treating patients with impaired renal or hepatic
function should be observed. </p>

<p>In patients where gastrointestinal or cardiovascular disorders coexist
with anxiety, it should be noted that lorazepam has not been shown to be
of significant benefit in treating the gastrointestinal or cardiovascular
component. </p>

<p>Esophageal dilation occurred in rats treated with lorazepam for more
than one year at 6 mg/kg/day. The no-effect dose was 1.25 mg/kg/day (approximately
6 times the maximum human therapeutic dose of 10 mg per day). The effect
was reversible only when the treatment was withdrawn within two months
of first observation of the phenomenon. The clinical significance of this
is unknown. However, use of lorazepam for prolonged periods and in geriatric
patients requires caution, and there should be frequent monitoring for
symptoms of upper G.I. disease. </p>

<p>Safety and effectiveness of Lorazepam in children of less than 12 years
have not been established. </p>

<p>INFORMATION FOR PATIENTS </p>

<p>To assure the safe and effective use of Lorazepam , patients should
be informed that, since benzodiazepines may produce psychological and physical
dependence, it is advisable that they consult with their physician before
either increasing the dose or abruptly discontinuing this drug. </p>

<p>ESSENTIAL LABORATORY TESTS </p>

<p>Some patients on Lorazepam have developed leukopenia, and some have
had elevations of LDH. As with other benzodiazepines, periodic blood counts
and liver-function tests are recommended for patients on long-term therapy.
</p>

<p>CLINICALLY SIGNIFICANT DRUG INTERACTIONS </p>

<p>The benzodiazepines, including Lorazepam , produce CNS depressant effects
when administered with such medications as barbiturates or alcohol. </p>

<p>CARCINOGENESIS AND MUTAGENESIS </p>

<p>No evidence of carcinogenic potential emerged in rats during an 18-month
study with Lorazepam . No studies regarding mutagenesis have been performed.
</p>

<p>PREGNANCY </p>

<p>Reproductive studies in animals were performed in mice, rats, and two
strains of rabbits. Occasional anomalies (reduction of tarsals, tibia,
metatarsals, malrotated limbs, gastroschisis, malformed skull, and microphthalmia)
were seen in drug-treated rabbits without relationship to dosage. Although
all of these anomalies were not present in the concurrent control group,
they have been reported to occur randomly in historical controls. At doses
of 40 mg/kg and higher, there was evidence of fetal resorption and increased
fetal loss in rabbits which was not seen at lower doses. </p>

<p>The clinical significance of the above findings is not known. However,
an increased risk of congenital malformations associated with the use of
minor tranquilizers (chlordiazepoxide, diazepam, and meprobamate) during
the first trimester of pregnancy has been suggested in several studies.
Because the use of these drugs is rarely a matter of urgency, the use of
lorazepam during this period should almost always be avoided. The possibility
that a woman of childbearing potential may be pregnant at the time of institution
of therapy should be considered. Patients should be advised that if they
become pregnant, they should communicate with their physician about the
desirability of discontinuing the drug. </p>

<p>In humans, blood levels obtained from umbilical cord blood indicate
placental transfer of lorazepam and lorazepam glucuronide. </p>

<p>NURSING MOTHERS </p>

<p>It is not known whether oral lorazepam is excreted in human milk like
the other benzodiazepine tranquilizers. As a general rule, nursing should
not be undertaken while a patient is on a drug, since many drugs are excreted
in human milk. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>CLINICALLY SIGNIFICANT DRUG INTERACTIONS </p>

<p>The benzodiazepines, including Lorazepam , produce CNS depressant effects
when administered with such medications as barbiturates or alcohol. </p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Adverse reactions, if they occur, are usually observed at the beginning
of therapy and generally disappear on continued medication or upon decreasing
the dose. In a sample of about 3,500 anxious patients, the most frequent
adverse reaction to Lorazepam is sedation (15.9%), followed by dizziness
(6.9%), weakness (4.2%), and unsteadiness (3.4%). Less frequent adverse
reactions are disorientation, depression, nausea, change in appetite, headache,
sleep disturbance, agitation, dermatological symptoms, eye function disturbance
together with various gastrointestinal symptoms and autonomic manifestations.
The incidence of sedation and unsteadiness increased with age. </p>

<p>Small decreases in blood pressure have been noted but are not clinically
significant, probably being related to the relief of anxiety produced by
Lorazepam . </p>

<p>Transient amnesia or memory impairment has been reported in association
with the use of benzodiazepines. </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>PHYSICAL AND PSYCHOLOGICAL DEPENDENCE </p>

<p>Withdrawal symptoms, similar in character to those noted with barbiturates
and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting,
and sweating), have occurred following abrupt discontinuance of lorazepam.
The more severe withdrawal symptoms have usually been limited to those
patients who received excessive doses over an extended period of time.
Generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have
been reported following abrupt discontinuance of benzodiazepines taken
continuously at therapeutic levels for several months. Consequently, after
extended therapy, abrupt discontinuation should generally be avoided and
a gradual dosage-tapering schedule followed. Addiction-prone individuals
(such as drug addicts or alcoholics) should be under careful surveillance
when receiving lorazepam or other psychotropic agents because of the predisposition
of such patients to habituation and dependence. </p>

<p>(See Also WARNINGS) </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>In the management of overdosage with any drug, it should be borne in
mind that multiple agents may have been taken. </p>

<p>Manifestations of Lorazepam overdosage include somnolence, confusion,
and coma. Induced vomiting and/or gastric lavage should be undertaken,
followed by general supportive care, monitoring of vital signs, and close
observation of the patient. Hypotension, though unlikely, usually may be
controlled with Levarterenol Bitartrate Injection, USP. The usefulness
of dialysis has not been determined. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Lorazepam is administered orally. For optimal results, dose, frequency
of administration, and duration of therapy should be individualized according
to patient response. To facilitate this, 0.5 mg, 1 mg, and 2 mg tablets
are available. </p>

<p>The usual range is 2 to 6 mg/day given in divided doses, the largest
dose being taken before bedtime, but the daily dosage may vary from 1 to
10 mg/day. </p>

<p>For anxiety, most patients require an initial dose of 2 to 3 mg/day
given b.i.d. or t.i.d. </p>

<p>For insomnia due to anxiety or transient situational stress, a single
daily dose of 2 to 4 mg may be given, usually at bedtime. </p>

<p>For elderly or debilitated patients, an initial dosage of 1 to 2 mg/day
in divided doses is recommended, to be adjusted as needed and tolerated.
</p>

<p>The dosage of Lorazepam should be increased gradually when needed to
help avoid adverse effects. When higher dosage is indicated, the evening
dose should be increased before the daytime doses. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-68</DOCNO>
<DOCOLDNO>IA018-000200-B037-115</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/carbam.htm 206.86.175.201 19970106225538 text/html 34393
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:49:24 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 34210
Last-modified: Wed, 10 Jul 1996 18:53:16 GMT
</DOCHDR>
<html>
<head>
   <title>Carbamazepine - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Carbamazepine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>WARNING </p>

<p>APLASTIC ANEMIA AND AGRANULOCYTOSIS HAVE BEEN REPORTED IN ASSOCIATION
WITH THE USE OF Carbamazepine. DATA FROM A POPULATION-BASED CASE-CONTROL
STUDY DEMONSTRATE THAT THE RISK OF DEVELOPING THESE REACTIONS IS 5-8 TIMES
GREATER THAN IN THE GENERAL POPULATION. HOWEVER, THE OVERALL RISK OF THESE
REACTIONS IN THE UNTREATED GENERAL POPULATION IS LOW, APPROXIMATELY SIX
PATIENTS PER ONE MILLION POPULATION PER YEAR FOR AGRANULOCYTOSIS AND TWO
PATIENTS PER ONE MILLION POPULATION PER YEAR FOR APLASTIC ANEMIA. </p>

<p>ALTHOUGH REPORTS OF TRANSIENT OR PERSISTENT DECREASED PLATELET OR WHITE
BLOOD CELL COUNTS ARE NOT UNCOMMON IN ASSOCIATION WITH THE USE OF Carbamazepine,
DATA ARE NOT AVAILABLE TO ESTIMATE ACCURATELY THEIR INCIDENCE OR OUTCOME.
HOWEVER, THE VAST MAJORITY OF THE CASES OF LEUKOPENIA HAVE NOT PROGRESSED
TO THE MORE SERIOUS CONDITIONS OF APLASTIC ANEMIA OR AGRANULOCYTOSIS. </p>

<p>BECAUSE OF THE VERY LOW INCIDENCE OF AGRANULOCYTOSIS AND APLASTIC ANEMIA,
THE VAST MAJORITY OF MINOR HEMATOLOGIC CHANGES OBSERVED IN MONITORING OF
PATIENTS ON Carbamazepine ARE UNLIKELY TO SIGNAL THE OCCURRENCE OF EITHER
ABNORMALITY. NONETHELESS, COMPLETE PRETREATMENT HEMATOLOGICAL TESTING SHOULD
BE OBTAINED AS A BASELINE. IF A PATIENT IN THE COURSE OF TREATMENT EXHIBITS
LOW OR DECREASED WHITE BLOOD CELL OR PLATELET COUNTS, THE PATIENT SHOULD
BE MONITORED CLOSELY. DISCONTINUATION OF THE DRUG SHOULD BE CONSIDERED
IF ANY EVIDENCE OF SIGNIFICANT BONE MARROW DEPRESSION DEVELOPS. </p>

<p>BEFORE PRESCRIBING Carbamazepine, THE PHYSICIAN SHOULD BE THOROUGHLY
FAMILIAR WITH THE DETAILS OF THIS PRESCRIBING INFORMATION, PARTICULARLY
REGARDING USE WITH OTHER DRUGS, ESPECIALLY THOSE WHICH ACCENTUATE TOXICITY
POTENTIAL. </p>

<p>DESCRIPTION: </p>

<p>Carbamazepine, is an anticonvulsant and specific analgesic for trigeminal.
Its chemical name is 5H-dibenz(b,f)azepine-5-carboxamide. </p>

<p>Carbamazepine USP is a white to off-white powder, practically insoluble
in water and soluble in alcohol and in acetone. Its molecular weight is
236.27. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>In controlled clinical trials, Carbamazepine has been shown to be effective
in the treatment of psychomotor and grand mal seizures, as well as trigeminal
neuralgia. </p>

<p>It has demonstrated anticonvulsant properties in rats and mice with
electrically and chemically induced seizures. It appears to act by reducing
polysynaptic responses and blocking the post-tetanic potentiation. Carbamazepine
greatly reduces or abolishes pain induced by stimulation of the infraorbital
nerve in cats and rats. It depresses thalamic potential and bulbar and
polysynaptic reflexes, including the linguomandibular reflex in cats. Carbamazepine
is chemically unrelated to other anticonvulsants or other drugs used to
control the pain of trigeminal neuralgia. The mechanism of action remains
unknown. </p>

<p>In clinical studies both suspension and conventional tablet delivered
equivalent amounts of drug to the systemic circulation. However, the suspension
was absorbed somewhat faster than the tablet. Following a b.i.d. dosage
regimen the suspension has higher peak plasma levels and lower trough levels
than those obtained from the tablet formulation for the same dosage regimen.
On the other hand, following a t.i.d. dosage regimen, Carbamazepine suspension
affords steady- state plasma levels comparable to Carbamazepine tablets
given b.i.d. when administered at the same total mg daily dose. Carbamazepine
chewable tablets may produce higher peak levels than the same dose given
as regular tablets. Carbamazepine in blood is 76% bound to plasma proteins.
Plasma levels of Carbamazepine are variable and may range from 0.5-25 mcgm/ml,
with no apparent relationship to the daily intake of the drug. Usual adult
therapeutic levels are between 4 and 12 mcgm/ml. Following chronic oral
administration of suspension, plasma levels peak at approximately 1.5 hours
compared to 4 to 5 hours after administration of oral tablets. The CSF/serum
ratio is 0.22, similar to the 22% unbound Carbamazepine in serum. Because
Carbamazepine may induce its own metabolism, the half-life is also variable.
Initial half-life values range from 25-65 hours, with 12-17 hours on repeated
doses. Carbamazepine is metabolized in the liver. After oral administration
of 14C-carbamazepine, 72% of the administered radioactivity was found in
the urine and 28% in the feces. This urinary radioactivity was composed
largely of hydroxylated and conjugated metabolites, with only 3% of unchanged
Carbamazepine. Transplacental passage of Carbamazepine is rapid (30 to
60 minutes), and the drug is accumulated in fetal tissues, with higher
levels found in liver and kidney than in brain and lungs. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>EPILEPSY: Carbamazepine is indicated for use as an anticonvulsant drug.
Evidence supporting efficacy of Carbamazepine as an anticonvulsant was
derived from active drug-controlled studies that enrolled patients with
the following seizure types: </p>

<p>1. Partial seizures with complex symptomatology (psychomotor, temporal
lobe). Patients with these seizures appear to show greater improvement
than those with other types. </p>

<p>2. Generalized tonic-clonic seizures (grand mal). </p>

<p>3. Mixed seizure patterns which include the above, or other partial
or generalized seizures. </p>

<p>Absence seizures (petit mal) do not appear to be controlled by Carbamazepine
(see PRECAUTIONS, General). </p>

<p>TRIGEMINAL NEURALGIA: Carbamazepine is indicated in the treatment of
the pain associated with true trigeminal neuralgia. </p>

<p>Beneficial results have also been reported in glossopharyngeal neuralgia.
</p>

<p>This drug is not a simple analgesic and should not be used for the relief
of trivial aches or pains. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Carbamazepine should not be used in patients with a history of previous
bone marrow depression, hypersensitivity to the drug, or known sensitivity
to any of the tricyclic compounds, such as amitriptyline, desipramine,
imipramine, protriptyline, nortriptyline, etc. Likewise, on theoretical
grounds its use with monoamine oxidase inhibitors is not recommended. Before
administration of Carbamazepine, MAO inhibitors should be discontinued
for a minimum of fourteen days, or longer if the clinical situation permits.
</p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>WARNING </p>

<p>APLASTIC ANEMIA AND AGRANULOCYTOSIS HAVE BEEN REPORTED IN ASSOCIATION
WITH THE USE OF Carbamazepine. DATA FROM A POPULATION-BASED CASE-CONTROL
STUDY DEMONSTRATE THAT THE RISK OF DEVELOPING THESE REACTIONS IS 5-8 TIMES
GREATER THAN IN THE GENERAL POPULATION. HOWEVER, THE OVERALL RISK OF THESE
REACTIONS IN THE UNTREATED GENERAL POPULATION IS LOW, APPROXIMATELY SIX
PATIENTS PER ONE MILLION POPULATION PER YEAR FOR AGRANULOCYTOSIS AND TWO
PATIENTS PER ONE MILLION POPULATION PER YEAR FOR APLASTIC ANEMIA. </p>

<p>ALTHOUGH REPORTS OF TRANSIENT OR PERSISTENT DECREASED PLATELET OR WHITE
BLOOD CELL COUNTS ARE NOT UNCOMMON IN ASSOCIATION WITH THE USE OF Carbamazepine,
DATA ARE NOT AVAILABLE TO ESTIMATE ACCURATELY THEIR INCIDENCE OR OUTCOME.
HOWEVER, THE VAST MAJORITY OF THE CASES OF LEUKOPENIA HAVE NOT PROGRESSED
TO THE MORE SERIOUS CONDITIONS OF APLASTIC ANEMIA OR AGRANULOCYTOSIS. </p>

<p>BECAUSE OF THE VERY LOW INCIDENCE OF AGRANULOCYTOSIS AND APLASTIC ANEMIA,
THE VAST MAJORITY OF MINOR HEMATOLOGIC CHANGES OBSERVED IN MONITORING OF
PATIENTS ON Carbamazepine ARE UNLIKELY TO SIGNAL THE OCCURRENCE OF EITHER
ABNORMALITY. NONETHELESS, COMPLETE PRETREATMENT HEMATOLOGICAL TESTING SHOULD
BE OBTAINED AS A BASELINE. IF A PATIENT IN THE COURSE OF TREATMENT EXHIBITS
LOW OR DECREASED WHITE BLOOD CELL OR PLATELET COUNTS, THE PATIENT SHOULD
BE MONITORED CLOSELY. </p>

<p>DISCONTINUATION OF THE DRUG SHOULD BE CONSIDERED IF ANY EVIDENCE OF
SIGNIFICANT BONE MARROW DEPRESSION DEVELOPS. </p>

<p>Patients with a history of adverse hematologic reaction to any drug
may be particularly at risk. </p>

<p>Severe dermatologic reactions including toxic epidermal necrolysis (Lyell's
syndrome) and Stevens-Johnson syndrome, have been reported with Carbamazepine.
These reactions have been extremely rare. However, a few fatalities have
been reported. </p>

<p>Carbamazepine has shown mild anticholinergic activity; therefore, patients
with increased intraocular pressure should be closely observed during therapy.
</p>

<p>Because of the relationship of the drug to other tricyclic compounds,
the possibility of activation of a latent psychosis and, in elderly patients,
of confusion or agitation should be borne in mind. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL: Before initiating therapy, a detailed history and physical
examination should be made. </p>

<p>Carbamazepine should be used with caution in patients with a mixed seizure
disorder that includes atypical absence seizures, since in these patients
Carbamazepine has been associated with increased frequency of generalized
convulsions (see INDICATIONS AND USAGE). </p>

<p>Therapy should be prescribed only after critical benefit-to-risk appraisal
in patients with a history of cardiac, hepatic or renal damage, adverse
hematologic reaction to other drugs, or interrupted courses of therapy
with Carbamazepine. </p>

<p>Since a given dose of Carbamazepine suspension will produce higher peak
levels than the same dose given as the tablet, it is recommended that patients
given the suspension be started on lower doses and increased slowly to
avoid unwanted side effects (see DOSAGE AND ADMINISTRATION). </p>

<p>INFORMATION FOR PATIENTS: Patients should be made aware of the early
toxic signs and symptoms of a potential hematologic problem, such as fever,
sore throat, ulcers in the mouth, easy bruising, petechial or purpuric
hemorrhage, and should be advised to report to the physician immediately
if any such signs or symptoms appear. </p>

<p>Since dizziness and drowsiness may occur, patients should be cautioned
about the hazards of operating machinery or automobiles or engaging in
other potentially dangerous tasks. </p>

<p>LABORATORY TESTS: Complete pretreatment blood counts, including platelets
and possibly reticulocytes and serum iron, should be obtained as a baseline.
If a patient in the course of treatment exhibits low or decreased white
blood cell or platelet counts, the patient should be monitored closely.
Discontinuation of the drug should be considered if any evidence of significant
bone marrow depression develops. </p>

<p>Baseline and periodic evaluations of liver function, particularly in
patients with a history of liver disease, must be performed during treatment
with this drug since liver damage may occur. The drug should be discontinued
immediately in cases of aggravated liver dysfunction or active liver disease.
</p>

<p>Baseline and periodic eye examinations, including slit-lamp, funduscopy
and tonometry, are recommended since many phenothiazines and related drugs
have been shown to cause eye changes. </p>

<p>Baseline and periodic complete urinalysis and BUN determinations are
recommended for patients treated with this agent because of observed renal
dysfunction. </p>

<p>Monitoring of blood levels (see ACTIONS/CLINICAL PHARMACOLOGY) has increased
the efficacy and safety of anticonvulsants. This monitoring may be particularly
useful in cases of dramatic increase in seizure frequency and for verification
of compliance. In addition, measurement of drug serum levels may aid in
determining the cause of toxicity when more than one medication is being
used. </p>

<p>Thyroid function tests have been reported to show decreased values with
Carbamazepine administered alone. </p>

<p>Hyponatremia has been reported in association with Carbamazepine use,
either alone or in combination with other drugs. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS : </b>The simultaneous
administration of phenobarbital, phenytoin, or<b> </b>primidone, or a combination
of two, produces a marked lowering of serum levels of Carbamazepine. The
effect of valproic acid on Carbamazepine blood levels is not clearly established,
although an increase in the ratio of active 10, 11-epoxide metabolite to
parent compound is a consistent finding. </p>

<p>The half-lives of phenytoin, warfarin, doxycycline, and theophylline
were significantly shortened when administered concurrently with Carbamazepine.
Haloperidol and valproic acid serum levels may be reduced when these drugs
are administered with Carbamazepine. The doses of these drugs may therefore
have to be increased when Carbamazepine is added to the therapeutic regimen.
</p>

<p>Concomitant administration of Carbamazepine with erythromycin, cimetidine,
propoxyphene, isoniazid, fluoxetine or calcium channel blockers has been
reported to result in elevated plasma levels of carbamazepine resulting
in toxicity in some cases. Also, concomitant administration of carbamazepine
and lithium may increase the risk of neurotoxic side effects. </p>

<p>Alterations of thyroid function have been reported in combination therapy
with other anticonvulsant medications. </p>

<p>Breakthrough bleeding has been reported among patients receiving concomitant
oral contraceptives and their reliability may be adversely affected. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Carbamazepine,
when administered to Sprague-Dawley rats for two years in the diet at doses
of 25, 75, and 250 mg/kg/day, resulted in a dose-related increase in the
incidence of hepatocellular tumors in females and of benign interstitial
cell adenomas in the testes of males. </p>

<p>Carbamazepine must, therefore, be considered to be carcinogenic in Sprague-
Dawley rats. Bacterial and mammalian mutagenicity studies using carbamazepine
produced negative results. The significance of these findings relative
to the use of carbamazepine in humans is, at present, unknown. </p>

<p>PREGNANCY CATEGORY C: Carbamazepine has been shown to have adverse effects
in reproduction studies in rats when given orally in dosages 10-25 times
the maximum human daily dosage of 1200 mg. In rat teratology studies, 2
of 135 offspring showed kinked ribs at 250 mg/kg and 4 of 119 offspring
at 650 mg/kg showed other anomalies (cleft palate, 1; talipes, 1; anophthalmos,
2). In reproduction studies in rats, nursing offspring demonstrated a lack
of weight gain and an unkempt appearance at a maternal dosage level of
200 mg/kg. </p>

<p>There are no adequate and well-controlled studies in pregnant women.
Epidemiological data suggest that there may be an association between the
use of carbamazepine during pregnancy and congenital malformations, including
spina bifida. Carbamazepine should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus. </p>

<p>Retrospective case reviews suggest that, compared with monotherapy,
there may be a higher prevalence of teratogenic effects associated with
the use of anticonvulsants in combination therapy. Therefore, monotherapy
is recommended for pregnant women. </p>

<p>It is important to note that anticonvulsant drugs should not be discontinued
in patients in whom the drug is administered to prevent major seizures
because of the strong possibility of precipitating status epilepticus with
attendant hypoxia and threat to life. In individual cases where the severity
and frequency of the seizure disorder are such that removal of medication
does not pose a serious threat to the patient, discontinuation of the drug
may be considered prior to and during pregnancy, although it cannot be
said with any confidence that even minor seizures do not pose some hazard
to the developing embryo or fetus. </p>

<p>LABOR AND DELIVERY: The effect of Carbamazepine on human labor and delivery
is unknown. </p>

<p>NURSING MOTHERS: During lactation, concentration of Carbamazepine in
milk is approximately 60% of the maternal plasma concentration. </p>

<p>Because of the potential for serious adverse reactions in nursing infants
from carbamazepine, a decision should be made whether to discontinue nursing
or to discontinue the drug, taking into account the importance of the drug
to the mother. </p>

<p>PEDIATRIC USE: Safety and effectiveness in children below the age of
6 years have not been established. </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>If adverse reactions are of such severity that the drug must be discontinued,
the physician must be aware that abrupt discontinuation of any anticonvulsant
drug in a responsive epileptic patient may lead to seizures or even status
epilepticus with its life-threatening hazards. </p>

<p>The most severe adverse reactions have been observed in the hemopoietic
system (see boxed WARNING), the skin and the cardiovascular system. </p>

<p>The most frequently observed adverse reactions, particularly during
the initial phases of therapy, are dizziness, drowsiness, unsteadiness,
nausea, and vomiting. To minimize the possibility of such reactions, therapy
should be initiated at the low dosage recommended. </p>

<p>The following additional adverse reactions have been reported: </p>

<p>Hemopoietic System: Aplastic anemia, agranulocytosis, pancytopenia,
bone marrow depression, thrombocytopenia, leukopenia, leukocytosis, eosinophilia,
acute intermittent porphyria. </p>

<p>Skin: Pruritic and erythematous rashes, urticaria, toxic epidermal necrolysis
(Lyell's syndrome) (see WARNINGS), Stevens-Johnson syndrome (see WARNINGS),
photosensitivity reactions, alterations in skin pigmentation, exfoliative
dermatitis, erythema multiforme and nodosum, purpura, aggravation of disseminated
lupus erythematosus, alopecia, and diaphoresis. In certain cases, discontinuation
of therapy may be necessary. Isolated cases of hirsutism have been reported,
but a causal relationship is not clear. </p>

<p>Cardiovascular System: Congestive heart failure, edema, aggravation
of hypertension, hypotension, syncope and collapse, aggravation of coronary
artery disease, arrhythmias and AV block, primary thrombophlebitis, recurrence
of thrombophlebitis, and adenopathy or lymphadenopathy. </p>

<p>Some of these cardiovascular complications have resulted in fatalities.
Myocardial infarction has been associated with other tricyclic compounds.
</p>

<p>Liver: Abnormalities in liver function tests, cholestatic and hepatocellular
jaundice, hepatitis. </p>

<p>Respiratory System: Pulmonary hypersensitivity characterized by fever,
dyspnea, pneumonitis or pneumonia. </p>

<p>Genitourinary System: Urinary frequency, acute urinary retention, oliguria
with elevated blood pressure, azotemia, renal failure, and impotence. </p>

<p>Albuminuria, glycosuria, elevated BUN and microscopic deposits in the
urine have also been reported. </p>

<p>Testicular atrophy occurred in rats receiving Carbamazepine orally from
4 to 52 weeks at dosage levels of 50 to 400 mg/kg/day. Additionally, rats
receiving Carbamazepine in the diet for two years at dosage levels of 25,
75, and 250 mg/kg/day had a dose-related incidence of testicular atrophy
and aspermatogenesis. In dogs, it produced a brownish discoloration, presumably
a metabolite, in the urinary bladder at dosage levels of 50 mg/kg and higher.
Relevance of these findings to humans is unknown. </p>

<p>Nervous System: Dizziness, drowsiness, disturbances of coordination,
confusion, headache, fatigue, blurred vision, visual hallucinations, transient
diplopia, oculomotor disturbances, nystagmus, speech disturbances, abnormal
involuntary movements, peripheral neuritis and paresthesias, depression
with agitation, talkativeness, tinnitus, and hyperacusis. </p>

<p>There have been reports of associated paralysis and other symptoms of
cerebral arterial insufficiency, but the exact relationship of these reactions
to the drug has not been established. </p>

<p>Digestive System: Nausea, vomiting, gastric distress and abdominal pain,
diarrhea, constipation, anorexia, and dryness of the mouth and pharynx,
including glossitis and stomatitis. </p>

<p>Eyes: Scattered, punctate, cortical lens opacities, as well as conjunctivitis
have been reported. Although a direct causal relationship has not been
established, many phenothiazines and related drugs have been shown to cause
eye changes. </p>

<p>Musculoskeletal System: Aching joints and muscles, and leg cramps. </p>

<p>Metabolism: Fever and chills. Inappropriate antidiuretic hormone (ADH)
secretion syndrome has been reported. Cases of frank water intoxication,
with decreased serum sodium (hyponatremia) and confusion, have been reported
in association with Carbamazepine use (see PRECAUTIONS, Laboratory Tests).
</p>

<p>Other: Isolated cases of a lupus erythematosus-like syndrome have been
reported. There have been occasional reports of elevated levels of cholesterol,
HDL cholesterol and triglycerides in patients taking anticonvulsants. </p>

<p>A case of aseptic meningitis, accompanied by myoclonus and peripheral
eosinophilia, has been reported in a patient taking carbamazepine in combination
with other medications. The patient was successfully dechallenged, and
the meningitis reappeared upon rechallenge with carbamazepine. </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>No evidence of abuse potential has been associated with Carbamazepine,
nor is there evidence of psychological or physical dependence in humans.
</p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>ACUTE TOXICITY </p>

<p>Lowest known lethal dose: adults, &gt;60 g (39-year-old man). Highest
known doses survived: adults, 30 g (31-year-old woman); children, 10 g
(6-year-old boy); small children, 5 g (3-year-old girl). </p>

<p>Oral LD50 in animals (mg/kg): mice, 1100-3750; rats, 3850-4025; rabbits,
1500- 2680; guinea pigs, 920. </p>

<p>SIGNS AND SYMPTOMS </p>

<p>The first signs and symptoms appear after 1-3 hours. Neuromuscular disturbances
are the most prominent. Cardiovascular disorders are generally milder,
and severe cardiac complications occur only when very high doses (&gt;60
g) have been ingested. </p>

<p>Respiration: Irregular breathing, respiratory depression. </p>

<p>Cardiovascular System: Tachycardia, hypotension or hypertension, shock,
conduction disorders. </p>

<p>Nervous System And Muscles: Impairment of consciousness ranging in severity
to deep coma. Convulsions, especially in small children. Motor restlessness,
muscular twitching, tremor, athetoid movements, opisthotonos, ataxia, drowsiness,
dizziness, mydriasis, nystagmus, adiadochokinesia, ballism, psychomotor
disturbances, dysmetria. Initial hyperreflexia, followed by hyporeflexia.
</p>

<p>Gastrointestinal Tract: Nausea, vomiting. </p>

<p>Kidneys And Bladder: Anuria or oliguria, urinary retention. </p>

<p>Laboratory Findings: Isolated instances of overdosage have included
leukocytosis, reduced leukocyte count, glycosuria and acetonuria. EEG may
show dysrhythmias. </p>

<p>Combined Poisoning: When alcohol, tricyclic antidepressants, barbiturates
or hydantoins are taken at the same time, the signs and symptoms of acute
poisoning with Carbamazepine may be aggravated or modified. </p>

<p>TREATMENT </p>

<p>The prognosis in cases of severe poisoning is critically dependent upon
prompt elimination of the drug, which may be achieved by inducing vomiting,
irrigating the stomach, and by taking appropriate steps to diminish absorption.
If these measures cannot be implemented without risk on the spot, the patient
should be transferred at once to a hospital, while ensuring that vital
functions are safeguarded. There is no specific antidote. </p>

<p>Elimination Of The Drug: Induction of vomiting. </p>

<p>Gastric lavage. Even when more than 4 hours have elapsed following ingestion
of the drug, the stomach should be repeatedly irrigated, especially if
the patient has also consumed alcohol. </p>

<p>Measures To Reduce Absorption: Activated charcoal, laxatives. </p>

<p>Measures To Accelerate Elimination: Forced diuresis. </p>

<p>Dialysis is indicated only in severe poisoning associated with renal
failure. Replacement transfusion is indicated in severe poisoning in small
children. </p>

<p>Respiratory Depression: Keep the airways free; resort, if necessary,
to endotracheal intubation, artificial respiration, and administration
of oxygen. </p>

<p>Hypotension, Shock: Keep the patient's legs raised and administer a
plasma expander. If blood pressure fails to rise despite measures taken
to increase plasma volume, use of vasoactive substances should be considered.
</p>

<p>Convulsions: Diazepam or barbiturates. </p>

<p>Warning: Diazepam or barbiturates may aggravate respiratory depression
(especially in children), hypotension, and coma. However, barbiturates
should NOT be used if drugs that inhibit monoamine oxidase have also been
taken by the patient either in overdosage or in recent therapy (within
one week). </p>

<p>Surveillance: Respiration, cardiac function (ECG monitoring), blood
pressure, body temperature, pupillary reflexes, and kidney and bladder
function should be monitored for several days. </p>

<p>Treatment Of Blood Count Abnormalities: If evidence of significant bone
marrow depression develops, the following recommendations are suggested:
(1) stop the drug, (2) perform daily CBC, platelet and reticulocyte counts,
(3) do a bone marrow aspiration and trephine biopsy immediately and repeat
with sufficient frequency to monitor recovery. </p>

<p>Special periodic studies might be helpful as follows: (1) white cell
and platelet antibodies, (2) 59Fe--ferrokinetic studies, (3) peripheral
blood cell typing, (4) cytogenetic studies on marrow and peripheral blood,
(5) bone marrow culture studies for colony-forming units, (6) hemoglobin
electrophoresis for A2 and F hemoglobin, and (7) serum folic acid and B12
levels. </p>

<p>A fully developed aplastic anemia will require appropriate, intensive
monitoring and therapy, for which specialized consultation should be sought.
</p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<pre> 
<font SIZE=-1>                   DOSAGE INFORMATION: TABLETS AND SUSPENSION                   
----------------------------------------------------------------------------    
Indication      Initial Dose       Subsequent Dose           Maximum Dose       
----------------------------------------------------------------------------    
         Tablet    Suspension   Tablet      Suspension   Tablet or Suspension   
----------------------------------------------------------------------------    
EPILEPSY                                                                        
6-12    100 mg    1/2         Add up to    Add up to 1      1000 mg/24 hours    
 years  b.i.d.   teaspoon     100 mg per   teaspoon (100                        
 of age (200       q.i.d.     day at       mg) per day at                       
        mg/day) (200 mg/day)  weekly       weekly intervals                     
                              intervals,   t.i.d. or q.i.d.                     
                              t.i.d. or                                         
                              q.i.d.                                            
                                                                                
 Over   200 mg   1            Add up to     Add up to 2      1000 mg/24 hours:  
 12     b.i.d.  teaspoon      200 mg per    teaspoons        12-15 years        
 years  (400      q.i.d.      day at        (200 mg) per                        
 of age (mg/day) (400         weekly        day at weekly    1200 mg/24 hours:  
                 mg/day)      intervals,    intervals,       Over 15 years      
                              t.i.d. or     t.i.d. or        1600 mg/24 hours:  
                              q.i.d.        q.i.d.           adults, in rare    
                                                               instances        
                                                                                
TRIGEMINAL 100 mg   1/2      Add up to      Add up to 2      1200 mg/24 hours   
NEURALGIA  b.i.d.  teaspoon  200 mg per     teaspoons                           
           on the   q.i.d.   day in         (200 mg)                            
           first    (200     increments     per day q.i.d.                      
           day     mg/day)   of 100 mg                                          
          (200               every 12                                           
          mg/day)            hours                                 </font></pre>

<p>Monitoring of blood levels has increased the efficacy and safety of
anticonvulsants (see PRECAUTIONS, Laboratory Tests). Dosage should be adjusted
to the needs of the individual patient. A low initial daily dosage with
a gradual increase is advised. As soon as adequate control is achieved,
the dosage may be reduced very gradually to the minimum effective level.
Medication should be taken with meals. </p>

<p>Since a given dose of Carbamazepine suspension will produce higher peak
levels than the same dose given as the tablet, it is recommended to start
with low doses (children 6-12 years: 1/2 teaspoon q.i.d.) and to increase
slowly to avoid unwanted side effects. </p>

<p>Conversion of patients from oral Carbamazepine tablets to Carbamazepine
suspension: Patients should be converted by administering the same number
of mg per day in smaller, more frequent doses (i.e., b.i.d. tablets to
t.i.d. suspension). </p>

<p>EPILEPSY (see INDICATIONS AND USAGE). </p>

<p>ADULTS AND CHILDREN OVER 12 YEARS OF AGE--INITIAL: Either 200 mg b.i.d.
for tablets or 1 teaspoon q.i.d. for suspension (400 mg per day). Increase
at weekly intervals by adding up to 200 mg per day using a t.i.d. or q.i.d.
regimen until the optimal response is obtained. Dosage should generally
not exceed 1000 mg daily in children 12 to 15 years of age, and 1200 mg
daily in patients above 15 years of age. Doses up to 1600 mg daily have
been used in adults in rare instances. </p>

<p>MAINTENANCE: Adjust dosage to the minimum effective level, usually 800-1200
mg daily. </p>

<p>CHILDREN 6-12 YEARS OF AGE--INITIAL: Either 100 mg b.i.d. for tablets
or 1/2 teaspoon q.i.d for suspension (200 mg per day). Increase at weekly
intervals by adding up to 100 mg per day using a t.i.d. or q.i.d. regimen
until the optimal response is obtained. Dosage generally should not exceed
1000 mg daily. </p>

<p>MAINTENANCE: Adjust dosage to the minimum effective level, usually 400-800
mg daily. </p>

<p>COMBINATION THERAPY: Carbamazepine may be used alone or with other anticonvulsants.
When added to existing anticonvulsant therapy, the drug should be added
gradually while the other anticonvulsants are maintained or gradually decreased
except phenytoin, which may have to be increased (see PRECAUTIONS, Drug
Interactions and Pregnancy Category C). </p>

<p>TRIGEMINAL NEURALGIA (see INDICATIONS AND USAGE). </p>

<p>INITIAL: On the first day, either 100 mg b.i.d. for tablets or 1/2 teaspoon
q.i.d. for suspension for a total daily dose of 200 mg. This daily dose
may be increased by up to 200 mg a day using increments of 100 mg every
12 hours for tablets or 50 mg (1/2 teaspoon) q.i.d. for suspension, only
as needed to achieve freedom from pain. Do not exceed 1200 mg daily. MAINTENANCE:
Control of pain can be maintained in most patients with 400 mg to 800 mg
daily. However, some patients may be maintained on as little as 200 mg
daily, while others may require as much as 1200 mg daily. At least once
every 3 months throughout the treatment period, attempts should be made
to reduce the dose to the minimum effective level or even to discontinue
the drug. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-69</DOCNO>
<DOCOLDNO>IA018-000200-B042-177</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/cortisne.htm 206.86.175.201 19970106231506 text/html 19859
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:08:52 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 19676
Last-modified: Fri, 27 Dec 1996 20:13:00 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
   <TITLE>Cortisone - RxList Generic Information</TITLE>
   <META NAME="keywords" CONTENT="Adreson, Altesona, Cortate, Cortelan, Cortison Ciba,Cortison Nycomed, Cortisone, Cortisone Acetate, Cortisoni Acetas,Cortistab, Cortisyl, Cortogen, Cortone, Cortone Acetato, Cortone-Azetat,Scheroson, Cortaid, Cortizone">
   <META NAME="GENERATOR" CONTENT="Mozilla/3.01Gold (Win95; I) [Netscape]">
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000EE" VLINK="#551A8B" ALINK="#FF0000">

<CENTER><P><A HREF="http://www.rxlist.com/cgi/rxlist.cgi"><IMG SRC="rx.gif" BORDER=0 HEIGHT=125 WIDTH=125></A></P></CENTER>

<H1 ALIGN=CENTER>Cortisone</H1>

<P>
<HR><FONT COLOR="#0000FF">[<A HREF="#DESCRIPTION">description</A>] [<A HREF="#ACTIONS/CLINICAL PHARMACOLOGY">action</A>]
[<A HREF="#INDICATIONS AND USAGE">use</A>] [<A HREF="#CONTRAINDICATIONS">contra</A>]
[<A HREF="#WARNINGS">warn!</A>] [<A HREF="#PRECAUTIONS">caution</A>] [<A HREF="#DRUG INTERACTIONS">drug-drug</A>]
[<A HREF="#ADVERSE REACTIONS">side effects</A>] [<A HREF="#OVERDOSAGE">toxicity</A>]
[<A HREF="#DOSAGE AND ADMINISTRATION">dosing</A>] </FONT></P>

<P><B>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</B></P>

<P>
<HR width="100%"></P>

<P><A NAME="DESCRIPTION"></A><B>DESCRIPTION </B></P>

<P>Glucocorticoids are adrenocortical steroids, both naturally occurring
and synthetic, which are readily absorbed from the gastrointestinal tract.
</P>

<P>Cortisone acetate is a white or practically white, odorless, crystalline
powder. It is stable in air. It is insoluble in water. The molecular weight
is 402.49. It is designated chemically as 21-(acetyloxy)-17-hydroxypregn-4-ene-3,11,20-
trione. The empirical formula is C23H30O6. </P>

<P><A NAME="ACTIONS/CLINICAL PHARMACOLOGY"></A><B>ACTIONS/CLINICAL PHARMACOLOGY
</B></P>

<P>Naturally occurring glucocorticoids (hydrocortisone and cortisone),
which also have salt-retaining properties, are used as replacement therapy
in adrenocortical deficiency states. They are also used for their potent
anti-inflammatory effects in disorders of many organ systems. </P>

<P>Glucocorticoids cause profound and varied metabolic effects. In addition,
they modify the body's immune responses to diverse stimuli. </P>

<P><A NAME="INDICATIONS AND USAGE"></A><B>INDICATIONS AND USAGE </B></P>

<P>1. Endocrine Disorders </P>

<P>Primary or secondary adrenocortical insufficiency (hydrocortisone or
cortisone is the first choice; synthetic analogs may be used in conjunction
with mineralocorticoids where applicable; in infancy mineralocorticoid
supplementation is of particular importance). </P>

<P>Congenital adrenal hyperplasia </P>

<P>Nonsuppurative thyroiditis </P>

<P>Hypercalcemia associated with cancer </P>

<P>2. Rheumatic Disorders </P>

<P>As adjunctive therapy for short-term administration (to tide the patient
over an acute episode or exacerbation) in: </P>

<P>Psoriatic arthritis </P>

<P>Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected
cases may require low-dose maintenance therapy) </P>

<P>Ankylosing spondylitis </P>

<P>Acute and subacute bursitis </P>

<P>Acute nonspecific tenosynovitis </P>

<P>Acute gouty arthritis </P>

<P>Post-traumatic osteoarthritis </P>

<P>Synovitis of osteoarthritis </P>

<P>Epicondylitis </P>

<P>3. Collagen Diseases </P>

<P>During an exacerbation or as maintenance therapy in selected cases of--
</P>

<P>Systemic lupus erythematosus </P>

<P>Acute rheumatic carditis </P>

<P>Systemic dermatomyositis (polymyositis) </P>

<P>4. Dermatologic Diseases </P>

<P>Pemphigus </P>

<P>Bullous dermatitis herpetiformis </P>

<P>Severe erythema multiforme (Stevens-Johnson syndrome) </P>

<P>Exfoliative dermatitis </P>

<P>Mycosis fungoides </P>

<P>Severe psoriasis </P>

<P>Severe seborrheic dermatitis </P>

<P>5. Allergic States </P>

<P>Control of severe or incapacitating allergic conditions intractable
to adequate trials of conventional treatment: </P>

<P>Seasonal or perennial allergic rhinitis </P>

<P>Bronchial asthma </P>

<P>Contact dermatitis </P>

<P>Atopic dermatitis </P>

<P>Serum sickness </P>

<P>Drug hypersensitivity reactions </P>

<P>6. Ophthalmic Diseases </P>

<P>Severe acute and chronic allergic and inflammatory processes involving
the eye and its adnexa, such as-- </P>

<P>Allergic conjunctivitis </P>

<P>Keratitis </P>

<P>Allergic corneal marginal ulcers </P>

<P>Herpes zoster ophthalmicus </P>

<P>Iritis and iridocyclitis </P>

<P>Chorioretinitis </P>

<P>Anterior segment inflammation </P>

<P>Diffuse posterior uveitis and choroiditis </P>

<P>Optic neuritis </P>

<P>Sympathetic ophthalmia </P>

<P>7. Respiratory Diseases </P>

<P>Symptomatic sarcoidosis </P>

<P>Loeffler's syndrome not manageable by other means </P>

<P>Berylliosis </P>

<P>Fulminating or disseminated pulmonary tuberculosis when used concurrently
with appropriate antituberculous chemotherapy </P>

<P>Aspiration pneumonitis </P>

<P>8. Hematologic Disorders </P>

<P>Idiopathic thrombocytopenic purpura in adults </P>

<P>Secondary thrombocytopenia in adults </P>

<P>Acquired (autoimmune) hemolytic anemia </P>

<P>Erythroblastopenia (RBC anemia) </P>

<P>Congenital (erythroid) hypoplastic anemia </P>

<P>9. Neoplastic Diseases </P>

<P>For palliative management of: </P>

<P>Leukemias and lymphomas in adults </P>

<P>Acute leukemia of childhood </P>

<P>10. Edematous States </P>

<P>To induce a diuresis or remission of proteinuria in the nephrotic syndrome,
without uremia, of the idiopathic type or that due to lupus erythematosus
</P>

<P>11. Gastrointestinal Diseases </P>

<P>To tide the patient over a critical period of the disease in: </P>

<P>Ulcerative colitis </P>

<P>Regional enteritis </P>

<P>12. Miscellaneous </P>

<P>Tuberculous meningitis with subarachnoid block or impending block when
used concurrently with appropriate antituberculous chemotherapy </P>

<P>Trichinosis with neurologic or myocardial involvement </P>

<P><A NAME="CONTRAINDICATIONS"></A><B>CONTRAINDICATIONS </B></P>

<P>Systemic fungal infections </P>

<P>Hypersensitivity to cortisone. </P>

<P><A NAME="WARNINGS"></A><B>WARNINGS </B></P>

<P>In patients on corticosteroid therapy subjected to unusual stress, increased
dosage of rapidly acting corticosteroids before, during, and after the
stressful situation is indicated. </P>

<P>Drug-induced secondary adrenocortical insufficiency may result from
too rapid withdrawal of corticosteroids and may be minimized by gradual
reduction of dosage. This type of relative insufficiency may persist for
months after discontinuation of therapy; therefore, in any situation of
stress occurring during that period, hormone therapy should be reinstituted.
If the patient is receiving steroids already, dosage may have to be increased.
Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid
should be administered concurrently. </P>

<P>Corticosteroids may mask some signs of infection, and new infections
may appear during their use. There may be decreased resistance and inability
to localize infection when corticosteroids are used. Moreover, corticosteroids
may affect the nitroblue-tetrazolium test for bacterial infection and produce
false negative results. </P>

<P>In cerebral malaria, a double-blind trial has shown that the use of
corticosteroids is associated with prolongation of coma and a higher incidence
of pneumonia and gastrointestinal bleeding. </P>

<P>Corticosteroids may activate latent amebiasis. Therefore, it is recommended
that latent or active amebiasis be ruled out before initiating corticosteroid
therapy in any patient who has spent time in the tropics or any patient
with unexplained diarrhea. </P>

<P>Prolonged use of corticosteroids may produce posterior subcapsular cataracts,
glaucoma with possible damage to the optic nerves, and may enhance the
establishment of secondary ocular infections due to fungi or viruses. </P>

<P>Usage In Pregnancy: Since adequate human reproduction studies have not
been done with corticosteroids, use of these drugs in pregnancy or in women
of childbearing potential requires that the anticipated benefits be weighed
against the possible hazards to the mother and embryo or fetus. Infants
born of mothers who have received substantial doses of corticosteroids
during pregnancy should be carefully observed for signs of hypoadrenalism.
</P>

<P>Corticosteroids appear in breast milk and could suppress growth, interfere
with endogenous corticosteroid production, or cause other unwanted effects.
Mothers taking pharmacologic doses of corticosteroids should be advised
not to nurse. </P>

<P>Average and large doses of hydrocortisone or cortisone can cause elevation
of blood pressure, salt and water retention, and increased excretion of
potassium. These effects are less likely to occur with the synthetic derivatives
except when used in large doses. Dietary salt restriction and potassium
supplementation may be necessary. All corticosteroids increase calcium
excretion. </P>

<P>Administration of live virus vaccines, including smallpox, is contraindicated
in individuals receiving immunosuppressive doses of corticosteroids. If
inactivated viral or bacterial vaccines are administered to individuals
receiving immunosuppressive doses of corticosteroids, the expected serum
antibody response may not be obtained. However, immunization procedures
may be undertaken in patients who are receiving corticosteroids as replacement
therapy, e.g., for Addison's disease. </P>

<P>Patients who are on drugs which suppress the immune system are more
susceptible to infections than healthy individuals. Chickenpox and measles,
for example, can have a more serious or even fatal course in non-immune
children or adults on corticosteroids. In such children or adults who have
not had these diseases, particular care should be taken to avoid exposure.
The risk of developing a disseminated infection varies among individuals
and can be related to the dose, route and duration of corticosteroid administration
as well as to the underlying disease. If exposed to chickenpox, prophylaxis
with varicella zoster immune globulin (VZIG) may be indicated. If chickenpox
develops, treatment with antiviral agents may be considered. If exposed
to measles, prophylaxis with immune globulin (IG) may be indicated. (See
the respective package inserts for VZIG and IG for complete prescribing
information.) </P>

<P>Similarly, corticosteroids should be used with great care in patients
with known or suspected Strongyloides (threadworm) infestation. In such
patients, corticosteroid-induced immunosuppression may lead to Strongyloides
hyperinfection and dissemination with widespread larval migration, often
accompanied by severe enterocolitis and potentially fatal gram-negative
septicemia. </P>

<P>The use of Cortisone Acetate tablets in active tuberculosis should be
restricted to those cases of fulminating or disseminated tuberculosis in
which the corticosteroid is used for the management of the disease in conjunction
with an appropriate antituberculous regimen. </P>

<P>If corticosteroids are indicated in patients with latent tuberculosis
or tuberculin reactivity, close observation is necessary as reactivation
of the disease may occur. During prolonged corticosteroid therapy, these
patients should receive chemoprophylaxis. </P>

<P>Literature reports suggest an apparent association between use of corticosteroids
and left ventricular free wall rupture after a recent myocardial infarction;
therefore, therapy with corticosteroids should be used with great caution
in these patients. </P>

<P><A NAME="PRECAUTIONS"></A><B>PRECAUTIONS </B></P>

<P>Following prolonged therapy, withdrawal of corticosteroids may result
in symptoms of the corticosteroid withdrawal syndrome including fever,
myalgia, arthralgia, and malaise. This may occur in patients even without
evidence of adrenal insufficiency. </P>

<P>There is an enhanced effect of corticosteroids in patients with hypothyroidism
and in those with cirrhosis. </P>

<P>Corticosteroids should be used cautiously in patients with ocular herpes
simplex because of possible corneal perforation. </P>

<P>The lowest possible dose of corticosteroid should be used to control
the condition under treatment, and when reduction in dosage is possible,
the reduction should be gradual. </P>

<P>Psychic derangements may appear when corticosteroids are used, ranging
from euphoria, insomnia, mood swings, personality changes, and severe depression,
to frank psychotic manifestations. Also, existing emotional instability
or psychotic tendencies may be aggravated by corticosteroids. </P>

<P>Aspirin should be used cautiously in conjunction with corticosteroids
in hypoprothrombinemia. </P>

<P>Steroids should be used with caution in nonspecific ulcerative colitis,
if there is a probability of impending perforation, abscess, or other pyogenic
infection, diverticulitis, fresh intestinal anastomoses, active or latent
peptic ulcer, renal insufficiency, hypertension, osteoporosis, and myasthenia
gravis. Signs of peritoneal irritation following gastrointestinal perforation
in patients receiving large doses of corticosteroids may be minimal or
absent. Fat embolism has been reported as a possible complication of hypercortisonism.
</P>

<P>When large doses are given, some authorities advise that corticosteroids
be taken with meals and antacids taken between meals to help to prevent
peptic ulcer. </P>

<P>Growth and development of infants and children on prolonged corticosteroid
therapy should be carefully observed. </P>

<P>Steroids may increase or decrease motility and number of spermatozoa
in some patients. </P>

<P>Phenytoin, phenobarbital, ephedrine, and rifampin may enhance the metabolic
clearance of corticosteroids, resulting in decreased blood levels and lessened
physiologic activity, thus requiring adjustment in corticosteroid dosage.
</P>

<P>The prothrombin time should be checked frequently in patients who are
receiving corticosteroids and coumarin anticoagulants at the same time
because of reports that corticosteroids have altered the response to these
anticoagulants. Studies have shown that the usual effect produced by adding
corticosteroids is inhibition of response to coumarins, although there
have been some conflicting reports of potentiation not substantiated by
studies. </P>

<P>When corticosteroids are administered concomitantly with potassium-depleting
diuretics, patients should be observed closely for development of hypokalemia.
</P>

<P>Information For Patients Susceptible patients who are on immunosuppressant
doses of corticosteroids should be warned to avoid exposure to chickenpox
or measles. Patients should also be advised that if they are exposed, medical
advice should be sought without delay. </P>

<P><A NAME="DRUG INTERACTIONS"></A><B>DRUG INTERACTIONS </B></P>

<P>See <A HREF="#PRECAUTIONS">PRECAUTIONS</A> </P>

<P><A NAME="ADVERSE REACTIONS"></A><B>ADVERSE REACTIONS </B></P>

<P>Fluid And Electrolyte Disturbances </P>

<P>Sodium retention </P>

<P>Fluid retention </P>

<P>Congestive heart failure in susceptible patients </P>

<P>Potassium loss </P>

<P>Hypokalemic alkalosis </P>

<P>Hypertension </P>

<P>Musculoskeletal </P>

<P>Muscle weakness </P>

<P>Steroid myopathy </P>

<P>Loss of muscle mass </P>

<P>Osteoporosis </P>

<P>Vertebral compression fractures </P>

<P>Aseptic necrosis of femoral and humeral heads </P>

<P>Pathologic fracture of long bones </P>

<P>Tendon rupture </P>

<P>Gastrointestinal </P>

<P>Peptic ulcer with possible perforation and hemorrhage </P>

<P>Perforation of the small and large bowel, particularly in patients with
inflammatory bowel disease </P>

<P>Pancreatitis </P>

<P>Abdominal distention </P>

<P>Ulcerative esophagitis </P>

<P>Dermatologic </P>

<P>Impaired wound healing </P>

<P>Thin fragile skin </P>

<P>Petechiae and ecchymoses </P>

<P>Erythema </P>

<P>Increased sweating </P>

<P>May suppress reactions to skin tests </P>

<P>Other cutaneous reactions, such as allergic dermatitis, urticaria, angioneurotic
edema </P>

<P>Neurologic </P>

<P>Convulsions </P>

<P>Increased intracranial pressure with papilledema (pseudotumor cerebri),
usually after treatment </P>

<P>Vertigo </P>

<P>Headache </P>

<P>Psychic disturbances </P>

<P>Endocrine </P>

<P>Menstrual irregularities </P>

<P>Development of cushingoid state </P>

<P>Suppression of growth in children </P>

<P>Secondary adrenocortical and pituitary unresponsiveness, particularly
in times of stress, as in trauma, surgery, or illness </P>

<P>Decreased carbohydrate tolerance </P>

<P>Manifestations of latent diabetes mellitus </P>

<P>Increased requirements for insulin or oral hypoglycemic agents in diabetics
</P>

<P>Hirsutism </P>

<P>Ophthalmic </P>

<P>Posterior subcapsular cataracts </P>

<P>Increased intraocular pressure </P>

<P>Glaucoma </P>

<P>Exophthalmos </P>

<P>Metabolic </P>

<P>Negative nitrogen balance due to protein catabolism </P>

<P>Cardiovascular </P>

<P>Myocardial rupture following recent myocardial infarction (see WARNINGS).
</P>

<P>Other </P>

<P>Hypersensitivity </P>

<P>Thromboembolism </P>

<P>Weight gain </P>

<P>Increased appetite </P>

<P>Nausea </P>

<P>Malaise </P>

<P><A NAME="OVERDOSAGE"></A><B>OVERDOSAGE </B></P>

<P>Reports of acute toxicity and/or death following overdosage of glucocorticoids
are rare. In the event of overdosage, no specific antidote is available;
treatment is supportive and symptomatic. </P>

<P>The intraperitoneal LD50 of cortisone acetate in female mice was 1405
mg/kg. </P>

<P><A NAME="DOSAGE AND ADMINISTRATION"></A><B>DOSAGE AND ADMINISTRATION
</B></P>

<P>For Oral Administration </P>

<P>DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS
OF THE DISEASE AND THE RESPONSE OF THE PATIENT. </P>

<P>The initial dosage varies from 25 to 300 mg a day depending on the disease
being treated. In less severe diseases doses lower than 25 mg may suffice,
while in severe diseases doses higher than 300 mg may be required. The
initial dosage should be maintained or adjusted until the patient's response
is satisfactory. If satisfactory clinical response does not occur after
a reasonable period of time, discontinue Cortisone Acetate tablets and
transfer the patient to other therapy. </P>

<P>After a favorable initial response, the proper maintenance dosage should
be determined by decreasing the initial dosage in small amounts to the
lowest dosage that maintains an adequate clinical response. </P>

<P>Patients should be observed closely for signs that might require dosage
adjustment, including changes in clinical status resulting from remissions
or exacerbations of the disease, individual drug responsiveness, and the
effect of stress (e.g., surgery, infection, trauma). During stress it may
be necessary to increase dosage temporarily. </P>

<P>If the drug is to be stopped after more than a few days of treatment,
it usually should be withdrawn gradually. </P>

<P>
<HR width="100%"></P>

<H2 ALIGN=CENTER><A HREF="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</A><A HREF="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <A HREF="http://www.rxlist.com/top200.htm"><IMG SRC="redball.gif" BORDER=0 HEIGHT=17 WIDTH=17></A></A><A HREF="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</A> &nbsp;&nbsp;<IMG SRC="redball.gif" HEIGHT=17 WIDTH=17><A HREF="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</A></H2>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B10-70</DOCNO>
<DOCOLDNO>IA018-000200-B034-51</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/acetcod.htm 206.86.175.201 19970106224113 text/html 16471
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:34:58 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 16288
Last-modified: Tue, 12 Nov 1996 23:57:32 GMT
</DOCHDR>
<html>
<head>
   <title>Acetaminophen with codeine - RxList Generic Information</title>
<meta name="keywords" content="APAP W/Codeine, Acetaminophen W/Codeine, Atasol, Capital W/Codeine, Codaphen, Codisal, Codopar, Cosutone, Dolorol, Empracet W/Codeine Phosphate, Margesic, Maxadol, Medocodene, Myapap And Codeine, Panadeine, Panadiene, Panado-Co, Paracodol, Paradine, Parake, Phenaphen W/Codeine, Proval #3, Pyregesic-C, Sunetheton, Tricoton, Ty-Deine, Ty-Pap W/Codeine, Ty-Tab W/Codeine, Tylagesic 3, Tylenol With Codeine
">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 ></a></p></center>

<h1 align=center>Acetaminophen with codeine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate
analgesic and antipyretic which occurs as a white, odorless, crystalline
powder, possessing a slightly bitter taste. </p>

<p>C8H9NO2 : M.W. 151.16. </p>

<p>Codeine is an alkaloid, obtained from opium or prepared from morphine
by methylation. Codeine phosphate occurs as fine, white, needle-shaped
crystals, or white, crystalline powder. It is affected by light. Its chemical
name is: 7 8- didehydro-4,5alpha-epoxy-3-methoxy-17- methylmorphinan-6alpha-ol
phosphate (1:1) (salt) hemihydrate. </p>

<p>C18H21NO3.H3PO4.1/2 H2O </p>

<p>M.W. 406.37. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Acetaminophen with codeine combine the analgesic effects of a centrally
acting analgesic, codeine, with a peripherally acting analgesic, acetaminophen.
Both ingredients are well absorbed orally. The plasma elimination half-life
ranges from 1 to 4 hours for acetaminophen, and from 2.5 to 3 hours for
codeine. </p>

<p>Codeine retains at least one-half of its analgesic activity when administered
orally. A reduced first-pass metabolism of codeine by the liver accounts
for the greater oral efficacy of codeine when compared to most other morphine-like
narcotics. Following absorption, codeine is metabolized by the liver and
metabolic products are excreted in the urine. Approximately 10 percent
of the administered codeine is demethylated to morphine, which may account
for its analgesic activity. </p>

<p>Acetaminophen is distributed throughout most fluids of the body, and
is metabolized primarily in the liver. Little unchanged drug is excreted
in the urine, but most metabolic products appear in the urine within 24
hours. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Acetaminophen with codeine tablets (acetaminophen and codeine phosphate
tablets) are indicated for the relief of mild to moderately severe pain.
</p>

<p>Acetaminophen with codeine elixir (acetaminophen and codeine phosphate
oral solution USP) is indicated for the relief of mild to moderate pain.
</p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Acetaminophen with codeine tablets or elixir (acetaminophen and codeine
phosphate tablets and oral solution USP) should not be administered to
patients who have previously exhibited hypersensitivity to any component.
</p>

<pre><a name="WARNINGS"></a><b><font SIZE=+2>WARNINGS</font> 
</b> </pre>

<p>Acetaminophen with codeine tablets (acetaminophen and codeine phosphate
tablets) contain sodium metabisulfite, a sulfite that may cause allergic-type
reactions including anaphylactic symptoms and life-threatening or less
severe asthmatic episodes in certain susceptible people. The overall prevalence
of sulfite sensitivity in the general population is unknown and probably
low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic
people. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL Head Injury And Increased Intracranial Pressure: The respiratory
depressant effects of narcotics and their capacity to elevate cerebrospinal
fluid pressure may be markedly exaggerated in the presence of head injury,
other intracranial lesions or a pre-existing increase in intracranial pressure.
Furthermore, narcotics produce adverse reactions which may obscure the
clinical course of patients with head injuries. </p>

<p>Acute Abdominal Conditions: The administration of this product or other
narcotics may obscure the diagnosis or clinical course of patients with
acute abdominal conditions. </p>

<p>Special Risk Patients: This drug should be given with caution to certain
patients such as the elderly or debilitated, and those with severe impairment
of hepatic or renal function, hypothyroidism, Addison's disease, and prostatic
hypertrophy or urethral stricture. </p>

<p>INFORMATION FOR PATIENTS </p>

<p>Codeine may impair the mental and/or physical abilities required for
the performance of potentially hazardous tasks such as driving a car or
operating machinery. The patient using this drug should be cautioned accordingly.
</p>

<p>The patient should understand the single-dose and 24 hour dose limits,
and the time interval between doses. </p>

<p>DRUG INTERACTIONS </p>

<p>Patients receiving other narcotic analgesics, antipsychotics, antianxiety
agents, or other CNS depressants (including alcohol) concomitantly with
this drug may exhibit an additive CNS depression. When such combined therapy
is contemplated, the dose of one or both agents should be reduced.</p>

<p>The concurrent use of anticholinergics with codeine may produce paralytic
ileus. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY </p>

<p>No long-term studies in animals have been performed with acetaminophen
or codeine to determine carcinogenic potential or effects on fertility.
</p>

<p>Acetaminophen and codeine have been found to have no mutagenic potential
using the Ames Salmonella-Microsomal Activation test, the Basc test on
Drosophila germ cells, and the Micronucleus test on mouse bone marrow.
</p>

<p>PREGNANCY </p>

<p>Teratogenic Effects: Pregnancy Category C. </p>

<p>Codeine: A study in rats and rabbits reported no teratogenic effect
of codeine administered during the period of organogenesis in doses ranging
from 5 to 120 mg/kg. In the rat, doses at the 120 mg/kg level, in the toxic
range for the adult animal, were associated with an increase in embryo
resorption at the time of implantation. In another study a single 100 mg/kg
dose of codeine administered to pregnant mice reportedly resulted in delayed
ossification in the offspring. </p>

<p>There are no studies in humans, and the significance of these findings
to humans, if any, is not known. </p>

<p>Acetaminophen with codeine should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus. </p>

<p>Nonteratogenic Effects: </p>

<p>Dependence has been reported in newborns whose mothers took opiates
regularly during pregnancy. Withdrawal signs include irritability, excessive
crying, tremors, hyperreflexia, fever, vomiting, and diarrhea. These signs
usually appear during the first few days of life. </p>

<p>LABOR AND DELIVERY </p>

<p>Narcotic analgesics cross the placental barrier. The closer to delivery
and the larger the dose used, the greater the possibility of respiratory
depression in the newborn. Narcotic analgesics should be avoided during
labor if delivery of a premature infant is anticipated. If the mother has
received narcotic analgesics during labor, newborn infants should be observed
closely for signs of respiratory depression. Resuscitation may be required
(see OVERDOSAGE). The effect of codeine, if any, on the later growth, development,
and functional maturation of the child is unknown. </p>

<p>NURSING MOTHERS </p>

<p>Some studies, but not others, have reported detectable amounts of codeine
in breast milk. The levels are probably not clinically significant after
usual therapeutic dosage. The possibility of clinically important amounts
being excreted in breast milk in individuals abusing codeine should be
considered. </p>

<p>PEDIATRIC USE </p>

<p>Safe dosage of Acetaminophen with codeine elixir (acetaminophen and
codeine phosphate oral solution USP) has not been established in children
below the age of three years. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Patients receiving other narcotic analgesics, antipsychotics, antianxiety
agents, or other CNS depressants (including alcohol) concomitantly with
this drug may exhibit an additive CNS depression. When such combined therapy
is contemplated, the dose of one or both agents should be reduced. </p>

<p>The concurrent use of anticholinergics with codeine may produce paralytic
ileus. </p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The most frequently observed adverse reactions include lightheadedness,
dizziness, sedation, shortness of breath, nausea and vomiting. These effects
seem to be more prominent in ambulatory than in non-ambulatory patients,
and some of these adverse reactions may be alleviated if the patient lies
down. Other adverse reactions include allergic reactions, euphoria, dysphoria,
constipation, abdominal pain and pruritus. </p>

<p>At higher doses, codeine has most of the disadvantages of morphine including
respiratory depression. </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>Acetaminophen with codeine tablets (acetaminophen and codeine phosphate
tablets) are a Schedule III controlled substance. </p>

<p>Acetaminophen with codeine elixir (acetaminophen and codeine phosphate
oral solution USP) is a Schedule V controlled substance. </p>

<p>Codeine can produce drug dependence of the morphine type and, therefore,
has the potential for being abused. Psychic dependence, physical dependence
and tolerance may develop upon repeated administration of this drug, and
it should be prescribed and administered with the same degree of caution
appropriate to the use of other oral narcotic-containing medications. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>ACETAMINOPHEN </p>

<p>Signs And Symptoms: In acute acetaminophen overdosage, dose-dependent,
potentially fatal hepatic necrosis is the most serious adverse effect.
Renal tubular necrosis, hypoglycemic coma and thrombocytopenia may also
occur. </p>

<p>In adults, hepatic toxicity has rarely been reported with acute overdoses
of less than 10 grams and fatalities with less than 15 grams. Importantly,
young children seem to be more resistant than adults to the hepatotoxic
effect of an acetaminophen overdose. Despite this, the measures outlined
below should be initiated in any adult or child suspected of having ingested
an acetaminophen overdose. </p>

<p>Early symptoms following a potentially hepatotoxic overdose may include:
nausea vomiting, diaphoresis and general malaise. Clinical and laboratory
evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.
</p>

<p>Treatment: The stomach should be emptied promptly by lavage or by induction
of emesis with syrup of ipecac. Patients' estimates of the quantity of
a drug ingested are notoriously unreliable. Therefore, if an acetaminophen
overdose is suspected, a serum acetaminophen assay should be obtained as
early as possible, but no sooner than four hours following ingestion. Liver
function studies should be obtained initially and repeated at 24-hour intervals.
</p>

<p>The antidote, N-acetylcysteine, should be administered as early as possible,
preferably within 16 hours of the overdose ingestion for optimal results,
but in any case, within 24 hours. Following recovery, there are no residual,
structural or functional hepatic abnormalities. </p>

<p>CODEINE </p>

<p>Signs And Symptoms: Serious overdose with codeine is characterized by
respiratory depression (a decrease in respiratory rate and/or tidal volume,
Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to
stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes
bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse,
cardiac arrest and death may occur. </p>

<p>Treatment: Primary attention should be given to the reestablishment
of adequate respiratory exchange through provision of a patent airway and
the institution of assisted or controlled ventilation. The narcotic antagonist
naloxone is a specific antidote against respiratory depression which may
result from overdosage or unusual sensitivity to narcotics, including codeine.
Therefore, an appropriate dose of naloxone hydrochloride (see package insert)
should be administered, preferably by the intravenous route, and simultaneously
with efforts at respiratory resuscitation. Since the duration of action
of codeine may exceed that of the antagonist, the patient should be kept
under continued surveillance and repeated doses of the antagonist should
be administered as needed to maintain adequate respiration. </p>

<p>An antagonist should not be administered in the absence of clinically
significant respiratory or cardiovascular depression. Oxygen, intravenous
fluids, vasopressors and other supportive measures should be employed as
indicated. </p>

<p>Gastric emptying may be useful in removing unabsorbed drug. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Dosage should be adjusted according to severity of pain and response
of the patient. </p>

<p>It should be kept in mind, however, that tolerance to codeine can develop
with continued use and that the incidence of untoward effects is dose related.
Adult doses of codeine higher than 60 mg fail to give commensurate relief
of pain but merely prolong analgesia and are associated with an appreciably
increased incidence of undesirable side effects. Equivalently high doses
in children would have similar effects. </p>

<pre>The usual adult dosage for tablets is:  
 
                       Single Doses         Maximum                             
                         (Range)          24 Hour Dose                          
                       ------------       ------------                          
Codeine Phosphate       15 mg-60mg            360mg                             
Acetaminophen          300 mg-1000mg         4000mg                             
Doses may be repeated up to every 4 hours.  
 </pre>

<p>The prescriber must determine the number of tablets per dose, and the
maximum number of tablets per 24 hours, based upon the above dosage guidance.
This information should be conveyed in the prescription. </p>

<p>For children, the dose of codeine phosphate is 0.5 mg/kg. </p>

<p>Acetaminophen with codeine elixir (acetaminophen and codeine phosphate
oral solution USP) contains 120 mg of acetaminophen and 12 mg of codeine
phosphate/5 mL and is given orally. </p>

<pre>The usual doses are: 
 
Children:     (7 To 12 Years): 10 mL (2 teaspoonfuls) 3 or 4 times daily.       
              (3 To 6 Years): 5 mL (1 teaspoonful) 3 or 4 times daily.          
              (Under 3 Years): safe dosage has not been established.            
Adults:       15 mL (1 tablespoonful) every 4 hours as needed. </pre>

<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200 &nbsp;<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 ></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 ><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page&nbsp;</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-71</DOCNO>
<DOCOLDNO>IA018-000200-B034-69</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/furos.htm 206.86.175.201 19970106224127 text/html 24334
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:35:13 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 24151
Last-modified: Thu, 11 Jul 1996 06:07:44 GMT
</DOCHDR>
<html>
<head>
   <title>Furosemide - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Furosemide</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>WARNING Furosemide is a potent diuretic which, if given in excessive
amounts can lead to a profound diuresis with water and electrolyte depletion.
Therefore, careful medical supervision is required, and dose and dose schedule
must be adjusted to the individual patient's needs. (See &quot;DOSAGE AND
ADMINISTRATION.&quot;) </p>

<p>Furosemide is a diuretic which is an anthranilic acid derivative. Furosemide
tablets for oral administration contain furosemide as the active ingredient
and the following inactive ingredients: lactose USP, magnesium stearate
NF, starch NF and talc USP. Chemically, it is 4-chloro-N-furfuryl-5-sulfamoylanthranilic
acid. Furosemide is available as white tablets for oral administration
in dosage strengths of 20, 40 and 80 mg. Furosemide is a white to off-white
odorless crystalline powder. It is practically insoluble in water, sparingly
soluble in alcohol, freely soluble in dilute alkali solutions and insoluble
in dilute acids. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Investigations into the mode of action of Furosemide have utilized micropuncture
studies in rats, stop flow experiments in dogs, and various clearance studies
in both humans and experimental animals. It has been demonstrated that
Furosemide inhibits primarily the absorption of sodium and chloride not
only in the proximal and distal tubules but also in the loop of Henle.
The high degree of efficacy is largely due to this unique site of action.
The action on the distal tubule is independent of any inhibitory effect
on carbonic anhydrase and aldosterone. </p>

<p>Recent evidence suggests that furosemide glucuronide is the only or
at least the major bio-transformation product of furosemide in man. Furosemide
is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations
ranging from 1 to 400 mcgm/mL are 91 to 99% bound in healthy individuals.
The unbound fraction averages 2.3 to 4.1% at therapeutic concentrations.
</p>

<p>The onset of diuresis following oral administration is within 1 hour.
The peak effect occurs within the first or second hour. The duration of
diuretic effect is 6 to 8 hours. </p>

<p>In fasted normal men, the mean bioavailability of furosemide from Furosemide
Tablets and Furosemide Oral Solution is 64% and 60%, respectively, of that
from an intravenous injection of the drug. Although furosemide is more
rapidly absorbed from the oral solution (50 minutes) than from the tablet
(87 minutes), peak plasma levels and area under the plasma concentration-time
curves do not differ significantly. Peak plasma concentrations increase
with increasing dose but times-to-peak do not differ among doses. The terminal
half-life of furosemide is approximately 2 hours. </p>

<p>Significantly more furosemide is excreted in urine following the IV
injection than after the tablet or oral solution. There are no significant
differences between the two oral formulations in the amount of unchanged
drug excreted in urine. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Edema Furosemide is indicated in adults, infants, and children for the
treatment of edema associated with congestive heart failure, cirrhosis
of the liver, and renal disease, including the nephrotic syndrome. Furosemide
is particularly useful when an agent with greater diuretic potential is
desired. </p>

<p>Hypertension </p>

<p>Oral Furosemide may be used in adults for the treatment of hypertension
alone or in combination with other antihypertensive agents. Hypertensive
patients who cannot be adequately controlled with thiazides will probably
also not be adequately controlled with Furosemide alone. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Furosemide is contraindicated in patients with anuria and in patients
with a history of hypersensitivity to furosemide. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>WARNING </p>

<p>Furosemide is a potent diuretic which, if given in excessive amounts
can lead to a profound diuresis with water and electrolyte depletion. Therefore,
careful medical supervision is required, and dose and dose schedule must
be adjusted to the individual patient's needs. (See &quot;DOSAGE AND ADMINISTRATION.&quot;)
</p>

<p>In patients with hepatic cirrhosis and ascites, Furosemide therapy is
best initiated in the hospital. In hepatic coma and in states of electrolyte
depletion, therapy should not be instituted until the basic condition is
improved. Sudden alterations of fluid and electrolyte balance in patients
with cirrhosis may precipitate hepatic coma; therefore, strict observation
is necessary during the period of diuresis. Supplemental potassium chloride
and, if required, an aldosterone antagonist are helpful in preventing hypokalemia
and metabolic alkalosis. </p>

<p>If increasing azotemia and oliguria occur during treatment of severe
progressive renal disease, Furosemide should be discontinued. </p>

<p>Cases of tinnitus and reversible or irreversible hearing impairment
have been reported. Usually, reports indicate that Furosemide ototoxicity
is associated with rapid injection, severe renal impairment, doses exceeding
several times the usual recommended dose, or concomitant therapy with aminoglycoside
antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician
elects to use high dose parenteral therapy, controlled intravenous infusion
is advisable (for adults, an infusion rate not exceeding 4 mg Furosemide
per minute has been used). </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL </p>

<p>Excessive diuresis may cause dehydration and blood volume reduction
with circulatory collapse and possibly vascular thrombosis and embolism,
particularly in elderly patients. As with any effective diuretic, electrolyte
depletion may occur during Furosemide therapy, especially in patients receiving
higher doses and a restricted salt intake. Hypokalemia may develop with
Furosemide, especially with brisk diuresis, inadequate oral electrolyte
intake, when cirrhosis is present, or during concomitant use of corticosteroids
or ACTH. Digitalis therapy may exaggerate metabolic effects of hypokalemia,
especially myocardial effects. </p>

<p>All patients receiving Furosemide therapy should be observed for these
signs or symptoms of fluid or electrolyte imbalance (hyponatremia, hypochloremic
alkalosis, hypokalemia, hypomagnesemia or hypocalcemia); dryness of mouth,
thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps,
muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal
disturbances such as nausea and vomiting. </p>

<p>Increases in blood glucose and alterations in glucose tolerance tests
(with abnormalities of the fasting and 2-hour postprandial sugar) have
been observed, and rarely, precipitation of diabetes mellitus has been
reported. </p>

<p>Asymptomatic hyperuricemia can occur and gout may rarely be precipitated.
</p>

<p>Patients allergic to sulfonamides may also be allergic to Furosemide.
The possibility exists of exacerbation or activation of systemic lupus
erythematosus. </p>

<p>As with many other drugs, patients should be observed regularly for
the possible occurrence of blood dyscrasias, liver or kidney damage, or
other idiosyncratic reactions. </p>

<p>INFORMATION FOR PATIENTS </p>

<p>Patients receiving Furosemide should be advised that they may experience
symptoms from excessive fluid and/or electrolyte losses. The postural hypotension
that sometimes occurs can usually be managed by getting up slowly. Potassium
supplements and/or dietary measures may be needed to control or avoid hypokalemia.
</p>

<p>Patients with diabetes mellitus should be told that furosemide may increase
blood glucose levels and thereby affect urine glucose tests. The skin of
some patients may be more sensitive to the effects of sunlight while taking
furosemide. </p>

<p>Hypertensive patients should avoid medications that may increase blood
pressure including over-the-counter products for appetite suppression and
cold symptoms. </p>

<p>LABORATORY TESTS </p>

<p>Serum electrolytes (particularly potassium), CO2, creatinine and BUN
should be determined frequently during the first few months of Furosemide
therapy and periodically thereafter. Serum and urine electrolyte determinations
are particularly important when the patient is vomiting profusely or receiving
parenteral fluids. Abnormalities should be corrected or the drug temporarily
withdrawn. Other medications may also influence serum electrolytes. Reversible
elevations of BUN may occur and are associated with dehydration, which
should be avoided, particularly in patients with renal insufficiency. </p>

<p>Urine and blood glucose should be checked periodically in diabetics
receiving Furosemide, even in those suspected of latent diabetes. </p>

<p>Furosemide may lower serum levels of calcium (rarely cases of tetany
have been reported) and magnesium. Accordingly, serum levels should be
determined periodically. </p>

<p>DRUG INTERACTIONS </p>

<p>Furosemide may increase the ototoxic potential of aminoglycoside antibiotics,
especially in the presence of impaired renal function. Except in life-
threatening situations, avoid this combination. </p>

<p>Furosemide should not be used concomitantly with ethacrynic acid because
of the possibility of ototoxicity. Patients receiving high doses of salicylates
concomitantly with Furosemide, as in rheumatic disease, may experience
salicylate toxicity at lower doses because of competitive renal excretory
sites. </p>

<p>Furosemide has a tendency to antagonize the skeletal muscle relaxing
effect of tubocurarine and may potentiate the action of succinylcholine.
</p>

<p>Lithium generally should not be given with diuretics because they reduce
lithium's renal clearance and add a high risk of lithium toxicity. </p>

<p>Furosemide may add to or potentiate the therapeutic effect of other
antihypertensive drugs. Potentiation occurs with ganglionic or peripheral
adrenergic blocking drugs. </p>

<p>Furosemide may decrease arterial responsiveness to norepinephrine. However,
norepinephrine may still be used effectively. </p>

<p>Simultaneous administration of sucralfate and Furosemide tablets may
reduce the nutriuretic and antihypertensive effects of Furosemide. Patients
receiving both drugs should be observed closely to determine if the desired
diuretic and/or antihypertensive affect of Furosemide is achieved. The
intake of Furosemide and sucralfate should be separated by at least two
hours. </p>

<p>One study in six subjects demonstrated that the combination of furosemide
and acetylsalicylic acid temporarily reduced creatinine clearance in patients
with chronic renal insufficiency. There are case reports of patients who
developed increased BUN, serum creatinine and serum potassium levels, and
weight gain when furosemide was used in conjunction with NSAIDs. </p>

<p>Literature reports indicate that coadministration of indomethacin may
reduce the natriuretic and antihypertensive effects of Furosemide in some
patients by inhibiting prostaglandin synthesis. Indomethacin may also affect
plasma renin levels, aldosterone excretion, and renin profile evaluation.
Patients receiving both indomethacin and Furosemide should be observed
closely to determine if the desired diuretic and/or antihypertensive effect
of Furosemide is achieved. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY </p>

<p>No carcinogenic or mutagenic studies have been conducted with Furosemide
Furosemide produced no impairment of fertility in male or female rats,
at 100 mg/kg/day (the maximum effective diuretic dose in the rat and 8
times the maximal human dose of 600 mg/day). </p>

<p>PREGNANCY </p>

<p>PREGNANCY CATEGORY C--Furosemide has been shown to cause unexplained
maternal deaths and abortions in rabbits at 2, 4, and 8 times the maximal
recommended human dose. There are no adequate and well-controlled studies
in pregnant women. Furosemide should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus. </p>

<p>The effects of furosemide on embryonic and fetal development and on
pregnant dams were studied in mice, rats and rabbits. </p>

<p>Furosemide caused unexplained maternal deaths and abortions in the rabbit
at the lowest dose of 25 mg/kg (2 times the maximal recommended human dose
of 600 mg/day). In another study, a dose of 50 mg/kg (4 times the maximal
recommended human dose of 600 mg/day) also caused maternal deaths and abortions
when administered to rabbits between Days 12 and 17 of gestation. In a
third study, none of the pregnant rabbits survived a dose of 100 mg/kg.
Data from the above studies indicate fetal lethality that can precede maternal
deaths. </p>

<p>The results of the mouse study and one of the three rabbit studies also
showed an increased incidence and severity of hydronephrosis (distention
of the renal pelvis and, in some cases, of the ureters) in fetuses derived
from treated dams as compared to the incidence in fetuses from the control
group. </p>

<p>NURSING MOTHERS </p>

<p>Because it appears in breast milk, caution should be exercised when
Furosemide is administered to a nursing mother. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Furosemide may increase the ototoxic potential of aminoglycoside antibiotics,
especially in the presence of impaired renal function. Except in life-
threatening situations, avoid this combination. </p>

<p>Furosemide should not be used concomitantly with ethacrynic acid because
of the possibility of ototoxicity. Patients receiving high doses of salicylates
concomitantly with Furosemide, as in rheumatic disease, may experience
salicylate toxicity at lower doses because of competitive renal excretory
sites. </p>

<p>Furosemide has a tendency to antagonize the skeletal muscle relaxing
effect of tubocurarine and may potentiate the action of succinylcholine.
</p>

<p>Lithium generally should not be given with diuretics because they reduce
lithium's renal clearance and add a high risk of lithium toxicity. </p>

<p>Furosemide may add to or potentiate the therapeutic effect of other
antihypertensive drugs. Potentiation occurs with ganglionic or peripheral
adrenergic blocking drugs. </p>

<p>Furosemide may decrease arterial responsiveness to norepinephrine. However,
norepinephrine may still be used effectively. </p>

<p>Simultaneous administration of sucralfate and Furosemide tablets may
reduce the nutriuretic and antihypertensive effects of Furosemide. Patients
receiving both drugs should be observed closely to determine if the desired
diuretic and/or antihypertensive affect of Furosemide is achieved. The
intake of Furosemide and sucralfate should be separated by at least two
hours. </p>

<p>One study in six subjects demonstrated that the combination of furosemide
and acetylsalicylic acid temporarily reduced creatinine clearance in patients
with chronic renal insufficiency. There are case reports of patients who
developed increased BUN, serum creatinine and serum potassium levels, and
weight gain when furosemide was used in conjunction with NSAIDs. </p>

<p>Literature reports indicate that coadministration of indomethacin may
reduce the natriuretic and antihypertensive effects of Furosemide in some
patients by inhibiting prostaglandin synthesis. Indomethacin may also affect
plasma renin levels, aldosterone excretion, and renin profile evaluation.
Patients receiving both indomethacin and Furosemide should be observed
closely to determine if the desired diuretic and/or antihypertensive effect
of Furosemide is achieved. (See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Adverse reactions are categorized below by organ system and listed by
decreasing severity. </p>

<pre>             GASTROINTESTINAL SYSTEM REACTIONS                                  
1. pancreatitis               5. cramping                                       
2. jaundice (intrahepatic     6. diarrhea                                       
   cholestatic jaundice)      7. constipation                                   
3. anorexia                   8. nausea                                         
4. oral and gastric           9. vomiting                                       
   irritation                                                                   
             SYSTEMIC HYPERSENSITIVITY REACTIONS                                
1. systemic vasculitis                                                          
2. interstitial nephritis                                                       
3. necrotizing angiitis                                                         
             CENTRAL NERVOUS SYSTEM REACTIONS                                   
1. tinnitus and               4. dizziness                                      
   hearing loss               5. headache                                       
2. paresthesias               6. blurred vision                                 
3. vertigo                    7. xanthopsia                                     
             HEMATOLOGIC REACTIONS                                              
1. aplastic anemia (rare)     4. hemolytic anemia                               
2. thrombocytopenia           5. leukopenia                                     
3. agranulocytosis (rare)     6. anemia                                         
             DERMATOLOGIC REACTIONS                                             
1. exfoliative dermatitis     5. urticaria                                      
2. erythema multiforme        6. rash                                           
3. purpura                    7. pruritus                                       
4. photosensitivity                                                             
             CARDIOVASCULAR REACTION                                            
Orthostatic hypotension may occur and be aggravated by                          
alcohol, barbiturates or narcotics.                                             
                 OTHER REACTIONS                                                
1. hyperglycemia              6. restlessness                                   
2. glycosuria                 7. urinary bladder spasm                          
3. hyperuricemia              8. thrombophlebitis                               
4. muscle spasm               9. fever                                          
5. weakness                                                                     </pre>

<p>Whenever adverse reactions are moderate or severe, Furosemide dosage
should be reduced or therapy withdrawn. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>The principal signs and symptoms of overdose with Furosemide are dehydration,
blood volume reduction, hypotension, electrolyte imbalance, hypokalemia
and hypochloremic alkalosis, and are extensions of its diuretic action.
</p>

<p>The acute toxicity of Furosemide has been determined in mice, rats and
dogs. In all three, the oral LD50 exceeded 1000 mg/kg body weight, while
the intravenous LD50 ranged from 300 to 680 mg/kg. The acute intragastric
toxicity in neonatal rats is 7 to 10 times that of adult rats. </p>

<p>The concentration of Furosemide in biological fluids associated with
toxicity or death is not known. </p>

<p>Treatment of overdosage is supportive and consists of replacement of
excessive fluid and electrolyte losses. Serum electrolytes, carbon dioxide
level and blood pressure should be determined frequently. Adequate drainage
must be assured in patients with urinary bladder outlet obstruction (such
as prostatic hypertrophy). </p>

<p>Hemodialysis does not accelerate furosemide elimination. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Edema </p>

<p>Therapy should be individualized according to patient response to gain
maximal therapeutic response and to determine the minimal dose needed to
maintain that response. </p>

<p>ADULTS--The usual initial dose of Furosemide is 20 to 80 mg given as
a single dose. Ordinarily a prompt diuresis ensues. If needed, the same
dose can be administered 6 to 8 hours later or the dose may be increased.
The dose may be raised by 20 or 40 mg and given not sooner than 6 to 8
hours after the previous dose until the desired diuretic effect has been
obtained. This individually determined single dose should then be given
once or twice daily (eg, at 8 am and 2 pm). The dose of Furosemide may
be carefully titrated up to 600 mg/day in patients with clinically severe
edematous states. </p>

<p>Edema may be most efficiently and safely mobilized by giving Furosemide
on 2 to 4 consecutive days each week. </p>

<p>When doses exceeding 80 mg/day are given for prolonged periods, careful
clinical observation and laboratory monitoring are particularly advisable.
(See PRECAUTIONS: LABORATORY TESTS.) </p>

<p>INFANTS AND CHILDREN--The usual initial dose of oral Furosemide in infants
and children is 2 mg/kg body weight, given as a single dose. If the diuretic
response is not satisfactory after the initial dose, dosage may be increased
by 1 or 2 mg/kg no sooner than 6 to 8 hours after the previous dose. Doses
greater than 6 mg/kg body weight are not recommended. For maintenance therapy
in infants and children, the dose should be adjusted to the minimum effective
level. </p>

<p>Hypertension </p>

<p>Therapy should be individualized according to the patient's response
to gain maximal therapeutic response and to determine the minimal dose
needed to maintain that therapeutic response. </p>

<p>ADULTS--The usual initial daily dose of Furosemide for hypertension
is 80 mg, usually divided into 40 mg twice a day. Dosage should then be
adjusted according to response. If response is not satisfactory, add other
antihypertensive agents. </p>

<p>Changes in blood pressure must be carefully monitored when Furosemide
is used with other antihypertensive drugs, especially during initial therapy.
To prevent excessive drop in blood pressure, the dosage of other agents
should be reduced by at least 50 percent when Furosemide is added to the
regimen. As the blood pressure falls under the potentiating effect of Furosemide,
a further reduction in dosage or even discontinuation of other antihypertensive
drugs may be necessary. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-72</DOCNO>
<DOCOLDNO>IA018-000200-B040-188</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/dihydram.htm 206.86.175.201 19970106230705 text/html 11158
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:00:51 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 10975
Last-modified: Wed, 16 Oct 1996 03:42:55 GMT
</DOCHDR>
<html>
<head>
   <title>Diphenhydramine - RxList Generic Information</title>
   <meta name="keywords" content="Allerdryl 50, Allergia-C, Allergina, Allermin, Amidryl,
Banophen, Beldin, Belix, Ben-A-Vance, Ben-Rex, Bena-D-10,
Benadryl, Benadryl Steri-Dose, Benahist, Benapon, Bendramine,
Benocten, Benoject, Bydramine, Desentol, Diabenyl, Dibenil, Dimidril,
Diphen, Diphenacen-50, Diphenhist, Dolestan, Dytuss, Fynex, Genahist,
Histergan, Hydramine, Hydril, Hyrexin, Insomnal, Menna, Noradryl,
Norafed, Nordryl, Pharm-A-Dry, Pheramin-N, Resmin, Restamin, Shodryl,
Tega Dryl, Truxadryl, Tusstat, Uad Dryl, Venasmin, Wehdryl">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Diphenhydramine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Diphenhydramine is an antihistamine drug having the chemical name 2-(Diphenylmethoxy)-N,
N-dimethylethylamine hydrochloride and has the empirical formula C17H21NO.HCl
(molecular weight 291.82). It occurs as a white, crystalline powder and
is freely soluble in water and alcohol. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Diphenhydramine hydrochloride is an antihistamine with anticholinergic
(drying) and sedative effects. Antihistamines appear to compete with histamine
for cell receptor sites on effector cells. </p>

<p>A single oral dose of diphenhydramine hydrochloride is quickly absorbed
with maximum activity occurring in approximately one hour. The duration
of activity following an average dose of Diphenhydramine is from four to
six hours. Diphenhydramine is widely distributed throughout the body, including
the CNS. Little, if any, is excreted unchanged in the urine; most appears
as the degradation products of metabolic transformation in the liver, which
are almost completely excreted within 24 hours. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Diphenhydramine in the oral form is effective for the following indications:
ANTIHISTAMINIC: For allergic conjunctivitis due to foods; mild, uncomplicated
allergic skin manifestations of urticaria and angioedema; amelioration
of allergic reactions to blood or plasma; dermatographism; as therapy for
anaphylactic reactions Adjunctive to epinephrine and other standard measures
after the acute manifestations have been controlled. </p>

<p>MOTION SICKNESS: For active and prophylactic treatment of motion sickness.
</p>

<p>ANTIPARKINSONISM: For parkinsonism (including drug-induced) in the elderly
unable to tolerate more potent agents; mild cases of parkinsonism (including
drug-induced) in other age groups; in other cases of parkinsonism (including
drug- induced) in combination with centrally acting anticholinergic agents.
</p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>USE IN NEWBORN OR PREMATURE INFANTS </p>

<p>This drug should Not be used in newborn or premature infants. </p>

<p>USE IN NURSING MOTHERS </p>

<p>Because of the higher risk of antihistamines for infants generally,
and for newborns and prematures in particular, antihistamine therapy is
contraindicated in nursing mothers. </p>

<p>Antihistamines are also contraindicated in the following conditions:
</p>

<p>Hypersensitivity to diphenhydramine hydrochloride and other antihistamines
of similar chemical structure. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>Antihistamines should be used with considerable caution in patients
with narrow- angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction,
symptomatic prostatic hypertrophy, or bladder-neck obstruction. </p>

<p>USE IN CHILDREN </p>

<p>In infants and children, especially, antihistamines in Overdosage may
cause hallucinations, convulsions, or death. </p>

<p>As in adults, antihistamines may diminish mental alertness in children.
In the young child, particularly, they may produce excitation. </p>

<p>USE IN THE ELDERLY (APPROXIMATELY 60 YEARS OR OLDER). </p>

<p>Antihistamines are more likely to cause dizziness, sedation, and hypotension
in elderly patients. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>General: Diphenhydramine hydrochloride has an atropine-like action and
therefore should be used with caution in patients with a history of lower
respiratory disease, including asthma, increased intraocular pressure,
hyperthyroidism, cardiovascular disease, or hypertension. </p>

<p>Information For Patients: Patients taking diphenhydramine hydrochloride
should be advised that this drug may cause drowsiness and has an additive
effect with alcohol. </p>

<p>Patients should be warned about engaging in activities requiring mental
alertness such as driving a car or operating appliances, machinery, etc.
Drug Interactions: Diphenhydramine hydrochloride has additive effects with
alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers,
etc). MAO inhibitors prolong and intensify the anticholinergic (drying)
effects of antihistamines. </p>

<p>Carcinogenesis, Mutagenesis, Impairment Of Fertility: Long-term studies
in animals to determine mutagenic and carcinogenic potential have not been
performed. </p>

<p>Pregnancy: Pregnancy Category B. Reproduction studies have been performed
in rats and rabbits at doses up to 5 times the human dose and have revealed
no evidence of impaired fertility or harm to the fetus due to diphenhydramine
hydrochloride. There are, however, no adequate and well-controlled studies
in pregnant women. Because animal reproduction studies are not always predictive
of human response, this drug should be used during pregnancy only if clearly
needed. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Diphenhydramine hydrochloride has additive effects with alcohol and
other CNS depressants (hypnotics, sedatives, tranquilizers, etc). </p>

<p>MAO inhibitors prolong and intensify the anticholinergic (drying) effects
of antihistamines. (See Also PRECAUTIONS.) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The most frequent adverse reactions are underscored. </p>

<p>1. General: Urticaria, drug rash, anaphylactic shock, photosensitivity,
excessive perspiration, chills, dryness of mouth, nose, and throat. </p>

<p>2. Cardiovascular System: Hypotension, headache, palpitations, tachycardia,
extrasystoles. </p>

<p>3. Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.
</p>

<p>4. Nervous System: SEDATION, SLEEPINESS, DIZZINESS, DISTURBED COORDINATION,
fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability,
insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus,
acute labyrinthitis, neuritis, convulsions. </p>

<p>5. GI System: EPIGASTRIC DISTRESS, anorexia, nausea, vomiting, diarrhea,
constipation. </p>

<p>6. GU System: Urinary frequency, difficult urination, urinary retention,
early menses. </p>

<p>7. Respiratory System: THICKENING OF BRONCHIAL SECRETIONS, tightness
of chest and wheezing, nasal stuffiness. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Antihistamine overdosage reactions may vary from central nervous system
depression to stimulation. Stimulation is particularly likely in children.
</p>

<p>Atropine-like signs and symptoms, dry mouth; fixed, dilated pupils;
flushing, and gastrointestinal symptoms may also occur. </p>

<p>If Vomiting Has Not Occurred Spontaneously the patient should be induced
to vomit. This is best done by having him drink a glass of water or milk
after which he should be made to gag. Precautions against aspiration must
be taken, especially in infants and children. </p>

<p>If Vomiting Is Unsuccessful gastric lavage is indicated within 3 hours
after ingestion and even later if large amounts of milk or cream were given
beforehand. Isotonic or 1/2 isotonic saline is the lavage solution of choice.
Saline Cathartics, as milk of magnesia, by osmosis draw water into the
bowel and therefore are valuable for their action in rapid dilution of
food content. Stimulants should not be used. </p>

<p>Vasopressors may be used to treat hypotension. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE
OF THE PATIENT. </p>

<p>A single oral dose of diphenhydramine hydrochloride is quickly absorbed
with maximum activity occurring in approximately one hour. The duration
of activity following an average dose of Diphenhydramine is from four to
six hours. ADULTS: 25 to 50 mg three or four times daily. The nighttime
sleep-aid dosage is 50 mg at bedtime. </p>

<p>CHILDREN: (over 20 lb): 12.5 to 25 mg three to four times daily. Maximum
daily dosage not to exceed 300 mg. For physicians who wish to calculate
the dose on the basis of body weight or surface area, the recommended dosage
is 5 mg/kg/24 hours or 150 mg/M(squared)/24 hours. </p>

<p>The basis for determining the most effective dosage regimen will be
the response of the patient to medication and the condition under treatment.
</p>

<p>In motion sickness, full dosage is recommended for prophylactic use,
the first dose to be given 30 minutes before exposure to motion and similar
doses before meals and upon retiring for the duration of exposure. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-73</DOCNO>
<DOCOLDNO>IA018-000200-B036-179</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/azith.htm 206.86.175.201 19970106225224 text/html 32405
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:46:09 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 32222
Last-modified: Sun, 07 Jul 1996 05:55:35 GMT
</DOCHDR>
<html>
<head>
   <title>Azithromycin - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Azithromycin</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [toxicity] [<a href="#DOSAGE AND ADMINISTRATION">dosing</a>]
</font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Azithromycin is an azalide, a subclass of macrolide antibiotics, for
oral administration. Azithromycin has the chemical name (2R,3S,4R,5R,8R,10R
11R,12S, 13S,14R)-13-((2,6-dideoxy-3-C-methyl-3-O-methyl-a- L-ribo- hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,
14- heptamethyl-11 ((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo- hexopyranosyl)oxy)-1-oxa-6
azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however,
it differs chemically from erythromycin in that a methyl-substituted nitrogen
atom is incorporated into the lactone ring. </p>

<p>Azithromycin, as the dihydrate, is a white crystalline powder with a
chemical formula of C38H72N2O122H2O and a molecular weight of 785.0. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Following oral administration, azithromycin is rapidly absorbed and
widely distributed throughout the body. Rapid distribution of azithromycin
into tissues and high concentration within cells result in significantly
higher azithromycin concentrations in tissues than in plasma or serum.
</p>

<p>The pharmacokinetic parameters of azithromycin in plasma after dosing
as per labeled recommendations (i.e., 500 mg loading dose on day 1 followed
by 250 mg q.d. on days 2 through 5) in healthy young adults (age 18-40
years old) are portrayed in the following chart: </p>

<pre><font SIZE=-1>PK Parameter (Mean)                              Total n=12                     
                                                   Day 1               Day 5    
Cmax(mcgm/mL)                                       0.41                0.24    
Tmax(h)                                             2.5                 3.2     
AUC 0-24 (mcgm.h/mL)                                2.6                 2.1     
Cmin(mcgm/mL)                                       0.05                0.05    
Urinary Excret. (% dose)                            4.5                 6.5     </font>
</pre>

<p>In this study, there was no significant difference in the disposition
of azithromycin between male and female subjects. Plasma concentrations
of azithromycin declined in a polyphasic pattern resulting in an average
terminal half-life of 68 hours. On the recommended dosing regimen, Cmin
and Cmax remained essentially unchanged from day 2 through day 5 of therapy.
However, without a loading dose, azithromycin Cmin levels required 5 to
7 days to reach steady- state. </p>

<p>When studied in healthy elderly subjects from age 65 to 85 years, the
pharmacokinetic parameters of azithromycin in elderly men were similar
to those in young adults; however, in elderly women, although higher peak
concentrations (increased by 30 to 50%) were observed, no significant accumulation
occurred. </p>

<p>The high values for apparent steady-state volume of distribution (31.1
L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life
is due to extensive uptake and subsequent release of drug from tissues.
Selected tissue (or fluid) to plasma/serum concentration ratios are shown
in the following table: </p>

<pre><font SIZE=-1>               AZITHROMYCIN CONCENTRATIONS FOLLOWING RECOMMENDED                
                            CLINICAL DOSAGE REGIMEN                             
----------------------------------------------------------------------------    
                                             CORRESPONDING                      
                  TIME    TISSUE OR FLUID      PLASMA OR       TISSUE (FLUID)   
TISSUE OR        AFTER     CONCENTRATION      SERUM LEVEL      PLASMA (SERUM)   
FLUID           DOSE (h)     (mcgm/g or        (mcgm/mL)         RATIO(1)       
                           mcgm/mL)(1)                                          
----------------------------------------------------------------------------    
SKIN             72-96          0.4               0.012              35         
----------------------------------------------------------------------------    
LUNG             72-96          4.0               0.012            &gt;100         
----------------------------------------------------------------------------    
SPUTUM*           2-4           1.0               0.64                2         
----------------------------------------------------------------------------    
SPUTUM**         10-12          2.9               0.1                30         
----------------------------------------------------------------------------    
TONSIL*/*         9-18          4.5               0.03             &gt;100         
----------------------------------------------------------------------------    
TONSIL*/*          180          0.9               0.006            &gt;100         
----------------------------------------------------------------------------    
CERVIX****         19           2.8               0.04               70         
----------------------------------------------------------------------------    
    (1)High tissue concentrations should not be interpreted to be               
        quantitatively related to clinical efficacy. The antimicrobial          
        activity of azithromycin is pH related. Azithromycin is concentrated    
        in cell lysosomes which have a low intraorganelle pH, at which the      
        drug's activity is reduced. However, the extensive distribution of      
        drug to tissues may be relevant to clinical activity.                   
     * Sample was obtained 2-4 hours after the first dose.                      
    ** Sample was obtained 10-12 hours after the first dose.                    
   */* Dosing regimen of 2 doses of 250 mg each, separated by 12 hours.         
  **** Sample was obtained 19 hours after a single 500 mg dose.      </font></pre>

<p>The extensive tissue distribution was confirmed by examination of additional
tissues and fluids (bone, ejaculum, prostate, ovary, uterus, salpinx, stomach,
liver, and gallbladder). As there are no data from adequate and well-controlled
studies of azithromycin treatment of infections in these additional body
sites, the clinical significance of these tissue concentration data is
unknown. </p>

<p>Only very low concentrations were noted in cerebrospinal fluid (less
than 0.01 mcgm/mL) in the presence of non-inflamed meninges. </p>

<p>The serum protein binding of azithromycin is variable in the concentration
range approximating human exposure, decreasing from 51% at 0.02 mcgm/mL
to 7% at 2 mcgm/mL. </p>

<p>Biliary excretion of azithromycin, predominantly as unchanged drug,
is a major route of elimination. Over the course of a week, approximately
6% of the administered dose appears as unchanged drug in urine. </p>

<p>There are no pharmacokinetic data available from studies in hepatically-
or renally-impaired individuals. </p>

<p>Food decreases the absorption of azithromycin, reducing the Cmax by
52% and the AUC by 43%. </p>

<p>The AUC of azithromycin was unaffected by co-administration of an aluminum
and magnesium hydroxide antacid on Azithromycin; however, the Cmax was
reduced by 24%. Administration of cimetidine (800 mg) two hours prior to
azithromycin had no effect on azithromycin absorption. </p>

<p>The effect of azithromycin on the plasma levels or pharmacokinetics
of theophylline administered in multiple doses adequate to reach therapeutic
steady-state plasma levels is not known. (See PRECAUTIONS.) </p>

<p>MICROBIOLOGY: </p>

<p>Azithromycin acts by binding to the 50S ribosomal subunit of susceptible
organisms and thus interfering with microbial protein synthesis. Nucleic
acid synthesis is not affected. </p>

<p>Azithromycin concentrates in phagocytes and fibroblasts as demonstrated
by In Vitro incubation techniques. Using such methodology, the ratio of
intracellular to extracellular concentration was &gt;30 after one hour
incubation. In Vivo studies suggest that concentration in phagocytes may
contribute to drug distribution to inflamed tissues. </p>

<p>Azithromycin has been shown to be active against most strains of the
following organisms--both In Vitro and in clinical infections: (See INDICATIONS
AND USAGE.) </p>

<pre>GRAM-POSITIVE AEROBES                                                           
Staphylococcus Aureus                     Streptococcus Pneumoniae              
Streptococcus Agalactiae                  Streptococcus Pyogenes</pre>

<p>NOTE: Azithromycin demonstrates cross-resistance with erythromycin-resistant
gram-positive strains. Most strains of Enterococcus Faecalis and methicillin-
resistant staphylococci are resistant to azithromycin. </p>

<pre>GRAM-NEGATIVE AEROBES                     OTHER ORGANISMS                       
Haemophilus Influenzae                    Chlamydia Trachomatis                 
Moraxella Catarrhalis </pre>

<p>Beta-lactamase production should have no effect on azithromycin activity.
</p>

<p>Azithromycin exhibits In Vitro minimum inhibitory concentrations of
2.0 mcgm/mL or less against most strains of the following organisms. The
safety and efficacy of azithromycin in treating infections due to these
organisms have not been established in adequate and well-controlled trials.
The following In Vitro data are available; However, Their Clinical Significance
Is Unknown. </p>

<pre>GRAM-POSITIVE AEROBES                     ANAEROBIC BACTERIA                    
Streptococci (Groups C, F, G)             Bacteroides Bivius                    
Viridans group streptococci               Clostridium Perfringens               
                                          Peptostreptococcus species            
GRAM-NEGATIVE AEROBES                     OTHER ORGANISMS                       
Bordetella Pertussis                      Borrelia Burgdorferi                  
Campylobacter Jejuni                      Mycoplasma Pneumoniae                 
Haemophilus Ducreyi                       Treponema Pallidum                    
Legionella Pneumophila                    Ureaplasma Urealyticum</pre>

<p>SUSCEPTIBILITY TESTS </p>

<p>Diffusion Techniques: Quantitative methods that require measurement
of zone diameters give the most precise estimate of the susceptibility
of bacteria to antimicrobial agents. One such standard procedure (REF.1)
which has been recommended for use with disks to test susceptibility of
organisms to azithromycin uses the 15-mcgm azithromycin disk. Interpretation
involves the correlation of the diameter obtained in the disk test with
the minimum inhibitory concentration (MIC) for azithromycin. </p>

<p>Reports from the laboratory giving results of the standard single-disk
susceptibility test with a 15-mcgm azithromycin disk should be interpreted
according to the following criteria: </p>

<p>Zone Diameter (mm)                                  Interpretation 
            
<br>             &gt;/=18                                  (S) Susceptible
            
<br>             14-17                                  (I) Intermediate
           
<br>             &lt; or =13                                   Resistant
</p>

<p>A report of &quot;Susceptible&quot; indicates that the pathogen is likely
to respond to monotherapy with azithromycin. A report of &quot;Intermediate&quot;
indicates that the result be considered equivocal, and, if the organism
is not fully susceptible to alternative clinically feasible drugs, the
test should be repeated. This category provides a buffer zone which prevents
small uncontrolled technical factors from causing major discrepancies in
interpretations. A report of &quot;Resistant&quot; indicates that achievable
drug concentrations are unlikely to be inhibitory and other therapy should
be selected. </p>

<p>Standardized procedures require the use of laboratory control organisms.
The 15 mcgm azithromycin disk should give the following zone diameter:
</p>

<pre>Organism                                               Zone diameter (mm)       
S. Aureus ATCC 25923                                         21-26              </pre>

<p>Dilution Techniques: Use a standardized dilution method (REF. 2) (broth,
agar, microdilution) or equivalent with azithromycin powder. The MIC values
obtained should be interpreted according to the following criteria: </p>

<pre>MIC (mcgm/mL)                                       Interpretation              
       &lt; or =2                                      (S) Susceptible 
          4                                         (I) Intermediate            
       &gt;/=8                                          Resistant</pre>

<p>The In Vitro potency of azithromycin is markedly affected by the pH
of the microbiological growth medium during incubation. Incubation in CO2
atmosphere will result in lowering of media pH (7.2 to 6.6, 18 hours in
10% CO2) and an apparent reduction in In Vitro potency of azithromycin.
Thus, the initial pH of the growth medium should be 7.2-7.4, and the CO2
content of the incubation atmosphere should be as low as practical. </p>

<p>Azithromycin can be solubilized for In Vitro testing by dissolving in
a minimum amount of 95% ethanol and diluting to working concentration with
water. </p>

<p>As with standard diffusion methods, dilution methods require the use
of laboratory control organisms. Standard azithromycin powder should provide
the following MIC values: </p>

<pre><font SIZE=-1>Organism                                                      MIC (mcgm/mL)     
E. Coli ATCC 25922                                                 2.0-8.0      
E. Faecalis ATCC 29212                                             1.0-4.0      
S. Aureus ATCC 29213                                              0.25-1.0 </font></pre>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Azithromycin is indicated for the treatment of individuals 16 years
of age and older with mild to moderate infections (pneumonia: see WARNINGS)
caused by susceptible strains of the designated microorganisms in the specific
conditions listed below: </p>

<p>LOWER RESPIRATORY TRACT </p>

<p>Acute bacterial exacerbations of chronic obstructive pulmonary disease
due to Haemophilus Influenzae, Moraxella Catarrhalis, or Streptococcus
Pneumoniae. </p>

<p>Community-acquired pneumonia of mild severity due to Streptococcus Pneumoniae
or Haemophilus Influenzae in patients appropriate for outpatient oral therapy.
</p>

<p>NOTE: AZITHROMYCIN SHOULD NOT BE USED IN PATIENTS WITH PNEUMONIA WHO
ARE JUDGED TO BE INAPPROPRIATE FOR OUTPATIENT ORAL THERAPY BECAUSE OF MODERATE
TO SEVERE ILLNESS OR RISK FACTORS SUCH AS ANY OF THE FOLLOWING: </p>

<p>PATIENTS WITH NOSOCOMIALLY ACQUIRED INFECTIONS, </p>

<p>PATIENTS WITH KNOWN OR SUSPECTED BACTEREMIA, </p>

<p>PATIENTS REQUIRING HOSPITALIZATION, </p>

<p>ELDERLY OR DEBILITATED PATIENTS, OR </p>

<p>PATIENTS WITH SIGNIFICANT UNDERLYING HEALTH PROBLEMS THAT MAY COMPROMISE
THEIR ABILITY TO RESPOND TO THEIR ILLNESS (INCLUDING IMMUNODEFICIENCY OR
FUNCTIONAL ASPLENIA). </p>

<p>UPPER RESPIRATORY TRACT </p>

<p>Streptococcal pharyngitis/tonsillitis--As an alternative to first line
therapy of acute pharyngitis/tonsillitis due to Streptococcus Pyogenes
occurring in individuals who cannot use first line therapy. </p>

<p>NOTE: Penicillin is the usual drug of choice in the treatment of Streptococcus
Pyogenes infections and the prophylaxis of rheumatic fever. Azithromycin
is often effective in the eradication of susceptible strains of Streptococcus
Pyogenes from the nasopharynx. Because some strains are resistant to Azithromycin,
susceptibility tests should be performed when patients are treated with
Azithromycin. Data establishing efficacy of azithromycin in subsequent
prevention of rheumatic fever are not available. </p>

<p>SKIN AND SKIN STRUCTURE </p>

<p>Uncomplicated skin and skin structure infections due to Staphylococcus
Aureus, Streptococcus Pyogenes, or Streptococcus Agalactiae. Abscesses
usually require surgical drainage. </p>

<p>SEXUALLY TRANSMITTED DISEASES </p>

<p>Non-gonococcal urethritis and cervicitis due to Chlamydia Trachomatis.
</p>

<p>Azithromycin, at the recommended dose, should not be relied upon to
treat gonorrhea or syphilis. Antimicrobial agents used in high doses for
short periods of time to treat non-gonococcal urethritis may mask or delay
the symptoms of incubating gonorrhea or syphilis. All patients with sexually
transmitted urethritis or cervicitis should have a serologic test for syphilis
and appropriate cultures for gonorrhea performed at the time of diagnosis.
Appropriate antimicrobial therapy and follow-up tests for these diseases
should be initiated if infection is confirmed. </p>

<p>Appropriate culture and susceptibility tests should be performed before
treatment to determine the causative organism and its susceptibility to
azithromycin. Therapy with Azithromycin may be initiated before results
of these tests are known; once the results become available, antimicrobial
therapy should be adjusted accordingly. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Azithromycin is contraindicated in patients with known hypersensitivity
to azithromycin, erythromycin, or any macrolide antibiotic. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>Rare serious allergic reactions, including angioedema and anaphylaxis,
have been reported in patients on azithromycin therapy. (See CONTRAINDICATIONS.)
Despite initially successful symptomatic treatment of the allergic symptoms,
when symptomatic therapy was discontinued, the allergic symptoms RECURRED
SOON THEREAFTER IN SOME PATIENTS WITHOUT FURTHER AZITHROMYCIN EXPOSURE.
These patients required prolonged periods of observation and symptomatic
treatment. The relationship of these episodes to the long tissue half-life
of azithromycin and subsequent prolonged exposure to antigen is unknown
at present. </p>

<p>If an allergic reaction occurs, the drug should be discontinued and
appropriate therapy should be instituted. Physicians should be aware that
reappearance of the allergic symptoms may occur when symptomatic therapy
is discontinued. </p>

<p>IN THE TREATMENT OF PNEUMONIA, AZITHROMYCIN HAS ONLY BEEN SHOWN TO BE
SAFE AND EFFECTIVE IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA OF
MILD SEVERITY DUE TO Streptococcus Pneumoniae OR Haemophilus Influenzae
IN PATIENTS APPROPRIATE FOR OUTPATIENT ORAL THERAPY. AZITHROMYCIN SHOULD
NOT BE USED IN PATIENTS WITH PNEUMONIA WHO ARE JUDGED TO BE INAPPROPRIATE
FOR OUTPATIENT ORAL THERAPY BECAUSE OF MODERATE TO SEVERE ILLNESS OR RISK
FACTORS SUCH AS ANY OF THE FOLLOWING: PATIENTS WITH NOSOCOMIALLY ACQUIRED
INFECTIONS, PATIENTS WITH KNOWN OR SUSPECTED BACTEREMIA, PATIENTS REQUIRING
HOSPITALIZATION, ELDERLY OR DEBILITATED PATIENTS, OR PATIENTS WITH SIGNIFICANT
UNDERLYING HEALTH PROBLEMS THAT MAY COMPROMISE THEIR ABILITY TO RESPOND
TO THEIR ILLNESS (INCLUDING IMMUNODEFICIENCY OR FUNCTIONAL ASPLENIA). PSEUDOMEMBRANOUS
COLITIS HAS BEEN REPORTED WITH NEARLY ALL ANTIBACTERIAL AGENTS AND MAY
RANGE IN SEVERITY FROM MILD TO LIFE-THREATENING. THEREFORE, IT IS IMPORTANT
TO CONSIDER THIS DIAGNOSIS IN PATIENTS WHO PRESENT WITH DIARRHEA SUBSEQUENT
TO THE ADMINISTRATION OF ANTIBACTERIAL AGENTS. </p>

<p>Treatment with antibacterial agents alters the normal flora of the colon
and may permit overgrowth of clostridia. Studies indicate that a toxin
produced by Clostridium Difficile is a primary cause of &quot;antibiotic-associated
colitis.&quot; </p>

<p>After the diagnosis of pseudomembranous colitis has been established,
therapeutic measures should be initiated. Mild cases of pseudomembranous
colitis usually respond to discontinuation of the drug alone. In moderate
to severe cases, consideration should be given to management with fluids
and electrolytes, protein supplementation, and treatment with an antibacterial
drug clinically effective against Clostridium Difficile colitis. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL: Because azithromycin is principally eliminated via the liver,
caution should be exercised when azithromycin is administered to patients
with impaired hepatic function. There are no data regarding azithromycin
usage in patients with renal impairment; thus, caution should be exercised
when prescribing azithromycin in these patients. </p>

<p>The following adverse event has not been reported in clinical trials
with azithromycin, an azalide. However, it has been reported with macrolide
products: ventricular arrhythmias, including ventricular tachycardia and
Torsades De Pointes, in individuals with prolonged QT intervals. </p>

<p>INFORMATION FOR PATIENTS: Patients should be cautioned to take this
medication at least one hour prior to a meal or at least two hours after
a meal. This medication should not be taken with food. </p>

<p>Patients should also be cautioned not to take aluminum- and magnesium
containing antacids and azithromycin simultaneously. </p>

<p>The patient should be directed to discontinue azithromycin immediately
and contact a physician if any signs of an allergic reaction occur. </p>

<p>LABORATORY TEST INTERACTIONS: There are no reported laboratory test
interactions. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Long-term studies
in animals have not been performed to evaluate carcinogenic potential.
Azithromycin has shown no mutagenic potential in standard laboratory tests:
mouse lymphoma assay, human lymphocyte clastogenic assay, and mouse bone
marrow clastogenic assay. </p>

<p>PREGNANCY: Teratogenic Effects. Pregnancy Category B: Reproduction studies
have been performed in rats and mice at doses up to moderately maternally
toxic dose levels (i.e., 200 mg/kg/day). These doses, based on a mg/M(square)
basis, are estimated to be 4 and 2 times, respectively, the human daily
dose of 500 mg. No evidence of impaired fertility or harm to the fetus
due to azithromycin was found. There are, however, no adequate and well-controlled
studies in pregnant women. Because animal reproduction studies are not
always predictive of human response, azithromycin should be used during
pregnancy only if clearly needed. </p>

<p>NURSING MOTHERS: It is not known whether azithromycin is excreted in
human milk. Because many drugs are excreted in human milk, caution should
be exercised when azithromycin is administered to a nursing woman. </p>

<p>PEDIATRIC USE: Safety and effectiveness in children or adolescents under
16 years of age have not been established. </p>

<p>GERIATRIC USE: Pharmacokinetic parameters in older volunteers (65-85
years old) were similar to those in younger volunteers (18-40 years old)
for the 5 day therapeutic regimen. Dosage adjustment does not appear to
be necessary for older patients with normal renal and hepatic function
receiving treatment with this dosage regimen. (See CLINICAL PHARMACOLOGY.)
</p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Aluminum- and magnesium-containing antacids reduce the peak serum levels
(rate) but not the A.U.C. (extent) of azithromycin absorption. </p>

<p>Administration of cimetidine (800 mg) two hours prior to azithromycin
had no effect on azithromycin absorption. </p>

<p>Azithromycin did not affect the plasma levels or pharmacokinetics of
theophylline administered as a single intravenous dose. The effect of azithromycin
on the plasma levels or pharmacokinetics of theophylline administered in
multiple doses resulting in therapeutic steady state levels of theophylline
is not known. However, concurrent use of macrolides and theophylline has
been associated with increases in the serum concentrations of theophylline.
Therefore, until further data are available, prudent medical practice dictates
careful monitoring of plasma theophylline levels in patients receiving
azithromycin and theophylline concomitantly. </p>

<p>Azithromycin did not affect the prothrombin time response to a single
dose of warfarin. However, prudent medical practice dictates careful monitoring
of prothrombin time in all patients treated with azithromycin and warfarin
concomitantly. Concurrent use of macrolides and warfarin in clinical practice
has been associated with increased anticoagulant effects. </p>

<p>The following drug interactions have not been reported in clinical trials
with azithromycin; however, no specific drug interaction studies have been
performed to evaluate potential drug-drug interaction. Nonetheless, they
have been observed with macrolide products. Until further data are developed
regarding drug interactions when azithromycin and these drugs are used
concomitantly, careful monitoring of patients is advised: </p>

<p>Digoxin--elevated digoxin levels. </p>

<p>Ergotamine or dihydroergotamine--acute ergot toxicity characterized
by severe peripheral vasospasm and dysesthesia. </p>

<p>Triazolam--decrease the clearance of triazolam and thus may increase
the pharmacologic effect of triazolam. </p>

<p>Drugs metabolized by the cytochrome P450 system--elevations of serum
carbamazepine, cyclosporine, hexobarbital, and phenytoin levels. </p>

<p>(See also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>In clinical trials most of the reported side effects were mild to moderate
in severity and were reversible upon discontinuation of the drug. Approximately
0.7% of the patients from the multiple-dose clinical trials discontinued
Azithromycin therapy because of treatment-related side effects. Most of
the side effects leading to discontinuation were related to the gastrointestinal
tract, e.g., nausea, vomiting, diarrhea, or abdominal pain. Rare, but potentially
serious side effects, were angioedema and cholestatic jaundice. </p>

<p>CLINICAL: </p>

<p>Multiple-dose Regimen: Overall, the most common side effects in patients
receiving the multiple-dose regimen of Azithromycin were related to the
gastrointestinal system with diarrhea/loose stools (5%), nausea (3%), and
abdominal pain (3%) being the most frequently reported. </p>

<p>No other side effects occurred in patients on the multiple-dose regimen
of Azithromycin with a frequency greater than 1%. Side effects that occurred
with a frequency of 1% or less included the following: </p>

<p>CARDIOVASCULAR: Palpitations, chest pain. </p>

<p>GASTROINTESTINAL: Dyspepsia, flatulence, vomiting, melena, and cholestatic
jaundice. </p>

<p>GENITOURINARY: Monilia, vaginitis, and nephritis. </p>

<p>NERVOUS SYSTEM: Dizziness, headache, vertigo, and somnolence. </p>

<p>GENERAL: Fatigue. </p>

<p>ALLERGIC: Rash, photosensitivity, and angioedema. </p>

<p>Single 1-gram Dose Regimen: Overall, the most common side effects in
patients receiving a single-dose regimen of 1 gram of Azithromycin were
related to the gastrointestinal system and were more frequently reported
than in patients receiving the multiple-dose regimen. </p>

<p>Side effects that occurred in patients on the single one-gram dosing
regimen of Azithromycin with a frequency of 1% or greater included diarrhea/loose
stools (7%) nausea (5%), vomiting (2%), and vaginitis (2%). </p>

<p>Laboratory Abnormalities: Significant abnormalities (irrespective of
drug relationship) occurring during the clinical trials were reported as
follows: </p>

<p>With an incidence of 1-2%, elevated serum creatinine phosphokinase,
potassium, ALT (SGPT), GGT, and AST (SGOT). </p>

<p>With an incidence of less than 1%, leukopenia, neutropenia, decreased
platelet count, elevated serum alkaline phosphatase, bilirubin, BUN, creatinine,
blood glucose, LDH, and phosphate. </p>

<p>When follow-up was provided, changes in laboratory tests appeared to
be reversible. </p>

<p>In multiple-dose clinical trials involving more than 3000 patients,
3 patients discontinued therapy because of treatment-related liver enzyme
abnormalities and 1 because of a renal function abnormality. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>(SEE INDICATIONS AND USAGE.) </p>

<p>Azithromycin Should Be Given At Least 1 Hour Before Or 2 Hours After
A Meal. </p>

<p>The recommended dose of Azithromycin for the treatment of individuals
16 years of age and older with mild to moderate acute bacterial exacerbations
of chronic obstructive pulmonary disease, pneumonia, pharyngitis/tonsillitis
(as second- line therapy), and uncomplicated skin and skin structure infections
due to the Azithromycin </p>

<p>indicated organisms is: 500 mg as a single dose on the first day followed
by 250 mg once daily on days 2 through 5 for a total dose of 1.5 grams
of Azithromycin. </p>

<p>The recommended dose of Azithromycin for the treatment of non-gonococcal
urethritis and cervicitis due to C. Trachomatis is: a single 1 gram (1000
mg) dose of Azithromycin. </p>

<p>ANIMAL PHARMACOLOGY </p>

<p>ANIMAL TOXICOLOGY </p>

<p>Phospholipidosis (intracellular phospholipid binding) has been observed
in some tissues of mice, rats, and dogs given multiple doses of azithromycin.
It has been demonstrated in numerous organ systems (e.g., eye, dorsal root
ganglia, liver, gallbladder, kidney, spleen, and pancreas) in dogs administered
doses which, based on pharmacokinetics, are as low as 2 times greater than
the recommended human dose and in rats at doses comparable to the recommended
human dose. This effect has been reversible after cessation of azithromycin
treatment. The significance of these findings for humans is unknown. </p>

<p>REFERENCES </p>

<p>1. National Committee for Clinical Laboratory Standards, Performance
Standards for Antimicrobial Disk Susceptibility Tests--Fourth Edition.
Approved Standard NCCLS Document M2-A4, Vol. 10, No. 7, NCCLS, Villanova,
PA, 1990. </p>

<p>2. National Committee for Clinical Laboratory Standards, Methods for
Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically--Second
Edition. Approved Standard NCCLS Document M7-A2, Vol. 10, No. 8, NCCLS,
Villanova, PA, 1990. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-74</DOCNO>
<DOCOLDNO>IA018-000200-B034-7</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/hctztri.htm 206.86.175.201 19970106224020 text/html 29995
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:34:02 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 29812
Last-modified: Sun, 11 Aug 1996 03:44:41 GMT
</DOCHDR>
<html>
<head>
   <title>Hydrochlorothiazide/triamterine - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Hydrochlorothiazide/triamterine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>


<hr width="100%" ><a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <p>
Hydrochlorothiazide is a diuretic/antihypertensive agent and triamterene is 
an antikaliuretic agent.  
 <p>
Hydrochlorothiazide is slightly soluble in water. It is soluble in dilute
ammonia, dilute aqueous sodium hydroxide and dimethylformamide. It is sparingly 
soluble in methanol.  
 <p>
Hydrochlorothiazide is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-
sulfonamide 1,1-dioxide.  
 <p>
At 50 deg C, triamterene is practically insoluble in water (less than 0.1%). It 
is soluble in formic acid, sparingly soluble in methoxyethanol and very
slightly soluble in alcohol.  <p>
 
Triamterene is 2,4,7-triamino-6-phenylpteridine.  
 
<p>
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 
</b> <p>
Hydrochlorothiazide/triamterine is a diuretic/antihypertensive 
drug product that combines natriuretic
and antikaliuretic effects. Each component complements the action of the other. 
The hydrochlorothiazide component blocks the reabsorption of sodium and
chloride ions, and thereby increases the quantity of sodium traversing the
distal tubule and the volume of water excreted. A portion of the additional
sodium presented to the distal tubule is exchanged there for potassium and
hydrogen ions. With continued use of hydrochlorothiazide and depletion of
sodium, compensatory mechanisms tend to increase this exchange and may produce
excessive loss of potassium, hydrogen and chloride ions. Hydrochlorothiazide
also decreases the excretion of calcium and uric acid, may increase the
excretion of iodide and may reduce glomerular filtration rate. The exact
mechanism of the antihypertensive effect of hydrochlorothiazide is not known. 
 <p>
The triamterene component of Hydrochlorothiazide/triamterine 
exerts its diuretic effect on the distal
renal tubule to inhibit the reabsorption of sodium in exchange for potassium
and hydrogen ions. Its natriuretic activity is limited by the amount of sodium
reaching its site of action. Although it blocks the increase in this exchange
that is stimulated by mineralocorticoids (chiefly aldosterone) it is not a
competitive antagonist of aldosterone and its activity can be demonstrated in
adrenalectomized rats and patients with Addison's disease. As a result, the
dose of triamterene required is not proportionally related to the level of
mineralocorticoid activity, but is dictated by the response of the individual
patients, and the kaliuretic effect of concomitantly administered drugs. By
inhibiting the distal tubular exchange mechanism, triamterene maintains or
increases the sodium excretion and reduces the excess loss of potassium,
hydrogen, and chloride ions induced by hydrochlorothiazide. As with
hydrochlorothiazide, triamterene may reduce glomerular filtration and renal
plasma flow. Via this mechanism it may reduce uric acid excretion although it
has no tubular effect on uric acid reabsorption or secretion. Triamterene does
not affect calcium excretion. No predictable antihypertensive effect has been
demonstrated for triamterene.  
 <p>
Duration of diuretic activity and effective dosage range of the
hydrochlorothiazide and triamterene components of 
Hydrochlorothiazide/triamterine are similar. Onset of 
diuresis with Hydrochlorothiazide/triamterine takes place 
within one hour, peaks at two to three hours
and tapers off during the subsequent seven to nine hours.  
 <p>
The bioavailability of the hydrochlorothiazide and the triamterene components
of Hydrochlorothiazide/triamterine is, in each case, 
about 50% of that observed with an aqueous
suspension of the components. (See PRECAUTIONS, Bioavailability.) 
 <p>
<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
THIS FIXED COMBINATION DRUG IS NOT INDICATED FOR THE INITIAL THERAPY OF EDEMA
OR HYPERTENSION EXCEPT IN INDIVIDUALS IN WHOM THE DEVELOPMENT OF HYPOKALEMIA
CANNOT BE RISKED.  
 <p>
Hydrochlorothiazide/triamterine is indicated for the 
treatment of hypertension or edema in patients who 
develop hypokalemia on hydrochlorothiazide alone.  
 <p>
Hydrochlorothiazide/triamterine is also indicated for 
those patients who require a thiazide diuretic
and in whom the development of hypokalemia cannot be risked.  
 <p>
Hydrochlorothiazide/triamterine may be used alone 
or as an adjunct to other antihypertensive drugs,
such as beta-blockers. Since Hydrochlorothiazide/triamterine 
may enhance the action of these agents,
dosage adjustments may be necessary.  
 <p>
<b>Usage In Pregnancy: </b>The routine use of diuretics in an otherwise healthy woman
is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics
do not prevent development of toxemia of pregnancy, and there is no
satisfactory evidence that they are useful in the treatment of developed
toxemia.  
 <p>
Edema during pregnancy may arise from pathological causes or from the
physiologic and mechanical consequences of pregnancy. Diuretics are indicated
in pregnancy when edema is due to pathologic causes, just as they are in the
absence of pregnancy. Dependent edema in pregnancy resulting from restriction
of venous return by the expanded uterus is properly treated through elevation
of the lower extremities and use of support hose; use of diuretics to lower
intravascular volume in this case is illogical and unnecessary. There is
hypervolemia during normal pregnancy which is harmful to neither the fetus nor
the mother (in the absence of cardiovascular disease), but which is associated
with edema, including generalized edema in the majority of pregnant women. If
this edema produces discomfort, increased recumbency will often provide relief. 
In rare instances this edema may cause extreme discomfort which is not
relieved by rest. In these cases a short course of diuretics may provide relief 
and may be appropriate.  
 <p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <p>
ANTIKALIURETIC THERAPY AND POTASSIUM SUPPLEMENTATION 
 <p>
Hydrochlorothiazide/triamterine should not be given 
to patients receiving other potassium-conserving
agents such as spironolactone, amiloride or other formulations containing
triamterene. Concomitant potassium-containing salt substitutes should also not
be used.  
 <p>
Potassium supplementation should not be used with 
Hydrochlorothiazide/triamterine except in severe
cases of hypokalemia. Such concomitant therapy can be associated with rapid
increases in serum potassium levels. If potassium supplementation is used,
careful monitoring of the serum potassium level is necessary.  
 <p>
IMPAIRED RENAL FUNCTION 
 <p>
Hydrochlorothiazide/triamterine is contraindicated in 
patients with anuria, acute and chronic renal
insufficiency or significant renal impairment.  
 <p>
HYPERSENSITIVITY 
 <p>
Hypersensitivity to either drug in the preparation or to other sulfonamide-
derived drugs is a contraindication.  
 <p>
HYPERKALEMIA 
 <p>
Hydrochlorothiazide/triamterine should not be used in patients with preexisting elevated serum
potassium.  
 <p>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <p>
HYPERKALEMIA 
 <p>
 
Abnormal elevation of serum potassium levels (greater than or equal to 5.5
mEq/liter) can occur with all potassium-conserving diuretic combinations,
including Hydrochlorothiazide/triamterine. Hyperkalemia 
is more likely to occur in patients with renal
impairment and diabetes (even without evidence of renal impairment), and in the 
elderly or severely ill. Since uncorrected hyperkalemia may be fatal, serum
potassium levels must be monitored at frequent intervals especially in patients 
first receiving Hydrochlorothiazide/triamterine, when 
dosages are changed or with any illness that may
influence renal function.  
 
 <p>
If hyperkalemia is suspected (warning signs include paresthesias, muscular
weakness, fatigue, flaccid paralysis of the extremities, bradycardia and shock) 
an electrocardiogram (ECG) should be obtained. However, it is important to
monitor serum potassium levels because hyperkalemia may not be associated with
ECG changes.  
 <p>
If hyperkalemia is present, Hydrochlorothiazide/triamterine 
should be discontinued immediately and a
thiazide alone should be substituted. If the serum potassium exceeds 6.5
mEq/liter more vigorous therapy is required. The clinical situation dictates
the procedures to be employed. These include the intravenous administration of
calcium chloride solution, sodium bicarbonate solution and/or the oral or
parenteral administration of glucose with a rapid-acting insulin preparation. 
Cationic exchange resins such as sodium polystyrene sulfonate may be orally or
rectally administered. Persistent hyperkalemia may require dialysis.  
 <p>
The development of hyperkalemia associated with potassium-sparing diuretics is
accentuated in the presence of renal impairment (see CONTRAINDICATIONS
section).  Patients with mild renal functional impairment should not receive
this drug without frequent and continuing monitoring of serum electrolytes.
Cumulative drug effects may be observed in patients with impaired renal
function. The renal clearances of hydrochlorothiazide and the pharmacologically 
active metabolite of triamterene, the sulfate ester of hydroxytriamterene, have 
been shown to be reduced and the plasma levels 
increased following Hydrochlorothiazide/triamterine
administration to elderly patients and patients with impaired renal function. 
 <p>
Hyperkalemia has been reported in diabetic patients with the use of potassium-
conserving agents even in the absence of apparent renal impairment. Accordingly 
serum electrolytes must be frequently monitored 
if Hydrochlorothiazide/triamterine is used in diabetic
patients.  
 <p>
METABOLIC OR RESPIRATORY ACIDOSIS 
 <p>
Potassium-conserving therapy should also be avoided in severely ill patients in 
whom respiratory or metabolic acidosis may occur. Acidosis may be associated
with rapid elevations in serum potassium levels. 
If Hydrochlorothiazide/triamterine is employed,
frequent evaluations of acid/base balance and serum electrolytes are necessary. 
 <p>
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
GENERAL 
 <p>
BIOAVAILABILITY: The bioavailability of the hydrochlorothiazide and triamterene 
components of Hydrochlorothiazide/triamterine 
is about 50% of the maximum obtainable with oral therapy. 
Theoretically, a patient transferred from therapy with hydrochlorothiazide
with or without triamterene might show an increase in blood pressure, fluid
retention, or change in serum potassium. Extensive clinical experience with
Hydrochlorothiazide/triamterine, however, 
suggests that these conditions have not been commonly
observed in clinical practice. (See ACTIONS/CLINICAL PHARMACOLOGY) 
 <p>
IMPAIRED HEPATIC FUNCTION 
 <p>
Thiazides should be used with caution in patients with impaired hepatic
function. They can precipitate hepatic coma in patients with severe liver
disease. Potassium depletion induced by the thiazide may be important in this
connection. Administer Hydrochlorothiazide/triamterine 
cautiously and be alert for such early signs of
impending coma as confusion, drowsiness and tremor; if mental confusion
increases discontinue Hydrochlorothiazide/triamterine 
for a few days. Attention must be given to other
factors that may precipitate hepatic coma, such as blood in the
gastrointestinal tract or preexisting potassium depletion.  
 <p>
HYPOKALEMIA 
 <p>
Hypokalemia is uncommon with Hydrochlorothiazide/triamterine; 
but, should it develop, corrective
measures should be taken such as potassium supplementation or increased intake
of potassium-rich foods. Institute such measures cautiously with frequent
determinations of serum potassium levels, especially in patients receiving
digitalis or with a history of cardiac arrhythmias. If serious hypokalemia
(serum potassium less than 3.0 mEq/L) is demonstrated by repeat serum potassium 
determinations, Hydrochlorothiazide/triamterine should be discontinued and potassium chloride
supplementation initiated. Less serious hypokalemia should be evaluated with
regard to other coexisting conditions and treated accordingly.  
 <p>
ELECTROLYTE IMBALANCE 
 <p>
Electrolyte imbalance, often encountered in such conditions as heart failure,
renal disease or cirrhosis of the liver, may also be aggravated by diuretics
and should be considered during Hydrochlorothiazide/triamterine 
therapy when using high doses for
prolonged periods or in patients on a salt-restricted diet. Serum
determinations of electrolytes should be performed, and are particularly
important if the patient is vomiting excessively or receiving fluids
parenterally. Possible fluid and electrolyte imbalance may be indicated by such 
warning signs as: dry mouth, thirst, weakness, lethargy, drowsiness,
restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria,
tachycardia and gastrointestinal symptoms.  
 <p>
HYPOCHLOREMIA 
 <p>
Although any chloride deficit is generally mild and usually does not require
specific treatment except under extraordinary circumstances (as in liver
disease or renal disease), chloride replacement may be required in the
treatment of metabolic alkalosis. Dilutional hyponatremia may occur in
edematous patients in hot weather; appropriate therapy is water restriction,
rather than administration of salt, except in rare instances when the
hyponatremia is life threatening. In actual salt depletion, appropriate
replacement is the therapy of choice.  
 <p>
RENAL STONES 
 <p>
Triamterene has been found in renal stones in association with the other usual
calculus components. Hydrochlorothiazide/triamterine 
should be used with caution in patients with a
history of renal stones.  
 <p>
LABORATORY TESTS 
 <p>
Serum Potassium: The normal adult range of serum potassium is 3.5 to 5.0 mEq
per liter with 4.5 mEq often being used for a reference point. If hypokalemia
should develop, corrective measures should be taken such as potassium
supplementation or increased dietary intake of potassium-rich foods.  
 <p>
Institute such measures cautiously with frequent determinations of serum
potassium levels. Potassium levels persistently above 6 mEq per liter require
careful observation and treatment. Serum potassium levels do not necessarily
indicate true body potassium concentration. A rise in plasma pH may cause a
decrease in plasma potassium concentration and an increase in the intracellular 
potassium concentration. Discontinue corrective measures for hypokalemia
immediately if laboratory determinations reveal an abnormal elevation of serum
potassium. Discontinue Hydrochlorothiazide/triamterine 
and substitute a thiazide diuretic alone until
potassium levels return to normal.  
 <p>
Serum Creatinine And BUN: Hydrochlorothiazide/triamterine 
may produce an elevated blood urea nitrogen
level, creatinine level or both. This apparently is secondary to a reversible
reduction of glomerular filtration rate or a depletion of intravascular fluid
volume (prerenal azotemia) rather than renal toxicity; levels usually return to 
normal when Hydrochlorothiazide/triamterine is 
discontinued. If azotemia increases, discontinue
Hydrochlorothiazide/triamterine.  Periodic BUN or 
serum creatinine determinations should be made,
especially in elderly patients and in patients 
with suspected or confirmed
renal insufficiency.  
 <p>
Serum PBI: Thiazide may decrease serum PBI levels without sign of thyroid
disturbance.  
 <p>
Parathyroid Function: Thiazides should be discontinued before carrying out
tests for parathyroid function. Calcium excretion is decreased by thiazides. 
Pathologic changes in the parathyroid glands with hypercalcemia and
hypophosphatemia have been observed in a few patients on prolonged thiazide
therapy. The common complications of hyperparathyroidism such as bone
resorption and peptic ulceration have not been seen.  
 <p>
DRUG INTERACTIONS 
 <p>
Angiotensin-converting Enzyme Inhibitors: Potassium-sparing agents should be
used with caution in conjunction with angiotensin-converting enzyme (ACE)
inhibitors due to an increased risk of hyperkalemia.  
 <p>
Oral Hypoglycemic Drugs: Concurrent use with chlorpropamide may increase the
risk of severe hyponatremia.  
 <p>
Nonsteroidal Anti-inflammatory Drugs: A possible interaction resulting in acute 
renal failure has been reported in a few patients on 
Hydrochlorothiazide/triamterine when treated with
indomethacin, a nonsteroidal anti-inflammatory agent. Caution is advised in
administering nonsteroidal anti-inflammatory agents with Hydrochlorothiazide/triamterine.  
 <p>
Lithium: Lithium generally should not be given with diuretics because they
reduce its renal clearance and increase the risk of lithium toxicity. Read
circulars for lithium preparations before use of such concomitant therapy with
Hydrochlorothiazide/triamterine.  
 <p>
Surgical Considerations: Thiazides have been shown to decrease arterial
responsiveness to norepinephrine (an effect attributed to loss of sodium). This 
diminution is not sufficient to preclude effectiveness of the pressor agent for 
therapeutic use. Thiazides have also been shown to increase the paralyzing
effect of nondepolarizing muscle relaxants such as tubocurarine (an effect
attributed to potassium loss); consequently caution should be observed in
patients undergoing surgery.  
 <p>
Other Considerations: Concurrent use of hydrochlorothiazide with amphotericin B 
or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, 
particularly hypokalemia, although the presence of triamterene minimizes the
hypokalemic effect.  
 <p>
Thiazides may add to or potentiate the action of other antihypertensive drugs.  
See INDICATIONS AND USAGE for concomitant use with other antihypertensive
drugs.  
 <p>
The effect of oral anticoagulants may be decreased when used concurrently with
hydrochlorothiazide; dosage adjustments may be necessary.  
 <p>
Hydrochlorothiazide/triamterine may raise the level of blood uric acid; 
dosage adjustments of antigout
medication may be necessary to control hyperuricemia and gout.  
 <p>
The following agents given together with triamterene may promote serum
potassium accumulation and possibly result in hyperkalemia because of the
potassium- sparing nature of triamterene, especially in patients with renal
insufficiency:  blood from blood bank (may contain up to 30 mEq of potassium
per liter of plasma or up to 65 mEq per liter of whole blood when stored for
more than 10 days); low-salt milk (may contain up to 60 mEq of potassium per
liter); potassium- containing medications (such as parenteral penicillin G
potassium); salt substitutes (most contain substantial amounts of potassium). 
Exchange resins, such as sodium polystyrene sulfonate, whether administered
orally or rectally, reduce serum potassium levels by sodium replacement of the
potassium; fluid retention may occur in some patients because of the increased
sodium intake.  
 <p>
Chronic or overuse of laxatives may reduce serum potassium levels by promoting
excessive potassium loss from the intestinal tract; laxatives may interfere
with the potassium-retaining effects of triamterene.  
 <p>
The effectiveness of methenamine may be decreased when used concurrently with
hydrochlorothiazide because of alkalinization of the urine.  
 <p>
DRUG/LABORATORY TEST INTERACTIONS 
 <p>
Triamterene and quinidine have similar fluorescence spectra; thus, 
Hydrochlorothiazide/triamterine will 
interfere with the fluorescent measurement of quinidine.  
 <p>
PREGNANCY: CATEGORY C 
 <p>
Teratogenic Effects--The safe use of Hydrochlorothiazide/triamterine in pregnancy has not been
established. Animal reproduction studies have not been conducted with Hydrochlorothiazide/triamterine.  
It is also not known if Hydrochlorothiazide/triamterine can cause fetal harm when administered to a
pregnant woman or can affect reproductive capacity. Hydrochlorothiazide/triamterine should be given to
a pregnant woman only if clearly needed.  
 <p>
Nonteratogenic Effects--Thiazides cross the placental barrier and appear in
cord blood. The use of thiazides in pregnant women requires that the
anticipated benefit be weighed against possible hazards to the fetus. These
hazards include fetal or neonatal jaundice, thrombocytopenia, and possible
other adverse reactions which have occurred in the adult.  
 <p>
Triamterene has been shown to cross the placental barrier and appear in the
cord blood of animals. The use of triamterene in pregnant women requires that
the anticipated benefit be weighed against possible hazards to the fetus. These 
possible hazards include adverse reactions which have occurred in the adult.  
 <p>
Nursing Mothers--Thiazides appear and triamterene may appear in breast milk. If 
use of the drug product is deemed essential, the patient should stop nursing. 
 <p>
Pediatric Use--Safety and effectiveness in children have not been established.  
 <p>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <p>
Angiotensin-converting Enzyme Inhibitors: Potassium-sparing agents should be
used with caution in conjunction with angiotensin-converting enzyme (ACE)
inhibitors due to an increased risk of hyperkalemia.  
 <p>
Oral Hypoglycemic Drugs: Concurrent use with chlorpropamide may increase the
risk of severe hyponatremia.  
 <p>
Nonsteroidal Anti-inflammatory Drugs: A possible interaction resulting in acute 
renal failure has been reported in a few patients on 
Hydrochlorothiazide/triamterine when treated with
indomethacin, a nonsteroidal anti-inflammatory agent. Caution is advised in
administering nonsteroidal anti-inflammatory agents with Hydrochlorothiazide/triamterine.  
 <p>
Lithium: Lithium generally should not be given with diuretics because they
reduce its renal clearance and increase the risk of lithium toxicity. Read
circulars for lithium preparations before use of such concomitant therapy with
Hydrochlorothiazide/triamterine.  
 <p>
Surgical Considerations: Thiazides have been shown to decrease arterial
responsiveness to norepinephrine (an effect attributed to loss of sodium). This 
diminution is not sufficient to preclude effectiveness of the pressor agent for 
therapeutic use. Thiazides have also been shown to increase the paralyzing
effect of nondepolarizing muscle relaxants such as tubocurarine (an effect
attributed to potassium loss); consequently caution should be observed in
patients undergoing surgery.  
 <p>
Other Considerations: Concurrent use of hydrochlorothiazide with amphotericin B 
or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, 
particularly hypokalemia, although the presence of triamterene minimizes the
hypokalemic effect.  
 <p>
Thiazides may add to or potentiate the action of other antihypertensive drugs.  
See INDICATIONS AND USAGE for concomitant use with other antihypertensive
drugs.  
 <p>
The effect of oral anticoagulants may be decreased when used concurrently with
hydrochlorothiazide; dosage adjustments may be necessary.  
 <p>
Hydrochlorothiazide/triamterine may raise the level of 
blood uric acid; dosage adjustments of antigout
medication may be necessary to control hyperuricemia and gout.  
 <p>
The following agents given together with triamterene may promote serum
potassium accumulation and possibly result in hyperkalemia because of the
potassium- sparing nature of triamterene, especially in patients with renal
insufficiency:  blood from blood bank (may contain up to 30 mEq of potassium
per liter of plasma or up to 65 mEq per liter of whole blood when stored for
more than 10 days); low-salt milk (may contain up to 60 mEq of potassium per
liter); potassium- containing medications (such as parenteral penicillin G
potassium); salt substitutes (most contain substantial amounts of potassium). 
 <p>
Exchange resins, such as sodium polystyrene sulfonate, whether administered
orally or rectally, reduce serum potassium levels by sodium replacement of the
potassium; fluid retention may occur in some patients because of the increased
sodium intake.  
 <p>
Chronic or overuse of laxatives may reduce serum potassium levels by promoting
excessive potassium loss from the intestinal tract; laxatives may interfere
with the potassium-retaining effects of triamterene.  
 <p>
The effectiveness of methenamine may be decreased when used concurrently with
hydrochlorothiazide because of alkalinization of the urine.  
 <p>
(See also PRECAUTIONS) 
 <p>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
Adverse effects are listed in decreasing order of frequency; however, the most
serious adverse effects are listed first regardless of frequency. The serious
adverse effects associated with Hydrochlorothiazide/triamterine 
have commonly occurred in less than
0.1% of patients treated with this product.  
 <p>
Hypersensitivity: anaphylaxis, rash, urticaria, photosensitivity.
Cardiovascular: arrhythmia, postural hypotension.  
 <p>
Metabolic: diabetes mellitus, hyperkalemia, hyperglycemia, glycosuria,
hyperuricemia, hypokalemia, hyponatremia, acidosis, hypochloremia.  
 <p>
Gastrointestinal: jaundice and/or liver enzyme abnormalities, pancreatitis,
nausea and vomiting, diarrhea, constipation, abdominal pain.  
 <p>
Renal: acute renal failure, interstitial nephritis, renal stones composed
primarily of triamterene, elevated BUN and serum creatinine, abnormal urinary
sediment.  
 <p>
Hematologic: leukopenia, thrombocytopenia and purpura, megaloblastic anemia.  
 <p>
Musculoskeletal: muscle cramps.  
 <p>
Central Nervous System: weakness, fatigue, dizziness, headache, dry mouth.  
 <p>
Miscellaneous: impotence, sialadenitis.  
 <p>
Thiazides alone have been shown to cause the following additional adverse
reactions:  
 <p>
Central Nervous System: paresthesias, vertigo.  
 <p>
Ophthalmic: xanthopsia, transient blurred vision.  
 <p>
Respiratory: allergic pneumonitis, pulmonary edema, respiratory distress.  
 <p>
Other: necrotizing vasculitis, exacerbation of lupus.  
 <p>
Hematologic: aplastic anemia, agranulocytosis, hemolytic anemia.  
 <p>
Neonate And Infancy: thrombocytopenia and pancreatitis--rarely, in newborns
whose mothers have received thiazides during pregnancy.  
 <p>
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <p>
Electrolyte imbalance is the major concern (see WARNINGS section). Symptoms
reported include: polyuria, nausea, vomiting, weakness, lassitude, fever,
flushed face, and hyperactive deep tendon reflexes. If hypotension occurs, it
may be treated with pressor agents such as levarterenol to maintain blood
pressure. Carefully evaluate the electrolyte pattern and fluid balance. Induce
immediate evacuation of the stomach through emesis or gastric lavage. There is
no specific antidote.  
 <p>
Reversible acute renal failure following ingestion of 50 tablets of a product
containing a combination of 50 mg triamterene and 25 mg hydrochlorothiazide has 
been reported.  
 <p>
Although triamterene is largely protein-bound (approximately 67%), there may be 
some benefit to dialysis in cases of overdosage.  
 <p>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
The usual dose of Hydrochlorothiazide/triamterine is 
one or two capsules given once daily, with
appropriate monitoring of serum potassium and of the clinical effect.  
<p>
 Note: Potency may vary between products.  Consult appropriate FDA approved information
for the specific product being prescribed.

 (See&nbsp;WARNINGS, Hyperkalemia and PRECAUTIONS, Bioavailability.) 

<p>
<hr width="100%" >

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a> 
<br></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-75</DOCNO>
<DOCOLDNO>IA018-000200-B043-196</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/sudafed.htm 206.86.175.201 19970106231830 text/html 8989
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:12:14 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 8807
Last-modified: Thu, 26 Dec 1996 22:43:00 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
   <TITLE>Pseudoephedrine - RxList Generic Information</TITLE>
   <META NAME="keywords" CONTENT="Bronalin Decongestant, Cenafed, Chlordrine,Maxiphed, Novafed; Pseudogest, Slofed-60, Sufedrin, Sudafed">
   <META NAME="GENERATOR" CONTENT="Mozilla/3.01Gold (Win95; I) [Netscape]">
   <META NAME="KeyWords" CONTENT="Efidac, Bronalin Decongestant, Bromaline Pediatric, Cenafed, Chlordrine, GNP, GNP Nasal, Maxiphed, Novafed, Pediacare,  Pseudogest, Slofed-60, Sufedrin, Sudafed">
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000EE" VLINK="#551A8B" ALINK="#FF0000">

<CENTER><P><A HREF="http://www.rxlist.com/cgi/rxlist.cgi"><IMG SRC="rx.gif" BORDER=0 HEIGHT=125 WIDTH=125></A></P></CENTER>

<H1 ALIGN=CENTER>Pseudoephedrine</H1>

<P>
<HR><FONT COLOR="#0000FF">[<A HREF="#DESCRIPTION">description</A>] [<A HREF="#ACTIONS/CLINICAL PHARMACOLOGY">action</A>]
[<A HREF="#INDICATIONS AND USAGE">use</A>] [<A HREF="#CONTRAINDICATIONS">contra</A>]
[<A HREF="#WARNINGS">warn!</A>] [<A HREF="#PRECAUTIONS">caution</A>] [<A HREF="#DRUG INTERACTIONS">drug-drug</A>]
[<A HREF="#ADVERSE REACTIONS">side effects</A>] [<A HREF="#OVERDOSAGE">toxicity</A>]
[<A HREF="#DOSAGE AND ADMINISTRATION">dosing</A>] </FONT></P>

<P><B>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</B></P>

<P>
<HR width="100%"></P>

<P><A NAME="DESCRIPTION"></A><B>DESCRIPTION </B></P>

<P>Pseudoephedrine sulfate is the synthetic salt of one of the naturally
occurring dextrorotatory diastereomers of ephedrine and is classified as
an indirect sympathomimetic amine. The empirical formula for pseudoephedrine
sulfate is (C10H15NO)2.H2SO4; the chemical name is (S- (R*,R*))-alpha-(1(methylamino)ethyl)
benzenemethanol sulfate (2:1) (salt).</P>

<P>The molecular weight of pseudoephedrine sulfate is 428.54. It is a white
powder, freely soluble in water and methanol and sparingly soluble in chloroform.</P>

<P><A NAME="ACTIONS/CLINICAL PHARMACOLOGY"></A><B>ACTIONS/CLINICAL PHARMACOLOGY
</B></P>

<P>Pseudoephedrine sulfate (d-isoephedrine sulfate) is an orally active
sympathomimetic amine which exerts a decongestant action on the nasal mucosa.
It is recognized as an effective agent for the relief of nasal congestion
due to allergic rhinitis. Pseudoephedrine produces peripheral effects similar
to those of ephedrine and central effects similar to, but less intense
than, amphetamines. It has the potential for excitatory side effects.</P>

<P><A NAME="INDICATIONS AND USAGE"></A><B>INDICATIONS AND USAGE </B></P>

<P>For the temporary relief of nasal congestion due to the common cold,
hay fever, or other upper respiratory allergies, and nasal congestion associated
with sinusitis. Helps decongest sinus openings and passages; temporarily
relieves sinus congestion and pressure. Temporarily restores freer breathing
through the nose. </P>

<P><A NAME="CONTRAINDICATIONS"></A><B>CONTRAINDICATIONS </B></P>

<P>Pseudoephedrine is contraindicated in patients with narrow-angle glaucoma
or urinary retention, and in patients receiving monoamine oxidase (MAO)
inhibitor therapy or within fourteen (14) days of stopping such treatment
(see DRUG INTERACTIONS section). It is also contraindicated in patients
with severe hypertension, severe coronary artery disease, and in those
who have shown hypersensitivity or idiosyncrasy to its components, to adrenergic
agents, or to other drugs of similar chemical structures. Manifestations
of patient idiosyncrasy to adrenergic agents include: insomnia, dizziness,
weakness, tremor, or arrhythmias.</P>

<P><A NAME="WARNINGS"></A><B>WARNINGS </B></P>

<P>DO NOT EXCEED RECOMMENDED DOSAGE. If nervousness, dizziness, or sleeplessness
occur, discontinue use and consult a doctor. If symptoms do not improve
within 7 days or are accompanied by fever, consult a doctor. Do not take
this product if you have heart disease, high blood pressure, thyroid disease,
diabetes, or difficulty in urination due to enlargement of the prostate
gland unless directed by a doctor. As with any drug, if you are pregnant
or nursing a baby, seek the advice of a health professional before using
this product. KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. In
case of accidental overdose, seek professional assistance or contact a
Poison Control Center immediately. </P>

<P><A NAME="PRECAUTIONS"></A><B>PRECAUTIONS </B></P>

<P>This product should not be used by patients who are hypersensitive to
it or to any of its ingredients. This product should not be used by patients
with narrow-angle glaucoma, urinary retention, or by patients receiving
a monoamine oxidase (MAO) inhibitor or within 14 days of stopping use of
an MAO inhibitor. It also should not be used by patients with severe hypertension
or severe coronary artery disease.</P>

<P>Pseudoephedrine administered alone also distributes into breast milk
of the lactating human female. Pseudoephedrine concentrations in milk are
consistently higher than those in plasma. The total amount of drug in milk
as judged by the area under the curve (AUC) is 2 to 3 times greater than
in plasma. The fraction of a pseudoephedrine dose excreted in milk is estimated
to be 0.4% to 0.7%. A decision should be made whether to discontinue nursing
or to discontinue the drug, taking into account the importance of the drug
to the mother. Caution should be exercised when Loratadine with pseudoephedrine
(extended release) Tablets are administered to a nursing woman.</P>

<P><A NAME="DRUG INTERACTIONS"></A><B>DRUG INTERACTIONS </B></P>

<P>Pseudoephedrine tablets are contraindicated in patients taking monoamine
oxidase inhibitors and for 2 weeks after stopping use of an MAO inhibitor.
The antihypertensive effects of beta-adrenergic blocking agents, methyldopa,
mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
Increased ectopic pacemaker activity can occur when pseudoephedrine is
used concomitantly with digitalis.</P>

<P>(See Also PRECAUTIONS.)</P>

<P><A NAME="ADVERSE REACTIONS"></A><B>ADVERSE REACTIONS </B></P>

<P>Pseudoephedrine may cause mild CNS stimulation in hypersensitive patients.
Nervousness, excitability, restlessness, dizziness, weakness, or insomnia
may occur. Headache, drowsiness, tachycardia, palpitation, pressor activity,
and cardiac arrhythmias have been reported. Sympathomimetic drugs have
also been associated with other untoward effects, such as fear, anxiety,
tenseness, tremor, hallucinations, seizures, pallor, respiratory difficulty,
dysuria, and cardiovascular collapse.</P>

<P>DRUG ABUSE AND DEPENDENCE:</P>

<P>Pseudoephedrine, like other central nervous system stimulants, has been
abused. At high doses, subjects commonly experience an elevation of mood,
a sense of increased energy and alertness, and decreased appetite. Some
individuals become anxious, irritable, and loquacious. In addition to the
marked euphoria, the user experiences a sense of markedly enhanced physical
strength and mental capacity. With continued use, tolerance develops, the
user increases the dose, and toxic signs and symptoms appear. Depression
may follow rapid withdrawal.</P>

<P><A NAME="OVERDOSAGE"></A><B>OVERDOSAGE </B></P>

<P>In the event of overdosage, general symptomatic and supportive measures
should be instituted promptly and maintained for as long as necessary.
Treatment of overdosage would reasonably consist of emesis (ipecac syrup),
except in patients with impaired consciousness, followed by the administration
of activated charcoal to absorb any remaining drug. If vomiting is unsuccessful,
or contraindicated, gastric lavage should be performed with normal saline.
Saline cathartics may also be of value for rapid dilution of bowel contents.
</P>

<P><A NAME="DOSAGE AND ADMINISTRATION"></A><B>DOSAGE AND ADMINISTRATION
</B></P>

<P>To be given every 4 to 6 hours. Do not exceed 4 doses in 24 hours. Adults
and children 12 years of age and over, 1 tablet (30-60mg). Extended Release
(60-240mg/day).<BR>
Children 6 to under 12 years of age, use 30 mg. tablets. <BR>
Children 2 to under 6 years of age, use 15mg of a liquid/drops preparation.
<BR>
Children under 2 years of age, consult a doctor.</P>

<H2 ALIGN=CENTER>
<HR width="100%"></H2>

<H2 ALIGN=CENTER><A HREF="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</A><A HREF="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <A HREF="http://www.rxlist.com/top200.htm"><IMG SRC="redball.gif" BORDER=0 HEIGHT=17 WIDTH=17></A></A><A HREF="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</A> &nbsp;&nbsp;<IMG SRC="redball.gif" HEIGHT=17 WIDTH=17><A HREF="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</A></H2>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B10-76</DOCNO>
<DOCOLDNO>IA018-000200-B033-172</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/nifedxl.htm 206.86.175.201 19970106223734 text/html 35523
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:31:11 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 35340
Last-modified: Thu, 11 Jul 1996 06:08:31 GMT
</DOCHDR>
<html>
<head>
   <title>Nifedipine Extended Release - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Nifedipine Extended Release</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Nifedipine is a drug belonging to a class of pharmacological agents
known as the calcium channel blockers. Nifedipine is 3,5-pyridinedicarboxylic
acid, 1,4- dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester, C17H18N2O6.
</p>

<p>Nifedipine is a yellow crystalline substance, practically insoluble
in water but soluble in ethanol. It has a molecular weight of 346.3. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Nifedipine is a calcium ion influx inhibitor (slow-channel blocker or
calcium ion antagonist) and inhibits the transmembrane influx of calcium
ions into cardiac muscle and smooth muscle. The contractile processes of
cardiac muscle and vascular smooth muscle are dependent upon the movement
of extracellular calcium ions into these cells through specific ion channels.
Nifedipine selectively inhibits calcium ion influx across the cell membrane
of cardiac muscle and vascular smooth muscle without altering serum calcium
concentrations. </p>

<p>MECHANISM OF ACTION </p>

<p>A) ANGINA </p>

<p>The precise mechanisms by which inhibition of calcium influx relieves
angina has not been fully determined, but includes at least the following
two mechanisms: </p>

<p>1) RELAXATION AND PREVENTION OF CORONARY ARTERY SPASM </p>

<p>Nifedipine dilates the main coronary arteries and coronary arterioles,
both in normal and ischemic regions, and is a potent inhibitor of coronary
artery spasm whether spontaneous or ergonovine-induced. This property increases
myocardial oxygen delivery in patients with coronary artery spasm, and
is responsible for the effectiveness of nifedipine in vasospastic (Prinzmetal's
or variant) angina. Whether this effect plays any role in classical angina
is not clear, but studies of exercise tolerance have not shown an increase
in the maximum exercise rate- pressure product, a widely accepted measure
of oxygen utilization. This suggests that, in general, relief of spasm
or dilation of coronary arteries is not an important factor in classical
angina. </p>

<p>2) REDUCTION OF OXYGEN UTILIZATION </p>

<p>Nifedipine regularly reduces arterial pressure at rest and at a given
level of exercise by dilating peripheral arterioles and reducing the total
peripheral resistance (afterload) against which the heart works. This unloading
of the heart reduces myocardial energy consumption and oxygen requirements,
and probably accounts for the effectiveness of nifedipine in chronic stable
angina. </p>

<p>B) HYPERTENSION </p>

<p>The mechanism by which nifedipine reduces arterial blood pressure involves
peripheral arterial vasodilatation and the resulting reduction in peripheral
vascular resistance. The increased peripheral vascular resistance that
is an underlying cause of hypertension results from an increase in active
tension in the vascular smooth muscle. Studies have demonstrated that the
increase in active tension reflects an increase in cytosolic free calcium.
</p>

<p>Nifedipine is a peripheral arterial vasodilator which acts directly
on vascular smooth muscle. The binding of nifedipine to voltage-dependent
and possibly receptor-operated channels in vascular smooth muscle results
in an inhibition of calcium influx through these channels. Stores of intracellular
calcium in vascular smooth muscle are limited and thus dependent upon the
influx of extracellular calcium for contraction to occur. The reduction
in calcium influx by nifedipine causes arterial vasodilation and decreased
peripheral vascular resistance which results in reduced arterial blood
pressure. </p>

<p>PHARMACOKINETICS AND METABOLISM </p>

<p>Nifedipine is completely absorbed after oral administration. Plasma
drug concentrations rise at a gradual, controlled rate after a Nifedipine
XL* Extended Release Tablet dose and reach a plateau at approximately six
hours after the first dose. For subsequent doses, relatively constant plasma
concentrations at this plateau are maintained with minimal fluctuations
over the 24 hour dosing interval. About a four-fold higher fluctuation
index (ratio of peak to trough plasma concentration) was observed with
the conventional immediate release nifedipine capsule at t.i.d. dosing
than with once daily Nifedipine XL* Extended Release Tablet. At steady-state
the bioavailability of the nifedipine XL Extended Release Tablet is 86%
relative to nifedipine capsules. Administration of the Nifedipine XL* Extended
Release Tablet in the presence of food slightly alters the early rate of
drug absorption, but does not influence the extent of drug bioavailability.
Markedly reduced GI retention time over prolonged periods (i.e., short
bowel syndrome), however, may influence the pharmacokinetic profile of
the drug which could potentially result in lower plasma concentrations.
Pharmacokinetics of Nifedipine XL* Extended Release Tablets are linear
over the dose range of 30 to 180 mg in that plasma drug concentrations
are proportional to dose administered. There was no evidence of dose dumping
either in the presence or absence of food for over 150 subjects in pharmacokinetic
studies. </p>

<p>Nifedipine is extensively metabolized to highly water-soluble, inactive
metabolites accounting for 60 to 80% of the dose excreted in the urine.
The elimination half-life of nifedipine is approximately two hours. Only
traces (less than 0.1% of the dose) of unchanged form can be detected in
the urine. The remainder is excreted in the feces in metabolized form,
most likely as a result of biliary excretion. Thus, the pharmacokinetics
of nifedipine are not significantly influenced by the degree of renal impairment.
Patients in hemodialysis or chronic ambulatory peritoneal dialysis have
not reported significantly altered pharmacokinetics of nifedipine. Since
hepatic biotransformation is the predominant route for the disposition
of nifedipine, the pharmacokinetics may be altered in patients with chronic
liver disease. Patients with hepatic impairment (liver cirrhosis) have
a longer disposition half-life and higher bioavailability of nifedipine
than healthy volunteers. The degree of serum protein binding of nifedipine
is high (92-98%). Protein binding may be greatly reduced in patients with
renal or hepatic impairment. </p>

<p>HEMODYNAMICS </p>

<p>Like other slow-channel blockers, nifedipine exerts a negative inotropic
effect on isolated myocardial tissue. This is rarely, if ever, seen in
intact animals or man, probably because of reflex responses to its vasodilating
effects. In man, nifedipine decreases peripheral vascular resistance which
leads to a fall in systolic and diastolic pressures, usually minimal in
normotensive volunteers (less than 5-10 mm Hg systolic), but sometimes
larger. With Nifedipine XL* Extended Release Tablets, these decreases in
blood pressure are not accompanied by any significant change in heart rate.
Hemodynamic studies in patients with normal ventricular function have generally
found a small increase in cardiac index without major effects on ejection
fraction, left ventricular end diastolic pressure (LVEDP) or volume (LVEDV).
In patients with impaired ventricular function, most acute studies have
shown some increase in ejection fraction and reduction in left ventricular
filling pressure. </p>

<p>ELECTROPHYSIOLOGIC EFFECTS </p>

<p>Although, like other members of its class, nifedipine causes a slight
depression of sinoatrial node function and atrioventricular conduction
in isolated myocardial preparations, such effects have not been seen in
studies in intact animals or in man. In formal electrophysiologic studies,
predominantly in patients with normal conduction systems, nifedipine has
had no tendency to prolong atrioventricular conduction or sinus node recovery
time, or to slow sinus rate. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>I. VASOSPASTIC ANGINA </p>

<p>Nifedipine XL* is indicated for the management of vasospastic angina
confirmed by any of the following criteria: 1) classical pattern of angina
at rest accompanied by ST segment elevation, 2) angina or coronary artery
spasm provoked by ergonovine, or 3) angiographically demonstrated coronary
artery spasm. In those patients who have had angiography, the presence
of significant fixed obstructive disease is not incompatible with the diagnosis
of vasospastic angina, provided that the above criteria are satisfied.
Nifedipine XL* may also be used where the clinical presentation suggests
a possible vasospastic component but where vasospasm has not been confirmed,
e.g., where pain has a variable threshold on exertion or in unstable angina
where electrocardiographic findings are compatible with intermittent vasospasm,
or when angina is refractory to nitrates and/or adequate doses of beta
blockers. </p>

<p>II. CHRONIC STABLE ANGINA </p>

<p>(CLASSICAL EFFORT-ASSOCIATED ANGINA) </p>

<p>Nifedipine XL* is indicated for the management of chronic stable angina
(effort- associated angina) without evidence of vasospasm in patients who
remain symptomatic despite adequate doses of beta blockers and/or organic
nitrates or who cannot tolerate those agents. </p>

<p>In chronic stable angina (effort-associated angina) nifedipine has been
effective in controlled trials of up to eight weeks duration in reducing
angina frequency and increasing exercise tolerance, but confirmation of
sustained effectiveness and evaluation of long term safety in these patients
are incomplete. </p>

<p>Controlled studies in small numbers of patients suggest concomitant
use of nifedipine and beta blocking agents may be beneficial in patients
with chronic stable angina, but available information is not sufficient
to predict with confidence the effects of concurrent treatment, especially
in patients with compromised left ventricular function or cardiac conduction
abnormalities. When introducing such concomitant therapy, care must be
taken to monitor blood pressure closely since severe hypotension can occur
from the combined effects of the drugs. (See WARNINGS.) </p>

<p>III. HYPERTENSION </p>

<p>Nifedipine XL* is indicated for the treatment of hypertension. It may
be used alone or in combination with other antihypertensive agents. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Known hypersensitivity reaction to nifedipine. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>EXCESSIVE HYPOTENSION </p>

<p>Although in most angina patients the hypotensive effect of nifedipine
is modest and well tolerated, occasional patients have had excessive and
poorly tolerated hypotension. These responses have usually occurred during
initial titration or at the time of subsequent upward dosage adjustment,
and may be more likely in patients on concomitant beta blockers. </p>

<p>Severe hypotension and/or increased fluid volume requirements have been
reported in patients receiving nifedipine together with a beta-blocking
agent who underwent coronary artery bypass surgery using high dose fentanyl
anesthesia. The interaction with high dose fentanyl appears to be due to
the combination of nifedipine and a beta blocker, but the possibility that
it may occur with nifedipine alone, with low doses of fentanyl, in other
surgical procedures, or with other narcotic analgesics cannot be ruled
out. In nifedipine-treated patients where surgery using high dose fentanyl
anesthesia is contemplated, the physician should be aware of these potential
problems and if the patient's condition permits, sufficient time (at least
36 hours) should be allowed for nifedipine to be washed out of the body
prior to surgery. </p>

<p>The following information should be taken into account in those patients
who are being treated for hypertension as well as angina: </p>

<p>INCREASED ANGINA AND/OR MYOCARDIAL INFARCTION </p>

<p>Rarely, patients, particularly those who have severe obstructive coronary
artery disease, have developed well documented increased frequency, duration
and/or severity of angina or acute myocardial infarction on starting nifedipine
or at the time of dosage increase. The mechanism of this effect is not
established. </p>

<p>BETA BLOCKER WITHDRAWAL </p>

<p>It is important to taper beta blockers if possible, rather than stopping
them abruptly before beginning nifedipine. Patients recently withdrawn
from beta blockers may develop a withdrawal syndrome with increased angina,
probably related to increased sensitivity to catecholamines. Initiation
of nifedipine treatment will not prevent this occurrence and on occasion
has been reported to increase it. </p>

<p>CONGESTIVE HEART FAILURE </p>

<p>Rarely, patients, usually receiving a beta blocker, have developed heart
failure after beginning nifedipine. Patients with tight aortic stenosis
may be at greater risk for such an event, as the unloading effect of nifedipine
would be expected to be of less benefit to those patients, owing to their
fixed impedance to flow across the aortic valve. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL--HYPOTENSION: Because nifedipine decreases peripheral vascular
resistance, careful monitoring of blood pressure during the initial administration
and titration of nifedipine is suggested. Close observation is especially
recommended for patients already taking medications that are known to lower
blood pressure. (See WARNINGS.) </p>

<p>PERIPHERAL EDEMA: Mild to moderate peripheral edema occurs in a dose
dependent manner with an incidence ranging from approximately 10% to about
30% at the highest dose studied (180 mg). It is a localized phenomenon
thought to be associated with vasodilation of dependent arterioles and
small blood vessels and not due to left ventricular dysfunction or generalized
fluid retention. With patients whose angina or hypertension is complicated
by congestive heart failure, care should be taken to differentiate this
peripheral edema from the effects of increasing left ventricular dysfunction.
</p>

<p>OTHER: As with any other non-deformable material, caution should be
used when administering Nifedipine XL* in patients with preexisting severe
gastrointestinal narrowing (pathologic or iatrogenic). There have been
rare reports of obstructive symptoms in patients with known strictures
in association with the ingestion of Nifedipine XL*. </p>

<p>INFORMATION FOR PATIENTS: Nifedipine XL* Extended Release Tablets should
be swallowed whole. Do not chew, divide or crush tablets. Do not be concerned
if you occasionally notice in your stool something that looks like a tablet.
In Nifedipine XL*, the medication is contained within a nonabsorbable shell
that has been specially designed to slowly release the drug for your body
to absorb. When this process is completed, the empty tablet is eliminated
from your body. </p>

<p>LABORATORY TESTS: Rare, usually transient, but occasionally significant
elevations of enzymes such as alkaline phosphatase, CPK, LDH, SGOT and
SGPT have been noted. The relationship to nifedipine therapy is uncertain
in most cases, but probable in some. These laboratory abnormalities have
rarely been associated with clinical symptoms; however, cholestasis with
or without jaundice has been reported. A small (5.4%) increase in mean
alkaline phosphatase was noted in patients treated with Nifedipine XL*.
This was an isolated finding not associated with clinical symptoms and
it rarely resulted in values which fell outside the normal range. Rare
instances of allergic hepatitis have been reported. In controlled studies,
Nifedipine XL* did not adversely affect serum uric acid, glucose, or cholesterol.
Serum potassium was unchanged in patients receiving Nifedipine XL* in the
absence of concomitant diuretic therapy, and slightly decreased in patients
receiving concomitant diuretics. </p>

<p>Nifedipine, like other calcium channel blockers, decreases platelet
aggregation In Vitro. Limited clinical studies have demonstrated a moderate
but statistically significant decrease in platelet aggregation and increase
in bleeding time in some nifedipine patients. This is thought to be a function
of inhibition of calcium transport across the platelet membrane. No clinical
significance for these findings has been demonstrated. </p>

<p>Positive direct Coombs test with/without hemolytic anemia has been reported
but a causal relationship between nifedipine administration and positivity
of this laboratory test, including hemolysis, could not be determined.
</p>

<p>Although nifedipine has been used safely in patients with renal dysfunction
and has been reported to exert a beneficial effect in certain cases, rare
reversible elevations in BUN and serum creatinine have been reported in
patients with pre- existing chronic renal insufficiency. The relationship
to nifedipine therapy is uncertain in most cases but probable in some.
</p>

<p>DRUG INTERACTIONS--Beta-adrenergic blocking agents: (See INDICATIONS
and WARNINGS) Experience in over 1400 patients with nifeipine capsules
in a noncomparative clinical trial has shown that concomitant administration
of nifedipine and beta-blocking agents is usually well tolerated but there
have been occasional literature reports suggesting that the combination
may increase the likelihood of congestive heart failure, severe hypotension,
or exacerbation of angina. </p>

<p>Long Acting Nitrates: Nifedipine may be safely co-administered with
nitrates, but there have been no controlled studies to evaluate the antianginal
effectiveness of this combination. </p>

<p>Digitalis: Administration of nifedipine with digoxin increased digoxin
levels in nine of twelve normal volunteers. The average increase was 45%.
Another investigator found no increase in digoxin levels in thirteen patients
with coronary artery disease. In an uncontrolled study of over two hundred
patients with congestive heart failure during which digoxin blood levels
were not measured, digitalis toxicity was not observed. Since there have
been isolated reports of patients with elevated digoxin levels, it is recommended
that digoxin levels be monitored when initiating, adjusting, and discontinuing
nifedipine to avoid possible over- or under-digitalization. </p>

<p>Coumarin Anticoagulants: There have been rare reports of increased prothrombin
time in patients taking coumarin anticoagulants to whom nifedipine was
administered. However, the relationship to nifedipine therapy is uncertain.
</p>

<p>Cimetidine: A study in six healthy volunteers has shown a significant
increase in peak nifedipine plasma levels (80%) and area-under-the-curve
(74%), after a one week course of cimetidine at 1000 mg per day and nifedipine
at 40 mg per day. Ranitidine produced smaller, non-significant increases.
The effect may be mediated by the known inhibition of cimetidine on hepatic
cytochrome P-450, the enzyme system probably responsible for the first-pass
metabolism of nifedipine. If nifedipine therapy is initiated in a patient
currently receiving cimetidine cautious titration is advised. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Nifedipine was
administered orally to rats for two years and was not shown to be carcinogenic.
When given to rats prior to mating, nifedipine caused reduced fertility
at a dose approximately 30 times the maximum recommended human dose. In
Vivo mutagenicity studies were negative. </p>

<p>PREGNANCY: Pregnancy Category C. Nifedipine has been shown to be teratogenic
in rats when given in doses 30 times the maximum recommended human dose.
Nifedipine was embryotoxic (increased fetal resorptions, decreased fetal
weight increased stunted forms, increased fetal deaths, decreased neonatal
survival) in rats, mice and rabbits at doses of from 3 to 10 times the
maximum recommended human dose. In pregnant monkeys, doses 2/3 and twice
the maximum recommended human dose resulted in small placentas and underdeveloped
chorionic villi. In rats, doses three times maximum human dose and higher
caused prolongation of pregnancy. There are no adequate and well controlled
studies in pregnant women. Nifedipine XL* Extended Release Tablets should
be used during pregnancy only if the potential benefit justifies the potential
risk to the fetus. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Beta-adrenergic blocking agents: (See INDICATIONS and WARNINGS) Experience
in over 1400 patients with nifedipine capsules in a noncomparative clinical
trial has shown that concomitant administration of nifedipine and beta-blocking
agents is usually well tolerated but there have been occasional literature
reports suggesting that the combination may increase the likelihood of
congestive heart failure, severe hypotension, or exacerbation of angina.
</p>

<p>Long Acting Nitrates: Nifedipine may be safely co-administered with
nitrates, but there have been no controlled studies to evaluate the antianginal
effectiveness of this combination. </p>

<p>Digitalis: Administration of nifedipine with digoxin increased digoxin
levels in nine of twelve normal volunteers. The average increase was 45%.
Another investigator found no increase in digoxin levels in thirteen patients
with coronary artery disease. In an uncontrolled study of over two hundred
patients with congestive heart failure during which digoxin blood levels
were not measured, digitalis toxicity was not observed. Since there have
been isolated reports of patients with elevated digoxin levels, it is recommended
that digoxin levels be monitored when initiating, adjusting, and discontinuing
nifedipine to avoid possible over- or under-digitalization. </p>

<p>Coumarin Anticoagulants: There have been rare reports of increased prothrombin
time in patients taking coumarin anticoagulants to whom nifedipine was
administered. However, the relationship to nifedipine therapy is uncertain.
</p>

<p>Cimetidine: A study in six healthy volunteers has shown a significant
increase in peak nifedipine plasma levels (80%) and area-under-the-curve
(74%), after one week course of cimetidine at 1000 mg per day and nifedipine
at 40 mg per day. Ranitidine produced smaller, non-significant increases.
The effect may be mediated by the known inhibition of cimetidine on hepatic
cytochrome P-450, the enzyme system probably responsible for the first-pass
metabolism of nifedipine. If nifedipine therapy is initiated in a patient
currently receiving cimetidine cautious titration is advised. </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>ADVERSE EXPERIENCES </p>

<p>Over 1000 patients from both controlled and open trials with Nifedipine
XL* Extended Release Tablets in hypertension and angina were included in
the evaluation of adverse experiences. All side effects reported during
nifedipine XL Extended Release Tablet therapy were tabulated independent
of their causal relation to medication. The most common side effect reported
with Nifedipine XL* was edema which was dose related and ranged in frequency
from approximately 10% to about 30% at the highest dose studied (180 mg).
Other common adverse experiences reported in placebo-controlled trials
include: </p>

<pre><font SIZE=-1>                         Nifedipine XL* (%)             PLACEBO (%)    
ADVERSE EFFECT                         (N=707)                     (N=266)      
Headache                                 15.8                        9.8        
Fatigue                                   5.9                        4.1        
Dizziness                                 4.1                        4.5        
Constipation                              3.3                        2.3        
Nausea                                    3.3                        1.9   </font></pre>

<p>Of these, only edema and headache were more common in Nifedipine XL*
patients than placebo patients. </p>

<p>The following adverse reactions occurred with an incidence of less than
3.0%. With the exception of leg cramps, the incidence of these side effects
was similar to that of placebo alone. </p>

<p>Body As A Whole/Systemic: asthenia, flushing, pain </p>

<p>Cardiovascular: palpitations </p>

<p>Central Nervous System: insomnia, nervousness, paresthesia, somnolence
</p>

<p>Dermatologic: pruritus, rash </p>

<p>Gastrointestinal: abdominal pain, diarrhea, dry mouth, dyspepsia, flatulence
</p>

<p>Musculoskeletal: arthralgia, leg cramps </p>

<p>Respiratory: chest pain (nonspecific), dyspnea </p>

<p>Urogenital: impotence, polyuria </p>

<p>Other adverse reactions were reported sporadically with an incidence
of 1.0% or less. These include: </p>

<p>Body As A Whole/Systemic: face edema, fever, hot flashes, malaise, periorbital
edema, rigors </p>

<p>Cardiovascular: arrhythmia, hypotension, increased angina, tachycardia,
syncope </p>

<p>Central Nervous System: anxiety, ataxia, decreased libido, depression,
hypertonia, hypoesthesia, migraine, paroniria, tremor, vertigo </p>

<p>Dermatologic: alopecia, increased sweating, urticaria, purpura </p>

<p>Gastrointestinal: eructation, gastroesophageal reflux, gum hyperplasia,
melena vomiting, weight increase </p>

<p>Musculoskeletal: back pain, gout, myalgias </p>

<p>Respiratory: coughing, epistaxis, upper respiratory tract infection,
respiratory disorder, sinusitis </p>

<p>Special Senses: abnormal lacrimation, abnormal vision, taste perversion,
tinnitus </p>

<p>Urogenital/Reproductive: breast pain, dysuria, hematuria, nocturia </p>

<p>Adverse experiences which occurred in less than 1 in 1000 patients cannot
be distinguished from concurrent disease states or medications. </p>

<p>The following adverse experiences, reported in less than 1% of patients,
occurred under conditions (e.g., open trials, marketing experience) where
a causal relationship is uncertain: gastrointestinal irritation, gastrointestinal
bleeding. </p>

<p>In multiple-dose U.S. and foreign controlled studies with nifedipine
capsules in which adverse reactions were reported spontaneously, adverse
effects were frequent but generally not serious and rarely required discontinuation
of therapy or dosage adjustment. Most were expected consequences of the
vasodilator effects of nifedipine.</p>

<pre><font SIZE=-1>                               NIFEDIPINE                    
                                               CAPSULES (%)      PLACEBO (%)    
ADVERSE EFFECT                                  (N=226)            (N=235)      
Dizziness, lightheadedness,                                                     
  giddiness                                        27                 15        
Flushing, heat sensation                           25                  8        
Headache                                           23                 20        
Weakness                                           12                 10        
Nausea, heartburn                                  11                  8        
Muscle cramps, tremor                               8                  3        
Peripheral edema                                    7                  1        
Nervousness, mood changes                           7                  4        
Palpitation                                         7                  5        
Dyspnea, cough, wheezing                            6                  3        
Nasal congestion, sore throat                       6                  8   
</font>     </pre>

<p>There is also a large uncontrolled experience in over 2100 patients
in the United States. Most of the patients had vasospastic or resistant
angina pectoris, and about half had concomitant treatment with beta-adrenergic
blocking agents. The relatively common adverse events were similar in nature
to those seen with Nifedipine XL*. </p>

<p>In addition, more serious adverse events were observed, not readily
distinguishable from the natural history of the disease in these patients.
It remains possible, however, that some or many of these events were drug
related. Myocardial infarction occurred in about 4% of patients and congestive
heart failure or pulmonary edema in about 2%. Ventricular arrhythmias or
conduction disturbances each occurred in fewer than 0.5% of patients. </p>

<p>In a subgroup of over 1000 patients receiving nifedipine with concomitant
beta blocker therapy, the pattern and incidence of adverse experiences
was not different from that of the entire group of nifedipine treated patients.
(See PRECAUTIONS.) </p>

<p>In a subgroup of approximately 250 patients with a diagnosis of congestive
heart failure as well as angina, dizziness or lightheadedness, peripheral
edema headache or flushing each occurred in one in eight patients. Hypotension
occurred in about one in 20 patients. Syncope occurred in approximately
one patient in 250. Myocardial infarction or symptoms of congestive heart
failure each occurred in about one patient in 15. Atrial or ventricular
dysrhythmias each occurred in about one patient in 150. </p>

<p>In post-marketing experience, there have been rare reports of exfoliative
dermatitis caused by nifedipine. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Experience with nifedipine overdosage is limited. Generally, overdosage
with nifedipine leading to pronounced hypotension calls for active cardiovascular
support including monitoring of cardiovasular and respiratory function,
elevation of extremities, judicious use of calcium infusion, pressor agents
and fluids. Clearance of nifedipine would be expected to be prolonged in
patients with impaired liver function. Since nifedipine is highly protein-bound,
dialysis is not likely to be of any benefit. </p>

<p>There has been one reported case of massive overdosage with Nifedipine
XL* Extended Release Tablets. The main effect of ingestion of approximately
4800 mg of Nifedipine XL* in a young man attempting suicide as a result
of cocaine induced depression was initial dizziness, palpitations, flushing,
and nervousness. Within several hours of ingestion, nausea, vomiting, and
generalized edema developed. No significant hypotension was apparent at
presentation, 18 hours post-ingestion. Electrolyte abnormalities consisted
of a mild, transient elevation of serum creatinine, and modest elevations
of LDH and CPK, but normal SGOT. Vital signs remained stable, no electrocardiographic
abnormalities were noted and renal function returned to normal within 24
to 48 hours with routine supportive measures alone. No prolonged sequelae
were observed. </p>

<p>The effect of a single 900 mg ingestion of nifedipine capsules in a
depressed anginal patient also on tricyclic antidepressants was a loss
of consciousness within 30 minutes of ingestion, and profound hypotension,
which responded to calcium infusion, pressor agents, and fluid replacement.
A variety of ECG abnormalities were seen in this patient with a history
of bundle branch block, including sinus bradycardia and varying degrees
of AV block. These dictated the prophylactic placement of a temporary ventricular
pacemaker, but otherwise resolved spontaneously. Significant hyperglycemia
was seen initially in this patient, but plasma glucose levels rapidly normalized
without further treatment. </p>

<p>A young hypertensive patient with advanced renal failure ingested 280
mg of nifedipine capsules at one time, with resulting marked hypotension
responding to calcium infusion and fluids. No AV conduction abnormalities,
arrhythmias, or pronounced changes in heart rate were noted, nor was there
any further deterioration in renal function. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Dosage must be adjusted to each patient's needs. Therapy for either
hypertension or angina should be initiated with 30 or 60 mg once daily.
Nifedipine XL* Extended Release Tablets should be swallowed whole and should
not be bitten or divided. In general, titration should proceed over a 7-14
day period so that the physician can fully assess the response to each
dose level and monitor blood pressure before proceeding to higher doses.
Since steady state plasma levels are achieved on the second day of dosing,
if symptoms so warrant, titration may proceed more rapidly provided the
patient is assessed frequently. Titration to doses above 120 mg is not
recommended. </p>

<p>Angina patients controlled on nifedipine capsules alone or in combination
with other antianginal medications may be safely switched to Nifedipine
XL* Extended Release Tablets at the nearest equivalent total daily dose
(e.g., 30 mg t.i.d. of nifedipine capsules may be changed to 90 mg once
daily of Nifedipine XL* Extended Release Tablets). Subsequent titration
to higher or lower doses may be necessary and should be initiated as clinically
warranted. Experience with doses greater than 90 mg in patients with angina
is limited. Therefore, doses greater than 90 mg should be used with caution
and only when clinically warranted. </p>

<p>No &quot;rebound effect&quot; has been observed upon discontinuation
of Nifedipine XL* Extended Release Tablets. However, if discontinuation
of nifedipine is necessary, sound clinical practice suggests that the dosage
should be decreased gradually with close physician supervision. </p>

<p>Care should be taken when dispensing Nifedipine XL* to assure that the
extended release dosage form has been prescribed.</p>

<p>CO-ADMINISTRATION WITH OTHER ANTIANGINAL DRUGS </p>

<p>Sublingual nitroglycerin may be taken as required for the control of
acute manifestations of angina, particularly during nifedipine titration.
See PRECAUTIONS, Drug Interactions, for information on co-administration
of nifedipine with beta blockers or long acting nitrates. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-77</DOCNO>
<DOCOLDNO>IA019-000201-B023-12</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi? 206.86.175.201 19970106233809 text/html 711
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:31:55 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
<hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3>Narrow Your Search With <font size=5>*</font> (examples: ampi*, 
*mycin, antibiotic*)</h3> 
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B10-78</DOCNO>
<DOCOLDNO>IA018-000200-B041-60</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/clomiph.htm 206.86.175.201 19970106230820 text/html 35184
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:02:04 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 35001
Last-modified: Sat, 19 Oct 1996 06:58:17 GMT
</DOCHDR>
<html>
<head>
   <title>Clomiphene - RxList Generic Information</title>
   <meta name="keywords" content="Arcafen, Biogen, Clomid, Clomifene, Clomivid,
Clostilbegyt, Duinum, Dyneric, Fertilan, Fertomid, Fertotab, Mestrolin, Milophene, Nefimol, 
Omicite, Omifin, Ovamit, Pergotime,
Phemilon, Serophene">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Clomiphene</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Clomiphene is an orally administered nonsteroidal, ovulatory stimulant
designated chemically as 2-(p- (2-chloro-1,2- diphenylvinyl)phenoxy) triethylamine
citrate (1:1). It has the molecular formula of C26H28ClNO . C5H8O7 and
a molecular weight of 598.09. </p>

<p>Clomiphene citrate is a white to pale yellow, essentially odorless,
crystalline powder. It is freely soluble in methanol; soluble in ethanol;
slightly soluble in acetone, water, and chloroform; and insoluble in ether.
Clomiphene is a mixture of two geometric isomers (cis (zuclomiphene) and
trans (enclomiphene)) containing between 30% and 50% of the cis-isomer.
</p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>ACTION </p>

<p>Clomiphene is a drug of considerable pharmacologic potency. With careful
selection and proper management of the patient, Clomiphene has been demonstrated
to be a useful therapy for the anovulatory patient desiring pregnancy.
</p>

<p>Clomiphene citrate is capable of interacting with estrogen-receptor-containing
tissues, including the hypothalamus, pituitary, ovary, endometrium, vagina,
and cervix. It may compete with estrogen for estrogen-receptor-binding
sites and may delay replenishment of intracellular estrogen receptors.
Clomiphene citrate initiates a series of endocrine events culminating in
a preovulatory gonadotropin surge and subsequent follicular rupture. The
first endocrine event in response to a course of clomiphene therapy is
an increase in the release of pituitary gonadotropins. This initiates steroidogenesis
and folliculogenesis, resulting in growth of the ovarian follicle and an
increase in the circulating level of estradiol. Following ovulation, plasma
progesterone and estradiol rise and fall as they would in a normal ovulatory
cycle. </p>

<p>Available data suggest that both the estrogenic and antiestrogenic properties
of clomiphene may participate in the initiation of ovulation. The two clomiphene
isomers have been found to have mixed estrogenic and antiestrogenic effects,
which may vary from one species to another. Some data suggest that zuclomiphene
has greater estrogenic activity then enclomiphene. </p>

<p>Clomiphene citrate has no apparent progestational, androgenic, or antiandrogenic
effects and does not appear to interfere with pituitary-adrenal or pituitary-
thyroid function. </p>

<p>Although there is no evidence of a &quot;carryover effect&quot; of Clomiphene,
spontaneous ovulatory menses have been noted in some patients after Clomiphene
therapy. </p>

<p>PHARMACOKINETICS </p>

<p>Based on early studies with 14C-labeled clomiphene citrate, the drug
was shown to be readily absorbed orally in humans and excreted principally
in the feces. Cumulative urinary and fecal excretion of the 14C averaged
about 50% of the oral dose and 37% of an intravenous dose after 5 days.
Mean urinary excretion was approximately 8% with fecal excretion of about
42%. </p>

<p>Some 14C label was still present in the feces 6 weeks after administration.
Subsequent single- dose studies in normal volunteers showed that zuclomiphene
(cis) has a longer half-life than enclomiphene (trans). Detectable levels
of zuclomiphene persisted for longer than a month in these subjects. This
may be suggestive of stereo- specific enterohepatic recycling or sequestering
of the zuclomiphene. Thus, it is possible that some active drug may remain
in the body during early pregnancy in women who conceive in the menstrual
cycle during Clomiphene therapy. </p>

<p>CLINICAL STUDIES </p>

<p>During clinical investigations, 7578 patients received Clomiphene, some
of whom had impediments to ovulation other than ovulatory dysfunction (see
INDICATIONS AND USAGE). In those clinical trials, successful therapy characterized
by pregnancy occurred in approximately 30% of these patients. </p>

<p>There were a total of 2635 pregnancies reported during the clinical
trial period. Of those pregnancies, information on outcome was only available
for 2369 of the cases. Table 1 summarizes the outcome of these cases. </p>

<p>Of the reported pregnancies, the incidence of multiple pregnancies was
7.98%: 6.9% twin, 0.5% triplet, 0.3% quadruplet, and 0.1% quintuplet. Of
the 165 twin pregnancies for which sufficient information was available,
the ratio of monozygotic to dizygotic twins was about 1:5. Table 1 reports
the survival rate of the live multiple births. </p>

<p>A sextuplet birth was reported after completion of original clinical
studies; none of the sextuplets survived (each weighed less than 400 g),
although each appeared grossly normal. </p>

<pre>TABLE 1. OUTCOME OF REPORTED PREGNANCIES IN CLINICAL TRIALS
(N = 2369)

                                            Total Number          Survival
Outcome                                    of Pregnancies           Rate

<hr width="100%" >Pregnancy Wastage
  Spontaneous Abortions                        483*
  Stillbirths                                   24

<hr width="100%" ></pre>

<pre>Live Births
  Single Births                               1697                98.16%**
  Multiple Births                              165                83.26%**

*   Includes 28 ectopic pregnancies, 4 hydatiform moles, and 1 fetus
     papyraceous.
**  Indicates percentage of surviving infants from these pregnancies.</pre>

<p>The overall survival of infants from multiple pregnancies including
spontaneous abortions, stillbirths, and neonatal deaths is 73%. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Clomiphene is indicated for the treatment of ovulatory dysfunction in
women desiring pregnancy. Impediments to achieving pregnancy must be excluded
or adequately treated before beginning Clomiphene therapy. Those patients
most likely to achieve success with clomiphene therapy include patients
with polycystic ovary syndrome (see WARNINGS: Ovarian Hyperstimulation
Syndrome), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive
amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology.
</p>

<p>Properly timed coitus in relationship to ovulation is important. A basal
body temperature graph or other appropriate tests may help the patient
and her physician determine if ovulation occurred. Once ovulation has been
established, each course of Clomiphene should be started on or about the
5th day of the cycle. If pregnancy has not been achieved after three ovulatory
responses to Clomiphene, further treatment is not recommended. </p>

<p>Clomiphene is indicated only in patients with demonstrated ovulatory
dysfunction who meet the conditions described below (see CONTRAINDICATIONS):
</p>

<p>1. Patients who are not pregnant. </p>

<p>2. Patients without ovarian cysts. Clomiphene should not be used in
patients with ovarian enlargement except those with polycystic ovary syndrome.
Pelvic examination is necessary prior to the first and each subsequent
course of Clomiphene treatment. </p>

<p>3. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding
is present, the patient should be carefully evaluated to ensure that neoplastic
lesions are not present. </p>

<p>4. Patients with normal liver function. </p>

<p>In addition, patients selected for Clomiphene therapy should be evaluated
in regard to the following: </p>

<p>1. ESTROGEN LEVELS. Patients should have adequate levels of endogenous
estrogen (as estimated from vaginal smears, endometrial biopsy, assay of
urinary estrogen, or from bleeding in response to progesterone). Reduced
estrogen levels, while less favorable, do not preclude successful therapy.
</p>

<p>2. PRIMARY PITUITARY OR OVARIAN FAILURE. Clomiphene therapy cannot be
expected to substitute for specific treatment of other causes of ovulatory
failure. </p>

<p>3. ENDOMETRIOSIS AND ENDOMETRIAL CARCINOMA. The incidence of endometriosis
and endometrial carcinoma increases with age as does the incidence of ovulatory
disorders. Endometrial biopsy should always be performed prior to Clomiphene
therapy in this population. </p>

<p>4. OTHER IMPEDIMENTS TO PREGNANCY. Impediments to pregnancy can include
thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor
infertility. </p>

<p>5. UTERINE FIBROIDS. Caution should be exercised when using Clomiphene
in patients with uterine fibroids due to the potential for further enlargement
of the fibroids. </p>

<p>There are no adequate or well-controlled studies that demonstrate the
effectiveness of Clomiphene in the treatment of male infertility. In addition,
testicular tumors and gynecomastia have been reported in males using clomiphene.
</p>

<p>The cause and effect relationship between reports of testicular tumors
and the administration of Clomiphene is not known. </p>

<p>Although the medical literature suggests various methods, there is no
universally accepted standard regimen for combined therapy (ie, Clomiphene
in conjunction with other ovulation-inducing drugs). Similarly, there is
no standard Clomiphene regimen for ovulation induction in In Vitro fertilization
programs to produce ova for fertilization and reintroduction. Therefore,
Clomiphene is not recommended for these uses. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>HYPERSENSITIVITY </p>

<p>Clomiphene is contraindicated in patients with a known hypersensitivity
or allergy to clomiphene citrate or to any of its ingredients. </p>

<p>PREGNANCY </p>

<p>Clomiphene should not be administered during pregnancy. Clomiphene may
cause fetal harm in animals (see Animal Fetotoxicity). Although no causative
evidence of a deleterious effect of Clomiphene therapy on the human fetus
has been established, there have been reports of birth anomalies which,
during clinical studies, occurred at an incidence within the range reported
for the general population (see Fetal/Neonatal Anomalies and Mortality;
ADVERSE REACTIONS). </p>

<p>To avoid inadvertent Clomiphene administration during early pregnancy,
appropriate tests should be utilized during each treatment cycle to determine
whether ovulation occurs. The patient should be evaluated carefully to
exclude pregnancy, ovarian enlargement, or ovarian cyst formation between
each treatment cycle. The next course of Clomiphene therapy should be delayed
until these conditions have been excluded. </p>

<p>FETAL/NEONATAL ANOMALIES AND MORTALITY. The following fetal abnormalities
have been reported subsequent to pregnancies following ovulation induction
therapy with Clomiphene during clinical trials. Each of the following fetal
abnormalities were reported at a rate of &lt;1% (experiences are listed
in order of decreasing frequency): Congenital heart lesions, Down syndrome,
club foot, congenital gut lesions, hypospadias, microcephaly, harelip and
cleft palate, congenital hip, hemangioma, undescended testicles, polydactyly,
conjoined twins and teratomatous malformation, patent ductus arteriosus,
amaurosis, arteriovenous fistula, inguinal hernia, umbilical hernia, syndactyly,
pectus excavatum, myopathy, dermoid cyst of scalp, omphalocele, spina bifida
occulta, ichthyosis, and persistent lingual frenulum. Neonatal death and
fetal death/stillbirth in infants with birth defects have also been reported
at a rate of &lt;1%. The overall incidence of reported birth anomalies
from pregnancies associated with maternal Clomiphene ingestion during clinical
studies was within the range of that reported for the general population.
</p>

<p>In addition, reports of birth anomalies have been received during postmarketing
surveillance of Clomiphene (see ADVERSE REACTIONS). </p>

<p>ANIMAL FETOTOXICITY. Oral administration of clomiphene citrate to pregnant
rats during organogenesis at doses of 1 to 2 mg/kg/day resulted in hydramnion
and weak, edematous fetuses with wavy ribs and other temporary bone changes.
Doses of 8 mg/kg/day or more also caused increased resorptions and dead
fetuses, dystocia, and delayed parturition, and 40 mg/kg/day resulted in
increased maternal mortality. Single doses of 50 mg/kg caused fetal cataracts,
while 200 mg/kg caused cleft palate. </p>

<p>Following injection of clomiphene citrate 2 mg/kg to mice and rats during
pregnancy, the offspring exhibited metaplastic changes of the reproductive
tract. Newborn mice and rats injected during the first few days of life
also developed metaplastic changes in uterine and vaginal mucosa, as well
as premature vaginal opening and anovulatory ovaries. These findings are
similar to the abnormal reproductive behavior and sterility described with
other estrogens and antiestrogens. </p>

<p>In rabbits, some temporary bone alterations were seen in fetuses from
dams given oral doses of 20 or 40 mg/kg/day during pregnancy, but not following
8 mg/kg/day. No permanent malformations were observed in those studies.
Also, rhesus monkeys given oral doses of 1.5 to 4.5 mg/kg/day for various
periods during pregnancy did not have any abnormal offspring. </p>

<p>LIVER DISEASE. Clomiphene therapy is contraindicated in patients with
liver disease or a history of liver dysfunction (see also INDICATIONS AND
USAGE and ADVERSE REACTIONS). </p>

<p>ABNORMAL UTERINE BLEEDING. Clomiphene is contraindicated in patients
with abnormal uterine bleeding of undetermined origin (see INDICATIONS
AND USAGE). </p>

<p>OVARIAN CYSTS. Clomiphene is contraindicated in patients with ovarian
cysts or enlargement not due to polycystic ovarian syndrome (see INDICATIONS
AND USAGE and WARNINGS). </p>

<p>OTHER. Clomiphene is contraindicated in patients with uncontrolled thyroid
or adrenal dysfunction or in the presence of an organic intracranial lesion
such as pituitary tumor (see INDICATIONS AND USAGE). </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>VISUAL SYMPTOMS </p>

<p>Patients should be advised that blurring or other visual symptoms such
as spots or flashes (scintillating scotomata) may occasionally occur during
therapy with Clomiphene. These visual symptoms increase in incidence with
increasing total dose or therapy duration and generally disappear within
a few days or weeks after Clomiphene is discontinued. Patients should be
warned that these visual symptoms may render such activities as driving
a car or operating machinery more hazardous than usual, particularly under
conditions of variable lighting. </p>

<p>These visual symptoms appear to be due to intensification and prolongation
of afterimages. Symptoms often first appear or are accentuated with exposure
to a brightly lit environment. While measured visual acuity usually has
not been affected, a study patient taking 200 mg Clomiphene daily developed
visual blurring on the 7th day of treatment, which progressed to severe
diminution of visual acuity by the 10th day. No other abnormality was found,
and the visual acuity returned to normal on the 3rd day after treatment
was stopped. </p>

<p>Ophthalmologically definable scotomata and retinal cell function (electroretinographic)
changes have also been reported. A patient treated during clinical studies
developed phosphenes and scotomata during prolonged Clomiphene administration,
which disappeared by the 32nd day after stopping therapy. Postmarketing
surveillance of adverse events has also revealed other visual signs and
symptoms during Clomiphene therapy (see ADVERSE REACTIONS). While the etiology
of these visual symptoms is not yet understood, patients with any visual
symptoms should discontinue treatment and have a complete ophthalmological
evaluation carried out promptly. </p>

<p>OVARIAN HYPERSTIMULATION SYNDROME </p>

<p>The ovarian hyperstimulation syndrome (OHSS) has been reported to occur
in patients receiving clomiphene citrate therapy for ovulation induction.
In some cases, OHSS occurred following cyclic use of clomiphene citrate
therapy or when clomiphene citrate was used in combination with gonadotropins.
Transient liver function test abnormalities suggestive of hepatic dysfunction,
which may be accompanied by morphologic changes on liver biopsy, have been
reported in association with ovarian hyperstimulation syndrome (OHSS).
</p>

<p>OHSS is a medical event distinct from uncomplicated ovarian enlargement.
The clinical signs of this syndrome in severe cases can include gross ovarian
enlargement, gastrointestinal symptoms, ascites, dyspnea, oliguria, and
pleural effusion. In addition, the following symptoms have been reported
in association with this syndrome: pericardial effusion, anasarca, hydrothorax,
acute abdomen, hypotension, renal failure, pulmonary edema, intraperitoneal
and ovarian hemorrhage, deep venous thrombosis, torsion of the ovary, and
acute respiratory distress. The early warning signs of OHSS are abdominal
pain and distention, nausea, vomiting, diarrhea, and weight gain. Elevated
urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia,
hemoconcentration, and hypoproteinemia may occur. Death due to hypovolemic
shock, hemoconcentration, or thromboembolism has occurred. Due to fragility
of enlarged ovaries in severe cases, abdominal and pelvic examination should
be performed very cautiously. If conception results, rapid progression
to the severe form of the syndrome may occur. </p>

<p>To minimize the hazard associated with occasional abnormal ovarian enlargement
associated with Clomiphene therapy, the lowest dose consistent with expected
clinical results should be used. Maximal enlargement of the ovary, whether
physiologic or abnormal, may not occur until several days after discontinuation
of the recommended dose of Clomiphene. Some patients with polycystic ovary
syndrome who are unusually sensitive to gonadotropin may have an exaggerated
response to usual doses of Clomiphene. Therefore, patients with polycystic
ovary syndrome should be started on the lowest recommended dose and shortest
treatment duration for the first course of therapy (see DOSAGE AND ADMINISTRATION).
</p>

<p>If enlargement of the ovary occurs, additional Clomiphene therapy should
not be given until the ovaries have returned to pretreatment size, and
the dosage or duration of the next course should be reduced. Ovarian enlargement
and cyst formation associated with Clomiphene therapy usually regress spontaneously
within a few days or weeks after discontinuing treatment. The potential
benefit of subsequent Clomiphene therapy in these cases should exceed the
risk. Unless surgical indication for laparotomy exists, such cystic enlargement
should always be managed conservatively. </p>

<p>A causal relationship between ovarian hyperstimulation and ovarian cancer
has not been determined. However, because a correlation between ovarian
cancer and nulliparity, infertility, and age has been suggested, if ovarian
cysts do not regress spontaneously, a thorough evaluation should be performed
to rule out the presence of ovarian neoplasia. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL </p>

<p>Careful attention should be given to the selection of candidates for
Clomiphene therapy. Pelvic examination is necessary prior to Clomiphene
treatment and before each subsequent course (see CONTRAINDICATIONS AND
WARNINGS). </p>

<p>INFORMATION FOR PATIENTS </p>

<p>The purpose and risks of Clomiphene therapy should be presented to the
patient before starting treatment. It should be emphasized that the goal
of Clomiphene therapy is ovulation for subsequent pregnancy. The physician
should counsel the patient with special regard to the following potential
risks: </p>

<p>VISUAL SYMPTOMS: Advise that blurring or other visual symptoms occasionally
may occur during or shortly after Clomiphene therapy. Warn that visual
symptoms may render such activities as driving a car or operating machinery
more hazardous than usual, particularly under conditions of variable lighting
(see WARNINGS). The patient should be instructed to inform the physician
whenever any unusual visual symptoms occur. If the patient has any visual
symptoms, treatment should be discontinued and complete ophthalmologic
evaluation performed. </p>

<p>ABDOMINAL/PELVIC PAIN OR DISTENTION: Ovarian enlargement may occur during
or shortly after therapy with Clomiphene. To minimize the risks associated
with ovarian enlargement, the patient should be instructed to inform the
physician of any abdominal or pelvic pain, weight gain, discomfort, or
distention after taking Clomiphene (see WARNINGS). </p>

<p>MULTIPLE PREGNANCY: Inform the patient that there is an increased chance
of multiple pregnancy, including bilateral tubal pregnancy and coexisting
tubal and intrauterine pregnancy, when conception occurs in relation to
Clomiphene therapy. The potential complications and hazards of multiple
pregnancy should be explained. </p>

<p>PREGNANCY WASTAGE AND BIRTH ANOMALIES: The physician should explain
the assumed risk of any pregnancy, whether ovulation is induced with the
aid of Clomiphene or occurs naturally. The patient should be informed of
the greater risks associated with certain characteristics or conditions
of any pregnant woman, eg, age of female and male partner, history of spontaneous
abortions, Rh genotype, abnormal menstrual history, infertility history,
organic heart disease, diabetes, exposure to infectious agents such as
rubella, familial history of birth anomaly, that may be pertinent to the
patient for whom Clomiphene is being considered. Based upon the evaluation
of the patient, genetic counseling may be indicated. </p>

<p>The overall incidence of reported birth anomalies from pregnancies associated
with maternal Clomiphene ingestion during the investigational studies was
within the range of that reported in published references for the general
population. (See CONTRAINDICATIONS: Pregnancy.) </p>

<p>During clinical investigation, the experience from patients with known
pregnancy outcome (Table 1) shows a spontaneous abortion rate of 20.4%
and stillbirth rate of 1.0%. (See ACTIONS/CLINICAL PHARMACOLOGY.) </p>

<p>DRUG INTERACTIONS </p>

<p>Drug interactions with Clomiphene have not been documented. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY </p>

<p>Long-term toxicity studies in animals have not been performed to evaluate
the carcinogenic or mutagenic potential of clomiphene citrate. </p>

<p>Oral administration of Clomiphene to male rats at doses of 0.3 or 1
mg/kg/day caused decreased fertility, while higher doses caused temporary
infertility. Oral doses of 0.1 mg/kg/day in female rats temporarily interrupted
the normal cyclic vaginal smear pattern and prevented conception. Doses
of 0.3 mg/kg/day slightly reduced the number of ovulated ova and corpora
lutea, while 3 mg/kg/day inhibited ovulation. </p>

<p>PREGNANCY </p>

<p>Pregnancy Category X. (See CONTRAINDICATIONS.) </p>

<p>NURSING MOTHERS </p>

<p>It is not known whether Clomiphene is excreted in human milk. Because
many drugs are excreted in human milk, caution should be exercised if Clomiphene
is administered to a nursing woman. In some patients, Clomiphene may reduce
lactation. </p>

<p>OVARIAN CANCER </p>

<p>Prolonged use of clomiphene citrate tablets USP may increase the risk
of a borderline or invasive ovarian tumor (see ADVERSE REACTIONS). </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Drug interactions with Clomiphene have not been documented. (See Also
PRECAUTIONS.) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>CLINICAL TRIAL ADVERSE EVENTS. Clomiphene, at recommended dosages, is
generally well tolerated. Adverse reactions usually have been mild and
transient and most have disappeared promptly after treatment has been discontinued.
Adverse experiences reported in patients treated with clomiphene citrate
during clinical studies are shown in Table 2. </p>

<pre>
TABLE 2. INCIDENCE OF ADVERSE EVENTS IN CLINICAL STUDIES
(EVENTS GREATER THAN 1%)
(N = 8029*)
Adverse Event                                                           %
<hr width="100%" >Ovarian Enlargement                                                  13.6
Vasomotor Flushes                                                    10.4
Abdominal-Pelvic Discomfort/
Distention/Bloating                                                   5.5
Nausea and Vomiting                                                   2.2
Breast Discomfort                                                     2.1
Visual Symptoms                                                       1.5
      Blurred vision, lights, floaters, waves,
      unspecified visual complaints, photophobia,
      diplopia, scotomata, phosphenes
Headache                                                              1.3
Abnormal Uterine Bleeding                                             1.3
      Intermenstrual spotting, menorrhagia

*   Includes 498 patients whose reports may have been duplicated in the event
     totals and could not be distinguished as such. Also, excludes 47 patients
     who did not report symptom data.</pre>

<p>The following adverse events have been reported in fewer than 1% of
patients in clinical trials: Acute abdomen, appetite increase, constipation,
dermatitis or rash, depression, diarrhea, dizziness, fatigue, hair loss/dry
hair, increased urinary frequency/volume, insomnia, light- headedness,
nervous tension, vaginal mucosa dry, vertigo, weight gain/loss. </p>

<p>Patients on prolonged Clomiphene therapy may show elevated serum levels
of desmosterol. This is most likely due to a direct interference with cholesterol
synthesis. However, the serum sterols in patients receiving the recommended
dose of Clomiphene are not significantly altered. Ovarian cancer has been
infrequently reported with fertility drugs. However, because infertility
is a primary risk factor for ovarian cancer, it cannot be determined if
the use of fertility drugs increases the risk beyond that associated with
infertility. </p>

<p>POSTMARKETING ADVERSE EVENTS </p>

<p>The following adverse experiences were reported spontaneously with Clomiphene.
The cause and effect relationship of the listed events to the administration
of Clomiphene is not known. </p>

<p>DERMATOLOGIC: Acne, allergic reaction, erythema, erythema multiforme,
erythema nodosum, hypertrichosis, pruritus </p>

<p>CENTRAL NERVOUS SYSTEM: Migraine headache, paresthesia, seizure, stroke,
syncope </p>

<p>PSYCHIATRIC: Anxiety, irritability, mood changes, psychosis </p>

<p>VISUAL DISORDERS: Abnormal accommodation, cataract, eye pain, macular
edema, optic neuritis, photopsia, posterior vitreous detachment, retinal
hemorrhage, retinal thrombosis, retinal vascular spasm, temporary loss
of vision </p>

<p>CARDIOVASCULAR: Arrhythmia, chest pain, edema, hypertension, palpitation,
phlebitis, pulmonary embolism, shortness of breath, tachycardia, thrombophlebitis
</p>

<p>MUSCULOSKELETAL: Arthralgia, back pain, myalgia </p>

<p>HEPATIC: Transaminases increased, hepatitis </p>

<p>NEOPLASMS: Liver (hepatic hemangiosarcoma, liver cell adenoma, hepatocellular
carcinoma); breast (fibrocystic disease, breast carcinoma); endometrium
(endometrial carcinoma); nervous system (astrocytoma, pituitary tumor,
prolactinoma, neurofibromatosis, glioblastoma multiforme, brain abscess);
ovary (luteoma of pregnancy, dermoid cyst of the ovary, ovarian carcinoma);
trophoblastic (hydatiform mole, choriocarcinoma); miscellaneous (melanoma,
myeloma, perianal cysts, renal cell carcinoma, Hodgkin's lymphoma, tongue
carcinoma, bladder carcinoma); and neoplasms of offspring (neuroectodermal
tumor, thyroid tumor, hepatoblastoma, lymphocytic leukemia) </p>

<p>GENITOURINARY: Endometriosis, ovarian cyst (ovarian enlargement or cysts
could, as such, be complicated by adnexal torsion), ovarian hemorrhage,
tubal pregnancy, uterine hemorrhage </p>

<p>BODY AS A WHOLE: Fever, tinnitus, weakness </p>

<p>OTHER: Leukocytosis, thyroid disorder </p>

<p>FETAL/NEONATAL ANOMALIES. The following fetal abnormalities have also
been reported during postmarketing surveillance: delayed development; abnormal
bone development including skeletal malformations of the skull, face, nasal
passages, jaw, hand, limb (ectromelia including amelia, hemimelia, and
phocomelia), foot, and joints; tissue malformations including imperforate
anus, tracheoesophageal fistula, diaphragmatic hernia, renal agenesis and
dysgenesis, and malformations of the eye and lens (cataract), ear, lung,
heart (ventricular septal defect and tetrology of Fallot), and genitalia;
as well as dwarfism, deafness, mental retardation, chromosomal disorders,
and neural tube defects (including anencephaly). </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>Tolerance, abuse, or dependence with Clomiphene has not been reported.
</p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>SIGNS AND SYMPTOMS </p>

<p>Toxic effects accompanying acute overdosage of Clomiphene have not been
reported. </p>

<p>Signs and symptoms of overdosage as a result of the use of more than
the recommended dose during Clomiphene therapy include nausea, vomiting,
vasomotor flushes, visual blurring, spots or flashes, scotomata, ovarian
enlargement with pelvic or abdominal pain. (See CONTRAINDICATIONS: Ovarian
Cyst.) </p>

<p>ORAL LD50. The acute oral LD50 of Clomiphene is 1700 mg/kg in mice and
5750 mg/kg in rats. The toxic dose in humans is not known. </p>

<p>DIALYSIS. It is not known if Clomiphene is dialyzable. </p>

<p>TREATMENT </p>

<p>In the event of overdose, appropriate supportive measures should be
employed in addition to gastrointestinal decontamination. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>GENERAL CONSIDERATIONS </p>

<p>The workup and treatment of candidates for Clomiphene therapy should
be supervised by physicians experienced in management of gynecologic or
endocrine disorders. Patients should be chosen for therapy with Clomiphene
only after careful diagnostic evaluation (see INDICATIONS AND USAGE). The
plan of therapy should be outlined in advance. Impediments to achieving
the goal of therapy must be excluded or adequately treated before beginning
Clomiphene. The therapeutic objective should be balanced with potential
risks and discussed with the patient and others involved in the achievement
of a pregnancy. </p>

<p>Ovulation most often occurs from 5 to 10 days after a course of Clomiphene.
Coitus should be timed to coincide with the expected time of ovulation.
Appropriate tests to determine ovulation may be useful during this time.
</p>

<p>RECOMMENDED DOSAGE </p>

<p>Treatment of the selected patient should begin with a low dose, 50 mg
daily (1 tablet) for 5 days. The dose should be increased only in those
patients who do not ovulate in response to cyclic 50 mg Clomiphene. A low
dosage or duration of treatment course is particularly recommended if unusual
sensitivity to pituitary gonadotropin is suspected, such as in patients
with polycystic ovary syndrome (see WARNINGS; Ovarian Hyperstimulation
Syndrome). </p>

<p>The patient should be evaluated carefully to exclude pregnancy, ovarian
enlargement, or ovarian cyst formation between each treatment cycle. If
progestin-induced bleeding is planned, or if spontaneous uterine bleeding
occurs prior to therapy, the regimen of 50 mg daily for 5 days should be
started on or about the 5th day of the cycle. Therapy may be started at
any time in the patient who has had no recent uterine bleeding. When ovulation
occurs at this dosage, there is no advantage to increasing the dose in
subsequent cycles of treatment. </p>

<p>If ovulation does not appear to occur after the first course of therapy,
a second course of 100 mg daily (two 50 mg tablets given as a single daily
dose) for 5 days should be given. This course may be started as early as
30 days after the previous one after precautions are taken to exclude the
presence of pregnancy. Increasing the dosage or duration of therapy beyond
100 mg/day for 5 days is not recommended. </p>

<p>The majority of patients who are going to respond will respond to the
first course of therapy. If pregnancy has not been achieved after three
ovulatory responses to Clomiphene, further treatment is not recommended.
Long-term Clomiphene therapy is not advised. If ovulatory menses do not
occur, the patient should be reevaluated. Further Clomiphene treatment
beyond this is not recommended in the patient who does not exhibit evidence
of ovulation. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-79</DOCNO>
<DOCOLDNO>IA018-000200-B039-60</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/carisop.htm 206.86.175.201 19970106230140 text/html 9425
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:55:25 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 9243
Last-modified: Mon, 15 Jul 1996 04:03:21 GMT
</DOCHDR>
<html>
<head>
   <title>Carisoprodol - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Carisoprodol</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Carisoprodol is N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate.
</p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Carisoprodol produces muscle relaxation in animals by blocking interneuronal
activity in the descending reticular formation and spinal cord. The onset
of action is rapid and effects last four to six hours. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Carisoprodol is indicated as an adjunct to rest, physical therapy, and
other measures for the relief of discomfort associated with acute, painful
musculoskeletal conditions. The mode of action of this drug has not been
clearly identified, but may be related to its sedative properties. Carisoprodol
does not directly relax tense skeletal muscles in man. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Acute intermittent porphyria as well as allergic or idiosyncratic reactions
to carisoprodol or related compounds such as meprobamate, mebutamate, or
tybamate. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>IDIOSYNCRATIC REACTIONS--On very rare occasions, the first dose of carisoprodol
has been followed by idiosyncratic symptoms appearing within minutes or
hours. Symptoms reported include: extreme weakness, transient quadriplegia,
dizziness, ataxia, temporary loss of vision, diplopia, mydriasis, dysarthria,
agitation, euphoria, confusion, and disorientation. Symptoms usually subside
over the course of the next several hours. Supportive and symptomatic therapy,
including hospitalization, may be necessary. </p>

<p>USAGE IN PREGNANCY AND LACTATION--Safe usage of this drug in pregnancy
or lactation has not been established. Therefore, use of this drug in pregnancy,
in nursing mothers, or in women of childbearing potential requires that
the potential benefits of the drug be weighed against the potential hazards
to mother and child. Carisoprodol is present in breast milk of lactating
mothers at concentrations two to four times that of maternal plasma. This
factor should be taken into account when use of the drug is contemplated
in breast-feeding patients. </p>

<p>USAGE IN CHILDREN--Because of limited clinical experience, carisoprodol
is not recommended for use in patients under 12 years of age. </p>

<p>POTENTIALLY HAZARDOUS TASKS--Patients should be warned that this drug
may impair the mental and/or physical abilities required for the performance
of potentially hazardous tasks such as driving a motor vehicle or operating
machinery. </p>

<p>ADDITIVE EFFECTS--Since the effects of carisoprodol and alcohol or carisoprodol
and other CNS depressants or psychotropic drugs may be additive, appropriate
caution should be exercised with patients who take more than one of these
agents simultaneously. </p>

<p>DRUG DEPENDENCE--In dogs, no withdrawal symptoms occurred after abrupt
cessation of carisoprodol from dosages as high as 1 gm/kg/day. In a study
in man, abrupt cessation of 100 mg/kg/day (about five times the recommended
daily adult dosage) was followed in some subjects by mild withdrawal symptoms
such as abdominal cramps, insomnia, chilliness, headache, and nausea. Delirium
and convulsions did not occur. In clinical use, psychological dependence
and abuse have been rare, and there have been no reports of significant
abstinence signs. Nevertheless, the drug should be used with caution in
addiction-prone individuals. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>Carisoprodol is metabolized in the liver and excreted by the kidney;
to avoid its excess accumulation, caution should be exercised in administration
to patients with compromised liver or kidney function. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>ADDITIVE EFFECTS--Since the effects of carisoprodol and alcohol or carisoprodol
and other CNS depressants or psychotropic drugs may be additive, appropriate
caution should be exercised with patients who take more than one of these
agents simultaneously. </p>

<p>(See Also WARNINGS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Central Nervous System--Drowsiness and other CNS effects may require
dosage reduction. Also observed: dizziness, vertigo, ataxia, tremor, agitation,
irritability, headache, depressive reactions, syncope, and insomnia. (See
also Idiosyncratic Reactions under &quot;Warnings.&quot;) </p>

<p>Allergic Or Idiosyncratic--Allergic or idiosyncratic reactions occasionally
develop. They are usually seen within the period of the first to fourth
dose in patients having had no previous contact with the drug. Skin rash,
erythema multiforme, pruritus, eosinophilia, and fixed drug eruption with
cross reaction to meprobamate have been reported with carisoprodol. Severe
reactions have been manifested by asthmatic episodes, fever, weakness,
dizziness, angioneurotic edema, smarting eyes, hypotension, and anaphylactoid
shock. (See also Idiosyncratic Reactions under &quot;Warnings.&quot;) </p>

<p>In case of allergic or idiosyncratic reactions to carisoprodol, discontinue
the drug and initiate appropriate symptomatic therapy, which may include
epinephrine, antihistamines, and in severe cases corticosteroids. In evaluating
possible allergic reactions, also consider allergy to excipients (information
on excipients is available to physicians on request). </p>

<p>Cardiovascular--Tachycardia, postural hypotension, and facial flushing.
</p>

<p>Gastrointestinal--Nausea, vomiting, hiccup, and epigastric distress.
</p>

<p>Hematologic--Leukopenia, in which other drugs or viral infection may
have been responsible, and pancytopenia, attributed to phenylbutazone,
have been reported. No serious blood dyscrasias have been attributed to
carisoprodol. </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>SEE WARNINGS </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Overdosage of carisoprodol has produced stupor, coma, shock, respiratory
depression, and, very rarely, death. The effects of an overdosage of carisoprodol
and alcohol or other CNS depressants or psychotropic agents can be additive
even when one of the drugs has been taken in the usual recommended dosage.
Any drug remaining in the stomach should be removed and symptomatic therapy
given. Should respiration or blood pressure become compromised, respiratory
assistance, central nervous system stimulants, and pressor agents should
be administered cautiously as indicated. Carisoprodol is metabolized in
the liver and excreted by the kidney. Although carisoprodol overdosage
experience is limited, the following types of treatment have been used
successfully with the related drug meprobamate: diuresis, osmotic (mannitol)
diuresis, peritoneal dialysis, and hemodialysis (carisoprodol is dialyzable).
Careful monitoring of urinary output is necessary and caution should be
taken to avoid overhydration. Observe for possible relapse due to incomplete
gastric emptying and delayed absorption. Carisoprodol can be measured in
biological fluids by gas chromatography (Douglas, J. F. et al: J Pharm
Sci 58: 145, 1969). </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>The usual adult dosage of carisoprodol is one 350 mg tablet, three times
daily and at bedtime.<b> </b>Usage in patients under age 12 is not recommended.
</p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-80</DOCNO>
<DOCOLDNO>IA018-000200-B040-177</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/cocaine.htm 206.86.175.201 19970106230658 text/html 7536
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:00:42 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 7354
Last-modified: Tue, 12 Nov 1996 08:47:21 GMT
</DOCHDR>
<html>
<head>
   <title>Cocaine - RxList Generic Information</title>
   <meta name="keywords" content="crack, rock, blow, snow, coke, coca, coca cola, erythoxylon">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Cocaine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [drug-drug]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Cocaine is 2Beta-carbomethoxy-3Beta-benzoxytropane; C17H21N04. Cocaine
Hydrochloride USP is a crystalline, granular, or powder substance, having
a saline, slightly bitter taste that numbs tongue and lips. Cocaine Hydrochloride
is a local anesthetic. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Cocaine blocks the initiation or conduction of the nerve impulse following
local application, thereby effecting local anesthetic action. </p>

<p>Cocaine is absorbed from all sites of application, including mucous
membranes and gastrointestinal mucosa. Cocaine is degraded by plasma esterases,
with the half-life in the plasma being, approximately one hour. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Cocaine Hydrochloride topical solution is indicated for the introduction
of local (topical) anesthesia of accessible mucous membranes of the oral,
laryngeal and nasal cavities. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Cocaine Hydrochloride is contraindicated in patients with a known history
of hypersensitivity to the drug or to the components of the solution. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>RESUSCITATIVE EQUIPMENT AND DRUGS SHOULD BE IMMEDIATELY AVAILABLE WHEN
ANY LOCAL ANESTHETIC IS USED. </p>

<p>CARCINOGENESIS, MUTAGENESIS: Long-term studies to determine the carcinogenic
and mutagenic potential of cocaine are not available. </p>

<p>PREGNANCY: TERATOGENIC EFFECTS - PREGNANCY CATEGORY C: Animal reproduction
studies have not been conducted with cocaine. It is also not known whether
the cocaine can cause fetal harm when administered to a pregnant woman
or can affect reproduction capacity. Cocaine should be given to a pregnant
woman only if needed. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>The safety and effectiveness of Cocaine Hydrochloride Topical Solution
depends on proper dosage, correct technique, adequate precautions, and
readiness for emergencies. Standard textbooks should be consulted for specific
techniques and precautions for various anesthetic procedures. </p>

<p>The lowest dosage that results in effective anesthesia should be used
to avoid high plasma levels and serious adverse effects. Debilitated, elderly
patients, acutely ill patients, and children should be given reduced doses
commensurate with their age and physical status. </p>

<p>Cocaine Hydrochloride topical solution should be used with caution in
patients with severely traumatized mucosa and sepsis in the region of the
proposed application. Use with caution in persons with known drug sensitivities.
</p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Adverse reactions may be due to high plasma levels as a result of excessive
and rapid absorption of the drug. Reactions are systemic in nature and
involve the central nervous system and/or the cardiovascular system. A
small number of reactions may result from hypersensitivity, idiosyncrasy
or diminished tolerance on the part of the patient. </p>

<p>CNS reactions are excitatory and/or depressant, and may be characterized
by nervousness, restlessness and excitement. Tremors and eventually clonicotonic
convulsions may result. Emesis may occur. Central stimulation is followed
by depression, with death resulting from respiratory failure. </p>

<p>Small doses of cocaine slow the heart rate, but after moderate doses,
the rate is increased due to central sympathetic stimulation. </p>

<p>Cocaine is pyrogenic, augmenting heat production in stimulating muscular
activity and causing vasoconstriction which decreases heat loss. Cocaine
is known to interfere with the uptake of norepinephrine by adrenergic nerve
terminals, producing sensitization to catecholamines, causing vasoconstriction
and mydriasis. </p>

<p>Cocaine causes sloughing of the corneal epithelium, causing clouding,
pitting, and occasionally ulceration of the cornea. The drug is not meant
for ophthalmic use. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>The fatal dose of cocaine has been approximated 1.2 g, although severe
toxic effects have been reported from doses as low as 20 mg. </p>

<p>SYMPTOMS: The symptoms of cocaine poisoning are referable to the CNS,
namely the patient becomes excited, restless, garrulous, anxious and confused.
Enhanced reflexes, headache, rapid pulse, irregular respiration, chills,
rise in body temperature, mydriasis, exophthalmos, nausea, vomiting, and
abdominal pain are noticed in severe overdoses, delirium, Cheyne-Stokes
respiration, convulsions, unconsciousness and death from respiratory arrest
result. Acute poisoning by cocaine is rapid in developing. </p>

<p>TREATMENT: The specific treatment of acute cocaine poisoning is the
intravenous administration of a short-acting barbiturate or diazepam. Artificial
respiration may be necessary. It is important to limit absorption of the
drug. If entrance of the drug into circulation can be checked, and respiratory
exchange maintained, the progress is favorable since cocaine is eliminated
fairly rapidly. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>The dosage varies and depends upon the area to be anesthetized, vascularity
of the tissues, individual tolerance, and the technique of anesthesia.
The lowest dosage needed to provide effective anesthesia should be administered.
Dosages should be reduced for children and for elderly and debilitated
patients. Cocaine Hydrochloride topical solution can be administered by
means of cotton applicators or packs, instilled into a cavity, or a spray.
</p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-81</DOCNO>
<DOCOLDNO>IA018-000200-B040-123</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/propran.htm 206.86.175.201 19970106230609 text/html 37436
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:59:55 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 37253
Last-modified: Sat, 12 Oct 1996 07:28:14 GMT
</DOCHDR>
<html>
<head>
   <title>Propranolol - RxList Generic Information</title>
   <meta name="keywords" content="Inderal, Inderal LA, Inderex, Indobloc, Indon, Kidoral, Lorol,
Nelderal, Noloten, Novopranol, Oposim, Procor, Prolol, Pronol,
Propadex, Propalong, Propayerst, Prosin, Pylapron, Rexigen,
Sagittol, Sawatol, Scandrug, Sinal, Sloprolol, Sudenol, Sumial,
Tensiflex, Tesnol">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Propranolol</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Propranolol is a synthetic beta-adrenergic receptor blocking agent chemically
described as 1-(Isopropylamino)-3-(1-naphthyloxy)-2- propanol hydrochloride.
Propranolol hydrochloride is a stable, white, crystalline solid which is
readily soluble in water and ethanol. Its molecular weight is 295.81. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Propranolol is a nonselective beta-adrenergic receptor blocking agent
possessing no other autonomic nervous system activity. It specifically
competes with beta- adrenergic receptor stimulating agents for available
receptor sites. When access to beta-receptor sites is blocked by Propranolol,
the chronotropic, inotropic, and vasodilator responses to beta- adrenergic
stimulation are decreased proportionately. </p>

<p>Propranolol is almost completely absorbed from the gastrointestinal
tract, but a portion is immediately bound by the liver. Peak effect occurs
in one to one and one-half hours. The biologic half-life is approximately
four hours. </p>

<p>There is no simple correlation between dose or plasma level and therapeutic
effect, and the dose-sensitivity range as observed in clinical practice
is wide. The principal reason for this is that sympathetic tone varies
widely between individuals. Since there is no reliable test to estimate
sympathetic tone or to determine whether total beta blockade has been achieved,
proper dosage requires titration. </p>

<p>The mechanism of the antihypertensive effect of Propranolol has not
been established. Among the factors that may be involved in contributing
to the antihypertensive action are (1) decreased cardiac output, (2) inhibition
of renin release by the kidneys, and (3) diminution of tonic sympathetic
nerve outflow from vasomotor centers in the brain. Although total peripheral
resistance may increase initially, it readjusts to or below the pretreatment
level with chronic use. Effects on plasma volume appear to be minor and
somewhat variable. Propranolol has been shown to cause a small increase
in serum potassium concentration when used in the treatment of hypertensive
patients. In angina pectoris, propranolol generally reduces the oxygen
requirement of the heart at any given level of effort by blocking the catecholamine-
induced increases in the heart rate, systolic blood pressure, and the velocity
and extent of myocardial contraction. Propranolol may increase oxygen requirements
by increasing left ventricular fiber length, end diastolic pressure, and
systolic ejection period. The net physiologic effect of beta-adrenergic
blockade is usually advantageous and is manifested during exercise by delayed
onset of pain and increased work capacity. Propranolol exerts its antiarrhythmic
effects in concentrations associated with beta- adrenergic blockade, and
this appears to be its principal antiarrhythmic mechanism of action. In
dosages greater than required for beta blockade, Propranolol also exerts
a quinidine-like or anesthetic- like membrane action, which affects the
cardiac action potential. The significance of the membrane action in the
treatment of arrhythmias is uncertain. </p>

<p>The mechanism of the antimigraine effect of propranolol has not been
established. Beta- adrenergic receptors have been demonstrated in the pial
vessels of the brain. </p>

<p>The specific mechanism of Propranolol's antitremor effects has not been
established, but beta-2 (noncardiac) receptors may be involved. A central
effect is also possible. Clinical studies have demonstrated that Propranolol
is of benefit in exaggerated physiological and essential (familial) tremor.
</p>

<p>Beta-receptor blockade can be useful in conditions in which, because
of pathologic or functional changes, sympathetic activity is detrimental
to the patient. But there are also situations in which sympathetic stimulation
is vital. For example, in patients with severely damaged hearts, adequate
ventricular function is maintained by virtue of sympathetic drive, which
should be preserved. In the presence of AV block greater than first degree,
beta blockade may prevent the necessary facilitating effect of sympathetic
activity on conduction. Beta blockade results in bronchial constriction
by interfering with adrenergic bronchodilator activity, which should be
preserved in patients subject to bronchospasm. </p>

<p>Propranolol is not significantly dialyzable. </p>

<p>The Beta-Blocker Heart Attack Trial (BHAT) was a National Heart, Lung
and Blood Institute- sponsored multicenter, randomized, double-blind, placebo-controlled
trial conducted in 31 U.S. centers (plus one in Canada) in 3,837 persons
without history of severe congestive heart failure or presence of recent
heart failure; certain conduction defects; angina since infarction, who
had survived the acute phase of myocardial infarction. Propranolol was
administered at either 60 or 80 mg t.i.d. based on blood levels achieved
during an initial trial of 40 mg t.i.d. Therapy with Propranolol, begun
5 to 21 days following infarction, was shown to reduce overall mortality
up to 39 months, the longest period of follow-up. This was primarily attributable
to a reduction in cardiovascular mortality. The protective effect of Propranolol
was consistent regardless of age, sex, or site of infarction. Compared
with placebo, total mortality was reduced 39% at 12 months and 26% over
an average follow-up period of 25 months. The Norwegian Multicenter Trial
in which propranolol was administered at 40 mg q.i.d. gave overall results
which support the findings in the BHAT. </p>

<p>Although the clinical trials used either t.i.d. or q.i.d. dosing, clinical,
pharmacologic, and pharmacokinetic data provide a reasonable basis for
concluding that b.i.d. dosing with propranolol should be adequate in the
treatment of postinfarction patients. </p>

<p>CLINICAL </p>

<p>In the BHAT, patients on Propranolol were prescribed either 180 mg/day
(82% of patients) or 240 mg/day (18% of patients). Patients were instructed
to take the medication 3 times a day at mealtimes. This dosing schedule
would result in an overnight dosing interval of 12 to 14 hours which is
similar to the dosing interval for a b.i.d regimen. In addition, blood
samples were drawn at various times and analyzed for propranolol. When
the patients were grouped into tertiles based on the blood levels observed
and the mortality in the upper and lower tertiles was compared, there was
no evidence that blood levels affected mortality. </p>

<p>PHARMACOLOGIC </p>

<p>Studies in normal volunteers have shown that a 90mg b.i.d. regimen maintains
beta blockade at, or above, the minimum for 60 mg t.i.d. dosing for 24
hours even though differences occurred at two time intervals. At 10 to
12 hours after the first dose of the day, t.i.d. dosing gave more beta
blockade than b.i.d. dosing; at 20 to 24 hours the trend of the relationship
was reversed. These relationships were similar in direction to those observed
for plasma propranolol levels. (See &quot;PHARMACOKINETIC.&quot;) </p>

<p>PHARMACOKINETIC </p>

<p>A bioavailability study in normal volunteers showed that the blood levels
produced by 180 mg/day given b.i.d. are below those provided by the same
daily dosage given t.i.d. at 10 to 12 hours after the first dose of the
day, but above those of a t.i.d. regimen at 20 to 24 hours. However, the
blood levels produced by b.i.d. dosing were always equivalent to or above
the minimum for t.i.d. dosing throughout the 24 hours. In addition, the
mean AUC on the fourth day for the b.i.d. regimen was about 17% greater
than for the t.i.d. regimen (1,194 Vs. 1,024 ng/mL-hr). </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>HYPERTENSION </p>

<p>Propranolol is indicated in the management of hypertension. It may be
used alone or used in combination with other antihypertensive agents, particularly
a thiazide diuretic. Propranolol is not indicated in the management of
hypertensive emergencies. </p>

<p>ANGINA PECTORIS DUE TO CORONARY ATHEROSCLEROSIS Propranolol is indicated
for the long-term management of patients with angina pectoris. </p>

<p>CARDIAC ARRHYTHMIAS </p>

<p>1.) Supraventricular arrhythmias </p>

<p>a) Paroxysmal atrial tachycardias, particularly those arrhythmias induced
by catecholamines or digitalis or associated with the Wolff-Parkinson-
White syndrome. (See W-P-W under &quot;Warnings.&quot;) </p>

<p>b) Persistent sinus tachycardia which is noncompensatory and impairs
the well- being of the patient. </p>

<p>c) Tachycardias and arrhythmias due to thyrotoxicosis when causing distress
or increased hazard and when immediate effect is necessary as adjunctive,
short- term (2 to 4 weeks) therapy. May be used with, but not in place
of, specific therapy. (See THYROTOXICOSIS under &quot;Warnings.&quot;)
</p>

<p>d) Persistent atrial extrasystoles which impair the well-being of the
patient and do not respond to conventional measures. </p>

<p>e) Atrial flutter and fibrillation when ventricular rate cannot be controlled
by digitalis alone, or when digitalis is contraindicated. </p>

<p>2.) Ventricular tachycardias. </p>

<p>Ventricular arrhythmias do not respond to propranolol as predictably
as do the supraventricular arrhythmias. </p>

<p>a) Ventricular tachycardias </p>

<p>With the exception of those induced by catecholamines or digitalis,
Propranolol is not the drug of first choice. In critical situations when
cardioversion techniques or other drugs are not indicated or are not effective,
Propranolol may be considered. If, after consideration of the risks involved,
Propranolol is used, it should be given intravenously in low dosage and
very slowly. (See &quot;Dosage and Administration.&quot;) Care In The Administration
Of Propranolol With Constant Electrocardiographic Monitoring Is Essential
As The Failing Heart Requires Some Sympathetic Drive For Maintenance Of
Myocardial Tone. </p>

<p>b) Persistent premature ventricular extrasystoles which do not respond
to conventional measures and impair the well-being of the patient. </p>

<p>3.) Tachyarrhythmias of digitalis intoxication </p>

<p>If digitalis-induced tachyarrhythmias persist following discontinuance
of digitalis and correction of electrolyte abnormalities, they are usually
reversible with Oral Propranolol. Severe bradycardia may occur. (See &quot;OVERDOSAGE.&quot;)
Intravenous propranolol hydrochloride is reserved for life-threatening
arrhythmias. Temporary maintenance with oral therapy may be indicated.
(See &quot;Dosage and Administration.&quot;) </p>

<p>4.) Resistant tachyarrhythmias due to excessive catecholamine action
during anesthesia </p>

<p>Tachyarrhythmias due to excessive catecholamine action during anesthesia
may sometimes arise because of release of endogenous catecholamines or
administration of catecholamines. When usual measures fail in such arrhythmias,
Propranolol may be given intravenously to abolish them. All general inhalation
anesthetics produce some degree of myocardial depression. Therefore, when
Propranolol is used to treat arrhythmias during anesthesia, it should be
used with extreme caution and constant ECG and central venous pressure
monitoring. (See &quot;Warnings.&quot;) </p>

<p>MYOCARDIAL INFARCTION </p>

<p>Propranolol is indicated to reduce cardiovascular mortality in patients
who have survived the acute phase of myocardial infarction and are clinically
stable. </p>

<p>MIGRAINE </p>

<p>Propranolol is indicated for the prophylaxis of common migraine headache.
The efficacy of propranolol in the treatment of a migraine attack that
has started has not been established, and propranolol is not indicated
for such use. </p>

<p>ESSENTIAL TREMOR </p>

<p>Propranolol is indicated in the management of familial or hereditary
essential tremor. Familial or essential tremor consists of involuntary,
rhythmic, oscillatory movements, usually limited to the upper limbs. It
is absent at rest but occurs when the limb is held in a fixed posture or
position against gravity and during active movement. Propranolol causes
a reduction in the tremor amplitude but not in the tremor frequency. Propranolol
is not indicated for the treatment of tremor associated with Parkinsonism.
</p>

<p>HYPERTROPHIC SUBAORTIC STENOSIS </p>

<p>Propranolol is useful in the management of hypertrophic subaortic stenosis,
especially for treatment of exertional or other stress-induced angina,
palpitations, and syncope. Propranolol also improves exercise performance.
The effectiveness of propranolol hydrochloride in this disease appears
to be due to a reduction of the elevated outflow pressure gradient, which
is exacerbated by beta-receptor stimulation. Clinical improvement may be
temporary. </p>

<p>PHEOCHROMOCYTOMA </p>

<p>After primary treatment with an alpha-adrenergic blocking agent has
been instituted, Propranolol may be useful as Adjunctive therapy if the
control of tachycardia becomes necessary before or during surgery. It is
hazardous to use Propranolol unless alpha-adrenergic blocking drugs are
already in use, since this would predispose to serious blood pressure elevation.
Blocking only the peripheral dilator (beta) action of epinephrine leaves
its constrictor (alpha) action unopposed. In the event of hemorrhage or
shock, there is a disadvantage in having both beta and alpha blockade since
the combination prevents the increase in heart rate and peripheral vasoconstriction
needed to maintain blood pressure. </p>

<p>With inoperable or metastatic pheochromocytoma, Propranolol may be useful
as an adjunct to the management of symptoms due to excessive beta- receptor
stimulation. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Propranolol is contraindicated in 1) cardiogenic shock, 2) sinus bradycardia
and greater than first degree block, 3) bronchial asthma, 4) congestive
heart failure (see &quot;Warnings&quot;) unless the failure is secondary
to a tachyarrhythmia treatable with Propranolol. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>CARDIAC FAILURE </p>

<p>Sympathetic stimulation may be a vital component supporting circulatory
function in patients with congestive heart failure, and its inhibition
by beta blockade may precipitate more severe failure. Although beta blockers
should be avoided in overt congestive heart failure, if necessary, they
can be used with close follow-up in patients with a history of failure
who are well compensated and are receiving digitalis and diuretics. Beta-adrenergic
blocking agents do not abolish the inotropic action of digitalis on heart
muscle. IN PATIENTS WITHOUT A HISTORY OF HEART FAILURE, continued use of
beta blockers can, in some cases, lead to cardiac failure. Therefore, at
the first sign or symptom of heart failure, the patient should be digitalized
and/or treated with diuretics, and the response observed closely, or Propranolol
should be discontinued (gradually, if possible). </p>

<pre>
                   *************************************************
                   *                                               *
                   *  IN PATIENTS WITH ANGINA PECTORIS, there      *
                   *  have been reports of exacerbation of angina  *
                   *  and, in some cases, myocardial infarction,   *
                   *  following Abrupt discontinuance of Propranolol   
                   *  therapy. Therefore, when discontinuance of   *
                   *  Propranolol is planned, the dosage should be    
                   *  gradually reduced over at least a few weeks  *
                   *  and the patient should be cautioned against  *
                   *  interruption or cessation of therapy         *
                   *  without the physician's advice. If Propranolol   
                   *  therapy is interrupted and exacerbation of   *
                   *  angina occurs, it usually is advisable to    *
                   *  reinstitute Propranolol therapy and take other   
                   *  measures appropriate for the management of   *
                   *  unstable angina pectoris. Since coronary     *
                   *  artery disease may be unrecognized, it may   *
                   *  be prudent to follow the above advice in     *
                   *  patients considered at risk of having        *
                   *  occult atherosclerotic heart disease who     *
                   *  are given propranolol for other              *
                   *  indications.                                 *
                   *                                               *
                   *************************************************
</pre>

<p>NONALLERGIC BRONCHOSPASM (E.G., CHRONIC BRONCHITIS, EMPHYSEMA) PATIENTS
WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA BLOCKERS.
Propranolol should be administered with caution since it may block bronchodilation
produced by endogenous and exogenous catecholamine stimulation of beta
receptors. </p>

<p>MAJOR SURGERY </p>

<p>The necessity or desirability of withdrawal of beta-blocking therapy
prior to major surgery is controversial. It should be noted, however, that
the impaired ability of the heart to respond to reflex adrenergic stimuli
may augment the risks of general anesthesia and surgical procedures. </p>

<p>Propranolol, like other beta blockers, is a competitive inhibitor of
beta-receptor agonists and its effects can be reversed by administration
of such agents, e.g., dobutamine or isoproterenol. However, such patients
may be subject to protracted severe hypotension. Difficulty in starting
and maintaining the heartbeat has also been reported with beta blockers.
</p>

<p>DIABETES AND HYPOGLYCEMIA </p>

<p>Beta blockers should be used with caution in diabetic patients if a
beta- blocking agent is required. Beta blockers may mask tachycardia occurring
with hypoglycemia, but other manifestations such as dizziness and sweating
may not be significantly affected. Following insulin- induced hypoglycemia,
propranolol may cause a delay in the recovery of blood glucose to normal
levels. </p>

<p>THYROTOXICOSIS </p>

<p>Beta blockade may mask certain clinical signs of hyperthyroidism. Therefore,
abrupt withdrawal of propranolol may be followed by an exacerbation of
symptoms of hyperthyroidism, including thyroid storm. Propranolol may change
thyroid- function tests, increasing T4 and reverse T3 and decreasing T3.
</p>

<p>IN PATIENTS WITH WOLFF-PARKINSON-WHITE SYNDROME, several cases have
been reported in which, after propranolol, the tachycardia was replaced
by a severe bradycardia requiring a demand pacemaker. In one case this
resulted after an initial dose of 5 mg propranolol. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL </p>

<p>Propranolol should be used with caution in patients with impaired hepatic
or renal function. Propranolol is not indicated for the treatment of hypertensive
emergencies. </p>

<p>Beta-adrenoreceptor blockade can cause reduction of intraocular pressure.
Patients should be told that Propranolol may interfere with the glaucoma
screening test. Withdrawal may lead to a return of increased intraocular
pressure. CLINICAL LABORATORY TESTS </p>

<p>Elevated blood urea levels in patients with severe heart disease, elevated
serum transaminase, alkaline phosphatase, lactate dehydrogenase. </p>

<p>DRUG INTERACTIONS </p>

<p>Patients receiving catecholamine-depleting drugs such as reserpine should
be closely observed if Propranolol is administered. The added catecholamine-
blocking action may produce an excessive reduction of resting sympathetic
nervous activity, which may result in hypotension, marked bradycardia,
vertigo, syncopal attacks, or orthostatic hypotension. </p>

<p>Caution should be exercised when patients receiving a beta blocker are
administered a calcium-channel blocking drug, especially intravenous verapamil,
for both agents may depress myocardial contractility or atrioventricular
conduction. On rare occasions, the concomitant intravenous use of a beta
blocker and verapamil has resulted in serious adverse reactions, especially
in patients with severe cardiomyopathy, congestive heart failure or recent
myocardial infarction. </p>

<p>Blunting of the antihypertensive effect of beta- adrenoceptor blocking
agents by nonsteroidal anti-inflammatory drugs has been reported. </p>

<p>Hypotension and cardiac arrest have been reported with the concomitant
use of propranolol and haloperidol. </p>

<p>Aluminum Hydroxide Gel greatly reduces intestinal absorption of propranolol.
</p>

<p>Ethanol slows the rate of absorption of propranolol. </p>

<p>Phenytoin, Phenobarbitone, and Rifampin accelerate propranolol clearance.
</p>

<p>Chlorpromazine, when used concomitantly with propranolol, results in
increased plasma levels of both drugs. </p>

<p>Antipyrine and Lidocaine have reduced clearance when used concomitantly
with propranolol. </p>

<p>Thyroxine may result in a lower than expected T3 concentration when
used concomitantly with propranolol. </p>

<p>Cimetidine decreases the hepatic metabolism of propranolol, delaying
elimination and increasing blood levels. </p>

<p>Theophylline clearance is reduced when used concomitantly with propranolol.
</p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY </p>

<p>Long-term studies in animals have been conducted to evaluate toxic effects
and carcinogenic potential. In 18-month studies, in both rats and mice,
employing doses up to 150 mg/kg/day, there was no evidence of significant
drug-induced toxicity. There were no drug-related tumorigenic effects at
any of the dosage levels. Reproductive studies in animals did not show
any impairment of fertility that was attributable to the drug. </p>

<p>PREGNANCY: PREGNANCY CATEGORY C </p>

<p>In a series of reproduction and developmental toxicology studies, propranolol
was given to rats at dosages up to 150 mg/kg/day by gavage or in the diet
throughout pregnancy and through lactation. In rats given 150 mg/kg/day
(about 10 times the maximum recommended human dose) propranolol was embryotoxic
(reduced litter sizes and increased resorption sites). In addition, an
unexplained increase in neonatal toxicity (death) was noted at all dosage
groups in some of the studies. Maternal toxicity (decreased body weight)
was evident at 150 mg/kg/day. Propranolol also was given to rabbits at
dosages up to 250 mg/kg/day (approximately 20 times the maximum recommended
human dose) throughout pregnancy. No evidence of embryotoxicity was noted.
</p>

<p>Teratogenicity was not noted in either species. </p>

<p>There are no adequate and well-controlled studies in pregnant women.
Intrauterine growth retardation has been reported in neonates whose mothers
received propranolol during pregnancy. Neonates whose mothers are receiving
propranolol at parturition have exhibited bradycardia, hypoglycemia and
respiratory depression. Adequate facilities for monitoring these infants
at birth should be available. Propranolol should be used during pregnancy
only if the potential benefit justifies the potential risk to the fetus.
</p>

<p>NURSING MOTHERS </p>

<p>Propranolol is excreted in human milk. Caution should be exercised when
Propranolol is administered to a nursing woman. </p>

<p>PEDIATRIC USE </p>

<p>High serum propranolol levels have been noted in patients with Down's
syndrome (trisomy 21), suggesting that the bioavailability of propranolol
may be increased in patients with this condition. </p>

<p>Evaluation of the effects of propranolol in children, relative to the
drug's efficacy and safety, has not been as systematically performed as
in adults. Information is available in the medical literature to allow
fair estimates, and specific dosing information has been reasonably studied.
</p>

<p>Cardiovascular diseases that are common to adults and children are generally
as responsive to propranolol intervention in children as they are in adults.
</p>

<p>Adverse reactions are also similar: for example, bronchospasm and congestive
heart failure related to propranolol therapy have been reported in children
and occur through the same mechanisms as previously described in adults.
The normal echocardiogram evolves through a series of changes as the heart
matures during growth and development in children. Should echocardiography
be used to monitor propranolol therapy in children, the age-related changes
in the echocardiogram need to be borne in mind. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Patients receiving catecholamine-depleting drugs such as reserpine should
be closely observed if Propranolol is administered. The added catecholamine-
blocking action may produce an excessive reduction of resting sympathetic
nervous activity, which may result in hypotension, marked bradycardia,
vertigo, syncopal attacks, or orthostatic hypotension. </p>

<p>Caution should be exercised when patients receiving a beta blocker are
administered a calcium-channel blocking drug, especially intravenous verapamil,
for both agents may depress myocardial contractility or atrioventricular
conduction. On rare occasions, the concomitant intravenous use of a beta
blocker and verapamil has resulted in serious adverse reactions, especially
in patients with severe cardiomyopathy, congestive heart failure or recent
myocardial infarction. </p>

<p>Blunting of the antihypertensive effect of beta- adrenoceptor blocking
agents by nonsteroidal anti-inflammatory drugs has been reported. </p>

<p>Hypotension and cardiac arrest have been reported with the concomitant
use of propranolol and haloperidol. </p>

<p>Aluminum Hydroxide Gel greatly reduces intestinal absorption of propranolol.
</p>

<p>Ethanol slows the rate of absorption of propranolol. </p>

<p>Phenytoin, Phenobarbitone, and Rifampin accelerate propranolol clearance.
</p>

<p>Chlorpromazine, when used concomitantly with propranolol, results in
increased plasma levels of both drugs. </p>

<p>Antipyrine and Lidocaine have reduced clearance when used concomitantly
with propranolol. </p>

<p>Thyroxine may result in a lower than expected T3 concentration when
used concomitantly with propranolol. </p>

<p>Cimetidine decreases the hepatic metabolism of propranolol, delaying
elimination and increasing blood levels. </p>

<p>Theophylline clearance is reduced when used concomitantly with propranolol.
(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Most adverse effects have been mild and transient and have rarely required
the withdrawal of therapy. </p>

<p>CARDIOVASCULAR: Bradycardia; congestive heart failure; intensification
of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura;
arterial insufficiency, usually of the Raynaud type. </p>

<p>CENTRAL NERVOUS SYSTEM: Light-headedness; mental depression manifested
by insomnia, lassitude, weakness, fatigue; reversible mental depression
progressing to catatonia; visual disturbances; hallucinations, vivid dreams,
an acute reversible syndrome characterized by disorientation for time and
place, short- term memory loss, emotional lability, slightly clouded sensorium,
and decreased performance on neuropsychometrics. Total daily doses above
160 mg (when administered as divided doses of greater than 80 mg each)
may be associated with an increased incidence of fatigue, lethargy, and
vivid dreams. </p>

<p>GASTROINTESTINAL: Nausea, vomiting, epigastric distress, abdominal cramping,
diarrhea, constipation, mesenteric arterial thrombosis, ischemic colitis.
</p>

<p>ALLERGIC: Pharyngitis and agranulocytosis, erythematous rash, fever
combined with aching and sore throat, laryngospasm, and respiratory distress.
</p>

<p>RESPIRATORY: Bronchospasm. </p>

<p>HEMATOLOGIC: Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic
purpura. </p>

<p>AUTOIMMUNE: In extremely rare instances, systemic lupus erythematosus
has been reported. </p>

<p>MISCELLANEOUS: Alopecia, LE-like reactions, psoriasiform rashes, dry
eyes, male impotence, and Peyronie's disease have been reported rarely.
Oculomucocutaneous reactions involving the skin, serous membranes and conjunctivae
reported for a beta blocker (practolol) have not been associated with propranolol.
</p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Propranolol is not significantly dialyzable. In the event of overdosage
or exaggerated response, the following measures should be employed: General--If
ingestion is or may have been recent, evacuate gastric contents, taking
care to prevent pulmonary aspiration. </p>

<p>BRADYCARDIA: ADMINISTER ATROPINE (0.25 mg to 1.0 mg); IF THERE IS NO
RESPONSE TO VAGAL BLOCKADE, ADMINISTER ISOPROTERENOL CAUTIOUSLY. </p>

<p>CARDIAC FAILURE: DIGITALIZATION AND DIURETICS. </p>

<p>HYPOTENSION: VASOPRESSORS, E.G., LEVARTERENOL OR EPINEPHRINE (THERE
IS EVIDENCE THAT EPINEPHRINE IS THE DRUG OF CHOICE). </p>

<p>BRONCHOSPASM: ADMINISTER ISOPROTERENOL AND AMINOPHYLLINE. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>THE DOSAGE RANGE FOR Propranolol IS DIFFERENT FOR EACH INDICATION. </p>

<p>ORAL </p>

<p>HYPERTENSION--Dosage Must Be Individualized. </p>

<p>The usual initial dosage is 40 mg Propranolol twice daily, whether used
alone or added to a diuretic. Dosage may be increased gradually until adequate
blood pressure control is achieved. The usual maintenance dosage is 120
mg to 240 mg per day. In some instances a dosage of 640 mg a day may be
required. The time needed for full antihypertensive response to a given
dosage is variable and may range from a few days to several weeks. </p>

<p>While twice-daily dosing is effective and can maintain a reduction in
blood pressure throughout the day, some patients, especially when lower
doses are used, may experience a modest rise in blood pressure toward the
end of the 12- hour dosing interval. This can be evaluated by measuring
blood pressure near the end of the dosing interval to determine whether
satisfactory control is being maintained throughout the day. If control
is not adequate, a larger dose, or 3- times-daily therapy may achieve better
control. </p>

<p>ANGINA PECTORIS--Dosage Must Be Individualized. </p>

<p>Total daily doses of 80 mg to 320 mg, when administered orally, twice
a day, three times a day, or four times a day, have been shown to increase
exercise tolerance and to reduce ischemic changes in the ECG. If treatment
is to be discontinued, reduce dosage gradually over a period of several
weeks. (See &quot;Warnings.&quot;) </p>

<p>ARRHYTHMIAS--10 mg to 30 mg three or four times daily, before meals
and at bedtime. </p>

<p>MYOCARDIAL INFARCTION--The recommended daily dosage is 180 mg to 240
mg per day in divided doses. Although a t.i.d. regimen was used in the
Beta-Blocker Heart Attack Trial and a q.i.d. regimen in the Norwegian Multicenter
Trial, there is a reasonable basis for the use of either a t.i.d. or b.i.d.
regimen (see &quot;Actions/Clinical Pharmacology.&quot;) The effectiveness
and safety of daily dosages greater than 240 mg for prevention of cardiac
mortality have not been established. However, higher dosages may be needed
to effectively treat coexisting diseases such as angina or hypertension
(see above). </p>

<p>MIGRAINE--Dosage Must Be Individualized. </p>

<p>The initial oral dose is 80 mg Propranolol daily in divided doses. The
usual effective dose range is 160 mg to 240 mg per day. The dosage may
be increased gradually to achieve optimum migraine prophylaxis. If a satisfactory
response is not obtained within four to six weeks after reaching the maximum
dose, Propranolol therapy should be discontinued. It may be advisable to
withdraw the drug gradually over a period of several weeks. </p>

<p>ESSENTIAL TREMOR--Dosage Must Be Individualized. </p>

<p>The initial dosage is 40 mg Propranolol twice daily. Optimum reduction
of essential tremor is usually achieved with a dose of 120 mg per day.
Occasionally, it may be necessary to administer 240 mg to 320 mg per day.
</p>

<p>HYPERTROPHIC SUBAORTIC STENOSIS--20 mg to 40 mg three or four times
daily, before meals and at bedtime. </p>

<p>PHEOCHROMOCYTOMA--Preoperatively--60 mg daily in divided doses for three
days prior to surgery, concomitantly with an alpha-adrenergic blocking
agent. </p>

<p>Management Of Inoperable Tumor--30 mg daily in divided doses. </p>

<p>USE IN CHILDREN: Intravenous administration of Propranolol is not recommended
in children. Oral dosage for treating hypertension requires individual
titration, beginning with a 1.0 mg perkg (body weight) per day dosage regimen
(i.e., 0.5 mg per kg b.i.d.). </p>

<p>The usual pediatric dosage range is 2 mg to 4 mg per kg per day in two
equally divided doses (i.e., 1.0 mg per kg b.i.d. to 2.0 mg per kg b.i.d.).
Pediatric dosage calculated by weight (recommended) generally produces
propranolol plasma levels in a therapeutic range similar to that in adults.
On the other hand, pediatric doses calculated on the basis of body surface
area (Not recommended) usually result in plasma levels above the mean adult
therapeutic range. Doses above 16 mg per kg per day should not be used
in children. If treatment with Propranolol is to be discontinued, a gradually
decreasing dose titration over a 7-to 14-day period is necessary. </p>

<p>INTRAVENOUS </p>

<p>Parenteral drug products should be inspected visually for particulate
matter and discoloration prior to administration, whenever solution and
container permit. Intravenous administration is reserved for life- threatening
arrhythmias or those occurring under anesthesia. The usual dose is from
1 mg to 3 mg administered under careful monitoring, e.g., electrocardiographic,
central venous pressure. The rate of administration should not exceed 1
mg (1 mL) per minute to diminish the possibility of lowering blood pressure
and causing cardiac standstill. Sufficient time should be allowed for the
drug to reach the site of action even when a slow circulation is present.
If necessary, a second dose may be given after two minutes. Thereafter,
additional drug should not be given in less than four hours. Additional
Propranolol should not be given when the desired alteration in rate and/or
rhythm is achieved. </p>

<p>Transference to oral therapy should be made as soon as possible. </p>

<p>The intravenous administration of Propranolol has not been evaluated
adequately in the management of hypertensive emergencies. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B10-82</DOCNO>
<DOCOLDNO>IA018-000200-B040-137</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/indometh.htm 206.86.175.201 19970106230626 text/html 50964
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:00:12 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 50781
Last-modified: Sat, 12 Oct 1996 06:52:03 GMT
</DOCHDR>
<html>
<head>
   <title>Indomethacin - RxList Generic Information</title>
   <meta name="keywords" content="indocin, Amuno, Antalgin, Areumatin, Argilex, Artherexin,
Arthrexin, Artrinovo, Bavilon, Bonidon, Boutycin, Chrono-Indocid,
Cidalgon, Confortid, Confortind, Domecid, Durametacin, Elemetacin,
Idicin, Imbrilon, Inacid, Indacin, Indameth, Indecin, Indocap,
Indocen, Indocid, Indoflex, Indolag, Indolar, Indomed, Indomee, Indometacinum, Indometicina,
Indometin, Indovis, Indox, Indozu, Indrenin, Indylon, Inflazon, Inpan, Lauzit,
Liometacen, Metacen, Metindol, Metocid, Mezolin, Mobilan, Neotica,
Novomethacin, Peralgon, Reflox, Rheumacid, Rheumacin, Salinac,
Servindomet, Toshisan,Vonum">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Indomethacin</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Indomethacin cannot be considered a simple analgesic and should not
be used in conditions other than those recommended under INDICATIONS. Indomethacin
is a non- steroidal anti-inflammatory indole derivative designated chemically
as 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole- 3- acetic acid. Indomethacin
is practically insoluble in water and sparingly soluble in alcohol. It
has a pKa of 4.5 and is stable in neutral or slightly acidic media and
decomposes in strong alkali. The suspension has a pH of 4.0- 5.0. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Indomethacin is a non-steroidal drug with anti- inflammatory, antipyretic
and analgesic properties. Its mode of action, like that of other anti-inflammatory
drugs, is not known. However, its therapeutic action is not due to pituitary-
adrenal stimulation. </p>

<p>Indomethacin is a potent inhibitor of prostaglandin synthesis In Vitro.
</p>

<p>Concentrations are reached during therapy which have been demonstrated
to have an effect In Vivo as well. Prostaglandins sensitize afferent nerves
and potentiate the action of bradykinin in inducing pain in animal models.
Moreover, prostaglandins are known to be among the mediators of inflammation.
Since indomethacin is an inhibitor of prostaglandin synthesis, its mode
of action may be due to a decrease of prostaglandins in peripheral tissues.
</p>

<p>Indomethacin has been shown to be an effective anti- inflammatory agent,
appropriate for long-term use in rheumatoid arthritis, ankylosing spondylitis,
and osteoarthritis. </p>

<p>Indomethacin affords relief of symptoms; it does not alter the progressive
course of the underlying disease. </p>

<p>Indomethacin suppresses inflammation in rheumatoid arthritis as demonstrated
by relief of pain, and reduction of fever, swelling and tenderness. Improvement
in patients treated with Indomethacin for rheumatoid arthritis has been
demonstrated by a reduction in joint swelling, average number of joints
involved, and morning stiffness; by increased mobility as demonstrated
by a decrease in walking time; and by improved functional capability as
demonstrated by an increase in grip strength. </p>

<p>Indomethacin has been reported to diminish basal and CO2 stimulated
cerebral blood flow in healthy volunteers following acute oral and intravenous
administration. In one study after one week of treatment with orally administered
indomethacin, this effect on basal cerebral blood flow had disappeared.
The clinical significance of this effect has not been established. Capsules
Indomethacin have been found effective in relieving the pain, reducing
the fever, swelling, redness, and tenderness of acute gouty arthritis.
Capsules Indomethacin rather than Capsules Indomethacin SR are recommended
for treatment of acute gouty arthritis--see INDICATIONS. </p>

<p>Following single oral doses of Capsules Indomethacin 25 mg or 50 mg,
indomethacin is readily absorbed, attaining peak plasma concentrations
of about 1 and 2 mcg/mL, respectively, at about 2 hours. Orally administered
Capsules Indomethacin are virtually 100% bioavailable, with 90% of the
dose absorbed within 4 hours. A single 50 mg dose of Oral Suspension Indomethacin
was found to be bioequivalent to a 50 mg Indomethacin capsule when each
was administered with food. Capsules Indomethacin SR 75 mg are designed
to release 25 mg of the drug initially and the remaining 50 mg over approximately
12 hours (90% of dose absorbed by 12 hours). When measured over a 24-hour
period, the cumulative amount and time- course of indomethacin absorption
from a single Capsule Indomethacin SR are comparable to those of 3 doses
of 25 mg Capsules Indomethacin given at 4-6 hour intervals. </p>

<p>Plasma concentrations of indomethacin fluctuate less and are more sustained
following administration of Capsules Indomethacin SR than following administration
of 25 mg Capsules Indomethacin given at 4-6 hour intervals. In multiple-
dose comparisons, the mean daily steady-state plasma level of indomethacin
attained with daily administration of Capsules Indomethacin SR 75 mg was
indistinguishable from that following Capsules Indomethacin 25 mg given
at 0, 6 and 12 hours daily. However, there was a significant difference
in indomethacin plasma levels between the two dosage regimens especially
after 12 hours. Controlled clinical studies of safety and efficacy in patients
with osteoarthritis have shown that one Capsule Indomethacin SR was clinically
comparable to one 25 mg Capsule Indomethacin t.i.d.; and in controlled
clinical studies in patients with rheumatoid arthritis, one Capsule Indomethacin
SR taken in the morning and one in the evening were clinically indistinguishable
from one 50 mg Capsule Indomethacin t.i.d. </p>

<p>Indomethacin is eliminated via renal excretion, metabolism, and biliary
excretion. Indomethacin undergoes appreciable enterohepatic circulation.
The mean half-life of indomethacin is estimated to be about 4.5 hours.
With a typical therapeutic regimen of 25 or 50 mg t.i.d., the steady-state
plasma concentrations of indomethacin are an average 1.4 times those following
the first dose. </p>

<p>The rate of absorption is more rapid from the rectal suppository than
from Capsules Indomethacin. Ordinarily, therefore, the total amount absorbed
from the suppository would be expected to be at least equivalent to the
capsule. In controlled clinical trials, however, the amount of indomethacin
absorbed was found to be somewhat less (80-90%) than that absorbed from
Capsules Indomethacin. This is probably because some subjects did not retain
the material from the suppository for the one hour necessary to assure
complete absorption. Since the suppository dissolves rather quickly rather
than melting slowly, it is seldom recovered in recognizable form if the
patient retains the suppository for more than a few minutes. </p>

<p>Indomethacin exists in the plasma as the parent drug and its desmethyl,
desbenzoyl, and desmethyl-desbenzoyl metabolites, all in the unconjugated
form. About 60 percent of an oral dosage is recovered in urine as drug
and metabolites (26 percent as indomethacin and its glucuronide), and 33
percent is recovered in feces (1.5 percent as indomethacin). </p>

<p>About 99% of indomethacin is bound to protein in plasma over the expected
range of therapeutic plasma concentrations. Indomethacin has been found
to cross the blood-brain barrier and the placenta. </p>

<p>In a gastroscopic study in 45 healthy subjects, the number of gastric
mucosal abnormalities was significantly higher in the group receiving Capsules
Indomethacin than in the group taking Suppositories Indomethacin or placebo.
</p>

<p>In a double-blind comparative clinical study involving 175 patients
with rheumatoid arthritis, however, the incidence of upper gastrointestinal
adverse effects with Suppositories or Capsules Indomethacin was comparable.
The incidence of lower gastrointestinal adverse effects was greater in
the suppository group. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Indomethacin has been found effective in active stages of the following:
</p>

<p>1. Moderate to severe rheumatoid arthritis including acute flares of
chronic disease. </p>

<p>2. Moderate to severe ankylosing spondylitis. </p>

<p>3. Moderate to severe osteoarthritis. </p>

<p>4. Acute painful shoulder (bursitis and/or tendinitis). </p>

<p>5. Acute gouty arthritis. </p>

<p>Capsules Indomethacin SR are recommended for all of the indications
for Capsules Indomethacin except acute gouty arthritis. </p>

<p>Indomethacin may enable the reduction of steroid dosage in patients
receiving steroids for the more severe forms of rheumatoid arthritis. In
such instances the steroid dosage should be reduced slowly and the patients
followed very closely for any possible adverse effects. </p>

<p>The use of Indomethacin in conjunction with aspirin or other salicylates
is not recommended. Controlled clinical studies have shown that the combined
use of Indomethacin and aspirin does not produce any greater therapeutic
effect than the use of Indomethacin alone. Furthermore, in one of these
clinical studies, the incidence of gastrointestinal side effects was significantly
increased with combined therapy (see DRUG INTERACTIONS). </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Indomethacin should not be used in: </p>

<p>Patients who are hypersensitive to this product. </p>

<p>Patients in whom acute asthmatic attacks, urticaria, or rhinitis are
precipitated by aspirin or other non-steroidal anti-inflammatory agents.
</p>

<p>Suppositories Indomethacin are contraindicated in patients with a history
of proctitis or recent rectal bleeding. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>General: </p>

<p>Because of the variability of the potential of Indomethacin to cause
adverse reactions in the individual patient, the following are strongly
recommended: </p>

<p>1. The lowest possible effective dose for the individual patient should
be prescribed. Increased dosage tends to increase adverse effects, particularly
in doses over 150-200 mg/day, without corresponding increase in clinical
benefits. </p>

<p>2. Careful instructions to, and observations of, the individual patient
are essential to the prevention of serious adverse reactions. As advancing
years appear to increase the possibility of adverse reactions, Indomethacin
should be used with greater care in the aged. </p>

<p>3. Effectiveness of Indomethacin in children has not been established.
Indomethacin should not be prescribed for children 14 years of age and
younger unless toxicity or lack of efficacy associated with other drugs
warrants the risk. </p>

<p>In experience with more than 900 children reported in the literature
or to the manufacturer who were treated with Capsules Indomethacin, side
effects in children were comparable to those reported in adults. Experience
in children has been confined to the use of Capsules Indomethacin. </p>

<p>If a decision is made to use indomethacin for children two years of
age or older, such patients should be monitored closely and periodic assessment
of liver function is recommended. There have been cases of hepatotoxicity
reported in children with juvenile rheumatoid arthritis, including fatalities.
</p>

<p>If indomethacin treatment is instituted, a suggested starting dose is
2 mg/kg/day given in divided doses. Maximum daily dosage should not exceed
4 mg/kg/day or 150-200 mg/day, whichever is less. As symptoms subside,
the total daily dosage should be reduced to the lowest level required to
control symptoms, or the drug should be discontinued. </p>

<p>4. If Capsules Indomethacin SR are used for initial therapy or during
dosage adjustment, observe the patient closely (see DOSAGE AND ADMINISTRATION).
</p>

<p>Gastrointestinal Effects: </p>

<p>Single or multiple ulcerations, including perforation and hemorrhage
of the esophagus, stomach, duodenum or small and large intestine, have
been reported to occur with Indomethacin. Fatalities have been reported
in some instances. Rarely, intestinal ulceration has been associated with
stenosis and obstruction. </p>

<p>Gastrointestinal bleeding without obvious ulcer formation and perforation
of pre-existing sigmoid lesions (diverticulum, carcinoma, etc.) have occurred.
Increased abdominal pain in ulcerative colitis patients or the development
of ulcerative colitis and regional ileitis have been reported to occur
rarely. </p>

<p>Because of the occurrence, and at times severity, of gastrointestinal
reactions to Indomethacin, the prescribing physician must be continuously
alert for any sign or symptom signaling a possible gastrointestinal reaction.
The risks of continuing therapy with Indomethacin in the face of such symptoms
must be weighed against the possible benefits to the individual patient.
</p>

<p>Indomethacin should not be given to patients with active gastrointestinal
lesions or with a history of recurrent gastrointestinal lesions except
under circumstances which warrant the very high risk and where patients
can be monitored very closely. </p>

<p>The gastrointestinal effects may be reduced by giving Capsules Indomethacin
or Capsules Indomethacin SR immediately after meals, with food, or with
antacids. Risk Of GI Ulcerations, Bleeding And Perforation With NSAID Therapy
Serious gastrointestinal toxicity such as bleeding, ulceration, and perforation,
can occur at any time, with or without warning symptoms, in patients treated
chronically with NSAID therapy. Although minor upper gastrointestinal problems,
such as dyspepsia, are common, usually developing early in therapy, physicians
should remain alert for ulceration and bleeding in patients treated chronically
with NSAIDs even in the absence of previous GI tract symptoms. In patients
observed in clinical trials of several months to two years duration, symptomatic
upper GI ulcers, gross bleeding or perforation appear to occur in approximately
1% of patients treated for 3-6 months, and in about 2-4% of patients treated
for one year. Physicians should inform patients about the signs and/or
symptoms of serious GI toxicity and what steps to take if they occur. </p>

<p>Studies to date have not identified any subset of patients not at risk
of developing peptic ulceration and bleeding. Except for a prior history
of serious GI events and other risk factors known to be associated with
peptic ulcer disease, such as alcoholism, smoking, etc., no risk factors
(e.g., age, sex) have been associated with increased risk. Elderly or debilitated
patients seem to tolerate ulceration or bleeding less well than other individuals
and most spontaneous reports of fatal GI events are in this population.
Studies to date are inconclusive concerning the relative risk of various
NSAIDs in causing such reactions. High doses of any NSAID probably carry
a greater risk of these reactions, although controlled clinical trials
showing this do not exist in most cases. In considering the use of relatively
large doses (within the recommended dosage range), sufficient benefit should
be anticipated to offset the potential increased risk of GI toxicity. </p>

<p>Renal Effects: </p>

<p>As with other non-steroidal anti-inflammatory drugs, long term administration
of indomethacin to animals has resulted in renal papillary necrosis and
other abnormal renal pathology. In humans, there have been reports of acute
interstitial nephritis with hematuria, proteinuria, and occasionally nephrotic
syndrome. </p>

<p>A second form of renal toxicity has been seen in patients with prerenal
and renal conditions leading to a reduction in renal blood flow or blood
volume, where the renal prostaglandins have a supportive role in the maintenance
of renal perfusion. In these patients administration of an NSAID may cause
a dose dependent reduction in prostaglandin formation and may precipitate
overt renal decompensation. Patients at greatest risk of this reaction
are those with conditions such as renal or hepatic dysfunction, diabetes
mellitus, advanced age, extracellular volume depletion from any cause,
congestive heart failure, septicemia, pyelonephritis, or concomitant use
of any nephrotoxic drug. Indomethacin or other NSAIDs should be given with
caution and renal function should be monitored in any patient who may have
reduced renal reserve. Discontinuation of NSAID therapy is typically followed
by recovery to the pretreatment state. Increases in serum potassium concentration,
including hyperkalemia, have been reported, even in some patients without
renal impairment. In patients with normal renal function, these effects
have been attributed to a hyporeninemic- hypoaldosteronism state (see PRECAUTIONS,
Drug Interactions). </p>

<p>Since Indomethacin is eliminated primarily by the kidneys, patients
with significantly impaired renal function should be closely monitored;
a lower daily dosage should be anticipated to avoid excessive drug accumulation.
</p>

<p>Ocular Effects: </p>

<p>Corneal deposits and retinal disturbances, including those of the macula,
have been observed in some patients who had received prolonged therapy
with Indomethacin. The prescribing physician should be alert to the possible
association between the changes noted and Indomethacin. It is advisable
to discontinue therapy if such changes are observed. Blurred vision may
be a significant symptom and warrants a thorough ophthalmological examination.
Since these changes may be asymptomatic, ophthalmologic examination at
periodic intervals is desirable in patients where therapy is prolonged.
</p>

<p>Central Nervous System Effects: </p>

<p>Indomethacin may aggravate depression or other psychiatric disturbances,
epilepsy, and parkinsonism, and should be used with considerable caution
in patients with these conditions. If severe CNS adverse reactions develop,
Indomethacin should be discontinued. </p>

<p>Indomethacin may cause drowsiness; therefore, patients should be cautioned
about engaging in activities requiring mental alertness and motor coordination,
such as driving a car. Indomethacin may also cause headache. Headache which
persists despite dosage reduction requires cessation of therapy with Indomethacin.
</p>

<p>Use In Pregnancy And The Neonatal Period </p>

<p>Indomethacin is not recommended for use in pregnant women, since safety
for use has not been established. The known effects of indomethacin and
other drugs of this class on the human fetus during the third trimester
of pregnancy include: constriction of the ductus arteriosus prenatally,
tricuspid incompetence, and pulmonary hypertension; non-closure of the
ductus arteriosus postnatally which may be resistant to medical management;
myocardial degenerative changes, platelet dysfunction with resultant bleeding,
intracranial bleeding, renal dysfunction or failure, renal injury-dysgenesis
which may result in prolonged or permanent renal failure, oligohydramnios,
gastrointestinal bleeding or perforation, and increased risk of necrotizing
enterocolitis. </p>

<p>Teratogenic studies were conducted in mice and rats at dosages of 0.5,
1.0, 2.0, and 4.0 mg/kg/day. Except for retarded fetal ossification at
4 mg/kg/day considered secondary to the decreased average fetal weights,
no increase in fetal malformations was observed as compared with control
groups. Other studies in mice reported in the literature using higher doses
(5 to 15 mg/kg/day) have described maternal toxicity and death, increased
fetal resorptions, and fetal malformations. Comparable studies in rodents
using high doses of aspirin have shown similar maternal and fetal effects.
</p>

<p>As with other non-steroidal anti-inflammatory agents which inhibit prostaglandin
synthesis, indomethacin has been found to delay parturition in rats. In
rats and mice, 4.0 mg/kg/day given during the last three days of gestation
caused a decrease in maternal weight gain and some maternal and fetal deaths.
An increased incidence of neuronal necrosis in the diencephalon in the
live-born fetuses was observed. At 2.0 mg/kg/day, no increase in neuronal
necrosis was observed as compared to the control groups. Administration
of 0.5 or 4.0 mg/kg/day during the first three days of life did not cause
an increase in neuronal necrosis at either dose level. </p>

<p>Use In Nursing Mothers </p>

<p>Indomethacin is excreted in the milk of lactating mothers. Indomethacin
is not recommended for use in nursing mothers. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>General </p>

<p>Non-steroidal anti-inflammatory drugs, including Indomethacin, may mask
the usual signs and symptoms of infection. Therefore, the physician must
be continually on the alert for this and should use the drug with extra
care in the presence of existing infection. </p>

<p>Fluid retention and peripheral edema have been observed in some patients
taking Indomethacin. Therefore, as with other non-steroidal anti- inflammatory
drugs, Indomethacin should be used with caution in patients with cardiac
dysfunction, hypertension, or other conditions predisposing to fluid retention.
</p>

<p>In a study of patients with severe heart failure and hyponatremia, Indomethacin
was associated with significant deterioration of circulatory hemodynamics,
presumably due to inhibition of prostaglandin dependent compensatory mechanisms.
</p>

<p>Indomethacin, like other non-steroidal anti- inflammatory agents, can
inhibit platelet aggregation. This effect is of shorter duration than that
seen with aspirin and usually disappears within 24 hours after discontinuation
of Indomethacin. </p>

<p>Indomethacin has been shown to prolong bleeding time (but within the
normal range) in normal subjects. Because this effect may be exaggerated
in patients with underlying hemostatic defects, Indomethacin should be
used with caution in persons with coagulation defects. </p>

<p>As with other non-steroidal anti-inflammatory drugs, borderline elevations
of one or more liver tests may occur in up to 15% of patients. These abnormalities
may progress, may remain essentially unchanged, or may be transient with
continued therapy. The SGPT (ALT) test is probably the most sensitive indicator
of liver dysfunction. Meaningful (3 times the upper limit of normal) elevations
of SGPT or SGOT (AST) occurred in controlled clinical trials in less than
1% of patients. A patient with symptoms and/or signs suggesting liver dysfunction,
or in whom an abnormal liver test has occurred, should be evaluated for
evidence of the development of more severe hepatic reaction while on therapy
with Indomethacin. </p>

<p>Severe hepatic reactions, including jaundice and cases of fatal hepatitis,
have been reported with Indomethacin as with other non-steroidal anti-inflammatory
drugs. Although such reactions are rare, if abnormal liver tests persist
or worsen, if clinical signs and symptoms consistent with liver disease
develop, or if systemic manifestations occur (e.g., eosinophilia, rash,
etc.), Indomethacin should be discontinued. </p>

<p>Information For Patients </p>

<p>Indomethacin, like other drugs of its class, is not free of side effects.
The side effects of these drugs can cause discomfort and, rarely, there
are more serious side effects such as gastrointestinal bleeding, which
may result in hospitalization and even fatal outcomes. </p>

<p>NSAIDs (Non-steroidal Anti-inflammatory Drugs) are often essential agents
in the management of arthritis; but they also may be commonly employed
for conditions which are less serious. </p>

<p>Physicians may wish to discuss with their patients the potential risks
(see WARNINGS, PRECAUTIONS and ADVERSE REACTIONS) and likely benefits of
NSAID treatment, particularly when the drugs are used for less serious
conditions where treatment without NSAIDs may represent an acceptable alternative
to both the patient and physician. </p>

<p>Laboratory Tests </p>

<p>Because serious GI tract ulceration and bleeding can occur without warning
symptoms, physicians should follow chronically treated patients for the
signs and symptoms of ulceration and bleeding and should inform them of
the importance of this follow-up (see WARNINGS, Risk Of GI Ulcerations,
Bleeding And Perforation With NSAID Therapy). </p>

<p>Carcinogenesis, Mutagenesis, Impairment Of Fertility </p>

<p>In an 81-week chronic oral toxicity study in the rat at doses up to
1 mg/kg/day, indomethacin had no tumorigenic effect. </p>

<p>Indomethacin produced no neoplastic or hyperplastic changes related
to treatment in carcinogenic studies in the rat (dosing period 73-110 weeks)
and the mouse (dosing period 62-88 weeks) at doses up to 1.5 mg/kg/day.
</p>

<p>Indomethacin did not have any mutagenic effect in In Vitro bacterial
tests (Ames test and E. Coli with or without metabolic activation) and
a series of In Vivo tests including the host- mediated assay, sex-linked
recessive lethals in Drosophila, and the micronucleus test in mice. </p>

<p>Indomethacin at dosage levels up to 0.5 mg/kg/day had no effect on fertility
in mice in a two generation reproduction study or a two litter reproduction
study in rats. </p>

<p>Drug Interactions </p>

<p>In normal volunteers receiving indomethacin, the administration of diflunisal
decreased the renal clearance and significantly increased the plasma levels
of indomethacin. In some patients, combined use of Indomethacin and diflunisal
has been associated with fatal gastrointestinal hemorrhage. Therefore,
diflunisal and Indomethacin should not be used concomitantly. </p>

<p>In a study in normal volunteers, it was found that chronic concurrent
administration of 3.6 g of aspirin per day decreases indomethacin blood
levels approximately 20%. </p>

<p>The concomitant use of INCOCIN with other NSAIDs is not recommended
due to the increased possibility of gastrointestinal toxicity, with little
or no increase in efficacy. </p>

<p>Clinical studies have shown that Indomethacin does not influence the
hypoprothrombinemia produced by anticoagulants. However, when any additional
drug, including Indomethacin, is added to the treatment of patients on
anticoagulant therapy, the patients should be observed for alterations
of the prothrombin time. </p>

<p>When Indomethacin is given to patients receiving probenecid, the plasma
levels of indomethacin are likely to be increased. Therefore, a lower total
daily dosage of Indomethacin may produce a satisfactory therapeutic effect.
When increases in the dose of Indomethacin are made, they should be made
carefully and in small increments. </p>

<p>Caution should be used if Indomethacin is administered simultaneously
with methotrexate. Indomethacin has been reported to decrease the tubular
secretion of methotrexate and to potentiate its toxicity. </p>

<p>Administration of non-steroidal anti-inflammatory drugs concomitantly
with cyclosporine has been associated with an increase in cyclosporine-
induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
NSAIDs should be used with caution in patients taking cyclosporine, and
renal function should be monitored. </p>

<p>Capsules Indomethacin 50 mg t.i.d. produced a clinically relevant elevation
of plasma lithium and reduction in renal lithium clearance in psychiatric
patients and normal subjects with steady state plasma lithium concentrations.
This effect has been attributed to inhibition of prostaglandin synthesis.
As a consequence, when Indomethacin and lithium are given concomitantly,
the patient should be carefully observed for signs of lithium toxicity.
(Read circulars for lithium preparations before use of such concomitant
therapy.) In addition, the frequency of monitoring serum lithium concentration
should be increased at the outset of such combination drug treatment. </p>

<p>Indomethacin given concomitantly with digoxin has been reported to increase
the serum concentration and prolong the half-life of digoxin. Therefore,
when Indomethacin and digoxin are used concomitantly, serum digoxin levels
should be closely monitored. </p>

<p>In some patients, the administration of Indomethacin can reduce the
diuretic, natriuretic, and, antihypertensive effects of loop, potassium-
sparing, and thiazide diuretics. Therefore, when Indomethacin and diuretics
are used concomitantly, the patient should be observed closely to determine
if the desired effect of the diuretic is obtained. </p>

<p>Indomethacin reduces basal plasma renin activity (PRA), as well as those
elevations of PRA induced by furosemide administration, or salt or volume
depletion. These facts should be considered when evaluating plasma renin
activity in hypertensive patients. </p>

<p>It has been reported that the addition of triamterene to a maintenance
schedule of Indomethacin resulted in reversible acute renal failure in
two of four healthy volunteers. Indomethacin and triamterene should not
be administered together. Indomethacin and potassium-sparing diuretics
each may be associated with increased serum potassium levels. The potential
effects of Indomethacin and potassium-sparing diuretics on potassium kinetics
and renal function should be considered when these agents are administered
concurrently. </p>

<p>Most of the above effects concerning diuretics have been attributed,
at least in part, to mechanisms involving inhibition of prostaglandin synthesis
by Indomethacin. </p>

<p>Blunting of the antihypertensive effect of beta- adrenoceptor blocking
agents by non-steroidal anti-inflammatory drugs including Indomethacin
has been reported. Therefore, when using these blocking agents to treat
hypertension, patients should be observed carefully in order to confirm
that the desired therapeutic effect has been obtained. There are reports
that Indomethacin can reduce the antihypertensive effect of captopril in
some patients. </p>

<p>False-negative results in the dexamethasone suppression test (DST) in
patients being treated with Indomethacin have been reported. Thus, results
of the DST should be interpreted with caution in these patients. </p>

<p>Pediatric Use </p>

<p>Effectiveness in children 14 years of age and younger has not been established
(see WARNINGS). </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>In normal volunteers receiving indomethacin, the administration of diflunisal
decreased the renal clearance and significantly increased the plasma levels
of indomethacin. In some patients, combined use of Indomethacin and diflunisal
has been associated with fatal gastrointestinal hemorrhage. Therefore,
diflunisal and Indomethacin should not be used concomitantly. </p>

<p>In a study in normal volunteers, it was found that chronic concurrent
administration of 3.6 g of aspirin per day decreases indomethacin blood
levels approximately 20%. </p>

<p>The concomitant use of INCOCIN with other NSAIDs is not recommended
due to the increased possibility of gastrointestinal toxicity, with little
or no increase in efficacy. </p>

<p>Clinical studies have shown that Indomethacin does not influence the
hypoprothrombinemia produced by anticoagulants. However, when any additional
drug, including Indomethacin, is added to the treatment of patients on
anticoagulant therapy, the patients should be observed for alterations
of the prothrombin time. </p>

<p>When Indomethacin is given to patients receiving probenecid, the plasma
levels of indomethacin are likely to be increased. Therefore, a lower total
daily dosage of Indomethacin may produce a satisfactory therapeutic effect.
When increases in the dose of Indomethacin are made, they should be made
carefully and in small increments. Caution should be used if Indomethacin
is administered simultaneously with methotrexate. Indomethacin has been
reported to decrease the tubular secretion of methotrexate and to potentiate
its toxicity. </p>

<p>Administration of non-steroidal anti-inflammatory drugs concomitantly
with cyclosporine has been associated with an increase in cyclosporine-
induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
NSAIDs should be used with caution in patients taking cyclosporine, and
renal function should be monitored. </p>

<p>Capsules Indomethacin 50 mg t.i.d. produced a clinically relevant elevation
of plasma lithium and reduction in renal lithium clearance in psychiatric
patients and normal subjects with steady state plasma lithium concentrations.
This effect has been attributed to inhibition of prostaglandin synthesis.
As a consequence, when Indomethacin and lithium are given concomitantly,
the patient should be carefully observed for signs of lithium toxicity.
(Read circulars for lithium preparations before use of such concomitant
therapy.) In addition, the frequency of monitoring serum lithium concentration
should be increased at the outset of such combination drug treatment. </p>

<p>Indomethacin given concomitantly with digoxin has been reported to increase
the serum concentration and prolong the half-life of digoxin. Therefore,
when Indomethacin and digoxin are used concomitantly, serum digoxin levels
should be closely monitored. </p>

<p>In some patients, the administration of Indomethacin can reduce the
diuretic, natriuretic, and, antihypertensive effects of loop, potassium-
sparing, and thiazide diuretics. Therefore, when Indomethacin and diuretics
are used concomitantly, the patient should be observed closely to determine
if the desired effect of the diuretic is obtained. </p>

<p>Indomethacin reduces basal plasma renin activity (PRA), as well as those
elevations of PRA induced by furosemide administration, or salt or volume
depletion. These facts should be considered when evaluating plasma renin
activity in hypertensive patients. </p>

<p>It has been reported that the addition of triamterene to a maintenance
schedule of Indomethacin resulted in reversible acute renal failure in
two of four healthy volunteers. Indomethacin and triamterene should not
be administered together. Indomethacin and potassium-sparing diuretics
each may be associated with increased serum potassium levels. The potential
effects of Indomethacin and potassium-sparing diuretics on potassium kinetics
and renal function should be considered when these agents are administered
concurrently. </p>

<p>Most of the above effects concerning diuretics have been attributed,
at least in part, to mechanisms involving inhibition of prostaglandin synthesis
by Indomethacin. Blunting of the antihypertensive effect of beta- adrenoceptor
blocking agents by non-steroidal anti-inflammatory drugs including Indomethacin
has been reported. Therefore, when using these blocking agents to treat
hypertension, patients should be observed carefully in order to confirm
that the desired therapeutic effect has been obtained. There are reports
that Indomethacin can reduce the antihypertensive effect of captopril in
some patients. </p>

<p>False-negative results in the dexamethasone suppression test (DST) in
patients being treated with Indomethacin have been reported. Thus, results
of the DST should be interpreted with caution in these patients. (See Also
PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The adverse reactions for Capsules Indomethacin listed in the following
table have been arranged into two groups: (1) incidence greater than 1%;
and (2) incidence less than 1%. The incidence for group (1) was obtained
from 33 double-blind controlled clinical trials reported in the literature
(1,092 patients). The incidence for group (2) was based on reports in clinical
trials, in the literature, and on voluntary reports since marketing. The
probability of a causal relationship exists between Indomethacin and these
adverse reactions, some of which have been reported only rarely. </p>

<p>In controlled clinical trials, the incidence of adverse reactions to
Capsules Indomethacin SR and equal 24-hour doses of Capsules Indomethacin
were similar. The adverse reactions reported with Capsules Indomethacin
may occur with use of the suppositories. In addition, rectal irritation
and tenesmus have been reported in patients who have received the suppositories.
</p>

<p>The adverse reactions reported with Capsules Indomethacin may also occur
with use of the suspension. </p>

<pre>
INCIDENCE GREATER THAN 1%   INCIDENCE LESS THAN 1%
------------------------------------------------------------------------------
GASTROINTESTINAL
nausea* with or             anorexia                gastrointestinal
 without vomiting           bloating (includes       bleeding without
dyspepsia*                   distention)             obvious ulcer
 (including                 flatulence               formation and
 indigestion,               peptic ulcer             perforation of pre-
 heartburn and              gastroenteritis          existing sigmoid
 epigastric pain)           rectal bleeding          lesions
diarrhea                    proctitis                (diverticulum,
abdominal distress          single or                carcinoma, etc.)
 or pain                     multiple ulcerations,   development of
constipation                 including               ulcerative colitis
                             perforation and         and regional ileitis
                             hemorrhage of          ulcerative stomatitis
                             the esophagus,         toxic hepatitis and
                             stomach,                jaundice (some
                             duodenum or             fatal cases have
                             small and large         been reported)
                             intestines             intestinal strictures
                            intestinal ulceration    (diaphragms)
                             associated with
                             stenosis and
                             obstruction

CENTRAL NERVOUS SYSTEM
headache (11.7%)            anxiety (includes       light-headedness
dizziness*                   nervousness)           syncope
vertigo                     muscle weakness         paresthesia
somnolence                  involuntary muscle      aggravation of epilepsy
depression and               movements                and parkinsonism
 fatigue (including         insomnia                depersonalization
 malaise and                muzziness               coma
 listlessness)              psychic distur-         peripheral neuropathy
                             bances including       convulsions
                             psychotic episodes     dysarthria
                            mental confusion
                             drowsiness


SPECIAL SENSES              ocular--corneal         blurred vision
tinnitus                     deposits and           diplopia
                             retinal distur-        hearing disturbances,
                             bances, including      deafness
                             those of the
                             macula, have been
                             reported in some
                             patients on pro-
                             longed therapy
                             with Indomethacin
CARDIOVASCULAR
none                        hypertension            congestive heart failure
                            hypotension             arrhythmia;
                            tachycardia              palpitations
                            chest pain
METABOLIC
none                        edema                   hyperglycemia
                            weight gain             glycosuria
                            fluid retention         hyperkalemia
                            flushing or sweating
INTEGUMENTARY
none                        pruritus                exfoliative
                            rash; urticaria          dermatitis
                            petechiae or            erythema nodosum
                             ecchymosis             loss of hair
                                                    Stevens-Johnson syndrome
                                                    erythema multiforme
                                                    toxic epidermal necrolysis
HEMATOLOGIC
none                        leukopenia              aplastic anemia
                            bone marrow             hemolytic anemia
                             depression             agranulocytosis
                            anemia secondary        thrombocytopenic
                             to obvious or           purpura
                             occult                 disseminated intravascular
                             gastrointestinal        coagulation
                             bleeding
HYPERSENSITIVITY
none                        acute anaphylaxis
                            acute respiratory       dyspnea
                             distress               asthma
                            rapid fall in blood     purpura
                             pressure               angiitis
                             resembling a           pulmonary edema
                             shock-like state       fever
                            angioedema
GENITOURINARY
none                        hematuria               BUN elevation
                            vaginal bleeding        renal insufficiency,
                            proteinuria              including renal
                            nephrotic syndrome       failure
                            interstitial nephritis
MISCELLANEOUS
none                        epistaxis
                            breast changes,
                             including
                             enlargement and
                             tenderness, or
                             gynecomastia
</pre>

<p>*Reactions occurring in 3% to 9% of patients treated with Indomethacin.
(Those reactions occurring in less than 3% of the patients are unmarked.)
</p>

<p>CAUSAL RELATIONSHIP UNKNOWN: Other reactions have been reported but
occurred under circumstances where a causal relationship could not be established.
However, in these rarely reported events, the possibility cannot be excluded.
Therefore, these observations are being listed to serve as alerting information
to physicians: </p>

<p>Cardiovascular: Thrombophlebitis </p>

<p>Hematologic: Although there have been several reports of leukemia, the
supporting information is weak. </p>

<p>Genitourinary: Urinary frequency. </p>

<p>A rare occurrence of fulminant necrotizing fasciitis, particularly in
association with Group A beta-hemolytic streptococcus, has been described
in persons treated with non-steroidal anti-inflammatory agents, including
indomethacin, sometimes with fatal outcome (see also PRECAUTIONS, General).
</p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>The following symptoms may be observed following overdosage: nausea,
vomiting, intense headache, dizziness, mental confusion, disorientation,
or lethargy. </p>

<p>There have been reports of paresthesias, numbness, and convulsions.
Treatment is symptomatic and supportive. The stomach should be emptied
as quickly as possible if the ingestion is recent. If vomiting has not
occurred spontaneously, the patient should be induced to vomit with syrup
of ipecac. If the patient is unable to vomit, gastric lavage should be
performed. Once the stomach has been emptied, 25 or 50 g of activated charcoal
may be given. </p>

<p>Depending on the condition of the patient, close medical observation
and nursing care may be required. The patient should be followed for several
days because gastrointestinal ulceration and hemorrhage have been reported
as adverse reactions of indomethacin. Use of antacids may be helpful. The
oral LD50 of indomethacin in mice and rats (based on 14 day mortality response)
was 50 and 12 mg/kg, respectively. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Indomethacin is available as 25 and 50 mg Capsules Indomethacin, 75
mg Capsules Indomethacin SR for oral use, Oral Suspension Indomethacin,
containing 25 mg of indomethacin per 5 mL, and 50 mg Suppositories Indomethacin
for rectal use. Capsules Indomethacin SR 75 mg once a day can be substituted
for Capsules Indomethacin 25 mg t.i.d. However, there will be significant
differences between the two dosage regimens in indomethacin blood levels,
especially after 12 hours (see ACTIONS/CLINICAL PHARMACOLOGY). In addition,
Capsules Indomethacin SR 75 mg b.i.d. can be substituted for Capsules Indomethacin
50 mg t.i.d. Capsules Indomethacin SR may be substituted for all the indications
for Capsules Indomethacin except acute gouty arthritis. </p>

<p>Adverse reactions appear to correlate with the size of the dose of Indomethacin
in most patients but not all. Therefore, every effort should be made to
determine the smallest effective dosage for the individual patient. </p>

<p>Always give Capsules Indomethacin, Capsules Indomethacin SR, or Oral
Suspension Indomethacin with food, immediately after meals, or with antacids
to reduce gastric irritation. </p>

<p>Pediatric Use </p>

<p>Indomethacin ordinarily should not be prescribed for children 14 years
of age and under (see WARNINGS). </p>

<p>Adult Use </p>

<p>Dosage Recommendations for Active Stages of the Following: </p>

<p>1. Moderate to severe rheumatoid arthritis including acute flares of
chronic disease; moderate to severe ankylosing spondylitis; and moderate
to severe osteoarthritis. </p>

<p>Suggested Dosage: </p>

<p>Capsules Indomethacin 25 mg b.i.d. or t.i.d. If this is well tolerated,
increase the daily dosage by 25 or by 50 mg, if required by continuing
symptoms, at weekly intervals until a satisfactory response is obtained
or until a total daily dose of 150-200 mg is reached. DOSES ABOVE THIS
AMOUNT GENERALLY DO NOT INCREASE THE EFFECTIVENESS OF THE DRUG. </p>

<p>In patients who have persistent night pain and/or morning stiffness,
the giving of a large portion, up to a maximum of 100 mg, of the total
daily dose at bedtime, either orally or by rectal suppositories, may be
helpful in affording relief. The total daily dose should not exceed 200
mg. In acute flares of chronic rheumatoid arthritis, it may be necessary
to increase the dosage by 25 mg or, if required, by 50 mg daily. </p>

<p>If Capsules Indomethacin SR 75 mg are used for initiating indomethacin
treatment, one capsule daily should be the usual starting dose in order
to observe patient tolerance since 75 mg per day is the maximum recommended
starting dose for indomethacin (see above). If Capsules Indomethacin SR
are used to increase the daily dose, patients should be observed for possible
signs and symptoms of intolerance since the daily increment will exceed
the daily increment recommended for the other dosage forms. For patients
who require 150 mg of Indomethacin per day and have demonstrated acceptable
tolerance, Indomethacin SR may be prescribed as one capsule twice daily.
</p>

<p>If minor adverse effects develop as the dosage is increased, reduce
the dosage rapidly to a tolerated dose and OBSERVE THE PATIENT CLOSELY.
If severe adverse reactions occur, STOP THE DRUG. After the acute phase
of the disease is under control, an attempt to reduce the daily dose should
be made repeatedly until the patient is receiving the smallest effective
dose or the drug is discontinued. </p>

<p>Careful instructions to, and observations of, the individual patient
are essential to the prevention of serious, irreversible, including fatal,
adverse reactions. </p>

<p>As advancing years appear to increase the possibility of adverse reactions,
Indomethacin should be used with greater care in the aged. </p>

<p>2. Acute painful shoulder (bursitis and/or tendinitis). </p>

<p>Initial Dose: </p>

<p>75-150 mg daily in 3 or 4 divided doses. </p>

<p>The drug should be discontinued after the signs and symptoms of inflammation
have been controlled for several days. The usual course of therapy is 7-14
days. </p>

<p>3. Acute gouty arthritis. </p>

<p>Suggested Dosage: </p>

<p>Capsules Indomethacin 50 mg t.i.d. until pain is tolerable. The dose
should then be rapidly reduced to complete cessation of the drug. Definite
relief of pain has been reported within 2 to 4 hours. Tenderness and heat
usually subside in 24 to 36 hours, and swelling gradually disappears in
3 to 5 days. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
